PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Aligue, R; Wu, L; Russell, P				Aligue, R; Wu, L; Russell, P			Regulation of Schizosaccharomyces pombe Wee1 tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; XENOPUS EGG EXTRACTS; FISSION YEAST; PROTEIN-KINASE; MITOTIC INDUCER; CDC25 PROTEIN; NEGATIVE REGULATION; SACCHAROMYCES-CEREVISIAE; PHOSPHORYLATION SITES; ACTIVATES P34CDC2	Wee1 tyrosine kinase regulates mitosis by carrying out the inhibitory tyrosine 15 phosphorylation of Cdc2 M-phase inducing kinase, Schizosaccharomyces pombe Wee1 is a large protein, consisting of a C-terminal catalytic domain of similar to 350 amino acids preceded by a N-terminal domain of similar to 550 residues, The functional proper ties of the Wee1 N-terminal domain were investigated by expressing truncated forms of Wee1 in S, pombe, Both positive and negative regulatory domains were identified, Sequences important for Wee1 function were mapped to a central region (residues 363-408), This region is not required for kinase activity or nuclear localization? suggesting it mag be involved in substrate recognition, The negative regulatory domain resides in the N-terminal third of Wee1, Wee1 constructs lacking this domain are more effective at delaying mitosis than wild-type Wee1, The negative regulatory domain contains clusters of potential Cdc2 phosphorylation sites. Investigations to monitor the abundance of Wee1 mRNA and protein during the cell cycle were also carried out.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NIGMS NIH HHS [GM41281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041281] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CAMPBELL SD, 1995, MOL BIOL CELL, V6, P1333, DOI 10.1091/mbc.6.10.1333; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; CREANOR J, 1982, J CELL SCI, V58, P263; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GALLAGHER IM, 1993, MOL BIOL CELL, V4, P1087, DOI 10.1091/mbc.4.11.1087; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HARLOW E, 1988, ANTIBODIES; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE MS, 1994, J BIOL CHEM, V269, P30530; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MONDESERT O, 1994, J BIOL CHEM, V269, P27996; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wu L, 1996, MOL BIOL CELL, V7, P1749, DOI 10.1091/mbc.7.11.1749; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0	58	54	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13320	13325		10.1074/jbc.272.20.13320	http://dx.doi.org/10.1074/jbc.272.20.13320			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148953	hybrid			2022-12-25	WOS:A1997WZ38400066
J	Serin, G; Joseph, G; Ghisolfi, L; Bauzan, M; Erard, M; Amalric, F; Bouvet, P				Serin, G; Joseph, G; Ghisolfi, L; Bauzan, M; Erard, M; Amalric, F; Bouvet, P			Two RNA-binding domains determine the RNA-binding specificity of nucleolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; HETERONUCLEAR MAGNETIC-RESONANCE; A-PROTEIN COMPONENT; HNRNP-C-PROTEINS; U1 RNA; CONSENSUS SEQUENCE; POLY(A)-BINDING PROTEIN; SECONDARY STRUCTURE; RECOGNITION MOTIF; CRYSTAL-STRUCTURE	Nucleolin is an abundant nucleolar RNA-binding protein that seems to be involved in many aspects of ribosome biogenesis. Nucleolin contains four copies of a consensus RNA-binding domain (CS-RBD) found in several other proteins. In vitro RNA-binding studies previously determined that nucleolin interacts specifically with a short RNA stem-loop structure. Taken individually, none of the four CS-RBDs interacts significantly with the RNA target, but a peptide that contains the first two adjacent CS-RBDs (R12) is sufficient to account for nucleolin RNA-binding specificity and affinity. The full integrity of these two domains is required, since N- or C-terminal deletion abolishes the specific interaction with the RNA. Mutation of conserved amino acids within the RNP-1 sequence of CS-RBD 1 or 2 drastically reduces the interaction with the RNA, whereas mutation of the analogous residues in CS-RBDs 3 and 4 has no effect in the context of the R1234G protein (which corresponds to the C-terminal end of nucleolin). Our results demonstrate that nucleolin RNA binding specificity is the result of a cooperation between two CS-RBDs (RBDs I and 2) and also suggests a direct or indirect involvement of the RNP-1 consensus sequence of both CS-RBDs in the recognition of the RNA target.	CNRS,INST BIOL CELLULAIRE & GENET,LAB BIOL MOL EUCARYOTE,UPR 9006,F-31062 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			, Bouvet/AAC-8779-2020; Nieto, Laurence/AAJ-5703-2021	Nieto, Laurence/0000-0002-1006-0168; Bouvet, Philippe/0000-0003-4524-2233				ABDULMANAN N, 1996, BIOCHEMISTRY-US, V35, P2545; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BOURBON HM, 1983, MOL BIOL REP, V9, P39, DOI 10.1007/BF00777472; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BUGLER B, 1987, J BIOL CHEM, V262, P10922; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GARRETT DS, 1994, BIOCHEMISTRY-US, V33, P2852, DOI 10.1021/bi00176a015; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; LU JR, 1995, J MOL BIOL, V247, P739, DOI 10.1016/S0022-2836(05)80152-4; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NARANDA T, 1994, J BIOL CHEM, V269, P14465; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3345, DOI 10.1021/bi00283a007; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; STEELY HT, 1986, BIOPOLYMERS, V25, P91, DOI 10.1002/bip.360250108; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; WOODY RW, 1995, METHOD ENZYMOL, V246, P35; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	65	80	82	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13109	13116		10.1074/jbc.272.20.13109	http://dx.doi.org/10.1074/jbc.272.20.13109			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148924	hybrid			2022-12-25	WOS:A1997WZ38400037
J	Carter, BZ; Wiseman, AL; Orkiszewski, R; Ballard, KD; Ou, CN; Lieberman, MW				Carter, BZ; Wiseman, AL; Orkiszewski, R; Ballard, KD; Ou, CN; Lieberman, MW			Metabolism of leukotriene C-4 in gamma-glutamyl transpeptidase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION; INFLAMMATION; KIDNEY	We have investigated the metabolism of leukotriene C-4 (LTC4) in gamma-glutamyl transpeptidase (GGT)-deficient mice (Lieberman, M. W., Wiseman, A. L., Shi, Z-Z., Carter, B. Z., Barrios, R., Ou, C-N., Chevez-Barrios, P., Wang, Y., Habib, G. M., Goodman, J. C., Huang, S. L., Lebovitz, R. Fd., and Matzuk, M. M. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 7923-7926) and have found substantial conversion of LTC4 to leukotriene D-4 by high performance liquid chromatography and continuous flow fast atom bombardment-tandem mass spectrometric analyses. LTC4-converting activity has a tissue distribution different from GGT with highest activity in spleen followed by small intestine, kidney, and pancreas and lower activity in liver and lung. The activity is membrane-bound and is inhibited by acivicin, a known inhibitor of GGT. The enzyme was partially purified from the small intestine of GGT-deficient mice by papain treatment and gel filtration chromatography. The partially purified fragment released by papain has an apparent molecular mass of 65-70 kDa and the same substrate specificity as the tissue homogenate. In addition to LTC4, S-decyl-GSH is also cleaved. GSH itself, oxidized GSH, and the synthetic substrates used to analyze GGT activity (gamma-glutamyl-p-nitroanilide and gamma-glutamyl-4-methoxy-2-naphthylamide) are not substrates for this newly discovered enzyme. These data demonstrate that in addition to GGT at least one other enzyme cleaves LTC4 in mice. To reflect this enzyme's preferred substrate, we suggest that it be named gamma-glutamyl leukotrienase.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIEHS NIH HHS [ES-07827] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007827] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAPRARO MA, 1985, J BIOL CHEM, V260, P3408; Curthoys N. P., 1990, GLUTATHIONE METABOLI, P217; DENZLINGER C, 1986, J BIOL CHEM, V261, P5601; Dixon M., 1979, ENZYMES, P55; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FREY A, 1991, EUR J BIOCHEM, V202, P421, DOI 10.1111/j.1432-1033.1991.tb16391.x; GASKELL SJ, 1990, CONTINUOUS-FLOW FAST ATOM BOMBARDMENT MASS SPECTROMETRY, P29; GHANDOUR MS, 1980, NEUROSCI LETT, V20, P125, DOI 10.1016/0304-3940(80)90133-0; GOFFINET AM, 1989, EUR J PHARMACOL, V161, P99, DOI 10.1016/0014-2999(89)90186-6; Habib GM, 1996, J BIOL CHEM, V271, P16273, DOI 10.1074/jbc.271.27.16273; HEISTERKAMP N, 1991, P NATL ACAD SCI USA, V88, P6303, DOI 10.1073/pnas.88.14.6303; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HINCHMAN CA, 1990, BIOCHEM PHARMACOL, V40, P1131, DOI 10.1016/0006-2952(90)90503-D; HUBER M, 1988, LEUKOTRIENES MERCAPT, P449; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; LE AQ, 1992, J BIOL CHEM, V267, P1072; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LEWIS RA, 1988, LEUKOTRIENES INFLAMM, P121; LIEBERMAN MW, 1995, AM J PATHOL, V147, P1175; Lieberman MW, 1996, P NATL ACAD SCI USA, V93, P7923, DOI 10.1073/pnas.93.15.7923; MARATHE GV, 1979, FEBS LETT, V107, P436, DOI 10.1016/0014-5793(79)80425-1; Meister A, 1981, Methods Enzymol, V77, P237; Meister A., 1995, METABOLIC BASIS INHE, P1461; NEIL GL, 1979, ADV ENZYME REGUL, V17, P375; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; RAFTERY MJ, 1990, BIOMED ENVIRON MASS, V19, P465, DOI 10.1002/bms.1200190804; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHINE HD, 1981, BRAIN RES, V217, P339, DOI 10.1016/0006-8993(81)90009-3; SPATER HW, 1980, P NATL ACAD SCI USA, V79, P3547; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5	32	43	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12305	12310		10.1074/jbc.272.19.12305	http://dx.doi.org/10.1074/jbc.272.19.12305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139674	hybrid			2022-12-25	WOS:A1997WY82900011
J	Forsberg, G; Forsgren, M; Jaki, M; Norin, M; Sterky, C; Enhorning, A; Larsson, K; Ericsson, M; Bjork, P				Forsberg, G; Forsgren, M; Jaki, M; Norin, M; Sterky, C; Enhorning, A; Larsson, K; Ericsson, M; Bjork, P			Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; IN-VIVO; TARGETED SUPERANTIGENS; FAB-FRAGMENTS; EXPRESSION; DOMAIN; PROTEINS; ANTIGEN; CHAIN; GLYCOPROTEIN	The monoclonal antibody 5T4, directed against a human tumor-associated antigen, was expressed as a secreted Fab superantigen fusion protein in Escherichia coli, The product is a putative agent for immunotherapy of non-small cell lung cancer. During fermentation, most of the fusion protein leaked out from the periplasm to the growth medium at a level of approximately 40 mg/liter, This level was notably low compared with similar products containing identical C(H)1, C-L, and superantigen moieties, and the Fv framework was therefore engineered, Using hybrid molecules, the light chain was found to limit high expression levels. Substituting five residues in V-L, increased the level almost 15 times, exceeding 500 mg/liter in the growth medium, Here, the substitutions Phe-10 --> Ser, Thr-45 --> Lys, Thr-77 --> Ser, and Leu-78 --> Val were most powerful. In addition, replacing four V-H residues diminished cell lysis during fermentation, Thereby the product was preferentially located in the periplasm instead of the growth medium, and the total yield was more than 700 mg/liter. All engineered products retained a high affinity for the tumor-associated antigen, It is suggested that at least some of the identified framework residues generally have to be replaced to obtain high level production of recombinant Fab products in E. coli.	PHARMACIA & UPJOHN INC,LUND RES CTR,S-22007 LUND,SWEDEN	Pfizer; Pharmacia Corporation	Forsberg, G (corresponding author), PHARMACIA & UPJOHN INC,DEPT BIOL & BIOTECHNOL,S-11287 STOCKHOLM,SWEDEN.							ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; ABRAHMSEN L, 1995, EMBO J, V14, P2978, DOI 10.1002/j.1460-2075.1995.tb07300.x; ABRAHMSEN L, 1986, NUCLEIC ACIDS RES, V14, P7487, DOI 10.1093/nar/14.18.7487; ALFTHAN K, 1993, GENE, V128, P203, DOI 10.1016/0378-1119(93)90564-J; ATKINSON A, 1973, BIOCHIM BIOPHYS ACTA, V308, P41, DOI 10.1016/0005-2787(73)90120-2; AYALA M, 1995, BIOTECHNIQUES, V18, P832; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BENDING MM, 1995, IMMUNOMETHODS, V8, P83; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BJORK P, 1993, J BIOL CHEM, V268, P24232; Blight Mark A., 1994, Current Opinion in Biotechnology, V5, P468, DOI 10.1016/0958-1669(94)90059-0; BRINKMANN U, 1993, J IMMUNOL, V150, P2774; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; DOHLSTEN M, 1995, P NATL ACAD SCI USA, V92, P9791, DOI 10.1073/pnas.92.21.9791; DOHLSTEN M, 1991, P NATL ACAD SCI USA, V88, P9287, DOI 10.1073/pnas.88.20.9287; DOHLSTEN M, 1994, P NATL ACAD SCI USA, V91, P8945, DOI 10.1073/pnas.91.19.8945; FORSBERG G, 1989, Biofactors, V2, P105; Freund C, 1996, BIOCHEMISTRY-US, V35, P8457, DOI 10.1021/bi952764a; GE LM, 1995, J BIOL CHEM, V270, P12446, DOI 10.1074/jbc.270.21.12446; HEWINSON RG, 1993, J GEN MICROBIOL, V139, P1253, DOI 10.1099/00221287-139-6-1253; HOCKNEY RC, 1994, TRENDS BIOTECHNOL, V12, P456, DOI 10.1016/0167-7799(94)90021-3; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; Kabat EA, 1991, SEQUENCES PROTEINS I; KALLAND T, 1993, MED ONCOL TUMOR PHAR, V10, P37; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; LEISTLER B, 1994, BIOCHEMISTRY-US, V33, P2773, DOI 10.1021/bi00176a005; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MYERS KA, 1994, J BIOL CHEM, V269, P9319; PACK P, 1993, BIO-TECHNOL, V11, P1271; PLUCKTHUN A, 1991, METHODS, V2, P88; RIETHMULLER G, 1993, CURR OPIN IMMUNOL, V5, P732, DOI 10.1016/0952-7915(93)90129-G; Sambrook J., 2002, MOL CLONING LAB MANU; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIBUI T, 1993, APPL MICROBIOL BIOT, V38, P770, DOI 10.1007/BF00167143; SKERRA A, 1991, PROTEIN ENG, V4, P971, DOI 10.1093/protein/4.8.971; SOMERVILLE JE, 1994, APPL MICROBIOL BIOT, V42, P595; SOUTHALL PJ, 1990, BRIT J CANCER, V61, P89, DOI 10.1038/bjc.1990.20; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; WARD ES, 1992, FASEB J, V6, P2422, DOI 10.1096/fasebj.6.7.1563594	41	67	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12430	12436		10.1074/jbc.272.19.12430	http://dx.doi.org/10.1074/jbc.272.19.12430			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139690	hybrid			2022-12-25	WOS:A1997WY82900027
J	Grentzmann, G; Kelly, PJ				Grentzmann, G; Kelly, PJ			Ribosomal binding site of release factors RF1 and RF2 - A new translational termination assay in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-G; ESCHERICHIA-COLI; TRANSFER-RNA; CRYSTAL-STRUCTURE; FACTOR RF-3; FACTOR-II; RECOGNITION; GENE; SIGNALS; CODON	We have established a new in vitro assay for translational termination. It consists of 70 S ribosomes bound to a synthetic RNA minimessenger via interaction with P-site binding fMet-tRNA(f)(Met). If the A-site codon is a stop signal, release activity can be measured by quantifying hydrolyzed formylmethionine, Characteristics of this assay in terms of reaction time, ion concentration, release factor RF1 and RF2 concentration, and competition with A-site-decoding tRNA are discussed. The new assay shows that polypeptide chain release activity is directly dependent on the presence of a stop codon in the ribosomal A-site.			Grentzmann, G (corresponding author), UNIV UTAH,HOWARD HUGHES MED INST,ECCLES INST HUMAN GENET,6160 ECCLES BLDG,SALT LAKE CITY,UT 84112, USA.							ADAMSKI FM, 1994, J MOL BIOL, V238, P302, DOI 10.1006/jmbi.1994.1293; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; ARKOV AL, 1993, NUCLEIC ACIDS RES, V21, P2891, DOI 10.1093/nar/21.12.2891; BUCKINGHAM K, 1987, BIOCHIM BIOPHYS ACTA, V909, P92, DOI 10.1016/0167-4781(87)90030-3; CAPECCHI MR, 1967, P NATL ACAD SCI USA, V58, P1144, DOI 10.1073/pnas.58.3.1144; CAPECCHI MR, 1969, COLD SPRING HARB SYM, V34, P469, DOI 10.1101/SQB.1969.034.01.053; CAPECCHI MR, 1965, SCIENCE, V149, P417, DOI 10.1126/science.149.3682.417; CASKEY CT, 1968, SCIENCE, V162, P135, DOI 10.1126/science.162.3849.135; CASKEY CT, 1977, MOL MECHANISMS PROTE, P443; CASKEY CT, 1971, METHOD ENZYMOL, V20, P367; CASKEY T, 1969, COLD SPRING HARB SYM, V34, P479, DOI 10.1101/SQB.1969.034.01.054; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GANOZA MC, 1966, COLD SPRING HARB SYM, V31, P273, DOI 10.1101/SQB.1966.031.01.035; GOLDSTEIN J, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P430, DOI 10.1073/pnas.65.2.430; GRENTZMANN G, 1995, J BIOL CHEM, V270, P10595, DOI 10.1074/jbc.270.18.10595; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; Ito K, 1996, P NATL ACAD SCI USA, V93, P5443, DOI 10.1073/pnas.93.11.5443; KAWAZU Y, 1995, J BACTERIOL, V177, P5547, DOI 10.1128/jb.177.19.5547-5553.1995; Laalami S, 1996, BIOCHIMIE, V78, P577, DOI 10.1016/S0300-9084(96)80004-6; Limbach Patrick A., 1995, Current Opinion in Biotechnology, V6, P96, DOI 10.1016/0958-1669(95)80015-8; Matsumura K, 1996, J MOL BIOL, V258, P588, DOI 10.1006/jmbi.1996.0271; MIKUNI O, 1994, P NATL ACAD SCI USA, V91, P5798, DOI 10.1073/pnas.91.13.5798; MILMAN G, 1969, P NATL ACAD SCI USA, V63, P183, DOI 10.1073/pnas.63.1.183; MOFFAT JG, 1993, EUR J BIOCHEM, V231, P749; MURGOLA EJ, 1990, RIBOSOME, P402; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; PEL HJ, 1993, NUCLEIC ACIDS RES, V21, P5308, DOI 10.1093/nar/21.23.5308; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; RHEINBERGER HJ, 1986, J BIOL CHEM, V261, P9133; SCOLNICK E, 1970, NATURE, V225, P152, DOI 10.1038/225152a0; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; Spedding G., 1990, RIBOSOMES PROTEIN SY; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; TATE WP, 1983, J BIOL CHEM, V258, P360; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; TATE WP, 1990, RIBOSOME, P393; Tate WP, 1995, BIOCHEM CELL BIOL, V73, P1095, DOI 10.1139/o95-118; TATE WP, 1990, RIBOSOMES PROTEIN SY, P81; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; Zhang SP, 1996, J MOL BIOL, V261, P98, DOI 10.1006/jmbi.1996.0444	40	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12300	12304		10.1074/jbc.272.19.12300	http://dx.doi.org/10.1074/jbc.272.19.12300			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139673	hybrid			2022-12-25	WOS:A1997WY82900010
J	Wesselborg, S; Bauer, MKA; Vogt, M; Schmitz, ML; SchulzeOsthoff, K				Wesselborg, S; Bauer, MKA; Vogt, M; Schmitz, ML; SchulzeOsthoff, K			Activation of transcription factor NF-kappa B and p38 mitogen-activated protein kinase is mediated by distinct and separate stress effector pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAMMALIAN-CELLS; INTACT-CELLS; HEAT-SHOCK; PHOSPHORYLATION; AP-1; CASCADE; DOMAIN; INTERLEUKIN-1; ANTIOXIDANTS	Mitogen-activated protein (MAP) kinases are important mediators of the cellular stress response. Here, we investigated the relationship between activation of the MAP kinase p38 and transcription factor NF-kappa B. Different forms of cellular stress were found to preferentially trigger either p38 or NF-kappa B. Arsenite or osmotic stress potently activated p38 but were ineffective in inducing NF-kappa B activation, Tumor necrosis factor-alpha and hydrogen peroxide, in contrast, led to NF-kappa B activation but only modestly stimulated p38, The activation of NF-kappa B was strongly abolished by antioxidants, while the activity of p38 and transcription factor AP-1 were increased, Inhibition of small GTPases including Rac and Cdc42 prevented p38 and AP-1 activation without interfering with NF-kappa B. In addition, inhibition of p38 by a pharmacological inhibitor or a dominant-negative mutant of MAP kinase kinase-6, an activator of the p38 pathway, interfered with NF-kappa B-dependent gene expression but not its DNA binding activity, Our results indicate that activation of p38 and NF-kappa B are mediated by separate pathways, which may converge further downstream in the cell nucleus, Different forms of cellular stress, however, initially trigger distinct signaling cascades involving either oxidative stress or GTPase coupled pathways.	UNIV TUBINGEN,DEPT INTERNAL MED,D-72076 TUBINGEN,GERMANY; UNIV FREIBURG,INST BIOCHEM & MOL BIOL,D-79104 FREIBURG,GERMANY	Eberhard Karls University of Tubingen; University of Freiburg			Schulze-Osthoff, Klaus/N-9025-2013; Schmitz, M. Lienhard/D-9328-2017	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Schmitz, M. Lienhard/0000-0002-6984-7192; Wesselborg, Sebastian/0000-0002-5236-942X				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Guyton KZ, 1996, CANCER RES, V56, P3480; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LOS M, 1995, EUR J IMMUNOL, V25, P159, DOI 10.1002/eji.1830250127; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRICHETT W, 1995, J INFLAMM, V45, P97; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1994, BIOTECHNIQUES, V17, P714; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	61	221	222	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12422	12429		10.1074/jbc.272.19.12422	http://dx.doi.org/10.1074/jbc.272.19.12422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139689	hybrid			2022-12-25	WOS:A1997WY82900026
J	Yan, SZ; Huang, ZH; Shaw, RS; Tang, WJ				Yan, SZ; Huang, ZH; Shaw, RS; Tang, WJ			The conserved asparagine and arginine are essential for catalysis of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; SOLUBLE GUANYLATE-CYCLASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; ALPHA-SUBUNIT; RAT-BRAIN; EXPRESSION; GENES; MUTAGENESIS; MECHANISM	Mammalian adenylyl cyclases have two homologous cytoplasmic domains (C-1 and C-2), and both domains are required for the high enzymatic activity, Mutational and genetic analyses of type I and soluble adenylyl cyclases suggest that the C-2 domain is catalytically active and the C-1 domain is not; the role of the C-1 domain is to promote the catalytic activity of the C-1 domain, Two amino acid residues, Asn-1025 and Arg-1029 of type II adenylyl cyclase, are conserved among the C-2 domains, but not among the C-1 domains, of adenylyl cyclases with 12 putative transmembrane helices. Mutations at each amino acid residue alone result in a 30-100-fold reduction in K-cat of adenylyl cyclase. However, the same mutations do not affect the K-m for ATP, the half-maximal concentration (EC50) for the C-2 domain of type II adenylyl cyclase to associate with the C-1 domain of type I adenylyl cyclase and achieve maximal enzyme activity, or the EC50 for forskolin to maximally activate enzyme activity with or without G(s alpha). This indicates that the mutations at these two residues do not cause gross structural alteration. Thus, these two conserved amino acid residues appear to be crucial for catalysis, and their absence from the C-1 domains may account for its lack of catalytic activity, Mutations at both amino acid residues together result in a 3,000-fold reduction in K-cat of adenylyl cyclase, suggesting that these two residues have additive effects in catalysis. A second site suppressor of the Asn-1025 to Ser mutant protein has been isolated, This suppressor has 17-fold higher activity than the mutant and has a Pro-101B to Ser mutation.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	University of Chicago				Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM53459] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BEUVE A, 1990, J BACTERIOL, V172, P2614, DOI 10.1128/jb.172.5.2614-2621.1990; BLACKLOW SC, 1990, BIOCHEMISTRY-US, V29, P4099, DOI 10.1021/bi00469a012; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FRASER ADE, 1978, CAN J MICROBIOL, V24, P1423, DOI 10.1139/m78-228; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LOW KB, 1972, BACTERIOL REV, V36, P587, DOI 10.1128/MMBR.36.4.587-607.1972; MANFREDI J, 1995, 9 INT C 2 MESS PHOSP, P158; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; PARENT CA, 1995, J BIOL CHEM, V270, P22693, DOI 10.1074/jbc.270.39.22693; Parent CA, 1996, J BIOL CHEM, V271, P18333, DOI 10.1074/jbc.271.31.18333; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; PETERS EP, 1991, MOL MICROBIOL, V5, P1175, DOI 10.1111/j.1365-2958.1991.tb01890.x; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANCHEZ MA, 1995, J BIOL CHEM, V270, P17551, DOI 10.1074/jbc.270.29.17551; SHAH S, 1995, J BIOL CHEM, V270, P15368, DOI 10.1074/jbc.270.25.15368; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TANG WJ, 1997, IN PRESS ADV 2 MESSE; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; VIK SB, 1994, J BIOL CHEM, V269, P30364; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WATANABE K, 1994, EUR J BIOCHEM, V226, P277, DOI 10.1111/j.1432-1033.1994.tb20051.x; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOUNG D, 1991, GENE, V102, P129, DOI 10.1016/0378-1119(91)90551-L; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	58	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12342	12349		10.1074/jbc.272.19.12342	http://dx.doi.org/10.1074/jbc.272.19.12342			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139678	hybrid			2022-12-25	WOS:A1997WY82900015
J	Benedetti, P; Silvestri, A; Fiorani, P; Wang, JC				Benedetti, P; Silvestri, A; Fiorani, P; Wang, JC			Study of yeast DNA topoisomerase II and its truncation derivatives by transmission electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; TRANSPORT; MECHANISM; BINDING	The 1429-amino acid residue long yeast DNA topoisomerase II and three of its deletion derivatives, a C-terminal truncation containing residues 1-1202, a 92-kDa fragment spanning residues 410-1202, and an A'-fragment spanning residues 660-1202, were examined by transmission electron microscopy, Analysis of rotary-shadowed images of these molecules shows that the full-length enzyme assumes a tripartite structure, in which a large globular core comprising the carboxyl parts of the dimeric enzyme is connected to a pair of smaller spherical masses comprising the ATPase domains of the enzyme, The linkers bridging the large globular structure and each of the smaller spheres are not visible in most of the images but appear to be sufficiently stiff to keep the relative positions of the connected parts, The angle extended by the pair of spherical masses is variable and falls in a range of 50-100 degrees for the majority of the images, On binding of a nonhydrolyzable ATP analog to the enzyme, this angle is significantly reduced as the two spherical masses swing into contact, These observations, together with results from previous biochemical and x-ray crystallographic studies of the enzyme, provide a sketch of the molecular architecture and conformational states of a catalytically active type II DNA topoisomerase.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University	Benedetti, P (corresponding author), CNR,INST BIOL CELLULARE,VIALE MARX 43,I-00137 ROME,ITALY.				NCI NIH HHS [CA47958] Funding Source: Medline; NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024544, R01GM024544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	16	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12132	12137		10.1074/jbc.272.18.12132	http://dx.doi.org/10.1074/jbc.272.18.12132			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115283	hybrid			2022-12-25	WOS:A1997WX56900071
J	Thamotharan, M; Lombardo, YB; Bawani, SZ; Adibi, SA				Thamotharan, M; Lombardo, YB; Bawani, SZ; Adibi, SA			An active mechanism for completion of the final stage of protein degradation in the liver, lysosomal transport of dipeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; HUMAN INTESTINE; BRUSH-BORDER; RAT	Accumulation of products of proteolysis (e.g. dipeptides) in lysosomes may have pathological consequences. In the present experiment we have investigated the existence of a dipeptide transporter in a membrane preparation of liver lysosomes using Gly-H-3-Gln as the probe. The results showed that (a) there was transport of Gly-Gln into an osmotically reactive space inside the lysosomal membrane vesicles; (b) transport was stimulated by acidification (pH 5.0) of the external medium; (c) there was a coupling between transport of protons and Gly-Gln with a stoichiometry of 1:1; (d) the presence of both acidic pH and membrane potential was necessary for uphill transport of Gly-Gln; (d) a single transporter with a K-m of 4.67 mM mediated the uptake of Gly-Gln; and (f) Gly-Gln uptake was inhibited by dipeptides and tripeptides but not by amino acids. The results suggest the presence of a low affinity proton-coupled oligopeptide transporter in the liver lysosomal membrane which mediates transfer of dipeptides from a region of low dipeptidase activity (intralysosome) to a region of high dipeptidase activity (cytosol). In this manner, the transporter provides an active mechanism for completion of the final stage of protein degradation.	UNIV PITTSBURGH,SCH MED,DEPT MED,CLIN NUTR RES UNIT,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Adibi SA, 1996, NEWS PHYSIOL SCI, V11, P133; ADIBI SA, 1973, J CLIN INVEST, V52, P1586, DOI 10.1172/JCI107335; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P46; BIRD SJ, 1995, CELL BIOCHEM FUNCT, V13, P79, DOI 10.1002/cbf.290130203; BIRD SJ, 1990, BIOCHIM BIOPHYS ACTA, V1024, P267, DOI 10.1016/0005-2736(90)90353-P; Boll M, 1996, P NATL ACAD SCI USA, V93, P284, DOI 10.1073/pnas.93.1.284; BOUMA JMW, 1976, BIOCHIM BIOPHYS ACTA, V444, P853, DOI 10.1016/0304-4165(76)90331-7; COFFEY JW, 1968, J BIOL CHEM, V243, P3255; DANIEL H, 1991, J BIOL CHEM, V266, P19917; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FORSTER S, 1988, BIOCHIM BIOPHYS ACTA, V947, P465, DOI 10.1016/0304-4157(88)90004-4; Gahl WASJ, 1995, METABOLIC MOL BASIS, V7th, P3763; GOLDMAN R, 1973, FEBS LETT, V33, P208, DOI 10.1016/0014-5793(73)80194-2; Hodges T K, 1974, Methods Enzymol, V32, P392; JONAS AJ, 1990, BIOCHEM J, V268, P41, DOI 10.1042/bj2680041; KIM YS, 1972, J CLIN INVEST, V51, P1419, DOI 10.1172/JCI106938; KUSSENDRAGER KD, 1972, BIOCHIM BIOPHYS ACTA, V279, P75, DOI 10.1016/0304-4165(72)90242-5; LLOYD JB, 1971, BIOCHEM J, V121, P245, DOI 10.1042/bj1210245; LOMBARDO YB, 1988, J BIOL CHEM, V263, P12920; MANCINI GMS, 1990, J BIOL CHEM, V265, P12380; MINAMI H, 1992, GASTROENTEROLOGY, V103, P3, DOI 10.1016/0016-5085(92)91088-L; NICHOLSON JA, 1979, EUR J CLIN INVEST, V9, P349, DOI 10.1111/j.1365-2362.1979.tb00895.x; PROSPERO TD, 1973, BIOCHEM J, V132, P449, DOI 10.1042/bj1320449; SCHNEIDER DL, 1983, J BIOL CHEM, V258, P1833; STEVENSONSTETLE.MA, 1981, AM J PHYSIOL, V241, pF117; SYMONS LJ, 1987, ANAL BIOCHEM, V164, P382, DOI 10.1016/0003-2697(87)90508-2	26	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11786	11790		10.1074/jbc.272.18.11786	http://dx.doi.org/10.1074/jbc.272.18.11786			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115234	hybrid			2022-12-25	WOS:A1997WX56900022
J	Garred, O; Dubinina, E; Polesskaya, A; Olsnes, S; Kozlov, J; Sandvig, K				Garred, O; Dubinina, E; Polesskaya, A; Olsnes, S; Kozlov, J; Sandvig, K			Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREFELDIN-A; SHIGELLA-DYSENTERIAE; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; SECRETORY PROTEINS; FACTOR-RECEPTOR; GOLGI-COMPLEX; CYTO-TOXIN; BINDING	Shiga toxin consists of an enzymatically active A-chain and a pentameric binding subunit. The A-chain has a trypsin-sensitive region, and upon cleavage two disulfide bonded fragments, A(1) and A(2), are generated. To study the role of the disulfide bond, it was eliminated by mutating cysteine 242 to serine. In T47D cells this mutated toxin was more toxic than wild type toxin after a short incubation, whereas after longer incubation times wild type toxin was most toxic. Cells cleaved not only wild type but also mutated A-chain into A(1) and A(2) fragments. The mutated A chain was more sensitive than wild type toxin to Pronase, and it was degraded at a higher rate in T47D cells. Subcellular fractionation demonstrated transport of both wild type and mutated toxin to the Golgi apparatus. Brefeldin A, which disrupts the Golgi apparatus, protected not only against Shiga toxin but also against the mutated toxin, indicating involvement of the Golgi apparatus. After prebinding of Shiga(C242S) toxin to wells coated with the Shiga toxin receptor, Gb(3), trypsin treatment induced dissociation of A(1) from the toxin-receptor complex demonstrating that in addition to stabilizing the A chain, the disulfide bond prevents dissociation of the A(1) fragment from the toxin-receptor complex.	NORWEGIAN RADIUM HOSP, INST CANC RES, N-0310 OSLO, NORWAY; UNIV OSLO, CTR MED STAT, N-0316 OSLO, NORWAY; RUSSIAN ACAD SCI, WA ENGELHARDT MOL BIOL INST, MOSCOW, RUSSIA	University of Oslo; University of Oslo; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS								COHEN A, 1987, J BIOL CHEM, V262, P17088; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAMKE H, 1991, J BIOL CHEM, V266, P24829; DAVID LL, 1993, J BIOL CHEM, V268, P1937; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; GARRED O, 1995, J BIOL CHEM, V270, P10817; GARRED O, 1995, EXP CELL RES, V218, P39, DOI 10.1006/excr.1995.1128; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; KOZLOV YV, 1988, GENE, V67, P213, DOI 10.1016/0378-1119(88)90398-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MANIATIS T, 1993, MOL CLONING; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OLSNES S, 1981, J BIOL CHEM, V256, P8732; OLSNES S, 1980, J BIOL CHEM, V255, P284; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SAXENA SK, 1989, J BIOL CHEM, V264, P596; SHITE S, 1990, J BIOL CHEM, V265, P17385; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992	36	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11414	11419						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111051	hybrid			2022-12-25	WOS:A1997WW00900067
J	Morgavi, P; Bonifaci, N; Pagani, M; Costigliolo, S; Sitia, R; Rubartelli, A				Morgavi, P; Bonifaci, N; Pagani, M; Costigliolo, S; Sitia, R; Rubartelli, A			The association of HIV-1 Tat with nuclei is regulated by Ca2+ ions and cytosolic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTION FACTOR; BETA-GALACTOSIDASE; TRANS-ACTIVATOR; PROTEIN; PHOSPHORYLATION; CELLS; IMPORT; KINASE; GROWTH	Human immunodeficiency virus-1 (HIV-1) Tat, a nuclear transcription factor, has been shown to function extracellularly, implying that some Tat molecules escape nuclear import and are secreted. This raises the question of what regulates, in HIV-1-infected cells, the nuclear targeting of the polypeptide. Here we show that cytosolic components activated by Ca2+ ions are required to reveal the karyophilic properties of Tat: in vitro translated Tat molecules do not associate with isolated nuclei unless preincubated with Ca2+. Moreover, Ca2+ ions induce karyophilicity of chemically synthesized Tat molecules only upon addition of cytosolic extracts. The Ca2+-induced karyophilicity is prevented by inhibitors of either tyrosine kinases (herbimycin A and genistein) or tyrosine phosphatases (vanadate), suggesting the involvement of Ca2+-dependent phosphorylation/dephosphorylation events. In line with these observations, the transcriptional activity of Tat is inhibited by treatment with either vanadate or genistein. The same occurs with Tat mutants lacking either one or both the two tyrosine residues (positions 26 and 47). Hence, Ca2+-dependent tyrosine kinase(s) and phosphatase(s) act on accessory cellular protein(s), which in turn are responsible of Tat karyophilicity.	NATL INST CANC RES,CLIN PATHOL LAB,I-16132 GENOA,ITALY; SAN RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY	University of Genoa; IRCCS AOU San Martino IST			Rubartelli, Anna/AAA-1259-2021; Pagani, Massimiliano/B-6354-2013	Sitia, Roberto/0000-0001-7086-4152; Pagani, Massimiliano/0000-0002-7017-9304				Albini A, 1996, ONCOGENE, V12, P289; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BONIFACI N, 1995, AIDS, V9, P995, DOI 10.1097/00002030-199509000-00003; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GOSH S, 1990, NATURE, V344, P678; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jones KA, 1993, CURR OPIN CELL BIOL, V5, P461, DOI 10.1016/0955-0674(93)90012-F; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V6, P331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	28	9	9	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11256	11260						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111028	hybrid			2022-12-25	WOS:A1997WW00900044
J	Ray, RB; Steele, R; Meyer, K; Ray, R				Ray, RB; Steele, R; Meyer, K; Ray, R			Transcriptional repression of p53 promoter by hepatitis C virus core protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; TUMOR-ANTIGEN; GENE; EXPRESSION; LOCALIZATION; TRANSACTIVATION; HETEROZYGOSITY; SUPPRESSION; ASSOCIATION; PRODUCTS	Our previous results have suggested that the putative core protein of hepatitis C virus (HCV) transcriptionally regulates cellular and viral genes, inhibits cisplatin and c-myc-mediated apoptotic cell death under certain conditions, and transforms primary rat embryo fibroblast cells with a cooperative oncogene. Because HCV appears to cause hepatocellular carcinoma, we evaluated the regulatory role of the HCV core protein on p53, a well known tumor Suppressor gene, by an in vitro transfection assay. HCV core protein repressed transcriptional activity of the p53 promoter when tested separately in COS7 and HeLa cells. Deletion mutational analysis of the HCV core gene indicated that the regulatory domain involved in the repression of p53 transcriptional activity is located around amino acid residues 80-122 encompassing a putative DNA binding motif and two major phosphorylation sites. Results from this study suggest that the putative core protein may have an important biological role in the promotion of cell growth by repressing p53 transcription, and this appears to be consistent with certain earlier observations about HCV core moving into the nucleus.	ST LOUIS UNIV,CTR HLTH SCI,DIV INFECT DIS & IMMUNOL,ST LOUIS,MO 63110	Saint Louis University					NCI NIH HHS [CA52799] Funding Source: Medline; NIAID NIH HHS [AI-45250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA052799, R01CA052799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; BUKH J, 1994, P NATL ACAD SCI USA, V91, P8239, DOI 10.1073/pnas.91.17.8239; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; FULTS D, 1992, CANCER RES, V52, P674; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Ito T, 1996, J GEN VIROL, V77, P1043, DOI 10.1099/0022-1317-77-5-1043; LAGGING LM, 1995, J VIROL, V69, P5859, DOI 10.1128/JVI.69.9.5859-5863.1995; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muralidhar S, 1996, J VIROL, V70, P8691, DOI 10.1128/JVI.70.12.8691-8700.1996; NOWELL PC, 1994, FASEB J, V8, P408, DOI 10.1096/fasebj.8.6.8168690; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAVAGGI A, 1994, J HEPATOL, V20, P833, DOI 10.1016/S0168-8278(05)80157-6; RAY R, 1995, J VIROL, V69, P1959, DOI 10.1128/JVI.69.3.1959-1963.1995; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; Srinivas RV, 1996, VIRUS RES, V45, P87, DOI 10.1016/S0168-1702(96)01361-5; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; SUZUKI R, 1995, J GEN VIROL, V76, P53, DOI 10.1099/0022-1317-76-1-53; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YUMOTO Y, 1995, J GASTROEN HEPATOL, V10, P179, DOI 10.1111/j.1440-1746.1995.tb01075.x; Zanotto PMD, 1996, J VIROL, V70, P6083, DOI 10.1128/JVI.70.9.6083-6096.1996	40	225	236	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					10983	10986						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9110985				2022-12-25	WOS:A1997WW00900001
J	Liu, YC; Bernard, HU; Apt, D				Liu, YC; Bernard, HU; Apt, D			NFI-B3, a novel transcriptional repressor of the nuclear factor I family, is generated by alternative RNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CELL-SPECIFIC TRANSCRIPTION; BASIC-PROTEIN PROMOTER; DNA-REPLICATION; BINDING-SITES; TERMINAL DOMAIN; ADENOVIRUS DNA; POLYMERASE-II; ACTIVATION; ENHANCER	Nuclear factor I (NFI) proteins constitute a family of sequence-specific transcription factors whose functional diversity is generated through transcription from four different genes (NFI-A, NFI-B, NFI-C, and NFI-X), alternative RNA splicing, and protein heterodimerization. Here we describe a naturally truncated isoform, NFI-B3, which is derived from the human NFI-B gene, in addition to characterizing further human NFI-B1 and NFI-B2, two differentially spliced variants previously isolated from hamster and chicken. Although NFI-B1 and NFI-B2 proteins are translated from an 8.7-kilobase message, the mRNA for NFI-E3 has a size of only 1.8 kilobases. The NFI-B3 message originates from the failure to excise the first intron downstream of the exons encoding the DNA binding domain and subsequent processing of this transcript at an intron-internal polyadenylation signal. The translation product includes the proposed DNA binding and dimerization domain and terminates after translation of two additional ''intron'' encoded codons. In SL-2 cells, which are void of endogenous NFI, NFI-B3 by itself had no effect on transcriptional regulation and failed to bind DNA. Coexpression of NFI-B3 with other isoforms of the NFI-B, -C, and -X family, however, led to a strong reduction of transcriptional activation compared with the expression of these factors alone. Gel shift analysis indicated that NFI-B3 disrupts the function of other NFI proteins by reducing their DNA binding activity by heterodimer formation. The efficiency of NFI-B3 heterodimers to bind to DNA correlated with the degree of transcriptional repression. The abundance of NFI-B transcripts varied significantly between different human cell Lines and tissues, suggesting a potential involvement of these factors in the complex mechanisms that generate cell type specificity.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES N, 1991, Current Biology, V1, P224, DOI 10.1016/0960-9822(91)90063-3; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; KRUSE U, 1991, NUCLEIC ACIDS RES, V19, P6641, DOI 10.1093/nar/19.23.6641; KUMAR KU, 1993, J VIROL, V67, P572, DOI 10.1128/JVI.67.1.572-576.1993; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MUL YM, 1992, EMBO J, V11, P751, DOI 10.1002/j.1460-2075.1992.tb05108.x; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; NOVAK A, 1992, J BIOL CHEM, V267, P12986; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PLUMB M, 1991, J VIROL, V65, P1991, DOI 10.1128/JVI.65.4.1991-1999.1991; Puzianowska-Kuznicka M, 1996, J BIOL CHEM, V271, P6273, DOI 10.1074/jbc.271.11.6273; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROULET E, 1995, MOL CELL BIOL, V15, P5552; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sumner C, 1996, J NEUROVIROL, V2, P87, DOI 10.3109/13550289609146542; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; WENDLER W, 1994, NUCLEIC ACIDS RES, V22, P2601, DOI 10.1093/nar/22.13.2601; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	46	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10739	10745						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099724				2022-12-25	WOS:A1997WV26200058
J	Rosenberg, MF; Callaghan, R; Ford, RC; Higgins, CF				Rosenberg, MF; Callaghan, R; Ford, RC; Higgins, CF			Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ESCHERICHIA-COLI; 3-DIMENSIONAL RECONSTRUCTION; RIBOSOMAL-SUBUNITS; SINGLE PARTICLES; ATPASE ACTIVITY; MEMBRANE TOPOLOGY; CRYSTAL-STRUCTURE; CYSTIC-FIBROSIS; PHOTOSYSTEM-II	P-glycoprotein (P-gp) is a member of the ATP binding cassette superfamily of active transporters and can confer multidrug resistance on cells and tumors by pumping chemotherapeutic drugs from the cytoplasm. P-gp was purified from CH(r)B30 cells and retained the ability to bind substrates and hydrolyze ATP. Labeling of P-gp with lectin-gold particles suggested it is monomeric. An initial structure of purified P-gp was determined to 2.5 nm resolution by electron microscopy and Single particle image analysis of both detergent-solubilized and lipid-reconstituted protein. The structure was further refined by three dimensional reconstructions from single particle images and by Fourier projection maps of small two-dimensional crystalline arrays (unit cell parameters: alpha, 14.2 nm; b, 18.5 nm; and gamma, 91.6 degrees). When viewed from above the membrane plane the protein is toroidal, with 6-fold symmetry and a diameter of about 10 nm. There is a large central pore of about 5 nn in diameter, which is closed at the inner (cytoplasmic) face of the membrane, forming an aqueous chamber within the membrane, An opening from this chamber to the lipid phase is present. The projection of the protein perpendicular to the membrane is roughly rectangular with a maximum depth of 8 nm and two 3-nm lobes exposed at the cytoplasmic face of the membrane, likely to correspond to the nucleotide binding domains. This study provides the first experimental insight into the three-dimensional architecture of any ATP binding cassette transporter.	UNIV OXFORD, JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN BIOCHEM, OXFORD OX3 9DU, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, IMPERIAL CANC RES FUND LABS, INST MOL MED, OXFORD OX3 9DU, ENGLAND; UNIV MANCHESTER, INST SCI & TECHNOL, DEPT BIOCHEM & APPL MOL BIOL, MANCHESTER M60 1QD, LANCS, ENGLAND	University of Oxford; Cancer Research UK; University of Oxford; University of Manchester			Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; Ford, Robert/0000-0002-0958-1505				BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; CALLAGHAN R, 1995, BRIT J CANCER, V71, P294, DOI 10.1038/bjc.1995.59; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; CARAZO JM, 1988, J MOL BIOL, V201, P393, DOI 10.1016/0022-2836(88)90146-5; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; FERRY DR, 1992, BIOCHEM BIOPH RES CO, V188, P440, DOI 10.1016/0006-291X(92)92404-L; FORD RC, 1995, MICRON, V26, P133, DOI 10.1016/0968-4328(95)00005-O; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; FRANK J, 1988, METHOD ENZYMOL, V164, P3; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; HARAUZ G, 1988, METHOD ENZYMOL, V164, P35; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLZENBURG A, 1993, NATURE, V363, P470, DOI 10.1038/363470a0; HOLZENBURG A, 1995, ION CHANNELS PRACTIC, P269; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; LEVER JE, 1977, J BIOL CHEM, V252, P1990; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; RAVIV Y, 1990, BIOCHEMISTRY-US, V30, P1163; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; ROSENBERG MF, 1996, IN PRESS BIOCH BIOPH; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SAXTON WO, 1977, ULTRAMICROSCOPY, V2, P219; SCHNEIDER E, 1995, J BACTERIOL, V177, P5364, DOI 10.1128/jb.177.18.5364-5367.1995; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; VANHEEL M, 1985, EMBO J, V4, P2389, DOI 10.1002/j.1460-2075.1985.tb03944.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0	56	318	325	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10685	10694						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099718				2022-12-25	WOS:A1997WV26200052
J	Schroers, A; Kramer, R; Wohlrab, H				Schroers, A; Kramer, R; Wohlrab, H			The reversible antiport-uniport conversion of the phosphate carrier from yeast mitochondria depends on the presence of a single cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE GLUTAMATE CARRIER; BEEF-HEART MITOCHONDRIA; BROWN FAT MITOCHONDRIA; TRANSPORT PROTEIN; ASYMMETRIC ORIENTATION; UNCOUPLING PROTEIN; MOLECULAR ASPECTS; ESCHERICHIA-COLI; SEQUENCE; MUTATIONS	Wild type and mutant phosphate carriers (PIG) from Saccharomyces cerevisiae mitochondria were expressed in Escherichia coli as inclusion bodies, solubilized, purified, and optimally reconstituted into liposomal membranes. This PIC can function as coupled antiport (P-i(-)/P-i(-) antiport and P-i(-) net transport, i.e. P-i(-)/OH- antiport) and uncoupled uniport (mercuric chloride-induced P-i(-) efflux). The basic kinetic properties of these three transport modes were analyzed. The kinetic properties closely resemble those of the reconstituted PIC from beef heart mitochondria. A competitive inhibitor of phosphate transport by the PIC, phosphonoformic acid, was used to establish functional overlap between the the physiological transport modes and the induced efflux mode. Replacement mutants were used to relate the reversible switch from antiport to uniport to a specific residue of the carrier, There are only three cysteines in the yeast PIC. They are at positions 28, 134, and 300 and were replaced by serine, both individually and in combinations, Cysteine 300 near the C-terminal loop and cysteine 134 located within the third transmembrane segment are accessible to bulky hydrophilic reagents from the cytosolic side, whereas cysteine 28 within the first transmembrane segment is not, None of the three cysteines is relevant to the two antiport modes. Cysteine 134 was identified to be the major target of bulky SH reagents, that lead to complete inactivation of the physiological transport modes, The reversible conversion between coupled antiport and uncoupled uniport of the PIC depends on the presence of one single cysteine (cysteine 28) in the PIC monomer, i.e. two cysteines in the functionally active dimer, The consequences of this result with respect to a functional model of the carrier protein are discussed.	FORSCHUNGSZENTRUM JULICH, FORSCHUNGSZENTRUM, INST BIOTECHNOL 1, D-52425 JULICH, GERMANY; HARVARD UNIV, SCH MED, BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02114 USA	Helmholtz Association; Research Center Julich; Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Wohlrab, Hartmut/0000-0002-2974-3460	NIGMS NIH HHS [GM 33357] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033357] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; DEPINTO V, 1982, FEBS LETT, V148, P103, DOI 10.1016/0014-5793(82)81252-0; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V937, P112, DOI 10.1016/0005-2736(88)90233-7; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P68; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; EELKEMA JA, 1991, J BIOL CHEM, V266, P4139; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; GUERIN B, 1990, J BIOL CHEM, V265, P19736; HERICK K, 1995, BBA-BIOMEMBRANES, V1238, P63, DOI 10.1016/0005-2736(95)00110-O; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1069, P110, DOI 10.1016/0005-2736(91)90110-T; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KEMPSON SA, 1988, NEWS PHYSIOL SCI, V3, P154; KING SC, 1990, MOL MICROBIOL, V4, P1433, DOI 10.1111/j.1365-2958.1990.tb02053.x; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; KRAMER R, 1994, BBA-BIOENERGETICS, V1185, P1, DOI 10.1016/0005-2728(94)90189-9; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LANOUE KF, 1984, BIOENERGETICS, P221; MURAKAMI H, 1993, P NATL ACAD SCI USA, V90, P3358, DOI 10.1073/pnas.90.8.3358; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; PALMIERI F, 1993, J BIOENERG BIOMEMBR, V25, P493, DOI 10.1007/BF01108406; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHELPS A, 1991, J BIOL CHEM, V266, P19882; Phelps A, 1996, BIOCHEMISTRY-US, V35, P10757, DOI 10.1021/bi961052x; PHELPS A, 1993, J BIOL CHEM, V7, P321; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; SCHWARZ M, 1994, J BIOL CHEM, V269, P29481; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; STAPPEN R, 1994, J BIOL CHEM, V269, P11240; STAPPEN R, 1994, THESIS U DUSSELDORF; TIKHONOVA IM, 1994, FEBS LETT, V337, P231, DOI 10.1016/0014-5793(94)80197-5; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; WEHRLE JP, 1989, J MEMBRANE BIOL, V111, P199, DOI 10.1007/BF01871006; WEHRLE JP, 1982, ARCH BIOCHEM BIOPHYS, V223, P477; WOHLRAB H, 1980, J BIOL CHEM, V255, P8170; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; WOHLRAB H, 1982, J BIOL CHEM, V257, P28; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	47	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10558	10564						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099701				2022-12-25	WOS:A1997WV26200035
J	Sone, M; Akiyama, Y; Ito, K				Sone, M; Akiyama, Y; Ito, K			Differential in vivo roles played by DsbA and DsbC in the formation of protein disulfide bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ALKALINE-PHOSPHATASE; SITE CYSTEINE RESIDUES; FORMATION IN-VIVO; ESCHERICHIA-COLI; PERIPLASMIC PROTEIN; FORMATION INVIVO; BETA-LACTAMASE; GENE; IDENTIFICATION; MEMBRANE	Several Escherichia coli proteins participate in protein disulfide bond formation, Among them, DsbA is the primary factor that oxidizes target cysteines. Biochemical evidence indicates that DsbC has disulfide isomerization activity, To study intracellular functions of DsbA and DsbC, we used an alkaline phosphatase mutant, PhoA[SCCC], with the most amino-terminal cysteine replaced by serine. It was found that the remaining 3 cysteines in PhoA[SCCC] form a disulfide bond of incorrect as well as correct combinations. An aberrant disulfide bond was preferentially formed in wild-type cells, which was converted slowly to the normal disulfide bond. This conversion did not occur in the dsbC-disrupted cells, Overproduction of DsbC stimulated the formation of the correct disulfide bond. In contrast, the inefficiently formed disulfide bonds in the dsbA-disrupted cells, and the more efficiently formed disulfide bonds in the same strain in the presence of oxidized glutathione were mostly in the correct form. These results suggest that the DsbA-catalyzed reaction can be too rapid for some proteins. DsbA may simply oxidize available pairs of cysteines, which happen to be in an incorrect combination in the case of PhoA[SCCC]. In contrast, DsbC stimulates the formation of correct disulfide bonds and corrects previously introduced aberrant ones. Thus, DsbC acts to isomerize disulfide bonds in vivo.	KYOTO UNIV, INST VIRUS RES, DEPT CELL BIOL, SAKYO KU, KYOTO 60601, JAPAN	Kyoto University								AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; ALKSNE LE, 1995, J BACTERIOL, V177, P462, DOI 10.1128/jb.177.2.462-464.1995; ALKSNE LE, 1996, J BACTERIOL, V173, P4306; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; CROOKE H, 1995, MOL MICROBIOL, V15, P1139, DOI 10.1111/j.1365-2958.1995.tb02287.x; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; Frech C, 1996, BIOCHEMISTRY-US, V35, P11386, DOI 10.1021/bi9608525; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller J. H., 1972, EXPT MOL GENETICS, P431; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038	34	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10349	10352						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099671				2022-12-25	WOS:A1997WV26200005
J	Parameswaran, KN; Cheng, XF; Chen, EC; Velasco, PT; Wilson, JH; Lorand, L				Parameswaran, KN; Cheng, XF; Chen, EC; Velasco, PT; Wilson, JH; Lorand, L			Hydrolysis of gamma:epsilon isopeptides by cytosolic transglutaminases and by coagulation factor XIII(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; HUMAN ERYTHROCYTE TRANSGLUTAMINASE; FIBRIN-STABILIZING FACTOR; PROTEIN CROSS-LINKING; TRANSAMIDATING ENZYMES; ALPHA-2-PLASMIN INHIBITOR; TISSUE TRANSGLUTAMINASE; PURIFICATION; PLASMA; LENS	N-epsilon (gamma-glutamyl)lysine cross-links, connecting various peptide chain segments, are frequently the major products in transglutaminase-catalyzed reactions. We have now investigated the effectiveness of these enzymes for hydrolyzing the gamma:epsilon linkage. Branched compounds were synthesized, in which the backbone on the gamma-side of the cross bridge was labeled with a fluorophor (5-(dimethylamino)-1-naphthalenesulfonyl or a-aminobenzoyl) attached through an epsilon-aminocaproyl linker in the N-terminal position, and the other branch of the bridge was constructed with Lys methylamide or diaminopentane blocked by 2,4-dinitrophenyl at the N-alpha position, Hydrolysis of the cross-link could be followed in these internally quenched substrates by an increase in fluorescence, In addition to the thrombin and Ca2+-activated human coagulation Factor XIII(a), cytosolic transglutaminases from human red cells and from guinea pig liver were tested, All three enzymes were found to display good isopeptidase activities, with K-m values of 10(-4) to 10(-5) M. Inhibitors of transamidation were effective in blocking the hydrolysis by the enzymes, indicating that expression of isopeptidase activity did not require unusual protein conformations, We suggest that transglutaminases may play a dynamic role in biology not only by promoting the formation but also the breaking of N-epsilon-(gamma-glutamyl)lysine isopeptides.	NORTHWESTERN UNIV,SCH MED,DEPT CELL & MOL BIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,CHICAGO,IL 60611	Northwestern University; Northwestern University					NEI NIH HHS [EY-03942] Funding Source: Medline; NHLBI NIH HHS [HL-02212, HL-16346] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003942] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016346, R01HL016346] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; BASKOVA I P, 1985, Biokhimiya, V50, P424; BENDER ML, 1971, MECH HOMOGENEOUS CAT, P503; BERGAMINI CM, 1993, BIOCHEM MOL BIOL INT, V30, P727; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BRENNER SC, 1978, BIOCHIM BIOPHYS ACTA, V522, P74, DOI 10.1016/0005-2744(78)90323-6; BRUNERLORAND J, 1966, BIOCHEM BIOPH RES CO, V23, P828; CHENG XF, 1996, FASEB J, V10, pA1110; CLARKE DD, 1959, ARCH BIOCHEM BIOPHYS, V79, P338, DOI 10.1016/0003-9861(59)90413-8; CROALL DE, 1986, CELL CALCIUM, V7, P29, DOI 10.1016/0143-4160(86)90028-X; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Fradkov A, 1996, FEBS LETT, V390, P145, DOI 10.1016/0014-5793(96)00644-8; FREUND KF, 1994, BIOCHEMISTRY-US, V33, P10109, DOI 10.1021/bi00199a039; ICHINOSE A, 1982, BIOCHIM BIOPHYS ACTA, V706, P158, DOI 10.1016/0167-4838(82)90482-4; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LOEWY AG, 1993, J BIOL CHEM, V268, P9071; LORAND L, 1985, BIOCHEMISTRY-US, V24, P1525, DOI 10.1021/bi00327a035; LORAND L, 1971, ANAL BIOCHEM, V44, P207, DOI 10.1016/0003-2697(71)90362-9; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1992, BIOCONJUGATE CHEM, V3, P37, DOI 10.1021/bc00013a006; LORAND L, 1963, ARCH BIOCHEM BIOPHYS, V102, P171, DOI 10.1016/0003-9861(63)90168-1; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1992, BIOCHEM BIOPH RES CO, V186, P334, DOI 10.1016/S0006-291X(05)80812-5; LORAND L, 1987, BIOCHEMISTRY-US, V26, P308, DOI 10.1021/bi00375a043; Lorand L, 1980, Prog Hemost Thromb, V5, P245; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; LORAND L, 1979, BIOCHEMISTRY-US, V18, P1756, DOI 10.1021/bi00576a019; LORAND L, 1971, ANAL BIOCHEM, V44, P221, DOI 10.1016/0003-2697(71)90363-0; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; LORAND L, 1976, HDB BIOCHEMISTRY MOL, V2, P669; MATACIC S, 1968, BIOCHEM BIOPH RES CO, V30, P356, DOI 10.1016/0006-291X(68)90750-X; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; MICANOVIC R, 1994, J BIOL CHEM, V269, P9190; MIMURO J, 1986, J CLIN INVEST, V77, P1006, DOI 10.1172/JCI112352; PARAMESWARAN KN, 1981, BIOCHEMISTRY-US, V20, P3703, DOI 10.1021/bi00516a006; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; PISANO JJ, 1969, BIOCHEMISTRY-US, V8, P871, DOI 10.1021/bi00831a016; RADEK JT, 1993, P NATL ACAD SCI USA, V90, P3152, DOI 10.1073/pnas.90.8.3152; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; STEWART JM, 1969, SOLID PHASE PEPTIDE, P62; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; WILLIAMS.HG, 1972, P NATL ACAD SCI USA, V69, P2322, DOI 10.1073/pnas.69.8.2322; ZAVALOVA L L, 1991, Biokhimiya, V56, P115	50	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10311	10317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092583				2022-12-25	WOS:A1997WU03900102
J	Yang, TT; Namba, H; Hara, T; Takmura, N; Nagayama, Y; Fukata, S; Ishikawa, N; Kuma, K; Ito, K; Yamashita, S				Yang, TT; Namba, H; Hara, T; Takmura, N; Nagayama, Y; Fukata, S; Ishikawa, N; Kuma, K; Ito, K; Yamashita, S			p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis of thyroid cells	ONCOGENE			English	Article						ionizing radiation; p53; DNA end-jointing; apoptosis; thyroid cell; thyroid carcinoma	WILD-TYPE P53; SEQUENCE SIMILARITY; ONCOGENE ACTIVATION; HIGH PREVALENCE; CYCLE CONTROL; EARLY EVENT; GENE; DEATH; BCL-2; EXPRESSION	To understand the effects of ionizing radiation on thyroid cells, we investigated the role of p53 in mediating apoptosis and in DNA repair following in vivo and in vitro irradiation of thyroid cells, In vitro exposure of human thyroid cells to ionizing radiation of up to 5-8 Gy failed to induce apoptosis in primary cells, The same results were obtained when the thyroid gland was irradiated in the intact rat, To explore the mechanism of failure of the wild-type p53 in inducing apoptosis in thyroid cells, we investigated the expression of apoptosis-related genes, bar, bcl-2 and fas/APO-1 following irradiation or induction of temperature-sensitive p53. The expression of Bar, Bcl-2 and Fas/APO-1 in human primary cultured thyroid cells did not change after irradiation, To further confirm the results, we established a clonal cell line (tsFRO) in which a temperature sensitive p53 (Val138) expression vector was stably transfected to a thyroid carcinoma cell line lacking endogenous p53, Incubation of tsFRO cells at the permissive temperature for three days, however, did not induce apoptosis although G(1) arrest was noted, Although enhanced expression of the bar mRNA level was observed, the expression of Bar, Bcl-2 and Fas/APO-1 protein did not change by shifting tsFRO cells to permissive temperature as well as irradiated primary cells, Furthermore, DNA end-jointing ability was examined by transfection of linearized luciferase plasmid into tsFRO cells, Increased luciferase activity occurred when the cells were cultured at the permissive temperature, indicating that the mild-type p53 enhances DNA end-jointing activity, Our results indicate that the wild-type p53 does not lead to apoptosis but facilitates DNA end-jointing in thyroid cells, These results may reflect specific responses in thyroid cells following irradiation.	NAGASAKI UNIV,SCH MED,INST ATOM DIS,DEPT CELL PHYSIOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PHARMACOL,NAGASAKI 852,JAPAN; ITO HOSP,TOKYO 150,JAPAN; KUMA HOSP,KOBE 650,JAPAN	Nagasaki University; Nagasaki University; Kuma Hospital			Ting-Ting, YANG/E-6009-2010; Yamashita, Shunichi/GVS-9508-2022	Ting-Ting, YANG/0000-0001-5975-8359; Yamashita, Shunichi/0000-0001-6399-6261				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARRIER F, 1994, J BIOL CHEM, V269, P32672; DEGROOT LJ, 1986, CURRENT THERAPY ENDO, P92; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; Fagin JA, 1996, CANCER RES, V56, P765; FAGIN JA, 1994, ANNU REV MED, V45, P45; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GORCZYCA W, 1992, CANCER RES, V52, P3491; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1992, CANCER RES, V52, P1369; KASTAN MB, 1991, CANCER RES, V51, P6304; KAWABE Y, 1989, J CLIN ENDOCR METAB, V68, P1174, DOI 10.1210/jcem-68-6-1174; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kitada S, 1996, ONCOGENE, V12, P187; Klugbauer S, 1995, ONCOGENE, V11, P2459; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEMOINE NR, 1989, ONCOGENE, V4, P159; LIN EY, 1993, J IMMUNOL, V151, P1979; LOWE SW, 1993, NATURE, V362, P786; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MIKIFOROV YE, 1996, ONCOGENE, V13, P687; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAGATAKI S, 1989, LANCET, V2, P385; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; NAMBA H, 1993, ENDOCRINOLOGY, V132, P839, DOI 10.1210/en.132.2.839; NAMBA H, 1995, CANCER RES, V55, P2075; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Santoro M, 1996, ONCOGENE, V12, P1821; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNEIDER AB, 1985, MEDICINE, V64, P1; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAMATO K, 1995, ONCOGENE, V11, P1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHAN QM, 1994, ONCOGENE, V9, P3743	69	73	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1511	1519		10.1038/sj.onc.1200979	http://dx.doi.org/10.1038/sj.onc.1200979			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129141				2022-12-25	WOS:A1997WQ54800001
J	Chen, WD; Otterson, GA; Lipkowitz, S; Khleif, SN; Coxon, AB; Kaye, FJ				Chen, WD; Otterson, GA; Lipkowitz, S; Khleif, SN; Coxon, AB; Kaye, FJ			Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding	ONCOGENE			English	Article						apoptosis; chemotherapy; cysteine protease; FAS; retinoblastoma protein	RETINOBLASTOMA GENE-PRODUCT; LUNG-CANCER; GROWTH SUPPRESSION; CELL-LINES; PROTEIN; IDENTIFICATION; DOMAIN; CLONING; MEMBER; FAMILY	Dephosphorylation of the RE protein has been reported to be associated with apoptosis, In contrast, we show that treatment of HL60 cells with etoposide or cytosine arabinoside or treatment of breast epithelial cells with alpha-FAS is associated with the cleavage of a 5 kDa fragment from the C-terminus of RE, resulting in a truncated product that we have designated as p100cl. This cleavage event coincides with the activation of cysteine proteases at the onset of apoptosis, is blocked by the addition of iodoacetamide to cells prior to the onset of apoptosis, and results in the expression of faster migrating protein species which can mimic dephosphorylated RE. The free 5 kDa fragment is detected only during apoptosis, predicts a cleavage site that we have mapped to a unique CPP32-like recognition sequence which is present at the C-terminus of all reported RE homologues, and results in a truncated RE protein with enhanced E2F binding affinity, While the causality for this cleavage event in the apoptotic process is still under investigation, our findings suggest distinct post-translational pathways for the RE product between cells examined during growth arrest (p105 hypophosphorylated RE) or apoptosis (p100cl).	USN,NCI,MED ONCOL BRANCH,DIV CLIN SCI,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy			CHEN, WEI-DONG/F-4521-2014; kaye, frederic/E-2437-2011	CHEN, WEI-DONG/0000-0003-2264-5515; 				BING A, 1996, CANCER RES, V56, P438; CARNEY DN, 1985, CANCER RES, V45, P2913; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAYOL X, 1993, ONCOGENE, V8, P2561; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEVINS JR, 1992, SCIENCE, V258, P424; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837	24	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1243	1248		10.1038/sj.onc.1201096	http://dx.doi.org/10.1038/sj.onc.1201096			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121775				2022-12-25	WOS:A1997WM78200015
J	Taniguchi, T; Okamoto, K; Reeve, AE				Taniguchi, T; Okamoto, K; Reeve, AE			Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour	ONCOGENE			English	Article						Wilms tumour; genomic imprinting; H19; IGF2; p57(KIP2)	GROWTH-FACTOR-II; DEPENDENT KINASE INHIBITOR; H19 GENE; MOUSE; RELAXATION; LOCUS; HETEROZYGOSITY; DELETION; DISRUPTION; CARCINOMA	Mouse p57(Kip2) arrests cells in G(1) by functioning as a strong inhibitor of several G(1) cyclin/Cdk complexes (Lee et al., 1995; Matsuoka et al., 1995; Sherr and Roberts, 1995), Human p57(K1P2) has been suggested to be a tumour suppressor gene because of its location at 11p15.5 which frequently undergoes maternal allele LOH in several types of cancer (Matsuoka et al., 1995; Sherr and Roberts, 1995; Hatada and Mukai, 1995), This suggestion was supported by the discovery that mouse p57(Kip2) is imprinted with expression from only the maternally inherited allele (Hatada and Mukai, 1995), Interestingly, p57(K1P2) is several hundred kilobases from the imprinted H19 and IGF2 genes which are involved in growth regulation (Hoovers et al., 1995), Here we show that human p57(K1P2) is imprinted with expression from the maternal allele, However, unlike the mouse, the imprinting is incomplete with significant expression from the paternal allele depending on the tissue examined, We have also shown that the imprinting of p57(K1P2) occurs independently of the H19/IGF2 domain and thus there must be at least two imprinted domains in 11p15.5. Finally, by examining Wilms tumours we have shown that following maternal 11p LOH, p57(K1P2) was expressed from the paternal allele, Therefore, p57(K1P2) cannot function as an imprinted tumour suppressor gene, at least in Wilms tumour.	UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,DUNEDIN,NEW ZEALAND	University of Otago								BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BYRNE JA, 1993, GENE CHROMOSOME CANC, V7, P1; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HOOVERS JMN, 1995, P NATL ACAD SCI USA, V92, P12346; JEN J, 1994, CANCER RES, V54, P6353; Jinno Y, 1996, HUM MOL GENET, V5, P1155, DOI 10.1093/hmg/5.8.1155; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; Orlow I, 1996, CANCER RES, V56, P1219; PAL N, 1990, ONCOGENE, V5, P1665; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reid LH, 1996, CANCER RES, V56, P1214; Saitoh S, 1996, P NATL ACAD SCI USA, V93, P7811, DOI 10.1073/pnas.93.15.7811; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	39	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1201	1206		10.1038/sj.onc.1200934	http://dx.doi.org/10.1038/sj.onc.1200934			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121769	Bronze			2022-12-25	WOS:A1997WM78200009
J	Boehlein, SK; Walworth, ES; Richards, NGJ; Schuster, SM				Boehlein, SK; Walworth, ES; Richards, NGJ; Schuster, SM			Mutagenesis and chemical rescue indicate residues involved in beta-aspartyl-AMP formation by Escherichia coli asparagine synthetase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; TRANSITION-STATE STABILIZATION; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ACTIVE-SITE; THYMIDYLATE SYNTHASE; NUCLEOTIDE-SEQUENCE; SUBSTRATE-BINDING; FUNCTIONAL ROLES; EXOGENOUS AMINES	Site-directed mutagenesis and kinetic studies have been employed to identify amino acid residues involved in aspartate binding and transition state stabilization during the formation of beta-aspartyl-AMP in the reaction mechanism of Eschen'chia coli asparasne synthetase B (AS-B). Three conserved amino acids in the segment defined by residues 317-330 appear particularly crucial for enzymatic activity. For example, when Arg-325 is replaced by alanine or lysine, the resulting mutant enzymes possess no detectable asparasne synthetase activity, The catalytic activity of the R325A AS-B mutant can, however, be restored to about 1/6 of that of wild-type AS-B by the addition of guanidinium HCl (Gdm-HCl). Detailed kinetic analysis of the rescued activity suggests that Arg-325 is involved in stabilization of a pentacovalent intermediate leading to the formation beta-aspartyl-AMP. This rescue experiment is the second example in which the function of a critical arginine residue that has been substituted by mutagenesis is restored by GdmHCl. Mutation of Thr-322 and Thr-323 also produces enzymes with altered kinetic properties, suggesting that these threonines are involved in aspartate binding and/or stabilization of intermediates en route to beta-aspartyl-AMP. These experiments are the first to identify residues outside of the N-terminal glutamine amide transfer domain that have any functional role in asparagine synthesis.	UNIV FLORIDA,ICBR,DEPT BIOCHEM & MOL BIOL,GAINESVILLE,FL 32611; UNIV FLORIDA,BIOTECHNOL PROGRAM,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT CHEM,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida					NCI NIH HHS [CA 28725] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; BATEMAN RC, 1989, J BIOL CHEM, V264, P6151; BERNT E, 1974, METHOD ENZYMAT AN, P331; BOEHLEIN SK, 1994, J BIOL CHEM, V269, P26789; BOEHLEIN SK, 1994, J BIOL CHEM, V269, P7450; Boehlein SK, 1996, BIOCHEMISTRY-US, V35, P3031, DOI 10.1021/bi952505l; BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; BROOME JD, 1968, J EXP MED, V244, P1055; CARLOW DC, 1995, BIOCHEMISTRY-US, V34, P4220, DOI 10.1021/bi00013a010; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CEDAR H, 1969, J BIOL CHEM, V244, P4112; CEDAR H, 1969, J BIOL CHEM, V244, P4122; CHAKRABARTI R, 1997, IN PRESS INT J PEDIA; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; COLMAN RF, 1990, ENZYMES, V19, P283; COONEY DA, 1976, CANCER TREAT REP, V60, P1493; DAHNKE T, 1992, BIOCHEMISTRY-US, V31, P6318, DOI 10.1021/bi00142a022; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERIANI G, 1995, J MOL EVOL, V40, P499; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FOOTE J, 1985, J BIOL CHEM, V260, P9624; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P13363, DOI 10.1021/bi961453c; GHOSH G, 1991, BIOCHEMISTRY-US, V30, P9569, DOI 10.1021/bi00104a002; GHOSH G, 1991, J BIOL CHEM, V266, P17136; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HARPEL MR, 1994, BIOCHEMISTRY-US, V33, P5553, DOI 10.1021/bi00184a026; HUMBERT R, 1980, J BACTERIOL, V142, P212, DOI 10.1128/JB.142.1.212-220.1980; LANDES C, 1995, BIOCHIMIE PARIS, V77, P1194; LEUHR CA, 1985, ARCH BIOCHEM BIOPHYS, V237, P335; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; LU Y, 1994, J BIOL CHEM, V269, P12137; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MEHLHAFF PM, 1985, BIOCHEMISTRY-US, V24, P1104, DOI 10.1021/bi00326a006; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; NAKAMURA M, 1981, NUCLEIC ACIDS RES, V9, P4669, DOI 10.1093/nar/9.18.4669; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; Parr IB, 1996, J MED CHEM, V39, P2367, DOI 10.1021/jm9601009; PERONA JJ, 1994, BIOCHEMISTRY-US, V33, P3252, DOI 10.1021/bi00177a016; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; PHILLIPS MA, 1992, PROTEIN SCI, V1, P517; REITZER LJ, 1982, J BACTERIOL, V151, P1299, DOI 10.1128/JB.151.3.1299-1313.1982; SATAR G, 1990, BIOTECHNIQUES, V8, P404; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SCOFIELD MA, 1990, J BIOL CHEM, V265, P12895; SHERMAN MA, 1990, J BIOL CHEM, V265, P10659; Stoker PW, 1996, BIOCHEMISTRY-US, V35, P3024, DOI 10.1021/bi952504t; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; VANHEEKE G, 1989, J BIOL CHEM, V264, P5503; WALKER PA, 1989, EUR J BIOCHEM, V183, P49, DOI 10.1111/j.1432-1033.1989.tb14895.x; WANG WY, 1995, J BIOL CHEM, V270, P13160, DOI 10.1074/jbc.270.22.13160; XU J, 1994, J BIOL CHEM, V269, P15553; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509	60	44	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12384	12392		10.1074/jbc.272.19.12384	http://dx.doi.org/10.1074/jbc.272.19.12384			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139684	hybrid			2022-12-25	WOS:A1997WY82900021
J	Dekker, LV; Parker, PJ				Dekker, LV; Parker, PJ			Regulated binding of the protein kinase C substrate GAP-43 to the VO/C2 region of protein kinase C-delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS INVITRO; RAT CORTICAL SYNAPTOSOMES; B-50 GAP-43; NORADRENALINE RELEASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; POLYACRYLAMIDE GELS; GROWTH-FACTOR; ANTIBODIES; SPECIFICITY	The interaction between protein kinase C-delta and its neuronal substrate, GAP-43, was studied. Two forms of protein kinase C-delta were isolated from COS cells and characterized by differences in gel mobility, GAP-43 binding, and specific GAP-43 and histone kinase activities. A slow migrating, low specific activity form of protein kinase C-delta bound directly to immobilized GAP-43. Binding was abolished in the presence of EGTA, suggesting Ca2+ dependence of the interaction. The free catalytic domain of protein kinase C-delta did not bind GAP-43, suggesting the existence of a binding site in the regulatory domain. Glutathione S-transferase-protein kinase C-delta regulatory domain fusion proteins were generated and tested for binding to GAP-43. The V0/C2-like aminoterminal domain was defined as the GAP-43-binding site. GAP-43 binding to this region is inhibited by EGTA and regulated at Ca2+ levels between 10(-7) and 10(-6) M. The interaction between protein kinase C-delta and GAP-43 was studied in intact cells by coexpression of the two proteins in human embryonic kidney cells followed by immunoprecipitation. Complex formation occurred only after treatment of the cells with the Ca2+ ionophore ionomycin, indicating that elevation of intracellular Ca2+ is required for interaction in vivo. It is concluded that protein kinase C-S interacts with GAP-43 through the V0/C2-like domain, outside the catalytic site, and that this interaction is modulated by intracellular Ca2+.			Dekker, LV (corresponding author), IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Dekker, Lodewijk/J-6934-2013; Parker, Peter j/D-5192-2013	Dekker, Lodewijk/0000-0001-5247-3297; parker, peter/0000-0002-6218-2933				AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; CAMPAGNE MV, 1992, NEUROSCIENCE, V50, P35, DOI 10.1016/0306-4522(92)90380-K; CAMPAGNE MV, 1992, NEUROSCIENCE, V51, P601, DOI 10.1016/0306-4522(92)90300-Q; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; DEKKER LV, 1990, J NEUROCHEM, V54, P1645, DOI 10.1111/j.1471-4159.1990.tb01217.x; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; Gamby C, 1996, J BIOL CHEM, V271, P10023, DOI 10.1074/jbc.271.17.10023; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; HENS JJH, 1995, J NEUROCHEM, V64, P1127; HENS JJH, 1993, J NEUROCHEM, V60, P1264, DOI 10.1111/j.1471-4159.1993.tb03286.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IVENS KJ, 1993, J NEUROCHEM, V60, P626; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; Maniatis T, 1989, DECONTAMINATION DILU; MEIRI KF, 1991, J NEUROSCI, V11, P3155; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NG SC, 1988, NEURON, V1, P133, DOI 10.1016/0896-6273(88)90197-3; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oehrlein SA, 1996, BIOCHEM J, V317, P219, DOI 10.1042/bj3170219; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; Ponting CP, 1996, PROTEIN SCI, V5, P162; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; SHEA TB, 1995, J NEUROSCI RES, V41, P347, DOI 10.1002/jnr.490410307; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	46	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12747	12753		10.1074/jbc.272.19.12747	http://dx.doi.org/10.1074/jbc.272.19.12747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139733				2022-12-25	WOS:A1997WY82900070
J	Valenzuela, SM; Martin, DK; Por, SB; Robbins, JM; Warton, K; Bootcov, MR; Schofield, PR; Campbell, TJ; Breit, SN				Valenzuela, SM; Martin, DK; Por, SB; Robbins, JM; Warton, K; Bootcov, MR; Schofield, PR; Campbell, TJ; Breit, SN			Molecular cloning and expression of a chloride ion channel of cell nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-FREE SYSTEM; PATCH-CLAMP; ANION SELECTIVITY; CONDUCTANCE; PROTEIN; MACROPHAGES; ENVELOPE; MEMBRANE	Ion channels are known to be present on the plasma membrane of virtually all cells and have been found on the membranes of various intracellular organelles. However, until recently they were believed not to occur at the nuclear membrane. In this study we describe the molecular cloning and characterization of a nuclear ion channel protein, designated nuclear chloride channel-27 (NCC27), from the human myelomonocytic cell line, U937. NCC27 is a novel chloride ion channel protein that was found to localize principally to the cell nucleus, Its only known homologue is a bovine chloride ion channel protein (p64) believed to localize to internal organelles. NCC27 therefore represents the first human member of a new class of organellar chloride ion channel proteins.	ST VINCENTS HOSP, CTR IMMUNOL, SYDNEY, NSW 2010, AUSTRALIA; UNIV NEW S WALES, SYDNEY, NSW 2010, AUSTRALIA; ST VINCENTS HOSP, DEPT CLIN PHARMACOL, SYDNEY, NSW 2010, AUSTRALIA; ST VINCENTS HOSP, DEPT CARDIOL, SYDNEY, NSW 2010, AUSTRALIA; GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA	St Vincents Hospital Sydney; University of New South Wales Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney; Garvan Institute of Medical Research			Valenzuela, Stella/R-6387-2019; Schofield, Peter/C-9669-2011	Valenzuela, Stella/0000-0001-5934-6047; Schofield, Peter/0000-0003-2967-9662; Martin, Donald/0000-0001-5913-2372; Bootcov, Michelle/0000-0001-7932-737X				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENNETT S, 1993, J IMMUNOL, V150, P2364; BENNETT S, 1992, J IMMUNOL METHODS, V153, P201, DOI 10.1016/0022-1759(92)90323-L; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; BUSTAMANTE JO, 1992, PFLUG ARCH EUR J PHY, V421, P473, DOI 10.1007/BF00370259; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EVANS MG, 1986, PFLUG ARCH EUR J PHY, V406, P65, DOI 10.1007/BF00582955; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; ISHIKAWA T, 1993, J MEMBRANE BIOL, V135, P261; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MARTIN DK, 1994, BRIT J PHARMACOL, V111, P873, DOI 10.1111/j.1476-5381.1994.tb14819.x; MARTIN DK, 1995, J MEMBRANE BIOL, V147, P305; MARTIN DK, 1990, PFLUG ARCH EUR J PHY, V417, P255, DOI 10.1007/BF00370989; MARTIN DK, 1993, BIOCHEM BIOPH RES CO, V192, P1266, DOI 10.1006/bbrc.1993.1553; MATZKE AJM, 1990, FEBS LETT, V271, P161, DOI 10.1016/0014-5793(90)80397-2; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1991, J MEMBRANE BIOL, V121, P189, DOI 10.1007/BF01870532; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PRZYWARA DA, 1991, FASEB J, V5, P217, DOI 10.1096/fasebj.5.2.2004666; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; Rousseau E, 1996, BIOPHYS J, V70, P703, DOI 10.1016/S0006-3495(96)79610-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STOCHAJ U, 1992, EUR J CELL BIOL, V59, P1; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TABARES L, 1991, J MEMBRANE BIOL, V123, P49, DOI 10.1007/BF01993962; WOTTON D, 1989, P NATL ACAD SCI USA, V86, P4195, DOI 10.1073/pnas.86.11.4195	36	167	177	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12575	12582		10.1074/jbc.272.19.12575	http://dx.doi.org/10.1074/jbc.272.19.12575			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139710	hybrid			2022-12-25	WOS:A1997WY82900047
J	Jiang, MY; Bourret, RB; Simon, MI; Volz, K				Jiang, MY; Bourret, RB; Simon, MI; Volz, K			Uncoupled phosphorylation and activation in bacterial chemotaxis - The 2.3 angstrom structure of an aspartate to lysine mutant at position 13 of CheY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOSIGNALING PROTEIN CHEY; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; RESPONSE REGULATOR; FLAGELLAR SWITCH; Y-PROTEIN; 3-DIMENSIONAL STRUCTURE; CONSERVED ASPARTATE; DEPENDENT BINDING; F-19 NMR	An aspartate to lysine mutation at position 13 of the chemotaxis regulatory protein CheY causes a constitutive tumbly phenotype when expressed at high copy number in vivo even though the mutant protein is not phosphorylatable. These properties suggest that the D13K mutant adopts the active, signaling conformation of CheY independent of phosphorylation, so knowledge of its structure could explain the activation mechanism of CheY. The x-ray crystallographic structure of the CheY D13K mutant has been solved and refined at 2.3 Angstrom resolution to an R-factor of 14.3%. The mutant molecule shows no significant differences in backbone conformation when compared with the wild-type, Mg2+-free structure, but there are localized changes within the active site. The side chain of lysine 13 blocks access to the active site, whereas its epsilon-amino group has no bonding interactions with other groups in the region. Also in the active site, the bond between lysine 109 and aspartate 57 is weakened, and the solvent structure is perturbed. Although the D13K mutant has the inactive conformation in the crystalline form, rearrangements in the active site appear to weaken the overall structure of that region, potentially creating a metastable state of the molecule. If a conformational change is required for signaling by CheY D13K, then it most likely proceeds dynamically, in solution.	UNIV ILLINOIS, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; California Institute of Technology			Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047522, R01GM039919] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19296] Funding Source: Medline; NIGMS NIH HHS [GM39919, GM47522] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; Bellsolell L, 1996, J MOL BIOL, V257, P116, DOI 10.1006/jmbi.1996.0151; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; Blat Y, 1996, J BIOL CHEM, V271, P1232, DOI 10.1074/jbc.271.2.1232; Blat Y, 1996, J BIOL CHEM, V271, P1226, DOI 10.1074/jbc.271.2.1226; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; BRUIX M, 1993, EUR J BIOCHEM, V215, P573, DOI 10.1111/j.1432-1033.1993.tb18068.x; CLEGG DO, 1984, P NATL ACAD SCI-BIOL, V81, P5056, DOI 10.1073/pnas.81.16.5056; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; GANGULI S, 1995, J BIOL CHEM, V270, P17386, DOI 10.1074/jbc.270.29.17386; HALL SR, 1988, XTAL 2 4 USERS MANUA; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, COLD SPRING HARB SYM, V53, P41, DOI 10.1101/SQB.1988.053.01.008; HESS JF, 1991, METHOD ENZYMOL, V200, P188; Hoch JA, 1995, 2 COMPONENT SIGNAL T; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KANAMARU K, 1992, J BIOCHEM-TOKYO, V111, P425, DOI 10.1093/oxfordjournals.jbchem.a123773; KAR L, 1992, BIOCHEM J, V287, P521, DOI 10.1042/bj2870521; KOEPPE RE, 1975, J MOL BIOL, V98, P155, DOI 10.1016/S0022-2836(75)80106-9; LARSEN SH, 1974, NATURE, V249, P74, DOI 10.1038/249074a0; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MOY FJ, 1994, BIOCHEMISTRY-US, V33, P10731, DOI 10.1021/bi00201a022; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SANTORO J, 1995, J MOL BIOL, V247, P717, DOI 10.1006/jmbi.1995.0175; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SHUKLA D, 1995, J BIOL CHEM, V270, P24414, DOI 10.1074/jbc.270.41.24414; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; VOLZ K, 1986, J BIOL CHEM, V261, P4723; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	56	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11850	11855		10.1074/jbc.272.18.11850	http://dx.doi.org/10.1074/jbc.272.18.11850			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115243	Green Accepted, hybrid			2022-12-25	WOS:A1997WX56900031
J	Liu, XF; Supek, F; Nelson, N; Culotta, VC				Liu, XF; Supek, F; Nelson, N; Culotta, VC			Negative control of heavy metal uptake by the Saccharomyces cerevisiae BSD2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACKING SUPEROXIDE-DISMUTASE; YEAST SECRETORY PATHWAY; ENDOPLASMIC-RETICULUM; TRANSPORT PROTEIN; ENCODES; MUTATIONS; SUPPRESS; MUTANTS; COPPER; INVIVO	We have previously shown that mutations in the Saccharomyces cerevisiae BSD2 gene suppress oxidative damage in cells lacking superoxide dismutase and also lead to hyperaccumulation of copper ions. We demonstrate here that bsd2 mutant cells additionally accumulate high levels of cadmium and cobalt. By biochemical fractionation and immunofluorescence microscopy, BSD2 exhibited localization to the endoplasmic reticulum, suggesting that BSD2 acts at a distance to inhibit metal uptake from the growth medium. This BSD2 control of ion transport occurs independently of the CTR1 and FET4 metal transport systems. Genetic suppressor analysis revealed that hyperaccumulation of copper and cadmium in bsd2 mutants is mediated through SMF1, previously shown to encode a plasma membrane transporter for manganese. A nonsense mutation removing the carboxyl-terminal hydrophobic domain of SMF1 was found to mimic a smf1 gene deletion by eliminating the copper and cadmium toxicity of bsd2 mutants and also by precluding the bsd2 suppression of superoxide dismutase deficiency. However, inactivation of SMF1 did not eliminate the elevated cobalt levels in bsd2 mutants. Instead, this cobalt accumulation was found to be specifically mediated through the SMF1 homologue, SMF2. Hence, BSD2 prevents metal hyperaccumulation by exerting negative control over the SMF1 and SMF2 metal transport systems.	JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV TOXICOL SCI, BALTIMORE, MD 21205 USA; UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; TEL AVIV UNIV, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL	Johns Hopkins University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Tel Aviv University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM050016] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 07141, ES 05794] Funding Source: Medline; NIGMS NIH HHS [GM 50016] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DIX DR, 1994, J BIOL CHEM, V269, P26092; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7; KEPES F, 1988, J BIOL CHEM, V263, P9155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; LEE KS, 1994, J BIOL CHEM, V269, P19725; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIU XF, 1992, J BIOL CHEM, V267, P18298; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rose MD., 1990, METHODS YEAST GENETI; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Strain J, 1996, MOL GEN GENET, V251, P139; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; WEST AH, 1992, J BIOL CHEM, V267, P24625; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	34	138	146	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11763	11769		10.1074/jbc.272.18.11763	http://dx.doi.org/10.1074/jbc.272.18.11763			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115231	hybrid			2022-12-25	WOS:A1997WX56900019
J	Thenot, S; Henriquet, C; Rochefort, H; Cavailles, V				Thenot, S; Henriquet, C; Rochefort, H; Cavailles, V			Differential interaction of nuclear receptors with the putative human transcriptional coactivator hTIF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HUMAN ESTROGEN-RECEPTOR; RETINOIC ACID RECEPTOR; LIGAND-BINDING DOMAIN; CONSERVED REGION; CO-REPRESSOR; DEPENDENT TRANSACTIVATION; ACTIVATION FUNCTION; CRYSTAL-STRUCTURE; CDNA CLONING	Hormonal regulation of gene activity is mediated by nuclear receptors acting as ligand-activated transcription factors. Intermediary factors interacting with their activation functions are required to mediate transcriptional stimulation. In search of such receptor interacting proteins, we have screened a human cDNA expression library and isolated a human protein that interacts in vitro with transcriptionally active estrogen receptors (ER). Sequence analysis reveals that this protein is the human homolog of mouse TIF1 (transcription intermediary factor 1) shown to enhance nuclear receptor ligand-dependent activation function 2 (AF2) in yeast. We have characterized the nuclear receptor binding site on hTIF1 and shown that a region of 26 residues is sufficient for hormone-dependent binding to the estrogen receptor. As shown by point mutagenesis, the AF2 activation domain of ER is required for the binding of hTIF1 but not sufficient, since a short region encompassing the conserved amphipathic alpha-helix corresponding to this domain fails to precipitate hTIF1. We also demonstrate that hTLF1 association with DNA-bound ER requires the presence of estradiol. Finally, we show that the interaction of hTLF1 with receptors is selective since strong in vitro hormone-dependent binding is only observed with some members of the nuclear receptor superfamily.	UNIV MONTPELLIER,F-34090 MONTPELLIER,FRANCE; INSERM,U148,F-34090 MONTPELLIER,FRANCE	Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			Cavailles, Vincent/Y-5379-2019; cavailles, vincent/C-6277-2017	Cavailles, Vincent/0000-0002-7160-3074; 				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AMERO SA, 1992, MOL ENDOCRINOL, V6, P3, DOI 10.1210/me.6.1.3; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Joyeux A, 1997, MOL ENDOCRINOL, V11, P193, DOI 10.1210/me.11.2.193; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LHorset F, 1996, MOL CELL BIOL, V16, P6029; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; ONATE SA, 1995, SCIENCE, V270, P1354; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	62	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12062	12068		10.1074/jbc.272.18.12062	http://dx.doi.org/10.1074/jbc.272.18.12062			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115274	hybrid			2022-12-25	WOS:A1997WX56900062
J	Vaandrager, AB; Edixhoven, M; Bot, AGM; Kroos, MA; Jarchau, T; Lohmann, S; Genieser, HG; deJonge, HR				Vaandrager, AB; Edixhoven, M; Bot, AGM; Kroos, MA; Jarchau, T; Lohmann, S; Genieser, HG; deJonge, HR			Endogenous type II cGMP-dependent protein kinase exists as a dimer in membranes and can be functionally distinguished from the type I isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; INTESTINAL ELECTROLYTE TRANSPORT; STABLE ENTEROTOXIN RECEPTOR; GUANYLYL CYCLASE-C; CYCLIC-GMP; CYSTIC-FIBROSIS; DIARRHEAL DISEASE; EXPRESSION; ACTIVATION; RELAXATION	In mammalian tissues two types of cGMP-dependent protein kinase (cGK) have been identified. In contrast to the dimeric cGK I, cGK II purified from pig intestine was shown previously to behave as a monomer. However, recombinant rat cGK II was found to have hydrody namic parameters indicative of a homodimer. Chemical cross-linking studies showed that pig cGK II in intestinal membranes has a dimeric structure as well. However, after purification, cGK II was found to be partly proteolyzed into C-terminal monomeric fragments. Phosphorylation studies in rat intestinal brush borders revealed that the potency of cGMP analogs to stimulate or inhibit native cGK II in vitro (i.e. 8-(4-chlorophenylthio)-cGMP > cGMP > beta-phenyl-1,N-2-etheno-8-bromoc-GMP > beta-phenyl-1,N-2-etheno-cGMP and R-p-8-(4-chlorophenylthio)-cGMPs > R-p-beta-phenyl-1,N-2-etheno-8-bromo-cGMPs, respectively) correlated well with their potency to stimulate or inhibit cGK II-mediated Cl- secretion across intestinal epithelium but differed strikingly from their potency to affect cGK I activity. These data show that the N terminus of cGK II is involved in dimerization and that endogenous cGK II displays a distinct activation/inhibition profile with respect to cGMP analogs, which permits a pharmacological dissection between cGK II- and cGK I-mediated physiological processes.	ERASMUS UNIV ROTTERDAM,FAC MED & HLTH SCI,DEPT CLIN GENET,NL-3000 DR ROTTERDAM,NETHERLANDS; MED UNIV CLIN WURZBURG,LAB CLIN BIOCHEM,D-97080 WURZBURG,GERMANY; BIOLOG LIFE SCI INST,D-28199 BREMEN,GERMANY	Erasmus University Rotterdam; University of Wurzburg	Vaandrager, AB (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,DEPT BIOCHEM,CARDIOVASC RES INST COEUR,POB 1738,NL-3000 DR ROTTERDAM,NETHERLANDS.			Vaandrager, Arie/0000-0001-9394-9239; Genieser, Hans-Gottfried/0000-0002-4904-5790				ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BRAUMANN T, 1985, J CHROMATOGR, V350, P105, DOI 10.1016/S0021-9673(01)93510-1; Butt E, 1995, BRIT J PHARMACOL, V116, P3110, DOI 10.1111/j.1476-5381.1995.tb15112.x; BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEJONGE H, 1987, EUR J BIOCHEM, V169, P503; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; FIELD M, 1989, NEW ENGL J MED, V321, P879; FIELD M, 1989, NEW ENGL J MED, V321, P800; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; HOFMANN F, 1983, EUR J BIOCHEM, V130, P599, DOI 10.1111/j.1432-1033.1983.tb07191.x; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager A B, 1994, Adv Pharmacol, V26, P253, DOI 10.1016/S1054-3589(08)60057-5; Vaandrager AB, 1997, GASTROENTEROLOGY, V112, P437, DOI 10.1053/gast.1997.v112.pm9024297; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Vaandrager AB, 1997, J BIOL CHEM, V272, P4195, DOI 10.1074/jbc.272.7.4195; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1994, J BIOL CHEM, V269, P16409; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; VANDOMMELEN FS, 1986, BIOCHEM J, V236, P771, DOI 10.1042/bj2360771; VEEZE HJ, 1991, GASTROENTEROLOGY, V101, P398, DOI 10.1016/0016-5085(91)90017-F; WALTER U, 1980, J BIOL CHEM, V255, P3757; WOLFE L, 1989, J BIOL CHEM, V264, P7734	38	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11816	11823		10.1074/jbc.272.18.11816	http://dx.doi.org/10.1074/jbc.272.18.11816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115239	Green Published, hybrid			2022-12-25	WOS:A1997WX56900027
J	Beall, AC; Kato, K; Goldenring, JR; Rasmussen, H; Brophy, CM				Beall, AC; Kato, K; Goldenring, JR; Rasmussen, H; Brophy, CM			Cyclic nucleotide-dependent vasorelaxation is associated with the phosphorylation of a small heat shock-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CONTRACTION; ALPHA-B-CRYSTALLIN; RELAXATION; KINASE; ACTIN; ELECTROPHORESIS; VASODILATION; MECHANISMS; CALCIUM; STRESS	Activation of cyclic nucleotide-dependent signaling pathways leads to the relaxation of various smooth muscles. One of the major phosphorylation events associated with cyclic nucleotide-dependent vasorelaxation in bovine trachealis and carotid artery smooth muscle is the phosphorylation of two 20-kDa phosphoproteins with pI values of 5.7 and 5.9 (previously designated pp8 and pp3, respectively). The present studies sought to determine the identities of pp3 and pp8 in vascular smooth muscle. The phosphopeptide maps for the pp8 and pp3 proteins were similar. Preparative two-dimensional gel electrophoresis and amino acid sequencing of a peptide fragment of the pp3 protein revealed a sequence identical to a 20-kDa heat shock-related protein (HSP20) previously purified from skeletal muscle. Western blot and immunoprecipitation analysis with anti-HSP20 antibodies demonstrated that the pp3 and pp8 proteins are phosphorylated forms of HSP20. In addition, HSP20 could be phosphorylated in vitro by both cAMP-dependent protein kinase and cGMP-dependent protein kinase, These data suggest that the phosphorylation of the heat shock-related protein HSP20 is associated with cyclic nucleotide-dependent relaxation of vascular smooth muscle.	MED COLL GEORGIA,INST MOL MED & GENET,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT SURG,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT MED,AUGUSTA,GA 30912; AUGUSTA VET ADM MED CTR,AUGUSTA,GA 30901; INST DEV RES,HUMAN SERV CTR,DEPT BIOCHEM,KASUGAI,AICHI 48083,JAPAN	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University					NIDDK NIH HHS [DK43405] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043405, R29DK043405] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BERGH CM, 1995, AM J PHYSIOL-HEART C, V268, pH202, DOI 10.1152/ajpheart.1995.268.1.H202; Brophy CM, 1997, J VASC SURG, V25, P390, DOI 10.1016/S0741-5214(97)70361-6; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DELANEROLLE P, 1984, SCIENCE, V223, P1415, DOI 10.1126/science.6322302; FURUKAWA KI, 1987, J BIOCHEM-TOKYO, V101, P287, DOI 10.1093/oxfordjournals.jbchem.a121904; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HAI CM, 1988, AM J PHYSIOL, V254, pC99, DOI 10.1152/ajpcell.1988.254.1.C99; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; ISHINE T, 1993, J PHARMACOL EXP THER, V266, P367; ITOH H, 1993, AM J PHYSIOL, V265, pC1319; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1994, J BIOL CHEM, V269, P15302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1987, BIOCHIM BIOPHYS ACTA, V914, P35, DOI 10.1016/0167-4838(87)90158-0; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; MCDANIEL NL, 1992, AM J PHYSIOL, V263, pC461, DOI 10.1152/ajpcell.1992.263.2.C461; MILLER JR, 1983, MOL PHARMACOL, V24, P235; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MURRAY KJ, 1990, PHARMACOL THERAPEUT, V47, P329, DOI 10.1016/0163-7258(90)90060-F; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; NISHIMURA J, 1989, BIOCHEM BIOPH RES CO, V163, P929, DOI 10.1016/0006-291X(89)92311-5; NORTH AJ, 1994, J CELL SCI, V107, P445; PARK S, 1986, J BIOL CHEM, V261, P5734; POPESCU LM, 1985, EUR J PHARMACOL, V107, P393, DOI 10.1016/0014-2999(85)90269-9; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; TAKUWA Y, 1988, MOL CELL ENDOCRINOL, V60, P71, DOI 10.1016/0303-7207(88)90121-9; TAKUWA Y, 1988, J BIOL CHEM, V263, P762; WHITNEY G, 1995, J VASC SURG, V22, P37, DOI 10.1016/S0741-5214(95)70086-2; YAMADA H, 1995, AM J PHYSIOL-GASTR L, V269, pG683, DOI 10.1152/ajpgi.1995.269.5.G683	31	126	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11283	11287						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111032				2022-12-25	WOS:A1997WW00900048
J	Hackett, RH; Wang, YD; Sweitzer, S; Feldman, G; Wood, WI; Larner, AC				Hackett, RH; Wang, YD; Sweitzer, S; Feldman, G; Wood, WI; Larner, AC			Mapping of a cytoplasmic domain of the human growth hormone receptor that regulates rates of inactivation of Jak2 and Stat proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; TYROSINE PHOSPHORYLATION; INTERFERON-GAMMA; MOTH-EATEN; PHOSPHATASE; KINASE; GENE; ERYTHROPOIETIN; IDENTIFICATION; TRANSCRIPTION	It has been previously demonstrated that growth hormone (GH)-stimulated tyrosine phosphorylation of Jak2 and Stat5a and Stat5b occurs in FDP-C1 cells expressing either the entire GH receptor or truncations of the cytoplasmic domain expressing only the membrane-proximal 80 amino acids, However, other receptor domains that might modulate rates of GH activation and inactivation of this cascade have not been examined, Here we have defined a region in the human GH receptor between amino acids 520 and 540 in the cytoplasmic domain that is required for attenuation of GH-activated Jak/Stat signaling, Immunoprecipitations with antibodies to Jak2 indicate that the protein tyrosine phosphatase SHP-1 is associated with this kinase in cells exposed to GH. To address the possibility that SHP-1 could function as a negative regulator of GH signaling, liver extracts from motheaten mice deficient in SHP-1 or unaffected littermates were analyzed for activation of Stats and Jak2, Extracts from motheaten mice displayed prolonged activation of the Stat proteins as measured by their ability to interact with DNA and prolonged tyrosine phosphorylation of Jak2. These results delineate a novel domain in the GH receptor that regulates the inactivation of the Jak/Stat pathway and appears to be modulated by SHP-1.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892; GENENTECH INC,DEPT MOL BIOL,S SAN FRANCISCO,CA 94080	US Food & Drug Administration (FDA); Roche Holding; Genentech								Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; COLOSI P, 1993, J BIOL CHEM, V268, P12617; David M, 1996, J BIOL CHEM, V271, P4585; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P1477; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	26	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11128	11132						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111009				2022-12-25	WOS:A1997WW00900025
J	Wink, DA; Cook, JA; Kim, SY; Vodovotz, Y; Pacelli, R; Krishna, MC; Russo, A; Mitchell, JB; Jourdheuil, D; Miles, AM; Grisham, MB				Wink, DA; Cook, JA; Kim, SY; Vodovotz, Y; Pacelli, R; Krishna, MC; Russo, A; Mitchell, JB; Jourdheuil, D; Miles, AM; Grisham, MB			Superoxide modulates the oxidation and nitrosation of thiols by nitric oxide-derived reactive intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PEROXYNITRITE; METALLOTHIONEIN; NITROSYLATION; INHIBITION; MECHANISM; KINETICS; CYSTEINE; CYCLASE; RELEASE	Thiol-containing proteins are key to numerous cellular processes, and their functions can be modified by thiol nitrosation or oxidation. Nitrosation reactions are quenched by O-2(radical anion), while the oxidation chemistry mediated by peroxynitrite is quenched by excess flux of either NO or O-2(radical anion). A solution of glutathione (GSH), a model thiol containing tripeptide, exclusively yielded S-nitrosoglutathione when exposed to the NO donor, Et2NN(O)NONa. However, when xanthine oxidase was added to the same mixture, the yield of S-nitrosoglutathione dramatically decreased as the activity of xanthine oxidase increased, such that there was a 95% reduction in nitrosation when the fluxes of NO and O-2(radical anion) were nearly equivalent. The presence of superoxide dismutase reversed O-2(radical anion)-mediated inhibition, while catalase had no effect. Increasing the flux of O-2(radical anion) yielded oxidized glutathione (GSSG), peaking when the flux of NO and O-2(radical anion) were approximately equivalent. The results suggest that oxidation and nitrosation of thiols by superoxide and NO are determined by their relative fluxes and may have physiological significance.	LOUISIANA STATE UNIV,MED CTR,DEPT PHYSIOL,SHREVEPORT,LA 71130; GRAMBLING STATE UNIV,DEPT CHEM,GRAMBLING,LA 71245	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Louisiana System; Grambling State University	Wink, DA (corresponding author), NCI,RADIAT BIOL BRANCH,TUMOR BIOL SECT,NIH,BLDG 10,RM B3-B69,BETHESDA,MD 20892, USA.		Pacelli, Roberto/AFS-0333-2022	Pacelli, Roberto/0000-0002-2048-7675; Jourd'heuil, David/0000-0002-6555-5061; Wink, David/0000-0002-5652-7480; Azad, Mahan/0000-0002-8633-3513				BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Cook JA, 1996, ANAL BIOCHEM, V238, P150, DOI 10.1006/abio.1996.0268; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1980, FEBS LETT, V110, P275, DOI 10.1016/0014-5793(80)80091-3; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LAVAL F, 1994, CARCINOGENESIS, V15, P443, DOI 10.1093/carcin/15.3.443; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Miles A.M., 1995, FREE RADICAL RES, V233, P379; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; Misra RR, 1996, CHEM RES TOXICOL, V9, P326, DOI 10.1021/tx950109y; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; Nims Raymond W., 1995, Methods (Orlando), V7, P48, DOI 10.1006/meth.1995.1007; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WINK DA, 1994, CARCINOGENESIS, V15, P2125, DOI 10.1093/carcin/15.10.2125; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; Wink DA, 1996, ARCH BIOCHEM BIOPHYS, V331, P241, DOI 10.1006/abbi.1996.0304	29	166	171	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11147	11151						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111012				2022-12-25	WOS:A1997WW00900028
J	Cunningham, ME; Stephens, RM; Kaplan, DR; Greene, LA				Cunningham, ME; Stephens, RM; Kaplan, DR; Greene, LA			Autophosphorylation of activation loop tyrosines regulates signaling by the TRK nerve growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; HUMAN INSULIN-RECEPTOR; KINASE DOMAIN AUTOPHOSPHORYLATION; PC12 CELLS; PROTEIN-KINASE; NEURONAL DIFFERENTIATION; BETA-SUBUNIT; PHOSPHATIDYLINOSITOL 3-KINASE; PHEOCHROMOCYTOMA CELLS; CONSERVED FEATURES	Many receptor tyrosine kinases possess an ''activation loop'' containing three similarly placed tyrosine autophosphorylation sites. To examine their roles in the TRI( NGF receptor, these residues (Tyr-670, Tyr-674, and Tyr-675) were mutated singly and in all combinations to phenylalanine and stably expressed in Trk-deficient PC12nnr5 cells. All mutant receptors showed significantly diminished nerve growth factor (NGF)-stimulated autophosphorylation, indicating impaired catalytic activity. NGF-induced neurite outgrowth exhibited dose-responsive behavior when transfectants were compared by relative receptor expression and exhibited a functional hierarchy: wild type > Y670F greater than or equal to Y674F much greater than Y675F greater than or equal to YY670/674FF = W670/675FF much greater than W674/675FF > YYY670/674/675FFF. NGF-induced tyrosine phosphorylation of She, ERKs, and SNT and immediate early gene inductions generally paralleled neurogenic potential. However, activation of phosphatidylinositol 3'-kinase and tyrosine phosphorylation of phospholipase C gamma-1 was essentially abolished. The latter effect appears due to selective inability of the mutated TRKs to autophosphorylate the tyrosine residue (Tyr-785) required for binding phospholipase C gamma-1 and indicates that the ''activation loop'' tyrosines participate in NGF-dependent changes in receptor conformation. Our findings stress the importance that expression levels play in assessing the consequences of receptor mutations and that all three activation loop tyrosines have roles regulating both overall and specific NGF-mediated signaling through TRK.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA; ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; MCGILL UNIV, MONTREAL NEUROL INST, MONTREAL, PQ H3A 2B4, CANADA	Columbia University; Columbia University; McGill University			Cunningham, Matthew/AAA-4994-2022	Cunningham, Matthew/0000-0003-3723-062X	NIGMS NIH HHS [GM07367] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARON V, 1992, J BIOL CHEM, V267, P23290; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BASU T, 1994, ONCOGENE, V9, P3483; BATISTATOU A, 1992, MOL BIOL CELL, V3, P363, DOI 10.1091/mbc.3.3.363; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1994, J CELL SCI, P121; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEENER EP, 1993, J BIOL CHEM, V268, P11256; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1984, TRENDS NEUROSCI, V7, P91, DOI 10.1016/S0166-2236(84)80164-2; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GREENE LA, 1997, CULTURING NERVE CELL; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; GUITON M, 1994, J BIOL CHEM, V269, P30370; GUITON M, 1995, BIOCHEM SOC T, V23, pS176, DOI 10.1042/bst023176s; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; Keegan K, 1993, Curr Opin Neurobiol, V3, P14, DOI 10.1016/0959-4388(93)90029-X; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KING MJ, 1991, BIOCHEM J, V275, P413, DOI 10.1042/bj2750413; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOMADA M, 1994, J BIOL CHEM, V269, P16131; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LI SW, 1994, J BIOL CHEM, V269, P32558; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOEB DM, 1993, J NEUROSCI, V13, P2919; LONGATI P, 1994, ONCOGENE, V9, P49; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCDONALD NQ, 1995, STRUCTURE, V3, P1, DOI 10.1016/S0969-2126(01)00129-0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Obermeier A, 1995, ANN NY ACAD SCI, V766, P1, DOI 10.1111/j.1749-6632.1995.tb26643.x; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Peng X, 1996, J NEUROCHEM, V66, P1191; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TAVARE JM, 1991, BIOCHEM J, V274, P173, DOI 10.1042/bj2740173; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSAO H, 1990, J BIOL CHEM, V265, P15471; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YU KT, 1984, J BIOL CHEM, V259, P5277; ZHANG B, 1991, J BIOL CHEM, V266, P990	91	118	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10957	10967						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099755				2022-12-25	WOS:A1997WV26200089
J	Koyota, S; Wimalasiri, KMS; Hoshi, M				Koyota, S; Wimalasiri, KMS; Hoshi, M			Structure of the main saccharide chain in the acrosome reaction-inducing substance of the starfish, Asterias amurensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; OLIGOSACCHARIDES; SPERMATOZOA; DESULFATION; MOLECULES	The structure of the main saccharide chain of the acrosome reaction-inducing substance in the egg jelly coat of the starfish, Asterias amurensis, is composed of the following pentasaccharide repeating units (Structure I), A polymer consisting of 10-11 repeating units has been observed to induce the acrosome reaction in starfish sperm at high calcium concentrations. GRAPHICS STRUCTURE I The identities and linkage positions of constituent sugars were established using sugar, methylation, and sulfate analyses together with one- and two-dimensional nmr spectroscopy, The structure was supported by the data obtained for desulfation products and the Smith degradation of the polysaccharide.	TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology								ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; HARRIS PJ, 1984, CARBOHYD RES, V127, P59, DOI 10.1016/0008-6215(84)85106-X; HEY GW, 1965, METHODS CARBOHYDR CH, V5, P377; HOSHI M, 1994, INT J DEV BIOL, V38, P167; IKADAI H, 1981, DEV GROWTH DIFFER, V23, P73; IKADAI H, 1981, DEV GROWTH DIFFER, V23, P81; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; ISHIHARA K, 1970, DEV GROWTH DIFFER, V12, P179; KELLER SH, 1994, DEV BIOL, V162, P304, DOI 10.1006/dbio.1994.1087; MATSUI T, 1986, DEV GROWTH DIFFER, V28, P339; MULLOY B, 1994, J BIOL CHEM, V269, P22113; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Nishigaki T, 1996, ZYGOTE, V4, P237, DOI 10.1017/S0967199400003154; NISHIYAMA I, 1987, DEV GROWTH DIFFER, V29, P171; OKINAGA T, 1992, BIOCHEM BIOPH RES CO, V188, P405; PARK JT, 1949, J BIOL CHEM, V181, P149; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; TERHO TT, 1971, ANAL BIOCHEM, V41, P471, DOI 10.1016/0003-2697(71)90167-9; Ushiyama A, 1995, ZYGOTE, V3, P351, DOI 10.1017/S0967199400002781; YAMAGUCHI M, 1989, DEV GROWTH DIFFER, V31, P233	23	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10372	10376						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099675				2022-12-25	WOS:A1997WV26200009
J	vanPuijenbroek, AAFL; vanWeering, DHJ; vandenBrink, CE; Bos, JL; vanderSaag, PT; deLaat, SW; denHertog, J				vanPuijenbroek, AAFL; vanWeering, DHJ; vandenBrink, CE; Bos, JL; vanderSaag, PT; deLaat, SW; denHertog, J			Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation	ONCOGENE			English	Article						Ret; ERK2; signal transduction; transcription; cell scattering; growth inhibition	NEURO-BLASTOMA CELLS; TRANSFORMING GENE; NEUROBLASTOMA-CELLS; RET/PTC ONCOGENE; PROTOONCOGENE; PROTEIN; EXPRESSION; MUTATIONS; GROWTH; SPECIFICITY	The c-ret proto-oncogene encodes a receptor tyrosine kinase which plays an important role in kidney and enteric nervous system development. Germline mutations in c-ret are responsible for the dominantly inherited cancer syndromes, multiple endocrine neoplasia types 2A and 2B and familial medullary thyroid carcinoma as well as the developmental disorder Hirschsprung's disease. Using SK-N-MC neuroepithelioma cells stably transfected with an EGFR/Ret chimeric receptor, we have studied cellular consequences and signalling events following activation of exogenous EGFR/Ret and endogenous FGF and PDGF receptor tyrosine kinases in cells of neuroectodermal origin. Here we report that Ret activation led to cell scattering, growth inhibition and loss of anchorage-independent growth. Basic FGF, but not PDGF, evoked similar responses in those cells. Nevertheless, activation of all three receptor tyrosine kinases led to ERK2 activation. Analysis of the kinetics of ERK2 activation and downstream events revealed that Ret and FGF receptor activation led to sustained ERK2 activation and SRE transactivation, while PDGF treatment led to transient ERK2 activation and failed to induce SRE transactivation. Our results suggest that sustained, but not transient ERK2 activation may be involved in cell scattering.	UNIV UTRECHT,PHYSIOL CHEM LAB,NL-3508 TA UTRECHT,NETHERLANDS	Utrecht University	vanPuijenbroek, AAFL (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,NL-3584 CT UTRECHT,NETHERLANDS.							ASAI N, 1995, MOL CELL BIOL, V15, P1613; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CALIFANO D, 1995, ONCOGENE, V11, P107; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARONE V, 1989, CANCER RES, V49, P219; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DEHNER LP, 1986, ARCH PATHOL LAB MED, V110, P997; Duband JL, 1995, ACTA ANAT, V154, P63; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MYERS SM, 1995, ONCOGENE, V11, P2039; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROMANO A, 1994, ONCOGENE, V9, P2923; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSS RA, 1983, J NATL CANCER I, V71, P741; SACHS A, 1996, J CELL BIOL, V133, P1095; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanWeering DHJ, 1995, ONCOGENE, V11, P2207	59	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1147	1157		10.1038/sj.onc.1200911	http://dx.doi.org/10.1038/sj.onc.1200911			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121763				2022-12-25	WOS:A1997WM78200003
J	Lougheed, M; Lum, CM; Ling, WH; Suzuki, H; Kodama, T; Steinbrecher, U				Lougheed, M; Lum, CM; Ling, WH; Suzuki, H; Kodama, T; Steinbrecher, U			High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; NONENZYMATICALLY GLYCOSYLATED PROTEINS; HERITABLE HYPERLIPIDEMIC RABBIT; HUMAN MONOCYTE MACROPHAGES; ALDEHYDE-MODIFIED PROTEINS; OXIDATIVELY MODIFIED LDL; CORONARY HEART-DISEASE; VITAMIN-E CONSUMPTION; HAMSTER OVARY CELLS; ENDOTHELIAL-CELLS	Oxidation of low density lipoproteins (LDL) has been implicated as a causal factor in the pathogenesis of atherosclerosis. Oxidized LDL has been found to exhibit numerous potentially atherogenic properties in vitro, including receptor mediated uptake by macrophages. Oxidized LDL is a ligand for the class A scavenger receptor type I/II (SR-AI/II), but cross-competition studies with cultured macrophages suggested that there is an additional receptor(s) that is specific for oxidized LDL and that does not interact with acetyl LDL or other chemically modified LDL. A number of macrophage membrane proteins, including CD36, Fc gamma RII-B2, scavenger receptor BI, and macrosialin/CD68, have been found to bind to oxidized LDL in vitro and have been proposed as candidate oxidized LDL receptors, However, because of overlapping ligand specificity with the SR-AI/II, it has been difficult to evaluate the relative importance of these proteins in the uptake of oxidized LDL by macrophages, In the present report, we have studied the uptake and degradation of oxidized LDL by macrophages from mice in which the SR-AI/II gene had been disrupted, The uptake of acetyl LDL was reduced by more than 80% in macrophages from scavenger receptor knockout mice, confirming that most of the uptake of acetyl LDL by macrophages can be attributed to this receptor, In contrast, the uptake of extensively oxidized LDL was reduced by only 30% and showed high affinity, saturable uptake with apparent K-m of about 5 mu g/ml, similar to that of the SR-AI/II, This indicates that about 70% of the uptake of oxidized LDL in macrophages is attributable to an alternate oxidized LDL receptor(s), In contrast to findings reported with CD36, mildly oxidized LDL was internalized much more slowly than extensively oxidized LDL, Unlabeled oxidized LDL, polyinosinic acid, phosphatidylserine-rich liposomes, and LDL or bovine albumin modified by fatty acid oxidation products were effective competitors for the uptake of radioiodinated oxidized LDL by macrophages from knockout mice, whereas acetyl LDL and malondialdehyde-modified LDL were relatively poor competitors, This ligand specificity differs from that of CD36-related (class B) scavenger receptors but is similar to the reported specificity of macrosialin/CD68 in ligand blots, However, the rate of uptake of oxidized LDL by knockout macrophages was not increased by phorbol ester or in thioglycollate-elicited macrophages, both of which are expected to increase the amount of macrosialin on the cell surface, In macrophages from SR-AI/II knockout mice, ligand blots of membrane proteins with iodinated, oxidized, or acetylated LDL revealed several bands, with apparent molecular size on SDS-polyacrylamide gel electrophoresis of 60, 94, 124, and 210 kDa, but none of the bands were specific for oxidized LDL, These results provide direct evidence that a receptor other than SR-AI/II is responsible for most of the uptake of oxidized LDL in murine macrophages, but further studies are needed to identify the receptor(s) involved.	UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 4E3,CANADA; UNIV TOKYO,ADV SCI & TECHNOL RES CTR,DEPT MOL BIOL & MED,TOKYO 153,JAPAN	University of British Columbia; University of Tokyo								Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; ARDLIE NG, 1989, ATHEROSCLEROSIS, V76, P117, DOI 10.1016/0021-9150(89)90094-4; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DERIJKE YB, 1994, J BIOL CHEM, V269, P824; DOI T, 1993, J BIOL CHEM, V268, P2126; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; EMI M, 1993, J BIOL CHEM, V268, P212; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FOX PL, 1987, J BIOL CHEM, V262, P6046; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; FROSTEGARD J, 1991, ATHEROSCLEROSIS, V90, P119, DOI 10.1016/0021-9150(91)90106-D; FROSTEGARD J, 1992, ARTERIOSCLER THROMB, V12, P461, DOI 10.1161/01.ATV.12.4.461; FUKASAWA M, 1995, J BIOL CHEM, V270, P1921, DOI 10.1074/jbc.270.4.1921; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; Gey K. Fred, 1993, American Journal of Clinical Nutrition, V57, p787S, DOI 10.1093/ajcn/57.5.787S; GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S; HABERLAND M, 1988, SCIENCE, V24, P215; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HABERLAND ME, 1986, J CLIN INVEST, V77, P681, DOI 10.1172/JCI112362; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HOPPE G, 1994, J CLIN INVEST, V94, P1506, DOI 10.1172/JCI117490; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; KAMPS JAAM, 1992, ARTERIOSCLER THROMB, V12, P1079, DOI 10.1161/01.ATV.12.9.1079; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Lougheed M, 1996, J BIOL CHEM, V271, P11798, DOI 10.1074/jbc.271.20.11798; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRIS DL, 1994, JAMA-J AM MED ASSOC, V272, P1439, DOI 10.1001/jama.272.18.1439; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STREET DA, 1994, CIRCULATION, V90, P1154, DOI 10.1161/01.CIR.90.3.1154; SUZUKI H, 1996, IN PRESS NATURE; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V984, P273, DOI 10.1016/0005-2736(89)90293-9; TAKATA K, 1988, J BIOL CHEM, V263, P14819; TANGIRALA RK, 1995, ARTERIOSCL THROM VAS, V15, P1625, DOI 10.1161/01.ATV.15.10.1625; UEDA Y, 1993, ATHEROSCLEROSIS, V101, P25, DOI 10.1016/0021-9150(93)90098-F; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VLASSARA H, 1989, J CLIN INVEST, V84, P1813, DOI 10.1172/JCI114366; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG HF, 1993, J BIOL CHEM, V268, P5535	84	111	119	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12938	12944		10.1074/jbc.272.20.12938	http://dx.doi.org/10.1074/jbc.272.20.12938			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148899	hybrid			2022-12-25	WOS:A1997WZ38400012
J	Horne, MC; Donaldson, KL; Goolsby, GL; Tran, D; Mulheisen, M; Hell, JW; Wahl, AF				Horne, MC; Donaldson, KL; Goolsby, GL; Tran, D; Mulheisen, M; Hell, JW; Wahl, AF			Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE LYMPHOCYTES-B; LYMPHOMA-CELLS; TGF-BETA; NEGATIVE SELECTION; DEPENDENT KINASES; TRANSGENIC MICE; CDK INHIBITORS; PROTEIN-KINASE; CROSS-LINKING; ACTIVATION	Human cyclin G2 together with its closest homolog cyclin G1 defines a novel family of cyclins (Horne, M. C., Goolsby, G. L., Donaldson, K. L., Tran, D., Neubauer, M., and Wahl, A. F. (1996) J. Biol. Chem. 271, 6050-6061), Cyclin G2 is highly expressed in the immune system where immunologic tolerance subjects self-reactive lymphocytes to negative selection and clonal deletion via apoptosis. Here we investigated the effect of growth inhibitory signals on cyclin G2 mRNA abundance in different maturation stage-specific murine B cell lines. Upon treatment of wild type and p53 null B cell lines with the negative growth factor, transforming growth factor beta 1, or the growth inhibitory corticosteroid dexamethasone, cyclin G2 mRNA levels were increased in a time-dependent manner 5-14-fold over control cell levels. Unstimulated immature B cell lines (WEHI-231 and CH31) and unstimulated or IgM B cell receptor (BCR)-stimulated mature B cell lines (BAL-17 and CH12) rapidly proliferate and express low levels of cyclin G2 mRNA. In contrast, BCR-stimulated immature B cell lines undergo growth arrest and coincidentally exhibit an similar to 10-fold increase in cyclin G2 transcripts and a decrease in cyclin D2 message. Costimulation of WEHI-231 and CH31 cells with calcium ionophores and protein kinase C agonists partially mimics anti-IgM stimulation and elicits a strong up-regulation of cyclin G2 mRNA and down-regulation of cyclin D2 mRNA. Signaling mutants of WEHI-231 that are deficient in the phosphoinositide signaling pathway and consequently resistant to the BCR stimulus-induced growth arrest did not display a significant increase in cyclin G2 or decrease in cyclin D2 mRNAs when challenged with anti-IgM antibodies, The two polyclonal activators lipopolysaccharide and soluble gp39, which inhibit the growth arrest response of immature B cells, suppressed cyclin G2 mRNA expression induced by BCR stimulation. These results suggest that in murine B cells responding to growth inhibitory stimuli cyclin G2 may be a key negative regulator of cell cycle progression.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb	Horne, MC (corresponding author), UNIV WISCONSIN,DEPT PHARMACOL,3770 MSC,1300 UNIV AVE,MADISON,WI 53706, USA.		Hell, Johannes W./P-5085-2019	Horne, Mary/0000-0002-2799-3212				ANDO K, 1995, ONCOGENE, V10, P751; BAXTER JD, 1975, TRANSPLANT P, V7, P55; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BOYD AW, 1981, J IMMUNOL, V126, P2466; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; CROSS D, 1990, J IMMUNOL, V144, P432; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; DEFRANCO AL, 1987, IMMUNOL REV, V95, P161, DOI 10.1111/j.1600-065X.1987.tb00504.x; DEFRANCO AL, 1982, B T CELL TUMORS BIOL, P445; DENNIS G, 1987, J IMMUNOL, V139, P2516; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; Geng Y, 1996, ONCOGENE, V12, P1173; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLD MR, 1991, INT IMMUNOL, V3, P1091, DOI 10.1093/intimm/3.11.1091; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hunt T, 1991, Semin Cell Biol, V2, P213; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; ISHIDA T, 1995, J IMMUNOL, V155, P5527; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JAKWAY JP, 1986, J IMMUNOL, V137, P2225; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JOSEPH LF, 1995, CELL GROWTH DIFFER, V6, P51; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KASTAN MB, 1991, CANCER RES, V51, P6304; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KIENER PA, 1995, J IMMUNOL, V155, P4917; KIM KJ, 1979, J IMMUNOL, V122, P549; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KU G, 1986, J IMMUNOL, V137, P2802; LANIER LL, 1981, J IMMUNOL, V126, P626; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOMO J, 1995, J IMMUNOL, V154, P1634; MacDonald I, 1996, BLOOD, V87, P1147, DOI 10.1182/blood.V87.3.1147.bloodjournal8731147; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MERINO R, 1995, J IMMUNOL, V155, P3830; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; MONROE JG, 1985, J IMMUNOL, V135, P1674; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morita N, 1996, J NEUROSCI, V16, P5961; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NOSSAL GJV, 1980, P NATL ACAD SCI-BIOL, V77, P1602, DOI 10.1073/pnas.77.3.1602; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; NUGENT JHA, 1991, J CELL SCI, V99, P669; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PAGE DM, 1990, MOL CELL BIOL, V10, P3003, DOI 10.1128/MCB.10.6.3003; PAGE DM, 1991, J BIOL CHEM, V266, P5563; PAGE DM, 1988, J IMMUNOL, V140, P3717; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rickert P, 1996, ONCOGENE, V12, P2631; ROTHSTEIN TL, 1985, CELL IMMUNOL, V102, P364; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SCOTT DW, 1993, ADV IMMUNOL, V54, P393, DOI 10.1016/S0065-2776(08)60539-8; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; SEROZ T, 1995, CURR OPIN GENET DEV, V5, P217, DOI 10.1016/0959-437X(95)80011-5; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; TAMURA K, 1993, ONCOGENE, V8, P2113; Tanguay DA, 1996, J IMMUNOL, V156, P539; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; XIE HJ, 1995, J IMMUNOL, V154, P1717; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	98	107	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12650	12661		10.1074/jbc.272.19.12650	http://dx.doi.org/10.1074/jbc.272.19.12650			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139721	hybrid			2022-12-25	WOS:A1997WY82900058
J	Carty, MD; Lillquist, JS; Peshavaria, M; Stein, R; Soeller, WC				Carty, MD; Lillquist, JS; Peshavaria, M; Stein, R; Soeller, WC			Identification of cis- and trans-active factors regulating human islet amyloid polypeptide gene expression in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT PANCREAS; INSULIN GENE; TRANSCRIPTION FACTOR; HOMEODOMAIN PROTEIN; CONTROL REGION; AMYLIN; GLUCOSE; EFFICIENCY; RESPONSES; SEQUENCES	Islet amyloid polypeptide is expressed almost exclusively in pancreatic beta- and delta-cells. Here we report that beta cell-specific expression of the human islet amyloid polypeptide gene is principally regulated by promoter proximal sequences, The sequences that control tissue-specific expression were mapped between nucleotides -2798 and +450 of the human islet amyloid polypeptide (IAPP) gene using transgenic mice. To localize the cis-acting elements involved in this response, we examined the effects of mutations within these sequences using transfected islet amyloid polypeptide promoter expression constructs in pancreatic beta cell lines. The sequences between -222 and +450 bp were found to be necessary for beta cell-specific expression, Linker-scanning mutations of the 5'-promoter proximal region defined several key distinct control elements, including a negative-acting element at -111/-102 base pairs (bp), positive-acting elements like the basic helix-loop-helix-like binding site at -138/-131 bp, and the three A/T-rich, homeobox-like sites at -172/-163, -154/-142, and -91/-84 bp, Mutations within any one of these elements eliminated transcriptional expression by the promoter, Gel mobility shift assays revealed that the PDX-1 homeobox factor, which is required for insulin gene transcription in beta cells, interacted specifically at the -154/-142- and -91/ -84-bp sites, Since PDX-1 is highly enriched in beta and delta cells, these results suggest that this factor plays a principal role in defining islet beta cell- and delta cell-specific expression of the IAPP gene.	PFIZER INC, DIV CENT RES, DEPT MOL SCI, GROTON, CT 06340 USA; VANDERBILT UNIV, MED CTR, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA	Pfizer; Vanderbilt University					NIDDK NIH HHS [P60 DK20593, DK R01-50203] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK050203] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASH J, 1993, MOL CELL BIOL, V13, P1565, DOI 10.1128/MCB.13.3.1565; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BrethertonWatt D, 1996, BIOCHEM J, V313, P495, DOI 10.1042/bj3130495; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Couce M, 1996, J CLIN ENDOCR METAB, V81, P1267, DOI 10.1210/jc.81.3.1267; DEGANO P, 1993, REGUL PEPTIDES, V43, P91, DOI 10.1016/0167-0115(93)90411-Z; EFRAT S, 1991, J BIOL CHEM, V266, P11141; FEHMANN HC, 1990, FEBS LETT, V262, P279, DOI 10.1016/0014-5793(90)80210-A; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GUSTIN KE, 1993, BIOTECHNIQUES, V14, P22; GUZ Y, 1995, DEVELOPMENT, V121, P11; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KINGSTON RE, 1992, CURRENT PROTOCOLS MO, V1, P1; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUEHRSEN KR, 1991, MOL GEN GENET, V225, P81, DOI 10.1007/BF00282645; MOSSELMAN S, 1989, FEBS LETT, V247, P154, DOI 10.1016/0014-5793(89)81260-8; MOSSELMAN S, 1990, FEBS LETT, V271, P33, DOI 10.1016/0014-5793(90)80365-P; MULDER H, 1993, CELL TISSUE RES, V274, P467, DOI 10.1007/BF00314543; NAGAMATSU S, 1991, J BIOL CHEM, V266, P13737; OBRIEN T, 1995, AM J PATHOL, V147, P609; OBRIEN TD, 1993, LESSONS ANIMAL DIABE, V4, P117; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SILVESTRE RA, 1990, REGUL PEPTIDES, V31, P23, DOI 10.1016/0167-0115(90)90192-Y; STEIN R, 1993, TRENDS ENDOCRIN MET, V4, P96, DOI 10.1016/1043-2760(93)90086-T; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; Wang M, 1996, MOL ENDOCRINOL, V10, P243, DOI 10.1210/me.10.3.243; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; YOUNG AA, 1992, AM J PHYSIOL, V263, pE274, DOI 10.1152/ajpendo.1992.263.2.E274; ZAIDI M, 1991, VITAM HORM, V46, P87	43	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11986	11993		10.1074/jbc.272.18.11986	http://dx.doi.org/10.1074/jbc.272.18.11986			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115263	hybrid			2022-12-25	WOS:A1997WX56900051
J	Chitambar, CR; Wereley, JP				Chitambar, CR; Wereley, JP			Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; TRANSFERRIN RECEPTOR EXPRESSION; RESPONSIVE ELEMENT; MESSENGER-RNA; RIBONUCLEOTIDE REDUCTASE; CELLULAR PROLIFERATION; CONTINUOUS INFUSION; OXIDATIVE STRESS; INDUCTION; GA-67	The mechanism of drug resistance to gallium nitrate is not known. Since gallium can be incorporated into ferritin, an iron storage protein that protects cells from iron toxicity, we investigated whether ferritin expression was altered in gallium-resistant (R) CCRF-CEM cells. We found that the ferritin content of R cells was decreased, while heavy chain ferritin mRNA levels and iron regulatory protein-1 (IRP-1) RNA binding activity were increased. IRP-1 protein levels were similar in gallium-sensitive (S) and R cells, indicating that R cells contain a greater proportion of IRP-1 in a high affinity mRNA binding state. Fe-59 uptake and transferrin receptor expression were decreased in R cells. In both S and R cells, gallium inhibited cellular Fe-59 uptake, increased ferritin mRNA and protein, and decreased IRP-1 binding activity. Gallium uptake by R cells was markedly diminished; however, the sensitivity of R cells to gallium could be restored by increasing their uptake of gallium with excess transferrin. Our results suggest that R cells have developed resistance to gallium by down-regulating their uptake of gallium. In parallel, iron uptake by R cells is also decreased, leading to changes in iron homeostasis. Furthermore, since gallium has divergent effects on iron uptake and ferritin synthesis, its action may also include a direct effect on ferritin mRNA induction and IRP-1 activity.			Chitambar, CR (corresponding author), MED COLL WISCONSIN,DEPT MED,DIV HEMATOL ONCOL,9200 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.				NATIONAL CANCER INSTITUTE [R01CA068028] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA68028] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES GW, 1973, J BIOL CHEM, V248, P3228; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CHITAMBAR CR, 1986, J CLIN INVEST, V78, P1538, DOI 10.1172/JCI112746; CHITAMBAR CR, 1987, CANCER RES, V47, P3929; CHITAMBAR CR, 1983, J CLIN INVEST, V72, P1314, DOI 10.1172/JCI111087; CHITAMBAR CR, 1988, BLOOD, V72, P1930; CHITAMBAR CR, 1991, CANCER RES, V51, P6199; Chitambar CR, 1996, CLIN CANCER RES, V2, P1009; CHITAMBAR CR, 1992, BLOOD, V80, P505; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLEY AH, 1991, ANGEW CHEM INT EDIT, V30, P1143, DOI 10.1002/anie.199111431; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; FAHMY M, 1993, BIOCHEM J, V296, P175, DOI 10.1042/bj2960175; FOSTER BJ, 1986, CANCER TREAT REP, V70, P1311; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HARRIS WR, 1983, BIOCHEMISTRY-US, V22, P292, DOI 10.1021/bi00271a010; Harrison P. M., 1990, IRON TRANSPORT STORA, P81; HEGGE FN, 1977, J NUCL MED, V18, P937; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KELLER J, 1986, CANCER TREAT REP, V70, P1221; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON SM, 1980, JNCI-J NATL CANCER I, V64, P41; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; MASCOTTI DP, 1995, ANNU REV NUTR, V15, P239, DOI 10.1146/annurev.nu.15.070195.001323; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; RICHARDSON DR, 1995, BLOOD, V86, P3211; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIDMAN AD, 1991, CANCER, V68, P2561, DOI 10.1002/1097-0142(19911215)68:12<2561::AID-CNCR2820681205>3.0.CO;2-G; TANG CK, 1992, J BIOL CHEM, V267, P24466; THEIL EC, 1994, BIOCHEM J, V304, P1; TOTH I, 1995, J BIOL CHEM, V270, P19540, DOI 10.1074/jbc.270.33.19540; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; WARRELL RP, 1983, CANCER, V51, P1982, DOI 10.1002/1097-0142(19830601)51:11<1982::AID-CNCR2820511104>3.0.CO;2-L; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7	46	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12151	12157		10.1074/jbc.272.18.12151	http://dx.doi.org/10.1074/jbc.272.18.12151			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115286	hybrid			2022-12-25	WOS:A1997WX56900074
J	Gong, XQ; Gong, WH; Kuhns, DB; BenBaruch, A; Howard, OMZ; Wang, JM				Gong, XQ; Gong, WH; Kuhns, DB; BenBaruch, A; Howard, OMZ; Wang, JM			Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE LEUKOCYTE RECEPTORS; MOLECULAR-CLONING; CHEMOKINE; EXPRESSION; RANTES; IDENTIFICATION; INTERLEUKIN-8; TRANSDUCTION; MIGRATION; CYTOKINES	Monocyte chemotactic protein (MCP)-2 is a member of the C-C chemokine subfamily, which shares more than 60% sequence homology with MCP-1 and MCP-8 and about 30% homology with macrophage inflammatory protein (MIP)-1 alpha, regulated on activation of normal T cell expressed (RANTES), and MIP-1 beta. Despite this considerable sequence homology to other C-C chemokines, MCP-2 appears to have unique functional properties in comparison with other C-C chemokines such as MCP-1 and MCP-3. Although evidence obtained from studies on leukocytes suggested that MCP-2 may share the receptors with these C-C chemokines, the actual functional receptors for MCP-2 have not yet been identified. In this study, by using radioiodinated MCP-2, we identified high affinity binding sites for MCP-2 on human peripheral blood monocytes. The MCP-2 binding was competed for by MCP-1 and MCP-3, but less well by MIP-1 alpha or RANTES. In experiments using cells transfected with C-C chemokine receptors, I-125-MCP-2 bound to human embryonic kidney 293 cells transfected with CCR1 or CCR2B, known to also bind MIP-1 alpha/RANTES and MCP-1, respectively, but both shared by MCP-3. The binding of I-125-MCP-2 to these receptor-transfected cells was displaced completely by chemokines that bind to these receptors. Both CCR1- and CCR2B-transfected 293 cells showed significant migration in response to MCP-2, in addition to responding to other specific chemokines. These results clearly demonstrate that MCP-2, unlike MCP-1, uses both CCR1 as well as CCR2B as its functional receptors, and this accounts for the unique activities of MCP-2.	NCI,IRSP,SAIC FREDERICK,FCRDC,FREDERICK,MD 21702; NCI,CLIN IMMUNOL SERV,SAIC FREDERICK,FCRDC,FREDERICK,MD 21702; NCI,MOL IMMUNOREGULAT LAB,DIV BASIC SCI,FCRDC,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052				ALAM R, 1994, J IMMUNOL, V153, P3155; ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bates P, 1996, CELL, V86, P1, DOI 10.1016/S0092-8674(00)80070-7; BenBaruch A, 1997, CYTOKINE, V9, P37, DOI 10.1006/cyto.1996.0133; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COLOTTA F, 1985, J IMMUNOL, V134, P3524; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DECOCK B, 1990, BIOCHEM BIOPH RES CO, V167, P904, DOI 10.1016/0006-291X(90)90609-Q; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Proost P, 1996, J LEUKOCYTE BIOL, V59, P67, DOI 10.1002/jlb.59.1.67; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; SOZZANI S, 1994, J IMMUNOL, V152, P3615; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; WEBER M, 1995, J IMMUNOL, V154, P4166; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365	26	111	118	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11682	11685		10.1074/jbc.272.18.11682	http://dx.doi.org/10.1074/jbc.272.18.11682			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115216	hybrid			2022-12-25	WOS:A1997WX56900004
J	Streeper, RS; Svitek, CA; Chapman, S; Greenbaum, LE; Taub, R; OBrien, RM				Streeper, RS; Svitek, CA; Chapman, S; Greenbaum, LE; Taub, R; OBrien, RM			A multicomponent insulin response sequence mediates a strong repression of mouse glucose-6-phosphatase gene transcription by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; FACTOR-BINDING PROTEIN-1; TRANSGENIC MICE; PEPCK GENE; EXPRESSION; PROMOTER; GLUCOSE; ELEMENT; NIDDM; LIVER	Glucose-6-phosphatase (G6Pase) catalyzes the final step in the gluconeogenic and glycogenolytic pathways. The transcription of the gene encoding the catalytic subunit of G6Pase is stimulated by glucocorticoids, whereas insulin strongly inhibits both basal G6Pase gene transcription and the stimulatory effect of glucocorticoids. To identify the insulin response sequence (IRS) in the G6Pase promoter through which insulin mediates its action, we have analyzed the effect of insulin on the basal expression of mouse G6Pase-chloramphenicol acetyltransferase (CAT) fusion genes transiently expressed in hepatoma cells. Deletion of the G6Pase promoter sequence between -271 and -199 partially reduces the inhibitory effect of insulin, whereas deletion of additional sequence between -198 and -159 completely abolishes the insulin response. The presence of this multicomponent IRS may explain why insulin potently inhibits basal G6Pase-CAT expression. The G6Pase promoter region between -198 and -159 contains an IRS, since it can confer an inhibitory effect of insulin on the expression of a heterologous fusion gene. This region contains three copies of the T(G/A)TTTTG sequence, which is the core motif of the phosphoenolpyruvate carboxykinase (PEPCK) gene IRS. This suggests that a coordinate increase in both G6Pase and PEPCK gene transcription is likely to contribute to the increased hepatic glucose production characteristic of patients with non-insulin dependent diabetes mellitus.	VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOL BIOPHYS,NASHVILLE,TN 37232; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	Vanderbilt University; University of Pennsylvania				Tobin, Stacey/0000-0003-1674-9844	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P01DK049210] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49210, P60 DK 20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; BURCHELL A, 1985, DIABETOLOGIA, V28, P852, DOI 10.1007/BF00291077; CHEN M, 1994, J LIPID RES, V35, P1918; CONSOLI A, 1992, DIABETES CARE, V15, P430, DOI 10.2337/diacare.15.3.430; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; EFENDIC S, 1988, J CLIN INVEST, V81, P1953, DOI 10.1172/JCI113543; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER DK, 1992, DIABETES CARE, V15, P369, DOI 10.2337/diacare.15.3.369; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; Ludwig DS, 1996, J CLIN ENDOCR METAB, V81, P503, DOI 10.1210/jc.81.2.503; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; OBrien RM, 1995, BBA-GENE STRUCT EXPR, V1264, P284, DOI 10.1016/0167-4781(95)00194-8; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSELLA G, 1993, MOL ENDOCRINOL, V7, P1456, DOI 10.1210/me.7.11.1456; Sambrook J., 2002, MOL CLONING LAB MANU; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	44	130	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11698	11701		10.1074/jbc.272.18.11698	http://dx.doi.org/10.1074/jbc.272.18.11698			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115220	hybrid			2022-12-25	WOS:A1997WX56900008
J	Wang, SL; Liu, XQ				Wang, SL; Liu, XQ			Identification of an unusual intein in chloroplast ClpP protease of Chlamydomonas eugametos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEA DNA-POLYMERASE; SACCHAROMYCES-CEREVISIAE; INTERVENING SEQUENCES; BRANCHED INTERMEDIATE; GENE; INTRONS; SUBUNIT; ENDONUCLEASE; MECHANISM; ELEMENTS	The proteasome-like ClpP protease is widely distributed and structurally conserved among bacteria and eukaryotic cell organelles. In Chlamydomonas eugametos, however, the chloroplast clpP gene predicted a much larger ClpP protein containing large insertion sequences (ISs). One insertion sequence, IS2, is 456 amino acid residues long and not similar to known proteins. Here we show that IS2 is an unusual intein, and its protein splicing activity in Escherichia coli cells can be activated by a single amino acid substitution. Analysis of IS2 sequence revealed short sequence motifs that are similar to known intein motifs, including putative LA-GLI-DADG endonuclease motifs. But a histidine residue conserved at the C terminus of known inteins is replaced in the IS2 sequence by a glycine residue (Gly(455)), rendering the IS2 sequence incapable of detectable protein splicing when tested in E. coli cells. Changing Gly(455) to histidine activated the ability of IS2 to undergo protein splicing in E. coli cells. The IS2 sequence (intein) was precisely excised from a precursor protein, with the flanking sequences (exteins) joined together by a normal peptide bond.	DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX,NS B3H 4H7,CANADA	Dalhousie University			Wood, David W/B-2992-2012					Bross P, 1995, FEBS LETT, V377, P249, DOI 10.1016/0014-5793(95)01353-9; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CLARKE ND, 1994, P NATL ACAD SCI USA, V91, P11084, DOI 10.1073/pnas.91.23.11084; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; ENGELBERGKULKA H, 1993, TRENDS BIOCHEM SCI, V18, P294, DOI 10.1016/0968-0004(93)90039-P; FAIHI H, 1996, P NATL ACAD SCI USA, V93, P3410; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; GU HH, 1993, J BIOL CHEM, V268, P7372; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; HUANG CZ, 1994, MOL GEN GENET, V244, P151, DOI 10.1007/BF00283516; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; SHUB DA, 1992, CELL, V71, P183, DOI 10.1016/0092-8674(92)90345-D; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; WALLACE CJA, 1993, PROTEIN SCI, V2, P697, DOI 10.1002/pro.5560020501; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x	30	37	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11869	11873		10.1074/jbc.272.18.11869	http://dx.doi.org/10.1074/jbc.272.18.11869			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115246	hybrid			2022-12-25	WOS:A1997WX56900034
J	Chiao, JH; Roy, K; Tolner, B; Yang, CH; Sirotnak, FM				Chiao, JH; Roy, K; Tolner, B; Yang, CH; Sirotnak, FM			RFC-1 gene expression regulates folate absorption in mouse small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER-MEDIATED TRANSPORT; TISSUE-SPECIFIC EXPRESSION; BRUSH-BORDER MEMBRANE; ANALOG TRANSPORT; TUMOR-CELLS; MULTIPLE PROMOTERS; PROTEIN; PURIFICATION; RNA; NITROCELLULOSE	Mediated folate compound transport inward in isolated luminal epithelial cells from mouse small intestine was delineated as pH-dependent and non-pH-dependent components on the basis of their differential sensitivity to the stilbene inhibitor, 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, pH dependence was manifested as higher maximum capacity (V-max) for influx of l,L-5-CH3-H(4)folate at acidic pH compared with neutral or alkaline pH with no effect on saturability (K-m), The pH dependent component was relatively insensitive to inhibition by 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid and highly saturable (K-m or K-i = 2 to 4 mu M) in the case of folic acid, folate coenzymes, and 4-aminofolate analogues as permeants or inhibitors, The non-pH-dependent component was highly sensitive to 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid and poorly and variably saturable (K-m or K-i = 20 to > 2000 mu M) with respect to these folate compounds, Only the pH-dependent transport component was developmentally regulated, showing much higher maximum capacity for l,L-5-CH3-H(4)folate influx in mature absorptive rather than proliferative crypt cells, The increase in pH-dependent influx during maturation was associated with an increase in RFC-1 gene expression in the form of a 2.5-kilobase RNA transcript and 58-kDa brush-border membrane protein detected by folate-based affinity labeling and with anti-mouse RFC-1 peptide antibodies, The size of this protein was the same as that encoded by RFC-1 mRNA, The treatment of mature absorptive cells with either the affinity label or the anti RFC-1 peptide antibodies inhibited influx of l,L-[H-3]-5-CH3-H(4)folate in a concentration-dependent manner, These results strongly suggest that pH-dependent folate absorption in this tissue is regulated by RFC-1 gene expression.	MEM SLOAN KETTERING CANC CTR,LAB MOL THERAPEUT,MOL PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55617, CA 08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; CHIAO JH, 1995, J BIOL CHEM, V270, P29698; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; DIXON KH, 1994, J BIOL CHEM, V269, P17; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GUBLER V, 1983, GENE, V25, P269; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; MASAKOWSKI P, 1962, NUCLEIC ACIDS RES, V10, P7895; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; Ratnam M., 1990, FOLIC ACID METABOLIS, P91; RUSSELL RM, 1979, J LAB CLIN MED, V93, P428; SAID HM, 1996, BIOCHIM BIOPHYS ACTA, V323, P98; SAMUELS LL, 1985, CANCER RES, V45, P1488; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; SELHUB J, 1981, J BIOL CHEM, V256, P4489; SELHUB J, 1986, INT ENCY PHARM THERA, P147; SHEEHAN JC, 1965, J AM CHEM SOC, V87, P2492, DOI 10.1021/ja01089a034; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; SIROTNAK FM, 1984, CANCER RES, V44, P5204; SIROTNAK FM, 1968, CANCER RES, V28, P75; SMITH ME, 1970, BIOCHIM BIOPHYS ACTA, V219, P37, DOI 10.1016/0005-2736(70)90059-3; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; STRUM WB, 1979, BIOCHIM BIOPHYS ACTA, V554, P249, DOI 10.1016/0005-2736(79)90022-1; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOLNER B, 1997, IN PRESS GENE; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG CH, 1988, J BIOL CHEM, V263, P9703	36	85	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11165	11170						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111015	hybrid			2022-12-25	WOS:A1997WW00900031
J	Letellier, L; Howard, SP; Buckley, JT				Letellier, L; Howard, SP; Buckley, JT			Studies on the energetics of proaerolysin secretion across the outer membrane of Aeromonas species - Evidence for a requirement for both the protonmotive force and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR PROTEIN SECRETION; ESCHERICHIA-COLI-CELLS; PSEUDOMONAS-AERUGINOSA; SITES; HYDROPHILA; AEROLYSIN; TRANSPORT; BACTERIA; ENVELOPE; VIBRIO	Aeromonas spp. secrete the channel-forming protein proaerolysin across their inner and outer membranes in separate steps using the general secretion pathway. Here we show that treating A. hydrophila or A. salmonicida with the protonophore carbonyl cyanide m-chorophhenyl hydrazone blocks the second step in transport, secretion across the outer membrane from the periplasm, under conditions where the ATP levels in the cell are no different than the levels in control, secreting cells. A threshold for Delta Psi was observed in the region of 120 mV, below which secretion by both species was in hibited. Treatment of cells with arsenate, which lowered ATP levels but did not affect Delta Psi, also reduced secretion from the periplasm, an indication that there is an ATP requirement for this step independent of the requirement for Delta Psi. Secretion across the outer membrane was also arrested by increasing the osmotic pressure of the medium, even though cellular ATP levels and Delta Psi were not affected. This may be due to disruption of some necessary association between the inner and outer membranes.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA,BC V8W 3P6,CANADA; UNIV PARIS 11,CNRS,URA 1116,LAB BIOMEMBRANES,F-91405 ORSAY,FRANCE; UNIV REGINA,DEPT BIOL,SASKATOON,SK S4S 0A2,CANADA	University of Victoria; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Regina								BAYER ME, 1994, BACTERIAL CELL WALL, P447; BOUDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037; DRIESSEN AJM, 1996, HDB BIOL PHYS, V2, P759; FELIX H, 1982, ANAL BIOCHEM, V120, P211, DOI 10.1016/0003-2697(82)90340-2; GHAZI A, 1981, FEBS LETT, V139, P121; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; GUIHARD G, 1993, J BIOL CHEM, V268, P1775; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; HARDIE KR, 1995, MOL MICROBIOL, V17, P1035, DOI 10.1111/j.1365-2958.1995.mmi_17061035.x; HOUSSIN C, 1991, BIOCHIM BIOPHYS ACTA, V1056, P76, DOI 10.1016/S0005-2728(05)80075-1; HOWARD SP, 1985, J BACTERIOL, V161, P1118, DOI 10.1128/JB.161.3.1118-1124.1985; Howard SP, 1996, MOL MICROBIOL, V22, P595, DOI 10.1046/j.1365-2958.1996.d01-1713.x; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; JAHAGIRDAR R, 1994, J BACTERIOL, V176, P6819, DOI 10.1128/JB.176.22.6819-6826.1994; JIANG B, 1992, MOL MICROBIOL, V6, P1351, DOI 10.1111/j.1365-2958.1992.tb00856.x; KAZMIERCZAK BI, 1994, J MOL BIOL, V238, P187, DOI 10.1006/jmbi.1994.1280; LABEDAN B, 1981, P NATL ACAD SCI USA, V78, P315; MARINO PA, 1985, J BIOL CHEM, V260, P4965; Miller J. H., 1972, EXPT MOL GENETICS, P431; NUNN DN, 1991, P NATL ACAD SCI USA, V88, P3281, DOI 10.1073/pnas.88.8.3281; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; Pepe CM, 1996, MOL MICROBIOL, V19, P857, DOI 10.1046/j.1365-2958.1996.431958.x; POSSOT O, 1994, MOL MICROBIOL, V12, P287, DOI 10.1111/j.1365-2958.1994.tb01017.x; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SANDKVIST M, 1995, EMBO J, V14, P1664, DOI 10.1002/j.1460-2075.1995.tb07155.x; SKULACHEV V, 1988, MEMBRANE BIOENERGETI, P35; TURNER LR, 1993, J BACTERIOL, V175, P4962, DOI 10.1128/JB.175.16.4962-4969.1993; WEAST RC, 1976, HDB CHEM PHYSICS, pD218; WONG KR, 1989, SCIENCE, V246, P654, DOI 10.1126/science.2814486; WONG KR, 1989, J BACTERIOL, V171, P64; ZILBERSTEIN D, 1979, BIOCHEMISTRY-US, V18, P669, DOI 10.1021/bi00571a018	34	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11109	11113						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111006				2022-12-25	WOS:A1997WW00900022
J	Pugh, CW; ORourke, JF; Nagao, M; Gleadle, JM; Ratcliffe, PJ				Pugh, CW; ORourke, JF; Nagao, M; Gleadle, JM; Ratcliffe, PJ			Activation of hypoxia-inducible factor-1; Definition of regulatory domains within the alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; ERYTHROPOIETIN 3' ENHANCER; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTIONAL REGULATION; FUNCTIONAL DOMAINS; GENE-EXPRESSION; CELL-LINES; FACTOR-I; PROTEIN; BINDING	Hypoxia-inducible factor-1 (HIF-1), a heterodimeric DNA binding complex composed of two basic-helix-loop-helix Per-AHR-ARNT-Sim proteins (HIF-1 alpha and -1 beta), is a key component of a widely operative transcriptional response activated by hypoxia, cobaltous ions, and iron chelation, To identify regions of HIF-1 subunits responsible for oxygen-regulated activity, we constructed chimeric genes in which portions of coding sequence from HIF-1 genes were either linked to a heterologous DNA binding domain or encoded between such a DNA binding domain and a constitutive activation domain, Sequences from HIF-1 alpha but not HIF-1 beta conferred oxygen-regulated activity, Two minimal domains within HIF-1 alpha (amino acids 549-582 and amino acids 775-826) were defined by deletional analysis, each of which could act independently to convey inducible responses. Both these regions confer transcriptional activation, and in both cases adjacent sequences appeared functionally repressive in transactivation assays. The inducible operation of the first domain, but not the second, involved major changes in the level of the activator fusion protein in transfected cells, inclusion of this sequence being associated with a marked reduction of expressed protein level in normoxic cells, which was relieved by stimulation with hypoxia, cobaltous ions, or iron chelation, These results lead us to propose a dual mechanism of activation in which the operation of an inducible activation domain is amplified by regulation of transcription factor abundance, most likely occurring through changes in protein stability.			Pugh, CW (corresponding author), JOHN RADCLIFFE HOSP,INST MOL MED,ERYTHROPOIETIN GRP,RM 420,OXFORD OX3 9DU,ENGLAND.		Gleadle, Jonathan M/K-4188-2012	Gleadle, Jonathan M/0000-0002-5215-7208; Ratcliffe, Peter/0000-0002-2853-806X; Pugh, Chris/0000-0002-5170-1662	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BECK I, 1993, BLOOD, V82, P704; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; DECHASSEVAL R, 1992, NUCLEIC ACIDS RES, V20, P245, DOI 10.1093/nar/20.2.245; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; ESTES SD, 1995, J VIROL, V69, P6335, DOI 10.1128/JVI.69.10.6335-6341.1995; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; WOOD WM, 1989, J BIOL CHEM, V264, P14840	41	428	451	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11205	11214						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111021				2022-12-25	WOS:A1997WW00900037
J	Raja, S; Avraham, S; Avraham, H				Raja, S; Avraham, S; Avraham, H			Tyrosine phosphorylation of the novel protein-tyrosine kinase RAFTK during an early phase of platelet activation by an integrin glycoprotein IIb-IIIa-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; ACTIN-FILAMENTS; CALPAIN; ASSOCIATION; ALPHA(IIB)BETA(3); IDENTIFICATION; AGGREGATION; PP125(FAK); MEMBRANE	A key regulatory event controlling platelet activation is mediated through the phosphorylation of several cellular proteins by protein-tyrosine kinases, The related adhesion focal tyrosine kinase (RAFTK) is a novel cytoplasmic tyrosine kinase and a member of the focal adhesion kinase (FAR) gene family, FAK, phosphorylation in platelets is integrin-dependent, occurs in a late stage of platelet activation, and is dependent on platelet aggregation, In this study, we have investigated the involvement of RAFTK phosphorylation during different stages of platelet activation, Treatment of platelets with thrombin induced, in as early as 10 s, a rapid tyrosine phosphorylation of RAFTK:in a time- and concentration-dependent manner, Treatment of platelets with thrombin in the absence of stirring or pretreatment of platelets with RGDS peptide prevented platelet aggregation, but not RAFTK phosphorylation, Furthermore, phosphorylation of RAFTK did not require integrin engagement since platelets treated with the 7E3 inhibitory antibodies that block fibrinogen binding to glycoprotein IIb-IIIa did not inhibit RAFTK phosphorylation. Similarly, platelets treated with LIBS6 antibodies, which specifically activate glycoprotein IIb-IIIa, did not induce RAFTK phosphorylation. Stimulation of platelets by several agonists such as collagen, ADP, epinephrine, and calcium ionophore A23187 induced RAFTK phosphorylation, Tyrosine phosphorylation of RAFTK in platelets is regulated by calcium and is mediated through the protein kinase C pathway. Phosphorylation of RAFTK is dependent upon the formation of actin cytoskeleton as disruption of actin polymerization by cytochalasin D significantly inhibited this phosphorylation, The RAFTK protein appears to be proteolytically cleaved by calpain in an aggregation dependent manner upon thrombin stimulation, These results demonstrate that RAFTK is tyrosine-phosphorylated during an early phase of platelet activation by an integrin- independent mechanism and is not dependent on platelet aggregation, suggesting different mechanisms of regulation for FAK and RAFTK phosphorylation during platelet activation.	HARVARD UNIV, BETH ISRAEL DEACONESS MED CTR, DIV EXPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL DEACONESS MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center				Avraham, Hava/0000-0002-7545-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046668, R01HL051456, R01HL055445] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51456, HL46668, HL55445] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDO Y, 1987, BIOCHEM BIOPH RES CO, V144, P484, DOI 10.1016/S0006-291X(87)80535-1; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BLOCKMANS D, 1995, BLOOD REV, V9, P143, DOI 10.1016/0268-960X(95)90020-9; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1989, CIRCULATION, V80, P1766, DOI 10.1161/01.CIR.80.6.1766; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1987, THROMB DIATH HAEMO, P175; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FURMAN MI, 1993, THROMB HAEMOSTASIS, V70, P229; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWIGER J, 1994, HEMOSTASIS THROMBOSI, P603; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; KINLOUGHRATHBON.RL, 1987, PLATELETS BIOL PATHO, V3, P239; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; MORAN N, 1994, HEMOSTASIS THROMBOSI, P1623; MUSTARD JF, 1989, METHOD ENZYMOL, V169, P3; ODA A, 1993, J BIOL CHEM, V268, P12603; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; TSUJINAKA T, 1982, THROMB RES, V28, P149, DOI 10.1016/0049-3848(82)90257-2; VanObberghenSchilling E, 1995, ANN NY ACAD SCI, V766, P431, DOI 10.1111/j.1749-6632.1995.tb26692.x; WONG S, 1992, ONCOGENE, V7, P2407	45	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10941	10947						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099753				2022-12-25	WOS:A1997WV26200087
J	Kristensen, C; Kjeldsen, T; Wiberg, FC; Schaffer, L; Hach, M; Havelund, S; Bass, J; Steiner, DF; Andersen, AS				Kristensen, C; Kjeldsen, T; Wiberg, FC; Schaffer, L; Hach, M; Havelund, S; Bass, J; Steiner, DF; Andersen, AS			Alanine scanning mutagenesis of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; BIOLOGICAL-ACTIVITY; NEGATIVE COOPERATIVITY; RECEPTOR INTERACTIONS; SIDE-CHAIN; BINDING; AFFINITY; SITE	Alanine scanning mutagenesis has been used to identify specific side chains of insulin which strongly influence binding to the insulin receptor. A total of 21 new insulin analog constructs were made, and in addition 7 high pressure liquid chromatography-purified analogs were tested, covering alanine substitutions in positions B1, B2, B3, B4, B8, B9, B10, B11, B12, B13, B16, B17, B18, B20, B21, B22, B26, A4, A8, A9, A12, A13, A14, A15, A16, A17, A19, and A21. Binding data on the analogs revealed that the alanine mutations that were most disruptive for binding were at positions TyrA19, GlyB8, LeuB11, and GluB13, resulting in decreases in affinity of 1,000-, 33-, 14-, and 8-fold, respectively, relative to wild-type insulin. In contrast, alanine substitutions at positions GlyB20, ArgB22, and SerA9 resulted in an increase in affinity for the insulin receptor. The most striking finding is that B20Ala insulin retains high affinity binding to the receptor. GlyB20 is conserved in insulins from different species, and in the structure of the B-chain it appears to be essential for the shift from the alpha-helix B8-B19 to the beta-turn B20-B22. Thus, replacing GlyB20 with alanine most likely modifies the structure of the B-chain in this region, but this structural change appears to enhance binding to the insulin receptor.	NOVO NORDISK AS,DEPT CELL TECHNOL,DK-2880 BAGSVAERD,DENMARK; NOVO NORDISK AS,DEPT PROT CHEM,DK-2880 BAGSVAERD,DENMARK; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,ENDOCRINOL SECT,CHICAGO,IL 60637	Novo Nordisk; Novo Nordisk; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago	Kristensen, C (corresponding author), NOVO NORDISK AS,DEPT INSULIN RES,NOVO ALLE 6B1-74,DK-2880 BAGSVAERD,DENMARK.		Kristensen, Claus/O-8047-2015	Kristensen, Claus/0000-0002-2594-7722; Kjeldsen, Thomas/0000-0003-0094-9286				ADAMS MJ, 1969, NATURE, V224, P491, DOI 10.1038/224491a0; ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; BAJAJ M, 1986, BIOCHEM J, V238, P345, DOI 10.1042/bj2380345; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BASS J, 1996, J BIOL CHEM, V371, P19367; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COSMATOS A, 1978, J BIOL CHEM, V253, P6586; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P154, DOI 10.1016/S0006-291X(73)80072-5; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; DEREWENDA U, 1990, HDB EXPT PHARM, P23; FERDERIGOS N, 1983, J PROTEIN CHEM, V2, P147, DOI 10.1007/BF01025378; GAMMELTOFT S, 1984, PHYSIOL REV, V64, P1322; GLIEMANN J, 1974, DIABETOLOGIA, V10, P105, DOI 10.1007/BF01219665; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORUK R, 1979, NATURE, V279, P439, DOI 10.1038/279439a0; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; KITAGAWA K, 1984, BIOCHEMISTRY-US, V23, P4444, DOI 10.1021/bi00314a031; Kjeldsen T, 1996, GENE, V170, P107, DOI 10.1016/0378-1119(95)00822-5; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOBAYASHI M, 1984, BIOMED RES-TOKYO, V5, P267, DOI 10.2220/biomedres.5.267; KRISTENSEN C, 1995, BIOCHEM J, V305, P981, DOI 10.1042/bj3050981; KUROSE T, 1994, J BIOL CHEM, V269, P29190; MARKI F, 1979, H-S Z PHYSIOL CHEM, V360, P1619, DOI 10.1515/bchm2.1979.360.2.1619; MARKUSSEN J, 1987, PEPTIDES 1986, P190; MIRMIRA RG, 1991, BIOCHEMISTRY-US, V30, P8222, DOI 10.1021/bi00247a019; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; NAKAGAWA SH, 1991, J BIOL CHEM, V266, P11502; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; Sherman F, 1979, METHODS YEAST GENETI; SMITH GD, 1984, P NATL ACAD SCI-BIOL, V81, P7093, DOI 10.1073/pnas.81.22.7093; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766	34	175	213	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12978	12983		10.1074/jbc.272.20.12978	http://dx.doi.org/10.1074/jbc.272.20.12978			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148904	hybrid			2022-12-25	WOS:A1997WZ38400017
J	Vavvas, D; Apazidis, A; Saha, AK; Gamble, J; Patel, A; Kemp, BE; Witters, LA; Ruderman, NB				Vavvas, D; Apazidis, A; Saha, AK; Gamble, J; Patel, A; Kemp, BE; Witters, LA; Ruderman, NB			Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COENZYME-A CARBOXYLASE; FATTY-ACID OXIDATION; MALONYL-COA; CARNITINE PALMITOYLTRANSFERASE; RAT-LIVER; PHOSPHORYLATION; INHIBITION; TISSUES; ENZYME	The concentration of malonyl-CoA, a negative regulator of fatty acid oxidation, diminishes acutely in contracting skeletal muscle, To determine how this occurs, the activity and properties of acetyl-CoA carboxylase beta (ACC-beta), the skeletal muscle isozyme that catalyzes malonyl-CoA formation, were examined in rat gastrocnemius-soleus muscles at rest and during contractions induced by electrical stimulation of the sciatic nerve, To avoid the problem of contamination of the muscle extract by mitochondrial carboxylases, an assay was developed in which ACC-beta was first purified by immunoprecipitation with a monoclonal antibody, ACC-beta was quantitatively recovered in the immunopellet and exhibited a high sensitivity to citrate (12-fold activation) and a K-m for acetyl-CoA (120 mu M) similar to that reported for ACC-beta purified by other means, After 5 min of contraction, ACC-beta activity was decreased by 90% despite an apparent increase in the cytosolic concentration of citrate, a positive regulator of ACC, SDS-polyacrylamide gel electrophoresis of both homogenates and immunopellets from these muscles showed a decrease in the electrophoretic mobility of ACC, suggesting that phosphorylation could account for the decrease in ACC activity, In keeping With this notion, citrate activation of ACC purified from contracting muscle was markedly depressed, In addition, homogenization of the muscles in a buffer free of phosphatase inhibitors and containing the phosphatase activators glutamate and MgCl2 or treatment of immunoprecipitated ACC-beta with purified protein phosphatase 2A abolished the decreases in both ACC-beta activity and electrophoretic mobility caused by contraction, The rapid decrease in ACC-beta activity after the onset of contractions (50% by 20 s) and its slow restoration to initial values during recovery (60-90 min) were paralleled temporally by reciprocal changes in the activity of the alpha 2 but not the alpha 1 isoform of 5'-AMP-activated protein kinase (AMPK). In conclusion, the results suggest that the decrease in ACC activity during muscle contraction is caused by an increase in its phosphorylation, most probably due, at least in part, to activation of the alpha 2 isoform of AMPK. They also suggest a dual mechanism for ACC regulation in muscle in which inhibition by phosphorylation takes precedence over activation by citrate, These alterations in ACC and AMPK activity, by diminishing the concentration of malonyl-CoA, could be responsible for the increase in fatty acid oxidation observed in skeletal muscle during exercise.	BOSTON UNIV, MED CTR, EVANS DEPT MED, DIABET & METAB UNIT, BOSTON, MA 02118 USA; BOSTON UNIV, MED CTR, DEPT PHYSIOL, BOSTON, MA 02118 USA; DARTMOUTH COLL SCH MED, DEPT MED BIOCHEM, ENDOCRINOL METAB DIV, HANOVER, NH 03756 USA; ST VINCENTS INST MED RES, FITZROY, VIC 3065, AUSTRALIA	Boston University; Boston University; Dartmouth College; St. Vincent's Institute of Medical Research			Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Ruderman, Neil/0000-0002-6589-6587; Vavvas, Demetrios/0000-0002-8622-6478; Saha, Asish/0000-0003-1001-5110	NIDDK NIH HHS [DK-19514, T32 DK-07201, DK-49417] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019514, T32DK007201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAGON JJ, 1980, FEBS LETT, V117, pK56, DOI 10.1016/0014-5793(80)80570-9; ASSIMACOPOULOSJEANNET F, 1995, METABOLISM, V44, P228, DOI 10.1016/0026-0495(95)90270-8; AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BARMAN T, 1969, ENZYME HDB, V2, P912; BEATY NB, 1983, J BIOL CHEM, V258, P3043; BEATY NB, 1982, J BIOL CHEM, V257, P924; BEATY NB, 1983, J BIOL CHEM, V258, P3051; BIANCHI A, 1992, J CELL BIOCHEM, V48, P86, DOI 10.1002/jcb.240480113; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; COOK GA, 1984, J BIOL CHEM, V259, P2030; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DAVIES SP, 1992, EUR J BIOCHEM, V203, P615, DOI 10.1111/j.1432-1033.1992.tb16591.x; DUAN C, 1992, J APPL PHYSIOL, V72, P901, DOI 10.1152/jappl.1992.72.3.901; DUDLEY GA, 1985, AM J PHYSIOL, V248, pC43, DOI 10.1152/ajpcell.1985.248.1.C43; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; ELAYAN IM, 1991, J APPL PHYSIOL, V70, P1495, DOI 10.1152/jappl.1991.70.4.1495; GAO G, 1995, BBA-MOL CELL RES, V1266, P73, DOI 10.1016/0167-4889(94)00222-Z; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; Gaussin V, 1996, BIOCHEM J, V316, P217, DOI 10.1042/bj3160217; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; Ha J, 1996, P NATL ACAD SCI USA, V93, P11466, DOI 10.1073/pnas.93.21.11466; HA J, 1994, J BIOL CHEM, V269, P22162; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HARDIE DG, 1992, BIOESSAYS, V14, P699, DOI 10.1002/bies.950141011; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KIM KH, 1983, CURR TOP CELL REGUL, V22, P143; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KIM KH, 1994, J NUTR, V124, pS1273, DOI 10.1093/jn/124.suppl_8.1273S; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; LEE KH, 1978, J BIOL CHEM, V253, P8157; LOUIS NA, 1992, J BIOL CHEM, V267, P2287; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1995, BIOCHEM SOC T, V23, P321, DOI 10.1042/bst0230321; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SAGGERSON D, 1992, ADV ENZYME REGUL, V32, P285; SAHA AK, 1995, AM J PHYSIOL-ENDOC M, V269, pE283, DOI 10.1152/ajpendo.1995.269.2.E283; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; Sidossis LS, 1996, J CLIN INVEST, V98, P2244, DOI 10.1172/JCI119034; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; SUGDEN PH, 1975, BIOCHEM J, V150, P113, DOI 10.1042/bj1500113; THAMPY KG, 1988, J BIOL CHEM, V263, P6447; THAMPY KG, 1988, J BIOL CHEM, V263, P6454; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; TRUMBLE GE, 1991, LIFE SCI, V49, P39, DOI 10.1016/0024-3205(91)90577-X; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; Widmer J, 1996, BIOCHEM J, V316, P915, DOI 10.1042/bj3160915; WINDER WW, 1990, AM J PHYSIOL, V259, pE266, DOI 10.1152/ajpendo.1990.259.2.E266; WINDER WW, 1995, J APPL PHYSIOL, V78, P578, DOI 10.1152/jappl.1995.78.2.578; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; WINZ R, 1994, J BIOL CHEM, V269, P14438; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; ZIERZ S, 1987, BIOCHEM J, V245, P205, DOI 10.1042/bj2450205	61	333	345	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13255	13261		10.1074/jbc.272.20.13255	http://dx.doi.org/10.1074/jbc.272.20.13255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148944	hybrid			2022-12-25	WOS:A1997WZ38400057
J	Gils, A; Declerck, PJ				Gils, A; Declerck, PJ			Proteinase specificity and functional diversity in po plasminogen activator inhibitor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-SITE; ENDOTHELIAL-CELLS; SUBSTRATE PROPERTIES; ANTITHROMBIN-III; PURIFICATION; THROMBIN; TYPE-1; ALPHA-1-ANTITRYPSIN; MUTAGENESIS; MUTATION	Plasminogen activator inhibitor-1 (PAI-1) is a unique member of the serpin superfamily. The alternative behavior of PAI-1 as an inhibitor, a non-inhibitory substrate, or a non-reactive latent form has been shown to be dependent on the initial conformation. In this study, we have evaluated the effect of a substitution outside the reactive site loop (P18) or in the reactive site loop (P6 and P10) on proteinase specificity and conformational transitions in PAI-1. Wild-type PAI-1 (wtPAI-1) revealed the same conformational distribution pattern toward tissue-type plasminogen activator (t-PA) as toward urokinase-type plasminogen activator (u-PA) (i.e. 53 +/- 6.9% active, 36 +/- 6.8% latent, and 12 +/- 1.9% substrate). Inactivation of wtPAI-1 resulted in the conversion of the labile active form into the latent form while the stable substrate form remained unchanged. PAI-1-P6 (Val --> Pro at P6) revealed a target specificity for t-PA (39 +/- 7% versus 3 +/- 2% of the theoretical maximal value toward t-PA and u-PA, respectively), PAI-1-P10 (Ser --> Pro at P10) was 4-fold more active toward u-PA than toward t-PA, and PAI-1-P18 (Asn --> Pro at P18) exhibited inhibitory properties exclusively toward u-PA (41 +/- 10%). Surprisingly, inactivation of these mutants revealed functional and conformational transitions distinct from those observed for wtPAI-1. Inactivation of PAI-1-P6 (Val --> Pro) resulted in a total conversion of the active form into the latent form and in a partial conversion of the substrate form into the latent form, The active forms of both PAI-1-P10 (Ser --> Pro) and PAI-1-P18 (Asn --> Pro) are also labile but, in contrast to the active form of wtPAI-1, convert into substrate forms. Based on the existence of various conformations of PAI-1, we propose an alternative reaction scheme describing the putative interactions between serpins and their target proteinases. The unusual conformational and functional flexibility of PAI-1 that, according to the current study, appears not to be restricted to the reactive site loop further underlines the importance of potential structural rearrangements (e.g. upon binding to cofactors) in PAI-1 (or serpins in general) for its functional behavior at particular biological sites.	CATHOLIC UNIV LEUVEN,FAC PHARMACEUT SCI,LAB PHARMACEUT BIOL & PHYTOPHARMACOL,B-3000 LOUVAIN,BELGIUM	KU Leuven			Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105				ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DECLERCK PJ, 1994, J INTERN MED, V236, P425, DOI 10.1111/j.1365-2796.1994.tb00820.x; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P40; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOLMES WE, 1987, SCIENCE, V238, P209, DOI 10.1126/science.2958938; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JALLAT S, 1986, PROTEIN ENG, V1, P29, DOI 10.1093/protein/1.1.29; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LEVY NJ, 1990, P NATL ACAD SCI USA, V87, P265, DOI 10.1073/pnas.87.1.265; LINDAHL TL, 1990, BIOCHEM J, V265, P109, DOI 10.1042/bj2650109; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; OLSON ST, 1985, J BIOL CHEM, V260, P153; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PATSTON PA, 1994, SEMIN THROMB HEMOST, V20, P410, DOI 10.1055/s-2007-1001929; PATSTON PA, 1990, J BIOL CHEM, V265, P10786; PERRY DJ, 1989, MOL BIOL MED, V6, P239; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHERMAN PM, 1995, J BIOL CHEM, V270, P9301, DOI 10.1074/jbc.270.16.9301; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; SPRANG SR, 1992, TRENDS BIOCHEM SCI, V17, P49, DOI 10.1016/0968-0004(92)90495-U; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; YORK JD, 1991, J BIOL CHEM, V266, P8495	48	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12662	12666		10.1074/jbc.272.19.12662	http://dx.doi.org/10.1074/jbc.272.19.12662			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139722	hybrid			2022-12-25	WOS:A1997WY82900059
J	Gupta, S; Bose, A; Chatterjee, N; Saha, D; Wu, SY; Gupta, NK				Gupta, S; Bose, A; Chatterjee, N; Saha, D; Wu, SY; Gupta, NK			p67 transcription regulates translation in serum-starved and mitogen-activated KRC-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; PROTEIN-SYNTHESIS INITIATION; 67-KDA POLYPEPTIDE P67; EIF-2 ALPHA-SUBUNIT; RETICULOCYTE LYSATE; ANIMAL-CELLS; HELA-CELLS; PHOSPHORYLATION; INHIBITION; GLYCOSYLATION	The regulation of protein synthesis was studied in KRC-7 cells (rat hepatoma) grown in complete medium, during serum starvation, and mitogen activation. Upon serum starvation, the cells lost almost completely p67 mRNA, p67 protein, and protein synthesis activity. After phorbol 12-myristate 13-acetate addition, the same serum-starved cells regained p67 mRNA, p67 protein, and protein synthesis activity. Also, the extracts from the serum-starved cells phosphorylated the eukaryotic initiation factor-2 (eIF-2) alpha-subunit. This eIF-2 alpha-subunit phosphorylation was not observed when the extracts from either the cells grown in complete medium or mitogen-activated cells were used (Gupta, S., Wu, S., Chatterjee, N., Ilan, J., Ilan, J., Osterman, J. C., and Gupta, N. K. (1995) Gene Expr. 5, 113-122). We now report the following. 1) The eIF-2 kinase activity was the same in the cells grown in complete medium, after serum starvation, and subsequent mitogen stimulation. However, the eIF-2 kinase in the cells grown in complete medium and also after mitogen activation of the serum-starved cells cannot phosphorylate eIF-2 alpha-subunit as these cells contain p67. After removal of endogenous p67 by p67 antibodies, the extracts from all these cells similarly phosphorylated exogenously added eIF-2. 2) None of the cell extracts showed p67 deglycosylase activity. 3) The p67 mRNA was synthesized in serum-starved cells by expression of a p67 cDNA The appearance of p67 mRNA in the serum-starved cells was accompanied by the appearance of p67 protein. Also, the rates of protein synthesis in the serum starved cells were restored nearly to the level observed in the confluent cells. The expression of p67 cDNA also significantly increased protein synthesis rates in the cells grown in complete medium and in mitogen-activated cells. These results show that the loss of protein synthesis activity in serum-starved cells was due to loss of p67 mRNA. The expressed p67 mRNA was stable in serum-starved cells. These results, therefore, suggest that the loss of p67 mRNA in serum-starved cells is due to loss of p67 transcription. The p67 transcription regulates translation.	UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588	University of Nebraska System; University of Nebraska Lincoln			Wu, Shiyong/I-3359-2013	Wu, Shiyong/0000-0002-4104-4160	PHS HHS [2079] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOSE A, 1996, AM SOC BIOCH MOL BIO; CHAKRABORTY A, 1994, BIOCHEMISTRY-US, V33, P6700, DOI 10.1021/bi00187a041; Chatterjee N, 1997, J BIOL CHEM, V272, P12692, DOI 10.1074/jbc.272.19.12692; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTA B, 1988, INDIAN J BIOCHEM BIO, V25, P478; DATTA B, 1989, J BIOL CHEM, V264, P20620; DATTA B, 1988, P NATL ACAD SCI USA, V85, P3324, DOI 10.1073/pnas.85.10.3324; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; Gupta S, 1995, GENE EXPRESSION, V5, P113; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; WU SY, 1993, J BIOL CHEM, V268, P10796	19	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12699	12704		10.1074/jbc.272.19.12699	http://dx.doi.org/10.1074/jbc.272.19.12699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139727	hybrid			2022-12-25	WOS:A1997WY82900064
J	Muller, ML; IrkensKiesecker, U; Kramer, D; Taiz, L				Muller, ML; IrkensKiesecker, U; Kramer, D; Taiz, L			Purification and reconstitution of the vacuolar H+-ATPases from lemon fruits and epicotyls	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE TISSUE; BETA-VULGARIS; MEMBRANE; SUBUNIT	The vacuolar H+-ATPases CV-ATPases) of lemon fruits and epicotyls were detergent-solubilized, purified by column chromatography, and reconstituted into artificial proteoliposomes, During purification, a vanadate- and nitrate-sensitive ATPase activity, consisting of partially disassembled V-ATPase complexes, was resolved from the V-ATPase peak, ATPase and H+-transport activities of the purified, reconstituted V-ATPases of both fruit and epicotyl exhibited similar inhibitor profiles, except that the fruit V-ATPase retained partial vanadate sensitivity, Since the V-ATPase activity of native fruit tonoplast vesicles is insensitive to inhibitors (Muller, M, L,, Irkens-Kiesecker, U,, Rubinstein, B,, and Taiz, L. (1996) J, Biol, Chem, 271, 1916-1924), membrane lipids or other factors may protect the fruit V-ATPase from inactivation in vivo. A kinetic analysis of H+-pumping and H+-leakage indicated that the reconstituted epicotyl V-ATPase exhibited twice as much intrinsic uncoupling or slip as the reconstituted fruit V-ATPase, Comparison of their subunit compositions by SDS polyacrylamide gel electrophoresis indicated that the reconstituted fruit V-ATPase is enriched in two polypeptides of 33/34 and 16 kDa, Moreover, the stalks of negatively stained juice sac V-ATPases appeared thicker than those of epicotyl V-ATPases in electron micrographs.	UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,DEPT BIOL,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz								BANULS J, 1995, PLANT CELL ENVIRON, V18, P1341, DOI 10.1111/j.1365-3040.1995.tb00194.x; BELTRAN C, 1992, ACTA PHYSIOL SCAND, V146, P41; BENNETT AB, 1984, PLANT PHYSIOL, V74, P545, DOI 10.1104/pp.74.3.545; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; CHATTERJEE D, 1992, J EXP BIOL, V172, P193; David P, 1996, BBA-BIOMEMBRANES, V1280, P155, DOI 10.1016/0005-2736(95)00284-7; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRAICHARD A, 1995, U36438 AP; GUERN J, 1989, PLANT PHYSIOL, V89, P27, DOI 10.1104/pp.89.1.27; HERNANDO N, 1995, P NATL ACAD SCI USA, V92, P6087, DOI 10.1073/pnas.92.13.6087; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; KLINK R, 1991, BOT ACTA, V104, P121; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNIN T, 1995, PLANT PHYSIOL, V109, P285, DOI 10.1104/pp.109.1.285; MORIYAMA Y, 1988, ION PUMPS STRUCTURE, P387; Muller ML, 1996, J BIOL CHEM, V271, P1916; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; SCHMIDT AL, 1993, ARCH BIOCHEM BIOPHYS, V301, P165, DOI 10.1006/abbi.1993.1129; SINCLAIR WB, 1984, BIOCH PHYSL LEMON OT, P109; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Supekova L, 1996, J EXP BIOL, V199, P1147; TAIZ SL, 1990, BOT ACTA, V104, P117; TU SI, 1987, ARCH BIOCHEM BIOPHYS, V256, P625, DOI 10.1016/0003-9861(87)90620-5; WARD JM, 1995, METHODS PLANT CELL B, P149	24	54	58	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12762	12770		10.1074/jbc.272.19.12762	http://dx.doi.org/10.1074/jbc.272.19.12762			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139735	hybrid			2022-12-25	WOS:A1997WY82900072
J	Zarkowska, T; Mittnacht, S				Zarkowska, T; Mittnacht, S			Differential phosphorylation of the retinoblastoma protein by G(1)/S cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; GENE-PRODUCT; SUSCEPTIBILITY GENE; BINDING; PROGRESSION; SUPPRESSOR; EXPRESSION; GROWTH; CDC2	The retinoblastoma tumor suppressor protein, pRB, is inactivated by phosphorylation. While existing evidence is strong that such phosphorylation is mediated by one or more cyclin dependent kinases (CDKs) active during G(1)/S-1 it remains unclear which of the various CDKs is responsible. We show here that three candidate pRB inactivating kinases, CDK4-cyclin D1, CDK2-cyclin E, and CDK2-cyclin A, phosphorylate pRB differentially, each on a subset of authentic pRB phosphorylation sites. Notably, two neighboring pRB phosphate accepters, threonine 821 and threonine 826, which have previously been implicated in the regulation of LXCXE protein binding, are phosphorylated by different CDKs. We demonstrate that phosphorylation by either CDK2-cyclin A, which phosphorylates T821, or CDK4-cyclin D1, which phosphorylates threonine 826, can disable pRB for subsequent binding of an LXCXE, protein. However, only one of these two kinases, CDK2-cyclin A, can dissociate a pre-existing LXCXE protein-pRB complex. We provide evidence that prior binding of an LXCXE protein blocks access to certain residues specifically targeted by CDK4-cyclin D1, explaining the inability of this kinase to resolve such complexes. While these results are not direct proof of the relevance of differential pRB phosphorylation in cells, our findings support a model whereby full phosphorylation of pRB may require the action of more than one kinase and explains how such differential phosphorylation by different CDKs might translate into a differential regulation of downstream effector pathways.	INST CANC RES,DEPT CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1995, CRIT REV EUKAR GENE, V5, P79; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KATO J, 1993, GENE DEV, V7, P331; King LA, 1992, BACULOVIRUS SYSTEM L; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KRIPPL B, 1986, J VIROL, V59, P420, DOI 10.1128/JVI.59.2.420-427.1986; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MIYAJIMA M, 1995, NEUROREPORT, V6, P1130, DOI 10.1097/00001756-199505300-00014; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824	29	415	422	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12738	12746		10.1074/jbc.272.19.12738	http://dx.doi.org/10.1074/jbc.272.19.12738			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139732	hybrid			2022-12-25	WOS:A1997WY82900069
J	Perlman, JH; Colson, AO; Wang, W; Bence, K; Osman, R; Gershengorn, MC				Perlman, JH; Colson, AO; Wang, W; Bence, K; Osman, R; Gershengorn, MC			Interactions between conserved residues in transmembrane helices 1, 2, and 7 of the thyrotropin-releasing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BINDING; MODEL; RHODOPSIN; HELIX-2	The roles of conserved residues in transmembrane helices (TMs) of G protein-coupled receptors have not been well established, A computer-generated model of the thyrotropin-releasing hormone receptor (TRH-R) indicated that conserved Asp-71 (TM-2) could interact with conserved asparagines 316 (TM-7) and 43 (TM-1), To test this model, we constructed mutant TRH-Rs containing polar or alanine substitutions of these residues. The maximal activities of N43A and N316A TRH-Rs were diminished, whereas D71A (Perlman, J. H., Nussenzveig, D. R., Osman, R., and Gershengorn, M. C. (1992) J. Biol. Chem, 267, 24413-24417) and N43A/N316A TRH-Rs were inactive, Computer models of D71A and N43A/N316A TRH-Rs show similar changes from native TRH-R in their TM bundle conformations, The inactivity and the similarity of the computer models of D71A and N43A/N316A TRH-Rs are consistent with the idea that Asp-71 bridges Asn-43 and Asn-316 and suggest that activity is critically dependent on these interactions, The conservation of these residues suggests these specific interactions involving TMs 1, 2, and 7 may be structurally important for all members of the rhodopsin/beta-adrenergic receptor subfamily of G protein coupled receptors.	NEW YORK HOSP,NEW YORK,NY 10021; CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029	NewYork-Presbyterian Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Perlman, JH (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,DIV MOL MED,1300 YORK AVE,RM A328,NEW YORK,NY 10021, USA.			Bence, Kendra/0000-0002-5879-4726	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043036, K11DK002101] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43036, DK 02101] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GERSHENGORN MC, 1991, ENDOCRINOLOGY, V128, P1204, DOI 10.1210/endo-128-2-1204; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; GETHER U, 1994, J BIOL CHEM, V269, P23959; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KONVICKA K, 1995, BIOPHYS J, V62, pA446; Laakkonen LJ, 1996, BIOCHEMISTRY-US, V35, P7651, DOI 10.1021/bi952203j; LICATA VJ, 1995, BIOCHEMISTRY-US, V34, P3133, DOI 10.1021/bi00010a001; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; PERLMAN JH, 1995, J BIOL CHEM, V270, P24682, DOI 10.1074/jbc.270.42.24682; Perlman JH, 1996, BIOCHEMISTRY-US, V35, P7643, DOI 10.1021/bi952202r; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; ZHOU W, 1994, MOL PHARMACOL, V45, P165	30	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11937	11942		10.1074/jbc.272.18.11937	http://dx.doi.org/10.1074/jbc.272.18.11937			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115256	hybrid			2022-12-25	WOS:A1997WX56900044
J	Korner, CG; Wahle, E				Korner, CG; Wahle, E			Poly(A) tail shortening by a mammalian poly(A)-specific 3'-exoribonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; POLY(A)-BINDING PROTEIN; TRANSLATION INITIATION; YEAST; DEADENYLATION; BINDING; PURIFICATION; STABILITY; POLYMERASE; CLEAVAGE	3'-Exonucleolytic removal of the poly(A) tail is the first and often rate-limiting step in the decay of many eucaryotic mRNAs. In a cytoplasmic extract from HeLa cells, the poly(A) tail of mRNA was degraded from the 3'-end. In agreement with earlier in vivo observations, prominent decay intermediates differed in length by about 30 nucleotides. The Mg2+-dependent, poly(A)-specific 3'-exoribonuclease responsible for this poly(A) shortening activity was purified from calf thymus. A polypeptide of 74 kDa copurified with the activity. The deadenylating nuclease (DAN) required a free 3'-OH group, released solely 5'-AMP, degraded RNA in a distributive fashion, and preferred poly(A) as a substrate. At low salt concentration, the activity of purified DAN was strongly dependent on spermidine or other, yet unidentified factors. Under these reaction conditions, DAN was also stimulated by the cytoplasmic poly(A)-binding protein I (PAB I). At physiological salt concentration, the stimulatory effect of spermidine was weak and PAB I was inhibitory. At either salt concentration DAN and PAB I reconstituted poly(A) shortening with the same pattern of intermediates seen in cytoplasmic extract. The properties of DAN suggest that the enzyme might be involved in the deadenylation of mRNA in vivo.	UNIV GIESSEN,INST BIOCHEM,D-35392 GIESSEN,GERMANY; UNIV BASEL,DEPT CELL BIOL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	Justus Liebig University Giessen; University of Basel			Körner, Christian/B-6592-2014	Körner, Christian/0000-0001-7768-7638; Wahle, Elmar/0000-0003-2504-0677				ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; BAER BW, 1983, J CELL BIOL, V96, P717, DOI 10.1083/jcb.96.3.717; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KELLY JM, 1982, NUCLEIC ACIDS RES, V10, P4173, DOI 10.1093/nar/10.14.4173; KROWCZYNSKA A, 1986, J BIOL CHEM, V261, P397; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MANSBRIDGE JN, 1974, EUR J BIOCHEM, V44, P261, DOI 10.1111/j.1432-1033.1974.tb03481.x; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Pirrotta V, 1980, Methods Enzymol, V65, P89; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Saenger W, 1991, CURR OPIN STRUC BIOL, V1, P130, DOI 10.1016/0959-440X(91)90021-K; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; Sheflin LG, 1996, ENDOCRINOLOGY, V137, P2085, DOI 10.1210/en.137.5.2085; STOECKLE MY, 1993, NUCLEIC ACIDS RES, V21, P1613, DOI 10.1093/nar/21.7.1613; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1993, J BIOL CHEM, V268, P2937; Wahle E., 1994, RNA PROCESSING PRACT, VII, P1; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x	46	192	197	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10448	10456						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099687				2022-12-25	WOS:A1997WV26200021
J	Ruth, P; Pfeifer, A; Kamm, S; Klatt, P; Dostmann, WRG; Hofmann, F				Ruth, P; Pfeifer, A; Kamm, S; Klatt, P; Dostmann, WRG; Hofmann, F			Identification of the amino acid sequences responsible for high affinity activation of cGMP kinase I alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-GMP; BOVINE AORTA; BINDING SITES; CIRCULAR-DICHROISM; BACULOVIRUS SYSTEM; TERMINAL DOMAIN; EXPRESSION; BETA; ISOZYME	The cGMP-dependent protein kinases (cGK) I alpha and I beta have identical cGMP binding sites and catalytic domains, However, differences in their first 100 amino acids result in 15-fold different activation constants for cGMP, We constructed chimeras to identify those amino acid sequences that contribute to the high affinity cGK I alpha and low affinity cGK I beta phenotype, The cGK I alpha/I beta chimeras contained permutations of six amino-terminal regions (S1-S6) including the leucine zipper (S2), the autoinhibitory domain (S4), and the hinge domain (S5, S6). The exchange of S2 along with S4 switched the phenotype from cGK I alpha to cGK I beta and vice versa, suggesting that the domains with the highest homology between the two isozymes determine their affinity for cGMP, The high affinity cGK I alpha phenotype was also obtained by a specific substitution within the hinge domain, Chimeras with the sequence of cGK I alpha in S5 and cGK I beta in S6 were activated at up to 6-fold lower cGMP concentrations than cGK I alpha. Based on the activation constants of all chimeras constructed, empirical weighting factors have been calculated that quantitatively describe the contribution of the individual amino-terminal domains S1-S6 to the high affinity cGK I alpha phenotype.			Ruth, P (corresponding author), TECH UNIV MUNICH,INST PHARMAKOL & TOXIKOL,BIEDERSTEINER STR 29,D-80802 MUNICH,GERMANY.							AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; FEIL R, 1993, FEBS LETT, V336, P163, DOI 10.1016/0014-5793(93)81632-A; FEIL R, 1995, BIOCHEMISTRY-US, V34, P13152, DOI 10.1021/bi00040a029; FRANCIS S, 1993, FASEB J, V7, pA1123; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANDGRAF W, 1989, EUR J BIOCHEM, V181, P643, DOI 10.1111/j.1432-1033.1989.tb14771.x; LINCOLN TM, 1988, J BIOL CHEM, V263, P17632; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MCCUNE RW, 1979, J BIOL CHEM, V254, P5083; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157	32	53	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10522	10528						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099696				2022-12-25	WOS:A1997WV26200030
J	VanEyk, JE; Thomas, LT; Tripet, B; Wiesner, RJ; Pearlstone, JR; Farah, CS; Reinach, FC; Hodges, RS				VanEyk, JE; Thomas, LT; Tripet, B; Wiesner, RJ; Pearlstone, JR; Farah, CS; Reinach, FC; Hodges, RS			Distinct regions of troponin I regulate Ca2+-dependent activation and Ca2+ sensitivity of the Acto-S1-TM ATPase activity of the thin filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CONTRACTION; BIOLOGICAL-ACTIVITY; INHIBITORY PEPTIDE; SYNTHETIC PEPTIDES; ACANTHAMOEBA ACTIN; CARDIAC TROPONIN; F-ACTIN; TROPOMYOSIN; RABBIT; BINDING	The regions of troponin I (TnI) responsible for Ca2+-dependent activation and Ca2+ sensitivity of the actin-myosin subfragment 1-tropomyosin ATPase (acto-S1-TM) activity have been determined. A colorimetric ATPase assay at pH 7.8 has been applied to reconstituted skeletal muscle thin filaments at actin:S1:TM ratios of 6:1:2. Several TnI fragments (TnI-(104-115), TnI-(1-116), and TnI-(96-148)) and TnI mutants with single amino acid substitutions within the inhibitory region (residues 104-115) were assayed to determine their roles on the regulatory function of TnI. TnI-(104-115) is sufficient for achieving maximum inhibition of the acto-S1-TM ATPase activity and its importance was clearly shown by the reduced potency of TnI mutants with single amino acid substitutions within this region. However, the function of the inhibitory region is modulated by other regions of TnI as observed by the poor inhibitory activity of TnI-(1-116) and the increased potency of the inhibitory region by TnI-(96-148). The regulatory complex composed of TnI-(96-148) plus troponin T-troponin C complex (TnT.C) displays the same Ca2+ sensitivity (pCa(50)) as intact troponin (Tn) or TnI plus TnT.C while those regulatory complexes composed of TnT.C plus either TnI-(104-115) or TnI-(1-116) had an increase in their pCa(50) values. This indicates that the Ca2+ sensitivity or responsiveness of the thin filament is controlled by TnI residues 96-148. The ability of Tn to activate the acto-S1-TM ATPase activity in the presence of calcium to the level of the acto-sl rate was mimicked by the regulatory complex composed of TnI-(1-116) plus TnT.C and was not seen with complexes composed with either TnI-(104-115) or TnI-(96-148). This indicates that the N terminus of TnI in conjunction with TnT controls the degree of activation of the ATPase activity. Although the TnI inhibitory region (104-115) is the Ca2+-sensitive switch which changes binding sites from actin-TM to TnC in the presence of calcium, its function is modulated by both the C-terminal and N-terminal regions of TnI. Thus, distinct regions of TnI control different aspects of Tn's biological function.	UNIV HEIDELBERG,INST PHYSIOL 2,D-6900 HEIDELBERG,GERMANY; UNIV SAO PAULO,DEPT BIOQUIM,SAO PAULO,BRAZIL	Ruprecht Karls University Heidelberg; Universidade de Sao Paulo	VanEyk, JE (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,MRC,GRP PROT STRUCT & FUNCT,EDMONTON,AB,CANADA.		Farah, Chuck Shaker/G-5565-2012	Farah, Chuck Shaker/0000-0003-3110-6302				CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; EATON BL, 1975, BIOCHEMISTRY-US, V14, P2718, DOI 10.1021/bi00683a025; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; HEELEY DH, 1988, BIOCHEMISTRY-US, V27, P8227, DOI 10.1021/bi00421a036; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; INGRAHAM RH, 1988, BIOCHEMISTRY-US, V27, P5891, DOI 10.1021/bi00416a011; KLUWE L, 1993, FEBS LETT, V325, P83; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; NGAI SM, 1992, J BIOL CHEM, V267, P15715; PAN BS, 1991, J BIOL CHEM, V266, P12432; Pearlstone J. R., 1995, Biophysical Journal, V68, pA166; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SMILLIE LB, 1982, MEHTODS ENZYMOL, V851, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRAUSS JD, 1996, PFLUGERS ARCH, V431, P851; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Van Eyk Jennifer E., 1993, Methods (Orlando), V5, P264, DOI 10.1006/meth.1993.1033; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; VANEYK JE, 1993, FEBS LETT, V323, P223, DOI 10.1016/0014-5793(93)81344-Y; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WILKINSON JM, 1974, BIOCHIM BIOPHYS ACTA, V359, P379, DOI 10.1016/0005-2795(74)90238-4; YANG YZ, 1979, J BIOL CHEM, V254, P2084; YANG YZ, 1979, J BIOL CHEM, V254, P7137; Zhang R., 1995, Biophysical Journal, V68, pA165; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	40	66	67	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10529	10537						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099697				2022-12-25	WOS:A1997WV26200031
J	Isaacs, JS; Chen, PC; Garza, A; Hansen, MF; Barrett, JC; Weissman, BE				Isaacs, JS; Chen, PC; Garza, A; Hansen, MF; Barrett, JC; Weissman, BE			Failure of HPV E6 to rapidly degrade p53 in human HeLa x PNET cell hybrids	ONCOGENE			English	Article						p53; E6; tumor suppressor genes	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; MAMMARY EPITHELIAL-CELLS; GENE-MUTATIONS; HUMAN KERATINOCYTES; IN-VITRO; PROTEIN; EXPRESSION; UBIQUITIN; TUMOR	The ability of the E6 protein from high risk human papillomaviruses (HPVs) to degrade p53 via the ubiquitin pathway plays a major role in the development of cervical carcinomas. We have previously generated cell hybrids between a p53 null peripheral neuroepithelioma (PNET) cell line and a cervical carcinoma HeLa cell line which exhibits efficient E6-mediated degradation of p53. All of the resulting hybrids expressed HPV 18 E6 from the HeLa parent and some of the hybrids additionally expressed HPV 16 E6. Surprisingly, in spite of abundant E6 expression, the hybrids expressed relatively high steady-state levels of the wild-type p53 protein. We then examined the hybrids to determine whether other components of the E6-mediated degradation pathway were missing or nonfunctional. Specifically, we determined that the E6-associated protein (E6-AP), essential for E6-mediated degradation, was expressed. We further verified that these hybrids had a functional ubiquitination pathway, which suggests that this phenomenon is not due to a general defect in this pathway. We therefore conclude that other unidentified, possibly cell-specific factors can play a role in the E6-mediated degradative process and may act to inhibit this process.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; BOSTON UNIV,SCH MED,CTR HUMAN GENET,BOSTON,MA 02118; NATL INST ENVIRONM HLTH SCI,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NATIONAL CANCER INSTITUTE [R03CA053318, R01CA053318, U01CA060122, R01CA044470] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60122, CA 53318, CA 44470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; Bernard Bruno A., 1993, P207; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN PC, 1994, MOL CELL BIOL, V14, P534, DOI 10.1128/MCB.14.1.534; CHEN TM, 1992, ONCOGENE, V7, P1541; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CRIPPS KJ, 1994, ONCOGENE, V9, P2739; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DONNEHOWER L, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FOURET P, 1995, AM J PATHOL, V146, P599; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GUDAS JM, 1994, CELL GROWTH DIFFER, V5, P295; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HALL IJ, 1996, IN PRESS GENES CHROM; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANDESMAN Y, 1994, ONCOGENE, V9, P1241; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE KA, 1994, ANN ONCOL         S1, V5, P85; LI Y, 1994, ONCOGENE, V9, P2261; LIANG XH, 1993, ONCOGENE, V8, P2645; LOWRY DR, 1994, P NATL ACAD SCI USA, V91, P2436; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SPANDAU DF, 1994, ONCOGENE, V9, P1861; TERVAHAUTA AI, 1994, CYTOPATHOLOGY, V5, P282, DOI 10.1111/j.1365-2303.1994.tb00432.x; THOMAS M, 1995, ONCOGENE, V10, P261; TOMINAGA O, 1993, ONCOGENE, V8, P2653; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VILLUENDAS R, 1993, BLOOD, V82, P3151; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEISSMAN B, 1980, CYTOGENET CELL GENET, V28, P227, DOI 10.1159/000131536; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WEISSMAN BE, 1990, CANCER SURV, V9, P475; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	67	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1669	1678		10.1038/sj.onc.1201001	http://dx.doi.org/10.1038/sj.onc.1201001			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135068				2022-12-25	WOS:A1997WR89300005
J	Katz, BA; Cass, RT				Katz, BA; Cass, RT			In crystals of complexes of streptavidin with peptide ligands containing the HPQ sequence the pK(a) of the peptide histidine is less than 3.0	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIDIN-BIOTIN TECHNOLOGY; STRUCTURE-BASED DESIGN; PH-DEPENDENCE; ELECTROSTATIC INTERACTIONS; CORE STREPTAVIDIN; HYDROPHOBIC CORE; PHAGE DISPLAY; ASPARTIC-ACID; BINDING; PROTEIN	The pH dependences of the affinities for streptavidin of linear and cyclic peptide ligands containing the HPQ sequence discovered by phage display were determined by plasmon resonance measurements, At pH values ranging from 3.0 to 9.0, the K-d values for Ac-A-EFSHPQNTIEGRK-NH2, cyclo-Ac-AE[CHPQGPPC]IEGRK-NH2, and cyclo-Ac-AE[CHPQFC]IEGRK-NH2, were determined by competition, and those for cyclo-[5-S-valeramide-HPQGPPC]K-NH2 were determined directly by equilibrium affinity measurements. The K-d values of the ligands increase by an average factor of 3.0 +/- 0.8 per decrease in pH unit between pH similar to 4.5 and pH similar to 6.3. Below pH similar to 4.5 there is a smaller increase in K-d values, and above pH similar to 6.3 the K-d values become relatively pH-independent. We determined the crystal structures of complexes of streptavidin with cyclo-[5-S-valeramide-HPQGPPC]K-NH2 at pH 1.5, 2.5, 3.0, and 3.5, with cyclo-Ac-[CHPQFC]-NH2 at pH 2.0, 3.0, 3.6, 4.2, 4.8, and 11.8, with cyclo-Ac-[CHPQGPPC]-NH2 at pH 2.5, 2.9, and 3.7, and with FSHPQNT at pH 4.0 and compared the structures with one another and with those previously determined at other pH values, At pH values from 3.0 to 11.8, the electron density for the peptide His side chain is strong, flat, and well defined. A hydrogen bond between the N delta 1 atom of the His and the peptide Gin amide group indicates the His of the bound peptide in the crystals is uncharged at pH greater than or equal to 3.0. By determining selected structures in two different space groups, 1222 with two crystallographically inequivalent ligand sites and 14(1)22 with one site, we show that below pH similar to 3.0, the pK(a) of the bound peptide His in the crystals is influenced by crystal packing interactions, The presence of the N delta 1(His)-N-Gln hydrogen bond along with pH dependences of the peptide affinities suggest that deprotonation of the peptide His is required for high affinity binding of HPQ-containing peptides to streptavidin both in the crystals and in solution.			Katz, BA (corresponding author), ARRIS PHARMACEUT CORP,385 OYSTER POINT BLVD,SUITE 3,S SAN FRANCISCO,CA 94080, USA.							Antosiewicz J, 1996, BIOCHEMISTRY-US, V35, P7819, DOI 10.1021/bi9601565; ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BASHFORD D, 1990, BIOCHEMISTRY-US, V9, P327; BONIFACE JJ, 1993, BIOCHEMISTRY-US, V32, P11761, DOI 10.1021/bi00095a003; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P187; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHAMBERS JL, 1979, ACTA CRYSTALLOGR B, V35, P1861, DOI 10.1107/S0567740879007925; CHENG YG, 1995, BIOCHEMISTRY-US, V34, P14879, DOI 10.1021/bi00045a032; CHILKOTI A, 1995, BIO-TECHNOL, V13, P1198, DOI 10.1038/nbt1195-1198; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DSOUZA UM, 1995, BIOCHEMISTRY-US, V34, P13635, DOI 10.1021/bi00041a044; FAY SP, 1994, CYTOMETRY, V15, P148, DOI 10.1002/cyto.990150208; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; GELIN BR, 1977, P NATL ACAD SCI USA, V74, P801, DOI 10.1073/pnas.74.3.801; GIEBEL LB, 1995, BIOCHEMISTRY-US, V34, P15430, DOI 10.1021/bi00047a006; GILSON MK, 1995, CURR OPIN STRUC BIOL, V5, P216, DOI 10.1016/0959-440X(95)80079-4; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; GREEN NM, 1966, BIOCHEM J, V101, P774, DOI 10.1042/bj1010774; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HUANG SG, 1995, BIOCHEMISTRY-US, V34, P349, DOI 10.1021/bi00001a043; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; Katz BA, 1995, J BIOL CHEM, V270, P31210, DOI 10.1074/jbc.270.52.31210; Katz BA, 1996, J AM CHEM SOC, V118, P2535, DOI 10.1021/ja9536936; KATZ BA, 1995, CHEM BIOL, V2, P591, DOI 10.1016/1074-5521(95)90123-X; KATZ BA, 1995, BIOCHEMISTRY-US, V34, P15421, DOI 10.1021/bi00047a005; Katz BA, 1996, J AM CHEM SOC, V118, P7914, DOI 10.1021/ja961357z; KATZ BA, 1995, J AM CHEM SOC, V117, P8541, DOI 10.1021/ja00138a008; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; KONIG B, 1995, SCIENCE, V268, P1144; KOSSIAKOFF AA, 1983, ANNU REV BIOPHYS BIO, V12, P159, DOI 10.1146/annurev.bb.12.060183.001111; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; MCDONALD IK, 1994, PROTEIN ENG, V8, P217; PAHLER A, 1987, J BIOL CHEM, V262, P13933; PERSSON E, 1995, BIOCHEMISTRY-US, V34, P12775, DOI 10.1021/bi00039a038; PERUTZ MF, 1978, SCIENCE, V201, P1187, DOI 10.1126/science.694508; QAMAR R, 1993, BIOCHEMISTRY-US, V32, P6802, DOI 10.1021/bi00077a035; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; Reznik GO, 1996, NAT BIOTECHNOL, V14, P1007, DOI 10.1038/nbt0896-1007; ROBERTS D, 1993, GENE, V128, P67, DOI 10.1016/0378-1119(93)90154-U; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P570, DOI 10.1107/S0021889879013273; SAGGIO I, 1993, BIOCHEM J, V293, P613, DOI 10.1042/bj2930613; SANO T, 1995, J BIOL CHEM, V270, P28204; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)90795-8; SwintKruse L, 1996, BIOCHEMISTRY-US, V35, P171, DOI 10.1021/bi9517603; URRY DW, 1994, BIOPOLYMERS, V34, P889, DOI 10.1002/bip.360340708; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; WEBER PC, 1992, BIOCHEMISTRY-US, V31, P9350, DOI 10.1021/bi00154a004; WEBER PC, 1992, J AM CHEM SOC, V114, P3197, DOI 10.1021/ja00035a004; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WEBER PC, 1994, J AM CHEM SOC, V116, P2717, DOI 10.1021/ja00086a004; WILCHEK M, 1990, METHOD ENZYMOL, V184, P5; WILCHEK M, 1990, METHOD ENZYMOL, V184, P14; WILSON NA, 1995, BIOCHEMISTRY-US, V34, P8931, DOI 10.1021/bi00028a001; ZHENG RL, 1994, J BIOL CHEM, V269, P18475	62	32	37	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13220	13228		10.1074/jbc.272.20.13220	http://dx.doi.org/10.1074/jbc.272.20.13220			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148939	hybrid			2022-12-25	WOS:A1997WZ38400052
J	Kultz, D; GarciaPerez, A; Ferraris, JD; Burg, MB				Kultz, D; GarciaPerez, A; Ferraris, JD; Burg, MB			Distinct regulation of osmoprotective genes in yeast and mammals - Aldose reductase osmotic response element is induced independent of p38 and stress-activated protein kinase Jun N-terminal kinase in rabbit kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; DEHYDROGENASE; TRANSCRIPTION; CASCADE; BINDING; WATER	In yeast glycerol-3-phosphate dehydrogenase 1 is essential for synthesis of the osmoprotectant glycerol and is osmotically regulated via the high osmolarity glycerol (HOG1) kinase pathway. Homologous protein kinases, p38, and stress-activated protein kinase/Jun N-terminal kinase (SAPK/JNK) are hyperosmotically activated in some mammalian cell lines and complement HOG1 in yeast, In the present study we asked whether p38 or SAPK/JNK signal synthesis of the osmoprotectant sorbi tol in rabbit renal medullary cells (PAP-HT25), analogous to the glycerol system in yeast, Sorbitol synthesis is catalyzed by aldose reductase (AR). Hyperosmolality increases AR transcription through an osmotic response element (ORE) in the 5'-flanking region of the AR gene, resulting in elevated sorbitol, We tested if AR-ORE is targeted by p38 or SAPK/JNK pathways in PAP-HT25 cells. Hyperosmolality (adding 150 nM NaCl) strongly induces phosphorylation of p38 and of c-Jun, a specific target of SAPK/JNK, Transient lipofection of a dominant negative mutant of SAPK kinase, SEK1-AL, into PAP-HT25 cells specifically inhibits hyperosmotically induced c-Jun phosphorylation, Transient Lipofection of a dominant negative p38 kinase mutant, MKK3-AL, into PAP-HT25 cells specifically suppresses hyperosmotic induction of p38 phosphorylation, We cotransfected either one of these mutants or their empty vector with an AR ORE luciferase reporter construct and compared the hyperosmotically induced increase in luciferase activity with that in cells lipofected with only the AR-ORE luciferase construct, Hyperosmolality increased luciferase activity equally (5-7-fold) under all conditions, We conclude that hyperosmolality induces p38 and SAPK/JNK cascades in mammalian renal cells, analogous to inducing the HOG1 cascade in yeast. However, activation of p38 or SAPK/JNK pathways is not necessary for transcriptional regulation of AR through the ORE. This finding stands in contrast to the requirement for the HOG1 pathway for hyperosmotically induced activation of yeast GPD1.			Kultz, D (corresponding author), NHLBI,KIDNEY & ELECTROLYTE METAB LAB,NIH,BLDG 9,RM 1N105,9 MEM DR,MSC 0951,BETHESDA,MD 20892, USA.		, DK/AAU-3163-2021					ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alfieri R, 1996, BIOCHEM J, V319, P601, DOI 10.1042/bj3190601; BAGNASCO SM, 1988, AM J PHYSIOL, V254, pC788, DOI 10.1152/ajpcell.1988.254.6.C788; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DOUZOU P, 1994, P NATL ACAD SCI USA, V91, P1657, DOI 10.1073/pnas.91.5.1657; Egli M, 1996, BIOCHEMISTRY-US, V35, P8489, DOI 10.1021/bi9607214; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; Lundback T, 1996, P NATL ACAD SCI USA, V93, P4754, DOI 10.1073/pnas.93.10.4754; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; Stein W., 1990, CHANNELS CARRIERS PU; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	35	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13165	13170		10.1074/jbc.272.20.13165	http://dx.doi.org/10.1074/jbc.272.20.13165			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148932	hybrid			2022-12-25	WOS:A1997WZ38400045
J	Schlaepfer, DD; Hunter, T				Schlaepfer, DD; Hunter, T			Focal adhesion kinase overexpression enhances Ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; V-SRC; PHOSPHORYLATION; FIBRONECTIN; PP125(FAK); DOMAIN; SHC; IDENTIFICATION; ASSOCIATION; PP60(SRC)	Cell adhesion to extracellular matrix proteins such as fibronectin (FN) triggers a number of intracellular signaling events including the increased tyrosine phosphorylation of the cytoplasmic focal adhesion protein-tyrosine kinase (PTK) and also the stimulation of the mitogen-activated protein kinase ERK2, Focal adhesion kinase (FAK) associates with integrin receptors, and FN-stimulated phosphorylation of FAK at Tyr-397 and Tyr-925 promotes the binding of Src family PTKs and Grb2, respectively, To investigate the mechanisms by which FAR, c-Src, and Grb2 function in FN stimulated signaling events to ERK2, we expressed wild type and mutant forms of FAK in human 293 epithelial cells by transient transfection, FAK overexpression enhanced FN-stimulated activation of ERK2 similar to 4-fold, This was blocked by co-expression of the dominant negative Asn-17 mutant Ras, indicating that FN stimulation of ERK2 was Ras-dependent. FN-stimulated c-Src PTK activity was enhanced by wild type FAR expression, whereas FN-stimulated activation of ERK2 was blocked by expression of the c-Src binding site Phe-397 mutant of FAR, Expression of the Grb2 binding site Phe-925 mutant of FAK enhanced activation of ERK2, whereas a kinase-inactive Arg-454 mutant FAK did not, Expression of wild type and Phe-925 FAK, but not Phe-397 FAK, enhanced p130(Cas) association with FAR, She tyrosine phosphorylation, and Grb2 binding to Shc after FN stimulation, FN-induced Grb2-Shc association is another pathway leading to activation of ERK2 via Ras, The inhibitory effects of Tyr-397 FAK expression show that FAR-mediated association and activation of c-Src is essential for maximal signaling to ERK2. Moreover, multiple signaling pathways are activated upon the formation of an FAK-c-Src complex, and several of these can lead to Ras dependent ERK2 mitogen-activated protein kinase activation.	SALK INST BIOL STUDIES,MOL BIOL & VIROL LAB,LA JOLLA,CA 92037	Salk Institute					NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA14195, CA39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KLEMKE RL, 1997, IN PRESS J CELL BIOL, V137; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; OWENS LV, 1995, CANCER RES, V55, P2752; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	56	348	361	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13189	13195		10.1074/jbc.272.20.13189	http://dx.doi.org/10.1074/jbc.272.20.13189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148935	hybrid			2022-12-25	WOS:A1997WZ38400048
J	Stoppler, H; Hartmann, DP; Sherman, L; Schlegel, R				Stoppler, H; Hartmann, DP; Sherman, L; Schlegel, R			The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; OPEN READING FRAME; HUMAN-FIBROBLASTS; IMMORTAL CELLS; TRANSFORMATION; DNA; KERATINOCYTES; GENE; SUFFICIENT; PROTEINS	The ''high risk'' subgroup of human papillomaviruses (e,g. HPV-16 and HPV-18) infect and induce tumors of mucosal epithelium. These neoplasms, which can progress to malignancy, retain and express the papillomavirus E6 and E7 oncogenes, In vitro, the E6 and E7 proteins associate with the cellular p53 and Rb proteins and interfere with their normal growth-regulatory functions, We report here that primary human keratinocytes transduced with the HPV-16 E6 gene, but not the E7 gene, express significant telomerase activity, However, despite this detectable enzymatic activity, EG-transduced cells continue to shorten their telomeres during in vitro passaging similar to control cells and to cells expressing the E7 and E6+E7 genes, At late passages, however, E7-transduced cells partially restore telomere length, although they lack detectable telomerase activity, demonstrating that EG-independent, telomerase-independent events mediate this change.	GEORGETOWN UNIV, MED CTR, DEPT PATHOL, MOL PATHOL PROGRAM, WASHINGTON, DC 20007 USA; TEL AVIV UNIV, SACKLER SCH MED, DEPT HUMAN MICROBIOL, IL-69978 TEL AVIV, ISRAEL	Georgetown University; Tel Aviv University; Sackler Faculty of Medicine					NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CROSS SH, 1989, NATURE, V338, P771, DOI 10.1038/338771a0; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PEI XF, 1994, PATHOBIOLOGY, V62, P43, DOI 10.1159/000163876; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; POPESCU NC, 1990, CANCER RES, V50, P1316; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; STOREY A, 1993, ONCOGENE, V8, P919; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	43	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13332	13337		10.1074/jbc.272.20.13332	http://dx.doi.org/10.1074/jbc.272.20.13332			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148955	hybrid			2022-12-25	WOS:A1997WZ38400068
J	Desai, SH; Niles, RM				Desai, SH; Niles, RM			Characterization of retinoic acid-induced AP-1 activity in B16 mouse melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; MESSENGER-RNA; PKC-ALPHA; DIFFERENTIATION; EXPRESSION; TRANSCRIPTION; GENES; SERUM; PHOSPHORYLATION	Retinoic acid (RA) induces differentiation of Die mouse melanoma cells, which is accompanied by an increase in protein kinase C alpha (PKC alpha) as well as a selective enrichment of nuclear PKC alpha., We report here that RA also increases AP-1 activity in these cells, Transient transfection of B16 cells with luciferase reporter gene constructs indicated that RA induced a concentration-dependent increase in AP-1 activity, Acute treatment (2 h) of B16 cells with phorbol dibutyrate (PDB) increased AP-1 activity by 10-fold. RA treatment did not change the expression of Jun family members; however, it decreased the expression of c-Fos, In contrast acute PDB treatment induced c-Fos expression, while having little effect on c-Jun, Five DNA-protein complexes were formed with nuclear extracts from B16 cells and an oligonucleotide containing an AP-1 consensus sequence, Several complexes were decreased in cells treated with RA, Conversely, certain complexes were increased in cells acutely treated with PDB, The slowest migrating complexes were shown to contain Fos family members, Down-regulation of PKC inhibited both the acute PDB-induced and the RA-induced increase in AP-1 activity, The selective PKC enzyme inhibitor, bisindolylmaleimide, reduced PDB-stimulated AP-1 activity, but enhanced RA-induced AP-1 activity, These results together with our previous studies suggest the intriguing possibility that PKC protein, but not enzyme activity, may be required for RA-induced AP-1 activity.	MARSHALL UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,HUNTINGTON,WV 25755	Marshall University					NATIONAL CANCER INSTITUTE [R01CA059530] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1987, ONCOGENE, V2, P79; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURHAM JP, 1985, FEBS LETT, V185, P157, DOI 10.1016/0014-5793(85)80761-4; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P542; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GRUBER JR, 1995, EXP CELL RES, V221, P377, DOI 10.1006/excr.1995.1388; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LEVINE N, 1980, LANCET, V2, P224; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; NIES R, 1987, IN VITRO, V23, P803; NILES RM, 1989, CANCER RES, V49, P4483; NILES RM, 1996, J CELL PHYSL, V168, P549; OHNO S, 1990, J BIOL CHEM, V265, P6296; PFAHL M, 1993, SKIN PHARMACOL, V6, P8, DOI 10.1159/000211158; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; ROSENBAUM SE, 1992, ARCH BIOCHEM BIOPHYS, V294, P123, DOI 10.1016/0003-9861(92)90145-M; SAMBROOK J, 1989, MOL CLONING LABORATO, P1630; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; Singer WD, 1996, J BIOL CHEM, V271, P4504; Sporn M.B., 1984, RETINOIDS, V1-2; SPORN MB, 1984, RETINOIDS, V2; YANG YHF, 1993, NEW BIOL, V3, P1206; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12809	12815		10.1074/jbc.272.19.12809	http://dx.doi.org/10.1074/jbc.272.19.12809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139741	hybrid			2022-12-25	WOS:A1997WY82900078
J	Foster, JA; Friday, BB; Maulit, MT; Blobel, C; Winfrey, VP; Olson, GE; Kim, KS; Gerton, GL				Foster, JA; Friday, BB; Maulit, MT; Blobel, C; Winfrey, VP; Olson, GE; Kim, KS; Gerton, GL			AM67, a secretory component of the guinea pig sperm acrosomal matrix, is related to mouse sperm protein sp56 and the complement component 4-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P COMPONENT; SULFATED GLYCOPROTEIN-2 CLUSTERIN; C4B-BINDING PROTEIN; POLYACRYLAMIDE GELS; EGG RECOGNITION; BINDING-PROTEIN; SPERMATOZOA; LOCALIZATION; ACROSIN; SEQUENCE	The guinea pig sperm acrosomal matrix is the dense core of the acrosome and is likely to be important in acrosome biogenesis and fertilization. Isolated acrosomal matrices are composed of a limited number of major bands when analyzed by SDS polyacrylamide gel electrophoresis, among which is a M-r 67,000 protein that we have termed AM67. Indirect immunofluorescence demonstrated that AM67 is localized to the apical segment of the cauda epididymal sperm acrosome, Immunoelectron microscopy further refined the localization of AM67 to the M1 (dorsal bulge) domain within the acrosome, Using a polymerase chain reaction product based upon tryptic peptide sequences from AM67, a lambda gt11 guinea pig testis cDNA library was screened to yield two cDNA clones that encode the AM67 peptides. Northern analysis revealed that AM67 is transcribed as a 1.9-kilobase testis-specific mRNA. The complete AM67 sequence encodes a prepropolypeptide of 533 amino acids with a calculated M-r of 59,768. Following cleavage of a probable signal sequence, the polypeptide was predicted to have a M-r of 56,851 and seven consensus sites for asparagine-linked glycosylation. The deduced amino acid sequence of AM67 is most similar to those of the mouse sperm protein sp56 and the alpha-subunits of complement component 4-binding proteins from various mammalian species. Although mouse sp56 has been reported to be a cell-surface receptor for the murine zona pellucida glycoprotein ZP3, standard immunoelectron microscopy using the anti sp56 monoclonal antibody 7C5 detected sp56 within the mouse sperm acrosome, but failed to detect sp56 on the surface of acrosome-intact mouse sperm. Furthermore, acrosomal labeling was detected in mouse sperm prepared for immunofluorescence using paraformaldehyde fixation, but was not observed with live unfixed sperm. Thus, the finding that sp56 is present within the acrosome provides further support that sp56 and AM67 are orthologues and suggests that sp56 may function in acrosomal matrix-zona pellucida interactions during and immediately following the acrosome reaction in the mouse.	UNIV PENN,MED CTR,CTR RES REPROD & WOMENS HLTH,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT DEV & CELL BIOL,PHILADELPHIA,PA 19104; MEM SLOAN KETTERING CANC CTR,DEPT CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Memorial Sloan Kettering Cancer Center; Vanderbilt University			Gerton, George L/A-1039-2007	Gerton, George L/0000-0001-9894-5640	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022899] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-07305, HD06274, HD22899] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADELSON JW, 1985, SCIENCE, V228, P993, DOI 10.1126/science.2408334; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARBOLEDA CE, 1987, J EXP ZOOL, V244, P277, DOI 10.1002/jez.1402440212; ARBOLEDA CE, 1988, DEV BIOL, V125, P217, DOI 10.1016/0012-1606(88)90075-9; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; BABA T, 1994, J BIOL CHEM, V269, P10133; BARKA T, 1963, HISTOCHEMISTRY THEOR, P28; BARNUM SR, 1991, IMMUNOL RES, V10, P28, DOI 10.1007/BF02918165; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DEVRIES JWA, 1985, EUR J CELL BIOL, V37, P81; DICARLANTONIO G, 1988, GAMETE RES, V21, P425, DOI 10.1002/mrd.1120210410; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FOSTER JA, 1994, BIOL REPROD, V51, P1222, DOI 10.1095/biolreprod51.6.1222; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GERTON GL, 1986, BIOL REPROD, V35, P1025, DOI 10.1095/biolreprod35.4.1025; GREEN DPL, 1978, J CELL SCI, V32, P137; GREEN DPL, 1978, J CELL SCI, V32, P153; GREEN DPL, 1978, J CELL SCI, V32, P177; HARDY DM, 1991, BIOCHEM J, V275, P759, DOI 10.1042/bj2750759; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KASHIWABARA S, 1990, J BIOCHEM-TOKYO, V108, P785, DOI 10.1093/oxfordjournals.jbchem.a123281; KOPF GS, 1991, ELEMENTS MAMMALIAN F, V1, P153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAIS J, 1981, P NATL ACAD SCI-BIOL, V78, P7266, DOI 10.1073/pnas.78.12.7266; LAW GL, 1994, BIOL REPROD, V50, P669, DOI 10.1095/biolreprod50.3.669; MEIZEL S, 1976, BIOL REPROD, V14, P444, DOI 10.1095/biolreprod14.4.444; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; NOLAND TD, 1989, BIOL REPROD, V40, P1057, DOI 10.1095/biolreprod40.5.1057; NOLAND TD, 1994, J BIOL CHEM, V269, P32607; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; REID MS, 1994, J BIOL CHEM, V269, P32615; ROONEY IA, 1993, IMMUNOL RES, V12, P276, DOI 10.1007/BF02918258; SCHWALBE RA, 1991, J BIOL CHEM, V266, P12896; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUZUKITOYOTA F, 1995, J ELECTRON MICROSC, V44, P135; SYLVESTER SR, 1991, BIOL REPROD, V45, P195, DOI 10.1095/biolreprod45.1.195; TALBOT P, 1985, J HISTOCHEM CYTOCHEM, V33, P1169, DOI 10.1177/33.11.4056380; TALBOT P, 1974, J REPROD FERTIL, V39, P429, DOI 10.1530/jrf.0.0390429; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESTBROOKCASE VA, 1995, DEV BIOL, V167, P338, DOI 10.1006/dbio.1995.1028; WESTBROOKCASE VA, 1994, BIOL REPROD, V51, P1, DOI 10.1095/biolreprod51.1.1; ZAO PZR, 1985, J EXP ZOOL, V234, P63, DOI 10.1002/jez.1402340109	51	116	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12714	12722		10.1074/jbc.272.19.12714	http://dx.doi.org/10.1074/jbc.272.19.12714			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139729	hybrid			2022-12-25	WOS:A1997WY82900066
J	Tjernberg, LO; Lilliehook, C; Callaway, DJE; Naslund, J; Hahne, S; Thyberg, J; Terenius, L; Nordstedt, C				Tjernberg, LO; Lilliehook, C; Callaway, DJE; Naslund, J; Hahne, S; Thyberg, J; Terenius, L; Nordstedt, C			Controlling amyloid beta-peptide fibril formation with protease-stable ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MISSENSE MUTATIONS; IN-VITRO; GENE; NEUROTOXICITY; CHROMOSOME-1; AGGREGATION; MECHANISM; LOCUS	We have previously shown that short peptides incorporating the sequence KLVFF can bind to the similar to 40-amino acid residue Alzheimer amyloid beta-peptide (A beta) and disrupt amyloid fibril formation (Tjernberg, L. O., Naslund, J., Lindqvist, F., Johansson, J., Karlstrom, A. R., Thyberg, J., Terenius, L., and Nordstedt, C., (1996) J. Biol. Chem. 271, 8545-8548), Here, it is shown that KLVFF binds stereospecifically to the homologous sequence in A beta (i.e. A beta(16-20)), Molecular modeling suggests that association of the two homologous sequences leads to the formation of an atypical anti-parallel beta-sheet structure stabilized primarily by interaction between the Lys, Leu, and COOH-terminal Phe, By screening combinatorial pentapeptide libraries exclusively composed of D-amino acids, several ligands with a general motif containing phenylalanine in the second position and leucine in the third position were identified, Ligands composed of D-amino acids were not only capable of binding A beta but also prevented formation of amyloid-like fibrils, These ligands are protease-resistant and may thus be useful as experimental agents against amyloid fibril formation in vivo.	KAROLINSKA HOSP,DEPT CLIN NEUROSCI,LAB BIOCHEM & MOL PHARMACOL,SECT DRUG DEPENDENCE RES,S-17176 STOCKHOLM,SWEDEN; PICOWER INST MED RES,MANHASSET,NY 11030; KAROLINSKA INST,DEPT CELL & MOL BIOL,MED NOBEL INST,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Northwell Health; Karolinska Institutet								BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goodman Gilman G, 1996, GOODMAN GILMANS PHAR, V9th, P3; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hughes SR, 1996, P NATL ACAD SCI USA, V93, P2065, DOI 10.1073/pnas.93.5.2065; IVERSEN LL, 1995, BIOCHEM J, V311, P1; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; TEGGE W, 1995, BIOCHEMISTRY-US, V34, P10569, DOI 10.1021/bi00033a032; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	33	211	250	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12601	12605		10.1074/jbc.272.19.12601	http://dx.doi.org/10.1074/jbc.272.19.12601			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139713	hybrid			2022-12-25	WOS:A1997WY82900050
J	Chatterjee, TK; Liu, XB; Davisson, RL; Fisher, RA				Chatterjee, TK; Liu, XB; Davisson, RL; Fisher, RA			Genomic organization of the rat pituitary adenylate cyclase-activating polypeptide receptor gene - Alternative splicing within the 5'-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; HORMONE-RELATED PEPTIDE; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; TISSUE DISTRIBUTION; SIGNAL-TRANSDUCTION; CALCITONIN RECEPTOR; PARATHYROID-HORMONE; CELL-LINE; PACAP	Pituitary adenylate cyclase-activating polypeptide (PACAP) elicits its diverse biological actions by interacting with both PACAP selective type I PACAP receptors (PACAPRs) and type II PACAPRs that do not distinguish between PACAP and vasoactive intestinal polypeptide. Using long distance polymerase chain reaction, we amplified and characterized the entire coding region of the rat type I PACAPR (rPACAPR) gene, which spans 40 kilobases and contains 15 exons, Mapping of the exons and sequencing of all intron-exon boundaries revealed a structural organization of the rPACAPR gene that is very similar to those encoding other members of the calcitonin/secretin/parathyroid hormone receptor family. Southern blot analysis demonstrated a single copy of the rPACAPR gene. A combination of rapid amplification of cDNA ends and reverse transcriptase polymerase chain reaction revealed an unexpected diversity in the rPACAPR mRNA in the 5'-untranslated (5'-UTR) region. Four rPACAPR cDNAs were identified with 5'-UTR sequences that all diverged from the genomic sequence at a site 76 bp upstream of the ATG start codon, where a consensus 3' slice acceptor sequence was located. Sequence analysis of these amplified transcripts demonstrated that they arise by tissue-specific differential usage of four exons in the 5' non-coding region of the rPACAPR gene. This study is the first to elucidate the structural organization of a PACAPR gene and to demonstrate that alternative splicing generates rPACAPR transcripts with unique 5'-UTRs.	UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242	University of Iowa; University of Iowa			Chatterjee, Rima/J-8066-2017	Fisher, Rory/0000-0003-3108-4836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041071, R01HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41071] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BUSCAIL L, 1990, FEBS LETT, V262, P77, DOI 10.1016/0014-5793(90)80158-F; CHATTERJEE TK, 1995, METH NEUROSCI, V26, P29; CHRISTOPHE J, 1993, BIOCHIM BIOPHYS ACTA, V1154, P183, DOI 10.1016/0304-4157(93)90011-C; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GOTTSCHALL PE, 1994, BRAIN RES, V637, P197, DOI 10.1016/0006-8993(94)91233-5; HART GR, 1992, J ENDOCRINOL, V134, P33, DOI 10.1677/joe.0.1340033; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HERZOG H, 1993, J BIOL CHEM, V268, P6703; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOSODA K, 1992, J BIOL CHEM, V267, P18797; HOSOYA M, 1993, BIOCHEM BIOPH RES CO, V194, P133, DOI 10.1006/bbrc.1993.1795; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JARRY H, 1992, LIFE SCI, V51, P823, DOI 10.1016/0024-3205(92)90609-S; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOSAK M, 1986, P NATL ACAD SCI USA, V83, P2850; KOVES K, 1991, NEUROENDOCRINOLOGY, V54, P159, DOI 10.1159/000125864; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MORROW JA, 1993, FEBS LETT, V329, P99, DOI 10.1016/0014-5793(93)80202-6; NANDHA KA, 1991, J ENDOCRINOL, V129, P69, DOI 10.1677/joe.0.1290069; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; OGI K, 1993, BIOCHEM BIOPH RES CO, V196, P1511, DOI 10.1006/bbrc.1993.2423; OSUGA Y, 1992, ENDOCRINOL JAPON, V39, P153; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PESQUERO JB, 1994, J BIOL CHEM, V269, P26920; PICUS DW, 1990, NATURE, V343, P564; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; RAWLINGS SR, 1994, J BIOL CHEM, V269, P5680; REN HZ, 1994, J BIOL CHEM, V269, P3104; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P315, DOI 10.1210/en.134.1.315; SEYFRIED CE, 1992, GENOMICS, V13, P832, DOI 10.1016/0888-7543(92)90162-L; SHIVERS BD, 1991, ENDOCRINOLOGY, V128, P3055, DOI 10.1210/endo-128-6-3055; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; TsaiMorris CH, 1996, J BIOL CHEM, V271, P14519, DOI 10.1074/jbc.271.24.14519; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; WARREN JB, 1991, EUR J PHARMACOL, V197, P131, DOI 10.1016/0014-2999(91)90511-N; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; YADA T, 1994, J BIOL CHEM, V269, P1290; YOKOTA C, 1995, PEPTIDES, V16, P55, DOI 10.1016/0196-9781(94)00143-T; ZHONG Y, 1994, ENDOCRINOLOGY, V135, P207, DOI 10.1210/en.135.1.207; ZOLNIEROWICZ S, 1994, J BIOL CHEM, V269, P19530	57	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12122	12131		10.1074/jbc.272.18.12122	http://dx.doi.org/10.1074/jbc.272.18.12122			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115282	hybrid			2022-12-25	WOS:A1997WX56900070
J	Horiuchi, M; Yamada, T; Hayashida, W; Dzau, VJ				Horiuchi, M; Yamada, T; Hayashida, W; Dzau, VJ			Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AT2 BINDING-SITES; TRANSCRIPTION FACTOR IRF-1; IFN-INDUCIBLE GENES; CELL-GROWTH; R3T3 CELLS; RAT; EXPRESSION; BETA; INDUCTION; SUBTYPES	The expression of the angiotensin II type 2 (AT(2)) receptor is developmentally and growth regulated. In cultured R3T3 cells, expression of this receptor is markedly induced at the confluent state and with serum deprivation. In this study we demonstrated that the removal of serum from culture media resulted in the induction of apoptosis in these cells and the addition of angiotensin II further enhanced apoptosis. We have previously identified an interferon regulatory factor (IRF) binding motif in the mouse AT(2) receptor gene promoter region. In this report, we observed that serum removal increased IRF-1 expression, with a rapid and transient decrease of IRF-2. To prove that the changes in IRFs after serum removal mediated apoptosis and up-regulated AT(2) receptor, we transfected antisense oligonucleotides for IRF-1 or IRF-2 into R3T3 cells and observed that IRF-1 antisense oligonucleotide attenuated apoptosis and abolished the up-regulation of AT(2) receptor, IRF-2 antisense oligonucleotide pretreatment did not affect the onset of apoptosis after serum removal; instead, it increased AT(2) receptor binding and enhanced angiotensin II-mediated apoptosis. Taken together, these results suggest that increased IRF-1 after serum starvation contributes to the induction of apoptosis and that increased IRF-1 up-regulates the AT(2) receptor expression after serum starvation, resulting in enhanced angiotensin II-mediated apoptosis.			Horiuchi, M (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOL,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046631, R01HL035610, R01HL035252, R37HL035610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35252, HL46631, HL35610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DAUD AI, 1988, ENDOCRINOLOGY, V122, P2727, DOI 10.1210/endo-122-6-2727; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; DUDLEY DT, 1993, REGUL PEPTIDES, V44, P199, DOI 10.1016/0167-0115(93)90243-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HORIUCHI M, 1995, J BIOL CHEM, V270, P20225, DOI 10.1074/jbc.270.34.20225; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KAMBAYASHI Y, 1993, BIOCHEM BIOPH RES CO, V194, P478, DOI 10.1006/bbrc.1993.1844; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; LEUNG KH, 1992, EUR J PHARM-MOLEC PH, V227, P63, DOI 10.1016/0922-4106(92)90143-J; LOPEZ JJ, 1994, AM J PHYSIOL, V267, pH844, DOI 10.1152/ajpheart.1994.267.2.H844; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1993, BIOCHEM BIOPH RES CO, V197, P393, DOI 10.1006/bbrc.1993.2492; NAKAJIMA M, 1997, IN PRESS P NATL ACAD; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; PALLMAN M, 1996, CIRC RES, V79, P748; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pH667, DOI 10.1152/ajpheart.1991.261.3.H667; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; VISWANATHAN M, 1992, PEPTIDES, V13, P783, DOI 10.1016/0196-9781(92)90187-8; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156	41	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11952	11958		10.1074/jbc.272.18.11952	http://dx.doi.org/10.1074/jbc.272.18.11952			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115258	hybrid			2022-12-25	WOS:A1997WX56900046
J	Hu, CD; Kariya, K; Kotani, G; Shirouzu, M; Yokoyama, S; Kataoka, T				Hu, CD; Kariya, K; Kotani, G; Shirouzu, M; Yokoyama, S; Kataoka, T			Coassociation of Rap1A and Ha-Ras with Raf-1 N-terminal region interferes with Ras-dependent activation of Raf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; SUPPRESSOR ACTIVITY; EFFECTOR REGION; IDENTIFICATION; PROTEINS; GENE; TRANSFORMATION; MUTATIONS; P21(RAS); C-RAF-1	Raf-1 is a major downstream effector of mammalian Ras. Binding of the effector domain of Ras to the Ras binding domain of Raf-1 is essential for Ras-dependent Raf-1 activation. However, Rap1A, which has an identical effector domain to that of Ras, cannot activate Raf-1 and even antagonizes several Ras functions in vivo. Recently, we identified the cysteine-rich region (CRR) of Raf-1 as another Ras-binding domain. Ha-Ras proteins carrying mutations N26G and V45E, which failed to bind to CRR, also failed to activate Raf-1, Since these mutations replace Ras residues with those of Rap1A, we examined if Rap1A lacks the ability to bind to CRR, Contrary to the expectation, Rap1A exhibited a greatly enhanced binding to CRR compared with Ha-Ras. Enhanced CRR binding was also found with Ha-Ras carrying another Rap1A-type mutation E31K. Both Rap1A and Ha Ras(E31K) mutant failed to activate Raf-1 and interfered with Ha-Ras-dependent activation of Raf-1 in Sf9 cells. Enhanced binding of Rap1A to CRR led to co-association of Rap1A and Ha-Ras with Raf-1 N-terminal region through binding to CRR and Ras-binding domain, respectively. These results suggest that Rap1A interferes with Ras dependent Raf-1 activation by inhibiting binding of Ras to Raf-1 CRR.	KOBE UNIV, SCH MED, DEPT PHYSIOL 2, CHUO KU, KOBE, HYOGO 650, JAPAN; RIKEN, INST PHYS & CHEM RES, CELLULAR SIGNALING LAB, WAKO, SAITAMA 35101, JAPAN; UNIV TOKYO, SCH SCI, DEPT BIOCHEM & BIOPHYS, BUNKYO KU, TOKYO 113, JAPAN	Kobe University; RIKEN; University of Tokyo			Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; FUJITAYOSHIGAKI J, 1991, FEBS LETT, V294, P187, DOI 10.1016/0014-5793(91)80665-P; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KISELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MINATO T, 1994, J BIOL CHEM, V269, P20845; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PIZON V, 1988, ONCOGENE, V3, P201; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKODA T, 1992, ONCOGENE, V7, P1705; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	27	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11702	11705		10.1074/jbc.272.18.11702	http://dx.doi.org/10.1074/jbc.272.18.11702			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115221	hybrid			2022-12-25	WOS:A1997WX56900009
J	Leonard, AS; Hell, JW				Leonard, AS; Hell, JW			Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY FRACTION; HETEROMERIC NMDA RECEPTORS; LONG-TERM POTENTIATION; SPINAL DORSAL HORN; 2 SIZE FORMS; RAT-BRAIN; GLUTAMATE RECEPTORS; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; MOLECULAR DIVERSITY	Ca2+ influx through N-methyl-D-aspartate (NMDA)-type glutamate receptors plays a pivotal role in synaptic plasticity during brain development as well as in mature brain. Cyclic AMP-dependent protein kinase (PKA) and members of the protein kinase C (PKC) family are also essential for various forms of synaptic plasticity and regulate the activity of different ion channels including NMDA and non-NMDA receptors. We now demonstrate that PKA and various PKC isoforms phosphorylate the NMDA receptor in vitro. The stoichiometry of [P-32]phosphate incorporation per [H-3]MK-801 binding site is greater than 1 for both PKA and PKC. Double immunoprecipitation experiments show that all three NMDA receptor subunits that are prevalent in the cortical structures, NR1, NR2A, and NR2B, are substrates for PKA as well as PKC. Two-dimensional phosphopeptide mapping reveals that the major phosphorylation sites for PKA and PKC differ for all three subunits. We provide evidence that some if not most of these sites are phosphorylated in the central nervous system of rats in vivo. The results presented in this article together with earlier electrophysiological experiments demonstrating that PKA and PKC activation increases the activity of NMDA receptors indicate that NMDA receptor potentiation can be mediated by direct phosphorylation by PKA and PKC. Collectively, these results strongly suggest that NMDA receptor functions such as control of neuronal development or expression of synaptic plasticity are modulated by PKA- and PKC-mediated phosphorylation of NMDA receptors.	UNIV WISCONSIN, DEPT PHARMACOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison			Hell, Johannes W./P-5085-2019					AMADOR M, 1991, SYNAPSE, V7, P207, DOI 10.1002/syn.890070305; ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROSE N, 1993, J BIOL CHEM, V268, P22663; BROSE N, 1994, J BIOL CHEM, V269, P16780; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GERBER G, 1989, J NEUROSCI, V9, P3606; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HELL JW, 1994, J BIOL CHEM, V269, P7390; HELL JW, 1993, J BIOL CHEM, V268, P19451; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MARKRAM H, 1992, J PHYSIOL-LONDON, V457, P491, DOI 10.1113/jphysiol.1992.sp019389; MCKERNAN RM, 1989, J NEUROCHEM, V52, P777, DOI 10.1111/j.1471-4159.1989.tb02522.x; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; ROTHMAN SM, 1987, TRENDS NEUROSCI, V22, P227; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SIEGEL SJ, 1994, P NATL ACAD SCI USA, V91, P564, DOI 10.1073/pnas.91.2.564; SPRENGEL R, 1995, LIGAND VOLTAGE GATED, P213; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; URUSHIHARA H, 1992, J BIOL CHEM, V267, P11697; WALTON GM, 1987, ANAL BIOCHEM, V161, P425, DOI 10.1016/0003-2697(87)90471-4; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WONG EHF, 1988, J NEUROCHEM, V50, P274, DOI 10.1111/j.1471-4159.1988.tb13260.x; Xia ZG, 1996, J NEUROSCI, V16, P5425	66	247	249	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12107	12115		10.1074/jbc.272.18.12107	http://dx.doi.org/10.1074/jbc.272.18.12107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115280	hybrid			2022-12-25	WOS:A1997WX56900068
J	Rangan, VS; Smith, S				Rangan, VS; Smith, S			Alteration of the substrate specificity of the malonyl-CoA/adetyl-CoA:acyl carrier protein S-acyltransferase domain of the multifunctional fatty acid synthase by mutation of a single arginine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A; SYNTHETASE; ACETYL; MECHANISM; ENZYME; GENE	The structural basis for the dual specificity of the malonyl-CoA/acetyl-CoA:acyl carrier protein S-acyl-transferase associated with the multifunctional animal fatty acid synthase has been investigated by mutagenesis. Arginine 606, which is positionally conserved in the transacylase domains of all multifunctional fatty acid and polyketide synthases, was replaced by alanine or lysine in the context of the isolated transacylase domain, and the mutant proteins were expressed in Escherichia coli. Malonyl transacylase activity of the Arg-606 --> Ala and Arg-606 --> Lys mutant enzymes was reduced by 100- and 10-fold, respectively. In contrast, acetyl transacylase activity was increased 6.6-fold in the Arg-606 --> Ala mutant and 1.7-fold in the Arg-606 --> Lys mutant, Kinetic studies revealed that selectivity of the enzyme for acetyl-CoA was increased > 16,000-fold by the Ala mutation and 16 fold by the Lys mutation, Activity toward medium chain length acyl thioesters was also increased >3 orders of magnitude by mutation of Arg-606, so that the Ala-606 enzyme is an effective medium chain length fatty acyl transacylase. These results indicate that Arg-606 plays an important role in the binding of malonyl moieties to the transacylase domain but is not required for binding of acetyl moieties; these results are also consistent with a mechanism whereby interaction between the positively charged guanidinium group of Arg-606 and the free carboxylate anion of the malonyl moiety serves to position this substrate in the active site of the enzyme.	CHILDRENS HOSP OAKLAND,RES INST,OAKLAND,CA 94609	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG SI, 1990, ACCOUNTS CHEM RES, V23, P363, DOI 10.1021/ar00179a003; GRUNNET I, 1983, BIOCHEM J, V209, P215, DOI 10.1042/bj2090215; HANSEN JK, 1980, BIOCHEM J, V186, P287, DOI 10.1042/bj1860287; JAWORSKI JG, 1993, EUR J BIOCHEM, V213, P981, DOI 10.1111/j.1432-1033.1993.tb17843.x; KNUDSEN J, 1980, BIOCHEM BIOPH RES CO, V95, P1808, DOI 10.1016/S0006-291X(80)80109-4; KNUDSEN J, 1982, BIOCHEM J, V202, P139, DOI 10.1042/bj2020139; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCCARTHY AD, 1983, FEBS LETT, V160, P296, DOI 10.1016/0014-5793(83)80986-7; MIKKELSEN J, 1985, BIOCHEM J, V227, P981, DOI 10.1042/bj2270981; Oliynyk M, 1996, CHEM BIOL, V3, P833, DOI 10.1016/S1074-5521(96)90069-1; Rangan VS, 1996, J BIOL CHEM, V271, P31749, DOI 10.1074/jbc.271.49.31749; RANGAN VS, 1997, IN PRESS PROTEIN ENG, V10; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SOULIE JM, 1984, J BIOL CHEM, V259, P134; STERN A, 1982, J BIOL CHEM, V257, P799; TSAY JT, 1992, J BIOL CHEM, V267, P6807; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; YUAN ZY, 1985, J BIOL CHEM, V260, P3532	19	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11975	11978		10.1074/jbc.272.18.11975	http://dx.doi.org/10.1074/jbc.272.18.11975			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115261	hybrid			2022-12-25	WOS:A1997WX56900049
J	Satoh, T; Aramini, JM; Li, S; Friedman, TM; Gao, JM; Edling, AE; Townsend, R; Koch, U; Choksi, S; Germann, MW; Korngold, R; Huang, ZW				Satoh, T; Aramini, JM; Li, S; Friedman, TM; Gao, JM; Edling, AE; Townsend, R; Koch, U; Choksi, S; Germann, MW; Korngold, R; Huang, ZW			Bioactive peptide design based on protein surface epitopes - A cyclic heptapeptide mimics CD4 domain 1 CC' loop and inhibits CD4 biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CLASS-II MHC; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; GP120 BINDING; SOLUBLE FORM; RESOLUTION; ADHESION	The interaction between CD4 and major histocompatibility complex class II proteins provides a critical coreceptor function for the activation of CD4(+) T cells implicated in the pathogenesis of a number of autoimmune diseases and transplantation responses. A small synthetic cyclic heptapeptide was designed and shown by high resolution NMR spectroscopy to closely mimic the CD4 domain 1 CC' surface loop. This peptide effectively blocked stable CD4-major histocompatibility complex class II interaction, possessed significant immunosuppressive activity in vitro and in. vivo, and strongly resisted proteolytic degradation. These results demonstrate the therapeutic potential of this peptide as a novel immunosuppressive agent and suggest a general strategy of drug design by using small conformationally constrained peptide mimics of protein surface epitopes to inhibit protein interactions and biological functions.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC INST, PHILADELPHIA, PA 19107 USA	Jefferson University			German, Markus W/L-1531-2013; Korngold, Robert/AAF-2686-2020	Koch, Ute/0000-0001-7914-7061; Germann, Markus/0000-0002-1674-8166	NIAID NIH HHS [AI40081] Funding Source: Medline; NINDS NIH HHS [NS34928] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034928] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DOYLE C, 1987, NATURE, V356, P626; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; Friedman TM, 1996, J BIOL CHEM, V271, P22635, DOI 10.1074/jbc.271.37.22635; HAFLER DA, 1988, J IMMUNOL, V141, P131; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KORNGOLD R, 1986, IMMUNOGENETICS, V24, P309, DOI 10.1007/BF00395536; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; Li S, 1997, P NATL ACAD SCI USA, V94, P73, DOI 10.1073/pnas.94.1.73; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MISICKA A, 1994, J MED CHEM, V37, P141, DOI 10.1021/jm00027a017; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; Satoh T, 1996, BIOCHEM BIOPH RES CO, V224, P438, DOI 10.1006/bbrc.1996.1045; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WHITE RAH, 1978, J EXP MED, V148, P664, DOI 10.1084/jem.148.3.664; WIDER G, 1993, J MAGN RESON SER B, V102, P239, DOI 10.1006/jmrb.1993.1092; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	28	67	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12175	12180		10.1074/jbc.272.18.12175	http://dx.doi.org/10.1074/jbc.272.18.12175			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115290	hybrid			2022-12-25	WOS:A1997WX56900078
J	Steenaart, NAE; Shore, GC				Steenaart, NAE; Shore, GC			Alteration of a mitochondrial outer membrane signal anchor sequence that permits its insertion into the inner membrane - Contribution of hydrophobic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; UNCOUPLING PROTEIN; PRE-SEQUENCE; DOMAIN; PRECURSOR; POLYPEPTIDE; INFORMATION; MATRIX	Tom70p is targeted and inserted into the mitochondrial outer membrane in the N-in-C-cyto orientation, via an NH2-terminal signal anchor sequence. The signal anchor is comprised of two domains: an NH2-terminal hydrophilic region which is positively charged (amino acids 1-10) followed by the predicted transmembrane segment (amino acids 11-29), Substitution of the NH2-terminal domain with a matrix-targeting signal caused the signal anchor to adopt the reverse orientation in the outer membrane (N-cyto-C-in) or, if presented to mitoplasts, to arrest protein translocation at the inner membrane without insertion, Physically separating the transmembrane segment from the matrix-targeting signal by moving it downstream within the protein resulted in a failure to arrest in either membrane, and consequently the protein was imported to the matrix, However, if the mean hydrophobicity of the Tom70p transmembrane segment was increased in these constructs, the protein inserted into the inner membrane with an N-in-C-out orientation. Therefore we have determined conditions that allow the Tom70p transmembrane domain to insert in either membrane, pass through both membranes, or arrest without insertion in the inner membrane, These results identify the mean hydrophobicity of potential transmembrane domains within bitopic proteins as an important determinant for insertion into the mitochondrial inner membrane.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; EPAND RM, 1986, J BIOL CHEM, V261, P17; GLASER SM, 1990, MOL CELL BIOL, V10, P1873, DOI 10.1128/MCB.10.5.1873; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LI JM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P233, DOI 10.1016/0005-2736(92)90001-3; LIU XQ, 1990, J BIOL CHEM, V265, P9; LIU XQ, 1988, J CELL BIOL, V107, P503, DOI 10.1083/jcb.107.2.503; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MCBRIDE HM, 1995, BBA-BIOMEMBRANES, V1237, P162, DOI 10.1016/0005-2736(95)00088-K; Millar DG, 1996, J BIOL CHEM, V271, P25823, DOI 10.1074/jbc.271.42.25823; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; MILLAR DG, 1994, J BIOL CHEM, V269, P12229; MILLER BR, 1993, J CELL BIOL, V121, P1021, DOI 10.1083/jcb.121.5.1021; NGUYEN M, 1987, J CELL BIOL, V104, P1193, DOI 10.1083/jcb.104.5.1193; NGUYEN M, 1986, J BIOL CHEM, V261, P800; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NGUYEN M, 1987, J BIOL CHEM, V262, P3929; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SKERJANC IS, 1990, J BIOL CHEM, V265, P9444; SMITH MD, 1995, J BIOL CHEM, V270, P28331; Steenaart NAE, 1996, BIOCHEMISTRY-US, V35, P3764, DOI 10.1021/bi9528053; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; Whitley P, 1995, BIOCHEM SOC T, V23, P965, DOI 10.1042/bst0230965	37	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12057	12061		10.1074/jbc.272.18.12057	http://dx.doi.org/10.1074/jbc.272.18.12057			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115273	hybrid			2022-12-25	WOS:A1997WX56900061
J	Takahashi, K; Coulombe, PA				Takahashi, K; Coulombe, PA			Defining a region of the human keratin 6a gene that confers inducible expression in stratified epithelia of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL DIFFERENTIATION; HAIR-FOLLICLES; RETINOIC ACID; MOUSE SKIN; TGF-BETA; HYPERPROLIFERATION; CELLS; SEQUENCE; INDUCTION; GROWTH	Injury to the epidermis and other stratified epithelia triggers a repair response involving the rapid induction of several genes, including keratin 6 (K6). The signaling pathways and mechanisms presiding over this induction in keratinocytes at the wound edge remain to be defined, We reported previously that of the multiple genes encoding he isoforms in human, K6a is dominant in skin epithelia (Takahashi, K., Paladini, R., Coulombe, P. A. (1995) J. Biol. Chem. 270, 18581-18592). Using bacterial LacZ as a reporter gene in transgenic mice, we show that the proximal 5.2 kilobases of 5'-upstream sequence from the K6a gene fails to direct sustained expression in any adult tissue, including those where K6 is constitutively expressed (e.g. hair follicle, nail, oral mucosa, tongue, esophagus, forestomach). In contrast, the proximal 960 base pairs of 5'-upstream sequence suffice to mediate an induction of p-galactosidase expression in a near-correct spatial and temporal fashion after injury to epidermis and other stratified epithelia. Transgene expression also occurs following topical application of phorbol esters, all-trans-retinoic acid, or 2-4-dinitro-1-fluorobenzene, all known to induce he expression in skin. Our data show that critical regulatory sequences for this inducibility are located between -960 and -550 bp in the 5'-upstream sequence of K6a and that their activity is influenced by enhancer element(s) located between -2500 and -5200 base pairs. These findings have important implications for the control of gene expression after injury to stratified epithelia.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT DERMATOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042047, R55AR042047] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42047] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; BLUMENBERG M, 1988, J MOL EVOL, V27, P203, DOI 10.1007/BF02100075; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; CLARK RAF, 1993, DERMATOLOGY GEN MED, V1, P473; Coulombe P. A., 1996, CELL VISION J ANAL M, V3, P217; FALANGA V, 1993, DERMATOL CLIN, V11, P667, DOI 10.1016/S0733-8635(18)30219-5; FINCH J, 1991, CARCINOGENESIS, V12, P1519, DOI 10.1093/carcin/12.8.1519; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; FUCHS E, 1993, J CELL SCI, P197; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Hogan B, 1994, MANIPULATING MOUSE E; JIANG CK, 1991, J INVEST DERMATOL, V96, P162, DOI 10.1111/1523-1747.ep12460939; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; JUN BD, 1988, J INVEST DERMATOL, V90, P311, DOI 10.1111/1523-1747.ep12456158; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LI Z, 1993, DEVELOPMENT, V117, P947; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; OGUIN WM, 1990, CELLULAR MOL BIOL IN, P301; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; RAMIREZ A, 1995, P NATL ACAD SCI USA, V92, P4783, DOI 10.1073/pnas.92.11.4783; ROOP DR, 1984, J BIOL CHEM, V259, P8037; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; Schweizer Juergen, 1993, P33; STARK HJ, 1987, DIFFERENTIATION, V35, P236, DOI 10.1111/j.1432-0436.1987.tb00174.x; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; Takahashi K, 1996, P NATL ACAD SCI USA, V93, P14776, DOI 10.1073/pnas.93.25.14776; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; TYNER AL, 1986, J CELL BIOL, V103, P1945, DOI 10.1083/jcb.103.5.1945; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; YOSHIKAWA K, 1995, J INVEST DERMATOL, V104, P396, DOI 10.1111/1523-1747.ep12665888	43	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11979	11985		10.1074/jbc.272.18.11979	http://dx.doi.org/10.1074/jbc.272.18.11979			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115262	hybrid			2022-12-25	WOS:A1997WX56900050
J	Young, PR; McLaughlin, MM; Kumar, S; Kassis, S; Doyle, ML; McNulty, D; Gallagher, TF; Fisher, S; McDonnell, PC; Carr, SA; Huddleston, MJ; Seibel, G; Porter, TG; Livi, GP; Adams, JL; Lee, JC				Young, PR; McLaughlin, MM; Kumar, S; Kassis, S; Doyle, ML; McNulty, D; Gallagher, TF; Fisher, S; McDonnell, PC; Carr, SA; Huddleston, MJ; Seibel, G; Porter, TG; Livi, GP; Adams, JL; Lee, JC			Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; MAP KINASE; CYTOKINE BIOSYNTHESIS; SIGNAL-TRANSDUCTION; NUCLEOTIDE BINDING; YEAST; PHOSPHORYLATION; INTERLEUKIN-1; CELLS; CASCADE	The site of action of a series of pyridinyl imidazole compounds that are selective inhibitors of p38 mitogen-activated protein kinase in vitro and block proinflammatory cytokine production in vivo has been determined, Using Edman sequencing, I-125-SB206718 was shown to cross-link to the nonphosphorylated Escherichia coli-expressed p38 kinase at Thr(175), which is proximal to the ATP binding site, Titration calorimetric studies with E. coli-expressed p38 kinase showed that SB203580 bound with a stoichiometry of 1:1 and that binding was blocked by preincubation of p38 kinase with the ATP analogue, FSBA (5'-[p-(fluorosulfonyl)benzoyl]adenosine), which covalently modifies the ATP binding site, The intrinsic ATPase activity of the nonphosphorylated enzyme was inhibited by SB203580 with a K-m of 9.6 mM, Kinetic studies of active, phosphorylated yeast-expressed p38 kinase using a peptide substrate showed that SB203580 was competitive with ATP with a K-i of 21 nM and that kinase inhibition correlated with binding and biological activity, Mutagenesis indicated that binding of I-125-SB206718 was dependent on the catalytic residues K53 and D168 in the ATP pocket, These findings indicate that the pyridinyl imidazoles act in vivo by inhibiting p38 kinase activity through competition with ATP and that their selectivity is probably determined by differences in nonconserved regions within or near the ATP binding pocket.	SMITHKLINE BEECHAM PHARMACEUT,DEPT COMPARAT GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MACROMOL SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHYS & STRUCT CHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Young, PR (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL IMMUNOL,UE0548,POB 1539,KING OF PRUSSIA,PA 19406, USA.		Carr, Steven A./AAH-8366-2019	Doyle, Michael/0000-0003-4569-6315				ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Boehm JC, 1996, J MED CHEM, V39, P3929, DOI 10.1021/jm960415o; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; Garnes KT, 1996, J LABELLED COMPD RAD, V38, P637, DOI 10.1002/(SICI)1099-1344(199607)38:7<637::AID-JLCR871>3.0.CO;2-T; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAGIWARA M, 1987, MOL PHARMACOL, V31, P523; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HICKS JB, 1976, GENETICS, V83, P245; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOIDE K, 1995, CHEM BIOL, V2, P601, DOI 10.1016/1074-5521(95)90124-8; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JC, 1994, AGENTS ACTIONS, V41, pC191, DOI 10.1007/BF01987633; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	50	527	538	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12116	12121		10.1074/jbc.272.18.12116	http://dx.doi.org/10.1074/jbc.272.18.12116			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115281	hybrid			2022-12-25	WOS:A1997WX56900069
J	Baeckstrom, D				Baeckstrom, D			Post-translational fate of a mucin-like leukocyte sialoglycoprotein (CD43) aberrantly expressed in a colon carcinoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SIALOGLYCOPROTEIN; LEUKOSIALIN CD43; ANTIGEN; SIALOPHORIN; ACTIVATION; ADHESION; SELECTIN; ANTIBODY; CLONING; SURFACE	This paper describes the biosynthesis of L-CanAg, a mucin-like glycoprotein which carries the carcinoma-associated carbohydrate epitope sialyl-Lewis a and is secreted by the colon adenocarcinoma cell line COLO 205, Recently, it has been shown that L-CanAg is a novel glycoform of CD43, a surface sialoglycoprotein normally found only on hematopoietic cells. Immunoprecipitation with alpha-GPEP18, a novel antiserum against the cytoplasmic domain of CD43, detected a transmembrane form of L-CanAg carrying sialyl-Lewis a, Cell surface biotinylation experiments demonstrated the presence of transmembrane L-CanAg at the plasma membrane and that COLO 205, unlike the leukocyte cell line HL-60, contained significant amounts of glycosylated intracellular CD43, Immunoprecipitation of phosphate-labeled COLO 205 cells revealed that membrane bound L-CanAg, like leukocyte CD43, is a phosphoprotein. Interestingly, both surface- and phosphate-labeled L-CanAg were eluted earlier from a gel filtration column than their unlabeled counterparts, indicating that this method could separate membrane-bound L-CanAg from its soluble form, Immunoprecipitations of pulse-chase-labeled COLO 205 lysates fractionated by gel filtration showed that decrease in membrane-bound L-CanAg was concomitant with an increase in the intracellular soluble form, Together, these data indicate that transmembrane L-CanAg is fully glycosylated and phosphorylated before the extracellular domain is cleaved off and stored inside the cell before exocytosis.	GOTHENBURG UNIV,DEPT BIOCHEM MED,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg								AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BAECKSTROM D, 1995, J BIOL CHEM, V270, P13688, DOI 10.1074/jbc.270.23.13688; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; Forstner Janet F., 1994, P1255; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; JOHANSSON C, 1991, TUMOR BIOL, V12, P159, DOI 10.1159/000217701; LINDHOLM L, 1983, INT ARCH ALLER A IMM, V71, P178, DOI 10.1159/000233384; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; ORR GA, 1981, J BIOL CHEM, V256, P761; PILLER V, 1989, J BIOL CHEM, V264, P18824; REMOLD-O'DONNELL E, 1990, Immunodeficiency Reviews, V2, P151; RIEU P, 1992, EUR J IMMUNOL, V22, P3021, DOI 10.1002/eji.1830221138; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANCHEZMATEOS P, 1995, BLOOD, V86, P2228, DOI 10.1182/blood.V86.6.2228.bloodjournal8662228; Santamaria M, 1996, CANCER RES, V56, P3526; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; WONG RCK, 1990, J IMMUNOL, V144, P1455	24	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11503	11509						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111064				2022-12-25	WOS:A1997WW00900080
J	Belhassen, L; Feron, O; Kaye, DM; Michel, T; Kelly, RA				Belhassen, L; Feron, O; Kaye, DM; Michel, T; Kelly, RA			Regulation by cAMP of post-translational processing and subcellular targeting of endothelial nitric-oxide synthase (Type 3) in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN HEART-RATE; VENTRICULAR MYOCYTES; CAVEOLAE; INTERNALIZATION; PALMITOYLATION; ASSOCIATION; ACTIVATION; PROTEINS	Cardiac myocytes express the nitric-oxide synthase isoform originally identified in endothelial cells, termed eNOS or NOS3, where it plays a role in regulating myocyte responsiveness to both adrenergic and muscarinic cholinergic autonomic nervous system agonists, eNOS in endothelial cells has been shown to undergo extensive post-translational processing, and in cardiac myocytes as well as endothelial cells, eNOS has been shown to be targeted to plasmalemmal caveolae, a process that is dependent on myristoylation and palmitoylation, Other post-translational modifications essential for the correct subcellular targeting of eNOS have not been described previously, We demonstrate, using [S-35]methionine pulse-chase experiments, that native eNOS in adult rat ventricular myocytes is initially translated as a nonpalmitoylated 150-kDa isoform, which is associated with cytosolic and intracellular membrane-enriched fractions, This is subsequently processed to a palmitoylated 135-kDa isoform, which is found only in a sarcolemma-enriched membrane fraction, Forskolin, an agent that elevates intracellular cAMP, rapidly inhibited processing of the 150-kDa isoform to the 135-kDa isoform and transport of eNOS to the sarcolemma, effects paralleled by protein kinase A-dependent phosphorylation of the larger eNOS isoform, Forskolin also decreased palmitoylation of the 135-kDa isoform, although it did not accelerate depalmitoylation of sarcolemmal eNOS, as determined by pulse-chase experiments with [H-3]palmitate, Thus, post-translational processing of a 150-kDa isoform of myocyte eNOS appears to be necessary for intracellular trafficking of the enzyme to sarcolemmal caveolae, Both the post-translational processing and subcellular targeting of eNOS appear to be modified by changes in intracellular cAMP, an effect that may have important implications for cardiac myocyte responsiveness to autonomic agonists in vivo.	HARVARD UNIV, SCH MED,BRIGHAM & WOMENS HOSP,DEPT MED, DIV CARDIOVASC, BOSTON, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School			FERON, Olivier/AAM-6395-2020; Kaye, David/AAF-1202-2021	FERON, Olivier/0000-0001-5360-0286; Kaye, David/0000-0003-4058-0372	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046457, P50HL052320, R01HL046457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52320, HL46457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Belhassen L, 1996, J CLIN INVEST, V97, P1908, DOI 10.1172/JCI118622; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FINKEL MS, 1995, J PHARMACOL EXP THER, V272, P945; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; HAN X, 1995, J GEN PHYSIOL, V106, P45, DOI 10.1085/jgp.106.1.45; HAN X, 1994, J PHYSIOL-LONDON, V476, P309, DOI 10.1113/jphysiol.1994.sp020132; Han X, 1996, CIRC RES, V78, P998, DOI 10.1161/01.RES.78.6.998; Kaye DM, 1996, CIRC RES, V78, P217, DOI 10.1161/01.RES.78.2.217; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li SW, 1996, J BIOL CHEM, V271, P3863; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MERY PF, 1993, J BIOL CHEM, V268, P26286; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	35	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11198	11204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111020				2022-12-25	WOS:A1997WW00900036
J	Krejsa, CM; Nadler, SG; Esselstyn, JM; Kavanagh, TJ; Ledbetter, JA; Schieven, GL				Krejsa, CM; Nadler, SG; Esselstyn, JM; Kavanagh, TJ; Ledbetter, JA; Schieven, GL			Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors - Redox independent activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; T-CELL ACTIVATION; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; RAT ADIPOCYTES; KINASE-ACTIVITY; LYMPHOCYTES-T; PHOSPHORYLATION; VANADATE; INDUCTION	The role of intracellular oxidative stress in the mechanism of action of phosphotyrosine phosphatase (PTP) inhibitors was studied using three vanadium-based compounds, Sodium orthovanadate (Na3VO4), sodium oxodiperoxo(1,10-phenanthroline)vanadate(V) (pV(phen), and bis(maltolato) oxovanadium(IV) (BMOV) differentially induced oxidative stress in lymphocytes, Treatment with pV(phen), which caused intracellular oxidation, induced strong protein tyrosine phosphorylation compared with Na3VO4 and BMOV, Syk family kinases and the mitogen-activated protein kinase erk2 were rapidly activated by pV(phen) but not by BMOV or Na3VO4. In contrast, both BMOV and pV(phen) strongly activated NF-kappa B. The antioxidant pyrrolidine dithiocarbamate (PDTC) greatly diminished the intracellular oxidation and protein phosphotyrosine accumulation induced by pV(phen), Pretreatment of cells with PDTC reduced and delayed the activation of Syk kinases and erk2, However, NF-kappa B activation by pV(phen) was markedly enhanced in lymphocytes pretreated with PDTC, and another antioxidant, N-acetylcysteine, did not prevent the activation of NF-kappa B by BMOV, These results indicate a role for oxidative stress in the biological effects of some PTP inhibitors, whereas NF-kappa B activation by PTP inhibitors is mediated by mechanisms independent of intracellular redox status.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA; UNIV WASHINGTON, DEPT ENVIRONM HLTH, SEATTLE, WA 98195 USA	Bristol-Myers Squibb; University of Washington; University of Washington Seattle					NIA NIH HHS [AG01751] Funding Source: Medline; NIEHS NIH HHS [ES04696] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BASS DA, 1983, J IMMUNOL, V130, P1910; BEVAN AP, 1995, AM J PHYSIOL-ENDOC M, V268, pE60, DOI 10.1152/ajpendo.1995.268.1.E60; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixon JE, 1995, ANN NY ACAD SCI, V766, P18, DOI 10.1111/j.1749-6632.1995.tb26644.x; FANTUS IG, 1994, DIABETES, V43, P375, DOI 10.2337/diabetes.43.3.375; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; Goldfine AB, 1995, MOL CELL BIOCHEM, V153, P217, DOI 10.1007/BF01075941; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KOONG AC, 1994, CANCER RES, V54, P1425; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; McNeill JH, 1995, MOL CELL BIOCHEM, V153, P175, DOI 10.1007/BF01075935; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; NAKAI M, 1995, BIOL PHARM BULL, V18, P719; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OETKEN C, 1994, MOL IMMUNOL, V31, P1295, DOI 10.1016/0161-5890(94)90047-7; PENDERGRAST PS, 1994, SCIENCE, V265, P959, DOI 10.1126/science.8052855; POSNER BI, 1994, J BIOL CHEM, V269, P4596; SCHIEVEN GL, 1995, J BIOL CHEM, V270, P20824, DOI 10.1074/jbc.270.35.20824; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHIEVEN GL, 1994, TRENDS ENDOCRIN MET, V5, P383, DOI 10.1016/1043-2760(94)90106-6; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHAVER A, 1993, INORG CHEM, V32, P3109, DOI 10.1021/ic00066a024; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; STEVENSON MA, 1994, CANCER RES, V54, P12; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	54	127	133	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11541	11549						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111069				2022-12-25	WOS:A1997WW00900085
J	Redd, MJ; Arnaud, MB; Johnson, AD				Redd, MJ; Arnaud, MB; Johnson, AD			A complex composed of Tup1 and Ssn6 represses transcription in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN BETA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; GENE-EXPRESSION; HOMEO DOMAIN; ALPHA-2 REPRESSION; DIGEORGE-SYNDROME; REGULATORY GENE; DNA-BINDING; YEAST	The Saccharomyces cerevisiae Tup1 protein is a member of a family of WD repeat containing proteins that are involved in repression of transcription, Tup1, along with the Ssn6 protein, represses a wide variety of genes in yeast including cell type-specific and glucose repressed genes, Tup1 and Ssn6 are recruited to these specific gene sets by interaction with sequence-specific DNA binding proteins, In this work, a protein complex containing Ssn6 and Tup1 was purified to determine its composition. The size of the complex is estimated to be 440 kDa, Tup1 and Ssn6, which are both phosphoproteins, are the only proteins present in stoichiometric amounts in the complex, We also demonstrate that this purified complex represses transcription in an in vitro assay.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; CHEN SM, 1993, MOL CELL BIOL, V13, P831, DOI 10.1128/MCB.13.2.831; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; HALFORD S, 1993, HUM MOL GENET, V2, P2099, DOI 10.1093/hmg/2.12.2099; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KUMAR A, 1995, P NATL ACAD SCI USA, V92, P3343, DOI 10.1073/pnas.92.8.3343; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LAMOUR V, 1995, HUM MOL GENET, V4, P791, DOI 10.1093/hmg/4.5.791; MORTIMER RK, 1969, YEASTS, V1, P385; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; ROSENBLUMVOS LS, 1991, MOL CELL BIOL, V11, P5639, DOI 10.1128/MCB.11.11.5639; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SHERWOOD PW, 1993, MOL CELL BIOL, V13, P28, DOI 10.1128/MCB.13.1.28; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; Song WJ, 1996, MOL CELL BIOL, V16, P115; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TAL M, 1985, J BIOL CHEM, V260, P9976; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VARNASSI US, 1996, MOL CELL BIOL, V16, P6707; WAHI M, 1995, GENETICS, V140, P79; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	42	86	92	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11193	11197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111019				2022-12-25	WOS:A1997WW00900035
J	Schramek, H; Feifel, E; Healy, E; Pollack, V				Schramek, H; Feifel, E; Healy, E; Pollack, V			Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in Madin-Darby canine kidney-C7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; MAMMALIAN SOMATIC-CELLS; IN-VITRO; MAP; RAF; PATHWAY; TRANSFORMATION; CASCADE	Overexpression of a constitutively active mitogen-activated protein kinase kinase (MAPKK or MEK) induces neuronal differentiation in adrenal pheochromocytoma 12 cells but transformation in fibroblasts. In the present study, we used a constitutively active MAPK/extracellular signal-regulated kinase (ERK) kinase 1 (MEK1) mutant to investigate the function of the highly conserved MEK1-ERK2 signaling module in renal epithelial cell differentiation and proliferation. Stable expression of constitutively active MEK1 (CA-MEK1) in epithelial MDCK-C7 cells led to an increased basal and serum-stimulated ERK1 and ERK2 phosphorylation as well as ERK2 activation when compared with mock-transfected cells. In both mock-transfected and CA-MEK1-transfected MDCK C7 cells, basal and serum-stimulated ERK1 and ERK2 phosphorylation was almost abolished by the synthetic MEK inhibitor PD098059. Increased ERK2 activation due to stable expression of CA-MEK1 in MDCK-C7 cells was associated with epithelial dedifferentiation as shown by both a dramatic alteration in cell morphology and an abolished cytokeratin expression but increased vimentin expression. In addition, we obtained a delayed and reduced serum-stimulated cell proliferation in CA-MEK1-transfected cells (4.6-fold increase in cell number/cm(2) after 5 days of serum stimulation) as compared with mock-transfected controls (12.9-fold increase in cell number/cm(2) after 5 days), This result was confirmed by flow cytometric DNA analysis showing that stable expression of CA-MEK1 decreased the proportion of MDCK-C7 cells moving from G(0)G(1) to G(2)/M as compared with both untransfected and mock-transfected cells. Taken together, our data demonstrate an association of increased basal and serum-stimulated activity of the MEK1-ERK2 signaling module with epithelial dedifferentiation and growth inhibition in MDCK-C7 cells. Thus, the MIEK1-ERK2 signaling pathway could act as a negative regulator of epithelial differentiation thereby leading to an attenuation of MDCK-C7 cell proliferation.	NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND	University College Dublin	Schramek, H (corresponding author), UNIV INNSBRUCK, DEPT PHYSIOL, A-6010 INNSBRUCK, AUSTRIA.							BRUNET A, 1994, ONCOGENE, V9, P3379; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P318; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MORDRET G, 1993, BIOL CELL, V79, P193, DOI 10.1016/0248-4900(93)90138-5; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	20	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11426	11433						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111053				2022-12-25	WOS:A1997WW00900069
J	Stafford, GA; Morse, RH				Stafford, GA; Morse, RH			Chromatin remodeling by transcriptional activation domains in a yeast episome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; NUCLEOSOME DISRUPTION; ESTROGEN-RECEPTOR; PHO5 PROMOTER; SACCHAROMYCES-CEREVISIAE; IN-VIVO; DNA-BINDING; GAL4; GENE; TRANSACTIVATION	We examine the generality of transcription factor-mediated chromatin remodeling by monitoring changes in chromatin structure in a yeast (Saccharomyces cerevisiae) episome outside of the context of a natural promoter. The episome has a well defined chromatin structure and a binding site for the transcription factor GAL4 but lacks a nearby functional TATA element or transcription start site, so that changes in chromatin structure are unlikely to be caused by transcription, To separate changes caused by binding and by activation domains, we use both GAL4 and a chimeric, hormone-dependent activator consisting of the GAZA DNA-binding domain, an estrogen receptor (ER) hormone-binding domain, and a VP16 activation domain (Louvion, J.-F., Havaux-Copf, B. and Picard, D. (1993) Gene (Amst.) 131, 129-134). Both GAL4 and GAL4 . ER . VP1G show very little perturbation of chromatin structure in their nonactivating configurations. Substantial additional perturbation occurs upon activation. This additional perturbation is marked by changes in micrococcal nuclease cleavage patterns, restriction endonuclease accessibility, and DNA topology and is not seen with the nonactivating derivative GAL4 . ER. Remodeling by GAL4 . ER . VP1G is detectable within 15 min following hormone addition and is complete within 45 min, suggesting that replication is not required. We conclude that activation domains can exert a major influence on chromatin remodeling by increasing binding affinity and/or by recruitment of other chromatin remodeling activities and that this remodeling can occur outside the context of a bona fide promoter.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, MOL GENET PROGRAM, ALBANY, NY 12201 USA; SUNY ALBANY, SCH PUBL HLTH, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany				Morse, Randall/0000-0003-0000-8718	NIGMS NIH HHS [GM51993] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051993] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Bunker CA, 1996, P NATL ACAD SCI USA, V93, P10820, DOI 10.1073/pnas.93.20.10820; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANCIS MK, 1995, J BIOL CHEM, V270, P11502, DOI 10.1074/jbc.270.19.11502; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GILBERT DM, 1992, NUCLEIC ACIDS RES, V20, P4525, DOI 10.1093/nar/20.17.4525; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Givens RM, 1996, J MOL BIOL, V257, P53, DOI 10.1006/jmbi.1996.0146; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KLADDE MP, 1994, P NATL ACAD SCI USA, V91, P1361, DOI 10.1073/pnas.91.4.1361; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LOHR D, 1995, J BIOL CHEM, V270, P27671, DOI 10.1074/jbc.270.46.27671; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; MORSE RH, 1991, J MOL BIOL, V222, P133, DOI 10.1016/0022-2836(91)90198-F; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; PHAM TA, 1991, J BIOL CHEM, V266, P18179; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; ROSE MD, 1960, METHODS YEAST GENETI; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SAAVEDRA RA, 1986, CELL, V45, P65, DOI 10.1016/0092-8674(86)90538-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VASHEE S, 1995, P NATL ACAD SCI USA, V92, P10683, DOI 10.1073/pnas.92.23.10683; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x	62	30	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11526	11534						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111067				2022-12-25	WOS:A1997WW00900083
J	Allera, C; Lazzarini, G; Patrone, E; Alberti, I; Barboro, P; Sanna, P; Melchiori, A; Parodi, S; Balbi, C				Allera, C; Lazzarini, G; Patrone, E; Alberti, I; Barboro, P; Sanna, P; Melchiori, A; Parodi, S; Balbi, C			The condensation of chromatin in apoptotic thymocytes shows a specific structural change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; NUCLEAR CHROMATIN; CHICKEN ERYTHROCYTES; HISTONE ACETYLATION; DNA; ENDONUCLEASE; CLEAVAGE; ACTIVATION; ABSENCE	Chromatin condensation and DNA cleavage at internucleosomal sites have been recognized early as hallmarks of apoptosis, and it has been suggested that extensive DNA chain scission could directly result in the formation of dense chromatin bodies, Here we have shown that no causal relationship exists between DNA degradation and chromatin condensation in glucocorticoid-induced thymocyte apoptosis, The chromatin rearrangement occurred independent of as well as prior to DNA cleavage and involved a specific conformational change at the nucleosome level, in the early stages of the process, the core particles appeared to be tightly packed face-to-face in smooth 11-nm filaments that progressively folded to generate a closely woven network, The network finally collapsed, producing dense apoptotic bodies. Since trypsin digestion relaxed condensed chromatin and histone H4 underwent appreciable deacetylation in the apoptotic cell, we suggest that changes in the DNA-histone interactions represented a major modulating factor of condensation.	IST NAZL RIC CANC, I-16132 GENOA, ITALY; IST STUDI CHIMICOFIS MACROMOL SINTET & NAT, I-16146 GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST			Barboro, Paola/AAE-7144-2019	Barboro, Paola/0000-0001-9074-9290				ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BALBI C, 1989, BIOCHEMISTRY-US, V28, P3220, DOI 10.1021/bi00434a016; BARBORO P, 1993, BIOPHYS J, V65, P1690, DOI 10.1016/S0006-3495(93)81212-8; CAVAZZA B, 1991, BIOCHEMISTRY-US, V30, P9060, DOI 10.1021/bi00101a022; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Labarbe R, 1996, BIOCHEMISTRY-US, V35, P3319, DOI 10.1021/bi951636j; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGARKOVA MA, 1995, J BIOL CHEM, V270, P20239, DOI 10.1074/jbc.270.35.20239; LOIDL P, 1986, NUCLEIC ACIDS RES, V14, P3745; NICKEL BE, 1987, BIOCHEMISTRY-US, V26, P4417, DOI 10.1021/bi00388a034; NICKERSON JA, 1989, P NATL ACAD SCI USA, V86, P177, DOI 10.1073/pnas.86.1.177; NICOLINI C, 1983, SCIENCE, V219, P176, DOI 10.1126/science.6849127; OBERHAMMER F, 1993, J CELL SCI, V104, P317; REDDI KK, 1967, METHOD ENZYMOL, V12, P257; RUSSO I, 1995, BIOCHEMISTRY-US, V34, P301, DOI 10.1021/bi00001a037; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SOGO JM, 1989, METHOD ENZYMOL, V170, P142; SUN XM, 1994, BIOCHEM PHARMACOL, V47, P187; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; WALKER PR, 1994, BIOCHEM CELL BIOL, V72, P615, DOI 10.1139/o94-081; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WYLLIE AH, 1982, AM J PATHOL, V109, P78; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233; ZHANG DE, 1986, BIOCHEM J, V240, P857, DOI 10.1042/bj2400857; ZLATANOVA J, 1994, P NATL ACAD SCI USA, V91, P5277, DOI 10.1073/pnas.91.12.5277	29	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10817	10822						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099736				2022-12-25	WOS:A1997WV26200070
J	Chen, SP; Brockenbrough, JS; Dove, JE; Aris, JP				Chen, SP; Brockenbrough, JS; Dove, JE; Aris, JP			Homocitrate synthase is located in the nucleus in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR PROTEIN; LOCALIZATION; BIOSYNTHESIS; ENCODES; LYSINE; GENE	We have generated monoclonal antibodies against nuclear proteins from the yeast Saccharomyces cerevisiae. The monoclonal antibodies react with proteins of 47 and 49 kDa on immunoblots and with partially overlapping sets of proteins on two-dimensional nonequilibrium pH gradient electrophoresis-SDS blots. Immunofluorescence localization shows a nuclear staining pattern. Immunoscreening a yeast expression library yielded five independent full-length clones of two open reading frames from chromosome IV, corresponding to YDL182w (LYS20) and YDL131w in the Saccharomyces genome data base. These two open reading frames are predicted to encode homocitrate synthase isozymes of 47 and 49 kDa, respectively. A clone carrying YDL182w was sequenced in its entirety and directs the expression of a 47-kDa protein in Escherichia coli. A clone carrying YDL131w expresses a 49-kDa protein in E. coli. Yeast grown in minimal medium plus lysine show significant reductions in nuclear immunofluorescence staining. Cell fractionation studies localize the 47- and 49-kDa proteins to the nucleus. Nuclear fractionation studies reveal that a portion of the 47- and 49-kDa proteins can only be extracted with DNase digestion and high salt. The localization of homocitrate synthase to the nucleus is unexpected given previous reports that homocitrate synthase is present in mitochondria and the cytoplasm in S. cerevisiae.	UNIV FLORIDA, HLTH SCI CTR, DEPT ANAT & CELL BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida				Aris, John/0000-0002-6475-064X	NIGMS NIH HHS [GM48586, R01 GM048586-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BETTERTO.H, 1968, BIOCHIM BIOPHYS ACTA, V170, P459, DOI 10.1016/0304-4165(68)90036-6; BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; DEBEUS E, 1994, J CELL BIOL, V127, P1799, DOI 10.1083/jcb.127.6.1799; FELDHERR CM, 1994, INT REV CYTOL, V151, P183, DOI 10.1016/S0074-7696(08)62633-9; Hong B, 1997, MOL CELL BIOL, V17, P378, DOI 10.1128/MCB.17.1.378; JAKLITSCH WM, 1990, BIOCHEM J, V269, P247, DOI 10.1042/bj2690247; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KNULL HR, 1992, CURR TOP CELL REGUL, V33, P15; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Ramos F, 1996, YEAST, V12, P1315, DOI 10.1002/(SICI)1097-0061(199610)12:13<1315::AID-YEA20>3.3.CO;2-H; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SIRAGANIAN RP, 1983, METHOD ENZYMOL, V92, P17; TRACY JW, 1975, P NATL ACAD SCI USA, V72, P1802, DOI 10.1073/pnas.72.5.1802; TUCCI AF, 1972, ARCH BIOCHEM BIOPHYS, V153, P742, DOI 10.1016/0003-9861(72)90393-1; VERHASSELT P, 1995, YEAST, V11, P961, DOI 10.1002/yea.320111007; WOLFE KH, 1997, IN PRESS NATURE; ZELENAYATROITSKAYA O, 1995, EMBO J, V14, P3268, DOI 10.1002/j.1460-2075.1995.tb07330.x	24	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10839	10846						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099739				2022-12-25	WOS:A1997WV26200073
J	Clark, GJ; Kinch, MS; RogersGraham, K; Sebti, SM; Hamilton, AD; Der, CJ				Clark, GJ; Kinch, MS; RogersGraham, K; Sebti, SM; Hamilton, AD; Der, CJ			The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; TUMOR-SUPPRESSOR ACTIVITY; ONCOGENIC RAS; R-RAS; POINT MUTATIONS; MAMMALIAN-CELLS; AMINO-ACIDS; H-RAS; ACTIVATION; GENE	Presently, nothing is known about the function of the Pas-related protein Rheb. Since Rheb shares significant sequence identity with the core effector domains of Ras and KRev-1/Rap1A, it may share functional similarities with these two structurally related, yet functionally distinct, small GTPases. Furthermore, since like Pas, Rheb terminates with a COOP terminus that is likely to signal for farnesylation, it may be a target for the farnesyl-transferase inhibitors that block Pas processing and function. To compare Rheb function with those of Pas and KRev-1, we introduced mutations into Rheb that generate constitutively active or dominant negative forms of Pas and Ras-related proteins and were designated Rheb(64L) and Rheb(20N), respectively. Expression of wild type or mutant Rheb did not alter the morphology or growth properties of NIH 3T3 cells. Thus, aberrant Rheb function is distinct from that of Ras and fails to cause cellular transformation. Instead, similar to KRev-1, co-expression of Rheb antagonized oncogenic Ras transformation and signaling. In vitro and in vivo analyses showed that like Ras, Rheb proteins are farnesylated and are sensitive to farnesyltransferase inhibition. Thus, it is possible that Rheb function may be inhibited by farnesyltransferase inhibitors treatment and, consequently, may contribute to the ability of these inhibitors to impair Ras transformation.	PURDUE UNIV, DEPT BASIC MED SCI, W LAFAYETTE, IN 47907 USA; UNIV S FLORIDA, MOFFITT CANC RES CTR, TAMPA, FL 33612 USA; UNIV PITTSBURGH, DEPT CHEM, PITTSBURGH, PA 15260 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Clark, GJ (corresponding author), UNIV N CAROLINA, DEPT PHARMACOL, CB 7365, FLOB, CHAPEL HILL, NC 27599 USA.			Der, Channing/0000-0002-7751-2747; Kinch, Michael/0000-0003-3939-3756	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA042978, R01CA063071] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA42978, CA63071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1995, GTPASES BIOL, V1, P377; BOLLAG G, 1992, CANCER BIOL, V3, P199; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1994, ONCOGENE, V9, P3281; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DER CJ, 1996, ANTI-CANCER DRUG, V37, P165; FARRELL FX, 1993, BIOCHEM J, V289, P349, DOI 10.1042/bj2890349; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Foster R, 1996, MOL CELL BIOL, V16, P2689; GIBBS JB, 1997, IN PRESS ANN REV PHA; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KHOSRAVIFAR R, 1995, METHOD ENZYMOL, V255, P46; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MAGEE AI, 1992, BIOCHEM SOC T, V20, P497, DOI 10.1042/bst0200497; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAEZ R, 1994, ONCOGENE, V9, P2977; SATO KY, 1994, CANCER RES, V54, P552; SATTLER I, 1996, REGULATION RAS SIGNA; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	72	140	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10608	10615						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099708				2022-12-25	WOS:A1997WV26200042
J	deTurco, EBR; Deretic, D; Bazan, NG; Papermaster, DS				deTurco, EBR; Deretic, D; Bazan, NG; Papermaster, DS			Post-Golgi vesicles cotransport docosahexaenoyl-phospholipids and rhodopsin during frog photoreceptor membrane biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; ELECTRON-MICROSCOPIC AUTORADIOGRAPHY; RETINA SUBCELLULAR-FRACTIONS; NEWLY SYNTHESIZED RHODOPSIN; BOVINE RETINA; FATTY-ACIDS; <1-C-14>EICOSATETRAENOATE 20-4(N-6); DOCOSAPENTAENOATE 22-5(N-3); VERTEBRATE RETINA	Post-Golgi vesicles budding from the trans-Golgi network (TGN) are involved in the vectorial transport and delivery of rhodopsin to photoreceptor rod outer segments (ROS). We report here that newly synthesized docosahexaenoyl (DHA) phospholipids are sequestered and cotransported by rhodopsin-bearing post-Golgi vesicles to ROS, Frog retinas were pulse-labeled with [S-35]methionine/cysteine and [H-3]DHA prior to ROS isolation and subcellular fractionation. After a 1-h pulse, relatively uniform [H-3]DHA-lipid labeling (DPM/mu g protein) was observed in all fractions enriched in post-Golgi vesicles, TGN, Golgi, and endoplasmic reticulum (ER) membranes. During the subsequent 2-h chase translocation of free [H-3]DHA from ROS to the photoreceptor inner segment contributed to an additional overall increase in labeling of lipids. The specific activity (dpm/nmol DHA) in ER-enriched fraction was similar or higher than in other subcellular fractions after both the pulse and the chase, indicating that the bulk of [H-3]DHA-lipids was synthesized in the ER. After the chase a a-fold increase in labeling of lipids in the ER and Golgi and a 2.6-fold in lighter TGN-enriched fractions was observed. The highest labeling was in the post-Golgi vesicle fraction (4-fold increase), with [H-3]DHA-phosphatidylcholine and [H-3]DHA-phosphatidylethanolamine showing the greatest increase. At the same time, newly synthesized [S-35]rhodopsin shifted from the ER and Golgi toward TGN and post-Golgi fractions. Therefore, sequestration and association of [S-35]rhodopsin and [H-3]DHA-lipids in a TGN membrane domain occurs prior to their exit and subsequent vectorial cotransport on post-Golgi vesicles to ROS. Labeling of ROS lipids was very low, with phosphatidylinositol and diacylglycerols displaying the highest labeling, This indicates that other mechanisms by-passing Golgi, i.e. facilitated by lipid carrier proteins, may also contribute to molecular replacement of disc membrane DHA-phospholipids, particularly phosphatidylinositol.	LOUISIANA STATE UNIV,CTR NEUROSCI,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT OPHTHALMOL,NEW ORLEANS,LA 70112; UNIV MICHIGAN,DEPT OPHTHALMOL,ANN ARBOR,MI 48105; UNIV MICHIGAN,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48105; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284	Louisiana State University System; Louisiana State University System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Texas System; University of Texas Health San Antonio			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NEI NIH HHS [EY 6891] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adler R., 1986, RETINA MODEL CELL BI, P297; ANDREWS LD, 1981, EXP EYE RES, V33, P1, DOI 10.1016/S0014-4835(81)80076-0; ANDREWS LD, 1983, J CELL BIOL, V97, P749, DOI 10.1083/jcb.97.3.749; Aveldano de Caldironi M.I., 1980, Neurochemistry International, V1, P381, DOI 10.1016/0197-0186(80)90074-1; AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024; AVELDANO MI, 1983, J LIPID RES, V24, P620; BAZAN NG, 1986, PROG LIPID RES, V25, P595, DOI 10.1016/0163-7827(86)90122-0; BAZAN NG, 1982, PHOSPHOLIPIDS NERVOU, P49; BAZAN NG, 1990, NUTR BRAIN, P1; BESHARSE JC, 1980, J CELL BIOL, V87, P451, DOI 10.1083/jcb.87.2.451; BIBB C, 1974, J CELL BIOL, V61, P327, DOI 10.1083/jcb.61.2.327; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; CHEN YS, 1973, EXP EYE RES, V17, P517, DOI 10.1016/0014-4835(73)90082-1; CHOE HG, 1990, EXP EYE RES, V51, P167, DOI 10.1016/0014-4835(90)90069-7; CHOE HG, 1990, EXP EYE RES, V51, P159, DOI 10.1016/0014-4835(90)90068-6; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; DERETIC D, 1993, J CELL SCI, V106, P803; DERETIC D, 1991, J CELL BIOL, V113, P1281, DOI 10.1083/jcb.113.6.1281; DERETIC D, 1995, J CELL SCI, V108, P215; DERETIC D, 1995, PROG RETIN EYE RES, V14, P249, DOI 10.1016/1350-9462(94)00004-3; DERETIC D, 1994, J BIOL CHEM, V269, P16853; Deretic D, 1996, J BIOL CHEM, V271, P2279, DOI 10.1074/jbc.271.4.2279; DERETIC D, 1993, METH NEUROSCI, V15, P108; DETURCO EBR, 1990, J NEUROSCI RES, V27, P522, DOI 10.1002/jnr.490270413; DETURCO EBR, 1991, J NEUROSCI, V11, P3667; DETURCO EBR, 1992, INVEST OPHTHALMOL  S, V32, P705; DETURCO EBR, 1993, CURR EYE RES, V13, P21; DUDLEY PA, 1978, FEBS LETT, V95, P57, DOI 10.1016/0014-5793(78)80051-9; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; FLIESLER SJ, 1995, EXP EYE RES, V60, P57, DOI 10.1016/S0014-4835(05)80084-3; FLIESLER SJ, 1987, J BIOL CHEM, V262, P17516; FOLCH J, 1957, J BIOL CHEM, V226, P497; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GHALAYINI AJ, 1992, J BIOL CHEM, V267, P17977; GIUSTO NM, 1986, BIOCHIM BIOPHYS ACTA, V860, P137, DOI 10.1016/0005-2736(86)90508-0; GIUSTO NM, 1986, BIOCHIM BIOPHYS ACTA, V877, P440, DOI 10.1016/0005-2760(86)90210-9; GORDON WC, 1993, INVEST OPHTH VIS SCI, V34, P2402; GORDON WC, 1990, J NEUROSCI, V10, P2190; JIAO XD, 1993, INVEST OPHTH VIS SCI, V34, P1328; LEE J, 1995, INVEST OPHTH VIS SCI, V36, P2032; LOUIE K, 1991, EXP EYE RES, V53, P309, DOI 10.1016/0014-4835(91)90235-7; LOUIE K, 1988, BIOCHEMISTRY-US, V27, P9014, DOI 10.1021/bi00425a020; MARCHESELLI VL, 1990, J NUTR BIOCH, V1, P231; MATHEKE ML, 1984, J NEUROSCI, V4, P1086; MATHEKE ML, 1984, J NEUROSCI, V4, P1093; MERCURIO AM, 1982, J NEUROCYTOL, V11, P295, DOI 10.1007/BF01258248; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PAPERMASTER DS, 1975, BIOCHEMISTRY-US, V14, P1343, DOI 10.1021/bi00678a001; PAPERMASTER DS, 1986, J HISTOCHEM CYTOCHEM, V34, P5, DOI 10.1177/34.1.2934469; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; REDDY TS, 1984, CURR EYE RES, V3, P1225, DOI 10.3109/02713688409000826; ROQUE ME, 1995, EXP EYE RES, V60, P631, DOI 10.1016/S0014-4835(05)80005-3; ROTSTEIN NP, 1987, BIOCHIM BIOPHYS ACTA, V921, P221, DOI 10.1016/0005-2760(87)90022-1; ROTSTEIN NP, 1987, BIOCHIM BIOPHYS ACTA, V921, P235, DOI 10.1016/0005-2760(87)90023-3; SELLNER P, 1994, INVEST OPHTH VIS SCI, V35, P443; SELLNER PA, 1991, INVEST OPHTH VIS SCI, V32, P1149; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; URBANI L, 1990, J BIOL CHEM, V265, P1919; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; WETZEL MG, 1993, J NEUROCYTOL, V22, P397, DOI 10.1007/BF01195560; WIEGAND RD, 1983, EXP EYE RES, V37, P150; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700; ZIMMERMAN WF, 1988, EXP EYE RES, V47, P247, DOI 10.1016/0014-4835(88)90008-5	64	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10491	10497						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099692				2022-12-25	WOS:A1997WV26200026
J	Fukushima, K; HaraKuge, S; Ohkura, T; Seko, A; Ideo, H; Inazu, T; Yamashita, K				Fukushima, K; HaraKuge, S; Ohkura, T; Seko, A; Ideo, H; Inazu, T; Yamashita, K			Lectin-like characteristics of recombinant human interleukin-1 beta recognizing glycans of the glycosylphosphatidylinositol anchor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ALKALINE-PHOSPHATASE; CARBOHYDRATE MOIETY; TRYPANOSOMA-BRUCEI; IL-1 RECEPTOR; GROWTH; GLYCOPROTEIN; HEPARIN; PROTEIN; UROMODULIN; BINDING	We found that S-35-labeled recombinant human interleukin-1 beta (rhIL-1 beta) binds phosphatidylinositol-specific phospholipase C-treated human placental alkaline phosphatase, phosphatidylinositol-specific phospholipase C-treated trypanosome surface variant glycoproteins, and urinary uromodulin immobilized on plates or immobilized on CNBr-activated Sepharose 4B. The interaction between rhIL-1 beta and these glycoproteins was lectin-like, since it was inhibited in the presence of specific saccharides, i.e. mannose 6-phosphate or synthetic Ac-NH . CH2 . CH2 .PO(4) over bar-->6Man alpha 1-->(+/-2Man alpha 1-->+/-6Man alpha 1-->)-propyl at about 1 mu M. On the other hand, a wide variety of compounds including biantennary sugar chains derived from these glycoproteins as well as ethanolamine phosphate, inositol phosphate, mannose 6-sulfate, mannose 1-phosphate, glucose B-phosphate, and mannitol 6-phosphate did not show any inhibitory effect at concentrations up to 1 mM. These results indicate that rhIL-1 beta interacts with these glycoproteins via the mannose 6-phosphate diester of glycans on the glycosylphosphatidylinositol (GPI) anchor. Furthermore, when monolayers of polarized Madin-Darby canine kidney cells on polycarbonate filter membranes were incubated with n(35)S-rhlL-1 beta in either the apical or basolateral chamber, S-35-interleukin-1 beta was found to bind specifically to the apical membranes with a K-a value of 4.6 x 10(7) M-1, and the specific interaction was inhibited by 1 mu M mannose g-phosphate. Since the mannose 6-phosphate diester moiety exists only in the GPI glycans on plasma membranes, it was evident that interleukin-1 beta can directly interact with the mannose 6-phosphate diester component of the intact glycan of GPI anchors on plasma membranes.	NOGUCHI INST, ITABASHI KU, TOKYO 173, JAPAN; SASAKI INST, DEPT BIOCHEM, CHIYODA KU, TOKYO 101, JAPAN				Inazu, Toshiyuki/R-1966-2019					ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BACLAROVASTANDE.J, 1984, EMBO J, V3, P2687; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; ENDO T, 1988, J BIOCHEM-TOKYO, V103, P182, DOI 10.1093/oxfordjournals.jbchem.a122228; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FUKUSHIMA K, 1993, ARCH BIOCHEM BIOPHYS, V304, P144, DOI 10.1006/abbi.1993.1332; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; JOSEPHLIAUZUN E, 1990, GENE, V8, P291; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1989, METHOD ENZYMOL, V179, P304; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LUCAS R, 1994, SCIENCE, V263, P814, DOI 10.1126/science.8303299; MARUGG JE, 1986, TETRAHEDRON LETT, V27, P2661, DOI 10.1016/S0040-4039(00)84611-0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MUCHMORE AV, 1987, J IMMUNOL, V138, P2547; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; OGATA S, 1988, J BIOL CHEM, V263, P10489; PANNECOUCKE X, 1994, TETRAHEDRON, V50, P6569, DOI 10.1016/S0040-4020(01)89687-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PORAT R, 1991, SCIENCE, V254, P430, DOI 10.1126/science.1833820; REDMAN CA, 1994, BIOCHEM J, V302, P861, DOI 10.1042/bj3020861; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P600; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; SHERBLOM AP, 1989, J IMMUNOL, V143, P939; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLACK J, 1993, J BIOL CHEM, V268, P2513; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; TAMM I, 1952, J EXP MED, V95, P71, DOI 10.1084/jem.95.1.71; TOMOMURA M, 1990, BIOCHEM BIOPH RES CO, V171, P603, DOI 10.1016/0006-291X(90)91189-Y; VEHMEYER K, 1988, LIFE SCI, V43, P1591, DOI 10.1016/0024-3205(88)90530-9; YAMANOI T, 1994, B CHEM SOC JPN, V67, P1359, DOI 10.1246/bcsj.67.1359; YAMASHITA K, 1980, BIOCHEM BIOPH RES CO, V96, P1335, DOI 10.1016/0006-291X(80)90097-2; YAMASHITA K, 1981, J BIOL CHEM, V256, P4789	40	25	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10579	10584						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099704				2022-12-25	WOS:A1997WV26200038
J	Li, GP; D'Souza-Schorey, C; Barbieri, MA; Cooper, JA; Stahl, PD				Li, GP; D'Souza-Schorey, C; Barbieri, MA; Cooper, JA; Stahl, PD			Uncoupling of membrane ruffling and pinocytosis during Ras signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE KINASE; GTP-BINDING PROTEINS; IN-VITRO; ACTIVATION; 3-KINASE; PATHWAY; RAB5; WORTMANNIN; INTERACTS	Activation of Ras stimulates cell. surface membrane ruffling and pinocytosis. Although seen as coupled events, our study demonstrates that membrane ruffling and pinocytosis are regulated by distinct Ras signal transduction pathways, Ras controls membrane ruffling via the small GTPase Rac. In BHK-21 cells, expression of the constitutively active Rac1(G12V) mutant, via a Sindbis virus vector, resulted in a dramatic stimulation of membrane ruffling without affecting the uptake of horseradish peroxidase. Expression of Ha-Ras(G12V), an activated Pas mutant, stimulated both membrane ruffling and horseradish peroxidase uptake. The Ha-Ras(G12V)-stimulated pinocytosis but not membrane ruffling was abolished by either wortmannin or co-expression with a dominant negative mutant of Rab5, Rab5(S34N), Expression of the activated Rab5(Q79L) mutant mimics the stimulatory effect of Ha-Ras(G12V) on pinocytosis but not membrane ruffling. Our data indicate that Ha-Ras(G12V) separately activates Rab5-dependent pinocytosis and Rad-dependent membrane ruffling.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Washington University (WUSTL); Fred Hutchinson Cancer Center			Stahl, Philip/D-6315-2012; Li, Guangpu/GRS-5397-2022					AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LI GP, 1993, J BIOL CHEM, V268, P24475; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NOBES CD, 1995, J CELL SCI, V108, P225; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	34	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10337	10340						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099668				2022-12-25	WOS:A1997WV26200002
J	Longley, MJ; Pierce, AJ; Modrich, P				Longley, MJ; Pierce, AJ; Modrich, P			DNA polymerase delta is required for human mismatch repair in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLON-CANCER; AUXILIARY PROTEIN; TUMOR-CELLS; MICROSATELLITE INSTABILITY; NUCLEAR EXTRACTS; CALF THYMUS; HOMOLOG; REPLICATION; MUTATIONS; BINDING	HeLa nuclear extract was resolved into a depleted fraction incapable of supporting mismatch repair in vitro, and repair activity was restored upon the addition of a purified fraction isolated from HeLa cells by in vitro complementation assay, The highly enriched complementing activity copurified with a DNA polymerase, and the most pure fraction contained DNA polymerase delta but was free of detectable DNA polymerases alpha and epsilon. Calf thymus DNA polymerase delta also fully restored mismatch repair to the depleted extract, indicating DNA polymerase delta is required for mismatch repair in human cells. However, due to the presence of DNA polymerases a and epsilon in the depleted extract, potential involvement of one or both of these activities in the reaction cannot be excluded.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute				Modrich, Paul/0000-0001-8708-9885; Pierce, Andrew/0000-0001-9062-0307	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Aebi S, 1996, CANCER RES, V56, P3087; ANTHONEY A, 1996, CANCER RES, V56, P1374; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Brown NC, 1995, METHOD ENZYMOL, V262, P202; COOPER DL, 1993, J BIOL CHEM, V268, P11823; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; Downey KM, 1995, METHOD ENZYMOL, V262, P84; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HAWN MT, 1995, CANCER RES, V55, P3721; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAHUE RS, 1988, MUTAT RES, V198, P37, DOI 10.1016/0027-5107(88)90037-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Pirrotta V, 1980, Methods Enzymol, V65, P89; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TAN CK, 1986, J BIOL CHEM, V261, P2310; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang TSF, 1995, METHOD ENZYMOL, V262, P77; WANG TSF, 1996, DNA REPLICATION EUKA, P461; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002	50	166	173	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10917	10921						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099749				2022-12-25	WOS:A1997WV26200083
J	MyrsenAxcrona, U; Karlsson, S; Sundler, F; Ahren, B				MyrsenAxcrona, U; Karlsson, S; Sundler, F; Ahren, B			Dexamethasone induces neuropeptide Y (NPY) expression and impairs insulin release in the insulin-producing cell line RINm5F - Release of NPY and insulin through different pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET AMYLOID POLYPEPTIDE; IN-SITU HYBRIDIZATION; PANCREATIC-POLYPEPTIDE; CA-2+ CHANNELS; RAT PANCREAS; PEPTIDE-YY; SECRETION; MOUSE; BIOSYNTHESIS; PROHORMONE	Neuropeptide Y (NPY) occurs in adrenergic as well as in non-adrenergic nerves innervating the islets of Langerhans and inhibits glucose-stimulated insulin secretion, Recently we demonstrated that NPY is expressed within islet beta cells of the rat pancreas following treatment with dexamethasone in vivo. In this study we examined the cellular expression of NPY following dexamethasone treatment of the insulin-producing cell line RINm5F, which under control conditions does not express or release NPY. The cells were cultured with or without dexamethasone (100 nM) for 5 days. Over the 5-day culture period, dexamethasone time dependently induced an increased release of NPY with a concomitant decrease in the release of insulin. Northern blot and in situ hybridization revealed a corresponding time-dependent increase in the amount of NPY transcripts and in the number of cells labeled for NPY mRNA, whereas immunocytochemistry for NPY revealed only a few immunoreactive cells, indicating a rapid release of the formed peptide, Following 5 days of culture with dexamethasone, acute stimulation with D-glyceraldehyde (10 mM) or KCl (20 mM) Ca2+ dependently stimulated the release of insulin. In contrast neither stimulation with D-glyceraldehyde or KCI nor removal of extracellular Ca2+ affected the release of NPY, Furthermore the D-glyceraldehyde. and KCl-induced increase in cytosolic Ca2+ evident in control RINm5F cells, was impaired after dexamethasone treatment, We conclude that RINm5F cells show steroid-sensitive plasticity and express NPY after dexamethasone treatment concomitantly with a decreased insulin secretion and impaired increase in cytosolic Ca2+ upon depolarization with KCl or stimulation with D-glyceraldehyde, We also conclude that NPY and insulin secretion are regulated differently and suggest that the inability of the removal of extracellular Ca2+ to inhibit NPY secretion and the failure of D-glyceraldehyde and KCl to stimulate NPY secretion reflect a constitutive release of this peptide from the cells in contrast to the regulated release of insulin.	LUND UNIV,DEPT PHYSIOL & NEUROSCI,SECT NEUROENDOCRINE CELL BIOL,S-22185 LUND,SWEDEN; LUND UNIV,DEPT MED,S-20502 MALMO,SWEDEN	Lund University; Lund University								BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGIORGIO R, 1992, PEPTIDES, V13, P91, DOI 10.1016/0196-9781(92)90145-S; DUNNE MJ, 1986, J MEMBRANE BIOL, V93, P271, DOI 10.1007/BF01871181; FERNANDEZMEJIA C, 1992, ENDOCRINOLOGY, V130, P1660, DOI 10.1210/en.130.3.1660; FISCHER B, 1990, ENDOCRINOLOGY, V126, P2635, DOI 10.1210/endo-126-5-2635; Goodman PA, 1996, MOL CELL ENDOCRINOL, V120, P139, DOI 10.1016/0303-7207(96)03830-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; Hendry S. H. C., 1993, BIOL NEUROPEPTIDE Y, P65; JAMAL H, 1991, ENDOCRINOLOGY, V129, P3372, DOI 10.1210/endo-129-6-3372; KAHN SE, 1993, DIABETOLOGIA, V36, P570, DOI 10.1007/BF02743276; Karlsson S, 1996, PEPTIDES, V17, P909; Kayo T, 1996, J BIOL CHEM, V271, P10731, DOI 10.1074/jbc.271.18.10731; MA YH, 1995, ENDOCRINOLOGY, V136, P2622, DOI 10.1210/en.136.6.2622; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MISAKI N, 1992, NEUROCHEM INT, V21, P185, DOI 10.1016/0197-0186(92)90145-H; Myrsen U, 1996, DIABETES, V45, P1306, DOI 10.2337/diabetes.45.10.1306; MYRSEN U, 1995, REGUL PEPTIDES, V57, P65, DOI 10.1016/0167-0115(95)00020-C; MYRSEN U, 1995, REGUL PEPTIDES, V60, P19, DOI 10.1016/0167-0115(95)00114-5; MYRSENAXCRONA U, 1997, IN PRESS REGUL PEPT; OGAWA A, 1992, J CLIN INVEST, V90, P497, DOI 10.1172/JCI115886; PETTERSSON M, 1987, CELL TISSUE RES, V248, P43, DOI 10.1007/BF01239960; PHILIPPE J, 1990, ENDOCRINOLOGY, V127, P1640, DOI 10.1210/endo-127-4-1640; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; ROENFELDT M, 1992, N-S ARCH PHARMACOL, V346, P527; SATONAKA K, 1992, J MED SCI, V38, P191; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SHER E, 1992, EUR J PHARMACOL, V216, P407, DOI 10.1016/0014-2999(92)90438-A; SKOGLUND G, 1991, DIABETES, V40, P660, DOI 10.2337/diabetes.40.6.660; Sundler F., 1993, BIOL NEUROPEPTIDE Y, P157, DOI [10.1007/978-1-59259-465-8, DOI 10.1007/978-1-59259-465-8]; SUNDLER F, 1991, ENDOCRINE PANCREAS, P29; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WAEBER G, 1993, ENDOCRINOLOGY, V133, P1061, DOI 10.1210/en.133.3.1061; WAEBER G, 1995, PEPTIDES, V16, P921, DOI 10.1016/0196-9781(95)00057-Q; WELSH M, 1988, BIOMED BIOCHIM ACTA, V47, P299; WESTERMARK P, 1992, DIABETOLOGIA, V35, P297, DOI 10.1007/BF00401195; WIDERLOV E, 1988, J PSYCHIATR RES, V22, P69, DOI 10.1016/0022-3956(88)90030-1	44	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10790	10796						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099732				2022-12-25	WOS:A1997WV26200066
J	Ni, J; Abrahamson, M; Zhang, M; Fernandez, MA; Grubb, A; Su, J; Yu, GL; Li, YL; Parmelee, D; Xing, L; Coleman, TA; Gentz, S; Thotakura, R; Nguyen, N; Hesselberg, M; Gentz, R				Ni, J; Abrahamson, M; Zhang, M; Fernandez, MA; Grubb, A; Su, J; Yu, GL; Li, YL; Parmelee, D; Xing, L; Coleman, TA; Gentz, S; Thotakura, R; Nguyen, N; Hesselberg, M; Gentz, R			Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C AMYLOID ANGIOPATHY; CATHEPSIN-B; GEL ELECTROPHORESIS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; GENE FAMILY; GAMMA-TRACE; IDENTIFICATION; EXPRESSION; NUCLEOTIDES	A new member of the human cystatin superfamily, called cystatin E, has been found by expressed sequence tag (EST) sequencing in amniotic cell and fetal skin epithelial cell cDNA libraries. The sequence of a full-length amniotic cell cDNA clone contained an open reading frame encoding a putative 28-residue signal peptide and a mature protein of 121 amino acids, including four cysteine residues and motifs of importance for the inhibitory activity of Family 2 cystatins like cystatin C. Recombinant cystatin E was produced in a baculovirus expression system and isolated. An antiserum against the recombinant protein could be used for affinity purification of cystatin E hom human urine, as confirmed by N-terminal sequencing. The mature recombinant protein processed by insect cells started at amino acid 4 (cystatin C numbering), and displayed reversible inhibition of papain and cathepsin B (K-i values of 0.39 and 32 nM, respectively), in competition with substrate. Cystatin E is thus a functional cysteine proteinase inhibitor despite relatively low amino acid sequence similarities with human cystatins (26-34% identity with sequences for the Family 2 cystatins C, D, S, SN, and SA; <30% with the Family 1 cystatins, A and B, and domains 2 and 3 of the Family 3 cystatin, kininogen), Unlike other human low M-r cystatins, cystatin E is a glycoprotein, carrying an N-linked carbohydrate chain at position 108. Northern blot analysis revealed that the cystatin E gene is expressed in most human tissues, with the highest mRNA amounts found in uterus and liver. A strikingly high incidence of cystatin E clones in cDNA libraries from fetal skin epithelium and amniotic membrane cells (>0.5% of clones sequenced) indicates a protective role of cystatin E during fetal development.	UNIV LUND HOSP,DEPT CLIN CHEM,INST LAB MED,S-22185 LUND,SWEDEN; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	Lund University; Skane University Hospital; GlaxoSmithKline; Human Genome Sciences Inc			Abrahamson, Magnus/CAG-9507-2022	Grubb, Anders/0000-0002-0125-3662				ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ADAMS MD, 1995, NATURE, V377, P3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASSFALGMACHLEIDT I, 1988, BIOL CHEM H-S, V369, P263; BALBIN M, 1994, J BIOL CHEM, V269, P23156; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165; COLEMAN TA, 1997, IN PRESS GENE; COX SW, 1989, J PERIODONTAL RES, V24, P353, DOI 10.1111/j.1600-0765.1989.tb00882.x; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5, P9; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; ESNARD A, 1988, FEBS LETT, V236, P475, DOI 10.1016/0014-5793(88)80080-2; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; GENTZ R, 1992, EUR J BIOCHEM, V210, P545, DOI 10.1111/j.1432-1033.1992.tb17453.x; GRUBB A, 1982, P NATL ACAD SCI-BIOL, V79, P3024, DOI 10.1073/pnas.79.9.3024; GRUBB A, 1984, FEBS LETT, V170, P370, DOI 10.1016/0014-5793(84)81346-0; HALL A, 1992, J ENZYM INHIB, V6, P113, DOI 10.3109/14756369209040742; HALL A, 1995, J BIOL CHEM, V270, P5115, DOI 10.1074/jbc.270.10.5115; HALL A, 1993, BIOCHEM J, V291, P123, DOI 10.1042/bj2910123; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; ISEMURA S, 1991, J BIOCHEM, V110, P648, DOI 10.1093/oxfordjournals.jbchem.a123634; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; LINDAHL P, 1994, BIOCHEMISTRY-US, V33, P4384, DOI 10.1021/bi00180a036; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; NORTH MJ, 1990, PARASITOL TODAY, V6, P270, DOI 10.1016/0169-4758(90)90189-B; OLAFSSON I, 1990, SCAND J CLIN LAB INV, V50, P85, DOI 10.3109/00365519009091569; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNITTGER S, 1993, GENOMICS, V16, P50, DOI 10.1006/geno.1993.1139; Sloane B F, 1990, Semin Cancer Biol, V1, P137; THIESSE M, 1994, DNA CELL BIOL, V13, P97, DOI 10.1089/dna.1994.13.97; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	45	136	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10853	10858						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099741				2022-12-25	WOS:A1997WV26200075
J	Zumbansen, M; Stoffel, W				Zumbansen, M; Stoffel, W			Tumor necrosis factor alpha activates NF-kappa B in acid sphingomyelinase-deficient mouse embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK DISEASE; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR; HUMAN-URINE; CELL-DIFFERENTIATION; PHOSPHOLIPASE-C; PROTEIN-KINASE; CERAMIDE; PURIFICATION; EXPRESSION	Tumor necrosis factor alpha (TNF-alpha) is one of the most potent inducer of the nuclear transcription factor kappa B (NF-kappa B). Activation of NF-kappa B is initiated by phosphorylation of the inhibitory subunit of the I kappa B-alpha-NF-kappa B complex. This leads to the dissociation of the complex and degradation of I kappa B-alpha. NF-kappa B is translocated into the nucleus. The sphingomyelin pathway is thought to mediate the TNF-alpha-induced activation of NF-kappa B by its second messenger ceramide. We have used the recently established acid sphingomyelinase-deficient mouse line (asmase(-/-) mice) to evaluate the role of acid sphingomyelinase in the TNF-alpha-induced signal transduction pathway. Here we present experimental evidence that acid sphingomyelinase is not involved in the TNF-alpha-induced activation of NF-kappa B. TNF-alpha treatment induced the dissociation and degradation of I kappa B-alpha and the nuclear translocation of NF-kappa B in embryonic fibroblasts derived from asmase(-/-) and wild type mice indiscriminately.	UNIV COLOGNE, FAC MED, NEUROSCI LAB, INST BIOCHEM, D-50931 COLOGNE, GERMANY	University of Cologne								ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; LEVADE T, 1991, BIOCHEM J, V275, P211, DOI 10.1042/bj2750211; LIU J, 1994, J BIOL CHEM, V269, P3047; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARUYAMA EN, 1989, J NEUROCHEM, V52, P611, DOI 10.1111/j.1471-4159.1989.tb09163.x; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; QUINTERN LE, 1991, METHOD ENZYMOL, V197, P536; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1995, CYTOKINES PRACTICAL, P93; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SPENCE MW, 1979, BRAIN RES, V168, P543, DOI 10.1016/0006-8993(79)90308-1; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STUFFEL W, 1971, HOPPESEYLERS Z PHYSL, V352, P1058; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	51	66	66	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10904	10909						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099747				2022-12-25	WOS:A1997WV26200081
J	Bol, DK; Kiguchi, K; GimenezConti, I; Rupp, T; DiGiovanni, J				Bol, DK; Kiguchi, K; GimenezConti, I; Rupp, T; DiGiovanni, J			Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice	ONCOGENE			English	Article						insulin-like growth factor-1; skin; tumor promotion; hyperplasia	FACTOR-I RECEPTOR; FACTOR-ALPHA; GENE-EXPRESSION; MESSENGER-RNA; SKIN TUMORIGENESIS; MOUSE SKIN; PAPILLOMAS; EPIDERMIS; INDUCTION; CELLS	Transgenic animals were developed to assess the role of insulin-like growth factor 1 (IGF-1) in skin growth, differentiation and organization, as well as its importance in tumor formation. Expression of a human IGF-1 cDNA was targeted to the interfollicular epidermis of transgenic mice using a human keratin 1 promoter construct (HK1). Transgenic animals (HK1.IGF-1 mice) could be identified at birth by early ear unfolding and excessive ear and skin growth compared to nontransgenic littermates. Further examination of the skin from these mice showed epidermal hyperplasia and hyperkeratosis, marked thickening of the dermis and hypodermis, and early hair follicle generation in newborns. The severity of this phenotype correlated with transgene expression both of which subsided,vith age. Adult HK1.IGF-1 mice developed spontaneous tumors following treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) alone and exhibited an exaggerated epidermal proliferative response following treatment with the tumor promoter compared to non transgenic littermates. Additionally, HK1.IGF-1 transgenic mice developed papillomas faster and in markedly greater numbers compared to non-transgenic littermates in standard initiation-promotion experiments. The data presented suggest an important role for IGF-I in the process of multistage carcinogenesis in mouse skin.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV CARCINOGENESIS,DIV RES,SMITHVILLE,TX 78957	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA037111, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA37111] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDO Y, 1993, J INVEST DERMATOL, V100, P633, DOI 10.1111/1523-1747.ep12472297; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1995, CANCER RES, V55, P249; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAWSON TP, 1995, CANCER RES, V55, P915; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; ELDRIDGE SR, 1990, CARCINOGENESIS, V11, P2245, DOI 10.1093/carcin/11.12.2245; EWING MW, 1988, CANCER RES, V48, P7048; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GREENHALGH D, 1994, KERATINOCYTE HDB, P471; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KIGUCHI K, 1995, MOL CARCINOGEN, V12, P225, DOI 10.1002/mc.2940120407; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MATTHEWS L S, 1988, Endocrinology, V123, P2827; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MINUTO F, 1986, CANCER RES, V46, P985; NAITO M, 1987, CARCINOGENESIS, V8, P1807, DOI 10.1093/carcin/8.12.1807; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; RECHLER MM, 1992, GROWTH REGULAT, V2, P55; RESNICOFF M, 1995, CANCER RES, V55, P3739; Rho O, 1996, MOL CARCINOGEN, V17, P62, DOI 10.1002/(SICI)1098-2744(199610)17:2<62::AID-MC2>3.0.CO;2-V; ROGLER CE, 1994, J BIOL CHEM, V269, P1379; ROOP DR, 1984, J BIOL CHEM, V259, P8037; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1990, J INVEST DERMATOL, V94, P573; ROTWEIN P, 1993, MOL REPROD DEV, V35, P358, DOI 10.1002/mrd.1080350407; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; TAKAHASHI K, 1995, J BIOL CHEM, V270, P19041, DOI 10.1074/jbc.270.32.19041; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; TRICOLI JV, 1986, CANCER RES, V46, P6169; VARDY DA, 1995, J CELL PHYSIOL, V163, P257, DOI 10.1002/jcp.1041630206; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; WARD A, 1994, P NATL ACAD SCI USA, V91, P10365, DOI 10.1073/pnas.91.22.10365; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	46	115	122	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1725	1734		10.1038/sj.onc.1201011	http://dx.doi.org/10.1038/sj.onc.1201011			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135074				2022-12-25	WOS:A1997WR89300011
J	Yu, YJ; Li, CY; Little, JB				Yu, YJ; Li, CY; Little, JB			Abrogation of p53 function by HPV16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblast cells	ONCOGENE			English	Article						p53; HPV16 E6; radiosensitivity; apoptosis; mutability	WILD-TYPE P53; INDUCED G(1) ARREST; SV40 T-ANTIGEN; DNA-DAMAGE; CHROMOSOMAL-ABERRATIONS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; CYCLE PROGRESSION; X-IRRADIATION; SINGLE-DONOR	In order to gain a better understanding of the role of p53 in radiation-induced mitotic failure, apoptosis and mutagenesis, we introduced the HPV16 E6 gene via a retroviral vector into the TK6 human lymphoblast cell line which expresses wild type p53. Abrogation of p53 function by E6 resulted in a delayed and reduced apoptotic response and a moderate increase in the frequency of mutations at the thymidine kinase (tk) locus following gamma-irradiation, but failed to alter radiosensitivity. The apoptotic response of the E6-transduced line was intermediate between that of wild type TK6 and the WTK1 cell line. WTK1 is derived from the same parental cell line as TK6 but expresses mutant p53. The spontaneous and gamma-ray-induced mutation frequencies in E6-transduced TK6 cells, although higher than that of the parental TK6 cell line, were still much lower than that of the WTK1 line. No effect on apoptosis, radiosensitivity or mutability was observed when the HPV16 E6 gene was introduced into the WTK1 cells. These results indicate that p53 does not regulate the radiosensitivity of TK6 cells through the apoptotic pathway. Furthermore, the previously observed enhanced radioresistance and mutability in WTK1 cells must be attributed to a more complex mechanism than p53 status alone.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health			Li, Chuan-Yuan/H-4148-2013		NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47542, CA-09078] Funding Source: Medline; NIEHS NIH HHS [ES-00002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMUNDSON SA, 1993, MUTAT RES, V286, P233, DOI 10.1016/0027-5107(93)90188-L; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Carrier F, 1996, MUTAT RES-FUND MOL M, V352, P79, DOI 10.1016/0027-5107(95)00255-3; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FRAKER PJ, 1995, METHOD CELL BIOL, V46, P57; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; Gupta N, 1996, RADIAT RES, V145, P289, DOI 10.2307/3578984; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUANG H, 1996, IN PRESS INT J RAD B; KASTAN MB, 1991, CANCER RES, V51, P6304; KONDO S, 1995, ONCOGENE, V10, P2001; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVY JA, 1968, CANCER-AM CANCER SOC, V22, P517, DOI 10.1002/1097-0142(196809)22:3<517::AID-CNCR2820220305>3.0.CO;2-A; LI CY, 1995, ONCOGENE, V11, P1885; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI CY, 1995, INT J ONCOL, V7, P223; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LIVINGSTONE LR, 1992, CELL, V70, P925; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACILWRATH AJ, 1994, CANCER RES, V54, P3718; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; MURNANE JP, 1993, NATURE, V365, P22, DOI 10.1038/365022a0; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARTZ JL, 1995, MUTAGENESIS, V10, P227, DOI 10.1093/mutage/10.3.227; SLICHENMYER WJ, 1993, CANCER RES, V53, P5164; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SU LN, 1992, INT J RADIAT BIOL, V62, P201, DOI 10.1080/09553009214552021; SU LN, 1992, INT J RADIAT BIOL, V62, P461, DOI 10.1080/09553009214552341; TSANG NM, 1995, ONCOGENE, V10, P2403; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WILLIAMS AC, 1995, ONCOGENE, V11, P141; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHEN W, 1995, MUTAT RES LETT, V346, P85, DOI 10.1016/0165-7992(95)90055-1; Zhen W., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P602	52	77	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1661	1667		10.1038/sj.onc.1201026	http://dx.doi.org/10.1038/sj.onc.1201026			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135067				2022-12-25	WOS:A1997WR89300004
J	Peter, M; Couturier, J; Pacquement, H; Michon, J; Thomas, G; Magdelenat, H; Delattre, O				Peter, M; Couturier, J; Pacquement, H; Michon, J; Thomas, G; Magdelenat, H; Delattre, O			A new member of the ETS family fused to EWS in Ewing tumors	ONCOGENE			English	Article						ETS family; Ewing tumor; EWS; transcription; fusion	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; GENE FUSION; CHROMOSOMAL TRANSLOCATION; SARCOMA TRANSLOCATION; CHIMERIC TRANSCRIPTS; TRANSFORMING GENE; TEL GENE; PROTEIN	As a result of chromosome translocations, the EWS gene is fused to a variety of transcription factors in human solid neoplasia. In Ewing tumors EWS can be fused to four different members of the ETS family, namely FLI-1, ERG, ETV1 and E1AF We have identified a new member of the ETS family, called FEV, which is fused to EWS in a subset of Ewing tumors, FEV encodes a 238 amino acid protein which contains an ETS DNA binding domain closely related to that of FLI-1 and ERG, However, the N-terminal portion of FEV is only 42 amino acids long which suggests that FEV is lacking important transcription regulatory domains contained in FLI-1 and ERG N-terminal parts. The C-terminal end of FEV is rich in alanine residues which may indicate that FEV is a transcription repressor. The FEV gene is encoded by three exons and is located on chromosome 2. I;EV expression was only detected in adult prostate and small intestine but not in other adult nor in fetal tissues, thus indicating that FEV has a restricted expression pattern, Following a scheme similar to previously described translocations in Ewing tumors, a t(2;22) chromosome translocation fuses the N-terminal domain of EWS to the ETS DNA binding domain of FEV.	INST CURIE,LAB GENET TUMEURS,INSERM U434,F-75231 PARIS 05,FRANCE; INST CURIE,LAB TRANSFERT,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT PATHOL,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT PEDIAT ONCOL,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie				delattre, olivier/0000-0002-8730-2276				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BUIJS A, 1995, ONCOGENE, V10, P1511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark J, 1996, ONCOGENE, V12, P229; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Maniatis T., 1989, MOL CLONING LAB MAN; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OHNO T, 1993, CANCER RES, V53, P5859; Panagopoulos I, 1996, ONCOGENE, V12, P489; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZOUBEK A, 1994, BRIT J CANCER, V70, P908, DOI 10.1038/bjc.1994.419; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	35	290	301	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1159	1164		10.1038/sj.onc.1200933	http://dx.doi.org/10.1038/sj.onc.1200933			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121764				2022-12-25	WOS:A1997WM78200004
J	Hyndman, DJ; Takenoshita, R; Vera, NL; Pang, SC; Flynn, TG				Hyndman, DJ; Takenoshita, R; Vera, NL; Pang, SC; Flynn, TG			Cloning, sequencing, and enzymatic activity of an inducible aldo-keto reductase from Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; MOUSE VAS-DEFERENS; KM ALDEHYDE REDUCTASE; RAT-LIVER; PIG BRAIN; CARBONYL REDUCTASE; PROTEIN; GENE; IDENTIFICATION; PURIFICATION	Treatment of Chinese hamster ovary (CHO) cells by the aldehyde containing calpain inhibitor I resulted in the induction of a 35-kDa protein that was partially sequenced and shown to be a member of the aldo-keto reductase superfamily (Inoue, S,, Sharma, R. C,, Schimke, R, T,, and Simoni, R, D, (1993) J. Biol, Chem, 268, 5894-5898), Using rapid amplification of cDNA ends polymerase chain reaction, we have sequenced the cDNA for this protein (CHO reductase). This enzyme is a new member of the aldo-keto reductase superfamily and shows greatest amino acid sequence identity to mouse fibroblast growth factor-regulated protein and mouse vas deferens protein (92 and 80% sequence identity, respectively), The enzyme exhibits about 70% sequence identity with the aldose reductases (ALR2; EC 1.1.1.21) and about 47% with the aldehyde reductases (ALR1; EC 1.1.1.2), Northern analysis showed that it is induced in preference to either ALR1 or ALR2 and RNase protection assays showed gene expression in bladder, testis, jejunum, and ovary in descending order of expression, The cDNA for this inducible reductase was cloned into the pET16b vector and expressed in BL21(DE3) cells. Expressed CHO reductase showed kinetic properties distinct from either ALR1 or ALR2 including the ability to metabolize ketones, This protein joins a growing number of inducible aldo-keto reductases that may play a role in cellular regulation and protection.	QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT ANAT, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada; Queens University - Canada								CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIACCIO PJ, 1994, J BIOL CHEM, V269, P15558; CROMLISH JA, 1983, J BIOL CHEM, V258, P3583; CROMLISH JA, 1985, J NEUROCHEM, V44, P1485, DOI 10.1111/j.1471-4159.1985.tb08786.x; CROMLISH JA, 1983, BIOCHEM J, V209, P597, DOI 10.1042/bj2090597; DONOHUE PJ, 1994, J BIOL CHEM, V269, P8604; ELLIS EM, 1993, P NATL ACAD SCI USA, V90, P10350, DOI 10.1073/pnas.90.21.10350; FABRE S, 1994, J BIOL CHEM, V269, P5857; FELSTED RL, 1977, BIOCHEM PHARMACOL, V26, P1117, DOI 10.1016/0006-2952(77)90054-5; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; INOUE S, 1993, J BIOL CHEM, V268, P5894; Iwata N, 1996, EUR J BIOCHEM, V235, P444, DOI 10.1111/j.1432-1033.1996.00444.x; JAGT DLV, 1995, BBA-PROTEIN STRUCT M, V1249, P117; JEZ JM, 1997, IN PRESS BIOCH PHARM; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; LAENG P, 1995, ELECTROPHORESIS, V16, P1240, DOI 10.1002/elps.11501601205; LAU ET, 1995, BIOCHEM J, V312, P609, DOI 10.1042/bj3120609; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; MORJANA NA, 1989, J BIOL CHEM, V264, P2906; PAILHOUX EA, 1990, J BIOL CHEM, V265, P19932; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; SAMARAS N, 1989, J BIOL CHEM, V264, P4251; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; TAKAHASHI M, 1995, INT J CANCER, V62, P749, DOI 10.1002/ijc.2910620617; Takahashi M, 1996, JPN J CANCER RES, V87, P337, DOI 10.1111/j.1349-7006.1996.tb00227.x; TEMPLETON NS, 1993, BIOTECHNIQUES, V15, P52; TURNER AJ, 1972, BIOCHEM J, V130, P765, DOI 10.1042/bj1300765; TURNER AJ, 1976, BIOCHEM J, V159, P819, DOI 10.1042/bj1590819; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; WANG K, 1993, J BIOL CHEM, V268, P16052; WERMUTH B, 1981, J BIOL CHEM, V256, P1206; WILSON DK, 1995, BIOCHEMISTRY-US, V34, P14323, DOI 10.1021/bi00044a009; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; ZEINDLEBERHART E, 1994, J BIOL CHEM, V269, P14589	38	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13286	13291		10.1074/jbc.272.20.13286	http://dx.doi.org/10.1074/jbc.272.20.13286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148949	hybrid			2022-12-25	WOS:A1997WZ38400062
J	Malmgren, C; Wagner, EGH; Ehresmann, C; Ehresmann, B; Romby, P				Malmgren, C; Wagner, EGH; Ehresmann, C; Ehresmann, B; Romby, P			Antisense RNA control of plasmid R1 replication - The dominant product of the antisense RNA-mRNA binding is not a full RNA duplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULGED-OUT NUCLEOTIDES; REPA SYNTHESIS; TARGET RNA; IN-VITRO; COPA; INHIBITION; TRANSCRIPT; INVITRO; COMPLEX; INVIVO	The replication frequency of plasmid R1 is controlled by an antisense RNA (CopA) that binds to its target site (CopT) in the leader region of repA mRNA and inhibits the synthesis of the replication initiator protein RepA. Previous studies on CopA-CopT pairing in vitro revealed the existence of a primary loop-loop interaction (kissing complex) that is subsequently converted to an almost irreversible duplex. However, the structure of more stable binding intermediates that lead to the formation of a complete duplex was speculative. Here, we investigated the interaction between CopA and CopT by using Pb(II)-induced cleavages, The kissing complex was studied using a truncated antisense RNA (CopI) that is unable to form a full duplex with CopT, Furthermore, RNase III, which is known to process the CopA-CopT complex in vivo, was used to detect the existence of a full duplex, Our data indicate that the formation of a full CopA-CopT duplex appears to be a very slow process in vitro, Unexpectedly, we found that the loop-loop interaction persists in the predominant CopA-CopT complex and is stabilized by intermolecular base pairing involving the 5'-proximal 30 nucleotides of CopA and the complementary region of CopT, This almost irreversible complex suffices to inhibit ribosome binding at the tap ribosome binding site and may be the inhibitory complex in vivo.	INST BIOL MOL & CELLULAIRE,UPR 9002 CNRS,F-67084 STRASBOURG,FRANCE; UNIV UPPSALA,CTR BIOMED,DEPT MICROBIOL,S-75123 UPPSALA,SWEDEN; SWEDISH UNIV AGR SCI,DEPT MICROBIOL,SLU,UPPSALA GENET CTR,S-75007 UPPSALA,SWEDEN	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Uppsala University; Swedish University of Agricultural Sciences			ROMBY, Pascale/AGP-3328-2022					BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; BLOMBERG P, 1994, MOL MICROBIOL, V12, P49, DOI 10.1111/j.1365-2958.1994.tb00994.x; BLOMBERG P, 1992, EMBO J, V11, P2675, DOI 10.1002/j.1460-2075.1992.tb05333.x; BRANTL S, 1994, EMBO J, V13, P3599, DOI 10.1002/j.1460-2075.1994.tb06667.x; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275; HJALT T, 1992, NUCLEIC ACIDS RES, V20, P6723, DOI 10.1093/nar/20.24.6723; HJALT TAH, 1995, NUCLEIC ACIDS RES, V23, P580, DOI 10.1093/nar/23.4.580; HJALT TAH, 1995, NUCLEIC ACIDS RES, V23, P571, DOI 10.1093/nar/23.4.571; Li HL, 1996, EMBO J, V15, P1421, DOI 10.1002/j.1460-2075.1996.tb00484.x; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Malmgren C, 1996, RNA, V2, P1022; Maniatis T., 1982, MOL CLONING; MARINO JP, 1995, SCIENCE, V268, P1448, DOI 10.1126/science.7539549; NORDSTROM K, 1984, PLASMID, V12, P71, DOI 10.1016/0147-619X(84)90054-4; NORDSTROM K, 1994, TRENDS BIOCHEM SCI, V19, P294, DOI 10.1016/0968-0004(94)90008-6; OHMAN M, 1989, NUCLEIC ACIDS RES, V17, P2557, DOI 10.1093/nar/17.7.2557; PERSSON C, 1988, EMBO J, V7, P3279, DOI 10.1002/j.1460-2075.1988.tb03195.x; PERSSON C, 1990, EMBO J, V9, P3777, DOI 10.1002/j.1460-2075.1990.tb07591.x; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; SIEMERING KR, 1994, J BACTERIOL, V176, P2677, DOI 10.1128/JB.176.9.2677-2688.1994; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; WAGNER EGH, 1992, EMBO J, V11, P1195, DOI 10.1002/j.1460-2075.1992.tb05160.x; WILSON IW, 1994, J BACTERIOL, V175, P6476	27	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12508	12512		10.1074/jbc.272.19.12508	http://dx.doi.org/10.1074/jbc.272.19.12508			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139701	hybrid			2022-12-25	WOS:A1997WY82900038
J	Zhen, SJ; Dunn, IC; Wray, S; Liu, Y; Chappell, PE; Levine, JE; Radovick, S				Zhen, SJ; Dunn, IC; Wray, S; Liu, Y; Chappell, PE; Levine, JE; Radovick, S			An alternative gonadotropin-releasing hormone (GnRH) RNA splicing product found in cultured GnRH neurons and mouse hypothalamus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; GENE-EXPRESSION; GROWTH-FACTOR; LHRH NEURONS; BASAL FOREBRAIN; MESSENGER-RNA; FEMALE RATS; CELLS; SURGE	Gonadotropin-releasing hormone (GnRH) is encoded by the proGnRH gene which contains four exons and three introns, In this study, two immortalized GnRH-expressing cell lines (Gn11 and NLT) were characterized, The NLT and Gn11 cells, derived from a same brain tumor in a transgenic mouse, display neuronal morphology and neuron-specific markers, However, NLT cells secrete much higher levels of GnRH than Gn11 cells, To delineate the mechanism underlying this difference, reverse transcriptase-polymerase chain reaction and RNase protection assays were performed to examine proGnRH gene expression. While the mature proGnRH mRNA was predominately expressed in NLT cells, Gn11 cells express an abundant short transcript, Sequence analysis revealed that this short transcript contains exons 1, 3, and 4, but not exon 2, which encodes the GnRH decapeptide, RNase protection assays demonstrated that NLT cells express much higher levels of mature proGnRH mRNA than Gn11 cells, The lower level of GnRH secreting capacity in Gn11 cells is due, in part, to decreased expression of mature proGnRH mRNA. When proGnRH gene expression in the mouse brain was examined, the same short splicing variant was observed in the olfactory area and preoptic area-anterior hypothalamus, But the prevalent transcript in these regions was the mature proGnRH mRNA, In contrast, only the mature proGnRH mRNA was found in the caudal hypothalamus. These results suggest that alternative splicing may be one of the mechanisms regulating proGnRH gene expression in the animal brain.	CHILDRENS HOSP,DIV ENDOCRINOL,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GENET,BOSTON,MA 02115; NINCDS,NEUROCHEM LAB,NIH,BETHESDA,MD 20892; NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208; ROSLIN INST,DIV DEV & REPROD,ROSLIN EH25 9PS,MIDLOTHIAN,SCOTLAND	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Northwestern University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute			Wray, Susan/AAT-2088-2021; Dunn, Ian/C-7689-2013	wray, susan/0000-0001-7670-3915; Dunn, Ian/0000-0003-3630-0120	NICHD NIH HHS [HD30040] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD030040] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BESECKE LM, 1994, ENDOCRINOLOGY, V135, P1621, DOI 10.1210/en.135.4.1621; DONG KW, 1993, MOL ENDOCRINOL, V7, P1654, DOI 10.1210/me.7.12.1654; FISCHER I, 1991, EXP CELL RES, V194, P195, DOI 10.1016/0014-4827(91)90354-W; GOUBAU S, 1992, ENDOCRINOLOGY, V130, P3098, DOI 10.1210/en.130.5.3098; HIATT ES, 1992, ENDOCRINOLOGY, V130, P1030, DOI 10.1210/en.130.2.1030; HINEY JK, 1991, NEUROENDOCRINOLOGY, V54, P420, DOI 10.1159/000125924; KING JC, 1987, PEPTIDES, V8, P721, DOI 10.1016/0196-9781(87)90049-0; KING JC, 1992, SERONO SYMP, P161; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE WS, 1992, ENDOCRINOLOGY, V130, P3101, DOI 10.1210/en.130.5.3101; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA YJ, 1992, NEURON, V9, P657; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MAVILIA C, 1993, J NEUROCHEM, V61, P1073, DOI 10.1111/j.1471-4159.1993.tb03622.x; MCKEOWN M, 1992, ANN REV CELL BIOL, V8, P139; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MERCHENTHALER I, 1984, CELL TISSUE RES, V237, P15; PORKKAHEISKANEN T, 1994, J NEUROSCI, V14, P5548; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; RANCE NE, 1994, J COMP NEUROL, V339, P573, DOI 10.1002/cne.903390408; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; SEEBURG PH, 1984, NATURE, V311, P666, DOI 10.1038/311666a0; SHIVERS BD, 1983, NEUROENDOCRINOLOGY, V36, P1, DOI 10.1159/000123522; Silverman A.-J., 1988, P1283; WILSON TM, 1995, MOL ENDOCRINOL, V9, P44, DOI 10.1210/me.9.1.44; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; WRAY S, 1986, J COMP NEUROL, V252, P522, DOI 10.1002/cne.902520408; ZHEN S, 1996, 10 INT C END JUN 12, P1; ZHEN S, 1996, 26 ANN M NEUR NOV 19	30	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12620	12625		10.1074/jbc.272.19.12620	http://dx.doi.org/10.1074/jbc.272.19.12620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139717	hybrid			2022-12-25	WOS:A1997WY82900054
J	Houston, DS; Carson, CW; Esmon, CT				Houston, DS; Carson, CW; Esmon, CT			Endothelial cells and extracellular calmodulin inhibit monocyte tumor necrosis factor release and augment neutrophil elastase release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	37th Annual Meeting of the American-Society-of-Hematology	DEC 01-05, 1995	SEATTLE, WA	Amer Soc Hematol			PROTEIN-C ACTIVATION; GROWTH FACTOR-BETA; CYTOKINE PRODUCTION; BINDING-PROTEIN; NUCLEOTIDE PHOSPHODIESTERASE; GENE-EXPRESSION; TISSUE FACTOR; BOVINE BRAIN; PURIFICATION; IL-10	Cultured human umbilical vein endothelial cells inhibited tumor necrosis factor-alpha release from whole blood or isolated mononuclear cells exposed to endo toxin. In contrast, the endothelial cells augmented neutrophil elastase release in the same blood. A protein with these functional properties was isolated from endothelial cell-conditioned media and, surprisingly, was identified as calmodulin. Authentic calmodulin mimicked the effect of endothelium. I-125-Calmodulin bound to a high affinity site on monocytic cell lines (K-d similar to 30 nM, in agreement with its functional activity). Cross-linking of I-125-calmodulin to monocytic cells identified a candidate calmodulin receptor. We conclude that calmodulin possesses an extracellular signaling role in addition to its intracellular regulatory functions. Calmodulin released at sites of tissue injury or possibly by specific mechanisms in the endothelium can bind to receptors, modulating the activities of inflammatory cells.	UNIV MANITOBA,DEPT INTERNAL MED,WINNIPEG,MB R3E 0V9,CANADA; OKLAHOMA MED RES FDN,CARDIOVASC BIOL PROGRAM,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	University of Manitoba; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute	Houston, DS (corresponding author), UNIV MANITOBA,MANITOBA INST CELL BIOL,100 OLIVIA ST,WINNIPEG,MB R3E 0V9,CANADA.				NHLBI NIH HHS [5 T32 HL07207-17] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007207] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADERKA D, 1989, J IMMUNOL, V143, P3517; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOYNTON AL, 1980, BIOCHEM BIOPH RES CO, V95, P745, DOI 10.1016/0006-291X(80)90849-9; CARSON CW, 1991, AM J PATHOL, V139, P199; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CROCKER G, 1988, BIOCHEM J, V253, P877, DOI 10.1042/bj2530877; CRUTCHLEY DJ, 1994, J PHARMACOL EXP THER, V271, P446; Dalley A, 1996, BRIT J HAEMATOL, V93, P856, DOI 10.1046/j.1365-2141.1996.d01-1739.x; DAWSON RA, 1992, BRIT J HAEMATOL, V82, P151, DOI 10.1111/j.1365-2141.1992.tb04607.x; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; ESSNER R, 1989, J IMMUNOL, V142, P3857; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FURMANIAKKAZMIERCZAK E, 1993, BLOOD, V81, P405; GOBERDHAN NJ, 1993, BRIT J DERMATOL, V129, P678, DOI 10.1111/j.1365-2133.1993.tb03331.x; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ M, 1991, J CLIN INVEST, V88, P2026, DOI 10.1172/JCI115530; LEVRAUX V, 1993, LIFE SCI, V52, P1917, DOI 10.1016/0024-3205(93)90632-D; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MACNEIL S, 1984, J INVEST DERMATOL, V83, P15, DOI 10.1111/1523-1747.ep12261637; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MEANS AR, 1980, NATURE, V285, P73, DOI 10.1038/285073a0; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Ryan U S, 1983, Adv Exp Med Biol, V156, P671; SCUDERI P, 1991, CELL IMMUNOL, V135, P299, DOI 10.1016/0008-8749(91)90275-G; SEVERN A, 1992, J IMMUNOL, V148, P3441; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STONE KL, 1993, PRACTICAL GUIDE PROT; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; VANAMAN TC, 1983, METHOD ENZYMOL, V102, P296; WALLACE RW, 1983, METHOD ENZYMOL, V102, P39; WALLACE RW, 1980, CALCIUMC ELL FUNCTIO, P13; WALSH M, 1977, J BIOL CHEM, V252, P7440; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; WATTERSON DM, 1980, J BIOL CHEM, V255, P962	45	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11778	11785		10.1074/jbc.272.18.11778	http://dx.doi.org/10.1074/jbc.272.18.11778			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115233	hybrid			2022-12-25	WOS:A1997WX56900021
J	Tsiang, M; Jain, AK; Gibbs, CS				Tsiang, M; Jain, AK; Gibbs, CS			Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; BLOOD-COAGULATION; PROTEIN-C; KUNITZ INHIBITORS; CRYSTAL-STRUCTURE; COFACTOR-II; RESIDUES; IDENTIFICATION; THROMBOMODULIN; ANTICOAGULANT	Mutation of 79 highly exposed amino acids that comprise approximately 62% of the solvent accessible surface of thrombin identified residues that modulate the inhibition of thrombin by antithrombin III, the principal physiological inhibitor of thrombin, Mutations that decreased the susceptibility of thrombin to inhibition by antithrombin III in the presence and absence of heparin (W50A, E229A, and R233A) also decreased hydrolysis of a small tripeptidyl substrate, These residues were clustered around the active site cleft of thrombin and were predicted to interact directly with the ''substrate loop'' of antithrombin III, Despite the large size of antithrombin III (58 kDa), no residues outside of the active cleft were identified that interact directly with antithrombin III, Mutations that decreased the susceptibility of thrombin to inhibition by antithrombin III in the presence but not in the absence of heparin (R89A/R93A/E94A, R98A, R245A, K248A, K252A/D255A/Q256A) in general did not also affect hydrolysis of the tripeptidyl substrate, These residues were clustered among a patch of basic residues on a surface of thrombin perpendicular to the face containing the active site cleft and were predicted to interact directly with heparin, Three mutations (E25A, R178A/R180A/D183A, and E202A) caused a slight enhancement of inhibition by antithrombin III.	GILEAD SCI INC,FOSTER CITY,CA 94404	Gilead Sciences								BODE W, 1993, SEMIN THROMB HEMOST, V19, P321, DOI 10.1055/s-2007-993283; BODE W, 1992, PROTEIN SCI, V1, P426; BOUTON MC, 1995, EUR J BIOCHEM, V229, P526, DOI 10.1111/j.1432-1033.1995.0526k.x; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BROZE GJ, 1994, MOL BASIS BLOOD DISE, P629; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FURIE B, 1982, J BIOL CHEM, V257, P3875; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LIU LB, 1995, THROMB HAEMOSTASIS, V73, P405; LOBERMANN H, 1984, J MOL BIOL, V177, P531; LORAND L, 1992, THROMBIN STRUCTURE F, P257; Mann K.G.R., 1987, HEMOSTASIS THROMBOSI, P148; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; Perry DJ, 1996, HUM MUTAT, V7, P7, DOI 10.1002/(SICI)1098-1004(1996)7:1<7::AID-HUMU2>3.3.CO;2-A; PRATT CW, 1991, SEMIN HEMATOL, V28, P3; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; ROSENBERG RD, 1987, MOL BASIS BLOOD DISE, P534; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YE J, 1994, J BIOL CHEM, V269, P17965	40	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12024	12029		10.1074/jbc.272.18.12024	http://dx.doi.org/10.1074/jbc.272.18.12024			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115268	hybrid			2022-12-25	WOS:A1997WX56900056
J	Diaz, JL; Oltersdorf, T; Horne, W; McConnell, M; Wilson, G; Weeks, S; Garcia, T; Fritz, LC				Diaz, JL; Oltersdorf, T; Horne, W; McConnell, M; Wilson, G; Weeks, S; Garcia, T; Fritz, LC			A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; HOMOLOG BAK; APOPTOSIS; PROTEIN; GENE; DOMAINS; BH1	Bcl-2 inhibits apoptosis induced by a wide variety of stimuli. In contrast, the Bcl-2 homologue, Bax, antagonizes Bcl-2's death protecting function. Bcl-2 forms protein-protein homodimers with itself and heterodimers with Bax, and previous experiments have shown that point mutations in Bcl-2 can abrogate Bax binding while leaving homodimerization intact. These mutagenesis re suits can be interpreted to suggest that Bcl-2 has separate binding sites that are responsible for homodimer and heterodimer formation. Results from yeast two hybrid studies have also suggested that homodimerization and heterodimerization reflect distinct modes of interaction, However, using quantitative plate binding assays, we now show that Bax as well as peptides derived from the BH3 domains of Bax and Bak block both Bcl-2/Bax binding and Bcl-2/Bcl-2 binding. Similar assays demonstrate that Bcl-x(L) can form both homodimers and heterodimers and that these interactions are also inhibited by Bax and the BH3-derived peptides. These results demonstrate that the same binding motifs are responsible for both homodimerization and heterodimerization of Bcl-2 family members.	IDUN PHARMACEUT INC, LA JOLLA, CA 92037 USA									Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; MEIJERINK JPP, 1995, LEUKEMIA, V9, P1828; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; MIYASHITA T, 1993, BLOOD, V81, P151; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; ZHANG HC, 1995, BIOCHEM BIOPH RES CO, V208, P950, DOI 10.1006/bbrc.1995.1426	27	108	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11350	11355						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111042				2022-12-25	WOS:A1997WW00900058
J	High, S; Henry, R; Mould, RM; Valent, Q; Meacock, S; Cline, K; Gray, JC; Luirink, J				High, S; Henry, R; Mould, RM; Valent, Q; Meacock, S; Cline, K; Gray, JC; Luirink, J			Chloroplast SRP54 interacts with a specific subset of thylakoid precursor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; IRON-SULFUR PROTEIN; ESCHERICHIA-COLI; PATHWAY SPECIFICITY; BINDING POLYPEPTIDE; PEA-CHLOROPLASTS; ANCHOR SEQUENCES; 54-KDA SUBUNIT; CYTOCHROME-F; MEMBRANE	Signal recognition particles (SRPs) have been identified in organisms as diverse as mycoplasma and mammals; in several cases these SRPs have been shown to play a key role in protein targeting, In each case the recognition of appropriate targeting signals is mediated by SRP subunits related to the 54-kDa protein of mammalian SRP (SRP54), In this study we have characterized the specificity of 54CP, a chloroplast homologue of SRP54 which is located in the chloroplast stroma. We have used a nascent chain cross-linking approach to detect the interactions of 54CP with heterologous endoplasmic reticulum-targeting signals. 54CP functions as a bona fide signal recognition factor which can discriminate between functional and non-functional targeting signals, Using a range of authentic thylakoid precursor proteins we found that 54CP discriminates between thylakoid-targeting signals, interacting with only a subset of protein precursors. Thus, the light-harvesting chlorophyll a/b-binding protein, cytochrome f, and the Rieske FeS protein all showed strong cross-linking products with 54CP, In contrast, no cross-linking 60 the 23- and 33-kDa proteins of the oxygen-evolving complex were detected, The selectivity of 54CP correlates with the hydrophobicity of the thylakoid-targeting signal and, in the case of light-harvesting chlorophyll a/b-binding protein, with previously determined transport/integration requirements, We propose that 54CP mediates the targeting of a specific subset of precursors to the thylakoid membrane, i.e. those with particularly hydrophobic signal sequences.	UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; UNIV CAMBRIDGE,DEPT PLANT SCI,CAMBRIDGE CB2 3EA,ENGLAND; BIOCENTRUM AMSTERDAM,INST MOL BIOL SCI,DEPT MICROBIOL,NL-1081 HV AMSTERDAM,NETHERLANDS	State University System of Florida; University of Florida; University of Cambridge; University of Amsterdam	High, S (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,2-205 STOPFORD BLDG OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.		Luirink, Joen/AAB-8658-2021; Cline, Kenneth/J-6238-2013	High, Stephen/0000-0002-4532-8152	NIGMS NIH HHS [R01 GM56951] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CM, 1991, FEBS LETT, V280, P383, DOI 10.1016/0014-5793(91)80337-3; AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BURGI R, 1987, BIOCHIM BIOPHYS ACTA, V890, P346, DOI 10.1016/0005-2728(87)90162-9; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P3257, DOI 10.1093/nar/15.8.3257; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; HAUSER S, 1995, EMBO J, V14, P5485, DOI 10.1002/j.1460-2075.1995.tb00235.x; HENRY R, 1994, J BIOL CHEM, V269, P10189; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; HUANG LQ, 1992, PLANT PHYSIOL, V99, P247, DOI 10.1104/pp.99.1.247; HULFORD A, 1994, J BIOL CHEM, V269, P3251; KOHORN BD, 1989, PLANT CELL, V1, P159; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930; LUIRINK J, 1994, MOL MICROBIOL, V11, P9, DOI 10.1111/j.1365-2958.1994.tb00284.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MADUENO F, 1993, PLANT CELL, V5, P1865, DOI 10.1105/tpc.5.12.1865; MADUENO F, 1994, J BIOL CHEM, V269, P17458; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MOULD RM, 1991, J BIOL CHEM, V266, P12189; MOULD RM, 1997, IN PRESS PLANT J; NAKAI M, 1994, J BIOL CHEM, V269, P31338; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NOHARA T, 1995, FEBS LETT, V364, P305, DOI 10.1016/0014-5793(95)00415-6; Nohara T, 1996, BIOCHEM BIOPH RES CO, V224, P474, DOI 10.1006/bbrc.1996.1051; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; SALTER AH, 1992, PLANT MOL BIOL, V20, P569, DOI 10.1007/BF00040617; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; YUAN JG, 1994, J BIOL CHEM, V269, P18463; [No title captured]	58	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11622	11628						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111079				2022-12-25	WOS:A1997WW00900095
J	Taylor, GA; Stauber, R; Rulong, S; Hudson, E; Pei, V; Pavlakis, GN; Resau, JH; VandeWoude, GF				Taylor, GA; Stauber, R; Rulong, S; Hudson, E; Pei, V; Pavlakis, GN; Resau, JH; VandeWoude, GF			The inducibly expressed GTPase localizes to the endoplasmic reticulum, independently of GTP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INTERFERON-GAMMA; IFN-GAMMA; MULTIPLE-SCLEROSIS; PROTEIN FAMILY; CELLS; RAS; ACTIVATION; RECEPTOR; SURVIVAL	The inducibly expressed GTPase (IGTP) is representative of a newly identified group of interferon gamma-inducible GTPases, whose functions are currently unknown. We have begun to address the cellular function of IGTP by examining its subcellular distribution and its guanine nucleotide binding status. Using immunofluorescence, electron microscopy, and subcellular fractionation, IGTP was localized predominantly to the endoplasmic reticulum of both RAW 264.7 macrophages and C227 fibroblasts. In the immunostaining experiments, staining of discrete cytoplasmic structures on the periphery of the endoplasmic reticulum was also evident. Using polyethyleneimine-cellulose thin layer chromatography, the guanine nucleotides that complexed to immunoprecipitated IGTP, in both control and interferon gamma-stimulated cells, were 90-95% GTP and 5-10% GDP, suggesting that the protein was in an active state. A mutant IGTP protein was created that had no detectable complexed GTP, and in both subcellular fractionation and IGTP-green fluorescent protein fusion studies, this mutant also localized to the endoplasmic reticulum. These results suggested that the GTP binding status of IGTP is independent of its capacity to localize to the endoplasmic reticulum. Given these results, we propose that IGTP is representative of a new family of endoplasmic reticulum GTPases that may be involved in protein processing or trafficking.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Pei, Yang Veronica/0000-0003-3181-5539; Stauber, Roland/0000-0002-1341-4523				AULITZKY WE, 1993, INT ARCH ALLERGY IMM, V101, P221, DOI 10.1159/000236449; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRUNDA MJ, 1995, J IMMUNOTHER, V17, P71, DOI 10.1097/00002371-199502000-00001; CARLOW DA, 1995, J IMMUNOL, V154, P1767; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GILLY M, 1992, J IMMUNOL, V148, P3275; GREEN JM, 1995, HYBRIDOMA, V14, P347, DOI 10.1089/hyb.1995.14.347; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANDA K, 1983, J IMMUNOL, V130, P988; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KIM TS, 1995, MELANOMA RES, V5, P217, DOI 10.1097/00008390-199508000-00003; KING DP, 1983, J IMMUNOL, V133, P313; KURZROCK R, 1987, BLOOD, V70, P943; LAFUSE WP, 1995, J LEUKOCYTE BIOL, V57, P477, DOI 10.1002/jlb.57.3.477; LICHTOR T, 1995, J NEUROSURG, V83, P1038, DOI 10.3171/jns.1995.83.6.1038; LIEW FY, 1990, J IMMUNOL, V145, P4306; MUNRO JM, 1989, AM J PATHOL, V135, P121; OZELLO L, 1995, J INTERFERON CYTOKIN, V15, P839; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SORACE JM, 1995, J LEUKOCYTE BIOL, V58, P477, DOI 10.1002/jlb.58.4.477; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VILCEK J, 1985, LYMPHOKINES, V11, P1; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WARREN MK, 1985, J IMMUNOL, V134, P2462	36	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10639	10645						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099712				2022-12-25	WOS:A1997WV26200046
J	Illing, M; Molday, LL; Molday, RS				Illing, M; Molday, LL; Molday, RS			The 220-kDa Rim protein of retinal rod outer segments is a member of the ABC transporter superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC MEMBRANE-PROTEIN; PLASMA-MEMBRANE; P-GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; PHOTORECEPTOR CELLS; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; DISK MEMBRANES; GATED CHANNEL; IDENTIFICATION	Outer segments of mammalian rod photoreceptor cells contain an abundantly expressed membrane protein that migrates with an apparent molecular mass of 220 kDa by SDS gel electrophoresis. We have purified the bovine protein by immunoaffinity chromatography, determined its primary structure by cDNA cloning and direct peptide sequence analysis, and mapped its distribution in photoreceptors by immunocytochemical and biochemical methods, The full-length cDNA encodes a 2280-amino acid protein (calculated molecular mass of 257 kDa) consisting of two structurally related, tandem arranged halves, Each half consists of a hydrophobic domain containing six putative transmembrane segments followed by an ATP binding cassette, A data base homology search showed that the rod outer segment 220 kDa protein is 40-50% identical in amino acid sequence to the ABC1 and ABC2 proteins cloned from a mouse macrophage cell line, Photoaffinity labeling with 8-azido-ATP and nucleotide inhibition studies confirmed that both ATP and GTP bind to this protein with similar affinities, Concanavalin A labeling and endoglycosidase H digestion indicated that the rod outer segment protein contains at least one carbohydrate chain, Immunocytochemical and biochemical studies have revealed that the 220 kDa glycoprotein is distributed along the rim region and incisures of rod outer segment disc membranes, From these studies we conclude that the 220-kDa glycoprotein of bovine rod outer segment disc membranes or Rim ABC protein is a new member of the superfamily of ABC transporters and is the mammalian homolog of the frog photoreceptor rim protein.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOL BIOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia					NEI NIH HHS [EY 02422] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BURTON MD, 1989, ANAL BIOCHEM, V183, P225, DOI 10.1016/0003-2697(89)90472-7; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; CONVERSE CA, 1979, EXP EYE RES, V29, P409, DOI 10.1016/0014-4835(79)90057-5; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COOK NJ, 1989, J BIOL CHEM, V264, P6996; CORLESS JM, 1987, EXP EYE RES, V45, P883, DOI 10.1016/S0014-4835(87)80104-5; ELLIS RE, 1991, GENETICS, V129, P79; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EVANS IJ, 1986, GENE, V43, P95, DOI 10.1016/0378-1119(86)90012-0; EWART GD, 1994, J BIOL CHEM, V269, P10370; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; HELFMAN DM, 1983, P NATL ACAD SCI-BIOL, V80, P31, DOI 10.1073/pnas.80.1.31; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HSU SC, 1991, J BIOL CHEM, V266, P21745; JURANKA P, 1992, J BIOL CHEM, V267, P3764; Klugbauer N, 1996, FEBS LETT, V391, P61, DOI 10.1016/0014-5793(96)00700-4; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MACKENZIE D, 1982, J BIOL CHEM, V257, P7100; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; MOLDAY RS, 1979, J BIOL CHEM, V254, P4653; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; PAPERMASTER DS, 1982, VISION RES, V22, P1417, DOI 10.1016/0042-6989(82)90204-8; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; REID D M, 1990, Investigative Ophthalmology and Visual Science, V31, P78; REID DM, 1990, BIOCHEMISTRY-US, V29, P1601, DOI 10.1021/bi00458a035; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; SHUSTER TA, 1988, EXP EYE RES, V46, P475, DOI 10.1016/S0014-4835(88)80005-8; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307; SZUTS EZ, 1985, BIOCHEMISTRY-US, V24, P4176, DOI 10.1021/bi00336a054; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USUKURA J, 1981, BIOMED RES-TOKYO, V2, P177, DOI 10.2220/biomedres.2.177; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	52	234	242	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10303	10310		10.1074/jbc.272.15.10303	http://dx.doi.org/10.1074/jbc.272.15.10303			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092582	hybrid			2022-12-25	WOS:A1997WU03900101
J	Aasheim, HC; Pedeutour, F; Smeland, EB				Aasheim, HC; Pedeutour, F; Smeland, EB			Characterization, expression and chromosomal localization of a human gene homologous to the mouse Lsc oncogene, with strongest expression in hematopoetic tissues	ONCOGENE			English	Article						Lsc homologue; Rho GEF; Dbl-family; hematopoetic expression	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; CELL POLARITY; LYMPHOCYTES-B; RHO; CDC42; RAS; CLONING; YEAST; REGULATORS	A human cDNA clone, denoted sub1.5, was isolated from cDNA library generated from human T cells, The sub1.5 cDNA sequence was novel and was not identical to any known cDNA sequences in the GenBank. Recently, however, a mouse cDNA (Lsc) with high homology to sub1.5 was identified, indicating that the sub1.5 sequence may represent the human homologue of the mouse Lsc gene. The sub1.5 cDNA includes an open reading frame of 875 amino acids, predicting a protein with molecular weight of 97 kDa. Like Lsc, sub1.5 shows homology to the previous described oncogene Lbc, in particular to two functional domains in the Lbc protein; the Dbl protooncogene homology domain and the pleckstrin homology domain. Lsc is proposed to be an oncogene and is a member of a growing family of proteins that may function as activators of the Rho family GTPases. Members of the Rho family regulates the polymerization of actin to produce stress fibers. Activation of Rho GTPases by sub1.5 is also indicated by our studies, as stress fiber formation is observed in serum-starved stable NIH3T3 sub1.5 transfectants. Sub1.5 cDNA hybridizes to two major transcripts of 3.5 and 5 kb size and the strongest expression is seen in hematopoietic tissues like thymus, lymph nodes, peripheral blood leukocytes and spleen. We also show that both purified B and T cells express sub1.5. In addition, our data indicate that sub1.5 mRNA is abundantly expressed in CD34(+) human progenitor cells. Fluorescent in situ hybridisation, using sub1.5 cDNA as a probe on human metaphases, shows that the sub1.5 gene is localized to chromosome 19q13.13.	FAC MED,URA CNRS 1462,NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	Aasheim, HC (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,DEPT IMMUNOL,N-0310 OSLO,NORWAY.		Smeland, Erlend/AAO-3214-2020					AASHEIM HC, 1994, BIOTECHNIQUES, V16, P716; AASHEIM HC, 1969, METHODS MOL BIOL CDN, V69; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHAN AML, 1994, ONCOGENE, V9, P1057; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEDEUTOUR F, 1994, GENOMICS, V19, P31, DOI 10.1006/geno.1994.1008; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RASMUSSEN AM, 1992, J IMMUNOL METHODS, V146, P195, DOI 10.1016/0022-1759(92)90228-L; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUSTEN LS, 1994, BLOOD, V84, P1473; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TOKSOZ D, 1994, ONCOGENE, V9, P621; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	36	18	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1747	1752		10.1038/sj.onc.1200994	http://dx.doi.org/10.1038/sj.onc.1200994			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135076				2022-12-25	WOS:A1997WR89300013
J	Burshtyn, DN; Yang, WT; Yi, TL; Long, EO				Burshtyn, DN; Yang, WT; Yi, TL; Long, EO			A novel phosphotyrosine motif with a critical amino acid at position-2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; BINDING-SPECIFICITY; CRYSTAL-STRUCTURES; SH-PTP2; BETA; PHOSPHOPEPTIDES; STIMULATION; PEPTIDES; AFFINITY	SHP-1 is a protein-tyrosine phosphatase associated with inhibition of activation pathways in hematopoietic cells, The catalytic activity of SHP-1 is regulated by its two SH2 (Src homology 2) domains; phosphotyrosine peptides that bind to the SH2 domains activate SHP-1, The consensus sequence (I/V)XYXX(L/V) is present in the cytoplasmic tails of several lymphocyte receptors that interact with the second SH2 domain of SHP-1, In several of these receptors, there are two or three occurrences of the motif, Here we show that the conserved hydrophobic amino acid preceding the phosphotyrosine is critical for binding to and activation of SHP-1 by peptides corresponding to sequences from killer cell inhibitory receptors, The interaction of most SH2 domains with phosphopeptides requires only the phosphoty rosine and the three residues downstream of the tyrosine. In contrast, the shortest peptide able to bind or activate SHP-1 also included the two residues upstream of the phosphotyrosine, A biphosphopeptide corresponding to the cytoplasmic tail of a killer cell inhibitory receptor with the potential to interact simultaneously with both SH2 domains of SHP-1 was the most potent activator of SHP-1, The hydrophobic residue upstream of the tyrosine was also critical in the context of the biphosphopeptide, The contribution of a hydrophobic amino acid two residues upstream of the tyrosine in the SHP-1-binding motif may be an important feature that distinguishes inhibitory receptors from those that provide activation signals.	CLEVELAND CLIN FDN, RES INST, DEPT CANC BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation	Burshtyn, DN (corresponding author), NIAID, IMMUNOGENET LAB, NIH, TWINBROOK FACIL 2, 12441 PARKLAWN DR, ROCKVILLE, MD 20852 USA.		Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728; Burshtyn, Deborah/0000-0003-4829-3351				Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CASE RD, 1994, J BIOL CHEM, V269, P10467; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; HUYER G, 1995, BIOCHEMISTRY-US, V34, P1040, DOI 10.1021/bi00003a039; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Pregel MJ, 1995, PROTEIN ENG, V8, P1309, DOI 10.1093/protein/8.12.1309; Rojo S, 1997, J IMMUNOL, V158, P9; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YABE T, 1993, IMMUNOGENETICS, V37, P455; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	163	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13066	13072		10.1074/jbc.272.20.13066	http://dx.doi.org/10.1074/jbc.272.20.13066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148918	hybrid			2022-12-25	WOS:A1997WZ38400031
J	Ella, KM; Qi, C; McNair, AF; Park, JH; WisehartJohnson, AE; Meier, KE				Ella, KM; Qi, C; McNair, AF; Park, JH; WisehartJohnson, AE; Meier, KE			Phospholipase D activity in PC12 cells - Effects of overexpression of alpha(2A)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; LYSOPHOSPHATIDIC ACID; DEPENDENT ACTIVATION; PC-12 CELLS; PHOSPHORYLATION; FIBROBLASTS; HYDROLYSIS; MECHANISM; FAMILY	PC12 neuronal cells express a membrane phospholipase D (PLD) activity that is detected at similar levels in undifferentiated or differentiated cells. The regulation of this activity by agonists was explored, Membrane phospholipase D activity was increased by treatment of cells with the phorbol ester phorbol 12-myristate 13-acetate (PMA) or with nerve growth factor, The ability of PMA to activate PLD was confirmed in intact PC12 cells. Basal activity of PLD in membranes was reduced in RG20, a PC12 cell line overexpressing the human alpha(2A)-adrenergic receptor. PMA did not increase PLD activity in RG20 cells, as assessed both in membrane preparations and in intact cells, Cyclic AMP levels did not regulate phospholipase D activity in either cell type. However, incubation of RG20 cells with the alpha(2)-adrenergic antagonist rauwolscine or with pertussis toxin increased membrane PLD activity and restored activation of PLD by PMA. These data suggest that the effects of the overexpressed alpha(2A)-adrenergic receptor on PLD activity are mediated by precoupling of the receptor to the heterotrimeric GTP binding protein, G(i), but are independent of adenylate cyclase regulation. The results of this study suggest that membrane phospholipase D activity can be negatively regulated via G(i) in PC12 cells.	MED UNIV S CAROLINA,DEPT CELL & MOL PHARMACOL,CHARLESTON,SC 29425	Medical University of South Carolina					NATIONAL CANCER INSTITUTE [R01CA058640] Funding Source: NIH RePORTER; NCI NIH HHS [CA58640-04] Funding Source: Medline; NHLBI NIH HHS [HL07260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; Bokoch GM, 1996, FASEB J, V10, P1290, DOI 10.1096/fasebj.10.11.8836042; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; Bradshaw CD, 1996, IMMUNOL LETT, V53, P69, DOI 10.1016/S0165-2478(96)02614-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DANIEL LW, 1993, J BIOL CHEM, V268, P21519; DETH RC, 1995, FASEB J, V9, pA951; ELLA KM, 1994, ANAL BIOCHEM, V218, P136, DOI 10.1006/abio.1994.1152; ELLA KM, 1995, BIOCHEM J, V307, P799, DOI 10.1042/bj3070799; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; JINSI A, 1995, FASEB J, V9, pA105; JONES LG, 1994, J BIOL CHEM, V269, P23790; Knoepp SM, 1996, J BIOL CHEM, V271, P1678, DOI 10.1074/jbc.271.3.1678; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; SHI AG, 1994, J PHARMACOL EXP THER, V271, P1520; Singer WD, 1996, J BIOL CHEM, V271, P4504; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; TIAN WN, 1994, MOL PHARMACOL, V45, P524; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; WANG P, 1991, J BIOL CHEM, V266, P14877; WINITZ S, 1994, J BIOL CHEM, V269, P2869	42	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12909	12912		10.1074/jbc.272.20.12909	http://dx.doi.org/10.1074/jbc.272.20.12909			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148895	hybrid			2022-12-25	WOS:A1997WZ38400008
J	Omura, T; Heldin, CH; Ostman, A				Omura, T; Heldin, CH; Ostman, A			Immunoglobulin-like domain 4-mediated receptor receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF BETA-RECEPTOR; LIGAND-INDUCED DIMERIZATION; DOMINANT-NEGATIVE MUTANTS; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; TYROSINE KINASE; FACTOR-BB; FACTOR-AA; C-KIT; BINDING	Platelet-derived growth factor (PDGF) is a dimeric growth factor that activates its tyrosine kinase receptor by inducing receptor dimerization. In this study, we investigated if receptor-receptor interactions, in addition to ligand-receptor interactions, contribute to the ligand-induced dimerization of the PDGF receptors. Analysis of two deletion mutants of the PDGF alpha-receptor indicated a role for Ig-like domain 4 in ligand-receptor or receptor-receptor interactions. When the fourth Ig-like domain of the PDGF alpha-receptor instead was replaced with the corresponding sequence of the stem cell factor receptor, the binding of PDGF-AA and -BB was not affected, nor was the ability to form homodimeric receptor complexes. This indicates that Ig-like domain 4 does not participate in ligand-receptor interactions. However, the chimeras did not form heterodimers with wild-type PDGF alpha or beta-receptors. Together, these findings suggest that Ig-like domain 4 mediates specific receptor-receptor interactions. This notion was also supported by the finding that a soluble form of Ig-like domain 4 of the PDGF alpha-receptor acted as a PDGF alpha-receptor antagonist. We conclude that specific receptor-receptor interactions contribute to PDGF receptor dimerization in vivo and that complementary epitopes in Ig-like domain 4 mediate these interactions. Our experiments also identify Ig-like domain 4 as a target for PDGF antagonists.	LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research								ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLECHMAN JM, 1995, CELL, V80, P105; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1997, FRONTIERS MOL BIOL O; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KOVALENKO M, 1994, CANCER RES, V54, P6106; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VASSBOTN FS, 1993, MOL CELL BIOL, V13, P4066, DOI 10.1128/MCB.13.7.4066; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J BIOL CHEM, V269, P10668	37	40	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12676	12682		10.1074/jbc.272.19.12676	http://dx.doi.org/10.1074/jbc.272.19.12676			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139724	hybrid			2022-12-25	WOS:A1997WY82900061
J	Doyle, GAR; Pierce, RA; Parks, WC				Doyle, GAR; Pierce, RA; Parks, WC			Transcriptional induction of collagenase-1 in differentiated monocyte-like (U937) cells is regulated by AP-1 and an upstream C/EBP-beta site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTITIAL COLLAGENASE; MESSENGER-RNA; MATRIX METALLOPROTEINASES; SIGNAL TRANSDUCTION; GENE-EXPRESSION; C-FOS; NF-M; MACROPHAGE DIFFERENTIATION; RHEUMATOID-ARTHRITIS; 92-KDA GELATINASE	In this report, we demonstrate that the AP-1 site and a distal promoter element regulate transcriptional induction of collagenase-1 during monocytic differentiation. Chloramphenicol acetyltransferase expression constructs containing regions of the human collagenase-1 promoter were stably or transiently transfected into U937 cells, and reporter activity was assessed at various times after the onset of phorbol 12-myristate 13-acetate (PMA)-mediated differentiation. Rapid and strong induction of promoter activity was lost in constructs with a mutant AP-1 element; however, at 16-96 h post-PMA, the mutant collagenase-1 promoter displayed AP-1 independent PMA-mediated transactivation. The AP-1 mutant constructs also showed delayed transcriptional activation in PMA-treated fibroblasts. Western and supershift analyses indicated that functional Jun and Fos proteins were present in nuclear extracts of PMA-differentiated U937 cells. Promoter deletion constructs demonstrated the potential role of distal promoter sequences in regulating collagenase-1 transcription. In particular, Western, supershift, and promoter deletion analyses suggested a role for CCAAT/enhancer-binding protein-beta (C/EBP-beta) binding site between -2010 and -1954 in regulating transcription of collagenase-1 in monocytic cells. Our findings suggest that distinct regulatory elements, acting somewhat independently of each other, control expression of collagenase-1. In addition, our data suggests that the rapid PMA-mediated induction of collagenase-1 transcription is controlled by a mechanism distinct from that regulating the sustained expression of this proteinase in activated macrophages.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054049, P01HL029594, R01HL048762, R29HL054049] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54049, HL48762, HL29594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, ONCOGENE, V6, P2179; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Angel P, 1992, Matrix Suppl, V1, P156; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRINCKERHOFF C E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P145; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CHAMBERLAIN SH, 1993, J CELL BIOCHEM, V52, P337, DOI 10.1002/jcb.240520310; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chubinskaya S, 1996, LAB INVEST, V74, P232; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FRISCH SM, 1990, ONCOGENE, V5, P75; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAAS JG, 1992, J IMMUNOL, V149, P237; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hughes MJG, 1996, BIOTECHNIQUES, V20, P188; IMAI S, 1994, MOL CELL BIOL, V14, P7182, DOI 10.1128/MCB.14.11.7182; Jeffrey J. J., 1986, REGULATION MATRIX AC, P53; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LACRAZ S, 1994, J BIOL CHEM, V269, P22027; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATSUI M, 1990, ONCOGENE, V5, P249; MCCACHREN SS, 1990, J CLIN IMMUNOL, V10, P19, DOI 10.1007/BF00917494; Mignatti P., 1996, MOL CELLULAR BIOL WO, P427; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MOLLINEDO F, 1991, EUR J BIOCHEM, V200, P483, DOI 10.1111/j.1432-1033.1991.tb16208.x; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NATSUKA S, 1992, BLOOD, V79, P460; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; PARKS WC, 1996, CURR OPIN DERMATOL, V3, P240; Pierce RA, 1996, J CLIN INVEST, V97, P1890, DOI 10.1172/JCI118620; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SaarialhoKere UK, 1996, AM J PATHOL, V148, P519; SAARIALHOKERE UK, 1993, J INVEST DERMATOL, V100, P335, DOI 10.1111/1523-1747.ep12470032; SHAPIRO SD, 1993, BIOCHEMISTRY-US, V32, P4286, DOI 10.1021/bi00067a018; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; STRICKLIN GP, 1993, AM J PATHOL, V143, P1657; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; THOMPSON RW, 1995, J CLIN INVEST, V96, P318, DOI 10.1172/JCI118037; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WOLFE GC, 1993, ARTHRITIS RHEUM-US, V36, P1540, DOI 10.1002/art.1780361108; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209	72	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11840	11849		10.1074/jbc.272.18.11840	http://dx.doi.org/10.1074/jbc.272.18.11840			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115242	hybrid			2022-12-25	WOS:A1997WX56900030
J	Si, JT; Miller, DS; Mei, L				Si, JT; Miller, DS; Mei, L			Identification of an element required for acetylcholine receptor-inducing activity (ARIA)-induced expression of the acetylcholine receptor epsilon subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMUSCULAR-JUNCTION; MESSENGER-RNA; SYNAPSES; MUSCLE; ARIA; MYOGENIN; REGION; DOMAIN	Acetylcholine Receptor (AChR)-inducing activity (ARIA) is believed to be the trophic factor utilized by motoneurons to stimulate AChR synthesis in the subsynaptic area. Among the four AChR subunit genes, the epsilon subunit gene is strictly expressed in nuclei localized to the synaptic region of the muscle. To understand mechanisms of the regulation of synapse-specific transcription, we studied the promoter activity of the 5'-flanking region of the AChR epsilon subunit gene in response to ARIA. Transgenes containing the wild type or mutant 5'-flanking regions upstream of a luciferase gene were transfected in C2C12 muscle cells. The promoter activity of these transgenes was determined by assaying activity of expressed luciferase. Analyzing a combination of 5' deletion and site-directed mutants, we identified a 10-nucleotide element (position -55/-46), which was crucial for ARIA-induced expression from the epsilon subunit promoter. This element was named ARE for ARIA-responsive element, Mutation of ARE greatly diminished ARIA-induced transgene expression and deletion of ARE abolished completely the ARIA response. Electrophoretic mobility shift analyses revealed a DNA binding activity in muscle nuclear extract that interacted with ARE. Such interaction was enhanced by ARIA stimulation of muscle cells and appeared to be dependent on nuclear protein phosphorylation.	UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia			Mei, Lin/G-8755-2012		NINDS NIH HHS [NS34062] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Duclert A, 1996, J BIOL CHEM, V271, P17433, DOI 10.1074/jbc.271.29.17433; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; Sambrook J., 2002, MOL CLONING LAB MANU; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Walke W, 1996, J NEUROSCI, V16, P3641; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; ZHU X, 1995, EMBO J, V23, P5842	29	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10367	10371						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099674				2022-12-25	WOS:A1997WV26200008
J	Teramoto, H; Salem, P; Robbins, KC; Bustelo, XR; Gutkind, JS				Teramoto, H; Salem, P; Robbins, KC; Bustelo, XR; Gutkind, JS			Tyrosine phosphorylation of the vav proto-oncogene product links Fc epsilon RI to the Rac1-JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; KINASE; RECEPTOR; PROTEINS; ACTIVATION; DOMAIN; CELL; SYK; TCR	Stimulation of high affinity IgE Fc receptors (Fc epsilon RI) in basophils and mast cells activates the tyrosine kinases Lyn and Syk and causes the tyrosine phosphorylation of phospholipase C-gamma resulting in the Ca2(+)- and protein kinase C-dependent secretion of inflammatory mediators. Concomitantly, Fc epsilon RI stimulation initiates a number of signaling events resulting in the activation of mitogen-activated protein kinase (MAPK) and c-Jun NH2-terminal kinase (JNK), which, in turn, regulate nuclear responses, including cytokine gene expression. To dissect the signaling pathway(s) linking Fc epsilon RI to MAPK and JNK, we reconstructed their respective biochemical routes by expression of a chimeric interleukin-2 receptor alpha subunit (Tac)-Fc epsilon RI gamma chain (Tac gamma) in COS-7 cells, Cross-linking of Tac gamma did not affect MAPK in COS-7 cells, but when coexpressed with the tyrosine kinase Syk, Tac gamma stimulation potently induced Syk and Shc tyrosine phosphorylation and MAPK activation. In contrast, Tac gamma did not signal JNK activation, even when coexpressed with Syk. Ectopic expression of a hematopoietic-specific guanine nucleotide exchange factor (GEF), Vav, reconstituted the Tac gamma-induced, Syk- and Rac1-dependent JNR activation; and tyrosine-phosphorylation of Vav by Syk stimulated its GEF activity for Rac1. Thus, these data strongly suggest that Vav plays a critical role linking Fc epsilon RI and Syk to the Rac1-JNK pathway. Furthermore, these findings define a novel signal transduction pathway involving a multimeric cell surface receptor acting on a cytosolic tyrosine kinase, which, in turn, phosphorylates a GEF, thereby regulating its activity toward a small GTP-binding protein and promoting the activation of a kinase cascade.	NIDR,NIH,MOL SIGNALING UNIT,ORAL & PHARYNGEAL CANC BRANCH,BETHESDA,MD 20892; SUNY STONY BROOK,SCH MED,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK HOSP,STONY BROOK,NY 11794	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Bustelo, Xose R./A-9526-2010	Gutkind, J. Silvio/0000-0002-5150-4482; Bustelo, Xose R./0000-0001-9398-6072				BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; EISEMAN E, 1992, NATURE, V355, P78; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; HART MJ, 1994, J BIOL CHEM, V269, P62; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; OZAWA K, 1993, J BIOL CHEM, V268, P1749; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SCHARENBERG AM, 1995, CHEM IMMUNOL, V61, P72; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	24	106	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10751	10755						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099726				2022-12-25	WOS:A1997WV26200060
J	Kotani, H; Takaishi, K; Sasaki, T; Takai, Y				Kotani, H; Takaishi, K; Sasaki, T; Takai, Y			Rho regulates association of both the ERM family and vinculin with the plasma membrane in MDCK cells	ONCOGENE			English	Article						Rho; ERM family; vinculin; peripheral bundle; cortical bundle; focal adhesion	GTP-BINDING PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; GDP DISSOCIATION INHIBITOR; SACCHAROMYCES-CEREVISIAE; FOCAL ADHESIONS; GENE-PRODUCT; EXCHANGE PROTEIN; BRAIN CYTOSOL; BUD FORMATION; KINASE-C	Rho small G protein regulates various actin-dependent cell functions. As to the functioning sites of Rho, Rho regulates formation of stress fibers and focal adhesions in many types of cultured cells, whereas we have shown that the association sites of actin filaments with the plasma membrane controlled by the ERM (Ezrin, Radixin, Moesin) family are the functioning sites of Rho in MDCK cells stably expressing myc-RhoA. We have investigated here the effect of microinjection of Rho GDI, a negative regulator of Rho which inhibits activation of Rho, C3, an exoenzyme of Clostridium botulinum which ADP-ribosylates Rho and inhibits its functions, or guanosine 5'-(3-O-thio) triphosphate-bound active form of Rho on the intracellular localization of both the ERM family and vinculin, which is one of the structural proteins of focal adhesions, in wild type MDCK cells. The ERM family was preferentially localized at peripheral bundles of actin filaments which are localized at the outer edge of colonies of the cells, microvilli and low Gaze-induced cortical bundles of actin filaments in wild type MDCK cells. Microinjection of Rho GDI or C3 inhibited the localization of the ERM family at both the peripheral bundles and the low Ca2+-induced cortical bundles. On the other hand, vinculin was localized at both focal adhesions and basal edges of the colonies of the cells, and microinjection of Rho GDI or C3 inhibited the localization of vinculin at both of these sites. These results indicate that activation of Rho is necessary for the association of both the ERM family and vinculin with the plasma membrane in wild type MDCK cells. Microinjection of the guanosine 5'-(3-O-thio) triphosphate-bound form of Rho induced an increase in the localization of vinculin at focal adhesions, but did not induce an increase in the localization of the ERM family at the plasma membrane, indicating that activation of Rho itself is sufficient only for the association of vinculin with the plasma membrane at focal adhesions.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University								AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PAKKANEN R, 1987, J HISTOCHEM CYTOCHEM, V35, P809, DOI 10.1177/35.8.3298422; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATO N, 1992, J CELL SCI, V103, P131; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TANAKA K, 1995, METHOD ENZYMOL, V256, P41; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; UEDA T, 1990, J BIOL CHEM, V265, P9373; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	47	67	69	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1705	1713		10.1038/sj.onc.1200998	http://dx.doi.org/10.1038/sj.onc.1200998			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135072				2022-12-25	WOS:A1997WR89300009
J	Pirollo, KF; Hao, ZM; Rait, A; Jang, YJ; Fee, WE; Ryan, P; Chiang, YW; Chang, EH				Pirollo, KF; Hao, ZM; Rait, A; Jang, YJ; Fee, WE; Ryan, P; Chiang, YW; Chang, EH			p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy	ONCOGENE			English	Article						p53; adenovirus; head and neck; cancer; radiosensitization	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; IN-VIVO; RECOMBINANT ADENOVIRUS; RADIATION-RESISTANT; IONIZING-RADIATION; CANCER-THERAPY; APOPTOSIS; EXPRESSION; GROWTH	Radiation resistant squamous cell carcinoma of the head and neck cell line JSQ-3 carries a mutant form of tumor suppressor gene p53. Treatment of these cells with an adenoviral vector containing wild-type p53 (Av1p53) was able to inhibit their growth in vitro and in vivo while having no effect on normal cells. More significantly, introduction of wtp53 also reduced the radiation-resistance level of this cell line in vitro, in a viral dose-dependent manner, Furthermore, this radiosensitization also carried over to the in vivo situation where the response of JSQ-3 cell-induced mouse xenografts to radiotherapy was markedly enhanced after treatment with Av1p53, Complete, long-term regression of the tumors for up to 162 days was observed when a single dose of Av1p53 was administered in combination with ionizing radiation, demonstrating the effectiveness of this combination of gene therapy and conventional radiotherapy, This sensitization of tumors to radiation therapy by replacement of wtp53 could significantly decrease the rate of recurrence after radiation treatment. Since radiation is one of the most prevalent forms of adjunctive therapy for a variety of cancers, these results have great relevance in moving toward an improved cancer therapy.	STANFORD UNIV,DEPT SURG,DIV OTOLARYNGOL,STANFORD,CA 94305; GENET THERAPY INC,NOVARTIS,GAITHERSBURG,MD 20878	Stanford University; Novartis					NCI NIH HHS [R01 CA45158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; *AM CANC SOC, 1993, PUB AM CANC SOC; *AM JOINT COMM CAN, 1983, MAN STAG CANC, P25; AWAN AM, 1991, HEMATOL ONCOL CLIN N, V5, P635, DOI 10.1016/S0889-8588(18)30406-4; BLAU HM, 1995, NEW ENGL J MED, V333, P1204, DOI 10.1056/NEJM199511023331808; BRACHMAN DG, 1994, SEMIN ONCOL, V21, P320; BRAMSON JL, 1995, CURR OPIN BIOTECH, V6, P590, DOI 10.1016/0958-1669(95)80097-2; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLAYMAN GL, 1995, CANCER RES, V55, P1; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DIMERY IW, 1993, JNCI-J NATL CANCER I, V85, P95, DOI 10.1093/jnci/85.2.95; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELSTNER E, 1995, CANCER RES, V55, P2822; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; FUJIWARA T, 1993, CANCER RES, V53, P4129; FUJIWARA T, 1994, CANCER RES, V54, P2287; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; HARPER JW, 1993, CELL, V75, P805; Hawkins DS, 1996, CANCER RES, V56, P892; Janat M. Fouad, 1994, Molecular and Cellular Differentiation, V2, P241; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUNG M, 1992, CANCER RES, V52, P6390; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KOECHLI OR, 1994, LANCET, V344, P1647, DOI 10.1016/S0140-6736(94)90447-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, COLD SPRING HARB SYM, V59, P419, DOI 10.1101/SQB.1994.059.01.047; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MITTEREDER N, 1994, HUM GENE THER, V5, P717, DOI 10.1089/hum.1994.5.6-717; NABEYA Y, 1995, INT J CANCER, V64, P37, DOI 10.1002/ijc.2910640109; NEWCOMB EW, 1995, LEUKEMIA LYMPHOMA, V17, P211, DOI 10.3109/10428199509056825; OCONNOR PM, 1993, CANCER RES, V53, P4776; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PITTS JD, 1994, MOL CARCINOGEN, V11, P127, DOI 10.1002/mc.2940110302; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SEACHRIST L, 1994, J NATL CANCER I, V86, P82, DOI 10.1093/jnci/86.2.82; SETOGUCHI Y, 1994, J RESPIR CELL MOL BI, V10, P369; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shin DM, 1996, J NATL CANCER I, V88, P519, DOI 10.1093/jnci/88.8.519; SILBER R, 1994, BLOOD, V84, P3440; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1995, UROLOGY, V46, P843, DOI 10.1016/S0090-4295(99)80355-0; STEWART FM, 1995, J CELL BIOCHEM, V58, P416, DOI 10.1002/jcb.240580404; STEWART N, 1995, ONCOGENE, V10, P109; TRAPNELL BC, 1993, ADV DRUG DELIVER REV, V12, P185, DOI 10.1016/0169-409X(93)90059-D; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V15, P575, DOI 10.1016/0360-3016(88)90297-0; WU SG, 1996, NAT MED, V2, P255; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG CL, 1995, CANCER RES, V55, P4210; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	69	112	133	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1735	1746		10.1038/sj.onc.1201116	http://dx.doi.org/10.1038/sj.onc.1201116			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135075				2022-12-25	WOS:A1997WR89300012
J	Xu, X; Gelinas, C				Xu, X; Gelinas, C			A mutant Rel-homology domain promotes transcription by p50/NF kappa B1	ONCOGENE			English	Article						c-Rel; p50; NF kappa B; transcription; protein conformation	NF-KAPPA-B; DNA-BINDING SUBUNIT; C-REL; V-REL; ONCOGENIC TRANSFORMATION; MAMMALIAN-CELLS; GENE ACTIVATION; FAMILY PROTEINS; NUCLEAR FACTOR; P50 SUBUNIT	Previous studies showed that the binding of p50/NF kappa B1 to particular kappa B DNA sites altered its conformation in a way that correlated with transcriptional activation. Here, we investigated the effects of protein-protein interactions on the transcriptional activity of p50. We show that the association of p50 with a mutant Rel-homology domain (RHD) defective for DNA binding led to synergistic activation of kappa B site-dependent transcription, whereas neither protein alone had any effect. Partial proteolytic analysis showed that the conformation of p50 in these complexes differed from that in wild-type c-Rel-RHD/p50 complexes, and correlated with activated transcription. These results suggest that the Rel-homology domain can act as an allosteric effector to promote transcription by p50/NF kappa B1 and that the configuration of p50 is important for its activity. This also suggests that Rel proteins can promote transcription by other Rel-family members without binding to their DNA recognition site. These studies emphasize the important role of protein-protein interactions in Rel and NF kappa B-mediated transcription.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,GRAD PROGRAM BIOCHEM & MOL BIOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; INST CANC RES,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R29CA054999, R01CA054999] Funding Source: NIH RePORTER; NCI NIH HHS [CA54999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGHERTY JP, 1989, J VIROL, V63, P3209, DOI 10.1128/JVI.63.7.3209-3212.1989; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RATTNER A, 1991, MOL CELL BIOL, V11, P1017, DOI 10.1128/MCB.11.2.1017; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; White DW, 1996, MOL CELL BIOL, V16, P1169; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	60	10	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1521	1530		10.1038/sj.onc.1200985	http://dx.doi.org/10.1038/sj.onc.1200985			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129142				2022-12-25	WOS:A1997WQ54800002
J	Kamano, H; Klempnauer, KH				Kamano, H; Klempnauer, KH			B-Myb and cyclin D1 mediate heat shock element dependent activation of the human HSP70 promoter	ONCOGENE			English	Article						B-Myb; heat shock element; HSP70 promoter; cyclin D1	DNA-BINDING ACTIVITY; A-MYB; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATOR; RETINOBLASTOMA PROTEIN; V-MYB; C-MYB; HEMATOPOIETIC-CELLS; GENE-TRANSCRIPTION; REGULATORY DOMAINS	Previous studies have shown that B-Myb, a conserved member of the Myb transcription factor family, is a potent activator of the promoter of the human HSP70 gene but does not activate promoters containing Myb binding sites. We have now investigated the transactivation properties of B-Myb in more detail. We here report that B-Myb activates the HSP70 promoter by a novel mechanism which involves the heat shock element (HSE). Deletion analysis of B-Myb shows that a specific domain in the center of B-Myb, but not the DNA-binding domain is required for HSE-dependent transactivation. We also show that deletion of the C-terminal domain of B-Myb does not affect HSE-dependent transactivation but allows the protein to activate a promoter containing Myb binding sites. This suggests that the ability to activate Myb binding site containing promoters is repressed in the context of full length B-Myb and that HSE dependent and Myb binding site dependent transactivation are distinct functions of B-Myb. Finally, we report that cyclin D1 like B-Myb strongly activates the HSP70 promoter via the HSE. HSE-dependent transactivation is a novel activity of cyclin D1 and appears to be independent of the phosphorylation of the Rb protein. Our results reveal an interesting and unexpected connection between HSE-dependent gene activation and proteins expressed during the G1/S-transition of the cell cycle.	MAX PLANCK INST IMMUNOBIOL, HANS SPEMANN LAB, D-79108 FREIBURG, GERMANY	Max Planck Society								AMIN J, 1985, MOL CELL BIOL, V5, P197, DOI 10.1128/MCB.5.1.197; ARSURA M, 1992, BLOOD, V79, P2708; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Kamano H, 1995, ONCOGENE, V11, P2575; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KAO HT, 1985, MOL CELL BIOL, V5, P628, DOI 10.1128/MCB.5.4.628; KATO J, 1993, GENE DEV, V7, P331; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NEVINS JR, 1992, SCIENCE, V258, P424; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Sitzmann J, 1996, ONCOGENE, V12, P1889; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TASHIRO S, 1995, ONCOGENE, V10, P1699; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	52	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1223	1229		10.1038/sj.onc.1200945	http://dx.doi.org/10.1038/sj.onc.1200945			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121772				2022-12-25	WOS:A1997WM78200012
J	Rolfes, RJ; Zhang, F; Hinnebusch, AG				Rolfes, RJ; Zhang, F; Hinnebusch, AG			The transcriptional activators BAS1, BAS2, and ABF1 bind positive regulatory sites as the critical elements for adenine regulation of ADE5,7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; HIS4 TRANSCRIPTION; ESCHERICHIA-COLI; HO PROMOTER; ADE2 GENE; YEAST; PROTEIN; SEQUENCE; TRANSFORMATION	Adenine repression of the purine nucleotide biosyn thetic genes in Saccharomyces cerevisiae involves downregulation of the activator protein BAS1 or BASS by an unknown mechanism, To determine the minimal cis-acting requirements for adenine regulation, hybrid promoter constructs were made between ADE5,7 promoter fragments and a CYC1-lacZ reporter, A 139-nucleotide fragment containing two BAS1 binding sites was sufficient to confer adenine regulation on the CYC1-lacZ reporter, Analysis of deletion and substitution mutations led to the conclusion that the proximal BAS1 binding site is both necessary and sufficient for regulation, whereas the distal site augments the function of the proximal site, By performing saturation mutagenesis, we found two essential regions that flank the proximal site, An ABF1 consensus sequence is within one of these regions, and mutations that impaired in vitro ABF1 binding impaired promoter activity in vivo. A second region is AT-rich and appears to bind BASS, No substitution mutations led to high level constitutive promoter activity as would be expected from removal of an upstream repression sequence. Our results indicate that ABF1, BAS1, and BASS are required for ADE5,7 pro meter function and that adenine repression most likely involves activator modification or a negative regulator that does not itself bind DNA.	NICHHD, LAB EUKARYOT GENE REGULAT, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rolfes, RJ (corresponding author), GEORGETOWN UNIV, DEPT BIOL, WASHINGTON, DC 20057 USA.							ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BRAZAS RM, 1993, MOL CELL BIOL, V13, P5524, DOI 10.1128/MCB.13.9.5524; BRAZAS RM, 1993, P NATL ACAD SCI USA, V90, P11237, DOI 10.1073/pnas.90.23.11237; BRAZAS RM, 1995, J BIOL CHEM, V270, P29151, DOI 10.1074/jbc.270.49.29151; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DORSMAN JC, 1990, NUCLEIC ACIDS RES, V18, P2769, DOI 10.1093/nar/18.9.2769; GEDVILAITE A, 1994, CURR GENET, V25, P475, DOI 10.1007/BF00351665; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HALFTER H, 1989, EMBO J, V8, P3029, DOI 10.1002/j.1460-2075.1989.tb08453.x; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HENIKOFF S, 1986, J MOL BIOL, V190, P519, DOI 10.1016/0022-2836(86)90238-X; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; HOVRING PI, 1994, J BIOL CHEM, V269, P17663; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; MCBROOM LDB, 1994, J BIOL CHEM, V269, P16455; MCBROOM LDB, 1994, J BIOL CHEM, V269, P1641; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; MOSCH HU, 1991, J BIOL CHEM, V266, P20453; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STOTZ A, 1993, CURR GENET, V24, P472, DOI 10.1007/BF00351708; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; ZHANG F, 1997, IN PRESS MOL CELL BI, V17	36	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13343	13354		10.1074/jbc.272.20.13343	http://dx.doi.org/10.1074/jbc.272.20.13343			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148957	hybrid			2022-12-25	WOS:A1997WZ38400070
J	Wong, K; Meyers, R; Cantley, LC				Wong, K; Meyers, R; Cantley, LC			Subcellular locations of phosphatidylinositol 4-kinase isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PHOSPHOINOSITIDE 3-KINASE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; KINETIC-PROPERTIES; KINASE; PURIFICATION; MEMBRANE; YEAST; GOLGI	Phosphatidylinositol (PtdIns) 4-kinase catalyzes the synthesis of PtdIns-4-P, the precursor of an array of lipid second messengers generated by additional phosphorylation by PtdIns-4-P Fi kinase and PtdIns 3-kinase. PtdIns l-kinase activity is conserved from yeast to higher eukaryotes, Multiple isoforms of mammalian PtdIns 4-kinase have been purified, and the activities have been detected in almost all subcellular locations, We previously reported the cloning and characterization of the first mammalian PtdIns 4-kinase named PI4K alpha (Wong, K,, and Cantley, L. C, (1994) J. Biol, Chem. 269, 28878-28884), Alternatively spliced forms of PI4K alpha have also been identified from several sources including bovine brain (Gehrmann, T., Vereb, G., Schmidt, M,, Klix, D,, Meyer, H. E,, Varsanyi, M., and Heilmeyer, L,, M., Jr, (1996) Biochim. Biophys. Acta 1311, 53-63). Recently Re isolated a distinct human PtdIns 4-kinase gene, named PI4K beta, that encodes an enzyme that is wortmannin sensitive (Meyers, R,, and Cantley, L. C, (1997) J. Biol. Chem. 272, 4384-4390), Here we report the locations of these enzymes and provide evidence for other yet unidentified isoforms present in specific organelles, PI4K alpha is mostly membrane-bound and located at the endoplasmic reticulum; whereas PI4K beta is in the cytosol and also present in the Golgi region, Neither of these isoforms accounts for the major type II PtdIns 4-kinase activity detected in the lysosomes and plasma membrane fraction.	HARVARD UNIV, BETH ISRAEL HOSP,INST MED,DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [GM 36624] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1990, METHODS INOSITIDE RE, P155; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COCHET C, 1984, J BIOL CHEM, V259, P2553; COCKCROFT S, 1985, BIOCHIM BIOPHYS ACTA, V845, P163, DOI 10.1016/0167-4889(85)90173-9; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; FLANAGAN CA, 1993, SCIENCE, V262, P144; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gehrmann T, 1996, BBA-MOL CELL RES, V1311, P53, DOI 10.1016/0167-4889(95)00180-8; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HUSEBYE ES, 1989, BIOCHIM BIOPHYS ACTA, V1010, P250, DOI 10.1016/0167-4889(89)90169-9; HUSEBYE ES, 1988, BIOCHIM BIOPHYS ACTA, V968, P261, DOI 10.1016/0167-4889(88)90015-8; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JERGIL B, 1983, J BIOL CHEM, V258, P7968; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; KUROSAWA M, 1986, J IMMUNOL, V136, P616; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; PERTILE P, 1995, BBA-PROTEIN STRUCT M, V1248, P129, DOI 10.1016/0167-4838(95)00016-N; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SMITH CD, 1983, J BIOL CHEM, V258, P9368; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WONG K, 1994, J BIOL CHEM, V269, P28878; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	37	158	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13236	13241		10.1074/jbc.272.20.13236	http://dx.doi.org/10.1074/jbc.272.20.13236			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148941	hybrid			2022-12-25	WOS:A1997WZ38400054
J	Fabian, JR; Kimball, SR; Heinzinger, NK; Jefferson, LS				Fabian, JR; Kimball, SR; Heinzinger, NK; Jefferson, LS			Subunit assembly and guanine nucleotide exchange activity of eukaryotic initiation factor-2B expressed in Sf9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; PROTEIN-SYNTHESIS; FACTOR-II; TRANSLATIONAL CONTROL; RAT-LIVER; RABBIT RETICULOCYTES; SKELETAL-MUSCLE; FACTOR EIF-2B; KINASE GCN2; PHOSPHORYLATION	Eukaryotic initiation factor-2B (eIF-2B) is a guanine nucleotide exchange factor (GEF) that plays a key role in the regulation of protein synthesis, In this study, we have used the baculovirus-infected Sf9 insect cell system to express and characterize the five dissimilar subunits of rat eIF-2B, GEF activity was detected in extracts of Sf9 cells expressing the epsilon-subunit alone and was greatly increased when all five subunits were coexpressed, In addition, high GEF activity was observed in extracts containing a four subunit complex lacking the alpha-subunit. Assembly of an eIF-2B holoprotein was confirmed by coimmunoprecipitation of all five subunits, Gel filtration chromatography revealed that recombinant eIF-2B had the same molecular mass as eIF-2B purified from rat liver and that it did indeed possess GEF activity, Phosphorylation of the substrate eIF-2 inhibited the GEF activity of the five-subunit eIF-2B; this inhibition required the eIF-2B alpha-subunit, The results demonstrate that eIF-2B alpha functions as a regulatory subunit that is not required for GEF activity, but instead mediates the regulation of eIF-2B by substrate phosphorylation. Furthermore, eIF-2B epsilon is necessary and is perhaps sufficient for GEF activity in vitro.	PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOL PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIDDK NIH HHS [DK 13499, DK 15658] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, R01DK015658, R01DK013499] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; Craddock BL, 1996, BIOCHEM BIOPH RES CO, V220, P843, DOI 10.1006/bbrc.1996.0495; CRADDOCK BL, 1995, BIOCHEM J, V309, P1009, DOI 10.1042/bj3091009; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DHOLAKIA JN, 1986, P NATL ACAD SCI USA, V83, P6746, DOI 10.1073/pnas.83.18.6746; Flowers KM, 1996, BBA-GENE STRUCT EXPR, V1307, P318, DOI 10.1016/0167-4781(96)00055-3; FLOWERS KM, 1995, BBA-GENE STRUCT EXPR, V1264, P163, DOI 10.1016/0167-4781(95)00160-I; FRASER MJ, 1992, CURR TOP MICROBIOL, V158, P131; FRECH M, 1995, METHOD ENZYMOL, V256, P125; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; JEFFREY IW, 1990, BIOCHIMIE, V72, P751, DOI 10.1016/0300-9084(90)90160-I; KARINCH AM, 1993, AM J PHYSIOL, V264, pE101, DOI 10.1152/ajpendo.1993.264.1.E101; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; KIMBALL SR, 1987, J BIOL CHEM, V262, P2220; KIMBALL SR, 1995, BIOCHEM BIOPH RES CO, V212, P1074, DOI 10.1006/bbrc.1995.2079; KIMBALL SR, 1988, BIOCHEM BIOPH RES CO, V156, P706, DOI 10.1016/S0006-291X(88)80900-8; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KIMBALL SR, 1994, BBA-GEN SUBJECTS, V1201, P473, DOI 10.1016/0304-4165(94)90079-5; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PANNIERS R, 1988, J BIOL CHEM, V263, P5519; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Price NT, 1996, BIOCHEM J, V318, P631, DOI 10.1042/bj3180631; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RICHARDSON C, 1995, BACULOVIRUS EXPRESSI, V39; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SINGH LP, 1994, BIOCHEMISTRY-US, V33, P9152, DOI 10.1021/bi00197a018; Singh LP, 1996, BIOCHEMISTRY-US, V35, P3206, DOI 10.1021/bi9522099; SINGH LP, 1995, BIOCHEM BIOPH RES CO, V212, P1007, DOI 10.1006/bbrc.1995.2070; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	47	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12359	12365		10.1074/jbc.272.19.12359	http://dx.doi.org/10.1074/jbc.272.19.12359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139680	hybrid			2022-12-25	WOS:A1997WY82900017
J	Chaika, OV; Chaika, N; Volle, DJ; Wilden, PA; Pirrucello, SJ; Lewis, RE				Chaika, OV; Chaika, N; Volle, DJ; Wilden, PA; Pirrucello, SJ; Lewis, RE			CSF-1 receptor insulin receptor chimera permits CSF-1-dependent differentiation of 3T3-L1 preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PHOSPHOTYROSINE-DEPENDENT INTERACTION; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; BETA-SUBUNIT; JUXTAMEMBRANE REGION; SIGNAL-TRANSDUCTION; GLUCOSE TRANSPORTER; HEXOSE-TRANSPORT; NPEY MOTIF	A chimeric growth factor receptor (CSF1R/IR) was constructed by splicing cDNA sequences encoding the extracellular ligand binding domain of the human colony stimulating factor-1 (CSF-1) receptor to sequences encoding the transmembrane and cytoplasmic domains of the human insulin receptor. The addition of CSF-1 to cells transfected with the CSF1R/IR chimera cDNA stimulated the tyrosine phosphorylation of a protein that was immunoprecipitated by an antibody directed against the carboxyl terminus of the insulin receptor. Phosphopeptide maps of the P-32-labeled CSF1R/IR protein revealed the same pattern of phosphorylation ob served in P-32-labeled insulin receptor beta subunits. CSF-1 stimulated the tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and Shc in cells expressing the CSF1R/IR chimera. Lipid accumulation and the expression of a differentiation specific marker demonstrated that 3T3-L1 preadipocytes undergo CSF-1-dependent differentiation when transfected with the CSF1R/IR chimera cDNA but not when transfected with the expression vector alone. A 12-amino acid deletion within the juxtamembrane region of the CSF1R/IR (CSF1R/IR Delta 960) blocked CSF-1-stimulated phosphorylation of IRS-1 and She but did not inhibit CSF-1-mediated differentiation of 3T3-L1 preadipocytes. These observations indicate that adipocyte differentiation can be initiated by intracellular pathways that do not require tyrosine phosphorylation of IRS-1 or Shc.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOL BIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198; UNIV MISSOURI,SCH MED,DEPT PHARMACOL,COLUMBIA,MO 65212	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Missouri System; University of Missouri Columbia			Lewis, Robert E./H-3404-2019		NCI NIH HHS [P30 CA36727] Funding Source: Medline; NIDDK NIH HHS [DK41896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1991, P NATL ACAD SCI USA, V88, P4708, DOI 10.1073/pnas.88.11.4708; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Houseknecht KL, 1996, J BIOL CHEM, V271, P11347, DOI 10.1074/jbc.271.19.11347; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; REIDEL H, 1989, EMBO J, V8, P2943; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SHERR CJ, 1989, BLOOD, V73, P1786; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH PJ, 1988, J BIOL CHEM, V263, P940; SPOONER PM, 1979, J BIOL CHEM, V254, P1305; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; THEIS RS, 1989, J BIOL CHEM, V264, P12820; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1995, J CELL PHYSIOL, V163, P9, DOI 10.1002/jcp.1041630103; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	61	30	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11968	11974		10.1074/jbc.272.18.11968	http://dx.doi.org/10.1074/jbc.272.18.11968			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115260	hybrid			2022-12-25	WOS:A1997WX56900048
J	Gamett, DC; Pearson, G; Cerione, RA; Friedberg, I				Gamett, DC; Pearson, G; Cerione, RA; Friedberg, I			Secondary dimerization between members of the epidermal growth factor receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; BREAST-CANCER; NEU ONCOGENE; ERBB3; HETERODIMERIZATION; HEREGULIN; CELLS; PHOSPHORYLATION; TRANSFORMATION; TYRPHOSTINS	Growth factor receptors of the epidermal growth factor (EGF) receptor family play pivotal roles in the regulation of cell proliferation and differentiation and are involved in the development of human cancers. It has been well documented that these receptors undergo growth factor-stimulated homo- and heterodimerization as a first step in the initiation of signaling cascades. Here we provide evidence for a new mechanism for growth factor stimulated receptor dimer formation, designated secondary dimerization. The growth factor-induced dimerization and ensuing receptor trans autophosphorylation results in the dissociation of the original (primary) receptor dimer. Each phosphorylated receptor monomer then interacts with a new (nonphosphorylated) receptor to form a secondary dimer. Treatment of cells with EGF yields Neu-ErbB3 secondary dimers, and heregulin treatment induces the formation of Neu-EGF receptor (secondary) dimers. The ability of EGF and heregulin to stimulate a cascade of dimerization events points to a novel mechanism by which multiple signaling activities and diverse biological responses are initiated by members of the EGF receptor family.	CORNELL UNIV,CTR VET MED,DEPT PHARMACOL,ITHACA,NY 14853; TEL AVIV UNIV,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	Cornell University; Tel Aviv University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAS M, 1977, P NATL ACAD SCI USA, V74, P2790, DOI 10.1073/pnas.74.7.2790; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; GAMETT DC, 1994, FEBS LETT, V351, P335, DOI 10.1016/0014-5793(94)00855-8; GAZIT A, 1993, J MED CHEM, V36, P3556, DOI 10.1021/jm00075a010; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GULLICK WJ, 1986, CANCER RES, V46, P285; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; GUY PM, 1992, J BIOL CHEM, V267, P13851; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lewis GD, 1996, CANCER RES, V56, P1457; MITRA AB, 1994, CANCER RES, V54, P637; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIAN XL, 1994, ONCOGENE, V9, P1507; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZHOU DJ, 1987, CANCER RES, V47, P6123	38	91	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12052	12056		10.1074/jbc.272.18.12052	http://dx.doi.org/10.1074/jbc.272.18.12052			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115272	hybrid			2022-12-25	WOS:A1997WX56900060
J	Greene, NM; Williams, DS; Newton, AC				Greene, NM; Williams, DS; Newton, AC			Identification of protein kinase C phosphorylation sites on bovine rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR KINASES; PHOTORECEPTORS; MECHANISM	The protein kinase C phosphorylation sites on bovine rhodopsin were identified using proteolytic, phosphoamino acid, mass spectrometric, and peptide sequencing analyses, Tryptic removal of the 9 carboxyl-terminal residues of rhodopsin revealed that a major fraction of the phosphates incorporated by protein kinase C are in a region containing Ser(334), Thr(335), and Thr(336). Phosphoamino acid analysis of the tryptic product established that Ser(334) accounts for approximately 65% of the phosphorylation in this region, Analysis of the endoproteinase Asp-N-generated carboxyl terminus of rhodopsin by mass spectrometry and peptide sequencing revealed that Ser(338) is also a primary phosphorylation site, with minor phosphorylation of Ser(343). Quantitation of high pressure liquid chromatography-separated phosphopeptides, taken together with phosphoamino acid analysis of the tryptic product, revealed that Ser(334) and Ser(338) were phosphorylated equally and each accounted for approximately 35% of the total phosphorylation; Thr(335/336) accounted for just under 20% of the phosphorylation, and Ser(343) accounted for 10%. Thus, the primary protein kinase C sites are Ser(334), and Ser(338), with minor phosphorylation of Thr(335/336), and Ser(343). Ser(334) and Ser(338) have recently been identified as the primary sites of phosphorylation of rhodopsin in vivo (Ohguro, H., Van Hooser, J. P. Milam, A, H., and Palczewski, K. (1995) J. Biol; Chem 270, 14259-14262), Of these sites, only Ser(338) is a significant substrate for rhodopsin kinase in vitro. Identification of Ser(334) as a primary protein kinase C target in vitro is consistent with protein kinase C modulating the phosphorylation of this site in vivo.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NEI NIH HHS [EY08820] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008820] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MOLDAY RS, 1985, BIOCHEMISTRY-US, V24, P776, DOI 10.1021/bi00324a036; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; Ohguro H, 1996, J BIOL CHEM, V271, P5215; ORR JW, 1992, J BIOL CHEM, V267, P15263; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; STRYER L, 1991, J BIOL CHEM, V266, P10711; UDOVICHENKO IP, 1997, IN PRESS J BIOL CHEM; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; Yeagle P L, 1996, Mol Vis, V2, P12	24	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10341	10344						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099669				2022-12-25	WOS:A1997WV26200003
J	Krischer, SM; Eisenmann, N; Bock, A; Mueller, MJ				Krischer, SM; Eisenmann, N; Bock, A; Mueller, MJ			Protein-facilitated export of arachidonic acid from pig neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; TRANSPORT-SYSTEM; PHOSPHOLIPASE A(2); MEMBRANE-VESICLES; LINOLEIC-ACID; FATTY-ACIDS; METABOLISM; LEUKOTRIENE-B4; MECHANISM; BINDING	Activated neutrophils release a variety of eicosanoids into the extracellular medium including arachidonic acid, 5-hydroxgicosatetraenoic acid, and leukotriene A(4) and B-4. In this study, the mechanism of arachidonic acid export has been examined using inside-out plasma membrane vesicles from pig polymorphonuclear leukocytes. Tritiated arachidonic acid associated rapidly with the membrane vesicles and crossed the membrane into the intravesicular space in a time-dependent and saturable manner, Half the maximal influx rate was measured at an arachidonate concentration of 5.7 mu M, and a maximal influx velocity of 3.0 nmol/mg x min was determined at pH 6.8. Influx into vesicles was sensitive to a number of common anion transport inhibitors including pentachlorophenol, phloretin, diiodosalicylic acid, and quercetin as well as to the proteases trypsin and Pronase, suggesting a protein-dependent process, Furthermore, influx was temperature-sensitive with an energy of activation of 11.6 kcal/mol. Varying extravesicular concentration of ATP, Na+, or K+ had no impact on arachidonate influx, whereas changes in pH had a profound effect; optimum transport activity was observed at an extravesicular pH of 6, whereas raising the pH to 9.5 essentially abolished uptake, These results indicate and initially characterize a novel protein-facilitated arachidonate export mechanism in pig neutrophils.	UNIV MUNICH,INST PHARMAZEUT BIOL,D-80333 MUNICH,GERMANY; UNIV MUNICH,INST BOT,D-80638 MUNICH,GERMANY	University of Munich; University of Munich			mueller, martin j/C-7616-2019					ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; ANTOINE C, 1992, BIOCHIM BIOPHYS ACTA, V1128, P139, DOI 10.1016/0005-2760(92)90299-B; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Berk PD, 1996, P SOC EXP BIOL MED, V212, P1; BJORNSDOTTIR US, 1993, IMMUNOL ALLERGY CLIN, V13, P861; BOJESEN IN, 1994, J LIPID RES, V35, P770; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BROM J, 1989, IMMUNOLOGY, V68, P479; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; COHEN N, 1994, CURR OPIN INVEST DR, V3, P13; DELBUONO BJ, 1989, J CELL PHYSIOL, V141, P636, DOI 10.1002/jcp.1041410323; DWIGHT JFS, 1995, CLIN CHIM ACTA, V238, P187, DOI 10.1016/0009-8981(95)06090-Z; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fitscher BA, 1996, P SOC EXP BIOL MED, V212, P15; FONTEH AN, 1993, J IMMUNOL, V150, P563; GORE J, 1994, LIPIDS, V29, P701, DOI 10.1007/BF02538914; Gosling M, 1996, J PHYSIOL-LONDON, V493, P613, DOI 10.1113/jphysiol.1996.sp021408; GRIMMINGER F, 1991, AM J PHYSIOL, V261, pL195, DOI 10.1152/ajplung.1991.261.2.L195; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; JAKOBSSON PJ, 1991, EUR J BIOCHEM, V196, P395, DOI 10.1111/j.1432-1033.1991.tb15829.x; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; LAM BK, 1990, J BIOL CHEM, V265, P13438; MACLOUF J, 1993, BAILLIERE CLIN HAEM, V6, P593, DOI 10.1016/S0950-3536(05)80190-8; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; RAMESHA CS, 1991, ANAL BIOCHEM, V192, P173, DOI 10.1016/0003-2697(91)90203-6; ROSENTHAL MD, 1995, BIOCHEM BIOPH RES CO, V208, P650, DOI 10.1006/bbrc.1995.1388; ROSENTHAL MD, 1994, J CELL PHYSIOL, V160, P522, DOI 10.1002/jcp.1041600315; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SAMPLES DR, 1989, AM J PHYSIOL, V257, pC1166; Schaffer J E, 1996, Eur J Med Res, V1, P176; Schaffer JE, 1995, TRENDS CARDIOVAS MED, V5, P218, DOI 10.1016/1050-1738(95)00102-6; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHURER NY, 1994, BBA-LIPID LIPID MET, V1211, P51, DOI 10.1016/0005-2760(94)90138-4; Sharpe M, 1996, FEBS LETT, V391, P134, DOI 10.1016/0014-5793(96)00721-1; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; SIMCHOWITZ L, 1989, J GEN PHYSIOL, V94, P95, DOI 10.1085/jgp.94.1.95; SIMCHOWITZ L, 1994, AM J PHYSIOL-CELL PH, V267, pC1525, DOI 10.1152/ajpcell.1994.267.6.C1525; SIMCHOWITZ L, 1992, J GEN PHYSIOL, V100, P341, DOI 10.1085/jgp.100.2.341; SIMCHOWITZ L, 1988, AM J PHYSIOL, V254, pC150, DOI 10.1152/ajpcell.1988.254.1.C150; Smirnov SV, 1996, CIRC RES, V79, P20, DOI 10.1161/01.RES.79.1.20; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORRELL TC, 1992, INFECT IMMUN, V60, P1779, DOI 10.1128/IAI.60.5.1779-1785.1992; STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; SWANN AC, 1984, ARCH BIOCHEM BIOPHYS, V233, P354, DOI 10.1016/0003-9861(84)90456-9; VOLPI M, 1982, BIOCHEM BIOPH RES CO, V106, P123, DOI 10.1016/0006-291X(82)92067-8; Xu XP, 1996, AM J PHYSIOL-HEART C, V270, pH1957, DOI 10.1152/ajpheart.1996.270.6.H1957; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5; ZHOU SL, 1994, BIOCHEM J, V297, P315, DOI 10.1042/bj2970315	52	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10601	10607						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099707	hybrid			2022-12-25	WOS:A1997WV26200041
J	Launay, S; Bobe, R; LacabaratzPorret, C; Bredoux, R; Kovacs, T; Enouf, J; Papp, B				Launay, S; Bobe, R; LacabaratzPorret, C; Bredoux, R; Kovacs, T; Enouf, J; Papp, B			Modulation of endoplasmic reticulum calcium pump expression during T lymphocyte activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET MEMBRANE-VESICLES; PHORBOL ESTER; INOSITOL TRISPHOSPHATE; SURFACE MOLECULES; CA-2+-ATPASE GENE; CA2+ STORES; CELLS; INTERLEUKIN-2; THAPSIGARGIN; CA2+-ATPASE	Calcium mobilization from intracellular storage organelles is a key component of the second messenger system inducing cell activation. Calcium transport ATPases associated with intracellular calcium storage organelles play a major role in controlling this process by accumulating calcium from the cytosol into intracellular calcium pools. In this study the modulation of the expression of the sarco-endoplasmic reticulum calcium transport ATPase (SERCA) isoenzymes has been studied in lymphocytes undergoing phorbol myristate acetate and ionomycin-induced activation. In several T lymphocyte cell lines a combined treatment by the two drugs resulted in an approximately 90% decrease of the expression of the calcium pump isoform recognized by the PLIM430 isoform-specific antibody, whereas the expression of the SERCA 2b isoform was increased approximately 2-fold. Phorbol ester or ionomycin applied separately was ineffective, In Jurkat T cells the downmodulation of expression of the SERCA isoform recognized by the PLIM430 antibody appeared concomitantly with the induction of interleukin-2 expression and could be inhibited by the immunosuppressant drug cyclosporine-A. These data indicate that T cell activation induces a selective and cyclosporine-A-sensitive modulation of the expression of the SERCA calcium pump isoforms, This reflects a profound reorganization of the calcium homeostasis of T cells undergoing activation and may open new avenues in the understanding of the plasticity of the calcium homeostasis of differentiating cells and in the pharmacological modulation of lymphocyte function.	HOP LARIBOISIERE,INST FEDERAT RECH CIRCULAT LARIBOISIERE,U348 INSERM,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kovács, Tünde/O-6020-2017; BOBE, Regis/F-4951-2016	Kovács, Tünde/0000-0003-1064-2616; BOBE, Regis/0000-0002-8225-9117; Lacabaratz, Christine/0000-0001-6925-0225; Papp, Bela/0000-0002-5025-3087				ALTMAN A, 1992, IMMUNOLOGY, V76, P465; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BOBE R, 1994, J BIOL CHEM, V269, P1417; BREITTMAYER JP, 1993, CELL IMMUNOL, V149, P248, DOI 10.1006/cimm.1993.1152; CAVALLINI L, 1995, BIOCHEM J, V310, P449, DOI 10.1042/bj3100449; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; Cheng GM, 1996, ARCH BIOCHEM BIOPHYS, V329, P65, DOI 10.1006/abbi.1996.0192; CLEMENTI E, 1994, EUR J IMMUNOL, V24, P1365, DOI 10.1002/eji.1830240619; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Dode L, 1996, BIOCHEM J, V318, P689, DOI 10.1042/bj3180689; ENGELENDER S, 1995, J BIOL CHEM, V270, P21050, DOI 10.1074/jbc.270.36.21050; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; HACK N, 1988, BIOCHEM J, V250, P355, DOI 10.1042/bj2500355; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HEIM R, 1992, J BIOL CHEM, V267, P24476; Holloway MP, 1996, J BIOL CHEM, V271, P8549, DOI 10.1074/jbc.271.15.8549; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; KOVACS T, 1994, J BIOL CHEM, V269, P6177; Lacabaratz C, 1996, BIOCHEM J, V318, P359, DOI 10.1042/bj3180359; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; LUGO JP, 1986, P NATL ACAD SCI USA, V83, P1862, DOI 10.1073/pnas.83.6.1862; Luo C, 1996, MOL CELL BIOL, V16, P3955; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; PAPP B, 1993, CELL CALCIUM, V14, P531, DOI 10.1016/0143-4160(93)90074-G; PAPP B, 1995, J BIOL CHEM, V270, P10278, DOI 10.1074/jbc.270.17.10278; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; PAPP B, 1991, J BIOL CHEM, V266, P14593; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1984, J IMMUNOL, V133, P123; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; WU KD, 1995, AM J PHYSIOL, V260, P775	49	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10746	10750						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099725				2022-12-25	WOS:A1997WV26200059
J	Simon, TC; Cho, A; Tso, P; Gordon, JI				Simon, TC; Cho, A; Tso, P; Gordon, JI			Suppressor and activator functions mediated by a repeated heptad sequence in the liver fatty acid-binding protein gene (Fabpl) - Effects on renal, small intestinal, and colonic epithelial cell gene expression in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; HORMONE FUSION GENES; GASTROINTESTINAL-TRACT; SPATIAL PATTERNS; GUT EPITHELIUM; DIFFERENTIATION; RENEWAL; ORIGIN; POPULATIONS; LINEAGE	A 35-nucleotide sequence in the liver fatty acid-binding protein gene (Fabpl) has been identified that interacts with nuclear proteins present in adult mouse liver, kidney, stomach, small intestine, and colon, The binding site consists of a direct heptad repeat (TTCTGNNTT) separated by five nucleotides, Both heptads are required for formation of stable complexes with nuclear proteins in gel mobility shift assays, The in vivo functions mediated by the repeats were determined by comparing the expression of four Fabpl/human growth hormone fusion genes in multiple pedigrees of adult transgenic mice, The transgenes contained (i) nucleotides -596 to +21 of Fabpl Linked to the human growth hormone reporter, (ii) 4 additional copies of the 35-base pair element placed at nucleotide -596 of Fabpl, (iii) 4 additional copies of the sequence placed just upstream of its endogenous site at nucleotide -132, and (iv) a sequence identical to (iii) but with all heptad repeats mutated within each of the 4 additional copies of the 35-base pair element, Transgene expression was defined by RNA blot hybridizations and by light and electron microscopic immunohistochemistry. The heptad repeat functions to suppress expression in tubular epithelial cells of the proximal nephron, in hepatocytes, in the mucus-producing pit cells of the gastric epithelium, and in absorptive enterocytes located in the proximal small intestine, There is a gradient of escape from enterocytic suppression as one moves from the proximal to distal small intestine, This escape progresses to involve successively less differentiated cells located closer and closer to the stem cell zone in crypts of Lieberkuhn. The heptad repeat activates gene expression in the colonic epithelium so that all proliferating and nonproliferating cells in colonic crypts distributed from the cecum to the rectum support transgene expression, The heptad has no obvious sequence similarities to known transcription factor binding sites, suggesting that mediators of its in vivo activities are likely to be novel, One candidate factor is a 90-kDa protein identified in Southwestern blots, The 90-kDa protein also binds to an element in the matrix metalloproteinase-2 gene that functions as an enhancer in renal cells, shares sequence homology with the heptad, and generates similar-sized complexes in gel mobility shift assays as the Fabpl repeat. The heptad repeat represents a target for identifying transcription factors that regulate gene expression between gut and renal epithelia and that also regulate the differentiation program of the intestine's principal epithelial lineage as a function of its location along the duodenal colonic axis, Finally, the Fabpl regulatory elements described in this report should be useful for delivering a variety of gene products throughout the colonic epithelium of transgenic mice.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; UNIV CINCINNATI,SCH MED,DEPT PATHOL,CINCINNATI,OH 45267	Washington University (WUSTL); Washington University (WUSTL); University System of Ohio; University of Cincinnati					NICHD NIH HHS [HD33688] Funding Source: Medline; NIDDK NIH HHS [DK30292] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD033688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BREM G, 1990, MOL REPROD DEV, V25, P42, DOI 10.1002/mrd.1080250108; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; COHN SM, 1984, J BIOL CHEM, V259, P2456; COHN SM, 1991, P NATL ACAD SCI USA, V88, P1034, DOI 10.1073/pnas.88.3.1034; COHN SM, 1992, J CELL BIOL, V119, P22; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HALL PA, 1994, J CELL SCI, V107, P3569; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Hermiston Michelle L., 1994, P521; HOGAN B, 1986, MANIPULATING MOUSE E, P79; REPONEN P, 1992, J BIOL CHEM, V267, P7856; RIJKE RPC, 1979, VIRCHOWS ARCH B, V30, P85; ROTH KA, 1992, AM J PHYSIOL, V263, pG186, DOI 10.1152/ajpgi.1992.263.2.G186; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; TROUGHTON WD, 1969, J CELL BIOL, V41, P251, DOI 10.1083/jcb.41.1.251; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x	34	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10652	10663						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099714				2022-12-25	WOS:A1997WV26200048
J	Stephen, AG; TrauschAzar, JS; HandleyGearhart, PM; Ciechanover, A; Schwartz, AL				Stephen, AG; TrauschAzar, JS; HandleyGearhart, PM; Ciechanover, A; Schwartz, AL			Identification of a region within the ubiquitin-activating enzyme required for nuclear targeting and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; TRANSCRIPTION FACTOR; T-ANTIGEN; LOCALIZATION; E1; TRANSPORT; SEQUENCE; PROTEASOMES; DEGRADATION	The ubiquitin-activating enzyme exists as two isoforms: Ela, localized predominantly in the nucleus, and E1b, localized in the cytoplasm, Previously we generated hemagglutinin (HA) epitope-tagged cDNA constructs, HA1-E1 (epitope tag placed after the first methionine) and HA2-E1 (epitope tag placed after the second methionine) (Handley-Gearhart, P, M,, Stephen, A. G,, Trausch-Azar, J, S,, Ciechanover, A., and Schwartz, A. L, (1994) J. Biol, Chem. 269, 35171-33178), which represent the native isoforms, HA1-E1 is exclusively nuclear, whereas HA2-E1 is found predominantly in the cytoplasm, Using high resolution isoelectric focusing and SDS-polyacrylamide gel electrophoresis, we confirm that these epitope-tagged constructs HA1-E1 and HA2-E1 represent the two isoforms Ela and E1b, HA1E1/E1a exists as one non-phosphorylated and four phosphorylated forms, and HA2-E1/E1b exists as one predominant non-phosphorylated form and two minor phosphorylated forms, We demonstrate that the first 11 amino acids are essential for phosphorylation and exclusive nuclear localization of HA1-E1, Within this region are four serine residues and a putative nuclear localization sequence (NLS; (PLSKKRR)-P-5), Removal of these four serine residues reduced phosphorylation levels by 60% but had no effect on nuclear localization of HA1-E1, Each serine residue was independently mutated to an alanine and analyzed by two-dimensional electrophoresis; only serine 4 was phosphorylated, Disruption of the basic amino acids within the NLS resulted in loss of exclusive nuclear localization and a 90-95% decrease in the phosphorylation of HA1-E1. This putative NLS was able to confer nuclear import on a nonnuclear protein in digitonin-permeabilized cells in a temperature- and ATP-dependent manner, Thus the predominant requirement for efficient phosphorylation of HA1-E1/E1a is a functional NLS, suggesting that Ela may be phosphorylated within the nucleus.	WASHINGTON UNIV, SCH MED, DEPT BIOL MOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PHARMACOL, ST LOUIS, MO 63110 USA; CHILDRENS HOSP, DIV PEDIAT HEMATOL ONCOL, ST LOUIS, MO 63110 USA; TECHNION ISRAEL INST TECHNOL, RAPPAPORT FAMILY INST RES MED SCI, FAC MED, IL-31096 HAIFA, ISRAEL; TECHNION ISRAEL INST TECHNOL, BIOCHEM UNIT, FAC MED, IL-31096 HAIFA, ISRAEL	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Stephen, AG (corresponding author), WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, ST LOUIS, MO 63110 USA.		Ciechanover, Aaron J/C-9166-2017; Stephen, Andrew/W-2636-2019	Stephen, Andrew/0000-0002-8259-621X				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK JC, 1995, P NATL ACAD SCI USA, V92, P3454, DOI 10.1073/pnas.92.8.3454; COOK JC, 1992, J BIOL CHEM, V267, P24315; CROUX O, 1996, ANNR EV BIOCH, V65, P801; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Knuehl C, 1996, EXP CELL RES, V225, P67, DOI 10.1006/excr.1996.0157; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; NAGAI Y, 1995, J CELL SCI, V108, P2145; Nederlof PM, 1995, P NATL ACAD SCI USA, V92, P12060, DOI 10.1073/pnas.92.26.12060; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Stephen AG, 1996, J BIOL CHEM, V271, P15608, DOI 10.1074/jbc.271.26.15608; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TRAUSCH JS, 1993, AM J PHYSIOL, V264, pC93, DOI 10.1152/ajpcell.1993.264.1.C93; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236	31	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10895	10903						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099746				2022-12-25	WOS:A1997WV26200080
J	Pan, BT; Zhang, Y; Brott, B; Chen, DH				Pan, BT; Zhang, Y; Brott, B; Chen, DH			The 96 kDa protein kinase activated by oncogenic Ras in Xenopus egg extracts is also activated by constitutively active Mek: Activation requires serine/threonine phosphorylation	ONCOGENE			English	Article						oncogenic Ras; Mek; Xenopus eggs; protein kinases and phosphatases; signal transduction; p96(h2bk)	SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; OOCYTE MATURATION; MEIOTIC MATURATION; EXTRACELLULAR SIGNALS; P34(CDC2) KINASE; CELL-CYCLE; IN-VITRO; M-PHASE; TYROSINE	In the Xenopus egg and oocyte system, oncogenic Ras protein can induce cell cycle arrest. The effect of oncogenic Ras on the cell cycle seems to be mediated by the Raf-Mek-Erk pathway of Ras signal transduction since constitutively active Raf, Mek, or Erk can mimic the effect of oncogenic Ras protein and since specific inhibition of these kinases can block the effect of oncogenic Ras. Using activated Xenopus egg extracts, we previously reported that the cell cycle arrest induced by oncogenic Ras correlates with the activation of a 96 kDa protein that phosphorylates histone h2b in vitro. This result raised the possibility that the 96 kDa kinase (designated as p96(h2bk)) is a potential target of the Raf-Mek-Erk pathway that links the pathway to the control of the cell cycle. We report here that constitutively active Mek1 could activate p96(h2bk) in the absence of oncogenic Ras. Moreover, inhibition of endogenous Mek by a specific inhibitor, PD 098059, suppressed the activation of p96(h2bk) by oncogenic Ras. These results are consistent with the concept that p96(h2bk) is a component or target of the Raf-Mek-Erk pathway. Furthermore, we have shown that activation of p96(h2bk) requires serine/threonine phosphorylation of p96(h2bk).	UNIV KENTUCKY,CHANDLER MED CTR,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,CHANDLER MED CTR,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	University of Kentucky; University of Kentucky; Harvard University	Pan, BT (corresponding author), UNIV KENTUCKY,DEPT SURG,DIV NEUROSURG,CHANDLER MED CTR,800 ROSE ST,LEXINGTON,KY 40536, USA.							ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHEN CT, 1994, J BIOL CHEM, V269, P28034; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Hung W., 1994, P NATL ACAD SCI USA, V91, P8960; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, ONCOGENE, V8, P467; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAN BT, 1994, J BIOL CHEM, V269, P5968; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; ZHANG CF, 1994, EMBO J, V13, P1123	46	3	3	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1653	1660		10.1038/sj.onc.1201009	http://dx.doi.org/10.1038/sj.onc.1201009			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135066				2022-12-25	WOS:A1997WR89300003
J	Marshall, AD; Darbyshire, JF; Hunter, AP; McPhie, P; Jakoby, WB				Marshall, AD; Darbyshire, JF; Hunter, AP; McPhie, P; Jakoby, WB			Control of activity through oxidative modification at the conserved residue Cys(66) of aryl sulfotransferase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-ESTER SULFOTRANSFERASE; S-THIOLATION; PHENOL SULFOTRANSFERASE; RESPIRATORY BURST; RAT-LIVER; GLUTATHIONE; DISULFIDE; PROTEINS; IDENTIFICATION; STIMULATION	Oxidation at Cys(66) of rat liver aryl sulfotransferase IV alters the enzyme's catalytic activity, pH optima and substrate specificity. Although this is a cytosolic detoxication enzyme, the pH optimum for the standard assay substrate 4-nitrophenol is at pH 5.5; upon oxidation, the optimum changes to the physiological pH range. The principal effect of the change in pH optimum is activation, which is manifest by an increase in K'(cat) without any major influence on substrate binding. In contrast, with tyrosine methyl ester as a substrate, the enzyme's optimum activity occurs at pH 8.0; upon oxidation, it ceases to be a substrate at any pH. The presence of Cys(66) was essential for activation to occur, thereby providing a putative reason underlying the conserved nature of this cysteine throughout the phenol sulfotransferase family. Mapping of disulfides by mass spectrometry showed the critical event to be the oxidation of Cys(66) to form a disulfide with either Cys(232) or glutathione, either one is effective. These results point to a mechanism for regulating the activity of a key enzyme in xenobiotic detoxication during cellular oxidative stress.	NIDDK,SECT ENZYMES,BIOCHEM & METAB LAB,NATL INST HLTH,BETHESDA,MD 20892; UNIV WASHINGTON,SCH PHARM,DEPT MED CHEM,SEATTLE,WA 98195	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Washington; University of Washington Seattle			Hunter, Ann/S-4396-2018	Hunter, Ann/0000-0002-9618-4785				BAILLIE TA, 1993, BIOL MASS SPECTROM, V22, P319, DOI 10.1002/bms.1200220602; BORCHARDT RT, 1982, BIOCHIM BIOPHYS ACTA, V708, P280, DOI 10.1016/0167-4838(82)90438-1; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; CHEN X, 1992, PROTEIN EXPRES PURIF, V3, P421, DOI 10.1016/S1046-5928(05)80045-2; Dafre AL, 1996, ARCH BIOCHEM BIOPHYS, V332, P288, DOI 10.1006/abbi.1996.0344; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; DUFFEL MW, 1981, J BIOL CHEM, V256, P1123; FALANY CN, 1994, CHEM-BIOL INTERACT, V92, P57, DOI 10.1016/0009-2797(94)90053-1; FILBERT HF, 1990, ADV ENZYMOL, V63, P96; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GUO WXA, 1994, CHEM-BIOL INTERACT, V92, P25, DOI 10.1016/0009-2797(94)90050-7; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KETLEY JN, 1975, J BIOL CHEM, V250, P8670; KNOTT GD, 1995, AM LAB           MAR, P48; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTOCK P, 1970, Biochemical Journal, V116, P797; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NOIVA R, 1992, J BIOL CHEM, V267, P3553; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10039; RAMASWAMY SG, 1987, METHOD ENZYMOL, V143, P201; ROKUTAN K, 1991, J IMMUNOL, V147, P260; SEKURA RD, 1981, ARCH BIOCHEM BIOPHYS, V211, P352, DOI 10.1016/0003-9861(81)90464-1; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Yang YS, 1996, PROTEIN EXPRES PURIF, V8, P423, DOI 10.1006/prep.1996.0120; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	28	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9153	9160						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9139043				2022-12-25	WOS:A1997WU03700050
J	Ninkina, N; Grashchuck, M; Buchman, VL; Davies, AM				Ninkina, N; Grashchuck, M; Buchman, VL; Davies, AM			TrkB variants with deletions in the leucine-rich motifs of the extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; NEUROTROPHIC FACTOR; DIFFERENTIAL RESPONSE; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; MOLECULAR-CLONING; MESSENGER-RNAS; RAT TRKC	We have isolated two novel variants involving the extracellular domain of TrkB from developing sensory neurons. These variants are generated by alternative splicing and lack two or all three of the leucine-rich motifs. Each of these variants is expressed as isoforms that possess or lack the intracellular tyrosine kinase domain. Fibroblast cell lines stably expressing these variants do not bind any of the TrkB ligands (brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5) and neither survive nor undergo morphological transformation in response to neurotrophins. These results demonstrate that the leucine-rich motifs in TrkB are essential for ligand binding and signaling and indicate that the extracellular immunoglobulin-like domains alone are insufficient to confer neurotrophin binding to TrkB.	UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AJ,FIFE,SCOTLAND	University of St Andrews			Davies, Alun M/A-4334-2010; Buchman, Vladimir L/A-4814-2010; Ninkina, Natalia N/A-1732-2011	Davies, Alun M/0000-0001-5841-8176; Buchman, Vladimir L/0000-0002-7631-8352; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP TE, 1993, J CELL BIOL, V123, P1555, DOI 10.1083/jcb.123.6.1555; ARMANINI MP, 1995, EUR J NEUROSCI, V7, P1403, DOI 10.1111/j.1460-9568.1995.tb01132.x; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BECK KD, 1993, J NEUROSCI, V13, P4001; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BIFFO S, 1995, DEVELOPMENT, V121, P2461; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; DAVIES AM, 1995, EMBO J, V14, P4482, DOI 10.1002/j.1460-2075.1995.tb00127.x; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; FUNAKOSHI H, 1993, J CELL BIOL, V123, P455, DOI 10.1083/jcb.123.2.455; GARNER AS, 1994, NEURON, V13, P457, DOI 10.1016/0896-6273(94)90360-3; GARNER AS, 1996, J NEUROSCI, V16, P1710; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HANIU M, 1995, ARCH BIOCHEM BIOPHYS, V322, P256, DOI 10.1006/abbi.1995.1460; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; Ninkina N, 1996, EMBO J, V15, P6385, DOI 10.1002/j.1460-2075.1996.tb01029.x; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; WINDISCH JM, 1995, FEBS LETT, V374, P125, DOI 10.1016/0014-5793(95)01047-I; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	50	49	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13019	13025		10.1074/jbc.272.20.13019	http://dx.doi.org/10.1074/jbc.272.20.13019			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148911	hybrid			2022-12-25	WOS:A1997WZ38400024
J	Cai, CX; Birk, DE; Linsenmayer, TF				Cai, CX; Birk, DE; Linsenmayer, TF			Ferritin is a developmentally regulated nuclear protein of avian corneal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; MONOCLONAL-ANTIBODIES; MESSENGER-RNA; TRANSLATIONAL REGULATION; HYDROGEN-PEROXIDE; DNA-DAMAGE; IN-VITRO; LOCALIZATION; COLLAGEN; EXPRESSION	We have now observed that one group of these antibodies reacts with a developmentally regulated component of corneal epithelial cell nuclei. This component is the heavy chain of ferritin, as determined by analyses of immunoisolated cDNA clones and immunoblotting of the protein. Immunoblotting also suggests that the nuclear ferritin may be in a supramolecular form that is similar to the iron-binding ferritin complex found in the cytoplasm of many cells. In vitro cultures and transfection studies show that the nuclear localization depends predominantly on cell type but can be altered by the in vitro environment. The appearance of nuclear ferritin is at least partially under translational regulation, as is known to be true for the cytoplasmic form of the molecule, The tissue and developmental distributions of the mRNA for the molecule are much more extensive than the protein itself, and the removal of iron from cultures of corneal epithelial cells with the iron chelator deferoxamine prevents the appearance of nuclear ferritin. At present the functional role(s) of nuclear ferritin remain unknown, but previous studies on cytoplasmic ferritin raise the possibility that it prevents damage due to free radical generation (''oxidative stress'') by sequestering iron, Although it remains to be tested whether nuclear ferritin prevents oxidative damage, we find this an attractive possibility, Since the corneal epithelium is transparent and is constantly exposed to free radical-generating UV light, it is possible that the cells of this tissue have evolved a specialized mechanism to prevent oxidative damage to their nuclear components.	TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Tufts University			Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088	NEI NIH HHS [EY05129, EY05191] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005191, R37EY005191, R01EY005129] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CAI CX, 1994, DEV DYNAM, V201, P206, DOI 10.1002/aja.1002010304; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P666; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; COULOMBRE AJ, 1964, EXP EYE RES, V3, P105, DOI 10.1016/S0014-4835(64)80024-5; COULOMBRE AJ, 1958, J CELL COMPAR PHYSL, V51, P1, DOI 10.1002/jcp.1030510102; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; Drysdale J W, 1976, Birth Defects Orig Artic Ser, V12, P105; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FITCH JM, 1988, DEV BIOL, V128, P396, DOI 10.1016/0012-1606(88)90301-6; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLCONDA MS, 1993, KIDNEY INT, V44, P1228, DOI 10.1038/ki.1993.373; Gurgueira SA, 1996, J BIOL CHEM, V271, P13616, DOI 10.1074/jbc.271.23.13616; GUTTERIDGE JMC, 1994, CHEM-BIOL INTERACT, V91, P133, DOI 10.1016/0009-2797(94)90033-7; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; HAYDEN BJ, 1990, EXP EYE RES, V50, P11, DOI 10.1016/0014-4835(90)90004-E; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Kubota T, 1996, J BIOL CHEM, V271, P6555, DOI 10.1074/jbc.271.11.6555; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; LADDA R, 1962, EXP CELL RES, V28, P595, DOI 10.1016/0014-4827(62)90266-5; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIAU G, 1991, J BIOL CHEM, V266, P18819; PASSANITI A, 1989, BIOCHEM J, V258, P413, DOI 10.1042/bj2580413; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; QI Y, 1994, J NEUROCHEM, V63, P1485; RADTKE K, 1994, BIOCHEM J, V302, P655, DOI 10.1042/bj3020655; REDMOND TM, 1984, EXP EYE RES, V38, P369, DOI 10.1016/0014-4835(84)90192-1; RICHTER GW, 1961, J BIOPHYS BIOCHEM CY, V9, P263, DOI 10.1083/jcb.9.2.263; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; ROMANOFF AL, 1967, BIOCH AVIAN EMBRYO, P172; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SMITH AG, 1990, HEPATOLOGY, V12, P1399, DOI 10.1002/hep.1840120622; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TOTH I, 1995, J BIOL CHEM, V270, P2846, DOI 10.1074/jbc.270.6.2846; WHITE K, 1988, J BIOL CHEM, V263, P8938; ZAK NB, 1985, EXP EYE RES, V40, P537, DOI 10.1016/0014-4835(85)90075-2; ZAK NB, 1983, DEV BIOL, V99, P373, DOI 10.1016/0012-1606(83)90287-7; ZAK NB, 1985, DEV BIOL, V108, P443, DOI 10.1016/0012-1606(85)90047-8	52	50	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12831	12839		10.1074/jbc.272.19.12831	http://dx.doi.org/10.1074/jbc.272.19.12831			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139744	hybrid			2022-12-25	WOS:A1997WY82900081
J	Masse, E; Phoenix, P; Drolet, M				Masse, E; Phoenix, P; Drolet, M			DNA topoisomerases regulate R-loop formation during transcription of the rrnB operon in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA TRANSCRIPTION; CONFERS SPECIFICITY; RIBONUCLEASE-H; REPLICATION; TEMPLATE; REGION; ORIGIN; ANTITERMINATION; RECOMBINATION; REQUIREMENT	Recent in vivo and in vitro studies have suggested an important role for DNA topoisomerases in regulating R-loop formation during transcription in Escherichia coli, In the present report we present genetic and biochemical evidence strongly suggesting that R-loop formation can occur during transcription of a portion of the rrnB operon and that it is regulated by DNA topoisomerase activity, We found that a multicopy plasmid (pBR322) carrying an heavily transcribed portion of the rrnB operon cannot be transformed in topA mutants unless RNase H is overproduced. Transcription of the 567-base pair HindIII fragment from the rrnB operon allows the extraction of large amount of R-looped plas mid DNAs from a topA mutant, in a manner that depends on the intracellular level of RNase H activity, When DNA gyrase is sufficiently active, hypernegatively super colied plasmid DNA is produced if the same DNA fragment is transcribed in a topA mutant, The formation of such topoisomers most likely reflect the presence of extensive R-loops since it is sensitive to the intracellular level of RNase H activity, Finally, the formation of R-looped plasmid DNAs in an in vitro transcription system using phage RNA polymerases is also detected when the 567-base pair HindIII fragment is transcribed on a negatively supercolied DNA template.	UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal			Drolet, Marc/M-1328-2019					AKSOY S, 1984, J BACTERIOL, V159, P260, DOI 10.1128/JB.159.1.260-264.1984; BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; BOCKRATH R, 1987, GENETICS, V115, P33; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; CONDON C, 1995, J BACTERIOL, V177, P4152, DOI 10.1128/jb.177.14.4152-4156.1995; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; DROLET M, 1994, J BIOL CHEM, V269, P2068; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; GUINEY DG, 1979, MOL GEN GENET, V176, P183, DOI 10.1007/BF00273212; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; KAGUNI JM, 1984, J BIOL CHEM, V259, P8578; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KOGOMA T, 1993, BIOCHIMIE, V75, P89, DOI 10.1016/0300-9084(93)90029-R; LEVIN NA, 1993, GENETICS, V133, P799; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; OGAWA T, 1984, P NATL ACAD SCI-BIOL, V81, P1040, DOI 10.1073/pnas.81.4.1040; Phoenix P, 1997, J BIOL CHEM, V272, P1473, DOI 10.1074/jbc.272.3.1473; REABAN ME, 1994, J BIOL CHEM, V269, P21850; RICHARDSON JP, 1975, J MOL BIOL, V98, P565, DOI 10.1016/S0022-2836(75)80087-8; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; XU BJ, 1995, MOL CELL BIOL, V15, P580, DOI 10.1128/MCB.15.1.580	32	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12816	12823		10.1074/jbc.272.19.12816	http://dx.doi.org/10.1074/jbc.272.19.12816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139742	hybrid			2022-12-25	WOS:A1997WY82900079
J	Ogihara, T; Shin, BC; Anai, M; Katagiri, H; Inukai, K; Funaki, M; Fukushima, Y; Ishihara, H; Takata, K; Kikuchi, M; Yazaki, Y; Oka, Y; Asano, T				Ogihara, T; Shin, BC; Anai, M; Katagiri, H; Inukai, K; Funaki, M; Fukushima, Y; Ishihara, H; Takata, K; Kikuchi, M; Yazaki, Y; Oka, Y; Asano, T			Insulin receptor substrate (IRS)-2 is dephosphorylated more rapidly than IRS-1 via its association with phosphatidylinositol 3-kinase in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE KINASE-ACTIVITY; MAMMALIAN-CELLS; SH3 DOMAIN; PROTEIN; PHOSPHORYLATION; BINDING; MICE; GENE; STIMULATION; DISRUPTION	Insulin receptor substrate (IRS)-2 is structurally and functionally similar to IRS-1. Indeed, stimulation with insulin or insulin-like growth factor I led to the rapid tyrosine phosphorylation of both IRS-1 and IRS-2, which in turn activated phosphatidylinositol (PI) 3-kinase in L6 cells and rat skeletal muscle. However, IRS-P was rapidly dephosphorylated (3-10 min after the addition of insulin/insulin-like growth factor I), whereas IRS-1 phosphorylation continued for at least 60 min. The time courses of the PI 3-kinase activity associated with IRS-1 and IRS-S paralleled the tyrosine phosphorylation of these proteins. Preincubation with sodium orthovanadate, an inhibitor of protein tyrosine phosphatase, blocked the rapid dephosphorylation of IRS-2, suggesting the involvement of tyrosine phosphatase. The activation of PI3-kinase apparently plays an important role in the rapid dephosphorylation of IRS-2, as IRS-2 dephosphorylation was inhibited markedly by suppressing PI3-kinase activity with wortmannin or overexpression of the dominant negative p85 subunit of PI3-kinase, which cannot bind the p110 catalytic subunit. In addition, platelet-derived growth factor stimulation prior to insulin stimulation decreased IRS-associated PI3-kinase and significantly inhibited the dephosphorylation of IRS-2. Taken together, these observations suggest that IRS-2 plays a unique role in mediating the signals from the insulin receptor to downstream molecules and that this effect is more transient than that of Tyrosine Tyrosine phosphatase and IRS-associated PI3-kinase activity thus contribute to the rapid dephosphorylation of IRS-2.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; GUNMA UNIV,INST MOL & CELLULAR REGULAT,LAB MOL & CELLULAR MORPHOL,MAEBASHI,GUMMA 371,JAPAN; ASAHI LIFE FDN,INST ADULT DIS,SHINJUKU KU,TOKYO 160,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	University of Tokyo; Gunma University; Asahi Life Foundation; Yamaguchi University				Shin, Bo-Chul/0000-0002-7569-5121				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEENER EP, 1992, P NATL ACAD SCI USA, V89, P11239; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; IMUKAI K, 1996, J BIOL CHEM, V271, P5317; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; LAM K, 1994, J BIOL CHEM, V269, P20648; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; OKA Y, 1988, J BIOL CHEM, V263, P13432; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; PONS S, 1995, MOL CELL BIOL, V15, P4453; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017	31	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12868	12873		10.1074/jbc.272.19.12868	http://dx.doi.org/10.1074/jbc.272.19.12868			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139749	hybrid			2022-12-25	WOS:A1997WY82900086
J	Ali, H; Fisher, I; Haribabu, B; Richardson, RM; Snyderman, R				Ali, H; Fisher, I; Haribabu, B; Richardson, RM; Snyderman, R			Role of phospholipase C beta 3 phosphorylation in the desensitization of cellular responses to platelet-activating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; FACTOR RECEPTOR; ALPHA-SUBUNITS; RBL-2H3 CELLS; CLONING; CHEMOATTRACTANTS; PURIFICATION; EXPRESSION; INHIBITION	Platelet-activating factor (PAF) stimulates a diverse array of cellular responses through receptors coupled to G proteins that activate phospholipase C (PLC). Truncation of the cytoplasmic tail of the receptor to remove phosphorylation sites (mutant PAF receptor, mPAFR) results in enhancement of PAF-stimulated responses. Here we demonstrate that PAF or phorbol 12-myristate 13-acetate (PMA) pretreatment inhibited wild type PAFR-induced PLC-mediated responses by similar to 90%, whereas these responses to the phosphorylation deficient mPAFR mere inhibited by similar to 50%, despite normal G protein coupling, suggesting a distal inhibitory locus. PAF and PR as well as a membrane permeable cyclic AMP analog, stimulated phosphorylation of PLC beta 3. A protein kinase C (PKC) inhibitor blocked phosphorylation of PLC beta 3 stimulated by PAF and PMA but not by cAMP, Activation of protein kinase A (PKA) by cAMP did not result in inhibition of Ca2+ mobilization stimulated by PAF. In contrast, cAMP did inhibit the response to formylpeptide chemoattractant receptor. These data suggest that homologous desensitization of PAF-mediated responses is regulated via phosphorylation at two levels in the signaling pathway, one at the receptor and the other at PLC beta 3 mediated by PKC but not by PKA, Phosphorylation of PLC beta 3 by PKA could explain the inhibition of formylpeptide chemoattractant receptor signaling by cAMP. As PAF and formylpeptide chemoattractant receptors activate PLC via different G proteins, phosphorylation of PLC beta 3 by PKC and PKA could provide distinct regulatory control for classes of G protein-coupled receptors.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University	Ali, H (corresponding author), DUKE UNIV,MED CTR,DEPT MED,201C MSRB,BOX 3680,DURHAM,NC 27710, USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NHLBI NIH HHS [HL-54166] Funding Source: Medline; NIAID NIH HHS [AI-38910] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038910, R29AI038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; DHAR A, 1994, J BIOL CHEM, V269, P9123; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIM UH, 1989, J BIOL CHEM, V264, P20167; KUNZ D, 1992, J BIOL CHEM, V267, P9101; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LAGERCRANTZ J, 1995, GENOMICS, V26, P467, DOI 10.1016/0888-7543(95)80164-H; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE CW, 1994, J BIOL CHEM, V269, P25335; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; OZAWA K, 1993, J BIOL CHEM, V268, P2280; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARK DJ, 1992, J BIOL CHEM, V267, P1496; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; RYU SH, 1990, J BIOL CHEM, V265, P17941; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAKANO T, 1994, J BIOL CHEM, V269, P22453; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WU DQ, 1992, J BIOL CHEM, V267, P25798	31	84	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11706	11709		10.1074/jbc.272.18.11706	http://dx.doi.org/10.1074/jbc.272.18.11706			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115222	Green Published, hybrid			2022-12-25	WOS:A1997WX56900010
J	Jordi, BJAM; Fielder, AE; Burns, CM; Hinton, JCD; Dover, N; Ussery, DW; Higgins, CF				Jordi, BJAM; Fielder, AE; Burns, CM; Hinton, JCD; Dover, N; Ussery, DW; Higgins, CF			DNA binding is not sufficient for H-NS-mediated repression of proU expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PROTEIN; SALMONELLA-TYPHIMURIUM; CURVED DNA; GENE-EXPRESSION; OSMOTIC REGULATION; TRANSCRIPTIONAL SILENCER; PROLINE TRANSPORT; GLYCINE BETAINE; OPERON; PROMOTERS	H-NS is a major component of bacterial chromatin and influences the expression of many genes. H-NS has been shown to exhibit a binding preference for certain AT-rich curved DNA elements in vitro. In this study we have addressed the factors that determine the specificity of H-NS action in vitro and in vivo, In bandshift studies, H-NS showed a slight binding preference for all curved sequences tested whether GC-based or AT-based; the specific architecture of the curve also influenced H-NS binding. In filter retention assays little difference in affinity could be detected for any sequence tested, including the downstream regulatory element (DRE) a downstream curved DNA element required for H-NS to repress transcription of the Salmonella typhimurium proU operon in vivo. A K-d of 1-2 mu M was estimated for binding of H-NS to each of these sequences. In vivo, the distance between the proU promoter and the DRE, their relative orientations on the face of the DNA helix, and translation of the DRE had no major effect on proU regulation. None of the synthetic curved sequences tested could functionally replace the DRE in vivo. These data show that differential binding to curved DNA cannot account for the specificity of H-NS action in vivo. Furthermore, binding of H-NS to DNA per se is insufficient to repress the proU promoter. Thus, the DRE does not simply act as an H-NS binding site but must have a more specific role in mediating H-NS regulation of proU transcription.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND LABS,INST MOL MED,OXFORD OX3 9DU,ENGLAND	University of Oxford; Cancer Research UK; University of Oxford			Ussery, David/J-2026-2019; Hinton, Jay C. D./B-2142-2008	Ussery, David/0000-0003-3632-5512; Hinton, Jay C. D./0000-0003-2671-6026	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DATTANANDA CS, 1991, J BACTERIOL, V173, P7481, DOI 10.1128/jb.173.23.7481-7490.1991; DUNLAP VJ, 1985, J BACTERIOL, V163, P296, DOI 10.1128/JB.163.1.296-304.1985; FALCONI M, 1993, MOL MICROBIOL, V10, P273, DOI 10.1111/j.1365-2958.1993.tb01953.x; FLETCHER SA, 1995, J BACTERIOL, V177, P4508, DOI 10.1128/jb.177.15.4508-4513.1995; FRIEDRICH K, 1988, FEBS LETT, V229, P197, DOI 10.1016/0014-5793(88)80826-3; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HINTON JCD, 1992, MOL MICROBIOL, V6, P2327, DOI 10.1111/j.1365-2958.1992.tb01408.x; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; HULTON CSJ, 1993, THESIS U OXFORD; JORDI BJAM, 1995, EMBO J, V14, P5690, DOI 10.1002/j.1460-2075.1995.tb00256.x; JORDI BJAM, 1992, EMBO J, V11, P2627, DOI 10.1002/j.1460-2075.1992.tb05328.x; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; MAY G, 1990, MOL GEN GENET, V224, P81, DOI 10.1007/BF00259454; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; MCNAMARA PT, 1991, J BIOL CHEM, V266, P12548; MOJICA FJM, 1997, IN PRESS J BACTERIOL; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PARK SF, 1989, MOL MICROBIOL, V3, P1011, DOI 10.1111/j.1365-2958.1989.tb00252.x; PAVITT GD, 1993, MOL MICROBIOL, V10, P685, DOI 10.1111/j.1365-2958.1993.tb00940.x; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; Sambrook J., 2002, MOL CLONING LAB MANU; SHPIGELMAN ES, 1993, COMPUT APPL BIOSCI, V9, P435; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPURIO R, 1992, MOL GEN GENET, V231, P201, DOI 10.1007/BF00279792; STIRLING DA, 1989, MOL MICROBIOL, V3, P1025, DOI 10.1111/j.1365-2958.1989.tb00253.x; TIPPNER D, 1994, MOL MICROBIOL, V11, P589, DOI 10.1111/j.1365-2958.1994.tb00339.x; TIPPNER D, 1995, J BIOL CHEM, V270, P22243, DOI 10.1074/jbc.270.38.22243; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Ueguchi C, 1996, J MOL BIOL, V263, P149, DOI 10.1006/jmbi.1996.0566; ULANOVSKY L, 1986, P NATL ACAD SCI USA, V83, P862, DOI 10.1073/pnas.83.4.862; USSERY DW, 1994, BIOCHIMIE, V76, P968, DOI 10.1016/0300-9084(94)90022-1; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x; ZUBER F, 1994, MOL MICROBIOL, V12, P231, DOI 10.1111/j.1365-2958.1994.tb01012.x	46	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12083	12090		10.1074/jbc.272.18.12083	http://dx.doi.org/10.1074/jbc.272.18.12083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115277	hybrid			2022-12-25	WOS:A1997WX56900065
J	Johnson, KA; Fink, SP; Marnett, LJ				Johnson, KA; Fink, SP; Marnett, LJ			Repair of propanodeoxyguanosine by nucleotide excision repair in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HUMAN EXCINUCLEASE; DNA GLYCOSYLASE; ADDUCTS; MUTAGENESIS; 3-METHYLADENINE; CHLOROACETALDEHYDE; REPLICATION; MECHANISM; NUCLEASE	Repair of the exocyclic DNA adduct propanodeoxyguanosine (PdG) was assessed in both in vivo and in vitro assays. PdG was site specifically incorporated at position 6256 of M13MB102 DNA, and the adducted viral genome was electroporated into repair-proficient and repair-deficient Escherichia coli strains. Comparable frequencies of PdG --> T and PdG --> A mutations at position 6256 were detected following replication of the adducted genomes in wild-type E. coli strains. A 4-fold increase in the frequencies of transversions and transitions was observed in E. coli strains deficient in Vvr(A)BC-dependent nucleotide excision repair. A similar increase in the replication of the adduct containing strand was observed in the repair deficient strains. No change in the frequency of targeted mutations was observed in strains deficient in one or both of the genes coding for 3-methyladenine glycosylase. Incubation of purified E. coli Uvr(A)BC proteins with a duplex 156-mer containing a single PdG adduct resulted in removal of a 12-base oligonucleotide containing the adduct. Incubation of the same adducted duplex with Chinese hamster ovary cell-free extracts also resulted in removal of the adduct, PdG was a better substrate for repair by the mammalian nucleotide excision repair complex than the bacterial repair complex and was approximately equal to a thymine-thymine dimer as a substrate for the former. The results of these in vivo and in vitro experiments indicate that PdG, a homolog of several endogenously produced DNA adducts, is repaired by the nucleotide excision repair pathway.	VANDERBILT UNIV, SCH MED, CTR MOL TOXICOL, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, CTR MOL TOXICOL, DEPT CHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, VANDERBILT CANC CTR, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University				Fink, Stephen/0000-0003-4107-7912	NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline; NIEHS NIH HHS [ES07028] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAAS PD, 1985, BIOCHIM BIOPHYS ACTA, V825, P111, DOI 10.1016/0167-4781(85)90096-X; BENAMIRA M, 1995, CARCINOGENESIS, V16, P93, DOI 10.1093/carcin/16.1.93; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; CHENNA A, 1995, P NATL ACAD SCI USA, V92, P5890, DOI 10.1073/pnas.92.13.5890; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; EDER E, 1992, ENVIRON MOL MUTAGEN, V19, P338, DOI 10.1002/em.2850190413; Fink SP, 1996, CHEM RES TOXICOL, V9, P277, DOI 10.1021/tx950060w; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; Hang B, 1996, CARCINOGENESIS, V17, P155, DOI 10.1093/carcin/17.1.155; HUANG JC, 1994, J BIOL CHEM, V269, P19034; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Marnett L J, 1994, IARC Sci Publ, P151; MARNETT LJ, 1985, MUTAT RES, V148, P25; MATIJASEVIC Z, 1992, P NATL ACAD SCI USA, V89, P9331, DOI 10.1073/pnas.89.19.9331; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; MYLES GM, 1989, CHEM RES TOXICOL, V2, P197, DOI 10.1021/tx00010a001; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; OLEYKOWSKI CA, 1993, J BIOL CHEM, V268, P7990; ONAIR J, 1995, CARCINOGENESIS, V16, P613; Sambrook J., 2002, MOL CLONING LAB MANU; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SINGER B, 1992, P NATL ACAD SCI USA, V89, P9386, DOI 10.1073/pnas.89.20.9386; Singer B., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P645; SINGER B, 1986, ROLE CYCLIC NUCL ACI; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; THOMAS DC, 1985, J BIOL CHEM, V260, P9875	32	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11434	11438						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111054				2022-12-25	WOS:A1997WW00900070
J	Bilderback, TR; Grigsby, RJ; Dobrowsky, RT				Bilderback, TR; Grigsby, RJ; Dobrowsky, RT			Association of p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; CELL-SURFACE; RECEPTOR; CYCLE; ACTIVATION; CERAMIDE; ENCODES; BINDING; FAMILY	Caveolae are plasma membrane microdomains that are enriched in caveolin, the structural protein of caveolae, sphingomyelin, and other signaling molecules, We previously suggested that neurotrophin-induced p75(NTR)-dependent sphingomyelin hydrolysis may be localized to the plasma membrane. Therefore, we examined if caveolae were a major site of p75(NTR)-dependent sphingomyelin hydrolysis in p75(NTR)-NIH 3T3 fibroblasts, Caveolin-enriched membranes (CEMs) were prepared by either detergent or detergent-free extraction and separated from noncaveolar membranes by centrifugation through sucrose gradients, Immunoblot analysis of the individual gradient fractions indicated that caveolin and p75(NTR) were enriched in CEMs, The localization of p75(NTR) to CEMs was not an artifact of receptor overexpression in the fibroblasts because a similar distribution of p75(NTR) was evident from PC12 cells, which endogenously express p75(NTR), I, the p75(NTR) fibroblasts, nerve growth factor induced a time-dependent hydrolysis of sphingomyelin only in CEMs with no hydrolysis detected in noncaveolar membranes, Intriguingly, endogenous p75(NTR) was found to co-immunoprecipitate with caveolin, suggesting that p75(NTR) may associate with caveolin in vivo, This interaction was confirmed in vitro by the co-immunoprecipitation of a glutathione S-transferase fusion protein expressing the cytoplasmic domain of p75(NTR) with caveolin, Collectively, these results demonstrate that neurotrophin-induced p75(NTR). dependent sphingomyelin hydrolysis localizes to CEMs and suggest that the interaction of p75(NTR) With caveolin may affect signaling through p75(NTR).	UNIV KANSAS, DEPT PHARMACOL & TOXICOL, LAWRENCE, KS 66045 USA	University of Kansas								ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; BARKER PA, 1994, J BIOL CHEM, V269, P30645; Blochl A, 1996, J BIOL CHEM, V271, P21100; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Canossa M, 1996, EMBO J, V15, P3369, DOI 10.1002/j.1460-2075.1996.tb00702.x; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Frade JM, 1996, NATURE, V383, P166; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; OHMICHI M, 1991, CELL REGUL, V2, P691, DOI 10.1091/mbc.2.9.691; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; VanderZee CEEM, 1996, SCIENCE, V274, P1729, DOI 10.1126/science.274.5293.1729; VOLONTE C, 1993, J BIOL CHEM, V268, P21410	39	152	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10922	10927						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099750				2022-12-25	WOS:A1997WV26200084
J	Brohmann, H; Pinnecke, S; HoyerFender, S				Brohmann, H; Pinnecke, S; HoyerFender, S			Identification and characterization of new cDNAs encoding outer dense fiber proteins of rat sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL ASSIGNMENT; FIBROUS SHEATH; MESSENGER-RNA; DNA; FRAGMENTS; SEQUENCES; GENE; POLYACRYLAMIDE; NITROCELLULOSE; HYBRIDIZATION	A main structure of the mammalian sperm tail is a structure known as the outer dense fibers whose molecular composition as well as their function are still mostly unknown, We report here the isolation and characterization of new cDNAs (odf2) that identifies a highly variable gene locus encoding outer dense fiber proteins, Transcription of odf2 is restricted to testis and more specifically to round spermatids. Transcription starts in step 6 spermatids, which coincides with transcription of the major outer dense fiber protein gene odf1 (Burmester, S., and Hoyer-Fender, S. (1996) Mol. Reprod. Dev. 45, 10-20) and with the formation of the sperm tail, Affinity-purified anti-Odf2 antibodies identified isolated outer dense fibers immunocytochemically and detected at least three protein bands in the molecular mass range of 65,000 to 70,000 Da in total Odf protein preparations, Presence of several protein bands corre lates with the presence of several transcripts and the isolation of slightly different cDNA clones, whereas Southern blot hybridization does not indicate the presence of multiple genes, Computer analyses of the structure of the encoded Odf2 protein revealed an overall alpha-helical structure with two regions identical to the dimerization region of the leucine zipper motif.	UNIV GOTTINGEN,DEPT ZOOL DEV BIOL 3,D-37073 GOTTINGEN,GERMANY	University of Gottingen			Hoyer-Fender, Sigrid/AAV-9181-2020					BACCETTI B, 1973, J SUBMICR CYTOL PATH, V5, P237; BALTZ JM, 1990, BIOL REPROD, V43, P485, DOI 10.1095/biolreprod43.3.485; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BURFEIND P, 1993, EUR J BIOCHEM, V216, P497, DOI 10.1111/j.1432-1033.1993.tb18168.x; BURFEIND P, 1991, DEV BIOL, V148, P195, DOI 10.1016/0012-1606(91)90329-2; Burmester S, 1996, MOL REPROD DEV, V45, P10, DOI 10.1002/(SICI)1098-2795(199609)45:1&lt;10::AID-MRD2&gt;3.0.CO;2-V; CALVIN HI, 1979, BIOL REPROD, V21, P873, DOI 10.1095/biolreprod21.4.873; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FAWCETT DW, 1975, DEV BIOL, V44, P394, DOI 10.1016/0012-1606(75)90411-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GASTMANN O, 1993, MOL REPROD DEV, V36, P407, DOI 10.1002/mrd.1080360402; HENKEL R, 1992, BIOL CHEM H-S, V373, P685, DOI 10.1515/bchm3.1992.373.2.685; HOYERFENDER S, 1995, CYTOGENET CELL GENET, V70, P200, DOI 10.1159/000134033; KNORR DW, 1970, ENDOCRINOLOGY, V86, P1298, DOI 10.1210/endo-86-6-1298; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; OKO R, 1988, BIOL REPROD, V39, P169, DOI 10.1095/biolreprod39.1.169; OKO R, 1989, ANAT REC, V225, P46, DOI 10.1002/ar.1092250108; OLSON GE, 1980, BIOL REPROD, V22, P319, DOI 10.1095/biolreprod22.2.319; PRICE M, 1973, J CELL BIOL S, V59, pA272; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER M, 1990, EMBO J, V9, P4519, DOI 10.1002/j.1460-2075.1990.tb07903.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERA JC, 1984, J BIOL CHEM, V259, P5970; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	34	86	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10327	10332						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092585	hybrid			2022-12-25	WOS:A1997WU03900104
J	Adachi, M; Ishino, M; Torigoe, T; Minami, Y; Matozaki, T; Miyazaki, T; Taniguchi, T; Hinoda, Y; Imai, K				Adachi, M; Ishino, M; Torigoe, T; Minami, Y; Matozaki, T; Miyazaki, T; Taniguchi, T; Hinoda, Y; Imai, K			Interleukin-2 induces tyrosine phosphorylation of SHP-2 through IL-2 receptor beta chain	ONCOGENE			English	Article						SHP-2; IL-2; tyrosine phosphorylation; signal transduction	GROWTH-FACTOR RECEPTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; CYTOLYTIC EFFECTOR FUNCTION; C-MYC; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; GAMMA-CHAIN; T-CELL; PROTEIN	Coupling of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) induces rapid increase in tyrosine phosphorylation of cellular substrates through activation of non-receptor protein tyrosine kinases, Here, we report that stimulation through the IL-2R induced tyrosine phosphorylation of the SH2-containing protein-tyrosine phosphatase SHP-2 in F7, a hematopoietic BAF-B03 transfectant clone expressing the IL-2R beta chain. The tyrosine phosphorylation of SHP-2 was specific since another protein-tyrosine phosphatase SHP-1, which is structurally homologous to SHP-2, was not tyrosine phosphorylated, The IL-2-induced tyrosine phosphorylation of SHP-2 required the acidic region within the IL-2R beta chain where Src-family PTKs interact. Though the serine-rich region within IL-2R beta chain was also required for the phosphorylation of SHP-2, Jak3 activation was dispensable, In COS-7 cells, co-expression of SHP-2 with Lyn resulted in increased tyrosine phosphorylation levels of SHP-2, whereas coexpression of SHP-2 with Fyn failed to alter the levels significantly. Considering that Lyn and Fyn are major Src-family PTKs expressed in BAF-B03 cells, our data suggest that Lyn may be principally responsible for the tyrosine phosphorylation of SHP-2 in F7 cells. Furthermore, the IL-2 stimulation also induced tyrosine phosphorylation of SHP-2 in the human IL-2-dependent T-cell line ILT-Mat. Taken together, these studies demonstrate an involvement of SHP-2 in the IL-2-mediated signaling events through the activation of specific PTKs.	HOKKAIDO UNIV,SCH MED,DEPT BIOCHEM,CANC RES INST,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT PATHOL,SAPPORO,HOKKAIDO 060,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM 1,CHUO KU,KOBE 650,JAPAN; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Hokkaido University; Hokkaido University; Kobe University; Kobe University; University of Tokyo	Adachi, M (corresponding author), HOKKAIDO UNIV,SCH MED,DEPT INTERNAL MED 1,SAPPORO,HOKKAIDO 060,JAPAN.		Miyazaki, Tadaaki/D-9368-2012					ADACHI M, 1995, FEBS LETT, V372, P113, DOI 10.1016/0014-5793(95)00952-6; Adachi M, 1996, CELL, V85, P15; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CASE RD, 1994, J BIOL CHEM, V269, P10467; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; Ishino M, 1995, ONCOGENE, V11, P2331; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PENG ZY, 1995, ONCOGENE, V11, P1955; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TORIGOE T, 1992, BLOOD, V80, P617; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TORIGOE T, 1994, J EXP MED, V180, P1115, DOI 10.1084/jem.180.3.1115; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	36	37	37	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1629	1633		10.1038/sj.onc.1200981	http://dx.doi.org/10.1038/sj.onc.1200981			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129156				2022-12-25	WOS:A1997WQ54800016
J	Voitenleitner, C; Fanning, E; Nasheuer, HP				Voitenleitner, C; Fanning, E; Nasheuer, HP			Phosphorylation of DNA polymerase alpha-primase by cyclin A-dependent kinases regulates initiation of DNA replication in vitro	ONCOGENE			English	Article						DNA replication; cyclins; cyclin-dependent kinases; DNA polymerase alpha primase	P34CDC2 PROTEIN-KINASE; SV40 ORIGIN DNA; CELL-CYCLE; IN-VITRO; INVITRO; ANTIGEN; SUBUNIT	DNA polymerase alpha-primase is the only known eukaryotic enzyme that can start DNA replication de novo. In this study, we investigated the regulation of DNA replication by phosphorylation of DNA polymerase alpha-primase. The p180 and the p68 submits of DNA polymerase alpha-primase were phosphorylated using Cyclin A-, B- and E- dependent kinases. This phosphorylation did not influence its DNA polymerase activity on activated DNA, but slightly stimulated primase activity using poly(dT) single-stranded DNA (ssDNA) without changing the product length of primers. In contrast, site-specific initiation of replication on plasmid DNA containing the SV40 origin is affected: Cyclin A-Cdk2 and Cyclin A-Cdc2 inhibited initiation of SV40 DNA replication in vitro, Cyclin B-Cdc2 had no effect and Cyclin E-Cdk2 stimulated the initation reaction. DNA polymerase alpha-primase that was pre-phosphorylated by Cyclin A-Cdk2 was completely unable to initiate the SV40 DNA replication in vitro; Cyclin B-Cdc2-phosphorylated enzyme was moderately inhibited, while Cyclin E-Cdk2-treated DNA polymerase alpha-primase remained fully active in the initiation reaction.	UNIV MUNICH, INST BIOCHEM, D-81375 MUNICH, GERMANY; VANDERBILT UNIV, DEPT MOL BIOL, NASHVILLE, TN 37235 USA; INST MOL BIOTECHNOL, BIOCHEM ABT, D-07745 JENA, GERMANY	University of Munich; Vanderbilt University			Nasheuer, Heinz P./B-9025-2008	Nasheuer, Heinz Peter/0000-0002-9218-9079				BRUCKNER A, 1995, MOL CELL BIOL, V15, P1716; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fanning Ellen, 1994, Trends in Cell Biology, V4, P250, DOI 10.1016/0962-8924(94)90123-6; Ferrari M, 1996, J BIOL CHEM, V271, P8661, DOI 10.1074/jbc.271.15.8661; FOIANI M, 1995, MOL CELL BIOL, V15, P883; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOAREFI IF, 1993, J VIROL, V67, P4992, DOI 10.1128/JVI.67.8.4992-5002.1993; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PODUST V, 1990, EUR J BIOCHEM, V193, P189, DOI 10.1111/j.1432-1033.1990.tb19322.x; PRUSSAK CE, 1989, BIOCHEM BIOPH RES CO, V159, P1397, DOI 10.1016/0006-291X(89)92265-1; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHNEIDER C, 1994, MOL CELL BIOL, V14, P3176, DOI 10.1128/MCB.14.5.3176; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; TANAKA S, 1982, J BIOL CHEM, V257, P8386; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	30	60	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1611	1615		10.1038/sj.onc.1200975	http://dx.doi.org/10.1038/sj.onc.1200975			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129153				2022-12-25	WOS:A1997WQ54800013
J	Boland, MP; Foster, SJ; ONeill, LAJ				Boland, MP; Foster, SJ; ONeill, LAJ			Daunorubicin activates NF kappa B and induces kappa B-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ACIDIC SPHINGOMYELINASE; ALPHA PROTEOLYSIS; INDUCED APOPTOSIS; REACTIVE OXYGEN; DEATH; LYMPHOCYTES; CERAMIDE; SIGNALS; PHOSPHORYLATION	The anthracycline antibiotic, daunorubicin, can induce programmed cell death (apoptosis) in cells, Recent work suggests that this event is mediated by ceramide via enhanced ceramide synthase activity, Since the generation of ceramide has been directly linked with the activation of the transcription factor, NF kappa B, this was investigated as a novel target for the action of daunorubicin, Here we describe how treatment of HL-60 promyelocytes and Jurkat T lymphoma cells with daunorubicin results in the activation of the transcription factor NF kappa B. The effect of daunorubicin was evident following 1-2 h treatment, which was in contrast to the time course of activation obtained with the cytokine, tumor necrosis factor, where NF kappa B activation was detected within minutes of cellular stimulation, Activated complexes were shown to contain predominantly p50 and p65/RelA subunit components, Daunorubicin also induced I kappa B degradation and increased the expression of an NF kappa B linked reporter gene. In addition, the drug was found to strongly potentiate the ability of tumor necrosis factor to induce an NF kappa B-linked reporter gene, suggesting a synergy between these two agents in this response, These events were sensitive to the iron chelator, deferoxamine mesylate (desferal), and the anti-oxidant and metal chelator pyrrolidine dithiocarbamate, A structurally related compound, mitoxantrone, which, unlike daunorubicin, is unable to undergo redox cycling in cells, also activated NF kappa B in a pyrrolidine dithiocarbamate-sensitive manner, A specific inhibitor of ceramide synthase, fumonisin B1, had no effect on daunorubicin induced NF kappa B activation at a range of concentrations previously reported to block apoptosis induced by this drug, However, this agent could inhibit increases in ceramide induced by daunorubicin, in addition to blocking ceramide synthase activity from HL-60 cells which was activated in response to daunorubicin treatment, These data therefore suggest that the effect of daunorubicin on NF kappa B is unlikely to involve ceramide, but may involve reactive oxygen species generated as a result of endogenous cellular processes rather than reductive metabolism of the drug, As NF kappa B may be involved in apoptosis, this effect may be an important aspect of the cellular responses to this agent.	ZENECA PHARMACEUT,CAM,RES DEPT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND		Boland, MP (corresponding author), TRINITY COLL DUBLIN,DEPT BIOCHEM,DUBLIN,IRELAND.							ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldassarre F, 1995, J BIOL CHEM, V270, P31244, DOI 10.1074/jbc.270.52.31244; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERTRAND R, 1991, CANCER RES, V51, P6280; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Bowie Andrew, 1997, Biochemical Society Transactions, V25, p125S; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CALABRESI P, 1990, PHARMACOL BASIS THER, P1202; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; FISHER GR, 1992, CANCER CHEMOTH PHARM, V30, P451, DOI 10.1007/BF00685596; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; Powis G., 1987, METABOLISM ACTION AN, P211; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; QUINTO I, 1993, J BIOL CHEM, V268, P26719; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRUM JC, 1994, J BIOL CHEM, V269, P15493; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VILE GF, 1989, CANCER CHEMOTH PHARM, V24, P105; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; YANG ZH, 1993, J BIOL CHEM, V268, P20520	46	120	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12952	12960		10.1074/jbc.272.20.12952	http://dx.doi.org/10.1074/jbc.272.20.12952			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148901	hybrid, Green Published			2022-12-25	WOS:A1997WZ38400014
J	Craiu, A; Gaczynska, M; Akopian, T; Gramm, CF; Fenteany, G; Goldberg, AL; Rock, KL				Craiu, A; Gaczynska, M; Akopian, T; Gramm, CF; Fenteany, G; Goldberg, AL; Rock, KL			Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-ACTIVATING ENZYME; CELL-LINE; THERMOPLASMA-ACIDOPHILUM; PROTEOLYTIC PATHWAY; LYMPHOCYTES-T; EXPRESSION; PEPTIDES; GENES; GENERATION; MOLECULES	The antibiotic lactacystin was reported to covalently modify beta-subunit X of the mammalian 20 S proteasome and inhibit several of its peptidase activities, However, we demonstrate that [H-3]lactacystin treatment modifies all the proteasome's catalytic beta-subunits. Lactacystin and its more potent derivative beta-lactone irreversibly inhibit protein breakdown and the chymotryptic, tryptic, and peptidylglutamyl activities of purified 20 S and 26 S particles, although at different rates, Exposure to these agents for 1 to 2 h reduced the degradation of short- and long-lived proteins in four different mammalian cell lines, Unlike peptide aldehyde inhibitors, lactacystin and the beta-lactone do not inhibit lysosomal degradation of an endocytosed protein, These agents block class I antigen presentation of a model protein, ovalbumin (synthesized endogenously or loaded exogenously), but do not affect presentation of the peptide epitope SIINFEKL, which does not require proteolysis for presentation. Generation of most peptides required for formation of stable class I heterodimers is also inhibited, Because these agents inhibited protein breakdown and antigen presentation similarly in interferon-gamma-treated cells (where proteasomes contain LMP2 and LMP7 subunits in place of X and Y), all beta-subunits must be affected similarly, These findings confirm our prior conclusions that proteasomes catalyze the bulk of protein breakdown in mammalian cells and generate the majority of class I-bound epitopes for immune recognition.	DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard Medical School			Fenteany, Gabriel/F-4944-2018	Fenteany, Gabriel/0000-0001-7407-2195; Fenteany, Gabriel/0000-0003-0335-4587				Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; CHAMBERLAIN JW, 1991, MOL CELL BIOL, V11, P3564, DOI 10.1128/MCB.11.7.3564; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARS R, 1983, HUM IMMUNOL, V8, P123, DOI 10.1016/0198-8859(83)90008-3; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DICK LR, 1994, J IMMUNOL, V152, P3884; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GRANT EP, 1995, J IMMUNOL, V155, P3750; GREY HM, 1982, J IMMUNOL, V129, P2389; GROPPER R, 1991, J BIOL CHEM, V266, P3602; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KOVACSOVICSBANKOWSKI M, 1994, EUR J IMMUNOL, V24, P2421; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Michalek MT, 1996, J IMMUNOL, V157, P617; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1983, J EXP MED, V157, P1618, DOI 10.1084/jem.157.5.1618; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SIBILLE C, 1995, CURR BIOL, V5, P923, DOI 10.1016/S0960-9822(95)00182-5; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	53	353	384	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13437	13445		10.1074/jbc.272.20.13437	http://dx.doi.org/10.1074/jbc.272.20.13437			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148969	hybrid			2022-12-25	WOS:A1997WZ38400082
J	Fassler, JS; Gray, WM; Malone, CL; Tao, W; Lin, H; Deschenes, RJ				Fassler, JS; Gray, WM; Malone, CL; Tao, W; Lin, H; Deschenes, RJ			Activated alleles of yeast SLN1 increase Mcm1-dependent reporter gene expression and diminish signaling through the Hog1 osmosensing pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-LACZ; SACCHAROMYCES-CEREVISIAE; TRANSDUCTION MUTATIONS; TRANSCRIPTION FACTOR; MCM1; PROTEIN; PHOSPHORYLATION; BINDING; TRANSFORMATION; CHEY	Two-component signal transduction systems involving histidine autophosphorylation and phosphotransfer to an aspartate residue on a receiver molecule have only recently been discovered in eukaryotes, although they are well studied in prokaryotes. The Sln1 protein of Saccharomyces cerevisiae is a two-component regulator involved in osmotolerance. Phosphorylation of Sln1p leads to inhibition of the Hog1 mitogen-activated protein kinase osmosensing pathway. We have discovered a second function of Sln1p by identifying recessive activated alleles (designated nrp2) that regulate the essential transcription factor Mcm1. nrp2 alleles cause a 5-fold increase in the activity of an Mcm1-dependent reporter, whereas deletion of SLN1 causes a 10-fold decrease in reporter activity and a corresponding decrease in expression of Mcm1-dependent genes. In addition to activating Mcm1p, nrp2 mutants exhibit reduced phosphorylation of Hog1p and increased osmosensitivity suggesting that nrp2 mutations shift the Sln1p equilibrium toward the phosphorylated state, Two nrp2 mutations map to conserved residues in the receiver domain (P1148S and P1196L) and correspond to residues implicated in bacterial receivers to control receiver phosphorylation state, Thus, it appears that increased Sln1p phosphorylation both stimulates Mcm1p activity and diminishes signaling through the Hog1 osmosensing pathway.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa	Fassler, JS (corresponding author), UNIV IOWA, DEPT BIOL SCI, IOWA CITY, IA 52242 USA.		Gray, William M/F-9402-2010; Deschenes, Robert J/E-4926-2010	Gray, William M/0000-0002-1320-290X; Deschenes, Robert J/0000-0001-8325-4257				AIBA H, 1989, J BIOL CHEM, V264, P14090; ALTHOEFER H, 1995, MOL CELL BIOL, V15, P5917; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHANG CH, 1992, J BACTERIOL, V174, P7033, DOI 10.1128/JB.174.21.7033-7039.1992; CHEN YR, 1995, MOL CELL BIOL, V15, P4631; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IUCHI S, 1993, J BIOL CHEM, V268, P23972; KALMAN LV, 1990, J BACTERIOL, V172, P7049, DOI 10.1128/jb.172.12.7049-7056.1990; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; LARSON GP, 1983, GENE, V22, P31, DOI 10.1016/0378-1119(83)90061-6; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MILLER JF, 1992, J BACTERIOL, V174, P970, DOI 10.1128/jb.174.3.970-979.1992; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; Perego M, 1996, TRENDS GENET, V12, P97, DOI 10.1016/0168-9525(96)81420-X; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; ROSE AB, 1990, METHOD ENZYMOL, V185, P234; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1986, METHODS YEAST GENETI, P163; SHUKLA D, 1995, J BIOL CHEM, V270, P24414, DOI 10.1074/jbc.270.41.24414; SIKORSKI RS, 1989, GENETICS, V122, P19; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; Volz K., 1995, 2 COMPONENT SIGNAL T, P53; YU GY, 1995, J BIOL CHEM, V270, P8739, DOI 10.1074/jbc.270.15.8739; YU GY, 1993, MOL CELL BIOL, V13, P63, DOI 10.1128/MCB.13.1.63	37	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13365	13371		10.1074/jbc.272.20.13365	http://dx.doi.org/10.1074/jbc.272.20.13365			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148959	hybrid			2022-12-25	WOS:A1997WZ38400072
J	Grove, A; Figueiredo, ML; Galeone, A; Mayol, L; Geiduschek, EP				Grove, A; Figueiredo, ML; Galeone, A; Mayol, L; Geiduschek, EP			Twin hydroxymethyluracil-A base pair steps define the binding site for the DNA-bending protein TF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE; RNA; KINKING; BULGES	The DNA bending protein TF1 is the Bacillus subtilis bacteriophage SPO1-encoded homolog of the bacterial HU proteins and the Escherichia coli integration host factor, We recently proposed that TF1, which binds with high affinity (K-d was similar to 3 nM) to preferred sites within the hydroxymethyluracil (hmU)-containing phage genome, identifies its binding sites based on sequence-dependent DNA flexibility, Here, we show that two hmU-A base pair steps coinciding with two previously proposed sites of DNA distortion are critical for complex formation, The affinity of TF1 is reduced 10-fold when both of these hmU-A base pair steps are replaced with A-hmU, G-C, or C-G steps; only modest changes in affinity result when substitutions are made at other base pairs of the TP1 binding site, Replacement of all hmU residues with thymine decreases the affinity of TF1 greatly; remarkably, the high affinity is restored when the two hmU-A base pair steps corresponding to previously suggested sites of distortion are reintroduced into otherwise T-containing DNA. T-DNA constructs with 3-base bulges spaced apart by 9 base pairs of duplex also generate nM affinity of TF1. We suggest that twin hmU-A base pair steps located at the proposed sites of distortion are key to target site selection by TF1 and that recognition is based largely, if not entirely, on sequence-dependent DNA flexibility.	UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; UNIV NAPLES FEDERICO II,DIPARTIMENTO CHIM SOSTANZE NAT,I-80131 NAPLES,ITALY	University of California System; University of California San Diego; University of Naples Federico II	Grove, A (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Grove, Anne/O-5998-2015; Galeone, Aldo/H-7248-2019	Grove, Anne/0000-0002-4390-0354; Galeone, Aldo/0000-0001-8805-6348; MAYOL, Luciano/0000-0002-9162-5799				ANDERA L, 1994, J MOL BIOL, V236, P139, DOI 10.1006/jmbi.1994.1124; Bailly C, 1996, P NATL ACAD SCI USA, V93, P13623, DOI 10.1073/pnas.93.24.13623; BAILLY C, 1995, J MOL BIOL, V253, P1, DOI 10.1006/jmbi.1995.0530; BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; CHOY HA, 1986, J MOL BIOL, V191, P59, DOI 10.1016/0022-2836(86)90422-5; CONTE MR, 1992, BIOORG MED CHEM LETT, V2, P79, DOI 10.1016/S0960-894X(00)80660-5; DIEKMANN S, 1987, P NATL ACAD SCI USA, V84, P8257, DOI 10.1073/pnas.84.23.8257; GOHLKE C, 1994, P NATL ACAD SCI USA, V91, P11660, DOI 10.1073/pnas.91.24.11660; GREENE JR, 1985, EMBO J, V4, P1345, DOI 10.1002/j.1460-2075.1985.tb03783.x; Grove A, 1996, J MOL BIOL, V260, P196, DOI 10.1006/jmbi.1996.0392; Grove A, 1996, J MOL BIOL, V260, P120, DOI 10.1006/jmbi.1996.0386; HARD T, 1989, BIOCHEMISTRY-US, V28, P396; HUNTER CA, 1993, J MOL BIOL, V230, P1025, DOI 10.1006/jmbi.1993.1217; Jia X, 1996, J MOL BIOL, V263, P259, DOI 10.1006/jmbi.1996.0573; JOHNSON GG, 1977, BIOCHEMISTRY-US, V16, P1473, DOI 10.1021/bi00626a036; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; LEE G, 1980, J MOL BIOL, V139, P407, DOI 10.1016/0022-2836(80)90138-2; LILLEY DMJ, 1995, P NATL ACAD SCI USA, V92, P7140, DOI 10.1073/pnas.92.16.7140; MELLAC S, 1993, BIOCHEMISTRY-US, V32, P7779, DOI 10.1021/bi00081a025; MILLAR DP, 1982, J CHEM PHYS, V76, P2080, DOI 10.1063/1.443182; Pasternack LB, 1996, NUCLEIC ACIDS RES, V24, P2740, DOI 10.1093/nar/24.14.2740; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; SAYRE MH, 1990, J MOL BIOL, V216, P819, DOI 10.1016/S0022-2836(99)80004-7; SCHNEIDER GJ, 1991, J MOL BIOL, V221, P777, DOI 10.1016/0022-2836(91)80175-T; VIS H, 1995, J MOL BIOL, V254, P692, DOI 10.1006/jmbi.1995.0648; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WOLFFE AP, 1997, FRONTIERS MOL BIOL	28	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13084	13087		10.1074/jbc.272.20.13084	http://dx.doi.org/10.1074/jbc.272.20.13084			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148920	Green Published, hybrid			2022-12-25	WOS:A1997WZ38400033
J	Jia, LG; Wang, XM; Shannon, JD; Bjarnason, JB; Fox, JW				Jia, LG; Wang, XM; Shannon, JD; Bjarnason, JB; Fox, JW			Function of disintegrin-like/cysteine-rich domains of atrolysin A - Inhibition of platelet aggregation by recombinant protein and peptide antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTHROPS-JARARACA VENOM; GLYCOPROTEIN-IIB-IIIA; HEMORRHAGIC TOXIN-E; SPERM-EGG FUSION; CROTALUS-ATROX; VIPER VENOMS; GENE FAMILY; GPIIB-IIIA; INTEGRIN; METALLOPROTEASE	Snake venom hemorrhagic metalloproteinase toxins that have metalloproteinase, disintegrin-like and cysteine-rich domains are significantly more potent than toxins with only a metalloproteinase domain. The disintegrin like domains of these toxins differ from the disintegrin peptides found in crotalid and viperid venoms by the nature of their different disulfide bond structure and, in lieu of the disintegrins' signature Arg-Gly-Asp (RGD) integrin binding sequence, there is an XXCD disulfide bonded cysteinyl sequence in that region, Due to these apparent differences, the contribution to the overall function of the hemorrhagic metalloproteinases by the disintegrin like domain has been unknown. In this investigation we have expressed in insect cells the disintegrin-like/cysteine-rich (DC) domains of the Crotalus atrox hemorrhagic metalloproteinase atrolysin A and demonstrated that the recombinant protein (A/DC) can inhibit collagen- and ADP-stimulated platelet aggregation, Using synthetic peptides, we have evidence that the region of the disintegrin-like domain that is positionally analogous to the RGD loop of the disintegrins is the site responsible for inhibition of platelet aggregation, For these synthetic peptides to have significant inhibitory activity, the -RSECD- cysteinyl residue must be constrained by participation in a disulfide bond with another cysteinyl residue, The two acidic amino acids adjacent to the middle cysteinyl residue in these peptides are also important for biological activity, These studies emphasize a functional role for the disintegrin-like domain in toxins and suggest structural possibilities for the design of antagonists of platelet aggregation.	UVA, CTR HLTH SCI, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV ICELAND, INST SCI, IS-107 REYKJAVIK, ICELAND	University of Virginia; University of Iceland					NIGMS NIH HHS [GM49042] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER M, 1993, BIOCHEMISTRY-US, V32, P282, DOI 10.1021/bi00052a036; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; ATKINSON RA, 1994, INT J PEPT PROT RES, V43, P563; AU LC, 1993, BIOCHIM BIOPHYS ACTA, V1173, P243, DOI 10.1016/0167-4781(93)90190-O; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BARAMOVA EN, 1989, ARCH BIOCHEM BIOPHYS, V275, P63, DOI 10.1016/0003-9861(89)90350-0; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; BJARNASON JB, 1978, BIOCHEMISTRY-US, V17, P3395, DOI 10.1021/bi00609a033; BJARNASON JB, 1994, J PHARM THER, V62, P321; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALVETE JJ, 1991, BIOCHEMISTRY-US, V30, P5225, DOI 10.1021/bi00235a016; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; FERRY ACF, 1994, BBA-PROTEIN STRUCT M, V1207, P134, DOI 10.1016/0167-4838(94)90062-0; FOX JW, 1996, ZINC METALLOPROTEINA, P47; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GINSBERG MH, 1995, THROMB HAEMOSTASIS, V74, P352; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432-1033.1992.tb17495.x; HITE LA, 1992, BIOCHEMISTRY-US, V31, P6203, DOI 10.1021/bi00142a005; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; Kamiguti AS, 1996, TOXICON, V34, P627, DOI 10.1016/0041-0101(96)00017-7; KUNICKI TJ, 1995, J BIOL CHEM, V270, P16660, DOI 10.1074/jbc.270.28.16660; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; MCLANE MA, 1994, BIOCHEM J, V301, P429, DOI 10.1042/bj3010429; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; TENG CM, 1991, PLATELETS, V2, P1; USAMI Y, 1994, BIOCHEM BIOPH RES CO, V201, P331, DOI 10.1006/bbrc.1994.1706; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	45	128	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13094	13102		10.1074/jbc.272.20.13094	http://dx.doi.org/10.1074/jbc.272.20.13094			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148922	hybrid			2022-12-25	WOS:A1997WZ38400035
J	Plouet, J; Moro, F; Bertagnolli, S; Coldeboeuf, N; Mazarguil, H; Clamens, S; Bayard, F				Plouet, J; Moro, F; Bertagnolli, S; Coldeboeuf, N; Mazarguil, H; Clamens, S; Bayard, F			Extracellular cleavage of the vascular endothelial growth factor 189 amino acid form by urokinase is required for its mitogenic effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-CORTEX; PERMEABILITY FACTOR; CELL MITOGEN; BREAST-CANCER; BINDING; VASCULOTROPIN; ACTIVATION; RECEPTOR; PROTEIN; IDENTIFICATION	Alternative splicing of vascular endothelial growth factor (VEGF) mRNA results in three distinct molecular forms of 121 or 165 (V165) amino acids that are released in the conditioned medium of cultured cells and one longer isoform of 189 amino acids (V189) that remains cell-associated. V189 has been expressed in wild type CHO-K1 cells and in glycosaminoglycan deficient pgsA-745 Chinese hamster ovary (CHO) mutant cells, It could be released from CHO-K1 cell membranes by heparin or a synthetic peptide designed on the sequence encoded by exon 6 but was freely released from CHO mutant cells, In both cases, the immunoreactive V189 was mainly released as a 40-kDa cleaved form, provided that the serine protease urokinase, but not plasmin, was active, Recombinant V189 was purified from insect cells infected with a recombinant baculovirus as a nonmitogenic 50-kDa precursor that binds to the receptor Flt-1 but not to Flk-1. It could be matured by urokinase as a 38-kDa fragment able to bind to Flk-1 and to trigger cell proliferation, V165 and V189, however, could be cleaved by plasmin as 34-kDa fragments that exhibit a decreased mitogenic activity, These findings indicate that the carboxyl-terminal domain of V189 masks its binding do main to Flk-1.	CNRS,UPR 9062,INST PHARMACOL & BIOL STRUCT,F-31062 TOULOUSE,FRANCE; CHU RANGUEIL,INSERM,U397,INST LOUIS BUGNARD,F-31062 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Plouet, J (corresponding author), CNRS,UPR 9006,LAB BIOL MOL EUCARYOTES,118 ROUTE NARBONNE,F-31062 TOULOUSE,FRANCE.							ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BOENSCH C, 1995, J BIOL CHEM, V270, P1807, DOI 10.1074/jbc.270.4.1807; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BRUNETTE E, 1992, NUCLEIC ACIDS RES, V20, P1151, DOI 10.1093/nar/20.5.1151; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Lachgar S, 1996, J INVEST DERMATOL, V106, P17, DOI 10.1111/1523-1747.ep12326964; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEWIS CE, 1995, J LEUKOCYTE BIOL, V57, P747, DOI 10.1002/jlb.57.5.747; LOKEN MR, 1982, J IMMUNOL METHODS, V50, pR85, DOI 10.1016/0022-1759(82)90161-2; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; PARK JE, 1994, J BIOL CHEM, V269, P25646; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1990, EXP EYE RES, V51, P519, DOI 10.1016/0014-4835(90)90082-6; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PRALORAN V, 1991, CR ACAD SCI III-VIE, V313, P21; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHMITT M, 1992, FIBRINOLYSIS S4, V6, P2; SCHWEIKI D, 1992, NATURE, V359, P843; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SIMORREPINATEL V, 1994, INVEST OPHTH VIS SCI, V35, P3393; TISCHER E, 1991, J BIOL CHEM, V266, P11947	38	188	210	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13390	13396		10.1074/jbc.272.20.13390	http://dx.doi.org/10.1074/jbc.272.20.13390			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148962	hybrid			2022-12-25	WOS:A1997WZ38400075
J	Zhang, C; Baumgartner, RA; Yamada, K; Beaven, MA				Zhang, C; Baumgartner, RA; Yamada, K; Beaven, MA			Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells - Indications of communication between p38 and p42 MAP kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); BASOPHILIC LEUKEMIA-CELLS; CYTOKINE BIOSYNTHESIS; RBL-2H3 CELLS; IGE-RECEPTOR; INHIBITORS; PATHWAY; LINE; RECONSTITUTION; RAF-1	Aggregation of the high affinity IgE receptor (Fc epsilon RI) in a mast cell line resulted in activation of the p42 and the stress-activated p38 mitogen-activated protein (MAP) kinases. Selective inhibition of these respective kinases with PD 098059 and SE 203580 indicated that p42 MAP kinase, but not p38 MAP kinase, contributed to the production of the cytokine, tumor necrosis factor a, and the release of arachidonic acid in these cells. Neither kinase, however, was essential for Fc epsilon RI-mediated degranulation or constitutive production of tumor growth factor-beta. Studies with SE 203580 and the p38 MAP kinase activator anisomycin also revealed that p38 MAP kinase negatively regulated activation of p42 MAP kinase and the responses mediated by this kinase.	NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ADAMS JL, 1993, Patent No. 14081; ALESSI DR, 1995, J BIOL CHEM, V270, P27849; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Baumgartner RA, 1996, J IMMUNOL, V157, P4087; Baumgartner RA, 1996, J IMMUNOL, V157, P1625; BAUMGARTNER RA, 1994, J IMMUNOL, V153, P2609; BAUMGARTNER RA, 1996, HDB EXPT IMMUNOLOGY, V4; Beaven MA, 1996, CURR BIOL, V6, P798, DOI 10.1016/S0960-9822(02)00598-5; BRIDGE AJ, 1995, Patent No. 5525625; CHOCK SP, 1994, BIOCHEM J, V300, P619, DOI 10.1042/bj3000619; Choi OH, 1996, NATURE, V380, P634; COLLADOESCOBAR D, 1990, J IMMUNOL, V144, P244; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7656; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Galli SJ, 1996, NATURE, V381, P21, DOI 10.1038/381021a0; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; IGARASHI Y, 1993, IMMUNOPHARMACOLOGY, V25, P131, DOI 10.1016/0162-3109(93)90016-J; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MCGIVNEY A, 1981, ARCH BIOCHEM BIOPHYS, V212, P572, DOI 10.1016/0003-9861(81)90400-8; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; NAKATANI Y, 1994, J IMMUNOL, V153, P796; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARK JH, 1993, BLOOD, V82, P2470; RAO GN, 1994, J BIOL CHEM, V269, P32586; REIMANN T, 1994, J IMMUNOL, V153, P5740; Rider LG, 1996, J IMMUNOL, V157, P2374; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VAZQUEZ D, 1979, MOL BIOL BIOCH BIOPH, V130, P513; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; YAMADA K, 1992, J IMMUNOL, V149, P1031; ZHANG C, 1997, IN PRESS J IMMUNOL, V158	41	189	193	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13397	13402		10.1074/jbc.272.20.13397	http://dx.doi.org/10.1074/jbc.272.20.13397			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148963	hybrid			2022-12-25	WOS:A1997WZ38400076
J	Dzeletovic, N; McGuire, J; Daujat, M; Tholander, J; Ema, M; FujiiKuriyama, Y; Bergman, J; Maurel, P; Poellinger, L				Dzeletovic, N; McGuire, J; Daujat, M; Tholander, J; Ema, M; FujiiKuriyama, Y; Bergman, J; Maurel, P; Poellinger, L			Regulation of dioxin receptor function by omeprazole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DNA-BINDING ACTIVITY; XENOBIOTIC-RESPONSIVE ELEMENT; PROTON PUMP INHIBITOR; AH-RECEPTOR; GLUCOCORTICOID RECEPTOR; STEROID-RECEPTOR; AROMATIC-HYDROCARBONS; SIGNAL-TRANSDUCTION; NUCLEAR RECEPTORS	The intracellular dioxin (aryl hydrocarbon) receptor mediates signal transduction by dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin) and related environmental pollutants and functions as a ligand-activated transcription factor. In this study we have examined the effects on dioxin receptor function of a potentially novel ligand, omeprazole, which is widely clinically used as a gastric anti-ulcer drug. In primary human hepatocytes omeprazole potently induced cytochrome P4501A1 mRNA expression, whereas this effect was not detected in mouse primary hepatocytes, In human hepatoma cells omeprazole was found to induce transcription of reporter genes via the xenobiotic response element that is recognized by the ligand-activated dioxin receptor, In contrast, the human dioxin receptor was not activated by omeprazole upon expression in a receptor-deficient mouse hepatoma cell line. In a reconstituted yeast (Saccharomyces cerevisiae) model system, however, both the mouse and human dioxin receptors were potently activated by omeprazole, Although omeprazole failed to displace dioxin in in vitro ligand binding assays, a residue within the ligand binding domain that is critical for dioxin binding in vitro was also critical for omeprazole responsiveness in vivo. Consistent with this observation, both omeprazole and dioxin responsiveness of the dioxin receptor was inhibited in mutant yeast cells expressing low levels of the molecular chaperone hsp90 that is critical for ligand binding activity, The sulfoxide group that is essential for formation of a planar conversion product of omeprazole was found to be critical for dioxin receptor activation, Taken together, these data suggest that omeprazole represents a precursor for a novel class of dioxin receptor agonists that are bona fide dioxin receptor ligands but generated in a strictly species-specific manner.	KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOL BIOL,S-17177 STOCKHOLM,SWEDEN; NOVUM,UNIT ORGAN CHEM,DEPT BIOSCI,S-14157 HUDDINGE,SWEDEN; CNRS,INSERM,U128,F-34033 MONTPELLIER,FRANCE; TOHOKU UNIV,FAC SCI,DEPT CHEM,SENDAI,MIYAGI 980,JAPAN	Karolinska Institutet; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Tohoku University			Daujat-Chavanieu, Martine/AAU-2908-2020; Daujat-Chavanieu, Martine/T-5155-2018	Daujat-Chavanieu, Martine/0000-0001-5560-1610; Daujat-Chavanieu, Martine/0000-0001-5560-1610; Ema, Masatsugu/0000-0003-0645-6183				ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BRANDSTROM A, 1985, SCAND J GASTROENTE S, V108, P15; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARVER LA, 1994, J BIOL CHEM, V269, P30109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; CURIPEDROSA R, 1994, J PHARMACOL EXP THER, V269, P384; CUTHILL S, 1991, MOL CELL BIOL, V11, P404; DAHMANE N, 1995, P NATL ACAD SCI USA, V92, P9191, DOI 10.1073/pnas.92.20.9191; Daujat M, 1996, EUR J BIOCHEM, V237, P642, DOI 10.1111/j.1432-1033.1996.0642p.x; DAUJAT M, 1991, EUR J BIOCHEM, V200, P501, DOI 10.1111/j.1432-1033.1991.tb16211.x; DAUJAT M, 1992, BIOCHEM BIOPH RES CO, V188, P820, DOI 10.1016/0006-291X(92)91130-I; DIAZ D, 1990, GASTROENTEROLOGY, V99, P737, DOI 10.1016/0016-5085(90)90963-2; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1994, J BIOL CHEM, V269, P27337; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILLNER M, 1993, MOL PHARMACOL, V44, P336; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOWDEN CW, 1991, CLIN PHARMACOKINET, V20, P38, DOI 10.2165/00003088-199120010-00003; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; ISOM HC, 1984, P NATL ACAD SCI-BIOL, V81, P6378, DOI 10.1073/pnas.81.20.6378; Kikuchi H, 1996, ARCH BIOCHEM BIOPHYS, V334, P235, DOI 10.1006/abbi.1996.0451; KLEMAN MI, 1994, J BIOL CHEM, V269, P5137; KUHLER TC, 1995, J MED CHEM, V38, P4906; LIND T, 1983, GUT, V24, P270, DOI 10.1136/gut.24.4.270; LINDBERG P, 1986, J MED CHEM, V29, P1327, DOI 10.1021/jm00158a001; LINDBERG P, 1990, MED RES REV, V10, P1, DOI 10.1002/med.2610100102; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCDONNELL WM, 1992, GASTROENTEROLOGY, V103, P1509, DOI 10.1016/0016-5085(92)91171-Y; MUNTANERELAT J, 1995, HEPATOLOGY, V22, P1143; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; REGARDH CG, 1985, SCAND J GASTROENTERO, V20, P79, DOI 10.3109/00365528509095821; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RIDDICK DS, 1994, J BIOL CHEM, V269, P12118; ROBINSON B, 1963, J CHEM SOC, P3097, DOI 10.1039/jr9630003097; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; [No title captured]	64	70	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12705	12713		10.1074/jbc.272.19.12705	http://dx.doi.org/10.1074/jbc.272.19.12705			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139728	hybrid			2022-12-25	WOS:A1997WY82900065
J	Kusakabe, T; Richardson, CC				Kusakabe, T; Richardson, CC			Gene 4 DNA primase of bacteriophage T7 mediates the annealing and extension of ribo-oligonucleotides at primase recognition sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PRIMASE; SINGLE-STRANDED-DNA; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; RNA PRIMER SYNTHESIS; DEOXYRIBONUCLEIC-ACID; TEMPLATE RECOGNITION; INITIATION SITES; BINDING PROTEIN; 2.5 PROTEIN; REPLICATION	The 63-kDa gene 4 primase of bacteriophage T7 recognizes a core trinucleotide sequence, 5'-GTC-3', on single-stranded DNA at which it catalyzes the synthesis of the ribodinucleotide pppAC. The dinucleotide is extended to a tetranucleotide primer at the sites 5'-(G/T)GGTC-3' and 5'-GTGTC-3'. In the presence of T7 primase, T7 DNA polymerase extends the synthetic ribotetranucleotide pACCA (1 mu M), but not pCACA, on M13 DNA templates. The reaction is specific for T7 DNA polymerase and depends on dTTP and translocation of the gene 4 protein, T7 primase extends the dinucleotide AC and trinucleotide ACC to ACCC in the presence of CTP and an appropriate template, whereas other dinucleotides are extended less efficiently; the deoxyribodinucleotide dAC is not extended. The Cys, zinc motif of the primase is essential for extension of the dinucleotides. The 5'-cryptic cytidine of the recognition sequence is essential for extension of the dinucleotide AC to tri- and tetranucleotides. At a preformed replication fork, the dinucleotide AC provides for primer synthesis on the lagging strand. The synthesis of all Okazaki fragments is initiated by primers arising from the recognition sequence 5'-GGGTC-3'; none arise at an adjacent 5'-GGGTT-3' sequence. If ADP or AMP replaces ATP in the primase reaction, primers terminating in di- or monophosphate, respectively, are synthesized.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5267; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CHA TA, 1986, J BIOL CHEM, V261, P7001; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; ENGLER MJ, 1983, J BIOL CHEM, V258, P1197; FUJIYAMA A, 1981, P NATL ACAD SCI-BIOL, V78, P903, DOI 10.1073/pnas.78.2.903; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HINTON DM, 1987, J BIOL CHEM, V262, P10873; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KORNBERG A, 1992, DNA REPLICATION, P275; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; Kusakabe T, 1997, J BIOL CHEM, V272, P5943, DOI 10.1074/jbc.272.9.5943; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MENDELMAN LV, 1995, BIOCHEMISTRY-US, V34, P1018; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; MUSTAEV AA, 1995, J BIOL CHEM, V270, P15711, DOI 10.1074/jbc.270.26.15711; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; Swart JR, 1995, BIOCHEMISTRY-US, V34, P16097, DOI 10.1021/bi00049a025; SWART JR, 1993, J BIOL CHEM, V268, P12970; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TOUGU K, 1994, J BIOL CHEM, V269, P4675; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698	43	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12446	12453		10.1074/jbc.272.19.12446	http://dx.doi.org/10.1074/jbc.272.19.12446			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139692	hybrid			2022-12-25	WOS:A1997WY82900029
J	Wright, K; Ward, SG; Kolios, G; Westwick, J				Wright, K; Ward, SG; Kolios, G; Westwick, J			Activation of phosphatidylinositol 8-kinase by interleukin-13 - An inhibitory signal for inducible nitric-oxide synthase expression in epithelial, cell line HT-29	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; HUMAN B-CELLS; TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; HEMATOPOIETIC-CELLS; PROTEIN-KINASE; IL-4 RECEPTOR; MYELOID CELLS; INSULIN; TRANSDUCTION	The human colonic epithelial cell line HT-29 can be induced by a combination of the cytokines interleukin (IL)-1 alpha, tumor necrosis factor alpha, and interferon-gamma to express the inducible form of nitric-oxide synthase (iNOS; Kolios, G., Brown, Z., Robson, R., Robertson, D. A. F., & Westwick, J. (1995) Br. J. Pharmacol. 116, 2866-2872), IL-13 is a potent inhibitor of cytokine-induced iNOS mRNA expression and nitric oxide generation in HT-29 cells via an unknown mechanism. We report here that in HT-29 cells, IL-13 induces a concentration and time-dependent increase in the formation of the lipid products of phosphatidylinositol (PtdIns) 3-kinase, namely phosphatidylinositol (3,4)-bisphosphate and phosphatidylinositol (3,4,5)-trisphosphate. IL-13 also induces a parallel concentration and time-dependent increase in the in vitro lipid kinase activity present in immunoprecipitates of the p85 regulatory subunit of PtdIns 3-kinase. In addition, we also demonstrate that IL-13 stimulates the tyrosine phosphorylation of the adaptor molecule insulin receptor substrate 1, which may facilitate receptor coupling to PtdIns 3-kinase. Both the increases in D-3 phosphatidylinositol lipids and the increased in vitro lipid kinase activity of p85 immunoprecipitates were inhibited by wortmannin and LY294002. Inhibition of the PtdIns 3-kinase activity was paralleled by a reversal of the ability of IL-13 to inhibit iNOS mRNA expression and nitrite generation in HT-29 cells. These data demonstrate that the activation of PtdIns 3-kinase by IL-13 is a key signal that is responsible for the inhibition of iNOS transcription in activated epithelial cells.	UNIV BATH, SCH PHARM & PHARMACOL, DEPT PHARMACOL, BATH BA2 7AY, AVON, ENGLAND	University of Bath			Ward, Stephen/AAE-4341-2020; Wright, Karen Leslie/C-7959-2011; Kolios, George/N-6641-2013	Wright, Karen Leslie/0000-0003-0040-9247; Kolios, George/0000-0002-2066-4782; Ward, Stephen G./0000-0002-6795-6002	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; DOYLE AG, 1994, EUR J IMMUNOL, V24, P1441, DOI 10.1002/eji.1830240630; FINNEY M, 1990, EUR J IMMUNOL, V20, P151, DOI 10.1002/eji.1830200122; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kolios G, 1996, BRIT J PHARMACOL, V119, P351, DOI 10.1111/j.1476-5381.1996.tb15993.x; KOLIOS G, 1995, BRIT J PHARMACOL, V116, P2866, DOI 10.1111/j.1476-5381.1995.tb15938.x; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; MALEFYT RD, 1993, J IMMUNOL, V150, pA180; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Murata T, 1996, J IMMUNOL, V156, P2972; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Saura M, 1996, BIOCHEM J, V313, P641, DOI 10.1042/bj3130641; Schnyder B, 1996, BIOCHEM J, V315, P767, DOI 10.1042/bj3150767; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; SOZZANI P, 1995, J BIOL CHEM, V270, P5084, DOI 10.1074/jbc.270.10.5084; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; WARD SG, 1992, J BIOL CHEM, V267, P23862; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	62	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12626	12633		10.1074/jbc.272.19.12626	http://dx.doi.org/10.1074/jbc.272.19.12626			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139718	hybrid			2022-12-25	WOS:A1997WY82900055
J	Coleman, CS; Pegg, AE				Coleman, CS; Pegg, AE			Proteasomal degradation of spermidine/spermine N-1-acetyltransferase requires the carboxyl-terminal glutamic acid residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANALOG-INDUCED INCREASES; ORNITHINE DECARBOXYLASE; SPERMINE N1-ACETYLTRANSFERASE; GROWTH-INHIBITION; INTRACELLULAR DEGRADATION; POLYAMINE METABOLISM; PEST HYPOTHESIS; CANCER-CELLS; LUNG-CANCER; STABILIZATION	The rapid turnover of spermidine/spermine N-1-acetyltransferase (SSAT), a key enzyme in the regulation of polyamine levels, was found to be mediated via ubiquitination and the proteasomal system. SSAT degradation was blocked by the binding of polyamines or of the polyamine analog, N-1,N-12-bis(ethyl)spermine (BE-3-4-3), to the protein, providing a mechanism for the increase of SSAT activity in response to these agents. Site-directed mutagenesis indicated that a number of residues including arginine 19, cysteine 122, histidine 126, glutamic acid 152, arginine 155, and methionine 167 were needed for protection of SSAT by BE-3-4-3. These residues have previously been shown to reduce the affinity for the binding of polyamines to the SSAT protein, and these results indicate that the change in protein configuration brought about by this binding renders the protein resistant to proteasomal degradation. Mutations to alanines of residues arginine 7, cysteine 14, and lysine 141 also prevented the protection by BE-3-4-3, and these residues may be required for the formation of the protected conformation. The rapid degradation of SSAT required the carboxyl terminal region of the protein, and the two terminal glutamic acid residues at positions 170 and 171 were found to be of critical importance. Truncation of the protein to remove these residues or the mutation of either of these acidic residues to glutamine completely abolished the rapid degradation of SSAT. The addition of two extra lysine residues at the carboxyl terminus or the conversion of the glutamic acids at positions 170 and 171 to lysines also prevented SSAT deg-radation by the proteasome. These results show the key role of the acidic residues at the carboxyl terminus of the protein in reacting with the proteasome. In contrast, mutation of lysine 166 to alanine, which extends the length of the acidic region in the carboxyl-terminal fragment of SSAT, actually increased the rate of degradation of SSAT without affecting its stabilization by BE-3-4-3. The binding of BE-3-4-3 or polyamines is therefore likely to change the configuration of the SSAT protein in a way that prevents the exposure of the carboxyl-terminal region of the ubiquitinated protein to the proteasome.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOL PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERCOVICH Z, 1993, EUR J BIOCHEM, V213, P205, DOI 10.1111/j.1432-1033.1993.tb17749.x; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1994, CANCER RES, V54, P3955; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAVIDSON NE, 1993, CANCER RES, V53, P2071; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; ELIAS S, 1995, EUR J BIOCHEM, V229, P276, DOI 10.1111/j.1432-1033.1995.0276l.x; ERWIN BG, 1986, BIOCHEM J, V238, P581, DOI 10.1042/bj2380581; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HAYASHI SI, 1995, BIOCHEM J, V306, P1; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; LIBBY PR, 1989, CANCER RES, V49, P6226; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MATSUI I, 1981, BIOCHIM BIOPHYS ACTA, V675, P373; MIYAZAKI Y, 1993, EUR J BIOCHEM, V214, P837, DOI 10.1111/j.1432-1033.1993.tb17987.x; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; PERSSON L, 1984, J BIOL CHEM, V259, P2364; PORTER CW, 1991, CANCER RES, V51, P3715; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAAB NH, 1993, J MED CHEM, V36, P2998, DOI 10.1021/jm00072a020; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; WALLACE HM, 1994, BIOCHEM SOC T, V22, P870, DOI 10.1042/bst0220870	46	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12164	12169		10.1074/jbc.272.18.12164	http://dx.doi.org/10.1074/jbc.272.18.12164			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115288	hybrid			2022-12-25	WOS:A1997WX56900076
J	Musci, MA; HendricksTaylor, LR; Motto, DG; Paskind, M; Kamens, J; Turck, CW; Koretzky, GA				Musci, MA; HendricksTaylor, LR; Motto, DG; Paskind, M; Kamens, J; Turck, CW; Koretzky, GA			Molecular cloning of SLAP-130, an SLP-76-associated substrate of the T cell antigen receptor-stimulated protein tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRB2	Previous work has demonstrated that SLP-76, a Grb2-associated tyrosine-phosphorylated protein, augments Interleukin-2 promoter activity when overexpressed in the Jurkat T cell line. This activity requires regions of SLP-76 that mediate protein-protein interactions with other molecules in T cells, suggesting that SLP-76-associated proteins also function to regulate signal transduction. Here we describe the molecular cloning of SLAP-130, a SLP-76-associated phosphoprotein of 130 kDa. We demonstrate that SLAP-130 is hematopoietic cell-specific and associates with the SH2 domain of SLP-76. Additionally, we show that SLAP-130 is a substrate of the T cell antigen receptor-induced protein tyrosine kinases. Interestingly, we find that in contrast to SLP-76, overexpression of SLAP-130 diminishes T cell antigen receptor-induced activation of the interleukin-2 promoter in Jurkat T cells and interferes with the augmentation of interleukin-2 promoter activity seen when SLP-76 is overexpressed in these cells. These data suggest that SLP-76 recruits a negative regulator, SLAP-130, as well as positive regulators of signal transduction in T cells.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, GRAD PROGRAM IMMUNOL, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; BASF BIORES CORP, WORCESTER, MA 01605 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of Iowa; University of Iowa; University of Iowa; BASF; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Koretzky, Gary/AAU-5381-2021	Kamens, Joanne/0000-0002-7000-1477	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053256, R37GM053256] Funding Source: NIH RePORTER; NIA NIH HHS [AG00214-05] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NIGMS NIH HHS [GM53256] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Fang N, 1996, J IMMUNOL, V157, P3769; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V158, P1565; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9	15	217	220	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11674	11677		10.1074/jbc.272.18.11674	http://dx.doi.org/10.1074/jbc.272.18.11674			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115214	hybrid			2022-12-25	WOS:A1997WX56900002
J	Robinson, NA; Lapic, S; Welter, JF; Eckert, RL				Robinson, NA; Lapic, S; Welter, JF; Eckert, RL			S100A11, S100A10, annexin I, desmosomal proteins, small proline-rich proteins, plasminogen activator inhibitor-2, and involucrin are components of the cornified envelope of cultured human epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; CROSS-LINKED ENVELOPE; CELL-ENVELOPE; CDNA SEQUENCE; LIPOCORTIN-I; HUMAN SKIN; IMMUNOHISTOCHEMICAL LOCALIZATION; ULTRASTRUCTURAL-LOCALIZATION; PHOSPHORYLATED CYSTATIN; TISSUE TRANSGLUTAMINASE	The cornified envelope (CE) is an insoluble sheath of epsilon-(gamma-glutamyl)lysine cross-linked protein, which is deposited beneath the plasma membrane during keratinocyte terminal differentiation. We have probed the structure of the CE by proteolytic cleavage of purified CE fragments isolated from CEs formed spontaneously in cell culture. CNBr digestion, followed by trypsin and then proteinase K treatment released 25%, 42%, and 18%, respectively, of the CE protein. Purification and sequencing of released peptides has identified two novel CE precursors, S100A11 (S100C, calgizzarin) and S100A10 (calpactin light chain). We also sequenced peptides derived from annexin I and plasminogen activator inhibitor 2, two putative envelope precursors, as well as portions of the well established CE precursor proteins SPR1A, SPR1B, and involucrin. Many desmosomal components were identified (desmoglein 3, desmocolin A/B, desmoplakin I, plakoglobin, and plakophilin), indicating that desmosomes become cross-linked into the CE. Fragments derived from envoplakin, the recently sequenced 210-kDa membranous CE precursor protein, which also appears to be a desmosomal component, were also identified. Analysis of the pattern of peptide release following the sequential digestion indicates that S100A11 is anchored to the envelope via Gln(102) and/or Lys(103) at the carboxyl terminus and at Lys(3), Lys(23), and/or Gln(22) in the amino terminus. A similar type of analysis indicates that small proline-rich proteins 1A and 1B (SPR1A and SPR1B) become cross-linked at the amino terminus (residues 1-23) and the carboxyl terminus (residues 86-89). No loricrin, cystatin A, or elafin peptides were detected.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT ONCOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT ORTHOPED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT MATH,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NHLBI NIH HHS [HL07653] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NIGMS NIH HHS [GM43751] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; ANDO Y, 1989, BIOCHEM BIOPH RES CO, V163, P944, DOI 10.1016/0006-291X(89)92313-9; ANDO Y, 1991, J BIOL CHEM, V266, P1101; BAZZI MD, 1993, CELL SIGNAL, V5, P357, DOI 10.1016/0898-6568(93)90075-W; BORNSLAEGER EA, 1994, MOL BIOL DESMOSOMES, P35; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULARD JF, 1992, J INVEST DERMATOL, V98, P436, DOI 10.1111/1523-1747.ep12499850; DOOLEY TP, 1992, GENOMICS, V13, P866, DOI 10.1016/0888-7543(92)90171-N; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FAVA RA, 1993, J INVEST DERMATOL, V101, P732, DOI 10.1111/1523-1747.ep12371684; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; GOLDSMITH LA, 1975, J INVEST DERMATOL, V64, P316, DOI 10.1111/1523-1747.ep12512262; GRECO MA, 1995, J INVEST DERMATOL, V104, P204, DOI 10.1111/1523-1747.ep12612759; HAFTEK M, 1991, J HISTOCHEM CYTOCHEM, V39, P1531, DOI 10.1177/39.11.1717544; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; Holbrook KA, 1987, DERMATOLOGY GENERAL, P93; IKAI K, 1993, ARCH DERMATOL RES, V285, P296, DOI 10.1007/BF00371600; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1987, NUCLEIC ACIDS RES, V15, P5945, DOI 10.1093/nar/15.15.5945; KITAJIMA Y, 1991, J INVEST DERMATOL, V97, P1032, DOI 10.1111/1523-1747.ep12492494; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SC, 1993, J BIOL CHEM, V268, P12164; LERSCH R, 1988, MOL CELL BIOL, V8, P486, DOI 10.1128/MCB.8.1.486; LUTZ CM, 1995, INT J CANCER, V63, P297; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; MALMQVIST KG, 1983, SCAN ELECTRON MICROS, P1815; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MICHEL S, 1987, J INVEST DERMATOL, V88, P301, DOI 10.1111/1523-1747.ep12466177; MING ME, 1994, J INVEST DERMATOL, V103, P780, DOI 10.1111/1523-1747.ep12413024; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOORE KG, 1992, EXP CELL RES, V200, P186, DOI 10.1016/S0014-4827(05)80087-4; Moss S. E., 1992, ANNEXINS, P1; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; NAKA M, 1994, BBA-MOL CELL RES, V1223, P348, DOI 10.1016/0167-4889(94)90094-9; NONOMURA K, 1994, J INVEST DERMATOL, V103, P88, DOI 10.1111/1523-1747.ep12391802; OGAWA H, 1976, J BIOL CHEM, V251, P7281; OHTA H, 1991, FEBS LETT, V295, P93, DOI 10.1016/0014-5793(91)81393-M; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PEPINSKY RB, 1989, BIOCHEM J, V263, P97, DOI 10.1042/bj2630097; RASMUSSEN HH, 1992, ELECTROPHORESIS, V13, P960, DOI 10.1002/elps.11501301199; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RICHARDS S, 1988, BIOCHEM J, V253, P153, DOI 10.1042/bj2530153; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHALKWIJK J, 1993, J INVEST DERMATOL, V100, P390, DOI 10.1111/1523-1747.ep12471990; SCHMIDT A, 1994, EUR J CELL BIOL, V65, P229; SERRES M, 1994, ARCH DERMATOL RES, V286, P268, DOI 10.1007/BF00387599; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEVEN AC, 1994, J CELL SCI, V107, P693; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; TAKAHASHI M, 1994, FEBS LETT, V340, P173, DOI 10.1016/0014-5793(94)80131-2; TAKAHASHI M, 1992, FEBS LETT, V308, P79, DOI 10.1016/0014-5793(92)81055-Q; TANAKA M, 1995, CANCER LETT, V89, P195, DOI 10.1016/0304-3835(94)03687-E; TODOROKI H, 1991, J BIOL CHEM, V266, P18668; VIRATA MLA, 1992, P NATL ACAD SCI USA, V89, P544, DOI 10.1073/pnas.89.2.544; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WEBER K, 1992, ANNEXINS, P61; WENG XW, 1993, PROTEIN SCI, V2, P448; Wicki R, 1996, CELL CALCIUM, V20, P459, DOI 10.1016/S0143-4160(96)90087-1; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; YE RD, 1987, J BIOL CHEM, V262, P3718	84	193	198	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12035	12046		10.1074/jbc.272.18.12035	http://dx.doi.org/10.1074/jbc.272.18.12035			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115270	hybrid			2022-12-25	WOS:A1997WX56900058
J	Yan, YB; Chi, PP; Bourne, HR				Yan, YB; Chi, PP; Bourne, HR			RGS4 inhibits G(q)-mediated activation of mitogen-activated protein kinase and phosphoinositide synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALS; CELLS; GQ	Recombinant regulators of G protein-signaling (RGS) proteins stimulate hydrolysis of GTP by a subunits of the G(i) family but have not been reported to regulate other G protein alpha subunits. Expression of recombinant RGS proteins in cultured cells inhibits G(i)-mediated hormonal signals probably by acting as GTPase-activating proteins for G alpha(i) subunits. To ask whether an RGS protein can also regulate cellular responses mediated by G proteins in the G(q/11) family, we compared activation of mitogen-activated protein kinase (MAPK) by a G(q/11)-coupled receptor, the bombesin receptor (BR), and a G(i)-coupled receptor, the D-2 dopamine receptor, transiently co expressed with or without recombinant RGS4 in COS-7 cells. Pertussis toxin, which uncouples G(i) from receptors, blocked MAPK activation by the D-2 dopamine receptor but not by the BR. Go-expression of RGS4, however, inhibited activation of MAPK by both receptors causing a rightward shift of the concentration-effect curve for both receptor agonists, RGS4 also inhibited BR-stimulated synthesis of inositol phosphates by an effector target of G(q/11), phospholipase C. Moreover, RGS4 inhibited inositol phosphate synthesis activated by addition of AlF4- to cells overexpressing recombinant alpha(q), probably by binding to alpha(q).GDP.AlF4-. These results demonstrate that RGS4 can regulate G(q/11)-mediated cellular signals by competing for effector binding as well as by acting as a GTPase-activating protein.	UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOL PHARMACOL, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM BIOMED SCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, INST CARDIOVASC RES, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER; NCI NIH HHS [CA54427] Funding Source: Medline; NIGMS NIH HHS [GM17533, GM27800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0	21	130	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11924	11927		10.1074/jbc.272.18.11924	http://dx.doi.org/10.1074/jbc.272.18.11924			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115254	hybrid			2022-12-25	WOS:A1997WX56900042
J	Daude, N; Lehmann, S; Harris, DA				Daude, N; Lehmann, S; Harris, DA			Identification of intermediate steps in the conversion of a mutant prion protein to a scrapie-like form in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROBLASTOMA-CELLS; CELLULAR PRP; PROPAGATION; REPLICATION; ISOFORM; SURFACE; BLOCKS	The central causative event in infectious, familial, and sporadic forms of prion disease is thought to be a conformational change that converts the cellular isoform of the prion protein (PrPC) into the scrapie isoform (PrPSc) that is the primary constituent of infectious prion particles, To provide a model system for analyzing the mechanistic details of this critical transformation, we have previously prepared cultured Chinese hamster ovary cells that stably express mouse PrP molecules carrying mutations homologous to those seen in familial prion diseases of humans, In the present work, we have analyzed the kinetics with which a PrP molecule containing an insertional mutation associated with Creutzfeldt-Jakob disease acquires several biochemical properties characteristic of PrPSc. Within 10 min of pulse labeling, the mutant protein undergoes a molecular alteration that is detectable by a change in Triton X-114 phase partitioning and phenyl-Sepharose binding. After 30 min of labeling, a detergent-insoluble and protease-sensitive form of the protein appears, After a chase period of several hours, the protein becomes protease-resistant. Incubation of cells at 18 degrees C or treatment with brefeldin A inhibits acquisition of detergent insolubility and protease resistance but does not affect Triton X-114 partitioning and phenyl-Sepharose binding, Our results support a model in which conversion of mutant PrPs to a PrPSc-like state proceeds in a stepwise fashion via a series of identifiable biochemical intermediates, with the earliest step occurring during or very soon after synthesis of the polypeptide in the endoplasmic reticulum.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Lehmann, Sylvain/P-1301-2017	Lehmann, Sylvain/0000-0001-6117-562X; Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35496] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DAVITZ MA, 1988, POSTTRANSLATIONAL MO, P40; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; GAJDUSEK DC, 1994, MOL NEUROBIOL, V8, P1, DOI 10.1007/BF02778003; GAJDUSEK DC, 1996, VIROLOGY, P2851; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Huang Z, 1996, CURR TOP MICROBIOL, V207, P49; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PARCHI P, 1995, CURR OPIN NEUROL, V8, P286, DOI 10.1097/00019052-199508000-00007; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PRIOLA SA, 1995, J VIROL, V69, P7754, DOI 10.1128/JVI.69.12.7754-7758.1995; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1996, VIROLOGY, P2901; RACE RE, 1988, J VIROL, V62, P2845, DOI 10.1128/JVI.62.8.2845-2849.1988; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	49	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11604	11612						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111077	hybrid			2022-12-25	WOS:A1997WW00900093
J	Babitt, J; Trigatti, B; Rigotti, A; Smart, EJ; Anderson, RGW; Xu, SZ; Krieger, M				Babitt, J; Trigatti, B; Rigotti, A; Smart, EJ; Anderson, RGW; Xu, SZ; Krieger, M			Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; HAMSTER-CELL MUTANTS; APOPROTEIN-A-I; SIGNAL-TRANSDUCTION; CHOLESTEROL ESTERS; GOLGI-COMPLEX; LIMP-II; RAT; SURFACE; PALMITOYLATION	The class B, type I scavenger receptor, SR-BI, was the first molecularly well defined cell surface high density lipoprotein (HDL) receptor to be described, It mediates transfer of lipid from HDL to cells via selective lipid uptake, a mechanism distinct from receptor-mediated endocytosis via clathrin-coated pits and vesicles, SR-BI is expressed most abundantly in steroidogenic tissues (adrenal gland, ovary), where trophic hormones coordinately regulate its expression with steroidogenesis, and in the liver, where it may participate in reverse cholesterol transport, Here we have used immunochemical methods to study the structure and subcellular localization of murine SR-BI (mSR-BI) expressed either in transfected Chinese hamster ovary cells or in murine adreno cortical Y1-BS1 cells, mSR-BI, an similar to 82-kDa glycoprotein, was initially synthesized with multiple high mannose N-linked oligosaccharide chains, and some, but not all, of these were processed to complex forms during maturation of the protein in the Golgi apparatus, Metabolic labeling with [H-3]palmitate and [H-3]myristate demonstrated that mSR-BI was fatty acylated, a property shared with CD36, another class B scavenger receptor, and other proteins that concentrate in specialized, cholesterol- and glycolipid-rich plasma membrane microdomains called caveolae. OptiPrep density gradient fractionation of plasma membranes established that mSR-BI copurified with caveolin-1, a constituent of caveolae; and immunofluorescence microscopy demonstrated that mSR-BI colocalized with caveolin-1 in punctate microdomains across the surface of cells and on the edges of cells, Thus, mSR-BI colocalizes with caveolae, and this raises the possibility that the unique properties of these specialized cell surface domains may play a critical role in SR EI mediated transfer of lipids between lipoproteins and cells.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD MASSACHUSETTS INST TECHNOL, DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA; UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	Massachusetts Institute of Technology (MIT); Harvard University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Krieger, Marco/AAE-8611-2020; Eckhardt, Erik/G-1567-2010	Trigatti, Bernardo (Dino) L./0000-0002-4556-119X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL020948, R01HL052212] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948, HL41484, HL52212] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Alessio M, 1996, J BIOL CHEM, V271, P1770, DOI 10.1074/jbc.271.3.1770; ALLAND L, 1994, J BIOL CHEM, V269, P16701; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson Richard G., 1993, Trends in Cell Biology, V3, P69, DOI 10.1016/0962-8924(93)90065-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTHAM KM, 1995, PROG LIPID RES, V34, P71, DOI 10.1016/0163-7827(94)00007-9; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GREENWALT DE, 1992, BLOOD, V80, P1105; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; Harlow E., 1988, ANTIBODIES LAB MANUA; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; JOCHEN A, 1993, J LIPID RES, V34, P1783; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KINGSLEY DM, 1986, MOL CELL BIOL, V6, P2734, DOI 10.1128/MCB.6.7.2734; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1983, P NATL ACAD SCI-BIOL, V80, P5607, DOI 10.1073/pnas.80.18.5607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LIETERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V796, P72; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Oram JF, 1996, J LIPID RES, V37, P2473; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PEARCE SFA, 1994, BLOOD, V84, P384; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1989, J LIPID RES, V30, P1551; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHLESINGER MJ, 1994, LIPID MODIFICATIONS; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1983, J CELL BIOL, V97, P1592, DOI 10.1083/jcb.97.5.1592; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WILLIAMS DL, 1995, J LIPID RES, V36, P745; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	91	332	338	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13242	13249		10.1074/jbc.272.20.13242	http://dx.doi.org/10.1074/jbc.272.20.13242			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148942	hybrid			2022-12-25	WOS:A1997WZ38400055
J	DeFlora, A; Guida, L; Franco, L; Zocchi, E; Bruzzone, S; Benatti, U; Damonte, G; Lee, HC				DeFlora, A; Guida, L; Franco, L; Zocchi, E; Bruzzone, S; Benatti, U; Damonte, G; Lee, HC			CD38 and ADP-ribosyl cyclase catalyze the synthesis of a dimeric ADP-ribose that potentiates the calcium-mobilizing activity of cyclic ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD+-GLYCOHYDROLASE; HUMAN ERYTHROCYTES; SKELETAL-MUSCLE; ANTIGEN CD38; INOSITOL TRISPHOSPHATE; SELF-AGGREGATION; SURFACE; RIBOSYLTRANSFERASE; HYDROLYSIS; ENZYME	CD38, a lymphocyte differentiation antigen, is also a bifunctional enzyme catalyzing the synthesis of cyclic ADP-ribose (cADPR) from NAD(+) and its hydrolysis to ADP-ribose (ADPR), An additional enzymatic activity of CD38 shared by monofunctional ADP ribosyl cyclase from Aplysia californica is the exchange of the base group of NAD(+) (nicotinamide) with various nucleophiles, Both human CD38 (either recombinant or purified from erythrocyte membranes) and Aplysia cyclase were found to catalyze the exchange of ADPR with the nicotinamide group of NAD(+) leading to the formation of a dimeric ADPR ((ADPR)(2)), The dimeric structure of the enzymatic product, which was generated by recombinant CD38 and by CD38(+) Namalwa cells from as low as 10 mu M NAD(+), was demonstrated using specific enzyme treatments (dinucleotide pyrophosphatase and 5'-nucleotidase) and mass spectrometry analyses of the resulting products, The linkage between the two ADPR units of (ADPR)(2) was identified as that between the N-1 of the adenine nucleus of one ADPR unit and the anomeric carbon of the terminal ribose of the second ADPR molecule by enzymatic analyses and by comparison with patterns of cADPR cleavage with Me2SO:tert-butoxide. Although (ADPR)(2) itself did not release Ca2+ from sea urchin egg microsomal vesicles, it specifically potentiated the Ca2+-releasing activity of subthreshold concentrations of cADPR, Therefore, (ADPR)(2) is a new product of CD38 that amplifies the Ca2+-mobilizing activity of cADPR.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	DeFlora, A (corresponding author), UNIV GENOA,INST BIOCHEM,VIALE BENEDETTO XV-1,I-16132 GENOA,ITALY.		Lee, Hon Cheung/C-4329-2009; Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484, R01HD032040] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32040, HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; ARTMAN M, 1979, ARCH BIOCHEM BIOPHYS, V195, P121, DOI 10.1016/0003-9861(79)90333-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CLAPPER DL, 1987, J BIOL CHEM, V262, P9651; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; DONG C, 1994, INT IMMUNOL, V6, P1353, DOI 10.1093/intimm/6.9.1353; FRANCO L, 1994, BIOCHEM BIOPH RES CO, V202, P1710, DOI 10.1006/bbrc.1994.2132; FRYXELL KB, 1995, PROTEIN EXPRES PURIF, V6, P329, DOI 10.1006/prep.1995.1043; Genazzani AA, 1996, BIOCHEM BIOPH RES CO, V223, P502, DOI 10.1006/bbrc.1996.0924; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GU QM, 1994, J AM CHEM SOC, V116, P7481, DOI 10.1021/ja00096a002; GUIDA L, 1995, FEBS LETT, V368, P481, DOI 10.1016/0014-5793(95)00715-L; Han MK, 1996, BIOCHEM J, V318, P903, DOI 10.1042/bj3180903; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACOBSON KB, 1957, J BIOPHYS BIOCHEM CY, V3, P31, DOI 10.1083/jcb.3.1.31; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KIM UH, 1988, BIOCHIM BIOPHYS ACTA, V965, P76, DOI 10.1016/0304-4165(88)90153-5; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KORNBERG A, 1950, J BIOL CHEM, V182, P763; Kukimoto I, 1996, EUR J BIOCHEM, V239, P177, DOI 10.1111/j.1432-1033.1996.0177u.x; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MULLER HM, 1983, BIOCHEM J, V212, P459, DOI 10.1042/bj2120459; MULLERSTEFFNER H, 1994, BIOCHEM BIOPH RES CO, V204, P1279, DOI 10.1006/bbrc.1994.2601; PEKALA PH, 1978, J BIOL CHEM, V253, P7453; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; Price S.R., 1987, PYRIDINE NUCLEOTIDE, V2B, P513; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TANUMA S, 1988, J BIOL CHEM, V263, P5485; TARNUS C, 1987, BIOORG CHEM, V15, P31, DOI 10.1016/0045-2068(87)90004-6; TARNUS C, 1988, BIOORG CHEM, V16, P38, DOI 10.1016/0045-2068(88)90036-3; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; Vu CQ, 1996, J BIOL CHEM, V271, P4747; WADA T, 1995, NUCLEOS NUCLEOT, V14, P1301, DOI 10.1080/15257779508010692; WANG J, 1994, J IMMUNOL, V153, P4048; ZATMAN LJ, 1953, J BIOL CHEM, V200, P197; ZOCCHI E, 1993, BIOCHEM J, V295, P121, DOI 10.1042/bj2950121; ZOCCHI E, 1995, FEBS LETT, V359, P35, DOI 10.1016/0014-5793(95)00005-T; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	55	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12945	12951		10.1074/jbc.272.20.12945	http://dx.doi.org/10.1074/jbc.272.20.12945			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148900	hybrid			2022-12-25	WOS:A1997WZ38400013
J	Leiros, CP; SterinBorda, L; Borda, ES; Goin, JC; Hosey, MM				Leiros, CP; SterinBorda, L; Borda, ES; Goin, JC; Hosey, MM			Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas' disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; BETA-ADRENOCEPTORS; TRYPANOSOMA-CRUZI; CHOLINERGIC RECEPTORS; INSECT CELLS; ANTIBODIES; PHOSPHORYLATION; AGONIST; LOCALIZATION; HEART	Chronic Chagas' disease is associated with pathologic changes of the cardiovascular, digestive, and autonomic nervous system, culminating in autonomic denervation and congestive heart failure. Previously, circulating autoantibodies that activate signaling by cardiac muscarinic acetylcholine receptors (mAChRs) have been described, However, it remains unclear whether the chagasic IgGs directly interact with the m2 mAChRs (predominant cardiac subtype), and, if so, whether chronic exposure of the mAChRs to such activating IgGs would result in receptor desensitization. Here we performed studies with purified and reconstituted hm2 mAChRs and demonstrate that IgGs from chagasic serum immunoprecipitated the mAChRs in a manner similar to an anti-m2 mAChR monoclonal antibody tested in parallel, The chagasic antibodies did not directly interact with the ligand binding site, because the binding of radiolabeled antagonist was unchanged by the addition of the chagasic IgG, In intact cells stably expressing the hm2 mAChR, the chagasic IgGs, but not normal IgGs, mimicked the ability of the agonist acetylcholine to induce two effects associated with agonist-induced receptor desensitization: a decrease in affinity for agonist binding to m2 mAChR and sequestration of the hm2 mAChRs from the cell surface. The results demonstrate that the chagasic IgGs can directly interact with and desensitize m2 mAChRs and provide support for the hypothesis of autoimmune mechanisms having a role in the pathogenesis of Chagas' cardioneuromyopathy.	NORTHWESTERN UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, CHICAGO, IL 60611 USA	Northwestern University	Leiros, CP (corresponding author), CONSEJO NACL INVEST CIENT & TECN, CEFYBO, SERRANO 669, RA-1414 BUENOS AIRES, DF, ARGENTINA.				NHLBI NIH HHS [HL50121] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACOSTA AM, 1985, CIRCULATION, V71, P1255, DOI 10.1161/01.CIR.71.6.1255; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BACMAN S, 1994, FASEB J, V8, P1170, DOI 10.1096/fasebj.8.14.7958624; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; FU M, 1994, J HISTOCHEM CYTOCHEM, V42, P337, DOI 10.1177/42.3.8308250; GOIN JC, 1994, J AUTONOM NERV SYST, V47, P45, DOI 10.1016/0165-1838(94)90064-7; GOIN JC, 1991, P SOC EXP BIOL MED, V197, P186, DOI 10.3181/00379727-197-43244; Goin Juan Carlos, 1994, Neuroimmunomodulation, V1, P284; HAGA K, 1983, J BIOL CHEM, V258, P3575; IOSA D, 1989, AM HEART J, V117, P882, DOI 10.1016/0002-8703(89)90627-3; IOSA D, 1990, J AUTONOM NERV SYST, V30, pS83, DOI 10.1016/0165-1838(90)90107-T; IOSA D, 1991, AM HEART J, V122, P775, DOI 10.1016/0002-8703(91)90525-M; KOBERLE F, 1961, Bol Oficina Sanit Panam, V51, P404; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P6892, DOI 10.1021/bi00396a003; MACHADO ABM, 1979, EXP PARASITOL, V47, P107, DOI 10.1016/0014-4894(79)90012-2; MORRIS SA, 1988, CIRC RES, V62, P800, DOI 10.1161/01.RES.62.4.800; MORRIS SA, 1984, MOL BIOCHEM PARASIT, V13, P227, DOI 10.1016/0166-6851(84)90115-4; MORRIS SA, 1990, CIRCULATION, V82, P1900, DOI 10.1161/01.CIR.82.6.1900; MOTT KE, 1965, CIRCULATION, V31, P273, DOI 10.1161/01.CIR.31.2.273; MUNDSON PJ, 1980, ANAL BIOCHEM, V107, P220; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PARKER EM, 1991, J BIOL CHEM, V266, P519; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; Sterin-Borda Leonor J., 1994, Acta Physiologica Pharmacologica et Therapeutica Latinoamericana, V44, P109; STERINBORDA L, 1988, CLIN EXP IMMUNOL, V74, P349; TAFURI WL, 1971, VIRCHOWS ARCH A, V354, P136, DOI 10.1007/BF00548079; TANOWITZ HB, 1983, J INFECT DIS, V147, P460, DOI 10.1093/infdis/147.3.460; TOEWS ML, 1984, J BIOL CHEM, V259, P2227; WHO-World Health Organization, 1991, TECHN REP SER, V811, P1; *WORLD BANK WHO, 1982, SPEC PROGR RES TRAIN, V6, P1	35	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12989	12993		10.1074/jbc.272.20.12989	http://dx.doi.org/10.1074/jbc.272.20.12989			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148906	hybrid			2022-12-25	WOS:A1997WZ38400019
J	Yao, LB; Suzuki, H; Ozawa, K; Deng, JB; Lehel, C; Fukamachi, H; Anderson, WB; Kawakami, Y; Kawakami, T				Yao, LB; Suzuki, H; Ozawa, K; Deng, JB; Lehel, C; Fukamachi, H; Anderson, WB; Kawakami, Y; Kawakami, T			Interactions between protein kinase C and pleckstrin homology domains - Inhibition by phosphatidylinositol 4,5-bisphosphate and phorbol 12-myristate 13-acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; BRUTON TYROSINE KINASE; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; IMMUNODEFICIENT XID MICE; PH DOMAIN; SIGNALING PROTEINS; INOSITOL PHOSPHATES; HEMATOPOIETIC-CELLS	Pleckstrin homology (PH) domains comprised of loosely conserved sequences of similar to 100 amino acid residues are a functional protein motif found in many signal-transducing and cytoskeletal proteins, Ne recently demonstrated that the PH domains of Tec family protein-tyrosine kinases Btk and Emt (equal to Itk and Tsk) interact with protein kinase C (PKC) and that PKC down regulates Btk by phosphorylation, In this study we have characterized the PKC-BtkPH domain interaction in detail, Using pure PKC preparations, it was shown that the Btk PH domain interacts with PRC with high affinity (K-D = 39 nM). Unlike other tested phospholipids, phosphatidylinositol 4,5-bisphosphate, which binds to several PH domains, competed with PKC for binding to the PH domain apparently because their binding sites on the amino-terminal portion of the PH domains overlap, The minimal PKC-binding sequence within the Btk PH domain was found to correspond roughly to the second and third beta-sheets of the PH domains of known tertiary structures, On the other hand, the C1 regulatory region of PKC epsilon containing the pseudosubstrate and zinc finger-like sequences was found to be sufficient for strong binding to the Btk PH domain, Phorbol 12-myristate 13-acetate (PMA), a potent activator of PKC that interacts with the C1 region of PHC, inhibited the PHC-PH domain interaction, whereas the bioinactive PMA (4-alpha-PMA) was ineffective, The zeta isoform of PKC, which has a single zinc finger-like motif instead of the two tandem zinc finger-like sequences present in conventional and novel PKC isoforms, does not bind PIMA. Thus, as expected, PH domain binding with PI(CS was not interfered with by PMA. Further, inhibitors that are known to attack the catalytic domains of serine/threonine kinases did not affect this PKC-PH domain interaction, In contrast, the presence of physiological concentrations of Ca2+ induced less than a 2-fold increase in PKC-PH domain binding, These results indicate that PKC binding to PH domains involve the beta 2-beta 3 region of the Btk PH domain and the C1 region of PKC, and agents that interact with either of these regions (i.e. phosphatidylinositol 4,5-bisphosphate binding to the PH domain and PMA binding to the C1 region of PKC) might act to regulate PKC-PH domain binding.	LA JOLLA INST ALLERGY & IMMUNOL,DIV ALLERGY,SAN DIEGO,CA 92121; KIRIN BREWERY CO LTD,PHARMACEUT RES LAB,TAKASAKI,GUMMA 37012,JAPAN; NCI,CELLULAR ONCOL LAB,NIH,BETHESDA,MD 20892	La Jolla Institute for Immunology; Kirin Brewery Company Limited; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kawakami, Toshiaki/O-1616-2015		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033617, R01AI038348] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38348, AI33617] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ARORA N, 1993, INT ARCH ALLERGY IMM, V100, P319, DOI 10.1159/000236432; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DEWEERS M, 1994, HUM MOL GENET, V3, P161, DOI 10.1093/hmg/3.1.161; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GREGORIO CC, 1992, P NATL ACAD SCI USA, V89, P4947, DOI 10.1073/pnas.89.11.4947; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3555; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lewin I, 1996, J BIOL CHEM, V271, P1514, DOI 10.1074/jbc.271.3.1514; LI T, 1995, IMMUNITY, V2, P1; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANO H, 1993, ONCOGENE, V8, P417; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEWTON AC, 1996, IN PRESS PROTEIN KIN; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; OLAH Z, 1995, BIOCHEM BIOPH RES CO, V214, P340, DOI 10.1006/bbrc.1995.2293; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	54	93	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13033	13039		10.1074/jbc.272.20.13033	http://dx.doi.org/10.1074/jbc.272.20.13033			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148913	hybrid			2022-12-25	WOS:A1997WZ38400026
J	McCoubrey, WK; Huang, TJ; Maines, MD				McCoubrey, WK; Huang, TJ; Maines, MD			Heme oxygenase-2 is a hemoprotein and binds heme through heme regulatory motifs that are not involved in heme catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RAT-LIVER; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CARBON-MONOXIDE; EXPRESSION; PROTEIN; BRAIN; CDNA; GENE	The heme oxygenase (HO) system degrades heme to biliverdin and CO and releases chelated iron. In the primary sequence of the constitutive form, HO-2, there are three potential heme binding sites: two heme regulatory motifs (HRMs) with the absolutely conserved Cys-Pro pair, and a conserved 24-residue heme catalytic pocket with a histidine residue, His(151) in rat HO-2. The visible and pyridine hemochromogen spectra suggest that the Escherichia coli expressed purified HO-2 is a hemoprotein. The absorption spectrum, heme fluorescence quenching, and heme titration analysis of the wild type protein versus those of purified double cysteine mutant (Cys(264)/Cys(281) --> Ala/Ala) suggest a role of the HRMs in heme binding. While the His(151) --> Ala mutation inactivates HO-2, Cys(264) --> Ala and Cys(281) --> Ala mutations individually or together (HO-2 mut) do not decrease HO activity. Also, Pro(265) --> Ala or Pro(282) --> Ala mutation does not alter HO-2 activity. Northern blot analysis of ptk cells indicates that HO-2 mRNA is not regulated by heme, The findings, together with other salient features of HO-2 and the ability of heme protein complexes to generate oxygen radicals, are consistent with HO-2, like five other HRM-containing proteins, having a regulatory function in the cell.	UNIV ROCHESTER,DEPT BIOCHEM & BIOPHYS,SCH MED,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT ENVIRONM MED,SCH MED,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003968, P30ES001247, R37ES004391] Funding Source: NIH RePORTER; NIEHS NIH HHS [MERIT R37ES04391, ES01247, ES03968] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AITKEN RJ, 1995, J CELL SCI, V108, P2017; BENYON J, 1983, CELL, V34, P665; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL AS, 1961, BIOCHEM J, V78, P246, DOI 10.1042/bj0780246; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CRUESOT F, 1988, J MOL BIOL, V204, P263; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; EVANS CO, 1991, BIOCHEM J, V273, P659, DOI 10.1042/bj2730659; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; EWING JF, 1995, ENDOCRINOLOGY, V136, P2294, DOI 10.1210/en.136.5.2294; HANIU M, 1983, BIOCHEM BIOPH RES CO, V116, P30, DOI 10.1016/0006-291X(83)90376-5; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11293, DOI 10.1021/bi960371l; HARGROVE MS, 1994, BIOCHEMISTRY-US, V33, P11767, DOI 10.1021/bi00205a012; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; KAGEYAMA H, 1988, CANCER RES, V48, P4795; KALB VF, 1988, P NATL ACAD SCI USA, V85, P7221, DOI 10.1073/pnas.85.19.7221; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; LANTHROP JT, 1993, SCIENCE, V259, P522; LEEHUANG S, 1993, GENE, V137, P203; Maines M.D., 1992, HEME OXYGENASE CLIN; MAINES MD, 1986, J BIOL CHEM, V261, P411; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; MCCOUBREY WK, 1992, ARCH BIOCHEM BIOPHYS, V295, P13, DOI 10.1016/0003-9861(92)90481-B; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; MCCOUBREY WK, 1995, BIOL REPROD, V53, P1330, DOI 10.1095/biolreprod53.6.1330; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; MULLER RM, 1987, J BIOL CHEM, V262, P6795; OW DW, 1983, P NATL ACAD SCI-BIOL, V80, P2524, DOI 10.1073/pnas.80.9.2524; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PRABHAKAR NR, 1995, P NATL ACAD SCI USA, V92, P1994, DOI 10.1073/pnas.92.6.1994; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; ROTENBERG MO, 1991, ARCH BIOCHEM BIOPHYS, V290, P336, DOI 10.1016/0003-9861(91)90549-X; RUBLEVSKAYA I, 1994, J BIOL CHEM, V269, P26390; SCHACTER BA, 1990, ARCH BIOCHEM BIOPHYS, V282, P404, DOI 10.1016/0003-9861(90)90136-M; SCHECHTER AN, 1968, J MOL BIOL, V35, P567, DOI 10.1016/S0022-2836(68)80015-4; SCOPES R, 1982, PROTEIN PURIFICATION, P21; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; STEINER RF, 1966, J BIOL CHEM, V241, P560; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; SUN Y, 1990, J BIOL CHEM, V265, P8212; TAPPEL AL, 1961, AUTOXIDAT ANTITOX, V1, P325; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; TRIGGSRAINE BL, 1988, J BACTERIOL, V170, P4415, DOI 10.1128/jb.170.9.4415-4419.1988; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; WEBER CM, 1994, J NEUROCHEM, V63, P953; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Wilks A, 1996, BIOCHEMISTRY-US, V35, P930, DOI 10.1021/bi952405f; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1993, J BIOL CHEM, V268, P22357; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x	61	157	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12568	12574		10.1074/jbc.272.19.12568	http://dx.doi.org/10.1074/jbc.272.19.12568			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139709	hybrid			2022-12-25	WOS:A1997WY82900046
J	Nelimarkka, L; Kainulainen, V; Schonherr, E; Moisander, S; Jortikka, M; Lammi, M; Elenius, K; Jalkanen, M; Jarvelainen, H				Nelimarkka, L; Kainulainen, V; Schonherr, E; Moisander, S; Jortikka, M; Lammi, M; Elenius, K; Jalkanen, M; Jarvelainen, H			Expression of small extracellular chondroitin/dermatan sulfate proteoglycans is differentially regulated in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; BOVINE ARTICULAR-CARTILAGE; MAMMARY EPITHELIAL-CELLS; DECORIN GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; DERMATAN SULFATE; CORE PROTEIN; SURFACE PROTEOGLYCANS; OSTEOINDUCTIVE FACTOR	We have examined the expression of the small extracellular chondroitin/dermatan sulfate proteoglycans (CS/DS PGs), biglycan, decorin, and PG-100, which is the proteoglycan form of colony stimulating factor-1, in the human endothelial cell line EA.hy 926. We have also examined whether modulation of the phenotype of EA.hy 926 cells by tumor necrosis factor-alpha (TNF-alpha) is associated with specific changes in the synthesis of these PGs. We demonstrate that EA.hy 926 cells, when they form monolayer cultures typical of macrovascular endothelial cells, express and synthesize detectable amounts of biglycan and PG-100, but not decorin. On SDS-polyacrylamide gel electrophoresis both PGs behave like proteins of the relative molecular weight of similar to 250,000, TNF-alpha that changed the morphology of the cells from a polygonal shape into a spindle shape and that also stimulated the detachment of the cells from culture dish, markedly decreased the net synthesis of biglycan, whereas the net synthesis of PG-100 was increased. These changes were parallel with those observed at the mRNA level of the corresponding PGs. The proportions of the different sulfated CS/DS disaccharide units of PGs were not affected by TNF-alpha. Several other growth factors/cytokines, such as interferon-gamma, fibroblast growth factors-2 (FGF-2) and -7 (FGF-7), interleukin-1 beta, and transforming growth factor-beta, unlike TNF-alpha, modulated neither the morphology nor the biglycan expression of EA.hy 926 cells under the conditions used in the experiments. However, PG-100 expression was increased also in response to PGF-2 and -7 and transforming growth factor-beta. None of the above cytokines, including TNF-alpha, was able to induce decorin expression in the cells. Our results indicate that the regulatory elements controlling the expression of the small extracellular CS/DS PGs in human endothelial cells are different.	UNIV TURKU,DEPT MED BIOCHEM,FIN-20520 TURKU,FINLAND; UNIV TURKU,DEPT INTERNAL MED,FIN-20520 TURKU,FINLAND; TURKU CTR BIOTECHNOL,FIN-20520 TURKU,FINLAND; UNIV MUNSTER,INST PHYSIOL CHEM & PATHOBIOCHEM,GER-4400 MUNSTER,GERMANY; UNIV KUOPIO,DEPT ANAT,FIN-70211 KUOPIO,FINLAND	University of Turku; University of Turku; University of Munster; University of Eastern Finland			Elenius, Klaus/AAI-7594-2021; Lammi, Mikko/B-9291-2008	Elenius, Klaus/0000-0001-5700-0827; Lammi, Mikko/0000-0002-6181-9904				BERETZ A, 1989, BIOCHEM J, V259, P35, DOI 10.1042/bj2590035; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; BOSSE A, 1993, J HISTOCHEM CYTOCHEM, V41, P13, DOI 10.1177/41.1.8417108; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CORDER R, 1995, BIOCHEM BIOPH RES CO, V207, P355, DOI 10.1006/bbrc.1995.1195; CORDER R, 1993, J CARDIOVASC PHARM, V22, pS42, DOI 10.1097/00005344-199322008-00013; DEBAULT LE, 1984, FED PROC, V43, P783; DETMAR M, 1992, J INVEST DERMATOL, V98, P147, DOI 10.1111/1523-1747.ep12555746; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ELENIUS K, 1994, J CELL SCI, V107, P2975; EMEIS JJ, 1988, BLOOD, V71, P1669; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRESSNER AM, 1994, EUR J CLIN CHEM CLIN, V32, P225; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JARVELAINEN H, 1985, SCAND J CLIN LAB INV, V45, P223, DOI 10.3109/00365518509160999; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Kainulainen V, 1996, J BIOL CHEM, V271, P18759, DOI 10.1074/jbc.271.31.18759; Kinsella MG, 1997, J BIOL CHEM, V272, P318; KINSELLA MG, 1986, J CELL BIOL, V102, P679, DOI 10.1083/jcb.102.3.679; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRESSE H, 1994, EUR J CLIN CHEM CLIN, V32, P259; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMI M, 1988, ANAL BIOCHEM, V168, P352, DOI 10.1016/0003-2697(88)90329-6; LAMMI MJ, 1991, J BIOCHEM BIOPH METH, V22, P301, DOI 10.1016/0165-022X(91)90036-V; MAATTA A, 1994, BBA-MOL BASIS DIS, V1225, P264, DOI 10.1016/0925-4439(94)90005-1; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; MALFAIT AM, 1994, J RHEUMATOL, V21, P314; MANN DM, 1990, J BIOL CHEM, V265, P5317; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MIDURA RJ, 1994, GLYCOBIOLOGY, V4, P333, DOI 10.1093/glycob/4.3.333; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NANTOSALONEN K, 1982, J INHERIT METAB DIS, V5, P197, DOI 10.1007/BF02179141; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NOYORI K, 1994, ARTHRITIS RHEUM, V37, P1656, DOI 10.1002/art.1780371115; PARTENHEIMER A, 1995, J IMMUNOL, V155, P5557; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; RAMASAMY S, 1995, J CELL PHYSL, V162, P11692; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; ROBAYE B, 1991, AM J PATHOL, V138, P447; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; ROUGHLEY PJ, 1989, BIOCHEM J, V262, P823, DOI 10.1042/bj2620823; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAIJONMAA O, 1991, BIOCHEM BIOPH RES CO, V181, P529, DOI 10.1016/0006-291X(91)91221-W; SALMI M, 1995, EUR J IMMUNOL, V25, P2803, DOI 10.1002/eji.1830251014; SANTALA P, 1994, J BIOL CHEM, V269, P1276; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHMIDT A, 1989, BIOCHEM SOC T, V17, P19, DOI 10.1042/bst0170019; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SHINOMURA T, 1984, DEV BIOL, V103, P211, DOI 10.1016/0012-1606(84)90022-8; SUGGS JE, 1986, BLOOD, V68, P825; SUZU S, 1992, J BIOL CHEM, V267, P16812; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; VOGEL KG, 1989, EUR J CELL BIOL, V49, P236; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WIGHT TN, 1992, EXP CELL RES, V203, P395; WILBRINK B, 1991, BRIT J RHEUMATOL, V30, P265; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	82	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12730	12737		10.1074/jbc.272.19.12730	http://dx.doi.org/10.1074/jbc.272.19.12730			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139731	hybrid			2022-12-25	WOS:A1997WY82900068
J	Swinney, DC; Mak, AY; Barnett, J; Ramesha, CS				Swinney, DC; Mak, AY; Barnett, J; Ramesha, CS			Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENDOPEROXIDE SYNTHASE; SELECTIVE-INHIBITION; CYCLOOXYGENASE ACTIVITIES; ALZHEIMERS-DISEASE; G/H SYNTHASE; MAST-CELLS; EXPRESSION; ASPIRIN	Prostaglandins are synthesized by prostaglandin H synthase (PGHS) 1 and 2. PGHS2 is regulated through inducible expression. We report here the regulation of PGHS1 activity by substrate-dependent cooperative activation, The cooperativity is characterized by a Hill coefficient of 1.29 +/- 0.06, a curved Eadie-Scatchard plot, and activation by low concentrations of competitive inhibitors, The activation also appears to induce a conformational change in the cyclooxygenase site. The cooperativity produces a 2-4-fold greater rate of PGHS2-dependent prostaglandin formation compared with PGHS1-dependent prostaglandin formation at arachidonic acid concentrations below 0.5 mu M. A consequence of the PGHS1 cooperativity is that the affinity of many cyclooxygenase inhibitors for PGHS1 decreases in parallel to the activation by arachidonic acid. In contrast, the affinity of these inhibitors for PGHS2 is unaffected by the changes in arachidonic acid concentration, This results in a dramatic difference in PGHS2/PGHS1 selectivity at different arachidonic acid concentrations.			Swinney, DC (corresponding author), ROCHE BIOSCI, INFLAMMATORY DIS UNIT, S3-1, 3401 HILLVIEW AVE, PALO ALTO, CA 94304 USA.							BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; Callan OH, 1996, J BIOL CHEM, V271, P3548; CHALUDA PC, 1996, ARCH BIOCHEM BIOPHYS, V330, P301; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DUBOIS RN, 1996, GASTROENTEROLOGY, V110, P1529; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1995, P NATL ACAD SCI USA, V92, P6107, DOI 10.1073/pnas.92.13.6107; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; REDDY ST, 1994, J BIOL CHEM, V269, P15473; REITZ DB, 1994, J MED CHEM, V37, P3878, DOI 10.1021/jm00049a005; RENOSTO F, 1990, J BIOL CHEM, V265, P10300; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; SEGEL IH, 1975, ENZYME KINETICS, P367; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0	30	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12393	12398		10.1074/jbc.272.19.12393	http://dx.doi.org/10.1074/jbc.272.19.12393			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139685	hybrid			2022-12-25	WOS:A1997WY82900022
J	Tang, DM; Chun, ACS; Zhang, MJ; Wang, JH				Tang, DM; Chun, ACS; Zhang, MJ; Wang, JH			Cyclin-dependent kinase 5 (CdkB) activation domain of neuronal Cdk5 activator - Evidence of the existence of cyclin fold in neuronal Cdk5a activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN-SPECIFIC ACTIVATOR; PROTEIN-KINASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; CDC2-LIKE KINASE; BOVINE BRAIN; TAU-PROTEIN; CDC2; PHOSPHORYLATION; BINDING	Neuronal Cdk5 activator (Nck5a) differs from other cyclin-dependent kinase (Cdk) activators in that its amino acid sequence is only marginally similar to the cyclin consensus sequence, Nevertheless, computer modeling has suggested that Nck5a contains the cyclin-fold motif recently identified in the crystal structure of cyclin A. In the present study, a number of truncation mutants and substitution mutants of the Nck5a were produced and tested for the Cdk5 activation and Cdk5 binding activity, The active domain of Nck5a determined by using the truncation mutants consists of the region spanning residues 150 to 291. The size of Nck5a active domain is essentially the same as that of cyclin A required for Cdk2 activation (Lees, E. M., and Harlow, E. (1993) Mol. Cell. Biol. 13, 1194-1201). The change, or the lack of change, in Cdk5 activation activity observed with a number of substitution mutants may be understood on the basis of structure and function relationship of cyclin A, These results provide support to the previous suggestion (Brown, N. R., Noble, M. E. M., Endicott, J. A., Garman, E. F., Wakatsuki, S., Mitchell, E., Rasmussen, B., Hunt, T., and Johnson, L. N. (1995) Structure 3, 1235-1247) that the activation domain of Nck5a adopts a conformation similar to that of cyclin A, They also provide a partial answer to the question of how Nck5a, a non-cyclin, activates a cyclin-dependent kinase.	HONG KONG UNIV SCI & TECHNOL,DEPT BIOCHEM,KOWLOON,HONG KONG	Hong Kong University of Science & Technology			Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; Bazan JF, 1996, PROTEINS, V24, P1; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HAYES TE, 1991, NEW BIOL, V3, P259; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Hunt T, 1991, Semin Cell Biol, V2, P213; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NUGENT JA, 1991, J CELL SCI, V99, P674; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1996, J BIOL CHEM, V272, P5703; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; RUST B, 1993, J MOL BIOL, V232, P584; Sambrook J., 2002, MOL CLONING LAB MANU; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0	44	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12318	12327		10.1074/jbc.272.19.12318	http://dx.doi.org/10.1074/jbc.272.19.12318			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139676	hybrid			2022-12-25	WOS:A1997WY82900013
J	Utley, RT; Cote, J; OwenHughes, T; Workman, JL				Utley, RT; Cote, J; OwenHughes, T; Workman, JL			SWI/SNF stimulates the formation of disparate activator-nucleosome complexes but is partially redundant with cooperative binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATORS; FACILITATED BINDING; MULTISUBUNIT COMPLEX; REMODELING FACTOR; DNA RECOGNITION; GENE-PRODUCTS; PHO5 PROMOTER; YEAST; GAL4; PROTEINS	To investigate the potential mechanisms by which the SWI/SNF complex differentially regulates different genes we have tested whether transcription factors with diverse DNA binding domains were able to exploit nucleosome disruption by SWI/SNF. In addition to GAL4-VP16, the SWI/SNF complex stimulated nucleosome binding by the Zn2+ fingers of Sp1, the basic helix-loop-helix domain of USF, and the rel domain of NF-kappa B. In each case SWI/SNF action resulted in the formation of a stable factor-nucleosome complex that persisted after detachment of SWI/SNF from the nucleosome. Thus, stimulation of factor binding by SWI/SNF appears to be universal. The degree of SWI/SNF stimulation of nucleosome binding by a factor appears to be inversely related to the extent that binding is inhibited by the histone octamer. Cooperative binding of 5 GAL4-VP16 dimers to a 5-site nucleosome enhanced GAL4 binding relative to a single-site nucleosome, but this also reduced the degree of stimulation by SWI/SNF. The SWI/SNF complex increased the affinity of 5 GAL4-VP16 dimers for nucleosomes equal to that of DNA but no further. Similarly, multimerized NF-kappa B sites enhanced nucleosome binding by NF-kappa B and reduced the stimulatory effect of SWI/SNF. Thus, cooperative binding of factors to nucleosomes is partially redundant with the function of the SWI/SNF complex.	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,ALTHOUSE LAB 306,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X; Owen-Hughes, Tom/0000-0002-0618-8185				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TEICH I, 1995, MOL CELL BIOL, V15, P4240; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Utley RT, 1996, METHOD ENZYMOL, V274, P276; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	42	71	74	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12642	12649		10.1074/jbc.272.19.12642	http://dx.doi.org/10.1074/jbc.272.19.12642			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139720	hybrid			2022-12-25	WOS:A1997WY82900057
J	Koenig, K; Menge, U; Kiess, M; Wray, V; Flohe, L				Koenig, K; Menge, U; Kiess, M; Wray, V; Flohe, L			Convenient isolation and kinetic mechanism of glutathionylspermidine synthetase from Crithidia fasciculata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PEROXIDE METABOLISM; TRYPANOSOMA-BRUCEI; ESCHERICHIA-COLI; TRYPANOTHIONE REDUCTASE; GLUTATHIONE-REDUCTASE; HYDROGEN-PEROXIDE; PURIFICATION; SUPEROXIDE; DISULFIDE; COFACTOR	Trypanothione, the essential metabolite in the oxidant defense system of trypanosomatids, is synthesized by two distinct proteins, glutathionylspermidine synthetase and trypanothione synthetase. Glutathionylspermidine synthetase was purified to homogeneity from the trypanosomatid Crithidia fasciculata by aqueous two-phase systems and chromatography. The enzyme showed a specific activity of 38 mu mol of glutathionylspermidine formed per min per mg of protein. Its molecular mass was 78 kDa in SDS polyacrylamide gel electrophoresis, and it appeared predominantly monomeric in native polyacrylamide gel electrophoresis and gel filtration. The isoelectric point was at pH 4.6, and the pH optimum was near 7.6, Partial amino acid sequencing revealed homology with, but low similarity to, the glutathionylspermidine synthetase/amidase of Escherichia coli, and amidase activity was not detected in glutathionylspermidine synthetase of C. fasciculata. The kinetics of trypanosomatid glutathionylspermidine synthetase revealed a rapid equilibrium random mechanism with limiting K-m values for Mg2+-ATP, GSH, and spermidine of 0.25 +/- 0.02, 2.51 +/- 0.33, and 0.47 +/- 0.09 mM, respectively, and a k(cat) of 415 +/- 78 min(-1). Partial reactions at restricted cosubstrate supply were not detected by P-31 NMR, supporting the necessity of a quarternary complex formation for catalysis. ADP inhibited competitively with respect to ATP (K-i = 0.08 mM) and trypanothione exerted a feedback inhibition competitive with GSH (K-i = 0.48 mM).	TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,DEPT PHYSIOL CHEM,D-38124 BRAUNSCHWEIG,GERMANY; GESELL BIOTECHNOL FORSCH MBH,D-38124 BRAUNSCHWEIG,GERMANY	Braunschweig University of Technology; Gesellschaft fur Biotechnologische Forschung mbH								BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BAILEY S, 1993, EUR J BIOCHEM, V213, P67, DOI 10.1111/j.1432-1033.1993.tb17734.x; BOLLINGER JM, 1995, J BIOL CHEM, V270, P14031, DOI 10.1074/jbc.270.23.14031; BOVERIS A, 1980, BIOCHEM J, V188, P643, DOI 10.1042/bj1880643; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARNIERI EGS, 1993, MOL BIOCHEM PARASIT, V61, P79, DOI 10.1016/0166-6851(93)90160-Y; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DALZIEL K, 1969, BIOCHEM J, V114, P547, DOI 10.1042/bj1140547; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1985, MOL BIOCHEM PARASIT, V14, P187, DOI 10.1016/0166-6851(85)90037-4; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1996, BIOCHEMIST, P11; FLOHE L, 1985, HDB INFLAMMATION, P255; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; HENDERSON GB, 1987, MOL BIOCHEM PARASIT, V24, P39, DOI 10.1016/0166-6851(87)90113-7; Klebanoff S.J., 1978, CIBA F S, V65, P263, DOI 10.1002/9780470715413.ch15; KRAUTHSIEGEL RL, 1995, FASEB J, V9, P1138, DOI 10.1096/fasebj.9.12.7672506; Kwon DS, 1997, J BIOL CHEM, V272, P2429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETRANT N, 1983, J BIOL CHEM, V258, P125; Maiorino M, 1996, EUR J BIOCHEM, V238, P838, DOI 10.1111/j.1432-1033.1996.0838w.x; MENGE U, 1992, FRONTIERS BIOPROCESS, V2, P331; PENKETH PG, 1986, MOL BIOCHEM PARASIT, V20, P111, DOI 10.1016/0166-6851(86)90023-X; PENKETH PG, 1987, FEBS LETT, V221, P427, DOI 10.1016/0014-5793(87)80968-7; Rosengren A, 1977, ELECTROFOCUSING ISOT, P165; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; SHIM H, 1988, J GEN MICROBIOL, V134, P807; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; SMITH K, 1995, BIOCHEM J, V312, P465, DOI 10.1042/bj3120465; TABOR H, 1975, J BIOL CHEM, V250, P2648; URSINI F, 1995, METHOD ENZYMOL, V252, P38; WENDEL A, 1975, H-S Z PHYSIOL CHEM, V356, P33, DOI 10.1515/bchm2.1975.356.1.33; WENDEL A, 1973, GLUATHIONE, P69	34	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11908	11915		10.1074/jbc.272.18.11908	http://dx.doi.org/10.1074/jbc.272.18.11908			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115252	hybrid			2022-12-25	WOS:A1997WX56900040
J	Reid, RJD; Kauh, EA; Bjornsti, MA				Reid, RJD; Kauh, EA; Bjornsti, MA			Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-I; BINDING CASSETTE TRANSPORTER; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; CELL-LINE; SHUTTLE VECTORS; GENE; EXPRESSION; MUTATION; MUTANTS	The antineoplastic alkaloid camptothecin interferes with the catalytic cycle of DNA topoisomerase I rendering it a cellular poison, Camptothecin stabilizes a covalent enzyme-DNA intermediate that is converted into lethal double strand DNA lesions during S phase of the cell cycle. Yeast SCT1 mutants were isolated in a screen for mutations in genes other than TOP1 that result in camptothecin resistance. Here we report SCT1 is allelic to PDR1 and that a Thr-879 to Met substitution in the PDR1-101 transcription factor confers multiple drug resistance. PDR1 regulates the expression of several gene products including the ATP-binding cassette transmembrane transport proteins PDR5, YOR1, and SNQ2. The PDR1 T879M mutant increased PDR5 transcription compared with wild-type PDR1 strains, Deletion of PDR1 or the downstream effector SNQ2 increased cell sensitivity to camptothecin, whereas deletion of YOR1 or PDR5 had little effect on camptothecin sensitivity, However, the camptothecin resistance accompanying GAL1-promoted overexpression of PDR5 suggests some substrate promiscuity among the ATP-binding cassette transporters. These data underscore the role of the pleiotropic drug resistance network in regulating camptothecin toxicity and are consistent with a model of decreased intracellular concentrations of camptothecin resulting from the increased expression of the SNQ2 transporter.	THOMAS JEFFERSON UNIV, DEPT BIOCHEM & MOL PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Reid, Robert/AAR-1560-2020	Reid, Robert/0000-0002-7424-3537	NATIONAL CANCER INSTITUTE [R01CA057855, T32CA009678] Funding Source: NIH RePORTER; NCI NIH HHS [CA57855, CA09678] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Beidler DR, 1996, CANCER RES, V56, P345; BENEDETTI P, 1993, CANCER RES, V53, P4343; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BJORNSTI MA, 1994, CANCER CHEMOTH PHARM, V34, pS1, DOI 10.1007/BF00684856; Bjornsti MA, 1991, CURR OPIN STRUC BIOL, V1, P99, DOI 10.1016/0959-440X(91)90017-N; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CARON PR, 1993, MOL BIOL DNA TOPOISO, P243; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1991, CANCER RES, V51, P6039; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHEN WN, 1991, YEAST, V7, P287, DOI 10.1002/yea.320070311; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; ENG WK, 1988, MOL PHARMACOL, V34, P755; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; FUJIMORI A, 1995, CANCER RES, V55, P1339; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HENDRICKS CB, 1992, CANCER RES, V52, P2268; HORWITZ SB, 1973, CANCER RES, V33, P2834; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; LOGAN TJ, 1995, CANCER RES, V55, P2883; MADELAINE I, 1993, BIOCHEM PHARMACOL, V45, P339, DOI 10.1016/0006-2952(93)90069-9; MATTERN MR, 1993, ONCOL RES, V5, P467; MCQUIRE TM, 1995, GENE, V167, P151; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Moore DD, 1995, GLOB MOB SURV; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NITISS J, 1991, DNA TOPOISOMERASES C, P77; NITISS JL, 1992, CANCER RES, V52, P4467; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RILES L, 1993, GENETICS, V134, P81; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUBY SW, 1985, MOL CELL BIOL, V5, P75, DOI 10.1128/MCB.5.1.75; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIKORSKI RS, 1989, GENETICS, V122, P19; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; TSAO YP, 1992, CANCER RES, V52, P1823; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YANG CHJ, 1995, CANCER RES, V55, P4004; [No title captured]	61	59	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12091	12099		10.1074/jbc.272.18.12091	http://dx.doi.org/10.1074/jbc.272.18.12091			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115278	hybrid			2022-12-25	WOS:A1997WX56900066
J	Reveal, PM; Henkels, KM; Turchi, JJ				Reveal, PM; Henkels, KM; Turchi, JJ			Synthesis of the mammalian telomere lagging strand in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; RIBONUCLEASE-H; CALF THYMUS; PRIMASE COMPLEX; REPLICATION; INITIATION; CHECKPOINT; MECHANISM; EXTRACTS; REPAIR	Using a synthetic telomere DNA template and whole cell extracts, we have identified proteins capable of synthesizing the telomere complementary strand. Synthesis of the complementary strand required a DNA template consisting of 10 repeats of the human telomeric sequence d(TTAGGG) and deoxy- and ribonucleosidetriphosphates and was inhibited by neutralizing antibodies to DNA polymerase alpha. No evidence for RNA-independent synthesis of the lagging strand was observed, suggesting that a stable DNA secondary structure capable of priming the lagging strand is unlikely. Purified DNA polymerase alpha/primase was capable of catalyzing synthesis of the lagging strand with the same requirements as those observed in crude cell extracts. A ladder of products was observed with an interval of six bases, suggesting a unique RNA priming site and site-specific pausing or dissociation of polymerase cu on the d(T-TAGGG)(10) template. Removal of the RNA primers was observed upon the addition of purified RNase HI. By varying the input rNTP, the RNA priming site was determined to be opposite the 3' thymidine nucleotide generating a five-base RNA primer with the sequence 5'-AACCC. The addition of UTP did not increase the efficiency of priming and extension, suggesting that the five-base RNA primer is sufficient for extension with dNTPs by DNA polymerase alpha. This represents the first experimental evidence for RNA priming and DNA extension as the mechanism of mammalian telomeric lagging strand replication.	WRIGHT STATE UNIV,DEPT BIOCHEM & MOL BIOL,SCH MED,DAYTON,OH 45435	University System of Ohio; Wright State University Dayton			Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NCI NIH HHS [CA64374] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064374] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; DIFRANCESCO RA, 1985, J BIOL CHEM, V260, P4764; EDER PS, 1991, J BIOL CHEM, V266, P6472; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HAGEMEIER A, 1989, EUR J BIOCHEM, V185, P621, DOI 10.1111/j.1432-1033.1989.tb15158.x; HARRINGTON C, 1995, NUCLEIC ACIDS RES, V23, P1003, DOI 10.1093/nar/23.6.1003; HOHN KT, 1987, BIOCHEMISTRY-US, V26, P2870, DOI 10.1021/bi00384a031; KAGUNI LS, 1988, BIOCHIM BIOPHYS ACTA, V950, P87, DOI 10.1016/0167-4781(88)90001-2; Longhese MP, 1996, MOL CELL BIOL, V16, P3235; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Sambrook J., 2002, MOL CLONING LAB MANU; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waltz SE, 1996, NUCLEIC ACIDS RES, V24, P1887, DOI 10.1093/nar/24.10.1887; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; ZAHLER AM, 1989, NUCLEIC ACIDS RES, V17, P6299, DOI 10.1093/nar/17.15.6299	25	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11678	11681		10.1074/jbc.272.18.11678	http://dx.doi.org/10.1074/jbc.272.18.11678			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115215	hybrid			2022-12-25	WOS:A1997WX56900003
J	Liu, L; Damen, JE; Ware, MD; Krystal, G				Liu, L; Damen, JE; Ware, MD; Krystal, G			Interleukin-3 induces the association of the inositol 5-phosphatase SHIP with SHP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MITOGENIC SIGNAL-TRANSDUCTION; PHOSPHOTYROSINE PHOSPHATASE; RECEPTOR; KINASE; ACTIVATION; SH-PTP2; PHOSPHORYLATION; CORKSCREW; INSULIN	We recently purified and cloned a 145-kDa protein that becomes tyrosine phosphorylated and associated with She in response to multiple cytokines. Based on its predicated amino acid sequence and its enzymatic activity, we have called this protein SHIP, for Src homology a-containing inositol phosphatase. To gain further insight into the intracellular pathways that this putative signal transduction intermediate might regulate we have investigated whether SHIP binds to intracellular proteins other than She. The results presented herein demonstrate that following interleukin-3 stimulation, SHIP binds to the tyrosine phosphatase, SHP2 (also called Syp, PTP1D, SHPTP2, and PTP2C) and that Shc is not present in these SHIP-SHP2 complexes. Time course studies reveal that SHIP's association with SHP2 is transient and is maximal at 10 min of stimulation with interleukin-3. me further show that the association of SHIP with SHP2 occurs through the direct interaction of the SH2 domain of SHIP with a pYXN(I/V) sequence within SHP2.	UNIV BRITISH COLUMBIA,BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA	British Columbia Cancer Agency; University of British Columbia				Krystal, Gerald/0000-0002-1961-6281				Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Chacko GW, 1996, J IMMUNOL, V157, P2234; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; LIU Q, 1996, TYR PHOSPH CELL SIGN, P149; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MURTHY SC, 1989, BLOOD, V73, P1180; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TOKER A, 1994, J BIOL CHEM, V269, P32358; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	36	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					10998	11001						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9110989				2022-12-25	WOS:A1997WW00900005
J	Moormann, M; Zahringer, U; Moll, H; Kaufmann, R; Schmid, R; Altendorf, K				Moormann, M; Zahringer, U; Moll, H; Kaufmann, R; Schmid, R; Altendorf, K			A new glycosylated lipopeptide incorporated into the cell wall of a smooth variant of Gordona hydrophobica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIA; CHROMATOGRAPHY; PERFORMANCE; BIOFILTERS; ROUGH	A cell wall component of a smooth variant of Gordona hydrophobica 1775/15 was isolated and purified, and its structure was determined by various chemical methods, including chemical synthesis of part structures, Edman degradation, gas chromatography/mass spectrometry analysis, matrix-assisted laser desorption ionization-post-source decay (MALDI-PSD) tandem mass spectrometry, and H-1 and C-13 NMR using one- and two-dimensional, homo- and heteronuclear correlated spectroscopy. The cell wall component was found to be a (mono-) glycosylated peptidolipid (GPL) consisting of a tridecapeptide interlinked by a beta-hydroxylated fatty acid (3-hydroxyeicosanoic acid, 20:0 (3-OH) to form a cyclic lactone ring structure. The main fraction of GPL, for which we propose the name gordonin, was identified as 3-hydroxyeicosanoyl-L-seryl-L-phenylalanyl-L-seryl-L-seryl-D-alanyl-L-(O-beta-D-glucopyranosyl)-threyonyl-glycyl-D-leucyl-L-valyl-L-seryl-L-phenylalanyl-glycyl-L-valyl lactone. The other GPLs constitute structural variations within the nature of the beta-hydroxylated fatty acid (20:0(3-OH) versus 22:1(3-OH)) in a ratio of about 1:0.9 as well as within one amino acid (D-Leu versus L-Phe) in about 30%. Sequence information was obtained in part by Edman degradation as well as gas chromatography/mass spectrometry analysis of di- and tripeptide fragments. However, the complete amino acid sequence could only be established by MALDI-PSD from the linear molecule, i.e. after ring opening of the lactone. In contrast, rough variants of G. hydrophobica 1775/15 lack these peptidolipids or synthesize them to a much lesser extent indicating that gordonin contributes significantly to the physicochemical character of the cell surface.	UNIV OSNABRUCK, ABT MIKROBIOL, D-49069 OSNABRUCK, GERMANY; FORSCHUNGSZENTRUM BORSTEL, DIV IMMUNOCHEM, D-23845 BORSTEL, GERMANY; UNIV DUSSELDORF, INST LASERMED, D-40001 DUSSELDORF, GERMANY; UNIV DUSSELDORF, BIOL MED FORSCHUNGSZENTRUM, D-40001 DUSSELDORF, GERMANY	University Osnabruck; Forschungszentrum Borstel; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf								ARIMA K, 1968, BIOCHEM BIOPH RES CO, V31, P488, DOI 10.1016/0006-291X(68)90503-2; ASSELINEAU J, 1991, PROGR CHEM ORGANIC N, P1; AYDIN M, 1985, LIEBIGS ANN CHEM, P2285; BARROW WW, 1982, J BACTERIOL, V150, P381, DOI 10.1128/JB.150.1.381-384.1982; BELISLE JT, 1989, J BACTERIOL, V171, P3465, DOI 10.1128/jb.171.6.3465-3470.1989; BENDINGER B, 1993, APPL ENVIRON MICROB, V59, P3973, DOI 10.1128/AEM.59.11.3973-3977.1993; BENDINGER B, 1995, INT J SYST BACTERIOL, V45, P544, DOI 10.1099/00207713-45-3-544; BENDINGER B, 1992, INT J SYST BACTERIOL, V42, P474, DOI 10.1099/00207713-42-3-474; Berger S., 1984, 13C NMR SPEKTROSKOPI; BODANSZKY M, 1973, J AM CHEM SOC, V95, P2352, DOI 10.1021/ja00788a040; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; CAMPHAUSEN RT, 1987, J BACTERIOL, V169, P5473, DOI 10.1128/jb.169.12.5473-5480.1987; DAFFE M, 1990, J BIOL CHEM, V265, P6734; Dobson G., 1985, CHEM METHODS BACTERI, P237; FREGNAN GB, 1962, J BACTERIOL, V83, P828, DOI 10.1128/JB.83.4.828-836.1962; HASE S, 1976, EUR J BIOCHEM, V63, P101, DOI 10.1111/j.1432-1033.1976.tb10212.x; HASENBOHLER A, 1974, ARCH MICROBIOL, V99, P307, DOI 10.1007/BF00696245; KAUFMANN R, 1994, INT J MASS SPECTROM, V131, P355, DOI 10.1016/0168-1176(93)03876-N; KOCHHAR S, 1989, ANAL BIOCHEM, V178, P17, DOI 10.1016/0003-2697(89)90348-5; KONIG WA, 1976, LIEBIGS ANN CHEM, P2011; KORONELLI TV, 1988, J CHROMATOGR, V440, P479, DOI 10.1016/S0021-9673(00)94553-9; LIPSKI A, 1995, THESIS U OSNABRUECK; MERSCHEL L, 1997, IN PRESS SECONDARY I; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; MINNIKIN DE, 1984, BIOL ACTINOMYCETES, P337; Minnikin DE, 1987, CHEMOTHERAPY TROPICA, P19; MORIKAWA M, 1993, J BACTERIOL, V175, P6459, DOI 10.1128/JB.175.20.6459-6466.1993; NAKAJIMA M, 1978, J ANTIBIOT, V31, P426, DOI 10.7164/antibiotics.31.426; NIEHUIS E, 1987, J VAC SCI TECHNOL A, V5, P1243, DOI 10.1116/1.574781; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; RYHAGE RAGNAR, 1960, JOUR LIPID RES, V1, P361; VILKAS E, 1963, BIOCHIM BIOPHYS ACTA, V70, P217, DOI 10.1016/0926-6542(63)90034-9; WEYGAND F, 1965, Z NATURFORSCH PT B, VB 20, P1169	33	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10729	10738						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099723				2022-12-25	WOS:A1997WV26200057
J	Felts, SJ; Stang, MT; Getz, MJ				Felts, SJ; Stang, MT; Getz, MJ			A c-Fos- and E1A-interacting component of the tissue factor basal promoter complex mediates synergistic activation of transcription by transforming growth factor-beta 1	ONCOGENE			English	Article						tissue factor; TGF-beta 1; c-Fos; transcriptional coactivators	NUCLEAR-PROTEIN CBP; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; E1A; COACTIVATOR; FAMILY; CREB; STIMULATION; COAGULATION	Stimulation of quiescent mouse fibroblasts with TGF-beta 1 and certain other growth factors result in cooperative activation of tissue factor (TF) gene transcription, an event accompanied by the rapid entry of c-Fos into specific AP-1 DNA-binding complexes (Felts et al, (1995) Biochemistry 34, 12355-12362), Here, we demonstrate that the ability of TGF-beta 1 to synergistically activate TF transcription in serum-stimulated fibroblasts is dependent upon both c-Fos and a promoter-specific factor with functional properties characteristic of transcriptional coactivators. Inhibition of TF promoter activity by an adenovirus E1A mutant deleted in an essential CREB binding protein (CBP) interaction domain suggests that this factor is distinct from the CBP/p300 family of transcriptional coactivators. Importantly, the ability of this factor to mediate molecular interactions with c-Fos required for transcriptional synergism is directly linked to TGF-beta 1 signaling. These data suggest a model in which a component of the TF basal transcription complex functions to integrate multiple signaling pathways required for full transcriptional activation of TF in fibroblasts.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,PROGRAM TUMOR BIOL,ROCHESTER,MN 55905	Mayo Clinic					NCI NIH HHS [CA65800-01E] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBEAU D, 1994, ONCOGENE, V9, P359; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACKMAN N, 1992, ARTERIOSCLER THROMB, V12, P474, DOI 10.1161/01.ATV.12.4.474; Martin ML, 1996, MOL CELL BIOL, V16, P2110; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; RANGANATHAN G, 1990, J BIOL CHEM, V265, P3001; RANGANATHAN G, 1991, J BIOL CHEM, V266, P496; RAO LVM, 1992, CANCER METAST REV, V11, P249; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Vrana JA, 1996, CANCER RES, V56, P5063; WARR TA, 1990, BLOOD, V75, P1481; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	45	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1679	1685		10.1038/sj.onc.1201006	http://dx.doi.org/10.1038/sj.onc.1201006			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135069				2022-12-25	WOS:A1997WR89300006
J	Servillo, G; Penna, L; Foulkes, NS; Magni, MV; DellaFazia, MA; SassoneCorsi, P				Servillo, G; Penna, L; Foulkes, NS; Magni, MV; DellaFazia, MA; SassoneCorsi, P			Cyclic AMP signalling pathway and cellular proliferation: Induction of CREM during liver regeneration	ONCOGENE			English	Article						cAMP; CREM; CREB; liver regeneration; proliferation; early response	PROTO-ONCOGENE EXPRESSION; LONG-TERM DESENSITIZATION; GENE-TRANSCRIPTION; TYROSINE AMINOTRANSFERASE; PARTIAL-HEPATECTOMY; GROWTH-FACTOR; RAT-LIVER; BINDING; CAMP; PHOSPHORYLATION	The CREM gene encodes both activators and repressors of cAMP-induced gene expression, An isoform of CREM encodes the powerful transcriptional repressor ICER (Inducible cAMP Early Repressor), which has been shown to be inducible by virtue of an alternative, intronic promoter, The CREM gene belongs to the early response class and displays a characteristic neuroendocrine cell- and tissue-specific expression, To date ICER inducibility has in non-replicating, terminally differentiated In this paper we document a robust induction of CREM expression in the regenerating rat liver after partial hepatectomy. This represents the first link of inducible CREM expression to the phenomenon of cellular proliferation, Furthermore, it represents the first example of transcriptional activation of a cAMP-responsive factor in the regenerating liver, This has significant physiological relevance since the adenylate cyclase signalling pathway is strongly implicated in liver regeneration, Finally, we show that the repressor ICER is inducible in the hepatoma cell line H35 upon activation of the adenylate cyclase and phosphorylation of the activator CREB.	INST GENET & BIOL MOL & CELLULAIRE, CNRS, INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV PERUGIA, MONTELUCE POLICLIN, INST PATOL GEN, I-06100 PERUGIA, ITALY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Perugia			Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891; Servillo, Giuseppe/0000-0001-7960-7689; Della Fazia, Maria Agnese/0000-0002-5373-8477				BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELLAFAZIA MA, 1992, BIOCHEM BIOPH RES CO, V182, P753, DOI 10.1016/0006-291X(92)91796-S; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; DIEHL AM, 1992, J CLIN INVEST, V89, P1706, DOI 10.1172/JCI115771; EKANGER R, 1989, J BIOL CHEM, V264, P4374; Fausto Nelson, 1994, P1059; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; GARCIASAINZ JA, 1989, AM J PHYSIOL, V256, pC384, DOI 10.1152/ajpcell.1989.256.2.C384; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOUSLAY MD, 1986, BIOCHEM SOC T, V14, P183, DOI 10.1042/bst0140183; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LALLI E, 1994, J BIOL CHEM, V269, P17359; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEFFERT HL, 1988, LIVER BIOL PATHOBIOL, P833; MACMANUS JP, 1972, BIOCHEM BIOPH RES CO, V49, P1201, DOI 10.1016/0006-291X(72)90596-7; Maniatis T, 1989, MOL CLONING; MCGOWAN JA, 1981, J CELL PHYSIOL, V108, P353, DOI 10.1002/jcp.1041080309; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; TAUB R, 1987, J BIOL CHEM, V262, P10893; TOMLINSON S, 1985, CLIN ENDOCRINOL, V23, P595, DOI 10.1111/j.1365-2265.1985.tb01120.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	45	51	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1601	1606		10.1038/sj.onc.1200996	http://dx.doi.org/10.1038/sj.onc.1200996			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129151				2022-12-25	WOS:A1997WQ54800011
J	Li, Y; Mangasarian, K; Mansukhani, A; Basilico, C				Li, Y; Mangasarian, K; Mansukhani, A; Basilico, C			Activation of FGF receptors by mutations in the transmembrane domain	ONCOGENE			English	Article						achondroplasia; differentiation; cell transformation; receptor phosphorylation	FIBROBLAST-GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; MYOGENIC DIFFERENTIATION; TARGETED EXPRESSION; POINT MUTATION; ACHONDROPLASIA; FAMILY; GENE; PHOSPHORYLATION; PROLIFERATION	Signaling through FGF receptors, which constitute a family of membrane-spanning tyrosine kinases, can stimulate cell proliferation, induce or inhibit cell differentiation and plays an important role in development. Recently, mutations in FGF receptors have been shown to be associated with a number of genetically dominant human skeletal disorders. A remarkably conserved mutation (Gly 380-->Arg) in the transmembrane region of FGFR-3 has been shown to be responsible for achondroplasia (ACH) but it was not clear whether such mutations result in loss of receptor function or constitutive activation. We have therefore made mutations in the transmembrane regions of murine FGFR-2 and FGFR-3 and studied their effect on receptor activity. We show here that the ACH mutation in FGFR-3 as well as two similar mutations in FGFR-2 result in constitutive activation of these receptors. This is manifested in their ability to become autophosphorylated in the absence of ligand in L6 cells, transforming activity on NIH3T3 fibroblasts, and the ability to inhibit myogenic differentiation in the absence of growth factor. Thus the transmembrane region of FGFR-2 and FGFR-3 plays a regulatory role in receptor function and the ACH mutation produces a dominant oversignaling receptor which is no longer regulated by FGF binding. These findings also support the newly identified role of FGF signaling as a negative regulator of bone growth.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				Mansukhani, Alka/0000-0003-1020-3242	NCI NIH HHS [CA42568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Campochiaro PA, 1996, J NEUROSCI, V16, P1679; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FOX JC, 1994, MOL CELL BIOL, V14, P4244, DOI 10.1128/MCB.14.6.4244; IANNOTTI JP, 1994, GROWTH PLATE BONE DE, P185; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO Y, 1990, J BIOL CHEM, V265, P5903; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LONARDO F, 1990, New Biologist, V2, P992; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MIMA T, 1995, P NATL ACAD SCI USA, V92, P467, DOI 10.1073/pnas.92.2.467; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STANESCU R, 1990, AM J MED GENET, V37, P412, DOI 10.1002/ajmg.1320370323; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	45	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1397	1406		10.1038/sj.onc.1200983	http://dx.doi.org/10.1038/sj.onc.1200983			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136983				2022-12-25	WOS:A1997WT58400002
J	Vedrenne, J; Assier, E; Pereno, R; BouzinbaSegard, H; Azzarone, B; Jasmin, C; Charron, D; Krief, P				Vedrenne, J; Assier, E; Pereno, R; BouzinbaSegard, H; Azzarone, B; Jasmin, C; Charron, D; Krief, P			Inhibitor (IK) of IFN-gamma induced HLA class II antigens expression also inhibits HLA class II constitutive expression in the human Raji B cell line	ONCOGENE			English	Article						MHC class II; IK; CIITA; IFN-gamma	BARE LYMPHOCYTE SYNDROME; DEFICIENT COMBINED IMMUNODEFICIENCY; TRANSACTIVATOR GENE CIITA; MONOCLONAL-ANTIBODIES; TRANSCRIPTION; SEQUENCES; CLONING	The expression of major histocompatibility complex (MHC) class II antigens is constitutive in professional antigen presenting cells (APCs) but can also be induced by interferon-gamma (IFN-gamma) on the majority of the non professional APCs (e.g. fibroblasts). We have recently characterised a new factor called IK which is an efficient inhibitor of IFN-gamma induction of MHC class II antigens expression. Here, we demonstrate a novel role for IK in MHC class II expression since over-expression of this protein by stable transfection into human B cells led to a total disappearance of constitutive MHC class II mRNA expression. The class II transactivator (CIITA) is necessary for both constitutive and IFN-gamma induced MHC class II expressions. Examination of CIITA mRNA in IK stably transfected clones revealed a marked reduction of CIITA mRNA transcription. Taken together these results demonstrate that the IK protein plays a keg role in the constitutive expression of MHC class II antigens and that inhibition induced by IK is upstream of CIITA in this regulatory pathway.	HOP PAUL BROUSSE,INSERM U268,F-94807 VILLEJUIF,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vedrenne, J (corresponding author), INSERM U396,INST BIOMED CORDELIERS,15 RUE ECOLE MED,F-75006 PARIS,FRANCE.		Azzarone, Bruno/AAH-9251-2019; Krief, Patricia/M-6073-2014	Azzarone, Bruno/0000-0002-5962-3849; Krief, Patricia/0000-0001-5106-466X; Assier, Eric/0000-0001-8366-1645				ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BROWN JA, 1995, IMMUNOGENETICS, V43, P88; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEPREVAL C, 1988, NEW ENGL J MED, V318, P1295, DOI 10.1056/NEJM198805193182003; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Griscelli C, 1989, Immunodefic Rev, V1, P135; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KRIEF P, 1994, ONCOGENE, V9, P3449; KRIEF P, 1987, EUR J IMMUNOL, V17, P1021, DOI 10.1002/eji.1830170719; MACH B, 1994, IMMUNOL REV, V138, P207, DOI 10.1111/j.1600-065X.1994.tb00853.x; PERROT JY, 1986, SCAND J IMMUNOL, V23, P623, DOI 10.1111/j.1365-3083.1986.tb01997.x; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEED JL, 1987, P NATL ACAD SCI USA, V84, P3305; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P410; TOURAINE JL, 1985, EXP HEMATOL, V13, P86; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9	26	13	15	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1453	1461		10.1038/sj.onc.1200971	http://dx.doi.org/10.1038/sj.onc.1200971			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136989				2022-12-25	WOS:A1997WT58400008
J	Zatsepina, O; Braspenning, J; Robberson, D; Hajibagheri, MAN; Blight, KJ; Ely, S; Hibma, M; Spitkovsky, D; Trendelenburg, M; Crawford, L; Tommasino, M				Zatsepina, O; Braspenning, J; Robberson, D; Hajibagheri, MAN; Blight, KJ; Ely, S; Hibma, M; Spitkovsky, D; Trendelenburg, M; Crawford, L; Tommasino, M			The human papillomavirus type 16 E7 protein is associated with the nucleolus in mammalian and yeast cells	ONCOGENE			English	Article						HPV; E7 protein; cellular localisation; nucleolus; mammalian and yeast cells	RETINOBLASTOMA GENE-PRODUCT; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; NUCLEAR; E2F; LOCALIZATION; E7-PROTEIN; SEQUENCES; THIAMINE	In this study we show, by immunofluorescence and electron microscopy immune-gold labelling, that the major transforming protein of Human Papillomavirus type 16 E7 is associated with the nucleolus of cells derived from the HPV16-positive cervical carcinoma line CaSki. The E7 nucleolar staining appeared to be cell cycle dependent, being considerably reduced in the G(2) phase. The total level of the protein in the cell, however, remained constant during all phases, We also show that the cellular protein Rb1, which is targeted by E7, is localised in the nucleus and nucleolus in CaSki cells. Thus, it is possible that the presence of E7 in the nucleolus correlates with a hypothetical function(s) of Rb1 in this particular intranuclear compartment. The nucleolar localisation of HPV16 E7 protein was also observed in the fission yeast Schizosaccharomyces pombe, suggesting that a targeting mechanism of HPV16 E7 protein into the nucleolus is common to both mammalian and yeast systems, Nucleolar localisation of HPV16 E7 protein may be independent from Rb1 since no Rb1 related proteins have been identified in fission yeast.	DEUTSCH KREBSFORSCHUNGSZENTRUM, ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; DEUTSCH KREBSFORSCHUNGSZENTRUM, BIOMED STRUKTURFORSCH, D-69120 HEIDELBERG, GERMANY; ST MARYS HOSP, SCH MED, WRIGHT FLEMING INST, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND; UNIV OTAGO, DEPT MICROBIOL, HRC VIRUS RES UNIT, DUNEDIN, NEW ZEALAND	Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK; Helmholtz Association; German Cancer Research Center (DKFZ); Imperial College London; University of Otago			Zatsepina, Olga/O-8753-2015; Spitkovsky, Dimitry/ABA-1605-2020	Zatsepina, Olga/0000-0001-5114-1127; 				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CICCOLINI F, 1994, ONCOGENE, V9, P2633; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEFEOJONES D, 1993, J VIROL, V67, P716, DOI 10.1128/JVI.67.2.716-725.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HU TH, 1995, INT J ONCOL, V6, P167; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; SATO H, 1989, VIROLOGY, V170, P311, DOI 10.1016/0042-6822(89)90386-3; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; TOMMASINO M, 1993, ONCOGENE, V8, P195; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TOMMASINO M, 1990, GENE, V93, P265, DOI 10.1016/0378-1119(90)90234-I; TOMMASINO M, 1991, CURR GENET, V20, P63, DOI 10.1007/BF00312766; TOMMASINO M, 1992, GENE, V111, P93, DOI 10.1016/0378-1119(92)90607-Q	34	25	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1137	1145		10.1038/sj.onc.1200946	http://dx.doi.org/10.1038/sj.onc.1200946			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121762				2022-12-25	WOS:A1997WM78200002
J	Barbeau, B; Bernier, R; Dumais, N; Briand, G; Olivier, M; Faure, R; Posner, BI; Tremblay, M				Barbeau, B; Bernier, R; Dumais, N; Briand, G; Olivier, M; Faure, R; Posner, BI; Tremblay, M			Activation of HIV-1 long terminal repeat transcription and virus replication via NF-kappa B-dependent and -independent pathways by potent phosphotyrosine phosphatase inhibitors, the peroxovanadium compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-TYROSINE-PHOSPHATASE; T-CELL ACTIVATION; ANTIGEN RECEPTOR; GENE-EXPRESSION; PHOSPHORYLATION; ALPHA; KINASE; LINE; CD45	Replication of human immunodeficiency virus type 1 (HIV-1) is increased by different cytokines and T cell activators, also known to modulate tyrosine phosphorylation levels, A novel class of protein tyrosine phosphatase (PTP) inhibitors, peroxovanadium (pV) compounds, were tested for a putative effect on HIV-1 long terminal repeat (LTR) activity, We found that these PTP inhibitors markedly enhanced HIV-1 LTR activity in 1G5 cells, a stably transfected cell line that harbors an HIV-1 LTR-driven luciferase construct, A direct correlation between the extent of tyrosine phosphorylation and the level of HIV-1 LTR inducibility was seen after treatment with three different pV compounds, Transient transfection experiments were carried out in several T cell lines, and after addition of pV, a marked increase in HIV-1 LTR activity was measured, Monocytoid cells were tested using U937-derived cell lines and were also found to be sensitive to the pV-mediated potentiating effect on HIV-1 LTR activity, A significant reduction of the pV-mediated increase in HIV-1 LTR activity was seen in cells transiently transfected with an HIV-1 LTR-driven luciferase construct bearing a mutation in both NF-kappa B binding sites although detectable levels of induction remained, Electrophoretic mobility shift assays allowed the identification of the nuclear translocation of the NF-kappa B p50.p65 heterodimer complex induced by pV compounds, A dominant negative version of the repressor I kappa B alpha mutated on serines 32 and 36 impeded pV-induced NF-kappa B-dependent luciferase activity, Western blot analysis showed a clear diminution in the protein level of I kappa B alpha starting 30 min after pV treatment of Jurkat E6.1 cells which is indicative of its degradation, On the other hand, no increase in tyrosine phosphorylation was ob sewed on I kappa B alpha itself, Finally, we tested the PTP inhibitors on four cell lines latently infected with HIV-1 and showed a consistent pV-mediated increase in virion production, Thus, our studies suggest that pV-mediated activation of HIV-1 LTR activity is controlled by the nuclear translocation of the NF-kappa B transcription factor, which is mediated by I kappa B alpha serine phosphorylation and degradation, but also by a still undefined NF-kappa B-independent pathway.	UNIV LAVAL,CTR RECH INFECTIOL,FAC MED,CTR HOSP UNIV QUEBEC,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,DEPT MICROBIOL,FAC MED,CTR HOSP UNIV QUEBEC,UNITE RECH PEDIAT,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,DEPT MED,FAC MED,CTR HOSP UNIV QUEBEC,ST FOY,PQ G1V 4G2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA	Laval University; Laval University; Laval University; McGill University			Barbeau, Benoit/A-1174-2010; Posner, Barry/B-6733-2008	Barbeau, Benoit/0000-0002-4108-8155; 				AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANTONI BA, 1994, ADV VIRUS RES, V43, P53, DOI 10.1016/S0065-3527(08)60047-0; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAUR A, 1994, J IMMUNOL, V152, P976; BERNIER R, 1995, J VIROL, V69, P291, DOI 10.1128/JVI.69.1.291-300.1995; Berube P, 1996, J VIROL, V70, P4009; BISWAS DK, 1994, MOL MED, V1, P31; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUTERA ST, 1991, J VIROL, V65, P4645, DOI 10.1128/JVI.65.9.4645-4653.1991; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V3, P372; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CLOUSE KA, 1989, J IMMUNOL, V142, P431; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HOHASHI N, 1995, INT IMMUNOL, V7, P1851, DOI 10.1093/intimm/7.11.1851; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kazazi F, 1996, FREE RADICAL BIO MED, V20, P813, DOI 10.1016/0891-5849(95)02214-7; KIKUKAWA R, 1986, J VIROL, V57, P1159, DOI 10.1128/JVI.57.3.1159-1162.1986; KOONG AC, 1994, CANCER RES, V54, P1425; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LAUGHLIN MA, 1995, J ACQ IMMUN DEF SYND, V9, P332; Lee JM, 1996, ONCOGENE, V12, P253; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MENON SD, 1995, J BIOL CHEM, V270, P18881; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MOSIER D, 1994, IMMUNOL TODAY, V15, P332, DOI 10.1016/0167-5699(94)90081-7; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PEREZ VL, 1991, J IMMUNOL, V147, P3145; POSNER BI, 1994, J BIOL CHEM, V269, P4596; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Sun SC, 1996, MOL CELL BIOL, V16, P1058; THEVENIN C, 1990, New Biologist, V2, P793; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WINSLOW BJ, 1993, VIROLOGY, V196, P849, DOI 10.1006/viro.1993.1545	57	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12968	12977		10.1074/jbc.272.20.12968	http://dx.doi.org/10.1074/jbc.272.20.12968			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148903	hybrid			2022-12-25	WOS:A1997WZ38400016
J	Biswas, I; Hsieh, P				Biswas, I; Hsieh, P			Interaction of MutS protein with the major and minor grooves of a heteroduplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING DEOXYTRIDECANUCLEOTIDE DUPLEXES; NUCLEAR-MAGNETIC-RESONANCE; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; MISMATCH-REPAIR; FLANKING SEQUENCE; DEOXYOLIGONUCLEOTIDE DUPLEX; CONFORMATIONAL TRANSITIONS; ENCODED PROTEIN; BASE-PAIRS	Thermus aquaticus MutS protein is a DNA mismatch repair protein that recognizes and binds to heteroduplex DNAs containing mispaired or unpaired bases. Using enzymatic and chemical probe methods, we have examined the binding of Tag MutS protein to a heteroduplex DNA having a single unpaired thymidine residue. DNase I footprinting identifies a symmetrical region of protection 24-28 nucleotides long centered on the unpaired base. Methylation protection and interference studies establish that Tag MutS protein makes contacts with the major groove of the heteroduplex in the immediate vicinity of the unpaired base. Hydroxyl radical and 1,10-phenanthroline-copper footprinting experiments indicate that MutS also interacts with the minor groove near the unpaired base. Together with the identification of key phosphate groups detected by ethylation interference, these data reveal critical contact points residing in the major and minor grooves of the heteroduplex DNA.	NIDDK,GENET & BIOCHEM BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ABOULELA F, 1993, J MOL BIOL, V229, P173, DOI 10.1006/jmbi.1993.1016; BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; Biswas I, 1996, J BIOL CHEM, V271, P5040; Dizdaroglu M., 1993, DNA FREE RADICALS, P19; FAZAKERLEY GV, 1986, EMBO J, V5, P3697, DOI 10.1002/j.1460-2075.1986.tb04702.x; HANAWALT PC, 1993, MUTAT RES, V289, P7, DOI 10.1016/0027-5107(93)90125-Y; HUNTER WN, 1992, METHOD ENZYMOL, V211, P221; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JONES M, 1987, GENETICS, V115, P605; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P294, DOI 10.1021/bi00427a040; KALNIK MW, 1990, J BIOL CHEM, V265, P636; KALNIK MW, 1989, J BIOL CHEM, V264, P3702; KAPPEN LS, 1992, BIOCHEMISTRY-US, V31, P9081, DOI 10.1021/bi00152a052; KENNARD O, 1985, J BIOMOL STRUCT DYN, V3, P205, DOI 10.1080/07391102.1985.10508412; KENNARD O, 1993, J BIOL CHEM, V268, P10701; KIMBALL AS, 1995, NUCLEIC ACIDS RES, V23, P3009, DOI 10.1093/nar/23.15.3009; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KUNKEL TA, 1995, CURR BIOL, V5, P1091, DOI 10.1016/S0960-9822(95)00218-1; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MORDEN KM, 1990, BIOCHEMISTRY-US, V29, P8835, DOI 10.1021/bi00489a047; MORDEN KM, 1983, BIOCHEMISTRY-US, V22, P5557, DOI 10.1021/bi00293a016; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; NIKONOWICZ E, 1989, BIOCHEMISTRY-US, V28, P8714, DOI 10.1021/bi00448a007; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; PALACEK E, 1992, METHOD ENZYMOL, V212, P139; Patel D.J., 1987, NUCL ACIDS MOL BIOL, V1, P70; PATEL DJ, 1987, ANNU REV BIOPHYS BIO, V16, P423; PATEL DJ, 1984, BIOCHEMISTRY-US, V23, P3218, DOI 10.1021/bi00309a016; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RICE JA, 1989, BIOCHEMISTRY-US, V28, P4512, DOI 10.1021/bi00436a058; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4004, DOI 10.1021/bi00131a016; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SELVA EM, 1995, GENETICS, V139, P1175; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; Turner DH, 1992, CURR OPIN STRUC BIOL, V2, P334; VANDENHOOGEN YT, 1988, NUCLEIC ACIDS RES, V16, P2971, DOI 10.1093/nar/16.7.2971; WANG YH, 1991, BIOCHEMISTRY-US, V30, P1358, DOI 10.1021/bi00219a028; WERNTGES H, 1986, NUCLEIC ACIDS RES, V14, P3773, DOI 10.1093/nar/14.9.3773; WOODSON SA, 1988, BIOCHEMISTRY-US, V27, P3130, DOI 10.1021/bi00409a004; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	49	39	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13355	13364		10.1074/jbc.272.20.13355	http://dx.doi.org/10.1074/jbc.272.20.13355			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148958	hybrid			2022-12-25	WOS:A1997WZ38400071
J	Horio, Y; Hibino, H; Inanobe, A; Yamada, M; Ishii, M; Tada, Y; Satoh, E; Hata, Y; Takai, Y; Kurachi, Y				Horio, Y; Hibino, H; Inanobe, A; Yamada, M; Ishii, M; Tada, Y; Satoh, E; Hata, Y; Takai, Y; Kurachi, Y			Clustering and enhanced activity of an inwardly rectifying potassium channel, Kir4.1, by an anchoring protein, PSD-95/SAP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; GLIAL-CELLS; HOMOLOG; GENE; FAMILY; SAP90	An inwardly rectifying potassium channel predominantly expressed in glial cells, Kir4.1/K-AB-2, has a sequence of Ser-Asn-Val in its carboxyl-terminal end, suggesting a possible interaction with an anchoring protein of the PSD-95 family. We examined the effects of PSD-95 on the distribution and function of Kir4.1 in a mammalian cell line. When Kir4.1 was expressed alone, the channel immunoreactivity was distributed homogeneously. In contrast, when co-expressed with PSD-95, prominent clustering of Kir4.1 in the cell membrane occurred, Kir4.1 was co-immunoprecipitated with PSD-95 in the co-expressed cells. Glutathione S-transferase-fusion protein of COOH terminus of Kir4.1 bound to PSD-95, These interactions disappeared when the Ser-Asn-Val motif was deleted. The magnitude of whole-cell Kir4.1 current was increased by a-fold in cells co-expressing Kir4.1 and PSD-95 compared with cells expressing Kir4.1 alone, SAP97, another member of the PSD-95 family, showed similar effects on Kir4.1. Furthermore, we found that Kir4.1 as well as SAP97 distributed not diffusely but clustered in retinal glial cells, Therefore, PSD-95 family proteins may be a physiological regulator of the distribution and function of Kir4.1 in glial cells.	OSAKA UNIV,FAC MED,DEPT PHARMACOL 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC MED,DEPT BIOCHEM & MOL BIOL,SUITA,OSAKA 565,JAPAN; YAMAGATA UNIV,SCH MED,DEPT CELL SIGNALING,YAMAGATA 99323,JAPAN; AKITA UNIV,SCH MED,DEPT PHARMACOL,AKITA 010,JAPAN; JAPAN SCI & TECHNOL CORP,ERATO,TAKAI BIOTIMER PROJECT,KOBE,HYOGO 65122,JAPAN	Osaka University; Osaka University; Yamagata University; Akita University; Japan Science & Technology Agency (JST)			Ishii, Masaru/D-2361-2009	Horio, Yoshiyuki/0000-0002-5021-5929				BLACK JA, 1990, TRENDS NEUROSCI, V13, P48, DOI 10.1016/0166-2236(90)90068-L; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; GERMINO FJ, 1993, P NATL ACAD SCI USA, V90, P933, DOI 10.1073/pnas.90.3.933; Horio Yoshiyuki, 1996, Journal of General Physiology, V108, p23A; Ito M, 1996, FEBS LETT, V388, P11, DOI 10.1016/0014-5793(96)00502-9; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kleiman RJ, 1996, CELL, V85, P461, DOI 10.1016/S0092-8674(00)81245-3; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; NEWMAN EA, 1987, J NEUROSCI, V7, P2423; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788, DOI 10.1152/jn.1966.29.4.788; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yamashita T, 1996, J PHYSIOL-LONDON, V493, P143, DOI 10.1113/jphysiol.1996.sp021370; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	20	115	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12885	12888		10.1074/jbc.272.20.12885	http://dx.doi.org/10.1074/jbc.272.20.12885			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148889	hybrid			2022-12-25	WOS:A1997WZ38400002
J	Wassmann, K; Ammerer, G				Wassmann, K; Ammerer, G			Overexpression of the G(1)-cyclin gene CLN2 represses the mating pathway in Saccharomyces cerevisiae at the level of the MEKK ste11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE-RESPONSE PATHWAY; YEAST-CELL CYCLE; SIGNAL-TRANSDUCTION PATHWAY; BUDDING YEAST; PROTEIN-KINASE; FACTOR RECEPTOR; GTPASE CDC42; G1 CYCLINS; A-FACTOR; S-PHASE	Basal and induced transcription of pheromone-dependent genes is regulated in a cell cycle dependent way, FUS1, a gene strongly induced after pheromone treatment, shows high mRNA levels in mitosis and early G(1) phase of the cell cycle, a decrease in G(1) after START and again an increase in S phase, Overexpression of CLN2 was shown to repress the transcript number of pheromone dependent genes (1), We asked whether the activities of components of the mating pathway fluctu ate during the cell cycle. We were also interested in determining at what level Cln2 represses the signal transduction machinery, Here we show that the activity of the mitogen-activated protein kinase Fus3 indeed fluctuates during the cell cycle, reflecting the oscillations of the gene transcripts. CLN2 overexpression represses Fus3 kinase activity, independently of the phosphatase Msg5. Additionally, we show that the activity of the MEK Ste7 also fluctuates during the cell cycle, Increased Cln2 levels repress the ability of hyperactive STE11 alleles to induce the pathway, G protein-independent activation of Ste11 caused by an rga1 pbs2 mutation is resistant to high levels of Cln2 kinase, Therefore our results suggest that Cln2-dependent repression of the mating pathway occurs at the level of Ste11.	UNIV VIENNA,LUDWIG BOLTZMANN FORSCHUNGSSTELLE,INST BIOCHEM & MOL CELL BIOL,A-1030 VIENNA,AUSTRIA	Ludwig Boltzmann Institute; University of Vienna				Wassmann, Katja/0000-0001-5442-5192				AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BENTON BK, 1993, EMBO J, V12, P5267, DOI 10.1002/j.1460-2075.1993.tb06222.x; BLINDER D, 1989, MOL CELL BIOL, V9, P3720, DOI 10.1128/MCB.9.9.3720; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; FUTCHER BA, 1991, SEMIN CELL BIOL, V2, P205; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HICKS JB, 1976, GENETICS, V83, P245; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MCKINNEY JD, 1995, MOL CELL BIOL, V15, P2509; MIHAJIMA I, 1987, CELL, V60, P1011; Nasmyth K, 1995, HARVEY LECT, V88, P141; OEHLEN LJWM, 1994, GENE DEV, V8, P1058, DOI 10.1101/gad.8.9.1058; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Sambrook J., 2002, MOL CLONING LAB MANU; Sherman F., 1982, METHODS YEAST GENETI; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZANOLARI B, 1991, MOL CELL BIOL, V11, P5251, DOI 10.1128/MCB.11.10.5251; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	68	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13180	13188		10.1074/jbc.272.20.13180	http://dx.doi.org/10.1074/jbc.272.20.13180			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148934	hybrid			2022-12-25	WOS:A1997WZ38400047
J	Coates, K; Cooke, SJ; Mann, DA; Harris, MPG				Coates, K; Cooke, SJ; Mann, DA; Harris, MPG			Protein kinase C-mediated phosphorylation of HIV-I Nef in human cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 NEF; HUMAN T-CELLS; NF-KAPPA-B; DOWN-REGULATION; BINDING-ACTIVITY; GENE-PRODUCT; SURFACE CD4; VITRO; EXPRESSION; INDUCTION	Stable human cell lines expressing the human immunodeficiency virus type I (HIV-I) Nef protein from inducible promoters were used to analyze the phosphorylation status of Nef in vivo. Nef phosphorylation in both HeLa and Jurkat cells was stimulated by phorbol ester treatment, Phosphoamino acid analysis revealed a predominance of phosphoserine with a small proportion of phosphothreonine. Treatment of cells with selective protein kinase inhibitors revealed that Nef phosphorylation was markedly reduced by bisindolylmaleimide, an inhibitor of protein kinase C, but was unaffected by inhibitors of mitogen-activated protein kinase kinase or cAMP-dependent kinase. These data implicate protein kinase C in Nef phosphorylation in vivo, and thus confirm and extend earlier in vitro data. Phosphorylation of a nonmyristoylated Nef mutant was impaired, suggesting that membrane targeting of Nef was required for phosphorylation, This was expected given that activated protein kinase C translocates from the cytosol to the plasma membrane. However, analysis of the subcellular localization of phosphorylated wild-type Nef revealed that both the cytosolic and membrane-associated pools of Nef were phosphorylated to an equivalent extent, Thus the significance of myristoylation for Nef function may be in influencing protein conformation, although these data could be explained by a transient and dynamic interaction between myristoylated Nef and the plasma membrane.	UNIV GLASGOW,DEPT VET PATHOL,MRC,RETROVIRUS RES LAB,GLASGOW G61 1QH,LANARK,SCOTLAND; UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SCH MED,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Glasgow; University of Southampton				Harris, Mark/0000-0002-9821-1003; Mann, Derek/0000-0003-0950-243X				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; BANDRES JC, 1994, J VIROL, V68, P3243, DOI 10.1128/JVI.68.5.3243-3249.1994; BODEUS M, 1995, J GEN VIROL, V76, P1337, DOI 10.1099/0022-1317-76-6-1337; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COATES K, 1995, J GEN VIROL, V76, P837, DOI 10.1099/0022-1317-76-4-837; Collette Y, 1996, J IMMUNOL, V156, P360; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; Cooke SJ, 1997, J GEN VIROL, V78, P381, DOI 10.1099/0022-1317-78-2-381; DE SK, 1994, J BIOL CHEM, V269, P6656; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HARRIS M, 1992, AIDS RES HUM RETROV, V8, P537, DOI 10.1089/aid.1992.8.537; HARRIS M, 1993, J GEN VIROL, V74, P1581, DOI 10.1099/0022-1317-74-8-1581; KAMINCHIK J, 1991, J VIROL, V65, P588; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Luo TC, 1996, J VIROL, V70, P6493, DOI 10.1128/JVI.70.9.6493-6496.1996; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MAKAROV SS, 1994, NUCLEIC ACIDS RES, V22, P1504, DOI 10.1093/nar/22.8.1504; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SCHWARTZ O, 1995, J VIROL, V69, P528, DOI 10.1128/JVI.69.1.528-533.1995; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; THOMAS J, 1991, J BIOL CHEM, V266, P10906; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; YU G, 1992, VIROLOGY, V187, P46, DOI 10.1016/0042-6822(92)90293-X; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	48	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12289	12294		10.1074/jbc.272.19.12289	http://dx.doi.org/10.1074/jbc.272.19.12289			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139671	hybrid			2022-12-25	WOS:A1997WY82900008
J	Kersten, S; Gronemeyer, H; Noy, N				Kersten, S; Gronemeyer, H; Noy, N			The DNA binding pattern of the retinoid X receptor is regulated by ligand-dependent modulation of its oligomeric state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ACID RECEPTORS; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; CO-REPRESSOR; RXR-ALPHA; AUXILIARY PROTEIN; CRYSTAL-STRUCTURE; DIRECT REPEATS; HIGH-AFFINITY	The retinoid X receptor (RXR) regulates target gene transcription via its association with cognate DNA response elements either as a homodimer or as a heterodimer with a number of other nuclear receptors. We previously demonstrated that, in solution, RXR forms tetramers with a high affinity and that ligand binding leads to dissociation of receptor tetramers to smaller species. Here it is shown that RXR tetramers form stable complexes with direct repeats (DR-1 or DR-5) or palindromic (TREpa1) response elements. Binding of RXR tetramers to cognate DNA occurs with a significantly higher affinity as compared with dimers. Ligand binding by DNA-bound RXR tetramers results in their dissociation to DNA-bound dimers, a process that is completely reversed upon removal of the ligand. Formation of stable tetramer-DNA complexes requires binding of two oligonucleotides/tetramer. It is proposed that ligand-dependent modulation of the oligomeric state of RXR is a regulatory feature of this nuclear receptor.	CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA; INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE	Cornell University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Gronemeyer, Hinrich/AAH-5575-2019; Kersten, Sander/A-1116-2011; Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/H-7002-2016	Gronemeyer, Hinrich/0000-0001-9454-2449; Kersten, Sander/0000-0003-4488-7734; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449	NCI NIH HHS [CA68150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Bollag D.M., 1991, PROTEIN METHODS, P143; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Jin CH, 1996, MOL ENDOCRINOL, V10, P196, DOI 10.1210/me.10.2.196; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P14263, DOI 10.1021/bi00043a034; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P13717, DOI 10.1021/bi00042a001; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; Kitareewan S, 1996, MOL BIOL CELL, V7, P1153, DOI 10.1091/mbc.7.8.1153; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE IJ, 1994, P NATL ACAD SCI USA, V91, P1647, DOI 10.1073/pnas.91.5.1647; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Lemotte PK, 1996, EUR J BIOCHEM, V236, P328, DOI 10.1111/j.1432-1033.1996.00328.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LHorset F, 1996, MOL CELL BIOL, V16, P6029; LUPISELLA JA, 1995, J BIOL CHEM, V270, P24884, DOI 10.1074/jbc.270.42.24884; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ONATE SA, 1995, SCIENCE, V270, P1354; Panariello L, 1996, J BIOL CHEM, V271, P25524, DOI 10.1074/jbc.271.41.25524; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12771	12777		10.1074/jbc.272.19.12771	http://dx.doi.org/10.1074/jbc.272.19.12771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139736	hybrid			2022-12-25	WOS:A1997WY82900073
J	Shore, LJ; Soler, AP; Gilmour, SK				Shore, LJ; Soler, AP; Gilmour, SK			Ornithine decarboxylase expression leads to translocation and activation of protein kinase CK2 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DNA TOPOISOMERASE-II; CASEIN KINASE-2; MOUSE SKIN; ADRENOCORTICAL-CELLS; CELLULAR-REGULATION; CATALYTIC ACTIVITY; NIH/3T3 CELLS; POLYAMINES; TRANSFORMATION	Ornithine decarboxylase (ODC) is the key initial enzyme in the biosynthesis of polyamines. Since polyamines have been shown to enhance protein kinase CK2 activity in vitro, ODC was overexpressed to examine the role of polyamines in CK2 regulation in vivo. Infection of Balb/MK cells with an ODC retrovirus to elevate ODC and polyamine levels increased overall protein phosphorylation as well as CK2 protein levels and enzyme activity in mimosine- or nocodazole- arrested cells. Immunofluorescence microscopy and enzyme analyses of subcellular fractions from ODC-overexpressing cells demonstrated translocation of CK2 from the cytoplasm to the nucleus with no apparent loss of cytoplasmic CK2 activity, suggesting polyamine activation of the remaining cytoplasmic enzyme. Similarly, K6/ODC transgenic mice exhibited higher ODC and CK2 enzyme activities than their normal littermates. ODC-immunostained cells in the transgenic skin also stained intensely for CK2 protein. Primary cultures of K6/ODC keratinocytes also exhibited increased ODC and CK2 enzyme activities compared with those from normal littermates. However, the addition of difluoromethylornithine, a specific ODC inhibitor, to the transgenic keratinocytes reduced both intracellular polyamine levels and CK2 enzyme activity, These results suggest that polyamines regulate the CK2 enzyme by affecting its cellular distribution as well as its enzyme activity and levels.	LANKENAU MED RES CTR, WYNNEWOOD, PA 19096 USA	Lankenau Medical Center; Lankenau Institute for Medical Research					NCI NIH HHS [CA 55066, CA 70739, CA 68762] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068762, R01CA070739, R29CA055066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AHMED K, 1993, P NATL ACAD SCI USA, V90, P4426, DOI 10.1073/pnas.90.10.4426; ALEXANDROW MG, 1995, CANCER RES, V55, P3928; ALGHISI GC, 1994, CELL MOL BIOL RES, V40, P563; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ASTRUP EG, 1982, CARCINOGENESIS, V3, P303, DOI 10.1093/carcin/3.3.303; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; Bryans M, 1996, BIOCHEM BIOPH RES CO, V226, P618, DOI 10.1006/bbrc.1996.1405; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHESTER N, 1995, J BIOL CHEM, V270, P7501, DOI 10.1074/jbc.270.13.7501; CLIFFORD A, 1995, CANCER RES, V55, P1680; COWARD JK, 1987, ADV ENZYME REGUL, V26, P107, DOI 10.1016/0065-2571(87)90008-2; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; DAVIS RH, 1990, J CELL BIOCHEM, V44, P199, DOI 10.1002/jcb.240440402; FEIGE JJ, 1986, ENDOCRINOLOGY, V118, P1059, DOI 10.1210/endo-118-3-1059; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P623, DOI 10.1016/S0006-291X(05)81111-8; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; GATICA M, 1995, BIOCHEMISTRY-US, V34, P122, DOI 10.1021/bi00001a015; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GILMOUR SK, 1987, CANCER RES, V47, P1221; GILMOUR SK, 1986, CARCINOGENESIS, V7, P943, DOI 10.1093/carcin/7.6.943; Gotz C, 1996, ONCOGENE, V13, P391; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HATHAWAY GM, 1984, ARCH BIOCHEM BIOPHYS, V233, P133, DOI 10.1016/0003-9861(84)90609-X; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HUBER M, 1995, CANCER RES, V55, P934; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KOZA RA, 1991, CARCINOGENESIS, V12, P1619, DOI 10.1093/carcin/12.9.1619; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MEGOSH L, 1995, CANCER RES, V55, P4205; MESTRES P, 1994, ACTA ANAT, V149, P13; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; Mitev Vanio, 1994, Journal of Dermatological Science, V8, P45, DOI 10.1016/0923-1811(94)90320-4; MOSHIER JA, 1995, CANCER RES, V55, P5358; MOSHIER JA, 1993, CANCER RES, V53, P2618; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OBRIEN TG, 1976, CANCER RES, V36, P2644; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SHANTZ LM, 1994, CANCER RES, V54, P2313; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; VALERO E, 1995, J BIOL CHEM, V270, P8345, DOI 10.1074/jbc.270.14.8345; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	58	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12536	12543		10.1074/jbc.272.19.12536	http://dx.doi.org/10.1074/jbc.272.19.12536			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139705	hybrid			2022-12-25	WOS:A1997WY82900042
J	Todorov, PT; Deacon, M; Tisdale, MJ				Todorov, PT; Deacon, M; Tisdale, MJ			Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; LINKED OLIGOSACCHARIDES; CANCER-PATIENTS; COLONIC MUCOSA; WEIGHT-LOSS; PROTEOLYSIS; METASTASES; CARCINOMA; LUTROPIN; ALBUMIN	A material of M-r 24,000 has been isolated from a cachexia-inducing mouse tumor (MAC16) and shown to initiate protein degradation in isolated gastrocnemius muscle, Biological activity was destroyed by preincubation with peptide N-glycosidase F (PNGase F) and endo-alpha-N-acetylgalactosaminidase (O-glycosidase) but not by neuraminidase or trypsin. Antibody reactivity was destroyed by treatment with periodate, indicating carbohydrate moieties to be the antigenic determinants. Antigenic activity was also reduced by treatment with PNGase F and O-glycosidase and was completely destroyed by treatment with chondroitinase ABC but was unaffected by treatment with either trypsin or chymotrypsin, confirming that the N- and O-linked sulfated oligosaccharide chains were both the antigenic and biological determinants. Biosynthetic labeling of MAC16 cells using a combination of [S-35]sulfate and [6-H-3]GlcN gave a single component of M-r 24,000 containing both radiolabels. Similar material could not be isolated from a cell line (MAC13) originating from a tumor that does not cause cachexia in vivo. Digestion of H-3/S-35 material with PNGase F produced two fragments of M-r 14,000 and 10,000 containing both radiolabels, and digestion with O-glycosidase produced three fragments of M-r 14,000, 6,000, and 4,000, the first two contained both radiolabels and the third contained only H-3. Digestion of the fragment of M-r 14,000 released by PNGase F with O-glycosidase also gave fragments of M-r 6,000 and 4,000. The products from both digestions were acidic as determined by anion exchange chromatography on DEAE-cellulose, The negative charge on the fragment of M-r 4,000 was removed by treatment with alkaline phosphatase. This suggests that the charge originated from phosphate residues, and this has been confirmed by biosynthetic labeling of MAC16 cells with [P-32]orthophosphate, where radiolabel was incorporated into material of M-r 24,000 and into the fragment of M-r 4,000 after treatment with O-glycosidase. To determine the size of the polypeptide core MAC16 cells were biosynthetically labeled with L-[2,5-H-3]His which after chemical deglycosylation produced a major component of M-r 4,000. These results suggest a model for the M-r 24,000 material consisting of a central polypeptide chain of M-r 4,000 and with phosphate residues that may be attached to the polypeptide or a short oligosaccharide chain containing GlcN, one O-linked sulfated oligosaccharide chain containing GlcN, and of M-r 6,000 and one N-linked sulfated oligosaccharide chain of M-r 10,000 also containing GlcN. Neither chain was cleaved into disaccharides with chondroitinase ABC, suggesting that the material is a sulfated glycoprotein.	ASTON UNIV,INST PHARMACEUT SCI,CRC NUTR BIOCHEM RES GRP,BIRMINGHAM B4 7ET,W MIDLANDS,ENGLAND	Aston University								BARACOS VE, 1986, AM J PHYSIOL, V251, pC588, DOI 10.1152/ajpcell.1986.251.4.C588; BELIZARIO JE, 1991, BRIT J CANCER, V63, P705, DOI 10.1038/bjc.1991.159; BISTRIAN BR, 1992, P SOC EXP BIOL MED, V200, P220; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; EVANS WK, 1985, CANCER RES, V45, P3347; GARCIAMARTINEZ C, 1994, CANCER LETT, V76, P1, DOI 10.1016/0304-3835(94)90126-0; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; HORTIN G, 1981, P NATL ACAD SCI-BIOL, V78, P7468, DOI 10.1073/pnas.78.12.7468; LUNDHOLM K, 1982, CANCER RES, V42, P4807; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; PEARSON CH, 1983, J BIOL CHEM, V258, P5101; RENNIE MJ, 1983, CLIN PHYSIOL, V3, P387, DOI 10.1111/j.1475-097X.1983.tb00847.x; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Todorov P, 1996, NATURE, V379, P739, DOI 10.1038/379739a0; Todorov PT, 1996, CANCER RES, V56, P1256; WAALKES TP, 1957, J LAB CLIN MED, V50, P733; WU GY, 1988, BIOCHEM J, V255, P139, DOI 10.1042/bj2550139; YAMASHITA K, 1983, J BIOL CHEM, V258, P4144; YAMORI T, 1987, CANCER RES, V47, P2741; YAMORI T, 1989, CANCER RES, V49, P887	23	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12279	12288		10.1074/jbc.272.19.12279	http://dx.doi.org/10.1074/jbc.272.19.12279			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139670	hybrid			2022-12-25	WOS:A1997WY82900007
J	Wang, AJ; Deems, RA; Dennis, EA				Wang, AJ; Deems, RA; Dennis, EA			Cloning, expression, and catalytic mechanism of murine lysophospholipase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL ESTER HYDROLASE; HUMAN PANCREATIC-JUICE; SUBSTRATE-SPECIFICITY; CELL-LINE; PHOSPHOLIPASE A(2); BEEF PANCREAS; PURIFICATION; LYSOLECITHIN; TRANSACYLASE; INHIBITION	A lysophospholipase (LysoPLA I) has been purified and characterized from the mouse macrophage-like P388D(1) cell line (Zhang, Y. Y, and Dennis, E. A. (1988) J. Biol. Chem. 263, 9965-9972). This enzyme has now been sequenced, cloned, and expressed in Escherichia coli cells. The enzyme contains 230 amino acid residues with a calculated molecular mass of 24.7 kDa. It has a high helical content in its predicated secondary structure, which is also indicated in its CD spectrum. The cloned LysoPLA I was purified to homogeneity from the transformed E. coli cells by a gel filtration column and an ion exchange column, The specific activity of the purified protein is 1.47 mu mol/min mg toward 1-palmitoyl-sn-glycero-3-phosphorylcholine at pH 8.0 and 40 degrees C, corresponding to the reported value of 1.3-1.7 mu mol/min mg for the protein purified from the P388D(1) cells. In addition, the cloned protein cross-reacted with an antibody raised against LysoPLA I also purified from the P388D(1) cells. The deduced LysoPLA I sequence contains a well conserved GXSXG motif found in the active site of many serine enzymes, and the activity of the LysoPLA I was irreversibly inhibited by the classical serine protease inhibitor diisopropyl fluorophosphate. Furthermore, site-directed mutagenesis was employed to change Ser-119 in the GXSXG motif to an Ala. The resulting mutant protein lost all of its lysophospholipase activity, even though it had the same overall protein conformation as that of the wild-type LysoPLA I. Therefore, LysoPLA I has been demonstrated to be a serine enzyme with Ser-119 at the active site.	UNIV CALIF SAN DIEGO, SCH MED, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, REVELLE COLL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NIGMS NIH HHS [GM 51606] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; AMBUDKAR IS, 1988, MOL CELL BIOCHEM, V79, P81, DOI 10.1007/BF00229401; ANTTINEN H, 1976, BIOCHEM J, V160, P29, DOI 10.1042/bj1600029; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; DEJONG JGN, 1974, BIOCHIM BIOPHYS ACTA, V369, P50, DOI 10.1016/0005-2760(74)90191-X; DEJONG JGN, 1973, BIOCHIM BIOPHYS ACTA, V296, P105, DOI 10.1016/0005-2760(73)90049-0; DUAN RD, 1993, BIOCHIM BIOPHYS ACTA, V1167, P326, DOI 10.1016/0005-2760(93)90236-3; GARSETTI D, 1992, BIOCHEM J, V288, P831, DOI 10.1042/bj2880831; GARSETTI DE, 1993, J LIPID MEDIATOR, V6, P223; GARSETTI DE, 1992, BIOCHIM BIOPHYS ACTA, V1165, P229, DOI 10.1016/0005-2760(92)90191-W; GROSS RW, 1983, J BIOL CHEM, V258, P5221; GROSS RW, 1983, J BIOL CHEM, V258, P5165; HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141; HONG KH, 1991, AGR BIOL CHEM TOKYO, V55, P2839, DOI 10.1080/00021369.1991.10871052; JARVIS AA, 1984, J BIOL CHEM, V259, P5188; KELLY RA, 1986, J BIOL CHEM, V261, P1704; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; LEPAGE N, 1995, BIOL REPROD, V52, P616, DOI 10.1095/biolreprod52.3.616; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P136, DOI 10.1016/0005-2744(80)90049-2; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROSS BM, 1994, J NEUROCHEM, V63, P1839; Rost B, 1996, METHOD ENZYMOL, V266, P525; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; STAFFORD RE, 1993, BIOCHIM BIOPHYS ACTA, V1167, P43, DOI 10.1016/0005-2760(93)90215-U; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; SUGIMOTO H, 1994, J BIOL CHEM, V269, P6252; SUNAGA H, 1995, BIOCHEM J, V308, P551, DOI 10.1042/bj3080551; VANDENBOSCH H, 1975, BIOCHIM BIOPHYS ACTA, V398, P244, DOI 10.1016/0005-2760(75)90140-X; VANDENBOSCH H, 1973, BIOCHIM BIOPHYS ACTA, V296, P94, DOI 10.1016/0005-2760(73)90048-9; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WITHIAMLEITCH M, 1995, J BIOL CHEM, V270, P3780, DOI 10.1074/jbc.270.8.3780; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; ZHANG Y, 1988, J BIOL CHEM, V263, P9965; ZHANG YY, 1991, METHOD ENZYMOL, V197, P456	38	57	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12723	12729		10.1074/jbc.272.19.12723	http://dx.doi.org/10.1074/jbc.272.19.12723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139730	hybrid, Green Published			2022-12-25	WOS:A1997WY82900067
J	LeMellay, V; Grosse, B; Lieberherr, M				LeMellay, V; Grosse, B; Lieberherr, M			Phospholipase C beta and membrane action of calcitriol and estradiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CONFLUENT MOUSE OSTEOBLASTS; ALPHA-SUBUNITS; GROWTH-FACTOR; SIGNAL TRANSDUCTION; BINDING-PROTEIN; GAMMA-SUBUNITS; GQ CLASS; ACTIVATION; RECEPTOR	We have shown that estrogens and calcitriol, the hormonally active form of vitamin D, increase the concentration of intracellular calcium ([Ca2+]i) within 5 s by mobilizing calcium from the endoplasmic reticulum and the formation of inositol 1,4,5-trisphosphate and diacylglycerol. Because the activation of effecters as phospholipase C (PLC) coupled to G-proteins is the early event in the signal transduction pathway leading 60 the inositol 1,4,5-trisphosphate formation and to [Ca2+](i) increase, we described different PLC isoforms (beta 1, beta 2, gamma 1, and gamma 2, but not beta 4) in female rat osteoblasts using Western immunoblotting. The data showed that phospholipase C beta was involved in the mobilization of Ca2+ from the endoplasmic reticulum of Fura-2-loaded confluent osteoblasts by calcitriol and 17 beta estradiol, and PLC gamma was ineffective. The data also showed that only a PLC beta 1 linked to a Pertussis toxin-insensitive G protein and a PLC beta 2 coupled to a Pertussis toxin-sensitive G-protein are involved in the effects of calcitriol and 17 beta estradiol on the mobilization of Ca2+ from intracellular Ca2+ stores. In conclusion, these results may be an important step toward understanding membrane effects of these steroids and may be an additional argument in favor of membrane receptors to steroid hormones.	UNIV PARIS 05, CNRS, URA 583, F-78350 JOUY EN JOSAS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALDASSARE JJ, 1986, J BIOL CHEM, V261, P1942; BARAN DT, 1994, J CELL BIOCHEM, V56, P510, DOI 10.1002/jcb.240560411; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOURDEAU A, 1990, ENDOCRINOLOGY, V127, P2738, DOI 10.1210/endo-127-6-2738; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANALIS E, 1987, J CLIN INVEST, V79, P52, DOI 10.1172/JCI112807; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; FAIN JN, 1988, FASEB J, V2, P2569, DOI 10.1096/fasebj.2.10.2838362; GAMETCHU B, 1987, SCIENCE, V236, P456, DOI 10.1126/science.3563523; GROSSE B, 1993, J BONE MINER RES, V8, P1059; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUCKLE WR, 1990, ENDOCRINOLOGY, V127, P1697, DOI 10.1210/endo-127-4-1697; JACKWOSKI S, 1986, SCIENCE, V232, P97; JHON DY, 1993, J BIOL CHEM, V268, P6654; JOSEPH SK, 1989, ARCH BIOCHEM BIOPHYS, V273, P1, DOI 10.1016/0003-9861(89)90156-2; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kim YS, 1996, ENDOCRINOLOGY, V137, P3649, DOI 10.1210/en.137.9.3649; KRIZ R, 1990, CIBA F SYMP, V150, P112; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; KUPPE A, 1990, BIOCHIM BIOPHYS ACTA, V1047, P41, DOI 10.1016/0005-2760(90)90258-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERHERR M, 1973, BIOCHIM BIOPHYS ACTA, V293, P160, DOI 10.1016/0005-2744(73)90387-2; LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; LITOSCH I, 1985, PHOSPHOLIPIDS CELLUL, P159; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN TFJ, 1991, PHARMACOL THERAPEUT, V49, P329, DOI 10.1016/0163-7258(91)90062-Q; MOSS DW, 1992, CLIN CHEM, V38, P2486; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TANAKA O, 1994, NEUROSCI LETT, V182, P17, DOI 10.1016/0304-3940(94)90194-5; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEHLING M, 1995, STEROIDS, V60, P153, DOI 10.1016/0039-128X(94)00027-A; WONG G, 1974, NATURE, V252, P713, DOI 10.1038/252713a0; WU DQ, 1992, J BIOL CHEM, V267, P1811	52	147	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11902	11907		10.1074/jbc.272.18.11902	http://dx.doi.org/10.1074/jbc.272.18.11902			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115251	Green Published, hybrid			2022-12-25	WOS:A1997WX56900039
J	Das, AK; Dasgupta, B; Bhattacharya, R; Basu, J				Das, AK; Dasgupta, B; Bhattacharya, R; Basu, J			Purification and biochemical characterization of a protein-palmitoyl acyltransferase from human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY ACYLTRANSFERASE; TRANSFERRIN RECEPTOR; SIGNALING PATHWAYS; ACYLATION; THIOESTERASE; P21N-RAS; H-3	Protein palmitoylation involves the post-translational attachment of palmitate in thioester linkage to cysteine residues of proteins, The labile nature of the thioester linkage makes possible the palmitoylation-depalmitoylation cycles that have emerged in recent times as additions to the repertoire of cellular control mechanisms, However, detailed understanding of these cycles has been limited by the lack of knowledge of the transferases and thioesterases likely to be involved, Here, we describe the purification of a protein palmitoyl acyltransferase (PAT) from human erythrocytes, PAT behaved as a peripheral membrane protein and catalyzed the attachment of palmitate in thioester linkage to the beta-subunit of spectrin. On SDS polyacrylamide gel electrophoresis, PAT appeared as a 70-kDa polypeptide. Antibody against this polypeptide could immunodeplete PAT activity from the crude extract, confirming the assignment of the 70-kDa polypeptide as PAT. PAT mediated spectrin palmitoylation could be inhibited by nonradioactive palmitoyl-, myristoyl-, or stearoyl-CoA. The apparent K-m for palmitoyl-CoA was 16 mu M.	BOSE INST, DEPT CHEM, CALCUTTA 700009, W BENGAL, INDIA	Department of Science & Technology (India); Bose Institute								ADAM M, 1984, J BIOL CHEM, V259, P5460; BENNETT V, 1983, METHOD ENZYMOL, V96, P316; BERGER M, 1985, FEBS LETT, V187, P289, DOI 10.1016/0014-5793(85)81261-8; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAS AK, 1992, BIOCHIM BIOPHYS ACTA, V1108, P128, DOI 10.1016/0005-2736(92)90016-F; DAS AK, 1994, EUR J BIOCHEM, V224, P575, DOI 10.1111/j.1432-1033.1994.00575.x; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; Galbiati F, 1996, BIOCHEM J, V313, P717, DOI 10.1042/bj3130717; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MARIANI M, 1993, J BIOL CHEM, V268, P12996; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; OMARY MB, 1981, J BIOL CHEM, V256, P2888; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; SCHLESINGER MJ, 1993, LIPID MODIFICATION P, P1; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHMIDT MFG, 1995, BBA-LIPID LIPID MET, V1257, P205, DOI 10.1016/0005-2760(95)00062-H; SKENE JHP, 1989, J CELL BIOL, V126, P127; SLOMIANY A, 1984, J BIOL CHEM, V259, P3304; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615	30	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11021	11025						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9110994				2022-12-25	WOS:A1997WW00900010
J	Szymanski, PT; Tao, T				Szymanski, PT; Tao, T			Localization of protein regions involved in the interaction between calponin and myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; CALCIUM-BINDING PROTEINS; ATPASE ACTIVITY; TROPOMYOSIN INTERACTIONS; CALDESMON BINDING; GIZZARD CALPONIN; TROPONIN-T; F-ACTIN; FRAGMENTS; PHOSPHORYLATION	Calponin is a 33-kDa smooth muscle-specific protein that has been suggested to play a role in muscle contractility. It has previously been shown to interact with actin, tropomyosin, and calmodulin. More recently we showed that calponin also interacts with myosin (Szymanski, P. T., and Tao, T. (1993) FEBS Lett. 331, 256-259). In the present study we used a combination of co-sedimentation and fluorescence assays to localize the regions in myosin and calponin that are involved in the interaction between these two proteins. We found that recombinant chicken gizzard alpha-calponin co-sediments with myosin rod and, to a lesser extent, with light meromyosin. Fluorescently labeled recombinant calponin shows interaction with heavy meromyosin and myosin subfragment 2 but not subfragment 1. A fragment comprising residues 7-182 and a synthetic peptide spanning residues 146-176 of calponin co-sediment with myosin, but fragments comprising residues 7-144 and 183-292 do not. Our results indicate that there are calponin binding sites in the subfragment 2 and light meromyosin regions of myosin, and that the region comprising residues 145-182 of calponin mediates its interaction with myosin.	BOSTON BIOMED RES INST,MUSCLE RES GRP,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Tufts University					NIAMS NIH HHS [P01-AR41637] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; CHILDS TJ, 1992, BIOCHIM BIOPHYS ACTA, V1121, P41, DOI 10.1016/0167-4838(92)90334-A; GIMONA M, 1996, BIOCH SMOOTH MUSCLE, P91; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; HAEBERLE JR, 1994, J BIOL CHEM, V269, P12424; HEMRIC ME, 1993, J BIOL CHEM, V268, P15305; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; Horowitz A, 1996, AM J PHYSIOL-HEART C, V270, pH1858, DOI 10.1152/ajpheart.1996.270.5.H1858; IKEBE M, 1978, J BIOCHEM, V83, P1643, DOI 10.1093/oxfordjournals.jbchem.a132077; IKEBE M, 1988, J BIOL CHEM, V263, P3055; ITOH T, 1995, J BIOL CHEM, V270, P20400, DOI 10.1074/jbc.270.35.20400; JAWOROWSKI A, 1995, FEBS LETT, V365, P161; KATAYAMA E, 1995, J BIOL CHEM, V270, P3919, DOI 10.1074/jbc.270.8.3919; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN Y, 1993, J BIOCHEM-TOKYO, V113, P643, DOI 10.1093/oxfordjournals.jbchem.a124096; Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON SB, 1992, J MUSCLE RES CELL M, V31, P206; MEZGUELDI M, 1995, J BIOL CHEM, V270, P8867, DOI 10.1074/jbc.270.15.8867; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NAKAMURA F, 1993, J BIOL CHEM, V268, P6194; Obara K, 1996, AM J PHYSIOL-CELL PH, V270, pC481, DOI 10.1152/ajpcell.1996.270.2.C481; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SZYMANSKI PT, 1993, FEBS LETT, V331, P256, DOI 10.1016/0014-5793(93)80348-X; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1988, HYPERTENSION, V11, P620, DOI 10.1161/01.HYP.11.6.620; TAKAHASHI K, 1988, J HYPERTENS, V6, pS40, DOI 10.1097/00004872-198812040-00008; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; WILLS FL, 1994, PROTEIN SCI, V3, P2311, DOI 10.1002/pro.5560031216; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1990, BIOCHEM INT, V22, P335	35	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11142	11146						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111011				2022-12-25	WOS:A1997WW00900027
J	Crider, BP; Andersen, P; White, AE; Zhou, ZM; Li, XJ; Mattsson, JP; Lundberg, L; Keeling, DJ; Xie, XS; Stone, DK; Peng, SB				Crider, BP; Andersen, P; White, AE; Zhou, ZM; Li, XJ; Mattsson, JP; Lundberg, L; Keeling, DJ; Xie, XS; Stone, DK; Peng, SB			Subunit G of the vacuolar proton pump - Molecular characterization and functional expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE H+-ATPASE; TRANSLOCATING ATPASE; RECONSTITUTION; PROTEIN; IDENTIFICATION; MEMBRANES; SEQUENCE; CDNA	The vacuolar type proton pump of clathrin-coated vesicles has a multisubunit ATP hydrolytic center that is peripheral to the membrane. Polypeptides present in this domain include the well characterized subunits A, B, C, D, E, and F; SFD, a dimer composed of 50- and 57-kDa polypeptides; and polypeptides termed G and H. Of these, subunits A, B, C, and E have been shown to be necessary but not sufficient for significant ATPase activity; in addition, either polypeptide G or H is also required for ATP hydrolysis (Xie, X.-S. (1996) J. Biol. Chem. 271, 30980-30985). In this study, the polypeptides G and H were purified and directly sequenced. Subsequent molecular analysis has revealed that these proteins are isoforms, which we designate G1 and G2. The cDNAs encoding the rat and bovine brain and chicken osteoclast forms of G1 have been cloned. The open reading frames of the rat and bovine clones encode hydrophilic proteins of 118 amino acids that differ at only five residues; bovine G1 has 36% identity with VMA10, a component of the proton channel of yeast. Northern blot analysis revealed a 1.0-kilobase pair transcript encoding G1 in bovine brain, kidney, heart, and spleen. The cDNA encoding bovine polypeptide H was cloned and sequenced, revealing this protein to be 64% identical to G1, constituting isoform G2. In Northern blot analysis, a single 1.7-kilobase pair transcript hybridized with a probe to G2 in brain, but not in heart, kidney, or spleen. An antibody against a bovine G1-specific domain reacts with V pump from bovine brain, kidney, and chromaffin granule, whereas an anti-G2 antibody reacts only with proton pump from brain. The bovine forms of G1 and G2 were subsequently expressed in Escherichia coli and Sf9 cells, respectively, and purified to homogeneity. Reconstitution of ATP hydrolysis was achieved by combination of recombinant subunits A, B, C, and E with either recombinant G1 or G2, demonstrating the role of these isoforms in pump function.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOL TRANSPORT,DALLAS,TX 75235; AB HASSLE,PRECLIN RES & DEV,S-43183 MOLNDAL,SWEDEN; GOTHENBURG UNIV,DEPT BIOCHEM & BIOPHYS,S-41390 GOTHENBURG,SWEDEN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Gothenburg					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK-33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FORGAC M, 1992, J EXP BIOL, V172, P155; GRINSTEIN S, 1992, J EXP BIOL, V172, P179; GU HH, 1993, J BIOL CHEM, V268, P7372; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lepier A, 1996, J BIOL CHEM, V271, P8502, DOI 10.1074/jbc.271.14.8502; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; Peng SB, 1996, J BIOL CHEM, V271, P3324, DOI 10.1074/jbc.271.6.3324; PENG SB, 1994, J BIOL CHEM, V269, P27778; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PENG SB, 1995, J BIOL CHEM, V270, P16926; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; Supekova L, 1996, J EXP BIOL, V199, P1147; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1994, J BIOL CHEM, V269, P25809; Xie XS, 1996, J BIOL CHEM, V271, P30980; XIE XS, 1988, J BIOL CHEM, V263, P9859; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	35	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10721	10728						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099722				2022-12-25	WOS:A1997WV26200056
J	Hiregowdara, D; Avraham, H; Fu, YG; London, R; Avraham, S				Hiregowdara, D; Avraham, H; Fu, YG; London, R; Avraham, S			Tyrosine phosphorylation of the related adhesion focal tyrosine kinase in megakaryocytes upon stem cell factor and phorbol myristate acetate stimulation and its association with paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-KIT RECEPTOR; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; SI-LOCUS; LIGAND; ACTIVATION; INTEGRIN; IDENTIFICATION; FIBROBLASTS; PATHWAYS	We have characterized signaling pathways involving the related adhesion focal tyrosine kinase (RAFTK, also known as PYK2 or CAK-beta) in CMK human megakaryocytic cells, Stem cell factor, which potentiates the growth of megakaryocytes and their progenitors, and phorbol myristate acetate, which causes differentiation of megakaryocytic cell lines, induced the tyrosine phosphorylation of RAFTK but not of focal adhesion kinase, Stimulation of CMK cells with stem cell factor resulted in an increase in the autophosphorylation and kinase activity of RAFTK. Phosphorylation of RAFTK under these conditions was mediated by a protein kinase C-dependent pathway, Cytochalasin D, which disrupts the cytoskeleton, abolished the phosphorylation of RAFTK upon phorbol myristate acetate and stem cell factor stimulation, indicating that RAFTK association with the actin cytoskeleton appears to be critical for its phosphorylation. In addition, we observed an association of RAFTK with paxillin, a 68-kDa cytoskeleton protein. Using in vitro binding assays, RAFTK and paxillin were shown to bind directly through the C-terminal proline-rich domain, Transient overexpression of a dominant-negative mutant of RAFTK inhibited significantly the tyrosine phosphorylation of paxillin upon phorbol myristate acetate stimulation. These observations indicate that RAFTK might play an important role in the phosphorylation of signaling pathways within the focal adhesions and that RAFTK participates in signaling events that link signals from the cell surface to the cytoskeleton, Furthermore, this study suggests that RAFTK might be involved in megakaryocyte proliferation and differentiation.	HARVARD UNIV, INST MED, BETH ISRAEL DEACONESS MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DIV EXPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Avraham, Hava/0000-0002-7545-3640	NHLBI NIH HHS [HL55445, HL51456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456, R01HL055445] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM H, 1992, BLOOD, V80, P1679; AVRAHAM H, 1995, STEM CELLS, V13, P380, DOI 10.1002/stem.5530130409; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BARRY ST, 1994, J CELL SCI, V107, P2033; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; BRIDDELL RA, 1991, BLOOD, V78, P2854; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLUMBO M, 1994, BIOCHEM PHARMACOL, V47, P2137, DOI 10.1016/0006-2952(94)90248-8; COWLEY SA, 1992, INT J CELL CLONING, V10, P223, DOI 10.1002/stem.5530100405; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GOTOH A, 1995, EXP HEMATOL, V23, P1153; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NAMCIU S, 1994, ONCOGENE, V9, P1407; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; OHTANI K, 1995, J NEUROCHEM, V65, P605; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SADOSHIMA J, 1995, CIRC RES, V76, P1; SAKAGUCHI M, 1991, BLOOD, V77, P481; SALGIA R, 1995, ONCOGENE, V11, P1149; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZIRRGIEBEL U, 1995, J NEUROCHEM, V65, P2241; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	53	88	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10804	10810						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099734				2022-12-25	WOS:A1997WV26200068
J	Keshvara, LM; Isaacson, C; Harrison, ML; Geahlen, RL				Keshvara, LM; Isaacson, C; Harrison, ML; Geahlen, RL			Syk activation and dissociation from the B-cell antigen receptor is mediated by phosphorylation of tyrosine 130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; KINASE; BINDING; ZAP-70; AUTOPHOSPHORYLATION; PATHWAYS; DOMAIN; BAND-3; MICE; LYN	Syk (p72(syk)) is a 72-kDa cytoplasmic protein-tyrosine kinase that serves as an essential component of the signal transduction machinery coupled to the B-cell antigen receptor. Syk is recruited to the receptor when it is cross-linked and, in response, becomes tyrosine-phosphorylated and activated before it dissociates from the receptor and appears in the cytoplasm. To begin to explore how tyrosine phosphorylation affects Syk activation and receptor binding, Tyr-130, which is localized within the Syk inter-Src homology 2 domain region, was substituted with Phe or Glu, Substitution of Tyr-130 with Phe enhanced the binding of Syk to the receptor and increased receptor-mediated protein tyrosine phosphorylation, while substitution with Glu greatly reduced this interaction, Replacement of Tyr-130 with Glu also increased the basal activity of the kinase, while replacement with Phe decreased its activity and uncoupled kinase activation from receptor engagement, These data suggest that the phosphorylation of Tyr-130 normally plays an important role in mediating both the activation of Syk and its release from the antigen receptor.	PURDUE UNIV,DEPT MED CHEM & MOL PHARMACOL,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NCI NIH HHS [CA37372] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BURG DL, 1994, J BIOL CHEM, V269, P28136; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; DEFRANCO AL, 1994, CURR OPIN IMMUNOL, V6, P364, DOI 10.1016/0952-7915(94)90114-7; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; Kong GH, 1996, MOL CELL BIOL, V16, P5026; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; KUROSAKI T, 1995, J EXP MED, V182, P115; Law CL, 1996, MOL CELL BIOL, V16, P1305; LOW PS, 1987, J BIOL CHEM, V262, P4592; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Peters JD, 1996, J BIOL CHEM, V271, P4755; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Schneider ML, 1995, BIOCHEMISTRY-US, V34, P16574, DOI 10.1021/bi00051a005; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	27	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10377	10381						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099676				2022-12-25	WOS:A1997WV26200010
J	Grammer, TC; Blenis, J				Grammer, TC; Blenis, J			Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases	ONCOGENE			English	Article						MAPK; MEK; phosphatidylinositol-3 kinase; protein kinase C	GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; CYCLIC-AMP; INSULIN; PHOSPHORYLATION; TYROSINE; WORTMANNIN; PP90RSK; CELLS; IDENTIFICATION	The mitogen-activated protein kinases (MAPKs) ERK-1 and ERK-2 are activated by a wide variety of oncogenes and extracellular stimuli. The MAPKs participate in a signalling cascade downstream of growth factor/cytokine receptors, Ras, Raf, and MEK. However, MAPK activation is more complicated than a simple linear pathway, and the evidence presented here supports a model of multiple, temporally distinct pathways converging on MAPK which are differentially utilized by various stimuli and cell types. In addition to MEK-dependent MAPK activation, we provide evidence for MEK-independent regulation of the MAPKs. Our results suggest that phosphatidylinositol-3-kinases (PI(3)K) or conventional protein kinase C isoforms (cPKCs) partially contribute to MEK-dependent activation. Importantly, we also find that PI3K and cPKCs play a major role in the MEK-independent, prolonged MAPK activation by platelet-derived growth factor signalling. This finding is of interest as the maintained activation of MAPK has been correlated by others to the regulation of cell proliferation and differentiation.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								BLENIS J, 1986, P NATL ACAD SCI USA, V83, P1733, DOI 10.1073/pnas.83.6.1733; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERBY IM, 1994, J BIOL CHEM, V269, P30485; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; YANG YC, 1993, FEBS LETT, V333, P287, DOI 10.1016/0014-5793(93)80672-H	26	178	179	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	1997	14	14					1635	1642		10.1038/sj.onc.1201000	http://dx.doi.org/10.1038/sj.onc.1201000			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135064				2022-12-25	WOS:A1997WR89300001
J	Jay, P; BergeLefranc, JL; Marsollier, C; Mejean, C; Taviaux, S; Berta, P				Jay, P; BergeLefranc, JL; Marsollier, C; Mejean, C; Taviaux, S; Berta, P			The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p	ONCOGENE			English	Article						CYR61; immediate early gene; CCN family; mosaic protein	IDENTIFICATION; EXPRESSION; PROTEIN; CELLS; HYBRIDIZATION; DELETION; PRODUCT; FAMILY; BETA; NOV	Complementary DNA encoding the human CYR61 protein was isolated from human embryonic tissues and mapped to chromosome 1p22-p31. We show that CYR61 encodes a 381 amino acid protein rich in cysteine and proline residues that is strongly conserved with the mouse homologue. Sequence analysis reveals the presence of several distinct protein domains which confer a mosaic structure to this protein and makes human CYR61 a member of a recently described growth regulator family that includes several proto-oncogene products. From our results we hypothesize that this new immediate early gene may play a role in cell commitment during embryogenesis and more generally in the control of cell proliferation.	CTR RECH BIOCHIM MACROMOL,CNRS ERS 155,INSERM U249,F-34033 MONTPELLIER,FRANCE; FAC MED MARSEILLE,INSERM U406,F-13385 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Jay, Philippe/I-7116-2016; Jay, Philippe/ABD-9223-2020	Jay, Philippe/0000-0003-0156-5700; Jay, Philippe/0000-0003-0156-5700				BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CHEN ZY, 1993, GENOMICS, V16, P533, DOI 10.1006/geno.1993.1224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GEHRING M, 1995, CANCER RES, V55, P5366; GORR SU, 1995, FEBS LETT, V361, P8, DOI 10.1016/0014-5793(95)00142-V; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JAY P, 1996, IN PRESS GENOMICS; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SIMON D, 1991, ONCOGENE, V6, P765; STOLER A, 1985, P NATL ACAD SCI USA, V82, P570, DOI 10.1073/pnas.82.2.570; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P121; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Ying ZT, 1996, GENE, V171, P243, DOI 10.1016/0378-1119(95)00891-8; ZABEL BU, 1985, P NATL ACAD SCI USA, V82, P469, DOI 10.1073/pnas.82.2.469	33	61	80	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1753	1757		10.1038/sj.onc.1200986	http://dx.doi.org/10.1038/sj.onc.1200986			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135077				2022-12-25	WOS:A1997WR89300014
J	Chen, HJ; Ke, YQ; Oates, AJ; Barraclough, R; Rudland, PS				Chen, HJ; Ke, YQ; Oates, AJ; Barraclough, R; Rudland, PS			Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line	ONCOGENE			English	Article						human metastasis-inducing DNAs; rat mammary cells; osteopontin regulation	CALCIUM-BINDING PROTEIN; HUMAN-BREAST-CANCER; TRANSFECTION; OSTEOPONTIN; BENIGN; TUMOR; ONCOGENES; SEQUENCE; GENE; FIBROBLASTS	Benign rat mammary epithelial cells transfected with restriction enzyme-fragmented DNA from a human malignant metastatic cell line (Ca2-83) produces transfectants that yield metastatic tumours in syngeneic rats. The six metastasis-inducing DNAs (Met-DNAs) that have been isolated from such transfectants are subgene in size and do not code for any expressed mRNAs, but correspond to potential regulatory regions of human DNA from malignant, metastatic cells. In pilot studies the one Met-DNA tested is detectable in some human breast tumours but not in normal tissue. Transfection of all six Met-DNAs singly into the benign mammary epithelial cells causes enhanced expression of osteopontin, whilst transfection of cDNA for osteopontin also induces the metastatic state. These results show that short regulatory DNAs exist in human cancer cells that can induce metastatic spread via a common effector gene, osteopontin, in model rat mammary cell lines.	UNIV LIVERPOOL, SCH BIOL SCI, CANC & POLIO RES FUND LABS, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; ANATHAWASWAMY HN, 1988, J CELL BIOCHEM, V36, P137; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BEHREND EI, 1994, CANCER RES, V54, P832; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 1996, INT J CANCER, V65, P104; DAVIES BR, 1994, CANCER RES, V54, P2785; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; ENGEL LW, 1978, CANCER RES, V38, P3352; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FISHER MS, 1981, CANCER RES, V41, P3018; GARDNER HAR, 1994, ONCOGENE, V9, P2321; GIBBINS JR, 1991, ANTICANCER RES, V11, P129; JAMIESON S, 1990, INT J CANCER, V46, P1071, DOI 10.1002/ijc.2910460621; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; KAMBY C, 1990, CANCER TREAT REV, V17, P37, DOI 10.1016/0305-7372(90)90075-Q; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oates AJ, 1996, ONCOGENE, V13, P97; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; RADLERPOHL A, 1988, INT J CANCER, V41, P840, DOI 10.1002/ijc.2910410611; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RUDLAND PS, 1985, CANCER RES, V45, P3864; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TARIN D, 1988, CIBA F SYMP, V141, P149; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0	43	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1581	1588		10.1038/sj.onc.1200993	http://dx.doi.org/10.1038/sj.onc.1200993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129149				2022-12-25	WOS:A1997WQ54800009
J	Asimakopoulos, FA; Hinshelwood, S; Gilbert, JGR; Delibrias, CC; Gottgens, B; Fearon, DT; Green, AR				Asimakopoulos, FA; Hinshelwood, S; Gilbert, JGR; Delibrias, CC; Gottgens, B; Fearon, DT; Green, AR			The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera	ONCOGENE			English	Article						polycythemia vera; SHP-1; myeloproliferative disorders	ERYTHROPOIETIN RECEPTOR GENE; PROTEIN-TYROSINE-PHOSPHATASE; VIRUS GP55 GLYCOPROTEIN; ERYTHROID PROGENITORS; MYELOPROLIFERATIVE DISORDERS; MOLECULAR ANALYSIS; DNA METHYLATION; MOTH-EATEN; C-KIT; INTERLEUKIN-3	Polycythemia vera (PV) is an acquired clonal disorder characterized by increased production of mature red cells and growth of erythroid colonies in the absence of erythropoietin. Mutation of the erythropoietin receptor has been demonstrated to cause familial polycythemia, but no mutations have been found in PV, Moreover, both erythroid and myeloid progenitors from patients with PV have been reported to be hypersensitive to a number of different growth factors. Attention has therefore focused on post-receptor signal transduction pathways, The SHP-1 gene is an especially attractive candidate gene. Firstly, SHP-1 binds to and negatively regulates signalling from the erythropoietin receptor and is likely to regulate other cytokine receptors in a similar manner, Secondly, absence of SHP-1 protein in the motheaten mouse is accompanied by increased sensitivity of hematopoietic progenitors to a number of cytokines including erythropoietin, Thirdly, familial or sporadic polycythemia in man may result from mutations of the SHP-1 binding domain of the erythropoietin receptor. We have therefore searched for mutations of the SHP-1 gene in genomic DNA from patients with PV. In this disease the majority of peripheral blood lymphocytes are not part of the malignant clone and a variable proportion of myeloid cells may arise from normal progenitors. We have therefore chosen to study DNA from purified peripheral blood granulocytes obtained from nine women in whom the granulocytes were clonally derived. Southern analysis was used to show that the gene was not rearranged and densitometry confirmed the presence of two copies of the gene in each DNA sample. Sequencing of the entire coding region and all splice junctions revealed no mutations, Hematopoietic transcription factor binding sites in the SHP-1 promoter region were intact and the methylation status of the two SHP-1 promoters in PV patients was identical to that in three normal controls, Finally, we showed that levels of SHP-1 protein in granulocytes from patients was similar to those from normal controls. These results demonstrate that the SHP-1 gene is structurally and transcriptionally intact in patients with PV.	UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, CAMBRIDGE CB2 2QH, ENGLAND; UNIV CAMBRIDGE, DEPT MED, WELLCOME TRUST IMMUNOL UNIT, MRC CTR, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge				Gottgens, Berthold/0000-0001-6302-5705; Gilbert, James/0000-0001-8079-3159; Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; Asimakopoulos FA, 1996, BLOOD, V88, P2690, DOI 10.1182/blood.V88.7.2690.bloodjournal8872690; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; CHRETIEN S, 1994, BLOOD, V83, P1813; Cooper D. N., 1993, HUMAN GENE MUTATION; CORREA PN, 1994, BLOOD, V83, P99; DAI CH, 1994, BRIT J HAEMATOL, V86, P12, DOI 10.1111/j.1365-2141.1994.tb03246.x; DAI CH, 1992, BLOOD, V80, P891; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DUDLEY JM, 1990, BRIT J HAEMATOL, V75, P188, DOI 10.1111/j.1365-2141.1990.tb02647.x; EAVES CJ, 1978, BLOOD, V52, P1196; ERIDANI S, 1987, BRIT J HAEMATOL, V67, P387, DOI 10.1111/j.1365-2141.1987.tb06158.x; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; Green AR, 1996, LANCET, V347, P844, DOI 10.1016/S0140-6736(96)91338-0; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOBAYASHI S, 1993, BRIT J HAEMATOL, V83, P539, DOI 10.1111/j.1365-2141.1993.tb04688.x; KRANTZ SB, 1991, BLOOD, V77, P419; LeCouedic JP, 1996, BLOOD, V87, P1502, DOI 10.1182/blood.V87.4.1502.bloodjournal8741502; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; PRCHAL JT, 1994, BLOOD, V83, P1; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; SOKOL L, 1994, EXP HEMATOL, V22, P447; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANZANT G, 1989, EXP HEMATOL, V17, P81; WARD JC, 1992, EXP HEMATOL, V20, P371; WASSERMAN LR, 1995, POLYCYTHEMIA VERA MY; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WINKELMANN JC, 1995, BLOOD, V85, P179, DOI 10.1182/blood.V85.1.179.bloodjournal851179; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	48	40	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1215	1222		10.1038/sj.onc.1200942	http://dx.doi.org/10.1038/sj.onc.1200942			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121771				2022-12-25	WOS:A1997WM78200011
J	Funatsuki, K; Tanaka, R; Inagaki, S; Konno, H; Katoh, K; Nakamura, H				Funatsuki, K; Tanaka, R; Inagaki, S; Konno, H; Katoh, K; Nakamura, H			acrB mutation located at carboxyl-terminal region of gyrase B subunit reduces DNA binding of DNA gyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI TOPOISOMERASE-IV; ESCHERICHIA-COLI; CATALYTIC PROPERTIES; NUCLEOTIDE-SEQUENCE; RESISTANT MUTATIONS; GYRB GENE; PROTEIN; PURIFICATION; CHROMATOGRAPHY; NOVOBIOCIN	Mutations that exhibit susceptibility to acriflavine have been isolated and classified as acr mutations in Escherichia coli. We cloned the acrB gene, which has been identified as a mutation of the gyrB gene, and found a double point mutation altering two consecutive amino acids (S759R/R760C) in the COOH-terminal region of the gyrase B subunit, The mutant B subunit was found to associate with the A subunit to make the quaternary structure, and the reconstituted gyrase showed an 80-fold reduction of specific activity in DNA supercoliing assay; the sensitivity to acriflavine was not different in the same unit of wild-type and mutant gyrases. The mutant enzyme retained intrinsic ATPase activity, but DNA dependent stimulation was observed infrequently. A gel shift assay showed that acriflavine inhibited the DNA binding of gyrase, The acrB mutation also reduced significantly the DNA binding of gyrase but did not change the sensitivity to acriflavine, These results revealed that the acrB mutation is related to the inhibitory mechanism of acriflavine; and the acriflavine sensitivity of the mutant, at least in vitro, is caused mainly by reduction of the enzyme activity, Further, our findings suggest that the COOH-terminal region of the B subunit is essential for the initial binding of gyrase to the substrate DNA.	OKAYAMA UNIV, BIORESOURCES RES INST, KURASHIKI, OKAYAMA 710, JAPAN; KONAN UNIV, FAC SCI, INST BIOL, KOBE, HYOGO 658, JAPAN	Okayama University; Konan University	Funatsuki, K (corresponding author), SHIONOGI & CO LTD, SHIONOGI RES LABS, ABURAHI LABS, 1405 GOTANDA, SHIGA 52034, JAPAN.							ADACHI T, 1987, NUCLEIC ACIDS RES, V15, P771, DOI 10.1093/nar/15.2.771; BACHELLIER S, 1994, MOL MICROBIOL, V12, P61, DOI 10.1111/j.1365-2958.1994.tb00995.x; BACHMANN BJ, 1983, MICROBIOL REV, V47, P180, DOI 10.1128/MMBR.47.2.180-230.1983; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; CONTRERAS A, 1992, MOL MICROBIOL, V6, P1617; COSLOY SD, 1973, MOL GEN GENET, V124, P1, DOI 10.1007/BF00267159; COZZARELLI NR, 1980, SCIENCE, V207, P953, DOI 10.1126/science.6243420; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRAKE JW, 1964, J CELL COMPAR PHYSL, V64, P19, DOI 10.1002/jcp.1030640404; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; HANSEN FG, 1979, MOL GEN GENET, V175, P135, DOI 10.1007/BF00425529; HASE A, 1990, PLANT CELL PHYSIOL, V31, P1053; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KLEIN JR, 1991, MOL GEN GENET, V230, P230, DOI 10.1007/BF00290673; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MENZEL R, 1987, P NATL ACAD SCI USA, V84, P4185, DOI 10.1073/pnas.84.12.4185; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; NAKAMURA H, 1978, J BACTERIOL, V134, P1184, DOI 10.1128/JB.134.3.1184-1187.1978; NAKAMURA H, 1965, J BACTERIOL, V90, P8, DOI 10.1128/JB.90.1.8-14.1965; NAKAMURA H, 1979, J BACTERIOL, V139, P8, DOI 10.1128/JB.139.1.8-12.1979; NAKAMURA H, 1968, J BACTERIOL, V96, P987, DOI 10.1128/JB.96.4.987-996.1968; NAKAMURA H, 1967, J BACTERIOL, V93, P1183, DOI 10.1128/JB.93.3.1183-1184.1967; NAKAMURA H, 1989, MEM KONAN U SCI SER, V36, P83; OTTER R, 1983, METHOD ENZYMOL, V100, P171; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; PENG H, 1993, J BIOL CHEM, V268, P24481; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; TAYLOR MW, 1981, J CHROMATOGR, V219, P133, DOI 10.1016/S0021-9673(00)80584-1; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012; YOSHIDA H, 1988, MOL GEN GENET, V211, P1, DOI 10.1007/BF00338386	43	11	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13302	13308		10.1074/jbc.272.20.13302	http://dx.doi.org/10.1074/jbc.272.20.13302			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148951	hybrid			2022-12-25	WOS:A1997WZ38400064
J	Marinelli, RA; Pham, L; Agre, P; LaRusso, NF				Marinelli, RA; Pham, L; Agre, P; LaRusso, NF			Secretin promotes osmotic water transport in rat cholangiocytes by increasing aquaporin-1 water channels in plasma membrane - Evidence for a secretin-induced vesicular translocation of aquaporin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	46th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases	NOV 08-12, 1996	CHICAGO, IL	Amer Assoc Study Liver Dis			DUCT EPITHELIAL-CELLS; MEDIATED MECHANISM; PERMEABILITY; VESICLES; LIVER; CHIP; PIG	Although secretin is known to stimulate ductal bile secretion by directly interacting with cholangiocytes, the precise cellular mechanisms accounting for this choleretic effect are unknown, We have previously shown that secretin stimulates exocytosis in cholangiocytes and that these cells transport water mainly via the water channel aquaporin-1 (AQP1), In this study, we tested the hypothesis that secretin promotes osmotic water movement in cholangiocytes by inducing the exocytic insertion of AQP1 into plasma membranes, Exposure of highly purified isolated rat cholangiocytes to secretin caused significant, dose-dependent increases in osmotic membrane water permeability (P-f) (e.g. increased by 60% with 10(-7) M secretin), which was reversibly inhibited by the water channel blocker HgCl2, Immunoblotting analysis of cholangiocyte membrane fractions showed that secretin caused up to a 3-fold increase in the amount of AQP1 in plasma membranes and a proportional decrease in the amount of the water channel in microsomes, suggesting a secretin-induced redistribution of AQP1 from intracellular to plasma membranes, Both the secretin-induced increase in cholangiocyte P-f and AQP1 redistribution were blocked by two perturbations that inhibit secretin-stimulated exocytosis in cholangiocytes, i.e. treatment with colchicine and exposure at low temperatures (20 and 4 degrees C). Our results demonstrate that secretin increases AQP1-mediated P-f in cholangiocytes. Moreover, our studies implicate the microtubule-dependent vesicular translocation of AQP1 water channels to the plasma membrane, a mechanism that appears to be essential for secretin-induced ductal bile secretion and suggests that AQP1 can be regulated by membrane trafficking.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,DEPT INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,DEPT BIOCHEM,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,DEPT BIOL MOL,ROCHESTER,MN 55905; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Mayo Clinic; Mayo Clinic; Mayo Clinic; Johns Hopkins University; Johns Hopkins University					NHLBI NIH HHS [HL 48268, HL 33991] Funding Source: Medline; NIDDK NIH HHS [DK 24031] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R37HL048268, R01HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK024031, R01DK024031] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPINI G, 1994, LIVER BIOL PATHOBIOL, V34, P623; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BOURGUET J, 1988, COMP BIOCHEM PHYS A, V90, P669, DOI 10.1016/0300-9629(88)90682-2; Boyer JL, 1996, AM J PHYSIOL-GASTR L, V270, pG1, DOI 10.1152/ajpgi.1996.270.1.G1; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; BREYER MD, 1994, ANNU REV PHYSIOL, V56, P711, DOI 10.1146/annurev.ph.56.030194.003431; BUANES T, 1988, GASTROENTEROLOGY, V95, P417, DOI 10.1016/0016-5085(88)90499-4; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ELKJAER ML, 1995, EUR J CELL BIOL, V67, P57; FAROUK M, 1992, GASTROENTEROLOGY, V102, P963, DOI 10.1016/0016-5085(92)90183-Y; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; KATO A, 1992, J BIOL CHEM, V267, P15523; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; Marinelli RA, 1996, SEMIN LIVER DIS, V16, P221, DOI 10.1055/s-2007-1007234; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; TIETZ PS, 1995, BIOCHEMISTRY-US, V34, P15436, DOI 10.1021/bi00047a007; TIETZ PS, 1995, AM J PHYSIOL-GASTR L, V269, pG110, DOI 10.1152/ajpgi.1995.269.1.G110; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VEEL T, 1990, ACTA PHYSIOL SCAND, V139, P603, DOI 10.1111/j.1748-1716.1990.tb08965.x; YAMAMOTO T, 1995, AM J PHYSIOL-CELL PH, V268, pC1546, DOI 10.1152/ajpcell.1995.268.6.C1546; Yano M, 1996, J BIOL CHEM, V271, P6702, DOI 10.1074/jbc.271.12.6702	28	150	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12984	12988		10.1074/jbc.272.20.12984	http://dx.doi.org/10.1074/jbc.272.20.12984			5	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148905	hybrid			2022-12-25	WOS:A1997WZ38400018
J	Meyer, HA; Hartmann, E				Meyer, HA; Hartmann, E			The yeast SPC22/23 homolog Spc3p is essential for signal peptidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; ROUGH MICROSOMES; SHUTTLE VECTORS; SEC11 PROTEIN; COMPLEX; PURIFICATION; GLYCOPROTEIN; SEQUENCE	In eucaryotic cells signal sequences of secretory and membrane proteins are cleaved by the signal peptidase complex during their transport into the lumen of the endoplasmic reticulum, The signal peptidase complex in yeast consists of four subunits, To date, three of these subunits have been functionally characterized. One of them, the Sec11p, is essential for viability of yeast cells. It shows significant homology to the mammalian SPC18 and SPC21 as well as to bacterial leader peptidases. Two other subunits, Spc1p and Spc2p, have been shown to be homologous to mammalian SPC12 and SPC25, respectively, and are not essential for protein translocation or signal peptide cleavage. We have purified and analyzed the fourth subunit of yeast signal peptidase, Spc3p. The protein is essential for viability of yeast cells. Depletion of SPC3 leads to accumulation of precursors of secretory proteins in vivo and to the loss of the signal peptidase activity in vitro. Therefore, in contrast to the bacterial leader peptidases, yeast signal peptidase requires a second subunit for its function.	MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Hartmann, Enno/C-5687-2013					BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; Fang H, 1996, J BIOL CHEM, V271, P16460, DOI 10.1074/jbc.271.28.16460; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Kalies KU, 1996, J BIOL CHEM, V271, P3925; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Mullins C, 1996, J BIOL CHEM, V271, P29094, DOI 10.1074/jbc.271.46.29094; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; NEWSOME AL, 1992, BIOCHEM J, V282, P447, DOI 10.1042/bj2820447; NIELSSON I, 1992, FEBS LETT, V299, P243; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SIKORSKI RS, 1989, GENETICS, V122, P19; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973; [No title captured]	36	29	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13159	13164		10.1074/jbc.272.20.13159	http://dx.doi.org/10.1074/jbc.272.20.13159			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148931	hybrid			2022-12-25	WOS:A1997WZ38400044
J	Mukhopadhyay, A; Funato, K; Stahl, PD				Mukhopadhyay, A; Funato, K; Stahl, PD			Rab7 regulates transport from early to late endocytic compartments in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; SENSITIVE FUSION PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; MEMBRANE-FUSION; INVOLVEMENT; PATHWAY; CELLS; YEAST	Rab7 has been shown to localize to late endosomes and to mediate transport from early to late endosome/lysosome in mammalian cells and in yeast. We developed a novel assay to quantify transport from early to late endosomes using the Xenopus oocyte. Oocytes were pulsed with avidin after which the oocytes were incubated to allow avidin transport to a late compartment. The oocytes were then allowed to internalize biotin-horseradish peroxidase (HRP), The oocytes were then injected with test proteins and incubated further to allow transport of biotin-HRP from early endosomes to late endosomal/lysosomal compartments. Transport was quantified by assessing the formation of HRP-biotin-avidin complexes, Injection of Rab7:wild-type (WT) and Rab7:Q67L, a GTPase defective mutant, stimulated transport. RabB:WT had no effect. Rab7:WT-stimulated transport was inhibited by nocodazole, suggesting a role for intact microtubules. Wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocked Rab7:WT-stimulated transport, but Rab7:Q67L-stimulated transport was unaffected by the drug. Rab7:Q67L is constitutively activated and may not require phosphatidylinositol 3-kinase activity for activation, Rab7-stimulated transport requires N-ethylmaleimide-sensitive factor (NSF) activity as transport was blocked by N-ethyhmaleimide and ATPase defective NSF mutants. Our results indicate that sequentially acting endocytic Rab GTPases utilize similar factors although their modes of action may be different.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Stahl, Philip/D-6315-2012					Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; GHOSH RN, 1994, J CELL SCI, V107, P2177; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GROVEL JP, 1991, CELL, V64, P915; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HASS A, 1995, EMBO J, V14, P5258; HASS A, 1996, EMBO J, V15, P296; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; LI G, 1997, IN PRESS J BIOL CHEM, V272; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MERESSE S, 1995, J CELL SCI, V108, P3349; MUKHOPADHYAY A, 1997, IN PRESS J CELL BIOL, V272; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; OPRESKO LK, 1987, CELL, V51, P557, DOI 10.1016/0092-8674(87)90125-5; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SOLDATI T, 1994, NATURE, V369, P18; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TEMESVARI L, 1994, J BIOL CHEM, V269, P25719; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; WOLTERS G, 1976, J CLIN PATHOL, V29, P873, DOI 10.1136/jcp.29.10.873; YANO H, 1993, J BIOL CHEM, V268, P25846; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	48	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13055	13059		10.1074/jbc.272.20.13055	http://dx.doi.org/10.1074/jbc.272.20.13055			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148916	hybrid			2022-12-25	WOS:A1997WZ38400029
J	Berninsone, P; Eckhardt, M; GerardySchahn, R; Hirschberg, CB				Berninsone, P; Eckhardt, M; GerardySchahn, R; Hirschberg, CB			Functional expression of the murine gels CMP-sialic acid transporter in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; YEAST GOLGI-APPARATUS; PROTEIN; SIGNAL; SIALYLTRANSFERASE; PROTEOLIPOSOMES; RECONSTITUTION; GLYCOSYLATION; LOCALIZATION; TOPOGRAPHY	We have functionally expressed the murine Golgi putative CMP-sialic acid transporter in Saccharomyces cerevisiae. Using a galactose-inducible expression system, S. cerevisiae vesicles were able to transport CMP sialic acid. Transport was dependent on galactose induction and was temperature-dependent and saturable with an apparent K-m of 2.9 mu M. Transport was inhibited by CMP, and upon vesicle disruption with Triton X-100 parameters were very similar to the previously described CMP-sialic acid transport characteristics observed with mammalian Golgi vesicles. CMP-sialic acid transport induction was specific as no transport of UDP-galactose was observed even though the latter putative transporter has a high degree of amino acid sequence identity with the CMP-sialic acid transporter. Together, the above results demonstrate that the previously described cDNA encoding the putative CMP-sialic acid transporter encodes the transporter protein per se and suggests that this heterologous expression system may be used for further structural and functional studies of other Golgi membrane transporter proteins.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01655 USA; HANNOVER MED SCH, INST MED MIKROBIOL, D-30625 HANNOVER, GERMANY	University of Massachusetts System; University of Massachusetts Worcester; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf				Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM R37-30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ABEIJON C, 1996, P NATL ACAD SCI NATL, V91, P10707; ARNOLD CE, 1994, J BIOL CHEM, V269, P30412; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; KREZDORN CH, 1994, EUR J BIOCHEM, V220, P809, DOI 10.1111/j.1432-1033.1994.tb18683.x; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MILLA ME, 1992, J BIOL CHEM, V267, P103; Munoz P, 1996, PLANT PHYSIOL, V112, P1585, DOI 10.1104/pp.112.4.1585; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; Schwientek T, 1996, J BIOL CHEM, V271, P3398; SCHWIENTEK T, 1995, J BIOL CHEM, V270, P5483, DOI 10.1074/jbc.270.10.5483	20	62	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12616	12619		10.1074/jbc.272.19.12616	http://dx.doi.org/10.1074/jbc.272.19.12616			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139716	hybrid			2022-12-25	WOS:A1997WY82900053
J	Duncan, EA; Brown, MS; Goldstein, JL; Sakai, J				Duncan, EA; Brown, MS; Goldstein, JL; Sakai, J			Cleavage site for sterol-regulated protease localized to a Leu-Ser bond in the lumenal loop of sterol regulatory element-binding protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; LDL RECEPTOR; TRANSCRIPTION; SREBP-1; GENE; SELECTION; PROMOTER; RNA	A sterol-regulated protease initiates release of the NH2-terminal segments of sterol regulatory element-binding proteins (SREBPs) from cell membranes, thereby allowing them to enter the nucleus and to stimulate transcription of genes involved in the uptake and synthesis of cholesterol and fatty acids, Using SREBP-2 as a prototype, we here identify the site of sterol-regulated cleavage as the Leu(522)-Ser(523) bond in the middle of the 31-residue hydrophilic loop that projects into the lumen of the endoplasmic reticulum and nuclear envelope, This site was identified through use of a vector encoding an SREBP-2/Ras fusion protein with a triple epitope tag that allowed immunoprecipitation of the cleaved COOH-terminal fragment, The NH, terminus of this fragment was pinpointed by radiochemical sequencing after replacement of selected codons with methionine codons and labeling the cells with [S-35]methionine, Alanine scanning mutagenesis revealed that only two amino acids are necessary for recognition by the sterol-regulated protease: 1) the leucine at the cleavage site (leucine 522), and 2) the arginine at the P4 position (arginine 519), These define a tetrapeptide sequence, RXXL, that is necessary for cleavage, Cleavage was not affected when the second transmembrane helix of SREBP-2 was replaced with the membrane-spanning region of the low density lipoprotein receptor, indicating that this sequence is not required for regulation, Glycosylation-site insertion experiments confirmed that leucine 522 is located in the lumen of the endoplasmic reticulum, We conclude that the sterol-regulated protease is a novel enzyme whose active site faces the lumen of the nuclear envelope, endoplasmic reticulum, or another membrane organelle to which the SREBPs may be transported before cleavage.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Sakai, Juro/0000-0003-4043-1035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BOLLAG DM, 1991, PROTEIN METHODS, P100; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; JAMES GL, 1994, J BIOL CHEM, V269, P27705; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Theopold U, 1996, P NATL ACAD SCI USA, V93, P1195, DOI 10.1073/pnas.93.3.1195; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TSAI DE, 1992, P NATL ACAD SCI USA, V89, P8864, DOI 10.1073/pnas.89.19.8864; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	27	143	151	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12778	12785		10.1074/jbc.272.19.12778	http://dx.doi.org/10.1074/jbc.272.19.12778			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139737	hybrid			2022-12-25	WOS:A1997WY82900074
J	Larkin, RM; Guilfoyle, TJ				Larkin, RM; Guilfoyle, TJ			Reconstitution of yeast and Arabidopsis RNA polymerase alpha-like subunit heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEIC-ACID POLYMERASE; TERMINAL ASSEMBLY DOMAIN; ESCHERICHIA-COLI; FUNCTIONAL MAP; IMMUNOLOGICAL PROPERTIES; PURIFICATION; BACTERIOPHAGE-T4; ARRANGEMENT; RECOGNITION; ANTIBODIES	Two subunits of about 36-44 kDa and 13-19 kDa in the eukaryotic nuclear RNA polymerases share limited amino acid sequence similarity to the alpha subunit in Escherichia coli RNA polymerase, The alpha subunit in the prokaryotic enzyme has a stoichiometry of 2, but the stoichiometry of the alpha-like subunits in the eukaryotic enzymes is not entirely clear. To gain insight into the subunit stoichiometry and assembly pathway for eukaryotic RNA polymerases, in vitro reconstitution experiments have been carried out with recombinant alpha-like subunits from yeast and plant RNA polymerase II. The large and small alpha-like subunits from each species formed stable heterodimers in vitro, but neither the large or small alpha-like subunits formed stable homodimers. Furthermore, mixed heterodimers were formed between corresponding subunits of yeast and plants, but were not formed between corresponding subunits in different RNA polymerases from the same species, Our results suggest that RNA polymerase II alpha-like heterodimers may be the equivalent of alpha homodimers found in E. coli RNA polymerase.	UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia								AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BURGESS RR, 1969, J BIOL CHEM, V244, P6168; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; ENGELKE DR, 1983, J BIOL CHEM, V258, P1921; GOFF CG, 1974, J BIOL CHEM, V249, P6181; GREENLEAF AL, 1975, EUR J BIOCHEM, V60, P169, DOI 10.1111/j.1432-1033.1975.tb20989.x; GUILFOYLE TJ, 1978, BIOCHEMISTRY-US, V17, P1860, DOI 10.1021/bi00603a009; HAGER GL, 1977, BIOCHEMISTRY-US, V16, P1, DOI 10.1021/bi00620a001; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HUET J, 1985, J BIOL CHEM, V260, P5304; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; IGARASHI K, 1991, J MOL BIOL, V218, P1, DOI 10.1016/0022-2836(91)90865-4; ISHIHAMA A, 1972, BIOCHEMISTRY-US, V11, P1250, DOI 10.1021/bi00757a021; Ishihama A, 1981, Adv Biophys, V14, P1; JENDRISAK J, 1978, BIOCHEMISTRY-US, V17, P1322, DOI 10.1021/bi00600a029; JENDRISAK JJ, 1977, BIOCHEMISTRY-US, V16, P1959, DOI 10.1021/bi00628a032; KIMURA M, 1995, J MOL BIOL, V248, P756, DOI 10.1006/jmbi.1995.0258; KIMURA M, 1994, J MOL BIOL, V242, P107, DOI 10.1006/jmbi.1994.1562; KIMURA M, 1995, J MOL BIOL, V254, P342, DOI 10.1006/jmbi.1995.0621; Klinger C, 1996, EMBO J, V15, P4643, DOI 10.1002/j.1460-2075.1996.tb00841.x; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; KRAMER A, 1981, EUR J BIOCHEM, V117, P449; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Larkin RM, 1996, GENE, V172, P211, DOI 10.1016/0378-1119(96)00030-3; MANN C, 1987, CELL, V48, P1908; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROHRER H, 1975, EUR J BIOCHEM, V60, P227, DOI 10.1111/j.1432-1033.1975.tb20995.x; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SANFORD T, 1985, J BIOL CHEM, V260, P8064; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARTZ LB, 1975, J BIOL CHEM, V250, P3221; SONG CZ, 1994, J BIOL CHEM, V269, P26976; STELLWAGEN E, 1990, METHOD ENZYMOL, V182, P317; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; Ulmasov T, 1995, GENE, V167, P203, DOI 10.1016/0378-1119(95)00643-5; Woychik Nancy A., 1993, Gene Expression, V3, P77; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZOU C, 1994, J MOL BIOL, V236, P1283, DOI 10.1016/0022-2836(94)90057-4; ZOU Y, 1993, CELL, V73, P375	48	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12824	12830		10.1074/jbc.272.19.12824	http://dx.doi.org/10.1074/jbc.272.19.12824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139743	hybrid			2022-12-25	WOS:A1997WY82900080
J	Thibault, C; Sganga, MW; Miles, MF				Thibault, C; Sganga, MW; Miles, MF			Interaction of phosducin-like protein with G protein beta gamma snbunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; BINDING; SUBUNITS; PHOSPHORYLATION; ACTIVATION; TRANSDUCIN; G(BETA-GAMMA); PURIFICATION; RHODOPSIN	Phosducin-like protein (PhLP), a widely expressed ethanol-responsive gene (Miles, M. F., Barhite, S., Sganga, M., and Elliott, M. (1993) Proc, Natl, Acad. Sci, U. S. A. 90, 10831-10835), is a homologue of phosducin, a known major regulator of G beta gamma signaling in retina and pineal gland, However, although phosducin has a well characterized role in retinal phototransduction, function of the PhLP remains unclear, In this study we examine the ability of PhLP to bind G beta gamma dimer in vitro and in vivo, Using PhLP glutathione S-transferase fusion proteins, we show that PhLP directly binds G beta gamma in vitro, Studies with a series of truncated PhLP fusion proteins indicate independent binding of G beta gamma to both the amino- and C-terminal halves of PhLP. Protein-protein interactions between G beta gamma and PhLP are inhibited by the alpha subunit of G(o) and G(i3), suggesting that PhLP can bind only free G beta gamma, Finally, we show that PhLP complexes, at least partially, with G beta gamma in vivo, Following overexpression of epitope-tagged PhLP together with G beta(1) gamma(2) proteins in COS-7 cells, a PhLP-G beta gamma complex is co-immunoprecipitated by monoclonal antibody directed against the epitope tag, Similarly, polyclonal anti-PhLP antibody co-precipitates endogenous PhLP and G beta gamma proteins from NG108-15 cell lysates, These data are consistent with the hypothesis that PhLP is a widely expressed modulator of G beta gamma function. Furthermore, because alternate forms of the PhLP transcript are expressed, there may be functional implications for the existence of two G beta gamma-binding domains on PhLP.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,ERNEST GALLO CLIN & RES CTR,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K02AA000118] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00118 (K02)] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1992, J BIOL CHEM, V267, P25104; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WANG JF, 1995, ALCOHOL CLIN EXP RES, V19, P34; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	20	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12253	12256		10.1074/jbc.272.19.12253	http://dx.doi.org/10.1074/jbc.272.19.12253			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139665	hybrid			2022-12-25	WOS:A1997WY82900002
J	Granovsky, AE; Natochin, M; Artemyev, NO				Granovsky, AE; Natochin, M; Artemyev, NO			The gamma subunit of rod cGMP-phosphodiesterase blocks the enzyme catalytic site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENTS; INHIBITORY SUBUNIT; BOVINE; TRANSDUCIN; ACTIVATION; MECHANISM; RHODOPSIN; PROTEIN; DOMAINS	Cyclic GMP phosphodiesterase (PDE) is the effector enzyme in the visual transduction cascade of vertebrate photoreceptor cells, In the dark, the activity of the enzyme catalytic alpha and beta subunits (P alpha beta) is inhibited by two gamma subunits (P gamma). Previous results have established that approximately 5-7 C-terminal residues of P gamma comprise the inhibitory domain, To study the interaction between the P gamma C-terminal region and P alpha beta, the P gamma mutant (Cys(68) --> Ser, and the last 4 C-terminal residues replaced with cysteine, P gamma-1-83Cys) was labeled with the fluorescent probe 3-(bromoacetyl)-7-diethylaminocoumarin (BC) at the cysteine residue (P gamma-1-83BC). P gamma-1-83BC was a more potent inhibitor of PDE activity than the unlabeled mutant, suggesting that the fluorescent probe in part substitutes for the P gamma C terminus in PDE inhibition, HoloPDE (P alpha beta gamma) had no effect on the P gamma-1-83BC fluorescence, but the addition of P alpha beta to P gamma-1-83BC resulted in an approximately 8-fold maximal fluorescence increase. A K-d for the P gamma-1-83BC-P alpha beta interaction was 4.0 +/- 0.5 nM. Zaprinast, a specific competitive inhibitor of PDE, effectively displaced the P gamma-1-83BC C terminus from its binding site on P alpha beta (IC50 = 0.9 mu M). cGMP and its analogs, 8-Br-cGMP and 2'-butyryl-cGMP, also competed with the P gamma-1-83BC C terminus for binding to P alpha beta. Our results provide new insight into the mechanism of PDE inhibition by showing that P gamma blocks the binding of cGMP to the PDE catalytic site.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa				Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-10843] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BELTMAN J, 1995, MOL PHARMACOL, V47, P330; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; JURNAK F, 1988, TRENDS BIOCHEM SCI, V13, P196; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	25	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11686	11689		10.1074/jbc.272.18.11686	http://dx.doi.org/10.1074/jbc.272.18.11686			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115217	hybrid			2022-12-25	WOS:A1997WX56900005
J	Hauser, CAE; Wetzel, CHR; Berning, B; Gerner, FM; Rupprecht, R				Hauser, CAE; Wetzel, CHR; Berning, B; Gerner, FM; Rupprecht, R			Flunitrazepam has an inverse agonistic effect on recombinant alpha(6)beta(2)gamma(2)-GABA(A) receptors via a flunitrazepam-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; SUBUNIT MESSENGER-RNAS; RAT-BRAIN; BENZODIAZEPINE RECEPTORS; ALCOHOL ANTAGONIST; ALPHA-SUBUNIT; AFFINITY; CELLS; LIGANDS; SUBTYPES	gamma-Aminobutyric acid type A (GABA(A)) receptor subtypes containing the alpha(6)-subunit are generally thought to be insensitive to the action of benzodiazepine agonists. We describe the specific binding of the benzodiazepine agonist flunitrazepam to alpha(6) beta(2) gamma(2)-containing GABA(A) receptors, which has not been observed before and differs from previous reports. With the whole-cell voltage-clamp technique, we observed a functional discrimination between alpha(1) beta(2) gamma(2)- and alpha(6) beta(2) gamma(2)-receptors. Different benzodiazepines had different effects on GABA-evoked chloride currents. The agonist flunitrazepam had an inverse agonistic effect, whereas the antagonist flumazenil increased GABA-induced chloride currents. The action of flunitrazepam on the channel activity of alpha(1) beta(2) gamma(2)-receptors was opposite to its action on alpha(1) beta(2) gamma(2)-receptors. We conclude that flunitrazepam can act as either an agonist or an inverse agonist, depending on the GABA(A) receptor configuration.			Hauser, CAE (corresponding author), MAX PLANCK INST PSYCHIAT,INST CLIN,KRAEPELINSTR 10,D-80804 MUNICH,GERMANY.		Wetzel, Christian H/N-9880-2017; Hauser, Charlotte A. E./C-1321-2014; Wetzel, Christian/C-2501-2009; Wetzel, Christian/F-1366-2018	Wetzel, Christian H/0000-0002-5762-0003; Hauser, Charlotte A. E./0000-0001-8251-7246; Wetzel, Christian/0000-0002-5762-0003; 				BASILE AS, 1989, J PHARMACOL EXP THER, V248, P463; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; GILLARD NP, 1991, EUR J PHARMACOL, V195, P407, DOI 10.1016/0014-2999(91)90484-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hauser CAE, 1996, BIOCHEM BIOPH RES CO, V219, P531, DOI 10.1006/bbrc.1996.0268; HAUSER CAE, 1995, EUR J PHARM-MOLEC PH, V289, P249, DOI 10.1016/0922-4106(95)90101-9; IM WB, 1993, BRIT J PHARMACOL, V110, P677, DOI 10.1111/j.1476-5381.1993.tb13864.x; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KLEINGOOR C, 1991, NEUROSCI LETT, V130, P169, DOI 10.1016/0304-3940(91)90389-B; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LUDDENS H, 1995, J PSYCHIATR RES, V29, P77, DOI 10.1016/0022-3956(94)00040-X; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; Nusser Z, 1996, J NEUROSCI, V16, P103; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; SIEGHART W, 1991, EUR J PHARMACOL, V197, P103, DOI 10.1016/0014-2999(91)90371-V; SUZDAK PD, 1986, SCIENCE, V234, P1243, DOI 10.1126/science.3022383; TURNER DM, 1991, J PHARMACOL EXP THER, V257, P1236; WAFFORD KA, 1993, MOL PHARMACOL, V43, P240; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; WISDEN W, 1991, FEBS LETT, V289, P227, DOI 10.1016/0014-5793(91)81076-K; WISDEN W, 1992, J NEUROSCI, V12, P1040; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x	26	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11723	11727		10.1074/jbc.272.18.11723	http://dx.doi.org/10.1074/jbc.272.18.11723			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115225	hybrid			2022-12-25	WOS:A1997WX56900013
J	Suzuki, M; Avicola, AK; Hood, L; Loeb, LA				Suzuki, M; Avicola, AK; Hood, L; Loeb, LA			Low fidelity mutants in the O-helix of Thermus aquaticus DNA polymerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; KLENOW FRAGMENT; MUTATIONAL SPECIFICITY; REVERSE-TRANSCRIPTASE; REDUCED FIDELITY; CHAIN-REACTION; REPLICATION; MUTAGENESIS; SITE	We screened 67 mutants in the O-helix of Thermus aquaticus (Tag) DNA polymerase I (pol I) for altered fidelity of DNA synthesis. These mutants were obtained (Suzuki, M., Baskin, D., Hood, L., and Loeb, L. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9670-9675) by substituting an oligonucleotide containing random sequences for codons 659-671, and selecting for complementation of a growth defect in Escherichia coli caused by temperature-sensitive host pol I, Thirteen mutants decreased fidelity in a screen that employed primer extension reactions lacking one of four complementary deoxynucleoside triphosphates (dNTPs). Three mutants were purified and exhibited 29-68% of wild-type specific activity. Homogeneous polymerases A661E, A661P, and T664R extended primers further than the wild-type, synthesizing past template nucleotides for which the complementary dNTP was absent, The data indicate that both misinsertion of incorrect nucleotides and extension of mispaired primer termini were increased, In a lacZ alpha forward mutation assay, A661E and T664R yielded mutation frequencies at least 7- and 25-fold greater, respectively, than that of the wild type polymerase, These findings emphasize the importance of the O-helix in substrate recognition and are compatible with a role for pyrophosphate release in enhancing fidelity of DNA synthesis.	UNIV WASHINGTON, JOSEPH GOTTSTEIN MEM CANC RES LAB, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MOL BIOTECHNOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006	NATIONAL CANCER INSTITUTE [R35CA039903] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-39903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BATTULA N, 1974, J BIOL CHEM, V249, P4086; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BECKMAN RA, 1993, Q REV BIOPHYS, V26, P225, DOI 10.1017/S0033583500002869; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BENENEK K, 1995, J BIOL CHEM, V270, P19516; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FEIG DI, 1993, BIOCHEMISTRY-US, V32, P4466, DOI 10.1021/bi00067a040; FEIG DI, 1994, J MOL BIOL, V235, P33, DOI 10.1016/S0022-2836(05)80009-9; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; FERRIN LJ, 1986, BIOCHEMISTRY-US, V25, P5131, DOI 10.1021/bi00366a023; FUCHAROEN S, 1989, J BIOL CHEM, V264, P7780; HILLEBRAND GG, 1984, NUCLEIC ACIDS RES, V12, P3155, DOI 10.1093/nar/12.7.3155; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; JOYCE CM, 1982, J BIOL CHEM, V257, P1958; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P7256, DOI 10.1021/bi960537i; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KORNBERG A, 1992, DNA REPLICATION, P130; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1979, J BIOL CHEM, V254, P5718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawyer F C, 1993, PCR Methods Appl, V2, P275; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; Loeb L A, 1996, Adv Pharmacol, V35, P321, DOI 10.1016/S1054-3589(08)60280-X; LOEB LA, 1981, J BIOL CHEM, V256, P3978; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; OSUMIDAVIS PA, 1994, J MOL BIOL, V237, P5, DOI 10.1006/jmbi.1994.1205; PANDEY VN, 1987, BIOCHEMISTRY-US, V26, P7744, DOI 10.1021/bi00398a031; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; TINDALL KR, 1988, GENETICS, V118, P551; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027	52	60	71	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11228	11235						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111024				2022-12-25	WOS:A1997WW00900040
J	Camp, HS; Tafuri, SR				Camp, HS; Tafuri, SR			Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; EPIDERMAL GROWTH-FACTOR; CO-REPRESSOR; ADIPOCYTE DIFFERENTIATION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; STIMULATION; PHOSPHORYLATION; TRANSCRIPTION; ADIPOGENESIS	Adipocyte differentiation is regulated both positively and negatively by external growth factors such as insulin, platelet-derived growth factor (PDGF), and epidermal growth factor (EGF). A key component of the adipocyte differentiation process is PPAR gamma, peroxisomal proliferator-activated receptor gamma. To determine the relationship between PPAR gamma activation and growth factor stimulation in adipogenesis, we investigated the effects of PDGF and EGF on PPAR gamma 1 activity. PDGF treatment decreased ligand-activated PPAR gamma 1 transcriptional activity in a transient reporter assay. In vivo [P-32]orthophosphate labeling experiments demonstrated that PPAR gamma 1 is a phosphoprotein that undergoes EGF-stimulated MEK/mitogen-activated protein (MAP) kinase-dependent phosphorylation. Purified PPAR gamma 1 protein was phosphorylated in vitro by recombinant activated MAP kinase. Examination of the PPAR gamma 1 sequence revealed a single MAP kinase consensus recognition site at Ser(82). Mutation of Ser(82) to Ala inhibited both in vitro and in vivo phosphorylation and growth factor-mediated transcriptional repression. Therefore, phosphorylation of PPAR gamma 1 by MAP kinase contributes to the reduction of PPAR gamma 1 transcriptional activity by growth factor treatment.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CELL BIOL,ANN ARBOR,MI 48105	Pfizer								ADACHI H, 1994, ENDOCRINOLOGY, V135, P1824, DOI 10.1210/en.135.5.1824; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; BRAUERKRIEGER HI, 1995, BIOCHEM J, V307, P549; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; SERRERO G, 1987, BIOCHEM BIOPH RES CO, V146, P194, DOI 10.1016/0006-291X(87)90710-8; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SHALEV A, 1996, MOL ENDOCRINOL, V137, P4499; Tafuri SR, 1996, ENDOCRINOLOGY, V137, P4706, DOI 10.1210/en.137.11.4706; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5623; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	34	388	397	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10811	10816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099735				2022-12-25	WOS:A1997WV26200069
J	Muller, G; Ertl, J; Gerl, M; Preibisch, G				Muller, G; Ertl, J; Gerl, M; Preibisch, G			Leptin impairs metabolic actions of insulin in isolated rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE-PRODUCT; GLUCOSE-TRANSPORT; FAT-CELLS; IN-VITRO; OB RNA; MICE; PROTEIN; EXPRESSION; HYPOTHALAMUS; GLIMEPIRIDE	Leptin is an adipocyte hormone involved in the regulation of energy homeostasis. Generally accepted biological effects of leptin are inhibition of food intake and stimulation of metabolic rate in ob/ob mice that are defective in the leptin gene. In contrast to these centrally mediated effects of leptin, we are reporting here on leptin effects on isolated rat adipocytes. Leptin impairs several metabolic actions of insulin, i.e. stimulation of glucose transport, glycogen synthase, lipogenesis, inhibition of isoproterenol-induced Lipolysis, and protein kinase A activation, as well as stimulation of protein synthesis. Insulin effects were reduced by leptin (2 nm) with a half-life of about 8 h. At low leptin concentrations (<1 nM), the insulin sensitivity was reduced leading to a shift to the right in the dose-response curve. At higher concentrations the responsiveness was diminished resulting in nearly complete inhibition of insulin effects at >30 nM leptin. The IC50 value of leptin was 3.1+/-1 nM after 15 h of preincubation of adipocytes in primary culture. The natural splice variant des-Gln49-leptin exhibited a significantly lower potency. Adipocytes regained full insulin sensitivity within a few hours after leptin removal. The stimulation of glucose transport by vanadate was not affected by leptin. These data show specific and potent impairment of insulin action by leptin in the physiological concentration range of both leptin and insulin, which may be related to the pathophysiology of insulin resistance in both non-insulin-dependent diabetes mellitus and obesity.			Muller, G (corresponding author), HOECHST AG,HMR,RES AREA FRANKFURT,TA METAB DIS,BLDG H825,D-65926 FRANKFURT,GERMANY.			Muller, Gunter/0000-0001-6178-8215				ALTAN N, 1985, DIABETES, V34, P281, DOI 10.2337/diabetes.34.3.281; Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; Berti L., 1996, Diabetologia, V39, pA59; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CZECH MP, 1974, J BIOL CHEM, V249, P5421; DagogoJack S, 1996, DIABETES, V45, P695, DOI 10.2337/diabetes.45.5.695; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; GLIEMANN J, 1972, BIOCHIM BIOPHYS ACTA, V286, P1, DOI 10.1016/0304-4165(72)90082-7; GLIEMANN J, 1984, BIOCHIM BIOPHYS ACTA, V804, P68, DOI 10.1016/0167-4889(84)90100-9; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOUSEKNECHT KL, 1996, EXP CLIN ENDOCR S2, V104, P8; KRODER G, 1996, EXP CLIN ENDOCR S2, V104, P66; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; LONDOS C, 1985, J BIOL CHEM, V260, P5139; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; MULLER G, 1993, DIABETES, V42, P1852, DOI 10.2337/diabetes.42.12.1852; MULLER G, 1994, BIOCHEM PHARMACOL, V48, P985, DOI 10.1016/0006-2952(94)90369-7; NECHAY BR, 1986, FASEB J, V45, P123; ORON Y, 1979, ANAL BIOCHEM, V94, P409, DOI 10.1016/0003-2697(79)90382-8; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; RODBELL M, 1964, J BIOL CHEM, V239, P375; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Stehling O, 1996, AM J PHYSIOL-REG I, V271, pR1770, DOI 10.1152/ajpregu.1996.271.6.R1770; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TRACEY AS, 1986, P NATL ACAD SCI USA, V83, P609, DOI 10.1073/pnas.83.3.609; VILA MD, 1990, BIOCHEMISTRY-US, V29, P8735, DOI 10.1021/bi00489a033; WIELAND O, 1974, METHODEN ENZYMATISCH, P1448; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	49	386	415	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10585	10593						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099705	hybrid			2022-12-25	WOS:A1997WV26200039
J	Prall, OWJ; Sarcevic, B; Musgrove, EA; Watts, CKW; Sutherland, RL				Prall, OWJ; Sarcevic, B; Musgrove, EA; Watts, CKW; Sutherland, RL			Estrogen-induced activation of Cdk4 and Cdk2 during G(1)-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; HUMAN-DIPLOID FIBROBLASTS; MAMMARY-CARCINOMA CELLS; MYC ONCOGENE EXPRESSION; C-MYC; RETINOBLASTOMA-PROTEIN; GROWTH-FACTOR; TUMOR-SUPPRESSOR; GENE-EXPRESSION; RAT UTERUS	Estrogens induce cell proliferation in target tissues by stimulating progression through G(1) phase of the cell cycle, but the underlying molecular targets remain undefined, To determine the role of the cyclin/cyclin-dependent kinase (CDK)/retinoblastoma protein (pRB) pathway in this response we treated MCF-7 breast cancer cells with the pure estrogen antagonist ICI 182780 to inhibit estrogen-induced gene expression and induce G(1) phase arrest, Subsequent treatment with 17 beta-estradiol resulted in the synchronous entry of cells into S phase commencing at 12 h, The proportion of cells in S phase reached a maximum of 60% at 21-24 h, Cells subsequently completed mitosis and entered a second semi-synchronous round of replication. Entry into S phase was preceded by increased activity of both Cdk4 and cyclin E-Cdk2 and hyperphosphorylation of pRB, all within the first 3-6 h of estradiol treatment, The increase in Cdk4 activity was accompanied by increases in cyclin D1 mRNA and protein, indicating that an initiating event in the activation of Cdk4 was increased cyclin D1 gene expression, In contrast, the levels of Cdk2 and the CDK inhibitors p21 (WAF1/CIP1/SDI1) and p27 (KIP1) in total cell lysates and in cyclin E immunoprecipitates were unaltered at these early time points. However, an inhibitory activity was present in antiestrogen-pretreated cell lysates toward recombinant cyclin E-Cdk2 and was relieved by estradiol treatment, This activity was attributable predominantly to p21, These apparently conflicting data were resolved by performing gel filtration chromatography, which revealed that only a minority of cyclin E-Cdk2 complexes were active following estradiol treatment, Active complexes eluted at a higher molecular weight than inactive complexes, were relatively deficient in both p21 and p27, and contained Cdk2 with increased threonine 160 phosphorylation, consistent with a mechanism of activation of cyclin E-Cdk2 involving both reduced CDK inhibitor association and CDK-activating kinase-mediated phosphorylation of Cdk2, These results provide an explanation for the early activation of both cyclin D1-Cdk4 and cyclin E-Cdk2 complexes that accompany G(1)-S phase progression in response to estradiol.	ST VINCENTS HOSP, GARVAN INST MED RES, CANC RES PROGRAM, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Sutherland, Robert L/A-8378-2008	Sarcevic, Boris/0000-0002-8063-1050				Adams PD, 1996, MOL CELL BIOL, V16, P6623; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Altucci L, 1996, ONCOGENE, V12, P2315; [Anonymous], 1992, Lancet, V339, P1; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Bonapace IM, 1996, ONCOGENE, V12, P753; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1992, ONCOGENE, V7, P1587; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EISENMAN RN, 1989, ONCOGENES MOL ORIGIN, P175; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Geng Y, 1996, ONCOGENE, V12, P1173; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HENDERSON BE, 1988, CANCER RES, V48, P246; HERMEKING H, 1995, ONCOGENE, V11, P1409; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEUNG BS, 1987, J CELL BIOCHEM, V34, P213, DOI 10.1002/jcb.240340307; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LIPPMAN M, 1976, CANCER RES, V36, P4595; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; Musgrove EA, 1996, J CELL BIOCHEM, V60, P363; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; NOVAKHOFER I, 1988, EXPERIENTIA, V44, P162, DOI 10.1007/BF01952203; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; SUTHERLAND RL, 1988, HORMONES THEIR ACT 1, P197; SUTHERLAND RL, 1987, ENDOCRINOLOGY MALIGN, P121; TAYLOR IW, 1983, CANCER RES, V43, P4007; THOMAS T, 1994, CANCER RES, V54, P1077; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAKELING AE, 1991, CANCER RES, V51, P3867; WAKELING AE, 1988, J STEROID BIOCHEM, V31, P645, DOI 10.1016/0022-4731(88)90014-3; WATSON PH, 1991, CANCER RES, V51, P3996; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU L, 1994, CANCER RES, V54, P5262; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	90	374	382	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10882	10894						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099745				2022-12-25	WOS:A1997WV26200079
J	Suzuki, H; Kamakura, M; Morii, M; Takeguchi, N				Suzuki, H; Kamakura, M; Morii, M; Takeguchi, N			The phospholipid flippase activity of gastric vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOSAL BARRIER; PARIETAL-CELLS; ACID-SECRETION; P-GLYCOPROTEIN; MEMBRANE; STIMULATION; ATPASE; ASYMMETRY; RETICULUM; INHIBITOR	We found that isolated gastric vesicles contain a novel Mg2+-ATP-dependent phospholipid translocation (flippase) activity, Fluorescence analogue of phosphatidylcholine, 2-(12-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino) dodecanoyl-1-hexadecanoyl-sn-glycero-3-phosphocholine, was ATP-dependently translocated from the outer (cytosolic) to inner (luminal) leaflet of the Lipid membrane bilayer of hog gastric vesicles, The translocation was saturable and depended on time and the ATP concentration (K-m = 3.1 mu M). The basal Mg2+-ATPase activity of gastric vesicles in the absence of K+ showed high (K-m = 1.6 mu m) and low (K-m = 80 mu M) affinities for ATP, indicating that the present flippase activity is driven mostly by the high affinity Mg2+-ATPase activity. It required Mg2+ but not K+. Verapamil, which is an inhibitor of mouse mdr2 phosphatidylcholine flippase, did not inhibit the present flippase activity, Isolated sarcoplasmic reticulum vesicles that contain Ca2+-ATPase did not show any flippase activity. Fluorescence analogues of phosphatidylserine and phosphatidylethanolamine were similarly translocated by the gastric flippase, These phospholipid flippase activities were inhibited by 2-methyl-8-(phenylmethoxy)imidazo[1,2-a]-pyridine-3-acetonitrile (SCH 28080) (IC50 = 0.14-0.25 mu M), a specific K+-ATPase inhibitor of gastric H+,K+-ATPase rich in gastric vesicles. IC50 value for the SCH 28080-inhibitable Mg2+-ATPase activity was about 0.13 mu m, indicating that the phospholipid translocation was driven mostly by the SCH 28080-sensitive Mg2+-ATPase activity, Possible physiological roles of flippases were discussed in relation with the gastric acid secretory and cytoprotective mechanisms.	TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,TOYAMA 93001,JAPAN	University of Toyama								ASANO S, 1987, J BIOL CHEM, V262, P13263; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; Buton X, 1996, J BIOL CHEM, V271, P6651, DOI 10.1074/jbc.271.12.6651; FADOK VA, 1992, J IMMUNOL, V148, P2207; HASHIMOTO A, 1992, PFLUG ARCH EUR J PHY, V422, P84, DOI 10.1007/BF00381517; HELANDER HF, 1986, ANAT REC, V216, P373, DOI 10.1002/ar.1092160306; HILLS BA, 1992, AUST NZ J MED, V22, P441, DOI 10.1111/j.1445-5994.1992.tb02167.x; HILLS BA, 1983, AM J PHYSIOL, V244, pG561, DOI 10.1152/ajpgi.1983.244.5.G561; KAYNE FJ, 1971, ARCH BIOCHEM BIOPHYS, V143, P232, DOI 10.1016/0003-9861(71)90204-9; KEELING DJ, 1988, BIOCHEM PHARMACOL, V37, P2231, DOI 10.1016/0006-2952(88)90586-2; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCIER F, 1989, J CELL BIOL, V108, P441, DOI 10.1083/jcb.108.2.441; MORII M, 1986, J BIOL CHEM, V261, P2343; Morii M, 1996, J BIOL CHEM, V271, P4068; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; OGATA T, 1993, ANAT REC, V237, P208, DOI 10.1002/ar.1092370208; OLAISSON H, 1985, J BIOL CHEM, V260, P1262; RABON E, 1982, BIOCHIM BIOPHYS ACTA, V688, P515, DOI 10.1016/0005-2736(82)90363-7; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Shin JM, 1996, J BIOL CHEM, V271, P1904, DOI 10.1074/jbc.271.4.1904; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63; TAKEGUCHI N, 1983, J BIOL CHEM, V358, P3094; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TOMINAGA M, 1995, J BIOL CHEM, V270, P27887, DOI 10.1074/jbc.270.46.27887; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; WOLOSIN JM, 1981, J BIOL CHEM, V256, P3149; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZACHOWSKI A, 1989, NATURE, V340, P75, DOI 10.1038/340075a0	36	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10429	10434						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099684				2022-12-25	WOS:A1997WV26200018
J	Zhao, J; Kessler, MM; Moore, CL				Zhao, J; Kessler, MM; Moore, CL			Cleavage factor II of Saccharomyces cerevisiae contains homologues to subunits of the mammalian cleavage/polyadenylation specificity factor and exhibits sequence-specific, ATP-dependent interaction with precursor RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLY(A) POLYMERASE; POLYADENYLATION FACTOR; BINDING PROTEINS; 3' END; SITE; AAUAAA; GENE; PURIFICATION; DOWNSTREAM	Cleavage of pre-mRNA during 3'-end formation in yeast requires two protein factors, cleavage factor I (CF I) and cleavage factor (CF II). A 5300-fold purification of CF II indicates that four polypeptides of 150, 105, 100, and 90 kDa copurify with CF II activity. The 150-kDa protein is recognized by antibodies against Cft1, the yeast homologue of the 160-kDa subunit of the mammalian cleavage/polyadenylation specificity factor (CPSF). The 100-kDa subunit is identical to Brr5/Ysh1, a yeast protein with striking similarity to the 73-kDa subunit of CPSF. The 105-kDa protein, designated Cft2 (cleavage factor two) exhibits significant homology to the CPSF 100-kDa subunit. Cft2 is cross-linked to pre-mRNA substrate containing the poly(A) site and wild type upstream and downstream flanking sequences, but not to precleaved RNA lacking downstream sequences or to substrate in which the CUA), processing signal has been deleted. The specific binding of Cft2 to the RNA substrate is ATP-dependent, in agreement with the requirement of ATP for cleavage. The sequence-specific binding of Cft2 and the similarities of CF II subunits to those of CPSF supports the hypothesis that CF II functions in the cleavage of yeast mRNA 3'-ends in a manner analagous to that of CPSF in the mammalian system. These results provide additional evidence that certain features of the molecular mechanism of mRNA 3'-end formation are conserved between yeast and mammals, but also highlight unexpected differences.	TUFTS UNIV, SCH MED, DEPT MOL BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041752] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM41752] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amrani N, 1997, MOL CELL BIOL, V17, P1102, DOI 10.1128/MCB.17.3.1102; Amrani N, 1996, MOL GEN GENET, V252, P552, DOI 10.1007/BF02172401; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; Chanfreau G, 1996, SCIENCE, V274, P1511, DOI 10.1126/science.274.5292.1511; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dunbar B.S., 1994, PROTEIN BLOTTING PRA; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; Guo ZJ, 1996, MOL CELL BIOL, V16, P2772; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; Kessler MM, 1996, J BIOL CHEM, V271, P27167, DOI 10.1074/jbc.271.43.27167; KESSLER MM, 1995, BIOCHEMISTRY-US, V34, P1750, DOI 10.1021/bi00005a032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MANDART E, 1995, MOL CELL BIOL, V15, P6979; Manley JL, 1996, SCIENCE, V274, P1481, DOI 10.1126/science.274.5292.1481; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; RUSSNAK R, 1995, MOL CELL BIOL, V15, P1689; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Stumpf G, 1996, SCIENCE, V274, P1517, DOI 10.1126/science.274.5292.1517; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; ZHELKOVSKY AM, 1995, J BIOL CHEM, V270, P26715, DOI 10.1074/jbc.270.44.26715	48	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10831	10838						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099738				2022-12-25	WOS:A1997WV26200072
J	Guan, GM; Dai, PH; Osborne, TF; Kim, JB; Shechter, I				Guan, GM; Dai, PH; Osborne, TF; Kim, JB; Shechter, I			Multiple sequence elements are involved in the transcriptional regulation of the human squalene synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; MOLECULAR-CLONING; BINDING PROTEIN-1; STEROL REGULATION; NF-Y; PROMOTER; SREBP-1; IDENTIFICATION; EXPRESSION	The expression of human squalene synthase (HSS) gene is transcriptionally regulated in HepG-2 cells, up to 10-fold, by variations in cellular cholesterol homeostasis, An earlier deletion analysis of the 5'-flanking region of the HSS gene demonstrated that most of the HSS promoter activity is detected within a 69-base pair sequence located between nucleotides -131 and -200, ADD1/SREBP-1c, a rat homologue of sterol regulatory element binding protein (SREBP)-1c binds to sterol regulatory element (SRE)-1-like sequence (HSS-SRE-1) present in this region (Guan, G., Jiang, G., Koch, R. L. and Shechter, I. (1995) J. Biol. Chem. 270, 21958-21965), In our present study, we demonstrate that mutation of this HSS-SRE-1 element significantly reduced, but did not abolish, the response of HSS promoter to change in sterol concentration, Mutation scanning indicates that two additional DNA promoter sequences are involved in sterol-mediated regulation, The first sequence contains an inverted SRE-3 element (Inv-SRE-3) and the second contains an inverted Y-box (Inv-Y-box) sequence, A single mutation in any of these sequences reduced, but did not completely remove, the response to sterols, Combination mutation studies showed that the HSS promoter activity was abolished only when all three elements were mutated simultaneously, Go-expression of SRE-1- or SRE-2-binding proteins (SREBP-1 or SREBP-2) with HSS promoter-luciferase reporter resulted in a dramatic increase of HSS promoter activity, Gel mobility shift studies indicate differential binding of the SREBPs to regulatory sequences in the HSS promoter. These results indicate that the transcription of the HSS gene is regulated by multiple regulatory elements in the promoter.	UNIFORMED SERV UNIV HLTH SCI,F EDWARD HEBERT SCH MED,DEPT BIOCHEM,BETHESDA,MD 20814; UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92717; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Uniformed Services University of the Health Sciences - USA; University of California System; University of California Irvine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				KIM, Jae Bum/0000-0003-2337-6935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050628, R01HL048540] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50628, HL48540] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUAN G, 1995, J BIOL CHEM, V270, P21968; HUA X, 1995, GENOMICS, V2535, P667; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; Kawabe Y, 1996, BIOCHEM BIOPH RES CO, V219, P515, DOI 10.1006/bbrc.1996.0265; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; REED GE, 1995, BRAIN RES, V682, P1, DOI 10.1016/0006-8993(95)00284-W; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SATO R, 1994, J BIOL CHEM, V269, P17267; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	32	97	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10295	10302						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092581				2022-12-25	WOS:A1997WU03900100
J	Ingram, MF; Shelness, GS				Ingram, MF; Shelness, GS			Folding of the amino-terminal domain of apolipoprotein B initiates microsomal triglyceride transfer protein-dependent lipid transfer a to nascent very low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; RAT-LIVER; DITHIOTHREITOL TREATMENT; INTRACELLULAR-TRANSPORT; SECRETORY PROTEINS; DISULFIDE BONDS; EXPRESSION; SEQUENCE	The initial assembly of apolipoprotein B100 (apoB) into lipoprotein particles occurs cotranslationally. To examine steps required to initiate this process, the intracellular folding and assembly of the amino-terminal 28% of apoB (apoB28) was examined using several criteria including nonreducing gel electrophoresis, sensitivity to dithiothreitol (DTT)-mediated reduction, and buoyant density gradient centrifugation, In hepatoma cells, after a 1-min pulse with radiolabeled amino acids, labeled apoB28 migrated during gel electrophoresis in the folded position and was resistant to reduction in vivo with 2 mM DTT. A similar rate and extent of folding was observed in Chinese hamster ovary cells, a microsomal triglyceride transfer protein (MTP)-negative cell line that can neither lipidate nor efficiently secrete apoB28, Amino terminal folding of apoB28 was essential for its subsequent intracellular lipidation as apoB28 synthesized in hepatoma cells under reducing conditions remained lipid poor (d > 1.25 g/ml) and was retained intracellularly. Upon DTT removal, reduced apoB28 underwent a process of rapid (t(1/2) approximate to 2 min) posttranslational folding followed by a slower process of MTP-dependent lipidation. As with the cotranslational assembly pathway, post-translational lipidation of apoB28 displayed a strict dependence upon amino-terminal folding. We conclude that: 1) folding of the aminoterminal disulfide bonded domain of apoB is achieved prior to the completion of translation and is independent of MTP and events associated with buoyant lipoprotein formation and 2) domain specific folding of apoBs amino-terminal region is required to initiate MTP-dependent lipid transfer to nascent apoB in the hepatic endoplasmic reticulum.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT COMPARAT MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NHLBI NIH HHS [HL49373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOREN J, 1993, BIOCHEM SOC T, V21, P487, DOI 10.1042/bst0210487; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHAN L, 1992, J BIOL CHEM, V267, P25621; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DIXON JL, 1993, J LIPID RES, V34, P167; ESSER V, 1988, J BIOL CHEM, V263, P13282; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; Ingram MF, 1996, J LIPID RES, V37, P2202; KAJI EH, 1993, J BIOL CHEM, V268, P22195; KAJI EH, 1993, J BIOL CHEM, V268, P22188; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LOSCH A, 1995, J BIOL CHEM, V270, P11543, DOI 10.1074/jbc.270.19.11543; OPSTELTEN DJE, 1993, J VIROL, V67, P7394, DOI 10.1128/JVI.67.12.7394-7401.1993; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Pease RJ, 1996, CURR OPIN LIPIDOL, V7, P132, DOI 10.1097/00041433-199606000-00004; PETERS T, 1982, J BIOL CHEM, V257, P8847; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	54	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10279	10286						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092579				2022-12-25	WOS:A1997WU03900098
J	Xian, WJ; Rosenberg, MP; DiGiovanni, J				Xian, WJ; Rosenberg, MP; DiGiovanni, J			Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: Possible role in mouse skin tumor promotion	ONCOGENE			English	Article						erbB2; c-src; phosphorylation; tumor promotion	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; NEU-ONCOGENE; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; HUMAN-BREAST; MOLECULAR-CLONING; CARCINOMA-CELLS; MAMMARY-TUMORS; PROTO-ONCOGENE	In recent work eve showed that the EGF receptor (EGFr) was activated in tumor promoter treated mouse epidermis (Cell Growth & Differentiation, 6: 1447-1455, 1995). In the present study, we have investigated the possible role of other erbB family members in the process of tumor promotion. Both erbB2 and erbB3, but not erbB4, were expressed in cultured mouse keratinocytes and in mouse epidermis in vivo. In cultured mouse keratinocytes, EGF stimulated rapid tyrosine phosphorylation of erbB2 followed by a time-dependent degradation of erbB2 protein. Furthermore, an increase in erbB2:EGFr heterodimer formation was also induced by EGF. In contrast to the results with erbB2, EGF did not induce tyrosine phosphorylation, the degradation of erbB3, or erbB3:EGFr heterodimer formation in cultured keratinocytes. Further analyses revealed that c-src kinase activity was dramatically elevated in cultured mouse keratinocytes exposed to EGF. In mouse epidermis following multiple treatments with 12-O-tetradecanoylphorbol-13-acetate (TPA), the phosphotyrosine content of erbB2 was significantly elevated in a dose-dependent manner. Concomittantly, erbB2:EGFr heterodimer formation and c-src kinase activity were also elevated in TPA-treated epidermis. Structure-activity relationships with several phorbol ester analogs showed that the elevated phosphorylation of erbB2 in mouse epidermis followed closely with tumor promoting ability. Activation of erbB2 and c-src kinase were also observed in the epidermis of TGF alpha transgenic mice where expression of human TGF alpha was targeted to basal keratinocytes with the human K14 promoter. Collectively, the current data suggest that the activation of erbB2 in phorbol ester treated skin can be explained solely by a mechanism involving elevation of EGFr ligands and activation of the EGFr. In addition, activation of c-spe may be an important downstream effector in mouse keratinocytes both in vivo and in vitro, following activation of the EGFr, erbB2, or both.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV SCI PK RES, SMITHVILLE, TX 78957 USA; GLAXO WELLCOME INC, RES TRIANGLE PK, NC 27709 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline				DiGiovanni, John/0000-0003-4233-6728	NCI NIH HHS [CA57596, CA16672] Funding Source: Medline; NIEHS NIH HHS [ES 07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA057596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALDAZ CM, 1985, CANCER RES, V45, P2753; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOUTWELL RK, 1976, CANCER RES, V36, P2631; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EWING MW, 1988, CARCINOGENESIS, V9, P405, DOI 10.1093/carcin/9.3.405; EWING MW, 1988, CANCER RES, V48, P7048; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KIGUCHI K, 1995, MOL CARCINOGEN, V12, P225, DOI 10.1002/mc.2940120407; Kiguchi K., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P149; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAEMMLI UK, 1970, NATURE, V301, P621; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASON S, 1995, BREAST, V4, P11, DOI 10.1016/0960-9776(95)90022-5; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; PARKINSON EK, 1985, BRIT J CANCER, V52, P479, DOI 10.1038/bjc.1985.219; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RAICK AN, 1972, CANCER RES, V32, P1562; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLAGA T J, 1989, P1; SLAGA TJ, 1983, ENVIRON HEALTH PERSP, V50, P3, DOI 10.2307/3429529; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; YUSPA SH, 1994, CANCER RES, V54, P1178	61	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1435	1444		10.1038/sj.onc.1200980	http://dx.doi.org/10.1038/sj.onc.1200980			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136987				2022-12-25	WOS:A1997WT58400006
J	Arendt, CW; Ostergaard, HL				Arendt, CW; Ostergaard, HL			Identification of the CD45-associated 116-kDa and 80-kDa proteins as the alpha- and beta-subunits of alpha-glucosidase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL SUCRASE-ISOMALTASE; AMINO-ACID-SEQUENCE; ASPARAGINE-LINKED OLIGOSACCHARIDES; C-KINASE SUBSTRATE; T-CELL MATURATION; ENDOPLASMIC-RETICULUM; TYROSINE-PHOSPHATASE; RAT-LIVER; PARTIAL-PURIFICATION; MEMBRANE-PROTEINS	CD45 is an abundant, highly glycosylated transmembrane protein-tyrosine phosphatase expressed on hematopoietic cells. Herein we demonstrate that two proteins of 116 kDa and 80 kDa copurify with CD45 from mouse T cells. Microsequence analysis of the 116-kDa protein revealed high similarity to an incomplete human open reading frame that has been suggested to correspond to the catalytic alpha-subunit of glucosidase II. We determined the nucleotide sequence of the mouse cDNA and observed that it encodes a protein product nearly identical to its human homologue and shares an active site consensus sequence with Family 31 glucosidases. Amino acid sequencing of the 80-kDa protein, followed by molecular cloning, revealed high homology to human and bovine cDNAs postulated to encode the beta-subunit of glucosidase II. Antisera developed to the mouse beta-subunit allowed us to demonstrate that the interaction between CD45 and glucosidase II can be reconstituted in vitro in an endoglycosidase H-sensitive manner. The strong interaction between glucosidase II and CD45 may provide a paradigm for investigating novel aspects of the biology of these proteins.	UNIV ALBERTA,DEPT MED MICROBIOL & IMMUNOL,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARENDT CW, 1995, J BIOL CHEM, V270, P2313; Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; BURNS DM, 1982, J BIOL CHEM, V257, P9991; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GINNA LS, 1979, J BIOL CHEM, V254, P8814; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Herbert Daniel N., 1995, Cell, V81, P425; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; HINO Y, 1985, BIOCHEMISTRY-US, V24, P800, DOI 10.1021/bi00324a040; HIRAI M, 1990, BIOCHEM J, V270, P583, DOI 10.1042/bj2700583; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HYMAN R, 1982, IMMUNOGENETICS, V15, P413, DOI 10.1007/BF00364264; JEFFREY PL, 1970, BIOCHEMISTRY-US, V9, P1403, DOI 10.1021/bi00808a015; KAUSHAL GP, 1993, J BIOL CHEM, V268, P14536; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KINSELLA BT, 1991, EUR J BIOCHEM, V202, P657, DOI 10.1111/j.1432-1033.1991.tb16420.x; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MICHAEL JM, 1980, ARCH BIOCHEM BIOPHYS, V199, P249, DOI 10.1016/0003-9861(80)90278-7; MINAMI Y, 1991, J BIOL CHEM, V266, P9222; NAIM HY, 1991, FEBS LETT, V294, P109, DOI 10.1016/0014-5793(91)81353-A; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OZAWA M, 1993, J BIOL CHEM, V268, P699; PALMER TN, 1971, BIOCHEM J, V124, P701, DOI 10.1042/bj1240701; PULIDO R, 1990, EUR J IMMUNOL, V20, P2667, DOI 10.1002/eji.1830201221; QUARONI A, 1976, J BIOL CHEM, V251, P3250; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; Shivnan E, 1996, J IMMUNOL, V157, P101; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; Sugimoto M, 1996, J BIOCHEM, V119, P500; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Uemura K, 1996, J BIOL CHEM, V271, P4581; UGALDE RA, 1980, EUR J BIOCHEM, V113, P97; UGALDE RA, 1978, FEBS LETT, V91, P209, DOI 10.1016/0014-5793(78)81174-0; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEIS K, 1994, J BIOL CHEM, V269, P19142; WILSON DW, 1993, J BIOL CHEM, V268, P7465; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	57	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13117	13125		10.1074/jbc.272.20.13117	http://dx.doi.org/10.1074/jbc.272.20.13117			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148925	hybrid			2022-12-25	WOS:A1997WZ38400038
J	Betts, JC; Blackstock, WP; Ward, MA; Anderton, BH				Betts, JC; Blackstock, WP; Ward, MA; Anderton, BH			Identification of phosphorylation sites on neurofilament proteins by nanoelectrospray mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN NEUROFILAMENTS; NF-L; REASSEMBLED NEUROFILAMENTS; ELECTROSPRAY-IONIZATION; INTERMEDIATE FILAMENTS; TRIPLET PROTEINS; AXONAL-TRANSPORT; SCHWANN-CELLS; TAIL DOMAIN; LEWY BODY	Neurofilament (NF) proteins are intermediate filaments found in the neuronal cytoskeleton, Phosphorylation of these proteins is considered an important factor in the assembly of filaments and determination of filament caliber and stability, Mammalian neurofilaments are composed of three polypeptide subunits, NF-L, NF-M, and NF-H, all of which are phosphorylated, Here we used techniques for the mass spectrometric sequencing of proteins from polyacrylamide gels to analyze in vivo phosphorylation sites on NF-M and NF-L, Neurofilaments were isolated from rat brain and enzymatically digested in gel, The resulting peptides were analyzed and sequence data obtained by nanoelectrospray mass spectrometry, Four phosphorylation sites have been found in the C-terminal domain of NF-M: serines 603, 608, 666, and 766, Two of these are found in lysine-serine-proline (KSP) motifs and two in the variant motifs, glutamic acid-serine-proline (ESP) and valine-serine-proline (VSP), Serine 55 in NF-L was not found to be phosphorylated, which confirms the possible role of phosphorylation and dephosphorylation of this site in early neurofilament assembly, The techniques used enable sequence data and characterization of posttranslational modifications to be obtained for each individual subunit directly from polyacrylamide gels.	INST PSYCHIAT, DEPT NEUROSCI, LONDON SE5 8AF, ENGLAND	University of London; King's College London	Betts, JC (corresponding author), GLAXO WELLCOME RES & DEV LTD, BIOMOL STRUCT UNIT, MED RES CTR, 2F 116, GUNNELS WOOD RD, STEVENAGE SG1 2NY, HERTS, ENGLAND.			Betts, Joanna/0000-0003-1729-1839				ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHIN SSM, 1990, J NEUROSCI, V10, P3714; COLE JS, 1994, J NEUROSCI, V14, P6956; COVEY T, 1991, ADV LIF SCI, P249; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1993, J BIOL CHEM, V268, P16679; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GEISLER N, 1985, EMBO J, V4, P57, DOI 10.1002/j.1460-2075.1985.tb02317.x; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; GOTOW T, 1994, J CELL SCI, V107, P1949; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1994, MOL BIOL CELL, V5, P161, DOI 10.1091/mbc.5.2.161; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; HSIEH ST, 1994, J NEUROSCI, V14, P6392; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; KARLSSON JE, 1987, J NEUROCHEM, V49, P1375, DOI 10.1111/j.1471-4159.1987.tb01002.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MIYASAKA H, 1993, J BIOL CHEM, V268, P22695; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1986, J BIOL CHEM, V261, P6298; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; OBLINGER MM, 1987, J NEUROSCI, V7, P2510; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; SHAW G, 1991, NEURONAL CYTOSKELETO, P185; SIHAG RK, 1989, J BIOL CHEM, V264, P457; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SIHAG RK, 1995, MOL BIOL CELL, V6, P375; SKALLI O, 1992, Trends in Cell Biology, V2, P308, DOI 10.1016/0962-8924(92)90121-3; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TROJANOWSKI JQ, 1993, BRAIN PATHOL, V3, P45, DOI 10.1111/j.1750-3639.1993.tb00725.x; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; XU Z, 1993, J CELL SCI S17, V106, P101; XU ZS, 1990, J NEUROSCI, V10, P1838; XU ZS, 1992, J BIOL CHEM, V267, P4467	57	53	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12922	12927		10.1074/jbc.272.20.12922	http://dx.doi.org/10.1074/jbc.272.20.12922			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148897	hybrid			2022-12-25	WOS:A1997WZ38400010
J	Fang, H; Mullins, C; Green, N				Fang, H; Mullins, C; Green, N			In addition to SEC11, a newly identified gene, SPC3, is essential for signal peptidase activity in the yeast endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN LIGHT-CHAINS; COLI LEADER PEPTIDASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CATALYTIC MECHANISM; MEMBRANE-PROTEINS; SHUTTLE VECTORS; HOST STRAINS; GLYCOPROTEIN; SEQUENCES	Among the three characterized subunits comprising the signal peptidase complex of the yeast Saccharomyces cerevisiae (Sec11p, Spc1p, and Spc2p), only Sec11p is essential for cell growth, signal peptide cleavage, and signal peptidase-dependent protein degradation, Here we report the cloning of the SPC3 gene encoding the homolog to mammalian signal peptidase subunit SPC22/23. We find that Spc3p is also required for cell growth and signal peptidase activity within the yeast endoplasmic reticulum.			Fang, H (corresponding author), VANDERBILT UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA.				NCI NIH HHS [2 T32 CA09385-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; Fang H, 1996, J BIOL CHEM, V271, P16460, DOI 10.1074/jbc.271.28.16460; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Kalies KU, 1996, J BIOL CHEM, V271, P3925; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leung DW, 1989, TECHNIQUE, V1, P11; LIVELY MO, 1994, SIGNAL PEPTIDASES, P59; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; MILSTEIN C, 1972, NATURE-NEW BIOL, V239, P117, DOI 10.1038/newbio239117a0; Mullins C, 1996, J BIOL CHEM, V271, P29094, DOI 10.1074/jbc.271.46.29094; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; NEWSOME AL, 1992, BIOCHEM J, V282, P447, DOI 10.1042/bj2820447; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STEVENS TB, 1982, CELL, V30, P443; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; SUNG M, 1992, J BIOL CHEM, V267, P13154; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	42	31	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13152	13158		10.1074/jbc.272.20.13152	http://dx.doi.org/10.1074/jbc.272.20.13152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148930	hybrid			2022-12-25	WOS:A1997WZ38400043
J	Horlacher, R; Boos, W				Horlacher, R; Boos, W			Characterization of TreR, the major regulator of the Escherichia coli trehalose system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC REPRESSOR; DNA-SEQUENCE; SALMONELLA-TYPHIMURIUM; PERIPLASMIC TREHALASE; LACTOSE REPRESSOR; CRYSTAL-STRUCTURE; CLONING VEHICLES; GENE-EXPRESSION; HIGH OSMOLARITY; PROTEINS	The pathway of trehalose utilization in Escherichia coli is different at low and high osmolarity. The low osmolarity system takes up trehalose as trehalose B-phosphate which is hydrolyzed to glucose and glucose 6-phosphate, treB and treC, the genes for the enzymes involved, form an operon that is controlled by TreR (encoded by treR), the repressor of the system, for which trehalose g-phosphate is the inducer, We have cloned and sequenced treR, The protein contains 315 amino acids with a molecular weight of 34,508, TreR was purified and shown to bind as a dimer trehalose B-phosphate and trehalose with a K-d of 10 and 280 mu M, respectively, The conformations of the protein differ from each other with either one or the other substrate-bound. Protease treatment removed the DNA-binding domain from the intact protein leaving the dimerization domain (a 29-kDa carboxyl-terminal fragment) intact, Nuclease protection experiments revealed a palindromic sequence located directly upstream of the -35 promoter sequence of treB that functions as the operator of the system.	UNIV KONSTANZ,DEPT BIOL,D-78434 CONSTANCE,GERMANY	University of Konstanz								ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATLUNG T, 1991, GENE, V107, P11, DOI 10.1016/0378-1119(91)90291-I; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BELEV TN, 1991, PLASMID, V26, P147, DOI 10.1016/0147-619X(91)90056-3; BELFORT M, 1985, CELL, V41, P375, DOI 10.1016/S0092-8674(85)80010-6; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOOS W, 1987, J BIOL CHEM, V262, P13212; BOOS W, 1990, J BACTERIOL, V172, P3450, DOI 10.1128/jb.172.6.3450-3461.1990; BURLAND V, 1995, NUCLEIC ACIDS RES, V23, P2105, DOI 10.1093/nar/23.12.2105; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COLACO C, 1992, BIO-TECHNOL, V10, P1007, DOI 10.1038/nbt0992-1007; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; GOTSCHE S, 1995, J BACTERIOL, V177, P2721, DOI 10.1128/jb.177.10.2721-2726.1995; GUTIERREZ C, 1989, MOL GEN GENET, V217, P347, DOI 10.1007/BF02464903; HELFERT C, 1995, MOL MICROBIOL, V16, P111, DOI 10.1111/j.1365-2958.1995.tb02396.x; HENGGEARONIS R, 1991, J BACTERIOL, V173, P7918, DOI 10.1128/jb.173.24.7918-7924.1991; Horlacher R, 1996, J BACTERIOL, V178, P6250, DOI 10.1128/jb.178.21.6250-6257.1996; KAASEN I, 1992, J BACTERIOL, V174, P889, DOI 10.1128/jb.174.3.889-898.1992; KAASEN I, 1994, GENE, V145, P9, DOI 10.1016/0378-1119(94)90316-6; KISTERSWOIKE B, 1991, EUR J BIOCHEM, V198, P411, DOI 10.1111/j.1432-1033.1991.tb16030.x; KLEIN W, 1991, RES MICROBIOL, V142, P359, DOI 10.1016/0923-2508(91)90105-J; KLEIN W, 1995, J BACTERIOL, V177, P4043, DOI 10.1128/jb.177.14.4043-4052.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LEHMING N, 1990, EMBO J, V9, P615, DOI 10.1002/j.1460-2075.1990.tb08153.x; LESLIE SB, 1995, APPL ENVIRON MICROB, V61, P3592, DOI 10.1128/AEM.61.10.3592-3597.1995; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; MARECHAL LR, 1984, ARCH MICROBIOL, V137, P70, DOI 10.1007/BF00425810; Miller J.H., 1972, EXPT MOL GENETICS; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; Nguyen CC, 1995, FEBS LETT, V377, P98, DOI 10.1016/0014-5793(95)01344-X; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; RIGGS AD, 1970, J MOL BIOL, V51, P303, DOI 10.1016/0022-2836(70)90144-0; RIMMELE M, 1994, J BACTERIOL, V176, P5654, DOI 10.1128/JB.176.18.5654-5664.1994; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schock F, 1996, J BACTERIOL, V178, P4576, DOI 10.1128/jb.178.15.4576-4581.1996; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; STROM AR, 1986, FEMS MICROBIOL LETT, V39, P79, DOI 10.1111/j.1574-6968.1986.tb01846.x; STYRVOLD OB, 1991, J BACTERIOL, V173, P1187, DOI 10.1128/jb.173.3.1187-1192.1991; TALUKDER AA, 1994, BIOSCI BIOTECH BIOCH, V58, P117, DOI 10.1271/bbb.58.117; TAO T, 1995, J BACTERIOL, V177, P2654, DOI 10.1128/jb.177.10.2654-2662.1995	50	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13026	13032		10.1074/jbc.272.20.13026	http://dx.doi.org/10.1074/jbc.272.20.13026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148912	hybrid			2022-12-25	WOS:A1997WZ38400025
J	Savitz, AJ; Meyer, DI				Savitz, AJ; Meyer, DI			Receptor-mediated ribosome binding to liposomes depends on lipid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; MEMBRANE INTERACTION; RAT-LIVER; MICROSOMAL-MEMBRANES; COMPONENTS; IDENTIFICATION	Ribosome binding to the endoplasmic reticulum has been traditionally studied using an in vitro assay in which potential ribosome receptors have been purified, incorporated into synthetic liposomes, and tested for activity, One such receptor (180 kDa; ''p180'') has been shown to bind ribosomes with high affinity in such a system when purified to homogeneity, This result has been challenged by data generated in other laboratories, and as a result, doubt has lingered as to the authen ticity of p180 as a ribosome receptor, The contribution of the major difference between these studies, the lipid composition of the liposomes used in the in vitro assays, was assessed when identical fractions of rough endoplasmic reticulum-specific membrane proteins were in corporated into liposomes composed of only phosphatidylcholine (as used in other laboratories), a 50:50 mix of phosphatidylcholine and phosphatidylserine (as used in our original studies), or lipids derived from canine pancreatic microsomes (as a physiologically relevant control). The presence of PS was found to be crucial for the incorporation into and ribosome binding activity of p180 in liposomes, These observations are compatible with published studies on the importance of acidic phos pholipids in ribosome binding to intact microsomes and reconcile the apparently conflicting in vitro results surrounding the assignment of p180 as a ribosome receptor.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOL BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; Blobel G., 1971, BIOMEMBRANE, P193; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HORTSCH M, 1985, EUR J BIOCHEM, V150, P559, DOI 10.1111/j.1432-1033.1985.tb09057.x; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; ICHIMURA T, 1993, FEBS LETT, V326, P241, DOI 10.1016/0014-5793(93)81799-6; ICHIMURA T, 1992, FEBS LETT, V296, P7, DOI 10.1016/0014-5793(92)80391-S; JOTHY S, 1975, CAN J BIOCHEM CELL B, V53, P1039, DOI 10.1139/o75-143; JOTHY S, 1973, BIOCHEM J, V132, P637, DOI 10.1042/bj1320637; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KRUPPA J, 1977, J CELL BIOL, V74, P414, DOI 10.1083/jcb.74.2.414; NEUHOF A, 1996, 1 CELL BIOL S MDC PR, P93; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NUNNARI JM, 1991, NATURE, V352, P638, DOI 10.1038/352638a0; OHSUMI T, 1993, BIOCHEM J, V294, P465, DOI 10.1042/bj2940465; ROSBASH M, 1971, J MOL BIOL, V59, P227, DOI 10.1016/0022-2836(71)90048-9; SAVITZ AJ, 1993, J CELL BIOL, V120, P853, DOI 10.1083/jcb.120.4.853; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29; YAMAGUCHI M, 1981, BIOCHEM J, V194, P907, DOI 10.1042/bj1940907; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811	27	6	6	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13140	13145		10.1074/jbc.272.20.13140	http://dx.doi.org/10.1074/jbc.272.20.13140			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148928	hybrid			2022-12-25	WOS:A1997WZ38400041
J	Garg, N; Tarleton, RL; MensaWilmot, K				Garg, N; Tarleton, RL; MensaWilmot, K			Proteins with glycosylphosphatidylinositol (GPI) signal sequences have divergent fates during a GPI deficiency - GPIs are essential for nuclear division in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOINOSITOL PHOSPHOLIPID ANCHOR; VARIANT SURFACE GLYCOPROTEIN; STRUCTURAL CHARACTERIZATION; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; BRUCEI; PHOSPHATIDYLINOSITOL; BIOSYNTHESIS; MEMBRANE; EXPRESSION	Glycosylphosphatidylinositols (GPIs) are membrane anchors for cell surface proteins of several major protozoan parasites of humans, including Trypanosoma cruzi, the causative agent of Chagas' disease, To investigate the general role of GPIs in T. cruzi, we generated GPI-deficient parasites by heterologous expression of T. brucei GPI-phospholipase C. Putative protein-GPI intermediates were depleted, causing the biochemical equivalent of a dominant-negative loss of function mutation in the GPI pathway, Cell surface expression of major GPI-anchored proteins was diminished in GPI-deficient T. cruzi, Four proteins that are normally GPI-anchored in T. cruzi exhibited different fates during the GPI shortage; Ssp-Li and p75 were secreted prematurely, while protease gp50/55 and p60 were degraded intracellularly. These observations demonstrate that secretion and intracellular degradation of GPI-anchored proteins may occur in the same genetic background during a GPI deficiency, We postulate that the interaction between a protein GPI transamidase and the COOH-terminal GPI signal sequence plays a pivotal role in determining the fate of these proteins, At a nonpermissive GPI deficiency, T. cruzi amastigotes inside mammalian cells replicated their single kinetoplast but failed at mitosis. Hence, in these protozoans, GPIs appear to be essential for nuclear division, but not for mitochondrial duplication.	UNIV GEORGIA, DEPT CELLULAR BIOL, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia			Nogueira, Raquel Tayar/F-6475-2019; Tarleton, Rick/AES-8572-2022	Nogueira, Raquel Tayar/0000-0002-0581-763X; Tarleton, Rick/0000-0002-9589-5243	NIAID NIH HHS [AI 33106, AI 33383] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033383, R29AI033383, R01AI033106] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CARRINGTON M, 1989, MOL BIOCHEM PARASIT, V33, P289, DOI 10.1016/0166-6851(89)90091-1; CASTELLANI O, 1967, J PROTOZOOL, V14, P447, DOI 10.1111/j.1550-7408.1967.tb02024.x; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FATEMI SH, 1986, CELL, V46, P4441; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1994, J BIOL CHEM, V269, P10830; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; Fra A, 1993, Subcell Biochem, V21, P143; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Heise N, 1996, J BIOL CHEM, V271, P16877, DOI 10.1074/jbc.271.28.16877; HEISE N, 1995, MOL BIOCHEM PARASIT, V70, P71, DOI 10.1016/0166-6851(95)00009-P; HERELD D, 1988, P NATL ACAD SCI USA, V85, P8914, DOI 10.1073/pnas.85.23.8914; HIROSE S, 1992, J BIOL CHEM, V267, P16968; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KINOSHITA T, 1994, PARASITOL TODAY, V10, P139, DOI 10.1016/0169-4758(94)90261-5; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MAXWELL SE, 1995, P NATL ACAD SCI USA, V92, P1550, DOI 10.1073/pnas.92.5.1550; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; MENSAWILMOT K, 1990, MOL CELL BIOL, V10, P720, DOI 10.1128/MCB.10.2.720; MORRIS JC, 1995, J BIOL CHEM, V270, P2517, DOI 10.1074/jbc.270.6.2853; MUNAIN CH, 1991, INFECT IMMUN, V59, P1409; OTSU K, 1993, MOL BIOCHEM PARASIT, V57, P317, DOI 10.1016/0166-6851(93)90207-E; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOODWARD R, 1990, J CELL SCI, V95, P49	42	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12482	12491		10.1074/jbc.272.19.12482	http://dx.doi.org/10.1074/jbc.272.19.12482			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139697	hybrid			2022-12-25	WOS:A1997WY82900034
J	Hallden, G; Aponte, GW				Hallden, G; Aponte, GW			Evidence for a role of the gut hormone PYY in the regulation of intestinal fatty acid-binding protein transcripts in differentiated subpopulations of intestinal epithelial cell hybrids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; TISSUE-SPECIFIC EXPRESSION; NEUROPEPTIDE-Y-RECEPTOR; CIS-ACTING ELEMENTS; PEPTIDE-YY; TRANSGENIC MICE; RAT-LIVER; MESSENGER-RNA; DEVELOPMENTAL REGULATION; REGIONAL DISTRIBUTION	Peptide tyrosine tyrosine (PYY) is a gut hormone present in endocrine cells in the lower intestine that can be released by the presence of luminal free fatty acids (FFAs). The biological action of this peptide includes inhibition of gut motility and gastrointestinal and pancreatic secretions. Intestinal fatty acid-binding protein (I-FABP) binds FFA and may be involved in their cytosolic trafficking. Quantitative in situ hybridization on heterogeneous populations of small intestinal somatic cell hybrids selected for endogenous I-FABP expression (hBRIE 380i cells) demonstrated a 5-fold increase in I-FABP transcripts in response to PYY (within 6 h) that was confined to clusters of differentiated cells, whereas ribonuclease protection assays performed on heterogeneous populations of these cells showed no significant differences. High affinity PW receptors, with an IC50 of 5-50 pw, were identified in both differentiated and nondifferentiated cell populations, as determined by competitive binding assays and autoradiography. In situ hybridization of rat ileal tissue also revealed differing patterns of mRNA expression for liver fatty acid-binding protein (L-FABP) and I-FABP. Only I-FABP mRNA was detected in the villus tips. This localization correlated with the expression pattern of I-FABP mRNA in the hBRIE 380i cells where changes in transcripts were observed only in differentiated cells that did not incorporate bromodeoxyuridine. The sustained expression of I-FABP transcripts in the villar tips suggests (unlike L-FABP) that older terminally differentiated cell populations of the mucosa can still be PW responsive. These studies demonstrate that physiological concentrations of PW can regulate I-FABP and place this peptide in a key position as part of a feedback system that determines the processing of cytosolic FFA in the enterocyte. In addition, these studies suggest a mechanism whereby luminal agents can modulate expression of proteins in terminally differentiated cells in the gastrointestinal mucosa.	UNIV CALIF BERKELEY,DEPT NUTR SCI,BERKELEY,CA 94720	University of California System; University of California Berkeley								ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; ANTRAS J, 1991, MOL CELL ENDOCRINOL, V82, P183, DOI 10.1016/0303-7207(91)90030-V; APONTE GW, 1988, AM J PHYSIOL, V254, pG829, DOI 10.1152/ajpgi.1988.254.6.G829; APONTE GW, 1985, AM J PHYSIOL, V249, pG745, DOI 10.1152/ajpgi.1985.249.6.G745; APONTE GW, 1989, FASEB J, V3, P1949, DOI 10.1096/fasebj.3.8.2721855; APONTE GW, 1991, P NATL ACAD SCI USA, V88, P5282, DOI 10.1073/pnas.88.12.5282; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1985, J BIOL CHEM, V260, P1432; BILCHIK AJ, 1993, GASTROENTEROLOGY, V105, P1441, DOI 10.1016/0016-5085(93)90149-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COX HM, 1990, BRIT J PHARMACOL, V101, P247, DOI 10.1111/j.1476-5381.1990.tb12695.x; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GANTZ I, 1989, J BIOL CHEM, V264, P20248; GORDON JI, 1985, J BIOL CHEM, V260, P1995; GORDON JI, 1983, J BIOL CHEM, V258, P3356; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; HALLDEN G, 1994, AM J PHYSIOL-GASTR L, V267, pG730, DOI 10.1152/ajpgi.1994.267.4.G730; HOCKFIELD S, 1993, MOL PROBES NERVOUS S; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Humason G. L., 1979, ANIMAL TISSUE TECHNI; ISEKI S, 1990, J HISTOCHEM CYTOCHEM, V38, P111, DOI 10.1177/38.1.2294146; ISEKI S, 1990, MOL CELL BIOCHEM, V98, P27; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KITAMURA K, 1980, FEBS LETT, V115, P27, DOI 10.1016/0014-5793(80)80719-8; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LUNDBERG JM, 1988, NEUROSCIENCE, V24, P659, DOI 10.1016/0306-4522(88)90359-4; MACKERELL AD, 1988, J COMPUT AID MOL DES, V2, P55, DOI 10.1007/BF01532053; MALLORDY A, 1993, MOL CELL BIOCHEM, V123, P85, DOI 10.1007/BF01076478; MALLORDY A, 1995, EUR J BIOCHEM, V227, P801, DOI 10.1111/j.1432-1033.1995.tb20204.x; MANNON PJ, 1994, AM J PHYSIOL-GASTR L, V267, pG901, DOI 10.1152/ajpgi.1994.267.5.G901; MISHKIN S, 1972, BIOCHEM BIOPH RES CO, V47, P997, DOI 10.1016/0006-291X(72)90931-X; MIURA M, 1994, AM J PHYSIOL-ENDOC M, V267, pE702, DOI 10.1152/ajpendo.1994.267.5.E702; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; PAPPAS TN, 1986, GASTROENTEROLOGY, V91, P1386, DOI 10.1016/0016-5085(86)90191-5; PAPPAS TN, 1986, J CLIN INVEST, V77, P49, DOI 10.1172/JCI112300; PAULUSSEN RJA, 1989, BIOCHIM BIOPHYS ACTA, V1001, P201, DOI 10.1016/0005-2760(89)90149-5; RICHARDS J, 1983, J TISSUE CULTURE MET, V8, P31, DOI DOI 10.1007/BF01834632; Richieri GV, 1996, J BIOL CHEM, V271, P11291, DOI 10.1074/jbc.271.19.11291; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SHEIKH SP, 1991, AM J PHYSIOL, V260, pG250, DOI 10.1152/ajpgi.1991.260.2.G250; SHEIKH SP, 1989, AM J PHYSIOL, V257, pF978, DOI 10.1152/ajprenal.1989.257.6.F978; SHIELDS HM, 1986, J LIPID RES, V27, P549; SIEGENTHALER G, 1994, BIOCHEM J, V302, P363, DOI 10.1042/bj3020363; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; SINGH G, 1992, AM J PHYSIOL, V262, pG756, DOI 10.1152/ajpgi.1992.262.4.G756; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; SUNDELIN J, 1985, J BIOL CHEM, V260, P6488; SUZUKI T, 1988, J HISTOCHEM CYTOCHEM, V36, P349, DOI 10.1177/36.4.3346538; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UNDEN A, 1984, EUR J BIOCHEM, V145, P525, DOI 10.1111/j.1432-1033.1984.tb08588.x; VEERKAMP JH, 1990, MOL CELL BIOCHEM, V98, P11, DOI 10.1007/BF00231362; VOISIN T, 1993, J BIOL CHEM, V268, P20547; VOISIN T, 1990, AM J PHYSIOL, V258, pG753, DOI 10.1152/ajpgi.1990.258.5.G753; WAHLESTEDT C, 1992, LIFE SCI, V50, pPL7, DOI 10.1016/0024-3205(92)90342-M; WHARTON J, 1993, P NATL ACAD SCI USA, V90, P687, DOI 10.1073/pnas.90.2.687; WILLIAMS JA, 1986, PEPTIDES, V7, P293, DOI 10.1016/0196-9781(86)90228-7	71	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12591	12600		10.1074/jbc.272.19.12591	http://dx.doi.org/10.1074/jbc.272.19.12591			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139712	hybrid			2022-12-25	WOS:A1997WY82900049
J	Sepulveda, AR; Huang, SL; Lebovitz, RM; Lieberman, MW				Sepulveda, AR; Huang, SL; Lebovitz, RM; Lieberman, MW			A 346-base pair region of the mouse gamma-glutamyl transpeptidase type II promoter contains sufficient cis-acting elements for kidney-restricted expression in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ENHANCER ELEMENTS; TRANSCRIPTION FACTOR; REGULATORY ELEMENTS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GENE-TRANSCRIPTION; EPITHELIAL-CELLS; MAMMALIAN-CELLS; CYCLIC-AMP; BINDING; IDENTIFICATION	The mouse gamma-glutamyl transpeptidase (GGT) gene encodes seven distinct mRNAs that are transcribed from seven separate promoters, Type II mRNA is the most abundant in kidney, We have developed a cell line with features of renal proximal tubular cells which expresses GGT mRNA types with a pattern similar to that of mouse kidney, Because a 346-bp sequence from the type II promoter directed the highest level of CAT activity in these cells, this region was used to drive the expression of a beta-galactosidase reporter gene in transgenic mice, Two transgenic mouse lines expressed beta-galactosidase limited to the renal proximal tubules, Site-directed deletions within this 346-bp promoter region demonstrated that cis-elements containing the consensus binding sites for AP2, a glucocorticoid response element (GRE)-like element, and the initiator region were required for transcriptional activity and were not additive, Purified AP2 bound and footprinted the AP2 consensus region, making it likely that transcription from the GGT type II promoter is regulated in part by AP2. These data suggest that transcription of the type II promoter requires multiple protein DNA interactions involving at least an AP2 element, and probably a GRE-like element and the initiator region.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NIEHS NIH HHS [ES-07827] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007827] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HABIB GM, 1995, J BIOL CHEM, V270, P13711, DOI 10.1074/jbc.270.23.13711; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HOGAN B, 1986, MANIPULATING MOUSE E; INNIS MA, 1991, PCR PROTOCOLS GUIDE, P21; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGLAU C, 1990, MOL CELL BIOL, V10, P528; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIEBERMAN MW, 1995, AM J PATHOL, V147, P1175; Lieberman MW, 1996, P NATL ACAD SCI USA, V93, P7923, DOI 10.1073/pnas.93.15.7923; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LOU Y, 1992, CELL, V71, P231; LOYA F, 1994, BLOOD, V84, P1831; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MAOUCHE L, 1994, NUCLEIC ACIDS RES, V22, P338, DOI 10.1093/nar/22.3.338; MATSUBASA T, 1994, J BIOCHEM, V116, P1044, DOI 10.1093/oxfordjournals.jbchem.a124626; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOORE DD, 1985, P NATL ACAD SCI USA, V82, P699, DOI 10.1073/pnas.82.3.699; MORRIS BJ, 1992, J HYPERTENS, V10, P337, DOI 10.1097/00004872-199204000-00003; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PAUL M, 1992, AM J PHYSIOL, V262, pE644, DOI 10.1152/ajpendo.1992.262.5.E644; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; RILEY DJ, 1995, SEMIN NEPHROL, V15, P57; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; SALTER EP, 1985, MOL CELL BIOL, P2984; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; SEPULVEDA AR, 1995, EXP CELL RES, V219, P494, DOI 10.1006/excr.1995.1257; SEPULVEDA AR, 1994, J BIOL CHEM, V269, P10699; Shi ZZ, 1996, ARCH BIOCHEM BIOPHYS, V331, P215, DOI 10.1006/abbi.1996.0301; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; SHOSHANI T, 1991, GENE, V101, P279, DOI 10.1016/0378-1119(91)90424-A; SHULL MM, 1990, GENOMICS, V6, P451, DOI 10.1016/0888-7543(90)90475-A; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TAUB M, 1980, J CELL PHYSIOL, V105, P369, DOI 10.1002/jcp.1041050220; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VALLET V, 1995, EXP CELL RES, V216, P363, DOI 10.1006/excr.1995.1046; Vina J., 1983, Functions of glutathione. Biochemical, physiological, toxicological, and clinical aspects, P23; VINA J, 1990, GLUTATHIONE METABOLI, P79; WANG ZM, 1994, AM J PHYSIOL, V267, pC450, DOI 10.1152/ajpcell.1994.267.2.C450; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8; WUTHRICH RP, 1990, KIDNEY INT, V37, P783, DOI 10.1038/ki.1990.46; YANG GY, 1994, J BIOL CHEM, V269, P32497	58	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11959	11967		10.1074/jbc.272.18.11959	http://dx.doi.org/10.1074/jbc.272.18.11959			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115259	hybrid			2022-12-25	WOS:A1997WX56900047
J	Aster, JC; Robertson, ES; Hasserjian, RP; Turner, JR; Kieff, E; Sklar, J				Aster, JC; Robertson, ES; Hasserjian, RP; Turner, JR; Kieff, E; Sklar, J			Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-J kappa or nuclear localization sequences retain the ability to associate with RBP-J kappa and activate transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARR-VIRUS EBNA2; SPLIT COMPLEX GENES; ANKYRIN REPEATS; CELL-FATE; CHROMOSOMAL TRANSLOCATIONS; LYMPHOBLASTIC NEOPLASMS; C-ELEGANS; PROTEIN; DNA; RECEPTOR	Truncated forms of the NOTCH1 transmembrane receptor engineered to resemble mutant forms of NOTCH1 found in certain cases of human T cell leukemia/lymphoma (T-ALL) efficiently induce T-ALL when expressed in the bone marrow of mice. Unlike full-sized NOTCH1, two such truncated forms of the protein either lacking a major portion of the extracellular domain (Delta E) or consisting only of the intracellular domain (ICN) were found to activate transcription in cultured cells, presumably through RBP-J kappa response elements within DNA. Both truncated forms also bound to the transcription factor RBP-J kappa in extracts prepared from human and murine T-ALL cell lines. Transcriptional activation required the presence of a weak RBP-J kappa-binding site within the NOTCH1 ankyrin repeat region of the intracellular domain. Unexpectedly, a second, stronger RBP-J kappa-binding site, which lies within the intracellular domain close to the transmembrane region and significantly augments association with RBP J kappa, was not needed for oncogenesis or for transcriptional activation. While ICN appeared primarily in the nucleus, Delta E localized to cytoplasmic and nuclear membranes, suggesting that intranuclear localization is not essential for oncogenesis or transcriptional activation. In support of this interpretation, mutation of putative nuclear localization sequences decreased nuclear localization and increased transcriptional activation by membrane bound Delta E. Transcriptional activation by this mutant form of membrane-bound Delta E was approximately equivalent to that produced by intranuclear ICN. These data are most consistent with NOTCH1 oncogenesis and tran scriptional activation being independent of association with RBP-J kappa at promoter sites.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT MICROBIOL & MOL GENET, PROGRAM VIROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard Medical School	Aster, JC (corresponding author), BRIGHAM & WOMENS HOSP, DEPT PATHOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Turner, Jerrold R/A-6895-2009; Turner, Jerrold/H-1502-2019	Turner, Jerrold R/0000-0003-0627-9455; 	NATIONAL CANCER INSTITUTE [R01CA047006, R29CA066849, R01CA062450, R35CA047006] Funding Source: NIH RePORTER; NCI NIH HHS [CA47006, CA66849, CA62450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER JC, 1995, COLD SPRING HARB SYM, V49, P125; AUSABEL FM, 1994, CURRENT PROTOCOLS MO, V1; AUSTIN CP, 1995, DEVELOPMENT, V121, P3637; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BUSSEAU I, 1994, GENETICS, V136, P585; Christensen S, 1996, DEVELOPMENT, V122, P1373; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Johannsen E, 1996, J VIROL, V70, P4179, DOI 10.1128/JVI.70.6.4179-4183.1996; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; LING PD, 1995, J VIROL, V69, P1944, DOI 10.1128/JVI.69.3.1944-1950.1995; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NYE JS, 1994, DEVELOPMENT, V120, P2421; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; REYNOLDS TC, 1987, CELL, V50, P107, DOI 10.1016/0092-8674(87)90667-2; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; ROBERTSON ES, 1995, J VIROL, V69, P3108, DOI 10.1128/JVI.69.5.3108-3116.1995; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SMITH SD, 1988, BLOOD, V71, P395; SMITH SD, 1989, BLOOD, V73, P2182; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	56	157	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11336	11343						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111040				2022-12-25	WOS:A1997WW00900056
J	Zhang, SS; Grosse, F				Zhang, SS; Grosse, F			Domain structure of human nuclear DNA helicase II (RNA helicase A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; DSRNA BINDING DOMAIN; INITIATION FACTOR-4A; ADENOSINE-DEAMINASE; MALELESS PROTEIN; ESCHERICHIA-COLI; MESSENGER-RNA; RICH DOMAIN; DROSOPHILA; CLONING	Full-length human nuclear DNA helicase II (NDH II) was cloned and overexpressed in a baculovirus derived expression system, Recombinant NDH II unwound both DNA and RNA, Limited tryptic digestion produced active helicases with molecular masses of 130 and 100 kDa. The 130-kDa helicase missed a glycine-rich domain (RGG-box) at the carboxyl terminus, while the 100-kDa form missed both its double-stranded RNA binding domains (dsRBDs) at the amino terminus and its RGG-box. Hence, the dsRBDs and the RGG-box were dispensable for unwinding, On the other hand, the isolated DEXH core alone could neither hydrolyze ATP nor unwind nucleic acids, These enzymatic activities were not rei gained by fusing a complete COOH or NH2 terminus to the helicase core, Hence, an active helicase required part of the NH2 terminus, the DEXH core, and a C-terminal extension of the core, Both dsRBDs and the RGG-box were bacterially expressed as glutathione S-transferase fusion proteins, The two dsRBDs had a strong affinity to double-stranded RNA and cooperated upon RNA binding, while the RGG-box bound preferentially to single-stranded DNA, A model is suggested in which the flanking domains influence and regulate the un winding properties of NDH II.	INST MOL BIOTECHNOL, BIOCHEM ABT, D-07708 JENA, GERMANY									BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHANG HW, 1993, VIROLOGY, V194, P537, DOI 10.1006/viro.1993.1292; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DORER DR, 1990, NUCLEIC ACIDS RES, V18, P5489, DOI 10.1093/nar/18.18.5489; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FERNANDEZ A, 1995, NUCLEIC ACIDS RES, V23, P1327, DOI 10.1093/nar/23.8.1327; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GURURAJAN R, 1991, NATURE, V349, P717, DOI 10.1038/349717a0; Ho CK, 1996, VIROLOGY, V217, P272, DOI 10.1006/viro.1996.0114; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIM U, 1994, J BIOL CHEM, V269, P13480; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEE CG, 1993, J BIOL CHEM, V268, P16822; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LI J, 1995, NUCLEIC ACIDS RES, V23, P1590, DOI 10.1093/nar/23.9.1590; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; ROUSSELL DL, 1993, P NATL ACAD SCI USA, V90, P9300, DOI 10.1073/pnas.90.20.9300; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; SUKEGAWA J, 1995, J BIOL CHEM, V270, P15702, DOI 10.1074/jbc.270.26.15702; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; ZHANG SS, 1995, J BIOL CHEM, V270, P16422, DOI 10.1074/jbc.270.27.16422; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	43	101	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11487	11494						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111062				2022-12-25	WOS:A1997WW00900078
J	Deshpande, N; Chopra, A; Rangarajan, A; Shashidhara, LS; Rodrigues, V; Krishna, S				Deshpande, N; Chopra, A; Rangarajan, A; Shashidhara, LS; Rodrigues, V; Krishna, S			The human transcription enhancer factor-1 TEF-1, can substitute for Drosophila scalloped during wingblade development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I TEF-1; GENE-EXPRESSION; ACTIVATION; CLONING; DOMAIN; VITRO	The human transcription enhancer factor-1 (TEF-1) belongs to a family of evolutionarily conserved proteins that have a DNA binding TEA domain, TEF-1 shares a 98% homology with Drosophila scalloped (sd) in the DNA binding domain and a 50% similarity in the activation domain. We have expressed human TEF-1 in Drosophila under the hsp-70 promoter and find that it can substitute for Sd function. The transformants rescue the wing-blade defects as well as the lethality of loss-of-function alleles. Observation of reporter activity in the imaginal wing discs of the enhancer-trap alleles suggests that TEF-1 is capable of promoting sd gene regulation. The functional capability of the TEF-1 product was assessed by comparing the extent of rescue by heat shock (hs)TEF-1 with that of hs-sd. The finding that TEF-1 can function in vivo during wingblade development offers a potent genetic system for the analysis of its function and in the identification of the molecular partners of TEF-1.	TATA INST FUNDAMENTAL RES,MOL BIOL UNIT,BOMBAY 400005,MAHARASHTRA,INDIA; NATL CTR BIOL SCI,TIFR CTR,BANGALORE 560012,KARNATAKA,INDIA	Tata Institute of Fundamental Research (TIFR); Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)				Chopra, Abha/0000-0001-5008-9080				ANAND A, 1990, J GENET, V69, P151, DOI 10.1007/BF02927976; Ashburner M., 1989, DROSOPHILA LAB HDB; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CAMPBELL SD, 1991, GENETICS, V127, P367; CHAUDHARY S, 1995, J BIOL CHEM, V270, P3631, DOI 10.1074/jbc.270.8.3631; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Cohen Stephen M., 1993, P747; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; HOLLAND P, 1995, NATURE, V358, P627; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; INAMDAR M, 1993, J NEUROGENET, V9, P123, DOI 10.3109/01677069309083454; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Waddington CH, 1939, P NATL ACAD SCI USA, V25, P299, DOI 10.1073/pnas.25.7.299; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	29	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10664	10668						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099715				2022-12-25	WOS:A1997WV26200049
J	Puder, M; Soberman, RJ				Puder, M; Soberman, RJ			Glutathione conjugates recognize the Rossmann fold of glyceraldehyde-3-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LEUKOTRIENE-C(4) SYNTHASE; HUMAN-LEUKOCYTES; PROTEIN; 5-LIPOXYGENASE; CELLS; EXPRESSION; IDENTIFICATION; TRANSLOCATION; PURIFICATION; ASSOCIATION	Leukotriene (LT) C-4 and other glutathione conjugates are synthesized intracellularly and then move to the plasma membrane for export. The intracellular proteins that bind these molecules and the significance of these interactions are poorly understood. To identify the binding sites of membrane-associated proteins that recognize these molecules, we utilized photoaffinity probes to label the inner leaflet of erythrocytes. The predominant molecule labeled with S-(p-nitrobenzyl)glutathione-[I-125]4-azidosalicylic acid (PNBG-[I-125]ASA) or LTC4[I-125]4-azidosalicylic acid (LTC4-[I-125]ASA) was 38 kDa, The protein was labeled with PNBG-[I-125]ASA, electroblotted to polyvinylidene difluoride membranes, digested in situ with lysyl endopeptidase, and two radiolabeled peptides isolated by reverse phase-high performance liquid chromatography, These contained an identity of 7/11 with amino acids 119-129, and 11/11 with amino acids 67-77 of human Liver glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively. Photoaffinity labeling with PNBG-[I-125]ASA was blocked completely by 100 mu M ATP and greater than 50% with 100 mu M NAD(+). LTC4-[I-125]ASA binding to the NAD(+) site was confirmed by V8 protease digestion of purified GAPDH labeled with LTC4-[I-125]ASA or PNBG-[I-125]ASA, with both labels localized to the 6.8-kDa N-terminal fragment. Photoaffinity labeling of ML-60 cells with (LTC4HI)-I-125-ASA identified GAPDH as the predominant cytoplasmic binding protein in these cells. These data indicate that GAPDH is a membrane-associated and cytoplasmic protein which binds glutathione conjugates including LTC4.	MASSACHUSETTS GEN HOSP EAST, MASSACHUSETTS GEN HOSP, ARTHRIT UNIT, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP EAST, MASSACHUSETTS GEN HOSP, DEPT MED, CHARLESTOWN, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [T32CA009580] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09580, CA-09031] Funding Source: Medline; NIEHS NIH HHS [ES-50859] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FLENS MJ, 1994, CANCER RES, V54, P4557; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; KAPLAN JH, 1993, CELL, V72, P13, DOI 10.1016/0092-8674(93)90045-R; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; KONDO T, 1982, EUR J BIOCHEM, V125, P551, DOI 10.1111/j.1432-1033.1982.tb06717.x; KONDO T, 1980, BIOCHIM BIOPHYS ACTA, V602, P127, DOI 10.1016/0005-2736(80)90295-3; LACHAAL M, 1990, J BIOL CHEM, V265, P15449; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEIER I, 1994, J BIOL CHEM, V269, P27807; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; RADMARK O, 1984, J BIOL CHEM, V259, P2339; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Steck T L, 1974, Methods Enzymol, V31, P172; SUN FF, 1986, J BIOL CHEM, V261, P8540; TSAI IH, 1982, J BIOL CHEM, V257, P1438; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	31	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10936	10940						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099752				2022-12-25	WOS:A1997WV26200086
J	Mao, SF; Neale, GAM; Goorha, RM				Mao, SF; Neale, GAM; Goorha, RM			T-cell oncogene rhombotin-2 interacts with retinoblastoma-binding protein 2	ONCOGENE			English	Article						oncogene; rhombotin-2; RBP2; transcription	LIM-DOMAIN PROTEINS; CYSTEINE-RICH MOTIF; LOOP-HELIX PROTEIN; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; TRANSCRIPTION FACTOR; TRANSGENIC MICE; ACUTE LEUKEMIAS; INSULIN GENE; RBTN2	The LIM domain protein rhombotin-2 (RBTN-2/TTG-2/Lmo2) has distinct functions in erythropoiesis and in T-cell leukemogenesis. Additional functions for RBTN2 are indicated by its expression in non-hematopoietic tissues. These diverse functions of RBTN2 are presumed to be accomplished through physical interaction with different protein partners that bind the LIM domains of RBTN2. To identify these proteins which may modulate the activity of RBTN2, a human cDNA library was screened using the yeast two-hybrid assay. Using the RBTN2 LIM domain region as 'bait', the retinoblastoma-binding protein 2 (RBP2) was identified as a partner for RBTN2. The interaction between RBTN2 and RBP2 was confirmed using in vitro binding assays, and by coimmunoprecipitation of the two proteins. Deletion analysis showed the second LM domain of RBTN2 was necessary and sufficient for binding to the last 69 amino acids of RBP2. The interaction between RBTN2 and RBP2 had a functional consequence: the combination of RBP2 and RBTN2 gave higher transcription in vitro, than RBTN2 alone. The interaction with RBP2 suggests tao additional functions for RBTN2: (i) RBTN2 may directly affect the activity of RBP2, and/or (ii) RBTN2 may indirectly modulate the functions of the retinoblastoma protein by binding to RBP2.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOL BIOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT PATHOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NATIONAL CANCER INSTITUTE [R01CA043237, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43237, P30 CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AUSEBEL F, 1993, CURRENT PROTOCOLS MO; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FATTAEY AR, 1993, ONCOGENE, V8, P3149; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HARPER JW, 1993, CELL, V75, P805; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LARSON RC, 1995, ONCOGENE, V11, P853; LARSON RC, 1994, ONCOGENE, V9, P3676; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; NEALE GAM, 1995, CELL GROWTH DIFFER, V6, P587; NEALE GAM, 1995, BLOOD, V86, P3060; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SANCHEZGARCIA I, 1995, ONCOGENE, V10, P1301; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	47	30	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1531	1539		10.1038/sj.onc.1200988	http://dx.doi.org/10.1038/sj.onc.1200988			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129143				2022-12-25	WOS:A1997WQ54800003
J	Martin, A; Duffy, PA; Liossis, C; GomezMunoz, A; OBrien, L; Stone, JC; Brindley, DN				Martin, A; Duffy, PA; Liossis, C; GomezMunoz, A; OBrien, L; Stone, JC; Brindley, DN			Increased concentrations of phosphatidate, diacylglycerol and ceramide in ras- and tyrosine kinase (fps)-transformed fibroblasts	ONCOGENE			English	Article						ceramides; diacylglycerol kinase; phosphatidate phosphohydrolase; phospholipase D	PHOSPHOLIPASE-D ACTIVITY; GTPASE ACTIVATING PROTEIN; CELL-PERMEABLE CERAMIDES; XENOPUS-LAEVIS OOCYTES; DNA-SYNTHESIS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLCHOLINE METABOLISM; QUANTITATIVE MEASUREMENT; TRANSFORMED FIBROBLASTS; LYSOPHOSPHATIDIC ACID	Concentrations of the bioactive lipids, phosphatidate and diacylglycerol, increased with time in culture in ras- and tyrosine kinase (fps)-transformed fibroblasts but not in control fibroblasts, On Day 3, diacylglycerol and phosphatidate concentrations were about 3.3- and 5.5-fold higher respectively in the Pas-transformed compared to control fibroblasts. These concentrations in fps-transformed fibroblasts were increased about twofold. The changes in phosphatidate and diacylglycerol resulted from enhanced phospholipid turnover rather than from synthesis de novo, The increased ratio of phosphatidate to diacylglycerol is explained by decreased activities of two distinct phosphatidate phosphohydrolases and increased diacylglycerol kinase in Pas-transformed fibroblasts. Ceramide concentrations were about 2.5- and threefold higher in the fps- and ras-transformed cells respectively on Day 3 compared to the controls, Incubating control fibroblasts from Days 1 to 3 with phosphatidylcholine-specific phospholipase C increased diacylglycerol, phosphatidate and ceramide concentrations, and decreased Mg2+-independent-phosphatidate phosphohydrolase activity, 8-(4-chlorophenylthio)-cAMP had a cytostatic effect in Pas-transformed cells, it decreased the concentrations of phosphatidate and diacylglycerol, but increased that of ceramide, The consequences of increased ceramide and phosphatidate concentrations in Pas-transformed cells are discussed in relation to signal transduction, cell division and the transformed phenotype.	UNIV ALBERTA, LIPID & LIPOPROT RES GRP, SIGNAL TRANSDUCT LABS, HERITAGE MED RES CTR 357, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, HERITAGE MED RES CTR 357, EDMONTON, AB T6G 2S2, CANADA	University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				ALAM MS, 1995, BIOCHEM BIOPH RES CO, V207, P460, DOI 10.1006/bbrc.1995.1210; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOS JL, 1989, CANCER RES, V49, P4682; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BRINDLEY DN, 1987, CRC SERIES ENZYME BI, V1, P1; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CHIARUGI V, 1989, BIOCHEM BIOPH RES CO, V164, P816, DOI 10.1016/0006-291X(89)91532-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DAVIES SA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P173, DOI 10.1016/0167-4889(89)90046-3; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELDAR H, 1993, J BIOL CHEM, V268, P12560; Fiske CH, 1925, J BIOL CHEM, V66, P375; FU T, 1992, BIOCHEM J, V283, P347, DOI 10.1042/bj2830347; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUANG C, 1992, BIOCHIM BIOPHYS ACTA, V1127, P242, DOI 10.1016/0005-2760(92)90227-M; HUANG CF, 1990, J BIOL CHEM, V265, P17468; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; JONES GA, 1993, J BIOL CHEM, V268, P20845; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MARTIN A, 1986, BIOCHIM BIOPHYS ACTA, V876, P581, DOI 10.1016/0005-2760(86)90047-0; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORGAN AR, 1974, BIOCH BIOPHYS RES CO, V61; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; MURPHY SK, 1994, BIOCHEM BIOPH RES CO, V205, P1121, DOI 10.1006/bbrc.1994.2782; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; Nakamura Y, 1996, J IMMUNOL, V156, P256; PATERSON A, 1991, BIOCHEM J, V280, P829, DOI 10.1042/bj2800829; PREISS J, 1986, J BIOL CHEM, V261, P8597; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; PRICE BD, 1989, J BIOL CHEM, V264, P16638; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAKELAM MJO, 1991, BIOCH SOC S, V56, P103; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	74	49	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1571	1580		10.1038/sj.onc.1200987	http://dx.doi.org/10.1038/sj.onc.1200987			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129148				2022-12-25	WOS:A1997WQ54800008
J	Dessolin, S; Schalling, M; Champigny, O; Lonnqvist, F; Ailhaud, G; Dani, C; Ricquier, D				Dessolin, S; Schalling, M; Champigny, O; Lonnqvist, F; Ailhaud, G; Dani, C; Ricquier, D			Leptin gene is expressed in rat brown adipose tissue at birth	FASEB JOURNAL			English	Article						birth; brown adipose tissue; ob; suckling	OBESE GENE; UNCOUPLING PROTEIN; MESSENGER-RNA; OB GENE; MICE; CLONING; THERMOGENESIS; STEP; CDNA	The ob gene product leptin is secreted from adipose tissue, Leptin has dramatic effects on food intake and energy expenditure in rodents. Brown adipose tissue is the first form of adipose tissue to appear during development, and is present at birth in most species, The development of a leptin feedback system in early life and the relative role of the brown and white adipose tissues have not yet been revealed. We have investigated the expression of ob/leptin mRNA in brown adipose tissue around birth and with respect to feeding, Northern blotting analysis and in situ hybridization experiments demonstrated the presence of leptin mRNA in brown adipose tissue at 0, 18, and 24 h after birth, The leptin mRNA level was decreased at 8 h postpartum in fed animals and at 18 or 24 h in the absence of feeding. In addition, circulating leptin was detected in the plasma of newborn rats at 0, 10, or 24 h after birth, whereas it was not detectable in 10 h-old animals that did not suckle at their mother. The presence at birth of ob mRNA and circulating leptin, as web as the early effect of suckling on ob mRNA levels, suggests the precocious involvement of leptin in the control of food intake.	CEREMOD, CNRS, F-92190 MEUDON, FRANCE; UNIV NICE, FAC SCI, CTR BIOCHIM, UMR 134 CNRS, NICE, FRANCE; KAROLINSKA HOSP & INST, DEPT MOL MED, NEUROGENET UNIT, STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MED, STOCKHOLM, SWEDEN; UNIV STOCKHOLM, HUDDINGE HOSP, RES CTR, STOCKHOLM, SWEDEN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Stockholm University			DANI, Christian/G-3639-2014; Schalling, Martin/F-1518-2015	DANI, Christian/0000-0003-3228-0230; Schalling, Martin/0000-0001-5011-2922; Ailhaud, Gerard/0000-0003-0596-2906				Barnard T, 1970, BROWN ADIPOSE TISSUE, P33; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collins S, 1996, J BIOL CHEM, V271, P9437, DOI 10.1074/jbc.271.16.9437; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HENNING SJ, 1979, AM J PHYSIOL, V237, pR187, DOI 10.1152/ajpregu.1979.237.3.R187; HIMMSHAGEN J, 1995, OBES RES, V3, P361, DOI 10.1002/j.1550-8528.1995.tb00162.x; HIMMSHAGEN J, 1997, IN PRESS HDB OBESITY; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; Lonnqvist F, 1996, QJM-MON J ASSOC PHYS, V89, P327; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MOINAT M, 1995, FEBS LETT, V373, P131, DOI 10.1016/0014-5793(95)01030-I; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; SCHALLING M, 1990, P NATL ACAD SCI USA, V87, P8427, DOI 10.1073/pnas.87.21.8427; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	24	73	74	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1997	11	5					382	387		10.1096/fasebj.11.5.9141506	http://dx.doi.org/10.1096/fasebj.11.5.9141506			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141506				2022-12-25	WOS:A1997WX15600012
J	Hobeika, AC; Subramaniam, PS; Johnson, HM				Hobeika, AC; Subramaniam, PS; Johnson, HM			IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells	ONCOGENE			English	Article						interferon alpha; prostate cancer; cyclin dependent; kinase 2; cyclin E; p21	RETINOBLASTOMA PROTEIN; INTERFERON-ALPHA; GROWTH; PHOSPHORYLATION; CARCINOMA; GENE; G1; TRANSITION; LINES	Prostate cancer, like other types of cancer, is associated with the loss of cell cycle control, resulting in unregulated growth of cells. We report here on the inhibitory effects of interferon alpha (IFN alpha) on the cell cycle of prostate cancer cells, using the human prostate carcinoma cell line DU145 that has mutations in the tumor suppressor genes pRB, p53 and KAI1. IFN alpha inhibited growth and colony formation of DU145 cells and analysis by flow cytometry suggests that IFN alpha inhibited the progression of these cancer cells from the G(1) through S phase of the cell cycle. IFN alpha treatment of DU145 cells reduced cyclin dependent kinase 2 (cdk2) activity, In particular, cyclin E dependent cdk2 activity was inhibited by IFN alpha treatment. IFN alpha treatment, however, did not affect the amount of cdk2 bound to cyclin E. Consistent with this data, IFN alpha was able to induce expression of the kinase inhibitor p21 in DU145 cells, Furthermore, IFN treatment increased the amounts of p21 complexed with cdk2 in these cells. These data support a role for p21 in mediating the antiproliferative action of IFN alpha. The induction of p21 and its growth inhibitory effects in DU145 cells appears independent of p53, pRB and KAI1 status.			Hobeika, AC (corresponding author), UNIV FLORIDA,DEPT MICROBIOL & CELL SCI,GAINESVILLE,FL 32611, USA.				NATIONAL CANCER INSTITUTE [R01CA069959] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLALOCK JE, 1980, CELL IMMUNOL, V49, P390, DOI 10.1016/0008-8749(80)90041-6; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BURKE LC, 1992, ONCOGENE, V7, P783; BYBEE A, 1992, BIOCHIM BIOPHYS ACTA, V1137, P73, DOI 10.1016/0167-4889(92)90102-H; CAVENEE WK, 1995, SCI AM           MAR, P72; CREASEY AA, 1980, P NATL ACAD SCI-BIOL, V77, P1471, DOI 10.1073/pnas.77.3.1471; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Familletti P C, 1981, Methods Enzymol, V78, P387; GARNICK MB, 1994, SCI AM           APR, P72; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; ISAACS WB, 1991, CANCER RES, V51, P4716; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; NAKAJIMA Y, 1994, BIOCHEM BIOPH RES CO, V200, P467, DOI 10.1006/bbrc.1994.1472; NETTO GJ, 1994, AM J CLIN PATHOL, V102, pS57; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PINES J, 1995, CELL CYCLE CONTROL, P144; PONTZER CH, 1991, CANCER RES, V51, P5304; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; ROOS G, 1984, CANCER RES, V44, P2358; SICA G, 1989, UROL RES, V17, P111; SUBRMANIAM PS, IN PRESS J INTERFERO; TAMM I, 1987, MECHANISMS INTERFERO, V2, P25; THOMAS NSB, 1991, ONCOGENE, V6, P317; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TSAI LH, 1993, ONCOGENE, V8, P1593	26	89	89	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1165	1170		10.1038/sj.onc.1200939	http://dx.doi.org/10.1038/sj.onc.1200939			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121765				2022-12-25	WOS:A1997WM78200005
J	Jung, YK; Yuan, JY				Jung, YK; Yuan, JY			Suppression of Interleukin-1 beta converting enzyme (ICE)-induced apoptosis by SV40 large T antigen	ONCOGENE			English	Article						ICE; ICH-1; SV40 large T antigen; p53	PROGRAMMED CELL-DEATH; TEMPERATURE-SENSITIVE MUTANT; IN-VIVO; GENE CED-3; C-ELEGANS; IL-1-BETA-CONVERTING ENZYME; TRANSGENIC MICE; CRMA GENE; BAX GENE; P53	The Interleukin-1 beta converting enzyme (ICE) family of proteins, homologs of the C elegans cell death gene product CED-3, play important roles in controlling vertebrate programmed cell death. Because inhibition of apoptosis may be an essential step in tumorigenesis, we investigated the interaction of the simian virus 40 large T antigen (T ag) with the ICE family, COS-1 cells which were transformed by the simian virus 40 do not die when transfected,vith expression constructs of Ice or Ich-1(L). We found that expression of T ag alone significantly prevents the ICE-induced apoptosis. p53, but not pRb or p107, antagonizes the effect of T ag on the suppression of ICE-induced cell death, but not on ICH-1(L)-mediated cell death. Thus, wild type p53 may potentiate ICE-induced apoptosis. Expression of a temperature sensitive mutant p53Val(135) sensitizes COS-1 cells to apoptosis induced by ICE at permissive but not at non-permissive temperature. While induction of bax, p21(WAF1/CIP), Or cyclin DI gene expression is observed in the COS-1 p53Val(135) cells at the permissive temperature, overexpression of bax, but not p2l(WAF1/CIP) Or cyclin D1, potentiates ICE-induced COS-1 cell death. Taken together, these results suggest that Tag may modulate the cells' susceptibility to death by suppressing activity of the ICE family through inhibiting p53.	MASSACHUSETTS GEN HOSP EAST, CARDIOVASC RES CTR, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Jung, Yong-Keun/0000-0002-9686-3120	NIA NIH HHS [AG12859-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012859, R37AG012859] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P39761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU J, 1991, J VIOL, V65, P6972	40	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1207	1214		10.1038/sj.onc.1200943	http://dx.doi.org/10.1038/sj.onc.1200943			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121770				2022-12-25	WOS:A1997WM78200010
J	Dittmar, KD; Pratt, WB				Dittmar, KD; Pratt, WB			Folding of the glucocorticoid receptor by the reconstituted hsp90-based chaperone machinery - The initial hsp90-p60-hsp70-dependent step is sufficient for creating the steroid binding conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; PROGESTERONE-RECEPTOR; FUNCTIONAL HETEROCOMPLEX; HSP90; COMPLEX; HSP70; FOLDOSOME; CYTOSOL; EXISTS; STI1	Rabbit reticulocyte lysate contains a multiprotein chaperone system that assembles steroid receptors into a complex with hsp90, The glucocorticoid receptor (GR) is bound to hsp90 via its hormone binding domain (HBD), which must be associated with hsp90 to have a steroid binding conformation, Recently, we have reconstituted a receptor-hsp90 heterocomplex assembly system with purified rabbit hsp90 and hsp70 and bacterially expressed human p23 and p60 (Dittmar, K.D., Hutchison, K.A., Owens-Grille, J.K., and Pratt, W.B. (1996) J. Biol. Chem. 271, 12833-12839), In this work we show that when the GR is incubated with hsp90, hsp70, and p60, steroid binding sites are generated despite the absence of p23, In this minimal reconstituted system, the GR is incubated with the chaperones in the presence of [H-3]triamcinolone acetonide ([H-3]TA), which binds to the receptor as GR.hsp90 complexes are formed. When molybdate or p23 is also present during the incubation with chaperones at 30 degrees C, the formation of steroid binding sites can be assayed by incubating the washed GR with [H-3]TA after heterocomplex assembly at 30 degrees C, However, in the absence of p23 or molybdate, rapid disassembly of GR.hsp90 complexes apparently occurs simultaneously with assembly, such that [H-3]TA must be present during the assembly process to trap evidence of conversion of the GR HBD from a non-steroid binding to a steroid binding conformation, Mixture of purified rabbit hsp90 and hsp70 with bacterial lysate containing human p60 results in spontaneous formation of an hsp90.p60.hsp70 complex that can be adsorbed with anti-p60 antibody, and the resulting immune complex converts the GR HBD to a steroid binding state in an ATP-dependent and K+-dependent manner. When the GR is incubated with hsp90, hsp70, and p60 in the presence of the hsp90-binding antibiotic geldanamycin, GR.hsp90.p60.hsp70 complexes are formed, but they have no steroid binding activity, Our data suggest that hsp90, hsp70, and p60 work together as a chaperone complex that possesses all of the folding/unfolding activity necessary to generate the high affinity steroid binding conformation of the receptor.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; HOHFELD J, 1995, CELL, V83, P589; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; Hutchison KA, 1996, J STEROID BIOCHEM, V58, P251, DOI 10.1016/0960-0760(96)00038-6; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OwensGrillo JK, 1996, BIOCHEMISTRY-US, V35, P15249, DOI 10.1021/bi9615349; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P2049; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHMID FX, 1993, ANN REV BIOMOL STRUC, V22, P122; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705	41	140	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13047	13054		10.1074/jbc.272.20.13047	http://dx.doi.org/10.1074/jbc.272.20.13047			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148915	hybrid			2022-12-25	WOS:A1997WZ38400028
J	Han, ZY; Hendrickson, EA; Bremner, TA; Wyche, JH				Han, ZY; Hendrickson, EA; Bremner, TA; Wyche, JH			A sequential two-step mechanism for the production of the mature p17:p12 form of caspase-3 in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; 70-KDA PROTEIN-COMPONENT; FACTOR-INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; THYMOCYTE APOPTOSIS; CELL-DEATH; CLEAVAGE; ACTIVATION; INHIBITION	The apoptotic cysteine protease, caspase-3, is expressed in cells as an inactive 32 kDa precursor from which 17 kDa (p17) and 12 kDa (p12) subunits of the mature caspase-3 are proteolytically generated during apoptosis, Two amino acid sequences, ESMD down arrow S (amino acids 25-29) and IETD down arrow S (amino acids 172-176), in the precursor have been defined as the cleavage sites for the production of the p17 and p12 subunits, Using a cell-free assay system, we demonstrate that the caspase-3 precursor appears to be cleaved first at the IETD down arrow S site, producing the p12 subunit and a 20-kDa (p20) peptide, Subsequently, the p20 is cleaved at the ESMD down arrow S site, generating the mature p17 subunit, The cleavage at the IETD down arrow S site required a protease activity that was selectively inhibited by the peptide, Ac-IETD-CHO (acetyl-IETD-aldehyde), and other protease inhibitors, such as the cowpox viral serine protease inhibitor, CrmA, and N-alpha-tosyl-L-phenylalanine chloromethyl ketone. The protease that catalyzed the cleavage at the ESMD/S site was selectively inhibited by another peptide, Ac-ESMD-CHO (acetyl-ESMD-aldehyde). More interestingly, the caspase-3 inhibitor, Ac-DEVD-CHO, but not the caspase-1 inhibitor, Ac-YVAD-CHO, also selectively inhibited the protease activity that cleaves at the ESMD down arrow S site. This indicated that the cleavage at the ESMD down arrow site was either autocatalytic or that it required a caspase-3-like activity. In summary, we demonstrate that production of the p17:p12 form of caspase-3 is a sequential two-step process and appears to require two distinct enzymatic activities.	HOWARD UNIV,DEPT BIOL,WASHINGTON,DC 20059	Howard University	Han, ZY (corresponding author), BROWN UNIV,DEPT BIOCHEM MOL BIOL & CELL BIOL,PROVIDENCE,RI 02912, USA.				NIAID NIH HHS [AI 35763] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035763] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FEARNHEAD HO, 1995, FEBS LETT, V357, P242, DOI 10.1016/0014-5793(94)01367-A; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Han ZY, 1996, CANCER RES, V56, P1621; KIM HK, 1995, J IMMUNOL, V154, P4741; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHAW E, 1970, PHYSIOL REV, V50, P244, DOI 10.1152/physrev.1970.50.2.244; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Turner P.C., 1994, VIROCEPTORS VIROKINE, P67; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391	34	211	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13432	13436		10.1074/jbc.272.20.13432	http://dx.doi.org/10.1074/jbc.272.20.13432			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148968	hybrid			2022-12-25	WOS:A1997WZ38400081
J	Gervais, FG; Veillette, A				Gervais, FG; Veillette, A			Reconstitution of interactions between protein-tyrosine phosphatase CD45 and tyrosine-protein kinase p56(lck) in nonlymphoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; HUMAN LYMPHOCYTES-T; CROSS-LINKING; CYTOPLASMIC DOMAINS; ESCHERICHIA-COLI; SH2 DOMAIN; PHOSPHORYLATION; P56LCK; RECEPTOR; LCK	To further understand the functional interactions between CD45 and p56(lck) in T-cells, we stably reconstituted their expression in a nonlymphoid system. The results of our analyses demonstrated that CD45 could dephosphorylate tyrosine 505 of p56(lck) in NIH 3T3 fibroblasts. As is the case for T-cells, removal of the unique domain of p56(lck) interfered with dephosphorylation of tyrosine 505 in fibroblasts, further stressing the importance of this region in the interactions between CD45 and p56(lck). The ability of CD45 to dephosphorylate tyrosine 505 in NIH 3T3 cells was also greatly influenced by the catalytic activity of p56(lck)., Indeed, whereas CD45 provoked dephosphorylation of kinase-defective Lck molecules in this system, it failed to stably dephosphorylate kinase active p56(lck) polypeptides. Finally, our studies showed that CD45 was also able to inhibit the oncogenic potential of a constitutively activated version of p56(lck) in NIH 3T3 cells. This effect did not require the Lck unique domain and apparently resulted from selective dephosphorylation of substrates of activated p56(lck) in fibroblasts, In addition to providing insights into the nature and regulation of the interactions between CD45 and p56(lck) in T-cells, these results indicated that CD45 clearly has the capacity to both positively and negatively regulate p56(lck)-mediated functions in vivo.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University								ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Bruyns E, 1995, J BIOL CHEM, V270, P31372; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CARTIER M, 1987, MOL CELL BIOL, V7, P1623, DOI 10.1128/MCB.7.5.1623; CASNELLIE JE, 1987, J BIOL CHEM, V262, P9858; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Doro U, 1996, MOL CELL BIOL, V16, P4996; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; KITAMURA K, 1995, J BIOL CHEM, V270, P21151, DOI 10.1074/jbc.270.36.21151; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; LUO K, 1990, ONCOGENE, V5, P803; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCFARLAND EDC, 1995, J BIOL CHEM, V270, P28103; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SOULA M, 1993, J BIOL CHEM, V268, P27420; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; Weil R, 1996, CURR TOP MICROBIOL, V205, P63; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yurchak LK, 1996, J BIOL CHEM, V271, P12549, DOI 10.1074/jbc.271.21.12549	53	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12754	12761		10.1074/jbc.272.19.12754	http://dx.doi.org/10.1074/jbc.272.19.12754			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139734	hybrid			2022-12-25	WOS:A1997WY82900071
J	Kureishi, Y; Kobayashi, S; Amano, M; Kimura, K; Kanaide, H; Nakano, T; Kaibuchi, K; Ito, M				Kureishi, Y; Kobayashi, S; Amano, M; Kimura, K; Kanaide, H; Nakano, T; Kaibuchi, K; Ito, M			Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; CA-2+; SENSITIVITY; PHOSPHATASE; MODULATION	Small GTPase Rho plays pivotal roles in the Ca2+ sensitization of smooth muscle. However, the GTP-bound active form of Rho failed to exert Ca2+-sensitizing effects in extensively Triton X-100-permeabilized smooth muscle preparations, due to the loss of the important diffusible cofactor (Gong, M. C., Iizuka, K., Nixon, G., Browne, J. P., Hall, A., Eccleston, J. F., Sugai, M., Kobayashi, S., Somlyo, A. V., and Somlyo, A. P. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 1340-1345), Here we demonstrate the contractile effects of Rho-associated kinase (Rho-kinase), recently identified as a putative target of Rho, on the Triton X-100-permeabilized smooth muscle of rabbit portal vein, Introduction of the constitutively active form of Rho-kinase into the cytosol of Triton X-100-permeabilized smooth muscle provoked a contraction and a proportional increase in levels of monophosphorylation of myosin light chain in both the presence and the absence of cytosolic Ca2+. These effects of constitutively active Rho-kinase were wortmannin (a potent myosin light chain kinase inhibitor)-insensitive. Immunoblot analysis revealed that the amount of native Rho-kinase was markedly lower in Triton X-100-permeabilized tissue than in intact tissue. Our results demonstrate that Rho-kinase directly modulates smooth muscle contraction through myosin light chain phosphorylation, independently of the Ca2+-calmodulin-dependent myosin light chain kinase pathway.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,NARA 63001,JAPAN; MIE UNIV,SCH MED,DEPT INTERNAL MED 1,TSU,MIE 514,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT PHYSIOL 1,UBE,YAMAGUCHI 755,JAPAN; KYUSHU UNIV,FAC MED,ANGIOCARDIOL RES INST,DIV MOL CARDIOL,FUKUOKA 812,JAPAN	Nara Institute of Science & Technology; Mie University; Yamaguchi University; Kyushu University			Bando, Yasuko K./M-4831-2014; Kimura, Kazushi/ABB-4007-2020; Kobayashi, Sei/E-7175-2010; Amano, Mutsuki/M-4820-2014	Bando, Yasuko K./0000-0003-4166-6784; Amano, Mutsuki/0000-0002-0662-1524				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; GONG MC, 1992, J BIOL CHEM, V267, P14662; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HIMPENS B, 1990, PFLUG ARCH EUR J PHY, V417, P21, DOI 10.1007/BF00370764; HIRATA K, 1992, J BIOL CHEM, V267, P8719; IIZUKA K, 1994, CELL CALCIUM, V16, P431, DOI 10.1016/0143-4160(94)90073-6; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Otto B, 1996, J PHYSIOL-LONDON, V496, P317, DOI 10.1113/jphysiol.1996.sp021687; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; WALSH MP, 1984, BIOCHEM J, V224, P117, DOI 10.1042/bj2240117	27	481	504	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12257	12260		10.1074/jbc.272.19.12257	http://dx.doi.org/10.1074/jbc.272.19.12257			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139666	hybrid			2022-12-25	WOS:A1997WY82900003
J	Niu, HW; ErdjumentBromage, H; Pan, ZQ; Lee, SH; Tempst, P; Hurwitz, J				Niu, HW; ErdjumentBromage, H; Pan, ZQ; Lee, SH; Tempst, P; Hurwitz, J			Mapping of amino acid residues in the p34 subunit of human single-stranded DNA-binding protein phosphorylated by DNA-dependent protein kinase and Cdc2 kinase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; POLYMERASE-ALPHA-PRIMASE; REPLICATION INVITRO; SV40 ORIGIN; T-ANTIGEN; RECOMBINATION; INITIATION; COMPLEX; RPA; P53	Human single-stranded DNA-binding protein (HSSB, also called RPA), is a heterotrimeric complex that consists of three subunits, p70, p34, and p11. HSSB is essential for the in vitro replication of SV40 DNA and nucleotide excision repair. It also has important functions in other DNA transactions, including DNA recombination, transcription, and double-stranded DNA break repair. The p34 subunit of HSSB is phosphorylated in a cell cycle dependent manner, Both Cdc2 kinase and the DNA-dependent protein kinase (DNA-PK) phosphorylate HSSB p34 in vitro. In this study, we show that efficient phosphorylation of HSSB-p34 by DNA-PK requires Ku as well as DNA. The DNA-PK phosphorylation sites in HSSB-p34 have been mapped at Thr-21 and Ser-33. Kinetic studies demonstrated that a phosphate residue is first incorporated at Thr-21 followed by the incorporation of a second phosphate residue at Ser-33, We also identified Ser-29 as the major Cdc2 kinase phosphorylation site in the p34 subunit.	CORNELL UNIV, GRAD SCH MED SCI, MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOL BIOL, NEW YORK, NY 10021 USA; MT SINAI MED CTR, DERALD H RUTTENBERG CANC CTR, NEW YORK, NY 10029 USA; ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOL BIOL, MEMPHIS, TN 38101 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; St Jude Children's Research Hospital			Hurwitz, Julia/N-2301-2018	Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052358] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM38559, GM 52358] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Henricksen LA, 1996, NUCLEIC ACIDS RES, V24, P3107, DOI 10.1093/nar/24.15.3107; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LI L, 1995, MOL CELL BIOL, V15, P5396; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; LIU VF, 1993, J CELL SCI, V106, P983; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; LUCHE RM, 1993, MOL CELL BIOL, V13, P5749, DOI 10.1128/MCB.13.9.5749; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SINGH KK, 1995, P NATL ACAD SCI USA, V92, P4907, DOI 10.1073/pnas.92.11.4907; SMITH J, 1995, MOL CELL BIOL, V15, P1632; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643	54	75	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12634	12641		10.1074/jbc.272.19.12634	http://dx.doi.org/10.1074/jbc.272.19.12634			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139719	hybrid			2022-12-25	WOS:A1997WY82900056
J	Scheele, JS; Kharitonov, VG; Martasek, P; Roman, LJ; Sharma, VS; Masters, BSS; Magde, D				Scheele, JS; Kharitonov, VG; Martasek, P; Roman, LJ; Sharma, VS; Masters, BSS; Magde, D			Kinetics of CO ligation with nitric-oxide synthase by flash photolysis and stopped-flow spectrophotometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE BINDING; L-ARGININE; GEMINATE RECOMBINATION; SPECTRAL CHARACTERIZATION; HEME COORDINATION; R-STATE; HEMOGLOBIN; MYOGLOBIN; BRAIN; CARBOXYHEMOGLOBIN	Interaction of CO with hemeproteins has physiological importance. This is especially true for nitric-oxide synthases (NOS), heme/flavoenzymes that produce (NO)-N-. and citrulline from L-arginine (Arg) and are inhibited by CO in vitro. The kinetics of CO ligation with both neuronal NOS and its heme domain module were determined in the presence and absence of tetrahydrobiopterin and Arg to allow comparison with other hemeproteins. Geminate recombination in the nanosecond time domain is followed by bimolecular association in the millisecond time domain. Complex association kinetics imply considerable heterogeneity but can be approximated with two forms, one fast (2-3 x 10(6) M-1 s(-1)) and another slow (2-4 x 10(4) M-1 s(-1)). The relative proportions of the two forms vary with conditions. For the heme domain, fast forms dominate except in the presence of both tetrahydrobiopterin and Arg, In the holoenzyme, slow forms dominate except when both reagents are absent. Geminate recombination is substantial, similar to 50%, only when fast forms predominate, Stopped-flow mixing found dissociation constants near 0.3 s(-1). These data imply an equilibrium constant such that very little CO should bind at physiological conditions unless large CO concentrations are present locally.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Health San Antonio			Martasek, Pavel/G-6622-2017	Martasek, Pavel/0000-0001-6165-4444	NHLBI NIH HHS [HL40818, HL13581] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CAMPBELL BF, 1985, J BIOL CHEM, V260, P2752; CHRISTODOULIDES N, 1995, CIRCULATION, V91, P2306, DOI 10.1161/01.CIR.91.9.2306; DAWSON TM, 1994, J NEUROSCI, V14, P5147; HILDEBRAND DP, 1995, BIOCHEMISTRY-US, V34, P11598, DOI 10.1021/bi00036a036; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KOLEY AP, 1995, J BIOL CHEM, V270, P5014, DOI 10.1074/jbc.270.10.5014; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Matsui T, 1996, BIOCHEMISTRY-US, V35, P13118, DOI 10.1021/bi960459z; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1992, J NEUROCHEM, V59, P2024; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Meilin S, 1996, J APPL PHYSIOL, V81, P1078, DOI 10.1152/jappl.1996.81.3.1078; MOORE EG, 1976, J BIOL CHEM, V251, P2788; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; Olson J S, 1981, Methods Enzymol, V76, P631; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V151, P427, DOI 10.1016/0003-9861(72)90518-8; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SHARMA VS, 1976, J BIOL CHEM, V251, P4267; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; SHARMA VS, 1980, J BIOL CHEM, V255, P5879; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TIAN WD, 1995, J BIOL CHEM, V270, P8673, DOI 10.1074/jbc.270.15.8673; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P17049; WALDA KN, 1994, BIOCHEMISTRY-US, V33, P2198, DOI 10.1021/bi00174a029; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	44	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12523	12528		10.1074/jbc.272.19.12523	http://dx.doi.org/10.1074/jbc.272.19.12523			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139703	hybrid			2022-12-25	WOS:A1997WY82900040
J	Takahashi, S; Onodera, K; Motohashi, H; Suwabe, N; Hayashi, N; Yanai, N; Nabesima, Y; Yamamoto, M				Takahashi, S; Onodera, K; Motohashi, H; Suwabe, N; Hayashi, N; Yanai, N; Nabesima, Y; Yamamoto, M			Arrest in primitive erythroid cell development caused by promoter-specific disruption of the GATA-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; DNA-BINDING PROTEIN; BETA-GLOBIN GENE; IN-VITRO; EXPRESSION; DIFFERENTIATION; MICE; LINEAGES	To elucidate the in vivo function of GATA-1 during hematopoiesis, we specifically disrupted the erythroid promoter of the GATA-1 gene in embryonic stem cells and generated germ line chimeras. Male offspring of chimeras bearing the targeted mutation were found to die by 12.5 days post coitus due to severe anemia while heterozygous females displayed characteristics ranging from severe anemia to normal erythropoiesis. When female heterozygotes were crossed with transgenic males carrying a reporter gene, which specifically marks primitive erythroid progenitors, massive accumulation of undifferentiated erythroid cells were observed in the yolk sacs of the GATA-1-mutant embryos, demonstrating that GATA-1 is required for the terminal differentiation of primitive erythroid cells in vivo.	UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,DEPT CELL BIOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; NATL INST NEUROSCI,DEPT MOL GENET,KODAIRA,TOKYO 187,JAPAN	University of Tsukuba; University of Tsukuba; Tohoku University; National Center for Neurology & Psychiatry - Japan			Yamamoto, Masayuki/A-4873-2010; Motohashi, Hozumi/AAZ-2628-2020	Yamamoto, Masayuki/0000-0002-9073-9436; 				BOEHM T, 1991, ONCOGENE, V6, P695; BUNGERT J, 1995, ANN MED, V28, P47; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MIWA Y, 1991, DEVELOPMENT, V111, P543; OKUYAMA R, 1995, BLOOD, V86, P2590; ONODERA K, 1997, IN PRESS P NATL ACAD; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	26	148	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12611	12615		10.1074/jbc.272.19.12611	http://dx.doi.org/10.1074/jbc.272.19.12611			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139715	hybrid			2022-12-25	WOS:A1997WY82900052
J	Buhr, A; Baur, R; Sigel, E				Buhr, A; Baur, R; Sigel, E			Subtle changes in residue 77 of the gamma subunit of alpha 1 beta 2 gamma 2 GABA(A) receptors drastically alter the affinity for ligands of the benzodiazepine binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC ACIDA RECEPTOR; A-RECEPTOR; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; POINT MUTATION; ALPHA-SUBUNIT; BETA-SUBUNIT; AMINO-ACID; PHARMACOLOGY; CHANNELS	Recombinant alpha 1 beta 2 gamma 2 gamma-aminobutyric acid type A (GABA(A)) receptors were functionally expressed in Xenopus oocytes, Upon the mutation F77L, diazepam and Ro 15-1788 retained the ability to interact with the benzodiazepine binding site, but zolpidem lost this ability. To quantify these data, radioligand binding experiments were performed using membrane preparations of transiently transfected human embryonic kidney 293 cells. The amino acid gamma 77, phenylalanine, was also mutated to tyrosine, tryptophan, and isoleucine. Although there was little effect on Ro 15-1788 binding upon mutation to tyrosine, the loss in affinity for diazepam was from 12 to 2,720 nM. The change to leucine, in contrast, resulted in little change in the diazepam affinity, whereas there was a strongly reduced affinity for zolpidem from 17 to 4,870 nM and for methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) from 1.9 to 1,780 nM, respectively. The change to tryptophan resulted in two-phasic displacement curves, and only about 50% of the [H-3]flunitrazepam binding could be displaced by zolpidem, DMCM, and Ro 15-1788, respectively, whereas midazolam and diazepam still resulted in 100% displacement, indicating the presence of two sites upon expression of this mutant receptor. Functional expression in Xenopus oocytes showed that all mutant channels displayed a comparatively small change (<4.3-fold) in their apparent agonist affinity and that these channels could still be functionally modulated by ligands of the benzodiazepine binding site. We conclude that subtle changes in gamma F77 drastically affect benzodiazepine pharmacology and that this residue probably interacts directly with most ligands of the benzodiazepine binding site and therefore defines part of the benzodiazepine binding pocket.	UNIV BERN, DEPT PHARMACOL, CH-3010 BERN, SWITZERLAND	University of Bern			Sigel, Erwin/F-7736-2015					BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; Buhr A, 1996, MOL PHARMACOL, V49, P1080; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CARTER DB, 1992, BIO-TECHNOL, V10, P679, DOI 10.1038/nbt0692-679; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DOBLE A, 1982, EUR J PHARMACOL, V83, P313, DOI 10.1016/0014-2999(82)90268-0; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; DUNN SMJ, 1994, INT REV NEUROBIOL, V36, P51, DOI 10.1016/S0074-7742(08)60303-7; FAUREHALLEY C, 1993, EUR J PHARM-MOLEC PH, V246, P283, DOI 10.1016/0922-4106(93)90043-9; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; HADINGHAM KL, 1993, MOL PHARMACOL, V44, P1211; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; KAROBATH M, 1982, NEUROSCI LETT, V31, P65, DOI 10.1016/0304-3940(82)90055-6; KORPI ER, 1993, NATURE, V361, P356, DOI 10.1038/361356a0; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; LUDDENS H, 1994, MOL PHARMACOL, V45, P810; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; MIHIC SJ, 1994, J BIOL CHEM, V269, P32768; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PRINZ H, 1993, J BIOL CHEM, V268, P18580; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIEGHART W, 1983, J NEUROCHEM, V41, P47, DOI 10.1111/j.1471-4159.1983.tb11812.x; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIGEL E, 1988, J NEUROSCI, V8, P289; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1983, J BIOL CHEM, V258, P6965; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; WIELAND HA, 1994, J MED CHEM, V37, P4576, DOI 10.1021/jm00052a019; WIELAND HA, 1992, J BIOL CHEM, V267, P1426	39	107	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11799	11804		10.1074/jbc.272.18.11799	http://dx.doi.org/10.1074/jbc.272.18.11799			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115236	hybrid			2022-12-25	WOS:A1997WX56900024
J	Dix, D; Bridgham, J; Broderius, M; Eide, D				Dix, D; Bridgham, J; Broderius, M; Eide, D			Characterization of the FET4 protein of yeast - Evidence for a direct role in the transport of iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FERRIC REDUCTASE; PLASMA-MEMBRANE; MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL CONTROL; SARCOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; ESCHERICHIA-COLI; GENE; TRANSFERRIN	The low affinity Fe2+ uptake system of Saccharomyces cerevisiae requires the FET4 gene. In this report, we present evidence that FET4 encodes the Fe2+ transporter protein of this system. Antibodies prepared against FET4 detected two distinct proteins with molecular masses of 63 and 68 kDa. In vitro synthesis of FET4 suggested that the 68-kDa form is the primary translation product, and the 63-kDa form may be generated by proteolytic cleavage of the full-length protein. Consistent with its role as an Fe2+ transporter, FET4 is an integral membrane protein present in the plasma membrane. The level of FET4 closely correlated with uptake activity over a broad range of expression levels and is itself regulated by iron. Furthermore, mutations in FET4 can alter the kinetic properties of the low affinity uptake system, suggesting a direct interaction between FET4 and its Fe2+ substrate. Mutations affecting potential Fe2+ ligands located in the predicted transmembrane domains of FET4 significantly altered the apparent K-m and/or V-max of the low affinity system. These mutations may identify residues involved in Fe2+ binding during transport.	UNIV MINNESOTA, DEPT BIOCHEM & MOL BIOL, DULUTH, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth					NIGMS NIH HHS [GM-48139] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048139] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; ECKER DJ, 1983, J BACTERIOL, V155, P616, DOI 10.1128/JB.155.2.616-622.1983; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; EIDE D, 1992, J BIOL CHEM, V267, P20774; EVANS SL, 1986, J BACTERIOL, V168, P1096, DOI 10.1128/jb.168.3.1096-1099.1986; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; GRUSAK MA, 1990, PLANT PHYSIOL, V94, P1353, DOI 10.1104/pp.94.3.1353; HAN O, 1995, J NUTR, V125, P1291; HARLOW E, 1988, ANTIBODIES LABORATOR, P514; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; JOHNSON W, 1991, INFECT IMMUN, V59, P2376, DOI 10.1128/IAI.59.7.2376-2381.1991; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P21; NUNEZ MT, 1994, AM J PHYSIOL-CELL PH, V267, pC1582, DOI 10.1152/ajpcell.1994.267.6.C1582; NUNEZ MT, 1992, J BIOL CHEM, V267, P11490; OSHIRO S, 1993, J BIOL CHEM, V268, P21586; PARKER R, 1991, METHOD ENZYMOL, V194, P415; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAJA KB, 1992, BIOCHIM BIOPHYS ACTA, V1135, P141, DOI 10.1016/0167-4889(92)90129-Y; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; ROMHELD V, 1983, PLANT PHYSIOL, V71, P949, DOI 10.1104/pp.71.4.949; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; WATKINS JA, 1992, BIOCHEMISTRY-US, V31, P5820, DOI 10.1021/bi00140a018; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	54	92	92	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11770	11777		10.1074/jbc.272.18.11770	http://dx.doi.org/10.1074/jbc.272.18.11770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115232	hybrid			2022-12-25	WOS:A1997WX56900020
J	Palaty, CK; Kalmar, G; Tai, G; Oh, S; Amankawa, L; Affolter, M; Aebersold, R; Pelech, SL				Palaty, CK; Kalmar, G; Tai, G; Oh, S; Amankawa, L; Affolter, M; Aebersold, R; Pelech, SL			Identification of the autophosphorylation sites of the Xenopus laevis pim-1 proto-oncogene-encoded protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; COLONY-STIMULATING FACTOR; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; GENE-PRODUCT; BONE-MARROW; EXPRESSION; LEUKEMIA; RECEPTOR	Pim-1 is an oncogene-encoded serine/threonine kinase expressed primarily in cells of the hematopoietic and germ line lineages. Previously identified only in mammals, pim-1 cDNA was cloned and sequenced from the African clawed frog Xenopus laevis. The coding region of Xenopus pim-1 encoded a protein of 324 residues, which exhibited 64% amino acid identity with the full-length human cognate, Xenopus Pim-1 was expressed in bacteria as a glutathione S-transferase (GST) fusion protein and in COS cells. Phosphoamino acid analysis revealed that recombinant Pim-1 autophosphorylated on serine and threonine and to a more limited extent on tyrosine. Electrospray ionization mass spectroscopy was undertaken to locate these phosphorylation sites, and the primary autophosphorylation site of GST-Pim-1 was identified as Ser-190 with Thr-205 and Ser-4 being minor sites. Ser-190, which immediately follows the high conserved Asp-Phe-Gly motif in catalytic subdomain VII, is also featured in more than 20 other protein kinases. To evaluate the importance of the Ser-190 site on the phosphotransferase activity of Pim-1, Ser-190 was mutated to either alanine or glutamic acid, and the constructs were expressed in bacteria as GST fusion proteins and in COS cells, These mutants confirmed that Ser-190 is a major autophosphorylation site of Pim-1 and indicated that phosphorylation of Pim-1 on the Ser-190 residue may serve to activate this kinase.	KINETEK PHARMACEUT INC,VANCOUVER,BC V5Z 1A1,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 1M9,CANADA; SIMON FRASER UNIV,INST MOL BIOL & BIOCHEM,BURNABY,BC V5A 1S6,CANADA; UNIV WASHINGTON,DEPT BIOTECHNOL,SEATTLE,WA 98105	University of British Columbia; Simon Fraser University; University of Washington; University of Washington Seattle				Affolter, Michael/0000-0003-1568-4516				AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BAYLIS SA, 1993, J VIROL, V67, P4549, DOI 10.1128/JVI.67.8.4549-4556.1993; BELLE R, 1986, CELL DIFFER DEV, V19, P253, DOI 10.1016/0045-6039(86)90102-8; BERNS A, 1988, ONCOGENE HDB, P121; BIANCHI MW, 1994, MOL GEN GENET, V242, P337, DOI 10.1007/BF00280424; BLACKETER MJ, 1993, MOL CELL BIOL, V13, P5567, DOI 10.1128/MCB.13.9.5567; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CUYPERS HT, 1984, CELL, V37, P141; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; DOMEN J, 1987, ONCOGENE RES, V1, P103; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOOVER D, 1991, J BIOL CHEM, V266, P14018; HUTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KINOSHITA T, 1995, EMBO J, V14, P2266; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; LILLY M, 1992, ONCOGENE, V7, P727; Maniatis T., 1982, MOL CLONING; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; MEEKER TC, 1987, J CELL BIOCHEM, V35, P105, DOI 10.1002/jcb.240350204; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; PADMA R, 1991, CANCER RES, V51, P2486; PADMANABHA R, 1991, MOL GEN GENET, V229, P1; Pelech S L, 1995, Prog Cell Cycle Res, V1, P33; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Saito Y, 1992, GROWTH FACTORS, V7, P297, DOI 10.3109/08977199209046412; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; VERON M, 1994, CELL MOL BIOL, V40, P587; VONLINDERN M, 1989, ONCOGENE, V4, P75; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183; WINGETT D, 1991, J IMMUNOL, V147, P3653; WINGETT D, 1995, J CELL BIOCH S, V19, P1; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YIPSCHNEIDER MT, 1995, BLOOD, V12, P3494; YUSHERMAN M, 1992, EMBO J, V11, P71; ZAKUTHOURI R, 1987, GENE, V54, P105, DOI 10.1016/0378-1119(87)90352-0; ZHANG SC, 1992, J EXP ZOOL, V262, P317, DOI 10.1002/jez.1402620312	59	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10514	10521						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099695				2022-12-25	WOS:A1997WV26200029
J	Thompson, MG; Mackie, SC; Thom, A; Palmer, RM				Thompson, MG; Mackie, SC; Thom, A; Palmer, RM			Regulation of phospholipase D in L6 skeletal muscle myoblasts - Role of protein kinase C and relationship to protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTING PHORBOL ESTER; RENAL MESANGIAL CELLS; SWISS 3T3 CELLS; D ACTIVATION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PHOSPHATIDYLCHOLINE BREAKDOWN; SIGNAL TRANSDUCTION; HUMAN PLATELETS; SMOOTH-MUSCLE; GROWTH-FACTOR	The addition of vasopressin or 12-O-tetradecanoylphorbol-13-acetate (TPA) to prelabeled L6 myoblasts elicited increases in [C-14]ethanolamine release, suggesting the activation of phospholipase D activity or activities, While the effects of both agonists on intracellular release were rapid and transient, when extracellular release of [C-14]ethanolamine was measured, the effect of vasopressin was again rapid and transient, whereas that of TPA was delayed but sustained, Effects of both agonists on intra- and extracellular release were inhibited by the protein kinase C (PKC) inhibitor, Re-31-8220, and PKC down-regulation by preincubation with TPA, The formation of phosphatidylbutanol elicited by vasopressin and TPA mirrored their effects on extracellular [C-14]ethanolamine release in that the former was transient, whereas the latter was sustained, Responses to both agonists were abolished by PKC down-regulation. When protein synthesis was examined, the stimulation of translation by TPA and transcription by vasopressin were inhibited by Re-31-8220, In contrast, down-regulation of PKC inhibited the synthesis response to TPA but not vasopressin, Furthermore, following down-regulation, the effect of vasopressin was still blocked by the PKC inhibitors, Re-31-8220 and bisindolylmaleimide. Analysis of PKC isoforms in L6 cells showed the presence of alpha, epsilon, delta, mu, iota, and zeta. Down-regulation removed both cytosolic (alpha) and membrane-bound (epsilon and delta) isoforms, Thus, the elevation of phospholipase D activity or activities induced by both TPA and vasopressin and the stimulation of translation by TPA involves PKC-alpha, -epsilon, and/or -delta, In contrast, the increase in transcription elicited by vasopressin involves mu, iota, and/or zeta. Hence, although phospholipase D may be linked to increases in translation elicited by TPA, it is not involved in the stimulation of transcription by vasopressin.			Thompson, MG (corresponding author), ROWETT RES INST,ABERDEEN AB21 9SB,SCOTLAND.							AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BECK SA, 1991, CANCER RES, V51, P6089; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; CRABOS M, 1992, BIOCHEM J, V288, P891, DOI 10.1042/bj2880891; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; EXTON JH, 1990, J BIOL CHEM, V265, P1; GOODMAN MN, 1987, BIOCHEM J, V247, P151, DOI 10.1042/bj2470151; HARRIS WE, 1992, BIOCHEM J, V281, P675, DOI 10.1042/bj2810675; HASSELGREN PO, 1986, ARCH SURG-CHICAGO, V121, P919; HELGAARD NHH, 1989, CRC HDB IMMUNOBLOTTI, V1, P1; HII CST, 1991, J BIOL CHEM, V266, P20238; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HONG DH, 1995, BBA-MOL CELL RES, V1267, P45, DOI 10.1016/0167-4889(95)00024-M; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KESTER M, 1992, J CELL PHYSIOL, V150, P578, DOI 10.1002/jcp.1041500319; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1991, BIOCHEM J, V273, P189, DOI 10.1042/bj2730189; KISS Z, 1989, J BIOL CHEM, V264, P1483; KISS Z, 1992, BIOCHEM J, V285, P229, DOI 10.1042/bj2850229; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MCNULTY S, 1992, NEUROSCI LETT, V139, P183, DOI 10.1016/0304-3940(92)90547-K; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; MORRISON KS, 1995, J CELL PHYSIOL, V165, P273, DOI 10.1002/jcp.1041650208; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PFEILSCHIFTER J, 1993, FEBS LETT, V331, P267, DOI 10.1016/0014-5793(93)80350-4; PLEVIN R, 1992, BIOCHEM J, V285, P759, DOI 10.1042/bj2850759; PLEVIN R, 1991, BRIT J PHARMACOL, V104, P39; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SOUTHORN BG, 1990, BIOCHEM J, V270, P737, DOI 10.1042/bj2700737; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STRELKOV AB, 1989, AM J PHYSIOL, V257, pC261, DOI 10.1152/ajpcell.1989.257.2.C261; Thompson MG, 1996, AM J PHYSIOL-CELL PH, V270, pC1875, DOI 10.1152/ajpcell.1996.270.6.C1875; THOMPSON MG, 1995, BIOSCIENCE REP, V15, P37, DOI 10.1007/BF01200213; THOMPSON MG, 1994, BBA-MOL CELL RES, V1224, P198, DOI 10.1016/0167-4889(94)90191-0; Thompson MG, 1996, BBA-MOL CELL RES, V1311, P37, DOI 10.1016/0167-4889(95)00194-8; THOMPSON MG, 1993, BIOSCIENCE REP, V13, P359, DOI 10.1007/BF01150480; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WANG P, 1991, J BIOL CHEM, V266, P14877; WAYS DK, 1992, CANCER RES, V52, P5604; WAYS DK, 1992, J BIOL CHEM, V267, P4799; YAMADA K, 1995, BIOCHEM J, V308, P177, DOI 10.1042/bj3080177; YAMADA K, 1991, BIOCHEM BIOPH RES CO, V175, P159, DOI 10.1016/S0006-291X(05)81214-8; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	65	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10910	10916						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099748				2022-12-25	WOS:A1997WV26200082
J	Beggah, AT; Jaunin, P; Geering, K				Beggah, AT; Jaunin, P; Geering, K			Role of glycosylation and disulfide bond formation in the beta subunit in the folding and functional expression of Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; INTRACELLULAR-TRANSPORT; EXTRACELLULAR DOMAIN; ALPHA-SUBUNIT; ENDOPLASMIC-RETICULUM; XENOPUS-OOCYTES; AMINO-ACIDS; K+; MATURATION; REDUCTION	Initial folding is a prerequisite for subunit assembly in oligomeric proteins, In this study, we have compared the role of co-translational modifications in the acquisition of an assembly competent conformation of the beta subunit, the assembly of which is required for the structural and functional maturation of the catalytic Na,K-ATPase alpha subunit. Cysteine or asparagine residues implicated in disulfide bond formation or N-glycosylation, respectively, in the Xenopus beta 1 subunit were eliminated by site-directed mutagenesis, and the assembly efficiency of the mutants and the functional expression of Na+,K+ pumps were studied after expression in Xenopus oocytes, Our results show that lack of each one of the two most C-terminal disulfide bonds indeed permits short term but completely abolishes long term assembly of the beta subunit, On the other hand, lack of the most N-terminal disulfide bonds allows the expression of a small number of functional Na+,K+ pumps at the cell surface, Elimination of all three but not of one or two glycosylation sites produces beta subunits that remain stably expressed in the endoplasmic reticulum, in association with binding protein but not as irreversible aggregates, The assembly efficiency of nonglycosylated beta subunits is decreased but a reduced number of functional Na+,K+ pumps is expressed at the cell surface, The lack of sugars does nob influence the apparent K+ or ouabain affinity of the Na+,K+ pumps. Thus, these data show that disulfide bond formation and N-glycosylation may play important but qualitatively distinct roles in the initial folding of oligomeric protein subunits, Moreover, the results suggest that an endoplasmic reticulum degradation pathway exists, which is glycosylation-dependent.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND	University of Lausanne								ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; CHOW DC, 1992, AM J PHYSIOL, V263, pC39; CREIGHTON T, 1995, PHILOS T ROY SOC B, V348, P5, DOI 10.1098/rstb.1995.0039; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; FERRY F, 1989, AM J PHYSIOL, V256, pF1034; Gahmberg CG, 1996, TRENDS BIOCHEM SCI, V21, P308, DOI 10.1016/0968-0004(96)10034-7; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GEERING K, 1996, MEMBRANE ASSEMBLY MO, P173; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JAENICKE R, 1995, PHILOS T ROY SOC B, V348, P97, DOI 10.1098/rstb.1995.0050; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAWAMURA M, 1985, BIOCHIM BIOPHYS ACTA, V821, P115, DOI 10.1016/0005-2736(85)90161-0; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER RP, 1988, BIOCHIM BIOPHYS ACTA, V954, P50, DOI 10.1016/0167-4838(88)90054-4; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMALZING G, 1989, BIOCHEM J, V260, P395, DOI 10.1042/bj2600395; SUN Y, 1994, BBA-PROTEIN STRUCT M, V1207, P236, DOI 10.1016/0167-4838(94)00074-3; TAKEDA K, 1988, FEBS LETT, V238, P201, DOI 10.1016/0014-5793(88)80256-4; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; TYAGARAJAN K, 1995, BBA-BIOMEMBRANES, V1236, P105, DOI 10.1016/0005-2736(95)00044-4; ZAMOFING D, 1989, AM J PHYSIOL, V256, pC958, DOI 10.1152/ajpcell.1989.256.5.C958; ZAMOFING D, 1988, J MEMBRANE BIOL, V104, P69, DOI 10.1007/BF01871903	42	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10318	10326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092584				2022-12-25	WOS:A1997WU03900103
J	Chang, CH; Scott, GK; Kuo, WL; Xiong, XH; Suzdaltseva, Y; Park, JW; Sayre, P; Erny, K; Collins, C; Gray, JW; Benz, CC				Chang, CH; Scott, GK; Kuo, WL; Xiong, XH; Suzdaltseva, Y; Park, JW; Sayre, P; Erny, K; Collins, C; Gray, JW; Benz, CC			ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis	ONCOGENE			English	Article						Ets; epithelial-restricted; breast cancer; HER2/neu	TRANSCRIPTION FACTORS; GENE FAMILY; PROTEIN; PROMOTER; BINDING; HYBRIDIZATION; ACTIVATOR; EVOLUTION; PATHWAY; CANCER	The >30 known members of the Ets multigene family of transcriptional regulators are increasingly being recognized for their involvement in early embryonic development and late tissue maturation, directing stage-specific and tissue-restricted programs of target gene expression. Identifiable primarily by their 85 amino acid ETS DNA-binding domain and dispersed across all metazoan lineages into distinct subfamilies, Ets genes also produce malignancies in humans and other vertebrates when overexpressed or rearranged into chimeras retaining the ETS domain, suggesting that their oncogenic potential is determined by the program of target genes they regulate. Searching for Ets factors that regulate expression of the HER2/neu (c-erbB2) oncogene in human breast cancer, we identified a new epithelium-restricted Ets encoding an ETS domain homologous to the Drosophila E74/human Elf-1 subfamily, an amino-terminal region (A-region or Pointed domain) homologous to the distantly related Ets-l subfamily, and a serine-rich box homologous to the transactivating domain of the lymphocyte-restricted High Mobility Group (HMG) protein, SOX4. Recombinant protein encoded by ESX (for epithelial-restricted with serine box) exhibits Ets-like DNA binding specificity in electrophoretic mobility shift assays and, in transient transfection assays, transactivates Ets-responsive promoter elements including that found in the HER2/neu oncogene. ESX is located at chromosome 1q32 in a region known to be amplified in 50% of early breast cancers, is heregulin-inducible and overexpressed in HER2/neu activated breast cancer cells. Tissue hybridization suggests that ESX becomes overexpressed at an early stage of human breast cancer development known as ductal carcinoma in situ (DCIS).	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV HEMATOL ONCOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV MOL CYTOMETRY,SAN FRANCISCO,CA 94143; LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory				Erny-Albrecht, Katrina/0000-0003-3538-1475	NCI NIH HHS [CA44768, CA36773, CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207, P01CA044768, R01CA036773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAGANTI RSK, 1986, CYTOGENET CELL GENET, V43, P181, DOI 10.1159/000132318; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GIOVANE A, 1995, GENOMICS, V29, P769, DOI 10.1006/geno.1995.9938; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; ISOLA JJ, 1995, AM J PATHOL, V147, P905; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KODANDAPANI R, 1996, NATURE, V380, P457; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li WL, 1996, ONCOGENE, V12, P2473; LIU E, 1992, ONCOGENE, V7, P1027; MORRIS CM, 1991, ONCOGENE, V6, P1093; NOONBERG SB, 1994, GENE, V149, P123, DOI 10.1016/0378-1119(94)90420-0; OHagan RC, 1996, ONCOGENE, V13, P1323; OHAGAN RC, 1996, AM ASS CANC RES, V37, P3575; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHIPLEY J, 1994, GENOMICS, V23, P710, DOI 10.1006/geno.1994.1564; STOKKE T, 1995, GENOMICS, V26, P134, DOI 10.1016/0888-7543(95)80092-Z; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Yang BS, 1996, MOL CELL BIOL, V16, P538	31	155	166	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1617	1622		10.1038/sj.onc.1200978	http://dx.doi.org/10.1038/sj.onc.1200978			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129154				2022-12-25	WOS:A1997WQ54800014
J	Genschik, P; Hall, J; Filipowicz, W				Genschik, P; Hall, J; Filipowicz, W			Cloning and characterization of the Arabidopsis cyclic phosphodiesterase which hydrolyzes ADP-ribose 1'',2''-cyclic phosphate and nucleoside 2',3'-cyclic phosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA LIGASE; HELA-CELL EXTRACT; WHEAT-GERM; INOSITOL TRISPHOSPHATE; NUCLEOTIDE-SEQUENCE; YEAST; PURIFICATION; GENE; ENDONUCLEASE; MECHANISM	In eukaryotic cells, pre-tRNAs spliced by a pathway that produces a 3',5'-phosphodiester, 2'-phosphomonoester linkage contain a 2'-phosphate group adjacent to the tRNA anticodon. This S'-phosphate is transferred to NAD to give adenosine diphosphate (ADP)-ribose 1 '',2 ''-cyclic phosphate (Appr>p), which is subsequently metabolized to ADP-ribose 1 ''-phosphate (Appr-1 '' p). The latter reaction is catalyzed by a cyclic phosphodiesterase (CPDase), previously identified in yeast and wheat. In the work presented here, we describe cloning of the Arabidopsis cDNA encoding the 20-kDa CPDase that hydrolyzes Appr>p to Appr-1 '' p. Properties of the bacterially overexpressed and purified Arabidopsis enzyme are similar to those of wheat CPDase. In addition to their transformation of Appr>p, both enzymes hydrolyze nucleoside 2',3'-cyclic phosphates to nucleoside S'-phosphates. For the Arabidopsis CPDase, the apparent K-m values for Appr>p, A>p, C>p, G>p, and U>p are 1.35, 1.34, 2.38, 16.86, and 17.67 mM, respectively. Southern analysis indicated that CPDase in Arabidopsis is encoded by a single copy gene that is expressed, at different levels, in all Arabidopsis organs that were analyzed. Indirect immunofluorescence, performed with transfected protoplasts, showed that CPDase is localized in the cytoplasm. Based on substrate specificity and products generated, the plant enzyme differs from other known cyclic phosphodiesterases. The Arabidopsis CPDase does not have recognizable structural similarity or motifs in common with proteins deposited in public data bases.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; CENT RES LABS, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research				GENSCHIK, Pascal/0000-0002-4107-5071				ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; AUSUBEL F, 1990, CURRENT PROTOCLOS MO; BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIRNS E, 1978, CELL BIOL, V75, P5557; CHABOUTE ME, 1987, PLANT MOL BIOL, V8, P179, DOI 10.1007/BF00025329; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Culver GM, 1997, J BIOL CHEM, V272, P13203, DOI 10.1074/jbc.272.20.13203; CULVER GM, 1994, J BIOL CHEM, V269, P24928; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILIPOWICZ W, 1990, METHOD ENZYMOL, V181, P499; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; GENSCHIK P, 1994, PLANT J, V6, P537, DOI 10.1046/j.1365-313X.1994.6040537.x; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; Hall J, 1996, HELV CHIM ACTA, V79, P1005, DOI 10.1002/hlca.19960790409; HALL TC, 1978, P NATL ACAD SCI USA, V75, P3196, DOI 10.1073/pnas.75.7.3196; HELFMAN DM, 1982, J BIOL CHEM, V257, P1044; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; KISS T, 1989, NUCLEIC ACIDS RES, V17, P796, DOI 10.1093/nar/17.2.796; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIHARA T, 1988, BIOCHEM BIOPH RES CO, V152, P837, DOI 10.1016/S0006-291X(88)80114-1; LASKI FA, 1983, J BIOL CHEM, V258, P1974; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LIU J, 1990, MOL GEN GENET, V222, P161, DOI 10.1007/BF00283039; LOFFLER A, 1992, PLANT PHYSIOL, V98, P1472, DOI 10.1104/pp.98.4.1472; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCKEON TA, 1991, ARCH BIOCHEM BIOPHYS, V290, P303, DOI 10.1016/0003-9861(91)90545-T; MONOH K, 1989, BIOCHEM BIOPH RES CO, V165, P1213, DOI 10.1016/0006-291X(89)92731-9; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NAGY JI, 1976, Z PFLANZENPHYSIOL, V78, P453, DOI 10.1016/S0044-328X(76)80093-1; NAIRN CJ, 1988, GENE, V65, P247, DOI 10.1016/0378-1119(88)90461-1; NEUHAUS G, 1984, EMBO J, V3, P2169, DOI 10.1002/j.1460-2075.1984.tb02108.x; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; OLAFSON RW, 1969, CAN J BIOCHEM CELL B, V47, P961, DOI 10.1139/o69-151; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6694; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SCHILDKNECHT H, 1983, ANGEW CHEM INT EDIT, V22, P695, DOI 10.1002/anie.198306951; SIMS NR, 1979, ADV NEUROCHEM, V3, P1; STANGE N, 1987, EMBO J, V6, P2811, DOI 10.1002/j.1460-2075.1987.tb02577.x; TANG WJ, 1970, BIOCHIM BIOPHYS ACTA, V212, P300, DOI 10.1016/0005-2744(70)90210-X; TORTI G, 1973, BIOCHIM BIOPHYS ACTA, V324, P254, DOI 10.1016/0005-2787(73)90142-1; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TYC K, 1987, J BIOL CHEM, V262, P12994; Westaway Shawn K., 1995, P79; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; ZILLMANN M, 1992, J BIOL CHEM, V267, P10289	65	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13211	13219		10.1074/jbc.272.20.13211	http://dx.doi.org/10.1074/jbc.272.20.13211			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148938	hybrid			2022-12-25	WOS:A1997WZ38400051
J	Grabs, D; Slepnev, VI; Zhou, SY; David, C; Lynch, M; Cantley, LC; DeCamilli, P				Grabs, D; Slepnev, VI; Zhou, SY; David, C; Lynch, M; Cantley, LC; DeCamilli, P			The SH3 domain of amphiphysin binds the proline-rich domain of dynamin at a single site that defines a new SH3 binding consensus sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIFF-MAN SYNDROME; SIGNAL-TRANSDUCTION PROTEINS; SRC HOMOLOGY-3 DOMAINS; BREAST-CANCER; NERVE-TERMINALS; ENDOCYTOSIS; GENE; GTP; MUTANT; RVS161	Amphiphysin is an SH3 domain-containing neuronal protein that is highly concentrated in nerve terminals where it interacts via its SH3 domain with dynamin I, a GTPase implicated in synaptic vesicle endocytosis. We show here that the SH3 domain of amphiphysin, but not a mutant SH3 domain, bound with high affinity to a single site in the long proline-rich region of human dynamin I, that this site was distinct from the binding sites for other SH3 domains, and that the mutation of two adjacent amino acids in dynamin I was sufficient to abolish binding. The dynamin I sequence critically required for amphiphysin binding (PSRPNR) fits in the novel SH3 binding consensus identified for the SH3 domain of amphiphysin via a combinatorial peptide library approach: PXRPXR(H)R(H). Our data demonstrate that the long proline-rich stretch present in dynamin I contained multiple SH3 domain binding sites that recognize interacting proteins with high specificity.	YALE UNIV, SCH MED, DEPT CELL BIOL, BOYER CTR MOL MED, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, BOYER CTR MOL MED, NEW HAVEN, CT 06510 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Yale University; Howard Hughes Medical Institute; Yale University; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KOENIG JH, 1989, J NEUROSCI, V9, P3844; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MIKI H, 1994, J BIOL CHEM, V269, P5489; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SHUPLIAKOV O, 1997, IN PRESS SCIENCE; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1995, METHOD ENZYMOL, V254, P523	41	199	201	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13419	13425		10.1074/jbc.272.20.13419	http://dx.doi.org/10.1074/jbc.272.20.13419			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148966	hybrid			2022-12-25	WOS:A1997WZ38400079
J	McFall, AJ; Rapraeger, AC				McFall, AJ; Rapraeger, AC			Identification of an adhesion site within the syndecan-4 extracellular protein domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; MOLECULAR-CLONING; FIBRONECTIN FRAGMENTS; FIBROBLASTIC CELLS; EXPRESSION; BINDING; DIFFERENTIATION; ORGANIZATION; ECTODOMAIN; BIOLOGY	The syndecan family of cell surface proteoglycans regulates cell adhesion and growth factor signaling by binding components of the extracellular matrix and growth factors. To date, all known ligand interactions are via the covalently attached glycosaminoglycan chains. To assay for potential extracellular interactions via the core proteins directly, the recombinant extracellular domain of syndecan-4 (S4ED), one of the four syndecan family members, was tested as a substratum for the attachment of mammalian cells. Human foreskin fibroblasts bind to mouse S4ED, and both mouse and chicken S4ED can block this binding, with 50% inhibition observed between 0.1 and 1 x 10(-7) M. The extracellular domain of another syndecan family member, syndecan-1, fails to compete for cell binding to mouse S4ED. Amino acids 56-109 of the 120-amino acid mouse S4ED compete fully, suggesting that the cell binding domain is within this region. The ability of syndecan-4 to interact with molecules at the cell surface via its core protein as well as its glycosaminoglycan chains may uniquely regulate the formation of cell surface signaling complexes following engagement of this proteoglycan with its extracellular ligands.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706; UNIV WISCONSIN,PROGRAM MOL & CELLULAR BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NICHD NIH HHS [HD21881] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD021881, R01HD021881] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BACIU PC, 1994, J BIOL CHEM, V269, P696; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; GOULD SE, 1995, DEV BIOL, V168, P438, DOI 10.1006/dbio.1995.1093; IIDA J, 1995, CANCER RES, V55, P2177; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; KIEFER MC, 1991, ANN NY ACAD SCI, V638, P167, DOI 10.1111/j.1749-6632.1991.tb49027.x; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; Martinho RG, 1996, MOL BIOL CELL, V7, P1771, DOI 10.1091/mbc.7.11.1771; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; WOODS A, 1992, J CELL SCI, V101, P277	28	56	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12901	12904		10.1074/jbc.272.20.12901	http://dx.doi.org/10.1074/jbc.272.20.12901			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148893	hybrid			2022-12-25	WOS:A1997WZ38400006
J	Knauer, MF; Hawley, SB; Knauer, DJ				Knauer, MF; Hawley, SB; Knauer, DJ			Identification of a binding site in protease nexin I (PN1) required for the receptor mediated internalization of PN1-thrombin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; PLASMINOGEN-ACTIVATOR; ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA-1-PROTEINASE INHIBITOR; UROKINASE RECEPTOR; DEGRADATION; DEFICIENCY; THROMBIN; PROTEINS; PEPTIDE	An overlapping synthetic peptide library was constructed representing most of the mature protease nexin I (PN1) sequence from the amino terminus to the reactive center. This library, along with peptides from the heparin binding domain and from the region carboxyl-terminal to the P1 residue of the cleavage site, was screened for the inhibition of I-125-thrombin (Th)-PN1 complex binding and degradation. A peptide corresponding to residues Pro(47)-Ile(58) in the PN1 sequence was identified as a potent inhibitor of I-125-Th-PN1 complex degradation, although it did not affect binding significantly. Pro(47)-Ile(58) was shown to competitively inhibit the low density lipoprotein receptor-related protein (LRP)/alpha(2)-macroglobulin receptor-mediated endocytosis of I-125-Th-PN1 complexes in mouse embryo fibroblasts. Pro(47)-Ile(58) is an apparent transition sequence in PN1, separating sheet-6B and helix-B. The sequence of Pro(47)-Ile(58), PHDNIVISPHGI, suggests that it forms a loop structure defined by the seven underlined amino acids bordered by proline residues at each end. These studies are the first to identify a putative binding site in a serine protease inhibitor that is required for LRP-mediated internalization.	UNIV CALIF IRVINE, DEPT DEV & CELL BIOL, IRVINE, CA 92697 USA; SCRIPPS RES INST, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA	University of California System; University of California Irvine; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM034001-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; CONESE M, 1994, J BIOL CHEM, V269, P17886; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GLABE C G, 1990, Technique (Philadelphia), V2, P138; GRONKE RS, 1989, BLOOD, V73, P472; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; HOWARD EW, 1986, J BIOL CHEM, V261, P684; HOWARD EW, 1987, J CELL PHYSIOL, V131, P276, DOI 10.1002/jcp.1041310219; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; KARDOWSKA A, 1990, J BIOL CHEM, V265, P21023; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; Maekawa H, 1996, J BIOL CHEM, V271, P18604, DOI 10.1074/jbc.271.31.18604; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIZZO SV, 1988, BIOCHIM BIOPHYS ACTA, V967, P158, DOI 10.1016/0304-4165(88)90005-0; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	27	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12261	12264		10.1074/jbc.272.19.12261	http://dx.doi.org/10.1074/jbc.272.19.12261			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139667	hybrid			2022-12-25	WOS:A1997WY82900004
J	Sauvadet, A; Rohn, T; Pecker, F; Pavoine, C				Sauvadet, A; Rohn, T; Pecker, F; Pavoine, C			Arachidonic acid drives mini-glucagon action in cardiac cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE A(2); FATTY-ACIDS; HEART-CELLS; CA-2+ PUMP; MYOCYTES; RAT; INHIBITION; ACTIVATION; CHANNELS; PHOSPHODIESTERASE	Recent studies have shown that glucagon is processed by cardiac cells into its COOH-terminal (19-29) fragment, mini-glucagon, and that this metabolite is an essential component of the contractile positive inotropic effect of glucagon (Sauvadet, A., Rohn, T., Pecker, F. and Pavoine, C. (1996) Circ. Res. 78, 102-109). We now show that mini-glucagon triggers arachidonic acid (AA) release from [H-3]AA-loaded embryonic chick ventricular myocytes via the activation of a phospholipase A(2) sensitive to submicromolar Ca2+ concentrations. The phospholipase A(2) inhibitor, AACOCF3, prevented mini-glucagon-induced [Ca-45(2+)] accumulation into the sarcoplasmic reticulum, but inhibitors of lipoxygenase, cyclooxygenase, or epoxygenase pathways were ineffective. AA applied exogenously, at 0.3 mu M, reproduced the effects of mini-glucagon on Ca2+ homeostasis and contraction. Thus AA: (i) caused [Ca-45(2+)] accumulation into a sarcoplasmic reticulum compartment sensitive to caffeine; 2) potentiated caffeine induced Ca2+ mobilization from cells loaded with Fura-a; 3) acted synergistically with glucagon or cAMP to increase both the amplitude of Ca2+ transients and contraction of electrically stimulated cells. AA action was dose-dependent and specific since it was mimicked by its non-hydrolyzable analog 5,8,11,14-eicosatetraynoic acid but not reproduced by other lipids such as, arachidic acid, linolenic acid, cis-5,8,11,14,17-eicosapentaenoic acid, cis-4,7,10,13,16,19-docosahexaenoic acid, or arachidonyl-CoA, even in the micromolar range. We conclude that AA drives mini-glucagon action in the heart and that the positive inotropic effect of glucagon on heart contraction relies on both second messengers, cAMP and AA.			Sauvadet, A (corresponding author), HOP HENRI MONDOR,INSERM UNITE 99,F-94010 CRETEIL,FRANCE.		Pavoine, Catherine/N-4405-2018	Pavoine, Catherine/0000-0002-0598-5545				ALTSCHULD RA, 1985, J BIOL CHEM, V260, P4325; AXELROD J, 1995, TRENDS NEUROSCI, V18, P64; BASSANI RA, 1992, J PHYSIOL-LONDON, V453, P591, DOI 10.1113/jphysiol.1992.sp019246; BLACHE P, 1990, J BIOL CHEM, V265, P21514; BLACHE P, 1993, J BIOL CHEM, V268, P21748; BRECHLER V, 1992, J BIOL CHEM, V267, P15496; CHEN J, 1994, J BIOL CHEM, V269, P23018; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DAMRON DS, 1995, CIRC RES, V76, P1011, DOI 10.1161/01.RES.76.6.1011; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; GALRON RY, 1985, BIOCHEM BIOPH RES CO, V163, P936; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; HSUEH W, 1977, PROSTAGLANDINS, V13, P1073, DOI 10.1016/0090-6980(77)90135-6; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; MALLAT A, 1987, NATURE, V325, P620, DOI 10.1038/325620a0; MATZUOKA I, 1985, THROMB RES, V37, P185; MERY PF, 1990, NATURE, V345, P158, DOI 10.1038/345158a0; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; PAVOINE C, 1991, AM J PHYSIOL, V260, pC993, DOI 10.1152/ajpcell.1991.260.5.C993; PECKER F, 1996, GLUCAGON, V3, P75; Piomelli Daniele, 1995, P595; PRASAD MR, 1991, BIOCHEM BIOPH RES CO, V174, P952, DOI 10.1016/0006-291X(91)91511-A; Sauvadet A, 1996, CIRC RES, V78, P102, DOI 10.1161/01.RES.78.1.102; SAUVADET A, 1995, CELL CALCIUM, V18, P76, DOI 10.1016/0143-4160(95)90047-0; SHARP JD, 1993, J LIPID MEDIATOR, V8, P183; VANBILSEN M, 1995, CARDIOVASC RES, V30, P518, DOI 10.1016/0008-6363(95)00098-4; VANDERVUSSE GJ, 1992, PHYSIOL REV, V72, P881, DOI 10.1152/physrev.1992.72.4.881	37	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12437	12445		10.1074/jbc.272.19.12437	http://dx.doi.org/10.1074/jbc.272.19.12437			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139691	hybrid			2022-12-25	WOS:A1997WY82900028
J	Yamamoto, M; Bharti, A; Li, YQ; Kufe, D				Yamamoto, M; Bharti, A; Li, YQ; Kufe, D			Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; CYTOPLASMIC DOMAIN; DROSOPHILA HOMOLOG; ARMADILLO PROTEIN; ALPHA-CATENIN; PLAKOGLOBIN; REGION; GENE; EPISIALIN; COMPLEX	The DF3/MUC1 mucin-like glycoprotein is aberrantly overexpressed in human breast carcinomas. The functional role of DF3 is unknown. The present studies demonstrate that DF3 associates with beta-catenin. Similar findings have been obtained for gamma-catenin but not alpha-catenin. DF3, like E-cadherin and the adenomatous polyposis coli gene product, contains an SXXXXXSSL site that is responsible for direct binding to beta-catenin. The results further demonstrate that interaction of DF3 and beta-catenin is dependent on cell adhesion. These findings and the role of beta-catenin in cell signaling support a role for DF3 in the adhesion of epithelial cells.			Yamamoto, M (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, 44 BINNEY ST, BOSTON, MA 02115 USA.							ABE M, 1989, BIOCHEM BIOPH RES CO, V165, P644, DOI 10.1016/S0006-291X(89)80014-2; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PANDEY P, 1995, CANCER RES, V55, P4000; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	29	279	300	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12492	12494		10.1074/jbc.272.19.12492	http://dx.doi.org/10.1074/jbc.272.19.12492			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139698	hybrid			2022-12-25	WOS:A1997WY82900035
J	Liu, Q; Leng, XH; Newman, PR; Vasilyeva, E; Kane, PM; Forgac, M				Liu, Q; Leng, XH; Newman, PR; Vasilyeva, E; Kane, PM; Forgac, M			Site-directed mutagenesis of the yeast V-ATPase A subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; ESCHERICHIA-COLI F1-ATPASE; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; COATED VESICLE (H+)-ATPASE; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; BETA-SUBUNIT; PROTON PUMP; CATALYTIC SUBUNIT; 14-KDA SUBUNIT	To investigate the function of residues at the catalytic nucleotide binding site of the V-ATPase, we have carried out site-directed mutagenesis of the VMA1 gene encoding the A subunit of the V-ATPase in yeast. Of the three cysteine residues that are conserved in all A subunits sequenced thus far, two (Cys(284) and Cys(539)) appear essential for correct folding or stability of the A subunit. Mutation of the third cysteine (Cys(261)), located in the glycine-rich loop, to valine, generated an enzyme that was fully active but resistant to inhibition by N-ethylmalemide, 7-chloro-4-nitrobenz-2-oxa-1,3-diazole, and oxidation. To test the role of disulfide bond formation in regulation of vacuolar acidification in vivo, we have also determined the effect of the C261V mutant on targeting and processing of the soluble vacuolar protein carboxypeptidase Y. No difference in carboxypeptidase Y targeting or processing is observed between the wild type and C261V mutant, suggesting that disulfide bond formation in the V-ATPase A subunit is not essential for controlling vacuolar acidification in the Golgi. In addition, fluid phase endocytosis of Lucifer Yellow, quinacrine staining of acidic intracellular compartments and cell growth are indistinguishable in the C261V and wild type cells. Mutation of G250D in the glycine-rich loop also resulted in destabilization of the A subunit, whereas mutation of the lysine residue in this region (K263Q) gave a V-ATPase complex which showed normal levels of A subunit on the vacuolar membrane but was unstable to detergent solubilization and isolation and was totally lacking in V-ATPase activity. By contrast, mutation of the acidic residue, which has been postulated to play a direct catalytic role in the homologous F-ATPases (E286Q), had no effect on stability or assembly of the V-ATPase complex, but also led to complete loss of V-ATPase activity. The E286Q mutant showed labeling by 2-azido-[P-32]ATP that was approximately 60% of that observed for wild type, suggesting that mutation of this glutamic acid residue affected primarily ATP hydrolysis rather than nucleotide binding.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, BOSTON, MA 02111 USA; SUNY HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, SYRACUSE, NY 13210 USA	Tufts University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322, R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34478, GM 50322, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P967; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; APPERSON M, 1990, BIOCHEM BIOPH RES CO, V168, P574, DOI 10.1016/0006-291X(90)92359-8; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; CREEK KE, 1984, LYSOSOM BIOL PATHOL, P63; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; FUTAI M, 1994, BBA-BIOENERGETICS, V1187, P165, DOI 10.1016/0005-2728(94)90104-X; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PARK MY, 1994, J BIOCHEM-TOKYO, V116, P1139, DOI 10.1093/oxfordjournals.jbchem.a124640; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; TAIZ L, 1994, BBA-BIOMEMBRANES, V1194, P329, DOI 10.1016/0005-2736(94)90315-8; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; Vasilyeva E, 1996, J BIOL CHEM, V271, P12775, DOI 10.1074/jbc.271.22.12775; WEBER J, 1993, J BIOL CHEM, V268, P6241; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	77	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11750	11756		10.1074/jbc.272.18.11750	http://dx.doi.org/10.1074/jbc.272.18.11750			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115229	hybrid			2022-12-25	WOS:A1997WX56900017
J	Takeuchi, M; Hata, Y; Hirao, K; Toyoda, A; Irie, M; Takai, Y				Takeuchi, M; Hata, Y; Hirao, K; Toyoda, A; Irie, M; Takai, Y			SAPAPs - A family of PSD-95/SAP90-associated proteins localized at postsynaptic density	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; SEPTATE JUNCTIONS; GENE DLG; MEMBRANE; BINDING; IDENTIFICATION; CALMODULIN; HOMOLOG; KINASE; ZO-1	PSD-95/SAP90 is a member of membrane-associated guanylate kinases localized at postsynaptic density (PSD) in neuronal cells. Membrane-associated guanylate kinases are a family of signaling molecules expressed at various submembrane domains which have the PDZ (DHR) domains, the SH3 domain, and the guanylate kinase domain. PSD-95/SAP90 interacts with N-methyl-D-aspartate receptors 2A/B, Shaker-type potassium channels, and brain nitric oxide synthase through the PDZ (DHR) domains and clusters these molecules at synaptic junctions. However, neither the function of the SH3 domain or the guanylate kinase domain of PSD-95/ SAP90, nor the protein interacting with these domains has been identified. We have isolated here a novel protein family consisting of at least four members which specifically interact with PSD-95/SAP90 and its related proteins through the guanylate kinase domain, and named these proteins SAPAPs (SAP90/PSD-95-Associated Proteins). SAPAPs are specifically expressed in neuronal cells and enriched in the PSD fraction. SAPAPs induce the enrichment of PSD-95/SAP90 to the plasma membrane in transfected cells. Thus, SAPAPs may have a potential activity to maintain the structure of PSD by concentrating its components to the membrane area.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; JCR PHARMACEUT CO LTD,JAPAN SCI & TECHNOL CORP,ERATO,TAKAI BIOTIMER PROJECT,NISHI KU,KOBE,HYOGO 65122,JAPAN	Osaka University; Japan Science & Technology Agency (JST)			Toyoda, Atsushi/AAA-5885-2020	Toyoda, Atsushi/0000-0002-0245-3244				Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; CARLIN RK, 1983, J CELL BIOL, V96, P443, DOI 10.1083/jcb.96.2.443; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1996, J NEUROSCI, V16, P24888; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hunt CA, 1996, J NEUROSCI, V16, P1380; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOEHNSSON U, 1991, BIOTECHNIQUES, V11, P520; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; KELLY PT, 1978, J CELL BIOL, V79, P173, DOI 10.1083/jcb.79.1.173; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mueller Bettina M., 1995, Journal of Neuroscience, V15, P2354; MUELLER BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Sambrook J., 2002, MOL CLONING LAB MANU; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALTERS BB, 1975, NATURE, V257, P496, DOI 10.1038/257496a0; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	41	307	323	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11943	11951		10.1074/jbc.272.18.11943	http://dx.doi.org/10.1074/jbc.272.18.11943			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115257	hybrid			2022-12-25	WOS:A1997WX56900045
J	GarciaRuiz, C; Colell, A; Mari, M; Morales, A; FernandezCheca, JC				GarciaRuiz, C; Colell, A; Mari, M; Morales, A; FernandezCheca, JC			Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species - Role of mitochondrial glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RAT HEPATOCYTES; NEUTRAL SPHINGOMYELINASE; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; CELLS; EXPRESSION; APOPTOSIS; TNF; INTERLEUKIN-1	Ceramide is a sphingolipid that is generated in the signaling of inflammatory cytokines such as tumor necrosis factor (TNF), which exerts many functional roles depending on the cell type where it is produced. Since TNF cytotoxicity is mediated by overproduction of reactive oxygen species from mitochondria, we have examined the role of ceramide in generation of oxidative stress in isolated rat liver mitochondria. The present studies demonstrate that addition of N-acetylsphingosine (C-2-ceramide) to mitochondria led to an increase of fluorescence of dihydrorhodamine 123 or dichlorofluorescein-stained mitochondria, indicating formation of hydrogen peroxide. Such effect was significant at 0.25 mu M and maximal at 1-5 mu M C-2, decreasing at greater concentrations. This inductive effect of ceramide was mimicked by N-hexanoylsphingosine at the same concentration range, whereas the immediate precursor of C-2, C-2-dihydroceramide increased hydrogen peroxide at 1-5 mu M. Sphingosine generated hydrogen peroxide at concentrations greater than or equal to 10 mu M, whereas diacylglycerol failed to increase hydrogen peroxide. The increase in hydrogen peroxide induced by C-2 was not triggered by mitochondrial permeability transition as C-2 did not induce mitochondrial swelling. Blocking electron transport chain at complex I and II prevented the increase in hydrogen peroxide induced by C-2; however, interruption of electron flow at complex III by antimycin A potentiated the inductive effect of C-2. Depletion of matrix GSH prior to exposure to ceramide resulted in a potentiated increase (2-fold) of hydrogen peroxide generation, leading to lipid peroxidation and loss of activity of respiratory chain complex IV compared with GSH-repleted mitochondria. Mitochondria isolated from TNF-treated cells showed an increase (2-3-fold) in the amount of ceramide compared with mitochondria from untreated cells. These results suggest that mitochondria are a target of ceramide produced in the signaling of TNF whose effect on mitochondrial electron transport chain leads to overproduction of hydrogen peroxide and consequently this phenomena may account for the generation of reactive oxygen species during TNF cytotoxicity.	UNIV BARCELONA,HOSP CLIN & PROV,DEPT MED,LIVER UNIT,E-08036 BARCELONA,SPAIN; CSIC,INST INVEST BIOMED,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN & PROV,DEPT MED,SERV BIOQUIM,E-08036 BARCELONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona			Morales, Albert/E-2988-2013; Fernández-Checa, José Carlos/L-8342-2014; Mari, Montserrat/A-7376-2013; Garcia-Ruiz, Carmen/L-8211-2014; Colell, Anna/N-8710-2014	Morales, Albert/0000-0001-8702-2269; Fernández-Checa, José Carlos/0000-0003-3422-2990; Mari, Montserrat/0000-0002-6116-3247; Garcia-Ruiz, Carmen/0000-0002-2652-6102; Colell, Anna/0000-0001-5236-1834	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009526] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09526] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRACH MA, 1992, CANCER RES, V52, P2197; BRACH MA, 1993, MOL CELL BIOL, V13, P4824; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; ELBAZ O, 1991, J CLIN INVEST, V87, P838, DOI 10.1172/JCI115087; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; FERNANDEZCHECA JC, 1989, J CLIN INVEST, V83, P1247, DOI 10.1172/JCI114008; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FUJII Y, 1994, HEPATOLOGY, V20, P177; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GARCIARUIZ C, 1995, J BIOL CHEM, V270, P15946, DOI 10.1074/jbc.270.27.15946; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; JONES AL, 1989, CANCER SURV, V8, P817; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P5290; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Nyberg L, 1996, BBA-LIPID LIPID MET, V1300, P42, DOI 10.1016/0005-2760(95)00245-6; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; SCHNAITMAN CA, 1968, J CELL BIOL, V33, P158; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P756; SPIEGEL S, 1996, FASEB J, V10, P188; TAYLOR DE, 1995, ARCH BIOCHEM BIOPHYS, V316, P70, DOI 10.1006/abbi.1995.1011; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZHANG Y, 1990, J BIOL CHEM, V265, P16330; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	47	678	692	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11369	11377						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111045				2022-12-25	WOS:A1997WW00900061
J	Kamura, T; Handa, H; Hamasaki, N; Kitajima, S				Kamura, T; Handa, H; Hamasaki, N; Kitajima, S			Characterization of the human thrombopoietin gene promoter - A possible role of an Ets transcription factor, E4TF1/GABP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MPL LIGAND; CHROMOSOMAL LOCALIZATION; MEGAKARYOCYTE GROWTH; BINDING; DOMAIN; ACTIVATION; SUBUNITS; CLONING; FAMILY; DIFFERENTIATION	Thrombopoietin (TPO), the ligand for c-Mpl, is a cytokine that regulates megakaryocyte growth and development. We have cloned the 5'-flanking region of the human TPO gene and analyzed its promoter activity. The human TPO gene promoter lacks a TATA box and directs transcription initiation at multiple sites over a 50-nucleotide region. Transient expression in a human liver cell line (PLC) of promoter fragment-luciferase reporter gene constructs containing a series of 5'-truncated sequences or site directed mutations identified a sequence 5'-ACTTCCG-3' from -69 to -63 as a positive cis-acting element for high level expression of TPO gene. This sequence contains a core motif (C/A)GGA(A/T) for Ets family proteins in the noncoding strand. Gel mobility shift assays performed with nuclear protein from PLC cells identified a DNA binding protein(s) specific for the element. Anti-E4TF1-60(GABP alpha) or anti-E4TF1-53/47(GABP beta) antibodies supershifted the complex in gel shift assay. Furthermore, co-expression of E4TF1-60 and E4TF1-53/47 squelched TPO gene expression in PLC and HepG2 cells. It is concluded that Ets family transcription factor E4TF1(GABP alpha/beta), an ubiquitously expressed protein, is required for high level expression of the TPO gene in liver.	KYUSHU UNIV,FAC MED,DEPT CLIN CHEM & LAB MED,FUKUOKA 81282,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	Kyushu University; Tokyo Institute of Technology								BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BERNSTEIN R, 1986, BLOOD, V68, P652; BOUSCARY D, 1995, BRIT J HAEMATOL, V91, P425, DOI 10.1111/j.1365-2141.1995.tb05316.x; CARBONELL F, 1982, CANC GENET CYTOGENET, V5, P153; CHANG MS, 1995, J BIOL CHEM, V270, P511, DOI 10.1074/jbc.270.2.511; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fielder PJ, 1996, BLOOD, V87, P2154, DOI 10.1182/blood.V87.6.2154.bloodjournal8762154; FOSTER DC, 1994, P NATL ACAD SCI USA, V91, P13023, DOI 10.1073/pnas.91.26.13023; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; GURNEY AL, 1995, BLOOD, V85, P981, DOI 10.1182/blood.V85.4.981.bloodjournal854981; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; MCCARTY JM, 1995, BLOOD, V86, P3668, DOI 10.1182/blood.V86.10.3668.bloodjournal86103668; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PAN JL, 1993, J BIOL CHEM, V268, P22600; PINTADO T, 1985, CANCER, V55, P535, DOI 10.1002/1097-0142(19850201)55:3<535::AID-CNCR2820550311>3.0.CO;2-4; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SOMA Y, 1994, FEBS LETT, V353, P57; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452	35	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11361	11368						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111044				2022-12-25	WOS:A1997WW00900060
J	Mackenney, VJ; Barnes, DE; Lindahl, T				Mackenney, VJ; Barnes, DE; Lindahl, T			Specific function of DNA ligase I in simian virus 40 DNA replication by human cell-free extracts is mediated by the amino-terminal non-catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPAIR; EXPRESSION; CDNA; 46BR; LOCALIZATION; CLONING; INVITRO; ENZYME; DEFECT	The joining of Okazaki fragments during lagging strand DNA replication in mammalian cells is believed to be due to DNA ligase I, This enzyme is composed of a 78-hDa carboxyl-terminal catalytic domain and a 24-kDa amino-terminal region that is not required for ligation activity in vitro, Extracts of the human cell line 46BR.1G1, in which DNA ligase I is mutationally altered, supported aberrant in vitro SV40 DNA replication; the joining of Okazaki fragments was defective, and unligated intermediates were unstable, Human DNA ligase I, but not DNA ligase III or bacteriophage T4 DNA ligase, complemented both defects in 46BR.1G1 extracts, The catalytic domain of DNA Ligase I was 10-fold less effective in complementation experiments than the full length protein, indicating that the amino-terminal region of the enzyme is required for efficient lagging strand DNA replication, Moreover, in vitro SV40 DNA replication in normal human cell extracts was inhibited by an excess of either full-length DNA ligase I or the amino-terminal region of the protein, but not by the catalytic domain, This inhibition may be mediated by the interaction of the amino-terminal region of DNA ligase I with other replication proteins.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND									BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Bentley DJ, 1996, NAT GENET, V13, P489, DOI 10.1038/ng0896-489; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; CECOTTI S, 1993, BIOCHEMISTRY-US, V32, P13664; HERENDEEN D, 1996, EUKARYOTIC DNA REPLI, P29; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LEHMANN AR, 1988, CANCER RES, V48, P6343; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; LONN U, 1989, CARCINOGENESIS, V10, P981, DOI 10.1093/carcin/10.6.981; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SOMIA NV, 1993, MUTAT RES, V294, P51, DOI 10.1016/0921-8777(93)90057-N; SUBRAMANYA HS, 1996, CELL, V85, P307; TEO IA, 1983, CARCINOGENESIS, V4, P559, DOI 10.1093/carcin/4.5.559; TERAOKA H, 1993, J BIOL CHEM, V268, P24156; TOMKINSON AE, 1993, NUCLEIC ACIDS RES, V21, P5425, DOI 10.1093/nar/21.23.5425; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	32	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11550	11556						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111070				2022-12-25	WOS:A1997WW00900086
J	Norris, FA; Atkins, RC; Majerus, PW				Norris, FA; Atkins, RC; Majerus, PW			Inositol polyphosphate 4-phosphatase is inactivated by calpain-mediated proteolysis in stimulated human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3,4-BISPHOSPHATE; ACTIVATION; INTEGRIN; PHOSPHORYLATION; CLEAVAGE; POLYPHOSPHOINOSITIDES; 3-KINASE; BINDING	Inositol polyphosphate 4-phosphatase (4-phosphatase), an enzyme that catalyzes the hydrolysis of the 4 position phosphate of phosphatidylinositol 3,4-bisphosphate, was shown to be a substrate for the calcium-dependent protease calpain in vitro and in stimulated human platelets. Stimulation of platelets with the calcium ionophore, A23187, resulted in complete proteolysis of 4-phosphatase and a 75% reduction in enzyme activity. Thrombin stimulation of platelets resulted in partial proteolysis of 4-phosphatase and a 41% reduction in enzyme activity (n = 8, range of 36-51%). In addition, preincubation with the calpain inhibitor, calpeptin, suppressed the accumulation of phosphatidylinositol 3,4 bisphosphate in thrombin stimulated platelets by 36% (n = 2, range = 35-37%). These data suggest that the calpain-mediated inhibition of 4-phosphatase is involved in the phosphatidylinositol 3,4-bisphosphate accumulation in thrombin stimulated platelets.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)	Norris, FA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R37HL016634, R01HL055672] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16634, HL 55672] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1960, J BIOL CHEM, V235, P769; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Baenziger N L, 1974, Methods Enzymol, V31, P149; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BANSAL VS, 1990, J BIOL CHEM, V265, P1806; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; LIPS DL, 1989, J BIOL CHEM, V264, P19911; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807	25	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					10987	10989						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9110986				2022-12-25	WOS:A1997WW00900002
J	Lahti, JM; Li, HM; Kidd, VJ				Lahti, JM; Li, HM; Kidd, VJ			Elimination of cyclin D1 in vertebrate cells leads to an altered cell cycle phenotype, which is rescued by overexpression of murine cyclins D1, D2, or D3 but not by a mutant cyclin D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE; RETINOBLASTOMA-PROTEIN; G1 PHASE; GENOMIC ORGANIZATION; GROWTH SUPPRESSION; DEPENDENT KINASES; MAMMARY-GLAND; EXPRESSION; CDK4	DT40 lymphoma B-cells normally express cyclins D1 and D2 but not D3, When cyclin D1 expression was extinguished in these cells by gene knockout, specific alterations in their ability to transit the cell cycle were observed, These changes are exemplified by a delay of approximately 2 h in their progression through a normal 14-h cell cycle, This delay results in an increase in the number of cells in the G(2)/M phase population, most likely due to triggering of checkpoints in G(2)/M, inability to enter G(1) normally, and/or alterations of crucial event(s) in early G(1). The defect(s) in the cell cycle of these D1 ''knockout'' cells can be rescued by overexpression of any normal mouse D-type cyclin but not by a mutant mouse cyclin D1 protein that lacks the LXCXE motif at its amino terminus. These data suggest that the cell cycle alterations observed in the D1-/- cells are a direct effect of the absence of the cyclin D1 protein and support the hypothesis that the D-type cyclins have separate, but overlapping, functions. Elimination of cyclin D1 also resulted in enhanced sensitivity to radiation, resulting in a significant increase in apoptotic cells. Expression of any normal murine D-type cyclin in the D1-/- cells reversed this phenotype. Intriguingly, expression of the mutant cyclin D1 in the D1 -/- cells partially restored resistance to radiation-induced apoptosis. Thus, there may be distinct differences in cyclin D1 complexes and/or its target(s) in proliferating and apoptotic DT40 lymphoma E-cells.			Lahti, JM (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE, MEMPHIS, TN 38101 USA.				NCI NIH HHS [CA 67938, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067938, P30CA021765, R56CA067938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDO K, 1995, ONCOGENE, V10, P751; ASKEW DS, 1991, ONCOGENE, V6, P1915; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BOEHMELT G, 1994, CELL GROWTH DIFFER, V5, P221; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GOBEL TWF, 1994, P NATL ACAD SCI USA, V91, P1094, DOI 10.1073/pnas.91.3.1094; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KHATIB ZA, 1993, CANCER RES, V53, P5535; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEHNER CF, 1989, CELL, V56, P967; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li HM, 1995, GENE, V167, P341, DOI 10.1016/0378-1119(95)00598-6; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MARTI A, 1995, CELL DEATH DIFFER, V2, P277; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLNER EW, 1996, CURR TOP MICROBIOL I, V211, P29; NEIMAN PE, 1994, MOL BIOL CELL, V5, P763, DOI 10.1091/mbc.5.7.763; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REED JA, 1995, CANCER RES, V55, P2713; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; SoferLevi Y, 1996, ONCOGENE, V13, P2431; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKEDA S, 1992, P NATL ACAD SCI USA, V89, P4023, DOI 10.1073/pnas.89.9.4023; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIANG JL, 1994, J BIOL CHEM, V269, P15786; ZHOU P, 1995, ONCOGENE, V11, P571; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	87	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10859	10869						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099742				2022-12-25	WOS:A1997WV26200076
J	Oliver, FJ; Collins, MKL; LopezRivas, A				Oliver, FJ; Collins, MKL; LopezRivas, A			Overexpression of a heterologous thymidine kinase delays apoptosis induced by factor deprivation and inhibitors of deoxynucleotide metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE ENTRY; CELL-DEATH; SIGNAL-TRANSDUCTION; STRAND BREAKS; GENE-TRANSFER; DNA-SYNTHESIS; EXPRESSION; PROTEIN; LINE; RESISTANCE	Perturbing deoxyribonucleoside triphosphate (dNTP) metabolism with inhibitors of the de novo synthesis of dNTP causes apoptosis in the interleukin-3 (IL-3)-dependent pre-B cell line BAF3. Under these conditions apoptosis is prevented when deoxyribonucleosides for dNTP synthesis are supplied in the culture medium, On the other hand, removal of IL-3 from cultures of BAF3 cells resulted in down-regulation of thymidine kinase activity, rapid imbalance in dNTP levels, and apoptosis, In this study we show that overexpression of a heterologous thymidine kinase, herpes simplex virus thymidine kinase (TK), in BAF3 cells protects these cells from apoptosis induced by either inhibitors of dNTP synthesis or IL-3 deprivation. This protection against apoptosis is abrogated by 9-(4-hydroxybutyl)-N-2-phenylguanine, a specific inhibitor of herpes simplex virus-1 TK. These results suggest that deoxyribonucleoside kinases, particularly TK, may be important in the regulation of apoptosis in hemopoietic cells.	CSIC,INST PARASITOL & BIOMED,GRANADA 18001,SPAIN; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Oliver, Javier/S-1725-2018; Lopez-Rivas, Abelardo/E-5115-2015	Oliver, Javier/0000-0001-8468-1998; Lopez-Rivas, Abelardo/0000-0002-9351-9690				ADLER R, 1974, CELL, V2, P113, DOI 10.1016/0092-8674(74)90100-7; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ALNABULSI I, 1994, CANCER RES, V54, P5614; ASKEW DS, 1991, ONCOGENE, V6, P1915; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BRADLEY MO, 1978, NATURE, V274, P707; BROX L, 1984, CANCER RES, V44, P934; CHANG ZF, 1993, J BIOL CHEM, V268, P1266; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; CURTIN NJ, 1991, CANCER RES, V51, P2346; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HALLEK M, 1992, ANN HEMATOL, V65, P1, DOI 10.1007/BF01715117; HOGLUND L, 1987, CANCER RES, V48, P3681; HONESS RW, 1974, J GEN VIROL, V22, P171, DOI 10.1099/0022-1317-22-2-171; KIT S, 1974, INT J CANCER, V13, P203, DOI 10.1002/ijc.2910130208; KOURY MJ, 1994, P NATL ACAD SCI USA, V91, P4067, DOI 10.1073/pnas.91.9.4067; LAGERGREN J, 1987, BIOCHEM PHARMACOL, V36, P2985, DOI 10.1016/0006-2952(87)90213-9; Leopardi R, 1996, P NATL ACAD SCI USA, V93, P9583, DOI 10.1073/pnas.93.18.9583; LEWIS JA, 1984, VIROLOGY, V133, P464, DOI 10.1016/0042-6822(84)90415-X; LEWIS JA, 1983, P NATL ACAD SCI-BIOL, V80, P26, DOI 10.1073/pnas.80.1.26; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LINDBERG U, 1979, ANAL BIOCHEM, V34, P152; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MARTIN DW, 1981, ANNU REV BIOCHEM, V50, P845, DOI 10.1146/annurev.bi.50.070181.004213; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MIYASHITA T, 1992, CANCER RES, V52, P5407; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NORTH TW, 1980, J BIOL CHEM, V255, P6640; Oliver FJ, 1996, BIOCHEM J, V316, P421, DOI 10.1042/bj3160421; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROTHSCHILD H, 1970, P NATL ACAD SCI USA, V67, P1042, DOI 10.1073/pnas.67.2.1042; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SMETS LA, 1994, ANTI-CANCER DRUG, V5, P3, DOI 10.1097/00001813-199402000-00001; TAYLORPAPADIMITRIOU J, 1979, EXP CELL RES, V119, P393, DOI 10.1016/0014-4827(79)90369-0; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; VANMOUWERIK TJ, 1987, BIOCHEM PHARMACOL, V36, P809, DOI 10.1016/0006-2952(87)90168-7; Wakazono Y, 1996, MUTAT RES-DNA REPAIR, V362, P119, DOI 10.1016/0921-8777(95)00042-9; WHETTON AD, 1988, BIOCHEM J, V256, P585, DOI 10.1042/bj2560585; WHETTON D, 1983, NATURE, V30, P639; XU H, 1984, J MED CHEM, V38, P49; YOSHIOKA A, 1987, J BIOL CHEM, V262, P8235; YUSA T, 1988, CANCER RES, V48, P5001	49	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10624	10630						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099710				2022-12-25	WOS:A1997WV26200044
J	Mils, V; Piette, J; Barette, C; Veyrune, JL; Tesniere, A; Escot, C; Guilhou, JJ; BassetSeguin, N				Mils, V; Piette, J; Barette, C; Veyrune, JL; Tesniere, A; Escot, C; Guilhou, JJ; BassetSeguin, N			The proto-oncogene c-fos increases the sensitivity of keratinocytes to apoptosis	ONCOGENE			English	Article						c-fos; c-jun; keratinocytes; apoptosis; differentiation	CELL-DEATH; PROTOONCOGENE EXPRESSION; CARCINOMA-CELLS; AP-1 ELEMENT; JUN; DIFFERENTIATION; GENE; PHOSPHORYLATION; PROLIFERATION; TRANSLATION	In human skin, most studies have suggested a role of c-fos or c-fos related genes in keratinocyte differentiation. The aim of our work was to more directly address this question by transfecting more or less differentiated keratinocyte cell lines (A431 and HaCaT) with constitutive expression vectors for c-Fos or c-Fos+c-Jun. Our results showed that c-Fos expression decreased keratinocyte growth, yet addition of c-Jun seemed to revert this c-Fos induced growth inhibition. Whereas no obvious differentiation program was turned on by c-Fos or c-Fos+c-Jun expression in our tissular model, apoptotic figures were observed and confirmed by in situ DNA fragmentation studies. These results do not rule out a role of c-Fos in keratinocyte differentiation but may indicate that the cell lines we used have reached an irreversible state of transformation so that they no longer respond to differentiation signals and rather die from apoptosis. These data add further evidence in favor of a role of c-Fos in epidermal homeostasis.	IURC,LAB DERMATOL MOL,F-34093 MONTPELLIER 5,FRANCE; INST MOL GENET,UMR5535,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier				BARETTE, Caroline/0000-0003-0999-7751				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1992, ONCOGENE, V7, P2271; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHEN SL, 1994, CANCER LETT, V85, P119, DOI 10.1016/0304-3835(94)90247-X; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; ESCOT C, 1991, ANAL CELL PATHOL, V3, P215; FISHER C, 1991, DEVELOPMENT, V111, P253; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORCZYCA W, 1993, CANCER RES, V53, P1945; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; KERR JFK, 1991, CURRENT COMMUNICATIO; MARTI A, 1994, ONCOGENE, V9, P1213; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Polakowska R R, 1994, Cell Death Differ, V1, P19; Preston GA, 1996, MOL CELL BIOL, V16, P211; PRUNIERAS M, 1983, J INVEST DERMATOL, V81, pS28, DOI 10.1111/1523-1747.ep12540324; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VEYRUNE JL, 1995, ONCOGENE, V11, P2127; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	40	34	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1555	1561		10.1038/sj.onc.1200991	http://dx.doi.org/10.1038/sj.onc.1200991			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129146				2022-12-25	WOS:A1997WQ54800006
J	Zhang, R; Zhang, H; Zhu, WM; Pardee, AB; Coffey, RJ; Liang, P				Zhang, R; Zhang, H; Zhu, WM; Pardee, AB; Coffey, RJ; Liang, P			Mob-1, a Ras target gene, is overexpressed in colorectal cancer	ONCOGENE			English	Article						ras oncogene; chemokines; colorectal cancer; cell transformation	DIFFERENTIAL DISPLAY; MESSENGER-RNA; EXPRESSION; CELLS; INDUCTION; PROTEINS	Mutations in the ras oncogenes have been linked to many different cancers, In contrast to the extensive body of knowledge related to the genetics of ras activation, relatively little is known of the transcriptional events triggered by ras, In previous work we have used differential display to identify Mob-1, a member of alpha-chemokine family, as one of the immediate transcriptional targets following Ras activation, Here, we provide additional experimental evidence to support this finding by the use of an inducible H-ras expression system, the treatment of Ras farnesyl transferase inhibitor and activation of endogenous Ras by serum growth factors, We further demonstrate that IP-10, the human homolog of Mob-1, is overexpressed in the majority of colorectal cancers.	VANDERBILT UNIV,DEPT CELL BIOL,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED & CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,VET AFFAIRS MED CTR,NASHVILLE,TN 37232; DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,BOSTON,MA 02115	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Harvard University; Dana-Farber Cancer Institute					NCI NIH HHS [R01 CA46413, R01 CA61232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413, R01CA061232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; GODWIN AK, 1990, ONCOGENE, V5, P1231; KIARIS H, 1995, INT J ONCOL, V7, P413; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MARTINEZ J, 1991, GENE DEV, V5, P152; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; OLDHAM S, 1996, IN PRESS P NATL ACAD; STOECKLE M Y, 1990, New Biologist, V2, P313; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANGURI P, 1990, J BIOL CHEM, V265, P15049	17	28	28	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1607	1610		10.1038/sj.onc.1200957	http://dx.doi.org/10.1038/sj.onc.1200957			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129152				2022-12-25	WOS:A1997WQ54800012
J	Urich, M; Senften, M; Shaw, PE; BallmerHofer, K				Urich, M; Senften, M; Shaw, PE; BallmerHofer, K			A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation	ONCOGENE			English	Article						polyomavirus; middle-T; cell transformation; serum response element; transcription; fos	ACTIN STRESS FIBERS; MAP KINASE KINASE; C-FOS PROMOTER; TUMOR-ANTIGEN; PROTEIN-KINASE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; PLASMA-MEMBRANE	The oncogenic proteins encoded by papovaviruses, the tumor antigens, have been extensively used as model systems to study mitogenic signaling and cell transformation, These proteins stimulate cell growth in cultured cells and induce tumors in virus infected or transgenic animals, One of these proteins, polyomavirus middle-T, acts like a constitutively activated tyrosine growth factor receptor, Middle-T recruits several cellular enzymes into a multifunctional complex located at cellular membranes, This results in the activation of cellular enzymes involved in the regulation of cell signaling, like tyrosine kinases of the Src family, a phosphatidylinositol 3-kinase and a GDP/GTP exchange factor for Ras, These activities are all required for stimulation of cell growth by middle-T and activate members of the MAP kinase family, Here we investigate the role of T antigen-activated pathways in the stimulation of transcription of immediate early genes, These genes are essential for progression of resting cells into S phase, Our data show that Rho family GTPases play an essential role in cell transformation by middle-T. Furthermore, we demonstrate that the c-fos promoter is activated by two Pas-initiated signaling cascades, One is Raf-dependent and requires binding of SHC and PI 3-kinase to the middle-T complex, This pathway signals via ternary complex factor (TCF) to the serum response element (SRE) of the c-fos promoter, Signaling to TCF by Raf also depends on functional Pac, but not CDC42, as demonstrated in luciferase reporter assays with an ETS domain-containing promoter, The second pathway is Raf-independent, does not require SHC but functional PI 3-kinase, and transduces signals via Pac to serum response factor (SRF), Microinjection of dominant negative Rad blocks nuclear translocation of ERK1 in middle-T-expressing cells, This lends support to the idea that the two signaling cascades initiated by Pas show crosstalk at the level of MAP kinase-mediated signaling to nuclear transcription factors.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV NOTTINGHAM,QUEENS MED CTR,DEPT BIOCHEM,NOTTINGHAM NG7 2UH,ENGLAND	Friedrich Miescher Institute for Biomedical Research; University of Nottingham				Ballmer-Hofer, Kurt/0000-0002-3800-9129; SHAW, Peter/0000-0002-2598-4283				Besser D, 1995, ONCOGENE, V11, P2383; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COURTNEIDGE SA, 1986, CANCER SURV, V5, P173; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JELINEK MA, 1992, ONCOGENE, V7, P1687; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Messerschmitt A, 1996, J GEN VIROL, V77, P17, DOI 10.1099/0022-1317-77-1-17; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Tooze J, 1980, DNA TUMOR VIRUSES; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	54	32	34	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1235	1241		10.1038/sj.onc.1200982	http://dx.doi.org/10.1038/sj.onc.1200982			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121774				2022-12-25	WOS:A1997WM78200014
J	Sun, YB; Jiang, YQ; Zhang, P; Zhang, SJ; Zhou, Y; Li, BQ; Toomey, NL; Lee, MYWT				Sun, YB; Jiang, YQ; Zhang, P; Zhang, SJ; Zhou, Y; Li, BQ; Toomey, NL; Lee, MYWT			Expression and characterization of the small subunit of human DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; REPLICATION; PROTEIN; ALPHA; PHOSPHORYLASE; PURIFICATION	DNA polymerase delta is a heterodimer consisting of a catalytic subunit of 125 kDa and a small subunit of 50 kDa (p50), We have overexpressed p50 in Escherichia coli and have characterized the recombinant protein, p50 was readily overexpressed using the pET vector as an insoluble protein, A procedure was developed for its purification and renaturation. Examination of the physicochemical properties of renatured p50 showed that it is a monomeric protein with an apparent molecular weight of 60,000, a Stokes radius of 34 Angstrom, and a sedimentation coefficient of 4.1 S, Its physical properties were indistinguishable from p50 expressed as a soluble protein using the pTACTAC vector, Examination of the effects of recombinant p50 on the activity of DNA polymerase delta showed that p50 is able to slightly stimulate (about 2-fold) the activity of the recombinant 125-kDa catalytic subunit using poly(dA).oligo(dT) as a template in the absence of proliferating cell nuclear antigen, In the presence of proliferating cell nulear antigen, activity is stimulated about B-fold, Seven stable hybridoma cell lines mere established that produced monoclonal antibodies against p50, One of these antibodies (13D5) inhibited the activity of calf thymus DNA polymerase delta. This antibody, when coupled to a solid support, also was found to provide a method for the immunoafffinity purification of recombinant p50 and of DNA polymerase delta from calf thymus or HeLa extracts, Immunoprecipitation and enzyme-linked immunosorbent assays also confirmed that p50 interacts with the catalytic subunit of DNA polymerase delta.	UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOL BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101	University of Miami; University of Miami					NIEHS NIH HHS [ES07634] Funding Source: Medline; NIGMS NIH HHS [GM31973] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN WC, 1993, J BIOL CHEM, V268, P21706; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2518; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HARLOW E, 1988, ANTIBODIES LAB MANUA, P232; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; LEE MYWT, 1989, ARCH BIOCHEM BIOPHYS, V272, P1, DOI 10.1016/0003-9861(89)90187-2; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE SSK, 1995, P NATL ACAD SCI USA, V92, P7882, DOI 10.1073/pnas.92.17.7882; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SUGIMOTO K, 1995, NUCLEIC ACIDS RES, V23, P3493, DOI 10.1093/nar/23.17.3493; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; YANG CL, 1991, BIOCHEMISTRY-US, V30, P7536; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG J, 1995, GENOMICS, V29, P179, DOI 10.1006/geno.1995.1229; ZHANG P, 1995, BIOCHEMISTRY-US, V34, P10703, DOI 10.1021/bi00034a002; ZHANG P, 1995, J BIOL CHEM, V270, P7993, DOI 10.1074/jbc.270.14.7993; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484	23	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13013	13018		10.1074/jbc.272.20.13013	http://dx.doi.org/10.1074/jbc.272.20.13013			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148910	hybrid			2022-12-25	WOS:A1997WZ38400023
J	Tano, K; Dunn, WC; Darroudi, F; Shiota, S; Preston, RJ; Natarajan, AT; Mitra, S				Tano, K; Dunn, WC; Darroudi, F; Shiota, S; Preston, RJ; Natarajan, AT; Mitra, S			Amplification of the DNA repair gene O-6-methylguanine-DNA methyltransferase associated with resistance to alkylating drugs in a mammalian cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY; ESCHERICHIA-COLI; WILD-TYPE; EXPRESSION; PROTEIN; HYBRIDIZATION; INSIGHTS; AGENTS; ORIGIN	The cytotoxic action of such alkylating chemotherapeutic drugs as 2-chloroethyl-N-nitrosourea (CNU) derivatives is countered by the repair protein O-6-methylguanine-DNA methyltransferase (MGMT), which removes O-6-alkylguanine induced in the DNA by these agents, Resistance to these drugs is often correlated with the MGMT levels in normal and tumor cells of human and rodent origin, Exposure of mouse 3T3 cells to increasing concentrations of CNU, and subsequent selection of resistant cells, led to the isolation of clones with 5-10 times higher levels of MGMT activity than in the control, The increased MGMT expression at both mRNA and protein levels resulted from 5- to 10-fold amplification of the Mgmt gene, Amplification of this gene was not associated with concomitant amplification of another alkylation damage repair gene, N-methylpurine-DNA glycosylase, No amplification of at least three other genes on chromosome 7 (which contains the Mgmt gene) was observed in the drug-resistant cells. Furthermore, the amplified Mgmt sequence was not associated with a homogeneously staining region, or double minute chromosomes, nor present as episomal DNA, In situ hybridization of metaphase chromosomes of the drug-resistant cells indicated both translocation and localized amplification of the Mgmt gene.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; LEIDEN STATE UNIV,DEPT RADIAT GENET & CHEM MUTAGENESIS,NL-2333 AL LEIDEN,NETHERLANDS	University of Texas System; University of Texas Medical Branch Galveston; United States Department of Energy (DOE); Oak Ridge National Laboratory; Leiden University; Leiden University - Excl LUMC					NCI NIH HHS [CA31721] Funding Source: Medline; NIEHS NIH HHS [ES06676, ES07572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007572, P30ES006676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALITALO K, 1993, SEMIN CANCER BIOL, V4, P1; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BERGER NA, 1993, CANCER PRINCIPLES PR, P400; BRENT TP, 1985, P NATL ACAD SCI USA, V82, P2985, DOI 10.1073/pnas.82.9.2985; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CARROLL SM, 1987, MOL CELL BIOL, V7, P1740, DOI 10.1128/MCB.7.5.1740; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DUNN WC, 1991, CARCINOGENESIS, V12, P83, DOI 10.1093/carcin/12.1.83; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOOTE RS, 1983, MUTAT RES, V119, P221, DOI 10.1016/0165-7992(83)90164-1; FOOTE RS, 1980, BIOCHEM BIOPH RES CO, V97, P654, DOI 10.1016/0006-291X(80)90314-9; FRIEDBERG EC, 1994, DNA REPAIR; Futscher Bernard W., 1993, P461; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; MORTEN JEN, 1992, CARCINOGENESIS, V13, P483, DOI 10.1093/carcin/13.3.483; NATARAJAN AT, 1992, MUTAGENESIS, V7, P83, DOI 10.1093/mutage/7.1.83; PEGG AE, 1990, CANCER RES, V50, P6119; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Sambrook J., 2002, MOL CLONING LAB MANU; SETARO F, 1976, ANAL BIOCHEM, V71, P313, DOI 10.1016/0003-2697(76)90043-9; SHIOTA S, 1992, BIOCHEMISTRY-US, V31, P1897, DOI 10.1021/bi00122a001; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; TISTY TD, 1995, MUTAT RES, V337, P1; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; VLAHOS NS, 1990, CARCINOGENESIS, V11, P479, DOI 10.1093/carcin/11.3.479; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WINTERSBERGER E, 1994, CHROMOSOMA, V103, P73, DOI 10.1007/BF00352315	38	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13250	13254		10.1074/jbc.272.20.13250	http://dx.doi.org/10.1074/jbc.272.20.13250			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148943	hybrid			2022-12-25	WOS:A1997WZ38400056
J	Zang, Q; Lu, ZM; Curto, M; Barile, N; Shalloway, D; Foster, DA				Zang, Q; Lu, ZM; Curto, M; Barile, N; Shalloway, D; Foster, DA			Association between v-Src and protein kinase C delta in v-Src-transformed fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; RAT FIBROBLASTS; 3T3 CELLS; ACTIVATION; EXPRESSION; PP60C-SRC; ISOFORMS; HYDROLYSIS; DEPENDENCE; MUTATION	In response to the kinase activity of v-Src there is an increase in the membrane association of the novel protein kinase C (PKC) isoform PRC delta (Zang, Q., Frankel, P., and Foster, D. A, (1995) Cell Growth Differ, 6, 1367-1373). Ne report here that in v-Src-transformed cells PKC delta co-immunoprecipitates with v-Src and is phosphorylated on tyrosine. The tyrosine-phosphorylated PKC delta had reduced enzymatic activity relative to the non-tyrosine-phosphorylated PKC delta from v-Src-transformed cells, The association between Src and PKC delta was dependent upon both an active Src kinase and membrane association, The association between c-Src Y527F and PKC 6 was substantially enhanced by mutating a PHC phosphorylation site at Ser-la in Src to Ala indicating that PKC delta phosphorylation of Src at Ser-la destabilizes the interaction, possibly in a negative feedback loop. These data demonstrate that upon recruitment of PKC delta to the membrane in v-Src-transformed cells there is the formation of a Src PKC delta complex in which PKC delta becomes phosphorylated on tyrosine and down-regulated.	CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021; CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853	City University of New York (CUNY) System; Hunter College (CUNY); Cornell University				Zang, Qun (Sophia)/0000-0002-6397-8896	NCI NIH HHS [CA46677, CA32317] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA032317, R01CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1993, ONCOGENE, V8, P803; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1992, J BIOL CHEM, V267, P12892; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Jiang YW, 1996, J BIOL CHEM, V271, P29529, DOI 10.1074/jbc.271.47.29529; JOHNSON PL, 1995, MOL CELL BIOL, V5, P1073; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; LI WQ, 1994, J BIOL CHEM, V269, P2349; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; QURESHI SA, 1991, ONCOGENE, V6, P995; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Singer WD, 1996, J BIOL CHEM, V271, P4504; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	29	92	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13275	13280		10.1074/jbc.272.20.13275	http://dx.doi.org/10.1074/jbc.272.20.13275			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148947	hybrid			2022-12-25	WOS:A1997WZ38400060
J	Chatterjee, N; Zou, C; Osterman, JC; Gupta, NK				Chatterjee, N; Zou, C; Osterman, JC; Gupta, NK			Cloning and characterization of the promoter region of a gene encoding a 67-kDa glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS-INITIATION; POLYMERASE-II TRANSCRIPTION; EIF-2 ALPHA-SUBUNIT; DIFFERENTIAL EXPRESSION; RETICULOCYTE LYSATE; FIREFLY LUCIFERASE; POLYPEPTIDE P67; INDUCTION; ELEMENT; SEQUENCES	A rat genomic library constructed in lambda-EMBL3 (SP6/T7) vector (CLONTECH) was screened using P-32-labeled rat p67 cDNA. A clone containing a segment of 5'-upstream region of p67 genomic DNA was obtained. The DNA (about 1.7 kilobase pairs) was isolated and characterized. Sequence analysis of this DNA fragment showed that the 898 base pairs at the 5'-end of the upstream region was identical to several long interspersed nucleotide sequences. One hundred forty eight base pairs at the 3'-end contained the beginning of the first exon including the ATG initiator codon. The remaining 652 base pairs in between contained two AT-rich regions and several regulatory sequences. The mRNA initiation site was identified at 89 base pairs upstream from the translation start codon. The DNA fragment was also analyzed by transient transfection. When linked to a firefly luciferase reporter gene, this fragment enhanced transcription in a rat hepatoma cell line (KRC-7). Using a series of deletions in the DNA, the minimum essential promoter region (from -177 to -60) was identified. The promoter activity was also enhanced by treatment with phorbol 13-myristate 12-acetate (PMA). This enhancement required an AP-1 sequence (-298 to -292; 5'-TGACTCA-3') and a similar sequence (-97 to -88; 5'-ATGACATCAT-3'), Deletion of either of these sequences significantly reduced PMA enhancement, Deletion of both of these sequences almost completely eliminated PMA enhancement.	UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588	University of Nebraska System; University of Nebraska Lincoln					PHS HHS [22079] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANWERX J, 1991, CELL, V64, P983; CHAKRABORTY A, 1994, BIOCHEMISTRY-US, V33, P6700, DOI 10.1021/bi00187a041; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLBERT RA, 1987, J BIOL CHEM, V262, P16763; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DAMBROSIO E, 1986, MOL CELL BIOL, V6, P411, DOI 10.1128/MCB.6.2.411; DATTA B, 1989, J BIOL CHEM, V264, P20620; DATTA B, 1988, P NATL ACAD SCI USA, V85, P3324, DOI 10.1073/pnas.85.10.3324; DEWET JR, 1986, METHOD ENZYMOL, V133, P3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUPTA NK, 1993, TRANSLATIONAL REGULA, P287; Gupta S, 1997, J BIOL CHEM, V272, P12699, DOI 10.1074/jbc.272.19.12699; Gupta S, 1995, GENE EXPRESSION, V5, P113; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; JACOB WF, 1989, J BIOL CHEM, V264, P20372; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; Kawakami K, 1996, EUR J BIOCHEM, V237, P440, DOI 10.1111/j.1432-1033.1996.0440k.x; Kuprash DV, 1996, J IMMUNOL, V156, P2465; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LONDON IM, 1987, ENZYMES, V17, P359; MCCOUBREY WK, 1995, GENE, V160, P235, DOI 10.1016/0378-1119(95)00112-J; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MULLER S, 1995, J INVEST DERMATOL, V104, P970, DOI 10.1111/1523-1747.ep12606225; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SANGER F, 1977, P NATL ACAD SCI USA, V74, P560; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WU SY, 1993, J BIOL CHEM, V268, P10796; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	45	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12692	12698		10.1074/jbc.272.19.12692	http://dx.doi.org/10.1074/jbc.272.19.12692			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139726	hybrid			2022-12-25	WOS:A1997WY82900063
J	Li, DX; Kolattukudy, PE				Li, DX; Kolattukudy, PE			Cloning of cutinase transcription factor 1, a transactivating protein containing Cys(6)Zn(2) binuclear cluster DNA-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-SP-PISI; ZINC-FINGER PROTEIN; REGULATORY GENE; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; SUBSTRATE-SPECIFICITY; NUCLEOTIDE-SEQUENCE; SYNTHETIC PEPTIDES; PLANT CUTICLE; PATHWAY	Hydroxy fatty acids from plant cutin were shown previously to induce the expression of the cutinase gene via a palindromic sequence located at -159 base pairs of the cutinase gene in Fusarium solani f. sp, pisi (Nectria hematococca mating type VI), Of the two overlapping palindromes in this sequence, palindrome 2 was found to be essential for the inducibility of cutinase by hydroxy fatty acids, Screening of a phage expression library with the concatenated palindrome 2 as probe detected a distinct cDNA clone encoding a polypeptide designated cutinase transcription factor 1 alpha (CTF1 alpha) with a calculated molecular weight of 101,109, This protein contains a Cys(6)Zn(2) binuclear cluster motif sharing homology to the Cys(6)Zn(2) binuclear cluster DNA-binding domains of transcription factors from Saccharomyces cerevisiae, S. carlsbergensis, Kluyveromyces lactis, Neurospora crassa, Aspergillus nidulans, and A, flavus., CTF1 alpha, expressed in Escherichia coli, showed specific binding to the palindrome 2 DNA fragment but not to palindrome 1 or mutant palindrome 2 DNA fragments, suggesting specific binding of CTF1 alpha to palindrome 2. When CTF1 alpha was expressed as a fusion protein with the nuclear localization sequence of SV40 in yeast, it transactivated the native cutinase promoter fused to the chloramphenicol acetyl transferase (cat) gene, Mutation of palindrome 2 but not palindrome I abolished this transactivation. Thus, CTF1 alpha positively acts in vivo by binding selectively to palindrome 2 of the cutinase gene promoter.	OHIO STATE UNIV,NEUROBIOTECHNOL CTR,COLUMBUS,OH 43210	University System of Ohio; Ohio State University			kolattukudy, pappachan e/A-1350-2012					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRE B, 1990, MOL GEN GENET, V220, P269; ANDRIANOPOULOS A, 1990, MOL CELL BIOL, V10, P3194, DOI 10.1128/MCB.10.6.3194; BAJAR A, 1989, P NATL ACAD SCI USA, V88, P8208; BALZI E, 1987, J BIOL CHEM, V262, P16871; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERI RK, 1987, NUCLEIC ACIDS RES, V15, P7991, DOI 10.1093/nar/15.19.7991; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BURGER G, 1991, MOL CELL BIOL, V11, P5746, DOI 10.1128/MCB.11.11.5746; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; KAMPER JT, 1994, J BIOL CHEM, V269, P9195; KEMP BE, 1991, METHOD ENZYMOL, V200, P63; KOLATTUKUDY PE, 1985, ANNU REV PHYTOPATHOL, V23, P223, DOI 10.1146/annurev.py.23.090185.001255; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LATCHMAN DS, 1995, EUCARYOTIC TRANSCRIP, P292; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LI D, 1995, J BIOL CHEM, V270, P11753, DOI 10.1074/jbc.270.20.11753; LIN TS, 1978, J BACTERIOL, V133, P942, DOI 10.1128/JB.133.2.942-951.1978; MARCZAK JE, 1991, MOL CELL BIOL, V11, P2609, DOI 10.1128/MCB.11.5.2609; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MESSENGUY F, 1986, EUR J BIOCHEM, V157, P77, DOI 10.1111/j.1432-1033.1986.tb09640.x; MICHELS CA, 1988, CURR GENET, V14, P319; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PODILA GK, 1988, SCIENCE, V242, P922, DOI 10.1126/science.242.4880.922; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Sambrook J., 2002, MOL CLONING LAB MANU; SUAREZ T, 1995, EMBO J, V14, P1453, DOI 10.1002/j.1460-2075.1995.tb07132.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WOLOSHUK CP, 1986, P NATL ACAD SCI USA, V83, P1704, DOI 10.1073/pnas.83.6.1704; WOLOSHUK CP, 1994, APPL ENVIRON MICROB, V60, P2408, DOI 10.1128/AEM.60.7.2408-2414.1994; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WRAY LV, 1987, MOL CELL BIOL, V7, P1111, DOI 10.1128/MCB.7.3.1111; YUAN GF, 1991, MOL CELL BIOL, V11, P5735, DOI 10.1128/MCB.11.11.5735; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110	39	40	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12462	12467		10.1074/jbc.272.19.12462	http://dx.doi.org/10.1074/jbc.272.19.12462			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139694	hybrid			2022-12-25	WOS:A1997WY82900031
J	Shuman, JD; Cheong, JH; Coligan, JE				Shuman, JD; Cheong, JH; Coligan, JE			ATF-2 and C/EBP alpha can form a heterodimeric DNA binding complex in vitro - Functional implications for transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER NUCLEAR-PROTEIN; SERUM-ALBUMIN GENE; LEUCINE ZIPPER; BASIC REGION; C-JUN; DIMERIZATION SPECIFICITY; 3T3-L1 PREADIPOCYTES; CRYSTAL-STRUCTURE; FACTOR FAMILY; FOS-JUN	We screened an expression cDNA library with a radiolabeled C/EBP alpha fusion protein and isolated three independent cDNAs encoding ATF-S, a bZIP protein that binds cAMP response elements (CRE), This interaction requires the respective bZIP domains, which form a typical bZIP heterodimer with altered DNA binding selectivity, C/EBP alpha and ATF-2 homodimers bind CRE sites, but ATF-2:C/EBP alpha heterodimers do not. Heterodimers bind an asymmetric sequence composed of one consensus half-site for each monomer, and may thus have a unique regulatory function, As predicted, co-transfection of ATF-2 with C/EBP alpha results in decreased activation of transcription driven from consensus C/EBP-binding sites. In contrast, C/EBP alpha and ATF-2 function cooperatively to activate transcription driven by the asymmetric sequence. Both factors are expressed in liver, where immunoprecipitation experiments show that ATF-2 co-precipitates with C/EBP alpha. These results are consistent with the interpretation that C/EBP alpha and ATF-2 can associate in vivo. Moreover, the formation of ATF-S:C/EBP beta heterodimers suggests that cross-family dimerization with ATF-S may be a general property for C/EBP family proteins.			Shuman, JD (corresponding author), NIAID,MOL STRUCT LAB,NIH,TWINBROOK 2 BLDG,RM 103,ROCKVILLE,MD 20892, USA.			Shuman, Jon/0000-0001-8412-9087				ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; An MR, 1996, MOL CELL BIOL, V16, P2295; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RORTH P, 1995, SCIENCE, V266, P1878; Sambrook J., 2002, MOL CLONING LAB MANU; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P469	61	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12793	12800		10.1074/jbc.272.19.12793	http://dx.doi.org/10.1074/jbc.272.19.12793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139739	hybrid			2022-12-25	WOS:A1997WY82900076
J	Wang, YW; McLeod, RS; Yao, ZM				Wang, YW; McLeod, RS; Yao, ZM			Normal activity of microsomal triglyceride transfer protein is required for the oleate-induced secretion of very low density lipoproteins containing apolipoprotein B from McA-RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL TRUNCATION; RAT-LIVER; ENDOPLASMIC-RETICULUM; APO-B; ABETALIPOPROTEINEMIA; EXPRESSION; PARTICLES; TRANSPORT; PLASMA; LINES	The requirement of the activity of microsomal triglyceride transfer protein (MTP) for very low density lipoprotein (VLDL) secretion was determined using McA-RH7777 cells stably transfected with human apoB48 (hB48), Secretion of VLDL containing hB48 (hB48-VLDL) by the transfected cells was induced by exogenous oleate (0.4 mM), and oleate-dependent VLDL secretion was selectively inhibited by brefeldin A (0.2 mu g/ml), Two protocols were used to determine the effect of MTP inhibition on VLDL secretion. In the first protocol, cell protein and lipid were labeled with radioactive amino acids and oleate prior to MTP inhibition (using 5 mu M of the photoaffinity inhibitor BMS-192951 to reduce MTP activity by 65-70%), and secretion of prelabeled apoB and triacylglycerol (TG) associated with lipoproteins was monitored during oleate-supplemented chase, In control cells, a 6-fold increase in incorporation of prelabeled TG into hB48-VLDL was observed after oleate supplement, while incorporation of prelabeled TG into VLDL containing endogenous rat apoB100 (rB100-VLDL) was unaffected, Inhibition of MTP activity abolished the oleate-induced utilization of prelabeled TG (by 80%) and hB48 (by 70%) for hB48-VLDL secretion but decreased utilization of pre-existing TG (by < 25%) and B100 (by 45%) for rB100-VLDL secretion to a lesser extent, Inhibition of MTP did not affect incorporation of prelabeled TG or hB48 into high density lipoproteins containing hB48 (hB48-HDL), In the second protocol, MTP was inactivated prior to metabolic labeling of protein and lipid, and secretion of newly labeled apoB and TG as lipoproteins was monitored after oleate supplement, Under this condition, MTP inhibition decreased incorporation of newly labeled TG (by 80%) and hB48 (80%) into hB48-VLDL but did not affect their incorporation into hB48-HDL. Additionally, MTP inhibition decreased incorporation of newly labeled TG (by 50%) and rB100 (by 90%) into rB100-VLDL. Thus, normal activity of MTP is required for the oleate induced secretion of hB48-VLDL from McA-RH7777 cells.	UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,INST HEART,DEPT PATHOL & LAB MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,INST HEART,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute			McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569				ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; CHAN L, 1992, J BIOL CHEM, V267, P25621; ELOVSON J, 1988, J LIPID RES, V29, P1461; ELOVSON J, 1994, CIRCULATION, V90, P185; Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Haghpassand M, 1996, J LIPID RES, V37, P1468; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MCLEOD RS, 1996, CIRCULATION S1, V94, P150; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; SELBY SL, 1995, ARTERIOSCL THROM VAS, V15, P1900, DOI 10.1161/01.ATV.15.11.1900; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WETTERAU JR, 1992, SCIENCE, V258, P999; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YAO ZM, 1991, J BIOL CHEM, V266, P3300	34	84	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12272	12278		10.1074/jbc.272.19.12272	http://dx.doi.org/10.1074/jbc.272.19.12272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139669	hybrid			2022-12-25	WOS:A1997WY82900006
J	Aumais, JP; Lee, HS; Lin, R; White, JH				Aumais, JP; Lee, HS; Lin, R; White, JH			Selective interaction of hsp90 with an estrogen receptor ligand-binding domain containing a point mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-90; STEROID-RECEPTOR; IN-VIVO; GLUCOCORTICOID RECEPTORS; ACTIVATION; KINASE; TRANSFORMATION; TRANSCRIPTION; DETERMINANTS; LOCALIZATION	The 90-kDa heat shock protein (hsp90) has been implicated in modulating steroid receptor function in vitro and in vivo. Previous studies have suggested that hsp90 interacts with large portions of the estrogen receptor (ER) ligand binding domain and sequences of the receptor required for stable DNA binding. To characterize the interaction of the ER ligand-binding domain with hsp90, we have compared the properties of chimeras created by coupling the ligand-binding domain to the constitutive transactivator VP16-GAL. Two types of chimeras were created: VP16-GAL-ERG, containing the wild-type ligand-binding domain derived from the cDNA HEG0, and VP16-GAL-ERV, containing the substitution G400V derived from the ligand-binding domain of the original ER cDNA isolate, HE0. The G400V mutation alters the physical properties of VP16-GAL-ERV, by rendering it hormone-dependent for DNA binding and more strongly dependent on estradiol for transactivation compared with VP16-GAL-ERG. Glycerol gradient analyses and chemical cross-linking/coimmunoprecipitation showed that, unlike VP16-GAL-ERG, VP16-GAL-ERV formed stable complexes with hsp90 in vitro. These data show that hsp90 selectively recognizes the altered ER ligand-binding domain containing the G400V substitution and indicate that the wild-type ER ligand-binding domain of VP16-GAL-ERG does not interact with hsp90 in vitro. Hormone binding studies showed that the ligand-binding domain of VP16-GAL-ERV was destabilized by incubation in the presence of high concentrations of salt or in the absence of sodium molybdate, conditions that disrupt its interaction with hsp90. The ligand-binding domain of the Val-400 ER thus behaves similarly to that of the wild-type glucocorticoid receptor, which has previously been shown to interact with hsp90 in vitro. These results provide evidence for the action of hsp90 as a molecular chaperone by selectively recognizing destabilized proteins.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University			white, john h/N-9782-2013	white, john h/0000-0002-4785-2687				Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CHURCH CJ, 1994, MOL ENDOCRINOL, V8, P1407; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FUXE K, 1987, J STEROID BIOCHEM, V27, P159, DOI 10.1016/0022-4731(87)90306-2; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P361; GREENE GL, 1986, J STEROID BIOCHEM, V26, P1; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; INANO K, 1992, J BIOCHEM-TOKYO, V112, P535, DOI 10.1093/oxfordjournals.jbchem.a123934; INANO K, 1990, FEBS LETT, V267, P157, DOI 10.1016/0014-5793(90)80313-8; ISHIBASHI T, 1989, BIOL REPROD, V40, P1275; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lee HS, 1996, J BIOL CHEM, V271, P25727, DOI 10.1074/jbc.271.42.25727; MADER S, 1993, NUCLEIC ACIDS RES, V21, P11205; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRESS MF, 1985, J HISTOCHEM CYTOCHEM, V33, P915, DOI 10.1177/33.9.4020102; REDEUILH G, 1987, J BIOL CHEM, V262, P6969; SALOMONSSON M, 1994, J STEROID BIOCHEM, V48, P447, DOI 10.1016/0960-0760(94)90192-9; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TZUKERMAN M, 1990, New Biologist, V2, P613; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZHUANG Y, 1995, MOL ENDOCRINOL, V9, P457, DOI 10.1210/me.9.4.457; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	43	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12229	12235		10.1074/jbc.272.18.12229	http://dx.doi.org/10.1074/jbc.272.18.12229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115298	hybrid			2022-12-25	WOS:A1997WX56900086
J	Gaetano, C; Matsuo, T; Thiele, CJ				Gaetano, C; Matsuo, T; Thiele, CJ			Identification and characterization of a retinoic acid-regulated human homologue of the unc-33-like phosphoprotein gene (hUlip) from neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEURO-BLASTOMA; NERVE GROWTH-FACTOR; EXPRESSION; DIFFERENTIATION; LINES; RECEPTORS; INDUCTION; OUTGROWTH; SURVIVAL; CULTURE	A cDNA, 7G1, was isolated from retinoic acid (RA) differentiated neuroblastoma cells whose expression was high in human fetal brain and spinal cord mRNA but undetectable in adult brain or non-neuronal tissues. Sequence analysis indicates that 7G1 is homologous to the Caenorhabditis elegans gene unc-33. A 5.5-kilobase pair full-length cDNA from a human fetal brain cDNA library contains an 1710-base pair open reading frame. Because the predicted 570 amino acid sequence of 7G1 shares 98% identity with the murine Ulip gene product, an unc-33-like-phosphoprotein, we refer to 7G1 as the human Ulip (hUlip). hUlip is also similar to the bacterial enzyme D-hydantoinase and the recently described vertebrate gene products CRMP62, TOAD-64, CRMP1, CRMP2, and mUNC. RA stimulates an increase in hUlip mRNA that is transcriptionally regulated. RA stimulates an increase in polypeptides of 58, 60, 65, and 70 kDa with the 58- and 65-kDa species being dephosphorylated forms of the 60- and 70-kDa species. This study presents a model in which to study the regulation and expression of the hUlip gene, a member of an emerging family of molecules that potentially mediates signals involved in axonal outgrowth.	NCI,CELL & MOL BIOL SECT,PEDIAT ONCOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Gaetano, Carlo/P-9997-2019	Gaetano, Carlo/0000-0002-5238-1832				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRODEUR GM, 1977, CANCER, V40, P2257; Byk T, 1996, J NEUROSCI, V16, P688; CICCARONE V, 1989, CANCER RES, V49, P219; COHEN PS, 1994, BLOOD, V84, P3465; COHEN PS, 1995, CANCER RES, V55, P2380; CORNAGLIA FP, 1992, CANC LETT, P215; FOX F, 1959, CANCER, V12, P108, DOI 10.1002/1097-0142(195901/02)12:1<108::AID-CNCR2820120116>3.0.CO;2-H; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; HASKELL BE, 1987, CELL TISSUE RES, V247, P67, DOI 10.1007/BF00216548; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; LI W, 1992, GENETICS, V132, P675; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; MINTURN JE, 1995, J NEUROSCI, V15, P6757; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; PRASAD KN, 1975, BIOL REV, V50, P129, DOI 10.1111/j.1469-185X.1975.tb01055.x; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SIDELL N, 1982, J NATL CANCER I, V68, P589; TAHIRA T, 1991, ONCOGENE, V6, P2333; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, ADV NEUROBLASTOMA RE, V2, P185; TRICHE TJ, 1986, PATHOLOGY NEOPLASIA, P145; WANG L, 1997, J NEUROSCI, V16, P6197; WEILER R, 1990, FEBS LETT, V265, P27, DOI 10.1016/0014-5793(90)80875-J	31	61	65	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12195	12201		10.1074/jbc.272.18.12195	http://dx.doi.org/10.1074/jbc.272.18.12195			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115293	hybrid			2022-12-25	WOS:A1997WX56900081
J	Nakamura, N; Hirata, A; Ohsumi, Y; Wada, Y				Nakamura, N; Hirata, A; Ohsumi, Y; Wada, Y			Vam2/Vps41p and Vam6/Vps39p are components of a protein complex on the vacuolar membranes and involved in the vacuolar assembly in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN-FLUORESCENT PROTEIN; PLASMA-MEMBRANE; MUTANTS; GENE; MORPHOGENESIS; BIOGENESIS; CELLS; ION; TRANSFORMATION; ENDOCYTOSIS	The VAM2/VPS41 and VAM6/VPS39 were shown to encode hydrophilic proteins of 113 and 123 kDa, respectively, Deletion of the VAM2 and VAM6 functions resulted in accumulation of numerous vacuole related structures of 200-400 nm in diameter that were much smaller than the normal vacuoles. Loss of functions of Vam2p and Vam6p resulted in inefficient processings of a set of vacuolar proteins, including proteinase A, proteinase B, and carboxypeptidase Y (CPY), and in severely defective maturation of another vacuolar protein, alkaline phosphatase. A part of newly synthesized CPY was missorted to the cell surface in the mutants, Epitope-tagged versions of Vam2p and Vam6p retained their functions, and they were found mostly in sedimentable fractions. The epitope-tagged Vam2p and Vam6p remained in the sedimentable fractions in the presence of Triton X-100, but they were extracted by urea or NaCI. Vam2p and Vam6p were cross-linked by the treatment of a chemical cross-linker. These observations indicated that Vam2p and Vam6p physically interact with each other and exist as components of a large protein complex. Vam6p fused with a green fluorescent protein were highly accumulated in a few specific regions of the vacuolar membranes. Large portions of Vam2p and Vam6p were fractionated into a vacuolar enriched fraction, indicating that they were localized mainly in the vacuolar membranes. These results showed that Vam2p and Vam6p execute their function in the vacuolar assembly as the components of a protein complex reside on the vacuolar membranes.	UNIV TOKYO, GRAD SCH ARTS & SCI, DEPT BIOL, MEGURO KU, TOKYO 153, JAPAN; UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo			Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166				ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1977, GENETICS, V85, P23; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; MATILE P, 1978, ANNU REV PLANT PHYS, V29, P193, DOI 10.1146/annurev.pp.29.060178.001205; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; SATO MH, 1997, IN PRESS BIOTECHNIQU; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; SIKORSKI RS, 1989, GENETICS, V122, P19; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; WADA Y, 1994, J BIOENERG BIOMEMBR, V26, P631, DOI 10.1007/BF00831538; WADA Y, 1987, J BIOL CHEM, V262, P17260; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WADA Y, 1992, J BIOL CHEM, V267, P18665; Wada Y, 1996, PROTOPLASMA, V191, P126, DOI 10.1007/BF01281810; WADA Y, 1992, J BIOL CHEM, V267, P18671; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5	33	126	129	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11344	11349						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111041				2022-12-25	WOS:A1997WW00900057
J	Wang, Y; Goligorsky, MS; Lin, M; Wilcox, JN; Marsden, PA				Wang, Y; Goligorsky, MS; Lin, M; Wilcox, JN; Marsden, PA			A novel, testis-specific mRNA transcript encoding an NH2-terminal truncated nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; MESSENGER-RNA; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; SKELETAL-MUSCLE; ALU REPEATS; RAT TESTIS; LOCALIZATION	mRNA diversity represents a major theme of neuronal nitric-oxide synthase (nNOS) gene expression in somatic cells/tissues. Given that gonads often express unique and biologically informative variants of complex genes, we determined whether unique variants of nNOS are expressed in the testis. Analysis of cDNA clones isolated from human testis identified a novel, testis-specific nNOS (TnNOS) mRNA transcript. A predicted 3294-base pair open reading frame encodes an NH2-terminal truncated protein of 1098 amino acids. Measurement of calcium-activated L-[C-14]citrulline formation and nitric oxide release in CHO-K1 cells stably transfected with the TnNOS cDNA indicates that this protein is a calcium-dependent nitric-oxide synthase with catalytic activity comparable to that of full-length nNOS. TnNOS transcripts exhibit novel 5' mRNA sequences encoded by two unique exons spliced to exon 4 of the full-length nNOS. Characterization of the genomic structure indicates that exonic regions used by the novel TnNOS are expressed from intron 3 of the NOS1 gene. Although lacking canonical TATA and CAAT boxes, the 5'-flanking region of the TnNOS exon 1 contains multiple putative cis regulatory elements including those implicated in testis-specific gene expression. The downstream promoter of the human nNOS gene, which directs testis-specific expression of a novel NH2-terminal truncated nitric-oxide synthase, represents the first reported example in the NOS gene family of transcriptional diversity producing a variant NOS protein.	UNIV TORONTO,ST MICHAELS HOSP,DIV RENAL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,ST MICHAELS HOSP,DEPT MED,TORONTO,ON M5S 1A8,CANADA; SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794; EMORY UNIV,DEPT MED,DIV HEMATOL,ATLANTA,GA 30322	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Emory University			Marsden, Philip A/B-1441-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48667] Funding Source: Medline; NIDDK NIH HHS [DK 45462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS ML, 1994, J PHARMACOL EXP THER, V269, P230; ARRANZ V, 1994, GENE, V149, P293, DOI 10.1016/0378-1119(94)90164-3; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BRINI AT, 1993, J BIOL CHEM, V268, P1355; BRYANT CE, 1995, J ENDOCRINOL, V146, P149, DOI 10.1677/joe.0.1460149; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Chung E, 1996, AM J HUM GENET, V58, P363; DAVIDOFF MS, 1995, ARCH HISTOL CYTOL, V58, P17, DOI 10.1679/aohc.58.17; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Gu W, 1996, MOL CELL BIOL, V16, P4535; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HALL AV, 1994, J BIOL CHEM, V269, P33082; HECKER M, 1994, J NEUROCHEM, V62, P1524; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; ICHIMORI K, 1994, REV SCI INSTRUM, V65, P1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; KADOWAKI K, 1994, ENDOCRINOLOGY, V134, P1011, DOI 10.1210/en.134.3.1011; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LACAZEMASMONTEIL T, 1987, P NATL ACAD SCI USA, V84, P7261, DOI 10.1073/pnas.84.20.7261; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEEGWATER PAJ, 1986, EMBO J, V5, P381, DOI 10.1002/j.1460-2075.1986.tb04223.x; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAOUCHE L, 1994, NUCLEIC ACIDS RES, V22, P338, DOI 10.1093/nar/22.3.338; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; MUNDEL P, 1992, KIDNEY INT, V42, P1017, DOI 10.1038/ki.1992.382; NAKAJIMA N, 1995, FEBS LETT, V365, P108, DOI 10.1016/0014-5793(95)00453-G; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PALLADINO MA, 1994, BIOL REPROD, V50, P320, DOI 10.1095/biolreprod50.2.320; PERSSON H, 1990, MOL CELL BIOL, V10, P4701, DOI 10.1128/MCB.10.9.4701; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; RAO SM, 1993, J BIOL CHEM, V268, P22164; RETTORI V, 1993, P NATL ACAD SCI USA, V90, P10130, DOI 10.1073/pnas.90.21.10130; RICCIO ML, 1993, DNA SEQUENCE, V4, P129, DOI 10.3109/10425179309020152; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SAEGUSA Y, 1993, BIOCHIM BIOPHYS ACTA, V1172, P274, DOI 10.1016/0167-4781(93)90214-X; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHWEIGER M, 1995, BIOCHIMIE, V77, P480, DOI 10.1016/0300-9084(96)88164-8; SHARIEF FS, 1994, BIOCHEM MOL BIOL INT, V33, P561; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TERADA Y, 1992, J CLIN INVEST, V90, P659, DOI 10.1172/JCI115908; TSUKAHARA H, 1994, J BIOL CHEM, V269, P21778; VanVoorhis BJ, 1995, J CLIN INVEST, V96, P2719, DOI 10.1172/JCI118339; VERGE VMK, 1992, P NATL ACAD SCI USA, V89, P11617, DOI 10.1073/pnas.89.23.11617; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; WOLFF DJ, 1992, BIOCHEM J, V285, P201, DOI 10.1042/bj2850201; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	80	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11392	11401						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111048				2022-12-25	WOS:A1997WW00900064
J	Murai, H; Ikeda, M; Kishida, S; Ishida, O; OkazakiKishida, M; Matsuura, Y; Kikuchi, A				Murai, H; Ikeda, M; Kishida, S; Ishida, O; OkazakiKishida, M; Matsuura, Y; Kikuchi, A			Characterization of Ral GDP dissociation stimulator-like (RGL) activities to regulate c-fos promoter and the GDP/GTP exchange of Ral	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING FACTOR; CELL-TRANSFORMATION; PLASMA-MEMBRANE; PROTEINS; ACTIVATION; P21; BINDING; KINASE; DOMAIN; RHO	Ral GDP dissociation stimulator-like (RGL) has been identified to be a possible effector protein of has. RGL shares 50% amino acid identity with Ral GDP dissociation stimulator and contains the CDC25-like domain in the central region and the Has-interacting domain in the C-terminal region. Since the modes of activation and action of RGL have not yet been clarified, in this paper we have analyzed the functions of RGL. In COS cells, RGL interacted with Ras(G12V/E37G) (a pus mutant in which Gly-12 and Glu-37 were changed to Val and Gly, respectively) which failed to bind to Raf, but not with Ras(G12V/T35S) which bound to Raf. Raf did not inhibit the binding of RGL to Ras(G12V/E37G) under the condition that Raf inhibited that of RGL to Ras(G12V). Expression of either RGL or Raf into NIH3T3 cells slightly activated c-fos promoter, while coexpression of both proteins greatly stimulated the c-fos promoter activity. RGL stimulated the GDP/GTP exchange of Ral and this action was enhanced by the post-translational modification of Ral. However, RGL was not active on Has, Rac, CDC42, Rap, or Rho. Furthermore, this action of RGL to stimulate the GDP/GTP exchange of Ral was dependent on Has in COS cells. These results suggest that RGL constitutes another Ras-signaling pathway which is distinct from the Raf pathway and indicate that the RGL pathway regulates the c-fos promoter activity and the GDP/GTP exchange of Ral.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; NATL INST HLTH,DEPT VIROL 2,SHINJYUKU KU,TOKYO 162,JAPAN	Hiroshima University				kishida, shosei/0000-0003-0405-851X				ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GORMAN C, 1985, DNA CLONING PRACTICA, V2; GORMAN C, 1985, DNA CLONING PRACTICA, V3; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee T, 1996, DEVELOPMENT, V122, P409; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Okazaki M, 1996, CANCER RES, V56, P2387; ORITA S, 1993, J BIOL CHEM, V268, P25542; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Wolthuis RMF, 1996, ONCOGENE, V13, P353	56	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10483	10490						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099691				2022-12-25	WOS:A1997WV26200025
J	Guerin, S; Mari, B; Maulon, L; Belhacene, N; Marguet, D; Auberger, P				Guerin, S; Mari, B; Maulon, L; Belhacene, N; Marguet, D; Auberger, P			CD10 plays a specific role in early thymic development	FASEB JOURNAL			English	Article						flow cytometry; FTOC; thymopentin; thymic epithelial cells; endopeptidase 24.11	ENDOPEPTIDASE 24.11 ENKEPHALINASE; LEUKEMIA ANTIGEN CALLA; THYMOPOIETIN; PROGENITORS; ACTIVATION; INHIBITION; HORMONES; ENZYMES; MICE	Development of T lymphocyte is a complex process that depends on both thymocyte-stromal cell interactions and the production of soluble factors such as cytokines, peptides, and hormones. In many tissues, the concentration of active biological peptides is regulated locally by a specialized family of enzymes: the ectopeptidases. We show here that treatment of fetal thymic organ cultures (FTOC) with the specific CD10 (endopeptidase 24.11)inhibitors SCH 32615: (N-[L-(1-carboxy-2-phenyl)ethyl]-L-phenylalanyl-beta-alanine), RB25: (N-(3-[(hydroaxyamino)carbonyl]-2-benzylidene-1-oxopropyl]-N-glycine), and thymopentin (TP5) results in the inhibition of thymocyte differentiation. Each agent induces a significant decrease in the number of double positive (CD4(+) CD8(+)) cells in favor of the TN (TcR alpha beta(-)CD4(-)Cd8(-)) population. RB25 also blocks T lymphocyte differentiation in FTOC when preinjected into pregnant mice. Finally, RB25 and TP5 were also shown to reduce the number of CD44(+)CD25(-) and CD44(-)CD25(-) thymocytes both in vitro and after preinjection in vivo in day 2 FTOC. Thus, agents that affect endopeptidase 24.11 activity impair T cell development both in vitro and in vivo. Our results show that the CD10 molecule plays a specific role in promoting early T cell development.	FAC MED NICE,CJF INSERM 9605,F-06107 NICE 02,FRANCE; CIML,INSERM U136,F-13288 MARSEILLE 09,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Marguet, Didier/B-9946-2008; Mari, Bernard P/GVS-3100-2022; Mari, Bernard/Q-5832-2019; Mari, Bernard P/F-8960-2013; Mari, Bernard P/D-7445-2015; Marguet, Didier/AGO-5421-2022; AUBERGER, Patrick/G-1491-2013	Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Marguet, Didier/0000-0003-3198-5095; AUBERGER, Patrick/0000-0002-2481-8275				AUDHYA T, 1984, P NATL ACAD SCI-BIOL, V81, P2847, DOI 10.1073/pnas.81.9.2847; DARDENNE M, 1994, IMMUNOL TODAY, V15, P518, DOI 10.1016/0167-5699(94)90207-0; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GOLDSTEIN G, 1979, SCIENCE, V204, P1309, DOI 10.1126/science.451537; Guerin S, 1997, CELL IMMUNOL, V175, P85, DOI 10.1006/cimm.1996.1045; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; HERNANDEZ JF, 1988, J MED CHEM, V31, P1825, DOI 10.1021/jm00117a025; KALLED SL, 1995, EUR J IMMUNOL, V25, P677, DOI 10.1002/eji.1830250308; Lalli E, 1996, EMBO J, V15, P528, DOI 10.1002/j.1460-2075.1996.tb00385.x; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MARI B, 1994, IMMUNOLOGY, V82, P833; MATTEI M, 1994, INT J IMMUNOPHARMACO, V16, P651, DOI 10.1016/0192-0561(94)90138-4; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SALLES G, 1993, P NATL ACAD SCI USA, V90, P7618, DOI 10.1073/pnas.90.16.7618; SALLES G, 1992, BLOOD, V80, P2021; SCHEID MP, 1978, J EXP MED, V147, P1727, DOI 10.1084/jem.147.6.1727; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Small M, 1996, EUR J IMMUNOL, V26, P961, DOI 10.1002/eji.1830260438; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	22	19	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					376	381		10.1096/fasebj.11.5.9141505	http://dx.doi.org/10.1096/fasebj.11.5.9141505			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141505				2022-12-25	WOS:A1997WX15600011
J	Marechal, V; Elenbaas, B; Taneyhill, L; Piette, J; Mechali, M; Nicolas, JC; Levine, AJ; Moreau, J				Marechal, V; Elenbaas, B; Taneyhill, L; Piette, J; Mechali, M; Nicolas, JC; Levine, AJ; Moreau, J			Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis	ONCOGENE			English	Article						MDM2; p53; ribosomal L5 protein; RING finger	WILD-TYPE P53; SOFT-TISSUE SARCOMAS; RING FINGER; TRANSCRIPTIONAL ACTIVATION; P53-ASSOCIATED PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOGENE PRODUCT; ONCOPROTEIN MDM2; BINDING DOMAIN	The Mdn2 gene is the best known cellular regulator of p53 tumor suppressor activity. We report here the cloning and characterization of Xdm2, its homolog in Xenopus laevis. Human, mouse and Xenopus MDM2 proteins are more than 65% identical in several regions which are likely to be important for the biological activities of MDM2. Region I is sufficient for binding p53 and inhibiting its G(I) arrest and apoptosis functions. Region II contains most of a central acidic region required for interaction with the L5 ribosomal protein and a putative C4 zinc finger. Region III is nearly identical from Xenopus to human and comprises the RING finger domain. We show that this structural conservation is associated with the conservation of three biochemical activities of MDM2; binding to the p53 and L5 proteins and specifically to RNA. Lastly, Xdm2 expression during early development is mainly restricted from the oocyte stage I/II to the blastula stage and is possibly independent of transcriptional activation by p53. These data as web as the utilization of Xenopus laevis to investigate the roles of MDM2 and p53 during early embryogenesis are discussed.	PRINCETON UNIV, DEPT MOL BIOL, PRINCETON, NJ 08544 USA; INST MOL GENET, UMR 5535, F-34033 MONTPELLIER, FRANCE; INST JACQUES MONOD, DEPT DEV BIOL, F-75251 PARIS, FRANCE	Princeton University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UDICE-French Research Universities; Universite Paris Cite	Marechal, V (corresponding author), HOP ROTHSCHILD, MICROBIOL SERV, F-75571 PARIS, FRANCE.		marechal, vincent/P-7719-2017; Taneyhill, Lisa/K-1815-2013					Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; AUGIAS D, 1966, IN PRESS; BAE I, 1995, EXP CELL RES, V217, P541, DOI 10.1006/excr.1995.1120; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BERBERICH S, 1994, ONCOGENE, V9, P1469; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1994, ONCOGENE, V9, P2951; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FREEDMAN D, 1996, UNPUB; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOEVER M, 1994, ONCOGENE, V9, P109; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LADANYI M, 1993, CANCER RES, V53, P16; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LENG P, 1995, ONCOGENE, V10, P1275; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOUSSI T, 1987, ONCOGENE, V1, P71; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WANG Y, 1995, ONCOGENE, V10, P779; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	61	37	38	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1427	1433		10.1038/sj.onc.1200967	http://dx.doi.org/10.1038/sj.onc.1200967			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136986				2022-12-25	WOS:A1997WT58400005
J	Ookawa, K; Tsuchida, S; Adachi, J; Yokota, J				Ookawa, K; Tsuchida, S; Adachi, J; Yokota, J			Differentiation induced by RB expression and apoptosis induced by p53 expression in an osteosarcoma cell line	ONCOGENE			English	Article						tumor suppressor gene; RB; p53; cell cycle; differentiation; apoptosis	TUMOR-SUPPRESSOR GENES; WILD-TYPE P53; RETINOBLASTOMA-PROTEIN; CYCLE CONTROL; HUMAN BLADDER; HUMAN CANCER; CDK4 AMPLIFICATION; MAMMALIAN-CELLS; CARCINOMA CELLS; LUNG-CARCINOMA	Multiple genetic alterations, including concurrent inactivation of RB and p53, occur frequently in several human cancers. To investigate the biological significance of RB and p53 gene inactivations, a wild-type RB or p53 cDNA expression vector regulated by tetracycline was introduced by stable transfection into an osteosarcoma cell line Saos-2, in which both the RB and p53 genes were inactivated. Induction of introduced RB expression resulted in suppression of cell growth, increased percentage of cells at the G(0)/G(1) phase, and enlargement of the cells. Furthermore, activity of alkaline phosphatase was increased and expression of fibronectin was decreased, suggesting the induction of cell differentiation by RB expression. Induction of p53 expression also resulted in significant suppression of cell growth with slight accumulation of cells at the G(0)/G(1) and G(2)/M phases. The cells mere detached from culture dishes and the dead cell fraction increased. Furthermore, condensation of chromatin and DIVA fragmentation were observed, suggesting the induction of apoptosis by p53. These results suggest that RB and p53 play different roles in carcinogenesis of osteoblast; RB inactivation releases cells from G(0)/G(1) arrest and suppresses cell differentiation while p53 inactivation assists the cells to proliferate by repressing both apoptosis and cell cycle arrest at G(0)/G(1) and G(2)/M.	NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; HIROSAKI UNIV,SCH MED,DEPT BIOCHEM 2,HIROSAKI,AOMORI 036,JAPAN	National Cancer Center - Japan; Hirosaki University			Tsuchida, Shigeki/L-3382-2013	Tsuchida, Shigeki/0000-0002-4404-5599				Adachi J, 1996, CELL GROWTH DIFFER, V7, P879; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNG YKT, 1993, ONCOGENE, V8, P2659; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIETTING T, 1995, BIOL CHEM HOPPESEYLE, V376, P441; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HE J, 1994, CANCER RES, V54, P5804; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLINGSWORTH RE, 1991, J NATL CANCER I, V83, P91, DOI 10.1093/jnci/83.2.91; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; ISHIKAWA J, 1991, CANCER RES, V51, P5736; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OOKAWA K, 1993, ONCOGENE, V8, P2175; PRESTI JC, 1991, CANCER RES, V51, P5405; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RUGGERI B, 1992, ONCOGENE, V7, P1503; Sambrook J., 2002, MOL CLONING LAB MANU; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STEWART N, 1995, ONCOGENE, V10, P109; STRATTON MR, 1990, ONCOGENE, V5, P1297; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU HJ, 1991, CANCER RES, V51, P2735; YAMATO K, 1995, ONCOGENE, V11, P1; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	67	35	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1389	1396		10.1038/sj.onc.1200976	http://dx.doi.org/10.1038/sj.onc.1200976			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136982				2022-12-25	WOS:A1997WT58400001
J	Bansal, A; Ramirez, RD; Minna, JD				Bansal, A; Ramirez, RD; Minna, JD			Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines	ONCOGENE			English	Article						MAP kinase pathway; MEK; human lung cancer	MAP KINASE KINASE; PROTEIN-KINASE; MYC GENE; INSULIN; TRANSFORMATION; PHOSPHORYLATES; AMPLIFICATION; EXPRESSION; ACTIVATOR; PATHWAY	Recently, constitutively active mutants of MEK (MAP/ ERI( kinase) were shown to be capable of transforming cells to tumorigenicity suggesting that MEK can function as a dominant oncogene and potentially play a role in human carcinogenesis, Human lung cancer cells exhibit mutations in other components of the MAP kinase signaling pathway such as the Her-2/neu and ras oncogenes. Thus, the coding sequences of both MEK-1 and MEK-2 cDNAs from human lung cancer cell lines were screened by single strand conformation polymorphism analysis and DNA sequencing for alterations in these two genes. In 37 lung cancer cell lines we found: an allelic variant in MEK-1 cDNA, nt 783 G-->A, (no amino acid change); a MEK-2 cDNA change (nt 977 C-->T mutation leading to 298 Pro-->Leu change); a MEK-2 cDNA change nt 537 C-->T (no amino acid change); and a frequent MEK-2 cDNA germline polymorphism nt 744, A-->C (no amino acid change) with an allele frequency of 0.5 for each form. These results suggest that mutations in the MEK-1 and MEK-2 gene occur at a very low frequency in human lung cancer.	UNIV TEXAS,SW MED CTR,HAMON CTR THERAPEUT ONCOL RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNET A, 1994, ONCOGENE, V9, P3379; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINNA J, 1994, LUNG CANC PRINCIPLES, P143; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; MINNA JD, 1997, CANC PRINCIPLES PRAC; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SEKIDO Y, 1995, CANCER RES, V55, P1227; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	26	21	24	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1231	1234		10.1038/sj.onc.1200947	http://dx.doi.org/10.1038/sj.onc.1200947			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121773				2022-12-25	WOS:A1997WM78200013
J	Meyerhardt, JA; Look, AT; Bigner, SH; Fearon, ER				Meyerhardt, JA; Look, AT; Bigner, SH; Fearon, ER			Identification and characterization of neogenin, a DCC-related gene	ONCOGENE			English	Article						tumor suppressor gene; DCC (deleted in colorectal cancer) gene; brain tumor; neuroblastoma; gene expression; chromosome 18q	COLORECTAL-CANCER; PANCREATIC ADENOCARCINOMA; ALLELOTYPE ANALYSIS; C-ELEGANS; CARCINOMA; CELL; DIFFERENTIATION; HETEROZYGOSITY; CHROMOSOME; EXPRESSION	DCC (deleted in colorectal cancer), a candidate tumor suppressor gene located in chromosome band 18q21.2, encodes a transmembrane protein of 1447 amino acids. Neogenin, a protein with nearly 50% amino acid identity to DCC, was recently identified because of its dynamic expression in the developing nervous system and gastrointestinal tract of the chicken. To explore a role for the human neogenin (NGN) gene in cancer, we have isolated cDNAs for two alternatively spliced forms of NGN, encoding proteins of 1461 and 1408 amino acids. Fluorescence in situ hybridization studies (FISH) localized NGN in chromosome band 15q22, a region infrequently affected by alterations in cancer. NGN transcripts of about 7.5 and 5.5 kb were detected in all adult tissues studied. In contrast to the frequent loss of DCC expression, no alterations in NGN expression were observed in more than 50 cancers studied, including glioblastoma, medulloblastoma, neuroblastoma, colorectal, breast, cervical and pancreatic cancer cell lines and xenografts. Based on their sequence conservation and similar expression during development, DCC and NGN may have related functions. However, the chromosomal location and ubiquitous expression of NGN in various human tumors suggest it is infrequently altered in cancer.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV MED & MOL GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; St Jude Children's Research Hospital; Duke University					NATIONAL CANCER INSTITUTE [R01CA070097, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71907, CA70097, CA23009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHAN S, 1995, WORM BREEDERS GAZETT, V13, P48; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; CLIBY W, 1993, CANCER RES, V53, P2393; Cooper HM, 1995, ONCOGENE, V11, P2243; CULOTTI JG, 1994, CURR OPIN GENET DEV, V4, P587, DOI 10.1016/0959-437X(94)90077-G; Ekstrand BC, 1995, ONCOGENE, V11, P2393; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1995, CLIN ONCOLOGY, P11; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; FUJINO T, 1994, CANCER RES, V54, P4294; HAHN SA, 1995, CANCER RES, V55, P4670; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KNOWLES MA, 1994, CANCER RES, V54, P531; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; MITRA AB, 1994, CANCER RES, V54, P4481; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; REALE MA, 1994, CANCER RES, V54, P4493; Reale MA, 1996, CLIN CANCER RES, V2, P1097; SATO T, 1990, CANCER RES, V50, P7184; Schold S C Jr, 1983, J Neurooncol, V1, P5; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SEYMOUR AB, 1994, CANCER RES, V54, P2761; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; Wick W, 1996, ONCOGENE, V12, P973; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	40	72	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1129	1136		10.1038/sj.onc.1200935	http://dx.doi.org/10.1038/sj.onc.1200935			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121761				2022-12-25	WOS:A1997WM78200001
J	Cook, SJ; Beltman, J; Cadwallader, KA; McMahon, M; McCormick, F				Cook, SJ; Beltman, J; Cadwallader, KA; McMahon, M; McCormick, F			Regulation of mitogen-activated protein kinase phosphatase-1 expression by extracellular signal-related kinase-dependent and Ca2+-dependent signal pathways in rat-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; DUAL-SPECIFICITY PHOSPHATASE; MAP KINASE; TYROSINE-PHOSPHATASE; LYSOPHOSPHATIDIC ACID; PLASMA-MEMBRANE; ENCODED PROTEIN; GROWTH-FACTORS; HEAT-SHOCK; IN-VITRO	Stimulation of Rat-1 cells with lysophosphatidic acid (LPA) or epidermal growth factor (EGF) results in a biphasic, sustained activation of extracellular signal-regulated kinase 1 (ERK1). Pretreatment of Rat-1 cells with either cycloheximide or sodium orthovanadate had Little effect on the early peak of ERK1 activity but potentiated the sustained phase, Cycloheximide also potentiated ERK1 activation in Rat-1 cells expressing Delta Raf-1:ER, an estradiol-regulated form of the oncogenic, human Raf-l, Since cycloheximide did not potentiate MEK activity but abrogated the expression of mitogen-activated protein kinase phosphatase (MKP-1) normally seen in response to EGF and LPA, we speculated that the level of MKP-1 expression may be an important regulator of ERK1 activity in Rat-1 cells, Inhibition of LPA-stimulated MEK and ERR activation with PD98059 and pertussis toxin, a selective inhibitor of G(i)-protein-coupled signaling pathways, reduced LPA-stimulated MKP-1 expression by only 50%, suggesting the presence of additional MEK- and ERR-independent pathways for MKP-1 expression, Specific activation of the MEK/ERK pathway by Delta Raf-1:ER had little or no effect on MKP-1 expression, suggesting that activation of the Raf/MEK/ERK pathway is necessary but not sufficient for MKP-1 expression in Rat-1 cells, Activation of PKC played little part in growth factor-stimulated MKP-1 expression, but LPA- and EGF-induced MKP-1 expression was blocked by buffering [Ca2+](i), leading to a potentiation of the sustained phase of ERK1 activation without potentiating MEK activity, in Rat-1 Delta Raf-1:ER cells, we observed a strong synergy of MKP-1 expression when cells were stimulated with estradiol, in the presence of ionomycin, phorbol la-myristate 13-acetate, or okadaic acid under conditions where these agents did not synergize for ERR activation, These results suggest that activation of the Raf/MEK/ERK pathway is insufficient to induce expression of MKP-1 but instead requires other signals, such as Ca2+, to fully reconstitute the response seen with growth factors. In this way, ERR-dependent and -independent signals may regulate MKP-1 expression, the magnitude of sustained ERK1 activity, and therefore gene expression.	DNAX RES INST MOL & CELLULAR BIOL INC,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Cook, SJ (corresponding author), ONYX PHARMACEUT INC,3031 RES DR,RICHMOND,CA 94806, USA.		McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042	NIGMS NIH HHS [GM16575] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; King AG, 1995, ONCOGENE, V11, P2553; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Muda M, 1996, J BIOL CHEM, V271, P4319; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SAVILLE MK, 1994, BIOCHEM J, V301, P407, DOI 10.1042/bj3010407; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209	59	107	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13309	13319		10.1074/jbc.272.20.13309	http://dx.doi.org/10.1074/jbc.272.20.13309			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148952	hybrid			2022-12-25	WOS:A1997WZ38400065
J	Sagawa, K; Swaim, W; Zhang, J; Unsworth, E; Siraganian, RP				Sagawa, K; Swaim, W; Zhang, J; Unsworth, E; Siraganian, RP			Aggregation of the high affinity IgE receptor results in the tyrosine phosphorylation of the surface adhesion protein PECAM-1 (CD31)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; MAST-CELLS; IN-VIVO; MOLECULE-1 PECAM-1; HISTAMINE-RELEASE; KINASE P72(SYK); BINDING	One of the earliest events after aggregation of the high affinity receptor for IgE (Fc epsilon RI) on mast cells is the activation of protein tyrosine kinases resulting in tyrosine phosphorylation of numerous proteins, Using a monoclonal antibody raised against the rat basophilic leukemia RBL-2H3 cells, we identified that platelet/endothelial cell adhesion molecule 1 (PECAM-1 or CD31) was tyrosine phosphorylated in these cells, Aggregation of PECAM-1 did not induce a detectable increase in its tyrosine phosphorylation, nor did it result in degranulation, However, the minimal tyrosine phosphorylation of PECAM-1 in nonstimulated cells was dramatically increased after Fc epsilon RI aggregation, This receptor-induced tyrosine phosphorylation of PECAM-1 was an early event, independent of Ca2+ influx or of the activation of protein kinase C and of cell adhesion, PECAM-1 is an adhesion molecule that is required for the transmigration of leukocytes across the endothelium into sites of inflammation, Therefore tyrosine phosphorylation of PECAM-1 may modulate its interaction with other molecules, thereby regulating the migration of basophils into inflammatory sites.	NIDR,IMMUNOL LAB,NIH,BETHESDA,MD 20892; US FDA,FACIL BIOTECHNOL RESOURCES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); US Food & Drug Administration (FDA)								ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BERMAN ME, 1995, J IMMUNOL, V154, P299; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Busse WW, 1993, ALLERGY PRINCIPLES P, P105; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; Hamawy MM, 1997, J IMMUNOL METHODS, V201, P11, DOI 10.1016/S0022-1759(96)00197-4; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KIHARA H, 1994, J BIOL CHEM, V269, P22427; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; MULLER WA, 1995, J LEUKOCYTE BIOL, V57, P523, DOI 10.1002/jlb.57.4.523; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Murohara T, 1996, J IMMUNOL, V156, P3550; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; ORTEGA E, 1991, INT IMMUNOL, V3, P333, DOI 10.1093/intimm/3.4.333; ORTEGA E, 1988, EMBO J, V7, P4101, DOI 10.1002/j.1460-2075.1988.tb03304.x; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; SIRAGANIAN RP, 1983, METHOD ENZYMOL, V92, P17; SKUBITZ KM, 1994, J IMMUNOL, V152, P5902; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Stewart RJ, 1996, J IMMUNOL, V156, P1221; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; XIE Y, 1993, P NATL ACAD SCI USA, V90, P5569, DOI 10.1073/pnas.90.12.5569; YAN HC, 1995, J BIOL CHEM, V270, P23672, DOI 10.1074/jbc.270.40.23672; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	53	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13412	13418		10.1074/jbc.272.20.13412	http://dx.doi.org/10.1074/jbc.272.20.13412			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148965	hybrid			2022-12-25	WOS:A1997WZ38400078
J	Via, LE; Deretic, D; Ulmer, RJ; Hibler, NS; Huber, LA; Deretic, V				Via, LE; Deretic, D; Ulmer, RJ; Hibler, NS; Huber, LA; Deretic, V			Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOME FUSION; INTRACELLULAR PATHOGENS; CULTURED MACROPHAGES; MAMMALIAN-CELLS; ENDOSOME FUSION; PLASMA-MEMBRANE; PROTEIN; TUBERCULOSIS; TRANSPORT; COMPARTMENTS	Mycobacterium tuberculosis and the closely related organism Mycobacterium bovis can survive and replicate inside macrophages. Intracellular survival is at least in part attributed to the failure of mycobacterial phagosomes to undergo fusion with lysosomes, The transformation of phagosomes into phagolysosomes involves gradual acquisition of markers from the endosomal compartment, Members of the rab family of small GTPases which confer fusion competence in the endocytic pathway are exchanged sequentially onto the phagosomal membranes in the course of their maturation, To identify the step at which the fusion capability of phagosomes containing mycobacteria is compromised, we purified green fluorescent protein-labeled M. bovis BCG phagosomal compartments (MPC) and compared GTP-binding protein profiles of these vesicles with latex bead phagosomal compartments (LBC), We report that the MPC do not acquire rab7, specific for late endosomes, even 7 days postinfection, whereas this GTP-binding protein is present on the LBC within hours after phagocytosis, By contrast, rab5 is retained and enriched with time on the MPC, suggesting fusion competence with an early endosomal compartment. Prior infection of macrophages with M, bovis BCG also affected the dynamics of rab5 and rab7 acquisition by subsequently formed LBC, Selective exclusion of rab7, coupled with the retention of rab5 on the mycobacterial phagosome, may allow organisms from the M tuberculosis complex to avert the usual physiological destination of phagocytosed material.	UNIV MICHIGAN, SCH MED, DEPT IMMUNOL & MICROBIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT OPHTHALMOL & ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA; RES INST MOL PATHOL, A-1030 VIENNA, AUSTRIA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Texas System; University of Texas Health San Antonio; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Huber, Lukas Alfons/AAM-3499-2021; Via, Laura/AAD-3917-2021	Via, Laura/0000-0001-6074-9521; Huber, Lukas Alfons/0000-0003-1116-2120; Deretic, Vojo/0000-0002-3624-5208	NIAID NIH HHS [AI35217] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035217] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALPUCHEARANDA CM, 1995, INFECT IMMUN, V63, P4456, DOI 10.1128/IAI.63.11.4456-4462.1995; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAKRABORTY P, 1994, METHOD CELL BIOL, V45, P261; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; CLEMENS DL, 1996, TRENDS MICROBIOL, V4, P133; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; Dannenberg Arthur M. Jr., 1994, P459; DECHASTELLIER C, 1993, INFECT IMMUN, V61, P3775, DOI 10.1128/IAI.61.9.3775-3784.1993; DECHASTELLIER C, 1995, EUR J CELL BIOL, V68, P167; DERETIC D, 1995, J CELL SCI, V108, P215; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; GARCIADELPORTILLO F, 1995, TRENDS MICROBIOL, V3, P373, DOI 10.1016/S0966-842X(00)88982-9; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; HUBER LA, 1994, P NATL ACAD SCI USA, V91, P7874, DOI 10.1073/pnas.91.17.7874; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LOWRIE DB, 1975, NATURE, V254, P600, DOI 10.1038/254600a0; MCDONOUGH KA, 1993, INFECT IMMUN, V61, P2763, DOI 10.1128/IAI.61.7.2763-2773.1993; MERESSE S, 1995, J CELL SCI, V108, P3349; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; MOSSER DM, 1994, STRATEGIES INTRACELL, V2, P191; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; Russell DG, 1996, J IMMUNOL, V156, P4764; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SMALL PLC, 1994, SCIENCE, V263, P637, DOI 10.1126/science.8303269; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1995, J BIOL CHEM, V270, P25541, DOI 10.1074/jbc.270.43.25541; SPARGO BJ, 1991, P NATL ACAD SCI USA, V88, P737, DOI 10.1073/pnas.88.3.737; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; UKKONEN P, 1986, J EXP MED, V163, P952, DOI 10.1084/jem.163.4.952; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Via LE, 1996, J BACTERIOL, V178, P3314, DOI 10.1128/jb.178.11.3314-3321.1996; XU SM, 1994, J IMMUNOL, V153, P2568; ZERIAL M, 1992, METHOD ENZYMOL, V219, P398; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	61	428	434	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13326	13331		10.1074/jbc.272.20.13326	http://dx.doi.org/10.1074/jbc.272.20.13326			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148954	hybrid			2022-12-25	WOS:A1997WZ38400067
J	Colonna, TE; Huynh, L; Fambrough, DM				Colonna, TE; Huynh, L; Fambrough, DM			Subunit interactions in the Na,K-ATPase explored with the yeast two-hybrid system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; NA+-K+-ATPASE; PROTEIN-PROTEIN INTERACTIONS; H,K-ATPASE BETA-SUBUNIT; ALPHA-SUBUNIT; INTRACELLULAR-TRANSPORT; XENOPUS-OOCYTES; FUNCTIONAL EXPRESSION; EXTRACELLULAR DOMAIN; ADHESION MOLECULE	Subunit interactions of the alpha 1- and beta 1-subunits of the chicken Na,K-ATPase were explored with the yeast two-hybrid system, Gal4-fusion proteins containing domains of the alpha 1- and beta 1-subunits were designed for examining both intersubunit and intrasubunit protein-protein interactions, Regions of the alpha- and beta-subunits known to be involved in alpha-beta-subunit assembly were positive in two-hybrid assay, supporting the validity of the assays. A library of beta-subunit ectodomains with C-terminal truncations was screened to find the maximal truncation retaining an interaction with the alpha-subunit extracellular H7H8 loop (where H7 refers to the seventh membrane span, and so on), The maximal truncation removed all the cysteines involved in disulfide bridges, leaving only 63 amino acids of the beta-subunit ectodomain. Scanning alanine mutagenesis led to identification of an evolutionarily conserved sequence of four amino acids (SYGQ) in the extracellular H7H8 loop of the alpha-subunit that is crucial to alpha-beta-intersubunit interactions. Oligomerization studies with single domains failed to detect self-association of either of the two large cytosolic loops (H2H3 and H4H5) within the alpha-subunit. However, evidence was found for an interaction between these two cytoplasmic loops.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023241] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23241] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P9897, DOI 10.1021/bi00031a011; BLANCO G, 1994, J BIOL CHEM, V269, P23420; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; FAMBROUGH DM, 1983, J BIOL CHEM, V258, P3926; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; FROEHLICH JP, 1994, SODIUM PUMP, P441; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HORISBERGER JD, 1994, NA K ATPASE STRUCTUR; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORDAN C, 1995, J BIOL CHEM, V270, P29971; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; Kone BC., 1991, SODIUM PUMP RECENT D, P265; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; LEMAS MV, 1994, J BIOL CHEM, V269, P18651; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; Mercer Robert W., 1993, V137C, P139; MILLER RP, 1990, BIOCHEMISTRY-US, V29, P1524, DOI 10.1021/bi00458a025; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NOGUCHI S, 1990, BIOCHIM BIOPHYS ACTA, V1023, P247, DOI 10.1016/0005-2736(90)90420-S; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; NORBY JG, 1989, BIOCHEM SOC T, V17, P806, DOI 10.1042/bst0170806; NORBY JG, 1989, J BIOL CHEM, V264, P19548; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SARVAZYAN NA, 1995, J BIOL CHEM, V270, P26528, DOI 10.1074/jbc.270.44.26528; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; TAKEYASU K, 1990, AM J PHYSIOL, V259, pC619, DOI 10.1152/ajpcell.1990.259.4.C619; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; WELLS JA, 1991, METHOD ENZYMOL, V202, P390	53	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12366	12372		10.1074/jbc.272.19.12366	http://dx.doi.org/10.1074/jbc.272.19.12366			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139681	hybrid			2022-12-25	WOS:A1997WY82900018
J	Takahashi, M; Pischetsrieder, M; Monnier, VM				Takahashi, M; Pischetsrieder, M; Monnier, VM			Molecular cloning and expression of amadoriase isoenzyme (fructosyl amine:oxygen oxidoreductase, EC 1.5.3) from Aspergillus fumigatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP SOIL STRAIN; GLYCATED PROTEIN; ACID OXIDASE; PURIFICATION; DEGRADATION; PRODUCT; BINDING; IDENTIFICATION; PENTOSIDINE; PRECURSORS	Amadoriase is an enzyme catalyzing the oxidative deglycation of Amadori products to yield corresponding amino acids, glucosone, and H2O2. We previously reported the purification and characterization of two amadoriase isozymes from Aspergillus sp, that degrade both glycated low molecular weight amines and amino acids (Takahashi, M., Pischetsrieder, M., and Monnier, V. M. (1997) J. Biol, Chem. 272, 3437-3443), To identify the primary structure of the enzymes, we have prepared a cDNA library from Aspergillus fumigatus induced with fructosyl propylamine and isolated a clone using polyclonal anti-amadoriase II antibody, The primary structure of the enzyme deduced from the nucleotide sequence comprises 438 amino acid residues with a predicted molecular mass of 48,798 Da. The deduced primary structure exhibits the presence of an ADP-binding motif near the NH2 terminus. The identity of the amadoriase II cDNA was further confirmed by expression in Escherichia coli cells with an inducible expression system, Northern blotting analysis revealed that amadoriase II was induced by fructosyl propylamine in a dose-dependent manner.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Monnier, Vincent M/B-1371-2009; Takahashi, Motoko/I-3154-2013	Takahashi, Motoko/0000-0002-2112-6142	NEI NIH HHS [EY07099] Funding Source: Medline; NIA NIH HHS [AG05601] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER JR, 1994, CLIN CHEM, V40, P1950; Baynes JW., 1989, PROG CLIN BIOL RES, V304, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DYER DG, 1991, J BIOL CHEM, V266, P11654; GERHARDINGER C, 1995, J BIOL CHEM, V270, P218, DOI 10.1074/jbc.270.1.218; GERHARDINGER C, 1994, J BIOL CHEM, V269, P27297; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; HORIUCHI T, 1989, AGR BIOL CHEM TOKYO, V53, P103, DOI 10.1080/00021369.1989.10869245; KAWAKISHI S, 1991, CARBOHYD RES, V211, P167, DOI 10.1016/0008-6215(91)84156-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SAKAI Y, 1995, BIOSCI BIOTECH BIOCH, V59, P487, DOI 10.1271/bbb.59.487; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SALAZAR R, 1995, BBA-MOL CELL RES, V1266, P57, DOI 10.1016/0167-4889(94)00221-Y; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saxena AK, 1996, J BIOL CHEM, V271, P32803, DOI 10.1074/jbc.271.51.32803; SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x; Takahashi M, 1997, J BIOL CHEM, V272, P3437, DOI 10.1074/jbc.272.6.3437; WATANABE N, 1990, AGR BIOL CHEM TOKYO, V54, P1063, DOI 10.1080/00021369.1990.10870059; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WU VY, 1994, BIOCHEM BIOPH RES CO, V198, P734, DOI 10.1006/bbrc.1994.1106; Yoshida N, 1996, EUR J BIOCHEM, V242, P499, DOI 10.1111/j.1432-1033.1996.0499r.x; YOSHIDA N, 1995, APPL ENVIRON MICROB, V61, P4487, DOI 10.1128/AEM.61.12.4487-4489.1995; ZIYADEH FN, 1993, MOL CELL BIOCHEM, V125, P19, DOI 10.1007/BF00926830; 1993, Patent No. 5261501	29	51	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12505	12507		10.1074/jbc.272.19.12505	http://dx.doi.org/10.1074/jbc.272.19.12505			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139700	hybrid			2022-12-25	WOS:A1997WY82900037
J	Batra, RK; Olsen, JC; Hoganson, DK; Caterson, B; Boucher, RC				Batra, RK; Olsen, JC; Hoganson, DK; Caterson, B; Boucher, RC			Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans glycosaminoglycans in malignant pleural effusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SURFACE HEPARAN-SULFATE; HERPES-SIMPLEX VIRUS; APE LEUKEMIA-VIRUS; MONOCLONAL-ANTIBODIES; SELECTIVE INHIBITORS; MESOTHELIAL CELLS; EPITHELIAL-CELLS; VECTORS; EXPRESSION	Gene therapy may be an important adjuvant for treating cancer in the pleural space. The initial results of retroviral gene transfer to cancer cells in malignant pleural effusions revealed that transduction was markedly inhibited, and studies to characterize the inhibitory factor(s) were performed. The inhibition was contained within the soluble, rather than cellular, components of the effusions and was demonstrated with amphotropic, gibbon ape leukemia virus, and vesicular stomatitis virus-glycoprotein pseudotyped retroviral vectors. After excluding complement proteins, a series of studies identified chondroitin sulfates (CSs) as the inhibitory substances. First, treatment of the effusions with mammmalian hyaluronidase or chondroitinases, but not Streptomyces hyaluronidase, abolished the inhibitory activity, Second, addition of exogenous CS glycosaminoglycans mimicked the inhibition observed with pleural effusions. Third, immunoassays and biochemical analyses of malignant pleural effusion specimens revealed CS in relevant concentrations within pleural fluid. Fourth, proteoglycans/glycosaminoglycans isolated from the effusions inhibited retroviral gene transfer. Analyses of the mechanism of inhibition indicate that the chondroitin sulfates interact with vector in solution rather than at the target cell surface. These results suggest that drainage of the malignant pleural effusion, and perhaps enzymatic pretreatment of the pleural cavity, will be necessary for efficient retroviral vector mediated gene delivery to pleural metastases.	UNIV WALES COLL CARDIFF,CONNECT TISSUE BIOL LAB,CARDIFF CF1 3US,S GLAM,WALES	Cardiff University	Batra, RK (corresponding author), UNIV N CAROLINA,DEPT MED,DIV PULM DIS,7011 THURSTON BOWLES BLDG,CHAPEL HILL,NC 27599, USA.		Caterson, Bruce/A-8085-2010	Caterson, Bruce/0000-0001-6016-0661; Batra, Raj K./0000-0002-1126-543X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007106, P01HL051818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032666] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000046] Funding Source: Medline; NHLBI NIH HHS [HL51818, HL07106] Funding Source: Medline; NIAMS NIH HHS [AR32666] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM MA, 1991, J VIROL, V65, P4985, DOI 10.1128/JVI.65.9.4985-4990.1991; Alberts B., 1989, MOL BIOL CELL; BABA M, 1990, ANTIMICROB AGENTS CH, V34, P134, DOI 10.1128/AAC.34.1.134; BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; BATRA RK, 1996, AM J RESP CRIT CARE, V153, pA111; Baumann MH, 1996, EXP LUNG RES, V22, P101, DOI 10.3109/01902149609074020; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BROADDUS VC, 1994, TXB RESP MED, P2145; CALLAHAN LN, 1991, J VIROL, V65, P1543, DOI 10.1128/JVI.65.3.1543-1550.1991; CATERSON B, 1985, FED PROC, V44, P386; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; DERBY MA, 1978, HISTOCHEM J, V10, P529, DOI 10.1007/BF01003135; DEY P, 1992, CONNECT TISSUE RES, V28, P317, DOI 10.3109/03008209209016823; Iozzo R V, 1994, EXS, V70, P199; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; KNEPPER PA, 1984, INVEST OPHTH VIS SCI, V25, P286; LAMBERG SI, 1974, J INVEST DERMATOL, V63, P433, DOI 10.1111/1523-1747.ep12680346; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; Liu ML, 1996, J VIROL, V70, P2497, DOI 10.1128/JVI.70.4.2497-2502.1996; MAKAROV SS, 1995, GENE THER, V2, P424; MCCLAIN DS, 1994, VIROLOGY, V198, P690, DOI 10.1006/viro.1994.1081; MEYER K, 1960, ENZYMES HYDROLYTIC A, P447; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLIGAN SA, 1995, EXP LUNG RES, V21, P559, DOI 10.3109/01902149509031759; NAKANO T, 1986, CANCER-AM CANCER SOC, V57, P106, DOI 10.1002/1097-0142(19860101)57:1<106::AID-CNCR2820570122>3.0.CO;2-C; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; OLSEN JC, 1993, NUCLEIC ACIDS RES, V21, P663, DOI 10.1093/nar/21.3.663; OLSEN JC, 1995, HUM GENE THER, V6, P1195, DOI 10.1089/hum.1995.6.9-1195; OWENS MW, 1993, AM J PHYSIOL, V265, pL382, DOI 10.1152/ajplung.1993.265.4.L382; RASMUSSEN KN, 1967, SCAND J RESPIR DIS, V48, P366; RENNARD SI, 1984, AM REV RESPIR DIS, V130, P267; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; ROTHER RP, 1995, HUM GENE THER, V6, P429, DOI 10.1089/hum.1995.6.4-429; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUSSELL DW, 1995, HUM GENE THER, V6, P635, DOI 10.1089/hum.1995.6.5-635; SAHN SA, 1993, CLIN CHEST MED, V14, P189; SHIEH MT, 1994, J VIROL, V68, P1224, DOI 10.1128/JVI.68.2.1224-1228.1994; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; SORRELL JM, 1990, J HISTOCHEM CYTOCHEM, V38, P393, DOI 10.1177/38.3.1689338; SPEAR PG, 1992, ADV EXP MED BIOL, V313, P341; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219	46	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11736	11743		10.1074/jbc.272.18.11736	http://dx.doi.org/10.1074/jbc.272.18.11736			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115227	Green Accepted, Green Published, hybrid			2022-12-25	WOS:A1997WX56900015
J	Schievella, AR; Chen, JH; Graham, JR; Lin, LL				Schievella, AR; Chen, JH; Graham, JR; Lin, LL			MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CYTOSOLIC PHOSPHOLIPASE A(2); FACTOR TNF RECEPTOR; NF-KAPPA-B; MAP KINASE; ARACHIDONIC-ACID; BINDING PROTEINS; HUMAN PLATELETS; AP-1 ACTIVITY; FACTOR-ALPHA	The death domain of the type 1 tumor necrosis factor receptor (TNFR1) mediates interactions with several proteins involved in signaling the downstream effects of TNF. We have used the yeast interaction trap to isolate a protein, MADD, that associates with the death domain of TNFR1 through its own C-terminal death domain. MADD interacts with TNFR1 residues that are critical for signal generation and coimmunoprecipitates with TNFR1, implicating MADD as a component of the TNFR1 signaling complex. Importantly, we have found that overexpression of MADD activates the mitogen-activated protein (MAP) kinase extracellular signal-regulated kinase (ERK), and expression of the MADD death domain stimulates both the ERK and c-JUN N-terminal kinase MAP kinases and induces the phosphorylation of cytosolic phospholipase A(2). These data indicate that MADD links TNFR1 with MAP kinase activation and arachidonic acid release and provide further insight into the mechanisms by which TNF exerts its pleiotropic effects.	GENET INST INC,SMALL MOL DRUG DISCOVERY GRP,CAMBRIDGE,MA 02140									ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WATERMAN WH, 1995, BIOCHEM BIOPH RES CO, V209, P271, DOI 10.1006/bbrc.1995.1499; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WONG GHW, 1992, J IMMUNOL, V149, P3550	54	136	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12069	12075		10.1074/jbc.272.18.12069	http://dx.doi.org/10.1074/jbc.272.18.12069			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115275	hybrid			2022-12-25	WOS:A1997WX56900063
J	Lee, JM; Greenleaf, AL				Lee, JM; Greenleaf, AL			Modulation of RNA polymerase II elongation efficiency by C-terminal heptapeptide repeat domain kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ELONGATION; PHOSPHORYLATION STATE; LARGEST SUBUNIT; PROTEIN-KINASE; CTD; 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE; INITIATION; INVITRO; TFIIH; GENE	Hyperphosphorylation of the C-terminal heptapeptide repeat domain (CTD) of the RNA polymerase II largest subunit has been suggested to play a key role in regulating transcription initiation and elongation, To facilitate investigating functional consequences of CTD phosphorylation we developed new templates, the double G-less cassettes, which make it possible to assay simultaneously the level of initiation and the efficiency of elongation. Using these templates, we examined the effects of yeast CTD kinase I or CTD kinase inhibitors on transcription and CTD phosphorylation in HeLa nuclear extracts. Our results showed that polymerase II elongation efficiency and CTD phosphorylation are greatly reduced by CTD kinase inhibitors, whereas both are greatly increased by CTD kinase I; in contrast, transcription initiation is much less affected. These results demonstrate that CTD kinase I modulates the elongation efficiency of RNA polymerase II and are consistent with the idea that one function of CTD phosphorylation is to promote effective production of long transcripts by stimulating the elongation efficiency of RNA polymerase II.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040505] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40505] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; Egyhazi E, 1996, CHROMOSOMA, V104, P422, DOI 10.1007/s004120050134; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Herrmann CH, 1996, NUCLEIC ACIDS RES, V24, P501, DOI 10.1093/nar/24.3.501; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Steinmetz EJ, 1996, MOL CELL BIOL, V16, P6993, DOI 10.1128/mcb.16.12.6993; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WEST ML, 1995, GENETICS, V140, P1223; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YUREV A, 1996, P NATL ACAD SCI USA, V93, P6975	42	83	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					10990	10993						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9110987				2022-12-25	WOS:A1997WW00900003
J	Schaller, A; Martin, F; Muller, B				Schaller, A; Martin, F; Muller, B			Characterization of the calf thymus hairpin-binding factor involved in histone pre-mRNA 3' end processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR-RNA; MESSENGER-RNA; STEM-LOOP; CELL-CYCLE; U7 SNRNA; SEQUENCES; PRECURSOR; INVITRO; PROTEIN; GENERATION	Using ion exchange chromatography we have enriched the RNA hairpin-binding factor involved in histone pre-mRNA processing from calf thymus whole cell extract. We demonstrate that the interaction of the factor with its target RNA sequence, the hairpin structure located at the 3' end of mature histone mRNA, is sequence-specific and highly salt-resistant. We have developed a simple in vitro system which allows detection of activities stimulating histone pre-mRNA 3' end processing, based on mouse cell nuclear extract fractionated by Mono Q column chromatography. Using this system, we show that the bovine hairpin-binding factor participates in histone pre-mRNA 3' end processing in vitro. We have further purified the hairpin-binding factor in form of a RNA protein complex by RNA-mediated elution from phosphocellulose. This led to a fraction highly enriched for 2 proteins of 40 and 43 kDa.	UNIV BERN,ABT ENTWICKLUNGSBIOL,INST ZOOL,CH-3012 BERN,SWITZERLAND	University of Bern			Schaller, André/L-4174-2018; MARTIN, Franck/D-9042-2015	Schaller, André/0000-0001-5174-5764; MARTIN, Franck/0000-0001-9724-4025; Muller, Berndt/0000-0003-1279-5421				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTEN M, 1988, EMBO J, V7, P801, DOI 10.1002/j.1460-2075.1988.tb02878.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dominski Z, 1995, RNA, V1, P915; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; ECKNER R, 1992, NUCLEIC ACIDS RES, V20, P1023, DOI 10.1093/nar/20.5.1023; GALLI G, 1983, CELL, V34, P823, DOI 10.1016/0092-8674(83)90539-1; GICK O, 1987, P NATL ACAD SCI USA, V84, P8937, DOI 10.1073/pnas.84.24.8937; GICK O, 1986, EMBO J, V5, P1319, DOI 10.1002/j.1460-2075.1986.tb04362.x; Hanson RJ, 1996, BIOCHEMISTRY-US, V35, P2146, DOI 10.1021/bi9521856; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; LINMARQ N, 1995, J MOL BIOL, V245, P81, DOI 10.1006/jmbi.1994.0008; Martin F, 1997, EMBO J, V16, P769, DOI 10.1093/emboj/16.4.769; MEIER VS, 1989, NUCLEIC ACIDS RES, V17, P795, DOI 10.1093/nar/17.2.795; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOWRY KL, 1987, SCIENCE, V238, P1682, DOI 10.1126/science.2825355; MOWRY KL, 1989, MOL CELL BIOL, V9, P3105, DOI 10.1128/MCB.9.7.3105; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANDEY NB, 1991, NUCLEIC ACIDS RES, V19, P5653, DOI 10.1093/nar/19.20.5653; PANDEY NB, 1994, MOL CELL BIOL, V14, P1709, DOI 10.1128/MCB.14.3.1709; SCHALLER A, 1995, CHARACTERIZATION PAR; SCHAUFELE F, 1986, NATURE, V323, P777, DOI 10.1038/323777a0; SCHUMPERLI D, 1988, TRENDS GENET, V4, P187, DOI 10.1016/0168-9525(88)90074-1; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SMITH HO, 1991, P NATL ACAD SCI USA, V88, P9784, DOI 10.1073/pnas.88.21.9784; SOLDATI D, 1988, MOL CELL BIOL, V8, P1518, DOI 10.1128/MCB.8.4.1518; SPYCHER C, 1994, NUCLEIC ACIDS RES, V22, P4023, DOI 10.1093/nar/22.20.4023; STAUBER C, 1986, EMBO J, V5, P3297, DOI 10.1002/j.1460-2075.1986.tb04643.x; STREIT A, 1993, NUCLEIC ACIDS RES, V21, P1569, DOI 10.1093/nar/21.7.1569; STRUB K, 1984, EMBO J, V3, P2801, DOI 10.1002/j.1460-2075.1984.tb02212.x; VASSEROT AP, 1989, P NATL ACAD SCI USA, V86, P4345, DOI 10.1073/pnas.86.12.4345; WANG Z, 1997, GENE DEV, V10, P3028; WILLIAMS AS, 1994, NUCLEIC ACIDS RES, V22, P4660, DOI 10.1093/nar/22.22.4660; WILLIAMS AS, 1995, NUCLEIC ACIDS RES, V23, P654, DOI 10.1093/nar/23.4.654	34	7	7	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10435	10441						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099685				2022-12-25	WOS:A1997WV26200019
J	Luo, WP; Wood, CG; Earley, K; Hung, MC; Lin, SH				Luo, WP; Wood, CG; Earley, K; Hung, MC; Lin, SH			Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): The adhesion and growth suppression are mediated by different domains	ONCOGENE			English	Article						cell adhesion molecule; breast cancer; tumor suppression	BILIARY GLYCOPROTEIN-I; TUMOR-SUPPRESSOR; C-CAM; CARCINOEMBRYONIC ANTIGEN; SECONDARY-STRUCTURE; CYTOPLASMIC DOMAIN; LIVER DEVELOPMENT; PROSTATE-CANCER; RAT-TISSUES; ECTO-ATPASE	C-CAM1 is an epithelial adhesion molecule of immunoglobulin supergene family and has been implicated in the growth suppression of prostate cancer cells. Here we show that C-CAM1 can also suppress the tumorigenicity of breast cancer cells. These observations suggest that C-CAM1 may be a general growth suppressor in epithelial cells. In addition, we have identified the cytoplasmic domain, but not the extracellular adhesion domain, of C-CAM1 as critical for the growth suppression. Thus, the adhesion and the growth suppression functions of C-CAM1 are independent of each other. Furthermore, mutation at the tyrosine phosphorylation site in the cytoplasmic domain of C-CAM1 did not obliterate C-CAM1's growth suppression function, suggesting that tyrosine phosphorylation is not involved in the signal transduction pathway leading to cell growth suppression. These studies provide the structural basis for future development of therapeutics that may selectively activate C-CAM1's growth suppression function.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; ROSENBERG M, 1993, CANCER RES, V53, P4938; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; THOMPSON NL, 1993, CELL GROWTH DIFFER, V4, P257	27	82	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1697	1704		10.1038/sj.onc.1200999	http://dx.doi.org/10.1038/sj.onc.1200999			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135071				2022-12-25	WOS:A1997WR89300008
J	David, G; Terris, B; Marchio, A; Lavau, C; Dejean, A				David, G; Terris, B; Marchio, A; Lavau, C; Dejean, A			The acute promyelocytic leukemia PML-RAR alpha protein induces hepatic preneoplastic and neoplastic lesions in transgenic mice	ONCOGENE			English	Article						PML-RAR alpha; APL; translocation; hepatocarcinoma; transgenic mice	RETINOIC ACID RECEPTOR; ZINC FINGER GENE; T(1517) TRANSLOCATION; CELL-PROLIFERATION; NUCLEAR RECEPTORS; GROWTH-SUPPRESSOR; FUSION PROTEIN; TGF-ALPHA; HEPATOCARCINOGENESIS; DIFFERENTIATION	The PML-RAR alpha hybrid protein generated by the t(15;17) translocation in acute promyelocytic leukemia (APL) is thought to play a central role in the oncogenic process. However, analysis of the oncogenic activity of the fusion protein in tissue culture assays or in mice has been hampered by its apparent toxicity in multiple murine cells. To circumvent this problem, we generated an inducible line of transgenic mice, MT135, in which the expression of PML-RAR alpha is driven by the metallothionein promoter. After 5 days zinc stimulation, 27 out of 54 mice developed hepatic preneoplasia and neoplasia including foci of basophilic hepatocytes, dysplasia and carcinoma with a significantly higher incidence of lesions in females than in males. The rapid onset of liver pathologies was dependent on overexpression of the transgene since it was not detected in noninduced transgenic animals of the same age. The PML-RAR alpha protein was always present in altered tissues at much higher levels than in the surrounding normal liver tissues. In addition, overexpression of PML-RAR alpha resulted in a strong proliferative response in the hepatocytes. We conclude that overexpression of PML-RAR alpha deregulates cell proliferation and can induce tumorigenic changes in vivo.	INST PASTEUR,UA CNRS,INSERM U163,UNITE RECOMBINAISON & EXPRESS GENET,PARIS,FRANCE; HOP BEAUJON,LAB ANATOMOPATHOL,CLICHY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite			Dejean, Anne/L-5145-2018; Lavau, Catherine/Q-2928-2019; Terris, Benoit/P-1497-2017	Lavau, Catherine/0000-0003-4800-1320; , gregory/0000-0002-3371-4558				ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; BENNOUN M, 1993, AM J PATHOL, V143, P1326; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FACTOR VM, 1993, EXP TOXICOL PATHOL, V45, P239, DOI 10.1016/S0940-2993(11)80399-4; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; Lavau C, 1996, EXP HEMATOL, V24, P544; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TERRIS B, 1995, CANCER RES, V55, P1590; TOSHKOV I, 1990, J CANCER RES CLIN, V116, P581, DOI 10.1007/BF01637078; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEBER E, 1994, CARCINOGENESIS, V15, P1235, DOI 10.1093/carcin/15.6.1235; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	56	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1547	1554		10.1038/sj.onc.1200989	http://dx.doi.org/10.1038/sj.onc.1200989			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129145				2022-12-25	WOS:A1997WQ54800005
J	Lohman, FP; Gibbs, S; Fischer, DF; Borgstein, AMB; vandePutte, P; Backendorf, C				Lohman, FP; Gibbs, S; Fischer, DF; Borgstein, AMB; vandePutte, P; Backendorf, C			Involvement of c-JUN in the regulation of terminal differentiation genes in normal and malignant keratinocytes	ONCOGENE			English	Article						keratinocytes; terminal differentiation; c-JUN; SPRR2; involucrin	CORNIFIED CELL-ENVELOPE; PROLINE-RICH PROTEINS; DELETION MUTANT; FOS; CULTURE; TRANSFORMATION; PROTOONCOGENE; EXPRESSION; EVOLUTION; PROMOTER	In stratifying cultures of human keratinocytes, expression of the proto-oncoprotein c-JUN and the small proline rich 2 (SPRR2) protein, a precursor of the cornified cell envelope, are inversely related. Whereas c-JUN is typically found in basal proliferating cells, SPRR2 is restricted to suprabasal differentiating layers. Malignant keratinocytes (derived from squamous cell carcinoma, SCC) have reduced sprr2 expression, consistent with their low potential to differentiate, and express c-jun at higher levels than normal keratinocytes. A direct relation between c-jun and sprr2 expression was shown in several ways: transient ectopic expression of c-jun inhibits sprr2a promoter activity in normal differentiating cells, whereas in malignant keratinocytes a dominant negative c-jun mutant restored at least partially both the low promoter activity and the expression of endogenous sprr2. These effects are mediated via a 134 bp promoter fragment which does not include the sprr2a AP-1 binding site. Interestingly, in an SCC cell line, constitutively expressing the dominant c-jun mutant, expression of the terminal differentiation marker involucrin is also strongly increased, suggesting that c-JUN is a general modulator of keratinocyte terminal differentiation rather than only affecting the expression of sprr2.	LEIDEN INST CHEM, GENET MOL LAB, NL-2300 RA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT DERMATOL, NL-2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University; Leiden University Medical Center (LUMC)				Fischer, David/0000-0002-6690-0197				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOISJOYEUX B, 1995, J BIOL CHEM, V270, P10204, DOI 10.1074/jbc.270.17.10204; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HILBERG F, 1992, ONCOGENE, V7, P2371; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LICHTENAUERKALIGIS EGR, 1993, HUM MOL GENET, V2, P173, DOI 10.1093/hmg/2.2.173; PONEC M, 1989, IN VITRO CELL DEV B, V25, P689, DOI 10.1007/BF02623721; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; WATT FM, 1991, J CELL SCI, V99, P397	30	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1623	1627		10.1038/sj.onc.1200974	http://dx.doi.org/10.1038/sj.onc.1200974			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129155				2022-12-25	WOS:A1997WQ54800015
J	Dick, FA; Karamanou, S; Trumpower, BL				Dick, FA; Karamanou, S; Trumpower, BL			QSR1, an essential yeast gene with a genetic relationship to a subunit of the mitochondrial cytochrome bc(1) complex, codes for a 60 S ribosomal subunit protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; TRANSPORT; MEMBRANE; DIFFERENTIATION; TRANSLOCATION; VESICLES; IMPORT; RNA	QSR1 (quinol-cytochrome c reductase subunit-requiring) is a highly conserved, essential gene in Saccharomyces cerevisiae that was identified through a synthetic lethal screen by its genetic relationship to QCR6, the gene for subunit 6 (Qcr6p) of the mitochondrial cytochrome be, complex. The function of the QSR1-encoded protein (Qsr1p) and its relationship to the QCR6 encoded protein are unknown. When yeast cell lysates are fractionated by density gradient centrifugation, Qsr1p separates from organelles and sediments with a uniformly sized population of particles that are similar to eukaryotic ribosomes upon velocity gradient centrifugation. When 40 S and 60 S ribosomal subunits are separated on velocity gradients, Qsr1p is found exclusively with the 60 S subunits, where it is a stoichiometric component, Extracts pre pared from qsr1-1 cells are defective in in vitro translation assays relative to the wild type. In yeast cell. lysates in which QCR6 rescues an otherwise lethal qsr1-1 mutation, Qcr6p is found only in mitochondria, both in respiratory-competent cells and in rho(0) cells in which the be, complex is no longer present, These results suggest that suppression of the qsr1-1 mutation by QCR6 occurs by a trans-relationship across the outer mitochondrial membrane.	DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College			Karamanou, Spyridoula/H-7485-2018	Karamanou, Spyridoula/0000-0002-8803-1404	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ADES IZ, 1980, J BIOL CHEM, V255, P9918; ATKIN AL, 1995, MOL BIOL CELL, V6, P611; BARMAN TE, 1969, ENZYME HDB, P377; Chan YL, 1996, BIOCHEM BIOPH RES CO, V225, P952, DOI 10.1006/bbrc.1996.1277; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHMUKH M, 1993, MOL CELL BIOL, V13, P2835, DOI 10.1128/MCB.13.5.2835; DOWDY SF, 1991, NUCLEIC ACIDS RES, V19, P5763, DOI 10.1093/nar/19.20.5763; EISINGER DP, 1993, BIOCHEM BIOPH RES CO, V196, P1227, DOI 10.1006/bbrc.1993.2383; FARMER AA, 1994, HUM MOL GENET, V3, P723, DOI 10.1093/hmg/3.5.723; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GOLDRING ES, 1970, J MOL BIOL, V52, P323, DOI 10.1016/0022-2836(70)90033-1; Hanahan D., 1985, DNA CLONING; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; Koller HT, 1996, YEAST, V12, P53, DOI 10.1002/(SICI)1097-0061(199601)12:1<53::AID-YEA886>3.0.CO;2-M; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOWITZ MJ, 1991, METHOD ENZYMOL, V194, P536; MARTY I, 1993, PLANT J, V4, P265, DOI 10.1046/j.1365-313X.1993.04020265.x; MASSON JY, 1996, GENE, V170, P143; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; Moore DD, 1995, GLOB MOB SURV; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; SCHMITT ME, 1991, J BIOL CHEM, V266, P14958; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRON T, 1995, J BIOL CHEM, V270, P9961, DOI 10.1074/jbc.270.17.9961; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7; WISE JA, 1991, METHOD ENZYMOL, V194, P405; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; YANG MJ, 1994, J BIOL CHEM, V269, P1270; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	38	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13372	13379		10.1074/jbc.272.20.13372	http://dx.doi.org/10.1074/jbc.272.20.13372			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148960	hybrid			2022-12-25	WOS:A1997WZ38400073
J	Pardanani, A; Gibson, QH; Colotti, G; Royer, WE				Pardanani, A; Gibson, QH; Colotti, G; Royer, WE			Mutation of residue Phe(97) to Leu disrupts the central allosteric pathway in Scapharca dimeric hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; INAEQUIVALVIS; KINETICS; CONFORMATION; RESOLUTION; REDUCTION; PROTEINS; SYSTEM	Residue Phe(97), which is thought to play a central role in the cooperative functioning of Scapharca dimeric hemoglobin, has been mutated to leucine to test its proposed role in mediating cooperative oxygen binding. This results in an 8-fold increase in oxygen affinity and a marked decrease in cooperativity, Kinetic measurements of ligand binding to the Leu(97) mutant suggest an altered unliganded (deoxy) state, which has been confirmed by high resolution crystal structures in the unliganded and carbon monoxide-liganded states, Analysis of the structures at allosteric end points reveals them to be remarkably similar to the corresponding wild-type structures, with differences confined to the disposition of residue 97 side chain, F-helix geometry, and the interface water structure, Increased oxygen affinity results from the absence of the Phe(97) side chain, whose tight packing in the heme pocket of the deoxy state normally restricts the heme from assuming a high affinity conformation, The absence of the Phe(97) side chain is also associated with diminished cooperativity, since Leu(97) packs in the heme pocket in both states, Residual cooperativity appears to be coupled with observed structural transitions and suggests that parallel pathways for communication exist in Scapharca dimeric hemoglobin.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01605 USA; CORNELL UNIV, DEPT BIOCHEM MOL & CELL BIOL, ITHACA, NY 14853 USA; UNIV TEXAS, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77025 USA; UNIV ROMA LA SAPIENZA, CNR, CTR MOL BIOL, DEPT BIOCHEM SCI, I-00185 ROME, ITALY	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Cornell University; University of Texas System; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Colotti, Gianni/AAG-4918-2019; Colotti, Gianni/D-2015-2010	Colotti, Gianni/0000-0002-9913-0635	NIDDK NIH HHS [DK43323] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adair GS, 1925, J BIOL CHEM, V63, P529; ANTONINI E, 1984, J BIOL CHEM, V259, P6730; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; CAUGHEY WS, 1975, ANN NY ACAD SCI, V244, P1, DOI 10.1111/j.1749-6632.1975.tb41517.x; CHIANCONE E, 1993, J BIOL CHEM, V268, P5711; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; CONDON PJ, 1994, J BIOL CHEM, V269, P25259; GIBSON QH, 1964, BIOCHEM J, V91, P161, DOI 10.1042/bj0910161; GIBSON QH, 1973, P NATL ACAD SCI USA, V70, P1, DOI 10.1073/pnas.70.1.1; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HSU MC, 1971, J AM CHEM SOC, V93, P3515; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMBETH DO, 1973, J BIOL CHEM, V248, P6095; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; ROSSIFANELLI A, 1958, ARCH BIOCHEM BIOPHYS, V77, P478, DOI 10.1016/0003-9861(58)90094-8; Royer WE, 1996, P NATL ACAD SCI USA, V93, P14526, DOI 10.1073/pnas.93.25.14526; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; Sambrook J, 1989, MOL CLONING; STARK PA, 1970, INTRO NUMERICAL METH; SUMMERFORD CM, 1995, PROTEIN ENG, V8, P593, DOI 10.1093/protein/8.6.593; VALENTINE JS, 1979, P NATL ACAD SCI USA, V76, P1009, DOI 10.1073/pnas.76.3.1009; WANG CM, 1979, BIOCHEMISTRY-US, V18, P4960, DOI 10.1021/bi00589a026	24	32	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13171	13179		10.1074/jbc.272.20.13171	http://dx.doi.org/10.1074/jbc.272.20.13171			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148933	hybrid			2022-12-25	WOS:A1997WZ38400046
J	Richmond, C; Gorbea, C; Rechsteiner, M				Richmond, C; Gorbea, C; Rechsteiner, M			Specific interactions between ATPase subunits of the 26 S protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; TAT-MEDIATED TRANSACTIVATION; RABBIT RETICULOCYTE LYSATE; PROTEOLYTIC PATHWAY; BINDING-PROTEIN; THERMOPLASMA-ACIDOPHILUM; COILED COILS; UBIQUITIN; DEGRADATION; FAMILY	The regulatory complex of the 26 S protease contains at least 15 distinct subunits, Six of these subunits (S4, S6, S6', S7, S8, and S10b) belong to a novel subfamily of presumptive nucleotidases that we call subunit 4 (S4)like ATPases, Each of these putative ATPases was synthesized in reticulocyte lysate containing [S-35]methionine, and the radiolabeled proteins were used in binding studies, S4, S6, S10b, and S6' displayed specific binding to components of the regulatory complex separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) or two-dimensional PAGE, S4 bound to S7, and S6 bound two proteins: S8 and centractin, a component of the dynactin complex, S10b bound to S6' and bound much more weakly to SI and p50, another component of the dynactin complex, S6' bound to S10b, Two subunits, S7 and S8, did not bind any components present on nitrocellulose membranes, presumably because S7 and S8 are already oligomeric following synthesis, Go-translation and sucrose gradient sedimentation of S-35-labeled ATPases demonstrated the formation of S6'-S10b dimers in solution but revealed more complex associations, namely the formation of trimers and tetramers, among S4, S6, S7, and S8. Progressive COOH-terminal deletions that removed as much as 300 amino acids from S4 had no effect on the binding of S4 to S7. In striking contrast, truncation of 85 NH2-terminal amino acids from S4 abrogated binding, clearly implicating the NH2, terminus of S4 in its specific interaction with S7, Since S4-like ATPases contain putative coiled-coils within the first 150 NH2-terminal amino acids, we propose that coiled-coil interactions are responsible for the specificity of the observed subunit associations and that these associations are important for self-assembly of the regulatory complex.	UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah			Gorbea, Carlos/L-4406-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEMARINI DJ, 1995, MOL CELL BIOL, V15, P6311; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1994, BIOL CHEM H-S, V375, P237, DOI 10.1515/bchm3.1994.375.4.237; DUBIEL W, 1995, FEBS LETT, V363, P97, DOI 10.1016/0014-5793(95)00288-K; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; FUJINAMI K, 1994, J BIOL CHEM, V269, P25905; Fujiwara T, 1996, FEBS LETT, V387, P184, DOI 10.1016/0014-5793(96)00489-9; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HARLOW E, 1988, ANTIBODIES LABORATOR, P464; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PETERS JM, 1991, EUR J CELL BIOL, V56, P422; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USTRELL V, 1995, FEBS LETT, V376, P155, DOI 10.1016/0014-5793(95)01257-9; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	67	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13403	13411		10.1074/jbc.272.20.13403	http://dx.doi.org/10.1074/jbc.272.20.13403			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148964	hybrid			2022-12-25	WOS:A1997WZ38400077
J	Alam, MR; Johnson, RC; Darlington, DN; Hand, TA; Mains, RE; Eipper, BA				Alam, MR; Johnson, RC; Darlington, DN; Hand, TA; Mains, RE; Eipper, BA			Kalirin, a cytosolic protein with spectrin-like and GDP/GTP exchange factor-like domains that interacts with peptidylglycine alpha-amidating monooxygenase, an integral membrane peptide-processing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID BETA-SPECTRIN; TRANS-GOLGI NETWORK; CYTOPLASMIC DOMAIN; CELL-SURFACE; INTRACELLULAR TRAFFICKING; PROPROTEIN CONVERTASE; SECRETORY GRANULES; MOLECULAR-CLONING; ATT-20 CELLS; LOCALIZATION	Although the integral membrane proteins that catalyze steps in the biosynthesis of neuroendocrine peptides are known to contain routing information in their cytosolic domains, the proteins recognizing this routing information are not known, Using the yeast two-hybrid system, we previously identified P-CIP10 as a protein interacting with the cytosolic routing determinants of peptidylglycine alpha-amidating monooxygenase (PAM), P-CIP10 is a 217-kDa cytosolic protein with nine spectrin-like repeats and adjacent Db1 homology and pleckstrin homology domains typical of GDP/GTP exchange factors, In the adult rat, expression of P-CIP10 is most prevalent in the brain, Corticotrope tumor cells stably expressing P-CIP10 and PAM produce longer and more highly branched neuritic processes than nontransfected cells or cells expressing only PAM, The turnover of newly synthesized PAM is accelerated in cells co-expressing P-CIP10, P-CIP10 binds to selected members of the Rho subfamily of small GTP binding proteins (Rad, but not RhoA or Cdc42). P-CIP10 (kalirin), a member of the Db1 family of proteins, may serve as part of a signal transduction system linking the catalytic domains of PAM in the lumen of the secretory pathway to cytosolic factors regulating the cytoskeleton and signal transduction pathways.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; UNIV MARYLAND,SCH MED,DEPT SURG,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201	Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Darlington, Daniel/CAG-1917-2022		NIDDK NIH HHS [DK-32949, DK-32948] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032948, R37DK032948, R56DK032949, R37DK032949, R01DK032949, R01DK032948] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BLOOM ML, 1993, BLOOD, V82, P2906, DOI 10.1182/blood.V82.9.2906.bloodjournal8292906; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BULT A, 1996, J NEUROSCI, V16, P781; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; Cui L, 1996, J BIOL CHEM, V271, P24817, DOI 10.1074/jbc.271.40.24817; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; EIPPER BA, 1993, PROTEIN SCI, V2, P489; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; JOHNSON RC, 1994, ENDOCRINOLOGY, V135, P1178, DOI 10.1210/en.135.3.1178; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; LUO L, 1997, GENE DEV, V8, P1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OHASHI M, 1994, J BIOL CHEM, V269, P24897; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Paquet L, 1996, J NEUROSCI, V16, P964; PASTERIS NG, 1994, CELL, V79, P669; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wasmeier C, 1996, J BIOL CHEM, V271, P18161, DOI 10.1074/jbc.271.30.18161; WHITEHEAD I, 1995, ONCOGENE, V10, P713; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YUN HY, 1995, J BIOL CHEM, V270, P30075; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	68	111	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12667	12675		10.1074/jbc.272.19.12667	http://dx.doi.org/10.1074/jbc.272.19.12667			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139723	hybrid			2022-12-25	WOS:A1997WY82900060
J	Harding, CO; Williams, P; Wagner, E; Chang, DS; Wild, K; Colwell, RE; Wolff, JA				Harding, CO; Williams, P; Wagner, E; Chang, DS; Wild, K; Colwell, RE; Wolff, JA			Mice with genetic gamma-glutamyl transpeptidase deficiency exhibit glutathionuria, severe growth failure, reduced life spans, and infertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE TRANSPEPTIDASE; MESSENGER-RNAS; RAT-KIDNEY; MOUSE; ETHYLNITROSOUREA; METABOLISM; PROTEINS; GENOME; ACIDS	A mouse mutant with glutathionuria was discovered by screening for amino acidurias in the progeny of ethylnitrosourea-mutagenized mice. Total glutathione concentration was increased in both blood and urine but decreased in liver homogenates from affected mice, Glutathionuric mice exhibited lethargy, severe growth failure, shortened life spans and infertility, gamma-Glutamyl transpeptidase activity was deficient in kidney homogenates of glutathionuric mice, The glutathionuric phenotype in these mice is inherited as an autosomal recessive trait, This mouse mutant will be a useful animal model for the study of gamma-glutamyl transpeptidase physiology and glutathione metabolism.	UNIV WISCONSIN,SCH MED,DEPT PEDIAT,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT MED GENET & NEUROL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Harding, CO (corresponding author), UNIV WISCONSIN,WAISMAN CTR,RM 349,1500 HIGHLAND AVE,MADISON,WI 53705, USA.				NIDDK NIH HHS [R01 DK42709] Funding Source: Medline; NIGMS NIH HHS [5T32GM07131-15] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN SELDON E., 1966, P337; CAPRARO MA, 1983, FEBS LETT, V157, P139, DOI 10.1016/0014-5793(83)81132-6; COLOMA J, 1986, BIOCHEM BIOPH RES CO, V135, P304, DOI 10.1016/0006-291X(86)90977-0; CURTHOYS NP, 1979, ENZYME, V24, P383, DOI 10.1159/000458694; CURTO KA, 1988, J HISTOCHEM CYTOCHEM, V36, P159, DOI 10.1177/36.2.2891746; FIGLEWICZ DA, 1993, GENOMICS, V17, P299, DOI 10.1006/geno.1993.1325; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P268, DOI 10.1073/pnas.76.1.268; GRIFFITH OW, 1980, P NATL ACAD SCI-BIOL, V77, P3384, DOI 10.1073/pnas.77.6.3384; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P4932; HAMMOND JW, 1995, J INHERIT METAB DIS, V18, P82, DOI 10.1007/BF00711381; Harding Cary O., 1995, P245; HARDING CO, 1992, P NATL ACAD SCI USA, V89, P2644, DOI 10.1073/pnas.89.7.2644; HOFFMANN G, 1989, CLIN CHEM, V35, P587; HUGHEY RP, 1976, J BIOL CHEM, V251, P7863; KING TR, 1989, P NATL ACAD SCI USA, V86, P222, DOI 10.1073/pnas.86.1.222; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson A., 1983, FUNCTIONS GLUTATHION; Lieberman MW, 1996, P NATL ACAD SCI USA, V93, P7923, DOI 10.1073/pnas.93.15.7923; MCINTYRE TM, 1980, INT J BIOCHEM, V12, P545, DOI 10.1016/0020-711X(80)90005-1; MEISTER A, 1984, FED PROC, V43, P3031; MEISTER A, 1976, ANNU REV BIOCHEM, V45, P559, DOI 10.1146/annurev.bi.45.070176.003015; MEISTER A, 1973, SCIENCE, V180, P33, DOI 10.1126/science.180.4081.33; MEISTER A, 1975, METABOLISM SULFUR CO, V7, P102; Meister A, 1995, METABOLIC MOL BASES, V1, P1461; ODALY S, 1968, IRISH J MED SCI, V7, P578; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; PAWLAK A, 1989, BIOCHEM BIOPH RES CO, V164, P912, DOI 10.1016/0006-291X(89)91545-3; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; Reed D J, 1981, Adv Exp Med Biol, V136 Pt A, P75; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; SCHULMAN JD, 1975, BIOCHEM BIOPH RES CO, V65, P68, DOI 10.1016/S0006-291X(75)80062-3; SCOTT RD, 1987, AM J PHYSIOL, V252, pF877, DOI 10.1152/ajprenal.1987.252.5.F877; SHEDLOVSKY A, 1993, GENETICS, V134, P1205; Shi ZZ, 1995, GENE, V167, P233, DOI 10.1016/0378-1119(95)00618-4; Shih VE, 1991, TECHNIQUES DIAGNOSTI, P49; Slocum RH, 1991, TECHNIQUES DIAGNOSTI, P87; SMITH I, 1960, CHROMATOGR ELECTROPH, P82; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TATE SS, 1974, J BIOL CHEM, V249, P7593; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wright EC, 1979, J INHERITED METAB DI, V2, P3	43	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12560	12567		10.1074/jbc.272.19.12560	http://dx.doi.org/10.1074/jbc.272.19.12560			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139708	hybrid			2022-12-25	WOS:A1997WY82900045
J	Franchimont, N; Rydziel, S; Delany, AM; Canalis, E				Franchimont, N; Rydziel, S; Delany, AM; Canalis, E			Interleukin-6 and its soluble receptor cause a marked induction of collagenase 3 expression in rat osteoblast cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; INTERSTITIAL COLLAGENASE; MESSENGER-RNA; TISSUE INHIBITOR; GROWTH-FACTOR; BONE-MARROW; POTENTIATING ACTIVITY; EXTRACELLULAR-MATRIX; STROMAL CELLS; IN-VITRO	Interleukin-6 (IL-6), a cytokine produced by skeletal cells, increases bone resorption, but its effects on collagenase expression are unknown. We tested the effects of IL-6 and its soluble receptor on collagenase 3 expression in osteoblast enriched cells from fetal rat calvariae (Ob cells). IL-6 caused a small increase in collagenase mRNA levels, but in the presence of IL-6-soluble receptor (IL-6sR), IL-6 caused a marked increase in collagenase transcripts after 2-24 h. In addition, IL-6sR increased collagenase mRNA when tested alone. IL-6 and IL-6sR increased immunoreactive collagenase levels. Cycloheximide and indomethacin did not prevent the effect of IL-6 and IL-6sR on collagenase mRNA levels. IL-6 and IL-6sR did not alter the decay of collagenase mRNA in transcriptionally arrested Ob cells and increased the levels of collagenase heterogeneous nuclear RNA and the rate of collagenase gene transcription in Ob cells. IL-6 and IL-6sR increased collagenase 3 mRNA in MC3T3 cells but only modestly in skin fibroblasts. IL-6 and IL-6sR enhanced the expression of tissue inhibitor of metalloproteinases 1. In conclusion, IL-6, in the presence of IL-6sR, increases collagenase 3 synthesis in osteoblasts by transcriptional mechanisms. This effect may contribute to the action of IL-6 on bone matrix degradation and bone resorption.	ST FRANCIS HOSP & MED CTR,DEPT RES,HARTFORD,CT 06105; ST FRANCIS HOSP & MED CTR,DEPT MED,HARTFORD,CT 06105; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06030	Saint Francis Hospital & Medical Center; Saint Francis Hospital & Medical Center; University of Connecticut					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021707, R37AR021707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009038] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 21707] Funding Source: Medline; NIDDK NIH HHS [DK-09038] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BELLIDO T, 1995, J CLIN INVEST, V95, P2883; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; CANALIS E, 1995, ENDOCRINOLOGY, V136, P1348, DOI 10.1210/en.136.4.1348; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; CHENKIANG S, 1993, CURR OPIN IMMUNOL, V5, P124, DOI 10.1016/0952-7915(93)90091-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVITELLI R, 1989, ENDOCRINOLOGY, V124, P2928, DOI 10.1210/endo-124-6-2928; CLOHISY JC, 1994, ENDOCRINOLOGY, V135, P1447, DOI 10.1210/en.135.4.1447; DELAMATA J, 1995, J CLIN INVEST, V95, P2846, DOI 10.1172/JCI117990; Delany AM, 1996, ENDOCRINOLOGY, V137, P4665, DOI 10.1210/en.137.11.4665; DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; EMONARD H, 1992, MATRIX, V12, P471, DOI 10.1016/S0934-8832(11)80091-0; FANG MA, 1991, J BONE MINER RES, V6, P133; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FLANAGAN AM, 1995, J PATHOL, V176, P289, DOI 10.1002/path.1711760311; FORSTER E, 1994, BIOTECHNIQUES, V16, P1006; FRANCHIMONT N, 1995, ENDOCRINOLOGY, V136, P5469, DOI 10.1210/en.136.12.5469; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GAILLARD JP, 1993, EUR J IMMUNOL, V23, P820, DOI 10.1002/eji.1830230408; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GIRASOLE G, 1995, J BONE MINER RES, V10, pS160; Heinrich PC, 1995, ANN NY ACAD SCI, V762, P222; HILL PA, 1995, BIOCHEM J, V308, P167, DOI 10.1042/bj3080167; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; ITO A, 1992, ARTHRITIS RHEUM, V35, P1197, DOI 10.1002/art.1780351012; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; LORENZO JA, 1992, MATRIX, V12, P282, DOI 10.1016/S0934-8832(11)80080-6; LOTZ M, 1991, J BIOL CHEM, V266, P2017; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; RIFAS L, 1995, ENDOCRINOLOGY, V136, P4056, DOI 10.1210/en.136.9.4056; RIFAS L, 1994, ENDOCRINOLOGY, V134, P213, DOI 10.1210/en.134.1.213; Rose-John S, 1995, ANN NY ACAD SCI, V762, P207; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; Sokal R. R, 1981, BIOMETRY; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Tang KT, 1996, J CELL BIOCHEM, V61, P152, DOI 10.1002/(SICI)1097-4644(19960401)61:1<152::AID-JCB16>3.0.CO;2-Q; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; Varghese S, 1996, ENDOCRINOLOGY, V137, P431, DOI 10.1210/en.137.2.431; Varghese S, 1997, ENDOCRINOLOGY, V138, P1035, DOI 10.1210/en.138.3.1035; VARGHESE S, 1995, ENDOCRINOLOGY, V136, P2156, DOI 10.1210/en.136.5.2156; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503	67	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12144	12150		10.1074/jbc.272.18.12144	http://dx.doi.org/10.1074/jbc.272.18.12144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115285	hybrid			2022-12-25	WOS:A1997WX56900073
J	Godwin, SL; Soltoff, SP				Godwin, SL; Soltoff, SP			Extracellular calcium and platelet-derived growth factor promote receptor-mediated chemotaxis in osteoblasts through different signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; DNA-SYNTHESIS; CELLS; MOBILIZATION; MECHANISM; MONOCYTES; MC3T3-E1; CA2+; BETA; OSTEOCLASTS	The discovery of a calcium receptor has stimulated interest in the signaling events underlying extracellular calcium ([Ca2+](o))-induced cell-specific responses, In osteoblasts, elevated levels of extracellular calcium mediate both mitogenesis and chemotaxis. Here we provide evidence that [Ca2+](o)-stimulated chemotaxis of MC3T3-E1 osteoblast-like cells involves a G-protein-linked calcium-sensing receptor, [Ca2+](o) promotes chemotaxis in a concentration-dependent manner. Pertussis toxin blocked almost all of [Ca2+](o)-stimulated chemotaxis but had only a small effect on platelet-derived growth factor (PDGF)-stimulated chemotaxis. Consistent with the signaling model for PDGF mediated chemotaxis, activation of phospholipase C played a critical role in [Ca2+](o)-initiated chemotaxis: U-73122, an inhibitor of the activation of phospholipase C, blocked approximately 50% of PDGF-stimulated chemotaxis but blocked nearly all of the [Ca2+](o)-stimulated chemotaxis, Down-regulation of protein kinase C also blocked about 50% of PDGF-stimulated chemotaxis but aid riot block [Ca2+](o)-stimulated chemotaxis. Thus, unlike PDGF-mediated chemotaxis, chemotaxis stimulated by [Ca2+](o) does not appear to require protein kinase C activation. This finding suggests events downstream of inositol 1,4,5-trisphosphate production rather than diacylglycerol production are critical to [Ca2+](o)-promoted chemotaxis of MC3T3-E1 cells. The signal transduction mechanism underlying PDGF-induced chemotaxis involves the activation of phosphoinositide 3-kinase, as judged by the in vivo production of phosphatidylinositol 3,4-diphosphate and 3,4,5-trisphosphate and the partial sensitivity of chemotaxis to wortmannin, an inhibitor of phosphoinositide 3-kinase, In contrast, [Ca2+](o)-stimulated chemotaxis was not blocked by wortmannin and elevations in [Ca2+](o) did not increase the production of lipid products of phosphoinositide 3-kinase, Overall, [Ca2+](o)-promoted chemotaxis of osteoblasts appears to utilize a unique signaling mechanism via a calcium-sensing receptor.	HARVARD UNIV,INST MED,DEPT MED,BETH ISRAEL DEACONNESS MED CTR,DIV SIGNAL TRANSDU,BOSTON,MA 02115; HARVARD UNIV,SCH DENT MED,DEPT ORTHODONT,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard School of Dental Medicine					NIDCR NIH HHS [DE10877, DE00275] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010877] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CANALIS E, 1988, J CLIN INVEST, V81, P277, DOI 10.1172/JCI113318; CLYMAN RI, 1994, CELL ADHES COMMUN, V1, P333, DOI 10.3109/15419069409097264; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Derman MP, 1996, J BIOL CHEM, V271, P4251; FRAY JCS, 1987, ENDOCR REV, V8, P53, DOI 10.1210/edrv-8-1-53; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HUGHES FJ, 1992, BONE MINER, V19, P63, DOI 10.1016/0169-6009(92)90844-4; KANATANI M, 1991, BIOCHEM BIOPH RES CO, V181, P1425, DOI 10.1016/0006-291X(91)92098-5; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LASKIN DL, 1981, CANCER RES, V41, P1923; LEIS HJ, 1994, CELL CALCIUM, V15, P447, DOI 10.1016/0143-4160(94)90109-0; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; LOCHT C, 1995, BIOCHIMIE, V77, P333, DOI 10.1016/0300-9084(96)88143-0; MOLSKI TFP, 1984, BIOCHEM BIOPH RES CO, V124, P644, DOI 10.1016/0006-291X(84)91603-6; NEMETH EF, 1986, J BIOL CHEM, V261, P2668; NEMETH EF, 1994, NEWS PHYSL, V10, P1; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081-198712000-00004; POWIS G, 1994, CANCER RES, V54, P2419; QUARLES LD, 1994, J CELL BIOCHEM, V56, P106, DOI 10.1002/jcb.240560115; QUARLES LD, 1996, J BONE MINER RES  S1, V11, pS141; ROSEN EM, 1991, CANCER RES, V51, P5315; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SOLTOFF SP, 1993, METH NEUROSCI, V18, P100; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUGIMOTO T, 1993, J BONE MINER RES, V8, P1445; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; TSUKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V175, P745, DOI 10.1016/0006-291X(91)91629-Q; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; Wang C, 1996, J IMMUNOL, V156, P786; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V163, P1461, DOI 10.1016/0006-291X(89)91143-1; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	42	93	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11307	11312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111036				2022-12-25	WOS:A1997WW00900052
J	Hansen, OC; Stougaard, P				Hansen, OC; Stougaard, P			Hexose oxidase from the red alga Chondrus crispus - Purification, molecular cloning, and expression in Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYVINYLIDENE DIFLUORIDE; ENZYMATIC DIGESTION; ASPERGILLUS-NIGER; SEQUENCE-ANALYSIS; GLUCOSE-OXIDASE; PROTEINS; GENES; ENZYMES; METHANOL; BINDING	Hexose oxidase from Chondrus crispus catalyzes the oxidation of a variety of mono- and disaccharides including D-glucose, D-galactose, maltose, and lactose, The enzyme has previously been partially purified and was reported to be a highly glycosylated, copper-containing protein with a relative molecular mass of approximately 130,000 (Sullivan, J, D,, and Ikawa, M, (1973) Biochim, Biophys, Acta 309, 11-22). We report here the purification to homogeneity of hexose oxidase from C, crispus. The purified enzyme was cleaved with cyanogen bromide and endoproteinase Lys-C and the peptide fragments were subjected to amino acid sequence analysis, Oligonucleotides were designed on the basis of the peptide sequences and a cDNA clone encoding C, crispus hexose oxidase was obtained using polymerase chain reaction on reverse transcribed cDNA, The nucleotide sequence of the hexose oxidase cDNA contained an open reading frame of 546 amino acid residues with a predicted relative molecular mass of 61,898, No significant sequence similarity was found between hexose oxidase and other protein sequences available in data bases. Expression of the hexose oxidase cDNA in Pichia pastoris as an active enzyme confirmed the identity of the DNA sequence, Native hexose oxidase from C, crispus was characterized and compared with purified, recombinant enzyme.	INST BIOTECHNOL,DK-2970 HORSHOLM,DENMARK				Stougaard, Peter/G-9978-2014	Stougaard, Peter/0000-0002-2796-7137				BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BEAN RC, 1959, J BIOL CHEM, V218, P425; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSCH R, 1987, EUR J BIOCHEM, V167, P315, DOI 10.1111/j.1432-1033.1987.tb13338.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; ESAKA M, 1990, EUR J BIOCHEM, V191, P537, DOI 10.1111/j.1432-1033.1990.tb19154.x; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; HUANG KX, 1995, J BIOL CHEM, V270, P21495, DOI 10.1074/jbc.270.37.21495; JANOWICZ ZA, 1985, NUCLEIC ACIDS RES, V13, P3043, DOI 10.1093/nar/13.9.3043; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KERSCHENSTEINER DA, 1978, FED PROC, V37, P1816; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KOUTZ P, 1989, YEAST, V5, P167, DOI 10.1002/yea.320050306; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAUD MF, 1993, PLANT MOL BIOL, V23, P981, DOI 10.1007/BF00021813; LIAUD MF, 1994, J MOL EVOL, V38, P319, DOI 10.1007/BF00163149; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MEYER AS, 1995, TRENDS FOOD SCI TECH, V6, P300, DOI 10.1016/S0924-2244(00)89140-2; ROH JH, 1995, BIOCHEM BIOPH RES CO, V212, P1107, DOI 10.1006/bbrc.1995.2083; SAHM H, 1973, EUR J BIOCHEM, V36, P250, DOI 10.1111/j.1432-1033.1973.tb02907.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOCK J, 1988, ANAL BIOCHEM, V171, P310, DOI 10.1016/0003-2697(88)90492-7; SULLIVAN JD, 1973, BIOCHIM BIOPHYS ACTA, V309, P11, DOI 10.1016/0005-2744(73)90312-4; SWOBODA BEP, 1965, J BIOL CHEM, V240, P2209; TIPPING AJ, 1995, J BIOL CHEM, V270, P1639; Yun DF, 1996, MOL MICROBIOL, V19, P1225, DOI 10.1111/j.1365-2958.1996.tb02468.x	33	29	35	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11581	11587						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111074				2022-12-25	WOS:A1997WW00900090
J	Yan, ZH; Medvedev, A; Hirose, T; Gotoh, H; Jetten, AM				Yan, ZH; Medvedev, A; Hirose, T; Gotoh, H; Jetten, AM			Characterization of the response element and DNA binding properties of the nuclear orphan receptor germ cell nuclear factor retinoid receptor-related testis-associated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; INVITRO TRANSCRIPTION; PROTAMINE-2 GENES; ACID RECEPTORS; MOUSE; SUPERFAMILY; PROTEIN; PROMOTER; MEMBER; HETERODIMERS	Recently, we have reported the cloning of the germ cell-specific, nuclear orphan receptor germ cell nuclear factor (GCNF)/RTR. In this study, we characterize the RTR response elements by an electrophoretic mobility shift assay/polymerase chain reaction-based, DNA binding site selection strategy. RTR binds with the greatest affinity to response elements containing TCA(AG(G/T)TCA)(2) (consensus RTR response element; conRTRE), to which it binds as a homodimer. RTR is also able to bind as a monomer to a single core motif TCAAG(G/T)TCA, albeit with a lower affinity. Mutation analysis supports the specific requirements of the 5'-flanking sequence and the core motif of the RTRE for optimal binding of RTR. An RTR-specific antiserum (RTR-Ab2) was raised that causes supershift of the RTR-conRTRE complex in EMSA. Based on the sequence of the conRTRE, we located a putative RTRE, referred to as P2-RE, in the 5' promoter-flanking region of the mouse protamine 2 gene, which is induced during the same stage of spermatogenesis as RTR. The ability of RTR-Ab2 to cause a supershift of an RTR-RTRE complex with nuclear extracts from different tissues correlated with the tissue- and development-specific expression of RTR. Transfection of RTR in CV-1 cells was unable to cause RTRE-dependent transactivation of a CAT reporter gene; however, an RTR-VP16 fusion protein could induce transactivation through several RTREs, including PS-RE.	NIEHS, PULM PATHOBIOL LAB,CELL BIOL SECT, GAMETE BIOL SECT,NIH, RES TRIANGLE PK, NC 27709 USA; NIEHS, REPROD & DEV TOXICOL LAB, NIH, RES TRIANGLE PK, NC 27709 USA; OSAKA UNIV, SCH MED, DEPT MED 3, SUITA, OSAKA 565, JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Osaka University			Hirose, Takahisa/E-6117-2011; Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445; Medvedev, Alexander/0000-0001-6983-1687				BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; DE LUCA LM, 1991, FASEB J, V5, P2924; Eddy EM, 1993, MOL BIOL MALE REPROD, P181; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HIROSE T, 1995, GENE, V152, P247, DOI 10.1016/0378-1119(94)00656-D; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; HIROSE T, 1995, BIOCHEM BIOPH RES CO, V211, P83, DOI 10.1006/bbrc.1995.1781; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; JOHNSON PA, 1991, BIOL REPROD, V44, P127, DOI 10.1095/biolreprod44.1.127; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Medvedev A, 1996, GENE, V181, P199, DOI 10.1016/S0378-1119(96)00504-5; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; ONATE SA, 1995, SCIENCE, V270, P1354; QUI Y, 1994, TRENDS ENDOCRIN MET, V5, P234; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340	38	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10565	10572						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099702				2022-12-25	WOS:A1997WV26200036
J	Casola, S; Pedone, PV; Cavazzana, AO; Basso, G; Luksch, R; dAmore, ESG; Carli, M; Bruni, CB; Riccio, A				Casola, S; Pedone, PV; Cavazzana, AO; Basso, G; Luksch, R; dAmore, ESG; Carli, M; Bruni, CB; Riccio, A			Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma	ONCOGENE			English	Article						genomic imprinting; 11p15 LOH; pediatric cancer	GROWTH-FACTOR-II; WILMS-TUMOR; ALVEOLAR RHABDOMYOSARCOMA; MATERNAL ALLELES; RNA; LOCUS; IGF2; HEPATOBLASTOMA; TUMORIGENESIS; METHYLATION	The expression of Insulin-like Growth Factor 2 (IGF-2) and H19, two genes located on human chromosome 11p15 and provided with cell growth modulating activity, is regulated by parental imprinting, in that the activity of their alleles is dependent on the parental origin. Parental bias in the genetic alterations of chromosome 11p15 observed in several pediatric cancers suggests the involvement of imprinted genes in tumor development. We have previously reported that the number of functional IGF-2 alleles is frequently increased in rhabdomyosarcoma (RMS), as a consequence of either relaxation of imprinting (LOI) or gene duplication. Here we show that the expression of the H19 gene is significantly suppressed with respect to normal muscle tissue in 13 out of 15 rhabdomyosarcomas with embryonal histology (ERMS) and in three out of 11 rhabdomyosarcomas classified as alveolar subtype (ARMS). Since a growth-inhibitory activity has been found associated with the H19 gene, the extinction of its expression can contribute to RMS development. Parental imprinting of the H19 gene was found conserved in all informative RMSs, including those whose IGF-2 imprinting was relaxed, indicating that LOI is a gene-specific event. Seven ERMSs and one ARMS displaying low H19 RNA levels showed an underrepresentation of the expressed allele in their genotype. This result is consistent with the paternal imprinting of the H19 gene and with the preferential loss of the maternal 11p15 alleles in these neoplasms. Low H19 expression was also found in four out of eight RMSs retaining the heterozygosity at 11p15, but showing IGF-2 LOI. These findings suggest that the genetic and epigenetic alterations affecting chromosome 11p15 in a high number of RMSs cause deregulation of more than one imprinted gene, possibly affecting tumor growth, including the extinction of H19 expression and an increase in the number of active IGF-2 alleles.	CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY; UNIV NAPLES 2,FAC SCI AMBIENTALI,NAPLES,ITALY; UNIV ROMA TOR VERGATA,IST ANAT PATOL,ROME,ITALY; UNIV PADUA,CLIN PEDIAT 2,DIV ONCOEMATOL,PADUA,ITALY; UNIV PADUA,IST ANAT PATOL,PADUA,ITALY; IST NAZL TUMORI,I-20133 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita della Campania Vanvitelli; University of Rome Tor Vergata; University of Padua; University of Padua; Fondazione IRCCS Istituto Nazionale Tumori Milan			Riccio, Andrea/A-4991-2015; Cerrato, Flavia/O-8315-2015; Luksch, Roberto/K-2206-2016; Casola, Stefano/AAN-8319-2021; Riccio, Andrea/AAY-7571-2020; Casola, Stefano/O-3922-2014	Riccio, Andrea/0000-0001-7990-3576; Cerrato, Flavia/0000-0003-3794-3021; Luksch, Roberto/0000-0002-7203-4176; Casola, Stefano/0000-0001-5580-0986; Riccio, Andrea/0000-0001-7990-3576; Pedone, Paolo Vincenzo/0000-0002-0828-5843; BASSO, GIUSEPPE/0000-0002-2634-9302				ALBRECHT S, 1994, CANCER RES, V54, P5041; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CASOLA S, 1995, ONCOGENE, V11, P711; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS RJ, 1994, CANCER RES, V54, P2869; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ELBADRY OM, 1990, CELL GROWTH DIFFER, V84, P829; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Ferracini R, 1996, ONCOGENE, V12, P1697; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Kondo M, 1996, ONCOGENE, V12, P1365; LEIBOVITCH MP, 1995, ONCOGENE, V10, P251; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI XR, 1995, ONCOGENE, V11, P221; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NEWTON WA, 1995, CURRENT TOPICS PATHO, V89; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PAL N, 1990, ONCOGENE, V5, P1665; Pappo Alberto S., 1995, Current Opinion in Oncology, V7, P361, DOI 10.1097/00001622-199507000-00012; PEDONE PV, 1994, J BIOL CHEM, V269, P23970; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAINIER S, 1995, CANCER RES, V55, P1836; RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753; Sambrook J., 2002, MOL CLONING LAB MANU; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; YUN K, 1992, LAB INVEST, V67, P653; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	51	49	51	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1503	1510		10.1038/sj.onc.1200956	http://dx.doi.org/10.1038/sj.onc.1200956			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136994				2022-12-25	WOS:A1997WT58400013
J	Middeler, G; Zerf, K; Jenovai, S; Thulig, A; TschodrichRotter, M; Kubitscheck, U; Peters, R				Middeler, G; Zerf, K; Jenovai, S; Thulig, A; TschodrichRotter, M; Kubitscheck, U; Peters, R			The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited	ONCOGENE			English	Article						nucleocytoplasmic shuttling; nucleocytoplasmic transport; nuclear import signal; nuclear export signal; subcellular localization	SCANNING MICROPHOTOLYSIS; NUCLEOCYTOPLASMIC FLUX; PROGESTERONE-RECEPTOR; LOCALIZATION SIGNALS; PROTEIN IMPORT; MESSENGER-RNA; GROWTH ARREST; DNA-BINDING; MUTANT P53; IN-VIVO	Human p53 was expressed in E. coli, purified, labeled with fluorescein iodoacetamide (IAF) and characterized for sequence-specific DNA binding and epitope disposition. Injected into the cytoplasm or nuclei of 3T3 cells IAF-p53 was imported into or exported from nuclei within minutes. Import was inhibited by coinjection of the lectin wheat germ agglutinine (WGA). In contrast, the peptide-protein conjugate NLS-HSA carrying the nuclear localization sequence (NLS) of the SV40 T antigen was only imported but not exported. 3T3 polykaryons were injected with IAF-p53 and photobleached by Scanning Microphotolysis in such a manner that only a single nucleus per polykaryon remained non-bleached. IAF-p53 was found to migrate rapidly (halftime similar to 10 min) from non-bleached into bleached nuclei, while NLS-HSA did not. In digitonin permeabilized cells IAF-p53 was imported into nuclei. When removed from the medium after nuclear accumulation IAF-p53 was exported from the nuclei. Nuclear import and export of IAF-p53 both were rapid (halftimes of a few minutes, 22 degrees C) and strongly inhibited by WGA or incubation on ice. NLS-HSA was only imported but not exported. We conclude that the nucleocytoplasmic transport of p53, in contrast to that of NLS-HSA, is bidirectional and that transport in both directions is carrier mediated and energy dependent. These results suggest that p53 contains nuclear export signals (NES) in addition to import signals (NLS) and thus open new views on the potential regulation of p53 cellular fractions.	UNIV MUNSTER,INST MED PHYS & BIOPHYS,D-48149 MUNSTER,GERMANY	University of Munster			Kubitscheck, Ulrich/GPS-8017-2022; Peters, Reiner/E-7352-2011	Kubitscheck, Ulrich/0000-0003-3750-5355				ACKERMANN M, 1991, EXPERIENTIA, V47, pA55; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; ADDISON C, 1990, ONCOGENE, V5, P423; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DANG CV, 1989, J BIOL CHEM, V264, P18019; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FRITSCHE M, 1993, ONCOGENE, V8, P3007; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOLDSTEIN L, 1958, EXP CELL RES, V15, P635, DOI 10.1016/0014-4827(58)90118-6; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; GUIOCHONMANTEL A, 1994, BIOCHEM PHARMACOL, V47, P21, DOI 10.1016/0006-2952(94)90433-2; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUBITSCHECK U, 1994, BIOPHYS J, V67, P948, DOI 10.1016/S0006-3495(94)80596-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MEIER UT, 1992, CELL, V70, P127; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MICHAEL WM, 1995, CELL, V83, P415; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PETERS R, 1984, EMBO J, V3, P1831, DOI 10.1002/j.1460-2075.1984.tb02055.x; PETERS R, 1974, BIOCHIM BIOPHYS ACTA, V367, P282, DOI 10.1016/0005-2736(74)90085-6; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SCHMIDT M, 1994, EUR J CELL BIOL, V65, P70; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; TAKAHASHI K, 1994, ONCOGENE, V9, P183; THULIG A, 1994, MOL BIOL CELL, V5, pA458; TschodrichRotter M, 1996, BIOPHYS J, V70, P723, DOI 10.1016/S0006-3495(96)79612-1; WALASCHEWSKI U, 1995, METHOD MOL CELL BIOL, V5, P87; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEDEKIND P, 1994, J MICROSC-OXFORD, V176, P23, DOI 10.1111/j.1365-2818.1994.tb03496.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	62	78	79	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1407	1417		10.1038/sj.onc.1200949	http://dx.doi.org/10.1038/sj.onc.1200949			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136984				2022-12-25	WOS:A1997WT58400003
J	Molnar, A; Theodoras, AM; Zon, LI; Kyriakis, JM				Molnar, A; Theodoras, AM; Zon, LI; Kyriakis, JM			Cdc42Hs, but not rad, inhibits serum-stimulated cell cycle progression at G(1)/S through a mechanism requiring p38/RK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GTP-BINDING PROTEIN; P70 S6 KINASE; SIGNAL-TRANSDUCTION; C-JUN; PATHWAY; RHO; IDENTIFICATION; FAMILY; YEAST	Antimitogenic stimuli such as environmental or genotoxic stress, transforming growth factor-beta, and the inflammatory cytokines tumor necrosis factor and inter interleukin-1 activate two extracellular signal-regulated kinase (ERK)-based signaling pathways: the stress-activated protein kinase (SAPK/JNK) pathway and the p38 pathway. Activated p38 phosphorylates transcription factors important in the regulation of cell growth and apoptosis, including activating transcription factor 2 (ATF2), Max, cAMP response element-binding protein-homologous protein/growth arrest DNA damage 153 (CHDP/GADD153). In turn, p38 lies downstream of the Rho family GTPases Cdc42Hs and Rac1, as well as at least three mitogen-activated protein kinase (MAPK)/ERK-kinases (MEKs): MAPK kinases-3, -6, and SAPK/ERK-kinase-1. Although many of the stimuli that activate p38 can also inhibit cell cycle progression, a clearcut role for the p38 pathway in cell cycle regulation has not been established. Using a quantitative microinjection approach, we show here that Cdc42Hs, but not Rad or RhoA, can inhibit cell cycle progression at G(1)/S through a mechanism requiring activation of p38. These results suggest a novel role for Cdc42Hs in cell cycle inhibition. Furthermore, these results suggest that although both Cdc42Hs and Rad can activate p38 Sn situ, the effects of Cdc42Hs and Rad on cell cycle progression are, in fact, quite distinct.	MASSACHUSETTS GEN HOSP E, DIABET RES LAB, CHARLESTOWN, MA 02129 USA; MITOTIX INC, CAMBRIDGE, MA 02139 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041513] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41513] Funding Source: Medline; NIGMS NIH HHS [GM53697] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Cardoso M. C., 1995, CELL CYCLE MAT METHO, P15; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PEPPERKOK R, 1995, CELL CYCLE MAT METHO, P75; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	42	165	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13229	13235		10.1074/jbc.272.20.13229	http://dx.doi.org/10.1074/jbc.272.20.13229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148940	hybrid			2022-12-25	WOS:A1997WZ38400053
J	Ali, MS; Schieffer, B; Delafontaine, P; Bernstein, KE; Ling, BN; Marrero, MB				Ali, MS; Schieffer, B; Delafontaine, P; Bernstein, KE; Ling, BN; Marrero, MB			Angiotensin II stimulates tyrosine phosphorylation and activation of insulin receptor substrate 1 and protein-tyrosine phosphatase 1D in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; KINASE; SYP; PHARMACOLOGY; PP60(C-SRC); PATHWAY; DOMAINS	Angiotensin II (Ang II) and insulin-like growth factor I (IGF I) stimulate intracellular signaling events through binding to their respective G-protein-coupled and growth factor receptors. In rat aortic vascular smooth muscle cells, IGF I (20 ng/ml) induced a sustained (>30 min) increase in the tyrosine phosphorylation of both Src-homology 2 domain docking insulin receptor substrate 1 (IRS-1) and Src-homology 2-binding tyrosine phosphatase 1D (PTP-1D). In addition, IGF I stimulated PTP-1D phosphatase activity. Ang II (10(-7) M) also increased the tyrosine phosphorylation of IRS-1 (4-fold), PTP-1D (5-fold), and PTP-1D activity (3-4-fold), but with a more transient time course. Ang II also induced PTP-1D IRS-1 complex formation. These Ang II-induced events were not affected by preincubation with an anti-IGF I antibody, suggesting that Ang II's actions were not mediated via the autocrine secretion of IGF I. Anti-PTP-1D antibody electroporation attenuated Ang II-induced PTP-1D-IRS-1 complex formation and PTP-1D tyrosine phosphorylation and activation. Our findings show that the tyrosine phosphorylation of IRS-1 and PTP-1D represents a convergent intracellular signaling cascade stimulated by both growth factor (i.e. IGF I) and G protein-coupled (i.e. AT(1)) receptors.	EMORY UNIV, SCH MED, CTR CELL & MOL SIGNALING, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT PATHOL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT MED, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DIV RENAL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DIV CARDIOL, ATLANTA, GA 30322 USA; VET AFFAIRS MED CTR, ATLANTA, GA 30322 USA	Emory University; Emory University; Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System				Delafontaine, Patrice/0000-0003-3744-3617; Bernstein, Kenneth/0000-0001-8097-3272	NHLBI NIH HHS [HL-45317, HL-47035] Funding Source: Medline; NIDDK NIH HHS [DK-45215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047035, R01HL045317, R29HL045317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIU AT, 1991, AM J HYPERTENS, V4, pS282, DOI 10.1093/ajh/4.4.282S; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; DELAFONTAINE P, 1993, J BIOL CHEM, V268, P16866; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRERO MB, 1995, CARDIOVASC RES, V30, P530, DOI 10.1016/0008-6363(95)00094-1; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Thomas M L, 1995, Semin Immunol, V7, P279, DOI 10.1006/smim.1995.0032; TIMMERMANS PB, 1983, PHARMACOL REV, V45, P205; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WOLF G, 1993, J AM SOC NEPHROL, V3, P1531; XIAO S, 1994, J BIOL CHEM, V269, P21244	44	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12373	12379		10.1074/jbc.272.19.12373	http://dx.doi.org/10.1074/jbc.272.19.12373			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139682	hybrid			2022-12-25	WOS:A1997WY82900019
J	Gorbunov, NV; Yalowich, JC; Gaddam, A; Thampatty, P; Ritov, VB; Kisin, ER; Elsayed, NM; Kagan, VE				Gorbunov, NV; Yalowich, JC; Gaddam, A; Thampatty, P; Ritov, VB; Kisin, ER; Elsayed, NM; Kagan, VE			Nitric oxide prevents oxidative damage produced by tert-butyl hydroperoxide in erythroleukemia cells via nitrosylation of heme and non-heme iron - Electron paramagnetic resonance evidence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LOW-DENSITY-LIPOPROTEIN; HUMAN ENDOTHELIAL-CELLS; RED-BLOOD-CELLS; SPIN-RESONANCE; HYDROGEN-PEROXIDE; RIBONUCLEOTIDE REDUCTASE; K562 CELLS; ACTIVATED MACROPHAGES; REOXYGENATION INJURY; LIPID-PEROXIDATION	We studied protective effects of NO against tert-butyl-hydroperoxide (t-BuOOH)-induced oxidations in a subline of human erythroleukemia K562 cells with different intracellular hemoglobin (Hb) concentrations. t-BuOOH-induced formation of oxoferryl-Hb-derived free radical species in cells was demonstrated by low temperature EPR spectroscopy, Intensity of the signals was proportional to Hb concentrations and was correlated with cell viability, Peroxidation of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and cardiolipin metabolically labeled with oxidation-sensitive cis-parinaric acid was induced by t-BuOOH. An NO donor, (Z)-1-[N-(3-ammoniopropyl)-N-(n-propyl)amino]-diazen-1-ium-1,2-diolate], produced nonheme iron dinitrosyl complexes and hexa- and pentacoordinated Hb-nitrosyl complexes in the cells. Nitrosylation of non heme iron centers and Hb-heme protected against t-BuOOH-induced: (a) formation of oxoferryl-Hb-derived free radical species, (b) peroxidation of cis-parinaric acid-labeled phospholipids, and (c) cytotoxicity. Since NO did not inhibit peroxidation induced by an ate-initiator of peroxyl radicals, 2,2'-azobis(2,4-dimethylvaleronitrile), protective effects of NO were due to formation of iron-nitrosyl complexes whose redox interactions with t-BuOOH prevented generation of oxoferryl-Hb-derived free radical species.	UNIV PITTSBURGH, DEPT ENVIRONM & OCCUPAT HLTH, PITTSBURGH, PA 15238 USA; UNIV PITTSBURGH, DEPT PHARMACOL, PITTSBURGH, PA 15238 USA; PITTSBURGH CANC INST, PITTSBURGH, PA 15238 USA; WALTER REED ARMY INST RES, DEPT RESP RES, DIV MED, WASHINGTON, DC 20307 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)				Yalowich, Jack/0000-0001-5414-573X				[Anonymous], 1993, CA-CANCER J CLIN, V43, P47; BARNARD ML, 1993, BIOCHEM BIOPH RES CO, V192, P82, DOI 10.1006/bbrc.1993.1384; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; BASTIAN NR, 1994, BBA-MOL BASIS DIS, V1226, P225, DOI 10.1016/0925-4439(94)90033-7; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Bienvenu P, 1992, EXS, V62, P257; BRUNEL C, 1994, J AM CHEM SOC, V116, P11827, DOI 10.1021/ja00105a024; CASTNER T, 1960, J CHEM PHYS, V32, P668, DOI 10.1063/1.1730779; CERMAK J, 1993, CANCER RES, V53, P5308; CHAMULITRAT W, 1995, ARCH BIOCHEM BIOPHYS, V316, P30, DOI 10.1006/abbi.1995.1006; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; DEBONO DP, 1994, CARDIOVASC RES, V28, P1641; DEMONTELLANO PRO, 1995, BIOCHIMIE, V77, P581, DOI 10.1016/0300-9084(96)88174-0; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; ERIKSSON LEG, 1994, BIOCHEM BIOPH RES CO, V203, P176, DOI 10.1006/bbrc.1994.2165; Fabisiak JP, 1997, AM J PHYSIOL-CELL PH, V272, pC675, DOI 10.1152/ajpcell.1997.272.2.C675; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; FAULK WP, 1980, LANCET, V2, P390; FOLCH J, 1957, J BIOL CHEM, V226, P497; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Geng YJ, 1996, CANCER RES, V56, P866; GIULIVI C, 1992, ARCH BIOCHEM BIOPHYS, V299, P302, DOI 10.1016/0003-9861(92)90279-6; GORBUNOV NV, 1995, BIOCHEMISTRY-US, V34, P6689, DOI 10.1021/bi00020a014; GOSS SPA, 1995, CHEM RES TOXICOL, V8, P800, DOI 10.1021/tx00047a021; GRINBERG LN, 1994, BIOCHEM PHARMACOL, V48, P643, DOI 10.1016/0006-2952(94)90040-X; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMMER A, 1988, EICOSANOIDS LIPID PE, P221; HANN HWL, 1990, HEPATOLOGY, V11, P566, DOI 10.1002/hep.1840110407; HARA A, 1993, AM J PHYSIOL, V265, pH1478; HAREL S, 1988, FREE RADICAL RES COM, V5, P11, DOI 10.3109/10715768809068554; HAYASHI K, 1995, FEBS LETT, V370, P37, DOI 10.1016/0014-5793(95)00786-9; HE K, 1995, BIOCHEMISTRY-US, V34, P15614, DOI 10.1021/bi00048a002; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HENRY Y, 1993, FEBS LETT, V334, P170; HILLE R, 1979, J BIOL CHEM, V254, P2110; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; HOGG N, 1993, FEBS LETT, V326, P199, DOI 10.1016/0014-5793(93)81790-7; Hoshino M, 1996, J AM CHEM SOC, V118, P5702, DOI 10.1021/ja953311w; INMAN RS, 1994, BIOCHEMISTRY-US, V33, P11850, DOI 10.1021/bi00205a022; IULIANO L, 1992, ARCH BIOCHEM BIOPHYS, V299, P220, DOI 10.1016/0003-9861(92)90267-Z; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Juckett MB, 1996, FREE RADICAL BIO MED, V20, P63, DOI 10.1016/0891-5849(95)02024-1; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; Kawasaki N, 1996, ARCH BIOCHEM BIOPHYS, V328, P289, DOI 10.1006/abbi.1996.0175; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KOZLOV AV, 1992, FREE RADICAL BIO MED, V13, P9, DOI 10.1016/0891-5849(92)90159-E; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LARANJINHA J, 1995, ARCH BIOCHEM BIOPHYS, V323, P373, DOI 10.1006/abbi.1995.0057; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MACK CP, 1995, BIOCHEM BIOPH RES CO, V212, P35, DOI 10.1006/bbrc.1995.1932; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MULLEREBERHARD U, 1989, SEMIN HEMATOL, V26, P86; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NIKI E, 1990, METHOD ENZYMOL, V186, P100; NOHL H, 1993, FREE RADICAL BIO MED, V15, P257, DOI 10.1016/0891-5849(93)90072-3; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PIETRAFORTE D, 1995, BIOCHEMISTRY-US, V34, P7177, DOI 10.1021/bi00021a032; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; REDDY D, 1983, SCIENCE, V221, P769, DOI 10.1126/science.6308761; REIN H, 1972, FEBS LETT, V24, P24, DOI 10.1016/0014-5793(72)80817-2; RICHARDSON DR, 1995, BLOOD, V86, P3211; RICHARDSON DR, 1995, BBA-MOL CELL RES, V1266, P250, DOI 10.1016/0167-4889(95)00022-K; RITKE MK, 1994, BRIT J CANCER, V69, P687, DOI 10.1038/bjc.1994.131; Ritov VB, 1996, BBA-BIOMEMBRANES, V1283, P127, DOI 10.1016/0005-2736(96)00083-1; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SALERNO JC, 1979, BIOCHIM BIOPHYS ACTA, V547, P270, DOI 10.1016/0005-2728(79)90010-0; SEIBERT AF, 1991, AM J PHYSIOL, V260, pH1980, DOI 10.1152/ajpheart.1991.260.6.H1980; SEVILLA MD, 1990, INT J RADIAT BIOL, V57, P65, DOI 10.1080/09553009014550351; SHERTZER HG, 1992, BIOCHEM PHARMACOL, V44, P1367, DOI 10.1016/0006-2952(92)90538-T; SHIGA T, 1975, ARCH BIOCHEM BIOPHYS, V167, P469, DOI 10.1016/0003-9861(75)90489-0; SIMONI J, 1994, ARTIF CELL BLOOD SUB, V22, P777, DOI 10.3109/10731199409117911; SIMONI J, 1995, ASAIO J, V41, pM641, DOI 10.1097/00002480-199507000-00090; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; SUSSMAN HH, 1992, PATHOBIOLOGY, V60, P2, DOI 10.1159/000163690; SZABO A, 1976, BIOCHEMISTRY-US, V15, P4427, DOI 10.1021/bi00665a013; TAKEDA S, 1992, ANTICANCER RES, V12, P329; TAKEHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V323, P27, DOI 10.1006/abbi.1995.0005; TAKETA F, 1978, J BIOL CHEM, V253, P5448; TAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1019, DOI 10.1093/oxfordjournals.jbchem.a134017; UKEI T, 1994, TRANSPLANTATION, V58, P287; VALLANCE P, 1992, LANCET, V339, P572; VanderZee J, 1996, FREE RADICAL BIO MED, V20, P199, DOI 10.1016/0891-5849(95)02031-4; VANIN AF, 1975, STUD BIOPHYS, V49, P13; WAYLAND BB, 1974, J AM CHEM SOC, V96, P6037, DOI 10.1021/ja00826a013; WEINBERG ED, 1981, BIOL TRACE ELEM RES, V3, P55, DOI 10.1007/BF02789123; WHITBURN KD, 1982, J BIOL CHEM, V257, P1860; WINK DA, 1995, ARCH BIOCHEM BIOPHYS, V319, P402, DOI 10.1006/abbi.1995.1310; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; WU F, 1994, BBA-MOL BASIS DIS, V1225, P158, DOI 10.1016/0925-4439(94)90073-6; Yalowich JC, 1996, FASEB J, V10, P4071; YEGOROV DY, 1993, FREE RADICAL BIO MED, V15, P565, DOI 10.1016/0891-5849(93)90158-Q; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	106	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12328	12341		10.1074/jbc.272.19.12328	http://dx.doi.org/10.1074/jbc.272.19.12328			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139677	hybrid			2022-12-25	WOS:A1997WY82900014
J	Vogel, U; Jensen, KF				Vogel, U; Jensen, KF			NusA is required for ribosomal antitermination and for modulation of the transcription elongation rate of both antiterminated RNA and mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID STARVATION; ESCHERICHIA-COLI; CHAIN ELONGATION; GROWTH-RATE; GUANOSINE TETRAPHOSPHATE; PHAGE-LAMBDA; POLYMERASE; PROTEIN; TERMINATION; PPGPP	Ribosomal RNA (rRNA) is elongated twice as fast as mRNA in vivo due to the presence of antitermination sequences in the 5' part of the rRNA transcripts. A number of Nus factors bind to RNA polymerase at the antitermination sites and help confer resistance to Rho-dependent termination of transcription. In this paper, the effects of the nusAcs10 allele on the elongation rate of both mRNA and antiterminated RNA were investigated. The results indicate that NusA is required to achieve a high elongation rate of RNA chains carrying the ribosomal antitermination boxA and that antitermination is defective when the rate of transcription elongation is decreased by the nusAcs10 allele. Furthermore, the nusAcs10 allele had no significant effects on the elongation rate of normal lacZ mRNA during steady state growth, but it abolished the inhibition of lacZ mRNA elongation by guanosine 3',5'-bis(diphosphate) (ppGpp). These results suggest that NusA is the component of the transcription elongation complex required for inhibition of mRNA elongation by ppGpp.	UNIV COPENHAGEN,CTR ENZYME RES,INST MOL BIOL,DK-1307 COPENHAGEN K,DENMARK; UNIV COPENHAGEN,DEPT BIOL CHEM,DK-1307 COPENHAGEN K,DENMARK	University of Copenhagen; University of Copenhagen			Vogel, Ulla B/I-5048-2012; Vogel, Ulla/ABC-2212-2020	Vogel, Ulla B/0000-0001-6807-1524; Vogel, Ulla/0000-0001-6807-1524				AKSOY S, 1984, J BACTERIOL, V159, P260, DOI 10.1128/JB.159.1.260-264.1984; ANDERSEN JT, 1991, MOL MICROBIOL, V5, P327, DOI 10.1111/j.1365-2958.1991.tb02113.x; BARACCHINI E, 1988, MOL GEN GENET, V213, P379, DOI 10.1007/BF00339606; BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; BREMER H, 1995, BBA-GENE STRUCT EXPR, V1262, P15, DOI 10.1016/0167-4781(95)00042-F; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; CRAVEN MG, 1991, J BACTERIOL, V173, P1485, DOI 10.1128/jb.173.4.1485-1491.1991; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; FAST R, 1977, J BIOL CHEM, V252, P7620; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HORWITZ RJ, 1989, CELL, V51, P631; JENSEN KF, 1988, EUR J BIOCHEM, V175, P587, DOI 10.1111/j.1432-1033.1988.tb14232.x; Jensen KF, 1996, EUR J BIOCHEM, V240, P637, DOI 10.1111/j.1432-1033.1996.0637h.x; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; LI J, 1992, J BIOL CHEM, V267, P6012; Miller J.H., 1972, EXPT MOL GENETICS; NAKAMURA Y, 1986, J MOL BIOL, V189, P103, DOI 10.1016/0022-2836(86)90384-0; SCHAUER AT, 1987, J MOL BIOL, V194, P679, DOI 10.1016/0022-2836(87)90245-2; SCHMIDT MC, 1984, BIOCHEMISTRY-US, V23, P197, DOI 10.1021/bi00297a004; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SORENSEN MA, 1994, J MOL BIOL, V236, P441, DOI 10.1006/jmbi.1994.1156; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; VOGEL U, 1991, J BACTERIOL, V173, P1168, DOI 10.1128/jb.173.3.1168-1174.1991; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; VOGEL U, 1994, J BIOL CHEM, V269, P16236; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x; ZHENG CH, 1994, P NATL ACAD SCI USA, V91, P7543, DOI 10.1073/pnas.91.16.7543	34	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12265	12271		10.1074/jbc.272.19.12265	http://dx.doi.org/10.1074/jbc.272.19.12265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139668	hybrid			2022-12-25	WOS:A1997WY82900005
J	Wu, S; Chen, WN; Murphy, E; Gabel, S; Tomer, KB; Foley, J; Steenbergen, C; Falck, JR; Moomaw, CR; Zeldin, DC				Wu, S; Chen, WN; Murphy, E; Gabel, S; Tomer, KB; Foley, J; Steenbergen, C; Falck, JR; Moomaw, CR; Zeldin, DC			Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID EPOXYGENASE; EPOXYEICOSATRIENOIC ACIDS; MICROSOMAL CYTOCHROME-P-450; ENANTIOFACIAL SELECTIVITY; STENOTOMUS-CHRYSOPS; SMOOTH-MUSCLE; HUMAN LIVER; K+-CHANNEL; METABOLITES; LOCALIZATION	A cDNA encoding a P450 monooxygenase was amplified from reverse transcribed rat heart and liver total RNA by polymerase chain reaction using primers based on the 5'- and 3'-end sequences of two rat pseudogenes, CYP2J3P1 and CYP2J3P2. Sequence analysis revealed that this 1,778-base pair cDNA contained an open reading frame and encoded a new 502 amino acid protein designated CYP2J3. Based on the deduced amino acid sequence, CYP2J3 was approximately 70% homologous to both human CYP2J2 and rabbit CYP2J1. Recombinant CYP2J3 protein was co expressed with NADPH-cytochrome P450 oxidoreductase in Sf9 insect cells using a baculovirus expression system. Microsomal fractions of CYP2J3/NADPH-cytochrome P450 oxidoreductase-transfected cells metabolized arachidonic acid to 14,15-, 11,12-, and 8,9-epoxyeicosatrienoic acids and 19-hydroxyeicosatetraenoic acid as the principal reaction products (catalytic turnover, 0.2 nmol of product/nmol of cytochrome P450/min at 37 degrees C). Immunoblotting of microsomal fractions prepared from rat tissues using a polyclonal antibody raised against recombinant CYP2J2 that cross-reacted with CYP2J3 but not with other known rat P450s demonstrated abundant expression of CYP2J3 protein in heart and liver, Immunohistochemical staining of formalin-fixed paraffin-embedded rat heart tissue sections using the anti-CYP2J2 IgG and avidin-biotin-peroxidase detection localized expression of CYP2J3 primarily to atrial and ventricular myocytes, In an isolated-perfused rat heart model, 20 min of global ischemia followed by 40 min of reflow resulted in recovery of only 44 +/- 6% of base-line contractile function, The addition of 5 mu M 11,12-epoxyeicosatrienoic acid to the perfusate prior to global ischemia resulted in a significant 1.6 fold improvement in recovery of cardiac contractility (69 +/- 5% of base line, p = 0.01 versus vehicle alone). Importantly, neither 14,15-epoxyeicosatrienoic acid nor 19-hydroxyeicosatetraenoic acid significantly improved functional recovery following global ischemia, demonstrating the specificity of the biological effect for the 11,12-epoxyeicosatrienoic acid regioisomer. Based on these data, we conclude that (a) CYP2J3 is one of the predominant enzymes responsible for the oxidation of endogenous arachidonic acid pools in rat heart myocytes and (b) 11,12-epoxyeicosatrienoic acid may play an important functional role in the response of the heart to ischemia.	NIEHS, PULM PATHOBIOL LAB, NIH, RES TRIANGLE PK, NC 27709 USA; NIEHS, MOL BIOPHYS LAB, NIH, RES TRIANGLE PK, NC 27709 USA; NIEHS, EXPT PATHOL LAB, NIH, RES TRIANGLE PK, NC 27709 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27719 USA; UNIV TEXAS, SW MED CTR, DEPT MOL GENET, DALLAS, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Zeldin, Darryl C/Y-7091-2018; Tomer, Kenneth B/E-8018-2013	Zeldin, Darryl C/0000-0002-2087-7307; Foley, Julie/0000-0001-9726-2821; Falck, John/0000-0002-9219-7845	NHLBI NIH HHS [R01 HL039752, HL39752] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039752, R29HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM NG, 1987, J MOL CELL CARDIOL, V19, P73, DOI 10.1016/S0022-2828(87)80546-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9; CAPDEVILA J, 1985, ARCH BIOCHEM BIOPHYS, V243, P8, DOI 10.1016/0003-9861(85)90768-4; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CAPDEVILA JH, 1986, ARCH BIOCHEM BIOPHYS, V231, P511; Capdevila Jorge H., 1995, P443; CARROLL MA, 1987, EUR J PHARMACOL, V138, P281, DOI 10.1016/0014-2999(87)90445-6; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CLARE RA, 1991, J CHROMATOGR-BIOMED, V562, P237, DOI 10.1016/0378-4347(91)80581-V; COCEANI F, 1994, CAN J PHYSIOL PHARM, V72, P217, DOI 10.1139/y94-034; COMPTE J, 1978, BIOCHIMIE PARIS, V60, P1289; COREY EJ, 1980, J AM CHEM SOC, V102, P1433, DOI 10.1021/ja00524a043; CRAIG PI, 1990, MOL PHARMACOL, V38, P313; ESCALANTE B, 1988, BIOCHEM BIOPH RES CO, V152, P1269, DOI 10.1016/S0006-291X(88)80422-4; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; FALCK JR, 1982, TETRAHEDRON LETT, V23, P1755, DOI 10.1016/S0040-4039(00)86732-5; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FORRESTER LM, 1992, BIOCHEM J, V281, P359, DOI 10.1042/bj2810359; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GEBREMEDHIN D, 1992, AM J PHYSIOL, V263, pH519, DOI 10.1152/ajpheart.1992.263.2.H519; GONZALEZ FJ, 1991, METHOD ENZYMOL, V206, P93; GROSS GJ, 1992, CIRC RES, V70, P223, DOI 10.1161/01.RES.70.2.223; GUENGERICH FP, 1979, MOL PHARMACOL, V15, P154; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HECKER M, 1994, J PHYSIOL-LONDON, V481, P407, DOI 10.1113/jphysiol.1994.sp020449; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; KAMINSKY LS, 1992, CRIT REV TOXICOL, V21, P407, DOI 10.3109/10408449209089881; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1993, J BIOL CHEM, V268, P13565; KARMAZYN M, 1991, CAN J PHYSIOL PHARM, V69, P719, DOI 10.1139/y91-108; KARMAZYN M, 1986, AM J PHYSIOL, V251, pH133, DOI 10.1152/ajpheart.1986.251.1.H133; KARMAZYN M, 1984, J MOL CELL CARDIOL, V16, P1071, DOI 10.1016/S0022-2828(84)80019-X; KARMAZYN M, 1985, PROSTA LEUKOTR MED, V17, P251, DOI 10.1016/0262-1746(85)90112-X; KARMAZYN M, 1989, CAN J PHYSIOL PHARM, V67, P912, DOI 10.1139/y89-144; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KIKUTA Y, 1991, J BIOL CHEM, V266, P17821; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; KUTSKY P, 1983, PROSTAGLANDINS, V26, P13, DOI 10.1016/0090-6980(83)90070-9; KUZUYA T, 1993, CARDIOVASC RES, V27, P1056, DOI 10.1093/cvr/27.6.1056; LEE CA, 1995, ARCH BIOCHEM BIOPHYS, V319, P157, DOI 10.1006/abbi.1995.1278; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MOFFAT MP, 1993, AM J PHYSIOL, V264, pH1154, DOI 10.1152/ajpheart.1993.264.4.H1154; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; MURPHY E, 1995, CIRC RES, V76, P457, DOI 10.1161/01.RES.76.3.457; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OMURA T, 1964, J BIOL CHEM, V239, P2370; ORELLANA M, 1989, ARCH BIOCHEM BIOPHYS, V274, P251, DOI 10.1016/0003-9861(89)90437-2; PIEPER GM, 1990, AM J PHYSIOL, V258, pH923, DOI 10.1152/ajpheart.1990.258.4.H923; PORTER NA, 1979, J ORG CHEM, V44, P3177, DOI 10.1021/jo01332a017; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; RIFKIND AB, 1994, J BIOL CHEM, V269, P3387; SCHERER RW, 1990, J GEN PHYSIOL, V96, P735, DOI 10.1085/jgp.96.4.735; SERABJITSINGH CJ, 1985, MOL PHARMACOL, V28, P72; SMOLOWITZ RM, 1991, DRUG METAB DISPOS, V19, P113; STEENBERGEN C, 1993, CIRC RES, V72, P112, DOI 10.1161/01.RES.72.1.112; STEENBERGEN C, 1993, BASIC RES CARDIOL, V88, P456, DOI 10.1007/BF00795412; STEGEMAN JJ, 1982, MOL PHARMACOL, V21, P517; STEGEMAN JJ, 1989, MOL PHARMACOL, V36, P723; STRUM JM, 1990, AM J RESP CELL MOL, V2, P493, DOI 10.1165/ajrcmb/2.6.493; WATKINS PB, 1987, J CLIN INVEST, V80, P1029, DOI 10.1172/JCI113156; WRIGHT K, 1991, MOL PHARMACOL, V39, P468; Wu S, 1996, J BIOL CHEM, V271, P3460; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; ZELDIN DC, 1995, J CLIN INVEST, V95, P2150, DOI 10.1172/JCI117904	74	201	223	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12551	12559		10.1074/jbc.272.19.12551	http://dx.doi.org/10.1074/jbc.272.19.12551			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139707	hybrid			2022-12-25	WOS:A1997WY82900044
J	Baker, BF; Lot, SS; Condon, TP; ChengFlournoy, S; Lesnik, EA; Sasmor, HM; Bennett, CF				Baker, BF; Lot, SS; Condon, TP; ChengFlournoy, S; Lesnik, EA; Sasmor, HM; Bennett, CF			2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; ANTISENSE OLIGONUCLEOTIDES; CAP STRUCTURE; SECONDARY STRUCTURE; GENE INHIBITION; EXPRESSION; OLIGODEOXYNUCLEOTIDES; STABILITY; BINDING; REGION	Little is known about the mechanisms that account for inhibition of gene expression by antisense oligonucleotides at the level of molecular cell biology, For this purpose, we have selected potent 2'-O-(a-methoxy) ethyl antisense oligonucleotides (IC50 = 2 and 6 nM) that target the 5' cap region of the human intercellular adhesion molecule 1 (ICAM-1) transcript to determine their effects upon individual processes of mRNA metabolism in HUVECs. Given the functions of the 5' cap structure throughout mRNA metabolism, antisense oligonucleotides that target the 5' cap region of a target transcript have the potential to modulate one or more metabolic stages of the message inside the cell. In this study we found that inhibition of protein expression by these RNase H independent antisense oligonucleotides was not due to effects on splicing or transport of the ICAM-1 transcript, but due instead to selective interference with the formation of the 80 S translation initiation complex. Interestingly, these antisense oligonucleotides also caused an increase in ICAM-1 mRNA abundance in the cytoplasm. These results imply that ICAM-1 mRNA turnover is coupled in part to translation.			Baker, BF (corresponding author), ISIS PHARMACEUT, 2292 FARADAY AVE, CARLSBAD, CA 92008 USA.			Baker, Brenda/0000-0001-8586-768X				ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; [Anonymous], 1995, HELV CHIM ACTA, DOI DOI 10.1002/HLCA.19950780219; Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; BAKER BF, 1993, ANTISENSE RES APPL, P37; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BEAUCAGE SL, 1992, TETRAHEDRON, V48, P2223, DOI 10.1016/S0040-4020(01)88752-4; BENIMETSKAYA L, 1995, NUCLEIC ACIDS RES, V23, P4239, DOI 10.1093/nar/23.21.4239; Bennett C F, 1994, Adv Pharmacol, V28, P1, DOI 10.1016/S1054-3589(08)60492-5; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BENNETT CF, 1996, THERAPEUTIC MODULATI, P171; BERGER SL, 1989, METHOD ENZYMOL, V180, P3; BONHAM MA, 1995, NUCLEIC ACIDS RES, V23, P1197, DOI 10.1093/nar/23.7.1197; Brady H R, 1993, Curr Opin Nephrol Hypertens, V2, P171, DOI 10.1097/00041552-199303000-00001; BROWN DA, 1994, J BIOL CHEM, V269, P26801; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1991, J BIOL CHEM, V266, P2466; Condon TP, 1996, J BIOL CHEM, V271, P30398, DOI 10.1074/jbc.271.48.30398; Crooke ST, 1996, MED RES REV, V16, P319, DOI 10.1002/(SICI)1098-1128(199607)16:4<319::AID-MED2>3.0.CO;2-#; CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; Fresco LD, 1996, RNA, V2, P584; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GILES RV, 1995, ANTISENSE RES DEV, V5, P23, DOI 10.1089/ard.1995.5.23; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; HERSHEY JWB, 1996, TRANSLATION CONTROL; HOGG N, 1991, CHEM IMMUNOL, V50, P98; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; IRIBARREN AM, 1990, P NATL ACAD SCI USA, V87, P7747, DOI 10.1073/pnas.87.19.7747; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Mesmaeker A. D., 1995, ACCOUNTS CHEM RES, V28, P366; MIRABELLI CK, 1993, ANTISENSE RES APPL, P7; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PILEWSKI JM, 1995, AM J RESP CELL MOL, V12, P1; RHOADS RE, 1991, TRANSLATION EUROKARY; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Schwer B, 1996, RNA, V2, P574; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WICKSTROM E, 1986, J BIOCHEM BIOPH METH, V13, P97, DOI 10.1016/0165-022X(86)90021-7	56	298	378	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11994	12000		10.1074/jbc.272.18.11994	http://dx.doi.org/10.1074/jbc.272.18.11994			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115264	hybrid			2022-12-25	WOS:A1997WX56900052
J	Nelson, KL; Raja, SM; Buckley, JT				Nelson, KL; Raja, SM; Buckley, JT			The glycosylphosphatidylinositol-anchored surface glycoprotein Thy-1 is a receptor for the channel-forming toxin aerolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MEMBRANE; RECONSTITUTION; BIOSYNTHESIS; ANTIGEN; MOUSE; LYSIS	Aerolysin is a channel forming protein secreted by virulent Aeromonas spp. Some eucaryotic cells, including T-lymphocytes, are sensitive to very low concentrations of the toxin (<10(-9) M). Here we show that aerolysin binds selectively and with high affinity to the glycosylphosphatidylinositol (GPI)-anchored surface protein Thy-1, which is found on T-lymphocyte populations as well as in brain. Less than 1 ng of purified Thy-1 could be detected by probing Western blots with the toxin. Mutant T-cell lines that lack the ability to add GPI anchors to Thy-1 and other surface proteins were much less sensitive to aerolysin, as were wild-type cells that were pretreated with phosphatidylinositol-specific phospholipase C to remove GPI anchored proteins. Phosphatidylcholine/cholesterol liposomes containing purified Thy-1 in their membranes were much more sensitive to aerolysin than protein-free liposomes.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA,BC V8W 3P6,CANADA	University of Victoria								AMES BN, 1960, J BIOL CHEM, V235, P769; BERNHEIMER AW, 1975, INFECT IMMUN, V11, P1312, DOI 10.1128/IAI.11.6.1312-1319.1975; BINDON CI, 1988, EUR J IMMUNOL, V18, P1507, DOI 10.1002/eji.1830181006; CAMPBELL DG, 1981, BIOCHEM J, V195, P15, DOI 10.1042/bj1950015; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; GRUBER HJ, 1994, MOL MICROBIOL, V14, P1093, DOI 10.1111/j.1365-2958.1994.tb01341.x; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; HUEBER AO, 1994, J EXP MED, V179, P785, DOI 10.1084/jem.179.3.785; KNIGHT PJK, 1995, J BIOL CHEM, V270, P17765, DOI 10.1074/jbc.270.30.17765; LOW MG, 1987, BIOCHEM J, V244, P1; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MORRIS RJ, 1975, EUR J IMMUNOL, V5, P274, DOI 10.1002/eji.1830050412; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKETH RB, 1987, EMBO J, V6, P1233; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; WAITE DJ, 1993, CELL IMMUNOL, V152, P82, DOI 10.1006/cimm.1993.1269; WILLIAMS AF, 1982, SCIENCE, V216, P696, DOI 10.1126/science.6177036; XIA MQ, 1993, BIOCHEM J, V293, P633, DOI 10.1042/bj2930633; XU CS, 1987, MOL IMMUNOL, V24, P791, DOI 10.1016/0161-5890(87)90063-0; ZANG F, 1992, P NATL ACAD SCI USA, V89, P5231	26	95	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12170	12174		10.1074/jbc.272.18.12170	http://dx.doi.org/10.1074/jbc.272.18.12170			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115289	hybrid			2022-12-25	WOS:A1997WX56900077
J	Pecci, A; Scholz, A; Pelster, D; Beato, M				Pecci, A; Scholz, A; Pelster, D; Beato, M			Progestins prevent apoptosis in a rat endometrial cell line and increase the ratio of bcl-X-L to bcl-X-S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; GENE-EXPRESSION; MAMMALIAN-CELLS; UTERINE EPITHELIUM; MENSTRUAL-CYCLE; IN-VIVO; DEATH; DNA; BCL-X(L); PROGESTERONE	Endometrial cell proliferation and cell death are regulated by ovarian hormones. The fall of ovarian progesterone in late secretory phase, or the artificial withdrawal of ovarian hormones during early pregnancy, are followed by programmed cell death of uterine epithelial cells. Aspects of this cell-specific response have been reproduced in a newly established rat endometrial cell line which expresses functional progesterone receptor. At low concentrations of serum and in the absence of glucocorticoids, these cells were dependent on progestins for survival. Removal of progesterone or addition of the antiprogestins RU38486 or ZK98299 led to a substantial increase of apoptotic cells indicated by the accumulation of internucleosomally degraded DNA. The hormonal control of cell proliferation and cell death correlated with the overall quantity and distribution of the different bcl-X transcripts. Progesterone administration not only increased total bcl-X mRNA level but also shifted the quantitative ratio between the different mRNA isoforms in favor for the apoptosis inhibiting form, bcl-X-L, compared with the apoptosis promoting form, bcl-X-S. These effects were rapid and could not be prevented by inhibitors of protein synthesis. As the low level of bcl-2 and bax mRNA was not influenced by progesterone treatment, the observed changes in total amount of bcl-X transcripts and spliced isoforms could represent the mechanism by which progesterone controls cell death in epithelial cells of the endometrium.	UNIV MARBURG, INST MOL BIOL & TUMORFORSCH, D-35033 MARBURG, GERMANY	Philipps University Marburg			Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI SS, 1995, ONCOGENE, V11, P1693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELALUNA S, 1988, GENE, V62, P121; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERSCHENSON LE, 1981, J STEROID BIOCHEM, V14, P959, DOI 10.1016/0022-4731(81)90203-X; GERSCHENSON LE, 1991, APOPTOSIS MOL BASIS, P175; GOMPEL A, 1994, AM J PATHOL, V144, P1195; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HELFTENBEIN G, 1993, ONCOGENE, V8, P2075; HENSEL G, 1995, J GEN VIROL, V76, P1591, DOI 10.1099/0022-1317-76-7-1591; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HOPWOOD D, 1976, J PATHOL, V119, P159; HORWITZ KB, 1978, CANCER RES, V38, P2434; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOH EAT, 1995, HUM REPROD, V10, P1557, DOI 10.1093/HUMREP/10.6.1557; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; LYNCH MP, 1986, P NATL ACAD SCI USA, V83, P4784, DOI 10.1073/pnas.83.13.4784; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MUKHERJEE AB, 1993, MOL CELL ENDOCRINOL, V94, pR15, DOI 10.1016/0303-7207(93)90176-K; NAWAZ S, 1987, AM J PATHOL, V127, P51; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTSUKI Y, 1994, LANCET, V344, P28; ROTELLO RJ, 1992, AM J PATHOL, V140, P449; SANDOW BA, 1979, AM J ANAT, V156, P15, DOI 10.1002/aja.1001560103; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; Suhonen S, 1996, FERTIL STERIL, V65, P776, DOI 10.1016/S0015-0282(16)58213-2; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; Watson MA, 1996, CANCER RES, V56, P860; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WIEHLE RD, 1990, ONCOGENE, V5, P787; XU HM, 1993, EXP CELL RES, V209, P367, DOI 10.1006/excr.1993.1322; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	49	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11791	11798		10.1074/jbc.272.18.11791	http://dx.doi.org/10.1074/jbc.272.18.11791			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115235	hybrid			2022-12-25	WOS:A1997WX56900023
J	Dickinson, LA; Dickinson, CD; KohwiShigematsu, T				Dickinson, LA; Dickinson, CD; KohwiShigematsu, T			An atypical homeodomain in SATB1 promotes specific recognition of the key structural element in a matrix attachment region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; SCAFFOLD-ASSOCIATED REGIONS; CELL TYPE SPECIFICATION; NUCLEAR-MATRIX; POU-DOMAIN; HOMEO DOMAIN; CUT REPEATS; IN-VITRO; DROSOPHILA; ENHANCER	SATB1 is a cell type-specific nuclear matrix attachment region (MAR) DNA-binding protein, predominantly expressed in thymocytes. We identified an atyp ical homeodomain and two Cut like repeats in SATB1, in addition to the known MAR-binding domain. The isolated MAR-binding domain recognizes a certain DNA sequence context within MARs that is highly potentiated for base unpairing. Unlike the MAR-binding domain, the homeodomain when isolated binds poorly and with low specificity to DNA. However, the combined action of the MAR-binding domain and the homeodomain allows SATB1 to specifically recognize the core unwinding element within the base-unpairing region. The core unwinding element is critical for MAR structure, since point mutations within this core abolish the unwinding propensity of the MAR. The contribution of the homeodomain is abolished by alanine substitutions of arginine 3 and arginine 5 in the N-terminal arm of the homeodomain. Site-directed mutagenesis of the core unwinding element in the 3' MAR of the immunoglobulin heavy chain gene enhancer revealed the sequence 5'-(C/A)TAATA-3' to be essential for the increase in affinity mediated by the homeodomain. SATB1 may regulate T-cell development and function at the level of higher order chromatin structure through the critical DNA structural elements within MARs.	LA JOLLA CANC RES CTR,BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA039681] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA 39681] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3578; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DIETZ A, 1994, NUCLEIC ACIDS RES, V22, P2744, DOI 10.1093/nar/22.14.2744; EARNSHAW WC, 1988, BIOESSAYS, V9, P147, DOI 10.1002/bies.950090502; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; JACK J, 1991, DEVELOPMENT, V113, P735; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIU S, 1992, DEV BIOL, V150, P133, DOI 10.1016/0012-1606(92)90013-7; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURROCK SS, 1993, MPSRCH VERSION 1 3; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TSUTSUI K, 1993, J BIOL CHEM, V268, P12886; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WANG BC, 1995, J BIOL CHEM, V270, P23239, DOI 10.1074/jbc.270.40.23239; Yanagisawa J, 1996, CANCER RES, V56, P457; YU JH, 1994, GENE, V139, P139, DOI 10.1016/0378-1119(94)90747-1; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	58	98	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11463	11470						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111059				2022-12-25	WOS:A1997WW00900075
J	Hofmann, F; Busch, C; Prepens, U; Just, I; Aktories, K				Hofmann, F; Busch, C; Prepens, U; Just, I; Aktories, K			Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-PROTEINS; CRYSTAL-STRUCTURE; GENE; ENTEROTOXIN; DOMAIN; CELLS	Clostridium difficile toxin B that is one of the largest cytotoxins (270 kDa) known acts on Rho subfamily proteins by monoglucosylation (Just, I., Selzer, J., Wilm, M., von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500-503), By deletion analysis we identified the enzyme and cytotoxic activity of the toxin to be located at the N terminus of the holotoxin, A 63-kDa fragment of toxin B covering the first 546 amino acid residues glucosylated Rho, Rac, and Cdc42, but not Ras, by using UDP-glucose as a cosubstrate, As known for the holotoxin, glucosylation by the toxin fragment was favored with the GDP-bound form of the low molecular mass GTPases. Microinjection of the toxin fragment into MH-3T3 cells induced rounding up of cells and redistribution of the actin cytoskeleton. In contrast, a toxin fragment encompassing the first 516 amino acid residues was at least 1000-fold less active than toxin fragment 1-546 and cytotoxically inactive. The data give direct evidence for location of the enzyme activity of C. difficile toxin B at the N-terminal 546 amino acids residues and indicate a functionally and/or structurally important role of the region from amino acid residues 516 through 546 for enzyme and cytotoxic activities.	UNIV FREIBURG, INST PHARMAKOL & TOXIKOL, D-79104 FREIBURG, GERMANY	University of Freiburg			Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; BARROSO LA, 1990, NUCLEIC ACIDS RES, V18, P4004, DOI 10.1093/nar/18.13.4004; BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DOVE CH, 1990, INFECT IMMUN, V58, P480, DOI 10.1128/IAI.58.2.480-488.1990; Eichel-Streiber C. von, 1992, Molecular & General Genetics, V233, P260, DOI 10.1007/BF00587587; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Prepens U, 1996, J BIOL CHEM, V271, P7324, DOI 10.1074/jbc.271.13.7324; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; Thielman NM, 1995, BACTERIAL TOXINS VIR, P327; VONEICHELSTREIBER C, 1995, MOL MICROBIOL, V17, P313, DOI 10.1111/j.1365-2958.1995.mmi_17020313.x; WREN BW, 1987, J CLIN MICROBIOL, V25, P2402, DOI 10.1128/JCM.25.12.2402-2404.1987	20	140	159	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11074	11078						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111001				2022-12-25	WOS:A1997WW00900017
J	Shen, HF; Dowhan, W				Shen, HF; Dowhan, W			Regulation of phospholipid biosynthetic enzymes by the level of CDP-diacylglycerol synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLSERINE SYNTHASE; PHOSPHATIDYLINOSITOL SYNTHASE; NUCLEOTIDE-SEQUENCE; NEGATIVE REGULATOR; INO1 GENE; YEAST; INOSITOL; PROTEIN; EXPRESSION	Amine-containing phospholipid synthesis in Saccharomyces cerevisiae starts with the conversion of CDP-diacylglycerol (CDP-DAG) and serine to phosphatidylserine (PS), whereas phosphatidylinositol (PI) is formed from CDP-DAG and inositol (derived from inositol 1-phosphate). In this study the regulation of PS synthase (encoded by CHO1/PSS), PI synthase (encoded by PIS1), and inositol 1-phosphate synthase (encoded by INO1) activities by the in vivo level of CDP DAG synthase activity (encoded by CDS1) is described. Reduction in the level of CDP-DAG synthase activity from 10-fold over wild type levels to 10% of wild type levels results in a 7-fold increase in PS synthase activity, which follows a similar change in the CHO1/PSS mRNA level, INO1 mRNA also increases but only after CDP DAG synthase activity falls below the wild type level, PI synthase activity follows the decrease of the CDP-DAG synthase activity, but there is no parallel change in the level of PIS1 mRNA. These changes in CHO1/PSS and INO1 mRNA levels are mediated by a mechanism not dependent on changes in the expression of the INO2-OPI1 regulatory genes. CDS1 expression is repressed in concert with INO2 expression in response to inositol.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77225	University of Texas System								Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; ASHBURNER BP, 1995, P NATL ACAD SCI USA, V92, P9722, DOI 10.1073/pnas.92.21.9722; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BONNER JJ, 1991, GENE, V104, P113, DOI 10.1016/0378-1119(91)90475-Q; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CULBERTSON MR, 1976, J BACTERIOL, V126, P243, DOI 10.1128/JB.126.1.243-250.1976; CULBERTSON MR, 1975, GENETICS, V80, P23; *DIFC, 1984, DEH CULT MED REAG IN; DONAHUE TF, 1981, GENETICS, V98, P491; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; Greenberg ML, 1996, MICROBIOL REV, V60, P1; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HUDAK KA, 1994, GENETICS, V136, P475; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KIYONO K, 1987, J BIOCHEM-TOKYO, V102, P1089, DOI 10.1093/oxfordjournals.jbchem.a122147; KLIG LS, 1984, P NATL ACAD SCI-BIOL, V81, P3816, DOI 10.1073/pnas.81.12.3816; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; LESTER RL, 1968, J BIOL CHEM, V243, P4889; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; SCHULTZ LD, 1983, J BACTERIOL, V155, P8, DOI 10.1128/JB.155.1.8-14.1983; Shen H, 1996, J BIOL CHEM, V271, P29043, DOI 10.1074/jbc.271.46.29043; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; SIKORSKI RS, 1989, GENETICS, V122, P19; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Weeks R, 1997, DNA CELL BIOL, V16, P281, DOI 10.1089/dna.1997.16.281; WHITE MJ, 1991, J BIOL CHEM, V266, P863; YOSHIMOTO H, 1992, MOL GEN GENET, V233, P327, DOI 10.1007/BF00587597	44	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11215	11220						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111022				2022-12-25	WOS:A1997WW00900038
J	Hautmann, MB; Madsen, CS; Owens, GK				Hautmann, MB; Madsen, CS; Owens, GK			A transforming growth factor beta (TGF beta) control element drives TGF beta-induced stimulation of smooth muscle alpha-actin gene expression in concert with two CArG elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-RESPONSE-FACTOR; DNA-BINDING ACTIVITY; ANGIOTENSIN-II; TRANSCRIPTIONAL REGULATION; FUNCTIONAL PROMOTER; CHAIN GENE; CELLS; FACTOR-BETA-1; CIS; GROWTH-FACTOR-BETA-1	The goal of the present study was to determine the molecular mechanism whereby transforming growth factor beta (TGF beta) increases smooth muscle (SM) alpha-actin expression. Confluent, growth-arrested rat aortic smooth muscle cells (SMC) were transiently transfected with various SM alpha-actin promoter/chloramphenicol acetyltransferase deletion mutants and stimulated with TGF beta (2.5 ng/ml). Results demonstrated that the first 125 base pairs of the SM alpha-actin promoter were sufficient to confer TGF beta responsiveness. Three cis elements were shown to be required for TGF beta inducibility: two highly conserved CArG boxes, designated A (-62) and B (-112) and a novel TGF beta control element (TCE) (-42). Mutation of any one of these elements completely abolished TGF beta-induced reporter activity. Results of electrophoretic mobility shift assays demonstrated that nuclear extracts from TGF beta-treated SMC enhanced binding activity of serum response factor to the CArG elements and binding of an as yet unidentified factor to the TCE. Northern analysis showed that TGF beta also stimulated transcription of two other SM (SM myosin heavy chain) differentiation marker genes, SM myosin heavy chain and h(1) calponin, whose promoters also contained a TCE-like element. In summary, we identified a TGF beta response element in the SM alpha-actin promoter that may contribute to coordinate regulation of expression of multiple cell-type specific proteins during SMC differentiation.	UNIV VIRGINIA,DEPT MOL PHYSIOL & BIOL PHYS,CTR HLTH SCI,CHARLOTTESVILLE,VA 22906	University of Virginia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, R01HL038854] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 19242, R01 HL 38854] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGROTIS A, 1994, HYPERTENSION, V23, P593, DOI 10.1161/01.HYP.23.5.593; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BABIJ P, 1992, AM J PHYSIOL, V262, pC607, DOI 10.1152/ajpcell.1992.262.3.C607; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; BLANK RS, 1990, J CELL PHYSIOL, V142, P635, DOI 10.1002/jcp.1041420325; BLANK RS, 1992, J BIOL CHEM, V267, P984; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DARBY I, 1990, LAB INVEST, V63, P21; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GRAINGER DJ, 1994, BIOCHEM J, V229, P277; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HAUTMANN MB, 1996, CIRCULATION S1, V94, P226; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KIM JH, 1994, J BIOL CHEM, V269, P13740; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARIGO V, 1994, BIOCHEM BIOPH RES CO, V199, P1049, DOI 10.1006/bbrc.1994.1335; MATRISIAN LM, 1992, MOL REPROD DEV, V32, P111, DOI 10.1002/mrd.1080320206; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; MIN BH, 1990, J BIOL CHEM, V265, P16667; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MONICAL PL, 1993, AM J PHYSIOL, V264, pC1466, DOI 10.1152/ajpcell.1993.264.6.C1466; MORISAKI N, 1991, ATHEROSCLEROSIS, V88, P227, DOI 10.1016/0021-9150(91)90085-H; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NAKANO Y, 1991, GENE, V99, P285; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OWENS GK, 1995, PHYSIOL REV, V75, P487; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PAPADOPOULOS N, 1993, MOL CELL BIOL, V13, P6907, DOI 10.1128/MCB.13.11.6907; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SALTIS J, 1992, AM J PHYSIOL, V263, pC420, DOI 10.1152/ajpcell.1992.263.2.C420; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VERBEEK MM, 1994, AM J PATHOL, V144, P372; White SL, 1996, J BIOL CHEM, V271, P15008, DOI 10.1074/jbc.271.25.15008; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; WOODCOCKMITCHELL J, 1988, DIFFERENTIATION, V39, P161, DOI 10.1111/j.1432-0436.1988.tb00091.x; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	74	245	248	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10948	10956						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099754				2022-12-25	WOS:A1997WV26200088
J	Leibrecht, I; Kessler, D				Leibrecht, I; Kessler, D			A novel L-cysteine/cystine C-S-lyase directing [2Fe-2S] cluster formation of Synechocystis ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; CYANOBACTERIA; MECHANISM; CHLOROPLASTS; BINDING; PRODUCT; NIFS; DYE	Iron-sulfur proteins acquire their clusters by posttranslational assembly, To identify components involved in this process an in vitro assay for holoprotein formation was established using the [2Fe-2S] ferredoxin of the cyanobacterium Synechocystis as a model, Conversion of apoferredoxin to the holo- form was observed in an anaerobic reaction medium containing Fe(NH4)(2)(SO4)(2), L-cysteine, glutathione, and catalytic amounts of Synechocystis extract, specifically depleted of endogeneous ferredoxin, An approximate 2500-fold purification of the converter activity yielded a monomeric, 43-kDa, pyridoxal phosphate-containing enzyme, which catalyzed the breakdown of L-cysteine to yield sulfide (assembled in ferredoxin), pyruvate, and ammonia; 1 mol of [2Fe-2S] ferredoxin was formed per 2 mol of cysteine utilized, The purified enzyme also catalyzed the p-elimination reaction with cysteine in the absence of apoferredoxin. An increased reactivity was found with cystine instead of cysteine, which should yield cysteine persulfide as the primary product, These results provide a function-based identification of a cysteine/cystine C-S-lyase as a participant in ferredoxin Fe-S cluster formation. A substrate-derived cysteine persulfide could be involved in this reaction.	UNIV HEIDELBERG, INST BIOL CHEM, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								Akerboom T P, 1981, Methods Enzymol, V77, P373; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT ME, 1993, J BIOL CHEM, V268, P17126; CERLETTI P, 1986, TRENDS BIOCHEM SCI, V11, P369, DOI 10.1016/0968-0004(86)90206-9; DELAVIER.C, 1965, BIOCHIM BIOPHYS ACTA, V99, P375, DOI 10.1016/S0926-6593(65)80137-0; FISCHER EH, 1958, J AM CHEM SOC, V80, P2906, DOI 10.1021/ja01544a082; FLAVIN M, 1962, J BIOL CHEM, V237, P768; Flint DH, 1996, J BIOL CHEM, V271, P16068; GREEN MR, 1973, ANAL BIOCHEM, V56, P43, DOI 10.1016/0003-2697(73)90167-X; HASE T, 1982, J BIOCHEM-TOKYO, V92, P1357, DOI 10.1093/oxfordjournals.jbchem.a134059; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; HUTSON KG, 1980, FEMS MICROBIOL LETT, V7, P279, DOI 10.1111/j.1574-6941.1980.tb01604.x; HUTSON KG, 1978, BIOCHEM J, V172, P465, DOI 10.1042/bj1720465; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; Kaneko T, 1996, DNA Res, V3, P109; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KREDICH NM, 1973, J BIOL CHEM, V248, P6187; KREDICH NM, 1972, J BIOL CHEM, V247, P7157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALKIN R, 1966, BIOCHEM BIOPH RES CO, V23, P822, DOI 10.1016/0006-291X(66)90561-4; MEYER J, 1986, BIOCHIM BIOPHYS ACTA, V871, P243, DOI 10.1016/0167-4838(86)90205-0; MUROPASTOR MI, 1992, EUR J BIOCHEM, V203, P99, DOI 10.1111/j.1432-1033.1992.tb19833.x; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; PILON M, 1992, J BIOL CHEM, V267, P2548; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SCHMIDT A, 1988, METHOD ENZYMOL, V167, P572; Shin M, 1971, METHOD ENZYMOL, V23, P440; TAKAHASHI Y, 1991, PLANT PHYSIOL, V95, P104, DOI 10.1104/pp.95.1.104; TAKAHASHI Y, 1986, P NATL ACAD SCI USA, V83, P2434, DOI 10.1073/pnas.83.8.2434; TANIGUCHI T, 1974, BIOCHIM BIOPHYS ACTA, V364, P284, DOI 10.1016/0005-2744(74)90014-X; WASHTIEN W, 1977, BIOCHEMISTRY-US, V16, P2485, DOI 10.1021/bi00630a026; WHITE RH, 1983, BIOCHEM BIOPH RES CO, V112, P66, DOI 10.1016/0006-291X(83)91798-9; WILLIAMS DE, 1964, ANN NY ACAD SCI, V121, P373, DOI 10.1111/j.1749-6632.1964.tb14210.x; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	38	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10442	10447						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099686				2022-12-25	WOS:A1997WV26200020
J	Minetti, CASA; Tai, JY; Blake, MS; Pullen, JK; Liang, SM; Remeta, DP				Minetti, CASA; Tai, JY; Blake, MS; Pullen, JK; Liang, SM; Remeta, DP			Structural and functional characterization of a recombinant PorB class 2 protein from Neisseria meningitidis - Conformational stability and porin activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; INFLUENZAE TYPE-B; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; BACTERIAL PORIN; GONORRHOEAE; CHANNELS; IDENTIFICATION; DETERGENT; TYROSINE	An outer membrane PorB class 2 protein from Neisseria meningitidis has been overexpresed in Escherichia coli, isolated from inclusion bodies, and refolded in the presence of zwitterionic detergent. The purified recombinant and native (strain M986) counterpart exhibit most of the typical functional and structural properties that are characteristic of bacterial porins. Channel forming activity has been monitored by incorporating class 2 into reconstituted liposomes and measuring the permeation rates of various oligosaccharides through the proteoliposomes to derive a pore diameter of similar to 1.6 nm, Structural studies employing a combination of spectroscopic and electrophoretic techniques reveal that recombinant and native class 2 are identical in terms of overall conformational stability, Both proteins form stable trimers in zwitterionic detergent and retain significant secondary and tertiary structure in the presence of SDS. The thermal unfolding of zwittergen-solubilized class 2 trimers (T-m = 88 degrees C) is reversible and characterized by solvent exposure of aromatic residues with concomitant disruption of tertiary and partial loss of secondary structures. SDS-induced destabilization and irreversible unfolding of the native trimeric assembly occurs at temperatures above 60 degrees C. Our physicochemical studies of PorB class 2 protein furnish significant insight regarding the structural and functional properties of this meningococcal outer membrane protein within the porin superfamily.	NHLBI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Minetti, CASA (corresponding author), N AMER VACCINE INC,12103 INDIAN CREEK CT,BELTSVILLE,MD 20705, USA.		Minetti, Conceicao/B-5077-2009; Minetti, Conceicao/AGD-6419-2022; PULLEN, JEFFREY/Q-7144-2019	Minetti, Conceicao/0000-0002-9682-2898; Minetti, Conceicao/0000-0002-9682-2898; Liang, Shu-Mei/0000-0001-8926-4747; Remeta, David/0000-0002-4142-0904				BASH MC, 1995, INFECT IMMUN, V63, P1484, DOI 10.1128/IAI.63.4.1484-1490.1995; BLAKE MS, 1987, BACTERIAL OUTER MEMB, P377; CARBONETTI NH, 1988, P NATL ACAD SCI USA, V85, P6841, DOI 10.1073/pnas.85.18.6841; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COULTON JW, 1992, J INFECT DIS, V165, pS188, DOI 10.1093/infdis/165-Supplement_1-S188; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DOUGLAS JT, 1981, FEMS MICROBIOL LETT, V12, P305; EISELE JL, 1990, J BIOL CHEM, V265, P10217; FRASCH CE, 1985, REV INFECT DIS, V7, P504; FRASCH CE, 1978, J BACTERIOL, V136, P1127, DOI 10.1128/JB.136.3.1127-1134.1978; FRASCH CE, 1990, P 7 INT PATH NEISS C, P213; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; Knuth M. W., 1987, PROTEIN PURIFICATION, P279; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LINDORFER MA, 1990, CURRENT RES PROTEIN, P309; LYNCH EC, 1984, BIOPHYS J, V45, P104, DOI 10.1016/S0006-3495(84)84127-2; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARCOVICHOUSLEY Z, 1986, BIOCHIM BIOPHYS ACTA, V869, P158; MAURO A, 1988, P NATL ACAD SCI USA, V85, P1071, DOI 10.1073/pnas.85.4.1071; MINETTI CAS, 1995, PROTEIN SCI S1, V3, P150; MURAKAMI K, 1989, INFECT IMMUN, V57, P2318, DOI 10.1128/IAI.57.8.2318-2323.1989; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; PALVA ET, 1978, J BACTERIOL, V133, P279, DOI 10.1128/JB.133.1.279-286.1978; PARK K, 1992, PROTEIN SCI, V1, P1032, DOI 10.1002/pro.5560010809; PEBAYPEYROULA E, 1995, STRUCTURE, V3, P1051, DOI 10.1016/S0969-2126(01)00241-6; POOLMAN JT, 1980, INFECT IMMUN, V30, P642; POOLMAN JT, 1989, INFECT IMMUN, V57, P1005, DOI 10.1128/IAI.57.3.1005-1007.1989; PULLEN JK, 1995, GENE, V152, P85, DOI 10.1016/0378-1119(94)00706-X; QI HL, 1994, INFECT IMMUN, V62, P2432, DOI 10.1128/IAI.62.6.2432-2439.1994; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; RENKIN EM, 1954, J GEN PHYSIOL, V38, P225; ROCQUE WJ, 1990, BIOCHEMISTRY-US, V29, P5344, DOI 10.1021/bi00474a020; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; Rudel T, 1996, CELL, V85, P391, DOI 10.1016/S0092-8674(00)81117-4; SCHIMID B, 1996, FEBS LETT, V381, P111; SCHINDLER M, 1984, FEBS LETT, V173, P85, DOI 10.1016/0014-5793(84)81022-4; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SRIKUMAR R, 1993, INFECT IMMUN, V61, P3334, DOI 10.1128/IAI.61.8.3334-3341.1993; TANDON S, 1987, J BIOL CHEM, V262, P4486; TOKUNAGA M, 1979, EUR J BIOCHEM, V95, P441, DOI 10.1111/j.1432-1033.1979.tb12983.x; TOMASSEN J, 1990, INFECT IMMUN, V58, P1355; ULMER JB, 1992, J BIOL CHEM, V267, P19266; VANDERLEY P, 1991, INFECT IMMUN, V59, P2963, DOI 10.1128/IAI.59.9.2963-2971.1991; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; WETZLER LM, 1988, J EXP MED, V168, P1883, DOI 10.1084/jem.168.5.1883; YOUNG JDE, 1983, P NATL ACAD SCI-BIOL, V80, P3831, DOI 10.1073/pnas.80.12.3831	48	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10710	10720						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099721				2022-12-25	WOS:A1997WV26200055
J	McGilvray, ID; Lu, ZY; Bitar, R; Dackiw, APB; Davreux, CJ; Rotstein, OD				McGilvray, ID; Lu, ZY; Bitar, R; Dackiw, APB; Davreux, CJ; Rotstein, OD			VLA-4 integrin cross-linking on human monocytic THP 1 cells induces tissue factor expression by a mechanism involving mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MAP KINASE; LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; FACTOR PROMOTER; GENE INDUCTION; LIPOPOLYSACCHARIDE; BINDING	Adhesion molecules such as VLA 4 are important not only for monocyte adhesion to extracellular matrix proteins, but also for subsequent cell activation. Monocyte adherence to fibronectin or engagement of VLA-4 has been demonstrated to stimulate production of potent inflammatory mediators such as tumor necrosis factor-alpha, interleukin-1, and the procoagulant tissue factor protein, However, the intracellular signaling cascades leading to gene expression have not been elucidated, Using the human monocytic THP-1 cell line, VLA-4 cross-linking by monoclonal antibodies directed against its alpha(4) and beta(1) subunits produced a time-dependent increase in tyrosine phosphorylation of a broad range of cellular proteins, Using Western blot analysis directed against the phosphorylated form of the extracellular signal-related kinase (ERK) mitogen-activated protein (MAP) kinase proteins, as well as immunoprecipitation and in vitro kinase assays, we found that VLA-4 crosslinking increased ERK1/ERK2 tyrosine phosphorylation and activity, In conjunction, integrin cross-linking also increased NF-kappa B nuclear translocation and 4-h expression of tissue factor, Inhibition of tyrosine kinase activity with genistein (10 mu g/ml) as well as selective MAP kinase inhibition with the MEK-1 inhibitor PD98059 abolished the VLA-4-dependent ERK tyrosine phosphorylation, inhibited NF kappa B nuclear binding, and abrogated tissue factor expression induced by both VLA-4 cross-linking and adhesion to fibronectin in THP-1 cells and human peripheral blood monocytes, These studies point to the involvement of the MAP kinase pathway in the activation of monocytic cells during transmigration to inflammatory sites.	TORONTO GEN HOSP,GEN DIV,DEPT SURG,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,TORONTO,ON M5G 2C4,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto				McGilvray, Ian/0000-0003-4649-546X				ADUNYAH SE, 1995, BIOCHEM BIOPH RES CO, V206, P103, DOI 10.1006/bbrc.1995.1015; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; BRISSEAU GF, 1993, ROLE PROCOAGULANT AC, P69; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEFRANCO AL, 1995, BACTERIAL ENDOTOXINS, P407; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DURDEN DL, 1995, J IMMUNOL, V154, P4039; FAN ST, 1993, J IMMUNOL, V150, P2972; FAN ST, 1995, J IMMUNOL, V154, P3266; GARNOTEL R, 1995, J BIOL CHEM, V270, P27495, DOI 10.1074/jbc.270.46.27495; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HOGG N, 1995, IMMUNOL TODAY, V16, P327, DOI 10.1016/0167-5699(95)80147-2; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; KOONG AC, 1994, CANCER RES, V54, P5273; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LETARTE M, 1993, LEUKEMIA, V7, P93; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LIU MK, 1994, J IMMUNOL, V153, P2642; LIU MK, 1994, INFECT IMMUN, V62, P2722, DOI 10.1128/IAI.62.7.2722-2731.1994; LO SK, 1995, J IMMUNOL, V154, P4768; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MCRITCHIE DI, 1991, J LAB CLIN MED, V118, P48; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NGSIKORSKI J, 1991, EXP CELL RES, V195, P504, DOI 10.1016/0014-4827(91)90402-G; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARK JH, 1993, BLOOD, V82, P2470; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; ROTSTEIN OD, 1988, J INFECT DIS, V158, P766, DOI 10.1093/infdis/158.4.766; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; SATO T, 1995, J IMMUNOL, V155, P2939; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHAW RJ, 1990, J CELL BIOL, V111, P2139, DOI 10.1083/jcb.111.5.2139; SPORN SA, 1990, J IMMUNOL, V144, P4434; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; WHARRAM BL, 1991, J IMMUNOL, V146, P1437; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	53	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10287	10294						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092580				2022-12-25	WOS:A1997WU03900099
J	Nakagawa, H; Wang, TC; Zukerberg, L; Odze, R; Togawa, K; May, GHW; Wilson, J; Rustgi, AK				Nakagawa, H; Wang, TC; Zukerberg, L; Odze, R; Togawa, K; May, GHW; Wilson, J; Rustgi, AK			The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach	ONCOGENE			English	Article						cyclin D1; oncogene; squamous epithelial cells; transgenic mice	SQUAMOUS-CELL CARCINOMA; NECK-CANCER; P53 GENE; EXPRESSION; PROGRESSION; OVEREXPRESSION; AMPLIFICATION; FIBROBLASTS; G(1); HEAD	Cyclin D1 in cooperation with its major catalytic partners, cyclin-dependent kinases cdk4 and cdk6, facilitates progression through the G(1) phase of the eukaryotic cell cycle, in part through phosphorylation of the retinoblastoma protein, Cyclin D1's oncogenic properties have been suggested by its cooperation with ras or adenovirus E1a to transform cultured cells, as well its overexpression in transgenic mice that leads to breast cancer. Activated by a number of different mechanisms in human cancers, the cyclin D1 gene is frequently amplified in squamous epithelial cancers derived from the head/neck and esophageal regions. In order to study the functional consequences of cyclin D1 overexpression in these squamous epithelial specific sites, we have linked the Epstein-Barr virus ED-L2 promoter to the human cyclin D1 cDNA and utilized this transgene to generate founder lines. This transgene is transcribed specifically in the tongue, esophagus and forestomach, all sharing a stratified squamous epithelium. The transgene protein product localizes to the basal and suprabasal compartments of these squamous epithelial tissues, and mice from different lines develop dysplasia, a prominent precursor to carcinoma, by 16 months of age in contrast to age-matched wild-type mice, This transgenic model is useful in demonstrating cyclin D1 may be a tumor initiating event in aero-upper digestive squamous epithelial tissues.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV GLASGOW,INST BIOMED & LIFE SCI,ROBERTSON LAB BIOTECHNOL,GLASGOW,LANARK,SCOTLAND	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Glasgow					NATIONAL CANCER INSTITUTE [R01CA067463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P30DK040561] Funding Source: NIH RePORTER; NCI NIH HHS [CA67463] Funding Source: Medline; NIDDK NIH HHS [DK43351, DK40561] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHUNG KY, 1993, CANCER RES, V53, P1676; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; LIU QY, 1995, ONCOGENE, V10, P619; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORI T, 1994, CANCER RES, V54, P3396; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; VANDERRIET P, 1994, CANCER RES, V54, P1156; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILLIAMS ME, 1992, CANCER RES, V52, pS5541; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	105	110	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1185	1190		10.1038/sj.onc.1200937	http://dx.doi.org/10.1038/sj.onc.1200937			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121767				2022-12-25	WOS:A1997WM78200007
J	Takenoshita, S; Tani, M; Nagashima, M; Hagiwara, K; Bennett, WP; Yokota, J; Harris, CC				Takenoshita, S; Tani, M; Nagashima, M; Hagiwara, K; Bennett, WP; Yokota, J; Harris, CC			Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and Intron primers	ONCOGENE			English	Article						transforming growth factor beta type II receptor; colon carcinogenesis; tumor biology	MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CARCINOMA-CELLS; TGF-BETA	Mutations in the transforming growth factor beta type II receptor (TGF beta RII) gene have been detected in several human cancers exhibiting microsatellite instability. To extend analyses of this gene, we previously investigated the exon-intron organization of the TGF beta RII. gene and defined seven exons and flanking intron sequences. In this study, we further determined the nucleotide sequences surrounding these seven exons and designed eight sets of intron-based primers to examine the entire coding region of the TGF beta RII gene. Using these primers, we screened genomic DNA sequences from 30 sporadic colorectal cancers for mutations of the TGF beta RII. gene. TGF beta RII mutations were detected in two of 30 tumors and both displayed microsatellite instability. One had a deletion in a polyadenine tract in exon 3 and the other had a point mutation in the kinase domain located in exon 7. There were no mutations in exons 1, 2, 4, 5 and 6. These results further implicate the polyadenine tract and kinase domain as mutational hotspots in the TGF beta RII gene in cells,vith genomic instability and suggest that TGF beta RII gene mutations occur rarely in cells lacking genomic instability.	NCI,HUMAN CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892; NATL CANC CTR,RES INST,DIV BIOL,TOKYO 104,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan								GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISHIMARU G, 1995, INT J CANCER, V64, P153, DOI 10.1002/ijc.2910640302; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takenoshita S, 1996, GENOMICS, V36, P341, DOI 10.1006/geno.1996.0471; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044	12	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1255	1258		10.1038/sj.onc.1200938	http://dx.doi.org/10.1038/sj.onc.1200938			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121777				2022-12-25	WOS:A1997WM78200017
J	Culver, GM; McCraith, SM; Consaul, SA; Stanford, DR; Phizicky, EM				Culver, GM; McCraith, SM; Consaul, SA; Stanford, DR; Phizicky, EM			A 2'-phosphotransferase implicated in tRNA splicing is essential in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASES; WHEAT-GERM; BINDING-PROTEINS; YEAST LIGASE; ATP-BINDING; PURIFICATION; MECHANISM; SEQUENCE; ENDONUCLEASE; PHOSPHATE	The last step of tRNA splicing in the yeast Saccharo myces cerevisiae is catalyzed by an NAD dependent 2'-phosphotransferase, which transfers the splice junction 2'-phosphate from ligated tRNA to NAD to produce ADP-ribose 1 ''-2 '' cyclic phosphate. We have purified the phosphotransferase about 28,000-fold from yeast extracts and cloned its structural gene by reverse genetics. Expression of this gene (TPT1) in yeast or in Escherichia coli results in overproduction of 2'-phosphotransferase activity in extracts. Tpt1 protein is essential for vegetative growth in yeast, as demonstrated by gene disruption experiments. No obvious binding motifs are found within the protein. Several candidate homologs in other organisms are identified by searches of the data base, the strongest of which is in Schizosaccharomyces pombe.	UNIV ROCHESTER, SCH MED, DEPT BIOCHEM & BIOPHYS, ROCHESTER, NY 14642 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT BIOL CHEM, HERSHEY, PA 17033 USA	University of Rochester; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			McCraith, Stephen/AAX-9625-2020		NIDCR NIH HHS [T32-DE07202] Funding Source: Medline; NIGMS NIH HHS [GM-52347] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052347] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI DG, 1985, EMBO J, V4, P3289, DOI 10.1002/j.1460-2075.1985.tb04079.x; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BELFORD HG, 1993, J BIOL CHEM, V268, P2444; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Briggs MW, 1996, GENETICS, V143, P1149; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; CULVER GM, 1994, J BIOL CHEM, V269, P24928; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; CUSSACK S, 1993, BIOCHEMIE PARIS, V758, P1077; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; Genschik P, 1997, J BIOL CHEM, V272, P13211, DOI 10.1074/jbc.272.20.13211; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GREER CL, 1986, MOL CELL BIOL, V6, P635, DOI 10.1128/MCB.6.2.635; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HOPPER AK, 1993, MOL CELLULAR BIOL YE, P99; HOUNTONDJI C, 1993, BIOCHIMIE, V75, P1137, DOI 10.1016/0300-9084(93)90013-I; JONSSON ZO, 1994, GENE, V151, P177, DOI 10.1016/0378-1119(94)90652-1; KIERZEK R, 1994, NUCLEOS NUCLEOT, V13, P1757, DOI 10.1080/15257779408009478; KIKUCHI Y, 1982, NUCLEIC ACIDS RES, V10, P7521, DOI 10.1093/nar/10.23.7521; KISSELEV LL, 1993, BIOCHIMIE, V75, P1027, DOI 10.1016/0300-9084(93)90002-A; KNAPP G, 1979, CELL, V18, P37, DOI 10.1016/0092-8674(79)90351-9; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; LASKI FA, 1983, J BIOL CHEM, V258, P1974; MARHALL T, 1984, ANAL BIOCHEM, V136, P340; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6684; PICK L, 1986, J BIOL CHEM, V261, P6694; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3634, DOI 10.1128/MCB.14.6.3634; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMBROOK J, 1989, MOL CLONING LAB MANU, P318; SCHWARTZ RC, 1983, J BIOL CHEM, V258, P8374; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SZEKELY E, 1988, J BIOL CHEM, V263, P13839; TYC K, 1987, J BIOL CHEM, V262, P12994; UCHIDA K, 1994, MOL CELL BIOCHEM, V138, P25, DOI 10.1007/BF00928439; VANTOL H, 1988, NUCLEIC ACIDS RES, V16, P1951, DOI 10.1093/nar/16.5.1951; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; ZILLMANN M, 1992, J BIOL CHEM, V267, P10289	55	81	91	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13203	13210		10.1074/jbc.272.20.13203	http://dx.doi.org/10.1074/jbc.272.20.13203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148937	hybrid			2022-12-25	WOS:A1997WZ38400050
J	Nishikawa, S; Endo, T				Nishikawa, S; Endo, T			The yeast JEM1p is a DnaJ-like protein of the endoplasmic reticulum membrane required for nuclear fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; KARYOGAMY GENE; BIP; ER; TRANSLOCATION; BIP/KAR2P; HOMOLOG; PATHWAY; KAR2	DnaJ-like proteins are functional partners for Hsp70 molecular chaperones, Complete nucleotide sequencing of yeast chromosome X has revealed that an open reading frame YJL073w encodes a novel member of the DnaJ-like protein family. The open reading frame represents a protein of 692 amino acids with a J-domain and one putative membrane-spanning segment. An epitope-tagged version of the protein was anchored in the endoplasmic reticulum (ER) membrane and its J-domain faced the ER lumen. We therefore propose to designate this gene JEM1 (DnaJ-like protein of the ER membrane) and to designate its gene product JEM1p. The JEM1 gene is not essential for cell growth, but double disruption of the JEM1 gene and the SCJ1 gene, which encodes another DnaJ-like protein in the ER lumen, causes growth arrest at elevated temperature. The Delta jem1 mutant is defective in nuclear fusion, karyogamy, during mating. A mutant JEM1p carrying a mutation in the highly conserved His-Pro-Asp sequence in the J-domain could not complement either temperature-sensitive growth of the Delta jem1 Delta scj1 double mutant or defects in karyogamy of the Delta jem1 mutant. JEM1p likely assists the functions of BiP, Hsp70 in the ER, including karyogamy.	NAGOYA UNIV,FAC SCI,DEPT CHEM,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN	Nagoya University								AZPIROZ R, 1993, MOL BIOL CELL, V4, P21, DOI 10.1091/mbc.4.1.21; Baxter BK, 1996, MOL CELL BIOL, V16, P6444; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KESZENMANPEREYRA D, 1988, CURR GENET, V13, P21, DOI 10.1007/BF00365751; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; Ng DTW, 1996, J CELL BIOL, V132, P499, DOI 10.1083/jcb.132.4.499; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; QADOTA H, 1992, YEAST, V8, P735, DOI 10.1002/yea.320080906; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROSE MD, 1991, ANNU REV MICROBIOL, V45, P539; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; WAL D, 1994, J BIOL CHEM, V269, P5446; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	29	74	79	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12889	12892		10.1074/jbc.272.20.12889	http://dx.doi.org/10.1074/jbc.272.20.12889			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148890	hybrid			2022-12-25	WOS:A1997WZ38400003
J	Pons, J; Querol, E; Planas, A				Pons, J; Querol, E; Planas, A			Mutational analysis of the major loop of Bacillus 1,3-1,4-beta-D-glucan 4-glucanohydrolases - Effects on protein stability and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANIDINE-HYDROCHLORIDE DENATURATION; ACID-SEQUENCE SIMILARITIES; SITE-DIRECTED MUTAGENESIS; BETA-GLUCANASE GENE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; THERMAL-STABILITY; LICHENIFORMIS; SUBTILIS	The carbohydrate-binding cleft of Bacillus licheniformis mis 1,3-1,4-beta-D-glucan 4-glucanohydrolase is partially covered by the surface loop between residues 51 and 67, which is linked to beta-strand-(87-95) of the minor beta-sheet III of the protein core by a single disulfide bond at Cys(61)-Cys(90). An alanine scanning mutagenesis approach has been applied to analyze the role of loop residues from Asp(51) to Arg(64) in substrate binding and stability by means of equilibrium urea denaturation, enzyme thermotolerance, and kinetics, The Delta Delta G(U) between oxidized and reduced forms is approximately constant for all mutants, with a contribution of 5.3 +/- 0.2 kcal.mol(-1) for the disulfide bridge to protein stability, A good correlation is observed between Delta G(U) values by reversible unfolding and enzyme thermotolerance. The N57A mutant, however, is more thermotolerant than the wild-type enzyme, whereas it is slightly less stable to reversible urea denaturation, Mutants with a <2-fold increase in K-m correspond to mutations at residues not involved in substrate binding, for which the reduction in catalytic efficiency (k(cat)/K-m) is proportional to the loss of stability relative to the wild-type enzyme, Y53A, N55A, F59A, and W63A, on the other hand, show a pronounced effect on catalytic efficiency, with K-m > 2-fold and k(cat) < 5% of the wild-type values, These mutated residues are directly involved in substrate binding or in hydrophobic packing of the loop, Interestingly, the mutation M58A yields an enzyme that is more active than the wild-type enzyme (7-fold increase in k(cat)), but it is slightly less stable.	UNIV RAMON LLULL, INST QUIM SARRIA, BIOCHEM LAB, BARCELONA 08017, SPAIN; UNIV AUTONOMA BARCELONA, INST BIOL FONAMENTAL V VILLAR PALASI, BELLATERRA 08193, BARCELONA, SPAIN; UNIV AUTONOMA BARCELONA, DEPT BIOQUIM & BIOL MOL, BELLATERRA 08193, BARCELONA, SPAIN	Universitat Ramon Llull; Institut Quimic de Sarria; Autonomous University of Barcelona; Autonomous University of Barcelona			PLANAS, ANTONI/I-4803-2015	PLANAS, ANTONI/0000-0001-7073-3320				ANDERSON MA, 1975, FEBS LETT, V52, P202, DOI 10.1016/0014-5793(75)80806-4; BORRIS R, 1988, J BASIC MICROB, V28, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUENO A, 1990, J BACTERIOL, V172, P2160, DOI 10.1128/jb.172.4.2160-2167.1990; CANTWELL BA, 1983, GENE, V23, P211, DOI 10.1016/0378-1119(83)90053-7; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; FLINT HJ, 1993, J BACTERIOL, V175, P2943, DOI 10.1128/JB.175.10.2943-2951.1993; GONSALBES MJ, 1991, J BACTERIOL, V173, P7705; GOWARD CR, 1994, EUR J BIOCHEM, V224, P249, DOI 10.1111/j.1432-1033.1994.tb20018.x; GREENE RF, 1974, J BIOL CHEM, V249, P5388; HAHN M, 1995, J BIOL CHEM, V270, P3081, DOI 10.1074/jbc.270.7.3081; HAHN M, 1995, EUR J BIOCHEM, V232, P849, DOI 10.1111/j.1432-1033.1995.tb20883.x; HAHN M, 1995, FEBS LETT, V374, P221, DOI 10.1016/0014-5793(95)01111-Q; HARDY F, 1994, PROTEIN ENG, V7, P425, DOI 10.1093/protein/7.3.425; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HINCHLIFFE E, 1984, J GEN MICROBIOL, V130, P1285; HOFEMEISTER J, 1986, GENE, V49, P177, DOI 10.1016/0378-1119(86)90278-7; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; LLOBERAS J, 1991, EUR J BIOCHEM, V197, P337, DOI 10.1111/j.1432-1033.1991.tb15916.x; LOUW ME, 1993, APPL MICROBIOL BIOT, V38, P507, DOI 10.1007/BF00242946; MALET C, 1993, BIOCHEM J, V296, P753, DOI 10.1042/bj2960753; Malet C, 1996, J BIOTECHNOL, V48, P209, DOI 10.1016/0168-1656(96)01511-8; MALET C, 1995, CARBOHYD RES, V274, P285, DOI 10.1016/0008-6215(95)00102-Y; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; OKITA B, 1989, BIOTECHNOL BIOENG, V34, P854, DOI 10.1002/bit.260340615; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; PACE CN, 1992, J MOL BIOL, V226, P29, DOI 10.1016/0022-2836(92)90121-Y; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; Planas A, 1995, PROGR BIOTECHNOL, V10, P85, DOI 10.1016/S0921-0423(06)80096-1; PLANAS A, 1992, APPL MICROBIOL BIOT, V37, P583; Pons J, 1995, PROTEIN ENG, V8, P939, DOI 10.1093/protein/8.9.939; Sambrook J., 2002, MOL CLONING LAB MANU; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; SCHIMMING S, 1991, BIOCHEM BIOPH RES CO, V177, P447, DOI 10.1016/0006-291X(91)92004-4; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SHARP KA, 1991, BIOCHEMISTRY-US, V30, P9686, DOI 10.1021/bi00104a017; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; TEATHER RM, 1990, J BACTERIOL, V172, P3837, DOI 10.1128/jb.172.7.3837-3841.1990; TEATHER RM, 1982, APPL ENVIRON MICROB, V43, P777, DOI 10.1128/AEM.43.4.777-780.1982; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; Volkin D B, 1995, Methods Mol Biol, V40, P35; [No title captured]	50	17	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13006	13012		10.1074/jbc.272.20.13006	http://dx.doi.org/10.1074/jbc.272.20.13006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148909	hybrid			2022-12-25	WOS:A1997WZ38400022
J	Samsonoff, WA; Reston, J; McKee, M; OConnor, B; Galivan, J; Maley, G; Maley, F				Samsonoff, WA; Reston, J; McKee, M; OConnor, B; Galivan, J; Maley, G; Maley, F			Intracellular location of thymidylate synthase and its state of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; LOCALIZATION; PROTEIN; GENE; DNA; REDUCTASE; COMPLEX; DESIGN; ENZYME; RNA	Thymidylate synthase (TS), an enzyme that is essential for DNA synthesis, was found to be associated mainly with the nucleolar region of H35 rat hepatoma cells, as determined both by immunogold electron microscopy and by autoradiography, In the latter case, the location of TS was established through the use of [6-H-3]5-fluorodeoxyuridine, which forms a tight ternary complex of TS with 5-fluorodeoxyuridylate (FdUMP) and 5,10-methylenetetrahydrofolylpolyglutamate within the cell, However, with H35 cells containing 50-100-fold greater amounts of TS than unmodified H35 cells, the enzyme, although still in the nucleus, was located primarily in the cytoplasm as shown by autoradiography and immunohistochemistry. In addition, TS was also present in mitochondrial extracts of both cell lines, as determined by enzyme activity measurements and by ternary complex formation with [P-32]FdUMP and 5,10-methylenetetrahydrofolate. Another unique observation is that the enzyme appears to be a phosphoprotein, similar to that found for other proteins associated with cell division and signal transduction. The significance of these findings relative to the role of TS in cell division remains to be determined, but suggest that this enzyme's contribution to the cell cycle may be more complex than believed previously.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center					NATIONAL CANCER INSTITUTE [R35CA044355, R01CA025933] Funding Source: NIH RePORTER; NCI NIH HHS [CA25933, CA44355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], [No title captured]; AYUSAWA D, 1983, J BIOL CHEM, V258, P48; BROWN SS, 1965, BIOCHEM J, V97, pC34, DOI 10.1042/bj0970034C; CARO LG, 1962, J CELL BIOL, V15, P173, DOI 10.1083/jcb.15.2.173; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; CHU E, 1995, MOL CELL BIOL, V15, P179, DOI 10.1128/MCB.15.1.179; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CIESLA J, 1995, BBA-GENE STRUCT EXPR, V1261, P233, DOI 10.1016/0167-4781(95)00008-5; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HECHEMY KE, 1989, J CLIN MICROBIOL, V27, P377, DOI 10.1128/JCM.27.3.377-384.1989; HORIE N, 1992, BIOCHEM BIOPH RES CO, V185, P127, DOI 10.1016/S0006-291X(05)80965-9; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JOHNSTON PG, 1991, CANCER RES, V51, P6668; KUCERA R, 1986, EXP CELL RES, V167, P417, DOI 10.1016/0014-4827(86)90182-5; Ladner RD, 1996, J BIOL CHEM, V271, P7752, DOI 10.1074/jbc.271.13.7752; Ladner RD, 1996, J BIOL CHEM, V271, P7745, DOI 10.1074/jbc.271.13.7745; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Lyon CE, 1997, EXP CELL RES, V230, P84, DOI 10.1006/excr.1996.3380; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MALEY F, 1995, BIOCHEMISTRY-US, V34, P1469, DOI 10.1021/bi00005a001; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; Neuburger M, 1996, J BIOL CHEM, V271, P9466, DOI 10.1074/jbc.271.16.9466; NOGUCHI H, 1983, CELL, V32, P443, DOI 10.1016/0092-8674(83)90464-6; POON PP, 1994, J BIOL CHEM, V269, P8341; REDDY GPV, 1977, P NATL ACAD SCI USA, V74, P3152, DOI 10.1073/pnas.74.8.3152; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; REICH SH, 1992, J MED CHEM, V35, P847, DOI 10.1021/jm00083a007; Reston J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P493; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RHEE MS, 1990, CANCER RES, V50, P3979; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; Schiffer CA, 1995, BIOCHEMISTRY-US, V34, P16279, DOI 10.1021/bi00050a007; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; ULMAN B, 1978, P NATL ACAD SCI USA, V75, P980; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHEELER L, 1992, J BIOL CHEM, V267, P7664	39	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13281	13285		10.1074/jbc.272.20.13281	http://dx.doi.org/10.1074/jbc.272.20.13281			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148948	hybrid			2022-12-25	WOS:A1997WZ38400061
J	Makino, Y; Amada, K; Taguchi, H; Yoshida, M				Makino, Y; Amada, K; Taguchi, H; Yoshida, M			Chaperonin-mediated folding of green fluorescent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPHILIC BACTERIUM; THERMUS-THERMOPHILUS; HOLO-CHAPERONIN; GROEL; MICROSCOPY; EXPRESSION; BINDING; RELEASE	Chaperonin-mediated folding of green fluorescent protein (GFP) was examined by real time monitoring of recovery of fluorescence and by gel filtration high-performance liquid chromatography, Acid-denatured GFP can fold spontaneously upon dilution into the neutral buffer, When Escherichia coli GroEL/ES was present, folding of GFP was arrested. Folding was resumed by subsequent addition of 100 mu m or 1 mM ATP, and native GFP was regenerated to 100% yield. When folding was resumed by 10 mu M ATP (1.4 mol/mol GroEL subunit), about 60% of GFP recovered native structure, and one-half of them (30%) was found to be still bound to GroEL/ES, indicating the occurrence of folding in the central cavity of the GroEL ring underneath GroES (cis-folding), Because the overall rates of GroEL/ES, ATP-mediated GFP folding were all similar to that of spontaneous folding, it was concluded that cis-folding proceeded as fast as spontaneous folding, The GroEL/ES-bound native GFP was observed only when both GroES and ATP (but not ADP) were present in the folding mixture, Holo-chaperonin from Thermus thermophilus, which was purified as a cpn60/10 complex, exhibited the similar cis-folding, Consistently, ATP-dependent exchange of cpn10 in the holo-chaperonin with free cpn10 was observed.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			taguchi, hideki/AAM-2663-2021; Taguchi, Hideki/B-6946-2009	taguchi, hideki/0000-0002-6612-9339; Taguchi, Hideki/0000-0002-6612-9339				AMADA K, 1995, J BIOCHEM-TOKYO, V118, P347, DOI 10.1093/oxfordjournals.jbchem.a124913; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BOKMAN SH, 1981, BIOCHEM BIOPH RES CO, V101, P1372, DOI 10.1016/0006-291X(81)91599-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Muneyuki E, 1996, J BIOCHEM-TOKYO, V120, P940; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	36	76	78	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12468	12474		10.1074/jbc.272.19.12468	http://dx.doi.org/10.1074/jbc.272.19.12468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139695	hybrid			2022-12-25	WOS:A1997WY82900032
J	Goswami, A; Singh, S; Redkar, VD; Sharma, S				Goswami, A; Singh, S; Redkar, VD; Sharma, S			Characterization of P0, a ribosomal phosphoprotein of Plasmodium falciparum - Antibody against amino-terminal domain inhibits parasite growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TRYPANOSOMA-CRUZI; PROTEINS; ANTIGENS; INVITRO; RNA; LOCALIZATION; EXPRESSION; MALARIA	A cDNA expression clone of the human malarial parasite Plasmodium falciparum, lambda Pf4, which was reactive only to the immune sera and not to the patient sera, has recently been found to be the P. falciparum homologue of the P0 ribosomal phosphoprotein gene. A Northern analysis of the P0 gene revealed the presence of two transcripts, both present in all the different intraerythrocytic stages of the parasite life cycle. A 138-base pair amino-terminal domain of this gene was expressed as a fusion protein with glutathione S-transferase in Escherichia coli. Polyclonal antibodies raised against this domain immunoprecipitated the expected 38-kDa P0 protein from the S-35-labeled as well as P-32-labeled P. falciparum cultures. Monospecific human immune sera affinity-purified using the expression clone lambda Pf4 also immunoprecipitated the same size protein from [S-35]methionine labeled P. falciparum protein extract. Purified IgG from polyclonal antibodies raised against the amino-terminal domain of P0 protein completely inhibited the growth of P. falciparum in vitro. This inhibition appears to be mainly at the step of erythrocyte invasion by the parasites.	TATA INST FUNDAMENTAL RES,MOL BIOL UNIT,BOMBAY 400005,MAHARASHTRA,INDIA	Tata Institute of Fundamental Research (TIFR)								ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; Goswami A, 1996, MOL BIOCHEM PARASIT, V82, P117, DOI 10.1016/0166-6851(96)02717-X; JAKOBSEN PH, 1991, APMIS, V99, P155, DOI 10.1111/j.1699-0463.1991.tb05133.x; KOREN E, 1992, J CLIN INVEST, V89, P1236, DOI 10.1172/JCI115707; KUMAR N, 1991, MOL BIOCHEM PARASIT, V48, P47, DOI 10.1016/0166-6851(91)90163-Z; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LEVIN MJ, 1993, PARASITOL TODAY, V9, P381, DOI 10.1016/0169-4758(93)90088-W; LOBO CA, 1994, MOL BIOCHEM PARASIT, V68, P151, DOI 10.1016/0166-6851(94)00155-3; LOBO CA, 1994, INFECT IMMUN, V62, P651, DOI 10.1128/IAI.62.2.651-656.1994; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; NARANDA T, 1993, J BIOL CHEM, V268, P2451; RATHOD PK, 1992, ANTIMICROB AGENTS CH, V36, P704, DOI 10.1128/AAC.36.4.704; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; SANTOS C, 1994, J BIOL CHEM, V269, P15689; SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L; SKEIKY YAW, 1994, INFECT IMMUN, V62, P1643, DOI 10.1128/IAI.62.5.1643-1651.1994; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; ZINKER S, 1976, J BIOL CHEM, V251, P1799; ZUCKERMAN A, 1967, B WORLD HEALTH ORGAN, V37, P431; [No title captured]	29	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12138	12143		10.1074/jbc.272.18.12138	http://dx.doi.org/10.1074/jbc.272.18.12138			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115284	Green Submitted, hybrid			2022-12-25	WOS:A1997WX56900072
J	Hellermann, GR; Solomonson, LP				Hellermann, GR; Solomonson, LP			Calmodulin promotes dimerization of the oxygenase domain of human endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; ERYTHROCYTE CA-2+-ATPASE; ELECTRON-TRANSFER; BINDING DOMAINS; TETRAHYDROBIOPTERIN; OLIGOMERIZATION; EXPRESSION; ENZYME; IDENTIFICATION; ACTIVATION	The active form of endothelial nitric oxide synthase (eNOS) is a homodimer, The activity of the enzyme is regulated in vivo by calcium signaling involving the binding of calmodulin (CAM), which triggers the activation of eNOS, We have examined the possible role of calcium-mediated CAM binding in promoting dimerization of eNOS through the oxygenase domain of the enzyme, A recombinant form of the oxygenase domain of human eNOS was expressed in a prokaryotic expression system, This recombinant domain contains the catalytic cytochrome P-450 site for arginine oxidation by molecular oxygen as well as the binding sites for tetrahydrobiopterin and Ca2+-CAM but lacks the reductase domain and associated FAD, FMN, and NADPH binding sites, Binding of Ca2+-CAM caused an association of monomeric eNOS oxygenase domain as determined by changes in fluorescence, both intrinsic and extrinsic, and by gel filtration, chemical cross-linking, and particle-sizing, Dimerization of the domain was not dependent on the presence of the substrate, arginine, or the cofactor, tetrahydrobiopterin. A truncated form of the eNOS oxygenase domain lacking the Ca2+-CAM binding region did not undergo self-association to form dimers, These results show that the eNOS reductase domain is not required for Ca2+-CAM-induced dimerization of eNOS and suggest that this dimerization may be a primary event in the activation of eNOS by Ca2+.	UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; UNIV S FLORIDA,INST BIOMOL SCI,TAMPA,FL 33612; UNIV S FLORIDA,H LEE MOFFIT CANC CTR & RES INST,TAMPA,FL 33612	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida			Hellermann, Gary/A-8855-2013					ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BABIYCHUK EB, 1995, BIOCHEMISTRY-US, V34, P6366, DOI 10.1021/bi00019a015; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Hellermann Gary R., 1996, FASEB Journal, V10, pA437; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KINCAID RL, 1988, METHOD ENZYMOL, V159, P557; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P3772, DOI 10.1021/bi00467a025; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; Lowe PN, 1996, BIOCHEM J, V314, P55, DOI 10.1042/bj3140055; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHANG MJ, 1995, J BIOL CHEM, V270, P20901, DOI 10.1074/jbc.270.36.20901	30	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12030	12034		10.1074/jbc.272.18.12030	http://dx.doi.org/10.1074/jbc.272.18.12030			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115269	hybrid			2022-12-25	WOS:A1997WX56900057
J	Lehmann, S; Chiesa, R; Harris, DA				Lehmann, S; Chiesa, R; Harris, DA			Evidence for a six-transmembrane domain structure of presenilin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; GLUTAMATE-RECEPTOR; MEMBRANE-PROTEIN; GENE; TOPOLOGY; SEQUENCE	Mutations in genes encoding presenilin 1 and presenilin 2 account for the majority of cases of early-onset familial Alzheimer's disease, The presenilins have been localized to the endoplasmic reticulum and Golgi, but which of the multiple hydrophobic segments of the polypeptide chain span the lipid bilayer is unclear. To address this question, we have constructed a series of chimeric molecules in which a topologically neutral reporter protein (a C-terminal fragment of prolactin) containing three artificial glycosylation sites is fused to presenilin 1 following each of the 10 potential transmembrane domains identified in hydrophobicity plots. We have expressed these chimeras by translation in reticulocyte lysate containing canine pancreatic microsomes and by synthesis in transfected COS cells. Based on utilization of the glycosylation sites and sensitivity of the reporter to protease digestion, we provide evidence that presenilin 1 has six transmembrane segments with the N and C termini in the cytoplasm. This model provides important clues to the potential functions of different parts of the presenilin molecule and how these might relate to the pathogenesis of Alzheimer's disease.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Chiesa, Roberto/G-1561-2017; Lehmann, Sylvain/P-1301-2017	Chiesa, Roberto/0000-0002-3842-3733; Lehmann, Sylvain/0000-0001-6117-562X; Harris, David/0000-0002-6985-5790	Telethon [139/B] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Busfield Frances, 1995, P59, DOI 10.1016/B978-012286965-5/50006-6; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; HENNESSEY ES, 1993, CURR OPIN STRUC BIOL, V3, P524, DOI 10.1016/0959-440X(93)90078-Y; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; IQBAL K, 1995, RES ADV ALZHEIMERS D; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe D. J., 1996, Society for Neuroscience Abstracts, V22, P278; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SLUNT HH, 1995, AMYLOID, V2, P188, DOI 10.3109/13506129509036925; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yamamoto A, 1996, BIOCHEM BIOPH RES CO, V226, P536, DOI 10.1006/bbrc.1996.1390	31	138	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12047	12051		10.1074/jbc.272.18.12047	http://dx.doi.org/10.1074/jbc.272.18.12047			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115271	hybrid			2022-12-25	WOS:A1997WX56900059
J	Melillo, G; Taylor, LS; Brooks, A; Musso, T; Cox, GW; Varesio, L				Melillo, G; Taylor, LS; Brooks, A; Musso, T; Cox, GW; Varesio, L			Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; PICOLINIC-ACID; ERYTHROPOIETIN GENE; INTERFERON-GAMMA; MURINE MACROPHAGES; MOUSE MACROPHAGES; MAMMALIAN-CELLS; QUINOLINIC ACID; BONE-MARROW; FACTOR-I	We have previously reported that a 19-base pair element of the 5'-flanking region of the inducible nitric oxide synthase (iNOS) gene containing a sequence homology to a hypoxia-responsive enhancer (iNOS-HRE) mediates picolinic acid (PA)- or hypoxia-induced activation of the iNOS promoter in interferon-gamma (IFN-gamma)-treated murine macrophages. The iron chelator desferrioxamine (DFX) induces the activity of the human erythropoietin enhancer in Hep3B cells. We have investigated the influence of DFX on the activation of the iNOS promoter and iNOS gene expression in ANA-1 macrophages. We have found that DFX induced DNA-binding activity to the hypoxia-inducible factor 1 (HIF-1) consensus sequence of the iNOS promoter and activated the iNOS-HRE in murine macrophages. These activities of DFX were associated with a synergistic induction of iNOS mRNA expression and iNOS transcription in IFN-gamma-treated ANA-1 macrophages. Functional analysis of the 5'-flanking region of the iNOS gene demonstrated that IFN-gamma plus DFX activated the full-length iNOS promoter and that the iNOS-HRE was required for DFX-induced iNOS transcriptional activity. We also investigated the role of iron metabolism in the DFX- or PA dependent induction of HIF-1 activity and iNOS expression, We demonstrate that addition of iron sulfate completely abolished DFX or PA induction of HIF-1 binding and iNOS-HRE activation and abrogated IFN-gamma plus either DFX- or PA-induced iNOS expression. These data establish that DFX is a co-stimulus for the transcriptional activation of the iNOS gene in IFN-gamma-treated macrophages, and they provide evidence that the iNOS-HRE is required for the DFX-dependent activation of the iNOS promoter. Furthermore, our results indicate that the iNOS-HRE is a regulatory element of the iNOS pro meter responsive to iron chelation.	NCI, INTRAMURAL RES SUPPORT PROGRAM,SAIC FREDERICK, FREDERICK CANC RES & DEV CTR,NIH, FREDERICK, MD 21702 USA; NCI, EXPT IMMUNOL LAB,DIV BASIC SCI, FREDERICK CANC RES & DEV CTR,NIH, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			varesio, luigi/J-8261-2016	varesio, luigi/0000-0001-5659-2218; MUSSO, Tiziana/0000-0002-7487-6078	Telethon [A.075] Funding Source: Medline	Telethon(Fondazione Telethon)		ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BLATT J, 1994, ANTICANCER RES, V14, P2109; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RR, 1989, CANCER RES, V49, P4941; COBBS CS, 1995, CANCER RES, V55, P727; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONFRANCESCO A, 1995, EUR J CANCER, V31A, P612, DOI 10.1016/0959-8049(95)00068-T; FERNANDEZPOL JA, 1977, P NATL ACAD SCI USA, V74, P2889, DOI 10.1073/pnas.74.7.2889; FERNANDEZPOL JA, 1977, BIOCHEM BIOPH RES CO, V78, P136, DOI 10.1016/0006-291X(77)91231-1; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GIARDINA PJ, 1995, SEMIN HEMATOL, V32, P304; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLUB EI, 1989, NUCLEIC ACIDS RES, V17, P4902, DOI 10.1093/nar/17.12.4902; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HELFMAN T, 1993, AM J MED SCI, V306, P37, DOI 10.1097/00000441-199307000-00010; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KRUCK TPA, 1993, CLIN PHARMACOL THER, V53, P30, DOI 10.1038/clpt.1993.6; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MELILLO G, 1993, J IMMUNOL, V150, P4031; MELILLO G, 1994, J BIOL CHEM, V269, P8128; Melillo G, 1996, J IMMUNOL, V157, P2638; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; VARESIO L, 1990, J IMMUNOL, V145, P4265; VOEST EE, 1993, CANCER CHEMOTH PHARM, V31, P357, DOI 10.1007/BF00686148; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	50	184	191	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12236	12243		10.1074/jbc.272.18.12236	http://dx.doi.org/10.1074/jbc.272.18.12236			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115299	hybrid			2022-12-25	WOS:A1997WX56900087
J	Adak, S; Mazumdar, A; Banerjee, RK				Adak, S; Mazumdar, A; Banerjee, RK			Low catalytic turnover of horseradish peroxidase in thiocyanate oxidation - Evidence for concurrent inactivation by cyanide generated through one-electron oxidation of thiocyanate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HYDROGEN-PEROXIDE; NMR-SPECTROSCOPY; ESCHERICHIA-COLI; IODIDE OXIDATION; PROSTHETIC HEME; ACTIVE-SITE; LACTOPEROXIDASE; BINDING; MECHANISM	The catalytic turnover of horseradish peroxidase (HRP) to oxidize SCN- is a hundredfold lower than that oflactoperoxidase (LPO) at optimum pH. While studying the mechanism, HRP was found to be reversibly inactivated following pseudo-first order kinetics with a second order rate constant of 400 M-1 min(-1) when incubated with SCN- and H2O2. The slow rate of SCN- oxidation is increased severalfold in the presence of free radical traps, 5-5-dimethyl-1-pyrroline N-oxide or alpha-phenyl-tert-butylnitrone, suggesting the plausible role of free radical or radical derived product in the inactivation. Spectral studies indicate that SCN- at a lower concentrations slowly reduces compound II to native state by one-electron transfer as evidenced by a time-dependent spectral shift from 418 to 402 nm through an isosbestic point at 408 nm, In the presence of higher concentrations of SCN-, a new stable Soret peak appears at 421 nm with a visible peak at 540 nm, which are the characteristics of the inactivated enzyme. The one-electron oxidation product of SCN- was identified by electron spin resonance spectroscopy as 5-5-dimethyl-1-pyrroline N-oxide adduct of the sulfur-centered thiocyanate radical (a(N) = 15.0 G and a beta(H) = 16.5 G). The inactivation of the enzyme in the presence of SCN- and H2O2 is prevented by electron donors such as iodide or guaiacol, Binding studies indicate that both iodide and guaiacol compete with SCN- for binding at or near the SCN- binding site and thus prevent inactivation, The spectral characteristics of the inactivated enzyme are exactly similar to those of the native HRP-CN- complex, Quantitative measurements indicate that HRP produces a 10-fold higher amount of CN- than LPO when incubated with SCN- and H2O2. As HRP has higher affinity for CN- than LPO, it is concurrently inactivated by CN- formed during SCN- oxidation, which is not observed in case of LPO. This study further reveals that HRP catalyzes SCN- oxidation by two one electron transfers with the intermediate formation of thiocyanate radicals, The radicals dimerize to form thiocyanogen, (SCN)(2), which is hydrolyzed to form CN-. As LPO forms OSCN- as the major stable oxidation product through a two-electron transfer mechanism, it is not significantly inactivated by CN- formed in a small quantity.	INDIAN INST CHEM BIOL,DEPT PHYSIOL,CALCUTTA 700032,W BENGAL,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)								ADAK S, 1995, BIOCHEMISTRY-US, V34, P12998, DOI 10.1021/bi00040a010; Adak S, 1996, BIOCHEM J, V314, P985, DOI 10.1042/bj3140985; AIBARA S, 1982, J BIOCHEM-TOKYO, V92, P531, DOI 10.1093/oxfordjournals.jbchem.a133961; ARAISO T, 1976, BIOCHEMISTRY-US, V15, P3059, DOI 10.1021/bi00659a019; ATOR MA, 1987, J BIOL CHEM, V262, P1542; AUNE TM, 1978, BIOCHEMISTRY-US, V17, P1005, DOI 10.1021/bi00599a010; AUNE TM, 1977, EUR J BIOCHEM, V80, P209, DOI 10.1111/j.1432-1033.1977.tb11873.x; BANDYOPADHYAY U, 1995, BIOCHEM J, V306, P751, DOI 10.1042/bj3060751; BETTS RH, 1953, J AM CHEM SOC, V75, P5721, DOI 10.1021/ja01118a069; BHATTACHARYYA DK, 1994, BIOCHEM J, V298, P281, DOI 10.1042/bj2980281; BHATTACHARYYA DK, 1992, J BIOL CHEM, V267, P9800; BJORKSTEN F, 1970, BIOCHIM BIOPHYS ACTA, V212, P396, DOI 10.1016/0005-2744(70)90245-7; CARLSTROM A, 1969, ACTA CHEM SCAND, V23, P203, DOI 10.3891/acta.chem.scand.23-0203; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; CHANCE B, 1951, SCIENCE, V109, P204; CHUNG J, 1970, ARCH BIOCHEM BIOPHYS, V141, P73, DOI 10.1016/0003-9861(70)90108-6; DAS D, 1995, BIOCHEM J, V305, P59, DOI 10.1042/bj3050059; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DOLMAN D, 1968, BIOCHEMISTRY-US, V7, P3991, DOI 10.1021/bi00851a028; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; DUNFORD HB, 1985, J BIOL CHEM, V250, P2920; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HILDEBRANDT AG, 1975, ARCH BIOCHEM BIOPHYS, V171, P385, DOI 10.1016/0003-9861(75)90047-8; HOG DM, 1970, BIOCHEM J, V117, P779; HUGHES MN, 1975, CHEM BIOCH THIOCYANI, P1; JAGO GR, 1962, P SOC EXP BIOL MED, V111, P585, DOI 10.3181/00379727-111-27862; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; LAMAR GN, 1992, BIOCHEMISTRY-US, V31, P9158, DOI 10.1021/bi00153a007; LOEW GH, 1995, BIOCHEM SOC T, V23, P250, DOI 10.1042/bst0230250; MAGNUSSON RP, 1984, J BIOL CHEM, V259, P197; Mazumdar A, 1996, BIOCHEM J, V314, P413, DOI 10.1042/bj3140413; Mehlhorn H, 1996, FEBS LETT, V378, P203, DOI 10.1016/0014-5793(95)01448-9; METODIEWA D, 1992, ARCH BIOCHEM BIOPHYS, V296, P27, DOI 10.1016/0003-9861(92)90540-D; MODI S, 1990, INDIAN J CHEM A, V29, P301; MODI S, 1989, J BIOL CHEM, V264, P19677; MODI S, 1991, BIOCHIM BIOPHYS ACTA, V1080, P45, DOI 10.1016/0167-4838(91)90110-L; MODI S, 1991, BIOCHEMISTRY-US, V30, P118, DOI 10.1021/bi00215a018; MODI S, 1989, BIOCHEMISTRY-US, V28, P4689, DOI 10.1021/bi00437a027; MORRISON M, 1976, ANNU REV BIOCHEM, V45, P861, DOI 10.1146/annurev.bi.45.070176.004241; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; MOTTLEY C, 1988, ARCH BIOCHEM BIOPHYS, V267, P681, DOI 10.1016/0003-9861(88)90077-X; MOTTLEY C, 1982, J BIOL CHEM, V257, P5050; MOTTLEY C, 1987, MOL PHARMACOL, V31, P417; MOTTLEY C, 1989, BIOL MAGN RESON, V8, P502; OLEA F, 1992, J ANAL TOXICOL, V16, P258, DOI 10.1093/jat/16.4.258; PRUITT KM, 1982, BIOCHIM BIOPHYS ACTA, V704, P204, DOI 10.1016/0167-4838(82)90147-9; REITER B, 1976, INFECT IMMUN, V13, P800, DOI 10.1128/IAI.13.3.800-807.1976; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; SAKURADA J, 1987, J BIOL CHEM, V262, P4007; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; Saunders B.C., 1964, PEROXIDASE, P214; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; Tenovuo J. O., 1985, Immunology Series, V27, P101; THOMAS EL, 1981, BIOCHEMISTRY-US, V20, P3273, DOI 10.1021/bi00514a045; Thomas EL, 1985, LACTOPEROXIDASE SYST, P31; VEITCH NC, 1990, EUR J BIOCHEM, V189, P351, DOI 10.1111/j.1432-1033.1990.tb15496.x; VEITCH NC, 1995, EUR J BIOCHEM, V233, P650, DOI 10.1111/j.1432-1033.1995.650_2.x; VEITCH NC, 1992, EUR J BIOCHEM, V207, P521, DOI 10.1111/j.1432-1033.1992.tb17078.x; VEITCH NC, 1995, BIOCHEM SOC T, V23, P232, DOI 10.1042/bst0230232; YAMAZAKI I, 1960, J BIOL CHEM, V235, P2444; YAMAZAKI I, 1977, FREE RADICALS BIOL, V3, P183	68	39	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11049	11056						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9110998				2022-12-25	WOS:A1997WW00900014
J	Cheskis, BJ; Karathanasis, S; Lyttle, CR				Cheskis, BJ; Karathanasis, S; Lyttle, CR			Estrogen receptor ligands modulate its interaction with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-INDEPENDENT TRANSACTIVATION; RESPONSE ELEMENT; NUCLEAR RECEPTORS; BINDING-PROPERTIES; STEROID-HORMONES; UTERINE ESTROGEN; THYROID-HORMONE; IN-VITRO; TRANSCRIPTION; ANTIESTROGENS	The estrogen receptor (ER) belongs to a superfamily of ligand-inducible transcription factors. Functions of these proteins (dimerization, DNA binding, and interaction with other transcription factors) are modulated by binding of their corresponding ligands. It is, however, controversial whether various ER ligands affect the receptor's ability to bind its specific DNA element (ERE). By using real time interaction analysis we have investigated the kinetics of human (h)ER binding to DNA in the absence and presence of 17 beta estradiol, 17 alpha-ethynyl estradiol, analogs of tamoxifen, raloxifene, and ICI-182,780, We show that ligand binding dramatically influences the kinetics of hER interaction with specific DNA. We have found that binding of estradiol induces the rapid formation of a relatively unstable ER.ERE complex, and binding of ICI-182,780 leads to slow formation (k(alpha) is approximately 10 times lower) of a stable receptor-DNA complex (k(d) is almost 2 orders of magnitude lower). Therefore, binding of estradiol accelerates the frequency of receptor-DNA complex formation more than 50-fold, compared with unliganded ER, and more than 1000-fold compared with ER liganded with ICI-182,780. We hypothesize that a correlation exists between the rate of gene transcription and the frequency of receptor-DNA complex formation. We further show that a good correlation exists between the kinetics of hER-ERE interaction induced by a ligand and its biological effect.			Cheskis, BJ (corresponding author), WYETH AYERST RES,WOMENS HLTH RES INST,DEPT NUCL RECEPTORS,145 KING OF PRUSSIA RD,RADNOR,PA 19087, USA.							ARBUCKLE ND, 1992, NUCLEIC ACIDS RES, V20, P3839, DOI 10.1093/nar/20.15.3839; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BONDESON K, 1993, ANAL BIOCHEM, V214, P245, DOI 10.1006/abio.1993.1484; BROWN M, 1990, J BIOL CHEM, V265, P11238; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Cheskis B, 1996, BIOCHEMISTRY-US, V35, P3309, DOI 10.1021/bi952283r; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; CHESKIS B, 1995, MOL ENDOCRINOL, V9, P1814, DOI 10.1210/me.9.12.1814; CURTIS SW, 1991, MOL ENDOCRINOL, V5, P959, DOI 10.1210/mend-5-7-959; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHER RJ, 1994, PROTEIN SCI, V3, P257; Fisher Robert J., 1994, Methods (Orlando), V6, P121, DOI 10.1006/meth.1994.1015; FURLOW JD, 1993, J BIOL CHEM, V268, P12519; GORDON MS, 1986, J STEROID BIOCHEM, V25, P177, DOI 10.1016/0022-4731(86)90414-0; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HOFFMAN WL, 1989, ANAL BIOCHEM, V181, P318, DOI 10.1016/0003-2697(89)90250-9; HUTCHENS TW, 1989, J BIOL CHEM, V264, P17206; ING NH, 1992, J BIOL CHEM, V267, P17617; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KARLSON R, 1991, J IMMUNOL METHODS, V145, P287; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOMM BS, 1995, END SOC 77 ANN M, P424; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; SABBAH M, 1991, P NATL ACAD SCI USA, V88, P390, DOI 10.1073/pnas.88.2.390; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SASSON S, 1988, MOL ENDOCRINOL, V2, P307, DOI 10.1210/mend-2-4-307; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; SUNDSTROM SA, 1989, J BIOL CHEM, V264, P16941; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; XING H, 1993, J BIOL CHEM, V268, P23227	49	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11384	11391						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111047				2022-12-25	WOS:A1997WW00900063
J	Matern, H; Heinemann, H; Legler, G; Matern, S				Matern, H; Heinemann, H; Legler, G; Matern, S			Purification and characterization of a microsomal bile acid beta-glucosidase from human liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOLICHYL-PHOSPHATE GLUCOSYLTRANSFERASE; ENDOPLASMIC-RETICULUM; GEL-ELECTROPHORESIS; GAUCHER DISEASE; CALF LIVER; GLUCOCEREBROSIDASE; OLIGOSACCHARIDES; CHOLESTASIS; ENZYMES	A human liver microsomal beta-glucosidase has been purified to apparent homogeneity in sodium dodecyl sulfate-polyacrylamide gel electrophoresis where a single protein band of M-r 100,000 was obtained under reducing conditions, The enzyme was enriched about 73,000 fold over starting microsomal membranes by polyethylene glycol fractionation, anion exchange chromatographies on DEAE-Trisacryl, and Mono Q followed by affinity chromatography on N-(9-carboxynonyl)-1-deoxynojirimycin-AH-Sepharose 4B. The purified enzyme had a pH optimum between 5.0 and 6.4, was activated by divalent metal ions, and required phospholipids for exhibition of activity, The enzyme catalyzed the hydrolysis of 3 beta-D-glucosido-lithocholic and 3 beta-D-glucosido-chenodeoxycholic acids with high affinity (K-m, 1.7 and 6.2 mu M, respectively) and of the beta-D-glucoside (K-m, 210 mu M) and the beta-D-galactoside of 4-methylumbelliferone. The ratio of relative reaction rates for these substrates was about 6:3:11:1, No activity was detectable toward 6 beta-D-glucosido-hyodeoxycholic acid, glucocerebroside, and the following glycosides of 4-methylumbelliferone: alpha-D-glucoside, alpha-L-arabinoside, beta-D-fucoside or beta-D-xyloside. Immunoinhibition and immunoprecipitation studies using antibodies prepared against lysosomal glucocerebrosidase showed no cross-reactivity with microsomal beta-glucosidase suggesting that these two enzymes are antigenically unrelated.	RHEIN WESTFAL TH AACHEN, DEPT INTERNAL MED 3, D-52074 AACHEN, GERMANY; UNIV COLOGNE, INST BIOCHEM, D-50674 COLOGNE, GERMANY	RWTH Aachen University; University of Cologne								AERTS JMFG, 1990, BIOCHIM BIOPHYS ACTA, V1041, P55, DOI 10.1016/0167-4838(90)90122-V; CHESTER MA, 1976, BIOCHIM BIOPHYS ACTA, V429, P517, DOI 10.1016/0005-2744(76)90299-0; COLEMAN R, 1973, BIOCHIM BIOPHYS ACTA, V300, P1, DOI 10.1016/0304-4157(73)90010-5; DANIELS LB, 1981, J BIOL CHEM, V256, P3004; DINUR T, 1984, ANAL BIOCHEM, V136, P223, DOI 10.1016/0003-2697(84)90329-4; GARTUNG C, 1994, J HEPATOL, V20, P32, DOI 10.1016/S0168-8278(05)80464-7; GARTUNG C, 1993, GASTROENTEROLOGY, V104, pA905; GRABOWSKI GA, 1984, ARCH BIOCHEM BIOPHYS, V231, P144, DOI 10.1016/0003-9861(84)90371-0; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HO MW, 1973, BIOCHEM J, V136, P821, DOI 10.1042/bj1360821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legler G, 1977, Methods Enzymol, V46, P368; LEGLER G, 1988, ARCH BIOCHEM BIOPHYS, V260, P427, DOI 10.1016/0003-9861(88)90466-3; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; MARET A, 1981, EUR J BIOCHEM, V115, P455; MARSCHALL HU, 1987, FEBS LETT, V213, P411, DOI 10.1016/0014-5793(87)81532-6; MARSCHALL HU, 1994, J LIPID RES, V35, P1599; MATERN H, 1990, EUR J BIOCHEM, V190, P99, DOI 10.1111/j.1432-1033.1990.tb15551.x; MATERN H, 1992, FEBS LETT, V314, P183, DOI 10.1016/0014-5793(92)80970-R; MATERN H, 1984, P NATL ACAD SCI-BIOL, V81, P7036, DOI 10.1073/pnas.81.22.7036; MATERN H, 1990, FEBS LETT, V270, P11, DOI 10.1016/0014-5793(90)81223-B; MATERN H, 1982, J BIOL CHEM, V257, P7422; MATERN S, 1994, FALK SYMP, V75, P62; OSIECKINEWMAN KM, 1986, ENZYME, V35, P147, DOI 10.1159/000469336; PENTCHEV PG, 1973, J BIOL CHEM, V248, P5256; RACKER E, 1967, FED PROC, V26, P1335; RADOMINSKA A, 1993, SEMIN LIVER DIS, V13, P219, DOI 10.1055/s-2007-1007351; RADOMINSKA A, 1993, J BIOL CHEM, V268, P15127; SAUVE DM, 1995, ANAL BIOCHEM, V226, P382, DOI 10.1006/abio.1995.1242; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; SURESHKUMAR TK, 1993, ANAL BIOCHEM, V213, P226; TASHEVA B, 1983, ANAL BIOCHEM, V129, P98, DOI 10.1016/0003-2697(83)90057-X; WIETHOLTZ H, 1991, HEPATOLOGY, V13, P656, DOI 10.1002/hep.1840130408; YAQOOB M, 1980, BIOCHEM J, V185, P541, DOI 10.1042/bj1850541	35	44	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11261	11267						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111029				2022-12-25	WOS:A1997WW00900045
J	Wu, XJ; Sakata, N; Lele, KM; Zhou, MY; Jiang, HS; Ginsberg, HN				Wu, XJ; Sakata, N; Lele, KM; Zhou, MY; Jiang, HS; Ginsberg, HN			A two-site model for ApoB degradation in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; G2 CELLS; MCA-RH7777 CELLS; RAT HEPATOCYTES; OLEIC-ACID	Newly synthesized apolipoprotein B (apoB) under goes rapid degradation in a pre-Golgi compartment in HepG2 cells, A major site of this early degradation seems to be on the cytosolic side of the endoplasmic reticulum (ER) membrane and is sensitive to N-acetyl-leucinyl-leucinyl-norleucinal (ALLN), which can inhibit neutral cysteine proteases and/or proteasome activity, Oleate (OA) treatment, which facilitates translocation of nascent apoB across the ER membrane, also reduces early degradation, In the present studies, we have used brefeldin A (BFA), which inhibits vesicular transport from the ER to the Golgi, to demonstrate that apoB can also be degraded by an ER luminal proteolytic activity that is distinct from the ALLN-sensitive proteases, Thus, when BFA-treated HepGa cells were co-treated with ALLN, which protects apoB but does not facilitate its translocation into the ER lumen, degradation of newly synthesized apoB was significantly reduced compared with cells incubated with BFA alone, However, apoB degradation was rapid and complete when OA was added to media containing either BFA or ALLN/BFA, These results suggested that OA, by increasing translocation of nascent apoE into the ER lumen, exposed apoB to an ALLN-resistant proteolytic pathway, When we incubated HepGa cells with dithiothreitol (DTT)/OA/BFA or DTT/OA/ALLN/BFA, degradation of apoB was inhibited, Furthermore, addition of DTT resulted in the accumulation of a 70-kDa amino terminal fragment of apoB, Both full-length and amino terminal apoB were degraded if DTT was removed from the incubation media; both were secreted if only BFA was removed, Thus, even after apoE is translocated into the ER lumen (thereby avoiding the initial proteolytic pathway), it can potentially be degraded by a lumenal proteolytic process that is ALLN-resistant but DTT-sensitive, The present results, together with previous studies, suggest that at least two distinct steps may be involved in the posttranslational degradation of apoB: 1) the first occurs while apoB is partially translocated and is ALLN-sensitive; and 2) the second occurs in the ER lumen and is DTT-sensitive. Finally, our results support the hypothesis that degradation of partially translocated apoB generates a 70-kDa amino-terminal fragment that is mainly degraded in the ER lumen by a DTT sensitive pathway.			Wu, XJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,630 W 168TH ST,NEW YORK,NY 10032, USA.		Sakata, Nobuhiro/ACN-9770-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36000, HL 21007] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; DASHTI N, 1989, J LIPID RES, V30, P1365; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; ELOVSON J, 1994, CIRCULATION, V90, P185; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALLACH SM, 1995, BBA-MOL CELL RES, V1265, P29, DOI 10.1016/0167-4889(95)00239-O; SATO R, 1990, J BIOL CHEM, V265, P11880; Shelness GS, 1996, J LIPID RES, V37, P408; THRIFT RN, 1986, J LIPID RES, V27, P236; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	32	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11575	11580						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111073				2022-12-25	WOS:A1997WW00900089
J	Baca, M; Presta, LG; OConnor, SJ; Wells, JA				Baca, M; Presta, LG; OConnor, SJ; Wells, JA			Antibody humanization using monovalent phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; INTERLEUKIN-2 RECEPTOR; HYPERVARIABLE REGIONS; FRAMEWORK RESIDUES; BINDING-PROPERTIES; CONFORMATION; THERAPY; DNA; PHARMACOKINETICS; IMMUNOGLOBULINS	Antibody humanization often requires the replacement of key residues in the framework regions with corresponding residues from the parent non-human antibody. These changes are in addition to grafting of the antigen-binding loops, Although guided by molecular modeling, assessment of which framework changes are beneficial to antigen binding usually requires the analysis of many different antibody mutants, Here we describe a phage display method for optimizing the framework, of humanized antibodies by random mutagenesis of important framework residues. We have applied this method to humanization of the anti-vascular endothelial growth factor murine monoclonal antibody A4.6.1. Affinity panning of a library of humanized A4.6.1 antibody mutants led to the selection of one variant with greater than 125-fold enhanced affinity for antigen relative to the initial humanized antibody with no framework changes. A single additional mutation gave a further 6-fold improvement in binding, The affinity of this variant, 9.3 nnl, was only B-fold weaker than that of a murine/human chimera of A4.6,1, This method provides a general means of rapidly selecting framework mutations that improve the binding of humanized antibodies to their cognate antigens and may prove an attractive alternative to current methods of framework optimization based on cycles of site-directed mutagenesis.	GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA; GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ALLEN PM, 1985, J IMMUNOL, V135, P368; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; EIGENBROT C, 1994, PROTEINS, V18, P49, DOI 10.1002/prot.340180107; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GARRARD LJ, 1991, BIO-TECHNOL, V9, P1373, DOI 10.1038/nbt1291-1373; HAKIMI J, 1991, J IMMUNOL, V147, P1352; JAFFERS GJ, 1986, TRANSPLANTATION, V41, P572, DOI 10.1097/00007890-198605000-00004; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; JUNGHANS RP, 1990, CANCER RES, V50, P1495; Kabat EA, 1991, SEQUENCES PROTEINS I; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KETTLEBOROUGH CA, 1991, PROTEIN ENG, V4, P773, DOI 10.1093/protein/4.7.773; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MILLER RA, 1983, BLOOD, V62, P988; PADLAN EA, 1991, MOL IMMUNOL, V28, P489, DOI 10.1016/0161-5890(91)90163-E; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Pulito VL, 1996, J IMMUNOL, V156, P2840; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; ROGUSKA MA, 1994, P NATL ACAD SCI USA, V91, P969, DOI 10.1073/pnas.91.3.969; Rosok MJ, 1996, J BIOL CHEM, V271, P22611, DOI 10.1074/jbc.271.37.22611; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHALABY MR, 1992, J EXP MED, V175, P217, DOI 10.1084/jem.175.1.217; SHAWLER DL, 1985, J IMMUNOL, V135, P1530; STEPHENS S, 1995, IMMUNOLOGY, V85, P668; STUDNICKA GM, 1994, PROTEIN ENG, V7, P805, DOI 10.1093/protein/7.6.805; TEMPEST PR, 1991, BIO-TECHNOL, V9, P266, DOI 10.1038/nbt0391-266; TRAMONTANO A, 1990, J MOL BIOL, V215, P175, DOI 10.1016/S0022-2836(05)80102-0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	40	112	310	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10678	10684						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099717				2022-12-25	WOS:A1997WV26200051
J	Bousquet, C; Ray, DW; Melmed, S				Bousquet, C; Ray, DW; Melmed, S			A common pro-opiomelanocortin-binding element mediates leukemia inhibitory factor and corticotropin-releasing hormone transcriptional synergy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ANTERIOR-PITUITARY CELLS; GENE-EXPRESSION; PROTEIN-KINASE; C-FOS; RESPONSIVE ELEMENT; INTERFERON-ALPHA; FACTOR RECEPTOR; BETA-ENDORPHIN; TUMOR-CELLS	Using murine AtT20 pituitary cells transfected with a rat pro-opiomelanocortin (POMC) promoter (-706/+64) linked to the luciferase reporter, we showed leukemia inhibitory factor (LIF) to strongly potentiate corticotropin-releasing hormone (CRH) induction of POMC gene expression. We therefore tested mechanisms for molecular interactions between LIF and CRH. Although LIF and CRH synergized to induce an 8-fold induction of POMC transcription, CRH alone (but not LIF) induced cAMP response element-binding protein phosphorylation (5-fold) or an increase of c-fos mRNA levels (>100-fold), suggesting that these pathways are not implicated in LIF transcriptional synergistic effects. Using a DNase I footprint assay, POMC promoter regions protected by AtT20 cell nuclear extracts were identified (-121/-109,and -143/-134, and -173/-160). The protected -173/-160 element fused to a heterologous promoter conferred LIF-CRH synergy (6.5-fold induction of POMC) and formed a specific complex with AtT20 cell nuclear extracts. This complex was supershifted by an anti-phosphoserine antibody, and a serine/threonine kinase inhibitor also altered both this complex and LIF-CRH transcriptional synergy on the POMC promoter-luciferase reporter construct, indicating that these events depend on post-translational serine phosphorylations. LIF-CRH synergy on POMC transcription is therefore mediated at least in part by -173/-160 sequences conferring confluent transcriptional activity of both peptides.	UNIV CALIF LOS ANGELES,CEDARS SINAI RES INST,SCH MED,DEPT MED,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Bousquet, Corinne/P-2917-2014	Bousquet, Corinne/0000-0002-2501-0593; Ray, David/0000-0002-4739-6773				AKITA S, 1995, J CLIN INVEST, V95, P1288, DOI 10.1172/JCI117779; AUTELITANO DJ, 1989, ANNU REV PHYSIOL, V51, P715, DOI 10.1146/annurev.physiol.51.1.715; BERNARDINI R, 1990, ENDOCRINOLOGY, V126, P2876, DOI 10.1210/endo-126-6-2876; BERNTON EW, 1987, SCIENCE, V238, P519, DOI 10.1126/science.2821620; BOUTILLIER AL, 1995, MOL ENDOCRINOL, V9, P745, DOI 10.1210/me.9.6.745; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHIN R, 1988, CELL, V54, P541; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FANDREY J, 1994, EUR J BIOCHEM, V226, P335, DOI 10.1111/j.1432-1033.1994.tb20057.x; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GUILD S, 1987, J PHARMACOL EXP THER, V241, P125; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; JIN WD, 1994, MOL ENDOCRINOL, V8, P1377, DOI 10.1210/me.8.10.1377; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; Maniatis T., 1982, MOL CLONING; MIYAZAKI K, 1984, ENDOCRINOLOGY, V115, P1933, DOI 10.1210/endo-115-5-1933; Ray DW, 1996, J CLIN INVEST, V97, P1852, DOI 10.1172/JCI118615; REISINE T, 1985, P NATL ACAD SCI USA, V82, P8261, DOI 10.1073/pnas.82.23.8261; Sacerdote Paola, 1994, Neuroimmunomodulation, V1, P357, DOI 10.1159/000097188; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHUAI K, 1992, SCIENCE, V258, P1808; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SPANGELO BL, 1989, ENDOCRINOLOGY, V125, P575, DOI 10.1210/endo-125-1-575; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Stefana B, 1996, P NATL ACAD SCI USA, V93, P12502, DOI 10.1073/pnas.93.22.12502; SUDA T, 1989, ENDOCRINOLOGY, V124, P1444, DOI 10.1210/endo-124-3-1444; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VONDREDEN G, 1988, NEUROENDOCRINOLOGY, V47, P32, DOI 10.1159/000124887; Wang ZY, 1996, ENDOCRINOLOGY, V137, P2947, DOI 10.1210/en.137.7.2947; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Yarwood SJ, 1996, BIOCHEM BIOPH RES CO, V224, P734, DOI 10.1006/bbrc.1996.1092; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	43	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10551	10557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099700				2022-12-25	WOS:A1997WV26200034
J	Gong, MC; Fujihara, H; Somlyo, AV; Somlyo, AP				Gong, MC; Fujihara, H; Somlyo, AV; Somlyo, AP			Translocation of rhoA associated with Ca2+ sensitization of smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; GTP-BINDING PROTEINS; CLOSTRIDIUM-BOTULINUM; KINASE-C; SIGNAL-TRANSDUCTION; PHOSPHATASE; INVOLVEMENT; INHIBITION; EXOENZYME; SENSITIVITY	We determined the relationship between the localization of rhoA and Ca2+ sensitization of force in smooth muscle. In alpha-toxin-permeabilized rabbit portal vein at pCa 6.5, the particulate hydrophobic fraction of rhoA (10 +/- 1.6% of the total) was significantly increased by phenylephrine to 18 +/- 5.5% at 5 min, by AlF4- to 26 +/- 8.4% at 20 min, and dose-dependently up to 62 +/- 9.5% by guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S; 0.3-50 mu M). Translocation of rhoA was selective (Rac1 and Cdc42 were not translocated) and was quantitatively correlated (up to similar to 50%; r = 0.91, p < 0.05) with Ca2+ sensitization; high GTP gamma S concentrations (greater than or equal to 10 mu M) further increased translocation without increasing force. The initial recruitment of rhoA to the membrane paralleled the time course of contraction, but sensitization could be reversed without a decrease in particulate rhoA. High [Ca2+] (pCa 4.5) also increased particulate rhoA to 31 +/- 5.8%. Membrane-associated rhoA in unstimulated portal vein was a good substrate for in vitro ADP-ribosylation, whereas the large amount translocated by GTP gamma S was not. We conclude that 1) translocation of rhoA plays a causal role in Ca2+ sensitization, and 2) membrane bound rhoA can exist in two or more states.	UNIV VIRGINIA, CTR HLTH SCI, DEPT MOL PHYSIOL & BIOL PHYS, CHARLOTTESVILLE, VA 22906 USA; UNIV VIRGINIA, CTR HLTH SCI, DEPT PATHOL, CHARLOTTESVILLE, VA 22906 USA; UNIV VIRGINIA, CTR HLTH SCI, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22906 USA	University of Virginia; University of Virginia; University of Virginia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURMEYSTER N, 1992, BIOCHEMISTRY-US, V31, P12863, DOI 10.1021/bi00166a022; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; FRITZ G, 1994, BBA-MOL CELL RES, V1222, P331, DOI 10.1016/0167-4889(94)90038-8; FUJITA A, 1995, J PHARMACOL EXP THER, V274, P555; Gailly P, 1997, J PHYSIOL-LONDON, V500, P95, DOI 10.1113/jphysiol.1997.sp022002; Gong MC, 1997, MOL BIOL CELL, V8, P279, DOI 10.1091/mbc.8.2.279; GONG MC, 1992, J BIOL CHEM, V267, P21492; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; GONG MC, 1992, J BIOL CHEM, V267, P14662; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Horiguchi S, 1992, Osaka City Med J, V38, P79; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; ITAGAKI M, 1995, JPN J PHARMACOL, V67, P1, DOI 10.1254/jjp.67.1; Jensen PE, 1996, BIOCHEM J, V318, P469, DOI 10.1042/bj3180469; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1991, AM J PHYSIOL, V260, pC364, DOI 10.1152/ajpcell.1991.260.2.C364; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MESTERS JR, 1993, FEBS LETT, V321, P149, DOI 10.1016/0014-5793(93)80097-E; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	42	185	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10704	10709						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099720				2022-12-25	WOS:A1997WV26200054
J	Grundemann, D; BabinEbell, J; Martel, F; Ording, N; Schmidt, A; Schomig, E				Grundemann, D; BabinEbell, J; Martel, F; Ording, N; Schmidt, A; Schomig, E			Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; BASOLATERAL MEMBRANE-VESICLES; EFFICIENT METHOD; LINE LLC-PK1; TETRAETHYLAMMONIUM; INHIBITORS; DNA; TUBULE; RNA; PH	Renal secretion of organic cations involves at least two distinct transporters, located in the basolateral and apical membranes of proximal tubule cells. Whereas the basolateral transporter has recently been cloned, sequence information about the apical type was not yet available. An organic cation transporter, OCT2p, was cloned from LLC-PK1 cells, a porcine cell line with properties of proximal tubular epithelial cells. OCT2p was heterologously expressed and characterized in human embryonic kidney 293 cells, OCT2p-mediated uptake of the prototypical organic cation [C-14]tetraethylammonium ([C-14]TEA) into 293 cells was saturable. There was a highly significant correlation between the K-i values for the inhibition of apical [C-14]TEA uptake into LLC-PK1 cells and 293 cells transfected with OCT2p (r = 0.995; p < 0.001; n = 6). Although OCT2p is structurally related to OCT1r, the basolateral organic cation transporter from rat kidney, the transporters could be clearly discriminated pharmacologically with corticosterone, decynium22, and O-methylisoprenaline. The findings at hand suggest that OCT2 corresponds to the apical type of organic cation transporter. Reverse transcriptase-polymerase chain reaction indicates that mRNA of OCT1r is limited to non-neuronal tissue, whereas OCT2r, the OCT2p homologue from rat, was found in both the kidney and central nervous regions known to be rich in the monoamine transmitter dopamine.			Grundemann, D (corresponding author), UNIV HEIDELBERG, DEPT PHARMACOL, NEUENHEIMER FELD 366, D-69120 HEIDELBERG, GERMANY.		Gründemann, Dirk/AAD-2217-2022	Martel, Fatima/0000-0002-0525-3416				Aperia A, 1994, Curr Opin Nephrol Hypertens, V3, P39, DOI 10.1097/00041552-199401000-00005; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BABINEBELL J, 1991, N-S ARCH PHARMACOL, V343, pR92; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DANTZLER WH, 1989, AM J PHYSIOL, V256, pF290, DOI 10.1152/ajprenal.1989.256.2.F290; DANTZLER WH, 1988, AM J PHYSIOL, V255, pF167, DOI 10.1152/ajprenal.1988.255.1.F167; DAVID C, 1995, PFLUG ARCH EUR J PHY, V430, P477, DOI 10.1007/BF00373884; ESPELUND M, 1990, NUCLEIC ACIDS RES, V18, P6157, DOI 10.1093/nar/18.20.6157; FAUTH C, 1988, AM J PHYSIOL, V254, pF351, DOI 10.1152/ajprenal.1988.254.3.F351; FOUDA AK, 1990, J PHARMACOL EXP THER, V252, P286; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grundemann D, 1996, BIOTECHNIQUES, V21, P898; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; GSTRAUNTHALER GJA, 1988, RENAL PHYSIOL BIOCH, V11, P1; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; INUI K, 1985, BIOCHEM J, V227, P199, DOI 10.1042/bj2270199; KEPPLER K, 1992, Naunyn-Schmiedeberg's Archives of Pharmacology, V345, pR103; KUWAHARA M, 1994, BBA-MOL CELL RES, V1220, P132, DOI 10.1016/0167-4889(94)90128-7; LIU ZG, 1992, BIOTECHNIQUES, V12, P28; Martel F, 1996, N-S ARCH PHARMACOL, V354, P320; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MCKINNEY TD, 1990, J AM SOC NEPHROL, V1, P902; MCKINNEY TD, 1988, J CELL PHYSIOL, V137, P513, DOI 10.1002/jcp.1041370317; MILLER JH, 1992, BIOCHIM BIOPHYS ACTA, V1110, P209, DOI 10.1016/0005-2736(92)90361-O; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PALKOVITS M, 1989, CATECHOLAMINES, V2, P1; PFALLER W, 1990, J CELL PHYSIOL, V142, P247, DOI 10.1002/jcp.1041420205; RABITO CA, 1984, J BIOL CHEM, V259, P574; RENNICK BR, 1981, AM J PHYSIOL, V240, pF83, DOI 10.1152/ajprenal.1981.240.2.F83; RUSS H, 1993, J MED CHEM, V36, P4208, DOI 10.1021/jm00078a010; SAITO H, 1992, AM J PHYSIOL, V262, pC59, DOI 10.1152/ajpcell.1992.262.1.C59; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOMIG E, 1993, N-S ARCH PHARMACOL, V347, P379, DOI 10.1007/BF00165387; SCHOMIG E, 1990, N-S ARCH PHARMACOL, V341, P404; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; WRIGHT SH, 1988, J BIOL CHEM, V263, P19494; WRIGHT SH, 1985, AM J PHYSIOL, V249, pF903, DOI 10.1152/ajprenal.1985.249.6.F903; YUAN G, 1991, J BIOL CHEM, V266, P8978	45	171	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10408	10413						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099681				2022-12-25	WOS:A1997WV26200015
J	Pinckard, JK; Sheehan, KCF; Schreiber, RD				Pinckard, JK; Sheehan, KCF; Schreiber, RD			Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; IN-VIVO; ACTIVATION; EXPRESSION; INDUCTION; ENHANCER; DEATH	The p55 and p75 tumor necrosis factor receptors are known to mediate their effects on cells through distinct signaling pathways. Under certain circumstances, the two classes of TNF receptors cooperate with each another to produce enhanced cellular responses. The only molecular mechanism proposed thus far to explain this effect is the process of ''ligand passing,'' whereby TNF is concentrated at cell surfaces by binding to p75 and then following dissociation from this receptor class binds with high efficiency to p55. Using the in vivo model of TNF-induced TNF receptor shedding we have uncovered a novel ligand-dependent interaction of the two TNF receptors that occurs upon exposure of cells to TNF. Using TNF receptor-specific monoclonal antibodies that bind TNF receptors in the presence or absence of ligand, we report that TNF induces the formation of heterocomplexes consisting of both p55 and p75 TNF receptors. Whereas immunoprecipitates from untreated or human TNF-treated cells formed with either p55 or p75 TNF receptor-specific monoclonal antibodies contained only the relevant TNF receptor class, anti-p55 or anti-p75 precipitated both receptor types from murine TNF-treated cells. Ligand-induced complex formation was transient, occurred at physiologically relevant concentrations of TNF, and occurred with receptors lacking intracellular domains or that contained irrelevant transmembrane domains. Formation of TNF receptor heterocomplexes may therefore 1) define a novel molecular mechanism of ligand passing and/or 2) contribute to cooperative TNF receptor signaling via the juxtaposition of the intracellular domains of the two receptor classes and the signaling proteins that. they recruit.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341				BEMELMANS MHA, 1993, J IMMUNOL, V151, P5554; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MOOSMAYER D, 1994, LYMPHOKINE CYTOK RES, V13, P295; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; PINCKARD JK, 1997, IN PRESS J IMMUNOL; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RYFFEL B, 1993, INT REV EXP PATHOL, V34, P149; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TREFZER U, 1991, J INVEST DERMATOL, V97, P911, DOI 10.1111/1523-1747.ep12491668; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; WONG GHW, 1992, J IMMUNOL, V149, P3350; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	28	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10784	10789						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099731				2022-12-25	WOS:A1997WV26200065
J	Veenstra, JA; Pattillo, JM; Petzel, DH				Veenstra, JA; Pattillo, JM; Petzel, DH			A single cDNA encodes all three Aedes leucokinins, which stimulate both fluid secretion by the malpighian tubules and hindgut contractions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIURETIC HORMONE; MANDUCA-SEXTA; LEUCOPHAEA-MADERAE; TOBACCO HORNWORM; LOCUSTA-MIGRATORIA; CONSENSUS SEQUENCE; ACHETA-DOMESTICUS; ION-TRANSPORT; PEPTIDE; IDENTIFICATION	A cDNA encoding preproleucokinin was isolated from a cDNA library of the mosquito Aedes aegypti. The deduced amino acid sequence of Aedes preproleucokinin contains a putative signal peptide of 18 amino acid residues and a 210-amino acid residue proleucokinin. Within the proleucokinin are encoded one copy each of the Aedes leucokinins 1, 2, and 3 isolated previously from this species (Veenstra, J. A. (1994) Biochem. Biophys. Res. Commun. 202, 715-719). All three Aedes leucokinins depolarize the transepithelial voltage of the malpighian tubule in concentrations of less than 10(-9) M and increase the frequency of hindgut contractions at concentrations above 10(-8) M. At higher concentrations the Aedes leucokinins 1 and 3 but not Aedes leucokinin 2 are also able to increase the rate of fluid secretion by the malpighian tubules. The differences of the three Aedes leucokinins in their potencies to induce fluid secretion or depolarizations in the malpighian tubules suggest that there may be more than one type of leucokinin receptor in this tissue.	UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721; UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721; UNIV GEORGIA,DEPT ENTOMOL,ATHENS,GA 30602; CREIGHTON UNIV,DEPT BIOMED SCI,OMAHA,NE 68178	University of Arizona; University of Arizona; University System of Georgia; University of Georgia; Creighton University			Veenstra, Jan/B-4610-2008	Veenstra, Jan Adrianus/0000-0002-2783-0018	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033429, R01AI033108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049610] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 33429, AI 33108] Funding Source: Medline; NIDDK NIH HHS [DK 49610] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACKBURN MB, 1995, J INSECT PHYSIOL, V41, P723, DOI 10.1016/0022-1910(95)00005-F; BLACKBURN MB, 1991, BIOCHEM BIOPH RES CO, V181, P927, DOI 10.1016/0006-291X(91)92025-F; BOGERD J, 1995, J BIOL CHEM, V270, P23038, DOI 10.1074/jbc.270.39.23038; BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; BRADLEY TJ, 1985, COMPREHENSIVE INSECT, V4, P421; BURG M, 1966, AM J PHYSIOL, V210, P1293, DOI 10.1152/ajplegacy.1966.210.6.1293; CANTERA R, 1992, CELL TISSUE RES, V269, P65, DOI 10.1007/BF00384727; CANTERA R, 1992, CELL TISSUE RES, V269, P459, DOI 10.1007/BF00353901; CHEN YT, 1994, CELL TISSUE RES, V278, P493, DOI 10.1007/BF00331367; CHEN YT, 1994, CELL TISSUE RES, V276, P69, DOI 10.1007/BF00354786; CLOTTENS FL, 1994, PEPTIDES, V15, P971, DOI 10.1016/0196-9781(94)90059-0; COAST GM, 1990, J INSECT PHYSIOL, V36, P481, DOI 10.1016/0022-1910(90)90098-Z; Davies SA, 1995, AM J PHYSIOL-REG I, V269, pR1321, DOI 10.1152/ajpregu.1995.269.6.R1321; Delphin F., 1965, Transactions of the Royal Entomological Society of London, V117, P167; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DIGAN ME, 1992, P NATL ACAD SCI USA, V89, P11074, DOI 10.1073/pnas.89.22.11074; FOURNIER B, 1988, J INSECT PHYSIOL, V34, P309, DOI 10.1016/0022-1910(88)90141-2; Furuya K, 1995, P NATL ACAD SCI USA, V92, P12323, DOI 10.1073/pnas.92.26.12323; Gabe M., 1968, TECHNIQUES HISTOLOGI; GAUDE H, 1975, Zoologischer Anzeiger, V194, P151; GILLETT JD, 1983, PROC R SOC SER B-BIO, V217, P237, DOI 10.1098/rspb.1983.0008; GILLETT JD, 1982, PROC R SOC SER B-BIO, V216, P201, DOI 10.1098/rspb.1982.0070; HAYES TK, 1989, LIFE SCI, V44, P1259, DOI 10.1016/0024-3205(89)90362-7; HAYES TK, 1994, REGUL PEPTIDES, V52, P235, DOI 10.1016/0167-0115(94)90058-2; Holman G.M., 1990, P195; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V84, P205, DOI 10.1016/0742-8413(86)90084-8; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V84, P271, DOI 10.1016/0742-8413(86)90093-9; HOLMAN GM, 1987, COMP BIOCHEM PHYS C, V88, P31, DOI 10.1016/0742-8413(87)90043-0; HOLMAN GM, 1987, COMP BIOCHEM PHYS C, V88, P27, DOI 10.1016/0742-8413(87)90042-9; KATAOKA H, 1989, P NATL ACAD SCI USA, V86, P2976, DOI 10.1073/pnas.86.8.2976; KAY I, 1991, BIOL CHEM H-S, V372, P505, DOI 10.1515/bchm3.1991.372.2.505; KAY I, 1991, REGUL PEPTIDES, V42, P111; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; LEHMBERG E, 1991, BIOCHEM BIOPH RES CO, V179, P1036, DOI 10.1016/0006-291X(91)91923-Z; MESSER AC, 1995, J EXP BIOL, V198, P2325; MOWRY TM, 1987, J INSECT PHYSIOL, V33, P867, DOI 10.1016/0022-1910(87)90035-7; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NASSEL DR, 1992, J COMP NEUROL, V322, P45, DOI 10.1002/cne.903220105; ODonnell MJ, 1996, J EXP BIOL, V199, P1163; PANNABECKER TL, 1993, J MEMBRANE BIOL, V132, P63; PATEL M, 1994, PEPTIDES, V15, P591, DOI 10.1016/0196-9781(94)90081-7; PETZEL DH, 1985, AM J PHYSIOL, V249, pR701; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SCHOOFS L, 1992, REGUL PEPTIDES, V37, P49, DOI 10.1016/0167-0115(92)90063-Z; SHAPIRO JP, 1982, GEN COMP ENDOCR, V46, P176, DOI 10.1016/0016-6480(82)90199-X; THOMPSON KSJ, 1995, PEPTIDES, V16, P95, DOI 10.1016/0196-9781(94)00158-3; VEENSTRA JA, 1991, CELL TISSUE RES, V266, P359, DOI 10.1007/BF00318191; VEENSTRA JA, 1994, BIOCHEM BIOPH RES CO, V202, P715, DOI 10.1006/bbrc.1994.1989; VEENSTRA JA, 1988, J INSECT PHYSIOL, V34, P299, DOI 10.1016/0022-1910(88)90139-4; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS JC, 1983, J COMP PHYSIOL, V153, P257, DOI 10.1007/BF00689629; WILLIAMS JC, 1984, J COMP PHYSIOL, V154, P301, DOI 10.1007/BF02464411	53	83	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10402	10407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099680	hybrid			2022-12-25	WOS:A1997WV26200014
J	Gum, R; Wang, H; Lengyel, E; Juarez, J; Boyd, D				Gum, R; Wang, H; Lengyel, E; Juarez, J; Boyd, D			Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades	ONCOGENE			English	Article						MMP-9; type IV collagenase; JNK; ERK; AP-1	ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; C-JUN; MAP KINASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; TRANSDUCTION PATHWAYS; 92-KDA GELATINASE	The 92 kDa type IV collagenase (MMP-9), which degrades type IV collagen, has been implicated in tissue remodeling. The purpose of the current study was to determine the role of Jun amino-terminal kinase (JNK)- and extracellular signal-regulated kinase- (ERK)-dependent signaling cascades in the regulation of MMP-9 expression. Towards this end, we first determined the transcriptional requirements for MMP-9 promoter activity in a cell line (UM-SCC-1) which is an avid secretor of this collagenase. Transfection of these cells with a CAT reporter driven by progressive 5' deleted fragments of the MMP-9 promoter indicated the requirement of a region spanning -144 to -73 for optimal promoter activity. DNase I footprinting revealed a protected region of the promoter spanning nucleotides -91 to -68 and containing a consensus AP-1 motif at -79. Mutation of this AP-1 motif practically abolished the activity of the MMP-9 promoter-driven CAT reporter. Mobility shift assays indicated c-Fos and Jun-D bound to this motif and transfection of the cells with a mutated c-Jun, which quenches the function of endogenous Jun and Fos proteins, decreased MMP-9 promoter activity by 80%. UM-SCC-1 cells contained a constitutively activated JNK and the expression of a kinase-deficient JNK1 reduced the activity of a CAT reporter driven either by the MMP-9 promoter or by three tandem AP-1 repeats upstream of a thymidine kinase minimal promoter. Conditioned medium collected from UM-SCC-1 cells transfected with the dominant negative JNK1 expression vector diminished 92 kDa gelatinolysis. Similarly, interfering with MEKK, which lies upstream of JNK1, using a dominant negative expression vector reduced MMP-9 promoter activity over the same concentration range which repressed the AP-l-thymidine kinase CAT reporter construct. UM-SCC-1 cells also contained a constitutively activated ERK1. MMP-9 expression, as determined by CAT assays and by zymography, was reduced by the co-expression of a kinase-deficient ERK1. Interfering with MEK1, which is an upstream activator of ERK1, either with PD 098059, which prevents the activation of MEK1, or with a dominant negative expression construct, reduced 92 kDa gelatinolysis and MMP-9 promoter activity respectively. c-Raf-l is an upstream activator of MEK1 and a kinase-deficient c-Raf-l expression construct decreased the activity of a promoter driven by either the MMP-9 promoter or three tandem AP-1 repeats. Conversely, treatment of UM-SCC-1 cells with PMA, which activates c-Raf-l, increased 92 kDa gelatinolysis. These data suggest that MMP-9 expression in UM-SCC-1 cells, is regulated by JNK- and ERK-dependent signaling pathways.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG TUMOR BIOL,HOUSTON,TX 77030; TECH UNIV MUNICH,DEPT OBSTET & GYNECOL,D-8000 MUNICH,GERMANY	University of Texas System; UTMD Anderson Cancer Center; Technical University of Munich			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADLER V, 1994, J BIOL CHEM, V269, P11186; AGARWAL S, 1995, ONCOGENE, V11, P427; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson IC, 1996, CANCER RES, V56, P715; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cha HJ, 1996, CANCER RES, V56, P2281; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DECLERCK YA, 1992, CANCER RES, V52, P701; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRIDMAN R, 1995, CANCER RES, V55, P2548; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; HURWITZ A, 1993, ENDOCRINOLOGY, V132, P2709, DOI 10.1210/en.132.6.2709; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENGYEL E, 1995, CANCER RES, V55, P963; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NAKAJIMA M, 1993, CANCER RES, V53, P5802; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYKE C, 1992, CANCER RES, V52, P1336; RAO JS, 1993, CANCER RES, V53, P2208; RAO VN, 1993, CANCER RES, V53, P3449; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SOZERI O, 1992, ONCOGENE, V7, P2259; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	73	220	231	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1481	1493		10.1038/sj.onc.1200973	http://dx.doi.org/10.1038/sj.onc.1200973			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136992				2022-12-25	WOS:A1997WT58400011
J	Fan, JG; Bertino, JR				Fan, JG; Bertino, JR			Functional roles of E2F in cell cycle regulation	ONCOGENE			English	Article						E2F; cell cycle; gene regulation	DEPENDENT KINASE INHIBITORS; RETINOBLASTOMA PROTEIN; S-PHASE; TUMOR-SUPPRESSOR; IN-VIVO; GROWTH SUPPRESSION; GENE-EXPRESSION; MAMMALIAN-CELLS; DNA-REPLICATION; CDK6 INHIBITOR	The E2F family of transcription factors play a key role in G1-S progression. A dominant negative mutant (E2F97) of E2F1 containing the DNA binding domain of E2F1 under the control of a tetracycline-responsive promoter was constructed. Stable transfectants were produced in the pRb-lacking SaOS-2 cell line and SV40-transformed VA-13 cell line, respectively. Induction of E2F97 by tetracycline withdrawal resulted in strong inhibition of the E2F transcriptional activity and a decreased percentage of cells in S-phase, To understand the mechanism(s) by which E2F97 exerts its effect on the cell cycle, the effect of E2F97 on expression of various cell cycle proteins was examined. Upon induction of E2F97, a significant decrease in the levels of both dihydrofolate reductase and thymidylate synthase was observed in transfectants derived from both cell lines. Induction of E2F97 also led to a decrease in cyclin A and D1 protein levels. Regulation of cyclin A by E2F97 occurred at the transcriptional level. In addition, in VA13 cells, induction of E2F97 resulted in downregulation of the tumor suppressor protein p53. These data suggest that E2F regulates both G1 and S-phase cyclins and that there may be a potential positive feedback regulatory loop between E2F and cyclin D1.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOL PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [T32CA062948, P01CA047179] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-47179, CA62948-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCK V, 1995, ONCOGENE, V11, P31; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Geng Y, 1996, ONCOGENE, V12, P1173; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON LF, 1994, J CELL BIOCHEM, V54, P387, DOI 10.1002/jcb.240540405; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; LI Y, 1994, ONCOGENE, V9, P2261; LOWKVIST B, 1986, DEV BIOL, V116, P291, DOI 10.1016/0012-1606(86)90132-6; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MAYOL X, 1995, ONCOGENE, V11, P801; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; North S, 1996, CELL GROWTH DIFFER, V7, P339; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OSWALD F, 1994, ONCOGENE, V9, P2029; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETERS G, 1994, J CELL SCI, P89; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	86	53	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1191	1200		10.1038/sj.onc.1200940	http://dx.doi.org/10.1038/sj.onc.1200940			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121768				2022-12-25	WOS:A1997WM78200008
J	Puri, PL; Balsano, C; Burgio, VL; Chirillo, P; Natoli, G; Ricci, L; Mattei, E; Graessmann, A; Levrero, M				Puri, PL; Balsano, C; Burgio, VL; Chirillo, P; Natoli, G; Ricci, L; Mattei, E; Graessmann, A; Levrero, M			MyoD prevents cyclin A cdk2 containing E2F complexes formation in terminally differentiated myocytes	ONCOGENE			English	Article						MyoD; E2F; pRb2/p130; p21; cell cycle	TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA GENE FAMILY; DNA-BINDING ACTIVITY; LARGE T-ANTIGEN; S-PHASE ENTRY; MYOGENIC DIFFERENTIATION; CELL-PROLIFERATION; IN-VIVO; MUSCLE DIFFERENTIATION; DEPENDENT KINASE	Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130, Downstream effecters of 'pocket' proteins are the components of the E2F family of transcription factors, which regulate the G(1)/S-phase transition, We analysed by EMSA the composition of E2F complexes in cycling, quiescent undifferentiated and differentiated C2C12 skeletal muscle cells, An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G(0)/G(1) complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G(1)/S complex), Serum stimulation reinduces DNA synthesis and the re-appearance of E2F-G(1)/S complexes in quiescent myoblasts but not in differentiated C2C12 myotubes, In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced, Thus, during myogenic differentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis, Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle, Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.	UNIV ROMA LA SAPIENZA,MED CLIN 1,I-00161 ROME,ITALY; UNIV AQUILA,DIPARTIMENTO MED INTERNA,I-67100 LAQUILA,ITALY; CNR,IST TECNOL BIOMED,ROME,ITALY; FREE UNIV BERLIN,INST MOL BIOL & BIOCHEM,D-1000 BERLIN,GERMANY	Sapienza University Rome; University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Free University of Berlin	Puri, PL (corresponding author), UNIV ROMA LA SAPIENZA,FDN A CESALPINO,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Levrero, Massimo/0000-0002-4978-0875; Natoli, Gioacchino/0000-0003-0711-2411; Puri, Pier Lorenzo/0000-0003-4964-0095	Telethon [A.064] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CARUSO M, 1993, ONCOGENE, V8, P267; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1994, J BIOL CHEM, V269, P1306; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRAESSMANN A, 1973, DEV BIOL, V35, P180, DOI 10.1016/0012-1606(73)90016-X; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERTZINGER T, 1995, ONCOGENE, V10, P2079; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MAIONE R, 1992, ONCOGENE, V7, P85; MARTELLI F, 1994, ONCOGENE, V9, P3579; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NATOLI G, 1994, ONCOGENE, V9, P2837; NEVINS JR, 1992, SCIENCE, V258, P424; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PHILPOTT A, 1994, MOL CELL BIOL, V14, P5000, DOI 10.1128/MCB.14.7.5000; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SALA A, 1994, CANCER RES, V54, P1402; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WOLF DA, 1995, ONCOGENE, V10, P2067; YAFFE D, 1977, NATURE, V270, P225; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHANG YH, 1995, ONCOGENE, V10, P2085	84	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1171	1184		10.1038/sj.onc.1200941	http://dx.doi.org/10.1038/sj.onc.1200941			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121766				2022-12-25	WOS:A1997WM78200006
J	Imamoto, Y; Mihara, K; Hisatomi, O; Kataoka, M; Tokunaga, F; Bojkova, N; Yoshihara, K				Imamoto, Y; Mihara, K; Hisatomi, O; Kataoka, M; Tokunaga, F; Bojkova, N; Yoshihara, K			Evidence for proton transfer from Glu-46 to the chromophore during the photocycle of photoactive yellow protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM ECTOTHIORHODOSPIRA-HALOPHILA; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; PURPLE PHOTOTROPHIC BACTERIUM; SPECTROSCOPY; TEMPERATURE; ABSORBENCY; RHODOPSIN; SITE; ACID	Photoactive yellow protein (PYP) belongs to the novel group of eubacterial photoreceptor proteins, To fully understand its light signal transduction mechanisms, elucidation of the intramolecular pathway of the internal proton is indispensable because it closely correlates with the changes in the hydrogen-bonding network, which is likely to induce the conformational changes, For this purpose, the vibrational modes of PYP and its photoproduct mere studied by Fourier transform infrared spectroscopy at -40 degrees C, The vibrational modes characteristic for the anionic p-coumaryl chromophore (Kim, M., Mathies, R. A., Hoff, W. D., and Hellingwerf, K. J. (1995) Biochemistry 34, 12669-12672) were observed at 1482, 1437, and 1163 cm(-1) for PYP, However, the bands corresponding to these modes were not observed for PYPM, the blue-shifted intermediate, but the 1175 cm(-1) band characteristic of the neutral p-coumaryl chromophore was observed, indicating that the phenolic oxygen of the chromophore is protonated in PYPM, A 1736 cm(-1) band was observed for PYP, but the corresponding band for PYPM was not, Because it disappeared in the Glu-46 --> Gln mutant of PYP, this band was assigned to the C=O stretching mode of the COOH group of Glu-46, These results strongly suggest that the proton at Glu-46 is transferred to the chromophore during the photoconversion from PYP to PYPM.	OSAKA UNIV,GRAD SCH SCI,DEPT EARTH & SPACE SCI,TOYONAKA,OSAKA 560,JAPAN; SUNTORY INST BIOORGAN RES,SHIMAMOTO,OSAKA 618,JAPAN	Osaka University; Suntory Holdings Ltd			Kataoka, Mikio/H-4402-2011					BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; HOFF WD, 1992, PHOTOCHEM PHOTOBIOL, V56, P529, DOI 10.1111/j.1751-1097.1992.tb02197.x; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; HONIG B, 1976, BIOCHEMISTRY-US, V15, P4593, DOI 10.1021/bi00666a008; IMAMOTO Y, 1995, FEBS LETT, V374, P157, DOI 10.1016/0014-5793(95)01096-W; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P14047, DOI 10.1021/bi961342d; IMAMOTO Y, 1995, PHOTOMED PHOTOBIOL, V17, P111; KAKITANI H, 1985, PHOTOCHEM PHOTOBIOL, V41, P471, DOI 10.1111/j.1751-1097.1985.tb03514.x; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Koh M, 1996, BIOCHEMISTRY-US, V35, P2526, DOI 10.1021/bi951494t; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Kort R, 1996, EMBO J, V15, P3209, DOI 10.1002/j.1460-2075.1996.tb00685.x; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; Maeda A, 1995, ISR J CHEM, V35, P387; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1993, ARCH BIOCHEM BIOPHYS, V306, P515, DOI 10.1006/abbi.1993.1545; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; MIHARA K, 1997, IN PRESS J BIOCH TOK; SCHICHIDA Y, 1987, BIOCHEMISTRY-US, V26, P4422; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Spudich JL, 1996, CURR OPIN CELL BIOL, V8, P452, DOI 10.1016/S0955-0674(96)80020-2; VANBEEUMEN JJ, 1993, PROTEIN SCI, V2, P1114, DOI 10.1002/pro.5560020706; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035	28	84	84	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12905	12908		10.1074/jbc.272.20.12905	http://dx.doi.org/10.1074/jbc.272.20.12905			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148894	hybrid			2022-12-25	WOS:A1997WZ38400007
J	Jacquemin, P; Martial, JA; Davidson, I				Jacquemin, P; Martial, JA; Davidson, I			Human TEF-5 is preferentially expressed in placenta and binds to multiple functional elements of the human chorionic somatomammotropin-B gene enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; TRANSCRIPTION FACTOR TEF-1; ALPHA-ACTIN GENE; PROTEIN-KINASE-C; LARGE T-ANTIGEN; FACTOR-I TEF-1; M-CAT; SV40 ENHANCER; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE	We report the cloning of a cDNA encoding the human transcription factor hTEF-5, containing the TEA/ATTS DNA binding domain and related to the TEF family of transcription factors. hTEF-5 is expressed in skeletal and cardiac muscle, but the strongest expression is observed in the placenta and in placenta-derived JEG-3 choriocarcinoma cells, In correlation with its placental expression, we show that hTEF-5 binds to several functional enhansons of the human chorionic somatomammotropin (hCS)-B gene enhancer, We define a novel functional element in this enhancer comprising tandemly repeated sites to which hTEF-5 binds cooperatively. In the corresponding region of the hCS-A enhancer, which is known to be inactive, this element is inactivated by a naturally occurring single base mutation that disrupts hTEF-5 binding. We further show that the binding of the previously described placental protein f/chorionic somatomammotropin enhancer factor-1 to TEF-binding sites is disrupted by monoclonal antibodies directed against the TEA domain and that this factor is a proteolytic degradation product of the TEF factors. These results strongly suggest that hTEF-5 regulates the activity of the hCS-B gene enhancer.	ULP, COLL FRANCE,INSERM,CNRS, INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV LIEGE, INST CHIM B6, LAB BIOL MOL & GENIE GENET, B-4000 Sart Tilman Par Liege, BELGIUM	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Liege			Jacquemin, Patrick/ABA-7932-2021	Davidson, Irwin/0000-0001-5533-1171				ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; ANDRIANOPOULOS A, 1994, MOL CELL BIOL, V14, P2503, DOI 10.1128/MCB.14.4.2503; Azakie A, 1996, J BIOL CHEM, V271, P8260, DOI 10.1074/jbc.271.14.8260; Berger LC, 1996, J VIROL, V70, P1203, DOI 10.1128/JVI.70.2.1203-1212.1996; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CASAZ P, 1991, J VIROL, V65, P6535, DOI 10.1128/JVI.65.12.6535-6543.1991; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GRUDA MC, 1991, J VIROL, V65, P3553, DOI 10.1128/JVI.65.7.3553-3558.1991; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Hsu DKW, 1996, J BIOL CHEM, V271, P13786, DOI 10.1074/jbc.271.23.13786; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; INAMDAR M, 1993, J NEUROGENET, V9, P123, DOI 10.3109/01677069309083454; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JACQUEMIN P, 1994, DNA CELL BIOL, V13, P1037, DOI 10.1089/dna.1994.13.1037; Jacquemin P, 1996, DNA CELL BIOL, V15, P845, DOI 10.1089/dna.1996.15.845; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JIANG SW, 1995, J BIOL CHEM, V270, P13906, DOI 10.1074/jbc.270.23.13906; JIANG SW, 1994, J BIOL CHEM, V269, P10384; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KELLY JJ, 1991, NUCLEIC ACIDS RES, V19, P6799, DOI 10.1093/nar/19.24.6799; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LYTRAS A, 1994, MOL ENDOCRINOL, V8, P478, DOI 10.1210/me.8.4.478; Lytras A, 1996, MOL CELL ENDOCRINOL, V119, P1, DOI 10.1016/0303-7207(96)03777-X; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727	58	57	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12928	12937		10.1074/jbc.272.20.12928	http://dx.doi.org/10.1074/jbc.272.20.12928			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148898	hybrid			2022-12-25	WOS:A1997WZ38400011
J	Kho, CJ; Huggins, GS; Endege, WO; Patterson, C; Jain, MK; Lee, ME; Haber, E				Kho, CJ; Huggins, GS; Endege, WO; Patterson, C; Jain, MK; Lee, ME; Haber, E			The polymyositis-scleroderma autoantigen interacts with the helix-loop-helix proteins E12 and E47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STEP PURIFICATION; B-CELL DEVELOPMENT; NUCLEAR MATRIX; DNA-BINDING; MOLECULAR-CLONING; OVERLAP SYNDROMES; G(1) PROGRESSION; ESCHERICHIA-COLI; HOMEOBOX GENE; EXPRESSION	The basic helix-loop-helix (bHLH) transcription factors E12 and E47 regulate cellular differentiation and proliferation in diverse cell types, While looking for proteins that bind to E12 and E47 by the yeast interaction trap, we isolated the rat (r) homologue of the human ih) polymyositis-scleroderma autoantigen (PM-Scl), which has been localized to the granular layer of the nucleolus and to distinct nucleocytoplasmic foci. The rPM-Scl and hPM-Scl homologues are 96% similar and 91% identical, We found that rPM-Scl mRNA expression was regulated by growth factor stimulation in cultured rat aortic smooth muscle cells, rPM-Scl bound to E12 and E47 but not to Id3, Gax, Myb, OCT-1, or Max. The C terminus of rPM-Scl (amino acids 283-353) interacted specifically with a 54-amino acid domain in E12 that is distinct from the bHLH domain, Finally, cotransfection of rPM-Scl and E47 specifically increased the promoter activity of a luciferase reporter construct containing an E box and did not affect the basal activity of the reporter construct, rPM-Scl appears to be a novel non-HLH-interacting partner of E12/E47 that regulates E2A protein transcription.	HARVARD UNIV, SCH PUBL HLTH, CARDIOVASC BIOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, CARDIAC UNIT, BOSTON, MA 02114 USA; BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital					NIGMS NIH HHS [R01GM 53249] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Elefanty AG, 1996, EMBO J, V15, P319, DOI 10.1002/j.1460-2075.1996.tb00362.x; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GELPI C, 1990, CLIN EXP IMMUNOL, V81, P59; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARA E, 1994, J BIOL CHEM, V269, P2139; IVARONE A, 1994, GENE DEV, V8, P1270; IZAWA M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P492, DOI 10.1016/0167-4781(93)90021-5; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; Kaiser C., 1994, METHODS YEAST GENETI; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kim MK, 1996, MOL CELL BIOL, V16, P4366; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; REICHLIN M, 1984, J CLIN IMMUNOL, V4, P40, DOI 10.1007/BF00915286; REIMER G, 1986, J IMMUNOL, V137, P3802; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; TARGOFF IN, 1985, ARTHRITIS RHEUM, V28, P226, DOI 10.1002/art.1780280221; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; VANSTEENSEL B, 1995, J CELL BIOCHEM, V57, P465, DOI 10.1002/jcb.240570312; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	49	12	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13426	13431		10.1074/jbc.272.20.13426	http://dx.doi.org/10.1074/jbc.272.20.13426			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148967	hybrid			2022-12-25	WOS:A1997WZ38400080
J	Powell, MD; Ghosh, M; Jacques, PS; Howard, KJ; LeGrice, SFJ; Levin, JG				Powell, MD; Ghosh, M; Jacques, PS; Howard, KJ; LeGrice, SFJ; Levin, JG			Alanine-scanning mutations in the ''primer grip'' of p66 HTV-1 reverse transcriptase result in selective loss of RNA priming activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-POLYMERASE; ESCHERICHIA-COLI; H ACTIVITIES; B-DNA; HIV-1; BINDING; TYPE-1; DOMAIN; MUTAGENESIS	Alanine-scanning mutants of the primer grip region of human immunodeficiency virus type 1 reverse transcriptase were tested for their ability to extend RNA and DNA versions of the polypurine tract primer, and an oligonucleotide representing the 18-nucleotide sequence at the 3' end of tRNA(Lys3). A majority of the mutant enzymes were either completely or severely deficient in RNA priming activity, but, with only one exception, were able to efficiently extend DNA versions of the same primers, The mutant enzymes were able to bind to RNA primers, indicating that the defect in RNA priming was not simply a loss of binding activity, Mutations at positions 229, 233, and 235 dramatically reduced the amount of specific RNase H cleavage at the 3' terminus of the polypurine tract, which is required for primer removal, An alanine substitution at position 232 led to loss of cleavage specificity, although total activity was close to the wild-type level, Taken together, these results demonstrate for the first time that there are residues in human immunodeficiency virus type 1 reverse transcriptase which are specifically involved in protein-nucleic acid interactions with RNA primers.	NICHHD,MOL GENET LAB,NIH,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University					NIGMS NIH HHS [GM 52263] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052263] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arts EJ, 1996, ADV VIRUS RES, V46, P97, DOI 10.1016/S0065-3527(08)60071-8; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts Eric J., 1995, Journal of Biomedical Science, V2, P314, DOI 10.1007/BF02255218; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BOYER PL, 1994, J MOL BIOL, V243, P472, DOI 10.1006/jmbi.1994.1673; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2422, DOI 10.1021/bi00432a013; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FEDOROFF OY, 1997, IN PRESS J MOL BIOL; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; HEINEMANN U, 1989, J MOL BIOL, V210, P369, DOI 10.1016/0022-2836(89)90337-9; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HUBER HE, 1990, J BIOL CHEM, V265, P10565; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; POST K, 1993, BIOCHEMISTRY-US, V32, P5508, DOI 10.1021/bi00072a004; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VARMUS H, 1989, MOBILE DNA, P53; WILSON SH, 1992, TRANSFER RNA PROTEIN, P1; Yusupova G, 1996, J MOL BIOL, V261, P315, DOI 10.1006/jmbi.1996.0463	49	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13262	13269		10.1074/jbc.272.20.13262	http://dx.doi.org/10.1074/jbc.272.20.13262			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148945	hybrid			2022-12-25	WOS:A1997WZ38400058
J	Takahashi, Y; Okimura, Y; Mizuno, I; Iida, K; Takahashi, T; Kaji, H; Abe, H; Chihara, K				Takahashi, Y; Okimura, Y; Mizuno, I; Iida, K; Takahashi, T; Kaji, H; Abe, H; Chihara, K			Leptin induces mitogen-activated protein kinase-dependent proliferation of C3H10T1/2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EMBRYO CELLS; GROWTH-FACTOR; OBESE GENE; SWISS 3T3-CELLS; PHOSPHORYLATION; TYROSINE; CASCADE; INHIBITION; INSULIN; SPECIFICITY	Leptin, secreted by adipocytes, regulates satiety and energy expenditure. Several forms of leptin receptors produced by alternative mRNA splicing are found in many tissues, including the hypothalamus, Liver, lung, kidney, hematopoietic cells, and gonads, suggesting that leptin exerts effects in these tissues. In accordance with the distribution of leptin receptors, there is accumulating evidence that leptin plays various roles in reproduction, hematopoiesis, and the immune systems in addition to the regulation of food intake and energy expenditure. In the present study, we examined the in vitro effects of leptin on proliferation of a mouse embryonic cell line, C3H10T1/2, and its mechanism of action. Leptin caused a dose- and time-dependent increase in mitogen-activated protein kinase (MAPK) activity that was accompanied by an increase in C3H10T1/2 cell number. The MAPK kinase-1-specific inhibitor PD98059 completely blocked the increases in both MAPK activity and cell proliferation caused by leptin. These findings indicate that leptin stimulates the proliferation of C3H10T1/2 cells via the MAPK cascade.			Takahashi, Y (corresponding author), KOBE UNIV,SCH MED,DEPT MED,DIV 3,CHUO KU,7-5-1 KUSUNOKI CHO,KOBE,HYOGO 650,JAPAN.		Iida, Keiji/ABB-5126-2021	Iida, Keiji/0000-0002-1516-7757				AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARASH AI, 1996, ENDOCRINOLOGY, V137, P3144; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5899; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0; CONSTANTINIDES PG, 1978, DEV BIOL, V66, P57, DOI 10.1016/0012-1606(78)90273-7; DAVID M, 1995, SCIENCE, V269, P4721; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAEDEJ M, 1995, FEBS LEWTT, V373, P13; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONTGOMERY LB, 1990, DIABETES, V39, P675, DOI 10.2337/diabetes.39.6.675; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; POMBO CM, 1994, J BIOL CHEM, V269, P26546; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHLESSINGER J, 1994, CURR OPIN GENE DEV, V4, P225; Takahashi Y, 1996, BIOCHEM BIOPH RES CO, V228, P859, DOI 10.1006/bbrc.1996.1744; TALOR SM, 1979, CELL, V17, P771; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITE MF, 1994, J BIOL CHEM, V269, P1; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	50	169	177	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12897	12900		10.1074/jbc.272.20.12897	http://dx.doi.org/10.1074/jbc.272.20.12897			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148892	hybrid			2022-12-25	WOS:A1997WZ38400005
J	Calderwood, DA; Tuckwell, DS; Eble, J; Kuhn, K; Humphries, MJ				Calderwood, DA; Tuckwell, DS; Eble, J; Kuhn, K; Humphries, MJ			The integrin alpha 1 A-domain is a ligand binding site for collagens and laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; CR3 CD11B/CD18; ALPHA-2-BETA-1 VLA-2; ADHESION MOLECULE-1; CRYSTAL-STRUCTURE; RECOGNITION SITE; CELL-ADHESION; SUBUNIT; IDENTIFICATION; RECEPTOR	The integrin alpha 1 beta 1 is a cell surface receptor for collagens and laminin. The alpha 1 subunit contains an A-domain, and the A-domains of other integrins are known to mediate ligand binding. To determine the role of the alpha 1 A-domain in ligand binding and the extent to which it reproduced the ligand binding activity and specificity of the parent molecule, we produced recombinant alpha 1 A-domain and tested its ability to bind collagens and laminin. In solid phase assays, the A-domain from alpha 1 was found to bind to collagen I, collagen IV, and laminin in a largely cation-dependent manner. The alpha 2 A-domain, from the alpha 2 beta 1 integrin, also bound to these ligands, but the binding hierarchy differed from that seen for alpha 1. This is the first demonstration of laminin binding by A-domains. Specificity of A-domain-ligand binding was further investigated using the triple-helical proteolytic fragment of collagen IV, CB3, and its subfragments, F1 and F4. alpha 1 A-domain bound to all three fragments, while the alpha 2 A-domain bound CB3 less well and exhibited little binding to F1 and no binding to F4. These differences mirror previous reports of distinct integrin binding sites in collagen IV and for the first time identify a limited proteolytic fragment of a ligand that contains integrin A-domain binding activity. To gain insight into the contribution that the A-domain makes to ligand binding within the whole integrin heterodimer, we measured binding constants for A-domain-collagen interactions using surface plasmon resonance biosensor technology. The values obtained were similar to those reported for intact integrin binding, suggesting that the A-domain is the major collagen binding site in the alpha 1 beta 1 and alpha 2 beta 1 integrins.	UNIV MANCHESTER,SCH BIOL SCI,WELLCOME TRUST CTR CELL MATRIX RES,MANCHESTER M13 9PT,LANCS,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	University of Manchester; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Max Planck Society			Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD A P, 1991, Biochemical Society Transactions, V19, p361S; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TUCKWELL DS, 1993, CRIT REV ONCOL HEMAT, V15, P149, DOI 10.1016/1040-8428(93)90053-7; TUCKWELL DS, 1995, J CELL SCI, V107, P1629; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; Woska JR, 1996, J IMMUNOL, V156, P4680; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	35	126	127	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12311	12317		10.1074/jbc.272.19.12311	http://dx.doi.org/10.1074/jbc.272.19.12311			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139675	hybrid			2022-12-25	WOS:A1997WY82900012
J	Isobe, K; Kishino, S; Inoue, K; Takai, D; Hirawake, H; Kita, K; Miyabayashi, S; Hayashi, JI				Isobe, K; Kishino, S; Inoue, K; Takai, D; Hirawake, H; Kita, K; Miyabayashi, S; Hayashi, JI			Identification of inheritance modes of mitochondrial diseases by introduction of pure nuclei from mtDNA-less HeLa cells to patient-derived fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-OXIDASE DEFICIENCY; PROTEIN-SYNTHESIS; GENETIC-EVIDENCE; LEIGHS SYNDROME; DNA; MUTATION; TUMORIGENICITY; DEFECTS; DYSFUNCTION; RESPIRATION	A nuclear genome delivery system was developed to deduce the modes of inheritance of the clinical phenotypes observed in patients with mitochondrial diseases by transfer of pure nuclei from normal cells to fibroblasts from the patients, The problem of possible contamination of the nuclei with a small amount of mtDNA was overcome by using mtDNA-less (rho(O)) human cells as nuclear donors, In this study, intercellular transfer of pure nuclei was carried out by simple fusion of rho(O) HeLa cells with 533 fibroblasts from a patient with a fatal mitochondrial disease, which were deficient in cytochrome c oxidase and succinate dehydrogenase activities. The results showed that the cytochrome c oxidase and succinate dehydrogenase activities were restored by the introduction of pure HeLa nuclei, suggesting that the observed phenotypes of mitochondrial dysfunction were not due to mtDNA mutations but to nuclear, recessive mutations, Thus, our nuclear transfer system is effective for determining whether a mitochondrial or nuclear genome of a patient is responsible for a disease and whether deficiency of mitochondrial enzymes, including enzymes exclusively encoded by nuclear genomes, is transmitted in a nuclear recessive or nuclear dominant way, providing the parents of the patients with valuable information for genetic counseling on the risk of mitochondrial diseases in their next babies.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,DEPT PARASITOL,TOKYO 108,JAPAN; TOHOKU UNIV,DEPT PEDIAT,SCH MED,SENDAI,MIYAGI 980,JAPAN	University of Tsukuba; University of Tokyo; Tohoku University				Kita, Kiyoshi/0000-0002-0426-4308				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOUGERON T, 1995, NAT GENET, V11, P144; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAYASHI JI, 1986, CANCER RES, V46, P4001; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; HAYASHI JI, 1991, PROG NEUROPATH, V7, P93; HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; HAYASHI JI, 1987, EXP CELL RES, V172, P218, DOI 10.1016/0014-4827(87)90108-X; HAYASHI JI, 1984, CANCER RES, V44, P3957; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; KAGAWA Y, 1974, METHODS MEMBRANE BIO, P201; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; MIRANDA AF, 1989, NEUROLOGY, V39, P697, DOI 10.1212/WNL.39.5.697; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028; TIRANTI V, 1995, HUM MOL GENET, V4, P2017, DOI 10.1093/hmg/4.11.2017; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523	28	8	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12606	12610		10.1074/jbc.272.19.12606	http://dx.doi.org/10.1074/jbc.272.19.12606			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139714	hybrid			2022-12-25	WOS:A1997WY82900051
J	Ito, T; Deng, XM; Carr, B; May, WS				Ito, T; Deng, XM; Carr, B; May, WS			Bcl-2 phosphorylation required for anti-apoptosis function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-SURVIVAL; IN-VIVO; INTERLEUKIN-3; BAX	The protooncogene Bcl-2 functions as a suppressor of apoptosis in growth factor-dependent cells, but a postreceptor signaling mechanism is not known. We recently reported that interleukin 3 (IL-3) and erythropoietin, or the protein kinase C activator bryostatin-1 (Bryo), not only suppresses apoptosis but also stimulates the phosphorylation of Bcl-2 (May, W. S., Tyler, P. G., Ito, T., Armstrong, D. K., Qatsha, K. A., and Davidson, N. E. (1994) J. Biol. Chem. 269, 26865-26870). To test whether phosphorylation is required for Bcl-2 function, conservative serine --> alanine mutations were produced at the seven putative protein kinase C phosphorylation sites in Bcl-2. Results indicate that the S70A Bcl-2 mutant fails to be phosphorylated after IL-3 or Bryo stimulation and is unable 60 support prolonged cell survival either upon IL-3 deprivation or etoposide treatment when compared with wild-type Bcl-2. In contrast, a Ser --> Glu mutant, S70E, which may mimic a potential phosphate charge, more potently suppressed the etoposide-induced apoptosis than wild type in the absence of IL-3. Since the loss of function S70A mutant can heterodimerize with its partner protein and death effector Bax, these findings demonstrate that Bcl-2:Bax heterodimerization is not sufficient and Bcl-2 phosphorylation is required for full Bcl-2 death suppressor signaling activity.	UNIV TEXAS, MED BRANCH, SEALY CTR ONCOL & HEMATOL, GALVESTON, TX 77555 USA; UNIV TEXAS, MED BRANCH, DEPT INTERNAL MED, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA47993, CA44649] Funding Source: Medline; NHLBI NIH HHS [HL54083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047993, R01CA044649] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSWELL HS, 1990, EXP HEMATOL, V18, P794; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MAY WS, 1994, J BIOL CHEM, V269, P26865; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; TAKAYAMA S, 1994, DNA CELL BIOL, V13, P679, DOI 10.1089/dna.1994.13.679; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	20	486	490	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11671	11673		10.1074/jbc.272.18.11671	http://dx.doi.org/10.1074/jbc.272.18.11671			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115213	hybrid			2022-12-25	WOS:A1997WX56900001
J	Lee, YF; Pan, HJ; Burbach, JPH; Morkin, E; Chang, CS				Lee, YF; Pan, HJ; Burbach, JPH; Morkin, E; Chang, CS			Identification of direct repeat 4 as a positive regulatory element for the human TR4 orphan receptor - A modulator for the thyroid hormone target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; RETINOIC ACID RECEPTORS; MAJOR LATE PROMOTER; RESPONSE ELEMENTS; GLUCOCORTICOID RECEPTOR; COUP-TF; STEROID-RECEPTOR; MOLECULAR-CLONING; TRANS-ACTIVATION; MULTIPLE	While the TR4 orphan receptor (TR4) is able to repress the expression of its target genes via its interaction with the direct repeat 1-hormone response element (DR1-HRE) and DR2-HRE, we now report that TR4 can also induce the transcriptional activity of the reporter gene containing a DR4-HRE via chloramphenicol acetyltransferase assay. Electrophoretic mobility shift assay and Scatchard analysis reveal a strong binding affinity (dissociation constant = 2 nM) between TR4 and DR4-HRE. The induction mediated by TR4 was detected not only in the synthetic DR4-HRE but also in some genes, such as rat alpha-myosin heavy chain and S14 genes, containing the DR4 or DR4-like motif, which have been suggested to be the response elements for a thyroid hormone receptor. Our data also demonstrate this TR4-mediated gene induction is TR4 dose- and DR4 sequence-dependent. Together, our data suggest that DR4-HRE can be a positive regulatory element for TR4, which may be able to induce the transcriptional activity of the genes containing such positive HREs.	UNIV ROCHESTER,DEPT PATHOL,ROCHESTER,NY 14642; UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI 53792; UNIV ROCHESTER,DEPT UROL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV UTRECHT,DEPT MED PHARMACOL,NL-3584 CG UTRECHT,NETHERLANDS; UNIV ARIZONA,UNIV HEART CTR,TUCSON,AZ 85724	University of Rochester; University of Wisconsin System; University of Wisconsin Madison; University of Rochester; University of Rochester; Utrecht University; University of Arizona					NCI NIH HHS [CA55639] Funding Source: Medline; NIDDK NIH HHS [DK47258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055639, R29CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMERO SA, 1993, MOL CELL BIOL, V13, P5323, DOI 10.1128/MCB.13.9.5323; ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BAES M, 1995, BIOCHEM BIOPH RES CO, V215, P338, DOI 10.1006/bbrc.1995.2471; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHANG C, 1989, ENDOCRINOLOGY, V123, P1097; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Leng X, 1996, MOL CELL BIOL, V16, P2332; LIN TM, 1995, J BIOL CHEM, V270, P30121; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; QI JS, 1995, MOL CELL BIOL, V15, P1817; Rahman A, 1995, J BIOL CHEM, V270, P31059, DOI 10.1074/jbc.270.52.31059; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P397; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	42	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12215	12220		10.1074/jbc.272.18.12215	http://dx.doi.org/10.1074/jbc.272.18.12215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115296	hybrid			2022-12-25	WOS:A1997WX56900084
J	Strub, JM; Sorokine, O; VanDorsselaer, A; Aunis, D; MetzBoutigue, MH				Strub, JM; Sorokine, O; VanDorsselaer, A; Aunis, D; MetzBoutigue, MH			Phosphorylation and O-glycosylation sites of bovine chromogranin a from adrenal medullary chromaffin granules and their relationship with biological activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN-I; PARATHYROID CELL SECRETION; N-TERMINAL FRAGMENT; MESSENGER-RNA; CLEAVAGE SITES; PANCREASTATIN; PEPTIDES; SEQUENCE; ENDOCRINE; TYROSINE	Bovine adrenal medullary chromogranin A, the major soluble component of chromaffin granules, is a phosphorylated glycoprotein. In the present work, phosphorylation and glycosylation sites were determined using mild proteolysis, peptide separation, microsequencing, and mass analysis by electrospray and matrix-assisted laser desorption ionization time-of-flight techniques. Seven post-translational modification sites were detected. Two O-linked glycosylation sites, each consisting of the trisaccharide NeuAc alpha 2-3Gal beta 1-3GalNA alpha 1, were located in the middle part of the protein, on Ser(186) and on Thr(231). The former residue is present in the antibacterial peptide named chromacin. Four phosphorylation sites were located on serine residues at positions Ser(81) in the N-terminal region of the protein and Ser(307), Ser(372), and Ser(376) in the C-terminal end. One additional phosphorylation site was found on the tyrosine residue at position Tyr(173), the N-terminal amino acid of chromacin, With the exception of the phosphorylation on Tyr(173), all of the other post-translational modifications are located on highly conserved chromogranin A regions, implying some biological importance.	INSERM,U338,UNITE BIOL COMMUN CELLULAIRE,F-67084 STRASBOURG,FRANCE; CNRS,LAB SPECTROMETRIE MASSE BIOORGAN,URA 31,F-67084 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS)			Dominique, Aunis/W-1419-2019	Strub, Jean-Marc/0000-0001-6224-3428				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; AUNIS D, 1977, J NEUROCHEM, V29, P439, DOI 10.1111/j.1471-4159.1977.tb10692.x; BARBOSA JA, 1991, ENDOCRINOLOGY, V128, P174, DOI 10.1210/endo-128-1-174; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BURGOYNE RD, 1982, PROC R SOC SER B-BIO, V216, P111, DOI 10.1098/rspb.1982.0064; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; DESTE L, 1994, CELL TISSUE RES, V277, P341, DOI 10.1007/s004410050161; DILIBERTO EJ, 1976, P NATL ACAD SCI USA, V73, P4050, DOI 10.1073/pnas.73.11.4050; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; DILLEN L, 1992, BIOCHIM BIOPHYS ACTA, V1120, P105, DOI 10.1016/0167-4838(92)90430-L; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; EFENDIC S, 1987, P NATL ACAD SCI USA, V84, P7257, DOI 10.1073/pnas.84.20.7257; FALKENSAMMER G, 1985, J NEUROCHEM, V45, P1475, DOI 10.1111/j.1471-4159.1985.tb07215.x; FASCIOTTO BH, 1989, ENDOCRINOLOGY, V125, P1617, DOI 10.1210/endo-125-3-1617; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; FASCIOTTO BH, 1990, ENDOCRINOLOGY, V127, P1329, DOI 10.1210/endo-127-3-1329; FLANAGAN T, 1990, CELL MOL NEUROBIOL, V10, P507, DOI 10.1007/BF00712845; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HUDDLESTON MJ, 1993, ANAL CHEM, V65, P877, DOI 10.1021/ac00055a009; HUTTNER WB, 1987, NATURE, V325, P305, DOI 10.1038/325305b0; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTON JC, 1987, BIOCHEM J, V244, P457, DOI 10.1042/bj2440457; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; ISHIZUKA J, 1989, PANCREAS, V4, P277, DOI 10.1097/00006676-198906000-00001; JACQUINOID M, 1993, EUR J BIOCHEM, V218, P893; KIANG WL, 1982, J BIOL CHEM, V257, P1651; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAZURE C, 1990, PEPTIDES, V11, P79, DOI 10.1016/0196-9781(90)90114-K; LEWIS JJ, 1989, BIOCHEM BIOPH RES CO, V163, P667, DOI 10.1016/0006-291X(89)92275-4; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; METZBOUTIGUE MH, 1997, IN PRESS CELL MOL NE; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; NGUYEN MH, 1987, J NEUROCHEM, V49, P38, DOI 10.1111/j.1471-4159.1987.tb03391.x; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PETERSON JB, 1987, J BIOL CHEM, V262, P17264; REINECKE M, 1993, GEN COMP ENDOCR, V90, P251, DOI 10.1006/gcen.1993.1080; RIEKER S, 1988, J NEUROCHEM, V50, P1066, DOI 10.1111/j.1471-4159.1988.tb10574.x; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1645; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; SMITH AD, 1967, BIOCHEM J, V103, P483, DOI 10.1042/bj1030483; Strub JM, 1996, FEBS LETT, V379, P273, DOI 10.1016/0014-5793(95)01529-9; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; TREIMAN M, 1983, J NEUROCHEM, V40, P661, DOI 10.1111/j.1471-4159.1983.tb08031.x; WATKINSON A, 1992, REGUL PEPTIDES, V40, P51, DOI 10.1016/0167-0115(92)90083-7; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WOHLFARTER T, 1988, FEBS LETT, V231, P67, DOI 10.1016/0014-5793(88)80704-X; WU HJ, 1991, J BIOL CHEM, V266, P13130; Yanagihara N, 1996, J BIOL CHEM, V271, P17463, DOI 10.1074/jbc.271.29.17463	63	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11928	11936		10.1074/jbc.272.18.11928	http://dx.doi.org/10.1074/jbc.272.18.11928			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115255	hybrid			2022-12-25	WOS:A1997WX56900043
J	Vallejo, Y; Hortsch, M; Dubreuil, RR				Vallejo, Y; Hortsch, M; Dubreuil, RR			Ethanol does not inhibit the adhesive activity of Drosophila neuroglian or human L1 in Drosophila S2 tissue culture cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAM; MOLECULE; NEURONS	Members of the L1 family of homophilic neural cell adhesion molecules are thought to play an important role in nervous system development and function. It is also suggested that L1 is a direct target of ethanol in fetal alcohol syndrome, since ethanol inhibits the aggregation of cultured cells expressing L1 (Ramanathan, R., Wilkemeyer, M. F., Mittel, B., Perides, G., and Charness, M. E. (1996) J. Cell Biol. 133, 381-390). If ethanol acts directly on the homophilic adhesive function of the L1 molecule, then inhibition of aggregation by ethanol should be observed in any cell type that expresses L1. Here we examined the effect of physiologically relevant concentrations of ethanol on the aggregation of Drosophila S2 cells that expressed either neuroglian (the Drosophila homolog of L1) or human L1. The aggregation of these S2 cells is known to be solely dependent on the homophilic interactions between L1 or neuroglian molecules. Neither cell adhesion molecule was affected when cell aggregation assays were carried out in the presence of greater than or equal to 38 mM ethanol. The recruitment of membrane skeleton assembly at sites of cell cell contact (a transmembrane signaling function of human L1) was also unaffected by the presence of ethanol. Thus the previously described inhibition of cell adhesion by ethanol in L1-expressing cells cannot be explained by a simple direct effect on the adhesive activity of L1 family members.	UNIV CHICAGO, COMM CELL PHYSIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; UNIV MICHIGAN, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA	University of Chicago; University of Chicago; University of Michigan System; University of Michigan				Hortsch, Michael/0000-0002-3750-737X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029388, R29HD029388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049301] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29388] Funding Source: Medline; NIGMS NIH HHS [GM07151, GM49301] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; ASHBURNER M, 1989, DROSOPHILA LAB MANUA, P378; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; CHARNESS ME, 1994, J BIOL CHEM, V269, P9304; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DUBREUIL R, 1987, J CELL BIOL, V105, P2095, DOI 10.1083/jcb.105.5.2095; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; DUBREUIL RR, 1994, P NATL ACAD SCI USA, V91, P10282; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; HORTSCH M, 1997, IN PRESS CELL ADHESI; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; MIURA M, 1992, J BIOL CHEM, V267, P10752; MUJOO K, 1986, J BIOL CHEM, V261, P299; Ramanathan R, 1996, J CELL BIOL, V133, P381, DOI 10.1083/jcb.133.2.381; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6	20	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12244	12247		10.1074/jbc.272.18.12244	http://dx.doi.org/10.1074/jbc.272.18.12244			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115300	hybrid			2022-12-25	WOS:A1997WX56900088
J	Ding, MZ; StPierre, BA; Parkinson, JF; Medberry, P; Wong, JL; Rogers, NE; Ignarro, LJ; Merrill, JE				Ding, MZ; StPierre, BA; Parkinson, JF; Medberry, P; Wong, JL; Rogers, NE; Ignarro, LJ; Merrill, JE			Inducible nitric-oxide synthase and nitric oxide production in human fetal astrocytes and microglia - A kinetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; RELAXING FACTOR; GLIAL-CELLS; ACTIVATED MICROGLIA; GUANYLATE-CYCLASE; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; GROWTH-FACTOR; MACROPHAGES; BRAIN	The understanding of the induction and regulation of inducible nitric-oxide synthase (iNOS) in human cells may be important in developing therapeutic interventions for inflammatory diseases. In the present study, we not only demonstrated that human fetal mixed glial cultures, as well as enriched microglial cultures, synthesize iNOS and nitric oxide (NO) in response to cytokine stimulation, but also assessed the kinetics of iNOS and NO synthesis in human fetal mixed glial cultures. The iNOS mRNA was expressed within 2 h after stimulation and decreased to base line by 2 days. Significant levels of iNOS protein appeared within 24 h after stimulation and remained elevated during the culture period. A dramatic increase in NO production and NO-mediated events, such as the induction of cyclic guanosine monophosphate (cGMP), NADPH diaphorase activity, and nitrotyrosine occurred 3 days after stimulation, a delay of 48 h from the time of the first expression of iNOS en zyme. This delay of NO production was altered by the addition of tetrahydrobiopterin, but not by the addition of L-arginine, heme, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), or NADPH. These findings suggest that a post-translational regulatory event might be involved in iNOS-mediated NO production in human glia.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED & MOL PHARMACOL, LOS ANGELES, CA 90095 USA; BERLEX BIOSCI, DEPT IMMUNOL, RICHMOND, CA 94804 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ding, MZ (corresponding author), UNIV CALIF LOS ANGELES, SCH MED,DEPT NEUROL,REED NEUROL RES BLDG,RM A-134, 710 WESTWOOD PLAZA, LOS ANGELES, CA 90095 USA.				NIMH NIH HHS [5T32MH17140-11] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH017140] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albina JE, 1995, J LEUKOCYTE BIOL, V58, P643, DOI 10.1002/jlb.58.6.643; ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BLANCO FJ, 1995, J IMMUNOL, V154, P4018; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BOLANOS JP, 1994, J NEUROCHEM, V63, P910; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; BROWN GC, 1995, NEUROSCI LETT, V193, P201, DOI 10.1016/0304-3940(95)11703-Y; BUSH PA, 1992, BIOCHEM BIOPH RES CO, V185, P960, DOI 10.1016/0006-291X(92)91720-B; CHAKRAVARTHY U, 1995, CURR EYE RES, V14, P285, DOI 10.3109/02713689509033528; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; COLASANTI M, 1995, NEUROSCI LETT, V195, P45, DOI 10.1016/0304-3940(95)11778-U; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; EVANS T, 1994, EUR J BIOCHEM, V219, P563, DOI 10.1111/j.1432-1033.1994.tb19972.x; FUJISAWA H, 1995, J NEUROCHEM, V64, P85; GARTHWAITE J, 1995, TRENDS NEUROSCI, V18, P51; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Grabowski PS, 1996, BRIT J RHEUMATOL, V35, P207; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1992, BIOCHEM SOC T, V20, P465, DOI 10.1042/bst0200465; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; LIN RF, 1993, J EXP MED, V178, P643, DOI 10.1084/jem.178.2.643; Liu J, 1996, J IMMUNOL, V157, P3569; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARSAULT R, 1992, J NEUROCHEM, V59, P942, DOI 10.1111/j.1471-4159.1992.tb08334.x; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; MITROVIC B, 1995, NEUROSCIENCE, V65, P531, DOI 10.1016/0306-4522(94)00491-M; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293; PADGETT EL, 1992, BIOCHEM BIOPH RES CO, V186, P775, DOI 10.1016/0006-291X(92)90813-Z; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARK SK, 1994, J NEUROSCI RES, V39, P405, DOI 10.1002/jnr.490390407; PETERSON PK, 1994, J INFECT DIS, V170, P457, DOI 10.1093/infdis/170.2.457; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; STEINER AL, 1972, J BIOL CHEM, V247, P1106; STPIERRE BA, 1997, IN PRESS CELL BIOL P; Tracey W.R., 1992, NEUROPROTOCOLS, V1, P125, DOI 10.1016/1058-6741(92)90043-W; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WALKER DG, 1995, J NEUROSCI RES, V40, P478, DOI 10.1002/jnr.490400407; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WEINBERG JB, 1995, BLOOD, V86, P1184; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNER ER, 1993, ADV EXP MED BIOL, V338, P203; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	63	124	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11327	11335						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111039				2022-12-25	WOS:A1997WW00900055
J	Newcomb, R; Sun, XY; Taylor, L; Curthoys, N; Giffard, RG				Newcomb, R; Sun, XY; Taylor, L; Curthoys, N; Giffard, RG			Increased production of extracellular glutamate by the mitochondrial glutaminase following neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-DEPENDENT GLUTAMINASE; AMINO-ACIDS; CEREBRAL-ISCHEMIA; CELL-CULTURE; ORTHO-PHTHALDIALDEHYDE; CORTICAL-NEURONS; FOCAL ISCHEMIA; NEUROTOXICITY; ASTROCYTES; RELEASE	Elevated extracellular concentrations of the excitatory transmitter glutamate are an important cause of neuronal death in a variety of disorders of the nervous system, The concentrations and rates of clearance and production of extracellular glutamate were measured in the medium of primary cultures from mouse neocortex containing neurons, astrocytes, or both cell types, Measurements were performed in the presence and absence of 2 mM glutamine with or without neuronal injury caused by 5-h exposure to hypoxia or 500 mu M N-methyl-D-aspartate or a freeze-thaw cycle, High rates of glutamate generation (0.5-0.8 mu M/min in the 0.4-ml culture well) occurred if neurons were both damaged and exposed to glutamine, Intact neurons or glia exposed to glutamine generated only small amounts of glutamate (0.03 mu M/min). Glutamate generation by damaged neurons was dependent on the presence of glutamine, activated by phosphate, and inhibited by 6-diazo-5-oxo-L-norleucine and p-chloromercuriphenylsulfonic acid (pCMPS), strongly implicating the mitochondrial glutaminase, Following 5-h exposure to 500 mu M N-methyl-D-aspartate, the glutaminase was localized to fragments of damaged neurons and was accessible to inhibition by the membrane-impermeant pCMPS, The glutaminase activity from damaged neurons is sufficient to account for the neurotoxic concentrations of glutamate in hypoxic mixed neuronal glial cultures exposed to 2 mM glutamine, Finally, pCMPS is neuroprotective and also prevents the increased rate of generation of glutamate observed in neuronal cultures after prolonged exposure to glutamine, The cumulative data indicate the following: 1) excitotoxic neuronal death activates the hydrolysis of extracellular glutamine by the mitochondrial glutaminase, and 2) the glutaminase in damaged neurons is sufficient to cause neuronal death in in vitro models of neuronal injury.	STANFORD UNIV,SCH MED,DEPT ANESTHESIOL,STANFORD,CA 94305; COLORADO STATE UNIV,DEPT BIOCHEM & MOL BIOL,FT COLLINS,CO 80523	Stanford University; Colorado State University	Newcomb, R (corresponding author), NEUREX CORP,3760 HAVEN AVE,MENLO PK,CA 94025, USA.			Giffard, Rona/0000-0003-2173-4436	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS035406] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37124] Funding Source: Medline; NIGMS NIH HHS [GM49831] Funding Source: Medline; NINDS NIH HHS [1 R43 NS35406-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; BRADFORD HF, 1978, J NEUROCHEM, V30, P1453, DOI 10.1111/j.1471-4159.1978.tb10477.x; BRUCKNER H, 1989, J CHROMATOGR, V476, P73, DOI 10.1016/S0021-9673(01)93857-9; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CHOI DW, 1987, J NEUROSCI, V7, P357; Clarke DD., 1989, BASIC NEUROCHEMISTRY, P541; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; DICHTER MA, 1978, BRAIN RES, V149, P279, DOI 10.1016/0006-8993(78)90476-6; DREJER J, 1982, EXP BRAIN RES, V47, P259; DRISCOLL BF, 1993, J NEUROCHEM, V61, P1795, DOI 10.1111/j.1471-4159.1993.tb09818.x; DUGAN LL, 1995, J NEUROSCI, V15, P4545; GODFREY S, 1977, J BIOL CHEM, V252, P1927; GOLDBERG MP, 1988, NEUROSCI LETT, V94, P52, DOI 10.1016/0304-3940(88)90269-8; HASER WG, 1985, BIOCHEM J, V229, P399, DOI 10.1042/bj2290399; HERTZ L, 1978, NEUROCHEM RES, V3, P1, DOI 10.1007/BF00964356; HOGSTAD S, 1988, NEUROCHEM RES, V13, P383, DOI 10.1007/BF00972489; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KVAMME E, 1984, GLUTAMINE METABOLISM, P33; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; Matsumoto K, 1996, J CEREBR BLOOD F MET, V16, P114, DOI 10.1097/00004647-199601000-00014; MATSUMOTO K, 1993, J CEREBR BLOOD F MET, V13, P586, DOI 10.1038/jcbfm.1993.76; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; *NAT RES COUNC, 1996, GUID CAR US LAB; NEWCOMB R, 1989, LC GC-MAG SEP SCI, V7, P570; NICKLAS WJ, 1987, BIOCHEM SOC T, V15, P208, DOI 10.1042/bst0150208; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; ROBERTS DV, 1977, ENZYME KINETICS, P23; ROSENBERG PA, 1991, GLIA, V4, P91, DOI 10.1002/glia.440040111; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHAPIRO RA, 1979, J BIOL CHEM, V254, P2835; SHAPIRO RA, 1985, ARCH BIOCHEM BIOPHYS, V243, P1, DOI 10.1016/0003-9861(85)90767-2; SHAPIRO RA, 1991, J BIOL CHEM, V266, P18792; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SRINIVASAN M, 1995, J BIOL CHEM, V270, P1185, DOI 10.1074/jbc.270.3.1185; STEINBERG GK, 1989, STROKE, V20, P1247, DOI 10.1161/01.STR.20.9.1247; STEINBERG GK, 1988, NEUROSCI LETT, V89, P193, DOI 10.1016/0304-3940(88)90380-1; SWANSON RA, 1994, J CEREBR BLOOD F MET, V14, P1; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x; WARD HK, 1983, J NEUROCHEM, V40, P855, DOI 10.1111/j.1471-4159.1983.tb08058.x	41	64	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11276	11282						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111031				2022-12-25	WOS:A1997WW00900047
J	Field, H; Field, MC				Field, H; Field, MC			Tandem duplication of rab genes followed by sequence divergence and acquisition of distinct functions in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; FLAGELLAR POCKET; MESSENGER-RNAS; PROTEIN; EXPRESSION; FAMILY; GENOME; LOCALIZATION; PROCYCLIN; MEMBRANE	The Ras superfamily of small G proteins governs unidirectional cellular processes by virtue of GTP hydrolysis and concomitant conformational changes, which are in turn regulated by a number of accessory factors, Members of the Rab subfamily are important for correct targeting and fusion of intra-organellar vesicles loaded with trafficking proteins and lipids, During evolution from a prototype gene, novel functions may be acquired by duplicated daughter genes; for Rab proteins, this can be tested by location, which is specifically related to the function of each Rab, We have found an example of two rab genes in Trypanosoma brucei (trab genes) that clearly arose by tandem duplication, being highly related to each other and remaining juxtaposed in the genome, whose products have dramatically different subcellular locations, indicative of discrete functions. These two trab genes, isolated on a single genomic clone, are separated by a short intervening sequence and are in a head-to-tail orientation, The nucleotide sequences of the open reading frames and intervening sequence were determined and show that the genes are paralogues, probably arising from an ancient tandem duplication, Both genes are most homologous to ypt1 and sec4 in the Saccharomyces cerevisiae genome, while phylogenetic reconstruction indicates that although they have clearly diverged, the proteins are more closely related to each other than to other Rab protein sequences available in the data base, Immunofluorescence microscopy, using antibodies raised against the recombinant Trab proteins, clearly demonstrates that the native Trab proteins have completely distinct subcellular locations in the trypanosome, Trab1p is present in a widespread reticular location similar to BiP, suggesting an endoplasmic reticulum location, while Trab7p is observed in a discrete structure adjacent to the kinetoplast, Most interestingly, the Trab7p-positive compartment also appears to divide at the same time, or just prior to, the kinetoplast, i.e. early in mitosis, suggestive of association with structures in the flagellar pocket region, An estimate of the divergence time indicates that the trab1/trab7 duplication occurred similar to 100 million years ago, and therefore, the persistence of this pair suggests an essential role in the survival of T. brucei.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,CELL BIOL LAB,LONDON SW7 2AY,ENGLAND	Imperial College London			Field, Mark/AAD-6455-2021	Field, Mark/0000-0002-4866-2885	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANGS JD, 1993, J CELL SCI, V105, P1101; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; BRICKMAN MJ, 1994, J EUKARYOT MICROBIOL, V41, P533, DOI 10.1111/j.1550-7408.1994.tb01512.x; Clayton C, 1996, MOL BIOCHEM PARASIT, V77, P1, DOI 10.1016/0166-6851(96)02587-X; CLAYTON C, 1995, MICROBIOL REV, V59, P325, DOI 10.1128/MMBR.59.3.325-344.1995; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; Duszenko Michael, 1993, V2 (PARTS A AND B), P227; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; Field H, 1996, MOL BIOCHEM PARASIT, V82, P67, DOI 10.1016/0166-6851(96)02723-5; FIELD H, 1992, MOL BIOCHEM PARASIT, V50, P47, DOI 10.1016/0166-6851(92)90243-D; FIELD MC, 1995, MOL BIOCHEM PARASIT, V69, P131, DOI 10.1016/0166-6851(94)00209-6; Field MC, 1995, EXP PARASITOL, V81, P313, DOI 10.1006/expr.1995.1122; Field MC, 1996, J MOL EVOL, V42, P500, DOI 10.1007/BF02352280; Foster R, 1996, MOL CELL BIOL, V16, P2689; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HEHL A, 1994, PARASITOL TODAY, V10, P442, DOI 10.1016/0169-4758(94)90180-5; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; KLOCKNER T, 1995, MOL PAR M SEPT 17 21, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; Li FS, 1996, NUCLEIC ACIDS RES, V24, P534, DOI 10.1093/nar/24.3.534; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; STEELEMORTIMER O, 1994, EMBO J, V13, P34, DOI 10.1002/j.1460-2075.1994.tb06232.x; Swofford D.L., 1993, PHYLOGENETIC ANAL US; TENASBROEK ALM, 1996, NATURE, V348, P174; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P383; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZERIAL M, 1992, METHOD ENZYMOL, V219, P398; ZERIAL M, 1995, GUIDEBOOK SMALL GTPA, P12	47	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10498	10505						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099693	hybrid			2022-12-25	WOS:A1997WV26200027
J	Mineo, C; Anderson, RGW; White, MA				Mineo, C; Anderson, RGW; White, MA			Physical association with Ras enhances activation of membrane-bound Raf (RafCAAX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE-KINASE; SIGNAL-TRANSDUCTION PATHWAY; NIH 3T3 CELLS; PROTEIN-KINASE; PLASMA-MEMBRANE; TRANSFORMATION; PHOSPHORYLATION; BINDING	The transforming activity of artificially membrane-targeted Raf1 suggests that Pas-mediated recruitment of Raf1 to the plasma membrane is an important step in Raf1 activation, Cellular has is concentrated in the caveolae, a microdomain of the plasma membrane that is highly enriched in caveolin, glycosylphosphatidylinositol-anchored proteins, and signal transduction molecules, Growth factor stimulation recruits Raf1 to this membrane domain, Whether Pas simply promotes Raf1 association with caveolae membranes or also modulates subsequent activation events is presently unclear, We have identified a ras variant, ras12V,37G, that does not interact with Raf1 but does interact with a mutant raf1, raf1(257L), To examine the role of Pas in the activation of membrane-bound Raf1, raf1CAAX, and raf1(257L)CAAX, membrane-targeted variants of Raf1 and raf1(257L), respectively, were expressed in fibroblasts with or without coexpression of ras12V,37G, Cell fractionation localized both raf1CAAX and raf1(257L)CAAX to caveolae membranes independent of ras12V,37G expression; however, coexpression of ras12V,37G enhanced the activation of raf(257L)CAAX, but not raf1CAAX, as monitored by induction of cellular transformation, increased Raf kinase activity, and induction of activated MAP kinase. These results suggest that the Ras/Raf1 interaction plays a role in Raf1 activation that is distinct from membrane recruitment.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [CA71443] Funding Source: Medline; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM43169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Okada T, 1996, J BIOL CHEM, V271, P4671; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TRAVERSE S, 1993, ONCOGENE, V8, P3175; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	36	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10345	10348						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099670				2022-12-25	WOS:A1997WV26200004
J	Tillet, E; Ruggiero, F; Nishiyama, A; Stallcup, WB				Tillet, E; Ruggiero, F; Nishiyama, A; Stallcup, WB			The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; EGF-LIKE MOTIF; HEPARAN-SULFATE; EXTRACELLULAR-MATRIX; ALPHA-4-BETA-1 INTEGRIN; RECOMBINANT EXPRESSION; ADHESION; FIBRONECTIN	NG2 is a membrane-spanning proteoglycan with a primary structure unique among cell surface or extracellular matrix proteins. To characterize the interaction between NG2 and extracellular matrix proteins, we have used a eukaryotic expression system to produce and purify several recombinant fragments covering not only the entire ectodomain of NG2 but also distinct subdomains of the molecule. Using a solid phase binding assay with various extracellular matrix proteins, we have identified two main ligands for NG2, namely, collagens V and VI. Consistent with previous models of glycosaminoglycan attachment, roughly 50% of the recombinant NG2 fragments containing the central domain have chondroitin sulfate chains attached to the protein core. These glycosaminoglycan chains are not directly involved in collagen binding, since chondroitinase-treated fragments exhibit an unimpaired ability to bind to both collagens. Using more restricted recombinant fragments of NG2, we mapped the binding site for both collagens to the central domain of NG2. Electron microscopy after rotary shadowing of native NG2 molecules indicates that this extended nonglobular domain provides a flexible connection joining the two N- and C- terminal globular regions of NG2. Rotary shadowing of mixtures of NG2 and collagen V or VI confirms a direct interaction between the molecules and indicates that the collagens align with the central region of NG2, giving the appearance of a rod between the N- and C-terminal globules.	BURNHAM INST, LA JOLLA CANC RES CTR, LA JOLLA, CA 92037 USA; INST BIOL & CHIM PROT, F-69367 LYON 07, FRANCE; CLEVELAND CLIN FDN, DEPT NEUROSCI, CLEVELAND, OH 44195 USA	Sanford Burnham Prebys Medical Discovery Institute; Cleveland Clinic Foundation				RUGGIERO, Florence/0000-0003-2915-5359; Tillet, Emmanuelle/0000-0002-0076-8007	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021990] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS21990] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; Burg MA, 1996, J BIOL CHEM, V271, P26110, DOI 10.1074/jbc.271.42.26110; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; CHUN JS, 1993, MOL BIOL CELL, V4, P271; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IIDA J, 1995, CANCER RES, V55, P2177; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; KODA JE, 1985, J BIOL CHEM, V260, P8157; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEGER O, 1994, INT J CANCER, V58, P700, DOI 10.1002/ijc.2910580514; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Lin XH, 1996, J CELL BIOCHEM, V63, P463, DOI 10.1002/(SICI)1097-4644(19961215)63:4<463::AID-JCB8>3.0.CO;2-R; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; NISHIYAMA A, 1993, MOL BIOL CELL, V4, P1097, DOI 10.1091/mbc.4.11.1097; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819, DOI 10.1091/mbc.6.12.1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NISHIYAMA A, 1991, DEVELOPMENT, V111, P933; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Ruggiero F, 1996, J CELL SCI, V109, P1865; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SANANTONIO JD, 1994, GLYCOBIOLOGY, V4, P327; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHRAPPE M, 1991, CANCER RES, V51, P4986; STALLCUP WB, 1983, COLD SPRING HARB SYM, V48, P761, DOI 10.1101/SQB.1983.048.01.078; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183	54	135	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10769	10776						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099729				2022-12-25	WOS:A1997WV26200063
J	Cosgaya, JM; Recio, JA; Aranda, A				Cosgaya, JM; Recio, JA; Aranda, A			Influence of Ras and retinoic acid on nerve growth factor induction of transin gene expression in PC12 cells	ONCOGENE			English	Article						metalloproteinases; neurite extension; retinoic acid; nerve growth factor	PROTEIN-KINASE; FACTOR RECEPTOR; B-RAF; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; NGF-INDUCTION; STROMELYSIN; ONCOGENE; INHIBITION; PROMOTER	Nerve growth factor (NGF)- and ras-induced neuronal differentiation of PC12 cells is accompanied by expression of transin, a secreted metalloproteinase. Retinoic acid (RA) is known to exert important effects on neural cell proliferation and differentiation, In this study we have analysed different PC12 sublines which express either activated Ras or dominant negative p21(N17) Ras, to evaluate the influence of retinoic acid (RA) on the response of the transin gene to NGF and Ras. There was a good correlation between neurite extension and induction of transin mRNA levels in the different subclones. NGF did not induce transin mRNA in cells which do not differentiate in response to this neurotrophin. In addition, incubation with RA did not detectably increase basal transin mRNA levels, but caused a significant increase in the transin response to NGF or Ras in cells in which these factors induce a neuronal morphology. Sequences contained within 750 base pairs of the 5' flanking region of the transin gene confer responsiveness to NGF and Ras, but do not mediate the stimulatory effect of RA. In addition, expression of oncogenic Raf increases transin promoter activity in PC12 cells, but a dominant-negative Raf mutant was unable to block NGF-induced transin activity suggesting the existence of a bifurcation downstream of ras in the signaling mechanism leading to transin expression by NGF.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020; Cosgaya, Jose M/B-4936-2008	Aranda, Ana/0000-0002-8338-9589; Cosgaya, Jose Miguel/0000-0002-6005-2916; Recio, Juan Angel/0000-0002-7320-3832				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cosgaya JM, 1996, ONCOGENE, V12, P2651; Cosgaya JM, 1996, J NEUROCHEM, V66, P89; COSGAYA JM, 1996, IN PRESS ONCOGENE; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DESOUZA S, 1995, J BIOL CHEM, V270, P9106, DOI 10.1074/jbc.270.16.9106; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1585; GUIGUERE V, 1994, ENDOCR REV, V15, P61; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kerr L D, 1992, Matrix Suppl, V1, P176; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOSARDO JE, 1995, CLIN EXP METASTAS, V13, P236, DOI 10.1007/BF00133479; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	43	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1687	1696		10.1038/sj.onc.1200997	http://dx.doi.org/10.1038/sj.onc.1200997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135070				2022-12-25	WOS:A1997WR89300007
J	Borza, DB; Morgan, WT				Borza, DB; Morgan, WT			Acceleration of plasminogen activation by tissue plasminogen activator on surface-bound histidine-proline-rich glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; HEPARIN BINDING; EXTRACELLULAR-MATRIX; PLATELET FACTOR-4; FIBRIN; UROKINASE; PROTEINS; NEUTRALIZATION; PREKALLIKREIN; ANTITHROMBIN	Histidine-proline-rich glycoprotein (HPRG), also known as histidine-rich glycoprotein, is a major plasminogen-binding protein. In this work we characterized extensively the circumstances under which HPRG accelerates plasminogen activation and the specificity of this effect. Soluble HPRG did not significantly influence plasminogen activation. In contrast, native HPRG bound to hydrazide or nickel chelate surfaces strongly stimulated the activation of plasminogen by tissue plasminogen activator, but not by urokinase or streptokinase. The efficiency of activation on surface-bound HPRG was increased for Glu-plasminogen (41-fold), Lys-plasminogen (17-fold), and cross-linked Glu-plasminogen (11-fold) but not for mini-plasminogen, and was mainly due to a decrease in the apparent K-m. A reduced susceptibility to inhibition by chloride ions contributed to the higher activation rate of Glu-plasminogen on an HPRG surface. The immobilized N- and C-terminal domains, but not the histidine-proline-rich domain of HPRG, also bound plasminogen and stimulated its activation. HPRG-enhanced plasminogen activation was proportional to the quantity of HPRG immobilized and was abolished by anti-HPRG antiserum, by low concentrations of epsilon-aminocaproic acid, by methylation of lysine residues in HPRG, and by treatment of HPRG with carboxypeptidase B. Soluble HPRG and a plasminogen fragment, kringle 1-2-8, acted as competitive inhibitors by binding to plasminogen and immobilized HPRG, respectively. The interaction of the conserved C-terminal lysine of HPRG with the high affinity lysine binding site of plasminogen is necessary and sufficient to accelerate plasminogen activation, Unlike other stimulators of plasminogen activation, the effect of HPRG on fibrinolysis is modulated by factors that influence the equilibrium between solution and surface-bound HPRG.	UNIV MISSOURI,SCH BIOL SCI,DIV BIOCHEM & MOL BIOL,KANSAS CITY,MO 64110	University of Missouri System; University of Missouri Kansas City			Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037570] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-37570] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGLESCANO E, 1992, BIOCHIM BIOPHYS ACTA, V1156, P34, DOI 10.1016/0304-4165(92)90092-9; BANYAI L, 1984, J BIOL CHEM, V259, P6466; BECKMANN R, 1988, J BIOL CHEM, V263, P7176; Borza DB, 1996, BIOCHEMISTRY-US, V35, P1925, DOI 10.1021/bi952061t; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BURCH MK, 1987, BIOCHEMISTRY-US, V26, P7477, DOI 10.1021/bi00397a042; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; LANE DA, 1986, J BIOL CHEM, V261, P3980; LERCH PG, 1988, BRIT J HAEMATOL, V70, P219, DOI 10.1111/j.1365-2141.1988.tb02467.x; LEUNG LLK, 1986, J CLIN INVEST, V77, P1305, DOI 10.1172/JCI112435; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; LIJNEN HR, 1983, THROMB HAEMOSTASIS, V50, P560; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MARKUS G, 1978, J BIOL CHEM, V253, P733; Means G E, 1977, Methods Enzymol, V47, P469; MEIER HL, 1977, J CLIN INVEST, V60, P18, DOI 10.1172/JCI108754; MORGAN WT, 1978, BIOCHIM BIOPHYS ACTA, V535, P319, DOI 10.1016/0005-2795(78)90098-3; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NIWA M, 1985, THROMB RES, V37, P237, DOI 10.1016/0049-3848(85)90051-9; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POWELL JR, 1980, J BIOL CHEM, V255, P5329; RADCLIFFE R, 1981, ARCH BIOCHEM BIOPHYS, V211, P750, DOI 10.1016/0003-9861(81)90512-9; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; SAEZ CT, 1995, BIOCHEMISTRY-US, V34, P2496, DOI 10.1021/bi00008a013; SAIGO K, 1989, J BIOL CHEM, V264, P8249; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SILVERSTEIN RL, 1985, J CLIN INVEST, V75, P2065, DOI 10.1172/JCI111926; SORENSEN CB, 1993, FEBS LETT, V328, P285, DOI 10.1016/0014-5793(93)80945-Q; URANO T, 1987, J BIOL CHEM, V262, P15959; URANO T, 1988, BIOCHEMISTRY-US, V27, P6522, DOI 10.1021/bi00417a049; Verger R, 1980, Methods Enzymol, V64, P340; WIGGINS RC, 1977, P NATL ACAD SCI USA, V74, P4636, DOI 10.1073/pnas.74.10.4636; WU HL, 1990, J BIOL CHEM, V265, P19658	43	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	1997	272	9					5718	5726		10.1074/jbc.272.9.5718	http://dx.doi.org/10.1074/jbc.272.9.5718			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WK747	9102401	hybrid			2022-12-25	WOS:A1997WK74700051
J	Boorer, KJ; Fischer, WN				Boorer, KJ; Fischer, WN			Specificity and stoichiometry of the Arabidopsis H+ amino acid transporter AAP5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR-BEET LEAVES; SUBSTRATE-SPECIFICITY; EXPRESSION CLONING; COTRANSPORTER; THALIANA; SYMPORTS; KINETICS; YEAST; CELLS	The H+-dependent AAP5 amino acid transporter from Arabidopsis thaliana was expressed in Xenopus oocytes, and we used radiotracer flux and electrophysiology methods to investigate its substrate specificity and stoichiometry, Inward currents of up to 9 mu A were induced by a broad spectrum of amino acids, including anionic, cationic, and neutral amino acids, The apparent affinity of AAP5 for amino acids was influenced by the position of side chain branches, bulky ring structures, and charged groups, The maximal current was dependent on amino acid charge, but was relatively independent of amino acid structure, A detailed kinetic analysis of AAP5 using lysine, alanine, glutamate, and histidine revealed H+-dependent differences in the apparent affinity constants for each substrate, The differences were correlated to the effect of H+ concentration on the net charge of each amino acid and suggested that AAP5 transports only the neutral species of histidine and glutamate, Stoichiometry experiments, whereby the uptake of H-3-labeled amino acid and net inward charge were simultaneously measured in voltage-clamped oocytes, showed that the charge:amino acid stoichiometry was 2:1 for lysine and 1:1 for alanine, glutamate, and histi dine, The results confirm that histidine is transported in its neutral form and show that the positive charge on lysine contributes to the magnitude of its inward current, Thus, the transport stoichiometry of AAP5 is 1 H+:1 amino acid irrespective of the net charge on the transported substrate, Structural features of amino acid molecules that are involved in substrate recognition by AAP5 are discussed.	UNIV TUBINGEN,INST BOT,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen	Boorer, KJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,10833 LE CONTE AVE,LOS ANGELES,CA 90095, USA.				NIDDK NIH HHS [DK19567] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boorer KJ, 1996, J BIOL CHEM, V271, P25139, DOI 10.1074/jbc.271.41.25139; BOORER KJ, 1994, J BIOL CHEM, V269, P20417; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; BURKHARDT BC, 1992, PFLUEGERS ARCH, V420, P78; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; FROMMER WB, 1994, PLANT MOL BIOL, V26, P1651, DOI 10.1007/BF00016495; Frommer WB, 1995, P NATL ACAD SCI USA, V92, P12036, DOI 10.1073/pnas.92.26.12036; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; FROMMER WB, 1995, ANNU REV PLANT PHYS, V46, P419, DOI 10.1146/annurev.pp.46.060195.002223; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; KINRAIDE TB, 1980, PLANT PHYSIOL, V65, P1085, DOI 10.1104/pp.65.6.1085; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; LEIDREITER K, 1995, BOT ACTA, V108, P439, DOI 10.1111/j.1438-8677.1995.tb00518.x; LI ZC, 1990, PLANT PHYSIOL, V94, P268, DOI 10.1104/pp.94.1.268; LI ZC, 1992, ARCH BIOCHEM BIOPHYS, V294, P519, DOI 10.1016/0003-9861(92)90719-D; LI ZC, 1991, PLANT PHYSIOL, V96, P1338, DOI 10.1104/pp.96.4.1338; LOHAUS G, 1994, J EXP BOT, V277, P1097; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Mackenzie B, 1996, BBA-BIOMEMBRANES, V1284, P125, DOI 10.1016/S0005-2736(96)00170-8; RIENS B, 1991, PLANT PHYSIOL, V97, P227, DOI 10.1104/pp.97.1.227; SANDERS D, 1983, BIOCHIM BIOPHYS ACTA, V735, P67, DOI 10.1016/0005-2736(83)90261-4; Tanner W, 1996, ANNU REV PLANT PHYS, V47, P595, DOI 10.1146/annurev.arplant.47.1.595; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Wenzel U, 1996, J PHARMACOL EXP THER, V277, P831; WINTER H, 1992, PLANT PHYSIOL, V99, P996, DOI 10.1104/pp.99.3.996; WYSE RE, 1984, PLANT PHYSIOL, V76, P865, DOI 10.1104/pp.76.4.865	30	61	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13040	13046		10.1074/jbc.272.20.13040	http://dx.doi.org/10.1074/jbc.272.20.13040			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148914	hybrid			2022-12-25	WOS:A1997WZ38400027
J	Romoser, VA; Hinkle, PM; Persechini, A				Romoser, VA; Hinkle, PM; Persechini, A			Detection in living cells of Ca2+-dependent changes in the fluorescence emission of an indicator composed of two green fluorescent protein variants linked by a calmodulin-binding sequence - A new class of fluorescent indicators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; MYOSIN; ACTIVATION; DOMAIN	We have designed a novel fluorescent indicator composed of two green fluorescent protein variants joined by the calmodulin-binding domain from smooth muscle myosin light chain kinase. When (Ca2+)(4)-calmodulin is bound to the indicator (K-d = 0.4 nM), fluorescence resonance energy transfer between the two fluorophores is attenuated; the ratio of the fluorescence intensity measured at 505 nm to the intensity measured at 440 nm decreases B-fold. Images of microinjected living cells demonstrate that emission ratios can be used to monitor spatio temporal changes in the fluorescence of the indicator, Changes in indicator fluorescence in these cells are coupled with no discernible lag(<1 s) to changes in the cytosolic free Ca2+ ion concentration, ranging from below 50 nM to similar to 1 mu M. This observation suggests that the activity of a calmodulin target with a typical 1 nM affinity for (Ca2+)(4)-calmodulin is responsive to changes in the intracellular Ca2+ concentration over the physiological range. It is likely that the indicator we describe can be modified to detect the levels of ligands and proteins in the cell other than calmodulin.	UNIV ROCHESTER,MED CTR,DEPT PHYSIOL & PHARMACOL,ROCHESTER,NY 14642	University of Rochester					NCI NIH HHS [CA11198] Funding Source: Medline; NIDDK NIH HHS [DK44322, DK19974] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322, R01DK019974] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DELEGRAVE S, 1995, BIOTECHNOLOGY, V13, P151; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; VANAMAN TC, 1982, ADV PROTEIN CHEM, V35, P213; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; YU R, 1997, IN PRESS MOL PHARM	21	317	344	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13270	13274		10.1074/jbc.272.20.13270	http://dx.doi.org/10.1074/jbc.272.20.13270			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148946	hybrid			2022-12-25	WOS:A1997WZ38400059
J	Tang, W; Keesler, GA; Tabas, I				Tang, W; Keesler, GA; Tabas, I			The structure of the gene for murine CTP:phosphocholine cytidylyltransferase, Ctpct - Relationship of exon structure to functional domains and identification of transcriptional start sites and potential upstream regulatory elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; MESSENGER-RNA; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHORYLATION SITES; TERMINAL DOMAIN; PROMOTER REGION; ORGANIZATION; EXPRESSION; SEQUENCE; PROTEIN	Phosphatidylcholine (PC) is the most abundant eukaryotic phospholipid and serves critical structural and cell-signaling functions. CTP:phosphocholine cytidylyltransferase (CT) is the rate-limiting enzyme in the CDP-choline pathway of PC biosynthesis, which is utilized by all tissues and is the sole or major PC biosynthetic pathway in all non hepatic cells. Herein, we present the complete structure of the murine CT (Ctpct) gene. One P1 genomic clone and six subsequent plasmid subclones were isolated and analyzed for the exon-intron organi zation of the Ctpct gene. The gene spans approximately 26 kilobases and is composed of 9 exons and 8 introns. The exons match the distinct functional domains of the CT enzyme: exon 1 is untranslated; exon 2 codes for the nuclear localization signal domain; exons 4-7 encompass the catalytic domain; exon 8 codes for the alpha-helical membrane-binding domain; and exon 9 includes the C-terminal phosphorylation domain, Two transcriptional initiation sites, spaced 35 nucleotides apart, were identified using 5' rapid amplification of cDNA ends polymerase chain reaction. The 5' natural flanking region was found to lack TATA or CAAT boxes and to contain GC-rich regions, which are features typical of promoters of housekeeping genes. Several sites that have the potential to interact with transcription regulatory factors, such as Sp1, AP1, AP2, AP3, Y1, and TFIIIA, were identified in the 5'-region of the gene and found to be distributed in two distinct clusters, These data will provide the basis for future studies on the cis- and trans-acting factors involved in Ctpct gene transcription and for the creation of induced mutant mouse models of altered CT activity.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University; Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007343, P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54591, 5T32HL-07343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Cui Z, 1995, BIOCHEM J, V312, P939, DOI 10.1042/bj3120939; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KIM SH, 1986, NUCLEIC ACIDS RES, V14, P3103, DOI 10.1093/nar/14.7.3103; KOH J, 1993, J BIOL CHEM, V268, P15912; LATHANGUE NB, 1988, TRANSCRIPTION SPLICI, P1; LI WH, 1988, J LIPID RES, V29, P245; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Rhee S, 1996, J BIOL CHEM, V271, P28947, DOI 10.1074/jbc.271.46.28947; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; TU AY, 1995, BIOCHEM BIOPH RES CO, V207, P552, DOI 10.1006/bbrc.1995.1223; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; Veitch DP, 1996, BIOCHEMISTRY-US, V35, P10743, DOI 10.1021/bi960402c; WAHLE E, 1992, BIOESSAYS, V14, P113, DOI 10.1002/bies.950140208; Walkey CJ, 1996, J LIPID RES, V37, P2341; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	41	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13146	13151		10.1074/jbc.272.20.13146	http://dx.doi.org/10.1074/jbc.272.20.13146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148929	hybrid			2022-12-25	WOS:A1997WZ38400042
J	Wiegert, T; Sahm, H; Sprenger, GA				Wiegert, T; Sahm, H; Sprenger, GA			The substitution of a single amino acid residue (Ser-116->Asp) alters NADP-containing glucose-fructose oxidoreductase of Zymomonas mobilis into a glucose dehydrogenase with dual coenzyme specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS INOSITOL DEHYDROGENASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; BINDING FOLD; GENE; MUTAGENESIS; EXPRESSION; SITE; CDNA; LOCALIZATION	Glucose-fructose oxidoreductase (GFOR, EC 1.1.1.99.-) from the Gram-negative bacterium Zymomonas mobilis contains the tightly bound cofactor NADP, Based on the revision of the gfo DNA sequence, the derived GFOR sequence was aligned with enzymes catalyzing reactions with similar substrates, A novel consensus motif (AGKHVXCEKP) for a class of dehydrogenases was detected, From secondary structure analysis the serine-116 residue of GFOR was predicted as part of a Rossmann type dinucleotide binding fold, An engineered mutant protein (S116D) was purified and shown to have lost tight cofactor binding based on (a) altered tryptophan fluorescence; (b) lack of NADP liberation through perchloric acid treatment of the protein; and (c) lack of GFOR enzyme activity, The S116D mutant showed glucose dehydrogenase activity (3.6 +/- 0.1 units/mg of protein) with both NADP and NAD as coenzymes (K-m for NADP, 153 +/- 9 mu M; for NAD, 375 +/- 32 mu M. The single site mutation therefore altered GFOR, which in the wild-type situation contains NADP as nondissociable redox cofactor reacting in a ping-pong type mechanism, to a dehydrogenase with dissociable NAD(P) as cosubstrate and a sequential reaction type, After prolonged preincubation of the S116D mutant protein with excess NADP (but not NAD), GFOR activity could be restored to 70 units/mg, one-third of wild-type activity, whereas glucose dehydrogenase activity decreased sharply, A second site mutant (S116D/K121A/K123Q/I124K) showed no GFOR activity even after preincubation with NADP, but it retained glucose dehydrogenase activity (4.2 +/- 0.2 units/mg of protein).	FORSCHUNGSZENTRUM JULICH, FORSCHUNGSZENTRUM, INST BIOTECHNOL 1, D-52425 JULICH, GERMANY	Helmholtz Association; Research Center Julich			Sprenger, Georg A./E-2384-2011	Sprenger, Georg A./0000-0002-7879-8978				ADAMS MJ, 1994, STRUCTURE, V2, P385; ALDRICH HC, 1992, J BACTERIOL, V174, P4504, DOI 10.1128/JB.174.13.4504-4508.1992; BAKER PJ, 1992, J MOL BIOL, V228, P662, DOI 10.1016/0022-2836(92)90848-E; BASSO LA, 1995, EUR J BIOCHEM, V234, P603, DOI 10.1111/j.1432-1033.1995.603_b.x; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; Bisswanger H., 1994, ENZYMKINETIK THEORIE; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEHOOP M, 1991, PROTEIN ENG, V4, P821, DOI 10.1093/protein/4.7.821; FAKHRAI H, 1992, J BIOL CHEM, V267, P4023; FREY PA, 1987, PYRIDINE NUCLEOTID B, P461; FUJITA Y, 1991, GENE, V108, P121; GOMI T, 1989, J BIOL CHEM, V264, P16138; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HARDMAN MJ, 1988, EUR J BIOCHEM, V173, P203, DOI 10.1111/j.1432-1033.1988.tb13985.x; HARDMAN MJ, 1992, EUR J BIOCHEM, V205, P715, DOI 10.1111/j.1432-1033.1992.tb16834.x; KANAGASUNDARAM V, 1992, J BACTERIOL, V174, P1439, DOI 10.1128/jb.174.5.1439-1447.1992; KINGSTON RL, 1996, STRUCTURE, V4, P413; KIRK LA, 1993, BIOTECHNOL LETT, V15, P985, DOI 10.1007/BF00131769; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUVERGEAT V, 1995, BIOCHEMISTRY-US, V34, P12426, DOI 10.1021/bi00038a041; LEVY RL, 1996, ARCH BIOCHEM BIOPHYS, V326, P145; LINDROTH P, 1979, ANAL CHEM, V51, P1167; LOOS H, 1993, FEMS MICROBIOL LETT, V107, P293, DOI 10.1016/0378-1097(93)90325-V; LOOS H, 1994, J BACTERIOL, V176, P7688, DOI 10.1128/JB.176.24.7688-7693.1994; LOOS H, 1991, FEMS MICROBIOL LETT, V84, P211; LOOS H, 1994, PROTEIN SCI, V3, P2447, DOI 10.1002/pro.5560031228; MANSOURI K, 1991, MOL GEN GENET, V228, P459, DOI 10.1007/BF00260640; MITTL PRE, 1994, PROTEIN SCI, V3, P1504, DOI 10.1002/pro.5560030916; NOMURA Y, 1992, J FERMENT BIOENG, V74, P333, DOI 10.1016/0922-338X(92)90028-S; OGEL ZB, 1992, PROTEIN ENG, V5, P467, DOI 10.1093/protein/5.5.467; PESCHKE U, 1995, MOL MICROBIOL, V16, P1137, DOI 10.1111/j.1365-2958.1995.tb02338.x; RAMALEY R, 1979, J BIOL CHEM, V254, P7684; ROSKOSKI R, 1987, PYRIDINE NUCLEOTID B, P173; ROSSBACH S, 1994, MOL GEN GENET, V245, P11, DOI 10.1007/BF00279746; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SPERKA S, 1989, NUCLEIC ACIDS RES, V17, P5402, DOI 10.1093/nar/17.13.5402; SWINGS J, 1977, BACTERIOL REV, V41, P1; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wiegert T, 1996, ARCH MICROBIOL, V166, P32, DOI 10.1007/s002030050352; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZACHARIOU M, 1986, J BACTERIOL, V167, P863, DOI 10.1128/jb.167.3.863-869.1986	50	42	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13126	13133		10.1074/jbc.272.20.13126	http://dx.doi.org/10.1074/jbc.272.20.13126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148926	hybrid			2022-12-25	WOS:A1997WZ38400039
J	Wilson, LK; Dhillon, N; Thorner, J; Martin, GS				Wilson, LK; Dhillon, N; Thorner, J; Martin, GS			Casein kinase II catalyzes tyrosine phosphorylation of the yeast nucleolar immunophilin Fpr3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIERARCHICAL PROTEIN-PHOSPHORYLATION; DUAL-SPECIFICITY KINASE; SACCHAROMYCES-CEREVISIAE; GLYCOGEN-SYNTHASE; SUBSTRATE-SPECIFICITY; SIGNAL TRANSDUCTION; THREONINE; PATHWAY; SERINE; PHOSPHOTYROSINE	In the yeast Saccharomyces cerevisiae, the nucleolar immunophilin, Fpr3, is phosphorylated at tyrosine and dephosphorylated by the phosphotyrosine-specific phosphoprotein phosphatase, Ptp1, In Ptp1-deficient cells, Fpr3 contains phospho-Tyr at a single site (Tyr(184), but also contains phospho-Ser and phospho-Thr, Ser(186) (adjacent to Tyr(184)) is situated within a canonical site for phosphorylation by casein kinase II (CKII), Yeast cell lysates contain an activity that binds to Fpr3 in vitro and phosphorylates Fpr3 at Ser, Thr, and Tyr; this activity was found to be dependent on expression of functional yeast CKII, Moreover, purified Fpr3 was phosphorylated on Tyr(184) in vitro by either purified yeast CKII or purified, bacterially-expressed human CKII, Likewise, phosphorylation of Fpr3 at tyrosine in vivo was markedly enhanced in yeast cells overexpressing a heterologous (Drosophila) CKII, but was undetectable in yeast cells carrying only a temperature-sensitive allele of the endogenous CKII, even when the cells were grown at a permissive temperature. Phosphorylation of Fpr3 at Tyr(184) by CKII in vitro lagged behind phosphorylation of Fpr3 at Ser, and was accelerated by pre-phosphorylation of Fpr3 at Ser using CKII, Furthermore, synthetic peptides corresponding to the sequence surrounding Tyr(184) that contained P-Ser (or Glu) at position 186 were much more efficient substrates for CICTI phosphorylation of Tyr(184) than a synthetic peptide containing Ala at position 186. These findings indicate that CKII phosphorylates Fpr3 at tyrosine and serine both in vivo and in vitro and thus possesses dual specificity, These results also indicate that Tyr(184) is phosphorylated by CKII via a tao-step process, in which phosphorylation at the +2 position provides a negatively-charged specificity determinant that allows subsequent phosphorylation of Tyr(184).	UNIV CALIF BERKELEY, DIV BIOCHEM & MOL BIOL, DEPT CELL & MOL BIOL, BERKELEY, CA 94729 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NIGMS NIH HHS [GM21841, GM44173] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R01GM044173, R37GM021841] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BIDWAI AP, 1994, ARCH BIOCHEM BIOPHYS, V309, P348, DOI 10.1006/abbi.1994.1123; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHARDOT T, 1995, CR ACAD SCI III-VIE, V318, P937; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FOSTER R, 1989, J BACTERIOL, V171, P272, DOI 10.1128/jb.171.1.272-279.1989; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; HRUBEY TW, 1990, BIOCHEM BIOPH RES CO, V172, P190, DOI 10.1016/S0006-291X(05)80192-5; HUANG KP, 1983, J BIOL CHEM, V258, P7094; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LIM MY, 1993, J BIOL CHEM, V268, P21155; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEGGIO F, 1991, FEBS LETT, V279, P307, DOI 10.1016/0014-5793(91)80174-2; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WANG JYJ, 1985, J BIOL CHEM, V260, P64; WANG QM, 1994, J BIOL CHEM, V269, P14566; WILSON LK, 1995, J BIOL CHEM, V270, P25185, DOI 10.1074/jbc.270.42.25185; YUAN CJ, 1993, J BIOL CHEM, V268, P17683	42	83	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12961	12967		10.1074/jbc.272.20.12961	http://dx.doi.org/10.1074/jbc.272.20.12961			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148902	hybrid			2022-12-25	WOS:A1997WZ38400015
J	KoikeTakeshita, A; Koyama, T; Ogura, K				KoikeTakeshita, A; Koyama, T; Ogura, K			Identification of a novel gene cluster participating in menaquinone (vitamin K-2) biosynthesis - Cloning and sequence determination of the 2-heptaprenyl-1,4-naphthoquinone methyltransferase gene of Bacillus stearothermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; EXPRESSION; SUBTILIS; RESPIRATION; SYNTHASE; PROTEINS; RNA; DNA	We recently described the isolation and sequence analysis of a DNA region containing the genes of Bacillus stearothermophilus heptaprenyl diphosphate synthase, which catalyzes the synthesis of the prenyl side chain of menaquinone-7 of this bacterium, Sequence analyses revealed the presence of three open reading frames (ORFs), designated as ORF-1, ORF-2, and ORF-3, and the structural genes of the heptaprenyl diphosphate synthase were proved to consist of ORF-1 (heps-1) and ORF-3 (heps-2) (Koike-Takeshita, A., Koyama, T., Obata, S., and Ogura, K. (1995) J. Biol. Chem. 270, 18396-18400). The predicted amino acid sequence of ORF-2 (234 amino acids) contains a methyltransferase consensus sequence and shows a 22% identity with UbiG of Escherichia coli, which catalyzes S-adenosyl-L-methionine-dependent methylation of 2-octaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone. These pieces of information led us to identify the ORF-2 gene product. The cell-free homogenate of the transformant of E. coli with an expression vector of ORF-2 catalyzed the incorporation of S-adenosyl-L-methionine into menaquinone-8, indicating that ORF-2 encodes 2-heptaprenyl-1,4-naphthoquinone methyltransferase, which participates in the terminal step of the menaquinone biosynthesis. Thus it is concluded that the ORF-1, ORF-2, and ORF-3 genes, designated heps-1, menG, and heps-2, respectively, form another cluster involved in menaquinone biosynthesis in addition to the cluster of menB, menC, menD, and menE already identified in the Bacillus subtilis and E. coli chromosomes.	TOHOKU UNIV,INST CHEM REACT SCI,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; TOYOTA MOTOR CO LTD,BIO RES LAB,TOYOTA,AICHI 47171,JAPAN; TOHOKU UNIV,FAC ENGN,DEPT BIOCHEM & ENGN,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University; Toyota Motor Corporation; Tohoku University								ARONDEL V, 1993, J BIOL CHEM, V268, P16002; BENTLEY R, 1987, ESCHERICHIA COLI SAL, P512; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DICKENS ML, 1995, J BACTERIOL, V177, P536, DOI 10.1128/jb.177.3.536-543.1995; DRISCOLL JR, 1992, J BACTERIOL, V174, P5063, DOI 10.1128/JB.174.15.5063-5071.1992; FARRAND SK, 1973, J BACTERIOL, V115, P1035, DOI 10.1128/JB.115.3.1035-1044.1973; GUEST JR, 1981, MOL GEN GENET, V181, P379, DOI 10.1007/BF00425615; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELZER M, 1994, BBA-LIPID LIPID MET, V1212, P93, DOI 10.1016/0005-2760(94)90193-7; MILLER P, 1988, J BACTERIOL, V170, P2735, DOI 10.1128/jb.170.6.2735-2741.1988; PALANIAPPAN C, 1992, J BACTERIOL, V174, P8111, DOI 10.1128/JB.174.24.8111-8118.1992; Rowland B, 1995, GENE, V167, P105, DOI 10.1016/0378-1119(95)00662-1; SAITO Y, 1981, J BIOCHEM-TOKYO, V89, P1445, DOI 10.1093/oxfordjournals.jbchem.a133337; Sambrook J., 2002, MOL CLONING LAB MANU; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; SHARMA V, 1993, J BACTERIOL, V175, P4917, DOI 10.1128/JB.175.15.4917-4921.1993; SUZUKI K, 1994, BIOSCI BIOTECH BIOCH, V58, P1814, DOI 10.1271/bbb.58.1814; WISSENBACH U, 1992, ARCH MICROBIOL, V158, P68, DOI 10.1007/BF00249068; WU GH, 1992, J GEN MICROBIOL, V138, P2101, DOI 10.1099/00221287-138-10-2101; YAZDI MA, 1990, J GEN MICROBIOL, V136, P1335, DOI 10.1099/00221287-136-7-1335	25	31	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12380	12383		10.1074/jbc.272.19.12380	http://dx.doi.org/10.1074/jbc.272.19.12380			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139683	hybrid			2022-12-25	WOS:A1997WY82900020
J	Megonigal, MD; Fertala, J; Bjornsti, MA				Megonigal, MD; Fertala, J; Bjornsti, MA			Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUG CAMPTOTHECIN; SACCHAROMYCES-CEREVISIAE; SITE TYROSINE; GENE; MUTANTS; RESISTANCE; MECHANISM; SEQUENCE; MUTATION; POISONS	Eukaryotic DNA topoisomerase I catalyzes the relaxation of supercoiled DNA through a concerted mechanism of DNA strand breakage and religation. The cytotoxic activity of camptothecin results from the reversible stabilization of a covalent enzyme-DNA inter mediate. Mutations in two conserved regions of yeast DNA topoisomerase I induced a similar mechanism of cell killing, albeit through different effects on enzyme catalysis. In Top1T722Ap, substituting Ala for Thr(722) reduced enzyme specific activity by 3-fold, yet enhanced the stability of the covalent enzyme-DNA complex, In contrast, Top1R517Gp was 1,000-fold less active and camptothecin resistant. Nevertheless, salt-stable DNA-enzyme intermediates were detected. Mutation of the active-site tyrosine abrogated mutant enzyme activity and cytotoxicity, while sublethal levels of top1T722A expression increased rDNA recombination. In checkpoint proficient cells, pGAL1-induced top1 expression coincided with the accumulation of a terminal G(2),-arrested phenotype, Although the acquisition of this phenotype did not require Rad9p, Top1R517Gp- and Top1T722Ap-induced lethality was enhanced in rad9 Delta strains. Thus, despite mechanistic differences between Top1R517Gp and Top1T722Ap, the DNA lesions resulting from the enhanced stability of the covalent enzyme-DNA intermediates were sufficient to cause cell cycle arrest and cell death.	THOMAS JEFFERSON UNIV, DEPT MOL PHARMACOL & BIOCHEM, PHILADELPHIA, PA 19107 USA	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA058755] Funding Source: NIH RePORTER; NCI NIH HHS [CA58755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Allen JB, 1994, GENE DEV, V8, P2416; BENEDETTI P, 1993, CANCER RES, V53, P4343; BENNETT CB, 1993, P NATL ACAD SCI USA, V90, P5613, DOI 10.1073/pnas.90.12.5613; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BJORNSTI MA, 1994, CANCER CHEMOTH PHARM, V34, pS1, DOI 10.1007/BF00684856; Bjornsti MA, 1991, CURR OPIN STRUC BIOL, V1, P99, DOI 10.1016/0959-440X(91)90017-N; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BOSCHELLI F, 1994, MOL CELL BIOL, V14, P6409, DOI 10.1128/MCB.14.9.6409; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; CARON PR, 1993, MOL BIOL DNA TOPOISO, P243; CASERTA M, 1994, J CELL BIOCHEM, V55, P93, DOI 10.1002/jcb.240550111; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DARPA P, 1990, CANCER RES, V50, P6919; ENG WK, 1988, MOL PHARMACOL, V34, P755; ENG WK, 1989, J BIOL CHEM, V264, P13373; FELIX CA, 1995, CANCER RES, V55, P4287; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HILL DE, 1987, METHOD ENZYMOL, V155, P558; HOLM C, 1989, CANCER RES, V49, P6365; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JOHNSTON LH, 1978, MOL GEN GENET, V164, P217, DOI 10.1007/BF00267387; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; LEVIN NA, 1993, GENETICS, V133, P799; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; Lydall D, 1996, CURR OPIN GENET DEV, V6, P4, DOI 10.1016/S0959-437X(96)90003-9; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1992, CANCER RES, V52, P525; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; REID RJD, 1997, IN PRESS J BIOL CHEM, V272; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUBIN E, 1994, J BIOL CHEM, V269, P2433; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; SHARMA A, 1995, CURR OPIN STRUC BIOL, V5, P39, DOI 10.1016/0959-440X(95)80007-N; SIKORSKI RS, 1989, GENETICS, V122, P19; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; TSAO YP, 1992, CANCER RES, V52, P1823; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Zhu J, 1996, MOL CELL BIOL, V16, P1805	56	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12801	12808		10.1074/jbc.272.19.12801	http://dx.doi.org/10.1074/jbc.272.19.12801			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139740	hybrid			2022-12-25	WOS:A1997WY82900077
J	Veiga, SS; Elias, MCQB; Gremski, W; Porcionatto, MA; daSilva, R; Nader, HB; Brentani, RR				Veiga, SS; Elias, MCQB; Gremski, W; Porcionatto, MA; daSilva, R; Nader, HB; Brentani, RR			Post-translational modifications of alpha(5)beta(1) integrin by glycosaminoglycan chains - The alpha(5)beta(1) integrin is a facultative proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CELL-ADHESION; FIBRONECTIN RECEPTOR; CORE PROTEIN; BINDING; GLYCOSYLATION; COLLAGEN; LAMININ; BETA-1; LOCALIZATION	Cell-fibronectin interactions, mediated through several different receptors, have been implicated in a wide variety of cellular properties. Among the cell surface receptors for fibronectin, integrins are the best characterized, particularly the prototype alpha(5) beta(1) integrin. Using [I-125]iodine cell surface labeling or metabolic radiolabeling with sodium [S-35]sulfate, we identified alpha(5) beta(1) integrin as the only sulfated integrin among beta(1) integrin heterodimers expressed by the human melanoma cell line Mel-85. This facultative sulfation was confirmed not only by immunoprecipitation reactions using specific monoclonal antibodies but also by fibronectin affinity chromatography, two dimensional electrophoresis, and chemical reduction, The covalent nature of alpha(5) beta(1) integrin sulfation was evidenced by its resistance to treatments with high ionic, chaotrophic, and denaturing agents such as 4 nz NaCl, 4 hn MgCl2, 8 M urea, and 6 ar guanidine HCl. Based on deglycosylation procedures as chemical beta-elimination, proteinase K digestion, and susceptibility to glycosaminoglycan lyases (chondroitinase ABC and heparitinases I and II), it was demonstrated that the alpha(5) beta(1) heterodimer and alpha(5) and beta(1) integrin subunits were proteoglycans. The importance of alpha(5) beta(1) sulfation was strengthened by the finding that this molecule is also sulfated in MG-63 (human osteosarcoma) and HCT-8 (human colon adenocarcinoma) cells.	UNIV FED PARANA, CTR POLITECN, DEPT CELL BIOL, SETER CIENCIAS BIOL, BR-81531990 CURITIBA, PARANA, BRAZIL; UNIV FED SAO PAULO, ESCOLA PAULISTA MED, DEPT BIOCHEM, BR-04044020 SAO PAULO, BRAZIL	Universidade Federal do Parana; Universidade Federal de Sao Paulo (UNIFESP)	Veiga, SS (corresponding author), LUDWIG INST CANC RES, R PROF ANTONIO PRUDENTE 109, 4A, BR-01509010 SAO PAULO, BRAZIL.		Porcionatto, Marimelia/C-3322-2012; Elias, Maria QB/AAW-9284-2021; Nader, Helena Bonciani/D-9253-2012; Veiga, Silvio Sanches/C-2194-2013; Elias, Maria Carolina/E-9197-2015	Porcionatto, Marimelia/0000-0001-6287-916X; Veiga, Silvio Sanches/0000-0002-9691-1225; Elias, Maria Carolina/0000-0002-0501-8280; NADER, HELENA/0000-0002-7569-2166				AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAREY DJ, 1990, J BIOL CHEM, V265, P20627; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; COUCHMAN JR, 1988, J CELL PHYSIOL, V136, P226, DOI 10.1002/jcp.1041360204; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; DIETRICH CP, 1976, ANAL BIOCHEM, V70, P645, DOI 10.1016/0003-2697(76)90496-6; DIETRICH CP, 1978, BIOCHEM BIOPH RES CO, V84, P794, DOI 10.1016/0006-291X(78)90774-X; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; Elias MCQB, 1996, BRAZ J MED BIOL RES, V29, P1247; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HAUGEN DK, 1990, J CELL BIOL, V106, P1365; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1985, J BIOL CHEM, V260, P5246; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1987, J BIOL CHEM, V262, P16343; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; MANN DM, 1990, J BIOL CHEM, V265, P5317; MARTON LS, 1989, J BIOL CHEM, V264, P13145; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Morrison M, 1980, Methods Enzymol, V70, P214; NADER HB, 1990, J BIOL CHEM, V265, P16807; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PORCIONATTO MA, 1994, BRAZ J MED BIOL RES, V27, P2185; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; SONG WK, 1993, J CELL SCI, V106, P1139; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEIGA SS, 1995, INT J CANCER, V61, P420, DOI 10.1002/ijc.2910610324; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WHITTARD JD, 1995, MOL BIOL CELL, V6, P274; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; WOODS A, 1992, J CELL SCI, V101, P277; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	55	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12529	12535		10.1074/jbc.272.19.12529	http://dx.doi.org/10.1074/jbc.272.19.12529			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139704	hybrid			2022-12-25	WOS:A1997WY82900041
J	Odorizzi, G; Trowbridge, IS				Odorizzi, G; Trowbridge, IS			Structural requirements for major histocompatibility complex class II invariant chain trafficking in polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; DI-LEUCINE MOTIF; DENSITY-LIPOPROTEIN RECEPTOR; HUMAN TRANSFERRIN RECEPTOR; ROUS-SARCOMA VIRUS; MDCK CELLS; CYTOPLASMIC DOMAIN; ENDOCYTIC PATHWAY; EPITHELIAL-CELLS; BASOLATERAL LOCALIZATION	The invariant chain (Ii) targets major histocompatibility complex class II molecules to an endocytic processing compartment where they encounter antigenic peptides. Analysis of Ii-transferrin receptor chimeras expressed in polarized Madin-Darby canine kidney (MDCK) cells shows that the Ii cytoplasmic tail contains a dihydrophobic basolateral sorting signal, Met(16)-Leu(17), which is recognized in both the biosynthetic and endocytic pathways, Pro(15)-Met(16)-Leu(17) has previously been identified as one of two dihydrophobic Ii internalization signals active in non-polarized cells. Pro(15) is also required for endocytosis in MDCK cells but not for basolateral sorting, indicating that the internalization signal recognized at the plasma membrane is distinct from the sorting signal recognized by basolateral sorting machinery. Another dihydrophobic sequence, Leu(7)-Ile(8), is required for rapid internalization of the chimeric receptors in MDCK cells but not for basolateral sorting, providing further evidence that the structural requirements for basolateral sorting and internalization differ. Deletion analysis suggests that basolateral sorting of newly synthesized Ii-TR chimeras is also mediated by the membrane-proximal region of the Ii cytoplasmic tail. However, this region does not promote polarized basolateral recycling, indicating that the structural requirements for polarized sorting in the biosynthetic and endocytic pathways are not identical.	SALK INST BIOL STUDIES, DEPT CANC BIOL, SAN DIEGO, CA 92186 USA	Salk Institute				Odorizzi, Greg/0000-0002-1143-1098	NCI NIH HHS [T32-CA64041] Funding Source: Medline; NIDDK NIH HHS [DK 50825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA064041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BAUDEAU C, 1994, EXP NEPHROL, V2, P306; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BREMNES B, 1994, J CELL SCI, V107, P2021; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COLGAN SP, 1994, AM J PHYSIOL, V267, pC402, DOI 10.1152/ajpcell.1994.267.2.C402; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUGHES SH, 1990, J REPROD FERTIL, P39; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; ODORIZZI G, 1994, METHOD CELL BIOL, V43, P79; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; OGATA S, 1994, J BIOL CHEM, V269, P5210; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PIETERS J, 1993, J CELL SCI, V106, P831; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WHITNEY JA, 1995, CELL, V83, P703; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	49	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11757	11762		10.1074/jbc.272.18.11757	http://dx.doi.org/10.1074/jbc.272.18.11757			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115230	hybrid			2022-12-25	WOS:A1997WX56900018
J	Costa, J; Grabenhorst, E; Nimtz, M; Conradt, HS				Costa, J; Grabenhorst, E; Nimtz, M; Conradt, HS			Stable expression of the Golgi form and secretory variants of human fucosyltransferase III from BHK-21 cells - Purification and characterization of an engineered truncated form from the culture medium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ASSOCIATED ALPHA-3/4-FUCOSYL-TRANSFERASE; HAMSTER OVARY CELLS; BETA-TRACE PROTEIN; CARBOHYDRATE STRUCTURES; ACCEPTOR SPECIFICITY; SIALYL-LEX; HUMAN-MILK; OLIGOSACCHARIDES; SELECTIN; ANTIGEN	Stable BHK-21 cell Lines were constructed expressing the Golgi membrane bound form and two secretory forms of the human alpha 1,3/4-fucosyltransferase (amino acids 35-361 and 46-361). It was found that 40% of the enzyme activity synthesized by cells transfected with the Golgi form of the fucosyltransferase was constitutively secreted into the medium. The corresponding enzyme detected by Western blot had an apparent molecular mass similar to those of the truncated secretory forms. The secretory variant (amino acids 46-361) was purified by a single affinity-chromatography step on GDP-Fractogel resin with a 20% final recovery. The purified enzyme had a unique NH2 terminus and contained N-linked endo H sensitive carbohydrate chains at its two glycosylation sites. The fucosyltransferase transferred fucose to the O-4 position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides, and glycoproteins containing the type I Gal beta 1-3GlcNAc motif. The acceptor oligosaccharide in bovine asialofetuin was identified as the Man-3 branched triantennary isomer with one Gal beta 1-3GlcNAc. The type II motif Gal beta 1-4GlcNAc in bi-, tri-, or tetraantennary neutral or alpha 2-3/alpha 2-6 sialylated oligosaccharides with or without N-acetyllactosamine repeats and in native glycoproteins were not modified. The soluble forms of fucosyltransferase III secreted by stably transfected cells may be used for in vitro synthesis of the Lewis(a) determinant on carbohydrates and glycoproteins, whereas Lewis(x) and sialyl-Lewis(x) structures cannot be synthesized.	GESELL BIOTECHNOL FORSCH MBH, DEPT PROT GLYCOSYLAT, D-38124 BRAUNSCHWEIG, GERMANY; GESELL BIOTECHNOL FORSCH MBH, DEPT MOL & INSTRUMENTAL STRUCT RES, D-38124 BRAUNSCHWEIG, GERMANY	Gesellschaft fur Biotechnologische Forschung mbH; Gesellschaft fur Biotechnologische Forschung mbH			Costa, Júlia C/B-7131-2008	Costa, Júlia C/0000-0001-7782-6319				BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GRABENHORST E, 1993, EUR J BIOCHEM, V215, P189, DOI 10.1111/j.1432-1033.1993.tb18022.x; GRABENHORST E, 1995, EUR J BIOCHEM, V232, P718, DOI 10.1111/j.1432-1033.1995.718zz.x; GRABENHORST E, 1994, THESIS TU CAROLO WIL; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HOFFMANN A, 1994, J NEUROCHEM, V63, P2185; HOFFMANN A, 1997, IN PRESS GLYCOBIOLOG; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P251, DOI 10.1007/BF00731137; JOHNSON PH, 1993, GLYCOCONJUGATE J, V10, P152, DOI 10.1007/BF00737712; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P241, DOI 10.1007/BF00731136; KIMURA H, 1995, GLYCOCONJUGATE J, V12, P802, DOI 10.1007/BF00731242; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; NIMTZ M, 1990, FEBS LETT, V271, P14, DOI 10.1016/0014-5793(90)80361-L; NIMTZ M, 1993, EUR J BIOCHEM, V213, P39, DOI 10.1111/j.1432-1033.1993.tb17732.x; RICE KG, 1990, ANAL BIOCHEM, V184, P249, DOI 10.1016/0003-2697(90)90676-Z; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; ZETTLMEISSL G, 1989, J BIOL CHEM, V264, P21153	26	46	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11613	11621						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111078				2022-12-25	WOS:A1997WW00900094
J	Edelstein, C; Italia, JA; Scanu, AM				Edelstein, C; Italia, JA; Scanu, AM			Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase - Generation of mini-Lp(a) particles and apo(a) fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; PROTEASES; PROTEIN; PLASMINOGEN; NEUTROPHILS; LEUKOCYTE; INVITRO; PLASMA	Incubation of polymorphonuclear cells (PMN), isolated from human peripheral blood, with either lipoprotein(a) (Lp(a)) or free apolipoprotein(a) (apo(a)), derived from the parent Lp(a), caused in both cases a multisite fragmentation of apo(a) inhibited by methoxysuccinyl-Ala Ala-Pro-Val-CH2Cl, a specific elastase inhibitor. The major cut site was at the interkringle region between apo(a) kringles IV-4 and IV-5 (Ile(3520)-Leu(3521)). The other cleavages were between kringles IV-7 and IV-8 (Thr(3846)-Leu(3847)) and between kringles IV-10 and V (Ile(4196)-Gln(4197)). The elastase-induced fragmentation of apo(a) was the same whether free or as a member of Lp(a), indicating that the disulfide bond between apo(a) and the apoB100 component of Lp(a) did not hinder the ela stase action, Lp(a) fragments containing kringle IV-9 retained the linkage to apoB100 via the disulfide bond, forming mini-Lp(a) particles in which the size of apo(a) varied according to the size of the fragments produced by the elastase digestion, The proteolytic fragmentation was unaffected by apo(a) size polymorphism within the range examined, PMN elastase also caused a partial proteolysis of apoB100 whether as a component of Lp(a), Lp(a) freed of apo(a), or authentic low density lipoprotein without an apparent destabilization of these lipoprotein particles. Proteolysis of Lp(a) by PMN was due to an elastase activity that was 3.5% of that observed when PMN were activated by N-formyl-Met-Leu-Phe. A portion of the released elastase was found to be associated in an active form with both Lp(a) and low density lipoprotein even in an ultracentrifugal field at high salt concentrations, Taken together, our results indicate that apo(a) undergoes important proteolytic modifications by PMN elastase, which exhibits specificity for peptide bonds located in the interkringle domains of apo(a). In the case of Lp(a), elastase cleavage causes the formation of mini-Lp(a) particles with a protein moiety containing a truncated apo(a). Elastase-mediated proteolytic events may occur in vivo under conditions associated with either an excessive leakage of elastase from PMN and/or deficiencies of natural inhibitors of this enzyme.	UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637	University of Chicago	Edelstein, C (corresponding author), UNIV CHICAGO,DEPT MED,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.							BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; CASTILLO MJ, 1979, ANAL BIOCHEM, V99, P53, DOI 10.1016/0003-2697(79)90043-5; Edelstein C, 1996, J LIPID RES, V37, P1786; Edelstein C, 1995, BIOCHEMISTRY-US, V34, P16483, DOI 10.1021/bi00050a032; EGBRING R, 1977, BLOOD, V49, P219; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; GUEVARA J, 1993, ARTERIOSCLER THROMB, V13, P758, DOI 10.1161/01.ATV.13.5.758; HOFF HF, 1994, CHEM PHYS LIPIDS, V67-8, P271, DOI 10.1016/0009-3084(94)90147-3; KARIO K, 1995, THROMB HAEMOSTASIS, V74, P1020; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Mooser V, 1996, J CLIN INVEST, V98, P2414, DOI 10.1172/JCI119055; Mooser V, 1996, J CLIN INVEST, V97, P858, DOI 10.1172/JCI118487; MOROZ LA, 1981, BLOOD, V58, P97; OHLSSON K, 1974, EUR J BIOCHEM, V42, P519, DOI 10.1111/j.1432-1033.1974.tb03367.x; OIDA K, 1992, CLIN CHEM, V38, P2244; POLACEK D, 1988, J LIPID RES, V29, P797; POLACEK D, 1984, J BIOL CHEM, V259, P4531; POLACEK D, 1986, J BIOL CHEM, V261, P2057; PURSIAINEN M, 1994, CHEM PHYS LIPIDS, V67-8, P25, DOI 10.1016/0009-3084(94)90121-X; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; SCHMIDT W, 1974, H-S Z PHYSIOL CHEM, V355, P1077, DOI 10.1515/bchm2.1974.355.2.1077; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SENIOR RM, 1982, J CLIN INVEST, V69, P384, DOI 10.1172/JCI110462; SKLAR LA, 1982, J BIOL CHEM, V257, P5471; TRAVIS J, 1978, NEUTRAL PROTEASES HU, P118; UTERMANN G, 1995, METABOLIC MOL BASES, P1887; WILKIE SD, 1988, BIOCHROMATOGRAPHY, V5, P205	30	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11079	11087						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111002				2022-12-25	WOS:A1997WW00900018
J	Hong, SK; Spreitzer, RJ				Hong, SK; Spreitzer, RJ			Complementing substitutions at the bottom of the barrel influence catalysis and stability of ribulose-bisphosphate carboxylase/oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHESIS-DEFICIENT MUTANTS; CONDITIONAL CHLOROPLAST MUTANT; REDUCED CO2/O2 SPECIFICITY; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; CHLAMYDOMONAS-REINHARDTII; LARGE-SUBUNIT; ACTIVE-SITE; RIBULOSEBISPHOSPHATE CARBOXYLASE/OXYGENASE; NUCLEAR MUTATION; OXYGENASE	The temperature-conditional photosynthesis-deficient mutant 68-4PP of Chlamydomonas reinhardtii results from a Leu-290 to Phe substitution in the chloroplast-encoded large subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase (EC 4.1.1.39). Although this substitution occurs relatively far from the active site, the mutant enzyme has a reduced ratio of carboxylation to oxygenation in addition to reduced thermal stability in vivo and in, vitro. In an attempt to understand the role of this region in catalysis, photosynthesis-competent revertants were selected, Two revertants, named R96-4C and R96-8E, were found to arise from second site mutations that cause V262L and A222T substitutions, respectively, These intragenic suppressor mutations increase the CO2/O-2 specificity and carboxylation V-max back to wild-type values. Based on the crystal structure of the spinach holoenzyme, Leu-290 is not in van der Waals contact with either Val-262 or Ala-222, However, all three residues are located at the bottom of the alpha/beta-barrel active site and may interact with residues of the nuclear encoded small subunits, It appears that amino acid residues at the interface of large and small subunits can influence both stability and catalysis.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588	University of Nebraska System; University of Nebraska Lincoln								Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Z, 1988, P NATL ACAD SCI USA, V85, P4696, DOI 10.1073/pnas.85.13.4696; CHEN ZX, 1992, PHOTOSYNTH RES, V31, P157, DOI 10.1007/BF00028792; CHEN ZX, 1991, PLANTA, V183, P597, DOI 10.1007/BF00194282; CHEN ZX, 1990, ARCH BIOCHEM BIOPHYS, V283, P60, DOI 10.1016/0003-9861(90)90612-3; CHEN ZX, 1993, PLANT PHYSIOL, V101, P1189, DOI 10.1104/pp.101.4.1189; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; DEAN C, 1989, ANNU REV PLANT PHYS, V40, P415, DOI 10.1146/annurev.pp.40.060189.002215; FLACHMANN R, 1992, J BIOL CHEM, V267, P10576; GATENBY AA, 1994, ANNU REV PLANT PHYS, V45, P469; GOTOR C, 1994, PLANTA, V193, P313; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; Khrebtukova I, 1996, P NATL ACAD SCI USA, V93, P13689, DOI 10.1073/pnas.93.24.13689; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; OGREN WL, 1984, ANNU REV PLANT PHYS, V35, P415, DOI 10.1146/annurev.pp.35.060184.002215; READ BA, 1992, BIOCHEMISTRY-US, V31, P5553, DOI 10.1021/bi00139a018; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHREUDER HA, 1993, P NATL ACAD SCI USA, V90, P9968, DOI 10.1073/pnas.90.21.9968; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1988, PLANT PHYSIOL, V86, P773, DOI 10.1104/pp.86.3.773; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; SPREITZER RJ, 1995, PLANT PHYSIOL, V109, P681, DOI 10.1104/pp.109.2.681; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952	35	28	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11114	11117						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111007				2022-12-25	WOS:A1997WW00900023
J	Uma, S; Hartson, SD; Chen, JJ; Matts, RL				Uma, S; Hartson, SD; Chen, JJ; Matts, RL			Hsp90 is obligatory for the heme-regulated eIF-2 alpha kinase to acquire and maintain an activable conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RABBIT RETICULOCYTE LYSATE; SARCOMA-VIRUS; COMPLEX-FORMATION; CHAIN INITIATION; TRANSLATION; ASSOCIATION; PHOSPHORYLATION; INHIBITION; MEMBRANE	The heme regulated eukaryotic initiation factor 2 alpha (eIF-2 alpha) kinase (HRI) interacts with hsp90 in situ in rabbit reticulocyte lysate (RRL). In this report, we have examined the role of hsp90 in the maturation of newly synthesized HRI in both hemin-supplemented and heme-deficient RRL. Analysis of translating polyribosomes indicated that hsp90 interacts with nascent HRI cotranslationally. Coimmunoadsorption of HRI with hsp90 by the 8D3 anti-hsp90 antibody indicated that this interaction persisted after release of newly synthesized HRI from ribosomes. Incubation of HRI in heme-deficient lysate resulted in the transformation of a portion of the HRI polypeptides into an active heme-regulatable eIF-2 alpha kinase that exhibited slower electrophoretic mobility. Transformation of HRI was dependent on autophosphorylation, and transformed HRI was resistant to aggregation induced by treatment of RRL with N-ethylmaleimide. Transformed HRI did not coimmunoadsorb with hsp90, and regulation of the activity of transformed HRI by hemin was not hsp90-dependent. The hsp90 binding drug geldanamycin disrupted the interaction of hsp90 with HRI and inhibited the maturation of HRI into a form that was competent to undergo autophosphorylation. Additionally geldanamycin inhibited the transformation of HRI into a stable heme-regulatable kinase. These results indicate that hsp90 plays an obligatory role in HRI acquiring and maintaining a conformation that is competent to become transformed into an aggregation-resistant activable kinase.	OKLAHOMA STATE UNIV, DEPT BIOCHEM & MOL BIOL, STILLWATER, OK 74078 USA; MIT, HARVARD MIT DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Harvard University; Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004299, R29ES004299] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK016272] Funding Source: Medline; NIEHS NIH HHS [ES-04299] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CHEFALO PJ, 1994, J BIOL CHEM, V269, P25788; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GROSS M, 1972, BIOCHIM BIOPHYS ACTA, V287, P340, DOI 10.1016/0005-2787(72)90383-8; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P313, DOI 10.1111/j.1432-1033.1983.tb07264.x; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LONDON IM, 1987, ENZYMES, V58, P359; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MATTS RL, 1991, J BIOL CHEM, V266, P12695; MENDEZ R, 1992, J BIOL CHEM, V267, P11500; MENDEZ R, 1994, J BIOL CHEM, V269, P6170; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PALMQUIST K, 1994, FEBS LETT, V349, P239, DOI 10.1016/0014-5793(94)00676-8; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZIEMIECKI A, 1986, VIROLOGY, V151, P265, DOI 10.1016/0042-6822(86)90048-6	38	86	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11648	11656						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111082				2022-12-25	WOS:A1997WW00900098
J	Obermoeller, LM; Warshawsky, I; Wardell, MR; Bu, GJ				Obermoeller, LM; Warshawsky, I; Wardell, MR; Bu, GJ			Differential functions of triplicated repeats suggest two independent roles for the receptor-associated protein as a molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN-RECEPTOR; RAT HEPATOMA-CELLS; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; 39-KDA PROTEIN; LDL-RECEPTOR; BINDING; IDENTIFICATION; INHIBITOR; GENE	The 39-kDa receptor-associated protein (RAP) is a molecular chaperone for the low density lipoprotein receptor-related protein (LRP), a large endocytic receptor that binds multiple ligands, The primary function of RAP has been defined as promotion of the correct folding of LRP, and prevention of premature interaction of ligands with LRP within the early secretory pathway, Previous examination of the RAP sequence revealed an internal triplication, However, the functional implication of the triplicated repeats was unknown, In the current study using various RAP and LRP domain constructs, we found that the carboxyl-terminal repeat of RAP possesses high affinities to each of the three ligand-binding domains on LRP, whereas the amino-terminal and central repeats of RGP exhibit only low affinity to the second and the fourth ligand-binding domains of LRP, respectively, Using truncated soluble minireceptors of LRP, we identified five independent RAP-binding sites, two on each of the second and fourth, and one on the third ligand-binding domain of LRP. By coexpressing soluble LRP minireceptors and RAP repeat constructs, we found that only the carboxyl-terminal repeat of RAP was able to promote the folding and subsequent secretion of the soluble LRP minireceptors However, when the ability of each RAP repeat to inhibit Ligand interactions with LRP was examined, differential effects were observed for individual LRP ligands, Most striking, both the amino-terminal and central repeats, but not the carboxyl-terminal repeat, of RAP inhibited the interaction of alpha(2)-macroglobulin with LRP. These differential functions of the RAP repeats suggest that the roles of RAP in the folding of LRP and in the prevention of premature interaction of ligand with the receptor are independent.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								ARMSTRONG PB, 1991, J BIOL CHEM, V266, P2526; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SANT AJ, 1994, CURR OPIN IMMUNOL, V6, P57, DOI 10.1016/0952-7915(94)90034-5; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572	30	59	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10761	10768						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099728				2022-12-25	WOS:A1997WV26200062
J	Duprez, E; Tong, JH; Derre, J; Chen, SJ; Berger, R; Chen, Z; Lanotte, M				Duprez, E; Tong, JH; Derre, J; Chen, SJ; Berger, R; Chen, Z; Lanotte, M			JEM-1, a novel gene encoding a leucine-zipper nuclear factor upregulated during retinoid-induced maturation of NB4 promyelocytic leukaemia	ONCOGENE			English	Article						leukaemia; differentiation; retinoids; nuclear factors; cloning	LEUKEMIA-CELL LINE; ACID RECEPTORS; TRANSLOCATION; AP-1; PROLIFERATION; TRANSCRIPTION; PROTEASOME; PROMOTER; RNA	Retinoid-induced proliferation causing hyperleukocytosis is a severe complication of retinoid therapy in t(15;17) acute promyelocytic leukaemia. The molecular basis of this phenomenon is unknown. It is possible that the transiently enhanced cell proliferation results from RA-induction of growth regulatory genes. Using Differential Display of cDNAs from NB4 cells we have identified Jem, a novel gene transcript which is upregulated by retinoids during the early proliferative response in maturating cells but not in resistant cells. A 2.7 kb cDNA was cloned and sequenced. The open reading frame contains a 400 amino acid sequence corresponding to a novel 45 kDa basic protein (pI 8.9). The JEM DNA sequence is detected by FISH on human chromosome 1 at q24. The Jem peptide sequence shows a 'leucine-zipper' dimerisation motif with limited homology to Fos/Jun and ATF/CREB proteins and several putative phosphorylation sites. An atypical basic region may correspond to an unknown DNA-binding domain. The C-terminal end of Jem spans a long stretch featuring a PEST motif. After transfection into COS cells, the Jem protein shows a ponctuated nuclear localisation. We hypothesise that this novel nuclear factor may act as a transcription factor, or coregulator, involved in either cell growth control and/or maturation.	HOP ST LOUIS,INSERM U301,CTR G HAYEM,F-75475 PARIS,FRANCE; RUI JIN HOSP,INST HEMATOL,SHANGHAI,PEOPLES R CHINA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			duprez, estelle a/R-2357-2016					BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGNAM JDL, 1983, NUCLEIC ACIDS RES, V11, P1495; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; GRIGNANI F, 1994, BLOOD, V83, P10; Gudas Lorraine J., 1994, P443; Hong Waun Ki, 1994, P597; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES D, 1992, P NATL ACAD SCI USA, V89, P4042, DOI 10.1073/pnas.89.9.4042; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LANOTTE M, 1991, BLOOD, V77, P1080; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Peck Gary L., 1994, P631; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; SAKASHITA A, 1993, BLOOD, V81, P1009; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VINSON CR, 1989, SCIENCE, V246, P172; YANGYEN HF, 1991, NEW BIOL, V3, P1206	35	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1563	1570		10.1038/sj.onc.1200995	http://dx.doi.org/10.1038/sj.onc.1200995			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129147				2022-12-25	WOS:A1997WQ54800007
J	Harvey, NL; Butt, AJ; Kumar, S				Harvey, NL; Butt, AJ; Kumar, S			Functional activation of Nedd2/ICH-1 (Caspase-2) is an early process in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; CELL-DEATH; CYSTEINE PROTEASES; IDENTIFICATION; INHIBITION; FAMILY; EXPRESSION; INDUCTION; CLEAVAGE; ENCODES	The ICE/CED-3 family of proteases (caspases) play a central role in the execution phase of apoptosis, These proteases are synthesised as precursor molecules that require processing at specific aspartate residues to pro duce the two subunits that comprise the active enzyme. The activation of some of these proteases has been shown to occur during apoptosis. Here we show that Nedd2/ICH-1 (caspase-2) is activated during apoptosis induced by a variety of apoptotic stimuli, This activation occurs very early upon treatment of cells with apoptotic agents and appears to precede the activation of CPP32 (caspase-3). The activation of Nedd2 was not seen in cells that are resistant to apoptosis, These observations suggest that Nedd2 is an early effector in the pathway leading to cell death. Our observations also lend weight to the hypothesis that a group of caspases containing long prodomains are the first to be activated in response to apoptotic signals and that they lie upstream of a second class of caspases such as CPP32 containing short or no prodomains.	INST MED & VET SCI,HANSON CTR CANC RES INST,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia			Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814; Butt, Alison/0000-0002-6216-5105; Harvey, Natasha/0000-0001-9839-8966				ALLET B, 1996, J CELL BIOL, V135, P480; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DUAN, 1997, NATURE, V385, P86; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Faucheu C, 1996, EUR J BIOCHEM, V236, P207, DOI 10.1111/j.1432-1033.1996.t01-1-00207.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FLAWS JA, 1995, ENDOCRINOLOGY, V136, P5042, DOI 10.1210/en.136.11.5042; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH N, 1993, J BIOL CHEM, V268, P10932; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Khanna KK, 1996, CELL DEATH DIFFER, V3, P315; KINOSHITA M, 1997, IN PRESS J CEREB BLO; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; KUMAR S, 1997, IN PRESS CELL DEATH; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	53	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13134	13139		10.1074/jbc.272.20.13134	http://dx.doi.org/10.1074/jbc.272.20.13134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148927	hybrid			2022-12-25	WOS:A1997WZ38400040
J	Lange, Y; Steck, TL				Lange, Y; Steck, TL			Quantitation of the pool of cholesterol associated with acyl-CoA: Cholesterol acyltransferase in human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; HAMSTER OVARY CELLS; PLASMA-MEMBRANE; COENZYME-A; ENDOPLASMIC-RETICULUM; ESTERIFICATION PATHWAY; RAT-LIVER; LIPOPROTEINS; MACROPHAGES; LOCALIZATION	The esterification of cholesterol in homogenates of human fibroblasts was explored as a means of estimating the size of the pool of cholesterol associated with the endoplasmic reticulum (ER) in vivo. The rationale was that the acyl-coenzyme A:cholesterol acyltransferase (ACAT) in homogenates should have access only to cholesterol associated with the (rough) ER membrane fragments in which it resides. Reacting whole homogenates to completion with an excess of [C-14]oleoyl-CoA converted similar to 0.1-2% of total cell free cholesterol to [C-14]cholesteryl esters. Control studies indicated that membranes not associated with ACAT did not contribute cholesterol to this reaction. The extent of in vitro cholesterol esterification varied with pretreatment of the cells. Exposing intact cells to serum lipoproteins, oxysterols, or sphingomyelinase increased cholesterol esterification in homogenates severalfold; exposing the cells to mevinolin or cholesterol oxidase had the opposite effect. The variation in cholesterol esterification did not correlate with either the total cellular cholesterol or the intrinsic activity of ACAT, neither of which was changed significantly by the pretreatments. Rather, the total amount of cholesterol esterified in homogenates paralleled the rate of cholesterol esterification in the corresponding intact cells. The pool of cholesterol esterified in vitro therefore ap pears to reflect that associated with the ER in vivo. Since several of the mechanisms keeping cell cholesterol under tight feedback control are themselves located in the ER, this pool might not only be regulated physiologically, but could, in turn, help to regulate homeostatic effector pathways.	UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637	University of Chicago	Lange, Y (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.		Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028448, R55HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; BEAUFAY H, 1974, J CELL BIOL, V61, P213, DOI 10.1083/jcb.61.1.213; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; FIELDING CJ, 1985, BIOCH LIPIDS MEMBRAN, P404; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1978, P NATL ACAD SCI USA, V75, P1877, DOI 10.1073/pnas.75.4.1877; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1194, DOI 10.1073/pnas.78.2.1194; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; OKWU AK, 1994, J LIPID RES, V35, P644; ORCI L, 1984, CELL, V36, P835, DOI 10.1016/0092-8674(84)90033-3; PORN MI, 1995, BIOCHEM J, V308, P269; REINHART MP, 1987, J BIOL CHEM, V262, P9649; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SCHISSEL SL, 1995, BIOCHEMISTRY-US, V34, P10463, DOI 10.1021/bi00033a019; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; STECK TL, 1988, J BIOL CHEM, V263, P13023; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; VERTEL BM, 1994, CELL BIOL, V3, P325; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; XU XX, 1991, J BIOL CHEM, V266, P17040	45	102	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13103	13108		10.1074/jbc.272.20.13103	http://dx.doi.org/10.1074/jbc.272.20.13103			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148923	hybrid			2022-12-25	WOS:A1997WZ38400036
J	Vinals, F; Fandos, C; Santalucia, T; Ferre, J; Testar, X; Palacin, M; Zorzano, A				Vinals, F; Fandos, C; Santalucia, T; Ferre, J; Testar, X; Palacin, M; Zorzano, A			Myogenesis and MyoD down-regulate Sp1 - A mechanism for the repression of GLUT1 during muscle cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER EXPRESSION; BROWN ADIPOSE-TISSUE; TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; DEVELOPMENTAL REGULATION; NEGATIVE REGULATOR; BINDING-FACTOR; GROWTH-FACTOR; GENE FAMILY; DNA-BINDING	Muscle cell differentiation caused a reduction of glucose transport, GLUT1 glucose transporter expression, and GLUT1 mRNA levels. A fragment of 2.1 kilobases of the rat GLUT1 gene linked to chloramphenicol acetyltransferase drove transcriptional activity in myoblasts, and differentiation caused a decrease in transcription, Transient transfection of 5' and 3' deletion constructs showed that the fragment -99/-33 of the GLUT1 gene drives transcriptional activity of the GLUT1 gene and participates in the reduced transcription after muscle differentiation. Electrophoretic mobility shift assays showed the binding of Sp1 protein to the fragment -102/-37 in the myoblast state but not in myotubes, and Sp1 was found to transactivate the GLUT1 promoter. Western blot analysis indicated that Spl was drastically down-regulated during myogenesis. Furthermore, the forced over-expression of MyoD in C3H10T1/2 cells mimicked the effects observed during myogenesis, Sp1 down-regulation and reduced transcriptional activity of the GLUT1 gene promoter. In all, these data suggest a regulatory model in which MyoD activation during myogenesis causes the down-regulation of Spl, which contributes to the repression of GLUT1 gene transcription and, therefore, leads to the reduction in GLUT1 expression and glucose transport.	UNIV BARCELONA, FAC BIOL, DEPT BIOQUIM & BIOL MOL, E-08028 BARCELONA, SPAIN	University of Barcelona			Vinals, Francesc/P-6278-2019; Zorzano, Antonio/R-5479-2018; Santalucia, Tomas/B-6140-2012; Santalucia, Tomas/I-7411-2012; Viñals, Francesc/F-5928-2016; Palacín, Manuel/G-9786-2015	Santalucia, Tomas/0000-0003-4604-9195; Santalucia, Tomas/0000-0003-4604-9195; Viñals, Francesc/0000-0002-9918-6751; Palacin, Manuel/0000-0002-8670-293X; Fandos, Cesar/0000-0001-7348-1376				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODERRE L, 1992, ENDOCRINOLOGY, V131, P1821, DOI 10.1210/en.131.4.1821; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; Jiang SW, 1996, J BIOL CHEM, V271, P9510, DOI 10.1074/jbc.271.16.9510; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KURABAYASHI M, 1994, J BIOL CHEM, V269, P31162; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PATERSON BM, 1984, SCIENCE, V224, P1436, DOI 10.1126/science.6729461; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SIF S, 1993, ONCOGENE, V8, P2501; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; TODAKA M, 1994, J BIOL CHEM, V269, P29265; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	59	67	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12913	12921		10.1074/jbc.272.20.12913	http://dx.doi.org/10.1074/jbc.272.20.12913			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148896	hybrid, Green Published			2022-12-25	WOS:A1997WZ38400009
J	Argaud, D; Kirby, TL; Newgard, CB; Lange, AJ				Argaud, D; Kirby, TL; Newgard, CB; Lange, AJ			Stimulation of glucose-6-phosphatase gene expression by glucose and fructose-2,6-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; SITE-DIRECTED MUTAGENESIS; STORAGE-DISEASE TYPE-1A; FRUCTOSE 2,6-BISPHOSPHATE; RAT HEPATOMA; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; DEPENDENT REGULATION; BETA-CELL; LIVER; INSULIN	Glucose-6-phosphatase, a key enzyme in the homeostatic regulation of blood glucose concentration, catalyzes the terminal step in gluconeogenesis and glycogenolysis. Glucose, the product of the glucose-6-phosphatase reaction, dramatically increases the level of glu cose-6-phosphatase mRNA transcripts in primary hepatocytes (20-fold), and the maximum response is obtained at a glucose concentration as low as 11 mM. Glucose specifically increases glucose-6-phosphatase mRNA and L-type pyruvate kinase mRNA. In the rat hepatoma-derived cell line, Fao, glucose increases the glucose-6-phosphatase mRNA only modestly (3-fold). In the presence of high glucose concentrations, overexpression of glucokinase in Fao cells via recombinant adenovirus vectors increases lactate production to the level found in primary hepatocytes and increases glucose g-phosphatase gene expression by al-fold, Similar overexpression of hexokinase I in Fao cells with high levels of glucose does not increase lactate production nor does it change the response of glucose-g-phosphatase mRNA to glucose, Glucokinase overexpression in Fao cells blunts the previously reported inhibitory effect of insulin on glucose 6-phosphatase gene expression in these cells. Raising the cellular concentration of fructose-2,6-bisphosphate, a potent effector of the direction of carbon flux through the gluconeogenic and glycolytic pathways, also stimulated glucose-6-phosphatase gene expression in Fao cells. Increasing the fructose-2,6-bisphosphate concentration over a 15-fold range (12+/-1 to 187+/-17 pmol/plate) via an adenoviral vector overexpression system, led to a 6-fold increase (0.32+/-0.03 to 2.2+/-0.33 arbitrary units of mRNA) in glucose-6-phosphatase gene expression with a concomitant increase in glycolysis and a decrease in gluconeogenesis, Also, the effects of fructose-2,6-bisphosphate concentrations on fructose-1,6-bisphosphatase gene expression were stimulatory, leading to a 5-6-fold increase in mRNA level over a 15-fold range in fructose 2,6-bisphosphate level. Liver pyruvate kinase and phosphoenolpyruvate carboxykinase mRNA were unchanged by the manipulation of fructose-2,6-bisphosphate level.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046562] Funding Source: NIH RePORTER; NIDDK NIH HHS [501-DK46562-05] Funding Source: Medline; PHS HHS [1P50H2598801] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARGAUD D, 1995, J BIOL CHEM, V270, P24229, DOI 10.1074/jbc.270.41.24229; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; ARION WJ, 1975, MOL CELL BIOCHEM, V6, P75, DOI 10.1007/BF01732001; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; Bergmeyer H., 1974, METHOD ENZYMAT AN, V3, P1125; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BERRY MN, 1991, LAB TECHNIQUES BIOCH, V21, P265; CORI GT, 1939, P SOC EXP BIOL MED, V39, P337; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; ELMAGHRABI MR, 1991, J BIOL CHEM, V266, P2115; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HOD Y, 1984, J BIOL CHEM, V259, P5603; HUE L, 1983, BIOCHEM J, V214, P1019, DOI 10.1042/bj2141019; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; MARIASH CN, 1984, METABOLISM, V33, P545, DOI 10.1016/0026-0495(84)90010-6; MARIE S, 1993, J BIOL CHEM, V268, P23881; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MEIENHOFER MC, 1987, EUR J BIOCHEM, V169, P237, DOI 10.1111/j.1432-1033.1987.tb13603.x; NEWSHOLME EA, 1983, BIOCH MED SCI, P470; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P93; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Pilkis S J, 1975, Methods Enzymol, V42, P31; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; ROHNERJEANRENAUD F, 1986, DIABETES, V35, P1350, DOI 10.2337/diabetes.35.12.1350; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; SANCHEZGUTIERRE.JC, 1994, ENDOCRINOLOGY, V4, P1868; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; TAULER A, 1990, J BIOL CHEM, V265, P15617; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VENEZIALE CM, 1976, GLUCONEOGENESIS ITS, P463; WILSON JE, 1984, REGULATION CARBOHYDR, P45; WOODS HF, 1974, TOP GASTROENTEROL, V2, P589; YOOWARREN H, 1983, P NATL ACAD SCI USA, V80, P2656	52	94	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12854	12861		10.1074/jbc.272.19.12854	http://dx.doi.org/10.1074/jbc.272.19.12854			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139747	hybrid			2022-12-25	WOS:A1997WY82900084
J	Barco, A; Ventoso, I; Carrasco, L				Barco, A; Ventoso, I; Carrasco, L			The yeast Saccharomyces cerevisiae as a genetic system for obtaining variants of poliovirus protease 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-III; CYSTEINE PROTEASES; 2A(PRO) EXPRESSION; CELLULAR PROTEINS; CLEAVAGE ACTIVITY; SERINE PROTEASES; RNA REPLICATION; P220 CLEAVAGE; VIRUS; TRANSLATION	The inducible expression of poliovirus protease 2A (2A(pro)) blocks the growth of Saccharomyces cerevisiae. A number of yeast colonies that grow after 2A(pro) induction have been isolated. The majority of these clones express 2A(pro) to control levels, suggesting that their ability to divide is not due to the loss of 2A(pro) gene inducibility. The sequences of the 2A(pro) genes isolated from 22 clones were determined. Most of the 2A(pro) sequences from these colonies contain point mutations in the poliovirus protease. The different variant protease sequences were transferred to an infectious poliovirus cDNA clone. Translation of genomic RNA obtained from these poliovirus mutants in cell-free systems revealed that some of them had defects in their ability to cleave P1-2A in cis. In addition, several of these variants cleaved the translation initiation factor eIF-4G inefficiently. Transfection of the RNA generated from the full-length poliovirus genomes mutated in 2A(pro) yielded five viable polioviruses with a small plaque phenotype. These five polioviruses efficiently cleaved p220 but showed defects in viral protein synthesis, transactivation of a leader-luciferase mRNA, and 3CD cleavage to 3C' and 3D'. All 2A(pro) mutant sequences, including those that did not yield viable viruses, were cloned in pTM1 vector under a T7 promoter. Only the 2A(pro) variants that have activity to cleave 3CD produced viable poliovirus. Our findings indicate that S. cerevisiae represents a useful system for obtaining poliovirus 2A(pro) variants that may provide further insight into the role of this protease during the poliovirus replication cycle.			Barco, A (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOL, CANTO BLANCO, E-28049 MADRID, SPAIN.		Barco, Angel/ABF-1864-2021; Carrasco, Luis/H-3001-2017; Carrasco, Luis/E-2435-2012; Barco, Angel/C-3062-2008; Ventoso, Iván/N-4018-2014	Barco, Angel/0000-0002-0653-3751; Carrasco, Luis/0000-0003-3833-8835; Barco, Angel/0000-0002-0653-3751; Ventoso, Iván/0000-0001-7887-3520				ALDABE R, 1995, BIOCHEM BIOPH RES CO, V215, P928, DOI 10.1006/bbrc.1995.2553; BARCO A, 1995, FEBS LETT, V371, P4, DOI 10.1016/0014-5793(95)00841-V; BARCO A, 1995, GENE, V156, P19, DOI 10.1016/0378-1119(94)00872-P; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BLAIR WS, 1993, NATO ADV SCI INST SE, V240, P225; BOSCHELLI F, 1993, J CELL SCI, V105, P519; DASMAHAPATRA B, 1992, P NATL ACAD SCI USA, V89, P4159, DOI 10.1073/pnas.89.9.4159; DAVIES MV, 1991, J BIOL CHEM, V266, P14714; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; Feduchi E, 1995, EUR J BIOCHEM, V234, P849, DOI 10.1111/j.1432-1033.1995.849_a.x; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; HARMON SA, 1995, J VIROL, V69, P5576, DOI 10.1128/JVI.69.9.5576-5581.1995; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; IRURZUN A, 1995, J VIROL, V69, P7453, DOI 10.1128/JVI.69.12.7453-7460.1995; Klump H, 1996, VIROLOGY, V220, P109, DOI 10.1006/viro.1996.0291; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAWSON MA, 1990, CURR TOP MICROBIOL, V161, P49; LEE CK, 1988, VIROLOGY, V166, P405, DOI 10.1016/0042-6822(88)90511-9; LIEBIG HD, 1991, P NATL ACAD SCI USA, V88, P5979, DOI 10.1073/pnas.88.14.5979; LU HH, 1995, J VIROL, V69, P7445, DOI 10.1128/JVI.69.12.7445-7452.1995; MACADAM AJ, 1994, EMBO J, V13, P924, DOI 10.1002/j.1460-2075.1994.tb06336.x; MACREADIE IG, 1995, P NATL ACAD SCI USA, V92, P2770, DOI 10.1073/pnas.92.7.2770; MILLER G, 1993, J VIROL, V67, P7472, DOI 10.1128/JVI.67.12.7472-7481.1993; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; MOLLA A, 1993, VIROLOGY, V196, P739, DOI 10.1006/viro.1993.1531; Novoa I, 1996, J VIROL, V70, P3319, DOI 10.1128/JVI.70.5.3319-3324.1996; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PICCONE ME, 1995, J VIROL, V69, P5376, DOI 10.1128/JVI.69.9.5376-5382.1995; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SKERN T, 1994, METHOD ENZYMOL, V244, P583; SOMMERGRUBER W, 1992, J BIOL CHEM, V267, P22639; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; URZAINQUI A, 1989, J VIROL, V63, P4729, DOI 10.1128/JVI.63.11.4729-4735.1989; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; VENTOSO I, 1995, J VIROL, V69, P6280, DOI 10.1128/JVI.69.10.6280-6288.1995; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529; WYCKOFF EE, 1992, J VIROL, V66, P2943, DOI 10.1128/JVI.66.5.2943-2951.1992; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YU SF, 1995, J VIROL, V69, P247, DOI 10.1128/JVI.69.1.247-252.1995; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8; ZIEGLER E, 1995, VIROLOGY, V213, P549	49	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12683	12691		10.1074/jbc.272.19.12683	http://dx.doi.org/10.1074/jbc.272.19.12683			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139725	hybrid			2022-12-25	WOS:A1997WY82900062
J	BonnehBarkay, D; Shlissel, M; Berman, B; Shaoul, E; Admon, A; Vlodavsky, I; Carey, DJ; Asundi, VK; ReichSlotky, R; Ron, D				BonnehBarkay, D; Shlissel, M; Berman, B; Shaoul, E; Admon, A; Vlodavsky, I; Carey, DJ; Asundi, VK; ReichSlotky, R; Ron, D			Identification of glypican as a dual modulator of the biological activity of fibroblast growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; HIGH-AFFINITY RECEPTOR; CELL-SURFACE; FGF RECEPTOR; NERVOUS-SYSTEM; DIFFERENTIAL EXPRESSION; ENDOTHELIAL-CELLS; LUNG FIBROBLASTS; LIGAND-BINDING; CORE PROTEIN	Heparan sulfate moieties of cell-surface proteoglycans modulate the biological responses to fibroblast growth factors (FGFs), We have reported previously that cell-associated heparan sulfates inhibit the binding of the keratinocyte growth factor (KGF), but enhance the binding of acidic FGF to the KGF receptor, both in keratinocytes, which naturally express this receptor, and in rat myoblasts, which ectopically express it (Reich-Slotky, R., Bonneh-Barkay, D., Shaoul, E., Berman, B., Svahn, C.M., and Ron, D. (1994) J. Biol. Chem. 269, 32279-32285), The proteoglycan bearing these modulatory heparan sulfates was purified to homogeneity from salt extracts of rat myoblasts by anion-exchange and FGF affinity chromatography and was identified as rat glypican. Affinity-purified glypican augmented the binding of acidic FGF and basic FGF to human FGF receptor-1 in a cell-free system, This effect was abolished following digestion of glypican by heparinase, Addition of purified soluble glypican effectively replaced heparin in supporting basic FGF-induced cellular proliferation of heparan sulfate-negative cells expressing recombinant FGF receptor-1, In keratinocytes, glypican strongly inhibited the mitogenic response to KGF while enhancing the response to acidic FGF, Taken together, these findings demonstrate that glypican plays an important role in regulating the biological activity of fibroblast growth factors and that, for different growth factors, glypican can either enhance or suppress cellular responsiveness.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; HADASSAH UNIV HOSP,DEPT ONCOL,IL-91120 JERUSALEM,ISRAEL; GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822	Technion Israel Institute of Technology; Hebrew University of Jerusalem; Geisinger Medical Center				Admon, Arie/0000-0003-0504-3950				AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASHKIN P, 1992, J CELL PHYSIOL, V151, P126, DOI 10.1002/jcp.1041510117; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; CAMPOS A, 1993, EUR J BIOCHEM, V216, P587, DOI 10.1111/j.1432-1033.1993.tb18178.x; CAREY DJ, 1989, J CELL BIOL, V108, P1891, DOI 10.1083/jcb.108.5.1891; CAREY DJ, 1993, EXP CELL RES, V208, P10, DOI 10.1006/excr.1993.1217; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; EDGE ASB, 1987, J BIOL CHEM, V262, P6893; EISEMANN A, 1991, ONCOGENE, V6, P1195; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOMEZPINILLA F, 1995, EXP NEUROL, V133, P164, DOI 10.1006/exnr.1995.1019; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P395, DOI 10.1016/0006-291X(92)92398-H; KATO M, 1994, J BIOL CHEM, V269, P18881; LAMMI M, 1988, ANAL BIOCHEM, V168, P352, DOI 10.1016/0003-2697(88)90329-6; LITWACK ED, 1994, J NEUROSCI, V14, P3713; LORIES V, 1992, J BIOL CHEM, V267, P1116; MALI M, 1993, J BIOL CHEM, V268, P24215; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAPRAEGER A, 1989, ANAL BIOCHEM, V179, P361, DOI 10.1016/0003-2697(89)90145-0; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; REICHSLOTKY R, 1995, J BIOL CHEM, V270, P29813; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; TREARDY DJ, 1991, CANCER RES, V51, P4355; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WILCHEK M, 1982, BIOCHEM INT, V4, P629; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403; YUEN S, 1991, METHOD ENZYMOL, V198, P91	63	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12415	12421		10.1074/jbc.272.19.12415	http://dx.doi.org/10.1074/jbc.272.19.12415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139688	hybrid			2022-12-25	WOS:A1997WY82900025
J	Dorn, GW; Davis, MG; DAngelo, DD				Dorn, GW; Davis, MG; DAngelo, DD			Structural determinants for agonist binding affinity to thromboxane/prostaglandin endoperoxide (TP) receptors - Analysis of chimeric rat/human TP receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; HUMAN-PLATELETS; THROMBOXANE-A2 RECEPTOR; ADENOSINE RECEPTORS; ANTAGONIST BINDING; PROSTAGLANDIN-H2; CLONING; IDENTIFICATION; EXPRESSION; INHIBITION	The two most extensively characterized thromboxane/prostaglandin endoperoxide (TP) receptors, from human platelets and rat vascular smooth muscle, exhibit thromboxane agonist [15-(1 alpha,2 beta(5Z),3 alpha-(1E,3S),4 alpha]-7-[3-hydroxy-4-(p-iodophenoxy)-1-butenyl-7-oxabicycloheptenoic acid (I-BOP) binding affinities that differ by an order of magnitude, rat TP having the higher affinity, We utilized this difference in I-BOP affinity to identify structural determinants of TP receptor heterogeneity, No significant difference was found in the rank order of affinities for a series of thromboxane receptor ligands to bind to cloned human TP alpha versus rat TP, indicating that these represent species homologs, not distinct TP subtypes, Structural determinants for observed differences in I-BOP binding K-d were localized by creating chimeric human/rat TP followed by mutational substitution of specific critical amino acids, Initially, seven chimeric receptors with splice sites in transmembranes 1, 2, 4, or 7 were constructed and expressed in HEK293 cells for analysis of ligand binding properties, Substitution of any part except the carboxyl tail of the human TP into the rat TP resulted in a receptor with I-BOP binding affinity intermediate between the two, Analysis of chimeras in which only the extracellular amino terminus and a portion of transmembrane 1 were switched localized the determinant of high affinity binding to the region between amino acids 3 and 40, Using this chimera, amino acids in the human portion (extracellular amino terminus and part of transmembrane 1) were replaced with analogous amino acids from rat TP to regain high affinity I-BOP binding, Only when amino acid Val(37) and either Val(36) or Ala(40) were reverted to their respective rat TP counterparts (Ala(36), Leu(37), and Gly(40), respectively) was high affinity I-BOP binding recovered, The mechanism for the increased I-BOP affinity may be the lengthening of the amino acid side chain at position 37, thus extending this group further into the putative I-BOP binding pocket, with compensatory shortening of side chains in spatially adjacent amino acids.	VET ADM MED CTR,CINCINNATI,OH 45267	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Dorn, GW (corresponding author), UNIV CINCINNATI,231 BETHESDA AVE,ML 0542,CINCINNATI,OH 45267, USA.				NHLBI NIH HHS [HL49267, P50HL52318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052318, R01HL049267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE T, 1995, J CLIN INVEST, V96, P657, DOI 10.1172/JCI118108; Allan CJ, 1996, J PHARMACOL EXP THER, V277, P1132; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DAngelo DD, 1996, PROSTAGLANDINS, V52, P303, DOI 10.1016/S0090-6980(96)00091-3; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; DANGELO DD, 1994, J PHARMACOL EXP THER, V271, P1034; DORN GW, 1992, J BIOL CHEM, V267, P24897; DORN GW, 1991, AM J PHYSIOL, V261, pR145, DOI 10.1152/ajpregu.1991.261.1.R145; DORN GW, 1989, J CLIN INVEST, V84, P1883, DOI 10.1172/JCI114375; FOLGER W H, 1992, European Journal of Pharmacology Molecular Pharmacology Section, V9, P71; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FUNK CD, 1993, MOL PHARMACOL, V44, P934; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; MASUDA A, 1991, BIOCHEM PHARMACOL, V42, P537, DOI 10.1016/0006-2952(91)90316-W; MAYEUX PR, 1988, BIOCHEM BIOPH RES CO, V157, P733, DOI 10.1016/S0006-291X(88)80311-5; MAYEUX PR, 1991, J BIOL CHEM, V266, P13752; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; Paul RV, 1996, AM J PHYSIOL-RENAL, V270, pF31, DOI 10.1152/ajprenal.1996.270.1.F31; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; RIVKEES SA, 1995, J BIOL CHEM, V270, P20485, DOI 10.1074/jbc.270.35.20485; SAUSSY DL, 1986, J BIOL CHEM, V261, P3025; SCHROR K, 1995, BIOCHEM PHARMACOL, V49, P921, DOI 10.1016/0006-2952(95)00015-R; STEINHOFF HJ, 1994, SCIENCE, V266, P105, DOI 10.1126/science.7939627; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; WESS J, 1992, J BIOL CHEM, V267, P19313	28	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12399	12405		10.1074/jbc.272.19.12399	http://dx.doi.org/10.1074/jbc.272.19.12399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139686	hybrid			2022-12-25	WOS:A1997WY82900023
J	Meric, F; Matsumoto, K; Wolffe, AP				Meric, F; Matsumoto, K; Wolffe, AP			Regulated unmasking of in vivo synthesized maternal mRNA at oocyte maturation - A role for the chaperone nucleoplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE MESSENGER-RNA; XENOPUS EGG EXTRACTS; Y-BOX PROTEINS; RIBONUCLEOPROTEIN PARTICLES; TRANSLATIONAL REGULATION; SPERM CHROMATIN; ACIDIC PROTEIN; SOMATIC-CELLS; TRANSCRIPTION; LAEVIS	We examine the translational regulation of histone H4 mRNA when Xenopus laevis oocytes are induced to mature with progesterone, Histone H4 mRNA synthesized from plasmid templates microinjected into oocyte nuclei is translationally silenced (masked). This masked mRNA becomes translationally active only after oocyte maturation. In contrast, histone H4 mRNA injected into the oocyte cytoplasm is translationally active both before and after oocyte maturation. Thus, transcription in vivo is required to mask histone H4 mRNA and to allow subsequent translational regulation. Protein association with histone H4 mRNA synthesized in vivo was determined before and after oocyte maturation. UV cross linking of radiolabeled RNA to protein and immunoprecipitation of cross-linked proteins reveals an increased association of the chaperone nucleoplasmin with ribonucleoprotein particles dependent on the oocyte maturation process, The Y-box protein FRGY2 inhibits translation of histone H4 mRNA in vitro. Nucleoplasmin is able to partially relieve this repression, We discuss the potential role of nuleoplasmin in the remodeling of repressive ribonucleoprotein particles containing maternal mRNA to facilitate translational activation.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Matsumoto, Ken/F-9083-2013	Matsumoto, Ken/0000-0002-7864-3394				ADAMSON ED, 1977, DEV BIOL, V57, P136, DOI 10.1016/0012-1606(77)90360-8; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BALLANTINE JEM, 1985, FEBS LETT, V180, P224, DOI 10.1016/0014-5793(85)81075-9; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Davidson E. H., 1986, GENE ACTIVITY EARLY; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; Dimitrov S, 1996, EMBO J, V15, P5897, DOI 10.1002/j.1460-2075.1996.tb00976.x; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; Freeman L, 1996, P NATL ACAD SCI USA, V93, P12780, DOI 10.1073/pnas.93.23.12780; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIYOSHI H, 1991, EXP CELL RES, V194, P95, DOI 10.1016/0014-4827(91)90135-H; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMARCA MJ, 1975, DEV BIOL, V47, P384, DOI 10.1016/0012-1606(75)90292-4; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; Leno GH, 1996, J BIOL CHEM, V271, P7253, DOI 10.1074/jbc.271.13.7253; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; Meric F, 1996, J BIOL CHEM, V271, P30804, DOI 10.1074/jbc.271.48.30804; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MOREAU N, 1986, J CELL BIOL, V103, P683, DOI 10.1083/jcb.103.3.683; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; PANYIM S, 1969, BIOCHEMISTRY-US, V8, P3972, DOI 10.1021/bi00838a013; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RUDERMAN JV, 1979, DEV BIOL, V71, P71, DOI 10.1016/0012-1606(79)90083-6; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; STANDART N, 1994, CURR BIOL, V4, P939, DOI 10.1016/S0960-9822(00)00212-8; STANDART N, 1992, SEMIN DEV BIOL, V3, P369; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; Tata J R, 1979, Recent Prog Horm Res, V35, P47; TOYODA T, 1992, DEV BIOL, V153, P150, DOI 10.1016/0012-1606(92)90099-3; VARNUM SM, 1992, DEV BIOL, V153, P283, DOI 10.1016/0012-1606(92)90113-U; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WOODLAND HR, 1979, CELL, V18, P165, DOI 10.1016/0092-8674(79)90365-9; WOODLAND HR, 1977, DEV BIOL, V57, P118, DOI 10.1016/0012-1606(77)90359-1; WOODLAND HR, 1980, DEV BIOL, V75, P214, DOI 10.1016/0012-1606(80)90156-6; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804	53	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12840	12846		10.1074/jbc.272.19.12840	http://dx.doi.org/10.1074/jbc.272.19.12840			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139745	hybrid			2022-12-25	WOS:A1997WY82900082
J	Jallal, B; Mossie, K; Vasiloudis, G; Knyazev, P; Zachwieja, J; Clairvoyant, F; Schilling, J; Ullrich, A				Jallal, B; Mossie, K; Vasiloudis, G; Knyazev, P; Zachwieja, J; Clairvoyant, F; Schilling, J; Ullrich, A			The receptor-like protein-tyrosine phosphatase DEP-1 is constitutively associated with a 64-kDa protein serine/threonine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; HOMOPHILIC BINDING; CELLS; PHOSPHORYLATION; EXPRESSION; GROWTH; CD45; PHOSPHOTYROSINE; TRANSFORMATION; ACTIVATION	Protein-tyrosine phosphatases (PTPs) are involved in the regulation of diverse cellular processes and may function as positive effecters as well as negative regulators of intracellular signaling. Recent data demonstrate that malignant transformation of cells is frequently associated with changes in PTP expression or activity. Our analysis of PTP expression in mammary carcinoma cell lines resulted in the molecular cloning of a receptorlike PTP, also known as DEP-1. DEP-1 was found to be expressed at varying levels in mammary carcinoma cell lines and A431 cells. In all tumor cell lines analyzed, DEP-1 was constitutively phosphorylated on tyrosine residues. Phosphorylation of DEP-1 increased significantly after treatment of cells with the PTP inhibitor pervanadate. In A431 cells, tyrosine phosphorylation of DEP-1 was also observed after stimulation with epidermal growth factor, however, only after prolonged exposure of the cells to the ligand, suggesting an indirect mechanism of phosphorylation. In addition, DEP-1 coprecipitated with several tyrosine-phosphorylated proteins from pervanadate-treated cells. In vitro binding experiments using a glutathione S-transferase fusion protein containing the catalytically inactive PTP domain of DEP-1 (Gst-DEP-1-C/S) identify these proteins as potential substrates of DEP-1. In addition, we found a 64-kDa serine/threonine kinase to be constitutively associated with DEP-1 in all tumor cell lines tested. The 64-kDa kinase forms a stable complex with DEP-1 and phosphorylates DEP-1 and DEP-1-interacting proteins in vitro, These data suggest a possible mechanism of DEP-1 regulation in tumor cell lines involving serine/threonine and/or tyrosine phosphorylation.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society	Jallal, B (corresponding author), SUGEN INC,515 GALVESTON DR,REDWOOD CITY,CA 94063, USA.							AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1983, METHOD ENZYMOL, V99, P397; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Keane MM, 1996, CANCER RES, V56, P4236; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; LAU KHW, 1993, CRIT REV ONCOGEN, V4, P452; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; RO J, 1988, CANCER RES, V48, P161; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; Sambrok J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STONE RL, 1994, J BIOL CHEM, V269, P31323; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	38	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12158	12163		10.1074/jbc.272.18.12158	http://dx.doi.org/10.1074/jbc.272.18.12158			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115287	hybrid			2022-12-25	WOS:A1997WX56900075
J	Saito, M; Nelson, C; Salkoff, L; Lingle, CJ				Saito, M; Nelson, C; Salkoff, L; Lingle, CJ			A cysteine-rich domain defined by a novel exon in a Slo variant in rat adrenal chromaffin cells and PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; PROTEIN-KINASE-C; COBRA-VENOM PHOSPHOLIPASE-A2; CA2+-ACTIVATED K+ CHANNEL; TRANSITION-STATE ANALOG; DIACYLGLYCEROL KINASE; CRYSTAL-STRUCTURE; HIGH-CONDUCTANCE; SMOOTH-MUSCLE; BETA-SUBUNIT	cDNA libraries from rat chromaffin cells and PC12 cells were screened for homologs to the mouse mSlo gene that encodes a large conductance, calcium (Ca2+)- and voltage-activated potassium channel (BK channel). One Slo variant contained sequence encoding a cysteine-rich, 59-amino acid insert for a previously described site of alternative splicing. This insert is reminiscent of zinc-finger domains. The exon was found in RNA from pancreas, anterior pituitary, cerebellum, and hippocampus. Expression in Xenopus oocytes of a Slo construct containing this exon conferred a -30 to -20 mV shift of the conductance-voltage curve. A previously uncharacterized alternative splice junction near the C-terminal end of Slo was also identified. In contrast to BK channels in rat chromaffin cells, none of the Sb variants exhibited inactivation when expressed in Xenopus oocytes, PCR screening of chromaffin cell RNA failed to reveal a homolog of an accessory beta subunit known to influence Slo channel function, Furthermore, a beta-subunit-dependent Slo channel activator, dehydrosoyasaponin I, was without effect on chromaffin cell BK current. The results argue that an accessory subunit may not be a required component of the native chromaffin cell BK channel.	WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT ANESTHESIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)				Lingle, Christopher/0000-0002-9916-3795	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024785] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK046564, DK46564] Funding Source: Medline; NINDS NIH HHS [NS24785] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; Dichiara TJ, 1995, J PHYSIOL-LONDON, V489, P403, DOI 10.1113/jphysiol.1995.sp021061; DIJKSTRA BW, 1981, NATURE, V289, P604, DOI 10.1038/289604a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ferrer J, 1996, DIABETOLOGIA, V39, P891, DOI 10.1007/BF00403907; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; HERRINGTON J, 1995, J PHYSIOL-LONDON, V485, P297, DOI 10.1113/jphysiol.1995.sp020731; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KELLEY MJ, 1992, BIOCHIM BIOPHYS ACTA, V1118, P107, DOI 10.1016/0167-4838(92)90136-2; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; LAGRUTTA A, 1994, J BIOL CHEM, V269, P20347; Lingle C J, 1996, Ion Channels, V4, P261; MARAGANORE JM, 1987, TRENDS BIOCHEM SCI, V12, P176, DOI 10.1016/0968-0004(87)90082-X; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; Prakriya M, 1996, J NEUROSCI, V16, P4344; REDMAN C, 1995, BIOCHEM PHARMACOL, V50, P235, DOI 10.1016/0006-2952(95)00118-J; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Solaro C. R., 1995, Biophysical Journal, V68, pA30; SOLARO CR, 1995, J NEUROSCI, V15, P6110; SOLARO CR, 1992, SCIENCE, V257, P1694, DOI 10.1126/science.1529355; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787	38	120	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11710	11717		10.1074/jbc.272.18.11710	http://dx.doi.org/10.1074/jbc.272.18.11710			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115223	hybrid			2022-12-25	WOS:A1997WX56900011
J	Chueh, PJ; Morre, DM; Penel, C; DeHahn, T; Morre, DJ				Chueh, PJ; Morre, DM; Penel, C; DeHahn, T; Morre, DJ			The hormone-responsive NADH oxidase of the plant plasma membrane has properties of a NADH:Protein disulfide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOYBEAN HYPOCOTYLS; ELONGATION GROWTH; RESISTANT; DISPLACEMENT; MITOCHONDRIA	Plasma membranes of plant cells are characterized by a plant hormone (auxin)-responsive oxidation of NADH, The latter proceeds under argon, Also, when NADH oxidation is stimulated 50% by auxin addition, oxygen consumption is reduced by 40%. These findings are reconciled by direct assays using 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) (Ellman's reagent) that show protein disulfides to be electron accepters for auxin-stimulated NADH oxidation. In the presence of an external reducing agent such as NADH, cysteine, or dithiothreitol, protein disulfides of the membrane are reduced with a concomitant stoichiometric increase in free thiols, In the absence of an external reducing agent, or in the presence of oxidized glutathione, DTNB-reactive thiols of the plasma membrane are decreased in the presence of auxins, Several auxin-reductant combinations were effective, but the same reductants plus chemically related and growth-inactive auxin analogs were not. A cell surface location of the affected thiols demonstrated with detergents and impermeant thiol reagents suggests that the protein may have a different physiological role than oxidation of NADH. For example, it may carry out some other role more closely related to the function of the auxin hormones in cell enlargement such as protein disulfide-thiol interchange.	PURDUE UNIV, DEPT MED CHEM & MOL PHARMACOL, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT FOODS & NUTR, W LAFAYETTE, IN 47907 USA; UNIV GENEVA, GENEVA, SWITZERLAND	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Geneva				Chueh, Pin Ju/0000-0002-3200-7552				BIENFAIT F, 1988, PLANT PHYSIOL BIOCH, V26, P665; BRIGHTMAN AO, 1988, PLANT PHYSIOL, V86, P1264, DOI 10.1104/pp.86.4.1264; ELLIS JE, 1994, MICROBIOL-SGM, V140, P2489, DOI 10.1099/13500872-140-9-2489; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Moller I. M., 1990, The plant plasma membrane., P93; MOORE AL, 1991, BIOCHIM BIOPHYS ACTA, V1059, P121, DOI 10.1016/S0005-2728(05)80197-5; MORRE DJ, 1994, PROTOPLASMA, V180, P3, DOI 10.1007/BF01379219; MORRE DJ, 1988, PHYSIOL PLANTARUM, V73, P187, DOI 10.1111/j.1399-3054.1988.tb09215.x; MORRE DJ, 1991, J BIOENERG BIOMEMBR, V23, P469, DOI 10.1007/BF00771015; MORRE DJ, 1995, PLANT PHYSIOL, V109, P573, DOI 10.1104/pp.109.2.573; MORRE DJ, 1994, J BIOENERG BIOMEMBR, V26, P421, DOI 10.1007/BF00762783; MORRE DJ, 1986, PROTOPLASMA, V133, P195, DOI 10.1007/BF01304635; MORRE DJ, 1995, PLANT PHYSIOL, V107, P1285, DOI 10.1104/pp.107.4.1285; MORRE DJ, 1995, PROTOPLASMA, V184, P14, DOI 10.1007/BF01276896; MORRE DJ, 1970, PHYSIOL PLANTARUM, V23, P38, DOI 10.1111/j.1399-3054.1970.tb06389.x; SANDELIUS AS, 1987, PLANT SCI, V48, P1, DOI 10.1016/0168-9452(87)90062-8; SIEDOW JN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P165, DOI 10.1016/0005-2728(93)90098-Z; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRING O, 1988, PHYSIOL PLANTARUM, V72, P305, DOI 10.1111/j.1399-3054.1988.tb05837.x; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3	20	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11221	11227						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111023	hybrid			2022-12-25	WOS:A1997WW00900039
J	Kim, TW; Pettingell, WH; Hallmark, OG; Moir, RD; Wasco, W; Tanzi, RE				Kim, TW; Pettingell, WH; Hallmark, OG; Moir, RD; Wasco, W; Tanzi, RE			Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; AMYLOID PRECURSOR; GENE; CYTOSKELETON; PROTEIN; UBIQUITIN; ASSOCIATION; INHIBITION; MOLECULES	Mutations in the presenilin genes, PS1 and PS2, cause a major portion of early onset familial Alzheimer's disease (FAD), The biological roles of the presenilins and how their pathological mutations confer FAD are unknown, In this study, we set out to examine the processing and degradation pathways of PS2. For regulated expression of PS2, we have established inducible cell lines expressing PS2 under the tight control of the tetracycline-responsive transactivator. Western blot analysis revealed that PS2 was detected as an similar to 53-55-kDa polypeptide (54-kDa PS2) as well as a high molecular mass form (HMW-PS2). Using a stably transfected, inducible cell system, we have found that PS2 is proteolytically cleaved into two stable cellular polypeptides including an similar to 20-kDa C-terminal fragment and an similar to 34-kDa N-terminal fragment. PS2 is polyubiquitinated in vivo, and the degradation of PS2 is inhibited by proteasome inhibitors, N-acetyl-L-leucinal-L-norleucinal and lactacystin. Our studies suggest that PS2 normally undergoes endoproteolytic cleavage and is degraded via the proteasome pathway.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,GENET & AGING UNIT,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital			Moir, Robert D./M-7612-2017; Tanzi, Rudolph/AAE-9622-2019	Moir, Robert D./0000-0001-5431-3553; Tanzi, Rudolph/0000-0002-7032-1454				ALLINQUANT B, 1994, J NEUROSCI, V14, P6842; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; INOUE S, 1991, J BIOL CHEM, V266, P13311; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KIM TW, 1996, SOC NEUR ABSTR; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; OSBORN M, 1977, EXP CELL RES, V106, P339, DOI 10.1016/0014-4827(77)90179-3; Page K, 1996, P NATL ACAD SCI USA, V93, P14020, DOI 10.1073/pnas.93.24.14020; PAPADOPOULOS V, 1989, J CELL BIOL, V108, P553, DOI 10.1083/jcb.108.2.553; REFOLO LM, 1991, J NEUROSCI, V11, P3888; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WASCO W, 1995, MOL CELL NEUROBIOL, P51; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	44	209	218	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11006	11010						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9110991				2022-12-25	WOS:A1997WW00900007
J	Si-Tahar, M; Pidard, D; Balloy, V; Moniatte, M; Kieffer, N; VanDorsselaer, A; Chignard, M				Si-Tahar, M; Pidard, D; Balloy, V; Moniatte, M; Kieffer, N; VanDorsselaer, A; Chignard, M			Human neutrophil elastase proteolytically activates the platelet integrin alpha(IIb)beta(3) through cleavage of the carboxyl terminus of the alpha(IIB) subunit heavy chain - Involvement in the potentiation of platelet aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IIB; PROTEIN-KINASE-C; CATHEPSIN-G; FIBRINOGEN RECEPTOR; CELL-ADHESION; POLYMORPHONUCLEAR LEUKOCYTES; MONOCLONAL-ANTIBODY; SURFACE PROTEOLYSIS; SIGNAL-TRANSDUCTION; P-SELECTIN	Neutrophil elastase (NE) and cathepsin G are two serine proteinases released concomitantly by stimulated polymorphonuclear neutrophils. We previously demonstrated that while NE by itself does not activate human platelets, it strongly enhances the weak aggregation induced by a threshold concentration of cathepsin G (threshold of cathepsin G) (Renesto, P., and Chignard, M. (1993) Blood 82, 139-144), The aim of this study was to delineate the molecular mechanisms involved in this potentiation process, Two main pieces of data prompted us to focus on the activation of the platelet fibrinogen receptor, the alpha(III),beta(3) integrin, First, previous studies have shown this integrin to be particularly prone to proteolytic regulation of its function, Second, we found that the potentiating activity of NE on the threshold of cathepsin G-induced platelet aggregation was strictly dependent on the presence of exogenous fibrinogen, Using flow cytometry analysis, NE was shown to trigger a time dependent binding of PAC-1 and AP-5, two monoclonal antibodies specific for the activated and ligand-occupied conformers of alpha(IIb)beta(3) Furthermore, the potentiated aggregation was shown to result from an increased capacity of platelets to bind fibrinogen, Indeed, the combination of NE and threshold of cathepsin G increased the binding of PAC-1 approximate to 5.5-fold over basal values measured on nontreated platelets, whereas this binding raised only by approximate to 3-fold in threshold of cathepsin G-stimulated platelets (p < 0.05), By contrast, phosphatidic acid accumulation, pleckstrin phosphorylation, and calcium mobilization produced by the combination of NE and threshold of cathepsin G were not significantly different from those measured with threshold of cathepsin G alone (p > 0.05), indicating that the phospholipase C/protein kinase C pathway is not involved in the potentiation of aggregation, The foregoing data, as well as the requirement of catalytically active NE to trigger alpha(IIb)beta(3) activation and potentiate threshold of cathepsin G-initiated platelet aggregation, led us to examine whether the structure of this integrin was affected by NE, Immunoblot and flow cytometry analysis revealed a limited proteolysis of the carboxyl terminus of the alpha(IIb) subunit heavy chain (alpha(IIbH)), as judged by the disappearance of the epitope for the monoclonal antibody PMI-1, Mass spectrometry studies performed on a synthetic peptide mapping over the cleavage domain of alpha(IIbH) predicted the site of proteolysis as located between Val(837) and Asp(838), Treatment by NE of ATP-depleted platelets or Chinese hamster ovary cells expressing human recombinant alpha(IIb)beta(3) clearly established that activation of the integrin was independent of signal transduction events and was concomitant with the proteolysis of alpha(IIbH) In support of this latter observation, a close correlation was observed between the kinetics of proteolysis of alpha(IIbH), on platelets and that of expression of the ligand binding activity of alpha(IIb)beta(3) (r(2) = 0.902, p less than or equal to 0.005), However, only a subpopulation (approximate to 25%) of the proteolyzed alpha(IIb)beta(3) appeared to fully express the ligand binding capacity, Altogether, these results demonstrate that NE up-regulates the fibrinogen binding activity of alpha(III)beta(3) through a restricted proteolysis of the alpha(IIb) subunit, and that this process is relevant for the potentiation of platelet aggregation.	UNIV STRASBOURG 1, INST CHIM, LAB SPECTROMETRIE MASSE BIOORGAN, F-67008 STRASBOURG, FRANCE; CTR UNIV, LAB FRANCO LUXEMBOURGEOIS RECH BIOMED, GRAND DUCHY, LUXEMBOURG	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Luxembourg	Si-Tahar, M (corresponding author), INST PASTEUR, INSERM, U285, UNITE PHARMACOL CELLULAIRE, 25 RUE DR ROUX, F-75015 PARIS, FRANCE.		Chignard, Michel/B-4351-2008; SI-TAHAR, Mustapha/L-4149-2014; Balloy, Viviane/B-8551-2014; Si-Tahar, Mustapha/W-8034-2019	Chignard, Michel/0000-0003-3810-6575; SI-TAHAR, Mustapha/0000-0002-5792-7742; Balloy, Viviane/0000-0001-9093-9676; Si-Tahar, Mustapha/0000-0002-5792-7742; Moniatte, Marc/0000-0003-2235-4523; Pidard, Dominique/0000-0002-5732-3279				BEDNAR M, 1985, J CARDIOVASC PHARM, V7, P906, DOI 10.1097/00005344-198509000-00014; BYKOWSKA K, 1983, THROMB HAEMOSTASIS, V50, P768; CALVETE JJ, 1992, BIOCHEM J, V282, P523, DOI 10.1042/bj2820523; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CERLETTI C, 1995, THROMB HAEMOSTASIS, V74, P218; CHIGNARD M, 1986, P NATL ACAD SCI USA, V83, P8609, DOI 10.1073/pnas.83.22.8609; DELMASCHIO A, 1993, ANN HEMATOL, V67, P23, DOI 10.1007/BF01709662; DELMASCHIO A, 1990, AM J PHYSIOL, V258, pH870, DOI 10.1152/ajpheart.1990.258.3.H870; DU XP, 1993, J BIOL CHEM, V268, P23087; EVANGELISTA V, 1993, BLOOD, V81, P2947; FERRERLOPEZ P, 1990, AM J PHYSIOL, V258, pC1100, DOI 10.1152/ajpcell.1990.258.6.C1100; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FUJIL K, 1995, EXP CELL RES, V220, P201, DOI 10.1006/excr.1995.1307; GINSBERG MH, 1995, THROMB HAEMOSTASIS, V74, P352; GRABER SE, 1982, J BIOL CHEM, V257, P4606; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HUANG EM, 1981, BLOOD, V57, P685; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISSEKUTZ AC, 1983, LAB INVEST, V49, P716; JOLLES J, 1981, BIOCHEM J, V194, P283, DOI 10.1042/bj1940283; Kieffer N, 1996, CELL ADHES COMMUN, V4, P25, DOI 10.3109/15419069609010761; KORNECKI E, 1983, J BIOL CHEM, V258, P9349; KORNECKI E, 1986, J CLIN INVEST, V77, P750, DOI 10.1172/JCI112370; KORNECKI E, 1988, AM J PHYSIOL, V255, pH651, DOI 10.1152/ajpheart.1988.255.3.H651; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; Kunicki TJ, 1996, J BIOL CHEM, V271, P20315, DOI 10.1074/jbc.271.34.20315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA CA, 1994, J VASC SURG, V19, P306, DOI 10.1016/S0741-5214(94)70106-7; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; MARCUS AJ, 1995, THROMB HAEMOSTASIS, V74, P213; MEHRI Y, 1994, CIRCULATION, V90, P997; MOLINO M, 1993, BLOOD, V82, P2442; MOLINO M, 1992, BIOCHEM J, V288, P741, DOI 10.1042/bj2880741; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NIYA K, 1987, BLOOD, V70, P475; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PEERSCHKE EIB, 1984, BLOOD, V64, P59; PIDARD D, 1994, BIOCHEM J, V303, P489, DOI 10.1042/bj3030489; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PIDARD D, 1991, EUR J BIOCHEM, V200, P437, DOI 10.1111/j.1432-1033.1991.tb16202.x; PONCZ M, 1987, J BIOL CHEM, V262, P8476; RENESTO P, 1990, LAB INVEST, V62, P409; RENESTO P, 1993, BLOOD, V82, P139, DOI 10.1182/blood.V82.1.139.bloodjournal821139; RENESTO P, 1991, J IMMUNOL, V146, P2305; SELAK MA, 1988, BIOCHEM J, V251, P293, DOI 10.1042/bj2510293; SELAK MA, 1992, THROMB HAEMOSTASIS, V68, P570; SELAK MA, 1993, PLATELETS, V4, P85, DOI 10.3109/09537109309013201; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; Si-Tahar M, 1996, BIOCHEM J, V313, P401, DOI 10.1042/bj3130401; SI-TAHAR M, 1994, EUR CYTOKINE NETW, V5, P455; SIESS W, 1991, NEWS PHYSIOL SCI, V6, P51; STUIVER I, 1995, STEM CELLS, V13, P250, DOI 10.1002/stem.5530130306; TAUB R, 1989, J BIOL CHEM, V264, P259; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VERHOEVEN AJM, 1985, J BIOL CHEM, V260, P2621; VORM O, 1994, BIOL MASS SPECTROM, V23, P734, DOI 10.1002/bms.1200231204; WENCELDRAKE JD, 1986, AM J PATHOL, V124, P324	60	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11636	11647						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111081				2022-12-25	WOS:A1997WW00900097
J	Fujita, M; Kiyono, T; Hayashi, Y; Ishibashi, M				Fujita, M; Kiyono, T; Hayashi, Y; Ishibashi, M			In vivo interaction of human MCM heterohexameric complexes with chromatin - Possible involvement of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; LARGE T-ANTIGEN; DNA-REPLICATION; YEAST MCM3; PROTEINS; CYCLE; FAMILY; INITIATION; COMPONENT; MUTANTS	The MCM protein family, which consists of at least six members, has been implicated in the regulatory machinery causing DNA to replicate once in the S phase. Mammalian MCM proteins are present in the nucleus in two different forms, one extractable by nonionic detergents and the other resistant to such extraction. The latter is assumed to be tightly associated with nuclear structures and released at the time of initiation of replication. However, details of the mode of binding remain unclear. In the present study, we found that, in nonionic detergent-permeabilized nuclei, the association of human MCM (hMCM) proteins with them could be stabilized by the addition of ATP. The hMCMs bound to the nuclei in the presence of ATP were released by digestion with nucleases, suggesting that they are chromatin associated. The nuclease-directed solubilization of the chromatin-bound hMCMs thus provided a means to analyze them as well as soluble hMCMs by co-immunoprecipitation, The results indicate that the six hMCM members exist as heterocomplexes, whether bound or unbound. We therefore propose that hMCM proteins may function in DNA replication as heterohexamers associated with chromatin and that ATP is possibly involved in the association. Nuclease digestion-immunoprecipitation techniques of the type described here should facilitate further elucidation of the mode of interaction between hMCMs and chromatin.			Fujita, M (corresponding author), AICHI CANC CTR,RES INST,LAB VIRAL ONCOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.		Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; Fujita M, 1996, BIOCHEM BIOPH RES CO, V219, P604, DOI 10.1006/bbrc.1996.0280; Fujita M, 1996, J BIOL CHEM, V271, P4349; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GIBSON S, 1987, UCLA S MOL CELL BIOL, V47, P341; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Lei M, 1996, MOL CELL BIOL, V16, P5081; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; Miyake S, 1996, GENE, V175, P71, DOI 10.1016/0378-1119(96)00122-9; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; Su TT, 1996, MOL BIOL CELL, V7, P319, DOI 10.1091/mbc.7.2.319; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TREISMAN JE, 1995, GENE DEV, V9, P1709, DOI 10.1101/gad.9.14.1709; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	48	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10928	10935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099751				2022-12-25	WOS:A1997WV26200085
J	Katterle, B; Sahlin, M; Schmidt, PP; Potsch, S; Logan, DT; Graslund, A; Sjoberg, BM				Katterle, B; Sahlin, M; Schmidt, PP; Potsch, S; Logan, DT; Graslund, A; Sjoberg, BM			Kinetics of transient radicals in Escherichia coli ribonucleotide reductase - Formation of a new tyrosyl radical in mutant protein R2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; PEROXIDASE COMPOUND-ES; RADICAL-DIIRON(III) COFACTOR; MOSSBAUER SPECTROSCOPIES; PHENOTYPIC SELECTION; HYDROGEN-PEROXIDE; SMALL SUBUNIT; FE2+ REACTION; IRON; EPR	Reconstitution of the tyrosyl radical in ribonucleotide reductase protein R2 requires oxidation of a diferrous site by oxygen, The reaction involves one externally supplied electron in addition to the three electrons provided by oxidation of the Tyr-122 side chain and formation of the mu-oxo-bridged diferric site, Reconstitution of R2 protein Y122F, lacking the internal pathway involving Tyr-122, earlier identified two radical intermediates at Trp-107 and Trp-lll in the vicinity of the di-iron site, suggesting a novel internal transfer pathway (Sahlin, Ri,, Lassmann, G., Potsch, S., Sjoberg, B.-M., and Graslund, A. (1995) J. Biol, Chem, 270, 12361-12372), Here, we report the construction of the double mutant W107Y/Y122F and its three dimensional structure and demonstrate that the tyrosine Tyr-107 can harbor a transient, neutral radical (Tyr-107(.)), The Tyr-107(.) signal exhibits the hyperfine structure of a quintet with coupling constants of 1.3 mT for one beta-methylene proton and 0.75 mT for each of the 3 and 5 hydrogens of the phenyl ring, Rapid freeze quench kinetics of EPR-visible intermediates reveal a preferred radical transfer pathway via Trp-lll, Glu-204, and Fe-2, followed by a proton coupled electron transfer through the pi-interaction of the aromatic rings of Trp-(Tyr-)-107 and Trp-lll, The kinetic pattern observed in W107Y/Y122F is considerably changed as compared with Y122F: the Trp-111(.) EPR signal has vanished, and the Tyr-107(.) has the same formation rate as does Trp-111(.) in Y122F, According to the proposed consecutive reaction, Trp-111(.) becomes very short lived and is no longer detectable because of the faster formation of Tyr-107(.). We conclude that the phenyl rings of Trp-lll and Tyr-107 form a better stacking complex so that the proton-coupled electron transfer is facilitated compared with the single mutant, Comparison with the formation kinetics of the stable tyrosyl radical in wild type R2 suggests that these protein-linked radicals are substitutes for the missing Tyr-122, However, in contrast to Tyr-122(.) these radicals lack a direct connection to the radical transfer pathway utilized during catalysis.	UNIV STOCKHOLM,DEPT MOL BIOL,S-10691 STOCKHOLM,SWEDEN; UNIV STOCKHOLM,DEPT BIOPHYS,S-10691 STOCKHOLM,SWEDEN	Stockholm University; Stockholm University			Logan, Derek T/A-1114-2011; Logan, Derek/O-2497-2019	Logan, Derek T/0000-0002-0098-8560; Logan, Derek/0000-0002-0098-8560; Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, BIOCHEMISTRY-US, V26, P5541; Allard P, 1996, J AM CHEM SOC, V118, P895, DOI 10.1021/ja9529192; ASCHENBACH H, 1972, CHEM BER, V105, P784; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BERNHARD WA, 1989, J MAGN RESON, V82, P156, DOI 10.1016/0022-2364(89)90176-5; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Gray H. B., 1990, ALDRICHIM ACTA, V23, P87; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; LINDSTROM B, 1974, J LABELLED COMPD, V10, P187, DOI 10.1002/jlcr.2590100202; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; SAHLIN M, 1994, J BIOL CHEM, V269, P11699; SAHLIN M, 1996, ANNU REV BIOPH BIOM, V25, P259; Schmidt PP, 1996, J BIOL CHEM, V271, P23615, DOI 10.1074/jbc.271.39.23615; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P481; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; UN S, 1995, J AM CHEM SOC, V117, P10713, DOI 10.1021/ja00148a013; [No title captured]	48	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10414	10421						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099682				2022-12-25	WOS:A1997WV26200016
J	Komar, AA; Kommer, A; Krasheninnikov, IA; Spirin, AS				Komar, AA; Kommer, A; Krasheninnikov, IA; Spirin, AS			Cotranslational folding of globin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; NASCENT POLYPEPTIDE-CHAINS; LARGE RIBOSOMAL-SUBUNIT; MESSENGER-RNA; DISULFIDE BONDS; LIGHT-CHAINS; PROTEIN; SEQUENCE; PEPTIDE; CELL	Globin synthesis in a wheat germ cell-free translation system was performed in the presence of [H-3]hemin and [S-35]methionine to determine the minimal length of the nascent ribosome-bound globin chain capable of heme binding, Nascent polypeptides of predetermined size were synthesized on ribosomes by translation of truncated mRNA molecules. Analysis with the use of sucrose gradient centrifugation and puromycin reaction revealed that the ribosome-bound N-terminal alpha-globin fragments of 140, 100, and 86 amino acid residues are capable of an efficient heme binding, whereas those of 75, 65, and 34 amino acid residues display a significantly weaker, or just nonspecific, affinity to heme. This indicates that the ribosome-bound nascent chain of 86 amino acid residues has already acquired a spatial structure that allows its interaction with the heme group or that heme attachment promotes the formation of the proper tertiary structure in the ribosome-bound nascent peptide, In any case the cotranslational folding of globin is suggested.	MOSCOW MV LOMONOSOV STATE UNIV,FAC BIOL,DEPT MOL BIOL,MOSCOW 119899,RUSSIA; RUSSIAN ACAD SCI,INST PROT RES,PUSHCHINO 142292,MOSCOW REGION,RUSSIA	Lomonosov Moscow State University; Russian Academy of Sciences			Spirin, Alexander/A-7307-2016	Komar, Anton/0000-0003-4188-0633				Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; Antonini E., 1971, FRONTIERS BIOL, V21; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BERGMAN LW, 1979, J SUPRAMOL STR CELL, V11, P9, DOI 10.1002/jss.400110103; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; Bucci E, 1981, Methods Enzymol, V76, P97; CHANTRENE H, 1961, MODERN TRENDS PHYSL, P122; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CLEMENS MJ, 1984, TRANSCRIPTION T PRAC; COWIE DB, 1961, P NATL ACAD SCI USA, V47, P114, DOI 10.1073/pnas.47.1.114; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DECOEN JL, 1970, J MOL BIOL, V49, P405, DOI 10.1016/0022-2836(70)90253-6; DESANCTIS G, 1994, BBA-PROTEIN STRUCT M, V1204, P28, DOI 10.1016/0167-4838(94)90028-0; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; Freedman Robert B., 1992, P455; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAY GD, 1995, J MOL BIOL, V254, P968, DOI 10.1006/jmbi.1995.0669; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HAMLIN J, 1972, P NATL ACAD SCI USA, V69, P412, DOI 10.1073/pnas.69.2.412; JACKSON R, 1970, NATURE, V227, P672, DOI 10.1038/227672a0; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JAENICKE R, 1993, CHEMTRACTS BIOCH MOL, V4, P1; KIHO Y, 1964, P NATL ACAD SCI USA, V51, P111, DOI 10.1073/pnas.51.1.111; KIM JM, 1991, J BIOL CHEM, V266, P14931; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KOLB VA, 1987, DOKL AKAD NAUK SSSR+, V296, P1497; Kolb VA, 1995, BIOCHEM CELL BIOL, V73, P1217, DOI 10.1139/o95-131; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KOMAR AA, 1993, FEBS LETT, V326, P261, DOI 10.1016/0014-5793(93)81803-8; KRASHENINNIKOV IA, 1991, J PROTEIN CHEM, V10, P445, DOI 10.1007/BF01025472; KUDLICKI W, 1995, BIOCHEMISTRY-US, V34, P14284, DOI 10.1021/bi00044a003; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Lapham J, 1996, RNA, V2, P289; LEUTZINGER Y, 1981, P NATL ACAD SCI-BIOL, V78, P780, DOI 10.1073/pnas.78.2.780; LIM VI, 1986, J MOL BIOL, V188, P565, DOI 10.1016/S0022-2836(86)80006-7; LOCKARD RE, 1978, NUCLEIC ACIDS RES, V5, P37, DOI 10.1093/nar/5.1.37; Makeyev EV, 1996, FEBS LETT, V378, P166, DOI 10.1016/0014-5793(95)01438-1; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; Maniatis T., 1982, MOL CLONING; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; Ostermeier C, 1996, NUCLEIC ACIDS RES, V24, P1979, DOI 10.1093/nar/24.10.1979; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; PETERS T, 1982, J BIOL CHEM, V257, P8847; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; RYABOVA LA, 1988, FEBS LETT, V226, P255, DOI 10.1016/0014-5793(88)81434-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHISHKOV AV, 1976, DOKL AKAD NAUK SSSR+, V228, P1237; SMITH WP, 1978, P NATL ACAD SCI USA, V75, P5922, DOI 10.1073/pnas.75.12.5922; WAKS M, 1973, J BIOL CHEM, V248, P6462; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WINTERHALTER KH, 1971, BIOCHEMISTRY-US, V10, P3790, DOI 10.1021/bi00796a023; YIP YK, 1972, J BIOL CHEM, V247, P7237; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; YOSHIDA A, 1970, P NATL ACAD SCI USA, V67, P1600, DOI 10.1073/pnas.67.3.1600; ZIPSER D, 1963, COLD SPRING HARB SYM, V28, P533, DOI 10.1101/SQB.1963.028.01.071	65	119	126	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10646	10651						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099713				2022-12-25	WOS:A1997WV26200047
J	Liu, DR; Pavlopoulos, E; Modi, W; Moschonas, N; Mavrothalassitis, G				Liu, DR; Pavlopoulos, E; Modi, W; Moschonas, N; Mavrothalassitis, G			ERF: Genomic organization, chromosomal localization and promoter analysis of the human and mouse genes	ONCOGENE			English	Article						ets; transcriptional repressor; genomic organization; promoter	ETS DOMAIN PROTEIN; EWINGS-SARCOMA TRANSLOCATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; THYROID ADENOMAS; MYELOID-LEUKEMIA; ONCOGENE FAMILY; DROSOPHILA EYE; TEL GENE	ERF (Ets2 Repressor Factor) is a ubiquitously expressed ets-domain protein that exhibits strong transcriptional repressor activity, has been shown to suppress ets-induced transformation and has been suggested to be regulated by MAPK phosphorylation. We report here the sequence of the mouse gene, the genomic organization of the human and the mouse genes, their chromosomal position and the analysis of the promoter region. Genomic clones encompassing either the human ERI; or the mouse Erf gene were isolated and utilized to define their molecular organization. The gene in both species consists of 4 exons over a 10 kb region. Utilizing FISH, somatic cell hybrids and linkage analysis, we identified the chromosomal position of ERP on human chromosome 19q13.1 and on its syntenic region in the mouse, on chromosome 7. Sequence analysis of the mouse gene indicated a 90% identity to the human gene within the coding and promoter regions. The predicted Erf protein is 98% identical to the human protein and all of the identifiable motifs are conserved between the two proteins. However, the mouse protein is three amino acids longer (551 versus 548 aa). The area surrounding the region that is homologous to the 5' end of the human cDNA can serve as a promoter in transfection into eukaryotic cells. This region is highly conserved between the mouse and the human genes. A number of conserved transcription factor binding sites can be identified in the region including an ets binding site (EBS). Interestingly, removal of a small segment that includes the :EBS, seriously hampers promoter function, suggesting the ERF transcription may be regulated by ets-domain proteins.	NCI,FREDERICK CANC RES & DEV CTR,MOL ONCOL LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SAIC,FREDERICK,MD 21702; FORTH,INST MOL BIOL & BIOTECHNOL,IRAKLION 71110,GREECE; UNIV CRETE,DEPT BIOL,IRAKLION 71110,GREECE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Foundation for Research & Technology - Hellas (FORTH); University of Crete				Moschonas, Nicholas/0000-0002-2556-537X				BARTNITZKE S, 1989, CANCER GENET CYTOGEN, V39, P65, DOI 10.1016/0165-4608(89)90230-6; BELGE G, 1992, CANCER GENET CYTOGEN, V60, P23, DOI 10.1016/0165-4608(92)90227-Y; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GILLE H, 1992, NATURE, V358, P415; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HROMAS R, 1994, INT J HEMATOL, V59, P257; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; JOHANSSON B, 1994, CANCER GENET CYTOGEN, V74, P62, DOI 10.1016/0165-4608(94)90031-0; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; NUNN M, 1984, VIROLOGY, V133, P330; OHNO H, 1993, LEUKEMIA, V7, P2057; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAIETTA E, 1988, CANCER GENET CYTOGEN, V34, P19, DOI 10.1016/0165-4608(88)90162-8; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; RAO VN, 1994, ONCOGENE, V9, P1855; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sambrook J., 2002, MOL CLONING LAB MANU; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STARK B, 1995, LEUKEMIA RES, V19, P367, DOI 10.1016/0145-2126(94)00150-9; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; TANAKA S, 1990, CANCER GENET CYTOGEN, V49, P219, DOI 10.1016/0165-4608(90)90144-Y; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WLODARSKA I, 1995, BLOOD, V85, P2848, DOI 10.1182/blood.V85.10.2848.bloodjournal85102848; YABUMOTO K, 1994, INT J HEMATOL, V59, P211; Yang BS, 1996, MOL CELL BIOL, V16, P538; 1995, GENOME NEWS, V19, P21	56	17	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1445	1451		10.1038/sj.onc.1200965	http://dx.doi.org/10.1038/sj.onc.1200965			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136988				2022-12-25	WOS:A1997WT58400007
J	Bui, TD; Rankin, J; Smith, K; Huguet, EL; Ruben, S; Strachan, T; Harris, AL; Lindsay, S				Bui, TD; Rankin, J; Smith, K; Huguet, EL; Ruben, S; Strachan, T; Harris, AL; Lindsay, S			A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas	ONCOGENE			English	Article						WNT10B; cloning; breast carcinoma	MAMMARY EPITHELIUM; MOLECULAR-CLONING; TRANSGENIC MICE; TUMORS; ONCOGENE; FAMILY; INT-1; HYPERPLASIA; MULTIPLE; SEQUENCE	Several members of the Wnt gene family have been shown to cause mammary tumors in mouse. Using degenerate primer polymerase chain reaction (PCR) on human genomic DNA, and specific PCR of cDNA libraries, we have isolated a WNT gene which has not previously been described in human. The gene is the human homologue of mouse Wnt10b, recently shown to be one of the oncogenes cooperating with FGF3 in the development of mouse mammary tumour virus (MMTV) induced mouse mammary carcinomas. The human WNT10B sequence was 88% and 95% identical to the murine gene at nucleotide and amino acid levels, respectively, YAC FISH mapping localises the gene to 12q13, a chromosomal region frequently rearranged in human tumours and also containing the WNT1 gene. In normal and benign proliferations of human breast tissue, WNT10B expression was not detected by ribonuclease protection assays but was found at low levels in RT-PCR experiments. In contrast, using both methods, WNT10B expression was found to be elevated in 3 of 50 primary breast carcinomas. Southern blot analysis of the carcinoma expressing the highest levels of WNT10B showed no amplification or rearrangement of the gene. The WNT10B gene was also expressed in some cancer and non cancerous breast cell lines. These findings suggest that the WNT10B gene may be involved in human breast cancer, and show that there is differential expression of the WNT10B gene in benign and malignant disease.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,GROWTH FACTORS GRP,OXFORD OX3 9DU,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT HUMAN GENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	University of Oxford; Newcastle University - UK; GlaxoSmithKline; Human Genome Sciences Inc			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Lindsay, Susan/0000-0003-2980-4582				ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; FANTES JA, 1992, AM J HUM GENET, V51, P1286; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HUGUET EL, 1994, CANCER RES, V54, P2615; Lako M, 1996, GENOMICS, V35, P386, DOI 10.1006/geno.1996.0374; LAZO PA, 1992, FEBS LETT, V300, P109, DOI 10.1016/0014-5793(92)80175-G; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; LIN TP, 1992, CANCER RES, V52, P4413; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; MCMAHON AP, 1992, TIG, V8, P237; MOCK BA, 1993, ENCY MOUSE GENOME, V3; NILBERT M, 1995, CANCER GENET CYTOGEN, V83, P32, DOI 10.1016/S0165-4608(95)00016-X; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; TAYLORPAPADIMITRIOU J, 1993, CANCER SURV, V16, P59; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	28	70	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1249	1253		10.1038/sj.onc.1200936	http://dx.doi.org/10.1038/sj.onc.1200936			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121776				2022-12-25	WOS:A1997WM78200016
J	Collingwood, TN; Butler, A; Tone, Y; CliftonBligh, RJ; Parker, MG; Chatterjee, VKK				Collingwood, TN; Butler, A; Tone, Y; CliftonBligh, RJ; Parker, MG; Chatterjee, VKK			Thyroid hormone-mediated enhancement of heterodimer formation between thyroid hormone receptor beta and retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; DEPENDENT TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; GLUCOCORTICOID RECEPTOR; ACID RECEPTORS; LIGAND-BINDING; DIRECT REPEATS; RXR-BETA; IN-VIVO	A subset of nuclear receptors, including those for thyroid hormone (TR), retinoic acid, vitamin D-3, and eicosanoids, can form heterodimers with the retinoid X receptor (RXR) on DNA regulatory elements in the absence of their cognate ligands. In a mammalian two-hybrid assay, we have found that recruitment of a VP16-RXR chimera by a Ga14-TR beta ligand-binding domain fusion is enhanced up to 50-fold by thyroid hormone (T-3). This was also observed with a mutant fusion, Ga14-TR(L454A), lacking Ligand inducible activation function (AF-2) and unable to interact with putative coactivators, suggesting that the AF-2 activity of TR or intermediary cofactors is not involved in this effect, The wild-type and mutant Ga14-TR fusions also exhibited hormone-dependent recruitment of RXR in yeast, Hormone dependent recruitment of RXR was also evident with another Ga14-TR mutant, AHTm, which does not interact with the nuclear receptor corepressor N-CoR, suggesting that ligand-enhanced dimerization is not a result of T-3-induced corepressor release, Finally, we have shown that the interaction between RXR and TR is augmented by T-3 in vitro, arguing against altered expression of either partner in vitro mediating this effect, We propose that ligand dependent heterodimerization of TR and RXR in solution may provide a further level of control in nuclear receptor signaling.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; IMPERIAL CANC RES FUND,MOL ENDOCRINOL LAB,LONDON WC2A 3PX,ENGLAND	Addenbrooke's Hospital; University of Cambridge; Cancer Research UK; University of London; Queen Mary University London				Chatterjee, Vengalil Krishna/0000-0002-2654-8854; Clifton-Bligh, Roderick/0000-0002-1545-0368	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHESKIS B, 1995, MOL ENDOCRINOL, V9, P1814, DOI 10.1210/me.9.12.1814; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; QI JS, 1995, MOL CELL BIOL, V15, P1817; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SAKURAI A, 1990, MOL CELL ENDOCRINOL, V71, P83; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	57	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13060	13065		10.1074/jbc.272.20.13060	http://dx.doi.org/10.1074/jbc.272.20.13060			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148917	hybrid			2022-12-25	WOS:A1997WZ38400030
J	Methot, D; LaPointe, MC; Touyz, RM; Yang, XP; Carretero, OA; Deschepper, CF; Schiffrin, EL; Thibault, G; Reudelhuber, TL				Methot, D; LaPointe, MC; Touyz, RM; Yang, XP; Carretero, OA; Deschepper, CF; Schiffrin, EL; Thibault, G; Reudelhuber, TL			Tissue targeting of angiotensin peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE SECRETORY PATHWAY; ANTERIOR-PITUITARY; BLOOD-PRESSURE; SEQUENCE REQUIREMENTS; PRECURSOR PROTEINS; ANEPHRIC MAN; II RECEPTOR; HUMAN RENIN; IN-VITRO; SYSTEM	Angiotensin II (Ang II) is an octapeptide generated by the sequential proteolytic action of renin and angiotensin converting enzyme on the glycoprotein angiotensinogen, While numerous mammalian tissues have been shown to express some or all of the components of the renin-angiotensin system (RAS), the function of most of these tissue RAS remains a matter of conjecture, To test for tissue-specific functions of Ang II and as an alternative to co expressing all the components of RAS, we have engineered a fusion protein that leads to direct Ang II release within specific tissues, The angiotensin peptide is cleaved from the fusion protein within the secretory pathway by the ubiquitous endoprotease furin and is released from the cell by constitutive secretion, Direct injection of an expression vector encoding such a fusion protein into rat cardiac ventricles results in a highly localized expression of atrial natriuretic peptide mRNA (an angiotensin responsive marker of cardiac hypertrophy), demonstrating the utility of this approach for local targeting of mature peptides to tissues in animal models.	INST RECH CLIN MONTREAL,LAB MOL BIOCHEM HYPERTENS,MED RES COUNCIL CANADA,MONTREAL,PQ H2W 1R7,CANADA; HENRY FORD HLTH SCI CTR,HYPERTENS & VASC RES DIV,DETROIT,MI 48202	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Henry Ford Health System; Henry Ford Hospital			Schiffrin, Ernesto L/AAB-9061-2019; Touyz, Rhian/AAM-3564-2020; Deschepper, Christian/J-4783-2015	Schiffrin, Ernesto L/0000-0002-4502-2823; Touyz, Rhian/0000-0003-0670-0887; Deschepper, Christian/0000-0001-6234-4667	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028982] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03188, HL28982] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CAMPBELL DJ, 1991, J HYPERTENS, V9, P265, DOI 10.1097/00004872-199103000-00011; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; DESCHEPPER CF, 1986, ENDOCRINOLOGY, V119, P36, DOI 10.1210/endo-119-1-36; ERSPAMER V, 1979, EXPERIENTIA, V35, P1132, DOI 10.1007/BF01963240; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GANONG WF, 1989, HORM RES, V31, P24, DOI 10.1159/000181082; GANONG WF, 1995, NEUROSCI BIOBEHAV R, V19, P241, DOI 10.1016/0149-7634(94)00056-7; GANONG WF, 1993, FRONT NEUROENDOCRIN, V14, P233, DOI 10.1006/frne.1993.1008; GANONG WF, 1989, AM J HYPERTENS, V2, P320, DOI 10.1093/ajh/2.4.320; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; GOMEZ RA, 1995, AM J KIDNEY DIS, V26, P409, DOI 10.1016/0272-6386(95)90487-5; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSOI M, 1992, J CLIN ENDOCR METAB, V74, P680, DOI 10.1210/jc.74.3.680; HSUEH WA, 1991, HYPERTENSION, V17, P469, DOI 10.1161/01.HYP.17.4.469; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; KEUSCH G, 1989, NEPHRON, V51, P29, DOI 10.1159/000185568; KHOSLA MC, 1981, J MED CHEM, V24, P885, DOI 10.1021/jm00139a023; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; LAPOINTE MC, 1993, MOL ENDOCRINOL, V7, P1284, DOI 10.1210/me.7.10.1284; LEE MA, 1993, CIRCULATION, V87, P13; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; MULROW PJ, 1989, YALE J BIOL MED, V62, P503; NEURINGER JR, 1993, AM J KIDNEY DIS, V22, P98, DOI 10.1016/S0272-6386(12)70174-9; PAUL M, 1993, J CLIN INVEST, V91, P2058, DOI 10.1172/JCI116428; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SCHALKEN JA, 1987, J CLIN INVEST, V80, P545; SEALEY JE, 1989, AM J HYPERTENS, V2, P358, DOI 10.1093/ajh/2.5.358; TAKAHASHI S, 1994, J BIOCHEM-TOKYO, V116, P47, DOI 10.1093/oxfordjournals.jbchem.a124501; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; THIBAULT G, 1994, CIRC RES, V74, P460, DOI 10.1161/01.RES.74.3.460; Touyz RM, 1995, CAN J PHYSIOL PHARM, V73, P1262, DOI 10.1139/y95-178; Touyz RM, 1996, HYPERTENSION, V27, P1090, DOI 10.1161/01.HYP.27.5.1090; Touyz RM, 1996, AM J PHYSIOL-HEART C, V270, pH857, DOI 10.1152/ajpheart.1996.270.3.H857; TUCKER PW, 1979, SCIENCE, V206, P1299, DOI 10.1126/science.117548; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WEI YF, 1987, J CLIN INVEST, V79, P1325, DOI 10.1172/JCI112957; WU JP, 1988, AM J PHYSIOL, V255, pE388, DOI 10.1152/ajpendo.1988.255.3.E388	46	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12994	12999		10.1074/jbc.272.20.12994	http://dx.doi.org/10.1074/jbc.272.20.12994			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148907	hybrid			2022-12-25	WOS:A1997WZ38400020
J	Bokkala, S; Joseph, SK				Bokkala, S; Joseph, SK			Angiotensin II-induced down-regulation of inositol trisphosphate receptors in WB rat liver epithelial cells - Evidence for involvement of the proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE RECEPTOR; TYROSINE KINASE; HL-60 CELLS; DEGRADATION; UBIQUITIN; ACTIVATION; EXPRESSION; PROTEINS; BRAIN; CFTR	Chronic stimulation of WB rat liver epithelial cells by angiotensin II (Ang II) resulted in the down-regulation of both type I and type III myo-inositol 1,4,5-trisphosphate receptors (IP(3)Rs), Stimulation with vasopressin, bradykinin, epidermal growth factor, or 12-O-tetradecanoylphorbol-13-acetate was without effect. Ang II-induced down-regulation of IP(3)Rs could be detected within 2 h and resulted in an inhibition of IP3-induced Ca2+ release from permeabilized cells, IP3R down-regulation was reversible, and both home- and heterooligomers of IP(3)Rs were equally susceptible to Ang II-induced degradation. Chloroquine and NH4Cl increased the basal levels of IP(3)Rs by a-fold, suggesting that the basal turnover of IP(3)Rs occurs via a lysosomal pathway, However, Ang II-induced degradation of IP3R was not affected by these inhibitors, suggesting that stimulated degradation of IP(3)Rs occurs via a non-lysosomal pathway, The cysteine protease and proteasomal inhibitor N-acetyl-Leu-Leu-norleucinal completely prevented Ang II-mediated down-regulation of IP(3)Rs, whereas the structural analog N-acetyl-Leu-Leu-methioninal was without effect, Lactacystin, a highly specific proteasome inhibitor, also blocked Ang II-mediated IP3R degradation, Stimulation with Ang II increased the amount of LP3R immunoprecipitated by anti-ubiquitin antibodies, We conclude that Ang II-stimulated IP3R degradation involves enhanced ubiquitination of the protein and degradation by the proteasome pathway.	THOMAS JEFFERSON UNIV, DEPT PATHOL, SCH MED, PHILADELPHIA, PA 19107 USA	Jefferson University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010971, T32AA007463] Funding Source: NIH RePORTER; NIAAA NIH HHS [T32-AA07463, R01-AA10971] Funding Source: Medline; NIDDK NIH HHS [R01-DK34804] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; BRADFORD PG, 1993, MOL PHARMACOL, V44, P292; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; EARP HS, 1995, J BIOL CHEM, V270, P28440; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Harlow E., 1988, ANTIBODIES LAB MANUA; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; JOSEPH SK, 1994, J BIOL CHEM, V269, P5673; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Missiaen L, 1996, Subcell Biochem, V26, P59; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; Pietruszczak S., 1991, COMPUT GEOTECH, V12, P55, DOI DOI 10.1016/0266-352X(91)90011-4; ROBERTS BJ, 1995, J BIOL CHEM, V270, P29632; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Simpson PB, 1996, J NEUROCHEM, V67, P364; SIMPSON PB, 1994, J NEUROCHEM, V63, P2369; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	49	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12454	12461		10.1074/jbc.272.19.12454	http://dx.doi.org/10.1074/jbc.272.19.12454			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139693	hybrid			2022-12-25	WOS:A1997WY82900030
J	Chen, CG; Wang, XF; Sun, LZ				Chen, CG; Wang, XF; Sun, LZ			Expression of transforming growth factor beta (TGF beta) type III receptor restores autocrine TGF beta(1) activity in human breast cancer MCF-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; MICROSATELLITE INSTABILITY; PROTEOGLYCAN BETAGLYCAN; BINDING; LINES; GENE; PROLIFERATION; FACTOR-BETA-1; STIMULATION; SENSITIVITY	While transforming growth factor beta (TGF beta) type III receptor (RIII) is known to increase TGF beta(1) binding to its type nr receptor (RII), the significance of this phenomenon is not known. We used human breast cancer MCF-7 cells to study the role of RIII in regulating autocrine TGF beta(1), activity because they express very little RIII and no detectable autocrine TGF beta activity. A tetracycline-repressible RIII expression vector was stably transfected into this cell line. Expression of RIII increased TGF beta(1) binding to TGF beta type I receptor (RI) as well as RII. Treatment with tetracycline suppressed RIII expression and abolished TGF beta(1) binding to RI and RII. Growth of RIII-transfected cells was reduced by 40% when plated at low density on plastic. This reduction was reversed by tetracycline treatment and was partially reversed by treatment with a TGF beta(1) neutralizing antibody. The activity of a TGF beta-responsive promoter construct when transiently transfected was more than S-fold higher in the RIII-transfected cells than in the control cells. Treating the cells with tetracycline or the TGF beta(1) neutralizing antibody also significantly attenuated the increased promoter activity. These results suggest that expression of RIII restored autocrine TGF beta(1) activity in MCF-7 cells. The RIII-transfected cells mere also much less clonogenic in soft agarose than the control cells indicating a reversion of progression. Thus, RIII may be essential for an optimal level of the autocrine TGF beta activity in some cells, especially in the transformed cells with reduced RII expression.	UNIV KENTUCKY,COLL MED,DEPT PHARMACOL,LEXINGTON,KY 40536; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	University of Kentucky; Duke University			, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R29CA063480] Funding Source: NIH RePORTER; NCI NIH HHS [CA63480] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ARRICK BA, 1990, CANCER RES, V50, P299; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1988, CANCER RES, V48, P3898; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BEAUCHAMP RD, 1992, ENDOCRINOLOGY, V130, P2476, DOI 10.1210/en.130.5.2476; CHEIFETZ S, 1988, J BIOL CHEM, V263, P10783; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; FILMUS J, 1992, ONCOGENE, V7, P521; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kim IY, 1996, CANCER RES, V56, P44; KIM LY, 1996, CLIN CANCER RES, V2, P1255; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SUN LZ, 1994, EXP CELL RES, V214, P215, DOI 10.1006/excr.1994.1251; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; Xie W.Q., 1991, BIOTECHNIQUES, V11, P326; XIE WQ, 1991, BIOTECHNIQUES, V11, P324	44	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12862	12867		10.1074/jbc.272.19.12862	http://dx.doi.org/10.1074/jbc.272.19.12862			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139748	hybrid			2022-12-25	WOS:A1997WY82900085
J	Iwase, S; Furukawa, Y; Kikuchi, J; Nagai, M; Terui, Y; Nakamura, M; Yamada, H				Iwase, S; Furukawa, Y; Kikuchi, J; Nagai, M; Terui, Y; Nakamura, M; Yamada, H			Modulation of E2F activity is linked to interferon-induced growth suppression of hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR E2F; INTERLEUKIN-6 SUPPRESS; TRANS-ACTIVATION; KINASE-ACTIVITY; BINDING-SITES; CYCLE CONTROL; PROTEIN; EXPRESSION; PRODUCT	E2F is a heterodimeric transcription factor that controls transcription of several growth-regulatory genes including cdc2, To investigate the mechanism of interferon-alpha (IFN-alpha)-mediated growth suppression of hematopoietic cells, we examined the effect of IFN-alpha on the expression and function of E2F using IFN-sensitive Daudi cells, Down-regulation of E2F-1, a subunit of E2F, was observed after 8 h of culture with IFN-alpha; expression of E2F-4, another subunit of E2F, and DP-1, a heterodimeric partner of E2F, was unaffected, Gel shift assays revealed that the DNA binding activity of free E2F, which is composed of E2F-1 and E2F-4, was inhibited by IFN-alpha. In contrast, IFN-alpha did not affect the DNA binding ability of E2F-1 and E2F-4 in a complex with retinoblastoma (RE) susceptibility gene family proteins including pRB, p107, and p130, IFN-alpha could induce dephosphorylation of pRB, thereby turning active E2F-pRB complexes into transcriptional repressors, Transient chloramphenicol acetyltransferase assays revealed that the activity of the E2F-dependent cdc2 promoter was suppressed by IFN-alpha. These results suggest that the antiproliferative action of IFN-alpha is mediated through the modulation of E2F activity in two different ways: down-regulation of transcriptionally active free E2F and conversion of E2F-pRB complexes into transcriptional repressors.	JICHI MED SCH, INST HEMATOL, DIV HEMOPOIESIS, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; HITACHI KOKI CO LTD, KATSUTA RES LAB, HITACHINAKA, IBARAKI 312, JAPAN; JIKEI UNIV, SCH MED, DEPT INTERNAL MED AOTO, TOKYO 105, JAPAN; JIKEI UNIV, SCH MED, DEPT MOL GENET, INST DNA MED, TOKYO 105, JAPAN	Jichi Medical University; Hitachi Limited; Jikei University; Jikei University			Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				BEIJERBERGEN RL, 1992, GENE DEV, V8, P2680; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Guy CT, 1996, MOL CELL BIOL, V16, P685; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HU RQ, 1993, J BIOL CHEM, V268, P12591; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KNIGHT E, 1976, NATURE, V262, P302, DOI 10.1038/262302a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MANDELLI F, 1994, BAILLIERE CLIN HAEM, V7, P91, DOI 10.1016/S0950-3536(05)80008-3; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; YAMADA H, 1991, BLOOD, V78, P1988; YAMADA H, 1983, JPN J CANCER RES, V74, P299; YMADA H, 1994, MOL CELL BIOCHEM, V136, P117; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	60	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12406	12414		10.1074/jbc.272.19.12406	http://dx.doi.org/10.1074/jbc.272.19.12406			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139687	hybrid			2022-12-25	WOS:A1997WY82900024
J	Sakai, I; Kraft, AS				Sakai, I; Kraft, AS			The kinase domain of JakS mediates induction of Bcl-2 and delays cell death in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; COMMON BETA-SUBUNIT; SIGNAL-TRANSDUCTION; FACTOR-RECEPTOR; GM-CSF; C-MYC; ERYTHROPOIETIN RECEPTOR; EXPRESSION CLONING; CYTOPLASMIC DOMAIN	Granulocyte-macrophage colony-stimulating factor (GM CSF), interleukin (IL)-3, and IL-5 stimulate DNA synthesis and proliferation and inhibit apoptosis in hematopoietic cells. Multiple signal pathways are activated by binding of these ligands to their receptors, which share a common beta subunit. Janus protein kinase 2 (Jak2) binds to the membrane proximal domain of the beta chain and is phosphorylated on receptor ligation. To explore the role of Jak2 in the regulation of specific signal transduction pathways, we constructed fusion proteins with a CD16 external domain, a CD7 transmembrane region, and a Jak2 cytoplasmic domain, This cytoplasmic domain consisted either of wild type Jak2 (CD16/Jak2-W) or Jak2 mutations with deletions of (a) the amino terminus (CD16/Jak2-N), (b) kinase-like domain (CD16/Jak2-B), (c) kinase domain (CD16/Jak2-C), or (d) amino-terminal and kinase-like domains, leaving the kinase domain (CD16/Jak-K) intact. In contrast to the CD16/Jak2-W fusion protein, which requires cross-linking for activation, CD16/Jak2-N, CD16/Jak2-B, and CD16/Jak2-K were constitutively phosphorylated, and they stimulated She phosphorylation and increased binding of STAT to DNA in Ba/F3 cells. Cell lines derived from IL-3-dependent Ba/F3 cells stably transfected with CD16/Jak2-W, CD16/Jak2-N, or CD16/Jak2-B mammalian expression vectors died at a rate similar to that of the parental cells on IL-3 deprivation. In contrast, CD16/Jak2-K cell lines exhibited increased expression of bcl-2 and pim-1 mRNA and maintained their viability when compared with control cell lines. Thus, activation of tyrosine phosphorylation by creating a CD16/Jak2-K fusion is sufficient to activate pathways that prevent cell death.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV MED ONCOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIDDK NIH HHS [DK44741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DOMEN J, 1993, BLOOD, V82, P1445; DURONIO V, 1992, J BIOL CHEM, V267, P21856; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GUSHCIN D, 1995, EMBO J, V14, P1421; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; KANAKURA Y, 1990, BLOOD, V76, P706; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LILLY M, 1992, ONCOGENE, V7, P727; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RONCO LV, 1994, J BIOL CHEM, V269, P277; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SAKAMAKI K, 1994, FEBS LETT, V353, P133, DOI 10.1016/0014-5793(94)01024-2; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHUAI K, 1993, SCIENCE, V261, P1808; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; ZHUANG HM, 1995, J BIOL CHEM, V270, P14500, DOI 10.1074/jbc.270.24.14500; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	49	103	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12350	12358		10.1074/jbc.272.19.12350	http://dx.doi.org/10.1074/jbc.272.19.12350			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139679	hybrid			2022-12-25	WOS:A1997WY82900016
J	Schroeder, C; Beug, H; MullerEsterl, W				Schroeder, C; Beug, H; MullerEsterl, W			Cloning and functional characterization of the ornithokinin receptor - Recognition of the major kinin receptor antagonist, HOE140, as a full agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTING BRADYKININ-ANTAGONIST; G-PROTEIN; EXPRESSION CLONING; RAT; HOE-140; CELLS; IDENTIFICATION; POTENT; FAMILY; BRAIN	Kinins are proinflammatory peptides that dilate vessels, increase vascular permeability, contract smooth muscles, and provoke pain, The known mammalian kinin receptors are classified as two subtypes, i.e. the B1 receptor triggered by [des-Arg(9)]bradykinin and inhibited by [des-Arg(9),Leu(8)]bradykinin, and the B2 receptor stimulated by bradykinin and antagonized by HOE140. Here we report the cloning of a non-mammalian kinin receptor gene amplified from genomic chicken DNA, The protein predicted from the open reading frame shows 31 and 49% sequence identity to the human B1 and B2 receptors, respectively, suggesting that it represents a G protein-coupled receptor of the kinin receptor family, The recombinantly expressed chicken receptor had IC50 values of 4.7 nM for the authentic ligand, ornithokinin ([Thr(6),Leu(8)]bradykinin), 3.8 nM for HOE140, and greater than or equal to 10 mu M for bradykinin, [des-Arg(9)]bradykinin, and [des-Arg(9),Leu(8)]bradykinin. Ornithokinin and HOE140 at nanomolar concentrations stimulated intracellular inositol phosphate accumulation and induced a significant transient rise in intracelluar free Ca2+, whereas bradykinin was ineffective even at 100 nM. Hence the principal B2 receptor antagonist HOE140 is a potent agonist of the chicken kinin receptor, This unique pharmacological profile classifies the ornithokinin receptor as a novel subtype among kinin receptors and will facilitate further molecular studies on ligand binding and receptor activation.	INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Schroeder, C (corresponding author), UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,DUESBERGWEG 6,D-55099 MAINZ,GERMANY.							Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; ALLA SA, 1993, J BIOL CHEM, V268, P17277; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; BERRIDGE MJ, 1996, J BIOL CHEM, V271, P20811; BEUG H, 1995, ONCOGENE TECHNIQUES, P41; BLASZCZAK W, 1994, NEURON, V13, P1215; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; ENNES HS, 1992, AM J PHYSIOL, V263, pG365, DOI 10.1152/ajpgi.1992.263.3.G365; FELETOU M, 1994, BRIT J PHARMACOL, V112, P683, DOI 10.1111/j.1476-5381.1994.tb13130.x; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; HERMSDORF T, 1991, BIOMED BIOCHIM ACTA, V50, P1087; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; KIMURA M, 1987, EUR J BIOCHEM, V168, P493, DOI 10.1111/j.1432-1033.1987.tb13444.x; KISHIMURA H, 1976, CHEM PHARM BULL, V24, P2896, DOI 10.1248/cpb.24.2896; LIEBMANN C, 1990, BIOCHEM BIOPH RES CO, V167, P910, DOI 10.1016/0006-291X(90)90610-Y; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4412, DOI 10.1073/pnas.91.10.4412; PERKINS MN, 1993, PAIN, V53, P191, DOI 10.1016/0304-3959(93)90080-9; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1980, PHARMACOL REV, V32, P1; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMASSMANN A, 1994, GUT, V35, P270, DOI 10.1136/gut.35.2.270; SCHRODER E, 1964, EXPERIENTIA, V20, P529, DOI 10.1007/BF02150278; STERANKA LR, 1988, P NATL ACAD SCI USA, V85, P3245, DOI 10.1073/pnas.85.9.3245; TESFAMARIAM B, 1994, BRIT J PHARMACOL, V112, P55, DOI 10.1111/j.1476-5381.1994.tb13028.x; WATANABE M, 1976, ANIMAL PLANT MICROBI, V2, P105; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WERLE E, 1967, H-S Z PHYSIOL CHEM, V348, P352; WIRTH K, 1991, BRIT J PHARMACOL, V102, P774, DOI 10.1111/j.1476-5381.1991.tb12249.x	36	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12475	12481		10.1074/jbc.272.19.12475	http://dx.doi.org/10.1074/jbc.272.19.12475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139696	hybrid			2022-12-25	WOS:A1997WY82900033
J	Bjorkoy, G; Perander, M; Overvatn, A; Johansen, T				Bjorkoy, G; Perander, M; Overvatn, A; Johansen, T			Reversion of Ras- and phosphatidylcholine-hydrolyzing phospholipase C-mediated transformation of NIH 3T3 cells by a dominant interfering mutant of protein kinase C lambda is accompanied by the loss of constitutive nuclear mitogen-activated protein kinase/extracellular signal-regulated kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; MAP KINASE; IN-VITRO; RECEPTOR AUTOPHOSPHORYLATION; GROWTH-FACTORS; DNA-SYNTHESIS; FIBROBLASTS; PATHWAYS; ZETA; TRANSDUCTION	The transformed phenotype of v-Ras- or Bacillus cereus phosphatidylcholine-hydrolyzing phospholipase C (PC-PLC)-expressing NIH 3T3 cells is reverted by expressing a kinase defective mutant of protein kinase C lambda (lambda PKC). We report here that extracellular signal-regulated kinase (ERK)-1 and -2 are constitutively activated in v-Ras- and PC-PLC-transformed cells in the absence of added growth factors, Interestingly, the activated ERKs were exclusively localized to the cell nucleus, Consistently, the transactivating potential of the C-terminal domain of Elk-1, which is activated upon ERK-mediated phosphorylation, was strongly induced in serum-starved cells expressing v-Ras or PC-PLC, Reversion of v-Ras- or PC-PLC-induced transformation by expression of dominant negative lambda PKC abolished the nuclear ERK activation suggesting lambda PKC as a novel, direct or indirect, activator of mitogen-activated protein kinase/ERK kinase in response to activated Pas or elevated levels of phosphatidylcholine derived diacylglycerol, Transient transfection experiments confirmed that lambda PKC acts downstream of Pas but upstream of mitogen-activated protein kinase/ERK kinase. We found both the v-Rasand PC-PLC-transformed cells to be insensitive to stimulation with platelet-derived growth factor (PDGF), No detectable receptor level, autophosphorylation, or superinduction of DNA synthesis could be observed in response to treatment with PDGF, Reversion of the transformed cell lines by expression of dominant negative lambda PKC restored the receptor level and the ability to respond to PDGF in terms of receptor autophosphorylation, ERK activation, and induction of DNA synthesis.	UNIV TROMSO,INST MED BIOL,DEPT BIOCHEM,N-9037 TROMSO,NORWAY	UiT The Arctic University of Tromso			Johansen, Terje/N-2971-2015	Johansen, Terje/0000-0003-1451-9578; Perander, Maria/0000-0002-1177-2407				AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHEN MZ, 1995, MOL CELL BIOL, V15, P4727; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DIAZMECO MT, 1992, MOL CELL BIOL, V12, P302, DOI 10.1128/MCB.12.1.302; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUPTAS, 1996, EMBO J, V15, P2760; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JOHANSEN T, 1994, MOL CELL BIOL, V14, P646, DOI 10.1128/MCB.14.1.646; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; LACAL JC, 1987, NATURE, V330, P417; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marini NJ, 1996, EMBO J, V15, P3040, DOI 10.1002/j.1460-2075.1996.tb00667.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Sjottem E, 1996, J VIROL, V70, P188; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TOMASKA L, 1993, BIOCHEM J, V293, P215, DOI 10.1042/bj2930215; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WYKE AW, 1992, CELL SIGNAL, V4, P267, DOI 10.1016/0898-6568(92)90066-H; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YAO B, 1995, SCIENCE, V267, P2003; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	76	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11557	11565						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111071				2022-12-25	WOS:A1997WW00900087
J	Craparo, A; Freund, R; Gustafson, TA				Craparo, A; Freund, R; Gustafson, TA			14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL TYROSINES; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; NPEY MOTIF; 14-3-3-PROTEINS; CELLS; PHOSPHORYLATION; ACTIVATION; DOMAINS; SHC	The 14-3-3 proteins have been implicated as potential regulators of diverse signaling pathways, Here, using two-hybrid assays and in vitro assays of protein interaction, we show that the epsilon isoform of 14-3-3 interacts with the insulin-like growth factor I receptor (IGFIR) and with insulin receptor substrate I (IRS-1), but not with the insulin receptor (IR). Coprecipitation studies demonstrated an IGFI-dependent in vitro interaction between 14-3-3-glutathione S-transferase proteins and the IGFIR. In similar studies no interaction of 14-3-3 with the IR was observed. We present evidence to suggest that 14-3-3 interacts with phosphoserine residues within the COOH terminus of the IGFIR. Specifically, peptide competition studies combined with mutational analysis suggested that the 14-3-3 interaction was dependent upon phosphorylation of IGFIR serine residues 1272 and/or 1283, a region which has been implicated in IGFIR-dependent transformation. Phosphorylation of these serines appears to be dependent upon prior IGFIR activation since no interaction of 14-3-3 was observed with a kinase-inactive IGFIR in the two-hybrid assay nor was any in vitro interaction with unstimulated IGFIR derived from mammalian cells. We show that the interaction of 14-3-3 with IRS-1 also appears to be phosphoserine-independent, Interestingly, 14-3-3 appears to interact with IRS-1 before and after hormonal stimulation, In summary, our data suggest that 14-3-3 interacts with phosphoserine residues within the COOH terminus of the IGFIR and within the central domain of IRS-1. The potential functional roles which 14-3-3 may play in IGFIR and IRS-l-mediated signaling remain to be elucidated.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NIDDK NIH HHS [DK50602, DK44093] Funding Source: Medline; NIGMS NIH HHS [GM08181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050602, R29DK044093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; AUSUBEL FM, 1987, CURRENT PROTOCLS MOL; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hongo A, 1996, ONCOGENE, V12, P1231; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JACOBS S, 1986, J BIOL CHEM, V261, P934; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Li SW, 1996, J BIOL CHEM, V271, P12254, DOI 10.1074/jbc.271.21.12254; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139; Meller N, 1996, MOL CELL BIOL, V16, P5782; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MIURA M, 1995, CANCER RES, V55, P663; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PANG L, 1994, J BIOL CHEM, V269, P10604; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; PILLAY TS, 1991, FEBS LETT, V288, P206, DOI 10.1016/0014-5793(91)81035-7; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUBIN R, 1995, LAB INVEST, V73, P311; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TARTARE S, 1994, J BIOL CHEM, V269, P11449; Tauer TJ, 1996, J BIOL CHEM, V271, P331, DOI 10.1074/jbc.271.1.331; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	65	176	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11663	11669						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111084				2022-12-25	WOS:A1997WW00900100
J	Pirok, EW; Li, H; Mensch, JR; Henry, J; Schwartz, NB				Pirok, EW; Li, H; Mensch, JR; Henry, J; Schwartz, NB			Structural and functional analysis of the chick chondroitin sulfate proteoglycan (aggrecan) promoter and enhancer region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; CORE PROTEIN; TRANSCRIPTIONAL SILENCER; CARTILAGE PROTEOGLYCAN; NEGATIVE CONTROL; BINDING-SITE; GENE; SEQUENCE; IDENTIFICATION; EXPRESSION	Aggrecan is a large chondroitin sulfate proteoglycan, the expression of which is both tissue-specific and developmentally regulated. Here we report the cloning and sequencing of the 1.8-kilobase genomic 5' flanking sequence of the chick aggrecan gene and provide a functional and structural characterization of its promoter and enhancer region. Sequence analysis reveals potential Sp1, AP2, and NF-I related sites, as well as several putative transcription factor binding sites, including the cartilage-associated silencers CIIS1 and CIIS2. A number of these transcription factor binding motifs are embedded in a sequence flanked by prominent inverted repeats. Although lacking a classic TATA box, there are two instances in the 1.8-kb genomic fragment of TATA-like TCTAA sequences, as have been defined previously in other promoter regions. Primer extension and S1 protection analyses reveal three major transcription start sites, also located between the inverted repeats. Transient transfections of chick sternal chondrocytes and fibroblasts with reporter plasmids bearing progressively reduced portions of the aggrecan promoter region allowed mapping of chondrocyte-specific transcription enhancer and silencer elements that are consistent with the sequence analysis. These findings suggest the importance of this regulatory region in the tissue-specific expression of the chick aggrecan gene.	UNIV CHICAGO, DEPT PEDIAT, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, COMM DEV BIOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago			Mensch, James/P-9291-2017	Mensch, James/0000-0001-5644-0580	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD009402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR019622, R01AR019622] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07237] Funding Source: Medline; NIAMS NIH HHS [AR-19622] Funding Source: Medline; NICHD NIH HHS [HD-09402] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS ALP, 1992, BIOCH NUCL ACIDS; AVRAHAM S, 1992, J BIOL CHEM, V267, P610; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BOGUSKI MS, 1992, SEQUENCE ANAL PRIMER; BOHM SK, 1995, BIOCHEM J, V311, P835; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CAHN RO, 1967, METHODS DEV BIOL; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; CAMPBELL SC, 1990, BIOCHEMISTRY-US, V29, P907, DOI 10.1021/bi00456a009; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DEAK F, 1991, NUCLEIC ACIDS RES, V19, P4983, DOI 10.1093/nar/19.18.4983; DENNIS JE, 1990, J BIOL CHEM, V265, P12098; DOEGE KJ, 1994, J BIOL CHEM, V269, P29232; DOMOWICZ M, 1995, DEV BIOL, V171, P655, DOI 10.1006/dbio.1995.1312; DUDHIA J, 1994, BIOCHEM J, V303, P329, DOI 10.1042/bj3030329; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; *GEN COMP GROUP, PROGR MAN WISC PACK; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; HACHE RJG, 1988, NUCLEIC ACIDS RES, V16, P97, DOI 10.1093/nar/16.1.97; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; KRUEGER RC, 1990, J BIOL CHEM, V265, P12088; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LEE B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P173; LEVITT D, 1972, P NATL ACAD SCI USA, V69, P1253, DOI 10.1073/pnas.69.5.1253; Li H, 1995, J MOL EVOL, V41, P878; Li H, 1996, MOL BRAIN RES, V36, P309, DOI 10.1016/0169-328X(95)00269-X; LI H, 1993, J BIOL CHEM, V268, P23504; Long FX, 1995, J BIOL CHEM, V270, P31310, DOI 10.1074/jbc.270.52.31310; MYERS JC, 1990, EXTRACELLULAR MATRIX, P57; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SAITTA B, 1994, EUR J BIOCHEM, V223, P675, DOI 10.1111/j.1432-1033.1994.tb19040.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SCHWARTZ NB, 1995, TRENDS GLYCOSCI GLYC, V7, P429, DOI 10.4052/tigg.7.429; SCHWARTZ NB, 1993, PROG CLIN BIOL RES, V383, P505; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; Sharp P A, 1980, Methods Enzymol, V65, P750; STUMPH WE, 1984, P NATL ACAD SCI-BIOL, V81, P6667, DOI 10.1073/pnas.81.21.6667; SZABO P, 1995, J BIOL CHEM, V270, P10212, DOI 10.1074/jbc.270.17.10212; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535; VOGT P, 1990, HUM GENET, V84, P301; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WICK M, 1995, BIOCHEM J, V311, P549, DOI 10.1042/bj3110549	52	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11566	11574						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111072	hybrid			2022-12-25	WOS:A1997WW00900088
J	Bai, WL; Rowan, BG; Allgood, VE; OMalley, BW; Weigel, NL				Bai, WL; Rowan, BG; Allgood, VE; OMalley, BW; Weigel, NL			Differential phosphorylation of chicken progesterone receptor in hormone-dependent and ligand-independent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; PROTEIN KINASE-A; GROWTH-FACTOR-I; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; ANDROGEN RECEPTOR; ADENOVIRUS PARTICLES; SIGNALING PATHWAYS; NUCLEAR RECEPTORS; AGONIST ACTIVITY	Many steroid receptors, including chicken progesterone receptor, have been shown to be activated in the absence of their cognate ligands by modulators of kinases and phosphatases. To investigate the molecular mechanism of ligand-independent activation, chicken progesterone receptor mutants in which either one or all four of the previously identified phosphorylation sites have been changed to nonphosphorylatable alanine were analyzed for their ability to be activated by progesterone, 8-bromoadenosine 3':5'-cyclic monophosphate, or a dopamine agonist, SKF82958. Our current study shows that the receptor is differently phosphorylated in ligand-dependent and ligand-independent activation. The transcriptional activity of the receptor in response to 8-bromoadenosine 3':5'-cyclic monophosphate is affected by mutation of either Ser(211) or Ser(260). In addition, our data demonstrated that none of the four sites is absolutely required for the activation of the receptor by either 8-bromoadenosine 3':5'-cyclic monophosphate or the dopamine agonist. Treatment with 8-bromoadenosine 3':5'-cyclic monophosphate did not increase the overall level of receptor phosphorylation or cause phosphorylation of the receptor at alternate sites. These data raise the possibility that ligand-independent activation of the chicken progesterone receptor may be mediated through changes in the phosphorylation of coregulators or other protein factors interacting with the receptors.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NICHD NIH HHS [HD22061, HD07857, HD07495] Funding Source: Medline; NIDDK NIH HHS [F32 DK009151] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007857] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022061, P30HD007495, R37HD007857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009151] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; Bai WL, 1996, J BIOL CHEM, V271, P12801, DOI 10.1074/jbc.271.22.12801; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRIAN S, 1988, GENE, V67, P271; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CONNEELY OM, 1986, SCIENCE, V233, P767, DOI 10.1126/science.2426779; COTTEN M, 1994, VIROLOGY, V205, P254, DOI 10.1006/viro.1994.1641; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; CULIG Z, 1994, CANCER RES, V54, P5474; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JONES KE, 1994, ENDOCRINOLOGY, V134, P543, DOI 10.1210/en.134.2.543; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANSRA V, 1995, EUR J PHARM-MOLEC PH, V289, P391, DOI 10.1016/0922-4106(95)90119-1; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MENDEL DB, 1987, J BIOL CHEM, V262, P5641; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NIZNIK HB, 1992, J PSYCHIATR NEUROSCI, V17, P158; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; ONATE SA, 1995, SCIENCE, V270, P1354; Pedarzani P, 1995, J NEUROPHYSIOL, V74, P2749, DOI 10.1152/jn.1995.74.6.2749; POLETTI A, 1993, BIOCHEMISTRY-US, V32, P9563, DOI 10.1021/bi00088a007; POLETTI A, 1993, MOL ENDOCRINOL, V7, P241, DOI 10.1210/me.7.2.241; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P8, DOI 10.1210/me.6.1.8; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577	63	51	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10457	10463						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099688				2022-12-25	WOS:A1997WV26200022
J	Barleon, B; Totzke, F; Herzog, C; Blanke, S; Kremmer, E; Siemeister, G; Marme, D; MartinyBaron, G				Barleon, B; Totzke, F; Herzog, C; Blanke, S; Kremmer, E; Siemeister, G; Marme, D; MartinyBaron, G			Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL FACTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; ANGIOGENESIS; PLACENTA; EXPRESSION; SUPERFAMILY; CANCER; KDR	The vascular endothelial growth factor (VEGF) receptor FLT-1 has been shown to be involved in vasculogenesis and angiogenesis. The receptor is characterized by seven Ig-like loops within the extracellular domain, Upon VEGF binding FLT-1 becomes phosphorylated, which has been thought to be preceded by receptor dimerization, To further investigate high affinity binding of VEGF to FLT-1 and ligand-induced receptor dimerization, we expressed in Sf9 cells the entire extracellular domain comprising all seven Ig-like loops: sFLT-1(7) and several truncated mutants consisting of loop one, one and two, one to three, one to four, and one to five, The corresponding proteins, named sFLT-1(1), (2), (3), (4), and (5) were purified, Only mutants sFLT-1(3) to (7) were able to bind I-125-VEGF With high affinity, No binding of VEGF was observed with sFLT-1(1) and sFLT-1(2), indicating that the first three Ig-like loops are involved in high affinity binding of VEGF, The binding of VEGF to sFLT-1(3) could be competed with placenta growth factor (PlGF), a VEGF-related ligand, suggesting that high affinity binding of VEGF and PlGF is mediated by the same or closely related contact sites on sFLT-1. Deglycosylation of the sFLT-1(3), (4), (5), and (7) did not abolish VEGF binding, Furthermore, unglycosylated sFLT-1(3), expressed in Escherichia coli, was able to bind VEGF with similar affinity as sFLT-1(3) or sFLT-1(7), both expressed in Sf9 cells, This indicates that receptor glycosylation is not essential for high affinity binding, Dimerization of the extracellular domains of FLT-1 upon addition of VEGF was detected with all mutants containing the Ig-like loop four, Although sFLT-1(3) was able to bind VEGF, dimerization of this mutant was inefficient, indicating that sites on Ig-Like loop four are essential to stabilize receptor dimers.	TUMOR BIOL CTR, INST MOL MED, D-79106 FREIBURG, GERMANY; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GMBH, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health				, Gerhard/0000-0002-4712-0531				BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERREN B, 1993, J BIOL CHEM, V268, P15088; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KREMMER E, 1995, VIROLOGY, V208, P336, DOI 10.1006/viro.1995.1157; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; PARK JE, 1994, J BIOL CHEM, V269, P25646; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHIBUYA M, 1990, ONCOGENE, V5, P519; Siemeister G, 1996, BIOCHEM BIOPH RES CO, V222, P249, DOI 10.1006/bbrc.1996.0730; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	32	177	197	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10382	10388						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099677				2022-12-25	WOS:A1997WV26200011
J	Breen, GAM; Jordan, EM				Breen, GAM; Jordan, EM			Regulation of the nuclear gene that encodes the alpha-subunit of the mitochondrial F0F1-ATP synthase complex - Activation by upstream stimulatory factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; LOOP-HELIX PROTEIN; DNA-BINDING; MAMMALIAN-CELLS; BETA-SUBUNIT; PROMOTER; EXPRESSION; DOMAIN; FORMS; MYC	We have previously identified several positive cis-acting regulatory regions in the promoters of the bovine and human nuclear-encoded mitochondrial F0F1-ATP synthase oc subunit genes (ATPA). One of these cis-acting regions contains the sequence 5'-CACGTG-3' (an E-box), to which a number of transcription factors containing a basic helix-loop helix motif can bind, This E-box element is required for maximum activity of the ATPA promoter in HeLa cells, The present study identifies the human transcription factor, upstream stimulatory factor 2 (USF2), as a nuclear factor that binds to the ATPA E-box and demonstrates that USF2 plays a critical role in the activation of the ATPA gene in vivo. Evidence includes the following, Antiserum directed against USF2 recognized factors present in HeLa nuclear extracts that interact with the ATPA promoter in mobility shift assays. Wild-type USF2 proteins synthesized from expression vectors trans-activated the ATPA promoter through the E-box, whereas truncated USF2 proteins devoid of the amino-terminal activation domains did not, Importantly, expression of a dominant-negative mutant of USF2 lacking the basic DNA binding domain but able to dimerize with endogenous USF proteins significantly reduced the level of activation of the ATPA promoter caused by ectopically coexpressed USF2, demonstrating the importance of endogenous USF2 in activation of the ATPA gene.			Breen, GAM (corresponding author), UNIV TEXAS,DEPT MOL & CELL BIOL,FO 31,POB 830688,RICHARDSON,TX 75088, USA.							ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AYER DE, 1993, CELL, V72, P221; BASU A, 1993, J BIOL CHEM, V268, P4188; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Breen GAM, 1996, GENE EXPRESSION, V5, P181; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P9; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIN Q, 1994, J BIOL CHEM, V269, P23894; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; Moore DD, 1995, GLOB MOB SURV; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; PIERCE DJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P265, DOI 10.1016/0167-4781(92)90160-2; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Seelan RS, 1996, J BIOL CHEM, V271, P2112, DOI 10.1074/jbc.271.4.2112; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; VANDERZEE CA, 1994, J BIOL CHEM, V269, P6972; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	40	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10538	10542						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099698				2022-12-25	WOS:A1997WV26200032
J	Lamkin, TD; Walk, SF; Liu, L; Damen, JE; Krystal, G; Ravichandran, KS				Lamkin, TD; Walk, SF; Liu, L; Damen, JE; Krystal, G; Ravichandran, KS			Shc interaction with Src homology 2 domain containing inositol phosphatase (SHIP) in vivo requires the Shc-phosphotyrosine binding domain and two specific phosphotyrosines on SHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEIN; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; HEMATOPOIETIC-CELLS; ADAPTER PROTEIN; PTB DOMAIN; GRB2; ASSOCIATION; ACTIVATION	The adapter protein She has been implicated in mitogenic signaling via growth factor receptors, cytokine receptors, and antigen receptors on lymphocytes. Besides the well characterized interaction of She with molecules involved in Pas activation, She also associates with a 145-kDa tyrosine-phosphorylated protein upon triggering via antigen receptors and many cytokine receptors. This 145-kDa protein has been recently identified as an SH2 domain containing 5'-inositol phosphatase (SHIP) and has been implicated in the regulation of growth and differentiation in hematopoietic cells. In this report, we have addressed the molecular details of the interaction between She and SHIP in vivo. During T cell receptor signaling, tyrosine phosphorylation of SHIP and its association with She occurred only upon activation. We demonstrate that the phosphotyrosine binding domain of She is necessary and sufficient for its association with tyrosine-phosphorylated SHIP. Through site-directed mutagenesis, we have identified two tyrosines on SHIP, Tyr-917, and Tyr-1020, as the principal contact sites for the Shc-phosphotyrosine binding domain. Our data also suggest a role for the tyrosine kinase Lck in phosphorylation of SHIP. We also show that the SH2 domain of SHIP is dispensable for the She-SHIP interaction in vivo. These data have implications for the localization of the Shc-SHIP complex and regulation of SHIP function during T cell receptor signaling.	UNIV VIRGINIA,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA	University of Virginia; University of Virginia; British Columbia Cancer Agency				Krystal, Gerald/0000-0002-1961-6281	NIAID NIH HHS [AI07496-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007496] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAMBIER JC, 1995, IMMUNOL LETT, V44, P77, DOI 10.1016/0165-2478(94)00196-X; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Durstin M, 1996, J IMMUNOL, V157, P534; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; ROSS TS, 1991, J BIOL CHEM, V266, P20283; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; ZHOU M, 1995, J BIOL CHEM, V271, P31119; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHUNG X, 1996, P NATL ACAD SCI USA, V92, P5853	51	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10396	10401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099679				2022-12-25	WOS:A1997WV26200013
J	PerezEstevez, A; DiazJullien, C; Covelo, G; Salgueiro, MT; Freire, M				PerezEstevez, A; DiazJullien, C; Covelo, G; Salgueiro, MT; Freire, M			A 180-kDa protein kinase seems to be responsible for the phosphorylation of prothymosin alpha observed in proliferating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; CASEIN KINASE-2; RAT THYMUS; GENE; TISSUES; SITE; THYMOSIN-ALPHA-1; PARATHYMOSIN; EXPRESSION; NUCLEI	Prothymosin alpha (ProT alpha) is an acidic protein involved in cell proliferation, Its phosphorylation status is correlated with proliferative activity. Here we report the isolation and characterization of a ProT alpha-phosphorylating kinase (ProT alpha K) from mouse splenocytes that seems to be responsible for the in vivo phosphorylation of ProT alpha and that differs from other protein kinases reported to date, This enzyme, mainly located in the cytosol, has an molecular mass of 180 kDa and appears to be made up of two proteins of 64 and 60 kDa. Its activity was markedly enhanced by mitogenic activation of cells. The ProT alpha residues phosphorylated by the enzyme in vitro are a Thr at position 7 and another Thr at positions 12 or 13, both located within casein kinase 2 (CK-2) consensus motifs; these are the same residues as are phosphorylated in vivo. The new enzyme shows a number of clear structural and catalytic differences from CK-2, It phosphorylates histones H2B and H3, although with weaker activity than ProT alpha. An enzyme with the same characteristics was also found in other murine tissues and cell lines.	UNIV SANTIAGO, FAC BIOL, DEPT BIOQUIM & BIOL MOL, SANTIAGO DE COMPOSTELA 15706, SPAIN	Universidade de Santiago de Compostela			Diaz-Jullien, Cristina/L-4575-2018	Diaz-Jullien, Cristina/0000-0002-4307-8129				BARCIA MG, 1993, J BIOL CHEM, V268, P4704; BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; CLINTON M, 1989, ARCH BIOCHEM BIOPHYS, V269, P256, DOI 10.1016/0003-9861(89)90107-0; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; ECONOMOU M, 1988, FEBS LETT, V233, P342, DOI 10.1016/0014-5793(88)80456-3; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FRANCO FJ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P43, DOI 10.1016/0167-4838(92)90422-A; FRILLINGOS S, 1991, MOL CELL BIOCHEM, V108, P3853; GAST K, 1995, BIOCHEMISTRY-US, V34, P13211, DOI 10.1021/bi00040a037; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; HARITOS AA, 1989, FEBS LETT, V244, P287, DOI 10.1016/0014-5793(89)80547-2; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; INOUE A, 1984, BIOCHEM BIOPH RES CO, V123, P398, DOI 10.1016/0006-291X(84)90427-3; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAELANDSMO GM, 1989, EUR J BIOCHEM, V184, P529, DOI 10.1111/j.1432-1033.1989.tb15046.x; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; MOL PC, 1995, MOL CELL BIOL, V15, P6949; MORI M, 1993, ONCOGENE, V8, P2821; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SMITH MR, 1995, LEUKEMIA LYMPHOMA, V18, P209, DOI 10.3109/10428199509059609; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; WALTON GM, 1985, J BIOL CHEM, V260, P4745; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6	43	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10506	10513						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099694				2022-12-25	WOS:A1997WV26200028
J	Butters, CA; Tobacman, JB; Tobacman, LS				Butters, CA; Tobacman, JB; Tobacman, LS			Cooperative effect of calcium binding to adjacent troponin molecules on the thin filament-myosin subfragment 1 Mg ATPase rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; RABBIT PSOAS FIBERS; F-ACTIN; TROPOMYOSIN COMPLEX; DIRECTED MUTATION; REGULATORY SITES; FORCE GENERATION; CROSS-BRIDGES; CONTRACTION; KINETICS	The myosin subfragment 1 (S1) MgATPase rate was measured using thin filaments with known extents of Ca2+ binding controlled by varying the ratio of native cardiac troponin versus an inhibitory troponin with a mutation in the sole regulatory Ca2+ binding site of troponin C. Fractional MgATPase activation was less than the fraction of troponins that bound Ca2+, implying a cooperative effect of bound Ca2+ on cross-bridge cycling, Addition of phalloidin did not alter cooperative effects between bound Ca2+ molecules in the presence or absence of myosin S1. When the myosin S1 concentration was raised sufficiently to introduce cooperative myosin-myosin effects, lower Ca2+ concentrations were needed to activate the MgATPase rate. MgATPase activation remained less than Ca2+ binding, implying a true, not just an apparent, increase in Ca2+ affinity. MgATPase activation by Ca2+ was more cooperative than could be explained by cooperativeness of overall Ca2+ binding, the discrepancy between Ca2+ binding and MgATPase activation, or interactions between myosins, The results suggest the thin filament-myosin S1 MgATPase cycle requires calcium binding to adjacent troponin molecules and that this binding is cooperatively promoted by a single cycling cross-bridge, This mechanism is a potential explanation for Ca2+-mediated regulation of crossbridge kinetics in muscle fibers.	UNIV IOWA, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa				Tobacman, Jeremy/0000-0003-2905-577X				ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; Araujo A, 1996, BIOPHYS J, V70, P2316, DOI 10.1016/S0006-3495(96)79797-7; BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BREMEL RD, 1973, COLD SPRING HARB SYM, V37, P267, DOI 10.1101/SQB.1973.037.01.037; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; DANTZIG JA, 1988, P NATL ACAD SCI USA, V85, P6716, DOI 10.1073/pnas.85.18.6716; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; DOTSON DG, 1993, J BIOL CHEM, V268, P24067; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; FORTUNE NS, 1994, J PHYSIOL-LONDON, V474, P283, DOI 10.1113/jphysiol.1994.sp020021; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; GORDON AM, 1993, ADV EXP MED BIOL, V332, P183; GREENE L, 1982, J BIOL CHEM, V257, P3993; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; GUTH K, 1987, J BIOL CHEM, V262, P13627; Hill T. L., 1985, COOPERATIVITY THEORY; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HILL TL, 1993, P NATL ACAD SCI USA, V80, P60; HOFMANN PA, 1987, AM J PHYSIOL, V253, pC541, DOI 10.1152/ajpcell.1987.253.4.C541; HOLMES KC, 1995, BIOPHYS J, V68, pS2; Huynh Q, 1996, BIOPHYS J, V70, P1447, DOI 10.1016/S0006-3495(96)79704-7; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; JACKSON P, 1975, BIOCHEM J, V151, P85, DOI 10.1042/bj1510085; JULIAN FJ, 1971, J PHYSIOL-LONDON, V218, P117, DOI 10.1113/jphysiol.1971.sp009607; KAWAI M, 1981, BIOPHYS J, V35, P375, DOI 10.1016/S0006-3495(81)84796-0; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MARTYN DA, 1994, BIOPHYS J, V67, P1984, DOI 10.1016/S0006-3495(94)80681-2; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; METZGER JM, 1995, BIOPHYS J, V68, P1430, DOI 10.1016/S0006-3495(95)80316-4; Metzger JM, 1996, BIOPHYS J, V70, P409, DOI 10.1016/S0006-3495(96)79584-X; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; MURRAY JM, 1981, MOL CELL BIOCHEM, V35, P11, DOI 10.1007/BF02358183; MURRAY JM, 1982, BIOCHEMISTRY-US, V21, P906, DOI 10.1021/bi00534a015; MURRAY JM, 1975, CALCIUM TRANSPORT CO, P489; NABER N, 1993, PROTEINS, V17, P347, DOI 10.1002/prot.340170403; NEGELE JC, 1992, J BIOL CHEM, V267, P825; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; PAN BS, 1987, J BIOL CHEM, V262, P7839; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Regnier M, 1995, AM J PHYSIOL-CELL PH, V269, pC1532, DOI 10.1152/ajpcell.1995.269.6.C1532; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THAMES MD, 1974, J GEN PHYSIOL, V63, P509, DOI 10.1085/jgp.63.4.509; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WALKER JW, 1992, J BIOL CHEM, V267, P2459; WALSH TP, 1985, J MOL BIOL, V182, P265, DOI 10.1016/0022-2836(85)90344-4; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; Zhao Y, 1996, BIOPHYS J, V71, P2759, DOI 10.1016/S0006-3495(96)79469-9; ZOT HG, 1987, J MUSCLE RES CELL M, V8, P428, DOI 10.1007/BF01578432	70	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13196	13202		10.1074/jbc.272.20.13196	http://dx.doi.org/10.1074/jbc.272.20.13196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148936	hybrid			2022-12-25	WOS:A1997WZ38400049
J	Gallo, RL; Kim, KJ; Bernfield, M; Kozak, CA; Zanetti, M; Merluzzi, L; Gennaro, R				Gallo, RL; Kim, KJ; Bernfield, M; Kozak, CA; Zanetti, M; Merluzzi, L; Gennaro, R			Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBACTERIAL PEPTIDES; BOVINE NEUTROPHILS; CDNA SEQUENCE; BONE-MARROW; DEFENSINS; BACTENECINS; PROTEIN; FAMILY; PR-39; CELLS	Cathelicidins are the precursors of potent antimicrobial peptides that have been identified in several mammalian species, Prior work has suggested that members of this gene family can participate in host defense through their antimicrobial effects and activate mesenchymal cells during wound repair, To permit further study of these proteins a reverse transcriptase-polymerase chain reaction approach was used to identify potential mouse homologs, A full-length 562-base pair cDNA clone was obtained encoding an NH2-terminal prepro domain homologous to other cathelicidins and a unique COOH-terminal peptide, This gene, named Cramp for cathelin-related antimicrobial peptide, was mapped to chromosome 9 at a region of conserved synteny to which genes for cathelicidins have been mapped in pig and man. Northern blot analysis detected a 1-kilobase transcript that was expressed in adult bone marrow and during embryogenesis as early as E12, the earliest stage of blood development, Reverse transcriptase-polymerase chain reaction also detected CRAMP expression in adult testis, spleen, stomach, and intestine but not in brain, liver, heart, or skeletal muscle. To evaluate further the expression and function of CRAMP a peptide corresponding to the predicted COOH-terminal region was synthesized, CD spectral analysis showed that CRAMP will form an amphipathic alpha-helix similar to other antimicrobial peptides, Functional studies showed CRAMP to be a potent antibiotic against Gram-negative bacteria by inhibiting growth of a variety of bacterial strains (minimum inhibitory concentrations 0.5-8.0 mu M) and by permeabilizing the inner membrane of Escherichia coli directly at 1 mu M. Antiserum against CRAMP revealed abundant expression in myeloid precursors and neutrophils, Thus, CRAMP represents the first antibiotic peptide found in cells of myeloid lineage in the mouse, These data suggest that inflammatory cells in the mouse can use a nonoxidative mechanism for microbial killing and permit use of the mouse to study the role such peptides play in host defense and wound repair.	HARVARD UNIV, SCH MED, DEPT DERMATOL, BOSTON, MA 02115 USA; NIH, BETHESDA, MD 20892 USA; UNIV UDINE, DEPT SCI & TECNOL BIOMED, I-33100 UDINE, ITALY; NATL LAB CONSORZIO INTERUNIV BIOTECHNOL, I-34012 TRIESTE, ITALY	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; University of Udine	Gallo, RL (corresponding author), CHILDRENS HOSP, JOINT PROGRAM NEONATOL, 300 LONGWOOD AVE, ENDERS 9, BOSTON, MA 02115 USA.		Gallo, Richard L/A-8931-2009; Gennaro, Renato/AAJ-2511-2021	Gallo, Richard L/0000-0002-1401-7861; Gennaro, Renato/0000-0003-1331-3885	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044379, R01AR044379] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44379] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; BAGELLA L, 1995, FEBS LETT, V376, P225, DOI 10.1016/0014-5793(95)01285-3; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3446, DOI 10.1128/IAI.60.8.3446-3447.1992; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; IBARAKI K, 1995, MAMM GENOME, V6, P693, DOI 10.1007/BF00354289; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; Kozak CA, 1996, MAMM GENOME, V7, P787, DOI 10.1007/s003359900235; LARRICK JW, 1993, ANTIMICROB AGENTS CH, V37, P2534, DOI 10.1128/AAC.37.12.2534; Mahoney MM, 1995, FEBS LETT, V377, P519, DOI 10.1016/0014-5793(95)01390-3; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; Moscinski LC, 1995, J CELL BIOCHEM, V59, P431, DOI 10.1002/jcb.240590404; MURPHY CJ, 1993, J CELL PHYSIOL, V155, P408, DOI 10.1002/jcp.1041550223; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Popsueva AE, 1996, FEBS LETT, V391, P5, DOI 10.1016/0014-5793(96)00692-8; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; SCOCCHI M, 1992, EUR J BIOCHEM, V209, P589, DOI 10.1111/j.1432-1033.1992.tb17324.x; SHI JS, 1994, J LEUKOCYTE BIOL, V56, P807, DOI 10.1002/jlb.56.6.807; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1363, DOI 10.1006/bbrc.1993.2403; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1058, DOI 10.1006/bbrc.1993.2358; TOSSI A, 1994, FEBS LETT, V339, P108, DOI 10.1016/0014-5793(94)80395-1; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; YOUNT NY, 1995, J IMMUNOL, V155, P4476; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHAO CQ, 1994, FEBS LETT, V346, P285, DOI 10.1016/0014-5793(94)00493-5	37	309	324	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13088	13093		10.1074/jbc.272.20.13088	http://dx.doi.org/10.1074/jbc.272.20.13088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148921	hybrid			2022-12-25	WOS:A1997WZ38400034
J	Leung, HCE; Chen, YQ; Winkler, ME				Leung, HCE; Chen, YQ; Winkler, ME			Regulation of substrate recognition by the MiaA tRNA prenyltransferase modification enzyme of Escherichia coli K-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-GUANINE TRANSGLYCOSYLASE; REPRESSOR-OPERATOR INTERACTION; FARNESYL-DIPHOSPHATE SYNTHASE; PHENYLALANYL-TRANSFER RNA; SACCHAROMYCES-CEREVISIAE; STRUCTURAL REQUIREMENTS; MODIFYING ENZYMES; CODON CONTEXT; ANTICODON; GENE	We purified polyhistidine (His(6))-tagged and native Escherichia coli MiaA tRNA prenyltransferase, which uses dimethylallyl diphosphate (DMAPP) to isopentenylate A residues adjacent to the anticodons of most tRNA species that read codons starting with U residues. Kinetic and binding studies of purified MiaA were performed with several substrates, including synthetic wild-type tRNA(Phe), the anticodon stem-loop (ACSL(Phe)) of tRNA(Phe), and bulk tRNA isolated from a miaA mutant. Gel filtration shift and steady-state kinetic determinations showed that affinity-purified MiaA had the same properties as native MiaA and was completely active for tRNA(Phe) binding. MiaA had a K-m(app) (tRNA substrates) approximate to 3 nM, which is orders of magnitude lower than that of other purified tRNA modification enzymes, a K-m(app) (DMAPP) = 632 nM, and a k(cat)(app) = 0.44 s(-1). MiaA activity was minimally affected by other modifications or nonsubstrate tRNA. species present in bulk tRNA isolated from a miaA mutant. MiaA modified ACSL(Phe) with a k(cat)(app)/K-m(app) substrate specificity about 17-fold lower than that for intact tRNA(Phe) mostly due to a decrease in apparent substrate binding affinity. Quantitative Western immunoblotting showed that MiaA is an abundant protein in exponentially growing bacteria (660 monomers per cell; 1.0 mu M concentration) and is present in a catalytic excess. However, MiaA activity was strongly competitively inhibited for DMAPP by ATP and ADP (K-i(app) = 0.06 mu M), suggesting that MiaA activity is inhibited substantially in vivo and that DMAPP may bind to a conserved P-loop motif in this class of prenyltransferases. Band shift, filter binding, and gel filtration shift experiments support a model in which MiaA tRNA substrates are recognized by binding tightly to MiaA multimers possibly in a positively cooperative way (K-d(app) approximate to 0.07 mu M).	UNIV TEXAS, SCH MED, DEPT MICROBIOL & MOL GENET, HOUSTON, TX 77030 USA	University of Texas System								Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BARTZ JK, 1970, BIOCHEM BIOPH RES CO, V40, P1481, DOI 10.1016/0006-291X(70)90035-5; Bjork Glenn R., 1995, P165; BJORK GR, 1995, PROG NUCLEIC ACID RE, V50, P263, DOI 10.1016/S0079-6603(08)60817-X; BJORK GR, 1996, ESCHERICHIA COLI SAL, P861; BJORNSSON A, 1993, J MOL BIOL, V232, P1017, DOI 10.1006/jmbi.1993.1457; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOUADLOUN F, 1986, J BACTERIOL, V166, P1022, DOI 10.1128/jb.166.3.1022-1027.1986; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BUCK M, 1982, NUCLEIC ACIDS RES, V10, P2609, DOI 10.1093/nar/10.8.2609; BURDETT V, 1993, J BACTERIOL, V175, P7209, DOI 10.1128/JB.175.22.7209-7215.1993; CAILLET J, 1988, J BACTERIOL, V170, P4147, DOI 10.1128/jb.170.9.4147-4152.1988; CHONG S, 1995, BIOCHEMISTRY-US, V34, P3694, DOI 10.1021/bi00011a026; CONNOLLY DM, 1991, J BACTERIOL, V173, P1711, DOI 10.1128/jb.173.5.1711-1721.1991; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; DIAZ I, 1991, J MOL BIOL, V222, P1161, DOI 10.1016/0022-2836(91)90599-2; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; EISENBERG SP, 1979, J MOL BIOL, V135, P111, DOI 10.1016/0022-2836(79)90343-7; ERICSON JU, 1991, J MOL BIOL, V218, P509, DOI 10.1016/0022-2836(91)90697-5; ERICSON JU, 1986, J BACTERIOL, V166, P1013, DOI 10.1128/jb.166.3.1013-1021.1986; ESBERG B, 1995, J BACTERIOL, V177, P1967, DOI 10.1128/jb.177.8.1967-1975.1995; Feng G, 1996, J BACTERIOL, V178, P2388, DOI 10.1128/jb.178.8.2388-2396.1996; FENG G, 1995, BIOTECHNIQUES, V19, P956; GARCIA GA, 1993, J MOL BIOL, V231, P489, DOI 10.1006/jmbi.1993.1296; GEFTER ML, 1969, J MOL BIOL, V39, P145, DOI 10.1016/0022-2836(69)90339-8; GOLLNICK P, 1990, J BACTERIOL, V172, P3100, DOI 10.1128/jb.172.6.3100-3107.1990; GRAY J, 1992, J BACTERIOL, V174, P1086, DOI 10.1128/jb.174.4.1086-1098.1992; GROSJEAN H, 1985, NUCLEIC ACIDS RES, V13, P5697, DOI 10.1093/nar/13.15.5697; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GU XG, 1991, BIOCHEMISTRY-US, V30, P2999, DOI 10.1021/bi00226a003; Gu XR, 1996, BIOCHEMISTRY-US, V35, P11652, DOI 10.1021/bi9612125; HAGERVALL TG, 1990, BIOCHIM BIOPHYS ACTA, V1050, P263, DOI 10.1016/0167-4781(90)90178-5; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; HJALMARSSON KJ, 1983, J BIOL CHEM, V258, P1343; HOLMES WM, 1992, J BIOL CHEM, V267, P13440; HOLMES WM, 1995, BIOCHIMIE, V77, P62, DOI 10.1016/0300-9084(96)88105-3; HUISMAN GW, 1996, ESCHERICHIA COLI SAL, P1672; Kadner R. J., 1996, ESCHERICHIA COLI SAL, V2nd; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; KEALEY JT, 1995, BIOCHEMISTRY-US, V34, P2441, DOI 10.1021/bi00008a006; KLIG LS, 1987, NUCLEIC ACIDS RES, V15, P5339, DOI 10.1093/nar/15.13.5339; LANDICK R, 1990, J MOL BIOL, V216, P25, DOI 10.1016/S0022-2836(05)80058-0; MIKKOLA R, 1988, FEMS MICROBIOL LETT, V56, P265, DOI 10.1016/0378-1097(88)90071-7; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MUELLER SO, 1995, FEBS LETT, V361, P259, DOI 10.1016/0014-5793(95)00169-A; PETERSON ET, 1992, BIOCHEMISTRY-US, V31, P10380, DOI 10.1021/bi00157a028; PETRULLO LA, 1983, MOL GEN GENET, V190, P289, DOI 10.1007/BF00330653; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Romier C, 1996, EMBO J, V15, P2850, DOI 10.1002/j.1460-2075.1996.tb00646.x; ROSENBAUM N, 1972, J BIOL CHEM, V247, P5675; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; TIPTON K F, 1992, P1; TSANG TH, 1983, BIOCHIM BIOPHYS ACTA, V741, P180, DOI 10.1016/0167-4781(83)90058-1; TSUI HCT, 1994, BIOCHIMIE, V76, P1168, DOI 10.1016/0300-9084(94)90046-9; Tsui HCT, 1996, J BACTERIOL, V178, P5719, DOI 10.1128/jb.178.19.5719-5731.1996; TSUI HCT, 1994, MOL MICROBIOL, V13, P35, DOI 10.1111/j.1365-2958.1994.tb00400.x; VACHER J, 1984, J MOL BIOL, V177, P329, DOI 10.1016/0022-2836(84)90460-1; White R. W., 1996, ESCHERICHIA COLI SAL, P637; WILSON RK, 1989, P NATL ACAD SCI USA, V86, P409, DOI 10.1073/pnas.86.2.409; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; YANOFSKY C, 1977, J MOL BIOL, V113, P663, DOI 10.1016/0022-2836(77)90229-7; ZHAO GS, 1995, J BACTERIOL, V177, P883, DOI 10.1128/jb.177.4.883-891.1995; ZOLADEK T, 1995, MOL CELL BIOL, V15, P6884	72	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13073	13083		10.1074/jbc.272.20.13073	http://dx.doi.org/10.1074/jbc.272.20.13073			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148919	hybrid			2022-12-25	WOS:A1997WZ38400032
J	Lucas, M; Iverius, PH; Strickland, DK; Mazzone, T				Lucas, M; Iverius, PH; Strickland, DK; Mazzone, T			Lipoprotein lipase reduces secretion of apolipoprotein E from macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; MONOCYTE-DERIVED MACROPHAGES; APOPROTEIN-E; TERMINAL DOMAIN; EXPRESSION; BINDING; CELLS; ATHEROSCLEROSIS	Macrophages are a significant source of lipoprotein lipase (LPL) and apolipoprotein E (ape E) in the developing arterial wall lesion, and each of these proteins can importantly modulate lipid and lipoprotein metabolism by arterial wall cells, LPL and apo E share a number of cell surface binding sites, including proteoglycans, and we have previously shown that proteoglycans are important for modulating net secretion of apoprotein E from macrophages. We therefore evaluated a potential role for LPL in modulating net secretion of macrophage-derived apo E, In pulse-chase experiments, addition of LPL during the chase period produced a decrease in secretion of apoprotein E from human monocyte-derived macrophages, from the human monocytic THP1 cell line, and from J774 cells transfected to constitutively express a human apo E cDNA, LPL similarly reduced apo E secretion when it was prebound to the macrophage cell surface at 4 degrees C, A native LPL particle was required to modulate apo E secretion; addition of monomers and aggregates did not produce the same effect, Depletion of cell surface proteoglycans by a 72-h incubation in 4-methylumbelliferyl-beta-D-xyloside did not attenuate the ability of LPL to reduce apo E secretion, However, addition of receptor-associated protein attenuated the effect of LPL on apo E secretion, Although LPL could mediate removal of exogenously added apo E from the culture medium, detailed pulse-chase analysis suggested that it primarily prevented release of newly synthesized apo E from the cell layer, Cholesterol loading of cells or antibodies to the low density lipoprotein receptor attenuated LPL effects on apo E secretion, We postulate that LPL sequesters endogenously synthesized apo E at the cell surface by a low density lipoprotein receptor-dependent mechanism, Such post-translational regulation of macrophage apo E secretion by LPL could significantly influence apo E accumulation in arterial vessel wall lesions.	RUSH MED COLL,DEPT MED,CHICAGO,IL 60612; RUSH MED COLL,DEPT BIOCHEM,CHICAGO,IL 60612; UNIV UTAH,VET AFFAIRS MED CTR,SALT LAKE CITY,UT 84117; UNIV UTAH,DEPT INTERNAL MED,SALT LAKE CITY,UT 84117; AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855	Rush University; Rush University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; American Red Cross					NHLBI NIH HHS [HL39653, HL50787] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU SK, 1981, P NATL ACAD SCI USA, V78, P11657; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; CHAIT A, 1982, J CLIN INVEST, V69, P490, DOI 10.1172/JCI110473; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; DUAN HW, 1995, J CLIN INVEST, V96, P915, DOI 10.1172/JCI118139; Goldberg IJ, 1996, J LIPID RES, V37, P693; HATA A, 1992, J BIOL CHEM, V267, P20132; INABA T, 1995, ARTERIOSCL THROM VAS, V15, P522, DOI 10.1161/01.ATV.15.4.522; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MAZZONE T, 1994, J LIPID RES, V35, P1345; MAZZONE T, 1989, J LIPID RES, V30, P105; Medh JD, 1996, J BIOL CHEM, V271, P17073, DOI 10.1074/jbc.271.29.17073; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; OBRIEN KD, 1994, AM J PATHOL, V144, P538; RENIER G, 1993, ARTERIOSCLER THROMB, V13, P190, DOI 10.1161/01.ATV.13.2.190; Renier G, 1996, J LIPID RES, V37, P799; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; Salinelli S, 1996, J BIOL CHEM, V271, P21906, DOI 10.1074/jbc.271.36.21906; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Sivaram P, 1996, J BIOL CHEM, V271, P15261, DOI 10.1074/jbc.271.25.15261; STINS MF, 1993, J LIPID RES, V34, P1853; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; vanBarlingen HHJJ, 1996, J LIPID RES, V37, P754; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	35	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13000	13005		10.1074/jbc.272.20.13000	http://dx.doi.org/10.1074/jbc.272.20.13000			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148908	hybrid			2022-12-25	WOS:A1997WZ38400021
J	Bogdanov, YD; Dale, L; King, BF; Whittock, N; Burnstock, G				Bogdanov, YD; Dale, L; King, BF; Whittock, N; Burnstock, G			Early expression of a novel nucleotide receptor in the neural plate of Xenopus embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPHIBIAN EMBRYO; CHLORIDE CURRENT; PHOSPHOLIPASE-C; NERVOUS-SYSTEM; ATP RECEPTOR; SPINAL-CORD; INDUCTION; CLONING; OOCYTES; PURINOCEPTORS	Extracellular ATP functions as a neurotransmitter and neuromodulator in the adult nervous system, and a signaling molecule in non-neural tissue, acting either via ligand-gated ion channels (P2X) or G-protein-coupled receptors (P2Y), ATP can cause an increase in intracellular Ca2+ (Ca-i(2+)) in embryonic cells and so regulate cell proliferation, migration, and differentiation. We have isolated a Xenopus cDNA encoding a novel P2Y receptor, XlP2Y, which is expressed abundantly in developing embryos, Recombinant XlP2Y responds equally to all five naturally occurring nucleoside triphosphates (ATP, UTP, CTP, GTP, and ITP), which elicit a biphasic Ca2+-dependent Cl- current (I-Cl,I-Ca) where the second phase persists for up to 60 min, XlP2Y also causes a continuous release of Ca-i(2+), and a low level persistent activation of I-Cl,I-Ca in Xenopus oocytes through the spontaneous efflux of ATP, mRNAs for XIP2Y are expressed transiently in the neural plate and tailbud during Xenopus development, coincident with neurogenesis. This restricted pattern of expression and novel pharmacological features confer unique properties to XIP2Y, which may play a key role in the early development of neural tissue.	UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London				Bogdanov, Yury/0000-0003-4667-5890	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Burnstock G, 1996, DRUG DEVELOP RES, V38, P67, DOI 10.1002/(SICI)1098-2299(199605)38:1<67::AID-DDR9>3.0.CO;2-J; Burnstock G, 1996, CIBA F SYMP, V198, P1; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; COLAS JF, 1995, P NATL ACAD SCI USA, V92, P5441, DOI 10.1073/pnas.92.12.5441; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; HAGGBLAD J, 1988, FEBS LETT, V235, P133, DOI 10.1016/0014-5793(88)81248-1; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARTENSTEIN V, 1989, NEURON, V3, P399, DOI 10.1016/0896-6273(89)90200-6; HENDERSON DJ, 1995, BIOCHEM BIOPH RES CO, V212, P648, DOI 10.1006/bbrc.1995.2018; HENNING RH, 1993, BRIT J PHARMACOL, V110, P747, DOI 10.1111/j.1476-5381.1993.tb13875.x; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KELLY OG, 1995, TRENDS GENET, V11, P273, DOI 10.1016/S0168-9525(00)89074-5; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; King BF, 1996, J PHARMACOL EXP THER, V276, P93; King BF, 1996, BRIT J PHARMACOL, V117, P1111, DOI 10.1111/j.1476-5381.1996.tb16704.x; King BF, 1996, NEUROSCIENCE, V74, P1187, DOI 10.1016/0306-4522(96)00209-6; King BF, 1996, J PHYSIOL-LONDON, V494, P17, DOI 10.1113/jphysiol.1996.sp021472; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOZAK M, 1983, NUCLEIC ACIDS RES, V12, P865; LANDAU EM, 1994, METHOD ENZYMOL, V238, P140; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LOHMANN F, 1991, EXP CELL RES, V197, P326, DOI 10.1016/0014-4827(91)90441-V; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MESSENGER NJ, 1989, DEVELOPMENT, V107, P43; MIRANOV SL, 1994, NEUROPHARMACOLOGY, V33, P1; MOREAU M, 1994, P NATL ACAD SCI USA, V91, P12639, DOI 10.1073/pnas.91.26.12639; Nakamura F, 1996, P NATL ACAD SCI USA, V93, P10465, DOI 10.1073/pnas.93.19.10465; NAOKOAKA Y, 1995, J NEUROBIOL, V28, P23; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; ROWE SJ, 1993, DEVELOPMENT, V119, P1343; SALTER MW, 1995, J NEUROSCI, V15, P2961; Sambrook J., 2002, MOL CLONING LAB MANU; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; SHARPE CR, 1990, DEVELOPMENT, V109, P765; Simon J, 1995, EUR J PHARM-MOLEC PH, V291, P281, DOI 10.1016/0922-4106(95)90068-3; Sugioka M, 1996, J PHYSIOL-LONDON, V493, P855, DOI 10.1113/jphysiol.1996.sp021428; TAKATA K, 1981, ROUX ARCH DEV BIOL, V190, P92; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Webb TE, 1996, MOL PHARMACOL, V50, P258; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WU G, 1992, PFLUG ARCH EUR J PHY, V420, P227, DOI 10.1007/BF00374996; ZIGANSHIN AU, 1995, PFLUG ARCH EUR J PHY, V429, P412, DOI 10.1007/BF00374157	52	103	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12583	12590		10.1074/jbc.272.19.12583	http://dx.doi.org/10.1074/jbc.272.19.12583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139711	hybrid			2022-12-25	WOS:A1997WY82900048
J	Delaria, KA; Muller, DK; Marlor, CW; Brown, JE; Das, RC; Roczniak, SO; Tamburini, PP				Delaria, KA; Muller, DK; Marlor, CW; Brown, JE; Das, RC; Roczniak, SO; Tamburini, PP			Characterization of placental bikunin, a novel human serine protease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-SURGERY; BRAIN EDEMA; COAGULATION; APROTININ	We reported previously the cloning of a novel human serine protease inhibitor containing two Kunitz-like domains, designated as placental bikunin, and the subsequent purification of a natural counterpart from human placental tissue (Marlor, C. W., Delaria, K. A. Davis, G., Muller, D. K., Greve, J. M., and Tamburini, P. P. (1997) J. Biol. Chem. 272, 12202-12208). In this report, the 170 residue extracellular domain of placental bikunin (placental bikunin((1-170))) was expressed in baculovirus-infected Sf9 cells using its putative signal peptide. The resulting 21.3-kDa protein accumulated in the medium with the signal peptide removed and could be highly purified by sequential kallikrein-Sepharose and C-18 reverse-phase chromatography. To provide insights as to the potential in vivo functions of this protein, we performed an extensive investigation of the inhibitory properties of recombinant placental bikunin((1-170)) and both of its synthetically prepared Kunitz domains. All three proteins inhibited a number of serine proteases involved in the intrinsic pathway of blood coagulation and fibrinolysis. Placental bikunin((1-170)) formed inhibitor-protease complexes with a 1:2 stoichiometry and strongly inhibited human plasmin (K-i = 0.1 nM), human tissue kallikrein (K-i = 0.1 nM), human plasma kallikrein (K-i = 0.3 nM) and human factor XIa (K-i = 6 nM). Conversely, this protein was a weaker inhibitor of factor VIIa-tissue factor (K-i = 1.6 mu M), factor IXa (K-i = 206 nM), factor Xa (K-i = 364 nM), and factor XIIa (K-i = 430 nM). This specificity profile was to a large extent mimicked, albeit with reduced potency, by the individual Kunitz domains. As predicted from this in vitro specificity profile, recombinant placental bikunin((1-170)) prolonged the clotting time in an activated partial thromboplastin time assay.	BAYER CORP, DIV PHARMACEUT, BIOTECHNOL UNIT, West Haven, CT 06516 USA; BAYER CORP, DIV PHARMACEUT, INST BONE & JOINT DIS & CANC, West Haven, CT 06516 USA; BAYER CORP, DIV PHARMACEUT, INST RES TECHNOL, West Haven, CT 06516 USA; PROC SCI, BIOTECHNOL UNIT, BERKELEY, CA 94710 USA	Bayer AG; Bayer AG; Bayer AG								BOUDIER C, 1989, BIOCHIM BIOPHYS ACTA, V995, P36, DOI 10.1016/0167-4838(89)90230-6; CHASE T, 1970, METHOD ENZYMOL, V19, P20; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIS R, 1995, DRUGS, V49, P954, DOI 10.2165/00003495-199549060-00008; DIETRICH W, 1989, THORAC CARDIOV SURG, V37, P92, DOI 10.1055/s-2007-1013915; FRITZ H, 1983, ARZNEIMITTELFORSCH, V33-1, P479; GIRARD TJ, 1993, METHOD ENZYMOL, V222, P195; KAMIYA T, 1993, STROKE, V24, P571, DOI 10.1161/01.STR.24.4.571; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MANN KG, 1993, METHOD ENZYMOL, V222, P1; MARDER VJ, 1982, HEMOSTASIS THROMBOSI, P145; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; Miller Chad G., 1994, Methods (Orlando), V6, P315, DOI 10.1006/meth.1994.1032; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Petersen LC, 1996, EUR J BIOCHEM, V235, P310, DOI 10.1111/j.1432-1033.1996.0310f.x; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAMBURINI PP, 1990, ANAL BIOCHEM, V186, P363, DOI 10.1016/0003-2697(90)90095-Q; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x	24	98	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12209	12214		10.1074/jbc.272.18.12209	http://dx.doi.org/10.1074/jbc.272.18.12209			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115295	hybrid			2022-12-25	WOS:A1997WX56900083
J	McWherter, CA; Rocque, WJ; Zupec, ME; Freeman, SK; Brown, DL; Devadas, B; Getman, DP; Sikorski, JA; Gordon, JI				McWherter, CA; Rocque, WJ; Zupec, ME; Freeman, SK; Brown, DL; Devadas, B; Getman, DP; Sikorski, JA; Gordon, JI			Scanning alanine mutagenesis and de-peptidization of a Candida albicans myristoyl-CoA:protein N-myristolytransferase octapeptide substrate reveals three elements critical for molecular recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; SACCHAROMYCES-CEREVISIAE; CRYPTOCOCCUS-NEOFORMANS; FUNGAL-INFECTIONS; ESCHERICHIA-COLI; MYRISTOYLTRANSFERASE; MECHANISM; SPECIFICITIES; INHIBITORS; GENE	Candida albicans produces a single myristoyl CoA: protein N-myristoyltransferase (Nmt) that is essential for its viability. An ADP-ribosylation factor (Arf) is included among the few cellular protein substrates of this enzyme. An octapeptide (GLYASKLS-NH2) derived from a N-terminal Arf sequence was used as the starting point to identify elements critical for recognition by the acyltransferases's peptide-binding site. In vitro kinetic studies, employing purified Nmt and a panel of peptides with single Ala substitutions at each position of GLYASKLS-NH2, established that its Gly(1), Ser(5) and Lys(6) residues play predominant roles in binding. ALYASKLS-NH2 was found to be an inhibitor competitive for peptide (K-i = 15.3 +/- 6.4 mu M) and noncompetitive for myristoyl-CoA (K-i = 31.2 +/- 0.7 mu M). A survey of 26 derivatives of this inhibitor, representing (i) a complete alanine scan, (ii) progressive C terminal truncations, and (iii) manipulation of the physical-chemical properties of its residues 1, 5, and 6, confirmed the important stereochemical requirements for the N-terminal amine, the beta-hydroxyl of Ser(5), and the epsilon-amino group of Lys(6). Remarkably, replacement of the the N-terminal tetrapeptide of ALYASKLS-NH2 with an 11-aminoundecanoyl group produced a competitive inhibitor, 11-aminoundecanoyl-SKLS-NH2, that was 38-fold more potent (K-i = 0.40 +/- 0.03 mu M) than the starting octapeptide. Removing the primary amine (undecanoyl-SKLS-NH2), or replacing it with a methyl group (dodecanoyl-SKLS-NH2), resulted in 26- and 34-fold increases in IC50, confirming the important contribution of the amine to recognition. Removal of Leu-Ser from the C terminus (11-aminoundecanoyl-SK-NH2) yielded a competitive dipeptide inhibitor with a K-i (11.7 +/- 0.4 mu M) equivalent to that of the starting octapeptide, ALYASKLS-NH2. Substitution of Ser with homoserine, cis-4-hydroxyproline, or tyrosine reduces potency by 3-70-fold, emphasizing the requirement for proper presentation of the hydroxyl group in the dipeptide inhibitor. Substituting D- for L-Lys decreases its inhibitory activity > 100 fold, while deletion of the epsilon-amino group (Nle) or masking its charge (epsilon-N-acetyl-lysine) produces 4-7-fold attenuations. L-His, but not its D-isomer, can fully substitute for L-Lys, producing a competitive dipeptide inhibitor with similar potency (K-i 11.9 +/- 1.0 mu m). 11-Aminoundecanoyl-SK-NH2 and 11-aminoundecanoyl-SH-NH2, establish that a simple alkyl backbone can maintain an appropriate distance between three elements critical for recognition by the fungal enzyme's peptide-binding site: a simple omega-terminal amino group, a beta-hydroxyl, and an epsilon-amino group or an imidazole. These compounds contain one peptide bond and two chiral centers, suggesting that it may be feasible to incorporate these elements of recognition, or functionally equivalent mimics, into a fully de-peptidized Nmt inhibitor.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	McWherter, CA (corresponding author), MONSANTO CO,SEARLE DISCOVERY,BB3G,700 CHESTERFIELD PKWY N,ST LOUIS,MO 63198, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038200] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; BHATNAGAR RS, 1994, J BIOL CHEM, V269, P11045; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BRODBECK U, 1979, BIOCHIM BIOPHYS ACTA, V567, P357, DOI 10.1016/0005-2744(79)90122-0; DENICH KT, 1992, GENE, V110, P123, DOI 10.1016/0378-1119(92)90455-X; DEVADAS B, 1995, J MED CHEM, V38, P1837, DOI 10.1021/jm00011a001; DUPONT B, 1992, J MED VET MYCOL, V30, P19; GEORGOPAPADAKOU NH, 1994, SCIENCE, V264, P371, DOI 10.1126/science.8153622; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LEE FJS, 1994, J BIOL CHEM, V269, P20931; LODGE JK, 1994, J BIOL CHEM, V269, P2996; Lodge JK, 1997, MICROBIOL-UK, V143, P357, DOI 10.1099/00221287-143-2-357; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SADHU C, 1992, MOL CELL BIOL, V12, P1977, DOI 10.1128/MCB.12.5.1977; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; Stewart JM, 1984, SOLID PHASE PEPTIDE; TARBELL DS, 1972, P NATL ACAD SCI USA, V69, P730, DOI 10.1073/pnas.69.3.730; WEINBURG RA, 1995, MOL MICROBIOL, V16, P241, DOI 10.1111/j.1365-2958.1995.tb02296.x; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591	26	28	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11874	11880		10.1074/jbc.272.18.11874	http://dx.doi.org/10.1074/jbc.272.18.11874			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115247	hybrid			2022-12-25	WOS:A1997WX56900035
J	Oh, ES; Woods, A; Couchman, JR				Oh, ES; Woods, A; Couchman, JR			Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; FOCAL ADHESION FORMATION; MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; INTEGRIN; FIBRONECTIN; CYTOSKELETAL; ORGANIZATION; FIBROBLASTS	The transmembrane proteoglycan syndecan-4, which is a coreceptor with integrins in cytoskeleton-matrix interactions, appears to be multimerized in vivo. Both purified and recombinant core proteins form sodium dodecyl sulfate-resistant oligomers, and we now report that a synthetic peptide corresponding to the central region of syndecan-4 cytoplasmic domain (4V) also oligomerizes. The degree of oligomerization correlates with the previously reported ability to bind protein kinase C (PKC) and regulate its activity. Only multimeric recombinant syndecan-4 core protein, but not the monomeric protein, potentiated the activity of PKC alpha, and only oligomeric syndecan-4 cytoplasmic peptides were active. Changes in peptide sequence caused parallel loss of stable oligomeric status and ability to regulate a mixture of PKC alpha beta gamma activity. A synthetic peptide encompassing the whole cytoplasmic domain of syndecan-4 (4L) containing a membrane-proximal basic sequence did not form higher order oligomers and could not regulate the activity of PKC alpha beta gamma unless induced to aggregate by phosphatidylinositol 4,5-bisphosphate. Oligomerization and PKC regulatory activity of the 4V peptide were both increased by addition of N-terminal cysteine and reduced by phosphorylation of the cysteine thiol group. Concentration of syndecan-4 at sites of focal adhesion formation may enhance multimerization and both localize PKC and potentiate its activity to induce stable complex formation.	UNIV ALABAMA,DEPT CELL BIOL,CELL ADHES & MATRIX RES CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIGMS NIH HHS [GM50194] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BACIU PC, 1994, J BIOL CHEM, V269, P696; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHAUHAN A, 1991, ARCH BIOCHEM BIOPHYS, V287, P283, DOI 10.1016/0003-9861(91)90480-7; CHUN JS, 1993, MOL BIOL CELL, V4, P271; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; MIETTINEN HM, 1994, MOL BIOL CELL, V5, P1325, DOI 10.1091/mbc.5.12.1325; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NGSIKORSKI J, 1991, EXP CELL RES, V195, P504, DOI 10.1016/0014-4827(91)90402-G; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; PIERCE A, 1992, J BIOL CHEM, V267, P3894; PONTA H, 1994, BBA-REV CANCER, V1198, P1, DOI 10.1016/0304-419X(94)90002-7; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1992, P NATL ACAD SCI USA, V89, P6138, DOI 10.1073/pnas.89.13.6138; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VUORI K, 1993, J BIOL CHEM, V268, P21459; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; WOODS A, 1992, J CELL SCI, V101, P277	44	183	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11805	11811		10.1074/jbc.272.18.11805	http://dx.doi.org/10.1074/jbc.272.18.11805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115237	hybrid			2022-12-25	WOS:A1997WX56900025
J	Rajah, R; Valentinis, B; Cohen, P				Rajah, R; Valentinis, B; Cohen, P			Insulin like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53- and IGF-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; QUIESCENT HUMAN FIBROBLASTS; FLOW CYTOMETRIC DETECTION; PROSTATE-CANCER CELLS; ANNEXIN-V; PHOSPHATIDYLSERINE EXPRESSION; BALB/C FIBROBLASTS; GENE; IGFBP-3; PROLIFERATION	Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) is known to block IGF action and inhibit cell growth, IGFBP-3 is thought to act by sequestering free IGFs or, possibly, act via a novel IGF-independent mechanism. Supporting its role as a primary growth inhibitor, IGFBP-3 production has been shown to be increased by cell growth-inhibitory agents, such as transforming growth factor-beta (TGF-beta), and the tumor suppressor gene p53. In this paper, we demonstrate, for the first time, a novel function of IGFBP-3 as an apoptosis-inducing agent and show that this action is mediated through an IGF.IGF receptor independent pathway. In the p53 negative prostate cancer cell line, PC-3, the addition of recombinant IGFBP-3 resulted in a dose-dependent induction of apoptosis, I-125-IGFBP-3 bound with high affinity to specific proteins in PC-3 cell lysates and plasma membrane preparations. These membrane associated mole cules may serve as receptors that mediate the direct effect of IGFBP-3 on apoptosis, In addition, in an IGF receptor-negative mouse fibroblast cell line, treatment with recombinant IGFBP-3 as well as transfection of the IGFBP-3 gene induced apoptosis, suggesting that neither IGFs nor IGF receptors are required for this action. Furthermore, treatment with TGF-beta 1, a known apoptosis-inducing agent, resulted in the induction of IGFBP-3 expression 6-12 h before the onset of apoptosis. This effect of TGF-beta 1 was prevented by co-treatment with IGFBP-3-neutralizing antibodies or IGFBP-3-specific antisense thiolated oligonucleotides. These findings suggest that IGFBP-3 induces apoptosis through a novel pathway independent of either p53 or the IGF.IGF receptor-mediated cell survival pathway and that IGFBP-3 mediates TGF-beta 1 induced apoptosis in PC-3 cells.	UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19103	University of Pennsylvania; Jefferson University					NIDDK NIH HHS [WR01 DK47591] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047591] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1992, ENDOCRINOLOGY, V131, P1858, DOI 10.1210/en.131.4.1858; ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COHEN P, 1991, ACTA ENDOCRINOL-COP, V124, P74; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHEN P, 1993, GROWTH REGULAT, V3, P23; COHEN P, 1994, J ENDOCRINOL, V142, P407, DOI 10.1677/joe.0.1420407; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P3259, DOI 10.1210/endo-129-6-3259; DECKERS CLP, 1993, EXP CELL RES, V208, P362, DOI 10.1006/excr.1993.1257; ESTROV Z, 1995, BLOOD, V86, P4594, DOI 10.1182/blood.V86.12.4594.bloodjournal86124594; FIGUEROA JA, 1995, J CLIN ENDOCR METAB, V80, P3476, DOI 10.1210/jc.80.12.3476; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GIUDICE LC, 1993, J CLIN ENDOCR METAB, V76, P1115, DOI 10.1210/jc.76.5.1115; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Gucev ZS, 1996, CANCER RES, V56, P1545; HOMBURG CHE, 1995, BLOOD, V85, P532; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAICER E, 1993, GROWTH REGULAT, V3, P180; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1568, DOI 10.1210/en.131.3.1568; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MOERMAN EJ, 1993, EXP GERONTOL, V28, P361, DOI 10.1016/0531-5565(93)90063-J; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH Y, 1994, J BIOL CHEM, V268, P14964; PEEHL DM, 1995, WORLD J UROL, V13, P306; PERKEL VS, 1990, J CLIN ENDOCR METAB, V71, P533, DOI 10.1210/jcem-71-2-533; PLANCHON SM, 1995, CANCER RES, V55, P3706; Rajah R, 1996, ENDOCRINOLOGY, V137, P2676, DOI 10.1210/en.137.7.2676; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rocha RL, 1996, J NATL CANCER I, V88, P601, DOI 10.1093/jnci/88.9.601; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; ROSENFELD RG, 1994, ACTA PAEDIATR S, V399, P154; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; TSUKADA T, 1995, BIOCHEM BIOPH RES CO, V210, P1076, DOI 10.1006/bbrc.1995.1766; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; VelezYanguas MC, 1996, J CLIN ENDOCR METAB, V81, P93, DOI 10.1210/jc.81.1.93; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; YATEMAN ME, 1993, J ENDOCRINOL, V137, P151, DOI 10.1677/joe.0.1370151	52	648	673	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12181	12188		10.1074/jbc.272.18.12181	http://dx.doi.org/10.1074/jbc.272.18.12181			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115291	hybrid			2022-12-25	WOS:A1997WX56900079
J	Clementz, T; Zhou, ZM; Raetz, CRH				Clementz, T; Zhou, ZM; Raetz, CRH			Function of the Escherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A - Acylation by MsbB follows laurate incorporation by HtrB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; NULL MUTATIONS; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; BIOSYNTHESIS; LIPOPOLYSACCHARIDE; ENDOTOXINS; SALMONELLA; MEMBRANE; MUTANT; IDENTIFICATION	Overexpression of the Escherichia coli msbB gene on high copy plasmids suppresses the temperature-sensitive growth associated with mutations in the htrB gene, htrB encodes the lauroyl transferase of lipid A biosynthesis that acylates the intermediate (Kdo)(2)-lipid IVA (Brozek, It. A. and Raetz, C. R. H. (1990) J. Biol. Chem, 265, 15410-15417). Since msbB displays 27.5% identity and 42.2% similarity to htrB, me explored the possibility that msbB encodes a related acyltransferase, In contrast to htrB, extracts of strains with insertion mutations in msbB are not defective in transferring laurate from lauroyl acyl carrier protein to (Kdo)(2)-lipid IVA. However, extracts of msbB mutants do not efficiently acylate the product formed by HtrB, designated (IZdo)(2)-(lauroyl)-lipid IVA. Extracts of strains harboring msbB(+) bearing plasmids acylate (Kdo)(2)-(lauroyl)-lipid IVA very rapidly compared with wild type, We solubilized and partially purified MsbB from an overproducing strain, lacking HtrB, MsbB transfers myristate or laurate, activated on ACP, to (Kdo)(2)-(lauroyl)-lipid IVA. Decanoyl, palmitoyl, palmitoleoyl, and (R)-3-hydroxymyristoyl-ACP are poor acyl donors, MsbB acylates (Kdo)(2)-(lauroyl)-lipid IVA about 100 times faster than (Kdo)(2)-lipid IVA. The slow, but measurable, rate whereby MsbB acts on (Kdo)(2)-lipid IVA may explain why overexpression of MsbB suppresses the temperature-sensitive phenotype of htrB mutations, Presumably, the acyloxyacyl group generated by excess MsbB substitutes for the one normally formed by HtrB.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1995, FASEB J, V9, pA1311; ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31, DOI 10.1172/JCI117658; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEE NG, 1995, J BIOL CHEM, V270, P27151, DOI 10.1074/jbc.270.45.27151; MYERS KR, 1992, BIOCONJUGATE CHEM, V3, P540, DOI 10.1021/bc00018a013; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1986, J MICROBIOL METH, V5, P65, DOI 10.1016/0167-7012(86)90002-3; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; REATZ CRH, 1996, ESCHERICHIA COLI SAL, V1, P1035; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; VANALPHEN L, 1979, EUR J BIOCHEM, V101, P571; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; WOLLENWEBER HW, 1983, EUR J BIOCHEM, V130, P167	34	173	184	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10353	10360						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099672				2022-12-25	WOS:A1997WV26200006
J	Jucker, BM; Rennings, AJM; Cline, GW; Shulman, GI				Jucker, BM; Rennings, AJM; Cline, GW; Shulman, GI			C-13 and P-31 NMR studies on the effects of increased plasma free fatty acids on intramuscular glucose metabolism in the awake rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO REGULATION; SKELETAL-MUSCLE; GLYCOGEN-SYNTHESIS; CARBOHYDRATE-METABOLISM; DIABETES-MELLITUS; NORMAL MEN; INSULIN; INVIVO; CYCLE; EXERCISE	The effects of increased plasma free fatty acids (FFA) on insulin-dependent whole body glucose disposal, skeletal muscle glycolysis, glycogen synthesis, pyruvate versus FFA/ketone oxidation, and glucose 6-phosphate (Glu-6-P) were investigated in the awake rat, A control group (glycerol-infused) and high plasma FFA group (Liposyn-infused) were clamped at euglycemia (similar to 6 mM). hyperinsulinemia (10 milliunits/kg/min) throughout the experiment (180-240 min), In the initial experiment, C-13 NMR was used to observe [1-C-13]glucose incorporation into [1-C-13]glycogen in the rat hindlimb for glycogen synthesis calculations and into [3-C-13]lactate and [3-C-13]alanine for glycolytic flux calculations, These experiments were followed by P-31 NMR measurements of Glu-6-P changes under identical conditions of the initial experiment, Plasma FFA concentrations were 2.25 +/- 0.36 and 0.20 +/- 0.03 mM in the high plasma FFA and control groups respectively (p < 0.0005), Glucose infusion rates (G(inf)) decreased significantly in the Liposyn-infused rats (29.5 +/- 0.7 and 27.2 +/- 1.2 mg/kg/min for control and high plasma FFA group, respectively, at 15 min to 30.7 +/- 2.3 and 17.7 +/- 1.3 mg/kg/min, respectively, at the end of the experiment, p < 0.002), Glycogen synthesis rates were 163 +/- 32 and 104 +/- 17 nmol/g/min, and glycolytic rates were 57.9 +/- 8.0 and 19.5 +/- 3.6 nmol/g/min (p < 0.002) in the control and high plasma FFA groups, respectively, The relative flux of pyruvate versus free fatty acids and ketones entering the tricarboxylic acid cycle was greater in the control (57 +/- 9%) versus high plasma FFA group (25 +/- 4%) (p < 0.005) as assessed by [4-C-13]glutamate/[3-C-13]lactate steady state isotopic enrichment measurements, Finally, Glu-6-P concentrations increased by 29.8 +/- 7.0 and 52.8 +/- 12.3% (p < 0.05) in the control and high plasma FFA groups, respectively, above their basal concentrations by 180 min. In conclusion, we have demonstrated the ability to use in vivo MMR to elucidate the metabolic fate of glucose within skeletal muscle of an awake rat during a euglycemic-hyperinsulinemic clamp and increased levels of plasma FFA. These data suggest that increased concentrations of plasma FFA inhibit insulin-stimulated muscle glucose metabolism in the rat through inhibition of glycolysis.			Jucker, BM (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED,333 CEDAR ST,FITKIN 1, POB 208020, NEW HAVEN, CT 06520 USA.		Rennings, Alexander/H-3541-2015	Shulman, Gerald/0000-0003-1529-5668	NIDDK NIH HHS [R01 DK40936, P30 DK 45735, R01 DK040936] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK040936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATTY CH, 1971, AM J PHYSIOL, V220, P1928, DOI 10.1152/ajplegacy.1971.220.6.1928; BERGER M, 1976, BIOCHEM J, V158, P191, DOI 10.1042/bj1580191; BEVILACQUA S, 1990, DIABETES, V39, P383, DOI 10.2337/diabetes.39.3.383; BLOCH G, 1993, MAGNET RESON MED, V30, P347, DOI 10.1002/mrm.1910300311; BLOCH G, 1994, AM J PHYSIOL, V266, pE85, DOI 10.1152/ajpendo.1994.266.1.E85; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; BODEN G, 1991, DIABETES, V40, P686, DOI 10.2337/diabetes.40.6.686; BODEN G, 1991, J CLIN INVEST, V88, P960, DOI 10.1172/JCI115399; CLINE GW, 1991, J BIOL CHEM, V266, P4094; DEFRONZO RA, 1981, J CLIN INVEST, V68, P1468, DOI 10.1172/JCI110399; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; FRAHM J, 1987, J MAGN RESON, V72, P502, DOI 10.1016/0022-2364(87)90154-5; GOODMAN MN, 1974, DIABETES, V23, P881, DOI 10.2337/diab.23.11.881; HUNDAL HS, 1989, J PHYSIOL-LONDON, V408, P93, DOI 10.1113/jphysiol.1989.sp017449; JENKINS AB, 1988, J CLIN INVEST, V82, P293, DOI 10.1172/JCI113586; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; Keppler D., 1974, METHOD ENZYMAT AN, V3, P1127, DOI DOI 10.1242/JEB.037275; Kim JK, 1996, DIABETES, V45, P446, DOI 10.2337/diabetes.45.4.446; KRUSZYNSKA YT, 1990, DIABETOLOGIA, V33, P396, DOI 10.1007/BF00404087; KRUSZYNSKA YT, 1991, DIABETOLOGIA, V34, P205, DOI 10.1007/BF00405077; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; LI J, 1993, METABOLISM, V42, P451, DOI 10.1016/0026-0495(93)90102-T; LUECK JD, 1974, J BIOL CHEM, V249, P1341; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MASON GF, 1995, J CEREBR BLOOD F MET, V15, P12, DOI 10.1038/jcbfm.1995.2; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; NEWSHOLME EA, 1977, BIOCHEM J, V166, P123, DOI 10.1042/bj1660123; NOLTE LA, 1994, ACTA PHYSIOL SCAND, V151, P51, DOI 10.1111/j.1748-1716.1994.tb09720.x; NUUTILA P, 1992, J CLIN INVEST, V89, P1767, DOI 10.1172/JCI115780; RANDLE PJ, 1963, LANCET, V1, P785; RANDLE PJ, 1994, DIABETOLOGIA, V37, pS155, DOI 10.1007/BF00400839; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; ROSSELIN G, 1966, NATURE, V212, P355, DOI 10.1038/212355a0; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1993, AM J PHYSIOL, V265, pE761, DOI 10.1152/ajpendo.1993.265.5.E761; ROTH DA, 1993, J APPL PHYSIOL, V75, P1559, DOI 10.1152/jappl.1993.75.4.1559; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Sidossis LS, 1996, AM J PHYSIOL-ENDOC M, V270, pE733, DOI 10.1152/ajpendo.1996.270.4.E733; SMITH D, 1987, METABOLISM, V36, P1167, DOI 10.1016/0026-0495(87)90244-7; WOLFE BM, 1988, METABOLISM, V37, P323, DOI 10.1016/0026-0495(88)90131-X	42	73	74	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10464	10473						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099689				2022-12-25	WOS:A1997WV26200023
J	Qureshi, N; Kaltashov, I; Walker, K; Doroshenko, V; Cotter, RJ; Takayama, K; Sievert, TR; Rice, PA; Lin, JSL; Golenbock, DT				Qureshi, N; Kaltashov, I; Walker, K; Doroshenko, V; Cotter, RJ; Takayama, K; Sievert, TR; Rice, PA; Lin, JSL; Golenbock, DT			Structure of the monophosphoryl lipid a moiety obtained from the lipopolysaccharide of Chlamydia trachomatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; RHODOPSEUDOMONAS-SPHAEROIDES; SALMONELLA-TYPHIMURIUM; NEISSERIA-GONORRHOEAE; MASS-SPECTROMETRY; FATTY-ACIDS; INFECTION; PURIFICATION; DESORPTION; MUTANT	Monophosphoryl lipid A was prepared from the lipopolysaccharide of Chlamydia trachomatis, converted to the methyl ester, and fractionated by reverse-phase high-performance liquid chromatography. The peak fractions were collected and analyzed by mass spectrometry. Matrix-assisted laser desorption/ionization and liquid secondary ion mass spectrometry of the first of two major high-performance liquid chromatographic fractions showed multiple quasi-molecular ions of MNa+ at m/z 1780, 1794, 1808, 1822, and 1836. The positive-ion Liquid secondary ion mass spectrometry spectrum also showed a minor series of peaks at mit 1916, 1930, 1944, 1958, and 1971, consistent with the formation of matrix adducts with 3-nitrobenzyl alcohol. Oxonium ions representing the distal subunit were observed at mit 1057, 1071, 1085, 1099, and 1113. The second fraction was similarly analyzed and found to contain structural homologs of the first fraction. Based on this study, the major lipid A component of chlamydial lipopolysaccharide is a glucosamine disaccharide that contains five fatty acids and a phosphate in the distal segment. Three fatty acyl groups are in the distal segment, and two are in the reducing end segment. The acyloxyacyl group is located in the distal segment in amide linkage. Two structural series, differing by 14 atomic mass units in the reducing subunit, were observed. Chlamydial lipid A is complex and consists of at least 20 homologous structural components. The relatively low potency of Chlamydia trachomatis lipopolysaccharide in activating lipopolysaccharide-responsive cells might be related to the unusual fatty acid composition of the lipid A moiety.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; BOSTON MED CTR,MAXWELL FINLAND LAB INFECT DIS,BOSTON,MA 02118; BOSTON UNIV,SCH MED,BOSTON,MA 02118	University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; Boston Medical Center; Boston University	Qureshi, N (corresponding author), WILLIAM S MIDDLETON MEM VET ADM MED CTR,MYCOBACTERIOL RES LAB,2500 OVERLOOK TERRACE,RM D-2215,MADISON,WI 53705, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033087, U19AI038515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050870] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-33087, AI-38515] Funding Source: Medline; NIGMS NIH HHS [GM-50870] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADE L, 1990, INFECT IMMUN, V58, P205, DOI 10.1128/IAI.58.1.205-213.1990; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; Doroshenko VM, 1996, RAPID COMMUN MASS SP, V10, P65, DOI 10.1002/(SICI)1097-0231(19960115)10:1<65::AID-RCM447>3.0.CO;2-M; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; HOLST O, 1991, J BACTERIOL, V173, P1862, DOI 10.1128/jb.173.6.1862-1866.1991; INGALLS RR, 1995, INFECT IMMUN, V63, P3125, DOI 10.1128/IAI.63.8.3125-3130.1995; KIVIAT NB, 1990, HUM PATHOL, V21, P831, DOI 10.1016/0046-8177(90)90052-7; NURMINEN M, 1985, INFECT IMMUN, V48, P573, DOI 10.1128/IAI.48.2.573-575.1985; PATTON DL, 1989, J INFECT DIS, V159, P1105, DOI 10.1093/infdis/159.6.1105; QURESHI N, 1983, J BIOL CHEM, V258, P2947; QURESHI N, 1985, J BIOL CHEM, V260, P5271; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1988, J BIOL CHEM, V263, P5502; QURESHI N, 1991, J BIOL CHEM, V266, P6532; QURESHI N, 1994, J ENDOTOXIN RES, V1, P137; QURESHI N, 1995, BACTERIAL ENDOTOXINS, P151; TAKAYAMA K, 1983, J BIOL CHEM, V258, P2801; TAKAYAMA K, 1986, J BIOL CHEM, V261, P624; TAKAYAMA K, 1992, BACTERIAL ENDOTOXIN, V1, P44; TAM JE, 1992, BIOTECHNIQUES, V13, P374; TAUBER AI, 1989, INFECT IMMUN, V57, P1108, DOI 10.1128/IAI.57.4.1108-1112.1989; *US DEP HHS, 1981, NAT I ALL INF DIS S	22	52	52	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10594	10600						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099706				2022-12-25	WOS:A1997WV26200040
J	Wang, L; Groves, JD; Mawby, WJ; Tanner, MJA				Wang, L; Groves, JD; Mawby, WJ; Tanner, MJA			Complementation studies with co-expressed fragments of the human red cell anion transporter (band 3; AE1) - The role of some exofacial loops in anion transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE; PROTEOLYTIC CLEAVAGE; XENOPUS-OOCYTES; GLYCOPHORIN-A; PROTEIN; EXCHANGER; DOMAIN; ORIENTATION; SEQUENCE	We constructed cDNA clones encoding fragments of band 3 in which the membrane domain was truncated from either the N or the C terminus within each of the first four exofacial loops. The truncations containing the C terminus of the protein were fused with the cleavable N-terminal signal sequence of glycophorin A to facilitate the correct orientation of the most N-terminal band 3 membrane span, Cleavage of the glycophorin A signal sequence was observed, except when the truncation was in the first exofacial loop where the signal peptidase cleavage site was probably too close to the membrane. The anion transport activity of co-expressed complementary pairs of truncations which together contained the entire band 3 membrane domain was examined. The pairs of fragments divided in the third and fourth exofacial loops yielded transport activity, but the pair separated within the second exofacial loop was not active, We conclude that the integrity of the second exofacial loop, but not the third and fourth exofacial loops, is necessary for transport activity. The unusually stable association between the fragments divided in the second exofacial loop suggests that interactions may occur between polar surfaces on amphiphilic portions of the third and fifth transmembrane spans.	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAMBERG E, 1992, PROG CELL RES, V2, P1; ESPANOL MJ, 1995, MOL MEMBR BIOL, V12, P193, DOI 10.3109/09687689509027507; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; GROVES JD, 1992, J BIOL CHEM, V267, P22163; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; Kalo MS, 1996, BIOCHEMISTRY-US, V35, P999, DOI 10.1021/bi951702h; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; MAWBY WJ, 1982, BIOCHEM J, V205, P465, DOI 10.1042/bj2050465; OIKAWA K, 1985, BIOCHEMISTRY-US, V24, P2843, DOI 10.1021/bi00333a005; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TAM LY, 1994, J BIOL CHEM, V269, P32542; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; TANNER MJA, 1989, METHOD ENZYMOL, V173, P423; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; WANG DN, 1994, FEBS LETT, V346, P26, DOI 10.1016/0014-5793(94)00468-4; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WOOD PG, 1992, PROGR CELL RES, V2, P325	22	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10631	10638						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099711				2022-12-25	WOS:A1997WV26200045
J	Thompson, MA; Flegg, R; Westin, EH; Ramsay, RG				Thompson, MA; Flegg, R; Westin, EH; Ramsay, RG			Microsatellite deletions in the c-myb transcriptional attenuator region associated with over-expression in colon tumour cell lines	ONCOGENE			English	Article						c-myb; transcriptional attenuation; colon tumour cells	NONPOLYPOSIS COLORECTAL-CANCER; MESSENGER-RNA; MULTIPLE MECHANISMS; REPLICATION ERRORS; SUPPRESSOR PROTEIN; ADENOMATOUS POLYPS; SODIUM-BUTYRATE; GENE; DIFFERENTIATION; ELONGATION	In the hemopoietic system c-myb expression is required for proliferation of immature cells and its downregulation is required for differentiation. In colonic mucosa c-myb expression occurs at levels comparable to immature hemopoietic cells. Inhibition of c-myb expression in colon cell lines, using anti-sense oligonucleotides, indicates that c-myb expression is required for proliferation. However, the mechanism of c-myb regulation during colon cell differentiation has not been explored. Using the LIM1215 and CaCo-2 colon carcinoma cell lines induced to differentiate with sodium butyrate, we demonstrate that c-myb mRNA is down-regulated as an early event in differentiation by a mechanism involving transcriptional attenuation in intron 1. By analogy with procaryotic and eucaryotic genes, transcriptional attenuation probably occurs in a region containing nineteen consecutive thymidine residues. Computer prediction of the secondary structure of the nascent mRNA chain encoded by this region suggests a strong potential for stem-loop formation. Sequence analysis of several colon tumour cell lines reveals mutations in this region that may disrupt transcriptional attenuation and result in the increased c-myb expression observed in colon tumours and tumour cell lines.	PETER MACCALLUM CANC INST,MELBOURNE,VIC 3002,AUSTRALIA; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Peter Maccallum Cancer Center; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Virginia Commonwealth University			Ramsay, Robert G/C-3291-2015	Ramsay, Robert G/0000-0001-5003-0433				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; AUGERON C, 1984, CANCER RES, V44, P3961; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BOISE LH, 1992, ONCOGENE, V7, P1817; Bubb VJ, 1996, ONCOGENE, V12, P2641; CHEN JS, 1995, CANCER RES, V55, P174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DENG G, 1992, CANCER RES, V52, P3378; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FERRAO P, 1995, ONCOGENE, V11, P1631; GAMET L, 1992, INT J CANCER, V52, P286, DOI 10.1002/ijc.2910520222; GRECO C, 1994, ANTICANCER RES, V14, P1433; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACOBS SM, 1994, ONCOGENE, V9, P227; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KIM HG, 1994, AM J PATHOL, V145, P148; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KRUMM A, 1995, SCIENCE, V269, P1400, DOI 10.1126/science.7660121; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LOTHE RA, 1993, CANCER RES, V53, P5849; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MELANI C, 1991, CANCER RES, V51, P2897; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MELTZER SJ, 1987, GASTROENTEROLOGY, V92, P1174, DOI 10.1016/S0016-5085(87)91074-2; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PATHAK S, 1989, CELL MOL BIOL COLON, P139; PINTO M, 1983, BIOL CELL, V47, P323; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SPENCER CA, 1990, ONCOGENE, V5, P777; STROBL L, 1992, EMBO J, V9, P3307; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; Weston K M, 1990, Semin Cancer Biol, V1, P371; WHITEHEAD RH, 1987, CANCER RES, V47, P2683; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; WHITEHEAD RH, 1986, GUT, V27, P1447; WU C, 1994, ONCOGENE, V9, P991; XU L, 1995, ONCOGENE, V11, P1865; XU L, 1991, MOL CELL BIOL, V11, P7006; YOKATA J, 1986, SCIENCE, V231, P261; YOUNG J, 1993, ONCOGENE, V8, P671; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	63	51	54	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1715	1723		10.1038/sj.onc.1201007	http://dx.doi.org/10.1038/sj.onc.1201007			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135073				2022-12-25	WOS:A1997WR89300010
J	Avigad, S; Barel, D; Blau, O; Malka, A; Zoldan, M; Mor, C; Fogel, M; Cohen, IJ; Stark, B; Goshen, Y; Stein, J; Zaizov, R				Avigad, S; Barel, D; Blau, O; Malka, A; Zoldan, M; Mor, C; Fogel, M; Cohen, IJ; Stark, B; Goshen, Y; Stein, J; Zaizov, R			A novel germ line p53 mutation in intron 6 in diverse childhood malignancies	ONCOGENE			English	Article						p53; germ line mutation; intron; childhood malignancies	TUMOR-SUPPRESSOR GENE; CANCER-PRONE FAMILY; SPLICING MUTATION; FRAUMENI-SYNDROME; PATIENT; EXPRESSION; PREVALENCE; NEOPLASMS; CHILDREN; PROTEIN	Screening for p53 mutations in exons 5 to 8 in 124 pediatric malignancies identified 18 abnormal shifts using single strand conformation polymorphism: 12 were missense mutations and in 6, no mutation was detected in the exon or in the splice donor acceptor sequences. Sequencing was then performed in the adjacent introns, revealing a G to A base substitution at 39 base pairs upstream to exon 7. This mutation was identified in the germ line of five of the patients, and also in the father of one, whose parents mere available. For comparison, of the 184 normal controls similarly screened, only one had this mutation (P=0.036). Positive staining of p53 protein was observed in three of the paraffin embedded tissues that were available: brain tumor, rhabdomyosarcoma, and lymphocytes from a normal lymph node from the rhabdomyosarcoma patient. All tumors with the identified intron mutation were Li-Fraumeni syndrome tumors. Sequencing of all exons including splice sites was performed and revealed no mutation. We suggest that this mutation in intron 6 of the p53 gene stabilizes the mild type p53 protein, resulting in its abnormal accumulation. Mutations in the noncoding region of p53 should be further studied.	RABIN MED CTR,DEPT PATHOL,PETAH TIQWA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL; KAPLAN MED CTR,DIV IMMUNOL,REHOVOT,ISRAEL	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Kaplan Medical Center	Avigad, S (corresponding author), FELSENSTEIN RES CTR,SCHNEIDER CHILDRENS MED CTR ISRAEL,PETAH TIQWA,ISRAEL.		Cohen, Ian/H-3358-2013					BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BIRCH JM, 1994, CANCER RES, V54, P1298; BRUGIERES L, 1993, CANCER RES, V53, P452; FELIX CA, 1993, ONCOGENE, V8, P1203; FOGEL M, 1990, DIFFERENTIATION, V45, P242, DOI 10.1111/j.1432-0436.1990.tb00478.x; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JOLLY KW, 1994, ONCOGENE, V9, P97; LAW JC, 1991, CANCER RES, V51, P6358; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MALKINSON AM, 1994, MOL CARCINOGEN, V10, P61, DOI 10.1002/mc.2940100202; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PELLER S, 1995, DNA CELL BIOL, V14, P98; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; Sambrook J., 2002, MOL CLONING LAB MANU; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRAUSS EA, 1995, CANCER RES, V55, P3237; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	25	40	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1541	1545		10.1038/sj.onc.1200990	http://dx.doi.org/10.1038/sj.onc.1200990			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129144				2022-12-25	WOS:A1997WQ54800004
J	Yang, JJ; Stern, DB				Yang, JJ; Stern, DB			The spinach chloroplast endoribonuclease CSP41 cleaves the 3'-untranslated region of petD mRNA primarily within its terminal stem-loop structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' INVERTED REPEATS; ESCHERICHIA-COLI; GENE-EXPRESSION; PROTEIN; MUTAGENESIS; MATURATION; SEQUENCES; STABILITY; BINDING	3'-Untranslated region stem-loop structures are major determinants of chloroplast mRNA stability, The 3' stem-loop region of spinach petD precursor mRNA (pre-mRNA), a chloroplast gene encoding subunit nV of the cytochrome b(6) . f complex, forms a stable RNA-protein complex in vitro with chloroplast stem loop binding proteins (CSPs) of 55, 41, and 29 kDa. We have previously purified CSP41 and cloned the corresponding cDNA. In vitro studies demonstrated that CSP41 is a bifunctional protein that displays both endoribonuclease and RNA-binding activities, In this work, the RNase activity of CSP41 is further characterized using the bacterially expressed protein, Our data show that CSP41 cleaves both single-stranded and double-stranded RNAs but not DNA, However, it exhibits a preference for stem-loop-containing RNAs, When the 3'-untranslated region of petD pre-mRNA is provided as a substrate, CSP41 specifically cleaves it within the stem-loop region, implying that CSP41 has an important role in the control of petD mRNA stability, Our data also show that the sequence-specific RNA-binding activity of CSP41 affects the rate, but not the specificity, of its RNase activity, suggesting that CSP41 is probably involved in other events of chloroplast RNA metabolism in addition to RNA degradation. By analyzing C-terminal deletions of CSP41, the RNase domain was located between amino acid residues 73 and 191.	CORNELL UNIV, BOYCE THOMPSON INST PLANT RES, ITHACA, NY 14853 USA	Cornell University; Boyce Thompson Institute for Plant Research					NIGMS NIH HHS [1F32GM17056-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BLOWERS AD, 1993, MOL GEN GENET, V238, P339, DOI 10.1007/BF00291992; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CHEN HC, 1991, J BIOL CHEM, V266, P24205; CHEN QY, 1995, MOL CELL BIOL, V15, P2010; Court D. L., 1993, CONTROL MESSENGER RN, P71; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; Drager RG, 1996, RNA, V2, P652; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; GITE SU, 1995, CRIT REV MICROBIOL, V21, P101, DOI 10.3109/10408419509113536; Gruissem W., 1993, CONTROL MRNA STABILI, P329; GUARNEROS G, 1982, P NATL ACAD SCI-BIOL, V79, P238, DOI 10.1073/pnas.79.2.238; HAJNSDORF E, 1994, EMBO J, V13, P3368, DOI 10.1002/j.1460-2075.1994.tb06639.x; HaugelNielsen J, 1996, EMBO J, V15, P3144, DOI 10.1002/j.1460-2075.1996.tb00677.x; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; Higgins C.F., 1993, CONTROL MESSENGER RN, P13; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee H, 1996, PLANT MOL BIOL, V31, P337, DOI 10.1007/BF00021794; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; MAEKAWA K, 1991, EUR J BIOCHEM, V200, P651, DOI 10.1111/j.1432-1033.1991.tb16228.x; NICKELSEN J, 1993, PLANT J, V3, P537, DOI 10.1046/j.1365-313X.1993.03040537.x; PETERSEN C, 1992, MOL MICROBIOL, V6, P277, DOI 10.1111/j.1365-2958.1992.tb01469.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; STERN DB, 1993, MOL CELL BIOL, V13, P2277, DOI 10.1128/MCB.13.4.2277; STERN DB, 1989, J BIOL CHEM, V264, P18742; STERN DB, 1987, CELL, V51, P1145, DOI 10.1016/0092-8674(87)90600-3; STERN DB, 1991, PLANT CELL, V3, P285; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409	35	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12874	12880		10.1074/jbc.272.19.12874	http://dx.doi.org/10.1074/jbc.272.19.12874			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139750	hybrid			2022-12-25	WOS:A1997WY82900087
J	Liu, X; Gupta, AK; Corry, PM; Lee, YJ				Liu, X; Gupta, AK; Corry, PM; Lee, YJ			Hypoglycemia-induced c-Jun phosphorylation is mediated by c-Jun N-terminal kinase 1 and Lyn kinase in drug-resistant human breast carcinoma MCF-7/ADR cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED PROTEIN-KINASE; ENDOTHELIAL-CELLS; TYROSINE KINASES; HA-RAS; GENE; EXPRESSION; PROMOTER; BINDS	We studied the signal transduction mechanism that is involved in c-Jun phosphorylation evident after glucose deprivation in MCF-7/ADR cells, Glucose deprivation caused an immediate increase in tyrosine phosphorylation in MCF-7/ADR cells and specifically activated Lyn kinase, a src family tyrosine kinase. In addition, hypoglycemic treatment strongly activated c-Jun N-terminal kinase 1 (JNK1), leading to the phosphorylation and activation of c-Jun. Experiments with Lyn antisense oligonucleotides demonstrated that Lyn kinase activation was responsible for the activation of JNK1 but not extracellular signal-regulated kinase. We also observed glucose deprivation-induced Ras activation in MCF-7/ADR cells. These results indicate a possible Ras-dependent signaling pathway involving Lyn kinase and JNK1, which leads to the glucose deprivation-induced responses in MCF-7/ADR cells.	WILLIAM BEAUMONT HOSP,DEPT RADIAT ONCOL,RES LABS,ROYAL OAK,MI 48073	Beaumont Health					NCI NIH HHS [CA 8000, CA 44550] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044550, R37CA044550] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELHAFIZ HAM, 1992, MOL ENDOCRINOL, V6, P2079; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Galoforo SS, 1996, MOL CELL BIOCHEM, V155, P163; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GUPTA AK, 1996, IN PRESS MOL CELL BI; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KIM SJ, 1989, J BIOL CHEM, V264, P402; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P9575, DOI 10.1073/pnas.92.21.9575; PLATE KH, 1993, CANCER RES, V53, P5822; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SHIBATA F, 1991, GROWTH FACTORS, V4, P2177; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WINKLES JA, 1992, CANCER RES, V52, P1040; WITTE L, 1989, CANCER RES, V49, P5066; YAN MH, 1994, NATURE, V372, P798; YANG C, 1995, J BIOCHEM-TOKYO, V118, P33, DOI 10.1093/oxfordjournals.jbchem.a124888	37	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11690	11693		10.1074/jbc.272.18.11690	http://dx.doi.org/10.1074/jbc.272.18.11690			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115218	hybrid			2022-12-25	WOS:A1997WX56900006
J	Mertz, JR; Shang, EY; Piantedosi, R; Wei, SH; Wolgemuth, DJ; Blaner, WS				Mertz, JR; Shang, EY; Piantedosi, R; Wei, SH; Wolgemuth, DJ; Blaner, WS			Identification and characterization of a stereospecific human enzyme that catalyzes 9-cis-retinol oxidation - A possible role in 9-cis-retinoic acid formulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							11-CIS RETINOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; RAT; BIOSYNTHESIS; 9-CIS	All-trans- and 9-cis-retinoic acid are active retinoids for regulating expression of retinoid responsive genes, serving as ligands for two classes of ligand-dependent transcription factors, the retinoic acid receptors and retinoid X receptors. Little is known, however, regarding 9-cis retinoic acid formation. We have obtained a 1.4-kilobase cDNA clone from a normalized human breast tissue library, which when expressed in CHO cells encodes a protein that avidly catalyzes oxidation of 9-cis retinol to 9-cis-retinaldehyde. This protein also catalyzes oxidation of 13-cis-retinol at a rate approximately 10% of that of the 9-cis isomer but does not catalyze all-trans-retinol oxidation, NAD(+) was the preferred electron acceptor for oxidation of 9-cis-retinol, although NADP(+) supported low rates of 9-cis-retinol oxidation. The rate of 9-cis-retinol oxidation was optimal at pHs between 7.5 and 8. Sequence analysis indicates that the cDNA encodes a protein of 319 amino acids that resembles members of the short chain alcohol dehydrogenase protein family. mRNA for the protein is most abundant in human mammary tissue followed by kidney and testis, with lower levels of expression in liver, adrenals, lung, pancreas, and skeletal muscle. We propose that this cDNA encodes a previously unknown stereospecific enzyme, 9-cis-retinol dehydrogenase, which probably plays a role in 9-cis-retinoic acid formation.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT OBSTET & GYNECOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST HUMAN NUTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR CANC, NEW YORK, NY 10032 USA; CUNY, SCH MED, DEPT CELL BIOL & ANAT SCI, NEW YORK, NY 10031 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; City University of New York (CUNY) System								Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; Blaner William S., 1994, P229; BLANER WS, 1987, J BIOL CHEM, V262, P53; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; BOERMAN MHEM, 1995, ARCH BIOCHEM BIOPHYS, V321, P434, DOI 10.1006/abbi.1995.1415; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; DURSTER G, 1996, BIOCHEMISTRY-US, V35, P12221; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; Furr Harold C., 1994, P179; Gudas Lorraine J., 1994, P443; HEBUTERNE X, 1995, J LIPID RES, V36, P1264; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; LABRECQUE J, 1993, BIOCHEM CELL BIOL, V71, P85, DOI 10.1139/o93-013; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; Maniatis T., 1982, MOL CLONING; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; PAPPAS RS, 1993, BIOL REPROD, V48, P235, DOI 10.1095/biolreprod48.2.235; Ross A. Catharine, 1994, P521; Saari John C., 1994, P351; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Takatsuka J, 1996, CANCER RES, V56, P675; URBACH J, 1994, BIOCHEM J, V299, P459, DOI 10.1042/bj2990459; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	30	95	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11744	11749		10.1074/jbc.272.18.11744	http://dx.doi.org/10.1074/jbc.272.18.11744			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115228	hybrid			2022-12-25	WOS:A1997WX56900016
J	Kang, SM; Liao, PC; Gage, DA; Esselman, WJ				Kang, SM; Liao, PC; Gage, DA; Esselman, WJ			Identification of in vivo phosphorylation sites of CD45 protein-tyrosine phosphatase in 70Z/3.12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; T-CELLS; KINASE-C; PHOSPHOTYROSINE PHOSPHATASE; SERINE PHOSPHORYLATION; PEPTIDE DEGRADATION; NEGATIVE REGULATION; CHEMICAL PATHWAYS; RECEPTOR; ACTIVATION	Phosphorylation of CD45, a transmembrane protein-tyrosine phosphatase (PTPase), has been proposed to mediate docking of signaling proteins and to modulate PTPase activity, To study the role of phosphorylation in CD45, in vivo phosphorylation sites of CD45 from 70Z/3.12 cells were identified using P-32 labeling, trypsin digestion, two-dimensional peptide mapping, high performance liquid chromatography, phosphoamino acid analysis, matrix-assisted laser desorption/ionization mass spectrometry, and specific enzymatic degradation, Eight phosphopeptides, a through h, were isolated and four phosphorylation sites were identified, All four phosphorylation sites were in the membrane-distal PTPase domain (D2) and the C-terminal tail and none were in the membrane-proximal PTPase domain (D1), One site, Ser(P)(939) peptide h, was in the D2 domain and, by comparison to the three-dimensional structure of PTP1B, is predicted to lie at the apex of the substrate binding loop, Ser(939) was the only in vitro phosphorylation site for protein kinase C among the phosphorylation sites identified, Four of the C-terminal peptides identified (d, e, f, and g) spanned the same sequence and were derived from the same phosphorylation site in the C-terminal tail, Ser(1204), Peptide a was derived from the intact C terminus and comprised a mixture of monophosphorylated peptides containing either Ser(P)(1248) or. Thr(P)(1246). Knowledge of the precise phosphorylation sites of CD45 will lead to the design of experiments to define the role of phosphorylation in PTPase activity and in signaling.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University; Michigan State University					NCI NIH HHS [CA64393] Funding Source: Medline; NCRR NIH HHS [RR00480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA064393] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARENDT CW, 1995, J IMMUNOL, V155, P5095; AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRENNAN TV, 1993, PROTEIN SCI, V2, P331; DEANS JP, 1989, J IMMUNOL, V143, P1233; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; DONOVAN JA, 1993, J AM SOC NEPHROL, V4, P976; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IIDA N, 1994, J BIOL CHEM, V269, P28576; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; JUSTEMENT LB, 1994, IMMUNOL TODAY, V15, P399, DOI 10.1016/0167-5699(94)90268-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; Klaus SJ, 1996, J IMMUNOL, V156, P2743; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; MELKERSONWATSON LJ, 1994, J IMMUNOL, V153, P2004; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; OLIYAI C, 1994, PHARMACEUT RES, V11, P751, DOI 10.1023/A:1018944800691; OLIYAI C, 1993, PHARMACEUT RES, V10, P95, DOI 10.1023/A:1018981231468; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SHACKELFORD DA, 1986, J BIOL CHEM, V261, P8334; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STOVER DR, 1993, TECHNIQUES PROTEIN C, V4, P193; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; TSUDA T, 1990, J PHARM SCI-US, V79, P223, DOI 10.1002/jps.2600790309; VALENTINE MA, 1991, EUR J IMMUNOL, V21, P913, DOI 10.1002/eji.1830210409; VANDERGEER P, 1994, CELL BIOL LAB HDB, V3, P422; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; Woodford-Thomas T, 1993, Semin Cell Biol, V4, P409, DOI 10.1006/scel.1993.1049; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11588	11596						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111075				2022-12-25	WOS:A1997WW00900091
J	Lazarovici, P; Oshima, M; Shavit, D; Shibutani, M; Jiang, H; Monshipouri, M; Fink, D; Movsesyan, V; Guroff, G				Lazarovici, P; Oshima, M; Shavit, D; Shibutani, M; Jiang, H; Monshipouri, M; Fink, D; Movsesyan, V; Guroff, G			Down-regulation of epidermal growth factor receptors by nerve growth factor in PC12 cells is p140(trk)-, Ras-, and Src-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; TYROSINE KINASE; PHEOCHROMOCYTOMA CELLS; AFFINITY; BINDING; PHOSPHORYLATION; MODULATION; MECHANISM	Nerve growth factor (NGF) treatment causes a profound down-regulation of epidermal growth factor receptors during the differentiation of PC12 cells. This process is characterized by a progressive decrease in epidermal growth factor (EGF) receptor level measured by I-125-EGF binding, tyrosine phosphorylation, and Western blotting. Treatment of the cells with NGF for 5 days produces a 95% reduction in the amount of [S-35]methionine-labeled EGF receptors. This down-regulation does not occur in PC12nnr5 cells, which lack the p140(trk) NGF receptor. However, in PC12nnr5 cells stably transfected with p140(trk), the NGF-induced heterologous down-regulation of EGF receptors is reconstituted in part. NGF-induced heterologous down-regulation, but not EGF-induced homologous down-regulation of EGF receptors, is blocked in Ras- and Src-dominant-negative PC12 cells. Treatment with either pituitary adenylate cyclase-activating peptide (PACAP) or staurosporine stimulates neurite outgrowth in PC12 cell variants, but neither induces down-regulation of EGF receptors. NGF treatment of PC12 cells in suspension induces downregulation of EGF receptors in the absence of neurite outgrowth. These results strongly suggest a p140(trk)-, Has- and Src-dependent mechanism of NGF-induced down-regulation of EGF receptors and separate this process from NGF-induced neurite outgrowth in PC12 cells.	NICHHD,GROWTH FACTORS SECT,NIH,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); US Food & Drug Administration (FDA)			Shibutani, Makoto/AGK-2801-2022; Shibutani, Makoto/C-2510-2013	Shibutani, Makoto/0000-0003-3417-9697; 				BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1990, J BIOL CHEM, V265, P235; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BROWN AB, 1991, J NEUROCHEM, V57, P1740, DOI 10.1111/j.1471-4159.1991.tb06376.x; CHANDLER CE, 1983, J CELL PHYSIOL, V114, P321, DOI 10.1002/jcp.1041140311; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P13642; CRUISE JL, 1986, J CELL PHYSIOL, V127, P39, DOI 10.1002/jcp.1041270106; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJITA K, 1990, NEUROCHEM RES, V15, P373, DOI 10.1007/BF00969922; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GULLICK WJ, 1986, CANCER RES, V46, P285; Guroff G., 1985, CELL CULTURE NEUROSC, P245, DOI 10.1007/978-1-4613-2473-7_8; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Keegan K, 1993, Curr Opin Neurobiol, V3, P14, DOI 10.1016/0959-4388(93)90029-X; KHAN MA, 1995, FEBS LETT, V362, P201, DOI 10.1016/0014-5793(95)00250-D; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LAZAROVICI P, 1987, J CELL BIOL, V104, P1611, DOI 10.1083/jcb.104.6.1611; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; LOEB DM, 1993, J NEUROSCI, V13, P2919; MCCAFFREY PG, 1984, J BIOL CHEM, V259, P2502; MOTHE I, 1993, MOL BIOL CELL, V4, P737, DOI 10.1091/mbc.4.7.737; MUKKU VR, 1984, J BIOL CHEM, V259, P6543; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; OSHIMA M, 1995, J NEUROCHEM, V65, P427; REES AR, 1979, NATURE, V281, P309, DOI 10.1038/281309a0; ROZENGURT E, 1981, J BIOL CHEM, V256, P716; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WASILENKO WJ, 1987, J CELL PHYSIOL, V131, P450, DOI 10.1002/jcp.1041310318; Yakovchenko E, 1996, J NEUROCHEM, V67, P540; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	41	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11026	11034		10.1074/jbc.272.17.11026	http://dx.doi.org/10.1074/jbc.272.17.11026			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9110995	hybrid			2022-12-25	WOS:A1997WW00900011
J	Jung, K; Tjaden, B; Altendorf, K				Jung, K; Tjaden, B; Altendorf, K			Purification, reconstitution, and characterization of KdpD, the turgor sensor of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRIVEN POTASSIUM-TRANSPORT; 2 REGULATORY COMPONENTS; SIGNAL TRANSDUCTION; STRUCTURAL PROTEINS; CONTROL EXPRESSION; KINASE-ACTIVITY; KDPABC OPERON; PHOSPHORYLATION; OSMOSENSOR; SYSTEM	In response to K+ availability or medium osmolality, the sensor kinase KdpD and the response regulator KdpE control the expression of the kdpFABC operon, coding for the high affinity K+-translocating Kdp ATPase of Escherichia coli. The stimulus for KdpD to undergo autophosphorylation is believed to be a change in turgor or some effect thereof, reflecting the role of K+ as an important cytoplasmic osmotic solute, The membrane-bound sensor kinase KdpD was overproduced as a fusion protein containing six contiguous histidine residues two amino acids before the C terminus. This KdpD-His(6), protein was functional in vitro and in vivo, KdpD-His(6) was purified from everted membrane vesicles by solubilization with the zwitterionic detergent lauryldimethylamine oxide followed by nickel chelate chromatography and ion exchange chromatography to >99% homogeneity. The solubilized protein was not active with respect to autophosphorylation, but retained the ability to bind a-azido-ATP. KdpD-His(6), was reconstituted into proteoliposomes in a unidirectional inside-out orientation as revealed by ATP accessibility and protease susceptibility. Purified and reconstituted KdpD-His(6), exhibited autokinase activity, and the phosphoryl group could be transferred to KdpE, Furthermore, KdpD-His(6), was found to be the only protein that mediates dephosphorylation of KdpE similar to P.	UNIV OSNABRUCK, FACHBEREICH BIOL CHEM, ABT MIKROBIOL, D-49069 OSNABRUCK, GERMANY	University Osnabruck								AIBA H, 1989, J BIOL CHEM, V264, P14090; ALTENDORF K, 1994, RES MICROBIOL, V145, P374, DOI 10.1016/0923-2508(94)90084-1; ALTENDORF K, 1996, BIOMEMBR, V5, P403; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; Dutta R, 1996, J BIOL CHEM, V271, P1424, DOI 10.1074/jbc.271.3.1424; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; KAMBEROV ES, 1994, J BIOL CHEM, V269, P28294; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1978, P NATL ACAD SCI USA, V75, P3216, DOI 10.1073/pnas.75.7.3216; LJUNGQUIST C, 1989, EUR J BIOCHEM, V186, P563, DOI 10.1111/j.1432-1033.1989.tb15245.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miller J.H., 1972, EXPT MOL GENETICS; NAKASHIMA K, 1993, MOL MICROBIOL, V7, P109, DOI 10.1111/j.1365-2958.1993.tb01102.x; NAKASHIMA K, 1993, J BIOCHEM-TOKYO, V114, P615, DOI 10.1093/oxfordjournals.jbchem.a124226; NAKASHIMA K, 1992, MOL MICROBIOL, V6, P1777, DOI 10.1111/j.1365-2958.1992.tb01350.x; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Puppe W, 1996, J BIOL CHEM, V271, P25027, DOI 10.1074/jbc.271.40.25027; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; ROBERTS DL, 1994, J BIOL CHEM, V269, P8728; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER I, 1994, J BACTERIOL, V176, P4985, DOI 10.1128/jb.176.16.4985-4992.1994; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	45	82	83	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10847	10852						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099740				2022-12-25	WOS:A1997WV26200074
J	Komura, J; Sheardown, SA; Brockdorff, N; SingerSam, J; Riggs, AD				Komura, J; Sheardown, SA; Brockdorff, N; SingerSam, J; Riggs, AD			In vivo ultraviolet and dimethyl sulfate footprinting of the 5' region of the expressed and silent Xist alleles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-CHROMOSOME INACTIVATION; LIGATION-MEDIATED PCR; TRANSCRIPTION FACTORS; METHYLATION ANALYSIS; DROSOPHILA-MELANOGASTER; HETEROCHROMATIC GENE; CRYSTAL-STRUCTURE; HOT-SPOTS; INVIVO; DNA	The Xist (X inactive specific transcript) gene plays an essential role in X chromosome inactivation. To elucidate the mechanisms controlling Xist expression and X inactivation, we examined in vivo DNA-protein interactions in the Xist promoter region in a female mouse cell line (BMSL2), which has distinguishable Xist alleles. In vivo footprinting was accomplished by treatment of cells with dimethyl sulfate or ultraviolet light, followed by Ligation-mediated polymerase chain reaction of purified DNA. The expressed allele on the inactive X chromosome and the silent allele on the active X chromosome were separated by the use of a restriction fragment length polymorphism prior to ligation-mediated polymerase chain reaction, The chromatin structure of the Xist promoter was found to be consistent with the activity state of the Xist gene. The silent allele (on the active X chromosome) showed no footprints, while the expressed allele (on the inactive X chromosome) showed footprints at a consensus sequence for a CCAAT box, two weak Spl sites, and a weak TATA box.	CITY HOPE NATL MED CTR,BECKMAN RES INST,DEPT BIOL,DUARTE,CA 91010; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,SECT COMPARAT BIOL,MED RES COUNCIL CLIN SCI CTR,LONDON W12 0NN,ENGLAND	City of Hope; Beckman Research Institute of City of Hope; Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)				Brockdorff, Neil/0000-0003-4838-2653; Riggs, Arthur/0000-0002-8184-5288	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050575] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BUZIN CH, 1994, DEVELOPMENT, V120, P3529; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; DEVLIN RH, 1990, GENETICS, V125, P129; EBERL DF, 1993, GENETICS, V134, P277; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1993, TRENDS GENET, V9, P123, DOI 10.1016/0168-9525(93)90206-W; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGHEE JD, 1979, P NATL ACAD SCI USA, V76, P2133, DOI 10.1073/pnas.76.5.2133; MIGEON BR, 1993, P NATL ACAD SCI USA, V90, P12025, DOI 10.1073/pnas.90.24.12025; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; PARK JG, 1994, MOL CELL BIOL, V14, P7975, DOI 10.1128/MCB.14.12.7975; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1993, METHOD MOL BIOL, V16, P153; PFIEFER GP, 1993, METHOD ENZYMOL, V225, P567; Pillet N, 1995, P NATL ACAD SCI USA, V92, P12515, DOI 10.1073/pnas.92.26.12515; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; Sambrook J., 2002, MOL CLONING LAB MANU; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; Singer-Sam J., 1993, DNA methylation: molecular biology and biological significance., P358; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; WANG Z, 1988, P NATL ACAD SCI USA, V85, P654, DOI 10.1073/pnas.85.3.654	39	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10975	10980						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099757				2022-12-25	WOS:A1997WV26200091
J	Mira, JP; Dubois, T; Oudinet, JP; Lukowski, S; RussoMarie, F; Geny, B				Mira, JP; Dubois, T; Oudinet, JP; Lukowski, S; RussoMarie, F; Geny, B			Inhibition of cytosolic phospholipase A(2) by annexin V in differentiated permeabilized HL-60 cells - Evidence of crucial importance of domain I type II Ca2+-binding site in the mechanism of inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONIC-ACID RELEASE; TIGHT-BINDING INHIBITORS; MEMBRANE-BINDING; POLYPHOSPHOINOSITIDE PHOSPHODIESTERASE; ANTICOAGULANT PROTEIN; MOLECULAR-STRUCTURE; MONONUCLEAR-CELLS; CALCIUM IONOPHORE; HUMAN NEUTROPHILS	Annexin V belongs to a family of proteins that interact with phospholipids in a Ca2+-dependent manner. This protein has been demonstrated to have anti-phospholipase A(2) activity, However, this effect has never yet been reported with the 85-kDa cytosolic PLA(2) (cPLA(2)), We studied, in a model of differentiated and streptolysin O-permeabilized HL-60 cells, the effect of annexin V on cPLA(2) activity after stimulation by calcium, GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)), formyl-Met-Leu-Phe, or phorbol 12-myristate 13-acetate, Both recombinant and human placental purified annexin V inhibit cPLA(2) activity whatever the stimulus used, The decrease of arachidonic acid release is of 40 and 50%, respectively, at [Ca2+] of 3 and 10 mu M. The mechanism of inhibition was also analyzed, cPLA(2) requires calcium and protein kinase C (PKC) or mitogen activated protein kinase phosphorylation for its activation, As annexin V was shown to be an endogenous inhibitor of PKC, PKC-stimulated cPLA(2) activity was analyzed, Using GF109203x, a specific PKC inhibitor, we demonstrated that this pathway is of minor importance in our model, cPLA(2) inhibition by annexin V is not linked to PKC inhibition, To test the hypothesis of phospholipid depletion, mutants of annexin V were constructed using mutagenesis directed to Ca2+ site, We demonstrate that the Ca2+ site located in domain I is necessary for the inhibitory effect of annexin V on cPLA(2) activity, The site in domain IV is also involved but with less efficiency. In contrast, mutations in site II and III do not modify this effect, Moreover, annexin V mutated on all sites does not inhibit cPLA(2), Thus, we propose a predominant role of module (I/IV) in the biological action of annexin V, which, in physiological conditions, may control cPLA(2) activity by depletion of the phospholipid substrate.	INST COCHIN GENET MOL, INSERM, UNITE 332, F-75014 PARIS, FRANCE; COCHIN UNIV HOSP, MED INTENS CARE UNIT, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			Dubois, Thierry/D-2852-2017	Dubois, Thierry/0000-0003-4739-6164				AARSMAN AJ, 1987, FEBS LETT, V219, P176, DOI 10.1016/0014-5793(87)81212-7; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARROWMAN MM, 1987, J PHYSIOL-LONDON, V383, P115; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; Barwise JL, 1996, J CELL SCI, V109, P247; BASTIAN BC, 1993, J INVEST DERMATOL, V101, P359, DOI 10.1111/1523-1747.ep12365541; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURACK WR, 1994, CHEM PHYS LIPIDS, V73, P209, DOI 10.1016/0009-3084(94)90182-1; BURGER A, 1994, J MOL BIOL, V237, P479, DOI 10.1006/jmbi.1994.1249; CHAKRABORTI S, 1992, EUR J BIOCHEM, V206, P965, DOI 10.1111/j.1432-1033.1992.tb17007.x; CHAPLINSKI TJ, 1986, LEUKEMIA RES, V10, P611, DOI 10.1016/0145-2126(86)90263-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; COMERA C, 1990, EUR J BIOCHEM, V188, P139, DOI 10.1111/j.1432-1033.1990.tb15381.x; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; CROXTALL JD, 1995, BIOCHEM PHARMACOL, V50, P465, DOI 10.1016/0006-2952(95)00156-T; Croxtall JD, 1996, BIOCHEM BIOPH RES CO, V220, P491, DOI 10.1006/bbrc.1996.0432; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUBOIS T, 1995, J RHEUMATOL, V22, P1230; DUBOIS T, 1995, BIOCHEM J, V310, P243, DOI 10.1042/bj3100243; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; EVANS TC, 1994, BIOCHEMISTRY-US, V33, P13231, DOI 10.1021/bi00249a009; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P8087, DOI 10.1021/bi00399a011; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GENY B, 1989, CELL SIGNAL, V1, P165, DOI 10.1016/0898-6568(89)90006-5; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOOSSENS ELJ, 1995, FEBS LETT, V359, P155, DOI 10.1016/0014-5793(95)00032-5; HAYASHI H, 1990, BIOCHEM J, V269, P709, DOI 10.1042/bj2690709; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; KIM KM, 1994, FEBS LETT, V343, P251, DOI 10.1016/0014-5793(94)80566-0; KOSTER JJ, 1993, BIOCHEM J, V291, P595, DOI 10.1042/bj2910595; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; Liemann S, 1996, J MOL BIOL, V258, P555, DOI 10.1006/jmbi.1996.0268; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Maniatis T, 1989, MOL CLONING; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; NELSON MR, 1995, BIOCHEMISTRY-US, V34, P3121, DOI 10.1021/bi00009a044; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NIELSON CP, 1991, BIOCHIM BIOPHYS ACTA, V1095, P83, DOI 10.1016/0167-4889(91)90048-3; PALMI M, 1995, EUR J PHARMACOL, V281, P97, DOI 10.1016/0014-2999(95)00304-4; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; ROTHHUT B, 1987, FEBS LETT, V219, P169, DOI 10.1016/0014-5793(87)81211-5; RUSSOMARIE F, 1991, PROSTAG LEUKOTR ESS, V42, P83, DOI 10.1016/0952-3278(91)90072-D; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; RZIGALINSKI BA, 1994, BBA-MOL CELL RES, V1223, P219, DOI 10.1016/0167-4889(94)90229-1; SCHLAEPFER DD, 1992, BIOCHEMISTRY-US, V31, P1886, DOI 10.1021/bi00121a043; SierraHonigmann R, 1996, LAB INVEST, V74, P684; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; STUTCHFIELD J, 1988, BIOCHEM J, V250, P375, DOI 10.1042/bj2500375; TATHAM PER, 1990, PEPTIDE HORMONES PRA, P257; THIEL C, 1991, J BIOL CHEM, V266, P14732; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROTTER PJ, 1995, BIOCHEM J, V308, P591, DOI 10.1042/bj3080591; VANHEERDE WL, 1995, THROMB HAEMOSTASIS, V73, P172; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; XING MZ, 1992, J BIOL CHEM, V267, P25966; XING MZ, 1992, J BIOL CHEM, V267, P6602; YU H, 1995, J BIOL CHEM, V270, P15719, DOI 10.1074/jbc.270.26.15719	72	100	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10474	10482						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099690				2022-12-25	WOS:A1997WV26200024
J	Wilmer, WA; Tan, LC; Dickerson, JA; Danne, M; Rovin, BH				Wilmer, WA; Tan, LC; Dickerson, JA; Danne, M; Rovin, BH			Interleukin-1 beta induction of mitogen-activated protein kinases in human mesangial cells - Role of oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRESCENTIC GLOMERULONEPHRITIS; TYROSINE KINASE; REDOX REGULATION; IN-VITRO; PHOSPHORYLATION; EXPRESSION; RECEPTOR; ALPHA; RAT; CULTURES	Interleukin-1 beta (IL-1 beta) significantly influences renal cellular function through the induction of several gene products, The molecular mechanisms involved in gene regulation by IL-1 beta are poorly understood; however, the appearance of novel tyrosine phosphoproteins in IL-1 beta-treated cells suggests that IL-1 beta may function through tyrosine phosphoprotein intermediates, The mitogen-activated protein (MAP) kinases are tyrosine phosphoproteins that could potentially mediate the effects of IL-1 beta, Protein tyrosine phosphorylation following IL-1 beta treatment may be dependent on redox changes since the IL-1 beta receptor is not a protein-tyrosine kinase and oxidation has been shown to induce tyrosine phosphorylation, In this report we demonstrate that conditioning human glomerular mesangial cells with IL-1 beta results in the tyrosine phosphorylation and activation of two members of the MAP kinase family, extracellular signal-regulated protein kinase 2 (ERK2) and p54 Jun-NH2-terminal kinase (JNK), This effect of IL-1 beta is abrogated by pretreating cells with the antioxidants N-acetyl-L-cysteine or dithiothreitol, Furthermore, the effects of IL-1 beta on ERK and JNK activation are reproduced by treating mesangial cells with membrane-permeable oxidants, IL-1 beta and oxidants also cause phosphorylation and activation of the upstream ERK regulatory element MAP kinase kinase. Interestingly, IL-1 beta, but not exogenous oxidants, causes phosphorylation of the upstream JNK activator, JNK kinase. These data indicate that IL-1 beta activates ERK2 through an oxidation-dependent pathway, Exogenous oxidants and IL-1 beta activate JNK through different upstream mechanisms; however, antioxidant inhibition of JNK activation indicates that endogenous oxidants may play a role in IL-1 beta-induced JNK activation, Thus IL-1 beta may affect mesangial cell function by activating MAP kinases, which can then regulate gene transcription, Furthermore, reactive oxygen species released during inflammatory glomerular injury may also affect mesangial function through a MAP kinase signal.	OHIO STATE UNIV,DIV NEPHROL,DEPT MED,COLUMBUS,OH 43210	Ohio State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046055] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29 DK46055] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ATKINS RC, 1995, KIDNEY INT, V48, P576, DOI 10.1038/ki.1995.330; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BIRD TA, 1992, CYTOKINE, V4, P429, DOI 10.1016/1043-4666(92)90003-A; CANO E, 1995, J CELL SCI, V108, P3599; CHEN WP, 1995, J PATHOL, V175, P327, DOI 10.1002/path.1711750311; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DaphnaIken D, 1995, AM J PHYSIOL-RENAL, V269, pF831, DOI 10.1152/ajprenal.1995.269.6.F831; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Guan ZH, 1996, AM J PHYSIOL-RENAL, V270, pF634, DOI 10.1152/ajprenal.1996.270.4.F634; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HUWILER A, 1994, FEBS LETT, V350, P135, DOI 10.1016/0014-5793(94)00754-3; JENKINS DAS, 1994, NEPHROL DIAL TRANSPL, V9, P1228; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; LAN HY, 1995, KIDNEY INT, V47, P1303, DOI 10.1038/ki.1995.185; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LONNEMAN G, 1995, KIDNEY INT, V47, P837, DOI 10.1038/ki.1995.126; LOVETT DH, 1988, KIDNEY INT, V34, P26, DOI 10.1038/ki.1988.141; MATSUMOTO K, 1989, CLIN EXP IMMUNOL, V75, P123; MATSUMOTO K, 1988, AM J NEPHROL, V8, P463, DOI 10.1159/000167656; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MOUTABARRIK A, 1994, EXP NEPHROL, V2, P196; MUHL H, 1995, J CLIN INVEST, V95, P1941, DOI 10.1172/JCI117876; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NORONHA IL, 1993, KIDNEY INT, V43, P682, DOI 10.1038/ki.1993.98; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RADEKE HH, 1990, KIDNEY INT, V37, P767, DOI 10.1038/ki.1990.44; ROVIN BH, 1991, ANNU REV MED, V42, P25, DOI 10.1146/annurev.med.42.1.25; ROVIN BH, 1994, KIDNEY INT, V46, P1059, DOI 10.1038/ki.1994.367; ROVIN BH, 1992, J IMMUNOL, V148, P2148; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SEDOR JR, 1992, KIDNEY INT, V41, P595, DOI 10.1038/ki.1992.89; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; TANG WW, 1994, J CLIN INVEST, V93, P273, DOI 10.1172/JCI116956; TETSUKA T, 1995, AM J PHYSIOL-CELL PH, V269, pC55, DOI 10.1152/ajpcell.1995.269.1.C55; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WERBER HI, 1987, J IMMUNOL, V138, P3207; YAN MH, 1994, NATURE, V372, P798; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; ZOJA C, 1991, AM J PATHOL, V138, P991; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	50	108	110	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10877	10881						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099744				2022-12-25	WOS:A1997WV26200078
J	Woodward, R; Stevens, EB; MurrellLagnado, RD				Woodward, R; Stevens, EB; MurrellLagnado, RD			Molecular determinants for assembly of G-protein-activated inwardly rectifying K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC POTASSIUM CHANNEL; XENOPUS-OOCYTES; RECTIFIER; SUBUNITS; CLONING; SHAKER; FAMILY; EXPRESSION; PATTERNS; DOMAIN	Kir3.1 and Kir3.2 associate to form G-protein-activated, inwardly rectifying K+ channels. To identify regions involved in the coassembly of these subunits, truncated Kir3.1 polypeptides were coexpressed with epitope-tagged subunits in an in vitro translation system, N-terminal, C-terminal, and core region polypeptides were coimmunoprecipitated with both Kir3.2 and Kir3.1, suggesting that multiple elements distributed throughout the Kir3.1 polypeptide contribute to intersubunit binding interactions. The Kir3.2 C-terminal polypeptide coimmunoprecipitated with the Kir3.1 C-terminal polypeptide, but neither region recognized the N-terminal domain and core region of the Kir3.1 subunit. This suggests that within Kir3 channels the C-terminal domains of neighboring subunits interact. Coexpression of the truncated polypeptides with Kir3.1 and Kir3.2 in Xenopus oocytes reduced functional expression of the heteromeric channels. Constructs encoding the core region plus N-terminal and proximal C-terminal regions competed more effectively than the core region alone, which supports the contribution of all three regions to intersubunit binding interactions. Proximal and distal segments of the C-terminal domain were as effective at inhibiting functional expression as the entire C-terminal domain.	UNIV CAMBRIDGE, DEPT PHARMACOL, CAMBRIDGE CB2 1QJ, ENGLAND	University of Cambridge				Murrell-Lagnado, Ruth/0000-0003-2743-7977	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; CHANDY KG, 1993, TRENDS PHARMACOL SCI, V14, P434, DOI 10.1016/0165-6147(93)90181-I; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DREWE JA, 1992, J NEUROSCI, V12, P538; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; Fink M, 1996, FEBS LETT, V378, P64, DOI 10.1016/0014-5793(95)01388-1; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Kubo Y, 1996, BIOCHEM BIOPH RES CO, V227, P240, DOI 10.1006/bbrc.1996.1496; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Tucker SJ, 1996, J BIOL CHEM, V271, P5866, DOI 10.1074/jbc.271.10.5866; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7; ZHAO B, 1994, NEURON, V13, P1205, DOI 10.1016/0896-6273(94)90058-2	42	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10823	10830						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099737				2022-12-25	WOS:A1997WV26200071
J	Yurkova, MS; Murray, MT				Yurkova, MS; Murray, MT			A translation regulatory particle containing the Xenopus oocyte Y box protein mRNP3+4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEINS; NUCLEIC-ACID-BINDING; MESSENGER-RIBONUCLEOPROTEIN PARTICLES; CASEIN-KINASE-II; DNA-BINDING; RABBIT RETICULOCYTES; NUCLEOLAR PROTEIN; CYTOPLASMIC MRNP; SOMATIC-CELLS; TRANSCRIPTION	In oocytes, nontranslated maternal mRNAs are packaged by protein into messenger ribonucleoprotein particles (mRNPs) that are masked from translation by protein-RNA interactions. Proteins associated with such masked states of mRNAs are particularly abundant in amphibian oocytes, One of these mRNP proteins from Xenopus oocytes, mRNP3+4 (also called FRG Y2a/b or p54/p56), binds to diverse mRNAs independent of their sequence and is the germ line member of the evolutionarily conserved Y box protein multigene family. Xenopus oocytes contain soluble pools of mRNP3+4 6 S oligomers, probably dimers, and larger similar to 15 S particles containing mRNP3+4 and additional proteins. Here we report the purification of this larger form as an similar to 320-kDa particle that contains mRNP3+4 and nine additional polypeptides, including mRNA-binding polypeptides of 34 and 36 kDa and a doublet of 110/105 kDa that proved to be nucleolin, The particle has a protein kinase activity that phosphorylates its own mRNP3+4, nucleolin, and a 31-kDa polypeptide component and exhibits translational inhibition in both the wheat germ extract and rabbit reticulocyte lysate systems. The presence of mRNP3+4 and nucleolin in this large translation regulatory particle suggests that it participates in an early step of mRNP assembly and masking.	WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48202	Wayne State University								ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; BENEVENTE R, 1985, CELL, V41, P177; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; CUMMINGS A, 1988, J CELL BIOL, V107, P45, DOI 10.1083/jcb.107.1.45; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KANDROR KV, 1984, FEBS LETT, V170, P33, DOI 10.1016/0014-5793(84)81363-0; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KWON YK, 1993, DEV BIOL, V158, P90, DOI 10.1006/dbio.1993.1170; LADOMERY M, 1994, NUCLEIC ACIDS RES, V22, P5582, DOI 10.1093/nar/22.25.5582; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MCKNIGHT SL, 1976, CELL, P805; MINICH WB, 1993, EUR J BIOCHEM, V212, P633, DOI 10.1111/j.1432-1033.1993.tb17701.x; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MINICH WB, 1989, FEBS LETT, V257, P257, DOI 10.1016/0014-5793(89)81547-9; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; NIKOLAJCZYK BS, 1995, BIOL REPROD, V52, P524, DOI 10.1095/biolreprod52.3.524; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; Richter J. H., 1987, Terrestrial Propagation Characteristics in Modern Systems of Communications, Surveillance, Guidance and Control (AGARD-CP-407), p11/1; RICHTER JD, 1983, J BIOL CHEM, V258, P4864; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; SAKURA H, 1988, GENE, V73, P499; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SIMON R, 1992, GENE DEV, V6, P2580, DOI 10.1101/gad.6.12b.2580; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; STEPANOV AS, 1982, FEBS LETT, V141, P157, DOI 10.1016/0014-5793(82)80036-7; STICK R, 1985, CELL, V41, P191, DOI 10.1016/0092-8674(85)90073-X; Tafuri Sherrie R., 1993, Trends in Cell Biology, V3, P94, DOI 10.1016/0962-8924(93)90080-K; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	60	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10870	10876						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099743				2022-12-25	WOS:A1997WV26200077
J	Bunone, G; Mariotti, A; Compagni, A; Morandi, E; DellaValle, G				Bunone, G; Mariotti, A; Compagni, A; Morandi, E; DellaValle, G			Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma cells	ONCOGENE			English	Article						NGF receptors; apoptosis; neuroblastoma; tumor progression	NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; TRK PROTOONCOGENE; N-MYC; NEURONAL DIFFERENTIATION; INVERSE RELATIONSHIP; SIGNAL-TRANSDUCTION; RET PROTOONCOGENE; EXPRESSION; SYSTEM	The low-affinity nerve growth factor receptor p75(NTR) belongs to a membrane receptor superfamily whose members, in certain cell types, are able to transduce an apoptotic signal. To investigate the effect of p75(NTR) expression in neuroblastoma cells, we transfected the p75(NTR) CDNA into SK-N-BE cells, a neuroblastoma cell line that lacks expression of both p75(NTR) and TrkA. Cell clones expressing elevated levels of p75(NTR) showed a high degree of cell death by apoptosis, even in serum-supplemented medium. Moreover, the level of apoptosis correlated directly with the expression lever of the receptor, indicating that p75(NTR) could activate the cell death program by itself. Clones expressing p75(NTR) showed a dramatic increase of cell death when switched into serum-free medium; these cultures rapidly extinguished. This apoptotic effect was greatly inhibited by NGF treatment. Our results support the hypothesis that p75(NTR), when it is not bound by NGF, may play a role in neuronal selection during embryonic development and suggest that neuroblastomas may arise from immature neuroblasts that escape programmed cell death. Therefore, the loss of p75(NTR) expression in developing neural crest cells might be a primary event in the genesis of neuroblastoma.	UNIV PAVIA,DEPT GENET & MICROBIOL,I-27100 PAVIA,ITALY; UNIV BOLOGNA,DEPT BIOL,I-40126 BOLOGNA,ITALY	University of Pavia; University of Bologna				Mariotti, Agnese/0000-0002-3704-7908; compagni, amelia/0000-0003-1744-3134				AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BIEDLER JL, 1973, CANCER RES, V33, P2643; BONGARZONE I, 1994, CANCER RES, V54, P2979; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN H, 1990, ONCOGENE, V5, P437; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Frade JM, 1996, NATURE, V383, P166; GUIN GH, 1969, AM J CLIN PATHOL, V51, P126; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kinnier-Wilson LM, 1974, BRIT MED J, V3, P301; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOGNER P, 1993, CANCER RES, V53, P2044; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KF, 1994, DEVELOPMENT, V120, P1027; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Peverali FA, 1996, ONCOGENE, V12, P457; PFLUG BR, 1992, CANCER RES, V52, P5403; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REPRESA J, 1991, P NATL ACAD SCI USA, V88, P8016, DOI 10.1073/pnas.88.18.8016; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1	46	63	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1463	1470		10.1038/sj.onc.1200972	http://dx.doi.org/10.1038/sj.onc.1200972			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136990				2022-12-25	WOS:A1997WT58400009
J	Volpert, OV; Dameron, KM; Bouck, N				Volpert, OV; Dameron, KM; Bouck, N			Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity	ONCOGENE			English	Article						neovascularization; fibrosarcoma; VEGF; thrombospondin; tumor progression	ENDOTHELIAL GROWTH-FACTOR; SOFT-TISSUE SARCOMAS; WILD-TYPE P53; N-RAS; MALIGNANT PROGRESSION; EXPRESSION; THROMBOSPONDIN; ABNORMALITIES; INHIBITOR; CELLS	As normal cells progress to malignancy they must acquire an angiogenic phenotype that will enable them to attract the blood vessels necessary to support their progressive growth. Here we define the mechanism by which human fibroblasts cultured from Li Fraumeni patients and progressing to tumorigenicity in vitro become angiogenic. Initially cells were anti-angiogenic due to the secretion of high levels of inhibitory thrombospondin that overrode the modest amounts of the major inducer, vascular endothelial cell growth factor (VEGF), that were also produced. Cells became fully angiogenic in two steps, the first dependent on the loss of both alleles of wild-type p53 which caused a drop of at least 20-fold in secreted thrombospondin and a fourfold increase in secreted VEGF. Angiogenic activity increased again upon transformation by activated ras due to a further twofold increase in VEGF. Changes in relative levels of VEGF mRNA were sufficient to account for changes in secreted protein levels and in overall angiogenic activity. These studies demonstrate that an angiogenic phenotype able to support tumorigenicity can arise in a step-wise fashion in response to both oncogene activation and tumor suppressor gene loss and involve both a decrease in the secretion of inhibitors and the sequential ratcheting up of the secretion of inducers of angiogenesis.	NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center					NCI NIH HHS [CA52750, CA64239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDEOL Y, 1988, INT J CANCER, V41, P732, DOI 10.1002/ijc.2910410516; ANDREASSEN A, 1993, CANCER RES, V53, P468; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P138; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; CORDONCARDO C, 1994, CANCER RES, V54, P794; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DAMERON KM, 1994, COLD SPRING HARB SYM, V59, P483, DOI 10.1101/SQB.1994.059.01.053; DROBNJAK M, 1994, J NATL CANCER I, V86, P549, DOI 10.1093/jnci/86.7.549; Folkman J, 1995, MOL BASIS CANC, P206; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LEACH FS, 1993, CANCER RES, V53, P2231; MAILLET MW, 1992, MODERN PATHOL, V5, P410; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; POLLOCK RE, 1994, SEMIN SURG ONCOL, V10, P315, DOI 10.1002/ssu.2980100503; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RAK J, 1995, CANCER RES, V55, P4575; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SEIMEISTER G, 1996, CANCER RES, V56, P2299; STRATTON MR, 1989, CANCER RES, V49, P6324; SUGIHARA T, 1994, BBA-MOL CELL RES, V1224, P365, DOI 10.1016/0167-4889(94)90269-0; TANAKA T, 1986, CANCER RES, V46, P1465; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	32	170	187	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1495	1502		10.1038/sj.onc.1200977	http://dx.doi.org/10.1038/sj.onc.1200977			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136993				2022-12-25	WOS:A1997WT58400012
J	Dodson, RE; Shapiro, DJ				Dodson, RE; Shapiro, DJ			Vigilin, a ubiquitous protein with 14 K homology domains, is the estrogen-inducible vitellogenin mRNA 3'-untranslated region-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; EXPRESSION; SEQUENCE; GENE; RECEPTOR; CELLS; IDENTIFICATION; STABILIZATION; STABILITY; FMR1	RNA-binding proteins containing KH domains are widely distributed. One KH domain protein of unknown function, vigilin (also known as the high density lipoprotein-binding protein), contains 14 KH domains and is ubiquitous in vertebrate cells. We previously used RNA gel mobility shift assays to describe an estrogen-inducible protein which binds specifically to a segment of the 3'-untranslated region (3'-UTR) of vitellogenin mRNA, an area which has been implicated in the estrogen-mediated stabilization of vitellogenin mRNA, Here we show that the vitellogenin mRNA-binding protein (VitRNABP) is vigilin. The VitRNABP was isolated as a 150-155-kDa protein on a vitellogenin mRNA 3'-UTR affinity column. Peptide microsequencing revealed that the purified protein was vigilin, a conclusion confirmed in Western blot analysis with antibodies to vigilin. Direct confirmation that vigilin is the VitRNABP was obtained from RNA gel mobility shift assays which demonstrated that antibodies to chicken vigilin supershifted the Xenopus VitRNABP band. Xenopus liver vigilin mRNA and the VitRNABP exhibited similar induction by estrogen, providing additional confirmation that vigilin is the estrogen-inducible protein which binds to the 3'-UTR of estrogen-stabilized vitellogenin mRNA. These data support a role for vigilin in the hormonal control of mRNA metabolism.	UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050080] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50080] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BAKER HJ, 1977, J BIOL CHEM, V252, P8428; BARTON MC, 1988, P NATL ACAD SCI USA, V85, P7119, DOI 10.1073/pnas.85.19.7119; BLUME JE, 1989, NUCLEIC ACIDS RES, V17, P9003, DOI 10.1093/nar/17.22.9003; BROCK ML, 1983, J BIOL CHEM, V258, P5449; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEN ZJ, 1994, ENDOCRINOLOGY, V134, P2360, DOI 10.1210/en.134.6.2360; Dejgaard K, 1996, EUR J BIOCHEM, V241, P425, DOI 10.1111/j.1432-1033.1996.00425.x; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; DODSON RE, 1995, J STEROID BIOCHEM, V52, P505, DOI 10.1016/0960-0760(95)00018-U; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kruse C, 1996, BIOCHEM J, V320, P247, DOI 10.1042/bj3200247; Kugler S, 1996, FEBS LETT, V382, P330, DOI 10.1016/0014-5793(96)00204-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NAGAI K, 1994, RNA PROTEIN INTERACT; NEUYILIK G, 1993, EUR J BIOCHEM, V213, P727, DOI 10.1111/j.1432-1033.1993.tb17813.x; NIELSEN DA, 1990, MOL CELL BIOL, V10, P371, DOI 10.1128/MCB.10.1.371; PASTORI RL, 1990, BIOCHEMISTRY-US, V29, P2599, DOI 10.1021/bi00462a024; PLENZ G, 1994, HUM GENET, V93, P575; PLENZ G, 1993, CELL TISSUE RES, V273, P381, DOI 10.1007/BF00312841; Rumpel E, 1996, ANN ANAT, V178, P337, DOI 10.1016/S0940-9602(96)80089-6; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SHAPIRO DJ, 1989, RECENT PROG HORM RES, V45, P29; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; WHITE B, 1994, PCR PROTOCOLS METHOD, V15; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647	31	92	94	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12249	12252		10.1074/jbc.272.19.12249	http://dx.doi.org/10.1074/jbc.272.19.12249			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139664	hybrid			2022-12-25	WOS:A1997WY82900001
J	Santoyo, J; Alcalde, J; Mendez, R; Pulido, D; deHaro, C				Santoyo, J; Alcalde, J; Mendez, R; Pulido, D; deHaro, C			Cloning and characterization of a cDNA encoding a protein synthesis initiation factor-2 alpha (eIF-2 alpha) kinase from Drosophila melanogaster - Homology to yeast GCN2 protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; GUANINE-NUCLEOTIDE EXCHANGE; TRANSFER-RNA-SYNTHETASES; TRANSLATIONAL CONTROL; FACTOR-II; PHOSPHORYLATION; REGULATORS; SEQUENCE; EMBRYOS; EIF-2	Phosphorylation of the alpha subunit of the eukaryotic initiation factor 2 (eIF-2 alpha) is one of the best-characterized mechanisms for downregulating protein synthesis in mammalian cells in response to various stress conditions. In Drosophila, such a regulatory mechanism has not been elucidated, We report the molecular cloning and characterization of DGCN2, a Drosophila eIF-2 alpha kinase related to yeast GCN2 protein kinase, DGCN2 contains all of the 12 catalytic subdomains characteristic of eukaryotic Ser/Thr protein kinases and the conserved sequence of eIF-2 alpha kinases in subdomain V. A large insert of 94 amino acids, which is characteristic of eIF-2 alpha kinases, is also present between subdomains TV and V. It is particularly notable that DGCN2 possesses an amino acid sequence related to class II aminoacyl-tRNA synthetases, a unique feature of yeast GCN2 protein kinase, DGCN2 expression is developmentally regulated, During embryogenesis, DGCN2 mRNA is dynamically expressed in several tissues, Interestingly, at later stages this expression becomes restricted to a few cells of the central nervous system, Affinity-purified antibodies, raised against a synthetic peptide based on the predicted DGCN2 sequence, specifically immunoprecipitated an eIF-2 alpha kinase activity and recognized an similar to 175 kDa phosphoprotein in Western blots of Drosophila embryo extracts.	UNIV AUTONOMA MADRID,FAC CIENCIAS,CSIC,CTR BIOL MOL SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Santoyo-Lopez, Javier/C-9714-2012	Santoyo-Lopez, Javier/0000-0003-1988-5059; Mendez, Raul/0000-0002-1952-6905				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Campos-Ortega J.A., 1985, EMBRYONIC DEV DROSOP, P3, DOI 10.1007/978-3-662-02454-6_2; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHEFALO PJ, 1994, J BIOL CHEM, V269, P25788; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Harlow E., 1988, ANTIBODIES LAB MANUA; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Leptin M, 1995, ANNU REV CELL DEV BI, V11, P189; MATEU MG, 1987, EUR J BIOCHEM, V165, P507, DOI 10.1111/j.1432-1033.1987.tb11468.x; MENDEZ R, 1992, J BIOL CHEM, V267, P11500; MENDEZ R, 1994, J BIOL CHEM, V269, P6170; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P217; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	35	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12544	12550		10.1074/jbc.272.19.12544	http://dx.doi.org/10.1074/jbc.272.19.12544			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139706	hybrid			2022-12-25	WOS:A1997WY82900043
J	Scorrano, L; Petronilli, V; Bernardi, P				Scorrano, L; Petronilli, V; Bernardi, P			On the voltage dependence of the mitochondrial permeability transition pore - A critical appraisal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATIONS; MODULATION; MEMBRANE; PROTONS; MEGACHANNEL; TRANSPORT	The mitochondrial permeability transition pore, a cyclosporin A sensitive channel, can be opened by the addition of protonophoric uncouplers such as carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) after energy-dependent accumulation of Ca2+, We have proposed that the relevant effect of FCCP on the pore is membrane depolarization, suggesting that this channel is voltage-dependent (Bernardi, P. (1992) J. Biol. Chem. 267, 8334-8339), Here, we reconsider this hypothesis in the light of recent observations suggesting that increased production of reactive oxygen species and/or direct effects of FCCP, rather than membrane depolarization, could be the actual triggers of the FCCP-dependent permeability transition, We show that although reactive oxygen species can contribute to the permeability transition, pore opening by FCCP can still be observed under strict anaerobiosis after ATP-dependent Ca2+ accumulation and that the permeability transition can be induced by the addition of valinomycin to respiring mitochondria treated with nigericin in low potassium medium. In this system, pore opening in increasing fractions of mitochondria depends on the concentration of valinomycin, i.e. on the magnitude of the potassium current that determines the extent of membrane depolarization. We conclude that the permeability transition pore is directly modulated by the membrane potential in intact isolated rat liver mitochondria.	UNIV PADUA,SCH MED,DEPT BIOMED SCI,LAB BIOPHYS & MEMBRANE BIOL,I-35121 PADUA,ITALY; CNR,UNIT STUDY BIOMEMBRANES,I-35121 PADUA,ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR)			Bernardi, Paolo/C-3656-2008; Petronilli, Valeria/C-3558-2015; Scorrano, Luca/K-3967-2019; Scorrano, Luca/A-6652-2008	Bernardi, Paolo/0000-0001-9187-3736; Petronilli, Valeria/0000-0003-4026-6404; Scorrano, Luca/0000-0002-8515-8928; Scorrano, Luca/0000-0002-8515-8928				BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Massari S, 1996, J BIOL CHEM, V271, P31942; MCLAUGHLIN SGA, 1980, PHYSIOL REV, V60, P825, DOI 10.1152/physrev.1980.60.3.825; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; STARKOV AA, 1994, FEBS LETT, V355, P305, DOI 10.1016/0014-5793(94)01211-3; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1984, BIOCHIM BIOPHYS ACTA, V767, P231, DOI 10.1016/0005-2728(84)90192-0	26	162	163	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12295	12299		10.1074/jbc.272.19.12295	http://dx.doi.org/10.1074/jbc.272.19.12295			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139672	hybrid			2022-12-25	WOS:A1997WY82900009
J	Yio, XY; Mayer, L				Yio, XY; Mayer, L			Characterization of a 180-kDa intestinal epithelial cell membrane glycoprotein, gp180 - A candidate molecule mediating T cell epithelial cell interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RAT SMALL-INTESTINE; ORAL TOLERANCE; ANTIGEN PRESENTATION; PROTEIN ANTIGENS; OVALBUMIN; LYMPHOCYTES; MICE; RECOGNITION; INDUCTION	Previous studies have shown that normal human intestinal epithelial cells stimulate CD8(+) suppressor T cell proliferation in an allogeneic mixed epithelial/T cell coculture system, which is neither restricted by class I or class II major histocompatibility complex antigens nor by any soluble factors from epithelial cells, Two epithelial specific monoclonal antibodies (mAb), mAb B9 and mAb L12, are potent inhibitors of this mixed epithelial/T cell reaction but not of conventional mixed lymphocyte reactions, While phenotypically distinct by tissue staining, both mAbs recognize a 180-kDa epithelial membrane glycoprotein (gp180), Further characterization of gp180 revealed the following. 1) The protein migrated between 150 and 180 kDa in SDS polyacrylamide gel electrophoresis and could be resolved by Western blot using mAb B9 or mAb L12. 2) The molecule has two forms, an apically sorted glycosylphosphatidylinositol-anchored form and a basolateral transmembrane form, 3) gp180 is heavily N-glycosylated, since N-glycanase treatment results in a >50% reduction in size, 4) Purified gp180 can bind to peripheral blood T cells and activate p56(lck), 5) gp180 can activate p56(lck) in 3G8 (a murine T cell hybridoma transfected with human CD8 alpha cDNA) but not in 3G4 (CD4 transfectant), suggesting that gp180 binds to CD8, Thus, gp180 appears to be a novel regulator of mucosal immune responses.	MT SINAI MED CTR,DIV CLIN IMMUNOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA041583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024671, R01AI023504] Funding Source: NIH RePORTER; NCI NIH HHS [CA41583] Funding Source: Medline; NIAID NIH HHS [AI23504, AI24671] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B, 1989, MOL BIOL CELL, P405; ALSABBAGH A, 1994, EUR J IMMUNOL, V24, P2104, DOI 10.1002/eji.1830240926; ANDREW SM, 1991, CURRENT PROTOCOLS IM; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BLAND PW, 1986, IMMUNOLOGY, V58, P1; BLAND PW, 1986, IMMUNOLOGY, V58, P9; Blumberg R S, 1994, Int Rev Immunol, V11, P15, DOI 10.3109/08830189409061714; CAMPBELL NA, 1996, GASTROENTEROLOGY, V110, pA876; CERFBENSUSSAN N, 1991, MUCOSAL IMMUNOLOGY, V1, P549; HOYNE GF, 1993, IMMUNOLOGY, V80, P204; HOYNE GF, 1993, IMMUNOLOGY, V78, P534; LI Y, 1995, J EXP MED, V182, P1079, DOI 10.1084/jem.182.4.1079; MAYER L, 1990, ADVANCES IN MUCOSAL IMMUNOLOGY, P23; MAYER L, 1987, J EXP MED, V166, P1471, DOI 10.1084/jem.166.5.1471; MAYER L, 1985, J EXP MED, V161, P134, DOI 10.1084/jem.161.1.134; MAYER L, 1992, ANN NY ACAD SCI, V664, P39, DOI 10.1111/j.1749-6632.1992.tb39747.x; MILLER SD, 1979, J IMMUNOL, V123, P2344; MOWAT AM, 1985, IMMUNOLOGY, V56, P253; MOWAT AM, 1986, IMMUNOLOGY, V58, P179; MOWAT AM, 1982, IMMUNOLOGY, V45, P105; NGAN J, 1978, J IMMUNOL, V120, P861; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; PANJA A, 1994, J EXP MED, V179, P943, DOI 10.1084/jem.179.3.943; RATNOFSKY SE, 1987, J EXP MED, V166, P1747, DOI 10.1084/jem.166.6.1747; RICHMAN LK, 1978, J IMMUNOL, V121, P2429; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SELBY WS, 1981, GUT, V22, P169, DOI 10.1136/gut.22.3.169; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; TEITELL M, 1994, CRIT REV IMMUNOL, V14, P1; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; Whitacre CC, 1996, ANN NY ACAD SCI, V778, P217, DOI 10.1111/j.1749-6632.1996.tb21130.x; YOKOYAMA WM, 1991, CURRENT PROTOCOLS IM	32	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	1997	272	19					12786	12792		10.1074/jbc.272.19.12786	http://dx.doi.org/10.1074/jbc.272.19.12786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WY829	9139738	hybrid			2022-12-25	WOS:A1997WY82900075
J	Grolz, D; Laubinger, J; Wilmer, F; Troster, H; Bachmann, M				Grolz, D; Laubinger, J; Wilmer, F; Troster, H; Bachmann, M			Transfection analysis of expression of mRNA isoforms encoding the nuclear autoantigen La/SS-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; LUPUS ANTIGEN-LA; MONOCLONAL-ANTIBODIES; SJOGRENS-SYNDROME; LEADER RNA; PROTEIN; SEQUENCE; BINDING; TRANSCRIPTS; VIRUS	Transcription of the gene encoding for the nuclear autoantigen La resulted in La mRNA isoforms, A promoter switching combined with an alternative splicing pathway replaced the exon 1 with the exon 1', The exon 1' contained GC-rich regions and an oligo(U) tail of 23 uridine residues, Moreover, it encoded for three open reading frames upstream of the La protein reading frame. Despite this unusual structure, when exon 1' La mRNAs were expressed in transfected cells, both exon 1 and 1' La mRNAs were translated to La protein, whereas the upstream open reading frames of the exon 1' were not translated. In addition to full-length exon 1' La mRNAs 5'-shortened exon 1' La mRNAs were detected. The exon 1' 5'-starts varied in dependence on the analyzed tissues. Like the full-length exon 1' La mRNA a 5'-shortened exon 1' construct starting downstream of the oligo(U) tail but upstream of the open reading frames 2 and 3 was also well translated when transfected in mouse cells, Thus all La mRNA forms represent functional La mRNAs.	UNIV MAINZ,INST PHYSIOL CHEM,D-55099 MAINZ,GERMANY	Johannes Gutenberg University of Mainz			Bachmann, Michael P/E-8850-2010; Bachmann, Michael/AAA-5153-2020	Bachmann, Michael P/0000-0002-8029-5755; Bachmann, Michael/0000-0002-8029-5755				Bachmann M, 1996, J AUTOIMMUN, V9, P747, DOI 10.1006/jaut.1996.0097; BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; Bachmann M, 1996, J AUTOIMMUN, V9, P757, DOI 10.1006/jaut.1996.0098; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHAN EKL, 1989, NUCLEIC ACIDS RES, V17, P2233, DOI 10.1093/nar/17.6.2233; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; HENDRICK JP, 1981, MOL CELL BIOL, V12, P1138; Hilker M, 1996, CELL TISSUE RES, V284, P383, DOI 10.1007/s004410050599; KEECH CL, 1993, J AUTOIMMUN, V6, P543, DOI 10.1006/jaut.1993.1045; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KURILLA MG, 1984, J VIROL, V50, P773, DOI 10.1128/JVI.50.3.773-778.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADORE SJ, 1984, J BIOL CHEM, V259, P1929; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; PRUIJN GJM, 1995, EUR J BIOCHEM, V232, P611, DOI 10.1111/j.1432-1033.1995.tb20851.x; PRUIJN GJM, 1990, MOL BIOL REP, V14, P43, DOI 10.1007/BF00360410; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; SMITH PR, 1985, J IMMUNOL METHODS, V77, P63, DOI 10.1016/0022-1759(85)90184-X; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; TAN EM, 1989, ADV IMMUNOL, V44, P93; TROSTER H, 1994, J EXP MED, V180, P2059, DOI 10.1084/jem.180.6.2059; WILUSZ J, 1983, P NATL ACAD SCI-BIOL, V80, P5827, DOI 10.1073/pnas.80.19.5827	24	13	13	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12076	12082		10.1074/jbc.272.18.12076	http://dx.doi.org/10.1074/jbc.272.18.12076			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115276	hybrid			2022-12-25	WOS:A1997WX56900064
J	Luo, XM; Sando, JJ				Luo, XM; Sando, JJ			Deficient tyrosine phosphorylation of c-Cbl and associated proteins in phorbol ester-resistant EL4 mouse thymoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; PHOSPHOLIPASE C-GAMMA-1; SIGNAL-TRANSDUCTION; JURKAT CELLS; P85 SUBUNIT; SH3 DOMAIN; T-CELLS; ACTIVATION	Two tyrosine phosphoproteins in phorbol ester-sensitive EL4 (S-EL4) mouse thymoma cells have been identified as the p120 c-Cb1 protooncogene product and the p85 subunit of phosphatidylinositol 3-kinase. Tyrosine phosphorylation of p120 and p85 increased rapidly after phorbol ester stimulation. Phorbol ester-resistant EL4 (R-EL4) cells expressed comparable amounts of c-Cb1 and phosphatidylinositol 3-kinase protein but greatly diminished tyrosine phosphorylation. Co-immunoprecipitation experiments revealed complexes of c-Cb1 with p85, and of p85 with the tyrosine kinase Lck in phorbol ester-stimulated S-EL4 but not in unstimulated S-EL4 or in R-EL4 cells. In vitro binding of c-Cb1 with Lck SH2 or SH3 domains was detected in both S-EL4 and R-EL4 cells, suggesting that c-Cb1, p85, and Lck may form a ternary complex. In vitro kinase assays revealed phosphorylation of p85 by Lck only in phorbol ester-stimulated S-EL4 cells. Collectively, these results suggest that Cb1-p85 and Lck-p85 complexes may form in unstimulated S-EL4 and R-EL4 cells but were not detected due to absence of tyrosine phosphorylation of p85. Greatly decreased tyrosine phosphorylation of c-Cb1 and p85 in the complexes may contribute to the failure of R-EL4 cells to respond to phorbol ester.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,CTR CANC,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031184] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31184] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGERTON M, 1994, J BIOL CHEM, V269, P11435; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; EGERTON M, 1992, J IMMUNOL, V149, P1847; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HARRISON JR, 1987, J BIOL CHEM, V262, P234; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JENSEN DE, 1991, ONCOGENE, V6, P1219; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LIN YC, 1996, J BIOL CHEM, V271, P14591; LUO K, 1990, ONCOGENE, V5, P803; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; RESNICK MS, 1997, IN PRESS CANC RES; RICHARDSON AF, 1995, CELL SIGNAL, V7, P17, DOI 10.1016/0898-6568(94)00068-M; SANDO JJ, 1982, CANCER RES, V42, P1676; SANDO JJ, 1993, AM ASS CAN RES, V34, P176; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TAICHMAN R, 1993, J BIOL CHEM, V268, P20031; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					12221	12228		10.1074/jbc.272.18.12221	http://dx.doi.org/10.1074/jbc.272.18.12221			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115297	hybrid			2022-12-25	WOS:A1997WX56900085
J	Moyers, JS; Bilan, PJ; Zhu, JH; Kahn, CR				Moyers, JS; Bilan, PJ; Zhu, JH; Kahn, CR			Rad and Rad-related GTPases interact with calmodulin and calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; ACTIVATION; IDENTIFICATION; ADIPOCYTES; INSULIN; FAMILY; MUSCLE	Members of the Rad family of GTPases (including Rad, Gem, and Kir) possess several unique features of unknown function in comparison to other Ras like proteins, with major N terminal and C-terminal extensions, a lack of typical prenylation motifs, and several nonconservative changes in the sequence of the GTP binding domain. Here we show that Rad and Gem bind to calmodulin (CaM)-Sepharose in vitro in a calcium-dependent manner and that Rad can be co-immunoprecipitated with CaM in C2C12 cells. The interaction is influenced by the guanine nucleotide binding state of Rad with the GDP-bound form exhibiting 5-fold better binding to CaM than the GTP-bound protein. In addition, the dominant negative mutant of Rad (S105N) which binds GDP, but not GTP, exhibits enhanced binding to CaM in vivo when expressed in C2C12 cells. Peptide competition studies and expression of deletion mutants of Rad localize the binding site for CaM to residues 278-297 at the C terminus of Rad. This domain contains a motif characteristic of a calmodulin-binding region, consisting of numerous basic and hydrophobic residues. In addition, we have identified a second potential regulatory domain in the extended N terminus of Rad which, when removed, decreases Rad protein expression but increases the binding of Rad to CaM. The ability of Rad mutants to bind CaM correlates with their localization in cytoskeletal fractions of C2C12 cells. Immunoprecipitates of calmodulin-dependent protein kinase II, the cellular effector of Ca2+-calmodulin, also contain Rad, and in vitro both Rad and Gem can serve as substrates for this kinase. Thus, the Rad family of GTP-binding proteins possess unique characteristics of binding CaM and calmodulin-dependent protein kinase II, suggesting a role for Rad-like GTPases in calcium activation of serine/threonine kinase cascades.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [P30DK36836, DK 07260, DK 45935] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045935, T32DK007260, P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BERCHTOLD MW, 1996, KEYST S MOL CELL B E, V7, P304; BRUAN AP, 1995, ANNU REV PHYSIOL, V57, P417; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; CORMONT M, 1993, J BIOL CHEM, V268, P19491; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dorin D, 1995, ONCOGENE, V11, P2267; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; Zhu JH, 1996, J BIOL CHEM, V271, P768, DOI 10.1074/jbc.271.2.768; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	26	82	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11832	11839		10.1074/jbc.272.18.11832	http://dx.doi.org/10.1074/jbc.272.18.11832			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115241	hybrid			2022-12-25	WOS:A1997WX56900029
J	Natsume, T; Tomita, S; Iemura, S; Kinto, N; Yamaguchi, A; Ueno, N				Natsume, T; Tomita, S; Iemura, S; Kinto, N; Yamaguchi, A; Ueno, N			Interaction between soluble type I receptor for bone morphogenetic protein and bone morphogenetic protein-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; OSTEOGENIC PROTEIN-1; BETA FAMILY; INDUCTION; SILKWORM; CELLS; IDENTIFICATION; EXPRESSION; MESODERM; EMBRYOS	Bone morphogenetic proteins (BMPs) are multifunctional proteins that comprise the largest subfamily of the transforming growth factor-beta. These proteins bind to types I and II serine/threonine kinase receptors. Ligand-induced heteromeric dimerization of these receptors is the key event in initiation of biological responses. We report here large scale expression and purification of extracellular domain of the type I receptor for BMP-2/4, using a silkworm expression system. This soluble form of BMP receptor (sBMPR) was in monomer form in solution and bound to BMP-4 but not to activin or transforming growth factor-beta 1. Surface plasmon resonance studies showed that kinetic parameters of sBMPR for BMP-4 consisted of a relatively rapid association rate constant (k(a) = 3.81 +/- 0.19 x 10(4) s(-1) M-1) and an extremely slow dissociation rate constant (k(d) = 3.69 +/- 0.26 x 10(-4) s(-1)). From these two kinetic parameters, affinity was determined to be similar to that of the intact membrane-associated receptor expressed on COS cells. sBMPR inhibited the alkaline phosphatase activity in BMP responsive cell lines such as mouse osteoblastic cell MC3T3-E1 and bone marrow stromal cell ST2. These data indicate that the extracellular domain of type I receptor for BMP-2 and BMP-4 is sufficient for high affinity binding to its ligands and should prove useful in understanding the role of BMP-2/4 in vivo, because a suitable high-affinity anti-BMP antibody has yet to be developed.	NIPPON MEAT PACKERS INC, CTR RES & DEV, TSUKUBA, IBARAKI 30026, JAPAN; NATL INST SERICULTURAL & ENTOMOL SCI, DEPT INSECT GENET & BREEDING, TSUKUBA, IBARAKI 305, JAPAN; SHOWA UNIV, SCH DENT, DEPT ORAL PATHOL, SHINAGAWA KU, TOKYO 142, JAPAN; NIIGATA UNIV, SCH MED, DEPT ORTHOPED SURG, NIIGATA 951, JAPAN; HOKKAIDO UNIV, FAC PHARMACEUT SCI, SAPPORO, HOKKAIDO 060, JAPAN	NH Foods Ltd.; National Institute of Agrobiological Sciences - Japan; Showa University; Niigata University; Hokkaido University				Tomita, Shuichiro/0000-0002-0669-7721; Ueno, Naoto/0000-0002-8375-2317				FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; ISHIDA N, 1994, J BIOCHEM-TOKYO, V115, P279, DOI 10.1093/oxfordjournals.jbchem.a124329; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONES CM, 1992, DEVELOPMENT, V115, P639; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KOBAYASHI J, 1992, CYTOTECHNOLOGY, V8, P103, DOI 10.1007/BF02525492; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIU F, 1995, MOL CELL BIOL, V15, P3479; MAEDA S, 1985, NATURE, V315, P592, DOI 10.1038/315592a0; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Miyazono Kohei, 1994, Seminars in Cell Biology, V5, P389, DOI 10.1006/scel.1994.1046; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; PERIDES G, 1993, J BIOL CHEM, V268, P25197; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHODA A, 1993, GROWTH FACTORS, V8, P165, DOI 10.3109/08977199309011019; SHODA A, 1994, BIOCHEM BIOPH RES CO, V198, P1267, DOI 10.1006/bbrc.1994.1179; SUZUKI A, 1993, BIOCHEM J, V291, P413, DOI 10.1042/bj2910413; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; UEDA Y, 1993, J VET MED SCI, V55, P251, DOI 10.1292/jvms.55.251; Ueno N, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046927; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	36	70	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11535	11540						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111068				2022-12-25	WOS:A1997WW00900084
J	Obama, H; Ozawa, M				Obama, H; Ozawa, M			Identification of the domain of alpha-catenin involved in its association with beta-catenin and plakoglobin (gamma-catenin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADHERIN-ASSOCIATED PROTEIN; CELL-ADHESION MOLECULE; CYTOPLASMIC DOMAIN; BINDING-SITE; APC PROTEIN; N-CADHERIN; VINCULIN; HOMOLOG; EXPRESSION; DISTINCT	alpha-Catenin is a 102-kDa protein exhibiting homology to vincuin, and it forms complexes with cadherins or the tumor-suppressor gene product adenomatous polyposis coli through binding to beta-catenin or plakoglobin (gamma-catenin), The incorporation of alpha-catenin into the cadherin-catenin complexes is a prerequisite for expression of the cell-adhesive activity of cadherins. Using an in vitro assay system involving bacterially expressed proteins, we localized a region in alpha-catenin required for molecular interaction with beta-catenin and plakoglobin. Analysis of various truncated alpha-catenin molecules revealed that amino-terminal residues 48-163 are able to bind to beta-catenin and plakoglobin. Consistent with the observation that beta-catenin and plakoglobin bind to the same region of alpha-catenin, beta-catenin competed with the binding of plakoglobin to alpha-catenin and vice versa. Under the conditions used, beta-catenin bound to alpha-catenin with higher affinity than did plakoglobin. Scatchard analysis indicated that the affinity of the interaction between alpha-catenin and beta-catenin or that between alpha-catenin and plakoglobin was moderately strong (K-d = 3.8 x 10(-8) and 7.7 x 10(-8), respectively). When transfected into L cells expressing E-cadherin, the aminoterminal region of alpha-catenin (from residue 1 to 226) formed complexes with beta-catenin supporting the in vitro binding experiment results.	KAGOSHIMA UNIV,FAC MED,DEPT BIOCHEM,KAGOSHIMA 890,JAPAN	Kagoshima University								ABERLE H, 1994, J CELL SCI, V107, P3655; BLUM P, 1992, BIO-TECHNOL, V10, P301, DOI 10.1038/nbt0392-301; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GILMORE AP, 1992, J CELL SCI, V103, P719; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1995, J BIOCHEM-TOKYO, V118, P1077, DOI 10.1093/jb/118.5.1077; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V203, P1691, DOI 10.1006/bbrc.1994.2381; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAPLEY P, 1989, ONCOGENE, V4, P325; Tsutsui J, 1996, J BIOCHEM-TOKYO, V120, P1034; UCHIDA N, 1994, DEV BIOL, V163, P75, DOI 10.1006/dbio.1994.1124	33	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11017	11020						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9110993				2022-12-25	WOS:A1997WW00900009
J	Shan, Q; Cox, MM				Shan, Q; Cox, MM			RecA filament dynamics during DNA strand exchange reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ATP HYDROLYSIS; PROTEIN-BINDING; DUPLEX DNA; NUCLEOPROTEIN FILAMENTS; NUCLEOSIDE TRIPHOSPHATE; GENETIC-RECOMBINATION; COMPLEXES; PRODUCT; ASSOCIATION	The role of ATP hydrolysis in RecA protein-mediated DNA strand exchange reactions remains controversial, Competing models suggest that ATP hydrolysis is coupled either to a simple redistribution of RecA monomers within a filament to repair filament discontinuities, or more directly to rotation of the DNA substrates to drive branch movement unidirectionally, Here, we test key predictions of the RecA redistribution idea, When ATP is hydrolyzed, DNA strand exchange is accompanied by a RecA exchange reaction, between free and bound RecA protomers in the interior of RecA filaments, that meets a central prediction of the model, The RecA protomer exchange is not required for, and does not occur during, the ''search for homology'' in which the single-stranded DNA within a RecA-ssDNA nucleoprotein filament is homologously aligned with the duplex DNA, Instead, the RecA exchange is triggered by the completion of strand exchange (a strand switch to generate a hybrid DNA product) in any given segment of the filament, In effect, formation of hybrid DNA leads to a change in filament conformation to one with properties approximating those of RecA filaments bound to double-stranded DNA, Addition of the RecA K72R mutant protein to a reaction with the wild type protein leads to the formation of mixed filaments and a poisoning of the DNA strand exchange reaction, Under some conditions, a facile RecA protomer exchange is observed, and significant ATP is hydrolyzed, even though DNA strand exchange is entirely blocked by the mutant protein, A redistribution of RecA protomers coupled to ATP hydrolysis is not sufficient in itself to explain how ATP hydrolysis facilitates DNA strand exchange, A RecA protomer exchange may nevertheless play an important role in the DNA strand exchange process.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335, U01GM032335] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; BURNETT B, 1994, J MOL BIOL, V238, P540, DOI 10.1006/jmbi.1994.1313; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KAHN R, 1984, J BIOL CHEM, V259, P7495; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KUBISTA M, 1995, P 9 CONV UND MECH DN; KUZMINOV A, 1996, RECOMBINATIONAL REPA, P210; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; PUGH BF, 1987, J BIOL CHEM, V262, P1337; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; ULLSPERGER CJ, 1995, BIOCHEMISTRY-US, V34, P10859, DOI 10.1021/bi00034a019; UMEZU K, 1994, J BIOL CHEM, V269, P30005; ZYSKIND JW, 1992, MOL MICROBIOL, V6, P2525	43	47	47	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11063	11073						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111000				2022-12-25	WOS:A1997WW00900016
J	Snyders, S; Ramamurthy, V; Oliver, D				Snyders, S; Ramamurthy, V; Oliver, D			Identification of a region of interaction between Escherichia coli SecA and SecY proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SECRETORY PROTEINS; GENETIC-ANALYSIS; TRANSLOCATION; EXPORT; ATP; PHOSPHOLIPIDS; PREPROTEIN; DOMAINS; BINDING	SecA ATPase promotes Escherichia coli protein translocation by its association with the preprotein or preprotein-SecB complex, anionic phospholipids, and the other core component of translocase, integral membrane protein SecYEG, Using ligand affinity blotting we demonstrate a direct interaction of SecA with SecY protein, Proteolysis and gene truncation or fusion studies were used to further define this interaction. Our results demonstrate that the carboxyl-terminal third of SecA protein binds to the amino-terminal 107 amino acid residues of SecY protein, The direct demonstration of these interactions culminate studies that have inferred an interaction between SecA and SecYEG, and they are consistent with studies suggesting that this region of SecA interacts with the inner membrane.	WESLEYAN UNIV, DEPT MOL BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA	Wesleyan University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; BIRD TA, 1988, J BIOL CHEM, V263, P12063; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; ESTRADA EF, 1991, BIOCHEMISTRY-US, V30, P8611, DOI 10.1021/bi00099a017; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ITO K, 1992, MOL MICROBIOL, V6, P2423; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RAJAPANDI T, 1991, J BACTERIOL, V173, P7092, DOI 10.1128/jb.173.22.7092-7097.1991; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SOUTAR AK, 1986, J BIOL CHEM, V261, P7127; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	46	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11302	11306						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111035				2022-12-25	WOS:A1997WW00900051
J	Kosako, H; Amano, M; Yanagida, M; Tanabe, K; Nishi, Y; Kaibuchi, K; Inagaki, M				Kosako, H; Amano, M; Yanagida, M; Tanabe, K; Nishi, Y; Kaibuchi, K; Inagaki, M			Phosphorylation of glial fibrillary acidic protein at the same sites by cleavage furrow kinase and Rho-associated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT; SEPARATION; BINDING; INVITRO; CELLS; AREA; RAS	Site- and phosphorylation state-specific antibodies are useful to analyze spatiotemporal distribution of site-specific phosphorylation of target proteins in vivo. Using several polyclonal and monoclonal antibodies that can specifically recognize four phosphorylated sites on glial fibrillary acidic protein (GFAP), we have previously reported that Thr-7, Ser-13, and Ser-34 on this intermediate filament protein are phosphorylated at the cleavage furrow during cytokinesis. This observation suggests that there exists a protein kinase named cleavage furrow kinase specifically activated at metaphase-anaphase transition (Matsuoka, Y., Nishizawa, K., Yano, T., Shibata, M., Ando, S., Takahashi, T., and Inagaki, M. (1992) EMBO J. 11, 2895-2902; Sekimata, M., Tsujimura, a, Tanaka, J., Takeuchi, Y., Inagaki, N., and Inagaki, M. (1996) J. Cell Biol; 132, 635-641). Here we report that GFAP is phosphorylated specifically at Thr-7, Ser-13, and Ser-34 by Rho-associated kinase (Rho-kinase), which binds to the small GTPase Rho in its GTP-bound active form. The kinase activity of Rho-kinase toward GFAP is dramatically stimulated by guanosine 5'-(3-O-thio)-triphosphate-bound RhoA. Furthermore, the phosphorylation of GFAP by Rho-kinase results in a nearly complete inhibition of its filament formation in vitro. The possibility that Rho-kinase is a candidate for cleavage furrow kinase is discussed.	AICHI CANC CTR,RES INST,BIOCHEM LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,BIOPHYS UNIT,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nara Institute of Science & Technology			Amano, Mutsuki/M-4820-2014; Inagaki, Masaki/B-9920-2016	Amano, Mutsuki/0000-0002-0662-1524; 				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; ANDREASSEN PR, 1991, J CELL SCI, V99, P523; Beavo J A, 1974, Methods Enzymol, V38, P299; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; FUCKS E, 1994, ANN REV BIOCH, V63, P345; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MADAULE P, 1995, FEBS LETT, V377, P343; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TAKAISHI K, 1995, ONCOGENE, V11, P39; TSUJIMURA K, 1994, J BIOCHEM, V116, P426, DOI 10.1093/oxfordjournals.jbchem.a124542; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6	33	114	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10333	10336						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099667				2022-12-25	WOS:A1997WV26200001
J	Rani, CSS; Wang, F; Fuior, E; Berger, A; Wu, J; Sturgill, TW; BeitnerJohnson, D; LeRoith, D; Varticovski, L; Spiegel, S				Rani, CSS; Wang, F; Fuior, E; Berger, A; Wu, J; Sturgill, TW; BeitnerJohnson, D; LeRoith, D; Varticovski, L; Spiegel, S			Divergence in signal transduction pathways of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors - Involvement of sphingosine 1-phosphate in PDGF but not EGF signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; SMOOTH-MUSCLE CELLS; CELLULAR PROLIFERATION; CRK PROTEIN; PC12 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; MITOGENIC SIGNAL; 3T3 FIBROBLASTS; 2ND MESSENGER	Platelet-derived growth factor (PDGF) and serum, but not epidermal growth factor (EGF), stimulated sphingosine kinase activity in Swiss 3T3 fibroblasts and increased intracellular concentrations of sphingosine 1-phosphate (SPP), a sphingolipid second messenger (Olivera, A., and Spiegel, S. (1993) Nature 365, 557-560). We report herein that DL-threo-dihydrosphingosine (DHS), a competitive inhibitor of sphingosine kinase that prevents PDGF-induced SPP formation, specifically inhibited the activation of two cyclin-dependent kinases (p34(cdc2) kinase and Cdk2 kinase) induced by PDGF, but not by EGF. SPP reversed the inhibitory effects of DHS on PDGF-stimulated cyclin-dependent kinases and DNA synthesis, demonstrating that the DHS effects were mediated via inhibition of sphingosine kinase. DHS also markedly reduced PDGF-stimulated but not EGF-stimulated mitogen-activated protein kinase activity and DNA binding activity of activator protein-1. Examination of the early signaling events of PDGF action revealed that DHS did not affect PDGF-induced autophosphorylation of the growth factor receptor or phosphorylation of the SH2/SH3 adaptor protein She and its association with Grb2. This sphingosine kinase inhibitor did not abrogate activation of phosphatidylinositol 3-kinase by PDGF. In agreement, treatment with SPP had no effect on these responses but did, however, potently stimulate phosphorylation of Crk, another SH2/SH3 adaptor protein. Moreover, DHS inhibited PDGF-stimulated, but not EGF-stimulated, Crk phosphorylation. Thus, regulation of sphingosine kinase activity defines divergence in signal transduction pathways of PDGF and EGF receptors leading to mitogen-activated protein kinase activation.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007; UNIV VIRGINIA,HLTH SCI CTR,HOWARD HUGHES MED INST,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,HOWARD HUGHES MED INST,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; NIDDK,DIABET BRANCH,NIH,BETHESDA,MD 20892; TUFTS UNIV,SCH MED,DEPT MED & PHYSIOL,BOSTON,MA 02135	Georgetown University; Howard Hughes Medical Institute; University of Virginia; Howard Hughes Medical Institute; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tufts University			Fuior, Elena/AAP-2673-2020	Fuior, Elena/0000-0001-9166-8417; Varticovski, Lyuba/0000-0002-5105-9008	NATIONAL CANCER INSTITUTE [R01CA053094, R29CA053094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER; NCI NIH HHS [CA53094] Funding Source: Medline; NIDDK NIH HHS [NIDK41077] Funding Source: Medline; NIGMS NIH HHS [GM-43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Choi OH, 1996, NATURE, V380, P634; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAYER B, 1988, NATURE, V90, P5016; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SPIEGEL S, 1993, J LIPID MEDIATOR, V8, P169; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; SU Y, 1994, J BIOL CHEM, V269, P16512; SUSA M, 1992, J BIOL CHEM, V267, P22951; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WANG F, 1997, IN PRESS BIOCH J; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	58	112	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10777	10783						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099730				2022-12-25	WOS:A1997WV26200064
J	Diatchuk, V; Lotan, O; Koshkin, V; Wikstroem, P; Pick, E				Diatchuk, V; Lotan, O; Koshkin, V; Wikstroem, P; Pick, E			Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; SODIUM DODECYL-SULFATE; RESPIRATORY BURST OXIDASE; DEPENDENT SUPEROXIDE PRODUCTION; MEMBRANE-ASSOCIATED COMPONENT; SRC HOMOLOGY-3 DOMAINS; HUMAN-NEUTROPHILS; DIPHENYLENE IODONIUM; MACROPHAGES; P47-PHOX	The elicitation of an oxidative burst in phagocytes rests on the assembly of a multicomponental complex (NADPH oxidase) consisting of a membrane-associated flavocytochrome (cytochrome b(559)), representing the redox element responsible for the NADPH-dependent reduction of oxygen to superoxide (O-2(radical anion)), two cytosolic components (p47(phox), p67(phox)), and the small GTPase Rac (1 or 2), We found that 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), an irreversible serine protease inhibitor, prevented the elicitation of O-2(radical anion) production in intact macrophages and the amphiphile-dependent activation of NADPH oxidase in a cell free system, consisting of solubilized membrane or purified cytochrome b(559) combined with total cytosol or a mixture of recombinant p47(phox), p67(phox), and Rad. AEBSF acted at the activation step and did not interfere with the ensuing electron flour, It did not scavenge oxygen radicals and did not affect assay reagents, Five other serine protease inhibitors (three irreversible and two reversible) were found to lack an inhibitory effect on cell-free activation of NADPH oxidase, A structure-function study of AEBSF analogues demonstrated that the presence of a sulfonyl fluoride group was essential for inhibitory activity and that compounds containing an aminoalkylbenzene moiety were more active than amidinobenzene derivatives, Exposure of the membrane fraction or of purified cytochrome b(559), but not of cytosol or recombinant cytosolic components, to AEBSF, in the presence of a critical concentration of the activating amphiphile lithium dodecyl sulfate, resulted in a marked impairment of their ability to support cell-free NADPH oxidase activation upon complementation with untreated cytosol or cytosolic components, Kinetic analysis of the effect of varying the concentration of each of the three cytosolic components on the inhibitory potency of AEBSF indicated that this was inversely related to the concentrations of p47(phox) and, to a lesser degree, p67(phox), AEBSF also prevented the amphiphile-elicited translocation of p47(phox) and p67(phox) to the membrane, These results are interpreted as indicating that AEBSF interferes with the binding of p47(phox) and/or p67(phox) to cytochrome b(559), probably by a direct effect on cytochrome b(559).	TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL; PENTAPHARM LTD,CH-4002 BASEL,SWITZERLAND	Tel Aviv University; Sackler Faculty of Medicine			Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABRAMOVITZ AS, 1983, J BIOL CHEM, V258, P5153; AHARONI I, 1990, J LEUKOCYTE BIOL, V48, P107, DOI 10.1002/jlb.48.2.107; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CONSEILLER EC, 1989, EUR J BIOCHEM, V183, P107, DOI 10.1111/j.1432-1033.1989.tb14902.x; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; Dwyer SC, 1996, BBA-GEN SUBJECTS, V1289, P231, DOI 10.1016/0304-4165(95)00156-5; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; JEFFCOATE SL, 1974, J CLIN ENDOCR METAB, V38, P155, DOI 10.1210/jcem-38-1-155; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P, P541; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; Labadia ME, 1996, J LEUKOCYTE BIOL, V59, P116, DOI 10.1002/jlb.59.1.116; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; Leusen JHW, 1996, J LAB CLIN MED, V128, P461, DOI 10.1016/S0022-2143(96)90043-8; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MARKWARDT F, 1968, EUR J BIOCHEM, V6, P502, DOI 10.1111/j.1432-1033.1968.tb00473.x; MARKWARDT F, 1974, BIOCHEM PHARMACOL, V23, P2247, DOI 10.1016/0006-2952(74)90554-1; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; Megyeri P, 1995, IMMUNOLOGY, V86, P629; MINTZ GR, 1993, BIOPHARM-APPL T BIO, V6, P34; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; PARK JW, 1992, J BIOL CHEM, V267, P19901; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; PICK E, 1987, J BIOL CHEM, V262, P16476; PICK E, 1981, CELL IMMUNOL, V59, P301, DOI 10.1016/0008-8749(81)90411-1; REMOLDODONNELL E, 1995, BLOOD, V85, P337; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SHAAG D, 1989, J BIOCHEM BIOPH METH, V19, P121, DOI 10.1016/0165-022X(89)90056-0; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TSAN MF, 1983, BIOCHEM BIOPH RES CO, V112, P671, DOI 10.1016/0006-291X(83)91515-2; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; WAISMANN P, 1972, ACTA BIOL MED GER, V28, P577	57	168	174	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13292	13301		10.1074/jbc.272.20.13292	http://dx.doi.org/10.1074/jbc.272.20.13292			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148950	hybrid			2022-12-25	WOS:A1997WZ38400063
J	Lopes, UG; Erhardt, P; Yao, RJ; Cooper, GM				Lopes, UG; Erhardt, P; Yao, RJ; Cooper, GM			p53-dependent induction of apoptosis by proteasome inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-DEGRADATION; CELL-DEATH; ACTIVATION; UBIQUITIN; P53; PATHWAY; COMPLEX; ALPHA	Proteolysis by the ubiquitin/proteasome pathway controls the intracellular levels of a number of proteins that regulate cell proliferation and cell cycle progression, To determine whether this pathway of protein turnover was also linked to apoptosis, we treated Rat-1 and PC12 cells with specific proteasome inhibitors. The peptide aldehydes PSI and MG115, which specifically inhibit the chymotrypsin-like activity of the proteasome, induced apoptosis of both cell types, In contrast, apoptosis was not induced by inhibitors of lysosomal proteases or by an alcohol analog of PSI. The tumor suppressor p53 rapidly accumulated in cells treated with proteasome inhibitors, as did the p53-inducible gene products p21 and Mdm-2. In addition, apoptosis induced by proteasome inhibitors was inhibited by expression of dominant-negative p53, whereas overexpression of wild-type p53 was sufficient to induce apoptosis of Rat-1 cells in transient transfection assays. Although other molecules may also be involved, these results suggest that stabilization and accumulation of p53 plays a key role in apoptosis induced by proteasome inhibitors.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Lopes, Ulisses/N-4416-2013; Lopes, Ulisses Gazos/T-6634-2019		NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	25	441	450	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12893	12896		10.1074/jbc.272.20.12893	http://dx.doi.org/10.1074/jbc.272.20.12893			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148891	hybrid			2022-12-25	WOS:A1997WZ38400004
J	Mackay, K; Starr, JR; Lawn, RM; Ellsworth, JL				Mackay, K; Starr, JR; Lawn, RM; Ellsworth, JL			Phosphatidylcholine hydrolysis is required for pancreatic cholesterol esterase- and phospholipase A(2)-facilitated cholesterol uptake into intestinal Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; DIETARY-CHOLESTEROL; FATTY-ACID; ABSORPTION; BILE; ACYLTRANSFERASE; ESTERIFICATION; DIGESTION; INVITRO; ENZYMES	Pancreatic secretion is required for efficient cholesterol absorption by the intestine, but the factors responsible for this effect have not been clearly defined, To identify factors involved and to investigate their role in cholesterol uptake, we studied the effect of Viokase(R), a porcine pancreatic extract, on cholesterol uptake into human intestinal Caco-2 cells. Viokase is capable of facilitating cholesterol uptake into these cells such that the level of uptake is B-fold higher in the presence of solubilized Viokase. This stimulation is time-dependent and is dependent on the presence of bile salt. However, bile salt-stimulated pancreatic cholesterol esterase, which has been proposed to mediate cholesterol uptake, is not fully responsible, The major cholesterol transport activity was purified and identified as pancreatic phospholipase A(2). Anti-phospholipase A(2) antibodies abolished virtually all of the phospholipase A(2) and cholesterol transport activity of solubilized Viokase, We demonstrate that both phospholipase A(2) and cholesterol esterase increase cholesterol uptake by hydrolyzing the phosphatidylcholine that is used to prepare the cholesterol-containing micelles, In the absence of cholesterol esterase or phospholipase A(2), uptake of cholesterol from micelles containing phosphatidylcholine is not as efficient as uptake from micelles containing phospholipase A(2)-hydrolytic products, These results indicate that phospholipase A(2) may mediate cholesterol absorption by altering the physical-chemical state of cholesterol within the intestine.	CV THERAPEUT,PALO ALTO,CA 94304; STANFORD UNIV,FALK CARDIOVASC RES CTR,STANFORD,CA 94305	Stanford University				Starr, Jacqueline/0000-0002-3039-2311				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL CC, 1968, P SOC EXP BIOL MED, V128, P575; BORGSTROM B, 1980, GASTROENTEROLOGY, V78, P954; BORJA CR, 1964, AM J PHYSIOL, V206, P223, DOI 10.1152/ajplegacy.1964.206.1.223; Carey M. C., 1983, PHOSPHOLIPIDS ATHERO, P33; CAREY MC, 1970, AM J MED, V49, P590, DOI 10.1016/S0002-9343(70)80127-9; Chaikoff IL, 1935, J BIOL CHEM, V112, P155; COOPER HM, 1990, CURRENT PROTOCOLS MO; COX DG, 1990, BIOCHEMISTRY-US, V29, P3842, DOI 10.1021/bi00468a006; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P103, DOI 10.1016/0005-2744(68)90248-9; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; GALLO LL, 1984, J LIPID RES, V25, P604; GRUNDY SM, 1983, ANNU REV NUTR, V3, P71, DOI 10.1146/annurev.nu.03.070183.000443; GYLLING H, 1995, ATHEROSCLEROSIS, V117, P305, DOI 10.1016/0021-9150(95)05566-F; Hamosh M, 1986, Gastroenterology, V90, P1290; HERNELL O, 1990, BIOCHEMISTRY-US, V29, P2041, DOI 10.1021/bi00460a012; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; HUANG Y, 1990, J LIPID RES, V31, P2029; KATAN MB, 1987, AM J EPIDEMIOL, V125, P387, DOI 10.1093/oxfordjournals.aje.a114545; KLAUDA HC, 1971, LIPIDS, V6, P964, DOI 10.1007/BF02531184; LOPEZCANDALES A, 1993, BIOCHEMISTRY-US, V32, P12085, DOI 10.1021/bi00096a019; MANSBACH CM, 1990, GASTROENTEROLOGY, V98, P1369, DOI 10.1016/0016-5085(90)90359-9; MAROTTA F, 1989, DIGEST DIS SCI, V34, P456, DOI 10.1007/BF01536271; MOREAU H, 1988, GASTROENTEROLOGY, V95, P1221, DOI 10.1016/0016-5085(88)90354-X; PUIJK WC, 1979, BIOCHIM BIOPHYS ACTA, V580, P411, DOI 10.1016/0005-2795(79)90153-3; RAMPONE AJ, 1973, J PHYSIOL-LONDON, V229, P505, DOI 10.1113/jphysiol.1973.sp010150; RODGERS JB, 1975, BIOCHIM BIOPHYS ACTA, V409, P192, DOI 10.1016/0005-2760(75)90153-8; Rudd E.A., 1984, P185; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; SCHAEFER EJ, 1986, PHARM CONTROL HYPERL, P119; SHAMIR R, 1995, BIOCHEMISTRY-US, V34, P6351, DOI 10.1021/bi00019a013; SIPERSTEIN MD, 1952, J BIOL CHEM, V188, P111; SPILBURG CA, 1995, BIOCHEMISTRY-US, V34, P15532, DOI 10.1021/bi00047a019; VAHOUNY GV, 1964, P SOC EXP BIOL MED, V116, P496; Verheij HM, 1994, LIPASES THEIR STRUCT, P119; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; VUORISTO M, 1992, GASTROENTEROLOGY, V102, P647, DOI 10.1016/0016-5085(92)90115-F; WANG CS, 1988, BIOCHEMISTRY-US, V27, P4834, DOI 10.1021/bi00413a038; WATT SM, 1981, J LIPID RES, V22, P157; WILSON MD, 1994, J LIPID RES, V35, P943; WINKLER FK, 1994, LIPASES THEIR STRUCT, P139	41	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13380	13389		10.1074/jbc.272.20.13380	http://dx.doi.org/10.1074/jbc.272.20.13380			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148961	hybrid			2022-12-25	WOS:A1997WZ38400074
J	Olson, ST; Swanson, R; Patston, PA; Bjork, I				Olson, ST; Swanson, R; Patston, PA; Bjork, I			Apparent formation of sodium dodecyl sulfate-stable complexes between serpins and 3,4-dichloroisocoumarin-inactivated proteinases is due to regeneration of active proteinase from the inactivated enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASE INHIBITOR; MOBILE REACTIVE CENTER; BOND LOOP; MECHANISM; ANTITHROMBIN; SUBSTRATE; THROMBIN; SITE; ALPHA-1-ANTITRYPSIN; STABILITY	Protein proteinase inhibitors of the serpin family were recently reported to form SDS-stable complexes with inactive serine proteinases modified at the catalytic serine with 3,4-dichloroisocoumarin (DCI) that resembled the complexes formed with the active enzymes (Christensen, S,, Valnickova, Z,, Thogersen, I, B,, Pizzo, S, V,, Nielsen, H, R,, Roepstorff, P,, and Enghild, J, J, (1995) J, Biol, Chem, 270, 14859-14862), The discordance between these findings and other reports that similar active site modifications of serine proteinases block the ability of serpins to form SDS stable complexes prompted us to investigate the mechanism of complex formation between serpins and DCI-inactivated enzymes, Both neutrophil elastase and beta-trypsin inactivated by DCI appeared to form SDS-stable complexes with the serpin, alpha(1)-proteinase inhibitor (alpha(1)PI), as reported previously, However, several observations suggested that such complex formation resulted from a reaction not with the DCI enzyme but rather with active enzyme regenerated from the DCI enzyme by a rate-limiting hydrolysis reaction, Thus (i) complex formation was blocked by active site-directed peptide chloromethyl ketone inhibitors; (ii) the kinetics of complex formation indicated that the reaction was not second order but rather showed a first-order dependence on DCI enzyme concentration and zero-order dependence on inhibitor concentration; and (iii) complex formation was accompanied by stoichiometric release of a peptide having the sequence SIPPE corresponding to cleavage at the alpha(1)PI reactive center P1-P1' bond, Quantitation of kinetic constants for DCI and alpha(1)PI inactivation of human neutrophil elastase and trypsin and for reactivation of the DCI enzymes showed that the observed complex formation could be fully accounted for by alpha(1)PI preferentially reacting with active enzyme regenerated from DCI enzyme during the reaction, These results support previous findings of the critical importance of the proteinase catalytic serine in the formation of SDS-stable serpin-proteinase complexes and are in accord with an inhibitory mechanism in which the proteinase is trapped at the acyl inter mediate stage of proteolysis of the serpin as a substrate.	UNIV ILLINOIS,DEPT ORAL MED & DIAGNOST SCI,CHICAGO,IL 60612; SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Swedish University of Agricultural Sciences	Olson, ST (corresponding author), UNIV ILLINOIS,CTR MOL BIOL ORAL DIS,RM 530E,801 S PAULINA ST,CHICAGO,IL 60612, USA.				NHLBI NIH HHS [HL-39888, HL-49242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049242, R29HL039888, R29HL049242, R01HL039888, R37HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKO H, 1974, BIOCHEMISTRY-US, V13, P132, DOI 10.1021/bi00698a021; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BLOOM JW, 1978, J BIOL CHEM, V253, P547; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CHRISTENSEN S, 1995, J BIOL CHEM, V270, P14859, DOI 10.1074/jbc.270.25.14859; COHEN AB, 1973, J BIOL CHEM, V248, P7055; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; ENGHILD JJ, 1994, J BIOL CHEM, V269, P20159; FERGUSON WS, 1983, ARCH BIOCHEM BIOPHYS, V220, P301, DOI 10.1016/0003-9861(83)90414-9; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; GLASER CB, 1982, BIOCHEMISTRY-US, V21, P556, DOI 10.1021/bi00532a022; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIJNEN HR, 1991, J BIOL CHEM, V266, P4041; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; MORII M, 1979, J BIOCHEM, V86, P915, DOI 10.1093/oxfordjournals.jbchem.a132623; MOROI M, 1974, BIOCHIM BIOPHYS ACTA, V359, P130, DOI 10.1016/0005-2795(74)90138-X; MOROI M, 1977, BIOCHIM BIOPHYS ACTA, V482, P412, DOI 10.1016/0005-2744(77)90255-8; MOROI M, 1975, J BIOCHEM, V78, P925, DOI 10.1093/oxfordjournals.jbchem.a130998; NILSSON T, 1982, FEBS LETT, V142, P111, DOI 10.1016/0014-5793(82)80230-5; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; ROBINSON NC, 1971, BIOCHEMISTRY-US, V10, P2743; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; Stromqvist M, 1996, BBA-PROTEIN STRUCT M, V1295, P103, DOI 10.1016/0167-4838(96)00035-0; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT JP, 1974, BIOCHEMISTRY-US, V13, P4205, DOI 10.1021/bi00717a023; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WIMAN B, 1979, J BIOL CHEM, V254, P9291; YUNG BYK, 1980, J BIOL CHEM, V255, P9724	41	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					13338	13342		10.1074/jbc.272.20.13338	http://dx.doi.org/10.1074/jbc.272.20.13338			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9148956	hybrid			2022-12-25	WOS:A1997WZ38400069
J	Xu, J; Li, M				Xu, J; Li, M			Kv beta 2 inhibits the Kv beta 1-mediated inactivation of K+ channels in transfected mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNELS; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; BOVINE BRAIN; ALPHA-SUBUNITS; ION CHANNELS; PATCH-CLAMP; RAT-BRAIN; DROSOPHILA; CLONING	Cloned auxiliary beta-subunits (e.g. Kv beta 1) modulate the kinetic properties of the pore-forming cu subunits of a subset of Shaker-like potassium channels. Coexpression of the alpha-subunit and Kv beta 2, however, induces little change in channel properties. Since more than one beta-subunit has been found in individual K+ channel complexes and expression patterns of different beta-subunits overlap in vivo, it is important to test the possible physical and/or functional interaction(s) between different beta-subunits. In this report, we show that both Kv beta 2 and Kv beta 1 recognize the same region on the pore-forming alpha-subunits of the Kv1 Shaker-like potassium channels. In the absence of alpha-subunits the Kv beta 2 polypeptide interacts with additional beta-subunit(s) to form either a homomultimer with Kv beta 2 or a heteromultimer with Kv beta 1, When coexpressing alpha-subunits and Kv beta 1 in the presence of Kv beta 2, we find that Kv beta 2 is capable of inhibiting the Kv beta 1-mediated inactivation, Using deletion analysis, we have localized the minimal interaction region that is sufficient for Kv beta 2 to associate with both alpha-subunits and Kv beta 1. This mapped minimal interaction region is necessary and sufficient for inhibiting the Kv beta 1-mediated inactivation, consistent with the notion that the inhibitory activity of Kv beta 2 results from the coassembly of Kv beta 2 with compatible alpha-subunits and possibly with Kv beta 1. Together, these results provide biochemical evidence that Kv beta 2 may profoundly alter the inactivation activity of another beta-subunit by either differential subunit assembly or by competing for binding sites on alpha-subunits, which indicates that Kv beta 2 is capable of serving as an important determinant in regulating the kinetic properties of K+ currents.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University								BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; BUTLER A, 1990, NUCLEIC ACIDS RES, V18, P2173, DOI 10.1093/nar/18.8.2173; BYRNE JH, 1980, J NEUROPHYSIOL, V43, P651, DOI 10.1152/jn.1980.43.3.651; CASTELLINO RC, 1995, AM J PHYSIOL-HEART C, V269, pH385, DOI 10.1152/ajpheart.1995.269.1.H385; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANDY KG, 1993, TRENDS PHARMACOL SCI, V14, P434, DOI 10.1016/0165-6147(93)90181-I; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1991, IONIC CHANNELS EXCIT, P58; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; JEGLA T, 1995, RECEPTOR CHANNEL, V3, P51; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PAGANO H, 1993, PRINCIPLES BIOSTATIS; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1996, J NEUROSCI, V16, P4846; RHODES KJ, 1995, J NEUROSCI, V15, P5360; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROGAWSKI MA, 1985, TRENDS NEUROSCI, V8, P214, DOI 10.1016/0166-2236(85)90082-7; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHAO B, 1994, NEURON, V13, P1205, DOI 10.1016/0896-6273(94)90058-2	52	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	1997	272	18					11728	11735		10.1074/jbc.272.18.11728	http://dx.doi.org/10.1074/jbc.272.18.11728			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WX569	9115226	hybrid			2022-12-25	WOS:A1997WX56900014
J	Kasai, M; Matsuzaki, T; Katayanagi, K; Omori, A; Maziarz, RT; Strominger, JL; Aoki, K; Suzuki, K				Kasai, M; Matsuzaki, T; Katayanagi, K; Omori, A; Maziarz, RT; Strominger, JL; Aoki, K; Suzuki, K			The translin ring specifically recognizes DNA ends at recombination hot spots in the human genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL TRANSLOCATIONS; BREAKPOINT; SEQUENCE; BINDING; LOCUS; GENE	We previously showed that consensus sequences exist at the chromosomal breakpoints in lymphoid malignancies and that these sequences are specifically recognized by a novel DNA binding protein, Translin. In the present study, the native form of Translin was established to be a ring-shaped structure by electron microscopy and crystallographic studies. It was also determined that this multimeric Translin formed by the subunits is responsible for its binding to target sequences situated only at single-stranded DNA ends. Furthermore, DNA-damaging reagents were found to initiate a signaling pathway for the active nuclear transport of Translin. The results support the hypothesis that staggered breaks occur at recombination hot spots and Translin has a pivotal function in recognition of the generated single-stranded DNA ends.	NATL INST HLTH & NUTR,DEPT PATHOL,SHINJUKU KU,TOKYO 162,JAPAN; MITSUBISHI CHEM CORP,AOBA KU,YOKOHAMA,KANAGAWA 227,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; OREGON HLTH SCI UNIV,DIV HEMATOL & ONCOL,PORTLAND,OR 97207; VET AFFAIRS MED CTR,PORTLAND,OR 97207; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; UNIV TOKYO,SCH MED,DEPT INTERNAL MED 1,BUNKYO KU,TOKYO 113,JAPAN	National Institute of Health & Nutrition - Japan; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; University of Tokyo	Kasai, M (corresponding author), NATL INST HLTH & NUTR,DEPT IMMUNOL,SHINJUKU KU,1-23-1 TOYAMA,TOKYO 162,JAPAN.							AOKI K, 1994, ONCOGENE, V9, P1109; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; KASAI M, 1994, INT IMMUNOL, V6, P1017, DOI 10.1093/intimm/6.7.1017; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; *SERC DAR LAB, 1979, 4 SERC DAR LAB; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382	14	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1997	272	17					11402	11407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WW009	9111049				2022-12-25	WOS:A1997WW00900065
J	Hanna, MC; Turner, AJ; Kirkness, EF				Hanna, MC; Turner, AJ; Kirkness, EF			Human pyridoxal kinase - cDNA cloning, expression, and modulation by ligands of the benzodiazepine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN; SPECIFICITIES; PURIFICATION; VITAMIN-B-6; METABOLISM	Peptide fragments of a porcine benzodiazepine-binding protein were used to isolate the cDNA of a related human protein. The cDNA encodes a polypeptide of 312 amino acid residues that is homologous to a bacterial pyridoxal kinase. Transient expression of the cDNA in human embryonic kidney cells confirmed that it encodes human pyridoxal kinase. The recombinant enzyme displayed a Rm value of 3.3 mu M for pyridoxal and was inhibited competitively by 4-deoxypyridoxine (K-i = 2.8 mu M). Benzodiazepine receptor ligands that bound to the purified porcine protein also exerted a potent inhibitory effect on human pyridoxal kinase activity. Transcripts of the pyridoxal kinase gene were detectable in all human tissues examined, and were particularly abundant in the testes. The gene is localized on chromo some 21q22.3 and represents a candidate gene for at least one genetic disorder that has been mapped to this region (autoimmune polyglandular disease type 1).	INST GENOM RES,ROCKVILLE,MD 20850; UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	J. Craig Venter Institute; University of Leeds								AALTONEN J, 1994, NAT GENET, V8, P83, DOI 10.1038/ng0994-83; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Bjorses P, 1996, AM J HUM GENET, V59, P879; BRIN M, 1976, HUMAN VITAMIN B6 REQ, P1; CHURCHICH JE, 1990, J PROTEIN CHEM, V9, P613, DOI 10.1007/BF01025015; COBURN SP, 1991, J MENT DEFIC RES, V35, P543; DOMINICI P, 1988, J BIOL CHEM, V263, P14712; FINDLAY JBC, 1989, PROTEIN SEQUENCING P, P69; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HILL RE, 1996, ESCHERICHIA COLI SAL, P695; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; KIRKNESS EF, 1988, J NEUROCHEM, V50, P356, DOI 10.1111/j.1471-4159.1988.tb02920.x; KIRKNESS EF, 1996, CDNA LIB PROTOCOLS, P261; KWOK F, 1979, J BIOL CHEM, V254, P6489; Leklem J.E., 1991, HDB VITAMINS, P341; Lumeng L, 1980, VITAMIN B6 METABOLIS, P27; MCCORMICK D, 1961, J BIOL CHEM, V236, P2076; MCCOY EE, 1969, ANN NY ACAD SCI, V166, P116, DOI 10.1111/j.1749-6632.1969.tb54262.x; MERRILL AH, 1984, J NUTR, V114, P1664, DOI 10.1093/jn/114.9.1664; NEARY JT, 1970, J BIOL CHEM, V245, P5585; SUSSMANE S, 1995, ANAL BIOCHEM, V225, P109, DOI 10.1006/abio.1995.1115; TOKUNAGA K, 1987, CANCER RES, V47, P5616; UBBINK JB, 1990, ENZYME, V43, P72, DOI 10.1159/000468709; WAYMIRE KG, 1995, NAT GENET, V11, P45, DOI 10.1038/ng0995-45; Yang Y, 1996, FEMS MICROBIOL LETT, V141, P89, DOI 10.1016/0378-1097(96)00203-0	26	53	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10756	10760						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099727				2022-12-25	WOS:A1997WV26200061
J	Hua, SB; Wang, CC				Hua, SB; Wang, CC			Interferon-gamma activation of a mitogen-activated protein kinase, KFR1, in the bloodstream form of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; GROWTH-FACTOR-BETA; CD8+ T-CELLS; SIGNAL TRANSDUCTION; MEMBRANE-FORM; NITRIC-OXIDE; PURIFICATION; MATURATION; RECEPTOR; INVIVO	KFR1, a mitogen-activated protein (MAP) kinase identified in the African trypanosome, Trypanosoma brucei, is a serine protein kinase capable of phosphorylating the serine residues in histone H-1, myelin basic protein, and beta-casein. It phosphorylates four proteins with estimated molecular masses of 22, 54, 46, and 90 kDa from the T. brucei bloodstream-form lysate in vitro. KFR1 bears significant sequence similarity to the yeast MAP kinases KSS1 and FUS3 but cannot functionally complement the Kss1/fus3 yeast mutant. It is encoded by a single-copy gene in the diploid T. brucei, and only one of the two alleles can be successfully disrupted, suggesting an essential function of KFR1 in T. brucei. KFR1 activity is present at a much enhanced level in the bloodstream form of T. brucei when compared with that in the insect (procyclic) form. This enhanced activity can be eliminated in vitro by the treatment with protein phosphatase HVH2 known to act specifically on MAP kinases. It can also be decreased in the bloodstream form of T. brucei by serum starvation but induced specifically by interferon-gamma. The production of interferon-gamma in the mammalian host is known to be triggered by T. brucei infection, and this cytokine, as has been reported, promotes the proliferation of T. brucei in the mammalian blood. Since none of these phenomena can be observed in the procyclic form of T. brucei, activation of KFR1 is most likely involved in mediating the interferon-gamma-induced proliferation of T. brucei in the mammalian host.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI021786, R21AI021786, R01AI021786] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BAKHIET M, 1993, SCAND J IMMUNOL, V37, P165, DOI 10.1111/j.1365-3083.1993.tb01753.x; BAKHIET M, 1990, CLIN EXP IMMUNOL, V81, P195, DOI 10.1111/j.1365-2249.1990.tb03317.x; BAKHIET M, 1993, EUR J IMMUNOL, V23, P1535, DOI 10.1002/eji.1830230721; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; BULOW R, 1985, FEBS LETT, V187, P105, DOI 10.1016/0014-5793(85)81223-0; BULOW R, 1986, J BIOL CHEM, V261, P1918; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; Demaeyer E., 1988, INTERFERONS OTHER RE; ELION EA, 1991, COLD SPRING HARB SYM, V56, P41; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HUA SB, 1994, J CELL BIOCHEM, V54, P20, DOI 10.1002/jcb.240540104; HUA SB, 1995, J BIOL CHEM, V270, P10264, DOI 10.1074/jbc.270.17.10264; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KEITH K, 1990, MOL BIOCHEM PARASIT, V43, P107, DOI 10.1016/0166-6851(90)90135-9; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Li F, 1996, MOL BIOCHEM PARASIT, V78, P227, DOI 10.1016/S0166-6851(96)02630-8; MABBOTT NA, 1995, PARASITE IMMUNOL, V17, P143, DOI 10.1111/j.1365-3024.1995.tb01016.x; MANSFIELD JM, 1994, PARASITOL TODAY, V10, P267, DOI 10.1016/0169-4758(94)90143-0; Matsuo T, 1996, BIOCHEM J, V315, P505, DOI 10.1042/bj3150505; MAUDLIN I, 1988, TROP MED PARASITOL, V39, P56; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; OLSSON T, 1993, CELL, V72, P715, DOI 10.1016/0092-8674(93)90400-K; OLSSON T, 1991, EUR J IMMUNOL, V21, P2447, DOI 10.1002/eji.1830211022; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEN GC, 1992, J BIOL CHEM, V267, P5017; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; SOMMER JM, 1993, FEBS LETT, V316, P53, DOI 10.1016/0014-5793(93)81735-I; Sternberg JM, 1996, EUR J IMMUNOL, V26, P539, DOI 10.1002/eji.1830260306; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WELBURN SC, 1994, MED VET ENTOMOL, V8, P81, DOI 10.1111/j.1365-2915.1994.tb00391.x; WELBURN SC, 1990, MED VET ENTOMOL, V4, P43, DOI 10.1111/j.1365-2915.1990.tb00258.x; XU JH, 1994, MOL CELL BIOL, V14, P8018, DOI 10.1128/MCB.14.12.8018; XU JH, 1995, BLOOD, V86, P2774; ZENG FY, 1995, MOL CELL BIOCHEM, V142, P117, DOI 10.1007/BF00928932	58	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10797	10803						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099733	hybrid			2022-12-25	WOS:A1997WV26200067
J	Charest, A; Wagner, J; Kwan, M; Tremblay, ML				Charest, A; Wagner, J; Kwan, M; Tremblay, ML			Coupling of the murine protein tyrosine phosphatase PEST to the epidermal growth factor (EGF) receptor through a Src homology 3 (SH3) domain-mediated association with Grb2	ONCOGENE			English	Article						SH3 domain; Grb2; PTPase; EGF receptor; p120	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; HEMATOPOIETIC-CELL PHOSPHATASE; GUANINE-NUCLEOTIDE EXCHANGE; SIGNALING GENE SEM-5; BACULOVIRUS VECTOR; KINASE SUBSTRATE; ADAPTER PROTEIN; BINDING-SITE; RAS; SOS	The involvement of murine protein tyrosine phosphatase-PEST (MPTP-PEST) in signal transduction pathways is suggested by its ability to dephosphorylate phosphotyrosine residues, its interaction with the adaptor protein SHC and by the presence of five proline-rich stretches in its non-catalytic carboxyl terminus, Proline-rich sequences have been identified as binding sites for Src homology 3 (SH3) domains found in proteins associated with signal transduction events. The ability of these sequences to act as SH3 domain recognition motifs was investigated using bacterially expressed SH3 domains derived from several different signalling proteins. In vitro binding assays indicate that four of these proline-rich sequences constitute specific binding sites for both SH3 domains of the adaptor molecule Grb2, Wild type Grb2, but not Grb2 proteins corresponding to loss-of-function mutants in the Caenorhabditis elegans sem-5 protein, associate with MPTP-PEST in vivo. Experiments in EGF receptor expressing cells show that the interaction between MPTP-PEST and Grb2 results in the binding of this complex to activated EGF receptors. In addition, identification of putative substrate(s) of MPTP-PEST have revealed a candidate protein of similar to 120 kDa which is tyrosine phosphorylated upon EGF stimulation. Together, these results describe a novel SH3 domain-dependent recruitment of a protein tyrosine phosphatase to an activated receptor tyrosine kinase and establish a potential role for MPTP-PEST in signalling pathways at the molecular level.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								AMARNEH B, 1995, MOL CELL ENDOCRINOL, V109, pR1, DOI 10.1016/0303-7207(95)03524-B; AUSUBEL FM, 1995, CURR PROTO MOL BIOL; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHAREST A, 1995, GENOMICS, V28, P501, DOI 10.1006/geno.1995.1181; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORSTMAN DA, 1995, PROTEIN EXPRES PURIF, V6, P278, DOI 10.1006/prep.1995.1036; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI X, 1995, GENOMICS, V28, P442, DOI 10.1006/geno.1995.1173; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2369; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sambrook KJ, 1989, MOL CLONING LAB MANU; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YANG SS, 1995, J BIOL CHEM, V270, P18212, DOI 10.1074/jbc.270.31.18212; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	48	49	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1643	1651		10.1038/sj.onc.1201008	http://dx.doi.org/10.1038/sj.onc.1201008			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135065				2022-12-25	WOS:A1997WR89300002
J	Cadoret, A; Bertrand, F; BaronDelage, S; Levy, P; Courtois, G; Gespach, C; Capeau, J; Cherqui, G				Cadoret, A; Bertrand, F; BaronDelage, S; Levy, P; Courtois, G; Gespach, C; Capeau, J; Cherqui, G			Down-regulation of NF-kappa B activity and NF-kappa B p65 subunit expression by ras and polyoma middle T oncogenes in human colonic Caco-2 cells	ONCOGENE			English	Article						Ha-ras; polyoma middle T; NF-kappa B; p65 subunit; Caco-2 cells	PROTEIN-KINASE-C; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; P50 SUBUNIT; ADHESION MOLECULE-1; GROWTH-FACTOR; ACTIVATION; GENE; PROMOTER; ALPHA	The products of ras and src proto-oncogenes are frequently activated in a constitutive state in human colorectal cancer, In this study we attempted to establish whether the tumorigenic progression induced by oncogenic activation of p21(ras) or pp60(c-src) in human colonic cells is associated with alterations of the activity and expression of nuclear factor kappa B (NF-kappa B), a transcription factor suspected to participate in the development of cancer, To this end, we used Caco-2 cells made highly tumorigenic by transfection with an activated Val-12 human Ha-ras gene or with the polyoma middle T (PyMT) oncogene, a constitutive activator of pp60(c-src) tyrosine kinase activity, Compared with control vector-transfected Caco-2 cells, both oncogene-transfected cell lines exhibited: (i) decreased constitutive NF-kappa B DNA-binding activity and NF-kappa B-mediated reporter gene expression, without alteration of their response to TNF-alpha for activation of these parameters; (ii) reduced NF-kappa B cytosolic stores along with a decreased p65 expression due, at least in part, to destabilization of p65 mRNA; (iii) a decrease in adhesion to extracellular matrix component-coated substrata which was partially corrected when stimulating NF-kappa B transcriptional activity with TNF-alpha. These results indicate that the tumorigenic progression induced by oncogenic p21(ras) or PyMT/pp60(c-src) in human colonic Caco-2 cells is associated with a down-regulation of p65 expression and NF-kappa B activity which could be responsible for the reduced adhesive properties of these cells after oncogene transfection.	UNIV PARIS 06, BIOL CELLULAIRE LAB, INSERM U402, F-75571 PARIS 12, FRANCE; INST PASTEUR, CNRS URA 1149, UNITE BIOL MOL EXPRESS GEN, F-75724 PARIS, FRANCE; HOP ST ANTOINE, INSERM, U55, F-75571 PARIS 12, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Cadoret, Axelle/L-2529-2017	Cadoret, Axelle/0000-0002-4283-6864; COURTOIS, Gilles/0000-0003-3117-9595				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARGON J, 1992, J BIOL CHEM, V267, P16056; BaronDelage S, 1996, AM J PHYSIOL-GASTR L, V270, pG314, DOI 10.1152/ajpgi.1996.270.2.G314; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DELAGE S, 1993, CANCER RES, V53, P2762; deWit H, 1996, EXP HEMATOL, V24, P228; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HEMAR A, 1991, J IMMUNOL, V146, P2409; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JELINEK MA, 1992, ONCOGENE, V7, P1687; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOONG AC, 1994, CANCER RES, V54, P5273; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEVY P, 1996, IN PRESS BR J CANC; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; MUNOZ E, 1994, J VIROL, V68, P8035; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; NODA M, 1988, J BIOL CHEM, V263, P18574; PEREZ JR, 1994, MOL CELL BIOL, V14, P5326, DOI 10.1128/MCB.14.8.5326; ROUSSET M, 1980, JNCI-J NATL CANCER I, V65, P885; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIRINIAN MI, 1993, ONCOGENE, V8, P157; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; UEBERLA K, 1993, J ACQ IMMUN DEF SYND, V6, P227; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEISER MM, 1990, LAB INVEST, V62, P325; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995	56	28	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1589	1600		10.1038/sj.onc.1200992	http://dx.doi.org/10.1038/sj.onc.1200992			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129150				2022-12-25	WOS:A1997WQ54800010
J	Altabef, M; Garcia, M; VariorKrishnan, G; Samarut, J				Altabef, M; Garcia, M; VariorKrishnan, G; Samarut, J			A truncated RAR alpha co-operates with the v-erbB oncogene to transform early haematopoietic progenitors in vitro and in vivo	ONCOGENE			English	Article						nuclear hormone receptor; leukaemic transformation; haematopoietic differentiation	RETINOIC ACID RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; DOMINANT-NEGATIVE ACTIVITY; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; HORMONE RECEPTORS; CELLS-INVITRO; TARGET-CELLS; VIRUS; GENE	We have shown recently that a retrovirus vector expressing a natural mutant form of the PML-RAR alpha protein characteristic of human acute promyelocytic leukaemia can transform early chicken hematopoietic progenitors (Altabef et al., 1996). Neither truncated PML nor truncated RAR alpha alone could induce transformation which suggest that the two domains should co-operate for the oncogenicity of the fusion product. To further investigate the mechanisms of this co-operation, we have tested whether a truncated RAR alpha could co-operate with the v-erbB oncogene. This oncogene has previously been shown to co-operate with the rearranged thyroid hormone receptor, v-erbA, to transform erythrocytic progenitors. We show that v-erbB and a truncated RAR alpha co-operate when expressed simultaneously as independent products to transform very early chicken haematopoietic cells close to pluripotent stage. In addition, we show that v-erbB alters transcriptional abilities of RAR alpha by both enhancing its effects on RARE and reducing those on AP-1. Therefore, RAR alpha is able to co-operate with different kinds of proteins to induce transformation of early haematopoietic cells. This strongly suggests that RAR alpha are involved in the differentiation commitment of early haematopoietic progenitors during the normal process of haematopoietic differentiation. These data bring new insights in the mechanisms of oncogenic transformation by rearranged RAR alpha.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,UMR49 CNRS,INRA,LAB ASSOCIE 913,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); INRAE			Samarut, Jacques/AAD-2587-2019					ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALLENBY G, 1994, J BIOL CHEM, V269, P16689; ALTABEF M, 1996, EMBO J, V15, P270; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GANDRILLON O, 1995, INT J ONCOL, V6, P215; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HERMANN T, 1993, ONCOGENE, V8, P55; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NICOLSON RC, 1990, EMBO J, V9, P4443; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; YANGYEN HF, 1991, NEW BIOL, V3, P1206	43	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1471	1479		10.1038/sj.onc.1200984	http://dx.doi.org/10.1038/sj.onc.1200984			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136991				2022-12-25	WOS:A1997WT58400010
J	Sakai, R; Nakamoto, T; Ozawa, K; Aizawa, S; Hirai, H				Sakai, R; Nakamoto, T; Ozawa, K; Aizawa, S; Hirai, H			Characterization of the kinase activity essential for tyrosine phosphorylation of p130(Cas) in fibroblasts	ONCOGENE			English	Article						p130(Cas); tyrosine phosphorylation; Src homology 2; signal transduction	PHOSPHOTYROSINE-CONTAINING PROTEINS; SRC HOMOLOGY REGION-2; CRK ONCOGENE PRODUCT; V-CRK; TRANSFORMING ACTIVITY; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; GROWTH-FACTOR; SH3 DOMAIN; CELLS	The cellular transformation by v-Src or v-Crk induces tyrosine phosphorylation of a common substrate molecule, p130(Cas) (Cas), which tightly binds these oncoproteins in vivo. From its structure, Cas is deduced to be an ideal substrate for Src family kinases and Abl kinase. The tyrosine kinase activity associated with Cas was analysed using mouse variant fibroblasts lacking at least one of tyrosine kinases. In normal fibroblasts, Cas is associated with a significant level of tyrosine kinase activity which efficiently phosphorylates Cas in vitro. The Cas-associated tyrosine kinase activity was remarkably elevated in Csk(-/-) cells, which resulted in hyperphosphorylation of cellular Cas. The associated kinase activity was slightly increased in Src(-/-) cells whereas not significantly changed in Abl(-/-) nor Fak(-/-) cells. On the contrary, the Cas-associated kinase activity was remarkably decreased in Fyn(-/-) cells. At the same time, association of Cas with Fyn kinase in vitro was most obviously detected in normal fibroblasts as well as Csk(-/-) cells. Transient expression of v-Crk induced elevation of the Cas-associated kinase activity in all of these cell lines except the primary culture of Fyn(-/-) fibroblasts. These results indicate that Fyn kinase plays an essential role in v-Crk-mediated phosphorylation of Cas.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; JICHI MED SCH, DIV MOL BIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; KUMAMOTO UNIV, SCH MED, INST MOL EMBRYOL & GENET, DEPT MORPHOGENESIS, KUMAMOTO 860, JAPAN	University of Tokyo; Jichi Medical University; Kumamoto University				Sakai, Ryuichi/0000-0001-6833-1103				BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; DECUE JE, 1987, P NATL ACAD SCI USA, V84, P9064; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; ILLC D, 1995, NATURE, V377, P539; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; NADA S, 1994, ONCOGENE, V9, P3571; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAGI T, 1994, ONCOGENE, V9, P2433; ZAITSU H, 1988, BIOMED RES-TOKYO, V9, P181; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	60	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1419	1426		10.1038/sj.onc.1200954	http://dx.doi.org/10.1038/sj.onc.1200954			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136985				2022-12-25	WOS:A1997WT58400004
